PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	JANKNECHT, R; ZINCK, R; ERNST, WH; NORDHEIM, A				JANKNECHT, R; ZINCK, R; ERNST, WH; NORDHEIM, A			FUNCTIONAL DISSECTION OF THE TRANSCRIPTION FACTOR ELK-1	ONCOGENE			English	Note							ETS-RELATED PROTEIN; DNA-BINDING MOTIF; PUTATIVE ONCOGENE; FACTOR P62TCF; DOMAIN; EXPRESSION; KINASE; SRF; TRANSLOCATION; PROTOONCOGENE	The ternary complex factor Elk-1 belongs to the Ets oncoprotein family. We demonstrate that this transcription factor is localized predominantly in the nucleus, for which at least two regions of Elk-I are required. One of these regions is part of the N-terminal ETS-domain, while the other encompasses amino acids 137-157. In conjunction with the ETS-domain, which mediates autonomous binding of Elk-1 to some DNA target sequences, the conserved B-region is both necessary and sufficient for ternary complex formation with the c-fos serum response element and the serum response factor. However, the B-region must be linked to the ETS-domain by a spacer. Furthermore, the B-region impedes autonomous DNA-binding, possibly by masking the ETS-domain. A point mutation within the ETS-domain, homologous to the ts1.1 point mutation of v-Ets in the E26 virus, affects DNA-binding of Elk-1 in a temperature-dependent manner, which by analogy might be causative for the altered phenotype of ts1.1 E26. Finally we show that amino acids 83-428 contribute to Elk-1 mediated transactivation. In particular, the region 376-404 is indispensable for transactivation, while flanking amino acids on both sides are only required for enhancement of transcriptional efficacy.	HANNOVER MED SCH,INST MOLEC BIOL,D-30623 HANNOVER,GERMANY	Hannover Medical School				Janknecht, Ralf/0000-0003-1741-1562				BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1993, EUR J BIOCHEM, V216, P469, DOI 10.1111/j.1432-1033.1993.tb18165.x; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	29	87	87	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1273	1278						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134131				2022-12-17	WOS:A1994NC04800034
J	PARTANEN, J; ARMSTRONG, E; BERGMAN, M; MAKELA, TP; HIRVONEN, H; HUEBNER, K; ALITALO, K				PARTANEN, J; ARMSTRONG, E; BERGMAN, M; MAKELA, TP; HIRVONEN, H; HUEBNER, K; ALITALO, K			CYL ENCODES A PUTATIVE CYTOPLASMIC TYROSINE KINASE LACKING THE CONSERVED TYROSINE AUTOPHOSPHORYLATION SITE (Y416SRC)	ONCOGENE			English	Article							AMINO-TERMINAL DOMAIN; ROUS-SARCOMA VIRUS; PROTEIN-KINASE; ONC GENES; CELL-LINE; PP60C-SRC; PHOSPHORYLATION; TRANSFORMATION; ACTIVATION; SRC	We have isolated a cDNA encoding a novel tyrosine kinase family member, named cyl (consensus tyrosine-lacking kinase), from the K562 human leukemia cell line. The deduced cyl protein lacks signal and transmembrane sequences but contains features of known cytoplasmic tyrosine kinases, including amino-terminal SH3 and SH2 domains. However, having very short amino and carboxy termini, cyl does not seem to belong to any of the previously characterized subfamilies of cytoplasmic tyrosine kinases. Furthermore, cyl lacks the highly conserved tyrosine autophosphorylation site (Y416src) in the tyrosine kinase catalytic domain. The cyl gene is located on human chromosome 15. It is expressed ubiquitously as two independently regulated mRNA species of 2.6 and 3.4 kb in human leukemia cell lines and fetal tissues.	UNIV HELSINKI,DEPT VIROL,CANC BIOL LAB,SF-00290 HELSINKI 29,FINLAND; UNIV TURKU,DEPT MED BIOCHEM,SF-20520 TURKU 52,FINLAND; TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	University of Helsinki; University of Turku; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	PARTANEN, J (corresponding author), UNIV HELSINKI,DEPT PATHOL,CANC BIOL LAB,HAARTMANINK 3,SF-00290 HELSINKI 29,FINLAND.		makela, tomi/B-3734-2009; Alitalo, Kari K/J-5013-2014	makela, tomi/0000-0002-4869-8044; Alitalo, Kari K/0000-0002-7331-0902; Partanen, Juha/0000-0001-8850-4825				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; Bishop JM, 1985, RNA TUMOR VIRUSES, P249; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; CROSS FR, 1983, CELL, V34, P597, DOI 10.1016/0092-8674(83)90392-6; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P4714, DOI 10.1073/pnas.79.15.4714; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; GREENBERG SM, 1988, BLOOD, V72, P1968; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARPER ME, 1983, NATURE, V304, P169, DOI 10.1038/304169a0; HUEBNER K, 1988, ONCOGENE, V3, P449; HUEBNER K, 1985, SCIENCE, V230, P1282, DOI 10.1126/science.2999978; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LETWIN K, 1988, ONCOGENE, V3, P621; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LOZZIO CB, 1975, BLOOD, V45, P335; LYNCH SA, 1986, SCIENCE, V234, P873, DOI 10.1126/science.3095923; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MINOWADA J, 1972, J NATL CANCER I, V49, P891; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8670; MUSTELIN T, 1990, ONCOGENE, V5, P809; OKADA M, 1989, J BIOL CHEM, V264, P20886; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P9103; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PONCZ M, 1987, BLOOD, V69, P219; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SNYDER MA, 1983, CELL, V32, P891, DOI 10.1016/0092-8674(83)90074-0; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1990, CELL, V61, P243; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V64, P511; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603	58	87	90	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2013	2018						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1945408				2022-12-17	WOS:A1991GX11900011
J	SUBRAMANIAN, T; LAREGINA, M; CHINNADURAI, G				SUBRAMANIAN, T; LAREGINA, M; CHINNADURAI, G			ENHANCED RAS ONCOGENE MEDIATED CELL-TRANSFORMATION AND TUMORIGENESIS BY ADENOVIRUS-2 MUTANTS LACKING THE C-TERMINAL REGION OF E1A PROTEIN	ONCOGENE			English	Article									ST LOUIS UNIV,MED CTR,INST MOLEC VIROL,3681 PK AVE,ST LOUIS,MO 63110; ST LOUIS UNIV,MED CTR,DEPT COMPARAT MED,ST LOUIS,MO 63104	Saint Louis University; Saint Louis University					NATIONAL CANCER INSTITUTE [R01CA033616, R01CA031719] Funding Source: NIH RePORTER; NCI NIH HHS [CA-33616, CA-31719] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; CONE RD, 1988, MOL CELL BIOL, V8, P1036, DOI 10.1128/MCB.8.3.1036; COOK JL, 1986, P NATL ACAD SCI USA, V83, P6965, DOI 10.1073/pnas.83.18.6965; EAGER KB, 1985, P NATL ACAD SCI USA, V82, P5525, DOI 10.1073/pnas.82.16.5525; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HADDADA H, 1988, J VIROL, V62, P2755, DOI 10.1128/JVI.62.8.2755-2761.1988; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KUPPUSWAMY M, 1988, ONCOGENE, V2, P567; KUPPUSWAMY M, 1988, ONCOGENE, V2, P613; KUPPUSWAMY MN, 1987, VIROLOGY, V159, P31, DOI 10.1016/0042-6822(87)90344-8; LATHE R, 1984, DNA-J MOLEC CELL BIO, V3, P173, DOI 10.1089/dna.1984.3.173; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LYONS RH, 1987, MOL CELL BIOL, V7, P2451, DOI 10.1128/MCB.7.7.2451; Maniatis T., 1982, MOL CLONING; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; VANORMONDT H, 1980, GENE, V12, P63, DOI 10.1016/0378-1119(80)90016-5; VASAVADA R, 1986, P NATL ACAD SCI USA, V83, P5257, DOI 10.1073/pnas.83.14.5257; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887; [No title captured]	34	87	93	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1989	4	4					415	420						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5677	2524023				2022-12-17	WOS:A1989U567700004
J	Fu, QH; Zhang, Q; Lou, Y; Yang, JQ; Nie, G; Chen, Q; Chen, YW; Zhang, JY; Wang, JX; Wei, T; Qin, H; Dang, XW; Bai, XL; Liang, TB				Fu, Qihan; Zhang, Qi; Lou, Yu; Yang, Jiaqi; Nie, Gang; Chen, Qi; Chen, Yiwen; Zhang, Jingying; Wang, Jianxin; Wei, Tao; Qin, Hao; Dang, Xiaowei; Bai, Xueli; Liang, Tingbo			Primary tumor-derived exosomes facilitate metastasis by regulating adhesion of circulating tumor cells via SMAD3 in liver cancer	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; BREAST-CANCER; COLORECTAL-CANCER; NICHE FORMATION; TGF-BETA; RESECTION; SURVIVAL; GROWTH; PROLIFERATION; DISSEMINATION	Hepatocellular carcinoma (HCC) is a fatal disease and patients with HCC frequently die from metastasis. The mechanisms of HCC metastasis are not completely understood. In the present study, in vitro and in vivo data showed that HCC cells promoted cancer cell proliferation and lung metastases formation in a paracrinal/endocrinal way. We found that HCC-derived exosomes mediated this phenomenon and observed enhanced cell adhesion in the presence of these malignant exosomes. We further identified that reactive oxygen species (ROS) regulated the adhesive molecules. Intriguingly, attached HCC cells released exosomes containing both SMAD Family Member 3 (SMAD3) protein and mRNA, which were delivered to detached HCC cells and facilitated their adhesion. These exosomes induced enhanced SMAD3 signaling in the recipient HCC cells and increased their adhesive ability. In addition, we showed that SMAD3-abundant exosomes existed in the peripheral blood of patients with HCC, and their levels correlated with disease stage and the SMAD3 expression of primary tumors. Our study suggested a possible mechanism by which primary HCC supported metastases formation and revealed the role of SMAD3 in the exosomes-mediated crosstalk between primary and circulating HCC cells.	[Fu, Qihan; Zhang, Qi; Lou, Yu; Yang, Jiaqi; Nie, Gang; Chen, Qi; Chen, Yiwen; Zhang, Jingying; Wang, Jianxin; Wei, Tao; Qin, Hao; Bai, Xueli; Liang, Tingbo] Zhejiang Univ, Affiliated Hosp 2, Dept Hepatobiliary & Pancreat Surg, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Fu, Qihan; Zhang, Qi; Lou, Yu; Yang, Jiaqi; Nie, Gang; Chen, Qi; Chen, Yiwen; Zhang, Jingying; Wang, Jianxin; Wei, Tao; Qin, Hao; Bai, Xueli; Liang, Tingbo] Zhejiang Prov Key Lab Pancreat Dis, Hangzhou, Zhejiang, Peoples R China; [Fu, Qihan] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China; [Dang, Xiaowei] Zhengzhou Univ, Affiliated Hosp 1, Dept Hepatopancreatobiliary Surg, Zhengzhou, Henan, Peoples R China	Zhejiang University; Zhejiang University; Zhengzhou University	Bai, XL; Liang, TB (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Dept Hepatobiliary & Pancreat Surg, Sch Med, Hangzhou, Zhejiang, Peoples R China.; Bai, XL; Liang, TB (corresponding author), Zhejiang Prov Key Lab Pancreat Dis, Hangzhou, Zhejiang, Peoples R China.	liangtingbo@zju.edu.cn; shirleybai@zju.edu.cn			National Program on Key Basic Research Project (973 Program) [2014CB542101]; National Natural Science Foundation of China [81401954, 81472212]; Key Program of Medical Scientific Research Foundation of Zhejiang Province, China [WKJ-ZJ-1410]; Medical Science & Technology Program of Zhejiang Province, China [2015KYA114]; Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents; Key Program of Administration of Traditional Chinese Medicine of Zhejiang Province, China [2014ZZ007]	National Program on Key Basic Research Project (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Program of Medical Scientific Research Foundation of Zhejiang Province, China; Medical Science & Technology Program of Zhejiang Province, China; Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents; Key Program of Administration of Traditional Chinese Medicine of Zhejiang Province, China	This work was financially supported by the National Program on Key Basic Research Project (973 Program, No. 2014CB542101), the National Natural Science Foundation of China (No. 81401954, No. 81472212), Key Program of Medical Scientific Research Foundation of Zhejiang Province, China (No. WKJ-ZJ-1410), the Medical Science & Technology Program of Zhejiang Province, China (No. 2015KYA114), the Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents, and the Key Program of Administration of Traditional Chinese Medicine of Zhejiang Province, China (No. 2014ZZ007).	Azmi AS, 2013, CANCER METAST REV, V32, P623, DOI 10.1007/s10555-013-9441-9; Chiarugi P, 2003, J CELL BIOL, V161, P933, DOI 10.1083/jcb.200211118; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Coulouarn C, 2008, HEPATOLOGY, V47, P2059, DOI 10.1002/hep.22283; Demicheli R, 2008, ANN ONCOL, V19, P1821, DOI 10.1093/annonc/mdn386; Fu QH, 2016, TUMOR BIOL, V37, P7277, DOI 10.1007/s13277-015-4560-2; Garden OJ, 2006, GUT, V55, P1, DOI 10.1136/gut.2006.098053; He M, 2015, CARCINOGENESIS, V36, P1008, DOI 10.1093/carcin/bgv081; Hong YP, 2016, INT J ONCOL, V49, P2206, DOI 10.3892/ijo.2016.3747; Jiang F, 2014, REDOX BIOL, V2, P267, DOI 10.1016/j.redox.2014.01.012; Kim SH, 2012, HEPATOB PANCREAT DIS, V11, P51, DOI 10.1016/S1499-3872(11)60125-2; Li JM, 2012, FRONT ONCOL, V2, P1, DOI [10.3389/fonc.2012.00079, 10.3389/fonc.2012.00029]; Lim SO, 2008, GASTROENTEROLOGY, V135, P2128, DOI 10.1053/j.gastro.2008.07.027; Liu YF, 2016, CANCER CELL, V30, P243, DOI 10.1016/j.ccell.2016.06.021; Mao K, 2017, J CLIN ONCOL S15, V35; Musri FY, 2016, J GASTRIC CANCER, V16, P78, DOI 10.5230/jgc.2016.16.2.78; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; Peeters CFJM, 2006, INT J CANCER, V119, P1249, DOI 10.1002/ijc.21928; Pickup M, 2013, NAT REV CANCER, V13, P788, DOI 10.1038/nrc3603; Rashid OM, 2013, SURGERY, V153, P771, DOI 10.1016/j.surg.2013.02.002; Ren T, 2017, ONCOGENE, V36, P5897, DOI 10.1038/onc.2017.167; Rocken M, 2010, J CLIN INVEST, V120, P1800, DOI 10.1172/JCI43424; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Singletary SE, 2003, ONCOLOGIST, V8, P241, DOI 10.1634/theoncologist.8-3-241; SLOOTER GD, 1995, BRIT J SURG, V82, P129, DOI 10.1002/bjs.1800820144; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043; Wen SW, 2016, CANCER RES, V76, P6816, DOI 10.1158/0008-5472.CAN-16-0868; Xu H, 2015, SCI REP-UK, V5, DOI 10.1038/srep16516; Zhang Q, 2013, CARCINOGENESIS, V34, P962, DOI 10.1093/carcin/bgt027; Zhang ZC, 2017, CANCER LETT, V397, P33, DOI 10.1016/j.canlet.2017.03.004	33	86	89	4	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2018	37	47					6105	6118		10.1038/s41388-018-0391-0	http://dx.doi.org/10.1038/s41388-018-0391-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HB2PG	29991801	hybrid, Green Published			2022-12-17	WOS:000450883000001
J	Damsky, WE; Bosenberg, M				Damsky, W. E.; Bosenberg, M.			Melanocytic nevi and melanoma: unraveling a complex relationship	ONCOGENE			English	Review							ONCOGENE-INDUCED SENESCENCE; TERT PROMOTER MUTATIONS; CUTANEOUS MALIGNANT-MELANOMA; DNA-DAMAGE-RESPONSE; TUMOR-INFILTRATING LYMPHOCYTES; STRESS-INDUCED AUTOPHAGY; GENOME-WIDE ASSOCIATION; CELLULAR SENESCENCE; BRAF MUTATIONS; SPONTANEOUS REGRESSION	Approximately 33% of melanomas are derived directly from benign, melanocytic nevi. Despite this, the vast majority of melanocytic nevi, which typically form as a result of BRAFV600E-activating mutations, will never progress to melanoma. Herein, we synthesize basic scientific insights and data from mouse models with common observations from clinical practice to comprehensively review melanocytic nevus biology. In particular, we focus on the mechanisms by which growth arrest is established after BRAFV600E mutation. Means by which growth arrest can be overcome and how melanocytic nevi relate to melanoma are also considered. Finally, we present a new conceptual paradigm for understanding the growth arrest of melanocytic nevi in vivo termed stable clonal expansion. This review builds upon the canonical hypothesis of oncogene-induced senescence in growth arrest and tumor suppression in melanocytic nevi and melanoma.	[Damsky, W. E.; Bosenberg, M.] Yale Sch Med, Dept Dermatol, 333 Cedar St,LCI 501,POB 208059, New Haven, CT 06520 USA; [Bosenberg, M.] Yale Sch Med, Dept Pathol, New Haven, CT USA	Yale University; Yale University	Damsky, WE; Bosenberg, M (corresponding author), Yale Sch Med, Dept Dermatol, 333 Cedar St,LCI 501,POB 208059, New Haven, CT 06520 USA.	william.damsky@yale.edu; marcus.bosenberg@yale.edu			Melanoma Research Alliance; Melanoma Research Foundation; Hervey Family Foundation;  [R01 CA196660];  [P50 CA121974];  [P01CA128814]; NATIONAL CANCER INSTITUTE [P50CA121974, P01CA128814, R01CA196660] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007016] Funding Source: NIH RePORTER	Melanoma Research Alliance; Melanoma Research Foundation; Hervey Family Foundation; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We would like to acknowledge the following funding sources: R01 CA196660, P50 CA121974, P01CA128814, the Melanoma Research Alliance, the Melanoma Research Foundation and the Hervey Family Foundation (to MB).	Abildgaard C, 2015, TRENDS MOL MED, V21, P164, DOI 10.1016/j.molmed.2014.12.007; Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; AHMED AA, 1995, AM J DERMATOPATH, V17, P222, DOI 10.1097/00000372-199506000-00002; AHMED I, 1990, J AM ACAD DERMATOL, V22, P727, DOI 10.1016/0190-9622(90)70098-3; Aird KM, 2013, CELL REP, V3, P1252, DOI 10.1016/j.celrep.2013.03.004; Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Alaibac M, 2003, J AM ACAD DERMATOL, V49, P1020, DOI 10.1016/S0190-9622(03)02482-4; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Annessi G, 2001, J AM ACAD DERMATOL, V45, P77, DOI 10.1067/mjd.2001.114580; Aoude LG, 2015, PIGM CELL MELANOMA R, V28, P148, DOI 10.1111/pcmr.12333; Aoude LG, 2015, JNCI-J NATL CANCER I, V107, P1, DOI DOI 10.1093/JNCI/DJU40825505254; Aouthmany M, 2012, J AM ACAD DERMATOL, V67, P582, DOI 10.1016/j.jaad.2011.11.937; Arumi-Uria M, 2003, MODERN PATHOL, V16, P764, DOI 10.1097/01.MP.0000082394.91761.E5; Ascierto ML, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00152; Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105; Baek KH, 2017, METHODS MOL BIOL, V1534, P185, DOI 10.1007/978-1-4939-6670-7_18; BAKER MA, 1973, LANCET, V1, P1117; Bandyopadhyay D, 2007, AGING CELL, V6, P577, DOI 10.1111/j.1474-9726.2007.00308.x; Barnhill R.L., 2014, PATHOLOGY MELANOCYTI; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bastian BC, 2003, ARCH DERMATOL, V139, P667, DOI 10.1001/archderm.139.5.667; Bastian BC, 2003, ONCOGENE, V22, P3081, DOI 10.1038/sj.onc.1206463; Bastian BC, 2003, AM J DERMATOPATH, V25, P83, DOI 10.1097/00000372-200302000-00019; Bastian BC, 2000, AM J PATHOL, V157, P967, DOI 10.1016/S0002-9440(10)64609-3; Bastian BC, 2014, ANNU REV PATHOL-MECH, V9, P239, DOI 10.1146/annurev-pathol-012513-104658; Bataille V, 2007, CANCER EPIDEM BIOMAR, V16, P1499, DOI 10.1158/1055-9965.EPI-07-0152; Bauer J, 2003, PIGM CELL RES, V16, P297, DOI 10.1034/j.1600-0749.2003.00047.x; Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Bevona C, 2003, ARCH DERMATOL, V139, P1620, DOI 10.1001/archderm.139.12.1620; Bishop JAN, 2000, J INVEST DERMATOL, V114, P28, DOI 10.1046/j.1523-1747.2000.00823.x; BLACK WC, 1988, CANCER, V62, P163, DOI 10.1002/1097-0142(19880701)62:1<163::AID-CNCR2820620126>3.0.CO;2-N; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bogdan I, 2003, MELANOMA RES, V13, P213, DOI 10.1097/00008390-200304000-00018; Botella-Estrada R, 2015, AM J DERMATOPATH, V37, P376, DOI 10.1097/DAD.0000000000000205; Brewer JD, 2015, INT J DERMATOL, V54, pE287, DOI 10.1111/ijd.12564; Brito MB, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00166; Calado RT, 2013, SEMIN HEMATOL, V50, P165, DOI 10.1053/j.seminhematol.2013.03.030; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653; Cantor JR, 2012, CANCER DISCOV, V2, P881, DOI 10.1158/2159-8290.CD-12-0345; CARR J, 1994, BRIT J DERMATOL, V131, P72, DOI 10.1111/j.1365-2133.1994.tb08460.x; Ceol CJ, 2011, NATURE, V471, P513, DOI 10.1038/nature09806; Chai E, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12195; Chan MP, 2010, J CUTAN PATHOL, V37, P843, DOI 10.1111/j.1600-0560.2009.01491.x; Chandeck C, 2010, ADV ANAT PATHOL, V17, P42, DOI 10.1097/PAP.0b013e3181c66f4e; Chen B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042598; Chen HS, 2015, MOL CELL, V59, P719, DOI 10.1016/j.molcel.2015.07.011; Cheung M, 2008, CANCER RES, V68, P3429, DOI 10.1158/0008-5472.CAN-07-5867; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Cisowski J, 2016, ONCOGENE, V35, P1328, DOI 10.1038/onc.2015.186; CLARK WH, 1984, HUM PATHOL, V15, P1147, DOI 10.1016/S0046-8177(84)80310-X; Conway K, 2011, PIGM CELL MELANOMA R, V24, P352, DOI 10.1111/j.1755-148X.2011.00828.x; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; CURRAN RC, 1976, J PATHOL, V119, P135, DOI 10.1002/path.1711190303; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Dadzie OE, 2009, BRIT J DERMATOL, V160, P368, DOI 10.1111/j.1365-2133.2008.08887.x; Dai DL, 2005, J CLIN ONCOL, V23, P1473, DOI 10.1200/JCO.2005.07.168; Damsky WE, 2014, ONCOGENE, V33, P2413, DOI 10.1038/onc.2013.194; Damsky W, 2015, CANCER CELL, V27, P41, DOI 10.1016/j.ccell.2014.11.014; Damsky WE, 2011, CANCER CELL, V20, P741, DOI 10.1016/j.ccr.2011.10.030; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; de Snoo FA, 2005, CANCER LETT, V230, P153, DOI 10.1016/j.canlet.2004.12.033; Deichmann M, 2002, BRIT J CANCER, V87, P1431, DOI 10.1038/sj.bjc.6600653; Demunter A, 2001, J INVEST DERMATOL, V117, P1483, DOI 10.1046/j.0022-202x.2001.01601.x; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; Dhawan P, 2002, CANCER RES, V62, P7335; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Di Mitri D, 2014, NATURE, V515, P134, DOI 10.1038/nature13638; Duffy K, 2012, J AM ACAD DERMATOL, V67, P1, DOI DOI 10.1016/J.JAAD.2012.03.013; Eder J, 2014, BRIT J DERMATOL, V171, P1415, DOI 10.1111/bjd.13132; English DR, 2006, CANCER CAUSE CONTROL, V17, P103, DOI 10.1007/s10552-005-0425-0; Evdokimova V, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003184; Ezzedine K, 2015, LANCET, V386, P74, DOI 10.1016/S0140-6736(14)60763-7; Falchi M, 2009, NAT GENET, V41, P915, DOI 10.1038/ng.410; Famenini S, 2015, J AM ACAD DERMATOL, V72, P78, DOI 10.1016/j.jaad.2014.09.030; Ferrara G, 2013, DERMATOL CLIN, V31, P589, DOI 10.1016/j.det.2013.06.012; Ferringer T, 2012, DERMATOL CLIN, V30, P567, DOI 10.1016/j.det.2012.06.007; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Florell SR, 2005, J CUTAN PATHOL, V32, P45, DOI 10.1111/j.0303-6987.2005.00242.x; Florell SR, 2004, J INVEST DERMATOL, V123, P576, DOI 10.1111/j.0022-202X.2004.23312.x; Fox JC, 2011, ARCH PATHOL LAB MED, V135, P842, DOI 10.1043/2010-0429-RAR.1; Fumagalli M, 2012, NAT CELL BIOL, V14, P355, DOI 10.1038/ncb2466; Funk JO, 1998, J CUTAN PATHOL, V25, P291, DOI 10.1111/j.1600-0560.1998.tb01748.x; Gandini S, 2005, EUR J CANCER, V41, P28, DOI 10.1016/j.ejca.2004.10.015; Gao L, 2014, J INVEST DERMATOL, V134, P2957, DOI 10.1038/jid.2014.270; Gazzaniga S, 2007, J INVEST DERMATOL, V127, P2031, DOI 10.1038/sj.jid.5700827; Gerland LM, 2003, EXP GERONTOL, V38, P887, DOI 10.1016/S0531-5565(03)00132-3; Glaessl A, 1999, ARCH DERMATOL RES, V291, P81, DOI 10.1007/s004030050387; Glatz K, 2010, AM J DERMATOPATH, V32, P643, DOI 10.1097/DAD.0b013e3181d7ce6f; Godwin LS, 2014, CURR PROTOC CELL BIO, V63; Goel VK, 2009, ONCOGENE, V28, P2289, DOI 10.1038/onc.2009.95; GOLDGAR DE, 1991, J NATL CANCER I, V83, P1726, DOI 10.1093/jnci/83.23.1726; Gomes CBF, 2016, AM J PATHOL, V186, P1427, DOI 10.1016/j.ajpath.2016.01.020; Goodson AG, 2011, DERMATOL SURG, V37, P1620, DOI 10.1111/j.1524-4725.2011.02097.x; Goodson AG, 2010, DERMATOL SURG, V36, P1087, DOI 10.1111/j.1524-4725.2010.01589.x; GOOVAERTS G, 1988, AM J DERMATOPATH, V10, P20, DOI 10.1097/00000372-198802000-00003; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283; GUTTERMAN JU, 1973, LANCET, V1, P1208; Haenssle HA, 2016, JAMA DERMATOL, V152, P291, DOI 10.1001/jamadermatol.2015.3775; Haferkamp S, 2009, J INVEST DERMATOL, V129, P1983, DOI 10.1038/jid.2009.5; Hafner C, 2009, J INVEST DERMATOL, V129, P2730, DOI 10.1038/jid.2009.146; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hanna SC, 2013, J CLIN INVEST, V123, P2078, DOI 10.1172/JCI66715; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Harada M, 1997, J INVEST DERMATOL, V109, P656, DOI 10.1111/1523-1747.ep12337678; Harland M, 2016, FAM CANCER, V15, P139, DOI 10.1007/s10689-015-9841-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTRUP N, 1991, AM J DERMATOPATH, V13, P378, DOI 10.1097/00000372-199108000-00009; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Heidenreich B, 2014, CURR OPIN GENET DEV, V24, P30, DOI 10.1016/j.gde.2013.11.005; Held M, 2010, PIGM CELL MELANOMA R, V23, P481, DOI 10.1111/j.1755-148X.2010.00726.x; Helmbold P, 2012, J INVEST DERMATOL, V132, P687, DOI 10.1038/jid.2011.380; HERLYN M, 1987, LAB INVEST, V56, P461; HERLYN M, 1985, CANCER RES, V45, P5670; Herranz N, 2015, NAT CELL BIOL, V17, P1205, DOI 10.1038/ncb3225; Hewitt G, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1708; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Horn S, 2013, SCIENCE, V339, P959, DOI 10.1126/science.1230062; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Hui P, 2001, J CUTAN PATHOL, V28, P140, DOI 10.1034/j.1600-0560.2001.028003140.x; Hussein MR, 2006, J CLIN PATHOL, V59, P316, DOI 10.1136/jcp.2005.028860; Iannello A, 2013, J EXP MED, V210, P2057, DOI 10.1084/jem.20130783; Ivanov A, 2013, J CELL BIOL, V202, P129, DOI 10.1083/jcb.201212110; Jimenez-Gallo D, 2013, JAMA DERMATOL, V149, P624, DOI 10.1001/jamadermatol.2013.263; Juan J, 2014, GENE DEV, V28, P561, DOI 10.1101/gad.233627.113; Kakavand H, 2014, PATHOLOGY, V46, P193, DOI 10.1097/PAT.0000000000000077; Kalialis LV, 2009, MELANOMA RES, V19, P275, DOI 10.1097/CMR.0b013e32832eabd5; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; Kampilafkos P, 2015, AM J DERMATOPATH, V37, P138, DOI 10.1097/DAD.0b013e31828a2d54; KANG SW, 1993, J CUTAN PATHOL, V20, P126, DOI 10.1111/j.1600-0560.1993.tb00228.x; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Kanter-Lewensohn L, 2000, GROWTH FACTORS, V17, P193, DOI 10.3109/08977190009001068; Kantrow SM, 2007, J CUTAN PATHOL, V34, P593, DOI 10.1111/j.1600-0560.2006.00675.x; Kaplon J, 2013, NATURE, V498, P109, DOI 10.1038/nature12154; Kapoor A, 2010, NATURE, V468, P1105, DOI 10.1038/nature09590; Karbowniczek M, 2008, J INVEST DERMATOL, V128, P980, DOI 10.1038/sj.jid.5701074; Karim RZ, 2009, INT J SURG PATHOL, V17, P361, DOI 10.1177/1066896909336177; Karram S, 2013, AM J DERMATOPATH, V35, P412, DOI 10.1097/DAD.0b013e31826db181; Katlinskaya YV, 2016, CELL REP, V15, P171, DOI 10.1016/j.celrep.2016.03.006; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kennedy AL, 2011, MOL CELL, V42, P36, DOI 10.1016/j.molcel.2011.02.020; Khosravi S, 2015, J INVEST DERMATOL, V135, P1358, DOI 10.1038/jid.2014.552; Kidger AM, 2016, SEMIN CELL DEV BIOL, V50, P125, DOI 10.1016/j.semcdb.2016.01.009; King R, 2009, MODERN PATHOL, V22, P611, DOI 10.1038/modpathol.2009.22; Kittler H, 2000, ARCH DERMATOL, V136, P316, DOI 10.1001/archderm.136.3.316; Koh CM, 2015, J CLIN INVEST, V125, P2109, DOI 10.1172/JCI79134; Kolesnichenko M, 2012, CELL CYCLE, V11, P2391, DOI 10.4161/cc.20683; Kraehn GM, 2001, BRIT J CANCER, V84, P72, DOI 10.1054/bjoc.2000.1535; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Kuzbicki L, 2013, MELANOMA RES, V23, P8, DOI 10.1097/CMR.0b013e32835d5d6f; Laberge RM, 2015, NAT CELL BIOL, V17, P1049, DOI 10.1038/ncb3195; LaPak KM, 2014, MOL CANCER RES, V12, P167, DOI 10.1158/1541-7786.MCR-13-0350; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Laugier F, 2015, ONCOTARGET, V6, P28120, DOI 10.18632/oncotarget.4866; Lazova R, 2012, CLIN CANCER RES, V18, P370, DOI 10.1158/1078-0432.CCR-11-1282; Lazova R, 2010, J CUTAN PATHOL, V37, P256, DOI 10.1111/j.1600-0560.2009.01359.x; Lee BY, 2006, AGING CELL, V5, P187, DOI 10.1111/j.1474-9726.2006.00199.x; Lee HJ, 2000, J AM ACAD DERMATOL, V42, P936, DOI 10.1016/S0190-9622(00)90277-9; Lee S, 2016, PIGM CELL MELANOMA R, V29, P391, DOI 10.1111/pcmr.12471; Lee YJ, 2014, NATURE, V510, P547, DOI 10.1038/nature13267; Li MX, 2013, PROTEOMICS, V13, P2585, DOI 10.1002/pmic.201200298; Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033; Libon F, 2013, CLIN EXP DERMATOL, V38, P276, DOI 10.1111/j.1365-2230.2012.04452.x; Liko D, 2015, J MOL MED, V93, P1061, DOI 10.1007/s00109-015-1326-7; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin WM, 2015, J AM ACAD DERMATOL, V72, P54, DOI 10.1016/j.jaad.2014.09.028; Lindelof B, 2000, BRIT J DERMATOL, V143, P513, DOI 10.1111/j.1365-2133.2000.03703.x; Liu H, 2014, AUTOPHAGY, V10, P372, DOI 10.4161/auto.27163; Liu H, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005864; LIU L, 1995, ONCOGENE, V11, P405; Liu SJ, 2012, LAB INVEST, V92, P1084, DOI 10.1038/labinvest.2012.62; Lott JP, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12322; Lucas CR, 2003, J AM ACAD DERMATOL, V48, P663, DOI 10.1067/mjd.2003.283; Luther H, 1996, ARCH DERMATOL, V132, P1473, DOI 10.1001/archderm.132.12.1473; Lyle S, 2000, MODERN PATHOL, V13, P52, DOI 10.1038/modpathol.3880009; Ma XH, 2014, J CLIN INVEST, V124, P1406, DOI 10.1172/JCI70454; MacGregor S, 2011, NAT GENET, V43, P1114, DOI 10.1038/ng.958; MACKIE RM, 1985, BRIT J DERMATOL, V113, P167, DOI 10.1111/j.1365-2133.1985.tb02060.x; Maggi LB, 2014, BBA-MOL BASIS DIS, V1842, P831, DOI 10.1016/j.bbadis.2014.01.016; Maida Y, 2015, CANCER SCI, V106, P1486, DOI 10.1111/cas.12806; MANCIANTI ML, 1988, J INVEST DERMATOL, V90, P134, DOI 10.1111/1523-1747.ep12462099; Mannava S, 2013, AM J PATHOL, V182, P142, DOI 10.1016/j.ajpath.2012.09.011; Mannavola F, 2016, EXPERT REV CLIN IMMU, V12, P79, DOI 10.1586/1744666X.2016.1100965; Martincorena I, 2015, SCIENCE, V348, P880, DOI 10.1126/science.aaa6806; Martinez-Cardus A, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.06.20; Masaki T, 2014, PIGM CELL MELANOMA R, V27, P454, DOI 10.1111/pcmr.12226; Masoumi-Moghaddam S, 2014, CANCER METAST REV, V33, P695, DOI 10.1007/s10555-014-9497-1; Masui K, 2014, TRENDS ENDOCRIN MET, V25, P364, DOI 10.1016/j.tem.2014.04.002; Matin RN, 2008, AM J TRANSPLANT, V8, P1891, DOI 10.1111/j.1600-6143.2008.02326.x; McArthur GA, 2012, J CLIN ONCOL, V30, P1628, DOI 10.1200/JCO.2011.39.1938; McClenahan P, 2014, JAMA DERMATOL, V150, P1079, DOI 10.1001/jamadermatol.2014.436; Meng XX, 2015, CLIN EXP PHARMACOL P, V42, P811, DOI 10.1111/1440-1681.12436; Menzies SW, 2011, ARCH DERMATOL, V147, P655, DOI 10.1001/archdermatol.2011.133; Micevic G, 2016, CELL REP, V14, P2180, DOI 10.1016/j.celrep.2016.02.010; Michaloglou C, 2008, ONCOGENE, V27, P877, DOI 10.1038/sj.onc.1210704; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Miracco C, 2002, BRIT J DERMATOL, V146, P399, DOI 10.1046/j.1365-2133.2002.04600.x; Miracco C, 2010, HUM PATHOL, V41, P503, DOI 10.1016/j.humpath.2009.09.004; Mirza AM, 2004, MOL CELL BIOL, V24, P10868, DOI 10.1128/MCB.24.24.10868-10881.2004; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Mocellin S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008955.pub2; Montes M, 2016, FEBS J, V283, P2414, DOI 10.1111/febs.13679; Montes M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7967; MORTON DL, 1970, SURGERY, V68, P158; Muthusamy V, 2006, CANCER RES, V66, P11187, DOI 10.1158/0008-5472.CAN-06-1274; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Narita M, 2011, SCIENCE, V332, P966, DOI 10.1126/science.1205407; Nasr MR, 2008, AM J DERMATOPATH, V30, P117, DOI 10.1097/DAD.0b013e3181624054; NEWBOLD RF, 1982, NATURE, V299, P633, DOI 10.1038/299633a0; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; Nildtovic D, 2014, BBA-GEN SUBJECTS, V1840, P2471, DOI 10.1016/j.bbagen.2014.01.031; Nowsheen S., 2012, Experimental Oncology, V34, P243; O'Rourke EA, 2013, AM J DERMATOPATH, V35, P30, DOI 10.1097/DAD.0b013e3182587ef8; Oba J, 2011, J DERMATOL SCI, V62, P116, DOI 10.1016/j.jdermsci.2011.02.011; OBRIEN W, 1986, P NATL ACAD SCI USA, V83, P8659; Papp T, 2005, MELANOMA RES, V15, P401, DOI 10.1097/00008390-200510000-00008; Pathak S, 2000, INT J ONCOL, V17, P1219; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Pedersen M, 2014, PIGM CELL MELANOMA R, V27, P1162, DOI 10.1111/pcmr.12293; Pennoyer JW, 1997, J AM ACAD DERMATOL, V36, P378, DOI 10.1016/S0190-9622(97)80212-5; Perez LJ, 2006, J CUTAN PATHOL, V33, P139, DOI 10.1111/j.0303-6987.2006.00388.x; Perez-Mancera PA, 2014, NAT REV CANCER, V14, P547, DOI 10.1038/nrc3773; Perier-Muzet M, 2014, J INVEST DERMATOL, V134, P1351, DOI 10.1038/jid.2013.462; Pins A, 2015, HUM PATHOL, V46, P239, DOI 10.1016/j.humpath.2014.10.015; Pluquet O, 2015, AM J PHYSIOL-CELL PH, V308, pC415, DOI 10.1152/ajpcell.00334.2014; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Populo H, 2015, EXPERT OPIN THER TAR, V19, P733, DOI 10.1517/14728222.2015.1045416; Poynter JN, 2006, MELANOMA RES, V16, P267, DOI 10.1097/01.cmr.0000222600.73179.f3; Quijano C, 2012, CELL CYCLE, V11, P1383, DOI 10.4161/cc.19800; Radhi J M, 1999, J Cutan Med Surg, V3, P293; Ramirez Ruben D., 1999, Neoplasia (New York), V1, P42, DOI 10.1038/sj.neo.7900004; RHODES AR, 1983, J AM ACAD DERMATOL, V9, P563, DOI 10.1016/S0190-9622(83)70171-4; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Robbins HA, 2015, J INVEST DERMATOL, V135, P2657, DOI 10.1038/jid.2015.312; Robinson WA, 1998, MELANOMA RES, V8, P499, DOI 10.1097/00008390-199812000-00004; Robles-Espinoza CD, 2014, NAT GENET, V46, P478, DOI 10.1038/ng.2947; Rodic N, 2015, J CUTAN PATHOL, V42, P807, DOI 10.1111/cup.12564; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Roh MR, 2016, J INVEST DERMATOL, V136, P1002, DOI 10.1016/j.jid.2016.01.024; Roh MR, 2015, PIGM CELL MELANOMA R, V28, P661, DOI 10.1111/pcmr.12412; Romano E, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0059-z; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Rubegni P, 2007, SKIN RES TECHNOL, V13, P143, DOI 10.1111/j.1600-0846.2007.00180.x; Rudolph P, 1998, HUM PATHOL, V29, P1480, DOI 10.1016/S0046-8177(98)90019-3; Rudolph P, 2000, AM J PATHOL, V156, P1425, DOI 10.1016/S0002-9440(10)65011-0; SAGEBIEL RW, 1993, J INVEST DERMATOL, V100, pS322, DOI 10.1111/1523-1747.ep12470218; SAGER R, 1991, ENVIRON HEALTH PERSP, V93, P59, DOI 10.2307/3431170; Sanchez-Sosa S, 2013, CLIN EXP IMMUNOL, V173, P179, DOI 10.1111/cei.12096; Sarkar D, 2015, EPIGENETICS-US, V10, P103, DOI 10.1080/15592294.2014.1003746; Saroufim M, 2014, AM J DERMATOPATH, V36, P68, DOI 10.1097/DAD.0b013e318293f355; Schaffer JV, 2015, CLIN DERMATOL, V33, P368, DOI 10.1016/j.clindermatol.2014.12.015; Scortegagna M, 2014, ONCOGENE, V33, P4330, DOI 10.1038/onc.2013.383; Scortegagna M, 2015, CANCER RES, V75, P1399, DOI 10.1158/0008-5472.CAN-14-2785; Scurr LL, 2010, CELL, V141, P717, DOI 10.1016/j.cell.2010.04.021; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shain AH, 2016, NAT REV CANCER, V16, P345, DOI 10.1038/nrc.2016.37; Shain AH, 2015, NEW ENGL J MED, V373, P1926, DOI 10.1056/NEJMoa1502583; Shalapour S, 2015, J CLIN INVEST, V125, P3347, DOI 10.1172/JCI80007; Shi JX, 2014, NAT GENET, V46, P482, DOI 10.1038/ng.2941; Shitara D, 2015, BRIT J DERMATOL, V173, P671, DOI 10.1111/bjd.13829; Shitara D, 2014, AM J CLIN PATHOL, V142, P485, DOI 10.1309/AJCP4L5CJGKTJVDD; Slominski A, 2014, ARCH BIOCHEM BIOPHYS, V563, P79, DOI 10.1016/j.abb.2014.06.030; SOYER HP, 1989, DERMATOLOGICA, V179, P3, DOI 10.1159/000248090; Spain L, 2016, EXPERT OPIN PHARMACO, V17, P1031, DOI 10.1517/14656566.2016.1168805; Sprecher E, 1999, J CUTAN PATHOL, V26, P72, DOI 10.1111/j.1600-0560.1999.tb01805.x; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; STEGMAIER OC, 1959, J INVEST DERMATOL, V32, P413, DOI 10.1038/jid.1959.70; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; STOLZ W, 1991, J INVEST DERMATOL, V97, P903, DOI 10.1111/1523-1747.ep12491659; Strazzula L, 2014, J AM ACAD DERMATOL, V71, P1234, DOI 10.1016/j.jaad.2014.07.026; Sugianto JZ, 2016, SEMIN DIAGN PATHOL, V33, P219, DOI 10.1053/j.semdp.2016.04.006; Suram A, 2012, EMBO J, V31, P2839, DOI 10.1038/emboj.2012.132; Sviderskaya EV, 2002, JNCI-J NATL CANCER I, V94, P446; Talve L, 1997, INT J CANCER, V74, P255, DOI 10.1002/(SICI)1097-0215(19970620)74:3<255::AID-IJC4>3.0.CO;2-Y; Tan JM, 2015, JAMA DERMATOL, V151, P417, DOI 10.1001/jamadermatol.2014.3775; Teulings HE, 2015, J CLIN ONCOL, V33, P773, DOI 10.1200/JCO.2014.57.4756; Theodosakis N, 2015, MOL CANCER THER, V14, P1680, DOI 10.1158/1535-7163.MCT-15-0080; Tomasetti C, 2015, SCIENCE, V347, P78, DOI 10.1126/science.1260825; Tran SL, 2012, J INVEST DERMATOL, V132, P2226, DOI 10.1038/jid.2012.126; Tronnier M, 1997, BRIT J DERMATOL, V137, P534, DOI 10.1111/j.1365-2133.1997.tb03782.x; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; Tsao H, 2003, J AM ACAD DERMATOL, V49, P865, DOI 10.1016/S0190-9622(03)02473-3; Tsao H, 2003, ARCH DERMATOL, V139, P282, DOI 10.1001/archderm.139.3.282; Tschandl P, 2016, BRIT J DERMATOL, V174, P364, DOI 10.1111/bjd.14323; Tschandl P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069639; Uhlenhake Elizabeth E, 2013, Dermatol Online J, V19, P18184; Uribe P, 2006, J INVEST DERMATOL, V126, P161, DOI 10.1038/sj.jid.5700011; Vagner J, 2015, HISTOPATHOLOGY, V66, P747, DOI 10.1111/his.12501; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; VANDUINEN CM, 1994, HISTOPATHOLOGY, V24, P33; Vazquez F, 2013, CANCER CELL, V23, P287, DOI 10.1016/j.ccr.2012.11.020; Viros A, 2014, NATURE, V511, P478, DOI 10.1038/nature13298; Vredeveld LCW, 2012, GENE DEV, V26, P1055, DOI 10.1101/gad.187252.112; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Wajapeyee N, 2010, CELL, V141, P746, DOI 10.1016/j.cell.2010.05.014; Walesch SK, 2015, CANCERS, V7, P1233, DOI 10.3390/cancers7030834; Wang T, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1052929; Wang XY, 2015, CANCER RES, V75, P5001, DOI 10.1158/0008-5472.CAN-15-0563; Wasco MJ, 2008, HUM PATHOL, V39, P1614, DOI 10.1016/j.humpath.2008.03.007; Wei S, 1999, CANCER RES, V59, P1539; Whiteman DC, 2002, INT J CANCER, V99, P63, DOI 10.1002/ijc.10294; Wurm EMT, 2012, EXP DERMATOL, V21, P676, DOI 10.1111/j.1600-0625.2012.01543.x; Xu Y, 2012, BRIT J CANCER, V106, P553, DOI 10.1038/bjc.2011.568; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yeh I, 2013, JNCI-J NATL CANCER I, V105, P917, DOI 10.1093/jnci/djt119; Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709; Yu QJ, 2015, CELL REP, V11, P785, DOI 10.1016/j.celrep.2015.03.069; Zampino MR, 2006, DERMATOL SURG, V32, P1497, DOI 10.1111/j.1524-4725.2006.32362.x; Zeff RA, 1997, J AM ACAD DERMATOL, V37, P620, DOI 10.1016/S0190-9622(97)70181-6; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5; Zhuang D, 2008, ONCOGENE, V27, P6623, DOI 10.1038/onc.2008.258; Zhuang L, 2005, J CLIN PATHOL, V58, P1163, DOI 10.1136/jcp.2005.025957; Zhuang LQ, 2009, HISTOPATHOLOGY, V54, P462, DOI 10.1111/j.1365-2559.2009.03242.x	326	86	91	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5771	5792		10.1038/onc.2017.189	http://dx.doi.org/10.1038/onc.2017.189			22	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28604751	Green Accepted			2022-12-17	WOS:000413292900001
J	Combes, G; Alharbi, I; Braga, LG; Elowe, S				Combes, G.; Alharbi, I.; Braga, L. G.; Elowe, S.			Playing polo during mitosis: PLK1 takes the lead	ONCOGENE			English	Review							SPINDLE ASSEMBLY CHECKPOINT; CHROMOSOMAL PASSENGER COMPLEX; H3 KINASE HASPIN; AURORA B KINASE; CELL-DIVISION; KINETOCHORE ATTACHMENT; MICROTUBULE-BINDING; PROTEIN BUBR1; MITOTIC ENTRY; PHOSPHORYLATION	Polo-like kinase 1 (PLK1), the prototypical member of the polo-like family of serine/threonine kinases, is a pivotal regulator of mitosis and cytokinesis in eukaryotes. Many layers of regulation have evolved to target PLK1 to different subcellular structures and to its various mitotic substrates in line with its numerous functions during mitosis. Collective work is starting to illuminate an important set of substrates for PLK1: the mitotic kinases that together ensure the fidelity of the cell division process. Amongst these, recent developments argue that PLK1 regulates the activity of the histone kinases Aurora B and Haspin to define centromere identity, of MPS1 to initiate spindle checkpoint signaling, and of BUB1 and its pseudokinase paralog BUBR1 to coordinate spindle checkpoint activation and inactivation. Here, we review the recent work describing the regulation of these kinases by PLK1. We highlight common themes throughout and argue that a major mitotic function of PLK1 is as a master regulator of these key kinases.	[Combes, G.; Alharbi, I.; Braga, L. G.; Elowe, S.] Univ Laval, Fac Med, Program Mol & Cellular Biol, Quebec City, PQ, Canada; [Combes, G.; Alharbi, I.; Braga, L. G.; Elowe, S.] CHU Quebec, Res Ctr, Axe Reprod Mother & Youth Hlth, Quebec City, PQ, Canada; [Elowe, S.] Univ Laval, Dept Pediat, Fac Med, Quebec City, PQ, Canada	Laval University; Laval University; Laval University	Elowe, S (corresponding author), Univ Laval, Dept Pediat, 2705 Blvd Laurier,T3-67, Quebec City, PQ G1V 4G2, Canada.	Sabine.Elowe@crchuq.ulaval.ca	Combes, Guillaume/ABA-1771-2021	Combes, Guillaume/0000-0002-6202-1304; Elowe, Sabine/0000-0002-1212-7039				Archambault V, 2015, ONCOGENE, V34, P4799, DOI 10.1038/onc.2014.451; Archambault V, 2008, GENE DEV, V22, P2707, DOI 10.1101/gad.486808; Archambault V, 2009, NAT REV MOL CELL BIO, V10, P265, DOI 10.1038/nrm2653; Asghar A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9364; Asteriti IA, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00283; Burkard ME, 2007, P NATL ACAD SCI USA, V104, P4383, DOI 10.1073/pnas.0701140104; Burkard ME, 2012, ACS CHEM BIOL, V7, P978, DOI 10.1021/cb200551p; Burton JL, 2007, GENE DEV, V21, P655, DOI 10.1101/gad.1511107; Carmena M, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00073; Carmena M, 2014, OPEN BIOL, V4, DOI 10.1098/rsob.140162; Carmena M, 2012, NAT REV MOL CELL BIO, V13, P789, DOI 10.1038/nrm3474; Carmena M, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001250; Casenghi M, 2003, DEV CELL, V5, P113, DOI 10.1016/S1534-5807(03)00193-X; Cheeseman IM, 2004, GENE DEV, V18, P2255, DOI 10.1101/gad.1234104; Chmielewska AE, 2016, CELL CYCLE, V15, P740, DOI 10.1080/15384101.2016.1148842; Chu YJ, 2011, J MOL CELL BIOL, V3, P260, DOI 10.1093/jmcb/mjq037; Ciceri P, 2014, NAT CHEM BIOL, V10, P305, DOI 10.1038/nchembio.1471; Colnaghi R, 2010, J BIOL CHEM, V285, P22592, DOI 10.1074/jbc.M109.065003; Conde C, 2013, EMBO J, V32, P1761, DOI 10.1038/emboj.2013.109; Dai J, 2006, DEV CELL, V11, P741, DOI 10.1016/j.devcel.2006.09.018; Dai J, 2009, J CELL SCI, V122, P4168, DOI 10.1242/jcs.054122; de Carcer G, 2011, CELL CYCLE, V10, P2255, DOI 10.4161/cc.10.14.16494; Desai A, 2003, GENE DEV, V17, P2421, DOI 10.1101/gad.1126303; Di Fiore B, 2015, DEV CELL, V32, P358, DOI 10.1016/j.devcel.2015.01.003; Diaz-Martinez LA, 2015, J BIOL CHEM, V290, P2431, DOI 10.1074/jbc.M114.616490; Dou Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018793; Edgerton H, 2016, J CELL BIOL, V213, P651, DOI 10.1083/jcb.201511080; Elowe S, 2007, GENE DEV, V21, P2205, DOI 10.1101/gad.436007; Elowe S, 2011, MOL CELL BIOL, V31, P3085, DOI 10.1128/MCB.05326-11; Elowe S, 2010, J CELL SCI, V123, P84, DOI 10.1242/jcs.056507; Ember SWJ, 2014, ACS CHEM BIOL, V9, P1160, DOI 10.1021/cb500072z; Espert A, 2014, J CELL BIOL, V206, P833, DOI 10.1083/jcb.201406109; Espeut J, 2015, CELL REP, V12, P58, DOI 10.1016/j.celrep.2015.05.039; Eswaran J, 2009, P NATL ACAD SCI USA, V106, P20198, DOI 10.1073/pnas.0901989106; Etemad B, 2016, CURR OPIN CELL BIOL, V39, P101, DOI 10.1016/j.ceb.2016.02.016; Fisher D, 2012, J CELL SCI, V125, P4703, DOI 10.1242/jcs.106351; Foley EA, 2011, NAT CELL BIOL, V13, P1265, DOI 10.1038/ncb2327; Fu Z, 2008, NAT CELL BIOL, V10, P1076, DOI 10.1038/ncb1767; Garcia-Alvarez B, 2007, P NATL ACAD SCI USA, V104, P3107, DOI 10.1073/pnas.0609131104; Ghenoiu C, 2013, MOL CELL, V52, P734, DOI 10.1016/j.molcel.2013.10.002; Goto H, 2006, NAT CELL BIOL, V8, P180, DOI 10.1038/ncb1350; Grallert A, 2015, NATURE, V517, P94, DOI 10.1038/nature14019; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; Hegarat N, 2016, BIOESSAYS, V38, P627, DOI 10.1002/bies.201600057; Hennrich ML, 2013, J PROTEOME RES, V12, P2214, DOI 10.1021/pr400074f; Hertz EPT, 2016, MOL CELL, V63, P686, DOI 10.1016/j.molcel.2016.06.024; Hewitt L, 2010, J CELL BIOL, V190, P25, DOI 10.1083/jcb.201002133; Higgins JMG, 2010, CHROMOSOMA, V119, P137, DOI 10.1007/s00412-009-0250-4; Hiruma Y, 2015, SCIENCE, V348, P1264, DOI 10.1126/science.aaa4055; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Hornbeck PV, 2015, NUCLEIC ACIDS RES, V43, pD512, DOI 10.1093/nar/gku1267; Huang HM, 2008, J CELL BIOL, V183, P667, DOI 10.1083/jcb.200805163; Isokane M, 2016, J CELL BIOL, V212, P647, DOI 10.1083/jcb.201408089; Jelluma N, 2008, CELL, V132, P233, DOI 10.1016/j.cell.2007.11.046; Jelluma N, 2010, J CELL BIOL, V191, P281, DOI 10.1083/jcb.201003038; Jelluma N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002415; Ji ZJ, 2015, SCIENCE, V348, P1260, DOI 10.1126/science.aaa4029; Jia LY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10818; Kang JS, 2008, MOL CELL, V32, P394, DOI 10.1016/j.molcel.2008.09.017; Kettenbach AN, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001497; King EMJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000342; Kitagawa M, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00014; Klebig C, 2009, J CELL BIOL, V185, P841, DOI 10.1083/jcb.200902128; Klein UR, 2006, MOL BIOL CELL, V17, P2547, DOI 10.1091/mbc.E05-12-1133; Kraft C, 2003, EMBO J, V22, P6598, DOI 10.1093/emboj/cdg627; Krenn V, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00225; Krenn V, 2014, CURR BIOL, V24, P29, DOI 10.1016/j.cub.2013.11.046; Kruse T, 2013, J CELL SCI, V126, P1086, DOI 10.1242/jcs.122481; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Lee K, 2011, J CELL BIOL, V195, P1093, DOI 10.1083/jcb.201106093; Lenart P, 2007, CURR BIOL, V17, P304, DOI 10.1016/j.cub.2006.12.046; Lera RF, 2016, NAT CHEM BIOL, V12, P411, DOI 10.1038/nchembio.2060; Liu D, 2012, J CELL BIOL, V198, P491, DOI 10.1083/jcb.201205090; London N, 2012, CURR BIOL, V22, P900, DOI 10.1016/j.cub.2012.03.052; Maciejowski J, 2010, J CELL BIOL, V190, P89, DOI 10.1083/jcb.201001050; Malureanu LA, 2009, DEV CELL, V16, P118, DOI 10.1016/j.devcel.2008.11.004; Mardin BR, 2011, CURR BIOL, V21, P1145, DOI 10.1016/j.cub.2011.05.047; Matsumura S, 2007, J BIOL CHEM, V282, P15217, DOI 10.1074/jbc.M611053200; Moutinho-Santos T, 2014, EMBO REP, V15, P203, DOI 10.1002/embr.201438472; Moutinho-Santos T, 2012, J CELL SCI, V125, P576, DOI 10.1242/jcs.092445; Musacchio A., 2015, CURR BIOL, V25, P18; Nijenhuis W, 2014, NAT CELL BIOL, V16, P1257, DOI 10.1038/ncb3065; Nogueira C, 2014, G3-GENES GENOM GENET, V4, P1849, DOI 10.1534/g3.114.012823; Novak B, 2010, CURR OPIN CELL BIOL, V22, P801, DOI 10.1016/j.ceb.2010.07.001; O'Connor A, 2016, BIOL OPEN, V5, P11, DOI 10.1242/bio.014969; Oppermann FS, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.O111.012351; Overlack K, 2015, ELIFE, V4, DOI 10.7554/eLife.05269; Petronczki M, 2008, DEV CELL, V14, P646, DOI 10.1016/j.devcel.2008.04.014; Primorac I, 2013, ELIFE, V2, DOI 10.7554/eLife.01030; Qi W, 2006, MOL BIOL CELL, V17, P3705, DOI 10.1091/mbc.E06-03-0240; Raab M, 2015, MOL ONCOL, V9, P140, DOI 10.1016/j.molonc.2014.07.020; Rancati G, 2005, CELL CYCLE, V4, P972, DOI 10.4161/cc.4.7.1829; Salimian KJ, 2011, CURR BIOL, V21, P1158, DOI 10.1016/j.cub.2011.06.015; Santaguida S, 2010, J CELL BIOL, V190, P73, DOI 10.1083/jcb.201001036; Santamaria A, 2007, MOL BIOL CELL, V18, P4024, DOI 10.1091/mbc.E07-05-0517; Santamaria A, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.004457; Schittenhelm RB, 2009, EMBO J, V28, P2374, DOI 10.1038/emboj.2009.188; Schmucker S, 2014, MOL CELL ONCOL, V1, DOI 10.1080/23723548.2014.954507; Seki A, 2008, SCIENCE, V320, P1655, DOI 10.1126/science.1157425; Shepperd LA, 2012, CURR BIOL, V22, P891, DOI 10.1016/j.cub.2012.03.051; Strebhardt K, 2010, NAT REV DRUG DISCOV, V9, P643, DOI 10.1038/nrd3184; Suijkerbuijk SJE, 2012, DEV CELL, V23, P745, DOI 10.1016/j.devcel.2012.09.005; Suijkerbuijk SJE, 2012, DEV CELL, V22, P1321, DOI 10.1016/j.devcel.2012.03.009; Suijkerbuijk SJE, 2010, CANCER RES, V70, P4891, DOI 10.1158/0008-5472.CAN-09-4319; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; Tang ZY, 2004, MOL CELL, V16, P387, DOI 10.1016/j.molcel.2004.09.031; Thiru P, 2014, MOL BIOL CELL, V25, P1983, DOI 10.1091/mbc.E14-03-0837; Vader G, 2006, EMBO REP, V7, P85, DOI 10.1038/sj.embor.7400562; van der Horst A, 2014, CHROMOSOMA, V123, P25, DOI 10.1007/s00412-013-0437-6; Villa F, 2009, P NATL ACAD SCI USA, V106, P20204, DOI 10.1073/pnas.0908485106; Vleugel M, 2015, MOL CELL, V57, P824, DOI 10.1016/j.molcel.2014.12.036; Vleugel M, 2012, DEV CELL, V23, P239, DOI 10.1016/j.devcel.2012.06.013; von Schubert C, 2015, CELL REP, V12, P66, DOI 10.1016/j.celrep.2015.06.007; Wang FW, 2011, CURR BIOL, V21, P1061, DOI 10.1016/j.cub.2011.05.016; Wang FW, 2010, SCIENCE, V330, P231, DOI 10.1126/science.1189435; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Wang XH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104723; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; WINEY M, 1991, J CELL BIOL, V114, P745, DOI 10.1083/jcb.114.4.745; Wong OK, 2007, J CELL BIOL, V179, P611, DOI 10.1083/jcb.200708044; Wong OK, 2005, J CELL BIOL, V170, P709, DOI 10.1083/jcb.200502163; Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059; Xu P, 2013, BIOL OPEN, V2, P479, DOI 10.1242/bio.20134051; Xu QB, 2009, MOL BIOL CELL, V20, P10, DOI 10.1091/mbc.E08-03-0324; Yamagishi Y, 2014, FEMS MICROBIOL REV, V38, P185, DOI 10.1111/1574-6976.12049; Yamagishi Y, 2012, NAT CELL BIOL, V14, P746, DOI 10.1038/ncb2515; Yamagishi Y, 2010, SCIENCE, V330, P239, DOI 10.1126/science.1194498; Yoshida MM, 2016, J CELL BIOL, V213, P665, DOI 10.1083/jcb.201511079; Zhang G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8162; Zhang G, 2014, J CELL SCI, V127, P871, DOI 10.1242/jcs.139725; Zhou LL, 2014, EMBO REP, V15, P273, DOI 10.1002/embr.201338080; Zitouni S, 2014, NAT REV MOL CELL BIO, V15, P433, DOI 10.1038/nrm3819	132	86	90	3	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2017	36	34					4819	4827		10.1038/onc.2017.113	http://dx.doi.org/10.1038/onc.2017.113			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FE5EI	28436952				2022-12-17	WOS:000408234400001
J	Deng, Y; Cheng, J; Fu, B; Liu, W; Chen, G; Zhang, Q; Yang, Y				Deng, Y.; Cheng, J.; Fu, B.; Liu, W.; Chen, G.; Zhang, Q.; Yang, Y.			Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells	ONCOGENE			English	Article							CANCER-ASSOCIATED FIBROBLASTS; TUMOR MICROENVIRONMENT; PERIPHERAL-BLOOD; T-CELLS; INFLAMMATION; MECHANISM; PROMOTE; MODULATION; EXPANSION; MELANOMA	A major barrier to effective cancer immunotherapy is immune suppression in favor of tumor progression. Additionally, the accumulation of myeloid-derived suppressor cells (MDSCs) has recently been recognized as a major mechanism of the promotion of immune suppression. However, how MDSCs are induced and the cells from which they arise remains unknown. Although studies have demonstrated that tumor-derived cytokines promote MDSC accumulation and activation, little is known regarding the role of the tumor stroma in MDSC accumulation and activation. In this study, we identified a novel mechanism of MDSC differentiation. Tumor-associated fibroblasts (TAFs) attracted monocytes by the stromal cell-derived factor (SDF)-1a/CXCR4 pathway and induced their differentiation into MDSCs through interleukin (IL)-6-mediated STAT3 activation. TAF-treated monocytes (T-MDSCs) then impaired T-cell proliferation and altered the phenotype and/or function of T-cells in an STAT3-dependent manner. CD11b(+) myeloid cells, which resembled T-MDSCs both phenotypically and functionally, were primarily in the peritumoral stroma and a positive association with TAFs in vivo. Additionally, a negative association between CD11b(+) myeloid cell densities and overall survival was observed. An increased number of stromal CD11b(+) myeloid cells was correlated with Hepatocellular Carcinoma (HCC) progression. Together, our results are the first to show that TAF-derived cytokines, such as IL-6 and SDF-1a, can induce MDSC generation and activation and then impair human anti-tumor immune responses, which create favorable conditions for HCC progression. These data also suggest an important role for STAT3 activation in TAF-mediated MDSC generation and MDSC-mediated immune suppression. Consequently, methods in which immunotherapy is combined with IL-6, SDF-1a or STAT3 inhibition may offer an improved option to eliminate suppressive CD11b(+) myeloid cells in HCC patients.	[Deng, Y.; Cheng, J.; Fu, B.; Chen, G.; Yang, Y.] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Hepat Surg, 600 Tianhe Rd, Guangzhou 510630, Guangdong, Peoples R China; [Deng, Y.; Cheng, J.; Liu, W.; Chen, G.; Zhang, Q.; Yang, Y.] Guangdong Prov Key Lab Liver Dis Res, Guangzhou, Guangdong, Peoples R China; [Zhang, Q.] Sun Yat Sen Univ, Affiliated Hosp 3, Cell Gene Therapy Translat Med Res Ctr, Guangzhou 510630, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Yang, Y (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Dept Hepat Surg, 600 Tianhe Rd, Guangzhou 510630, Guangdong, Peoples R China.; Zhang, Q (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Cell Gene Therapy Translat Med Res Ctr, Guangzhou 510630, Guangdong, Peoples R China.	kee_kee@126.com; yysysu@163.com	yang, yang/HGT-7999-2022; yang, yang/GVT-5210-2022	Zhang, Qi/0000-0001-9916-8919	National Natural Science Foundation of China [81372243, 81172036, 81170451, 81370575, 81370555]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by: National Natural Science Foundation of China (81372243, 81172036, 81170451, 81370575, 81370555).	Almand B, 2001, J IMMUNOL, V166, P678, DOI 10.4049/jimmunol.166.1.678; Balsamo M, 2009, P NATL ACAD SCI USA, V106, P20847, DOI 10.1073/pnas.0906481106; Barclay WW, 2008, STEM CELLS, V26, P600, DOI 10.1634/stemcells.2007-0309; Barnas JL, 2010, J IMMUNOL, V185, P2681, DOI 10.4049/jimmunol.1000896; Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Berking C, 2001, CANCER RES, V61, P8306; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Condamine T, 2011, TRENDS IMMUNOL, V32, P19, DOI 10.1016/j.it.2010.10.002; Corzo CA, 2009, J IMMUNOL, V182, P5693, DOI 10.4049/jimmunol.0900092; Diaz-Montero CM, 2009, CANCER IMMUNOL IMMUN, V58, P49, DOI 10.1007/s00262-008-0523-4; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Filipazzi P, 2007, J CLIN ONCOL, V25, P2546, DOI 10.1200/JCO.2006.08.5829; Fortin CF, 2007, BIOGERONTOLOGY, V8, P173, DOI 10.1007/s10522-006-9067-1; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Goh PP, 2007, CURR CANCER DRUG TAR, V7, P743, DOI 10.2174/156800907783220462; Greten TF, 2011, INT IMMUNOPHARMACOL, V11, P802, DOI 10.1016/j.intimp.2011.01.003; Highfill SL, 2010, BLOOD, V116, P5738, DOI 10.1182/blood-2010-06-287839; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; Hoechst B, 2008, GASTROENTEROLOGY, V135, P234, DOI 10.1053/j.gastro.2008.03.020; Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714; Jia CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063243; Kuang DM, 2008, J IMMUNOL, V181, P3089, DOI 10.4049/jimmunol.181.5.3089; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Kusmartsev S, 2008, CLIN CANCER RES, V14, P8270, DOI 10.1158/1078-0432.CCR-08-0165; Lechner MG, 2010, J IMMUNOL, V185, P2273, DOI 10.4049/jimmunol.1000901; Li TJ, 2012, CANCER LETT, V318, P154, DOI 10.1016/j.canlet.2011.12.020; Liao D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007965; Mandruzzato S, 2009, J IMMUNOL, V182, P6562, DOI 10.4049/jimmunol.0803831; Marigo I, 2010, IMMUNITY, V32, P790, DOI 10.1016/j.immuni.2010.05.010; Morrison SJ, 2008, CELL, V132, P598, DOI 10.1016/j.cell.2008.01.038; Ohishi W, 2014, INT J CANCER, V134, P154, DOI 10.1002/ijc.28337; Ostrand-Rosenberg S, 2012, SEMIN CANCER BIOL, V22, P275, DOI 10.1016/j.semcancer.2012.01.011; Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740; Pavlides S, 2010, CELL CYCLE, V9, P2201, DOI 10.4161/cc.9.11.11848; Raychaudhuri B, 2011, NEURO-ONCOLOGY, V13, P591, DOI 10.1093/neuonc/nor042; Rodriguez PC, 2009, CANCER RES, V69, P1553, DOI 10.1158/0008-5472.CAN-08-1921; Serafini P, 2006, SEMIN CANCER BIOL, V16, P53, DOI 10.1016/j.semcancer.2005.07.005; Servais C, 2013, J PATHOL, V229, P198, DOI 10.1002/path.4103; Solito S, 2011, BLOOD, V118, P2254, DOI 10.1182/blood-2010-12-325753; Su XM, 2010, J IMMUNOL, V184, P1630, DOI 10.4049/jimmunol.0902813; Vered M, 2010, INT J CANCER, V127, P1356, DOI 10.1002/ijc.25358; Vuk-Pavlovic S, 2010, PROSTATE, V70, P443, DOI 10.1002/pros.21078; Xing F, 2010, FRONT BIOSCI-LANDMRK, V15, P166, DOI 10.2741/3613; Yan DH, 2013, EUR J IMMUNOL, V43, P2943, DOI 10.1002/eji.201343472; Zea AH, 2005, CANCER RES, V65, P3044, DOI 10.1158/0008-5472.CAN-04-4505	48	86	98	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1090	1101		10.1038/onc.2016.273	http://dx.doi.org/10.1038/onc.2016.273			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27593937				2022-12-17	WOS:000395371500007
J	Liang, L; Fang, JY; Xu, J				Liang, L.; Fang, J-Y; Xu, J.			Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy	ONCOGENE			English	Review							GROWTH-FACTOR RECEPTOR; IN-SITU HYBRIDIZATION; TUMOR-SUPPRESSOR GENE; MITOCHONDRIAL-DNA; MET AMPLIFICATION; POOR-PROGNOSIS; AURORA-KINASE; CLINICOPATHOLOGICAL FEATURES; HELICOBACTER-PYLORI; INTEGRATED ANALYSIS	Gastric cancer (GC) is among the most common malignancy in the world with poor prognosis and limited treatment options. It has been established that gastric carcinogenesis is caused by a complex interaction between host and environmental factors. Copy number variation (CNV) refers to a form of genomic structural variation that results in abnormal gene copy numbers, including gene amplification, gain, loss and deletion. DNA CNV is an important influential factor for the expression of both protein-coding and non-coding genes, affecting the activity of various signaling pathways. CNV arises as a result of preferential selection that favors cancer development, and thus, targeting the amplified 'driver genes' in GC may provide novel opportunities for personalized therapy. The detection of CNVs in chromosomal or mitochondrial DNA from tissue or blood samples may assist the diagnosis, prognosis and targeted therapy of GC. In this review, we discuss the recent CNV discoveries that shed light on the molecular pathogenesis of GC, with a specific emphasis on CNVs that display diagnostic, prognostic or therapeutic significances in GC.	[Fang, J-Y; Xu, J.] State Key Lab Oncogenes & Related Genes, Mid Shandong Rd 145, Shanghai 200001, Peoples R China; [Fang, J-Y; Xu, J.] Minist Hlth, Key Lab Gastroenterol & Hepatol, Mid Shandong Rd 145, Shanghai 200001, Peoples R China; [Fang, J-Y; Xu, J.] Shanghai Jiao Tong Univ, Div Gastroenterol & Hepatol, Renji Hosp, Sch Med, Mid Shandong Rd 145, Shanghai 200001, Peoples R China; [Fang, J-Y; Xu, J.] Shanghai Inst Digest Dis, Shanghai Canc Inst, Mid Shandong Rd 145, Shanghai 200001, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Fang, JY; Xu, J (corresponding author), State Key Lab Oncogenes & Related Genes, Mid Shandong Rd 145, Shanghai 200001, Peoples R China.; Fang, JY; Xu, J (corresponding author), Minist Hlth, Key Lab Gastroenterol & Hepatol, Mid Shandong Rd 145, Shanghai 200001, Peoples R China.; Fang, JY; Xu, J (corresponding author), Shanghai Jiao Tong Univ, Div Gastroenterol & Hepatol, Renji Hosp, Sch Med, Mid Shandong Rd 145, Shanghai 200001, Peoples R China.; Fang, JY; Xu, J (corresponding author), Shanghai Inst Digest Dis, Shanghai Canc Inst, Mid Shandong Rd 145, Shanghai 200001, Peoples R China.	jingyuanfang@yahoo.com; xujieletter@gmail.com	Xu, Jie/C-4283-2016; Xu, Jie/K-3712-2019	Xu, Jie/0000-0001-9163-3898; Xu, Jie/0000-0001-9163-3898; liang, lunxi/0000-0003-4178-9055	National Natural Science Foundation of China [30971330, 31371420, 81320108024, 81000861, 81322036, 81272383]; Foundation for Innovative Research Groups of the National Natural Science Foundation of China [81421001]; Program for Innovative Research Team of Shanghai Municipal Education Commission; Shanghai 'Oriental Scholars' project; Shanghai Science and Technology Commission 'Pujiang Project' [13PJ1405900]; Shanghai Natural Science Foundation [12ZR1417900]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Foundation for Innovative Research Groups of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Innovative Research Team of Shanghai Municipal Education Commission; Shanghai 'Oriental Scholars' project; Shanghai Science and Technology Commission 'Pujiang Project'; Shanghai Natural Science Foundation(Natural Science Foundation of Shanghai)	This project was supported by grants from National Natural Science Foundation of China (30971330, 31371420, 81320108024, 81000861, 81322036 and 81272383); Foundation for Innovative Research Groups of the National Natural Science Foundation of China (Grant No. 81421001), the Program for Innovative Research Team of Shanghai Municipal Education Commission; Shanghai 'Oriental Scholars' project (2013XJ); Shanghai Science and Technology Commission 'Pujiang Project' (13PJ1405900) and Shanghai Natural Science Foundation (12ZR1417900). The sponsors of this study had no role in the analysis and interpretation of the literatures, the decision to submit the manuscript for publication or the writing of the manuscript.	An J, 2013, J CELL BIOCHEM, V114, P2160, DOI 10.1002/jcb.24565; An X, 2014, CANCER-AM CANCER SOC, V120, P675, DOI 10.1002/cncr.28454; Ang TL, 2014, SINGAP MED J, V55, P621, DOI 10.11622/smedj.2014174; Bang YJ, 2010, LANCET, V376, P1302; Bellini MF, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/891961; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bi R, 2011, MUTAT RES-FUND MOL M, V709-10, P15, DOI 10.1016/j.mrfmmm.2011.02.016; Bonberg N, 2014, BMC CANCER, V14, P11; Bornschein J, 2010, DIGEST DIS, V28, P609, DOI 10.1159/000320061; Bria E, 2013, ANN ONCOL, V24, P693, DOI 10.1093/annonc/mds506; Buffart TE, 2012, ONCOLOGIST, V17, P653, DOI 10.1634/theoncologist.2010-0379; Calcagno DQ, 2010, CANCER GENET CYTOGEN, V202, P63, DOI 10.1016/j.cancergencyto.2010.05.020; Chang JJ, 2015, ONCOTARGET, V6, P2009, DOI 10.18632/oncotarget.2987; Chang VY, 2013, PEDIATR BLOOD CANCER, V60, P570, DOI 10.1002/pbc.24316; Chen KX, 2015, P NATL ACAD SCI USA, V112, P1107, DOI 10.1073/pnas.1422640112; Chen WQ, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.04.05; Cheng L, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-14; Chiodo J, 2012, ASSEMBLY AUTOM, V32, P8, DOI 10.1108/01445151211198683; Dar AA, 2008, CANCER-AM CANCER SOC, V112, P1688, DOI 10.1002/cncr.23371; Dar AA, 2010, MOL CANCER THER, V9, P268, DOI 10.1158/1535-7163.MCT-09-0765; Das K, 2014, CANCER LETT, V353, P167, DOI 10.1016/j.canlet.2014.07.021; Deng NT, 2012, GUT, V61, P673, DOI 10.1136/gutjnl-2011-301839; Despierre E, 2014, GYNECOL ONCOL, V135, P415, DOI 10.1016/j.ygyno.2014.09.014; Fan BA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029824; Fang ZY, 2012, CLIN TRANSL ONCOL, V14, P60, DOI 10.1007/s12094-012-0762-x; Fang ZY, 2011, MED ONCOL, V28, P1017, DOI 10.1007/s12032-010-9602-4; Fassan M, 2014, GASTRIC CANCER, V17, P442, DOI 10.1007/s10120-013-0315-1; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Fernandes J, 2014, CANCER EPIDEM BIOMAR, V23, P2430, DOI 10.1158/1055-9965.EPI-14-0471; da Costa JDFB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021988; Ferreira RM, 2014, BEST PRACT RES CL GA, V28, P1003, DOI 10.1016/j.bpg.2014.09.004; Figueiredo C, 2013, HELICOBACTER, V18, P28, DOI 10.1111/hel.12083; Fox SB, 2012, AM J SURG PATHOL, V36, P577, DOI 10.1097/PAS.0b013e318244adbb; Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137; Fuse N, GASTRIC CANC; Garcia-Garcia E, 2011, HISTOPATHOLOGY, V59, P8, DOI 10.1111/j.1365-2559.2011.03894.x; Gavine PR, 2015, MOL ONCOL, V9, P323, DOI 10.1016/j.molonc.2014.08.015; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Gray SE, 2011, CANCER GENOM PROTEOM, P8; Graziano F, 2011, J CLIN ONCOL, V29, P4789, DOI 10.1200/JCO.2011.36.7706; Guo X, 2010, ONCOGENE, V29, P3908, DOI 10.1038/onc.2010.143; Ha SY, 2013, MODERN PATHOL, V26, P1632, DOI 10.1038/modpathol.2013.108; Hatakeyama M, 2014, CELL HOST MICROBE, V15, P306, DOI 10.1016/j.chom.2014.02.008; Hayashi H, 2015, ONCOGENE, V34, P199, DOI 10.1038/onc.2013.547; He C, 2013, WORLD J GASTROENTERO, V19, P2171, DOI 10.3748/wjg.v19.i14.2171; Herold S, 2009, NAT REV CANCER, V9, P441, DOI 10.1038/nrc2640; Higaki E, GASTRIC CANC; Hong L, 2014, EXPERT REV GASTROENT, V8, P111, DOI 10.1586/17474124.2014.844648; Hong L, 2013, GENE, V529, P69, DOI 10.1016/j.gene.2013.07.106; Horpaopan S, 2015, INT J CANCER, V136, pE578, DOI 10.1002/ijc.29215; Hou JP, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0056-8; Hu LW, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0123-z; Hu Y, 2014, CANCER RES, V74, P6890, DOI 10.1158/0008-5472.CAN-14-0686; Hudler P, 2012, SCI WORLD J, DOI 10.1100/2012/761909; Hung WY, 2010, BBA-GEN SUBJECTS, V1800, P264, DOI 10.1016/j.bbagen.2009.06.006; Hwang-Verslues WW, 2013, P NATL ACAD SCI USA, V110, P12331, DOI 10.1073/pnas.1222684110; Janjigian YY, 2011, CANCER EPIDEM BIOMAR, V20, P1021, DOI 10.1158/1055-9965.EPI-10-1080; Jin GF, 2009, CARCINOGENESIS, V30, P987, DOI 10.1093/carcin/bgp090; Jung KH, 2012, ARCH PHARM RES, V35, P595, DOI 10.1007/s12272-012-0402-6; Kang JU, 2012, INT J MOL MED, V29, P81, DOI 10.3892/ijmm.2011.811; Kang JU, 2010, INT J ONCOL, V36, P1429, DOI 10.3892/ijo_00000628; Karaman A, 2010, GENET COUNSEL, V21, P439; Katoh M, 2013, INT J MOL MED, V32, P763, DOI 10.3892/ijmm.2013.1444; Katsha A, 2014, MOL ONCOL, V8, P1419, DOI 10.1016/j.molonc.2014.05.012; Katsha A, 2013, GASTROENTEROLOGY, V145, P1312, DOI 10.1053/j.gastro.2013.08.050; Kawakami H, 2013, ONCOTARGET, V4, P9, DOI 10.18632/oncotarget.718; Kim HK, 2012, PHARMACOGENOMICS J, V12, P119, DOI 10.1038/tpj.2010.87; Kim O, GASTRIC CANC; Kiyose S, 2012, PATHOL INT, V62, P728, DOI 10.1111/j.1440-1827.2012.02862.x; Kuo WH, 2014, ANTICANCER RES, V34, P4963; Labots M, 2014, CELL ONCOL, V37, P41, DOI 10.1007/s13402-013-0162-4; Leal MF, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/631268; Leary RJ, 2008, P NATL ACAD SCI USA, V105, P16224, DOI 10.1073/pnas.0808041105; Lee H, BIOINFORMATICS; Lee HE, 2013, EUR J CANCER, V49, P1448, DOI 10.1016/j.ejca.2012.10.018; Lee HC, 2014, WORLD J GASTROENTERO, V20, P3950, DOI 10.3748/wjg.v20.i14.3950; Lee J, 2011, ONCOL REP, V25, P1517, DOI 10.3892/or.2011.1219; Lee JW, 2012, EURASIP J IMAGE VIDE, DOI 10.1186/1687-5281-2012-7; Lee MC, 2010, J BIOL CHEM, V285, P9041, DOI 10.1074/jbc.M109.075358; Lennerz JK, 2011, J CLIN ONCOL, V29, P4803, DOI 10.1200/JCO.2011.35.4928; Li Z, 2012, ONCOGENE, V31, P1475, DOI 10.1038/onc.2011.351; Liao LM, 2011, CANCER EPIDEM BIOMAR, V20, P1944, DOI 10.1158/1055-9965.EPI-11-0379; Liu XD, 2010, TRENDS MOL MED, V16, P37, DOI 10.1016/j.molmed.2009.11.005; Liu YY, 2012, WORLD J GASTROENTERO, V18, P4522, DOI 10.3748/wjg.v18.i33.4522; Lordick F, 2013, LANCET ONCOL, V14, P490, DOI 10.1016/S1470-2045(13)70102-5; Maddox J, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003048; Matsumoto K, 2012, BRIT J CANCER, V106, P727, DOI 10.1038/bjc.2011.603; Matsuoka T, 2015, WORLD J CLIN CASES, V3, P42, DOI 10.12998/wjcc.v3.i1.42; Mauro JA, 2015, GENE, V554, P50, DOI 10.1016/j.gene.2014.10.021; Nakamura Y, 2009, J HUM GENET, V54, P1, DOI 10.1038/jhg.2008.6; Niels TF, 2013, EXPERT REV MOL DIAGN, V13, P10; Oh HS, 2014, GASTRIC CANCER, V17, P402, DOI 10.1007/s10120-013-0288-0; Okamoto W, 2012, MOL CANCER THER, V11, P1557, DOI 10.1158/1535-7163.MCT-11-0934; Okines AFC, 2010, EUR J CANCER, V46, P1949, DOI 10.1016/j.ejca.2010.05.003; Oshima T, 2012, SURG TODAY, V42, P313, DOI 10.1007/s00595-011-0065-9; Ozaki T, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/603925; Ozdemir M, 2014, TURK J MED SCI, V44, P461, DOI 10.3906/sag-1303-139; Park CH, 2010, J SURG ONCOL, V102, P454, DOI 10.1002/jso.21585; Park YS, 2012, HUM PATHOL, V43, P413, DOI 10.1016/j.humpath.2011.05.019; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Parmar NR, 2014, J MOL MICROB BIOTECH, V24, P249, DOI 10.1159/000365054; Patel R, 2012, CURR PHARM DESIGN, V18, P2672, DOI 10.2174/138161212800626148; Piazuelo MB, 2013, COLOMB MEDICA, V44, P192; Qian J, 2014, GUT, V64, P12; Qian ZL, 2014, GENE CHROMOSOME CANC, V53, P883, DOI 10.1002/gcc.22196; Silva TCR, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-85; Ribeiro HF, 2010, BRAZ J MED BIOL RES, V43, P717, DOI 10.1590/S0100-879X2010007500068; Rossi E, 2011, REV ESP ENFERM DIG, V103, P632, DOI 10.4321/s1130-01082011001200005; Samuels Y, 2004, SCIENCE, P304; Seshacharyulu P, 2012, EXPERT OPIN THER TAR, P16; Sheng WQ, 2013, ANN ONCOL, V24, P2360, DOI 10.1093/annonc/mdt232; Shi J, 2014, WORLD J GASTROENTERO, P20; Shi J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-50; Shi ZQ, 2014, CRIT REV EUKAR GENE, V24, P14; Shim JH, 2014, GENE, V546, P288, DOI 10.1016/j.gene.2014.05.064; Shinmura K, 2014, J SURG ONCOL, V109, P189, DOI 10.1002/jso.23482; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Silveira SM, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023-014-0181-x; Smalley SR, 2012, J CLIN ONCOL, V30, P2327, DOI 10.1200/JCO.2011.36.7136; Sonoda A, 2013, BMC MED GENOMICS, V6, DOI 10.1186/1755-8794-6-25; Stahl P, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0231-4; Stenzinger A, 2012, J MOL DIAGN, V14, P199, DOI 10.1016/j.jmoldx.2012.01.012; Sun KY, 2014, J CANCER RES CLIN, V140, P1537, DOI 10.1007/s00432-014-1714-3; Suzuki Kazufumi, 2011, J Biomed Biotechnol, V2011, P978312, DOI 10.1155/2011/978312; Takahashi Naoki, 2014, BMC Res Notes, V7, P271, DOI 10.1186/1756-0500-7-271; Takeshima H, 2015, CANCER LETT, V357, P328, DOI 10.1016/j.canlet.2014.11.038; de Souza CRT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064420; Teng LS, 2013, INT J MOL MED, V32, P1247, DOI 10.3892/ijmm.2013.1531; Tsai PC, 2014, PLOS ONE, P9; Krepischi ACV, 2012, FUTURE ONCOL, V8, P441, DOI [10.2217/fon.12.34, 10.2217/FON.12.34]; Waddell T, 2013, LANCET ONCOL, V14, P9; Wang JL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5735; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Wang X, GASTRIC CANC; Wang YK, 2011, MOL CYTOGENET, V4, DOI 10.1186/1755-8166-4-14; Weinberg SE, 2015, NAT CHEM BIOL, V11, P9, DOI 10.1038/nchembio.1712; Wen SL, 2013, ONCOL LETT, V6, P1098, DOI 10.3892/ol.2013.1492; Xia JZ, 2014, J CANCER RES CLIN, V140, P1451, DOI 10.1007/s00432-014-1649-8; Xie L, 2013, CLIN CANCER RES, V19, P2572, DOI 10.1158/1078-0432.CCR-12-3898; Xu HT, 2015, J CANCER, V6, P247, DOI 10.7150/jca.10747; Xu J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.75; Yang Q, 2014, CLIN BIOCHEM, V47, P111, DOI 10.1016/j.clinbiochem.2013.10.014; Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309; Yen CC, 2012, ANN SURG ONCOL, V19, P3491, DOI 10.1245/s10434-012-2389-0; Yoda Y, 2015, GASTRIC CANCER, V18, P65, DOI 10.1007/s10120-014-0348-0; Yoon JH, 2011, J PATHOL, V223, P618, DOI 10.1002/path.2838; Yoshida S, 2013, ANTICANCER RES, V33, P469; Zhang D, 2011, J SURG ONCOL, V103, P124, DOI 10.1002/jso.21792; Zhang L, 2014, J PATHOL, V233, P103, DOI 10.1002/path.4351; Zhang L, 2010, MOL CELL BIOCHEM, V344, P125, DOI 10.1007/s11010-010-0536-0; Zhao SD, 2011, J PATHOL, V223, P672, DOI 10.1002/path.2827; Zhu GJ, 2014, EXP THER MED, V8, P1501, DOI 10.3892/etm.2014.1982	153	86	87	1	48	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2016	35	12					1475	1482		10.1038/onc.2015.209	http://dx.doi.org/10.1038/onc.2015.209			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RJ	26073079				2022-12-17	WOS:000373063600001
J	Kroiss, A; Vincent, S; Decaussin-Petrucci, M; Meugnier, E; Viallet, J; Ruffion, A; Chalmel, F; Samarut, J; Allioli, N				Kroiss, A.; Vincent, S.; Decaussin-Petrucci, M.; Meugnier, E.; Viallet, J.; Ruffion, A.; Chalmel, F.; Samarut, J.; Allioli, N.			Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2	ONCOGENE			English	Article							RECEPTOR; EXPRESSION; GROWTH; RECOGNITION; PATHWAY; KINASE	Androgen signaling, via the androgen receptor (AR), is crucial in mediating prostate cancer (PCa) initiation and progression. Identifying new downstream effectors of the androgens/AR pathway will allow a better understanding of these mechanisms and could reveal novel biomarkers and/or therapeutic agents to improve the rate of patient survival. We compared the microRNA expression profiles in androgen-sensitive LNCaP cells stimulated or not with 1 nM R1881 by performing a high-throughput reverse transcriptase-quantitative PCR and found that miR-135a was upregulated. After androgen stimulation, we showed that AR directly activates the transcription of miR-135a2 gene by binding to an androgen response element in the promoter region. Our findings identify miR-135a as a novel effector in androgens/AR signaling. Using xenograft experiments in chick embryos and adult male mice, we showed that miR-135a overexpression decreases in vivo invasion abilities of prostate PC-3 cells. Through in vitro wound-healing migration and invasion assays, we demonstrated that this effect is mediated through downregulating ROCK1 and ROCK2 expression, two genes that we characterized as miR-135a direct target genes. In human surgical samples from prostatectomy, we observed that miR-135a expression was lower in tumoral compared with paired adjacent normal tissues, mainly in tumors classified with a high Gleason score (>= 8). Moreover, miR-135a expression is lower in invasive tumors, showing extraprostatic extension, as compared with intraprostatic localized tumors. In tumor relative to normal glands, we also showed a more frequently higher ROCK1 protein expression determined using a semi-quantitative immunohistochemistry analysis. Therefore, in tumor cells, the lower miR-135a expression could lead to a higher ROCK1 protein expression, which could explain their invasion abilities. The highlighted relationship between miR-135a expression level and the degree of disease aggressiveness suggests that miR-135a may be considered as a prognostic marker in human PCa.	[Kroiss, A.; Vincent, S.; Decaussin-Petrucci, M.; Ruffion, A.; Samarut, J.; Allioli, N.] Univ Lyon 1, Ecole Normale Super Lyon, Inst Genom Fonct Lyon, F-69365 Lyon, France; [Decaussin-Petrucci, M.; Ruffion, A.; Samarut, J.] Univ Lyon 1, Fac Med & Maieut Lyon Sud Charles Merieux, F-69365 Lyon, France; [Decaussin-Petrucci, M.] Ctr Hosp Lyon Sud, Hosp Civils Lyon, Serv Anat & Cytol Pathol, F-69310 Pierre Benite, France; [Meugnier, E.] Univ Lyon 1, Fac Med & Maieut Lyon Sud Charles Merieux, Lab CarMen, INRA1362,INSERM U1060, Oullins, France; [Viallet, J.] Univ Grenoble, CRI INSERM UJF U823, Inst Albert Bonniot, In Ovo, La Tronche, France; [Ruffion, A.] Ctr Hosp Lyon Sud, Hosp Civils Lyon, Serv Urol, F-69310 Pierre Benite, France; [Chalmel, F.] Univ Rennes 1, GERHM, INSERM Irset U1085, Rennes, France; [Samarut, J.] Ctr Hosp Lyon Sud, Hosp Civils Lyon, Serv Bioch Biol Mol Sud, F-69310 Pierre Benite, France; [Allioli, N.] Univ Lyon 1, Fac Pharm Lyon, Inst Sci Pharmaceut & Biol, F-69365 Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes 1; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Allioli, N (corresponding author), Inst Genom Fonct Lyon, 32-34 Ave Tony Garnier, F-69007 Lyon, France.	jacques.samarut@ens-lyon.fr; nathalie.allioli@univ-lyon1.fr	Chalmel, Frederic/M-1297-2016; Samarut, Jacques/AAD-2587-2019; DECAUSSIN PETRUCCI, MYRIAM/GWZ-7373-2022; Chalmel, Frédéric/AAM-1079-2021; Chalmel, Frédéric/L-5360-2018	Chalmel, Frédéric/0000-0002-0535-3628; Chalmel, Frédéric/0000-0002-0535-3628; meugnier, emmanuelle/0000-0002-2291-7691	Institut Merieux; Ligue Contre le Cancer	Institut Merieux; Ligue Contre le Cancer(Ligue nationale contre le cancer)	This work was supported by grants from the Institut Merieux and the Ligue Contre le Cancer. We thank Julien Dugas (CarMen Lab) for his contribution in statistical analyses, Celine Michaux, Karine Castellano and Beatrice Bancel (Service d'Anatomie et Cytologie Pathologiques, Hospices Civils de Lyon) for providing patient samples and performing IHC staining, Jean Viallet for performing in ovo assay, Christophe Chamot and Claire Lionnet (Microscopy core facility) and Patrick Manas (AniRA-PBES platform) of UMS3444/US8 SFR Biosciences Gerland-Lyon Sud, for assistance in wound-healing assay and performing xenograft assay in mice, respectively.	Allioli N, 2011, PROSTATE, V71, P1239, DOI 10.1002/pros.21340; Amano M, 2010, CYTOSKELETON, V67, P545, DOI 10.1002/cm.20472; Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bouyssou JMC, 2014, BBA-REV CANCER, V1845, P255, DOI 10.1016/j.bbcan.2014.02.002; Cao P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-108; Chen YT, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-111; Chen Y, 2009, LANCET ONCOL, V10, P981, DOI 10.1016/S1470-2045(09)70229-3; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Cunha GR, 2004, J STEROID BIOCHEM, V92, P221, DOI 10.1016/j.jsbmb.2004.10.017; Denayer S, 2010, MOL ENDOCRINOL, V24, P898, DOI 10.1210/me.2009-0310; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fang YX, 2014, ONCOGENE, V33, P135, DOI 10.1038/onc.2013.54; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Fendler A, 2011, CLIN CHEM, V57, P954, DOI 10.1373/clinchem.2010.157727; Fletcher CE, 2012, HUM MOL GENET, V21, P3112, DOI 10.1093/hmg/dds139; Golubovskaya VM, 2014, ANTI-CANCER AGENT ME, V14, P18, DOI 10.2174/187152061401140108113435; Gonzalez-Montelongo MC, 2010, MOL ENDOCRINOL, V24, P1007, DOI 10.1210/me.2009-0472; Green SM, 2012, MOL CELL ENDOCRINOL, V360, P3, DOI 10.1016/j.mce.2011.09.046; Hassan O, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-9; Jalava SE, 2012, ONCOGENE, V31, P4460, DOI 10.1038/onc.2011.624; Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006; Knudsen KE, 2010, TRENDS ENDOCRIN MET, V21, P315, DOI 10.1016/j.tem.2010.01.002; Leung CON, 2014, CARCINOGENESIS; Li YW, 2012, EPIGENETICS-US, V7, P940, DOI 10.4161/epi.21236; Ma S, 2011, CANCER RES, V71, P583, DOI 10.1158/0008-5472.CAN-10-2587; Matsumoto T, 2013, ANNU REV PHYSIOL, V75, P201, DOI 10.1146/annurev-physiol-030212-183656; Murata T, 2010, PROSTATE CANCER P D, V13, P356, DOI 10.1038/pcan.2010.32; Nadiminty N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032832; Rao S, 2012, ONCOGENE, V31, P716, DOI 10.1038/onc.2011.273; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Shin JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085205; Somlyo AV, 2000, BIOCHEM BIOPH RES CO, V269, P652, DOI 10.1006/bbrc.2000.2343; Sun D, 2014, ONCOGENE, V33, P1448, DOI 10.1038/onc.2013.77; Sun DD, 2011, CANCER RES, V71, P1313, DOI 10.1158/0008-5472.CAN-10-1031; Takayama K, 2011, ONCOGENE, V30, P619, DOI 10.1038/onc.2010.436; Takayama K, 2013, INT J UROL, V20, P756, DOI 10.1111/iju.12146; Waltering KK, 2011, PROSTATE, V71, P604, DOI 10.1002/pros.21276; Wang BD, 2013, PROSTATE CANCER, V2013, DOI 10.1155/2013/763569; Wang GH, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-S2-S22; Watahiki A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024950; Wen SM, 2013, PROSTATE, V73, P1306, DOI 10.1002/pros.22676; White RWD, 2009, UROL ONCOL-SEMIN ORI, V27, P307, DOI 10.1016/j.urolonc.2009.01.004; Xi Jianzhong Jeff, 2013, Cancer Treat Res, V158, P119, DOI 10.1007/978-3-642-31659-3_5; Zheng C, 2012, MED ONCOL, V29, P815, DOI 10.1007/s12032-011-9934-8; Zhou WW, 2012, ACTA BIOCH BIOPH SIN, V44, P838, DOI 10.1093/abbs/gms071	47	86	90	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2846	2855		10.1038/onc.2014.222	http://dx.doi.org/10.1038/onc.2014.222			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	25065599	Green Submitted			2022-12-17	WOS:000355324300004
J	Damsky, WE; Theodosakis, N; Bosenberg, M				Damsky, W. E.; Theodosakis, N.; Bosenberg, M.			Melanoma metastasis: new concepts and evolving paradigms	ONCOGENE			English	Review						melanocyte; melanoma; metastasis; BRAF; beta-catenin	EPITHELIAL-MESENCHYMAL TRANSITION; BETA-CATENIN EXPRESSION; SENTINEL LYMPH-NODE; MALIGNANT-MELANOMA; TUMOR PROGRESSION; NEVUS CELLS; SOMATIC MUTATIONS; GROWTH REQUIRES; BREAST-CANCER; MOUSE MODEL	Melanoma progression is typically depicted as a linear and stepwise process in which metastasis occurs relatively late in disease progression. Significant evidence suggests that in a subset of melanomas, progression is much more complex and less linear in nature. Epidemiologic and experimental observations in melanoma metastasis are reviewed here and are incorporated into a comprehensive model for melanoma metastasis, which takes into account the varied natural history of melanoma formation and progression.	[Damsky, W. E.; Theodosakis, N.; Bosenberg, M.] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA; [Damsky, W. E.] Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05495 USA	Yale University; University of Vermont	Damsky, WE (corresponding author), Univ Vermont, Coll Med, Dept Pathol, Given Box A14,189 Beaumont Ave, Burlington, VT 05495 USA.	william.damsky@gmail.com; marcus.bosenberg@yale.edu						Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Algra AM, 2012, LANCET ONCOL, V13, P518, DOI 10.1016/S1470-2045(12)70112-2; Arozarena I, 2011, ONCOGENE, V30, P4531, DOI 10.1038/onc.2011.162; Arozarena I, 2011, CANCER CELL, V19, P45, DOI 10.1016/j.ccr.2010.10.029; Bakalian S, 2008, CLIN CANCER RES, V14, P951, DOI 10.1158/1078-0432.CCR-06-2630; Balch C.M., 2003, CUTANEOUS MELANOMA; Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799; BALCH CM, 1993, ANN SURG, V218, P262, DOI 10.1097/00000658-199309000-00005; BAUTISTA NC, 1994, AM J CLIN PATHOL, V102, P102, DOI 10.1093/ajcp/102.1.102; Bedrosian I, 2000, ANN SURG ONCOL, V7, P262, DOI 10.1007/s10434-000-0262-z; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Bertolotto C, 2011, NATURE, V480, P94, DOI 10.1038/nature10539; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328; Boni R, 1996, J AM ACAD DERMATOL, V35, P416, DOI 10.1016/S0190-9622(96)90607-6; Borthwick NJ, 2011, J CLIN PATHOL, V64, P666, DOI 10.1136/jcp.2010.087999; Bos PD, 2010, CURR OPIN PHARMACOL, V10, P571, DOI 10.1016/j.coph.2010.06.003; BUTLER TP, 1975, CANCER RES, V35, P512; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Carmi Y, 2011, J IMMUNOL, V186, P3462, DOI 10.4049/jimmunol.1002901; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Carson KF, 1996, AM J SURG PATHOL, V20, P834, DOI 10.1097/00000478-199607000-00006; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cheli Y, 2012, ONCOGENE, V31, P2461, DOI 10.1038/onc.2011.425; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; CLARK WH, 1984, HUM PATHOL, V15, P1147, DOI 10.1016/S0046-8177(84)80310-X; Clawson GA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041052; Coleman RE, 2009, EUR J CANCER, V45, P1909, DOI 10.1016/j.ejca.2009.04.022; Colombino M, 2012, J CLIN ONCOL, V30, P2522, DOI 10.1200/JCO.2011.41.2452; Crawford NPS, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1389; CROWLEY NJ, 1990, ANN SURG, V212, P173, DOI 10.1097/00000658-199008000-00010; Damsky WE, 2011, CANCER CELL, V20, P741, DOI 10.1016/j.ccr.2011.10.030; Damsky William E, 2010, Cancers (Basel), V3, P126, DOI 10.3390/cancers3010126; Damsky WE, 2010, PIGM CELL MELANOMA R, V23, P853, DOI 10.1111/j.1755-148X.2010.00777.x; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Das SK, 2012, FRONT BIOSCI-LANDMRK, V17, P1, DOI 10.2741/3911; DASGUPTA T, 1964, CANCER, V17, P1323; De Giorgi V, 2010, ARCH DERMATOL, V146, P1120, DOI 10.1001/archdermatol.2010.264; Demicheli R, 2007, NAT CLIN PRACT ONCOL, V4, P699, DOI 10.1038/ncponc0999; Demunter A, 2002, MODERN PATHOL, V15, P454, DOI 10.1038/modpathol.3880546; Eichhoff OM, 2011, PIGM CELL MELANOMA R, V24, P631, DOI 10.1111/j.1755-148X.2011.00871.x; El-Osta H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025806; Ernfors P, 2010, EXP CELL RES, V316, P1397, DOI 10.1016/j.yexcr.2010.02.042; Eskelin S, 2000, OPHTHALMOLOGY, V107, P1443, DOI 10.1016/S0161-6420(00)00182-2; Eyles J, 2010, J CLIN INVEST, V120, P2030, DOI 10.1172/JCI42002; Faraji F, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002926; Ferguson J, 2013, ONCOGENE, V32, P86, DOI 10.1038/onc.2012.25; FIDLER IJ, 1970, JNCI-J NATL CANCER I, V45, P773; FISHER CJ, 1994, J CLIN PATHOL, V47, P245, DOI 10.1136/jcp.47.3.245; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Forbes SA, 2010, NUCLEIC ACIDS RES, V38, pD652, DOI 10.1093/nar/gkp995; Frahm SO, 2001, HUM PATHOL, V32, P1376, DOI 10.1053/hupa.2001.29658; Gallagher SJ, 2013, ONCOGENE, V32, P2230, DOI 10.1038/onc.2012.229; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Gartner JJ, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-505; GIULIANO AE, 1980, ANN SURG, V191, P98, DOI 10.1097/00000658-198001000-00018; Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285; Gradilone A, 2012, EUR REV MED PHARMACO, V16, P1367; Grossmann AH, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003398; Haakinson DJ, 2012, ANN SURG ONCOL, V19, P3012, DOI 10.1245/s10434-012-2320-8; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; Hari L, 2002, J CELL BIOL, V159, P867, DOI 10.1083/jcb.200209039; Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; Hood JL, 2011, CANCER RES, V71, P3792, DOI 10.1158/0008-5472.CAN-10-4455; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Ireland A, 2011, CLIN EXP METASTAS, V28, P327, DOI 10.1007/s10585-010-9368-2; Izraely S, 2012, INT J CANCER, V131, P1071, DOI 10.1002/ijc.27324; Jakob JA, 2012, CANCER-AM CANCER SOC, V118, P4014, DOI 10.1002/cncr.26724; Jarrett SG, 2013, CLIN EXP METASTAS, V30, P25, DOI 10.1007/s10585-012-9495-z; Javelaud D, 2011, PIGM CELL MELANOMA R, V24, P932, DOI 10.1111/j.1755-148X.2011.00893.x; Jensen TO, 2009, J CLIN ONCOL, V27, P3330, DOI 10.1200/JCO.2008.19.9919; Journe F, 2011, BRIT J CANCER, V105, P1726, DOI 10.1038/bjc.2011.451; Kabbarah O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010770; Kageshita T, 2001, BRIT J DERMATOL, V145, P210, DOI 10.1046/j.1365-2133.2001.04336.x; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Karnezis T, 2012, CANCER CELL, V21, P181, DOI 10.1016/j.ccr.2011.12.026; Kielhorn E, 2003, INT J CANCER, V103, P652, DOI 10.1002/ijc.10893; Kienast Y, 2010, NAT MED, V16, P116, DOI 10.1038/nm.2072; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Kingham TP, 2010, ANN SURG ONCOL, V17, P514, DOI 10.1245/s10434-009-0836-3; Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627; Ko JM, 2010, SEMIN CUTAN MED SURG, V29, P210, DOI 10.1016/j.sder.2010.10.004; Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Kumar R, 2004, J INVEST DERMATOL, V122, P342, DOI 10.1046/j.0022-202X.2004.22225.x; Larue L, 2006, FRONT BIOSCI-LANDMRK, V11, P733, DOI 10.2741/1831; LEE YTN, 1980, CA-CANCER J CLIN, V30, P137, DOI 10.3322/canjclin.30.3.137; Lindsay CR, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1560; Little EG, 2012, DERMATOL CLIN, V30, P355, DOI 10.1016/j.det.2012.04.001; Liu WJ, 2012, CANCER CELL, V21, P751, DOI 10.1016/j.ccr.2012.03.048; Lopez-Bergami P, 2011, PIGM CELL MELANOMA R, V24, P902, DOI 10.1111/j.1755-148X.2011.00908.x; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Madhunapantula SV, 2009, PIGM CELL MELANOMA R, V22, P400, DOI 10.1111/j.1755-148X.2009.00585.x; Makhzami S, 2012, PIGM CELL MELANOMA R, V25, P783, DOI 10.1111/pcmr.12013; McAllister SS, 2008, CELL, V133, P994, DOI 10.1016/j.cell.2008.04.045; MCCARTHY SW, 1974, PATHOLOGY, V6, P351, DOI 10.3109/00313027409077346; McGill GG, 2006, J BIOL CHEM, V281, P10365, DOI 10.1074/jbc.M513094200; Melnikova VO, 2009, PIGM CELL MELANOMA R, V22, P257, DOI 10.1111/j.1755-148X.2009.00570.x; Mervic L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032955; Meyer S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038222; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Mitra D, 2009, HEMATOL ONCOL CLIN N, V23, P447, DOI 10.1016/j.hoc.2009.03.003; Nagel G, 2012, BRIT J DERMATOL, V167, P59, DOI 10.1111/j.1365-2133.2012.10974.x; Nazarian RM, 2010, J CUTAN PATHOL, V37, P41, DOI 10.1111/j.1600-0560.2010.01505.x; Njauw CNJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035295; Nogueira C, 2010, ONCOGENE, V29, P6222, DOI 10.1038/onc.2010.349; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Omholt K, 2001, INT J CANCER, V92, P839, DOI 10.1002/ijc.1270; Orgaz JL, 2013, PIGM CELL MELANOMA R, V26, P39, DOI 10.1111/pcmr.12041; Ossowski L, 2010, PIGM CELL MELANOMA R, V23, P41, DOI 10.1111/j.1755-148X.2009.00647.x; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; Parlakian A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009299; PATEL JK, 1978, AM J SURG, V135, P807, DOI 10.1016/0002-9610(78)90171-X; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Peinado H, 2011, SEMIN CANCER BIOL, V21, P139, DOI 10.1016/j.semcancer.2011.01.002; Pierard GE, 2012, DERMATOL RES PRACT, V2012; Pinner S, 2009, CANCER RES, V69, P7969, DOI 10.1158/0008-5472.CAN-09-0781; Pittet MJ, 2011, CELL, V147, P983, DOI 10.1016/j.cell.2011.11.004; Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658; Podsypanina K, 2008, SCIENCE, V321, P1841, DOI 10.1126/science.1161621; Prickett TD, 2011, NAT GENET, V43, P1119, DOI 10.1038/ng.950; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Rabbani P, 2011, CELL, V145, P941, DOI 10.1016/j.cell.2011.05.004; REINTGEN DS, 1983, SURG GYNECOL OBSTET, V156, P335; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Riker AI, 2012, BMC MED, V10, DOI [10.1186/PREACCEPT-2032291833666638, 10.1186/1741-7015-10-19]; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Ross AL, 2011, ISRN DERMATOL, V2011; Rothberg BEG, 2009, J CLIN ONCOL, V27, P5772, DOI 10.1200/JCO.2009.22.8239; Rothwell PM, 2012, LANCET, V379, P1591, DOI 10.1016/S0140-6736(12)60209-8; Rozenberg GI, 2010, MELANOMA RES, V20, P361, DOI 10.1097/CMR.0b013e328336ee17; Schon CA, 2006, PATHOL RES PRACT, V202, P351, DOI 10.1016/j.prp.2005.12.008; Scott KL, 2011, CANCER CELL, V20, P92, DOI 10.1016/j.ccr.2011.05.025; Seong I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031477; Sharpless NE, 2006, NAT REV DRUG DISCOV, V5, P741, DOI 10.1038/nrd2110; Sinnberg T, 2010, CANCER RES, V70, P6999, DOI 10.1158/0008-5472.CAN-10-0645; SLINGLUFF CL, 1992, CANCER-AM CANCER SOC, V70, P1917, DOI 10.1002/1097-0142(19921001)70:7<1917::AID-CNCR2820700719>3.0.CO;2-5; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Stoecklein NH, 2010, INT J CANCER, V126, P589, DOI 10.1002/ijc.24916; Takahashi Y, 2008, INT J CANCER, V123, P2315, DOI 10.1002/ijc.23812; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Taube JM, 2009, AM J SURG PATHOL, V33, P568, DOI 10.1097/PAS.0b013e31818a64fb; Timar J, 2010, CLIN EXP METASTAS, V27, P371, DOI 10.1007/s10585-010-9307-2; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; Tucci MG, 2007, BRIT J DERMATOL, V157, P1212, DOI 10.1111/j.1365-2133.2007.08246.x; Turajlic S, 2012, GENOME RES, V22, P196, DOI 10.1101/gr.125591.111; Ugurel S, 2007, CLIN CANCER RES, V13, P6344, DOI 10.1158/1078-0432.CCR-06-2682; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Valsesia A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018369; van Akkooi ACJ, 2008, ANN SURG, V248, P949, DOI 10.1097/SLA.0b013e31818fefe0; van der Ploeg APT, 2011, J CLIN ONCOL, V29, P2206, DOI 10.1200/JCO.2010.31.6760; van der Ploeg APT, 2010, EUR J CANCER, V46, P2414, DOI 10.1016/j.ejca.2010.06.003; Walker GJ, 2011, PIGM CELL MELANOMA R, V24, P1158, DOI 10.1111/j.1755-148X.2011.00923.x; Webster MR, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004114; Widlund HR, 2002, J CELL BIOL, V158, P1079, DOI 10.1083/jcb.200202049; Wirtz D, 2011, NAT REV CANCER, V11, P512, DOI 10.1038/nrc3080; Wong SL, 2006, ANN SURG ONCOL, V13, P809, DOI 10.1245/ASO.2006.03.058; Wu CW, 2013, BJU INT, V111, pE310, DOI 10.1111/j.1464-410X.2012.11687.x; Yaguchi T, 2012, J IMMUNOL, V189, P2110, DOI 10.4049/jimmunol.1102282; Yajima I, 2011, J SKIN CANCER, V2011, DOI 10.1155/2011/730170; Yang PT, 2012, EMBO MOL MED, V4, P1294, DOI 10.1002/emmm.201201486; Yokoyama S, 2011, NATURE, V480, P99, DOI 10.1038/nature10630; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5	170	86	91	2	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2413	2422		10.1038/onc.2013.194	http://dx.doi.org/10.1038/onc.2013.194			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23728340				2022-12-17	WOS:000336033600001
J	Masciarelli, S; Fontemaggi, G; Di Agostino, S; Donzelli, S; Carcarino, E; Strano, S; Blandino, G				Masciarelli, S.; Fontemaggi, G.; Di Agostino, S.; Donzelli, S.; Carcarino, E.; Strano, S.; Blandino, G.			Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells	ONCOGENE			English	Article						mutant p53; gain of function; chemoresistance; miR-223; stathmin-1	BREAST-CANCER PATIENTS; STATHMIN INTERACTION; EXPRESSION; PROTEIN; MICRORNA-223; RESISTANCE; CARCINOMA; KINASE; TARGET; SENSITIVITY	Mutant p53 proteins are expressed at high frequency in human tumors and are associated with poor clinical prognosis and resistance to chemotherapeutic treatments. Here we show that mutant p53 proteins downregulate micro-RNA (miR)-223 expression in breast and colon cancer cell lines. Mutant p53 binds the miR-223 promoter and reduces its transcriptional activity. This requires the transcriptional repressor ZEB-1. We found that miR-223 exogenous expression sensitizes breast and colon cancer cell lines expressing mutant p53 to treatment with DNA-damaging drugs. Among the putative miR-223 targets, we focused on stathmin-1 (STMN-1), an oncoprotein known to confer resistance to chemotherapeutic drugs associated with poor clinical prognosis. Mutant p53 silencing or miR-223 exogenous expression lowers the levels of STMN-1 and knockdown of STMN-1 by small interfering RNA increases cell death of mutant p53-expressing cell lines. On the basis of these findings, we propose that one of the pathways affected by mutant p53 to increase cellular resistance to chemotherapeutic agents involves miR-223 downregulation and the consequent upregulation of STMN-1.	[Masciarelli, S.; Fontemaggi, G.; Di Agostino, S.; Donzelli, S.; Carcarino, E.; Blandino, G.] Regina Elena Inst Canc Res, Translat Oncogen Unit, I-00144 Rome, Italy; [Strano, S.] Regina Elena Inst Canc Res, Chemoprevent Unit, I-00144 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Blandino, G (corresponding author), Regina Elena Inst Canc Res, Translat Oncogen Unit, Via Elio Chianesi 53, I-00144 Rome, Italy.	blandino@ifo.it	donzelli, sara/J-8182-2016; Donzelli, Sara/AAA-2557-2021; Di Agostino, Silvia/H-1121-2018; Strano, Sabrina/K-9654-2016; Di Agostino, Silvia/S-8566-2019; Fontemaggi, Giulia/K-9702-2016	donzelli, sara/0000-0002-8529-2895; Donzelli, Sara/0000-0002-8529-2895; Di Agostino, Silvia/0000-0003-3730-1125; Fontemaggi, Giulia/0000-0001-8332-8842; MASCIARELLI, SILVIA/0000-0002-6738-6281; strano, sabrina/0000-0002-6341-4230	AIRC [10454]	AIRC(Fondazione AIRC per la ricerca sul cancro)	We are grateful for the support given by AIRC (Grant Number: 10454) to GB. We thank Francesca Fausti for providing the SW480-sh53 cell line and Dr Taro Fukao for kindly providing the ppri-hmiR-223<SUP>-669</SUP>-Luc luciferase reporter.	Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Ahn J, 1999, ONCOGENE, V18, P5954, DOI 10.1038/sj.onc.1202986; Alli E, 2002, CANCER RES, V62, P6864; Alli E, 2007, ONCOGENE, V26, P1003, DOI 10.1038/sj.onc.1209864; Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819; Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; Bane AL, 2009, BREAST CANCER RES TR, V117, P183, DOI 10.1007/s10549-008-0087-1; Belletti B, 2011, EXPERT OPIN THER TAR, V15, P1249, DOI 10.1517/14728222.2011.620951; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cheng AL, 2008, CLIN CANCER RES, V14, P435, DOI 10.1158/1078-0432.CCR-07-1215; Chicas A, 2000, BIOCHEM BIOPH RES CO, V279, P383, DOI 10.1006/bbrc.2000.3965; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Donzelli S, 2012, CELL DEATH DIFFER, V19, P1038, DOI 10.1038/cdd.2011.190; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; Fontemaggi G, 2009, NAT STRUCT MOL BIOL, V16, P1086, DOI 10.1038/nsmb.1669; Fukao T, 2007, CELL, V129, P617, DOI 10.1016/j.cell.2007.02.048; Gohler T, 2005, NUCLEIC ACIDS RES, V33, P1087, DOI 10.1093/nar/gki252; Golouh R, 2008, BREAST CANCER RES TR, V110, P317, DOI 10.1007/s10549-007-9724-3; Gottardo F, 2007, UROL ONCOL-SEMIN ORI, V25, P387, DOI 10.1016/j.urolonc.2007.01.019; Haddad Y, 2009, CLIN CANCER RES, V15, P532, DOI 10.1158/1078-0432.CCR-08-1733; Hainaut P, 2000, ADV CANCER RES, V77, P81; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Israel A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006045; Jia CY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027008; Jiang H, 2008, P NATL ACAD SCI USA, V105, P11299, DOI 10.1073/pnas.0801457105; Johnsen JI, 2000, INT J CANCER, V88, P685, DOI 10.1002/1097-0215(20001201)88:5<685::AID-IJC1>3.0.CO;2-Z; Kang W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033919; Laios A, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-35; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; Lu C, 2009, APOPTOSIS, V14, P597, DOI 10.1007/s10495-009-0330-1; Manceau V, 1999, ELECTROPHORESIS, V20, P409, DOI 10.1002/(SICI)1522-2683(19990201)20:2<409::AID-ELPS409>3.3.CO;2-E; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; MELHEM RF, 1991, BIOCHEM BIOPH RES CO, V179, P1649, DOI 10.1016/0006-291X(91)91764-4; Mistry SJ, 1998, BIOCHEM J, V334, P23, DOI 10.1042/bj3340023; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Ng DCH, 2006, J CELL BIOL, V172, P245, DOI 10.1083/jcb.200503021; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Phadke AP, 2011, DNA CELL BIOL, V30, P715, DOI 10.1089/dna.2011.1240; Pulikkan JA, 2010, BLOOD, V115, P1768, DOI 10.1182/blood-2009-08-240101; Rana S, 2008, EXPERT REV ANTICANC, V8, P1461, DOI 10.1586/14737140.8.9.1461; Rubin CI, 2004, J CELL BIOCHEM, V93, P242, DOI 10.1002/jcb.20187; Salvesen HB, 2009, P NATL ACAD SCI USA, V106, P4834, DOI 10.1073/pnas.0806514106; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; Shah AN, 2007, ANN SURG ONCOL, V14, P3629, DOI 10.1245/s10434-007-9583-5; Singer S, 2007, HEPATOLOGY, V46, P759, DOI 10.1002/hep.21736; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang L, 2012, ONCOGENE, V31, P2499, DOI 10.1038/onc.2011.444; Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988; Wong QWL, 2008, GASTROENTEROLOGY, V135, P257, DOI 10.1053/j.gastro.2008.04.003; Zheng P, 2010, J PROTEOME RES, V9, P4897, DOI 10.1021/pr100712t	58	86	88	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2014	33	12					1601	1608		10.1038/onc.2013.106	http://dx.doi.org/10.1038/onc.2013.106			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD4TS	23584479				2022-12-17	WOS:000333244200013
J	Galluzzi, L; Vacchelli, E; Michels, J; Garcia, P; Kepp, O; Senovilla, L; Vitale, I; Kroemer, G				Galluzzi, L.; Vacchelli, E.; Michels, J.; Garcia, P.; Kepp, O.; Senovilla, L.; Vitale, I.; Kroemer, G.			Effects of vitamin B6 metabolism on oncogenesis, tumor progression and therapeutic responses	ONCOGENE			English	Review						ALDH7A1; homocysteine; NSCLC; pyridoxal phosphatase; pyridoxine; stress response	ONE-CARBON METABOLISM; COLORECTAL-CANCER RISK; NON-HODGKIN-LYMPHOMA; BREAST-CANCER; PYRIDOXINE-DEFICIENCY; DIETARY-FOLATE; ALCOHOL-CONSUMPTION; NUTRIENT INTAKE; PLASMA FOLATE; FOLIC-ACID	Pyridoxal-5'-phosphate (PLP), the bioactive form of vitamin B6, reportedly functions as a prosthetic group for >4% of classified enzymatic activities of the cell. It is therefore not surprising that alterations of vitamin B6 metabolism have been associated with multiple human diseases. As a striking example, mutations in the gene coding for antiquitin, an evolutionary old aldehyde dehydrogenase, result in pyridoxine-dependent seizures, owing to the accumulation of a metabolic intermediate that inactivates PLP. In addition, PLP is required for the catabolism of homocysteine by transsulfuration. Hence, reduced circulating levels of B6 vitamers (including PLP as well as its major precursor pyridoxine) are frequently paralleled by hyperhomocysteinemia, a condition that has been associated with an increased risk for multiple cardiovascular diseases. During the past 30 years, an intense wave of clinical investigation has attempted to dissect the putative links between vitamin B6 and cancer. Thus, high circulating levels of vitamin B6, as such or as they reflected reduced amounts of circulating homocysteine, have been associated with improved disease outcome in patients bearing a wide range of hematological and solid neoplasms. More recently, the proficiency of vitamin B6 metabolism has been shown to modulate the adaptive response of tumor cells to a plethora of physical and chemical stress conditions. Moreover, elevated levels of pyridoxal kinase (PDXK), the enzyme that converts pyridoxine and other vitamin B6 precursors into PLP, have been shown to constitute a good, therapy-independent prognostic marker in patients affected by non-small cell lung carcinoma (NSCLC). Here, we will discuss the clinical relevance of vitamin B6 metabolism as a prognostic factor in cancer patients.	[Galluzzi, L.; Kroemer, G.] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Galluzzi, L.; Vacchelli, E.; Michels, J.; Garcia, P.; Kepp, O.; Senovilla, L.; Vitale, I.; Kroemer, G.] Inst Gustave Roussy, F-94805 Villejuif, Val De Marne, France; [Vacchelli, E.; Michels, J.; Garcia, P.; Kepp, O.; Senovilla, L.; Vitale, I.] Univ Paris 11, Paris, France; [Vacchelli, E.; Michels, J.; Garcia, P.; Kepp, O.; Senovilla, L.; Vitale, I.; Kroemer, G.] INSERM, U848, Villejuif, France; [Kroemer, G.] Ctr Rech Cordeliers, Equipe Labellisee Ligue Canc 11, Paris, France; [Kroemer, G.] Hop Europeen Georges Pompidou, Pole Biol, Paris, France	UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Galluzzi, L (corresponding author), Inst Gustave Roussy, INSERM, U848, Pavillon Rech 1,39,Rue Camille Desmoulins, F-94805 Villejuif, Val De Marne, France.	deadoc@vodafone.it; kroemer@orange.fr	KROEMER, Guido/B-4263-2013; Galluzzi, Lorenzo/AAG-6294-2019; Vitale, Ilio/M-3960-2017; Kepp, Oliver/GPX-8627-2022; Michels, Judith/Q-5693-2018; Galluzzi, Lorenzo/AAG-6432-2019; Vacchelli, Erika/E-5212-2018; Kroemer, Guido/AAY-9859-2020; Senovilla, Laura/AAX-5599-2021; Galluzzi, Lorenzo/AAH-3286-2021; Kepp, Oliver/N-2763-2017	KROEMER, Guido/0000-0002-9334-4405; Vitale, Ilio/0000-0002-5918-1841; Michels, Judith/0000-0002-9640-0222; Vacchelli, Erika/0000-0001-8010-0594; Kepp, Oliver/0000-0002-6081-9558; Senovilla, Laura/0000-0001-6887-2436	European Commission (ArtForce); Agence National de la Recherche (ANR); Ligue contre le Cancer (Equipe labellisee); Fondation pour la Recherche Medicale (FRM); Institut National du Cancer (INCa); LabEx Immuno-Oncologie; Fondation de France; Fondation Bettencourt-Schueller; AXA Chair for Longevity Research; Canceropole Ile-de-France; Paris Alliance of Cancer Research Institutes (PACRI)	European Commission (ArtForce)(European CommissionEuropean Commission Joint Research Centre); Agence National de la Recherche (ANR)(French National Research Agency (ANR)); Ligue contre le Cancer (Equipe labellisee); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); LabEx Immuno-Oncologie; Fondation de France(Fondation de France); Fondation Bettencourt-Schueller; AXA Chair for Longevity Research(AXA Research Fund); Canceropole Ile-de-France(Region Ile-de-France); Paris Alliance of Cancer Research Institutes (PACRI)	We acknowledge the valuable help of Federico Pietrocola for the compilation of Table 1. The authors are supported by the European Commission (ArtForce); Agence National de la Recherche (ANR); Ligue contre le Cancer (Equipe labellisee); Fondation pour la Recherche Medicale (FRM); Institut National du Cancer (INCa); LabEx Immuno-Oncologie; Fondation de France; Fondation Bettencourt-Schueller; AXA Chair for Longevity Research; Canceropole Ile-de-France and Paris Alliance of Cancer Research Institutes (PACRI).	Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Ames BN, 2001, MUTAT RES-FUND MOL M, V475, P7, DOI 10.1016/S0027-5107(01)00070-7; Ames BN, 1999, ANN NY ACAD SCI, V889, P87, DOI 10.1111/j.1749-6632.1999.tb08727.x; ATUKORALA TMS, 1983, CLIN ONCOL, V9, P3; BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3626, DOI 10.1093/nar/22.17.3626; BAKER H, 1992, J AM COLL NUTR, V11, P482; BAKER H, 1981, CANCER, V47, P2883, DOI 10.1002/1097-0142(19810615)47:12<2883::AID-CNCR2820471222>3.0.CO;2-I; Banque M, 2012, NUTR CANCER, V64, P386, DOI 10.1080/01635581.2012.657334; Bosetti C, 2007, INT J CANCER, V120, P892, DOI 10.1002/ijc.22374; Bourquin F, 2011, PROTEIN SCI, V20, P1492, DOI 10.1002/pro.679; Boyapati SM, 2004, CANCER CAUSE CONTROL, V15, P493, DOI 10.1023/B:CACO.0000036447.45446.2c; BYAR D, 1977, Urology, V10, P556, DOI 10.1016/0090-4295(77)90101-7; CHANG YC, 1987, BIOCHEMISTRY-US, V26, P360, DOI 10.1021/bi00376a005; Chou YC, 2011, J EPIDEMIOL, V21, P329, DOI 10.2188/jea.JE20100188; CHRISTENSEN HN, 1954, J BIOL CHEM, V209, P413; Clayton PT, 2006, J INHERIT METAB DIS, V29, P317, DOI 10.1007/s10545-005-0243-2; D'Agostini F, 2013, ARCH DERMATOL RES, V305, P25, DOI 10.1007/s00403-012-1253-1; DALTON K, 1987, ACTA NEUROL SCAND, V76, P8, DOI 10.1111/j.1600-0404.1987.tb03536.x; de Vogel S, 2008, J NUTR, V138, P2372, DOI 10.3945/jn.108.091157; de Vogel S, 2011, CANCER EPIDEM BIOMAR, V20, P1726, DOI 10.1158/1055-9965.EPI-11-0359; DISORBO D M, 1983, Nutrition and Cancer, V5, P10, DOI 10.1080/01635588309513773; DISORBO D M, 1985, Nutrition and Cancer, V7, P43, DOI 10.1080/01635588509513838; DISORBO D M, 1982, Nutrition and Cancer, V3, P216, DOI 10.1080/01635588109513725; Dong LF, 2008, ONCOGENE, V27, P4324, DOI 10.1038/onc.2008.69; DRAUDINKRYLENKO VA, 1989, VOP ONKOL+, V35, P34; Eussen SJPM, 2010, CANCER EPIDEM BIOMAR, V19, P2549, DOI 10.1158/1055-9965.EPI-10-0407; Eussen SJPM, 2010, CANCER EPIDEM BIOMAR, V19, P28, DOI 10.1158/1055-9965.EPI-08-1096; FEDDE KN, 1990, AM J HUM GENET, V47, P767; Figueiredo JC, 2008, CANCER EPIDEM BIOMAR, V17, P2136, DOI 10.1158/1055-9965.EPI-07-2895; FOLKERS K, 1993, BIOCHEM BIOPH RES CO, V193, P88, DOI 10.1006/bbrc.1993.1593; FRIEDMAN MA, 1986, J AM ACAD DERMATOL, V14, P915, DOI 10.1016/S0190-9622(86)70112-6; Fritz V, 2010, ONCOGENE, V29, P4369, DOI 10.1038/onc.2010.182; Frohlich DA, 2008, ONCOGENE, V27, P4353, DOI 10.1038/onc.2008.79; GAILANI S, 1966, ANN INTERN MED, V65, P1044, DOI 10.7326/0003-4819-65-5-1044; GAILANI SD, 1968, CANCER-AM CANCER SOC, V21, P975, DOI 10.1002/1097-0142(196805)21:5&lt;975::AID-CNCR2820210522&gt;3.0.CO;2-3; Galeone C, 2006, ANN ONCOL, V17, P521, DOI 10.1093/annonc/mdj107; Galluzzi L, 2006, ONCOGENE, V25, P4812, DOI 10.1038/sj.onc.1209598; Galluzzi L, 2011, FRONT ONCOL, V1, P1; Galluzzi L, 2013, CELL CYCLE IN PRESS; Galluzzi L, 2012, CELL REP, V2, P257, DOI 10.1016/j.celrep.2012.06.017; Galluzzi L, 2012, NAT REV DRUG DISCOV, V11, P215, DOI 10.1038/nrd3626; Garcia-Closas R, 2007, EUR J CANCER, V43, P1731, DOI 10.1016/j.ejca.2007.05.007; Garg MB, 2011, CANCER CHEMOTH PHARM, V67, P963, DOI 10.1007/s00280-010-1476-9; Gdynia HJ, 2008, NEUROMUSCULAR DISORD, V18, P156, DOI 10.1016/j.nmd.2007.09.009; GEBHARD KJ, 1990, NUTR CANCER, V14, P15, DOI 10.1080/01635589009514074; Gong ZH, 2009, CANCER CAUSE CONTROL, V20, P1317, DOI 10.1007/s10552-009-9352-9; GRIDLEY DS, 1987, J NATL CANCER I, V78, P951; GRIMALDI T, 1971, Pathologica (Genoa), V63, P89; Gyorgy P, 1940, BIOCHEM J, V34, P1143; HA C, 1984, J NUTR, V114, P938, DOI 10.1093/jn/114.5.938; HA C, 1984, CELL IMMUNOL, V85, P318, DOI 10.1016/0008-8749(84)90246-6; Haberkorn U, 2011, ONCOGENE, V30, P4141, DOI 10.1038/onc.2011.169; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harnack L, 2002, NUTR CANCER, V43, P152, DOI 10.1207/S15327914NC432_5; Harris HR, 2012, INT J CANCER, V131, pE518, DOI 10.1002/ijc.26455; Harrison LE, 1997, CANCER-AM CANCER SOC, V80, P1021; HOFSLI E, 1992, BIOTHERAPY, V5, P285, DOI 10.1007/BF02179046; Hong SW, 2013, ONCOGENE, V32, P1508, DOI 10.1038/onc.2012.176; Hotaling JM, 2011, J UROLOGY, V185, P1210, DOI 10.1016/j.juro.2010.11.081; Hubner RA, 2007, BRIT J CANCER, V97, P1449, DOI 10.1038/sj.bjc.6604056; INCULET RI, 1987, JPEN-PARENTER ENTER, V11, P243, DOI 10.1177/0148607187011003243; Ishihara J, 2007, J NUTR, V137, P1808, DOI 10.1093/jn/137.7.1808; Johansson M, 2010, JAMA-J AM MED ASSOC, V303, P2377, DOI 10.1001/jama.2010.808; Kaaks R, 1998, INT J CANCER, V78, P415, DOI 10.1002/(SICI)1097-0215(19981109)78:4&lt;415::AID-IJC4&gt;3.0.CO;2-X; Kanellis P, 2007, PLOS GENET, V3, P1438, DOI 10.1371/journal.pgen.0030134; Kayashima T, 2011, ONCOL LETT, V2, P1243, DOI 10.3892/ol.2011.370; Key TJA, 1997, BRIT J CANCER, V76, P678, DOI 10.1038/bjc.1997.445; King WD, 2012, MOL BIOL REP, V39, P7805, DOI 10.1007/s11033-012-1623-y; Komatsu S, 2003, BBA-PROTEINS PROTEOM, V1647, P127, DOI 10.1016/S1570-9639(03)00076-1; Komatsu S, 2002, J NUTR SCI VITAMINOL, V48, P65, DOI 10.3177/jnsv.48.65; Komatsu S, 2001, J NUTR, V131, P2204, DOI 10.1093/jn/131.8.2204; Komatsu SI, 2005, ONCOL REP, V14, P265; KORYTNYK W, 1977, J MED CHEM, V20, P745, DOI 10.1021/jm00216a002; KORYTNYK W, 1973, J MED CHEM, V16, P638, DOI 10.1021/jm00264a013; KORYTNYK W, 1976, J MED CHEM, V19, P999, DOI 10.1021/jm00230a003; KOSS LG, 1971, J NATL CANCER I, V46, P585; Kotsopoulos J, 2010, INT J CANCER, V126, P2191, DOI 10.1002/ijc.24723; KULCSAR G, 1995, CANCER BIOTHERAPY, V10, P157, DOI 10.1089/cbr.1995.10.157; Kulcsar G, 2013, INT J CANCER, V132, P1213, DOI 10.1002/ijc.27756; Kune G, 2006, NUTR CANCER, V56, P11, DOI 10.1207/s15327914nc5601_3; KURASHIGE S, 1988, JPN J EXP MED, V58, P197; Lajous M, 2006, CANCER EPIDEM BIOMAR, V15, P443, DOI 10.1158/1055-9965.EPI-05-0532; LAMM DL, 1994, J UROLOGY, V151, P21, DOI 10.1016/S0022-5347(17)34863-2; Larsson SC, 2005, GASTROENTEROLOGY, V128, P1830, DOI 10.1053/j.gastro.2005.03.005; Le Marchand L, 2011, CANCER CAUSE CONTROL, V22, P929, DOI 10.1007/s10552-011-9759-y; Le Marchand L, 2009, CANCER EPIDEM BIOMAR, V18, P2195, DOI 10.1158/1055-9965.EPI-09-0141; Lee JE, 2009, CANCER EPIDEM BIOMAR, V18, P1197, DOI 10.1158/1055-9965.EPI-08-1001; Lim U, 2005, AM J EPIDEMIOL, V162, P953, DOI 10.1093/aje/kwi310; Lim U, 2007, BLOOD, V109, P3050, DOI 10.1182/blood-2006-07-034330; Lim U, 2006, CANCER EPIDEM BIOMAR, V15, P1109, DOI 10.1158/1055-9965.EPI-05-0918; Lin J, 2008, AM J CLIN NUTR, V87, P734, DOI 10.1093/ajcn/87.3.734; LITTMAN ML, 1964, P SOC EXP BIOL MED, V116, P95, DOI 10.3181/00379727-116-29170; LUMENG L, 1974, J CLIN INVEST, V53, P693, DOI 10.1172/JCI107607; Lurie G, 2012, CANCER EPIDEM BIOMAR, V21, P1942, DOI 10.1158/1055-9965.EPI-12-0717-T; Ma E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-122; Ma E, 2009, NUTR CANCER, V61, P447, DOI 10.1080/01635580802610123; Manegold C, 2009, J INHERIT METAB DIS, V32, P371, DOI 10.1007/s10545-009-1076-1; Marchand LL, 2002, CANCER CAUSE CONTROL, V13, P239, DOI 10.1023/A:1015057614870; Mayne ST, 2001, CANCER EPIDEM BIOMAR, V10, P1055; McCullough ML, 2004, ONCOGENE, V23, P6349, DOI 10.1038/sj.onc.1207716; Mehta R, 2011, TOXICOL IN VITRO, V25, P1114, DOI 10.1016/j.tiv.2011.03.015; MEISLER NT, 1982, CANCER RES, V42, P3538; MIHICH E, 1965, CANCER RES, V25, P794; MIHICH E, 1962, CANCER RES, V22, P218; Mills PB, 2006, NAT MED, V12, P307, DOI 10.1038/nm1366; Molina A, 1997, NUTR CANCER, V28, P206, DOI 10.1080/01635589709514576; NANDI DL, 1978, ARCH BIOCHEM BIOPHYS, V188, P266, DOI 10.1016/S0003-9861(78)80008-3; Negri E, 2000, INT J CANCER, V86, P122, DOI 10.1002/(SICI)1097-0215(20000401)86:1&lt;122::AID-IJC19&gt;3.0.CO;2-2; NEWLING DWW, 1995, EUR UROL, V27, P110, DOI 10.1159/000475139; NIKONOVA TV, 1988, EKSP ONKOL, V10, P17; Otani T, 2005, NUTR CANCER, V53, P42, DOI 10.1207/s15327914nc5301_5; PAIS RC, 1990, CANCER, V66, P2421, DOI 10.1002/1097-0142(19901201)66:11&lt;2421::AID-CNCR2820661130&gt;3.0.CO;2-M; Pelucchi C, 2009, ANN ONCOL, V20, P160, DOI 10.1093/annonc/mdn536; Pierotti MA, 2013, ONCOGENE, V32, P1475, DOI 10.1038/onc.2012.181; Polesel J, 2007, NUTR CANCER, V57, P146, DOI 10.1080/01635580701274202; POTERA C, 1977, AM J CLIN NUTR, V30, P1677, DOI 10.1093/ajcn/30.10.1677; RAMASWAMY P G, 1984, Nutrition and Cancer, V6, P176, DOI 10.1080/01635588509513821; Rauf Mariam, 2011, J Med Case Rep, V5, P372, DOI 10.1186/1752-1947-5-372; Ravasco P., 2005, Nutr. Hosp., V20, P165; RIGGS TR, 1953, BIOCHIM BIOPHYS ACTA, V11, P303, DOI 10.1016/0006-3002(53)90041-9; Rosenthal GA, 1997, LIFE SCI, V60, P1635, DOI 10.1016/S0024-3205(96)00595-4; Roth-Maier DA, 2002, INT J FOOD SCI NUTR, V53, P171, DOI 10.1080/09637480220132184; SCHAUMBURG H, 1983, NEW ENGL J MED, V309, P445, DOI 10.1056/NEJM198308253090801; Schemhammer ES, 2008, CANCER EPIDEM BIOMAR, V17, P2895, DOI 10.1158/1055-9965.EPI-08-0638; Schernhammer E, 2007, CANCER RES, V67, P5553, DOI 10.1158/0008-5472.CAN-06-4463; Schernhammer ES, 2008, GASTROENTEROLOGY, V135, P770, DOI 10.1053/j.gastro.2008.06.033; Schernhammer ES, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021102; SCHNACKERZ KD, 1983, J BIOL CHEM, V258, P872; SCHWAN TJ, 1965, J MED CHEM, V8, P750, DOI 10.1021/jm00330a004; Selhub J, 1999, ANNU REV NUTR, V19, P217, DOI 10.1146/annurev.nutr.19.1.217; Semeraro N, 1970, Pathologica, V62, P133; Sharp L, 2008, BRIT J NUTR, V99, P379, DOI 10.1017/S0007114507801073; Shi QL, 2005, CANCER EPIDEM BIOMAR, V14, P1477, DOI 10.1158/1055-9965.EPI-04-0905; Shimada D, 2006, BIOSCI BIOTECH BIOCH, V70, P1038, DOI 10.1271/bbb.70.1038; Shimada D, 2005, NUTR CANCER, V53, P202, DOI 10.1207/s15327914nc5302_9; SHULTZ TD, 1988, ANTICANCER RES, V8, P1313; Slattery ML, 1999, CANCER EPIDEM BIOMAR, V8, P513; STOERK HC, 1950, P SOC EXP BIOL MED, V74, P798, DOI 10.3181/00379727-74-18053; Swaffar DS, 1999, ANTI-CANCER DRUG, V10, P113, DOI 10.1097/00001813-199901000-00014; Takeuchi PL, 2007, TOXICOL IN VITRO, V21, P665, DOI 10.1016/j.tiv.2007.01.004; Theodoratou E, 2008, CANCER EPIDEM BIOMAR, V17, P171, DOI 10.1158/1055-9965.EPI-07-0621; Toney MD, 2005, ARCH BIOCHEM BIOPHYS, V433, P279, DOI 10.1016/j.abb.2004.09.037; TREBUKHINA R V, 1982, Voprosy Pitaniya, P40; Tryfiates G P, 1981, Cancer Detect Prev, V4, P159; TRYFIATES GP, 1974, JNCI-J NATL CANCER I, V52, P1259, DOI 10.1093/jnci/52.4.1259; TRYFIATES GP, 1981, ANTICANCER RES, V1, P263; TRYFIATES GP, 1974, EUR J CANCER, V10, P147, DOI 10.1016/0014-2964(74)90147-9; TRYFIATES GP, 1976, ONCOLOGY, V33, P209, DOI 10.1159/000225146; TRYFIATES GP, 1975, J NATL CANCER I, V54, P171, DOI 10.1093/jnci/54.1.171; Tryfiates GP, 1996, CANCER RES, V56, P3670; TRYFIATES GP, 1991, ANTICANCER RES, V11, P1281; TRYFIATES GP, 1995, ANTICANCER RES, V15, P379; TRYFIATES GP, 1983, ANTICANCER RES, V3, P53; Tucker KL, 2004, AM J CLIN NUTR, V79, P805; Venkateswaran V, 2004, CANCER RES, V64, P5891, DOI 10.1158/0008-5472.CAN-04-0690; Vidal AC, 2012, J CANCER EPIDEMIOL, V2012, DOI 10.1155/2012/957467; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Wei EK, 2005, J NATL CANCER I, V97, P684, DOI 10.1093/jnci/dji116; Weinstein SJ, 2003, CANCER EPIDEM BIOMAR, V12, P1271; Weinstein SJ, 2008, CANCER EPIDEM BIOMAR, V17, P3233, DOI 10.1158/1055-9965.EPI-08-0459; WILLIAMS RD, 1984, CANCER RES, V44, P1918; WOLF H, 1979, SCAND J UROL NEPHROL, V13, P143, DOI 10.3109/00365597909181169; YUSPA SH, 1966, P SOC EXP BIOL MED, V123, P398, DOI 10.3181/00379727-123-31498; Zhang CX, 2011, BRIT J NUTR, V106, P936, DOI 10.1017/S0007114511001140; Zhang SMM, 2008, JAMA-J AM MED ASSOC, V300, P2012, DOI 10.1001/jama.2008.555; Zhang SM, 2006, AM J EPIDEMIOL, V163, P108, DOI 10.1093/aje/kwj016; Zhang SM, 2003, J NATL CANCER I, V95, P373, DOI 10.1093/jnci/95.5.373; Zhang XH, 2012, AM J CLIN NUTR, V96, P874, DOI 10.3945/ajcn.112.037267; Zhang ZF, 1997, NUTR CANCER, V27, P298, DOI 10.1080/01635589709514541; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936	170	86	90	2	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					4995	5004		10.1038/onc.2012.623	http://dx.doi.org/10.1038/onc.2012.623			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23334322				2022-12-17	WOS:000325937900001
J	Leushacke, M; Barker, N				Leushacke, M.; Barker, N.			Lgr5 and Lgr6 as markers to study adult stem cell roles in self-renewal and cancer	ONCOGENE			English	Review						Lgr5; Lgr6; adult stem cell; epithelial renewal; cancer	PROTEIN-COUPLED RECEPTORS; MOUSE SMALL INTESTINE; HAIR FOLLICLE; BETA-CATENIN; EPITHELIAL-CELLS; EXPRESSION; ORIGIN; DIFFERENTIATION; IDENTIFICATION; ACTIVATION	The extended longevity of many mammals imposes the need for an effective tissue renewal capacity within the vital organs to maintain optimal function. Resident adult stem cells are instrumental in delivering this renewal capacity by virtue of their characteristic ability to maintain themselves long-term as a population (self-renewal), whilst also supplying all functional cell-lineages of the respective tissue (multipotency). The homeostatic activity of these adult stem cell reservoirs is tailored to meet the specific renewal requirements of individual tissues through a combination of intrinsic genetic programming and local cues delivered from the surrounding environment (the niche). Considerable phenotypic diversity therefore exists between adult stem cell populations in different organs, making it a considerable challenge to identify broadly applicable markers that facilitate their identification and characterization. However, the 7-transmembrane receptor, Lgr5 has recently gained prominence as a marker of Wnt-regulated adult stem cell populations in the hair-follicle, intestine and stomach. A closely-related protein, Lgr6 marks adult stem cells responsible for fueling the renewal of the sebaceous gland and skin. The discovery of these markers has already greatly improved our understanding of stem cell biology in these rapidly renewing tissues and has major implications for the identification and isolation of human adult stem cell populations for exploitation of their regenerative medicine potential in the clinic. Oncogene (2012) 31, 3009-3022; doi: 10.1038/onc.2011.479; published online 17 October 2011	[Leushacke, M.; Barker, N.] A STAR Inst Med Biol, Singapore 138648, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB)	Barker, N (corresponding author), A STAR Inst Med Biol, 8A Biomed Grove,06-06 Immunos, Singapore 138648, Singapore.	nicholas.barker@imb.a-star.edu.sg	Barker, Nick/AAS-2774-2020; Barker, Nick/AAE-9833-2021; Barker, Nick/A-5535-2011	Barker, Nick/0000-0003-3566-4475; 				Barker N, 2007, GASTROENTEROLOGY, V7, P656; Barker N, 2008, GENE DEV, V22, P1856, DOI 10.1101/gad.1674008; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2010, CELL STEM CELL, V7, P656, DOI 10.1016/j.stem.2010.11.016; Barker N, 2010, GASTROENTEROLOGY, V138, P1681, DOI 10.1053/j.gastro.2010.03.002; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; BJERKNES M, 1981, AM J ANAT, V160, P77, DOI 10.1002/aja.1001600107; Bjerknes M, 2002, AM J PHYSIOL-GASTR L, V283, pG767, DOI 10.1152/ajpgi.00415.2001; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Bonfanti P, 2010, NATURE, V466, P978, DOI 10.1038/nature09269; Breault DT, 2008, P NATL ACAD SCI USA, V105, P10420, DOI 10.1073/pnas.0804800105; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; Clements WM, 2002, CANCER RES, V62, P3503; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4; de Lau W, 2011, NATURE, V476, P293, DOI 10.1038/nature10337; Dignass AU, 2001, EUR J GASTROEN HEPAT, V13, P763, DOI 10.1097/00042737-200107000-00002; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Flores I, 2005, SCIENCE, V309, P1253, DOI 10.1126/science.1115025; Fuchs E, 2008, GENE DEV, V22, P976, DOI 10.1101/gad.1645908; Fuchs E, 2009, CELL, V137, P811, DOI 10.1016/j.cell.2009.05.002; Fuller MT, 2007, SCIENCE, V316, P402, DOI 10.1126/science.1140861; Ghazizadeh S, 2001, EMBO J, V20, P1215, DOI 10.1093/emboj/20.6.1215; Greco V, 2009, CELL STEM CELL, V4, P155, DOI 10.1016/j.stem.2008.12.009; Green H, 2008, BIOESSAYS, V30, P897, DOI 10.1002/bies.20797; Haramis APG, 2004, SCIENCE, V303, P1684, DOI 10.1126/science.1093587; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1830, DOI 10.1210/me.12.12.1830; Hsu SY, 2000, MOL ENDOCRINOL, V14, P1257, DOI 10.1210/me.14.8.1257; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Jaks V, 2008, NAT GENET, V40, P1291, DOI 10.1038/ng.239; KARAM SM, 1993, ANAT REC, V236, P259, DOI 10.1002/ar.1092360202; KARAM SM, 1999, FRONT BIOSCI, V4, P286; Kasper M, 2011, P NATL ACAD SCI USA, V108, P4099, DOI 10.1073/pnas.1014489108; Kazanskaya O, 2004, DEV CELL, V7, P525, DOI 10.1016/j.devcel.2004.07.019; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kiel MJ, 2007, NATURE, V449, P238, DOI 10.1038/nature06115; Kim KA, 2005, SCIENCE, V309, P1256, DOI 10.1126/science.1112521; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; LEBLOND CP, 1948, ANAT REC, V100, P357, DOI 10.1002/ar.1091000306; Li LH, 2005, ANNU REV CELL DEV BI, V21, P605, DOI 10.1146/annurev.cellbio.21.012704.131525; Li LH, 2010, SCIENCE, V327, P542, DOI 10.1126/science.1180794; Lin SA, 2011, J GASTROENTEROL, V46, P1039, DOI 10.1007/s00535-011-0424-8; Livet J, 2007, NATURE, V450, P56, DOI 10.1038/nature06293; Lopez-Garcia C, 2010, SCIENCE, V330, P822, DOI 10.1126/science.1196236; Marshman E, 2002, BIOESSAYS, V24, P91, DOI 10.1002/bies.10028; Mazerbourg S, 2004, MOL ENDOCRINOL, V18, P2241, DOI 10.1210/me.2004-0133; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Montgomery RK, 2011, P NATL ACAD SCI USA, V108, P179, DOI 10.1073/pnas.1013004108; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; Mustata RC, 2011, EMBO REP, V12, P558, DOI 10.1038/embor.2011.52; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Offerhaus GJA, 1999, HEPATO-GASTROENTEROL, V46, P667; Orford KW, 2008, NAT REV GENET, V9, P115, DOI 10.1038/nrg2269; Oshima H, 2001, CELL, V104, P233, DOI 10.1016/S0092-8674(01)00208-2; Park WS, 1999, CANCER RES, V59, P4257; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; POTTEN CS, 1974, CELL TISSUE KINET, V7, P271, DOI 10.1111/j.1365-2184.1974.tb00907.x; POTTEN CS, 1977, NATURE, V269, P518, DOI 10.1038/269518a0; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Preston SL, 2003, CANCER RES, V63, P3819; Quyn AJ, 2010, CELL STEM CELL, V6, P175, DOI 10.1016/j.stem.2009.12.007; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; ROCHAT A, 1994, CELL, V76, P1063, DOI 10.1016/0092-8674(94)90383-2; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Sancho E, 2003, CURR OPIN CELL BIOL, V15, P763, DOI 10.1016/j.ceb.2003.10.012; Sangiorgi E, 2008, NAT GENET, V40, P915, DOI 10.1038/ng.165; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Schepers AG, 2011, EMBO J, V30, P1104, DOI 10.1038/emboj.2011.26; Shih LM, 2001, P NATL ACAD SCI USA, V98, P2640, DOI 10.1073/pnas.051629398; Snippert HJ, 2011, EMBO REP, V12, P113, DOI 10.1038/embor.2010.216; Snippert HJ, 2010, CELL, V143, P134, DOI 10.1016/j.cell.2010.09.016; Snippert HJ, 2010, SCIENCE, V327, P1385, DOI 10.1126/science.1184733; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; SPANA EP, 1995, DEVELOPMENT, V121, P3489; Takahashi H, 2011, ANN SURG ONCOL, V18, P1166, DOI 10.1245/s10434-010-1373-9; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Tomita H, 2007, CANCER RES, V67, P4079, DOI 10.1158/0008-5472.CAN-06-4025; Trempus CS, 2003, J INVEST DERMATOL, V120, P501, DOI 10.1046/j.1523-1747.2003.12088.x; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Uchida H, 2010, CANCER SCI, V101, P1731, DOI 10.1111/j.1349-7006.2010.01571.x; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Van Der Flier LG, 2007, GASTROENTEROLOGY, V132, P628, DOI 10.1053/j.gastro.2006.08.039; van der Flier LG, 2009, ANNU REV PHYSIOL, V71, P241, DOI 10.1146/annurev.physiol.010908.163145; van der Flier LG, 2009, CELL, V136, P903, DOI 10.1016/j.cell.2009.01.031; van Es JH, 2005, NAT CELL BIOL, V7, P381, DOI 10.1038/ncb1240; Van Schoore G, 2005, HISTOCHEM CELL BIOL, V124, P35, DOI 10.1007/s00418-005-0002-3; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Walker F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022733; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zeki SS, 2011, NAT REV GASTRO HEPAT, V8, P90, DOI 10.1038/nrgastro.2010.211; Zhang YV, 2009, CELL STEM CELL, V5, P267, DOI 10.1016/j.stem.2009.06.004; Zhu LQ, 2009, NATURE, V457, P603, DOI 10.1038/nature07589	104	86	93	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	25					3009	3022		10.1038/onc.2011.479	http://dx.doi.org/10.1038/onc.2011.479			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964OP	22002312				2022-12-17	WOS:000305705900001
J	Arzumanyan, A; Friedman, T; Kotei, E; Ng, IOL; Lian, Z; Feitelson, MA				Arzumanyan, A.; Friedman, T.; Kotei, E.; Ng, I. O. L.; Lian, Z.; Feitelson, M. A.			Epigenetic repression of E-cadherin expression by hepatitis B virus x antigen in liver cancer	ONCOGENE			English	Article						hepatocellular carcinoma; mSin3A; Snail-1; HDAC; miR-373	NF-KAPPA-B; HEPATOCELLULAR-CARCINOMA; CARRIER PATIENTS; GENE-EXPRESSION; DOWN-REGULATION; UP-REGULATION; IN-VIVO; PROTEIN; CELLS; SNAIL	Loss of E-cadherin is associated with acquisition of metastatic capacity. Numerous studies suggest that histone deacetylation and/or hypermethylation of CpG islands in E-cadherin gene (CDH1) are major mechanisms responsible for E-cadherin silencing in different tumors and cancer cell lines. The hepatitis B virus (HBV)-encoded X antigen, HBx, contributes importantly to the development of hepatocellular carcinoma using multiple mechanisms. Experiments were designed to test if in addition to CDH1 hypermethylation HBx promotes epigenetic modulation of E-cadherin transcriptional activity through histone deacetylation and miR-373. The relationships between HBx, E-cadherin, mSin3A, Snail-1 and miR-373 were evaluated in HBx expressing (HepG2X) and control (HepG2CAT) cells by western blotting, immunoprecipitation (IP), chromatin IP as well as by immunohistochemical staining of liver and tumor tissue sections from HBV-infected patients. In HepG2X cells, decreased levels of E-cadherin and elevated levels of mSin3A and Snail-1 were detected. Reciprocal IP with anti-HBx and anti-mSin3A demonstrated mutual binding. Furthermore, HBx-mSin3A colocalization was detected by immunofluorescent staining. HBx downregulated E-cadherin expression by the recruitment of the mSin3A/histone deacetylase complex to the Snail-binding sites in human CDH1. Histone deacetylation inhibition by Trichostatin-A treatment restored E-cadherin expression. Mir-373, a positive regulator of E-cadherin expression, was downregulated by HBx in HepG2X cells and tissue sections from HBV-infected patients. Thus, histone deacetylation of CDH1 and downregulation of miR-373, together with the previously demonstrated hypermethylation of CDH1 by HBx, may be important for the understanding of HBV-related carcinogenesis. Oncogene (2012) 31, 563-572; doi:10.1038/onc.2011.255; published online 27 June 2011	[Arzumanyan, A.; Friedman, T.; Kotei, E.; Lian, Z.; Feitelson, M. A.] Temple Univ, Coll Sci & Technol, Dept Biol, Philadelphia, PA 19122 USA; [Arzumanyan, A.; Feitelson, M. A.] Temple Univ, Coll Sci & Technol, Sbarro Hlth Res Org, Ctr Biotechnol, Philadelphia, PA 19122 USA; [Ng, I. O. L.] Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Pokfulam, Hong Kong, Peoples R China	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Hong Kong	Arzumanyan, A (corresponding author), Temple Univ, Coll Sci & Technol, Dept Biol, 1900 N 12th St,Suite 419,BioLife Sci Bldg, Philadelphia, PA 19122 USA.	alla.arzumanyan@temple.edu	Lian, Zhaorui/AAW-2379-2020; Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257; Ng, Irene Oi-lin/0000-0001-7532-2029	NIH [5R01CA104025, 5R01CA111427]; NATIONAL CANCER INSTITUTE [R01CA111427, R01CA104025] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH Grants 5R01CA104025 and 5R01CA111427 (to M Feitelson). We thank Drs Yongwen Chen and Cheng-ying Yang from the Third Military Medical University for the paraffin blocks of human liver tissue, and Dr Eugeney Bichenkov for assistance with the figures.	Agami R, 2010, EUR J CLIN INVEST, V40, P370, DOI 10.1111/j.1365-2362.2010.02279.x; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chung TW, 2004, FASEB J, V18, P1123, DOI 10.1096/fj.03-1429fje; Endo K, 2000, HUM PATHOL, V31, P558, DOI 10.1053/hp.2000.6683; FEITELSON MA, 1988, J MED VIROL, V24, P121, DOI 10.1002/jmv.1890240202; Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831; Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hirohashi S, 2003, CANCER SCI, V94, P575, DOI 10.1111/j.1349-7006.2003.tb01485.x; Iwatsuki M, 2010, CANCER SCI, V101, P293, DOI 10.1111/j.1349-7006.2009.01419.x; Janowski BA, 2007, NAT CHEM BIOL, V3, P166, DOI 10.1038/nchembio860; Jiao W, 2002, BRIT J CANCER, V86, P98, DOI 10.1038/sj.bjc.6600017; Kanai Y, 1997, INT J CANCER, V71, P355; Keasler VV, 2009, VIROLOGY, V390, P122, DOI 10.1016/j.virol.2009.05.001; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; Lee DK, 2001, GENE DEV, V15, P455, DOI 10.1101/gad.856201; Lee JO, 2005, ONCOGENE, V24, P6617, DOI 10.1038/sj.onc.1208827; Li LC, 2006, P NATL ACAD SCI USA, V103, P17337, DOI 10.1073/pnas.0607015103; Lian ZR, 2006, HEPATOLOGY, V43, P415, DOI 10.1002/hep.21053; Lian ZR, 1999, ONCOGENE, V18, P1677, DOI 10.1038/sj.onc.1202470; Liu J, 2006, ONCOGENE, V25, P1008, DOI 10.1038/sj.onc.1209138; Lupberger J, 2007, WORLD J GASTROENTERO, V13, P74, DOI 10.3748/wjg.v13.i1.74; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Nomura T, 1999, BBA-MOL BASIS DIS, V1453, P330, DOI 10.1016/S0925-4439(99)00004-6; Osada T, 1996, HEPATOLOGY, V24, P1460, DOI 10.1002/hep.510240627; Ou JN, 2007, BIOCHEM PHARMACOL, V73, P1297, DOI 10.1016/j.bcp.2006.12.032; Pan JB, 2004, J GEN VIROL, V85, P275, DOI 10.1099/vir.0.19650-0; Park IY, 2007, GASTROENTEROLOGY, V132, P1476, DOI 10.1053/j.gastro.2007.01.034; Park NH, 2006, POSTGRAD MED J, V82, P507, DOI 10.1136/pgmj.2006.047431; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Place RF, 2008, P NATL ACAD SCI USA, V105, P1608, DOI 10.1073/pnas.0707594105; MacPherson MR, 2010, MOL BIOL CELL, V21, P244, DOI 10.1091/mbc.E09-06-0504; Rikimaru T, 2007, ONCOLOGY-BASEL, V72, P69, DOI 10.1159/000111106; Ropero S, 2007, MOL ONCOL, V1, P19, DOI 10.1016/j.molonc.2007.01.001; Shona JK, 2009, VIRUS RES, V139, P14, DOI 10.1016/j.virusres.2008.09.006; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; Sugimachi K, 2003, CLIN CANCER RES, V9, P2657; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takeno S, 2004, AM J CLIN PATHOL, V122, P78, DOI 10.1309/WJL90JPEM17RBUHT; van Roy F, 2008, CELL MOL LIFE SCI, V65, P3756, DOI 10.1007/s00018-008-8281-1; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; WANG WL, 1991, CANCER RES, V51, P4971; WANG WL, 1991, HEPATOLOGY, V14, P29, DOI 10.1002/hep.1840140106; Waris G, 2001, MOL CELL BIOL, V21, P7721, DOI 10.1128/MCB.21.22.7721-7730.2001; Weil R, 1999, MOL CELL BIOL, V19, P6345; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yoo YG, 2008, ONCOGENE, V27, P3405, DOI 10.1038/sj.onc.1211000; Yoo YD, 1996, J CLIN INVEST, V97, P388, DOI 10.1172/JCI118427; Zeng PY, 2006, BIOTECHNIQUES, V41, P694, DOI 10.2144/000112297; Zheng DL, 2009, J HEPATOL, V50, P377, DOI 10.1016/j.jhep.2008.10.019; Zhou HY, 2009, CELL STEM CELL, V4, P381, DOI 10.1016/j.stem.2009.04.005	55	86	94	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	5					563	572		10.1038/onc.2011.255	http://dx.doi.org/10.1038/onc.2011.255			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MS	21706058	Green Accepted			2022-12-17	WOS:000300221800003
J	Holleman, A; Chung, I; Olsen, RR; Kwak, B; Mizokami, A; Saijo, N; Parissenti, A; Duan, Z; Voest, EE; Zetter, BR				Holleman, A.; Chung, I.; Olsen, R. R.; Kwak, B.; Mizokami, A.; Saijo, N.; Parissenti, A.; Duan, Z.; Voest, E. E.; Zetter, B. R.			miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo	ONCOGENE			English	Article						paclitaxel resistance; miRNA-135a; APC; carcinoma	MICRORNA EXPRESSION PROFILES; BREAST-CANCER CELLS; ALKYLATING-AGENTS; DRUG-RESISTANCE; SENSITIVITY; PROSTATE; APC; MECHANISMS; PROTEIN; GENE	Cancer cell resistance to paclitaxel continues to be a major clinical problem. In this study, we utilized microRNA (miRNA) arrays to screen for differentially expressed miRNAs in paclitaxel-resistant cell lines established in vitro. We observed concordant upregulation of miR-135a in paclitaxel-resistant cell lines representing three human malignancies. Subsequently, the role of miRNA-135a was evaluated in an in vivo model of paclitaxel resistance. In this model, mice were inoculated subcutaneously with a non-small cell lung carcinoma cell line and treated with paclitaxel for a prolonged period. In paclitaxel-resistant cell lines, established either in vitro or in vivo, blockage of miR-135a sensitized resistant cell lines to paclitaxel-induced cell death. We further demonstrated a correlation between paclitaxel response and miR-135a expression in paclitaxel-resistant subclones that were established in vivo. The paclitaxel-resistant phenotype of these subclones was maintained upon retransplantation in new mice, as shown by decreased tumor response upon paclitaxel treatment compared with controls. Upregulation of miR-135a was associated with reduced expression of the adenomatous polyposis coli gene (APC). APC knockdown increased paclitaxel resistance in parental cell lines. Our results indicate that paclitaxel resistance is associated with upregulation of miR-135a, both in vitro and in vivo, and is in part determined by miR-135a-mediated downregulation of APC. Oncogene (2011) 30, 4386-4398; doi:10.1038/onc.2011.148; published online 9 May 2011	[Holleman, A.; Chung, I.; Olsen, R. R.; Kwak, B.; Zetter, B. R.] Harvard Univ, Sch Med, Childrens Hosp Boston, Vasc Biol Program, Boston, MA 02115 USA; [Holleman, A.] Meander Med Ctr, Dept Internal Med, Amersfoort, Netherlands; [Mizokami, A.] Kanazawa Univ, Grad Sch Med Sci, Dept Integrat Canc Therapy & Urol, Kanazawa, Ishikawa, Japan; [Saijo, N.] Natl Canc Ctr, Res Inst, Div Med Oncol, Tokyo 104, Japan; [Parissenti, A.] Hop Reg Sudbury Reg Hosp, Reg Canc Program, Sudbury, ON, Canada; [Duan, Z.] Massachusetts Gen Hosp, Sarcoma Biol Lab, Ctr Sarcoma & Connect Tissue Oncol, Boston, MA 02114 USA; [Voest, E. E.] Utrecht Med Ctr, Dept Med Oncol, Utrecht, Netherlands	Harvard University; Boston Children's Hospital; Harvard Medical School; Meander Medisch Centrum; Kanazawa University; National Cancer Center - Japan; Health Sciences North; Harvard University; Massachusetts General Hospital; Utrecht University; Utrecht University Medical Center	Zetter, BR (corresponding author), Harvard Univ, Sch Med, Childrens Hosp Boston, Vasc Biol Program, 300 Longwood Ave,Karp Bldg,Room 11-125, Boston, MA 02115 USA.	bruce.zetter@childrens.harvard.edu	Chung, Ivy/C-3804-2012	de Haar-Holleman, Amy/0000-0003-4929-2860	National Institutes of Health; Kendle; KWF Cancer Foundation; Stichting Fonds Catherine van Tussenbroek; US Department of Defense; NATIONAL CANCER INSTITUTE [R37CA037393, R01CA037393] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Kendle; KWF Cancer Foundation; Stichting Fonds Catherine van Tussenbroek; US Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We sincerely thank Dr John Heymach of MD Anderson Cancer Institute, Houston, TX and Jeremy Force, Children's Hospital Boston, for kindly providing us with the A549TR cells. This work was supported in part by grant CA37393 from the National Institutes of Health (BRZ), Kendle (AH), KWF Cancer Foundation (AH), the Stichting Fonds Catherine van Tussenbroek (AH), and a US Department of Defense PCRP fellowship (IC).	Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Aoki K, 2007, J CELL SCI, V120, P3327, DOI 10.1242/jcs.03485; Blower PE, 2007, MOL CANCER THER, V6, P1483, DOI 10.1158/1535-7163.MCT-07-0009; Chu Q, 2005, LUNG CANCER, V50, P355, DOI 10.1016/j.lungcan.2005.06.010; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Cochrane DR, 2009, MOL CANCER THER, V8, P1055, DOI 10.1158/1535-7163.MCT-08-1046; Dikovskaya D, 2007, J CELL BIOL, V176, P183, DOI 10.1083/jcb.200610099; Dombernowsky P, 1996, SEMIN ONCOL, V23, P23; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Fong GH, 2008, ANGIOGENESIS, V11, P121, DOI 10.1007/s10456-008-9107-3; Fujita Y, 2010, J BIOL CHEM, V285, P19076, DOI 10.1074/jbc.M109.079525; GELFAND VI, 1991, ANNU REV CELL BIOL, V7, P93, DOI 10.1146/annurev.cb.07.110191.000521; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; GOLDIE JH, 1979, CANCER TREAT REP, V63, P1727; GREENBERGER LM, 1988, P NATL ACAD SCI USA, V85, P3762, DOI 10.1073/pnas.85.11.3762; Haldar S, 1996, CANCER RES, V56, P1253; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; HOFFMAN RM, 1991, CANCER CELL-MON REV, V3, P86; Huang GC, 2010, J CANCER RES CLIN, V136, P1201, DOI 10.1007/s00432-010-0770-6; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; KOBAYASHI H, 1993, P NATL ACAD SCI USA, V90, P3294, DOI 10.1073/pnas.90.8.3294; Kovalchuk O, 2008, MOL CANCER THER, V7, P2152, DOI 10.1158/1535-7163.MCT-08-0021; Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535-6108(03)00334-9; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Mackler NJ, 2005, NAT CLIN PRACT UROL, V2, P92, DOI 10.1038/ncpuro0099; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; McGrogan BT, 2008, BBA-REV CANCER, V1785, P96, DOI 10.1016/j.bbcan.2007.10.004; Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714; Mercatelli N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004029; Mozzetti S, 2005, CLIN CANCER RES, V11, P298; Nagel R, 2008, CANCER RES, V68, P5795, DOI 10.1158/0008-5472.CAN-08-0951; Oguri T, 2008, MOL CANCER THER, V7, P1150, DOI 10.1158/1535-7163.MCT-07-2088; Okugawa K, 2004, J CANCER RES CLIN, V130, P178, DOI 10.1007/s00432-003-0516-9; Patel N, 2010, P NATL ACAD SCI USA, V107, P2503, DOI 10.1073/pnas.0910649107; Perkins C, 1998, CANCER RES, V58, P4561; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Ritchie ME, 2007, BIOINFORMATICS, V23, P2700, DOI 10.1093/bioinformatics/btm412; Rottenberg S, 2007, P NATL ACAD SCI USA, V104, P12117, DOI 10.1073/pnas.0702955104; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Shi J, 2008, CANCER RES, V68, P3269, DOI 10.1158/0008-5472.CAN-07-6699; Sorrentino A, 2008, GYNECOL ONCOL, V111, P478, DOI 10.1016/j.ygyno.2008.08.017; STARLING JJ, 1990, CANCER RES, V50, P7634; Sudo T, 2004, CANCER RES, V64, P2502, DOI 10.1158/0008-5472.CAN-03-2013; Takeda M, 2007, PROSTATE, V67, P955, DOI 10.1002/pros.20581; TEICHER BA, 1990, SCIENCE, V247, P1457, DOI 10.1126/science.2108497; Villeneuve DJ, 2006, BREAST CANCER RES TR, V96, P17, DOI 10.1007/s10549-005-9026-6; Wakelee H, 2005, EXPERT REV ANTICANC, V5, P13, DOI 10.1586/14737140.5.1.13; Xia L, 2008, INT J CANCER, V123, P372, DOI 10.1002/ijc.23501; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Yang YH, 2002, NAT REV GENET, V3, P579, DOI 10.1038/nrg863; Zhang T, 2001, CANCER RES, V61, P8664; Zhou M, 2010, J BIOL CHEM, V285, P21496, DOI 10.1074/jbc.M109.083337	54	86	96	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2011	30	43					4386	4398		10.1038/onc.2011.148	http://dx.doi.org/10.1038/onc.2011.148			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HQ	21552288	Green Accepted			2022-12-17	WOS:000296356500002
J	Oneyama, C; Ikeda, J; Okuzaki, D; Suzuki, K; Kanou, T; Shintani, Y; Morii, E; Okumura, M; Aozasa, K; Okada, M				Oneyama, C.; Ikeda, J.; Okuzaki, D.; Suzuki, K.; Kanou, T.; Shintani, Y.; Morii, E.; Okumura, M.; Aozasa, K.; Okada, M.			MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways	ONCOGENE			English	Article						c-Src; tumor; miRNA; mTOR; FGFR3	PROTEIN-TYROSINE KINASE; HUMAN LUNG-CANCER; FACTOR RECEPTORS; FAMILY KINASES; C-SRC; V-SRC; MTOR; EXPRESSION; PHOSPHORYLATION; TRANSFORMATION	The tyrosine kinase c-Src is upregulated in various human cancers, but the molecular mechanisms underlying c-Src-mediated tumor growth remain unclear. Here we examined the involvement of microRNAs in the c-Src-mediated tumor growth. Microarray profiling revealed that c-Src activation downregulates a limited set of microRNAs, including miR-99a, which targets oncogenic mammalian target of rapamycin (mTOR) and fibroblast growth factor receptor 3 (FGFR3). Re-expression of miR-99a suppressed tumor growth of c-Src-transformed cells, and this effect was restored by the overexpression of mTOR. The downregulation of miR-99a was also observed in epidermal growth factor-and Ras-transformed cells, and it was suppressed by inhibiting the mitogen-activated protein kinase (MAPK) pathway. Furthermore, miR-99a downregulation is associated with mTOR/FGFR3 upregulation in various human lung cancer cells/tissues. The tumorigenicity of these cells was suppressed by the introduction of miR-99a. These findings suggest that the miR-99a-mTOR/FGFR3 pathway is crucial for controlling tumor growth in a wide range of human cancers that harbor upregulation of the Src-related oncogenic pathways. Oncogene (2011) 30, 3489-3501; doi:10.1038/onc.2011.63; published online 7 March 2011	[Oneyama, C.; Suzuki, K.; Kanou, T.; Okada, M.] Osaka Univ, Microbial Dis Res Inst, Dept Oncogene Res, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan; [Ikeda, J.; Morii, E.; Aozasa, K.] Osaka Univ, Grad Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan; [Okuzaki, D.] Osaka Univ, Microbial Dis Res Inst, DNA Chip Dev Ctr Infect Dis, Suita, Osaka 5650871, Japan; [Kanou, T.; Shintani, Y.; Okumura, M.] Osaka Univ, Grad Sch Med, Dept Gen Thorac Surg, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University; Osaka University	Oneyama, C (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Oncogene Res, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	coneyama@biken.osaka-u.ac.jp	Okuzaki, Daisuke/AAN-5641-2020; Okumura, Mitsutaka/L-5388-2013	Okuzaki, Daisuke/0000-0002-4552-783X; Okumura, Mitsutaka/0000-0001-7403-1318	Ministry of Education, Culture, Sports, Science and Technology of Japan; Osaka University; Grants-in-Aid for Scientific Research [22689009] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Osaka University; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Drs A Imamoto, T Akagi and M Yutsudo for generous gifts of reagents. This work was supported by a Grant-in-aid for Young Scientists from the Ministry of Education, Culture, Sports, Science and Technology of Japan and The Exciting Leading-Edge Research Project at Osaka University.	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Catto JWF, 2009, CANCER RES, V69, P8472, DOI 10.1158/0008-5472.CAN-09-0744; Doghman M, 2010, CANCER RES, V70, P4666, DOI 10.1158/0008-5472.CAN-09-3970; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Fornari F, 2010, CANCER RES, V70, P5184, DOI 10.1158/0008-5472.CAN-10-0145; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Ingley E, 2008, BBA-PROTEINS PROTEOM, V1784, P56, DOI 10.1016/j.bbapap.2007.08.012; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Li X, 2009, ONCOGENE, V28, P4272, DOI 10.1038/onc.2009.278; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Menon S, 2008, Oncogene, V27 Suppl 2, pS43, DOI 10.1038/onc.2009.352; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nagaraja AK, 2010, MOL ENDOCRINOL, V24, P447, DOI 10.1210/me.2009-0295; Nagayama K, 2007, GENE CHROMOSOME CANC, V46, P1000, DOI 10.1002/gcc.20485; Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731; Noro R, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-277; Nozawa H, 2007, CANCER LETT, V251, P105, DOI 10.1016/j.canlet.2006.11.008; OKADA M, 1991, J BIOL CHEM, V266, P24249; Oneyama C, 2008, GENES CELLS, V13, P1, DOI 10.1111/j.1365-2443.2007.01145.x; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Petroulakis E, 2006, BRIT J CANCER, V94, P195, DOI 10.1038/sj.bjc.6602902; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Shenouda SK, 2009, CANCER METAST REV, V28, P369, DOI 10.1007/s10555-009-9188-5; Trudel S, 2004, BLOOD, V103, P3521, DOI 10.1182/blood-2003-10-3650; van Rhijn BWG, 2001, CANCER RES, V61, P1265; Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005; Vojtechova M, 2008, NEOPLASIA, V10, P99, DOI 10.1593/neo.07905; Wang FZ, 2008, J VIROL, V82, P9065, DOI 10.1128/JVI.00961-08; Wong TS, 2008, CLIN CANCER RES, V14, P2588, DOI 10.1158/1078-0432.CCR-07-0666; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Xu Jianmin, 2011, J CANCER RES CLIN, V137, P1379, DOI [10.1007/s00432-011-0999-8, DOI 10.1007/S00432-011-0999-8, DOI 10.1007/S00432-011-0976-2]; Yamada H, 2008, GENE CHROMOSOME CANC, V47, P810, DOI 10.1002/gcc.20582; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yokota J, 2004, CANCER SCI, V95, P197, DOI 10.1111/j.1349-7006.2004.tb02203.x	49	86	90	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	32					3489	3501		10.1038/onc.2011.63	http://dx.doi.org/10.1038/onc.2011.63			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806CR	21383697				2022-12-17	WOS:000293782300002
J	Comb, WC; Cogswell, P; Sitcheran, R; Baldwin, AS				Comb, W. C.; Cogswell, P.; Sitcheran, R.; Baldwin, A. S.			IKK-dependent, NF-kappa B-independent control of autophagic gene expression	ONCOGENE			English	Article						autophagy; IKK; NF-kappa B; LC3; ATG5	TRANSCRIPTION; ACTIVATION; PATHWAYS	The induction of mammalian autophagy, a cellular catabolic bulk-degradation process conserved from humans to yeast, was recently shown to require I kappa B kinase (IKK), the upstream regulator of the nuclear factor (NF)-kappa B pathway. Interestingly, it was shown that this response did not involve NF-kappa B. Thus, the mechanism by which IKK promotes stimulus-induced autophagy is largely unknown. Here, we investigate the role of IKK/NF-kappa B in response to nutrient deprivation, the well-understood autophagy-inducing stimulus. IKK and both the classic and non-canonical pathways of NF-kappa B are robustly induced in response to cellular starvation. Notably, cells lacking either catalytic subunit of IKK (IKK-alpha or IKK-beta) fail to induce autophagy in response to cellular starvation. Importantly, we show that IKK activity but not NF-kappa B controls basal expression of the proautophagic gene LC3. We further demonstrate that starvation induces the expression of LC3 and two other essential autophagic genes ATG5 and Beclin-1 in an IKK-dependent manner. These results indicate that the IKK complex is a central mediator of starvation-induced autophagy in mammalian cells, and suggest that this requirement occurs at least in part through the regulation of autophagic gene expression. Interestingly, NF-kappa B subunits are dispensable for both basal and starvation-induced expression of proautophagic genes. However, starvation-induced activation of NF-kappa B is not inconsequential, as increases in expression of antiapoptotic NF-kappa B target genes such as Birc3 are observed in response to cellular starvation. Thus, IKK likely has multiple roles in response to starvation by regulating NF-kappa B-dependent antiapoptotic gene expression as well as controlling expression of autophagic genes through a yet undetermined mechanism. Oncogene (2011) 30, 1727-1732; doi:10.1038/onc.2010.553; published online 13 December 2010	[Comb, W. C.; Cogswell, P.; Sitcheran, R.; Baldwin, A. S.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Comb, W. C.; Baldwin, A. S.] Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; [Baldwin, A. S.] Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Baldwin, AS (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.	albert_baldwin@med.unc.edu		Sitcheran, Raquel/0000-0001-8916-9707	NIH [CA75080, AI035098, CA73756]; Waxman Cancer Research Foundation; NATIONAL CANCER INSTITUTE [R01CA075080, R01CA073756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035098, R01AI035098] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Waxman Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We are grateful to Dr Alexander Hoffmann for the p65/c-Rel DKO cells and to Dr Denis Guttridge for the RelB <SUP>/</SUP> and p52 <SUP>/</SUP> cells. We thank members of the Baldwin lab for thoughtful discussion and manuscript feedback. Research support was provided by NIH grants CA75080, AI035098, CA73756 and the Waxman Cancer Research Foundation.	Araki K, 2008, ONCOGENE, V27, P5696, DOI 10.1038/onc.2008.184; Barre B, 2007, EMBO J, V26, P4841, DOI 10.1038/sj.emboj.7601899; Barre B, 2010, MOL CELL, V38, P524, DOI 10.1016/j.molcel.2010.03.018; Bednarski BK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006992; Bensaad K, 2009, EMBO J, V28, P3015, DOI 10.1038/emboj.2009.242; Bubici C, 2006, ONCOGENE, V25, P6731, DOI 10.1038/sj.onc.1209936; Copetti T, 2009, MOL CELL BIOL, V29, P2594, DOI 10.1128/MCB.01396-08; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Criollo A, 2010, EMBO J, V29, P619, DOI 10.1038/emboj.2009.364; Djavaheri-Mergny M, 2006, J BIOL CHEM, V281, P30373, DOI 10.1074/jbc.M602097200; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; HACKER H, 2006, SCI STKE, DOI DOI 10.1126/STKE.3572006RE13; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hoffmann A, 2003, EMBO J, V22, P5530, DOI 10.1093/emboj/cdg534; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Klionsky DJ, 2004, NATURE, V431, P31, DOI 10.1038/431031a; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; LOMBARDI L, 1995, NUCLEIC ACIDS RES, V23, P2328, DOI 10.1093/nar/23.12.2328; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Polager S, 2008, ONCOGENE, V27, P4860, DOI 10.1038/onc.2008.117; Renner F, 2009, TRENDS BIOCHEM SCI, V34, P128, DOI 10.1016/j.tibs.2008.12.003; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Shaw J, 2008, P NATL ACAD SCI USA, V105, P20734, DOI 10.1073/pnas.0807735105; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Ziegelbauer K, 2005, BRIT J PHARMACOL, V145, P178, DOI 10.1038/sj.bjp.0706176	26	86	90	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	14					1727	1732		10.1038/onc.2010.553	http://dx.doi.org/10.1038/onc.2010.553			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	746IS	21151171	Green Accepted, Green Submitted			2022-12-17	WOS:000289239400010
J	Salvati, E; Scarsella, M; Porru, M; Rizzo, A; Iachettini, S; Tentori, L; Graziani, G; D'Incalci, M; Stevens, MFG; Orlandi, A; Passeri, D; Gilson, E; Zupi, G; Leonetti, C; Biroccio, A				Salvati, E.; Scarsella, M.; Porru, M.; Rizzo, A.; Iachettini, S.; Tentori, L.; Graziani, G.; D'Incalci, M.; Stevens, M. F. G.; Orlandi, A.; Passeri, D.; Gilson, E.; Zupi, G.; Leonetti, C.; Biroccio, A.			PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy	ONCOGENE			English	Article						PARP1; G4 ligand; combination therapy	POLY(ADP-RIBOSE) POLYMERASE-2 PARP-2; QUADRUPLEX LIGAND RHPS4; DNA-REPAIR; ANTITUMOR-ACTIVITY; HUMAN-CHROMOSOMES; CANCER-THERAPY; DAMAGE; INHIBITORS; CELLS; TRF2	New anti-telomere strategies represent important goals for the development of selective cancer therapies. In this study, we reported that uncapped telomeres, resulting from pharmacological stabilization of quadruplex DNA by RHPS4 (3,11-difluoro-6,8,13-trimethyl-8H-quino [4,3,2-kl] acridinium methosulfate), trigger specific recruitment and activation of poly-adenosine diphosphate (ADP) ribose polymerase I (PARP1) at the telomeres, forming several ADP-ribose polymers that co-localize with the telomeric repeat binding factor 1 protein and are inhibited by selective PARP(s) inhibitors or PARP1-specific small interfering RNAs. The knockdown of PARP1 prevents repairing of RHPS4-induced telomere DNA breaks, leading to increases in chromosome abnormalities and eventually to the inhibition of tumor cell growth both in vitro and in xenografts. More interestingly, the integration of a TOPO1 inhibitor on the combination treatment proved to have a high therapeutic efficacy ensuing a complete regression of the tumor as well as a significant increase in overall survival and cure of mice even when treatments started at a very late stage of tumor growth. Overall, this work reveals the unexplored link between the PARP1 and G-quadruplex ligands and demonstrates the excellent efficacy of a multi-component strategy based on the use of PARP inhibitors in telomere-based therapy. Oncogene (2010) 29, 6280-6293; doi:10.1038/onc.2010.344; published online 30 August 2010	[Salvati, E.; Scarsella, M.; Porru, M.; Rizzo, A.; Iachettini, S.; Zupi, G.; Leonetti, C.; Biroccio, A.] Regina Elena Inst Canc Res, Expt Chemotherapy Lab, I-00158 Rome, Italy; [Tentori, L.; Graziani, G.] Univ Roma Tor Vergata, Dept Neurosci, Rome, Italy; [D'Incalci, M.] Mario Negri Inst Pharmacol Res, Dept Oncol, Milan, Italy; [Stevens, M. F. G.] Univ Nottingham, Sch Pharm, Ctr Biomol Sci, Nottingham NG7 2RD, England; [Orlandi, A.; Passeri, D.] Univ Roma Tor Vergata, Dept Biopathol & Image Diagnost, Inst Pathol Anat, Rome, Italy; [Gilson, E.] Univ Nice Sophia Antipolis, Fac Med, INSERM, Lab Biol & Pathol Genomes,CNRS, Nice, France; CHU Nice, Archet Hosp 2, Dept Med Genet, Nice, France	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Rome Tor Vergata; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Nottingham; University of Rome Tor Vergata; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice	Biroccio, A (corresponding author), Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Via Messi Doro 156, I-00158 Rome, Italy.	leonetti@ifo.it; biroccio@ifo.it	Biroccio, Annamaria/B-2861-2018; Orlandi, Augusto/AHE-8753-2022; Porru, Manuela/AAA-5510-2021; Scarsella, Marco/AAA-1486-2020; D'Incalci, Maurizio/AAA-9021-2020; Rizzo, Angela/ABH-6753-2020; Leonetti, Carlo/B-2860-2018; IACHETTINI, SARA/AAY-6180-2021; Graziani, Grazia/G-5747-2012; PORRU, MANUELA/K-4809-2018	Biroccio, Annamaria/0000-0003-3198-3532; Porru, Manuela/0000-0002-6614-9110; D'Incalci, Maurizio/0000-0001-8784-1360; Rizzo, Angela/0000-0001-5421-3085; Leonetti, Carlo/0000-0002-3526-7827; IACHETTINI, SARA/0000-0002-9442-0326; Graziani, Grazia/0000-0002-0221-768X; PORRU, MANUELA/0000-0002-6614-9110; TENTORI, LUCIO/0000-0002-7691-527X; orlandi, augusto/0000-0001-7202-5854; Scarsella, Marco/0000-0002-3386-9664; Salvati, Erica/0000-0002-3373-7442	Italian Association for Cancer Research (AIRC); Ministero della Salute; Ligue Nationale contre le Cancer (EG equipe labellisee); Italian Foundation for Cancer Research (FIRC)	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero della Salute(Ministry of Health, Italy); Ligue Nationale contre le Cancer (EG equipe labellisee); Italian Foundation for Cancer Research (FIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by grants from the Italian Association for Cancer Research (AIRC), Ministero della Salute and Ligue Nationale contre le Cancer (EG equipe labellisee). ES and MP are recipients of fellowships from the Italian Foundation for Cancer Research (FIRC). We thank Mrs Carmen D'Angelo for generating HT29 cells that express the luciferase gene and Mrs Adele Petricca for her helpful assistance in typing the manuscript. We are also grateful to Tania Merlino for the English revision.	Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Bakondi E, 2002, J HISTOCHEM CYTOCHEM, V50, P91, DOI 10.1177/002215540205000110; Biroccio A, 2002, ONCOGENE, V21, P3011, DOI 10.1038/sj.onc.1205415; Brunori M, 2006, ONCOGENE, V25, P990, DOI 10.1038/sj.onc.1209135; BURKLE A, 2005, POLY ADP RIBOSYL ATI; Cook BD, 2002, MOL CELL BIOL, V22, P332, DOI 10.1128/MCB.22.1.332-342.2002; d'Adda di Fagagna F, 2003, NATURE, V426, P194, DOI [10.1038/nature02118, DOI 10.1038/NATURE02118]; Dantzer F, 2004, MOL CELL BIOL, V24, P1595, DOI 10.1128/MCB.24.4.1595-1607.2004; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Donigian JR, 2007, J BIOL CHEM, V282, P22662, DOI 10.1074/jbc.M702620200; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Gagne JP, 2006, CURR OPIN CELL BIOL, V18, P145, DOI 10.1016/j.ceb.2006.02.013; Gavathiotis E, 2003, J MOL BIOL, V334, P25, DOI 10.1016/j.jmb.2003.09.018; GERAN RI, 1972, CANC CHEMOTHER REP, V3, P1; Gomez M, 2006, MOL BIOL CELL, V17, P1686, DOI 10.1091/mbc.E05-07-0672; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Heald RA, 2002, J MED CHEM, V45, P590, DOI 10.1021/jm011015q; Kaminker PG, 2001, J BIOL CHEM, V276, P35891, DOI 10.1074/jbc.M105968200; Kelland L, 2007, CLIN CANCER RES, V13, P4960, DOI 10.1158/1078-0432.CCR-07-0422; Lenain C, 2006, CURR BIOL, V16, P1303, DOI 10.1016/j.cub.2006.05.021; Leonetti C, 2008, CLIN CANCER RES, V14, P7284, DOI 10.1158/1078-0432.CCR-08-0941; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Lord CJ, 2008, CURR OPIN PHARMACOL, V8, P363, DOI 10.1016/j.coph.2008.06.016; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Malanga M, 2005, BIOCHEM CELL BIOL, V83, P354, DOI 10.1139/o05-038; Marcellini M, 2006, AM J PATHOL, V169, P643, DOI 10.2353/ajpath.2006.051041; Oganesian L, 2007, BIOESSAYS, V29, P155, DOI 10.1002/bies.20523; Orlandi A, 2008, CELL CYCLE, V7, P3889, DOI 10.4161/cc.7.24.7323; Pisano C, 2008, MOL CANCER THER, V7, P2051, DOI 10.1158/1535-7163.MCT-08-0266; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Plummer ER, 2007, CLIN CANCER RES, V13, P6252, DOI 10.1158/1078-0432.CCR-07-0617; Ratnam K, 2007, CLIN CANCER RES, V13, P1383, DOI 10.1158/1078-0432.CCR-06-2260; Rippmann JF, 2002, J MOL BIOL, V323, P217, DOI 10.1016/S0022-2836(02)00946-4; Rizzo A, 2009, NUCLEIC ACIDS RES, V37, P5353, DOI 10.1093/nar/gkp582; Salvati E, 2007, J CLIN INVEST, V117, P3236, DOI 10.1172/JCI32461; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Smith S, 1999, J CELL SCI, V112, P3649; Sugimura K, 2008, J CELL BIOL, V183, P1203, DOI 10.1083/jcb.200806068; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tentori L, 2005, PHARMACOL RES, V52, P25, DOI 10.1016/j.phrs.2005.02.010; Tentori L, 2006, FASEB J, V20, P1709, DOI 10.1096/fj.06-5916fje; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801	43	86	90	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	47					6280	6293		10.1038/onc.2010.344	http://dx.doi.org/10.1038/onc.2010.344			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	685CG	20802516				2022-12-17	WOS:000284601700009
J	Tessema, M; Klinge, DM; Yingling, CM; Do, K; Van Neste, L; Belinsky, SA				Tessema, M.; Klinge, D. M.; Yingling, C. M.; Do, K.; Van Neste, L.; Belinsky, S. A.			Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis	ONCOGENE			English	Article						CXCL14; chemokines; lung cancer; DNA methylation; CXCL5; CXCL12	SQUAMOUS-CELL CARCINOMA; PROMOTER HYPERMETHYLATION; DNA METHYLATION; SUPPRESSOR GENES; CHEMOKINE CXCL14; DENDRITIC CELLS; DOWN-REGULATION; MULTIPLE GENES; IN-VIVO; EXPRESSION	Chemokines are important regulators of directional cell migration and tumor metastasis. A genome-wide transcriptome array designed to uncover novel genes silenced by methylation in lung cancer identified the CXCsubfamily of chemokines. Expression of 11 of the 16 known human CXC-chemokines was increased in lung adenocarcinoma cell lines after treatment with 5-aza-2'-deoxycytidine (DAC). Tumor-specific methylation leading to silencing of CXCL5, 12 and 14 was found in over 75% of primary lung adenocarcinomas and DAC treatment restored the expression of each of the silenced gene. Forced expression of CXCL14 in H23 cells, where this gene is silenced by methylation, increased cell death in vitro and dramatically reduced the in vivo growth of lung tumor xenografts through necrosis of up to 90% of the tumor mass. CXCL14 re-expression had a profound effect on the genome altering the transcription of over 1000 genes, including increased expression of 30 cell-cycle inhibitor and pro-apoptosis genes. In addition, CXCL14 methylation in sputum from asymptomatic early-stage lung cancer cases was associated with a 2.9-fold elevated risk for this disease compared with controls, substantiating its potential as a biomarker for early detection of lung cancer. Together, these findings identify CXCL14 as an important tumor suppressor gene epigenetically silenced during lung carcinogenesis. Oncogene (2010) 29, 5159-5170; doi:10.1038/onc.2010.255; published online 21 June 2010	[Tessema, M.; Klinge, D. M.; Yingling, C. M.; Do, K.; Belinsky, S. A.] Lovelace Resp Res Inst, Lung Canc Program, Albuquerque, NM 87108 USA; [Van Neste, L.] Univ Ghent, Dept Mol Biotechnol, Fac Biosci Engn, B-9000 Ghent, Belgium	Lovelace Respiratory Research Institute; Ghent University	Belinsky, SA (corresponding author), Lovelace Resp Res Inst, Lung Canc Program, 2425 Ridgecrest Dr SE, Albuquerque, NM 87108 USA.	sbelinsk@LRRI.org			NIH [R01 ES008801, P50 CA58184]; NATIONAL CANCER INSTITUTE [P50CA058184] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008801] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Grant support: supported largely by NIH Grant R01 ES008801 and in part by P50 CA58184.	Arenberg DA, 1998, J CLIN INVEST, V102, P465, DOI 10.1172/JCI3145; Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Belinsky SA, 2006, CANCER RES, V66, P3338, DOI 10.1158/0008-5472.CAN-05-3408; Belinsky SA, 2003, CANCER RES, V63, P7089; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Bennett KL, 2008, CANCER RES, V68, P4494, DOI 10.1158/0008-5472.CAN-07-6509; Chin LJ, 2008, CANCER RES, V68, P8535, DOI 10.1158/0008-5472.CAN-08-2129; Cirincione R, 2006, INT J CANCER, V118, P1248, DOI 10.1002/ijc.21473; Darash-Yahana M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006695; Deng T, 2009, BIOCHEM BIOPH RES CO, V387, P611, DOI 10.1016/j.bbrc.2009.07.093; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Hromas R, 1999, BIOCHEM BIOPH RES CO, V255, P703, DOI 10.1006/bbrc.1999.0257; Hsu HS, 2007, J PATHOL, V213, P412, DOI 10.1002/path.2246; Jacinto FV, 2007, CANCER RES, V67, P11481, DOI 10.1158/0008-5472.CAN-07-2687; Kim TY, 2006, CANCER RES, V66, P7490, DOI 10.1158/0008-5472.CAN-05-4552; Kurth I, 2001, J EXP MED, V194, P855, DOI 10.1084/jem.194.6.855; McKinnon CM, 2008, ONCOGENE, V27, P6856, DOI 10.1038/onc.2008.317; Meissner A, 2006, NATURE, V439, P212, DOI 10.1038/nature04257; Miyazaki H, 2006, CANCER RES, V66, P4279, DOI 10.1158/0008-5472.CAN-05-4398; Morris MR, 2008, BRIT J CANCER, V98, P496, DOI 10.1038/sj.bjc.6604180; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Mu X, 2009, ACTA BIOCH BIOPH SIN, V41, P631, DOI 10.1093/abbs/gmp051; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Ozawa S, 2006, BIOCHEM BIOPH RES CO, V348, P406, DOI 10.1016/j.bbrc.2006.07.070; Ozawa S, 2009, CANCER SCI, V100, P2202, DOI 10.1111/j.1349-7006.2009.01281.x; Palmisano WA, 2003, CANCER RES, V63, P4620; Parsanejad R, 2008, J INTERF CYTOK RES, V28, P703, DOI 10.1089/jir.2008.0139; Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC; Rauch TA, 2009, P NATL ACAD SCI USA, V106, P671, DOI 10.1073/pnas.0812399106; Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157; Schwarze SR, 2005, PROSTATE, V64, P67, DOI 10.1002/pros.20215; Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486; Shellenberger TD, 2004, CANCER RES, V64, P8262, DOI 10.1158/0008-5472.CAN-04-2056; Shurin GV, 2005, J IMMUNOL, V174, P5490, DOI 10.4049/jimmunol.174.9.5490; Speetjens FM, 2008, CLIN CANCER RES, V14, P2276, DOI 10.1158/1078-0432.CCR-07-4045; Strieter RM, 2004, ANN NY ACAD SCI, V1028, P351, DOI 10.1196/annals.1322.041; Tessema M, 2008, CANCER RES, V68, P1707, DOI 10.1158/0008-5472.CAN-07-6325; Tessema M, 2009, CARCINOGENESIS, V30, P1132, DOI 10.1093/carcin/bgp114; Wendt MK, 2008, ONCOGENE, V27, P1461, DOI 10.1038/sj.onc.1210751; Wendt MK, 2006, ONCOGENE, V25, P4986, DOI 10.1038/sj.onc.1209505; Yang AS, 2006, CANCER RES, V66, P5495, DOI 10.1158/0008-5472.CAN-05-2385; Yoshino M, 2009, INT J ONCOL, V35, P1201, DOI 10.3892/ijo_00000437; Yuvaraj S, 2009, MOL CANCER RES, V7, P1399, DOI 10.1158/1541-7786.MCR-08-0589; Zhou W, 2008, J NEUROSCI RES, V86, P3002, DOI 10.1002/jnr.21746	45	86	92	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	37					5159	5170		10.1038/onc.2010.255	http://dx.doi.org/10.1038/onc.2010.255			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650QZ	20562917	Green Accepted			2022-12-17	WOS:000281867200005
J	Wang, Y; Ngo, VN; Marani, M; Yang, Y; Wright, G; Staudt, LM; Downward, J				Wang, Y.; Ngo, V. N.; Marani, M.; Yang, Y.; Wright, G.; Staudt, L. M.; Downward, J.			Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells	ONCOGENE			English	Article						KRAS; synthetic lethal; oncogene addiction; epithelial-mesenchymal transition	EPITHELIAL-MESENCHYMAL TRANSITIONS; E-CADHERIN EXPRESSION; RNA INTERFERENCE; P53-MEDIATED APOPTOSIS; TUMOR PROGRESSION; CANCER-CELLS; FACTOR SLUG; LINES; GROWTH; GENE	Activating mutations in the KRAS gene are among the most prevalent genetic changes in human cancers. To identify synthetic lethal interactions in cancer cells harbouring mutant KRAS, we performed a large-scale screen in isogenic paired colon cancer cell lines that differ by a single allele of mutant KRAS using an inducible short hairpin RNA interference library. Snail2, a zinc finger transcriptional repressor encoded by the SNAI2 gene, was found to be selectively required for the long-term survival of cancer cells with mutant KRAS that have undergone epithelial-mesenchymal transition (EMT), a transdifferentiation event that is frequently seen in advanced tumours and is promoted by RAS activation. Snail2 expression is regulated by the RAS pathway and is required for EMT. Our findings support Snail2 as a possible target for the treatment of the broad spectrum of human cancers of epithelial origin with mutant RAS that have undergone EMT and are characterized by a high degree of chemoresistance and radioresistance. Oncogene (2010) 29, 4658-4670; doi:10.1038/onc.2010.218; published online 21 June 2010	[Wang, Y.; Marani, M.; Downward, J.] Canc Res UK London Res Inst, Signal Transduct Lab, London WC2A 3PX, England; [Ngo, V. N.; Yang, Y.; Staudt, L. M.] NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Wright, G.] NCI, Biometr Res Branch, DCTD, NIH, Bethesda, MD 20892 USA	Cancer Research UK; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Downward, J (corresponding author), Canc Res UK London Res Inst, Signal Transduct Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	julian.downward@cancer.org.uk	Downward, Julian/A-3251-2012; Wright, George W/M-1660-2017; Staudt, Louis/AAC-5324-2019	Wang, Yihua/0000-0001-5561-0648; Ngo, Vu/0000-0002-9501-6990; Downward, Julian/0000-0002-2331-4729	Cancer Research UK; NIH, National Cancer Institute, Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC011008, ZIABC011007] Funding Source: NIH RePORTER	Cancer Research UK(Cancer Research UK); NIH, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Alberto Bardelli for providing SW48 and SW48 KRAS G13D cells and Senji Shirasawa for providing HCT-116, HKe-3 and HKh-2 cells. This work was supported by funding from Cancer Research UK and from the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.	Alves CC, 2009, FRONT BIOSCI-LANDMRK, V14, P3041, DOI 10.2741/3433; Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Bernards R, 2006, NAT METHODS, V3, P701, DOI 10.1038/NMETH921; Cobaleda C, 2007, ANNU REV GENET, V41, P41, DOI 10.1146/annurev.genet.41.110306.130146; Come C, 2006, CLIN CANCER RES, V12, P5395, DOI 10.1158/1078-0432.CCR-06-0478; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Cully M, 2008, CELL, V133, P1292, DOI 10.1016/j.cell.2008.06.020; Dajee M, 2002, ONCOGENE, V21, P1527, DOI 10.1038/sj.onc.1205287; Di Nicolantonio F, 2008, P NATL ACAD SCI USA, V105, P20864, DOI 10.1073/pnas.0808757105; DOBZHANSKY T, 1946, GENETICS, V31, P269; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Downward J, 2004, ONCOGENE, V23, P8376, DOI 10.1038/sj.onc.1208073; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Hajra KM, 2002, CANCER RES, V62, P1613; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; Hemavathy K, 2000, GENE, V257, P1, DOI 10.1016/S0378-1119(00)00371-1; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Inoue A, 2002, CANCER CELL, V2, P279, DOI 10.1016/S1535-6108(02)00155-1; Iorns E, 2007, NAT REV DRUG DISCOV, V6, P556, DOI 10.1038/nrd2355; Jiang RL, 1998, DEV BIOL, V198, P277, DOI 10.1006/dbio.1998.8909; Joyce T, 2009, CLIN EXP METASTAS, V26, P569, DOI 10.1007/s10585-009-9256-9; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Katoh M, 2005, ONCOL REP, V14, P1083; Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Ngo VN, 2006, NATURE, V441, P106, DOI 10.1038/nature04687; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Perez-Losada J, 2003, ONCOGENE, V22, P4205, DOI 10.1038/sj.onc.1206467; Perez-Mancera PA, 2005, ONCOGENE, V24, P3073, DOI 10.1038/sj.onc.1208505; Saegusa M, 2009, AM J PATHOL, V174, P2107, DOI 10.2353/ajpath.2009.081018; Schmidt CR, 2005, SURGERY, V138, P306, DOI 10.1016/j.surg.2005.06.007; Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Shioiri M, 2006, BRIT J CANCER, V94, P1816, DOI 10.1038/sj.bjc.6603193; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Thomson S, 2005, CANCER RES, V65, P9455, DOI 10.1158/0008-5472.CAN-05-1058; Vannini I, 2007, CELL ONCOL, V29, P279; Vitali R, 2008, CLIN CANCER RES, V14, P4622, DOI 10.1158/1078-0432.CCR-07-5210; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Wang Z, 2007, ONCOGENE, V26, P1222, DOI 10.1038/sj.onc.1209902; Wu WS, 2005, CELL, V123, P641, DOI 10.1016/j.cell.2005.09.029	50	86	89	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	33					4658	4670		10.1038/onc.2010.218	http://dx.doi.org/10.1038/onc.2010.218			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	641LK	20562906	Green Accepted			2022-12-17	WOS:000281127400005
J	Wang, Z; Pedersen, E; Basse, A; Lefever, T; Peyrollier, K; Kapoor, S; Mei, Q; Karlsson, R; Chrostek-Grashoff, A; Brakebusch, C				Wang, Z.; Pedersen, E.; Basse, A.; Lefever, T.; Peyrollier, K.; Kapoor, S.; Mei, Q.; Karlsson, R.; Chrostek-Grashoff, A.; Brakebusch, C.			Rac1 is crucial for Ras-dependent skin tumor formation by controlling Pak1-Mek-Erk hyperactivation and hyperproliferation in vivo	ONCOGENE			English	Article						Rac1; tumor; Pak	ACTIVATOR TIAM1; ERK; PHOSPHORYLATION; PROLIFERATION; REQUIREMENT; DELETION; PAK	Rac1 has a role in proliferation and survival of tumor cells in vitro. The exact effects of Rac1 on growth, apoptosis and corresponding signaling pathways during tumorigenesis in vivo, however, have not been explored yet. Using mice with a keratinocyte-restricted deletion of the Rac1 gene, we found that Rac1 is essential for DMBA/TPA-induced skin tumor formation. This corresponded to a decreased keratinocyte hyperproliferation, although apoptosis was not detectably altered. Activated Rac1 promoted Erk-dependent hyperproliferation by Pak1-mediated Mek activation independent of Mek1 phosporylation at serine 298. Rac1 was furthermore required for Pak2-dependent hyperactivation of Akt, which under in vivo condition was restricted to the suprabasal cell layers corresponding to a suprabasal-specific expression of Pak2. It is surprising that none of these signaling pathways was altered in untreated Rac1-deficient skin, indicating a hyperproliferation- specific function of Rac1 in vivo. These data suggest that blocking of Rac1 function might allow tumor-specific growth repression, as Rac1 is not required for normal growth and growth signaling controlling pathways in skin in vivo. Oncogene (2010) 29, 3362-3373; doi:10.1038/onc.2010.95; published online 12 April 2010	[Wang, Z.; Pedersen, E.; Basse, A.; Lefever, T.; Peyrollier, K.; Kapoor, S.; Karlsson, R.; Brakebusch, C.] Univ Copenhagen, Inst Biomed, BRIC, DK-2200 Copenhagen, Denmark; [Wang, Z.; Mei, Q.] Fourth Mil Med Univ, Sch Pharm, Dept Pharmacol, Xian 710032, Peoples R China; [Lefever, T.] Univ Ghent, Dept Biomed Mol Biol, B-9000 Ghent, Belgium; [Chrostek-Grashoff, A.] Univ Virginia, Cardiovasc Res Ctr, Charlottesville, VA USA	University of Copenhagen; Air Force Military Medical University; Ghent University; University of Virginia	Brakebusch, C (corresponding author), Univ Copenhagen, Inst Biomed, BRIC, Ole Maaloes Vej 5, DK-2200 Copenhagen, Denmark.	cord.brakebusch@bric.dk	Basse, Astrid L/M-4630-2014	Basse, Astrid L/0000-0002-6532-9232; Brakebusch, Cord/0000-0002-9342-1634	Danish Cancer Foundation; Novo Nordisk Foundation	Danish Cancer Foundation(Danish Cancer Society); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited)	We thank Dr Peter Staller and Dr Chris Marshall for advice, Dr Anders Lund for providing the plasmids, Volkan Turan for excellent technical help, Anna Fossum for FACS, and Sahar Abelechian and Anita Friismose for help with mouse handling. This work was supported by the Danish Cancer Foundation and the Novo Nordisk Foundation.	Benitah SA, 2005, SCIENCE, V309, P933, DOI 10.1126/science.1113579; Castilho RM, 2007, ONCOGENE, V26, P5078, DOI 10.1038/sj.onc.1210322; Chrostek A, 2006, MOL CELL BIOL, V26, P6957, DOI 10.1128/MCB.00075-06; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Espina C, 2008, AM J PATHOL, V172, P156, DOI 10.2353/ajpath.2008.070561; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Higuchi M, 2008, NAT CELL BIOL, V10, P1356, DOI 10.1038/ncb1795; Hirsch E, 2002, J CELL BIOL, V157, P481, DOI 10.1083/jcb.200111065; Karlsson R, 2009, BBA-REV CANCER, V1796, P91, DOI 10.1016/j.bbcan.2009.03.003; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kissil JL, 2007, CANCER RES, V67, P8089, DOI 10.1158/0008-5472.CAN-07-2300; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Maruta Hiroshi, 2002, Methods Mol Biol, V189, P75; Mertens AEE, 2005, J CELL BIOL, V170, P1029, DOI 10.1083/jcb.200502129; Perez-Losada J, 2003, NAT REV CANCER, V3, P434, DOI 10.1038/nrc1095; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; Skeen JE, 2006, CANCER CELL, V10, P269, DOI 10.1016/j.ccr.2006.08.022; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Sundberg-Smith LJ, 2005, J BIOL CHEM, V280, P2055, DOI 10.1074/jbc.M406013200; Thomas EK, 2007, CANCER CELL, V12, P467, DOI 10.1016/j.ccr.2007.10.015; Tscharntke M, 2007, J CELL SCI, V120, P1480, DOI 10.1242/jcs.03426; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	24	86	87	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2010	29	23					3362	3373		10.1038/onc.2010.95	http://dx.doi.org/10.1038/onc.2010.95			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	608YU	20383193				2022-12-17	WOS:000278622700005
J	Lievre, A; Blons, H; Laurent-Puig, P				Lievre, A.; Blons, H.; Laurent-Puig, P.			Oncogenic mutations as predictive factors in colorectal cancer	ONCOGENE			English	Review						colorectal cancer; EGFR; cetuximab; panitumumab; KRAS; personalized medicine	GROWTH-FACTOR RECEPTOR; CETUXIMAB PLUS IRINOTECAN; ISLAND METHYLATOR PHENOTYPE; POPULATION-BASED SERIES; KIRSTEN RAS MUTATIONS; GENE COPY NUMBER; PHASE-III TRIAL; K-RAS; BRAF MUTATION; PIK3CA MUTATIONS	The anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies cetuximab and panitumumab have been demonstrated to be new therapeutic options for metastatic colorectal cancer (mCRC). Oncogenic activation of intracellular signalling pathways downstream of EGFR has a major role in colorectal carcinogenesis but has also been reported to be an important mechanism of resistance to anti-EGFR antibodies. Among the activating mutations found in colorectal cancers, tumour KRAS mutations, which are found in B40% of the cases, have been widely demonstrated as a major predictive marker of resistance to cetuximab or panitumumab, therefore, opening the way to individualized treatment for patients with mCRC. Other oncogenic mutations, such as BRAF or PIK3CA mutations or loss of PTEN expression, may also be additional interesting predictive markers of response to anti-EGFR monoclonal antibodies but required further evaluation before being incorporated in clinical practice. The identification of these molecular markers involved in the resistance of antiEGFR antibodies will allow the development of new therapies that should target 'escape mechanisms' used by tumours to circumvent a pathway that has been pharmacologically blocked by anti-EGFR. Oncogene (2010) 29, 3033-3043; doi: 10.1038/onc.2010.89; published online 12 April 2010	[Lievre, A.; Blons, H.; Laurent-Puig, P.] INSERM, UMR S Mol Basis Response Xenobiot 775, F-75006 Paris, France; [Lievre, A.] Hop Ambroise Pare, AP HP, Serv Hepatogastroenterol & Oncol Digest, Boulogne, France; [Lievre, A.] Univ Versailles St Quentin En Yvelines, Versailles, France; [Blons, H.; Laurent-Puig, P.] Univ Paris 05, Paris, France; [Blons, H.; Laurent-Puig, P.] Hop Europeen Georges Pompidou, AP HP, Serv Biochim, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Laurent-Puig, P (corresponding author), INSERM, Mol Basis Response Xenobiot U775, 45 Rue St Peres, F-75006 Paris, France.	pierre.laurent-puig@parisdescartes.fr	laurent-puig, pierre/B-2226-2013; Laurent-Puig, Pierre/K-3641-2019	laurent-puig, pierre/0000-0001-8475-5459; Laurent-Puig, Pierre/0000-0001-8475-5459; Blons, Helene/0000-0002-0572-8426	Institut National du Cancer [2009-1-RT03]; Region Ile de France	Institut National du Cancer(Institut National du Cancer (INCA) France); Region Ile de France(Region Ile-de-France)	We thank Institut National du Cancer (N degrees 2009-1-RT03) and the Region Ile de France for their financial support.	Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Andreyev HJN, 2001, BRIT J CANCER, V85, P692, DOI 10.1054/bjoc.2001.1964; Andreyev HJN, 1998, J NATL CANCER I, V90, P675, DOI 10.1093/jnci/90.9.675; Artale S, 2008, J CLIN ONCOL, V26, P4217, DOI 10.1200/JCO.2008.18.7286; Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; Barault L, 2008, CANCER RES, V68, P8541, DOI 10.1158/0008-5472.CAN-08-1171; Barault L, 2008, INT J CANCER, V122, P2255, DOI 10.1002/ijc.23388; Barber TD, 2004, NEW ENGL J MED, V351, P2883, DOI 10.1056/NEJM200412303512724; Benvenuti S, 2008, HUM MUTAT, V29, P284, DOI 10.1002/humu.20648; Benvenuti S, 2007, CANCER RES, V67, P2643, DOI 10.1158/0008-5472.CAN-06-4158; Bokemeyer C, 2007, J CLIN ONCOL, V25; BOKEMEYER C, 2009, EJC SUPPL, V7, P345; Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397; BOS JL, 1989, CANCER RES, V49, P4682; Brink M, 2003, CARCINOGENESIS, V24, P703, DOI 10.1093/carcin/bgg009; Cappuzzo F, 2008, BRIT J CANCER, V99, P83, DOI 10.1038/sj.bjc.6604439; Cappuzzo F, 2008, ANN ONCOL, V19, P717, DOI 10.1093/annonc/mdm492; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Roock W, 2008, ANN ONCOL, V19, P508, DOI 10.1093/annonc/mdm496; de Vogel S, 2009, ANN ONCOL, V20, P1216, DOI 10.1093/annonc/mdn782; Di Fiore F, 2008, BRIT J CANCER, V99, P551, DOI 10.1038/sj.bjc.6604451; Di Fiore F, 2007, BRIT J CANCER, V96, P1166, DOI 10.1038/sj.bjc.6603685; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Etienne-Grimaldi MC, 2008, CLIN CANCER RES, V14, P4830, DOI 10.1158/1078-0432.CCR-07-4906; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINKELSTEIN SD, 1993, ARCH SURG-CHICAGO, V128, P526; Finkelstein SD, 1993, ARCH SURG-CHICAGO, V128, P531; FINOCCHIARO G, 2007, P AN M AM SOC CLIN, V25, P4021; Frattini M, 2007, BRIT J CANCER, V97, P1139, DOI 10.1038/sj.bjc.6604009; French AJ, 2008, CLIN CANCER RES, V14, P3408, DOI 10.1158/1078-0432.CCR-07-1489; Gnanasampanthan G, 2001, J PATHOL, V195, P543, DOI 10.1002/path.990; Guanti G, 2000, HUM MOL GENET, V9, P283, DOI 10.1093/hmg/9.2.283; Haigis KM, 2008, NAT GENET, V40, P600, DOI 10.1038/ng.115; Harbison CT, 2008, J CLIN ONCOL, V26, P2230, DOI 10.1200/JCO.2008.16.0473; He YJ, 2009, CLIN CANCER RES, V15, P6956, DOI 10.1158/1078-0432.CCR-09-1165; Ikenoue T, 2005, CANCER RES, V65, P4562, DOI 10.1158/0008-5472.CAN-04-4114; Ince WL, 2005, JNCI-J NATL CANCER I, V97, P981, DOI 10.1093/jnci/dji174; Italiano A, 2008, ANN SURG ONCOL, V15, P649, DOI 10.1245/s10434-007-9667-2; Jacobs B, 2009, J CLIN ONCOL, V27, P5068, DOI 10.1200/JCO.2008.21.3744; Jhawer M, 2008, CANCER RES, V68, P1953, DOI 10.1158/0008-5472.CAN-07-5659; Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437; Kim JH, 2009, VIRCHOWS ARCH, V455, P485, DOI 10.1007/s00428-009-0857-0; Kohne C, 2009, J CLIN ONCOL, V27; Laurent-Puig P, 2009, J CLIN ONCOL, V27, P5924, DOI 10.1200/JCO.2008.21.6796; Lea IA, 2009, MUTAT RES-FUND MOL M, V670, P96, DOI 10.1016/j.mrfmmm.2009.06.011; Lenz HJ, 2006, J CLIN ONCOL, V24, P4914, DOI 10.1200/JCO.2006.06.7595; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Lievre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906; Loupakis F, 2009, BRIT J CANCER, V101, P715, DOI 10.1038/sj.bjc.6605177; Loupakis F, 2009, J CLIN ONCOL, V27, P2622, DOI 10.1200/JCO.2008.20.2796; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Moroni M, 2008, LANCET ONCOL, V9, P402, DOI 10.1016/S1470-2045(08)70109-8; Nosho K, 2008, NEOPLASIA, V10, P534, DOI 10.1593/neo.08336; Nosho K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003698; Ogino S, 2009, CLIN CANCER RES, V15, P6412, DOI 10.1158/1078-0432.CCR-09-1438; Ogino S, 2009, J CLIN ONCOL, V27, P1477, DOI 10.1200/JCO.2008.18.6544; Ogino S, 2009, GUT, V58, P90, DOI 10.1136/gut.2008.155473; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a; Perrone F, 2009, ANN ONCOL, V20, P84, DOI 10.1093/annonc/mdn541; Personeni N, 2005, SEMIN ONCOL, V32, pS59, DOI 10.1053/j.seminoncol.2005.04.029; Prenen H, 2009, CLIN CANCER RES, V15, P3184, DOI 10.1158/1078-0432.CCR-08-2961; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Razis E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-234; Roth AD, 2010, J CLIN ONCOL, V28, P466, DOI 10.1200/JCO.2009.23.3452; Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182; Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404; Samowitz WS, 2005, GASTROENTEROLOGY, V129, P837, DOI 10.1053/j.gastro.2005.06.020; Samowitz WS, 2000, CANCER EPIDEM BIOMAR, V9, P1193; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sartore-Bianchi A, 2007, J CLIN ONCOL, V25, P3238, DOI 10.1200/JCO.2007.11.5956; Sartore-Bianchi A, 2009, CANCER RES, V69, P1851, DOI 10.1158/0008-5472.CAN-08-2466; Sauer T, 2005, HISTOPATHOLOGY, V47, P560, DOI 10.1111/j.1365-2559.2005.02252.x; Scartozzi M, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-303; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shia J, 2005, MODERN PATHOL, V18, P1350, DOI 10.1038/modpathol.3800417; Shin KH, 2001, CANCER LETT, V174, P189, DOI 10.1016/S0304-3835(01)00691-7; Sobrero AF, 2008, J CLIN ONCOL, V26, P2311, DOI 10.1200/JCO.2007.13.1193; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Souglakos J, 2009, BRIT J CANCER, V101, P465, DOI 10.1038/sj.bjc.6605164; Taron M, 2005, CLIN CANCER RES, V11, P5878, DOI 10.1158/1078-0432.CCR-04-2618; Tejpar S, 2009, EJC SUPPL, V7, P322, DOI 10.1016/S1359-6349(09)71100-0; Tol J, 2009, NEW ENGL J MED, V361, P98, DOI 10.1056/NEJMc0904160; Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268; Vallbohmer D, 2005, J CLIN ONCOL, V23, P3536, DOI 10.1200/jco.2005.23.16_suppl.3536; Van Cutsem E, 2009, EJC SUPPL, V7, P345, DOI 10.1016/S1359-6349(09)71172-3; Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; VANCUTSEM E, 2007, P AN M AM SOC CLIN, V25, P4000; Velho S, 2005, EUR J CANCER, V41, P1649, DOI 10.1016/j.ejca.2005.04.022; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Wang ZJ, 1998, AM J PATHOL, V153, P363, DOI 10.1016/S0002-9440(10)65579-4; Wee S, 2009, CANCER RES, V69, P4286, DOI 10.1158/0008-5472.CAN-08-4765; Yen LC, 2009, CLIN CANCER RES, V15, P4508, DOI 10.1158/1078-0432.CCR-08-3179; ZLOBEC I, 2009, INT J CANC	100	86	87	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2010	29	21					3033	3043		10.1038/onc.2010.89	http://dx.doi.org/10.1038/onc.2010.89			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602IQ	20383189				2022-12-17	WOS:000278133100001
J	Dennemarker, J; Lohmuller, T; Mayerle, J; Tacke, M; Lerch, MM; Coussens, LM; Peters, C; Reinheckel, T				Dennemaerker, J.; Lohmueller, T.; Mayerle, J.; Tacke, M.; Lerch, M. M.; Coussens, L. M.; Peters, C.; Reinheckel, T.			Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis	ONCOGENE			English	Article						skin cancer; mouse model; protease; cathepsin	TRANSGENIC MICE; EMERGING ROLES; CANCER; EXPRESSION; CARCINOGENESIS; ANGIOGENESIS; CELLS; INVASION; MATRIX; GROWTH	To define a functional role for the endosomal/lysosomal cysteine protease cathepsin L (Ctsl) during squamous carcinogenesis, we generated mice harboring a constitutive Ctsl deficiency in addition to epithelial expression of the human papillomavirus type 16 oncogenes (human cytokeratin 14 (K14)-HPV16). We found enhanced tumor progression and metastasis in the absence of Ctsl. As tumor progression in K14 -HPV16 mice is dependent on inflammation and angiogenesis, we examined immune cell infiltration and vascularization without finding any effect of the Ctsl genotype. In contrast, keratinocyte-specific transgenic expression of cathepsin V, the human orthologue of mouse Ctsl, in otherwise Ctsl-deficient K14 HPV16 mice restored the phenotype observed in the control HPV16 skin. To better understand this phenotype at the molecular level, we measured several oncogenic signal transduction pathways in primary keratinocytes on stimulation with keratinocyte-conditioned cell culture medium. We found increased activation of protein kinase B/Akt and mitogen-activated protein kinase pathways in protease-deficient cells, especially if treated with media conditioned by Ctsl-deficient keratinocytes. Similarly, the level of active GTP-Ras was increased in Ctsl-deficient epidermis. We conclude that Ctsl is critical for the termination of growth factor signaling in the endosomal/lysosomal compartment of keratinocytes and, therefore, functions as an anti-tumor protease. Oncogene (2010) 29, 1611-1621; doi:10.1038/onc.2009.466; published online 21 December 2009	[Dennemaerker, J.; Lohmueller, T.; Tacke, M.; Peters, C.; Reinheckel, T.] Univ Freiburg, Inst Mol Med & Zellforsch, D-79104 Freiburg, Germany; [Mayerle, J.; Lerch, M. M.] Ernst Moritz Arndt Univ Greifswald, Dept Gastroenterol Endocrinol & Nutr, Greifswald, Germany; [Coussens, L. M.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA USA; [Coussens, L. M.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Peters, C.; Reinheckel, T.] Univ Freiburg, Ctr Biol Signalling Studies, Freiburg, Germany; [Peters, C.; Reinheckel, T.] Univ Freiburg, Ludwig Heilmeyer Comprehens Canc Ctr, Freiburg, Germany	University of Freiburg; Ernst Moritz Arndt Universitat Greifswald; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of Freiburg; University of Freiburg	Reinheckel, T (corresponding author), Univ Freiburg, Inst Mol Med & Zellforsch, Stefan Meier Str 17, D-79104 Freiburg, Germany.	Thomas.Reinheckel@uniklinik-freiburg.de	Coussens, Lisa/ABH-9834-2020; Lerch, Markus M./E-2206-2016; Mayerle, Julia/W-7907-2019; Reinheckel, Thomas/AAL-9761-2021	Lerch, Markus M./0000-0002-9643-8263; Reinheckel, Thomas/0000-0001-9866-9105; Mayerle, Julia/0000-0002-3666-6459	Deutsche Krebshilfe [Re106977]; Excellence Initiative of the German Federal and State Governments [EXC 294]; European Union [201279]; NATIONAL CANCER INSTITUTE [R01CA130980] Funding Source: NIH RePORTER	Deutsche Krebshilfe(Deutsche Krebshilfe); Excellence Initiative of the German Federal and State Governments; European Union(European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Ulrike Reif and Susanne Dollwet-Mack for excellent technical assistance and Dr Marie Follo for comments on the paper. The work was supported by a grant from the Deutsche Krebshilfe (Re106977) and in part by the Excellence Initiative of the German Federal and State Governments (EXC 294) and the European Union Framework Program (FP7 'MICRO-ENVIMET' No 201279).	Abboud-Jarrous G, 2008, J BIOL CHEM, V283, P18167, DOI 10.1074/jbc.M801327200; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Bernard D, 2003, J INVEST DERMATOL, V120, P592, DOI 10.1046/j.1523-1747.2003.12086.x; Bethel PA, 2009, BIOORG MED CHEM LETT, V19, P4622, DOI 10.1016/j.bmcl.2009.06.090; Boudreau F, 2007, FASEB J, V21, P3853, DOI 10.1096/fj.07-8113com; Bromme D., 2004, HDB PROTEOLYTIC ENZY, P1107; Chan RJ, 2007, BLOOD, V109, P862, DOI 10.1182/blood-2006-07-028829; Cheng T, 2006, J BIOL CHEM, V281, P15893, DOI 10.1074/jbc.M600694200; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Coussens LM, 1996, AM J PATHOL, V149, P1899; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Dano K, 1999, APMIS, V107, P120, DOI 10.1111/j.1699-0463.1999.tb01534.x; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; de Visser KE, 2005, CANCER CELL, V7, P411, DOI 10.1016/j.ccr.2005.04.014; DeClerck YA, 2004, AM J PATHOL, V164, P1131, DOI 10.1016/S0002-9440(10)63200-2; Felbor U, 2000, EMBO J, V19, P1187, DOI 10.1093/emboj/19.6.1187; Gocheva V, 2006, GENE DEV, V20, P543, DOI 10.1101/gad.1407406; Gondi CS, 2004, CANCER RES, V64, P4069, DOI 10.1158/0008-5472.CAN-04-1243; Goulet B, 2007, MOL CANCER RES, V5, P899, DOI 10.1158/1541-7786.MCR-07-0160; Gutierrez-Fernandez A, 2008, CANCER RES, V68, P2755, DOI 10.1158/0008-5472.CAN-07-5154; Hagemann S, 2004, EUR J CELL BIOL, V83, P775, DOI 10.1078/0171-9335-00404; Haider AS, 2006, J INVEST DERMATOL, V126, P869, DOI 10.1038/sj.jid.5700157; Jedeszko C, 2004, BIOL CHEM, V385, P1017, DOI 10.1515/BC.2004.132; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; Martin MD, 2007, CANCER METAST REV, V26, P717, DOI 10.1007/s10555-007-9089-4; Mayerle J, 2005, GASTROENTEROLOGY, V129, P1251, DOI 10.1053/j.gastro.2005.08.002; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Navab R, 2008, ONCOGENE, V27, P4973, DOI 10.1038/onc.2008.144; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Nyberg P, 2008, FRONT BIOSCI, V13, P6537, DOI 10.2741/3173; Reinheckel T, 2005, J CELL SCI, V118, P3387, DOI 10.1242/jcs.02469; Roth W, 2000, FASEB J, V14, P2075, DOI 10.1096/fj.99-0970com; Schneider MR, 2008, AM J PATHOL, V173, P14, DOI 10.2353/ajpath.2008.070942; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Tobin DJ, 2002, AM J PATHOL, V160, P1807, DOI 10.1016/S0002-9440(10)61127-3; Tolosa E, 2003, J CLIN INVEST, V112, P517, DOI 10.1172/JCI200318028; Urbich C, 2005, NAT MED, V11, P206, DOI 10.1038/nm1182; Vasiljeva O, 2008, ONCOGENE, V27, P4191, DOI 10.1038/onc.2008.59; Vasiljeva O, 2007, CURR PHARM DESIGN, V13, P387, DOI 10.2174/138161207780162962; Vasiljeva O, 2006, CANCER RES, V66, P5242, DOI 10.1158/0008-5472.CAN-05-4463; von Zastrow M, 2007, CURR OPIN CELL BIOL, V19, P436, DOI 10.1016/j.ceb.2007.04.021; Walz M, 2007, EXP DERMATOL, V16, P715, DOI 10.1111/j.1600-0625.2007.00579.x; Zheng X, 2004, CANCER RES, V64, P1773, DOI 10.1158/0008-5472.CAN-03-0820	48	86	88	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	2010	29	11					1611	1621		10.1038/onc.2009.466	http://dx.doi.org/10.1038/onc.2009.466			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	20023699	Green Accepted			2022-12-17	WOS:000275694700006
J	Wortham, NC; Ahamed, E; Nicol, SM; Thomas, RS; Periyasamy, M; Jiang, J; Ochocka, AM; Shousha, S; Huson, L; Bray, SE; Coombes, RC; Ali, S; Fuller-Pace, FV				Wortham, N. C.; Ahamed, E.; Nicol, S. M.; Thomas, R. S.; Periyasamy, M.; Jiang, J.; Ochocka, A. M.; Shousha, S.; Huson, L.; Bray, S. E.; Coombes, R. C.; Ali, S.; Fuller-Pace, F. V.			The DEAD-box protein p72 regulates ER alpha-/oestrogen-dependent transcription and cell growth, and is associated with improved survival in ER alpha-positive breast cancer	ONCOGENE			English	Article						p68 RNA helicase; p72 RNA helicase; oestrogen receptor-alpha; gene regulation; breast cancer; tamoxifen	ESTROGEN-RECEPTOR-ALPHA; P68 RNA HELICASE; PHOSPHORYLATION; COACTIVATOR; ACTIVATION; TAMOXIFEN; PROMOTER; COMPLEX; DIFFERENTIATION; IDENTIFICATION	The DEAD-box RNA helicases p68 (DDX5) and p72 (DDX17) have been shown to act as transcriptional co-activators for a diverse range of transcription factors, including oestrogen receptor-alpha (ER alpha). Here, we show that, although both proteins interact with and co-activate ER alpha in reporter gene assays, small interfering RNA-mediated knockdown of p72, but not p68, results in a significant inhibition of oestrogen-dependent transcription of endogenous ER alpha-responsive genes and oestrogen-dependent growth of MCF-7 and ZR75-1 breast cancer cells. Furthermore, immunohistochemical staining of ER alpha-positive primary breast cancers for p68 and p72 indicate that p72 expression is associated with an increased period of relapse-free and overall survival (P = 0.006 and 0.016, respectively), as well as being inversely associated with Her2 expression (P = 0.008). Conversely, p68 shows no association with relapse-free period, or overall survival, but it is associated with an increased expression of Her2 (P = 0.001), AIB-1 (P = 0.001) and higher tumour grade (P = 0.044). Our data thus highlight a crucial role for p72 in ER alpha co-activation and oestrogen-dependent cell growth and provide evidence in support of distinct but important roles for both p68 and p72 in regulating ER alpha activity in breast cancer. Oncogene (2009) 28, 4053-4064; doi:10.1038/onc.2009.261; published online 31 August 2009	[Ahamed, E.; Thomas, R. S.; Periyasamy, M.; Jiang, J.; Ochocka, A. M.; Coombes, R. C.; Ali, S.] Univ London Imperial Coll Sci Technol & Med, Dept Oncol, London W12 ONN, England; [Wortham, N. C.; Nicol, S. M.; Fuller-Pace, F. V.] Univ Dundee, Ninewells Hosp & Med Sch, Ctr Oncol & Mol Med, Dundee DD1 9SY, Scotland; [Jiang, J.; Shousha, S.] Univ London Imperial Coll Sci Technol & Med, Charing Cross Hosp, Dept Histopathol, London, England; [Huson, L.] Univ London Imperial Coll Sci Technol & Med, Stat Advisory Serv, London, England; [Bray, S. E.] Univ Dundee, Ninewells Hosp & Med Sch, Tayside Tissue Bank, Dundee DD1 9SY, Scotland	Imperial College London; University of Dundee; Imperial College London; Imperial College London; University of Dundee	Ali, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Oncol, Hammersmith Hosp Campus, London W12 ONN, England.	simak.ali@imperial.ac.uk; f.v.fullerpace@dundee.ac.uk	periyasamy, manikandan/AAB-7924-2020; Thomas, Ross/C-6434-2008; Periyasamy, Manikandan/AAL-6211-2020; Ali, Simak/M-6912-2018	Ali, Simak/0000-0002-1320-0816; Coombes, Raoul Charles/0000-0002-4811-1100; Periyasamy, Manikandan/0000-0001-7626-2531	Breast Cancer Campaign; Association for International Cancer Research; Cancer Research UK; Breast Cancer Research Trust; NIHR Biomedical Research Centre	Breast Cancer Campaign; Association for International Cancer Research; Cancer Research UK(Cancer Research UK); Breast Cancer Research Trust; NIHR Biomedical Research Centre(National Institute for Health Research (NIHR))	This work was supported by grants from the Breast Cancer Campaign, Association for International Cancer Research, Cancer Research UK and the Breast Cancer Research Trust. We are grateful for support from the NIHR Biomedical Research Centre funding scheme, and thank David Meek, Malcolm Parker and lab members for helpful discussions.	ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bates GJ, 2005, EMBO J, V24, P543, DOI 10.1038/sj.emboj.7600550; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Buzdar A, 2001, CLIN CANCER RES, V7, P2620; Caretti G, 2006, DEV CELL, V11, P547, DOI 10.1016/j.devcel.2006.08.003; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; Clark EL, 2008, CANCER RES, V68, P7938, DOI 10.1158/0008-5472.CAN-08-0932; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Fukuda T, 2007, NAT CELL BIOL, V9, P604, DOI 10.1038/ncb1577; Fuller-Pace FV, 2006, NUCLEIC ACIDS RES, V34, P4206, DOI 10.1093/nar/gkl460; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Goodman RH, 2000, GENE DEV, V14, P1553; Grisouard J, 2007, MOL ENDOCRINOL, V21, P2427, DOI 10.1210/me.2007-0129; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Hurtado A, 2008, NATURE, V456, P663, DOI 10.1038/nature07483; Jacobs AMF, 2007, ONCOGENE, V26, P5866, DOI 10.1038/sj.onc.1210387; Jensen ED, 2008, J CELL BIOCHEM, V103, P1438, DOI 10.1002/jcb.21526; Jiang J, 2007, CLIN CANCER RES, V13, P5769, DOI 10.1158/1078-0432.CCR-07-0822; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Lopez-Garcia J, 2006, NUCLEIC ACIDS RES, V34, P6126, DOI 10.1093/nar/gkl875; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Medunjanin S, 2005, J BIOL CHEM, V280, P33006, DOI 10.1074/jbc.M506758200; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Morris C, 2002, ENDOCR-RELAT CANCER, V9, P267, DOI 10.1677/erc.0.0090267; Ogilvie VC, 2003, NUCLEIC ACIDS RES, V31, P1470, DOI 10.1093/nar/gkg236; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rossow KL, 2003, ONCOGENE, V22, P151, DOI 10.1038/sj.onc.1206067; Sarwar N, 2006, ENDOCR-RELAT CANCER, V13, P851, DOI 10.1677/erc.1.01123; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shin S, 2007, J CELL BIOCHEM, V101, P1252, DOI 10.1002/jcb.21250; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; Thomas RS, 2008, J MOL ENDOCRINOL, V40, P173, DOI 10.1677/JME-07-0165; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Trowbridge JM, 1997, P NATL ACAD SCI USA, V94, P10132, DOI 10.1073/pnas.94.19.10132; Uhlmann-Schiffler H, 2002, J BIOL CHEM, V277, P1066, DOI 10.1074/jbc.M107535200; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Wilson BJ, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-11	43	86	94	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2009	28	46					4053	4064		10.1038/onc.2009.261	http://dx.doi.org/10.1038/onc.2009.261			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AE	19718048	Green Accepted, Green Submitted			2022-12-17	WOS:000272560500002
J	Bagci, T; Wu, JK; Pfannl, R; Ilag, LL; Jay, DG				Bagci, T.; Wu, J. K.; Pfannl, R.; Ilag, L. L.; Jay, D. G.			Autocrine semaphorin 3A signaling promotes glioblastoma dispersal	ONCOGENE			English	Article						proteomics; glioma; dispersal; semaphorin; neuropilin	ENDOTHELIAL GROWTH-FACTOR; PANCREATIC-CANCER CELLS; HUMAN GLIOMA-CELLS; CARCINOMA-CELLS; POOR-PROGNOSIS; TUMOR-CELLS; NEUROPILIN-1; MIGRATION; RECEPTOR; EXPRESSION	Glioblastoma multiforme (GBM) is the most malignant glioma type with diffuse borders due to extensive tumor cell infiltration. Therefore, understanding the mechanism of GBM cell dispersal is critical for developing effective therapies to limit infiltration. We identified neuropilin-1 as a mediator of cancer cell invasion by a functional proteomic screen and showed its role in GBM cells. Neuropilin-1 is a receptor for semaphorin3A (Sema3A), a secreted chemo-repellent that facilitates axon guidance during neural development. Although neuropilin-1 expression in GBMs was previously shown, its role as a Sema3A receptor remained elusive. Using fluorophore-assisted light inactivation and RNA interference, we showed that neuropilin-1 is required for GBM cell migration. We also showed that GBM cells secrete Sema3A endogenously, and RNA interference-mediated downregulation of Sema3A inhibits migration and alters cell morphology that is dependent on Rac1 activity. Sema3A depletion also reduces dispersal, which is recovered by supplying Sema3A exogenously. Extracellular application of Sema3A decreases cell-substrate adhesion in a neuropilin-1-dependent manner. Using immunohistochemistry, we showed that Sema3A is overexpressed in a subset of human GBMs compared with the non-neoplastic brain. Together, these findings implicate Sema3A as an autocrine signal for neuropilin-1 to promote GBM dispersal by modulating substrate adhesion and suggest that targeting Sema3A-neuropilin-1 signaling may limit GBM infiltration. Oncogene (2009) 28, 3537-3550; doi: 10.1038/onc.2009.204; published online 17 August 2009	[Jay, D. G.] Tufts Univ, Dept Physiol, Sch Med, Boston, MA 02111 USA; [Bagci, T.; Jay, D. G.] Tufts Univ, Sch Med, Dept Neurosci, Boston, MA 02111 USA; [Wu, J. K.] Tufts Univ, Sch Med, Dept Neurosurg, Boston, MA 02111 USA; [Pfannl, R.] Tufts Univ, Sch Med, Dept Neuropathol, Boston, MA 02111 USA; [Ilag, L. L.] Bio21 Mol Sci & Biotechnol Inst, Patrys Ltd, Parkville, Vic, Australia	Tufts University; Tufts University; Tufts University; Tufts University	Jay, DG (corresponding author), Tufts Univ, Dept Physiol, Sch Med, 136 Harrison Ave,M&V709, Boston, MA 02111 USA.	daniel.jay@tufts.edu	Onder, Tugba Bagci/AAN-1392-2021	Bagci Onder, Tugba/0000-0003-3646-2613	Goldhirsh Foundation; NIH [RO1 CA 116642]; NATIONAL CANCER INSTITUTE [R01CA116642] Funding Source: NIH RePORTER	Goldhirsh Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Alex Kolodkin (Johns Hopkins School of Medicine) for kindly providing function blocking anti-Nrp-1 antibody; Jean Stewart, Dean Yimlamai and Jennifer Salluzzo for technical help; Sonya Craig for discussions about the adhesion assay; Brenda Eustace for assistance with the invasion screen; Pat Hibberd for help with the statistical analysis; Laura Liscum, Tamer Onder and Jessica McCready for critically reading the paper. This work was supported by the Goldhirsh Foundation and the NIH, RO1 CA 116642.	Bachelder RE, 2001, CANCER RES, V61, P5736; Bachelder RE, 2003, CANCER RES, V63, P5230; Beck S, 2002, PROTEOMICS, V2, P247, DOI 10.1002/1615-9861(200203)2:3<247::AID-PROT247>3.0.CO;2-K; Berens Michael E., 1999, Neoplasia (New York), V1, P208, DOI 10.1038/sj.neo.7900034; Broholm H, 2004, APMIS, V112, P257, DOI 10.1111/j.1600-0463.2004.apm11204-0505.x; Castellani V, 2000, NEURON, V27, P237, DOI 10.1016/S0896-6273(00)00033-7; Castellani V, 2002, EMBO J, V21, P6348, DOI 10.1093/emboj/cdf645; Chen G, 2008, NAT NEUROSCI, V11, P36, DOI 10.1038/nn2018; Cox EA, 1998, MICROSC RES TECHNIQ, V43, P412, DOI 10.1002/(SICI)1097-0029(19981201)43:5<412::AID-JEMT7>3.0.CO;2-F; De Wit J, 2005, MOL CELL NEUROSCI, V29, P40, DOI 10.1016/j.mcn.2004.12.009; Del Duca D, 2004, J NEURO-ONCOL, V67, P295, DOI 10.1023/B:NEON.0000024220.07063.70; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; Ding H, 2000, INT J CANCER, V88, P584, DOI 10.1002/1097-0215(20001115)88:4<584::AID-IJC11>3.0.CO;2-T; Ellis LM, 2006, MOL CANCER THER, V5, P1099, DOI 10.1158/1535-7163.MCT-05-0538; Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131; Fukahi K, 2004, CLIN CANCER RES, V10, P581, DOI 10.1158/1078-0432.CCR-0930-03; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Halloran MC, 2006, CURR OPIN CELL BIOL, V18, P533, DOI 10.1016/j.ceb.2006.08.010; Hoelzinger DB, 2007, J NATL CANCER I, V99, P1583, DOI 10.1093/jnci/djm187; Holland EC, 2001, NAT REV GENET, V2, P120, DOI 10.1038/35052535; Hu B, 2007, ONCOGENE, V26, P5577, DOI 10.1038/sj.onc.1210348; Kawakami T, 2002, CANCER, V95, P2196, DOI 10.1002/cncr.10936; Klagsbrun M, 2002, ADV EXP MED BIOL, V515, P33; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Kreuter M, 2006, LEUKEMIA, V20, P1950, DOI 10.1038/sj.leu.2404384; Lee P, 2002, P NATL ACAD SCI USA, V99, P10470, DOI 10.1073/pnas.162366299; Li M, 2004, CANCER-AM CANCER SOC, V101, P2341, DOI 10.1002/cncr.20634; Mertsch S, 2008, J NEURO-ONCOL, V87, P1, DOI 10.1007/s11060-007-9484-2; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Mueller MW, 2007, INT J CANCER, V121, P2421, DOI 10.1002/ijc.22949; Nakada M, 2004, CANCER RES, V64, P3179, DOI 10.1158/0008-5472.CAN-03-3667; Nakada M, 2006, CANCER RES, V66, P8492, DOI 10.1158/0008-5472.CAN-05-4211; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Okada H, 1996, INT J CANCER, V66, P255, DOI 10.1002/(SICI)1097-0215(19960410)66:2<255::AID-IJC20>3.0.CO;2-A; Osada H, 2004, ANTICANCER RES, V24, P547; Pan Q, 2007, CANCER CELL, V11, P53, DOI 10.1016/j.ccr.2006.10.018; Parikh AA, 2004, AM J PATHOL, V164, P2139, DOI 10.1016/S0002-9440(10)63772-8; Polleux F, 2000, NATURE, V404, P567, DOI 10.1038/35007001; Raper JA, 2000, CURR OPIN NEUROBIOL, V10, P88, DOI 10.1016/S0959-4388(99)00057-4; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rieger J, 2003, GLIA, V42, P379, DOI 10.1002/glia.10210; Roche J, 2002, ADV EXP MED BIOL, V515, P103; Rossignol M, 2000, GENOMICS, V70, P211, DOI 10.1006/geno.2000.6381; Roush W, 1998, SCIENCE, V279, P2042, DOI 10.1126/science.279.5359.2042; Serini G, 2003, NATURE, V424, P391, DOI 10.1038/nature01784; Sloan KE, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-73; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Staton CA, 2007, J PATHOL, V212, P237, DOI 10.1002/path.2182; Subauste MC, 2000, J BIOL CHEM, V275, P9725, DOI 10.1074/jbc.275.13.9725; Tran TS, 2007, ANNU REV CELL DEV BI, V23, P263, DOI 10.1146/annurev.cellbio.22.010605.093554; Turner LJ, 2004, J BIOL CHEM, V279, P33199, DOI 10.1074/jbc.M402943200; Vales A, 2007, LEUKEMIA LYMPHOMA, V48, P1997, DOI 10.1080/10428190701534424; Vanveldhuizen PJ, 2003, ONCOL REP, V10, P1067; Wey JS, 2005, BRIT J CANCER, V93, P233, DOI 10.1038/sj.bjc.6602663; Zhou YP, 2008, TRENDS BIOCHEM SCI, V33, P161, DOI 10.1016/j.tibs.2008.01.006; Ziegler WH, 2006, TRENDS CELL BIOL, V16, P453, DOI 10.1016/j.tcb.2006.07.004	57	86	95	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2009	28	40					3537	3550		10.1038/onc.2009.204	http://dx.doi.org/10.1038/onc.2009.204			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KI	19684614				2022-12-17	WOS:000270851700003
J	Beverly, LJ; Varmus, HE				Beverly, L. J.; Varmus, H. E.			MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family	ONCOGENE			English	Article						BCL2; BCLxl; BCLw; MCL1; BFL1; BCLb	CELL LUNG-CANCER; BH3 MIMETIC ABT-737; C-MYC; DRUG-RESISTANCE; LEUKEMIA; APOPTOSIS; PROTEINS; SURVIVAL; DEATH; GENE	Signals that control the. ne balance between cell death and cell survival are altered during tumorigenesis. Understanding the mechanisms by which this balance is perturbed, leading to excessive cell survival, is important for designing effective therapies. Proteins belonging to the B-cell lymphoma (BCL) family are known to regulate death responses to apoptotic signals, especially those originating within cells. A subset of BCL family members capable of inhibiting cell death is known to contribute to tumorigenesis; however, it is not known whether all six antiapoptotic BCL family members play a causal role in tumor development. Using a mouse model of MYC-driven leukemia, we showed that, in addition to the well characterized BCL2 and BCLxl (BCL2L1), the other four family members-BCLw (BCL2L2), BCLb (BCL2L10), BFL1 (BCL2A1) and MCL1-also cooperate with MYC to accelerate leukemogenesis. In addition, high levels of each family member are found in either solid human tumors or cell lines derived from human leukemias or lymphomas.	[Beverly, L. J.; Varmus, H. E.] Mem Sloan Kettering Canc Ctr, Dept Canc Genet & Biol, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center	Beverly, LJ (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Canc Genet & Biol, 1275 York Ave,Box 62, New York, NY 10065 USA.	BeverlyL@mskcc.org			NIH [P01 2PO1CA094060-06A1]; NATIONAL CANCER INSTITUTE [P01CA094060] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Varmus laboratory, especially G Sanchez, A Giannakou and MA Melnick, for expert handling of the mouse colony, including genotyping, and for performing immunohistochemistry on embedded tissue sections. Funding for this project was provided, in part, by NIH P01 2PO1CA094060-06A1 to HEV.	Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chen S, 2007, CANCER RES, V67, P782, DOI 10.1158/0008-5472.CAN-06-3964; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; Horvitz HR, 1999, CANCER RES, V59, p1701S; Kawasaki T, 2007, CANCER SCI, V98, P1070, DOI 10.1111/j.1349-7006.2007.00491.x; Kohl TM, 2007, LEUKEMIA, V21, P1763, DOI 10.1038/sj.leu.2404776; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Lanave C, 2004, GENE, V333, P71, DOI 10.1016/j.gene.2004.02.017; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Letai A, 2004, CANCER CELL, V6, P241, DOI 10.1016/j.ccr.2004.07.011; Luo H, 2005, BLOOD, V106, P2452, DOI 10.1182/blood-2005-02-0734; Mandal M, 2005, J EXP MED, V201, P603, DOI 10.1084/jem.20041924; Reed JC, 2006, NAT CLIN PRACT ONCOL, V3, P388, DOI 10.1038/ncponc0538; Riedl SJ, 2007, NAT REV MOL CELL BIO, V8, P405, DOI 10.1038/nrm2153; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shoemaker AR, 2008, CLIN CANCER RES, V14, P3268, DOI 10.1158/1078-0432.CCR-07-4622; Swanson PJ, 2004, J IMMUNOL, V172, P6684, DOI 10.4049/jimmunol.172.11.6684; Valdez BC, 2008, LEUKEMIA RES, V32, P1684, DOI 10.1016/j.leukres.2008.01.016; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wesarg E, 2007, INT J CANCER, V121, P2387, DOI 10.1002/ijc.22977; Yasui K, 2004, CANCER RES, V64, P1403, DOI 10.1158/0008-5472.CAN-3263-2; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zhai D, 2006, CELL DEATH DIFFER, V13, P1419, DOI 10.1038/sj.cdd.4401937	26	86	89	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2009	28	9					1274	1279		10.1038/onc.2008.466	http://dx.doi.org/10.1038/onc.2008.466			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415AH	19137012	Green Accepted			2022-12-17	WOS:000263906200011
J	Tommiska, J; Bartkova, J; Heinonen, M; Hautala, L; Kilpivaara, O; Eerola, H; Aittomaki, K; Hofstetter, B; Lukas, J; von Smitten, K; Blomqvist, C; Ristimaki, A; Heikkila, P; Bartek, J; Nevanlinna, H				Tommiska, J.; Bartkova, J.; Heinonen, M.; Hautala, L.; Kilpivaara, O.; Eerola, H.; Aittomaki, K.; Hofstetter, B.; Lukas, J.; von Smitten, K.; Blomqvist, C.; Ristimaki, A.; Heikkila, P.; Bartek, J.; Nevanlinna, H.			The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer	ONCOGENE			English	Article						DNA damage response; triple-negative breast cancer; BRCA1/BRCA2 familial cancer; ATM defects; genetic instability	ONCOGENE-INDUCED SENESCENCE; DOUBLE-STRAND BREAKS; BRCA2 MUTATIONS; POLY(ADP-RIBOSE) POLYMERASE; HISTOPATHOLOGICAL FEATURES; ATAXIA-TELANGIECTASIA; ANTICANCER BARRIER; PROTEIN EXPRESSION; FAMILIES; TUMORS	The ataxia- telangiectasia- mutated ( ATM) kinase is a key transducer of DNA damage signals within the genome maintenance machinery and a tumour suppressor whose germline mutations predispose to familial breast cancer. ATM signalling is constitutively activated in early stages of diverse types of human malignancies and cell culture models in response to oncogene- induced DNA damage providing a barrier against tumour progression. As BRCA1 and BRCA2 are also components of the genome maintenance network and their mutations predispose to breast cancer, we have examined the ATM expression in human breast carcinomas of BRCA1/ 2 mutation carriers, sporadic cases and familial non- BRCA1/ 2 patients. Our results show that ATM protein expression is aberrantly reduced more frequently among BRCA1 ( 33%; P 0.0003) and BRCA2 ( 30%; P 0.0009) tumours than in non- BRCA1/ 2 tumours ( 10.7%). Furthermore, the non-BRCA1/ 2 tumours with reduced ATM expression were more often estrogen receptor ( ER) negative ( P 0.0002), progesterone receptor ( PR) negative ( P 0.004) and were of higher grade ( P 0.0004). In our series of 1013 non-BRCA1/ 2 cases, ATM was more commonly deficient ( 20%; P 0.0006) and p53 was overabundant ( 47%; P<0.0000000001) among the difficult- to- treat ER/ PR/ ERBB2- triple- negative subset of tumours compared with cases that expressed at least one of these receptors ( 10 and 16% of aberrant ATM and p53, respectively). We propose a model of conditional haploinsufficiency' for BRCA1/ 2 under conditions of enhanced DNA damage in precancerous lesions resulting in more robust activation and hence increased selection for inactivation or loss of ATM in tumours of BRCA1/ 2 mutation carriers, with implications for genomic instability and curability of diverse subsets of human breast cancer.	[Tommiska, J.; Hautala, L.; Kilpivaara, O.; Eerola, H.; Nevanlinna, H.] Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, FIN-00029 Helsinki, Finland; [Bartkova, J.; Hofstetter, B.; Lukas, J.; Bartek, J.] Danish Canc Soc, Inst Canc Biol, Copenhagen, Denmark; [Bartkova, J.; Hofstetter, B.; Lukas, J.; Bartek, J.] Danish Canc Soc, Ctr Genotox Stress Res, Copenhagen, Denmark; [Heinonen, M.; Ristimaki, A.; Heikkila, P.] HUSLAB, Dept Pathol, Helsinki, Finland; [Heinonen, M.; Ristimaki, A.; Heikkila, P.] Univ Helsinki, Cent Hosp, Haartman Inst, FIN-00029 Helsinki, Finland; [Heinonen, M.; Ristimaki, A.] Univ Helsinki, Genome Scale Biol Program, Helsinki, Finland; [Eerola, H.; Blomqvist, C.] Univ Helsinki, Cent Hosp, Dept Oncol, FIN-00029 Helsinki, Finland; [Aittomaki, K.] Univ Helsinki, Cent Hosp, Dept Clin Genet, FIN-00029 Helsinki, Finland; [von Smitten, K.] Univ Helsinki, Cent Hosp, Dept Surg, FIN-00029 Helsinki, Finland; [Blomqvist, C.] Univ Uppsala Hosp, Dept Oncol, S-75185 Uppsala, Sweden	University of Helsinki; Helsinki University Central Hospital; Danish Cancer Society; Danish Cancer Society; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; Uppsala University; Uppsala University Hospital	Nevanlinna, H (corresponding author), Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, POB 700, FIN-00029 Helsinki, Finland.	jb@cancer.dk; heli.nevanlinna@hus.fi	Bartek, Jiri/G-5870-2014	Nevanlinna, Heli/0000-0002-0916-2976; Lukas, Jiri/0000-0001-9087-506X; Blomqvist, Carl/0000-0003-3041-1938; Tommiska, Johanna/0000-0001-7958-8262; Hautala, Laura/0000-0002-5501-2792				Angele S, 2003, HISTOPATHOLOGY, V43, P347, DOI 10.1046/j.1365-2559.2003.01713.x; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bartek J, 2007, CELL CYCLE, V6, P2344, DOI 10.4161/cc.6.19.4754; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Bartkova J, 2005, CELL CYCLE, V4, P838, DOI 10.4161/cc.4.6.1742; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Cleator S, 2007, LANCET ONCOL, V8, P235, DOI 10.1016/S1470-2045(07)70074-8; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Eerola H, 2005, BREAST CANCER RES, V7, pR465, DOI 10.1186/bcr1025; Eerola H, 2005, BREAST CANCER RES, V7, pR93, DOI 10.1186/bcr953; Eerola H, 2000, EUR J CANCER, V36, P1143, DOI 10.1016/S0959-8049(00)00093-9; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Honrado E, 2005, MODERN PATHOL, V18, P1305, DOI 10.1038/modpathol.3800453; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kilpivaara O, 2005, INT J CANCER, V113, P575, DOI 10.1002/ijc.20638; Lassus H, 2004, GYNECOL ONCOL, V92, P31, DOI 10.1016/j.ygyno.2003.10.010; Lukas C, 2001, CANCER RES, V61, P4990; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; McCabe N, 2006, CANCER RES, V66, P8109, DOI 10.1158/0008-5472.CAN-06-0140; Palacios J, 2003, CLIN CANCER RES, V9, P3606; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Prokopcova J, 2007, BREAST CANCER RES TR, V104, P121, DOI 10.1007/s10549-006-9406-6; Pylkas K, 2007, CARCINOGENESIS, V28, P1040, DOI 10.1093/carcin/bgl237; Renwick A, 2006, NAT GENET, V38, P873, DOI 10.1038/ng1837; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Syrjakoski K, 2000, J NATL CANCER I, V92, P1529, DOI 10.1093/jnci/92.18.1529; Tanner M, 2000, AM J PATHOL, V157, P1467, DOI 10.1016/S0002-9440(10)64785-2; Tommiska J, 2005, CLIN CANCER RES, V11, P5098, DOI 10.1158/1078-0432.CCR-05-0173; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; Vahteristo P, 2001, BRIT J CANCER, V84, P704, DOI 10.1054/bjoc.2000.1626; Vehmanen P, 1997, HUM MOL GENET, V6, P2309, DOI 10.1093/hmg/6.13.2309; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446	41	86	90	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2501	2506		10.1038/sj.onc.1210885	http://dx.doi.org/10.1038/sj.onc.1210885			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17982490				2022-12-17	WOS:000254844900015
J	Faucherre, A; Taylor, GS; Overvoorde, J; Dixon, JE; den Hertog, J				Faucherre, A.; Taylor, G. S.; Overvoorde, J.; Dixon, J. E.; den Hertog, J.			Zebrafish pten genes have overlapping and non-redundant functions in tumorigenesis and embryonic development	ONCOGENE			English	Article						pten; zebrafish; tumorigenesis; development; proliferation; survival	LIPID PHOSPHATASE-ACTIVITY; LHERMITTE-DUCLOS-DISEASE; TUMOR-SUPPRESSOR PTEN; PROTEIN-KINASE B; SIGNALING PATHWAY; NEGATIVE REGULATION; GERMLINE MUTATIONS; CELL-SURVIVAL; CANCER-CELLS; PTEN/MMAC1	In human cancer, PTEN ( Phosphatase and TENsin homolog on chromosome 10, also referred to as MMAC1 and TEP1) is a frequently mutated tumor suppressor gene. We have used the zebrafish as a model to investigate the role of Pten in embryonic development and tumorigenesis. The zebrafish genome encodes two pten genes, ptena and ptenb. Here, we report that both Pten gene products from zebrafish are functional. Target-selected inactivation of ptena and ptenb revealed that Ptena and Ptenb have redundant functions in embryonic development, in that ptena-/- and ptenb-/- mutants did not show embryonic phenotypes. Homozygous single mutants survived as adults and they were viable and fertile. Double homozygous ptena-/- ptenb-/- mutants died at 5 days post fertilization with pleiotropic defects. These defects were rescued by treatment with the phosphatidylinositol-3-kinase inhibitor, LY294002. Double homozygous embryos showed enhanced cellular proliferation. In addition, cell survival was dramatically enhanced in embryos that lack functional Pten upon gamma-irradiation. Surprisingly, adult ptenb-/- zebrafish developed ocular tumors later in life, despite the expression of ptena in adult eyes. We conclude that whereas Ptena and Ptenb have redundant functions in embryonic development, they apparently do not have completely overlapping functions later in life. These pten mutant zebrafish represent a unique model to screen for genetic and/ or chemical suppressors of Pten loss-of-function.	[Faucherre, A.; Overvoorde, J.; den Hertog, J.] Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; [Taylor, G. S.; Dixon, J. E.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Taylor, G. S.; Dixon, J. E.] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Taylor, G. S.; Dixon, J. E.] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	den Hertog, J (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	j.denhertog@niob.knaw.nl		Faucherre, Adele/0000-0002-6099-3898				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Cole LK, 2001, DEV BIOL, V240, P123, DOI 10.1006/dbio.2001.0432; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; Croushore JA, 2005, DEV DYNAM, V234, P911, DOI 10.1002/dvdy.20576; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Gregorieff A, 2004, EMBO J, V23, P1825, DOI 10.1038/sj.emboj.7600191; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Kishimoto H, 2003, CELL STRUCT FUNCT, V28, P11; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lieschke GJ, 2007, NAT REV GENET, V8, P353, DOI 10.1038/nrg2091; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marcus RC, 1999, VISUAL NEUROSCI, V16, P417, DOI 10.1017/S095252389916303X; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Mihaylova VT, 1999, P NATL ACAD SCI USA, V96, P7427, DOI 10.1073/pnas.96.13.7427; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stokoe D, 2001, CURR BIOL, V11, pR502, DOI 10.1016/S0960-9822(01)00303-7; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Taylor GS, 2003, METHOD ENZYMOL, V366, P43; Westerfield M., 1995, GUIDE LAB USE ZEBRAF; Wienholds E, 2002, SCIENCE, V297, P99, DOI 10.1126/science.1071762; Wu ZX, 2007, TUMOR BIOL, V28, P9, DOI 10.1159/000097041; Zhou XP, 2003, AM J HUM GENET, V73, P1191, DOI 10.1086/379382	32	86	89	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2008	27	8					1079	1086		10.1038/sj.onc.1210730	http://dx.doi.org/10.1038/sj.onc.1210730			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17704803				2022-12-17	WOS:000253136700007
J	Srinivasan, D; Sims, JT; Plattner, R				Srinivasan, D.; Sims, J. T.; Plattner, R.			Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival	ONCOGENE			English	Article						Abl kinases; breast cancer; proliferation; survival; transformation; STAT3	TYROSINE KINASE; INHIBITOR; APOPTOSIS; LEUKEMIA; PATHWAY; TARGETS; GENES; STAT1	Mutant Abl kinases ( such as BCR-Abl) drive the development of leukemia; however little is known regarding whether Abl kinases contribute to the development or progression of solid tumors. We recently demonstrated that endogenous Abl kinases ( c-Abl, Arg) are activated by deregulated ErbB receptors and Src kinases, and drive invasion of aggressive breast cancer cells. In this study, we examined whether activation of endogenous Abl kinases affects transformation, proliferation and survival, which are major contributors to breast cancer development and metastatic progression. Using a pharmacological inhibitor and RNAi, we demonstrate that activation of endogenous Abl kinases dramatically promotes breast cancer cell proliferation and anchorage-independent growth in serum, as well as survival following nutrient deprivation. Activation of Abl kinases mediates phosphorylation of STAT3, and promotes proliferation by accelerating G(1)-> S progression. Moreover, we identify IGF-1R as a novel upstream activator of endogenous Abl kinases, and demonstrate that Abl kinase activation is required for IGF-1-stimulated cell cycle progression in breast cancer cells. Since activation of Abl kinases affects multiple steps of breast cancer development and progression, Abl kinase inhibitors are likely to be effective agents for the treatment of breast cancers containing highly active Abl kinases.	[Srinivasan, D.; Sims, J. T.; Plattner, R.] Univ Kentucky, Sch Med, Dept Mol & Biomed Pharmacol, Lexington, KY 40536 USA	University of Kentucky	Plattner, R (corresponding author), Univ Kentucky, Sch Med, Dept Mol & Biomed Pharmacol, 800 Rose St,Combs Res Bldg 209, Lexington, KY 40536 USA.	rplat2@uky.edu			NCI NIH HHS [R01 CA116784] Funding Source: Medline; NCRR NIH HHS [P20 RR20171] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA116784] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020171] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Buettner R, 2002, CLIN CANCER RES, V8, P945; Burkle A, 2005, FEBS J, V272, P4576, DOI 10.1111/j.1742-4658.2005.04864.x; Camirand A, 2005, BREAST CANCER RES, V7, pR570, DOI 10.1186/bcr1028; Chernicky CL, 2000, CANCER GENE THER, V7, P384, DOI 10.1038/sj.cgt.7700126; Chernicky CL, 2002, J CLIN PATHOL-MOL PA, V55, P102, DOI 10.1136/mp.55.2.102; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HINES SJ, 1995, CELL GROWTH DIFFER, V6, P769; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Hynes NE, 2000, BREAST CANCER RES, V2, P154, DOI 10.1186/bcr48; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kauffman EC, 2003, J UROLOGY, V169, P1122, DOI 10.1097/01.ju.0000051580.89109.4b; Kharas NG, 2005, CANCER RES, V65, P2047, DOI 10.1158/0008-5472.CAN-04-3888; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; Liliensiek SJ, 2006, EXP EYE RES, V83, P61, DOI 10.1016/j.exer.2005.11.007; Marra F, 1996, J CLIN INVEST, V98, P1218, DOI 10.1172/JCI118905; Morgensztern D, 2005, ANTI-CANCER DRUG, V16, P797, DOI 10.1097/01.cad.0000173476.67239.3b; Nagano K, 2006, ONCOGENE, V25, P493, DOI 10.1038/sj.onc.1208996; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; PENDERGAST AM, 2001, CHRONIC MYELOID LEUK, P19; Plattner R, 2003, CELL CYCLE, V2, P273, DOI 10.4161/cc.2.4.409; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Singer CF, 2004, ENDOCR-RELAT CANCER, V11, P861, DOI 10.1677/erc.1.00801; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; van Diest PJ, 2004, J CLIN PATHOL, V57, P675, DOI 10.1136/jcp.2003.010777; Vantaggiato Chiara, 2006, J Biol, V5, P14, DOI 10.1186/jbiol38; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Widschwendter A, 2002, CLIN CANCER RES, V8, P3065; Wu J, 1999, BRIT J CANCER, V79, P1572, DOI 10.1038/sj.bjc.6690250	33	86	90	3	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1095	1105		10.1038/sj.onc.1210714	http://dx.doi.org/10.1038/sj.onc.1210714			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700528				2022-12-17	WOS:000253136700009
J	Goto, T; Takano, M; Albergaria, A; Briese, J; Pomeranz, K; Cloke, B; Fusi, L; Feroze-Zaidi, F; Maywald, N; Sajin, M; Dina, R; Ishihara, O; Takeda, S; Lam, EF; Bamberger, A; Ghaem-Maghami, S; Brosens, J				Goto, T.; Takano, M.; Albergaria, A.; Briese, J.; Pomeranz, K. M.; Cloke, B.; Fusi, L.; Feroze-Zaidi, F.; Maywald, N.; Sajin, M.; Dina, R. E.; Ishihara, O.; Takeda, S.; Lam, EW-F; Bamberger, A. M.; Ghaem-Maghami, S.; Brosens, J. J.			Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells	ONCOGENE			English	Article						endometrial cancer; FOXO1; phosphatidylinositol-3 kinase/Akt; transcription; paclitaxel; GADD45 alpha	FORKHEAD TRANSCRIPTION FACTOR; ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER; STROMAL CELLS; PROTEIN; KINASE; PATHWAY; STRESS; FKHR; AKT	The forkhead transcription factor FOXO1, a downstream target of phosphatidylinositol-3-kinase/Akt signalling pathway, regulates cyclic differentiation and apoptosis in normal endometrium, but its role in endometrial carcinogenesis is unknown. Screening of endometrial cancer cell lines demonstrated that FOXO1 is expressed in HEC-1B cells, but not in Ishikawa cells, which in turn highly express the FOXO1 targeting E3-ubiquitin ligase Skp2. FOXO1 transcript levels were also lower in Ishikawa cells and treatment with the proteasomal inhibitor was insufficient to restore expression. Lack of FOXO1 expression in Ishikawa cells was not accounted for by differential promoter methylation or activity, but correlated with increased messenger RNA (mRNA) turnover. Comparative analysis demonstrated that HEC-1B cells proliferate slower, but are more resistant to paclitaxel-mediated cell death than Ishikawa cells, which were partially reversed upon silencing of FOXO1 in HEC-1B cells or its re-expression in Ishikawa cells. We further show that FOXO1 is required for the expression of the growth arrest-and DNA-damage-inducible gene GADD45 alpha. Analysis of biopsy samples demonstrated a marked loss of FOXO1 and GADD45 alpha mRNA and protein expression in endometrioid endometrial cancer compared to normal endometrium. Together, these observations suggest that loss of FOXO1 perturbs endometrial homeostasis, promotes uncontrolled cell proliferation and increases susceptibility to genotoxic insults.	[Goto, T.; Takano, M.; Cloke, B.; Fusi, L.; Feroze-Zaidi, F.; Ghaem-Maghami, S.; Brosens, J. J.] Univ London Imperial Coll Sci Technol & Med, Fac Med, Inst Reprod & Dev Biol, Hammersmith Hosp, London W12 0NN, England; [Albergaria, A.; Pomeranz, K. M.; Lam, EW-F] Univ London Imperial Coll Sci Technol & Med, Canc Res UK Labs, Dept Oncol, London, England; [Albergaria, A.; Pomeranz, K. M.; Lam, EW-F] Hammersmith Hosp, Sect Canc Cell Biol, London, England; [Briese, J.; Maywald, N.; Bamberger, A. M.] Univ Clin Hamburg, Sect Endocrinol & Metab Ageing, Dept Pathol, Hamburg, Germany; [Sajin, M.] Univ Bucharest, Dept Morphopathol, Bucharest, Romania; [Dina, R. E.] Univ London Imperial Coll Sci Technol & Med, Dept Histopathol, London, England; [Ishihara, O.; Takeda, S.] Saitama Med Univ, Dept Obstet & Gynaecol, Saitama, Japan; [Takano, M.] Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Hlth Sci, Braga, Portugal	Imperial College London; Cancer Research UK; Imperial College London; Imperial College London; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Bucharest; Imperial College London; Saitama Medical University; Universidade do Minho	Brosens, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Inst Reprod & Dev Biol, Hammersmith Hosp, London W12 0NN, England.	j.brosens@imperial.ac.uk	Lam, Eric W-F/AAW-8566-2020; Albergaria, André/J-6162-2013	Lam, Eric W-F/0000-0003-1274-3576; Albergaria, André/0000-0002-2315-2360; Ghaem-Maghami, Sadaf/0000-0002-7369-5080; Brosens, Jan/0000-0003-0116-9329; Takeda, Satoru/0000-0001-9547-1435				Amant F, 2005, LANCET, V366, P491, DOI 10.1016/S0140-6736(05)67063-8; Arden KC, 2006, EXP GERONTOL, V41, P709, DOI 10.1016/j.exger.2006.05.015; Bamberger AM, 1999, VIRCHOWS ARCH, V434, P423, DOI 10.1007/s004280050361; Brosens JJ, 1999, ENDOCRINOLOGY, V140, P4809, DOI 10.1210/en.140.10.4809; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Christian M, 2002, J BIOL CHEM, V277, P20825, DOI 10.1074/jbc.M201018200; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Kajihara T, 2006, MOL ENDOCRINOL, V20, P2444, DOI 10.1210/me.2006-0118; Kau TR, 2003, CANCER CELL, V4, P463, DOI 10.1016/S1535-6108(03)00303-9; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Labied S, 2006, MOL ENDOCRINOL, V20, P35, DOI 10.1210/me.2005-0275; Lahav-Baratz S, 2004, MOL HUM REPROD, V10, P567, DOI 10.1093/molehr/gah084; Lal A, 2006, MOL CELL, V22, P117, DOI 10.1016/j.molcel.2006.03.016; Laurent A, 2005, CANCER RES, V65, P948; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Risinger JI, 2003, CANCER RES, V63, P6; Schuur ER, 2001, J BIOL CHEM, V276, P33554, DOI 10.1074/jbc.M105555200; Shang YF, 2006, NAT REV CANCER, V6, P360, DOI 10.1038/nrc1879; Sun M, 2001, CANCER RES, V61, P5985; Sunters A, 2006, CANCER RES, V66, P212, DOI 10.1158/0008-5472.CAN-05-1997; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Varbiro G, 2001, FREE RADICAL BIO MED, V31, P548, DOI 10.1016/S0891-5849(01)00616-5; VILGELM A, 2006, CANCER RES, V66, P335; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Yeap BB, 2002, J BIOL CHEM, V277, P27183, DOI 10.1074/jbc.M202883200; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7; Zoumpoulidou G, 2004, MOL ENDOCRINOL, V18, P1988, DOI 10.1210/me.2003-0467	38	86	90	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2008	27	1					9	19		10.1038/sj.onc.1210626	http://dx.doi.org/10.1038/sj.onc.1210626			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17599040				2022-12-17	WOS:000252118700002
J	Ito, TK; Ishii, G; Chiba, H; Ochiai, A				Ito, T-K; Ishii, G.; Chiba, H.; Ochiai, A.			The VEGF angiogenic switch of. broblasts is regulated by MMP-7 from cancer cells	ONCOGENE			English	Article						broblasts; angiogenesis; VEGF; MMP-7; CTGF	ENDOTHELIAL GROWTH-FACTOR; MATRIX METALLOPROTEINASES; TUMOR ANGIOGENESIS; FIBROBLASTS; BINDING; CARCINOGENESIS; MATRILYSIN; TUMORIGENESIS; MACROPHAGES; FIBRONECTIN	Vascular endothelial growth factor (VEGF) production by stromal fibroblasts plays an important role in tumor angiogenesis. However, VEGF is also expressed by normal tissue fibroblasts, raising the question of how the VEGF activity of fibroblasts is regulated. Here we report that the latent VEGF angiogenic activity of fibroblasts is activated by cancer cells, resulting in tumor-selective utilization of fibroblast-derived VEGF. Through the production of VEGF, human VA-13 fibroblasts promote angiogenesis in and growth of human pancreas cancer Capan-1 xenograft tumors, whereas VA-13 fibroblasts alone do not show significant angiogenesis. Treatment of VA-13 fibroblast supernatant with matrix metalloproteinase-7 (MMP- 7), an extracellular proteinase characteristically expressed by cancer cells, elicits endothelial tube formation. This effect is abrogated by anti-VEGF antibody or connective tissue growth factor (CTGF), which was previously reported to sequester VEGF and be degraded by MMP-7. Suppression of MMP-7 in Capan-1 cells abrogates the tumor angiogenic activity of VA-13 fibroblasts, which is restored by suppression of CTGF in VA-13 fibroblasts. We further show that these molecular mechanisms that trigger angiogenesis are effective in human primary fibroblasts and human colorectal tissue. These data suggest that fibroblasts may store VEGF in a latent state in the extracellular environment for urgent use in angiogenesis.	Natl Canc Ctr Hosp E, Res Ctr Innovat Oncol, Div Pathol, Kashiwa, Chiba 2778577, Japan; Univ Tokyo, Grad Sch Frontier Sci, Dept Integrat Biosci, Canc Biol Lab, Kashiwa, Chiba, Japan	National Cancer Center - Japan; University of Tokyo	Ochiai, A (corresponding author), Natl Canc Ctr Hosp E, Res Ctr Innovat Oncol, Div Pathol, 6-5-1 Kashiwanoba, Kashiwa, Chiba 2778577, Japan.	aochiai@east.ncc.go.jp	Ishii, Genichiro/E-2913-2012					Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brigstock DR, 1997, J BIOL CHEM, V272, P20275, DOI 10.1074/jbc.272.32.20275; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chen YL, 2004, MOL BIOL CELL, V15, P5635, DOI 10.1091/mbc.E04-06-0490; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Crawford HC, 2002, J CLIN INVEST, V109, P1437, DOI 10.1172/JCI200215051; Dong JY, 2004, EMBO J, V23, P2800, DOI 10.1038/sj.emboj.7600289; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; GENGRINOVITCH S, 1995, J BIOL CHEM, V270, P15059, DOI 10.1074/jbc.270.25.15059; Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087; Gupta K, 1999, Angiogenesis, V3, P147, DOI 10.1023/A:1009018702832; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hashimoto G, 2002, J BIOL CHEM, V277, P36288, DOI 10.1074/jbc.M201674200; HLATKY L, 1994, CANCER RES, V54, P6083; Huo N, 2002, CANCER LETT, V177, P95, DOI 10.1016/S0304-3835(01)00772-8; Ichikawa Y, 2006, ONCOL REP, V15, P311; Ii M, 2006, EXP BIOL MED, V231, P20; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; Ishii G, 2005, INT J CANCER, V117, P212, DOI 10.1002/ijc.21199; Jang HS, 2004, MOL THER, V9, P464, DOI 10.1016/j.ymthe.2003.12.002; Jodele S, 2005, CANCER RES, V65, P3200, DOI 10.1158/0008-5472.CAN-04-3770; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Lee S, 2005, J CELL BIOL, V169, P681, DOI 10.1083/jcb.200409115; Luque A, 2003, J BIOL CHEM, V278, P23656, DOI 10.1074/jbc.M212964200; McCarthy M, 2003, LANCET, V361, P1959, DOI 10.1016/S0140-6736(03)13603-3; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Overall CM, 2006, NAT REV CANCER, V6, P227, DOI 10.1038/nrc1821; Parks WC, 1999, WOUND REPAIR REGEN, V7, P423, DOI 10.1046/j.1524-475X.1999.00423.x; Roy R, 2006, EXP CELL RES, V312, P608, DOI 10.1016/j.yexcr.2005.11.022; Wijelath ES, 2002, CIRC RES, V91, P25, DOI 10.1161/01.RES.0000026420.22406.79; Zanetta L, 2000, INT J CANCER, V85, P281, DOI 10.1002/(SICI)1097-0215(20000115)85:2<281::AID-IJC21>3.0.CO;2-3	39	86	93	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2007	26	51					7194	7203		10.1038/sj.onc.1210535	http://dx.doi.org/10.1038/sj.onc.1210535			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17525740				2022-12-17	WOS:000250955600003
J	Vincent, A; Perrais, M; Desseyn, JL; Aubert, JP; Pigny, P; Van Seuningen, I				Vincent, A.; Perrais, M.; Desseyn, J-L; Aubert, J-P; Pigny, P.; Van Seuningen, I.			Epigenetic regulation (DNA methylation, histone modifications) of the 11p15 mucin genes (MUC2, MUC5AC, MUC5B, MUC6) in epithelial cancer cells	ONCOGENE			English	Article						mucin; 11p15; methylation; acetylation; cancer; epithelial	TRANSCRIPTIONAL REGULATION; BILE-ACIDS; EXPRESSION; PROMOTER; CARCINOMA; HYPERMETHYLATION; IDENTIFICATION; CHROMOSOME-11; DEACETYLASES; SUPPRESSION	The human genes MUC2, MUC5AC, MUC5B and MUC6 are clustered on chromosome 11 and encode large secreted gel-forming mucins. The frequent occurrence of their silencing in cancers and the GC-rich structure of their promoters led us to study the influence of epigenetics on their expression. Pre- and post- confluent cells were treated with demethylating agent 5-aza-2 '-deoxycytidine and histone deacetylase ( HDAC) inhibitor, trichostatin A. Mapping of methylated cytosines was performed by bisulfate-treated genomic DNA sequencing. Histone modi. cation status at the promoters was assessed by chromatin immunoprecipitation assays. Our results indicate that MUC2 was regulated by site-specific DNA methylation associated with establishment of a repressive histone code, whereas hypermethylation of MUC5B promoter was the major mechanism responsible for its silencing. DNA methyltransferase 1 was identified by small interfering RNA approach as a regulator of MUC2 and MUC5B endogenous expression that was potentiated by HDAC2. MUC2 and MUC5B epigenetic regulation was cellspecific, depended on cell differentiation status and inhibited their activation by Sp1. The expression of MUC5AC was rarely influenced by epigenetic mechanisms and methylation of MUC6 promoter was not correlated to its silencing. In conclusion, this study demonstrates the important role for methylation and/or histone modi. cations in regulating the 11p15 mucin genes in epithelial cancer cells.	INSERM, U560, F-59045 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Van Seuningen, I (corresponding author), INSERM, U560, Place de Verdun, F-59045 Lille, France.	isabelvs@lille.inserm.fr	Desseyn, Jean-Luc/M-5070-2018; Vincent, Audrey/I-2934-2016; VAN SEUNINGEN, Isabelle/N-6176-2016	Desseyn, Jean-Luc/0000-0001-6876-8049; Vincent, Audrey/0000-0003-0058-2058; VAN SEUNINGEN, Isabelle/0000-0002-3131-2694				Bernier JN, 1999, ATHLET THER TODAY, V4, P5, DOI 10.1123/att.4.5.5; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; Copin MC, 2001, FRONT BIOSCI, V6, pD1264, DOI 10.2741/Copin; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; DEBUSTROS A, 1988, P NATL ACAD SCI USA, V85, P5693; Desseyn JL, 2000, MOL BIOL EVOL, V17, P1175, DOI 10.1093/oxfordjournals.molbev.a026400; Fahrner JA, 2002, CANCER RES, V62, P7213; Ferguson M, 2003, NUCLEIC ACIDS RES, V31, P3123, DOI 10.1093/nar/gkg403; Ghoshal K, 2000, J BIOL CHEM, V275, P539, DOI 10.1074/jbc.275.1.539; Gratchev A, 1998, ANN NY ACAD SCI, V859, P180, DOI 10.1111/j.1749-6632.1998.tb11122.x; Gratchev A, 2001, CANCER LETT, V168, P71, DOI 10.1016/S0304-3835(01)00498-0; Hamada T, 2005, CANCER LETT, V227, P175, DOI 10.1016/j.canlet.2004.11.058; Hanski C, 1997, LAB INVEST, V77, P685; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Ho JJL, 2003, INT J ONCOL, V22, P273; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Koo JS, 1999, AM J RESP CELL MOL, V20, P43, DOI 10.1165/ajrcmb.20.1.3310; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Leteurtre E, 2004, BIOL CELL, V96, P145, DOI 10.1016/j.biolcel.2003.12.005; Mariette C, 2004, BIOCHEM J, V377, P701, DOI 10.1042/BJ20031132; Mesquita P, 2003, CANCER LETT, V189, P129, DOI 10.1016/S0304-3835(02)00549-9; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Perrais M, 2002, J BIOL CHEM, V277, P32258, DOI 10.1074/jbc.M204862200; Perrais M, 2001, J BIOL CHEM, V276, P30923, DOI 10.1074/jbc.M104204200; Perrais M, 2001, J BIOL CHEM, V276, P15386, DOI 10.1074/jbc.M010534200; Piessen G, 2007, BIOCHEM J, V402, P81, DOI 10.1042/BJ20061461; Pigny P, 1996, GENOMICS, V38, P340, DOI 10.1006/geno.1996.0637; Reis CA, 1998, GLYCOCONJUGATE J, V15, P51, DOI 10.1023/A:1006939432665; Rousseau K, 2003, HYBRIDOMA HYBRIDOM, V22, P293, DOI 10.1089/153685903322538818; Siedow A, 2002, TUMOR BIOL, V23, P54, DOI 10.1159/000048689; Sylvester PA, 2001, J PATHOL, V195, P327; Van Seuningen I, 2000, BIOCHEM J, V348, P675; Van Seuningen I, 2001, FRONT BIOSCI-LANDMRK, V6, pD1216; Yamada N, 2006, INT J CANCER, V119, P1850, DOI 10.1002/ijc.22047; Zhu P, 2004, CELL CYCLE, V3, P1240, DOI 10.4161/cc.3.10.1195	35	86	88	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	45					6566	6576		10.1038/sj.onc.1210479	http://dx.doi.org/10.1038/sj.onc.1210479			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17471237	Green Published			2022-12-17	WOS:000249919800010
J	Jiang, WQ; Zhong, ZH; Henson, JD; Reddel, RR				Jiang, W-Q; Zhong, Z-H; Henson, J. D.; Reddel, R. R.			Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference	ONCOGENE			English	Article						telomeres; alternative lengthening of telomeres; ALT-associated PML bodies; PML; siRNA; methionine restriction	PROMYELOCYTIC LEUKEMIA BODIES; LARGE-BODY FORMATION; TUMOR-CELL-LINES; DNA-DAMAGE; MAMMALIAN-CELLS; METABOLIC DEFECT; PROTEIN COMPLEX; NUCLEAR-BODIES; CANCER-CELLS; HUMAN RAP1	Telomerase-negative cancer cells can maintain their telomeres by a recombination-mediated alternative lengthening of telomeres (ALT) process. We reported previously that sequestration of MRE11/RAD50/NBS1 complexes represses ALT-mediated telomere length maintenance, and suppresses formation of ALT-associated promyelocytic leukemia (PML) bodies (APBs). APBs are PML bodies containing telomeric DNA and telomere-binding proteins, and are observed only in a small fraction of cells within asynchronously dividing ALT-positive cell populations. Here, we report that methionine restriction caused a reversible arrest in G(0)/G(1) phase of the cell cycle and reversible induction of APB formation in most cells within an ALT-positive population. We combined methionine restriction with RNA interference to test whether the following proteins are required for APB formation: PML body-associated proteins, PML and Sp100; telomere-associated proteins, TRF1, TRF2, TIN2 and RAP1; and DNA repair proteins, MRE11, RAD50, NBS1 and 53BP1. APB formation was not decreased by depletion of Sp100 (as reported previously) or of 53BP1, although 53BP1 partially colocalizes with APBs. Depletion of the other proteins suppressed APB formation. Because of the close linkage between ALT-mediated telomere maintenance and ability to form APBs, the eight proteins identified by this screen as being required for APB formation are also likely to be required for the ALT mechanism. Oncogene	Childrens Med Res Inst, Canc Res Unit, Westmead, NSW 2145, Australia	Children's Medical Research Institute - Australia	Reddel, RR (corresponding author), Childrens Med Res Inst, Canc Res Unit, 214 Hawkesbury Rd, Westmead, NSW 2145, Australia.	rreddel@cmri.usyd.edu.au	Henson, Jeremy/ABD-3494-2021; Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107; Henson, Jeremy/0000-0002-1594-9310				Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Brachner A, 2006, CANCER RES, V66, P3584, DOI 10.1158/0008-5472.CAN-05-2839; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Cerone MA, 2005, ONCOGENE, V24, P7893, DOI 10.1038/sj.onc.1208934; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Fasching CL, 2005, CANCER RES, V65, P2722, DOI 10.1158/0008-5472.CAN-04-2881; GERDES J, 1984, J IMMUNOL, V133, P1710; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Gonzalo S, 2006, NAT CELL BIOL, V8, P416, DOI 10.1038/ncb1386; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Grobelny JV, 2000, J CELL SCI, V113, P4577; HALPERN BC, 1974, P NATL ACAD SCI USA, V71, P1133, DOI 10.1073/pnas.71.4.1133; Henson JD, 2005, CLIN CANCER RES, V11, P217; Houghtaling BR, 2004, CURR BIOL, V14, P1621, DOI 10.1016/j.cub.2004.08.052; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Jiang WQ, 2005, MOL CELL BIOL, V25, P2708, DOI 10.1128/MCB.25.7.2708-2721.2005; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; JUDDE JG, 1989, CANCER RES, V49, P4859; Kamei H, 1996, EXP CELL RES, V224, P302, DOI 10.1006/excr.1996.0140; Kamei H, 1997, EXP CELL RES, V237, P207, DOI 10.1006/excr.1997.3790; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Kim S, 2004, J BIOL CHEM, V279, P43799, DOI 10.1074/jbc.M408650200; Lei M, 2001, J CELL SCI, V114, P1447; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Li BB, 2003, MOL BIOL CELL, V14, P5060, DOI 10.1091/mbc.e03-06-0403; Lu S, 2000, NUTR CANCER, V38, P123, DOI 10.1207/S15327914NC381_17; Marciniak RA, 2005, CANCER RES, V65, P2730, DOI 10.1158/0008-5472.CAN-04-2888; MECHAM JO, 1983, BIOCHEM BIOPH RES CO, V117, P429, DOI 10.1016/0006-291X(83)91218-4; Molenaar C, 2003, EMBO J, V22, P6631, DOI 10.1093/emboj/cdg633; Moran-Jones K, 2005, NUCLEIC ACIDS RES, V33, P486, DOI 10.1093/nar/gki203; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Nabetani A, 2004, J BIOL CHEM, V279, P25849, DOI 10.1074/jbc.M312652200; O'Connor MS, 2004, J BIOL CHEM, V279, P28585, DOI 10.1074/jbc.M312913200; Pavillard V, 2004, BIOCHEM PHARMACOL, V67, P1587, DOI 10.1016/j.bcp.2004.01.006; Perrem K, 2001, MOL CELL BIOL, V21, P3862, DOI 10.1128/MCB.21.12.3862-3875.2001; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Silverman J, 2004, GENE DEV, V18, P2108, DOI 10.1101/gad.1216004; SMYTH CM, 1993, PATHOLOGY, V25, P388, DOI 10.3109/00313029309090865; Stavropoulos DJ, 2002, HUM MOL GENET, V11, P3135, DOI 10.1093/hmg/11.25.3135; STERN PH, 1986, J NATL CANCER I, V76, P629, DOI 10.1093/jnci/76.4.629; STERN PH, 1984, IN VITRO CELL DEV B, V20, P663; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tarsounas M, 2004, CELL, V117, P337, DOI 10.1016/S0092-8674(04)00337-X; TISDALE MJ, 1980, BRIT J CANCER, V42, P121, DOI 10.1038/bjc.1980.210; Toouli CD, 2002, ONCOGENE, V21, P128, DOI 10.1038/sj.onc.1205014; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Wu GK, 2003, CANCER RES, V63, P2589; Xu LF, 2004, J CELL BIOL, V167, P819, DOI 10.1083/jcb.200408181; Xu ZX, 2003, MOL CELL BIOL, V23, P4247, DOI 10.1128/MCB.23.12.4247-4256.2003; Yankiwski V, 2000, P NATL ACAD SCI USA, V97, P5214, DOI 10.1073/pnas.090525897; Ye JZS, 2004, J BIOL CHEM, V279, P47264, DOI 10.1074/jbc.M409047200; Ye JZS, 2004, NAT GENET, V36, P618, DOI 10.1038/ng1360; Yeager TR, 1999, CANCER RES, V59, P4175; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139; Zhu XD, 2003, MOL CELL, V12, P1489, DOI 10.1016/S1097-2765(03)00478-7	65	86	96	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2007	26	32					4635	4647		10.1038/sj.onc.1210260	http://dx.doi.org/10.1038/sj.onc.1210260			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297460				2022-12-17	WOS:000248037900004
J	Bubman, D; Guasparri, I; Cesarman, E				Bubman, D.; Guasparri, I.; Cesarman, E.			Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen	ONCOGENE			English	Article						KSHV; HHV-8; PEL; c-Myc; LANA	GLYCOGEN-SYNTHASE KINASE-3; CELLULAR GENE-EXPRESSION; EPSTEIN-BARR-VIRUS; BURKITT-LYMPHOMA; DNA-SEQUENCES; TRANSACTIVATION DOMAIN; CELLS; PHOSPHORYLATION; MUTATIONS; ONCOGENE	Primary effusion lymphoma (PEL) is a rare subtype of non-Hodgkin's lymphoma, which is associated with infection by Kaposi's sarcoma herpesvirus (KSHV)/ human herpesvirus-8. The c-Myc transcription factor plays an important role in cellular proliferation, differentiation and apoptosis. Lymphomas frequently have deregulated c-Myc expression owing to chromosomal translocations, ampli. cations or abnormal stabilization. However, no structural abnormalities were found in the c-myc oncogene in PEL. Given that c-Myc is often involved in lymphomagenesis, we hypothesized that it is deregulated in PEL. We report that PEL cells have abnormally stable c-Myc protein. The turnover of c-Myc protein is stringently regulated by post-transcriptional modi. cations, including phosphorylation of c-Myc threonine 58 (T58) by glycogen synthase kinase-3 beta (GSK-3b). Our data show that the impaired c-Myc degradation in PEL cells is associated with a signi. cant underphosphorylation of c-Myc T58. The KSHV latency-associated nuclear antigen (LANA) is responsible for this deregulation. Overexpression of LANA in human embryonic kidney 293 or peripheral blood B cells leads to post-transcriptional deregulation of c-Myc protein. Conversely, when LANA is eliminated from PEL cells using RNA interference, GSK-3bmediated c-Myc T58 phosphorylation is restored. The presence of c-Myc and LANA in GSK-3 beta-containing complexes in PEL cells further con. rms the signi. cance of these interactions in naturally KSHV-infected cells.	Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Dept Pathol & Lab Med, New York, NY USA	Cornell University; Cornell University	Cesarman, E (corresponding author), Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, 1300 york Ave,Room C410, New York, NY 10021 USA.	ecesarm@med.cornell.edu			NATIONAL CANCER INSTITUTE [R01CA068939] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA068939] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An FQ, 2005, J BIOL CHEM, V280, P3862, DOI 10.1074/jbc.M407435200; An JB, 2004, BLOOD, V103, P222, DOI 10.1182/blood-2003-05-1538; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; Ballestas ME, 1999, SCIENCE, V284, P641, DOI 10.1126/science.284.5414.641; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Bijur GN, 2003, NEUROREPORT, V14, P2415, DOI 10.1097/00001756-200312190-00025; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Dominguez-Sola D, 2004, NAT CELL BIOL, V6, P288, DOI 10.1038/ncb0404-288; Fakhari FD, 2006, J CLIN INVEST, V116, P735, DOI 10.1172/JCI26190; Fan W, 2005, J VIROL, V79, P1244, DOI 10.1128/JVI.79.2.1244-1251.2005; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Fujimuro M, 2003, NAT MED, V9, P300, DOI 10.1038/nm829; Gaidano G, 2003, BLOOD, V102, P1833, DOI 10.1182/blood-2002-11-3606; Gaidano G, 1996, ACTA HAEMATOL-BASEL, V95, P193; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Hayward S. D., 2006, SCI STKE, V335, pre4; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Horenstein MG, 1997, BLOOD, V90, P1186, DOI 10.1182/blood.V90.3.1186; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; Knight JS, 2001, J BIOL CHEM, V276, P22971, DOI 10.1074/jbc.M101890200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Pelengaris S, 2003, ARCH BIOCHEM BIOPHYS, V416, P129, DOI 10.1016/S0003-9861(03)00294-7; Polakis P, 2000, GENE DEV, V14, P1837; PULVERER BJ, 1994, ONCOGENE, V9, P59; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Renne R, 2001, J VIROL, V75, P458, DOI 10.1128/JVI.75.1.458-468.2001; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; SOULIER J, 1995, BLOOD, V86, P1275; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; YANO T, 1993, ONCOGENE, V8, P2741; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110	50	86	87	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					4979	4986		10.1038/sj.onc.1210299	http://dx.doi.org/10.1038/sj.onc.1210299			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17310999				2022-12-17	WOS:000248322500010
J	Minami, Y; Shimamura, T; Shah, K; LaFramboise, T; Glatt, KA; Liniker, E; Borgman, CL; Haringsma, HJ; Feng, W; Weir, BA; Lowell, AM; Lee, JC; Wolf, J; Shapiro, GI; Wong, KK; Meyerson, M; Thomas, RK				Minami, Y.; Shimamura, T.; Shah, K.; LaFramboise, T.; Glatt, K. A.; Liniker, E.; Borgman, C. L.; Haringsma, H. J.; Feng, W.; Weir, B. A.; Lowell, A. M.; Lee, J. C.; Wolf, J.; Shapiro, G. I.; Wong, K-K; Meyerson, M.; Thomas, R. K.			The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272	ONCOGENE			English	Article						lung cancer; targeted therapy; oncogene mutation; ERBB2; Her-2; kinase inhibitors	GROWTH-FACTOR RECEPTOR; EGF RECEPTOR; ACQUIRED-RESISTANCE; KINASE DOMAIN; CELL-LINES; BCR-ABL; GEFITINIB; MUTATIONS; ERLOTINIB; ADENOCARCINOMAS	Mutations in the ERBB2 gene were recently found in approximately 2% of primary non-small cell lung cancer (NSCLC) specimens; however, little is known about the functional consequences and the relevance to responsiveness to targeted drugs for most of these mutations. Here, we show tha t the major lung cancer-derived ERBB2 mutants, including the most frequent mutation, A775insYVMA, lead to oncogenic transformation in a cellular assay. Murine cells transformed with these mutants were relatively resistant to the reversible epidermal growth factor receptor (EGFR) inhibitor erlotinib, resembling the resistant phenotype found in cells carrying the homologous mutations in exon 20 of EGFR. However, the same cells were highly sensitive to the irreversible dual-specificity EGFR/ERBB2 kinase inhibitor HKI-272, as were those overexpressing wild-type ERBB2. Finally, the NSCLC cell line, Calu-3, overexpressing wild-type ERBB2 owing to a high-level amplification of the ERBB2 gene were highly sensitive to HKI-272. These results provide a rationale for treatment of patients with ERBB2-mutant or ERBB2-amplified lung tumors with HKI-272.	Univ Cologne, Klaus Joachim Zulch Labs, Max Planck Soc, D-50931 Cologne, Germany; Univ Cologne, Fac Med, D-50931 Cologne, Germany; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Cambridge, MA 02138 USA; MIT, Broad Inst, Cambridge, MA 02139 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Univ Cologne, Ctr Integrated Oncol, Dept Internal Med 1, D-5000 Cologne 41, Germany; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA	Max Planck Society; University of Cologne; University of Cologne; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Brigham & Women's Hospital; University of Cologne; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Thomas, RK (corresponding author), Univ Cologne, Klaus Joachim Zulch Labs, Max Planck Soc, Gleueler Str 50, D-50931 Cologne, Germany.	geoffrey_Shapiro@dfci.harvard.edu; kwong1@partners.org; matthew_meyerson@dfci.harvard.edu; roman.thomas@nf.mpg.de	Meyerson, Matthew L/E-7123-2012		NATIONAL CANCER INSTITUTE [P20CA090578] Funding Source: NIH RePORTER; NCI NIH HHS [P20 CA90578] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; JIANG J, 2004, BLOOD; Jiang JR, 2005, CANCER RES, V65, P8968, DOI 10.1158/0008-5472.CAN-05-1829; Kobayashi S, 2005, CANCER RES, V65, P7096, DOI 10.1158/0008-5472.CAN-05-1346; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Perez-Soler R, 2004, J CLIN ONCOL, V22, P3238, DOI 10.1200/JCO.2004.11.057; PIERCE JH, 1991, ONCOGENE, V6, P1189; Rabindran SK, 2005, CANCER LETT, V227, P9, DOI 10.1016/j.canlet.2004.11.015; Sharma SV, 2006, CANCER CELL, V10, P425, DOI 10.1016/j.ccr.2006.09.014; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shigematsu H, 2005, CANCER RES, V65, P1642, DOI 10.1158/0008-5472.CAN-04-4235; Shimamura T, 2006, CANCER RES, V66, P6487, DOI 10.1158/0008-5472.CAN-06-0971; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; Zhao XJ, 2005, CANCER RES, V65, P5561, DOI 10.1158/0008-5472.CAN-04-4603	26	86	93	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					5023	5027		10.1038/sj.onc.1210292	http://dx.doi.org/10.1038/sj.onc.1210292			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17311002				2022-12-17	WOS:000248322500015
J	Takayama, K; Kaneshiro, K; Tsutsumi, S; Horie-Inoue, K; Ikeda, K; Urano, T; Ijichi, N; Ouchi, Y; Shirahige, K; Aburatani, H; Inoue, S				Takayama, K.; Kaneshiro, K.; Tsutsumi, S.; Horie-Inoue, K.; Ikeda, K.; Urano, T.; Ijichi, N.; Ouchi, Y.; Shirahige, K.; Aburatani, H.; Inoue, S.			Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis	ONCOGENE			English	Article						androgen receptor; androgen response element; chromatin immunoprecipitation; prostate cancer; UGT1A	FUNCTIONAL-ANALYSIS; C-MET; RECEPTOR; PROTEIN; EXPRESSION; CARCINOMA; ELEMENTS; LOCUS; TES; SPECIFICITY	The androgen receptor (AR) plays a key role as a transcriptional factor in prostate development and carcinogenesis. Identification of androgen-regulated genes is essential to elucidate the AR pathophysiology in prostate cancer. Here, we identifi. ed androgen target genes that are directly regulated by AR in LNCaP cells, by combining chromatin immunoprecipitation (ChIP) with tiling microarrays (ChIP-chip). ChIP-enriched or control DNAs from the cells treated with R1881 were hybridized with the ENCODE array, in which a set of regions representing approximately 1% of the whole genome. We chose 10 bona fide AR-binding sites (ARBSs) (P < 1e-5) and validated their signifi. cant AR recruitment ligand dependently. Eight upregulated genes by R1881 were identifi. ed in the vicinity of the ARBSs. Among the upregulated genes, we focused on UGT1A and CDH2 as AR target genes, because the ARBSs close to these genes (in UGT1A distal promoter and CDH2 intron 1) were most significantly associated with acetylated histone H3/H4, RNA polymerase II and p160 family co-activators. Luciferase reporter constructs including those two ARBSs exhibited ligand-dependent transcriptional regulator/enhancer activities. The present study would be powerful to extend our knowledge of the diversity of androgen genetic network and steroid action in prostate cancer cells.	Univ Tokyo, Grad Sch Sci, Dept Geriatr Med, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Genome Sci Div, Tokyo, Japan; Saitama Med Univ, Res Ctr Genom Med, Div Gene Regulat & Signal Transduct, Saitama, Japan; Tokyo Inst Technol, Ctr Biol Res & Informat, Div Gene Res, Tokyo 152, Japan; Japan Sci & Technol Agcy, CREST, Tokyo, Japan	University of Tokyo; University of Tokyo; Saitama Medical University; Tokyo Institute of Technology; Japan Science & Technology Agency (JST)	Horie-Inoue, K (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Geriatr Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	INOUE-GER@h.u-tokyo.ac.jp	Takayama, Kenichi/AAK-9238-2020; Urano, Tomohiko/AFS-9574-2022					Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Chen SJ, 2005, J BIOL CHEM, V280, P37547, DOI 10.1074/jbc.M506683200; Chene L, 2004, INT J CANCER, V111, P798, DOI 10.1002/ijc.20337; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Coutts AS, 2003, J CELL SCI, V116, P897, DOI 10.1242/jcs.00278; Diaz M, 2002, INT J BIOL MARKER, V17, P125, DOI 10.1177/172460080201700208; Duguay Y, 2004, CANCER RES, V64, P1202, DOI 10.1158/0008-5472.CAN-03-3295; Feingold EA, 2004, SCIENCE, V306, P636, DOI 10.1126/science.1105136; Giuliani L, 2005, ONCOL REP, V13, P185; Gong QH, 2001, PHARMACOGENETICS, V11, P357, DOI 10.1097/00008571-200106000-00011; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Harrington WR, 2006, ENDOCRINOLOGY, V147, P3843, DOI 10.1210/en.2006-0358; Hazan RB, 1996, CELL ADHES COMMUN, V4, P399, DOI 10.3109/15419069709004457; Horie-Inoue K, 2006, BIOCHEM BIOPH RES CO, V339, P99, DOI 10.1016/j.bbrc.2005.10.188; Horie-Inoue K, 2004, BIOCHEM BIOPH RES CO, V325, P1312, DOI 10.1016/j.bbrc.2004.10.174; HUMPHREY PA, 1995, AM J PATHOL, V147, P386; Jaggi M, 2006, PROSTATE, V66, P193, DOI 10.1002/pros.20334; Katou Y, 2006, METHOD ENZYMOL, V409, P389, DOI 10.1016/S0076-6879(05)09023-3; Kawana Y, 2002, PROSTATE, V53, P60, DOI 10.1002/pros.10131; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Lepine J, 2004, J CLIN ENDOCR METAB, V89, P5222, DOI 10.1210/jc.2004-0331; Maeda A, 2006, BIOCHEM BIOPH RES CO, V347, P1158, DOI 10.1016/j.bbrc.2006.07.040; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; Monks DA, 2001, BRAIN RES, V895, P73, DOI 10.1016/S0006-8993(01)02031-5; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; PISTERS LL, 1995, J UROLOGY, V154, P293, DOI 10.1016/S0022-5347(01)67297-5; Porkka KP, 2002, LAB INVEST, V82, P1573, DOI 10.1097/01.LAB.0000038554.26102.C6; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Strassburg CP, 1997, CANCER RES, V57, P2979; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; Tobias ES, 2001, ONCOGENE, V20, P2844, DOI 10.1038/sj.onc.1204433; Tomita K, 2000, CANCER RES, V60, P3650; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Xie W, 2003, P NATL ACAD SCI USA, V100, P4150, DOI 10.1073/pnas.0438010100	40	86	88	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4453	4463		10.1038/sj.onc.1210229	http://dx.doi.org/10.1038/sj.onc.1210229			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17297473				2022-12-17	WOS:000247620000013
J	Shi, J; Kahle, A; Hershey, JWB; Honchak, BM; Warneke, JA; Leong, SPL; Nelson, MA				Shi, J.; Kahle, A.; Hershey, J. W. B.; Honchak, B. M.; Warneke, J. A.; Leong, S. P. L.; Nelson, M. A.			Decreased expression of eukaryotic initiation factor 3f deregulates translation and apoptosis in tumor cells	ONCOGENE			English	Article						eukaryotic initiation factor 3f; tumorigenesis; translation initiation; apoptosis; melanoma; pancreatic cancer	PREINITIATION COMPLEX; PROTEIN-SYNTHESIS; FACTOR EIF3; SUBUNITS; DEGRADATION; BINDING; DEATH; ACTIVATION; INDUCTION; INTERACTS	The eukaryotic initiation factor 3f (eIF3f) is the p47 subunit of the multi-subunit eIF3 complex. eIF3 plays an important role in translation initiation. In the present study, we investigate the biological function of eIF3f in translation and apoptosis in tumor cells. We demonstrated for the first time that eIF3f is downregulated in most human tumors using a cancer pro. ling array and confirmed by real-time reverse transcription PCR in melanoma and pancreatic cancer. Overexpression of eIF3f inhibits cell proliferation and induces apoptosis in melanoma and pancreatic cancer cells. Silencing of eIF3f protects melanoma cells from apoptosis. We further investigated the biological function of eIF3f. In vitro translation studies indicate that eIF3f is a negative regulator of translation and that the region between amino acids 170 and 248 of eIF3f is required for its translation regulatory function. Ectopic expression of eIF3f inhibits translation and overall cellular protein synthesis. Ribosome pro. le and ribosomal RNA (rRNA) fragmentation assays revealed that eIF3f reduces ribosomes, which may be associated with rRNA degradation. We propose that eIF3f may play a role in ribosome degradation during apoptosis. These data provide critical insights into the cellular function of eIF3f and in linking translation initiation and apoptosis.	Univ Arizona, Dept Pathol, Tucson, AZ 85724 USA; Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA; No Arizona Univ, Flagstaff, AZ 86011 USA; Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA; Univ Calif San Francisco, Dept Surg, Mt Zion Med Ctr, San Francisco, CA 94143 USA	University of Arizona; University of California System; University of California Davis; Northern Arizona University; Arizona Center Cancer Care; University of Arizona; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion	Nelson, MA (corresponding author), Univ Arizona, Dept Pathol, AHSC Rm 5226,1501 N Campbell Ave, Tucson, AZ 85724 USA.	mnelson@azcc.arizona.edu		Shi, Jiaqi/0000-0003-4893-1587	NCI NIH HHS [CA95060, CA70145, CA 09213] Funding Source: Medline; NIEHS NIH HHS [ES066694] Funding Source: Medline; NIGMS NIH HHS [GM22135] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA095060, T32CA009213, R29CA070145, R01CA070145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akiyoshi Y, 2001, J BIOL CHEM, V276, P10056, DOI 10.1074/jbc.M010188200; Aravind L, 1998, PROTEIN SCI, V7, P1250, DOI 10.1002/pro.5560070521; Ariza ME, 1999, J BIOL CHEM, V274, P28505, DOI 10.1074/jbc.274.40.28505; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Beyaert R, 1997, J BIOL CHEM, V272, P11694, DOI 10.1074/jbc.272.18.11694; Castelli J, 1998, BIOMED PHARMACOTHER, V52, P386, DOI 10.1016/S0753-3322(99)80006-7; Charalampopoulos L, 2004, P NATL ACAD SCI USA, V101, P8209, DOI 10.1073/pnas.0306631101; Clemens MJ, 1998, ONCOGENE, V17, P2921, DOI 10.1038/sj.onc.1202227; Dong JS, 2004, J BIOL CHEM, V279, P42157, DOI 10.1074/jbc.M404502200; Fraser CS, 2004, J BIOL CHEM, V279, P8946, DOI 10.1074/jbc.M312745200; Guo JJ, 2000, EMBO J, V19, P6891, DOI 10.1093/emboj/19.24.6891; Joseph P, 2002, CANCER RES, V62, P703; King KL, 2000, CELL DEATH DIFFER, V7, P994, DOI 10.1038/sj.cdd.4400731; Majumdar R, 2003, J BIOL CHEM, V278, P6580, DOI 10.1074/jbc.M210357200; Martinand C, 1998, EUR J BIOCHEM, V254, P248, DOI 10.1046/j.1432-1327.1998.2540248.x; Mayeur GL, 2003, EUR J BIOCHEM, V270, P4133, DOI 10.1046/j.1432-1033.2003.03807.x; MEYER LJ, 1982, BIOCHEMISTRY-US, V21, P4206, DOI 10.1021/bi00261a003; Mikolajczyk M, 2004, BIOCHEM J, V384, P461, DOI 10.1042/BJ20040848; Miura Y, 2002, BLOOD, V100, P2650, DOI 10.1182/blood-2002-01-0176; Morley SJ, 1998, FEBS LETT, V438, P41, DOI 10.1016/S0014-5793(98)01269-1; Nadano D, 2000, J BIOL CHEM, V275, P13967, DOI 10.1074/jbc.275.18.13967; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; PHILIP T, 1995, NEW ENGL J MED, V333, P1540, DOI 10.1056/NEJM199512073332305; Sheikh MS, 1999, ONCOGENE, V18, P6121, DOI 10.1038/sj.onc.1203131; Shi JQ, 2003, J BIOL CHEM, V278, P5062, DOI 10.1074/jbc.M206427200; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SONENBERG N, 2000, TRANSLATIONAL CONTRO, P33; Tang DM, 1998, J BIOL CHEM, V273, P16601, DOI 10.1074/jbc.273.26.16601; Thompson FH, 1996, CANCER GENET CYTOGEN, V87, P55, DOI 10.1016/0165-4608(95)00248-0; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; Watkins SJ, 2002, BRIT J CANCER, V86, P1023, DOI 10.1038/sj/bjc/6600222; Xiang Y, 2003, CANCER RES, V63, P6795	33	86	93	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2006	25	35					4923	4936		10.1038/sj.onc.1209495	http://dx.doi.org/10.1038/sj.onc.1209495			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16532022				2022-12-17	WOS:000239687100010
J	Chiaradonna, F; Sacco, E; Manzoni, R; Giorgio, M; Vanoni, M; Alberghina, L				Chiaradonna, F.; Sacco, E.; Manzoni, R.; Giorgio, M.; Vanoni, M.; Alberghina, L.			Ras-dependent carbon metabolism and transformation in mouse broblasts	ONCOGENE			English	Article						transformed cells; Ras; glucose metabolism; apoptosis; cell cycle	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; DEPRIVATION-INDUCED CYTOTOXICITY; HUMAN CANCER-CELLS; HUMAN TUMOR-CELLS; GLUCOSE DEPRIVATION; OXIDATIVE STRESS; PANCREATIC-CANCER; ANTISENSE OLIGONUCLEOTIDES; MALIGNANT-TRANSFORMATION; SIGNAL-TRANSDUCTION	Mutational activation of ras genes is required for the onset and maintenance of different malignancies. Here we show, using a combination of molecular physiology, nutritional perturbations and transcriptional pro. ling, that full penetrance of phenotypes related to oncogenic Ras activation, including the shift of carbon metabolism towards fermentation and upregulation of key cell cycle regulators, is dependent upon glucose availability. These responses are induced by Ras activation, being specifically reverted by downregulation of the Ras pathway obtained through the expression of a dominant-negative Ras-specific guanine nucleotide exchange protein. Our data allow to link directly to ras activation the alteration in energy metabolism of cancer cells, their fragility towards glucose shortage and ensuing apoptotic death.	Univ Milano Bicocca, Dept Biotechnol & Biosci, I-20126 Milan, Italy; European Inst Oncol, Dept Expt Oncol, Milan, Italy	University of Milano-Bicocca; IRCCS European Institute of Oncology (IEO)	Alberghina, L (corresponding author), Univ Milano Bicocca, Dept Biotechnol & Biosci, Piazza Sci 2, I-20126 Milan, Italy.	lilia.alberghina@unimib.it	Giorgio, Marco/I-9425-2012; Vanoni, Marco/AAA-3699-2021; Sacco, Elena/T-3274-2018; CHIARADONNA, Ferdinando/K-4959-2016	Giorgio, Marco/0000-0002-5842-6042; Vanoni, Marco/0000-0002-8690-2587; Sacco, Elena/0000-0002-3190-7671; CHIARADONNA, Ferdinando/0000-0001-8529-2732; Alberghina, Lilia/0000-0003-1694-931X				Ahmad IM, 2005, J BIOL CHEM, V280, P4254, DOI 10.1074/jbc.M411662200; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alberghina L, 2004, CHEMBIOCHEM, V5, P1322, DOI 10.1002/cbic.200400170; Arellano M, 1997, INT J BIOCHEM CELL B, V29, P559, DOI 10.1016/S1357-2725(96)00178-1; BAGGETTO LG, 1992, BIOCHIMIE, V74, P959, DOI 10.1016/0300-9084(92)90016-8; Blackburn RV, 1999, FREE RADICAL BIO MED, V26, P419, DOI 10.1016/S0891-5849(98)00217-2; Blum R, 2005, CANCER RES, V65, P999; BOARD M, 1990, BIOCHEM J, V265, P503, DOI 10.1042/bj2650503; BOS JL, 1995, EUR J CANCER, V31A, P1051, DOI 10.1016/0959-8049(95)00168-I; Bossu P, 2000, ONCOGENE, V19, P2147, DOI 10.1038/sj.onc.1203539; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chang FM, 2001, ONCOGENE, V20, P4354, DOI 10.1038/sj.onc.1204564; Chen CM, 1997, J BIOL CHEM, V272, P26803, DOI 10.1074/jbc.272.43.26803; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chiaradonna F, 2005, BIOCHEM SOC T, V33, P297, DOI 10.1042/BST0330297; Cochet O, 1999, CANCER DETECT PREV, V23, P506, DOI 10.1046/j.1525-1500.1999.99058.x; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; deVries JE, 1996, PATHOL RES PRACT, V192, P658, DOI 10.1016/S0344-0338(96)80087-2; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; GRUNICKE HH, 1993, CRIT REV ONCOGENESIS, V4, P389; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hellerstein MK, 2004, CURR OPIN MOL THER, V6, P249; Hlavata L, 2003, EMBO J, V22, P3337, DOI 10.1093/emboj/cdg314; Jinno S, 1999, P NATL ACAD SCI USA, V96, P13197, DOI 10.1073/pnas.96.23.13197; KAHN S, 1987, ANTICANCER RES, V7, P639; Kato-Stankiewicz J, 2002, P NATL ACAD SCI USA, V99, P14398, DOI 10.1073/pnas.222222699; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; Kijima H, 2004, INT J ONCOL, V24, P559; Kita K, 1999, INT J CANCER, V80, P553, DOI 10.1002/(SICI)1097-0215(19990209)80:4<553::AID-IJC12>3.0.CO;2-6; Kitano H, 2004, NAT REV CANCER, V4, P227, DOI 10.1038/nrc1300; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Kocher HM, 2005, NEPHROL DIAL TRANSPL, V20, P886, DOI 10.1093/ndt/gfh744; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee Ji-Won, 2004, Experimental & Molecular Medicine, V36, P1; Lee YJ, 1998, J BIOL CHEM, V273, P5294, DOI 10.1074/jbc.273.9.5294; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Mabuchi T, 2000, J BIOL CHEM, V275, P10492, DOI 10.1074/jbc.275.14.10492; Mathupala SP, 1997, J BIOENERG BIOMEMBR, V29, P339, DOI 10.1023/A:1022494613613; Mazurek S, 2003, ANTICANCER RES, V23, P1149; Mazurek S, 1999, J CELL PHYSIOL, V181, P136; Messer JI, 2004, AM J PHYSIOL-CELL PH, V286, pC565, DOI 10.1152/ajpcell.00146.2003; MONIA BP, 1992, J BIOL CHEM, V267, P19954; Nheu T, 2004, CELL CYCLE, V3, P71; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; Rajendran JG, 2004, CLIN CANCER RES, V10, P2245, DOI 10.1158/1078-0432.CCR-0688-3; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Rebollo A, 1999, ONCOGENE, V18, P4930, DOI 10.1038/sj.onc.1202875; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Robey IF, 2005, NEOPLASIA, V7, P324, DOI 10.1593/neo.04430; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; Rolland F, 2002, FEMS YEAST RES, V2, P183, DOI 10.1111/j.1567-1364.2002.tb00084.x; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Russell JS, 1999, CANCER RES, V59, P5239; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shoshan-Barmatz V, 2003, CELL BIOCHEM BIOPHYS, V39, P279, DOI 10.1385/CBB:39:3:279; Spitz DR, 2000, ANN NY ACAD SCI, V899, P349, DOI 10.1111/j.1749-6632.2000.tb06199.x; Takeuchi M, 2000, GENE THER, V7, P518, DOI 10.1038/sj.gt.3301125; Takuwa N, 2001, MOL CELL ENDOCRINOL, V177, P25, DOI 10.1016/S0303-7207(01)00439-7; Thomas S, 1998, EUR J BIOCHEM, V258, P956, DOI 10.1046/j.1432-1327.1998.2580956.x; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Vanoni M, 1999, J BIOL CHEM, V274, P36656, DOI 10.1074/jbc.274.51.36656; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; YAMAMOTO F, 1984, NUCLEIC ACIDS RES, V12, P8873, DOI 10.1093/nar/12.23.8873	75	86	86	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	39					5391	5404		10.1038/sj.onc.1209528	http://dx.doi.org/10.1038/sj.onc.1209528			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16607279				2022-12-17	WOS:000240144900004
J	Duensing, A; Liu, Y; Tseng, M; Malumbres, M; Barbacid, M; Duensing, S				Duensing, A.; Liu, Y.; Tseng, M.; Malumbres, M.; Barbacid, M.; Duensing, S.			Cyclin-dependent kinase 2 is dispensable for normal centrosome duplication but required for oncogene-induced centrosome overduplication	ONCOGENE			English	Article						centrosome; CDK2; HPV-16 E7; genomic instability	CELL-DIVISION; PRIMARY CILIA; CDK2; IMMORTALIZATION	Cyclin- dependent kinase 2 ( CDK2) has been proposed to function as a master regulator of centrosome duplication. Using mouse embryonic. broblasts ( MEFs) in which Cdk2 has been genetically deleted, we show here that CDK2 is not required for normal centrosome duplication, maturation and bipolar mitotic spindle formation. In contrast, Cdk2 deficiency completely abrogates aberrant centrosome duplication induced by a viral oncogene. Mechanistically, centrosome overduplication in MEFs wild- type for Cdk2 involves the formation of supernumerary immature centrosomes. These results indicate that normal and abnormal centrosome duplication have significantly different requirements for CDK2 activity and point to a role of CDK2 in licensing centrosomes for aberrant duplication. Furthermore, our findings suggest that CDK2 may be a suitable therapeutic target to inhibit centrosome- mediated chromosomal instability in tumor cells.	Univ Pittsburgh, Inst Canc, Mol Virol Program, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Ctr Nacl Invest Oncol, Mol Oncol Program, Madrid, Spain; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Duensing, S (corresponding author), Univ Pittsburgh, Inst Canc, Mol Virol Program, Hillman Canc Ctr, Res Pavil Suite 1-8,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	duensing@pitt.edu	Malumbres, Marcos/E-8834-2011; Holt, Janet E/B-2415-2013	Malumbres, Marcos/0000-0002-0829-6315; Duensing, Anette/0000-0002-0168-4067	NCI NIH HHS [R01 CA112598, R01 CA112598-03, CA112598] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA112598] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRECHTBUEHLER G, 1980, EXP CELL RES, V126, P427, DOI 10.1016/0014-4827(80)90282-7; Aleem E, 2005, NAT CELL BIOL, V7, P831, DOI 10.1038/ncb1284; Alvarez-Salas LM, 1998, P NATL ACAD SCI USA, V95, P1189, DOI 10.1073/pnas.95.3.1189; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; Delattre M, 2004, J CELL SCI, V117, P1619, DOI 10.1242/jcs.01128; Doxsey S, 2002, MOL CELL, V10, P439, DOI 10.1016/S1097-2765(02)00654-8; DUENSING A, 2004, P AM ASSOC CANC RES, V45, P2596; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2005, CELL BIOL INT, V29, P352, DOI 10.1016/j.cellbi.2005.03.005; Duensing S, 2004, ONCOGENE, V23, P8206, DOI 10.1038/sj.onc.1208012; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Guarguaglini G, 2005, MOL BIOL CELL, V16, P1095, DOI 10.1091/mbc.E04-10-0939; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Mason DX, 2004, ONCOGENE, V23, P9238, DOI 10.1038/sj.onc.1208172; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Matsumoto Y, 2004, SCIENCE, V306, P885, DOI 10.1126/science.1103544; MEIJER L, 1999, PHARM THER, V82; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Wheatley DN, 1996, CELL BIOL INT, V20, P73, DOI 10.1006/cbir.1996.0011; Wong C, 2003, NAT CELL BIOL, V5, P539, DOI 10.1038/ncb993	32	86	88	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2943	2949		10.1038/sj.onc.1209310	http://dx.doi.org/10.1038/sj.onc.1209310			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16331279	Green Accepted			2022-12-17	WOS:000237448200013
J	Khaleque, MA; Bharti, A; Sawyer, D; Gong, JL; Benjamin, IJ; Stevenson, MA; Calderwood, SK				Khaleque, MA; Bharti, A; Sawyer, D; Gong, JL; Benjamin, IJ; Stevenson, MA; Calderwood, SK			Induction of heat shock proteins by heregulin beta 1 leads to protection from apoptosis and anchorage-independent growth	ONCOGENE			English	Article						heregulin; heat shock protein; HSF1; anchorage independent growth; signal transduction	BREAST-CANCER; GENE-EXPRESSION; FACTOR-I; TRANSCRIPTIONAL ACTIVATION; TARGETED DISRUPTION; ESTROGEN-RECEPTOR; CELL-SURVIVAL; PHOSPHORYLATION; FACTOR-1; STRESS	Elevation of heat shock protein (HSP) levels is widespread in cancer and predicts a poor prognosis and resistance to therapy. We show that HSP elevation in tumor cells can be induced by the highly malignant factor heregulin beta 1 (HRG beta 1), which induces HSP expression through heat shock transcription factor 1 (HSF1). Inactivation of the hsf1 gene prevents HSP induction by HRG beta 1. HSP expression is induced through a cascade response initiated by HRG beta 1 binding to c-erbB receptors on the cell surface and which leads to the inhibition of intracellular HSF1 antagonist glycogen synthase kinase 3. HSF1 activated by this pathway plays a key role in the protection of cells from apoptosis and the mediation of anchorage independent growth by HRGb1, indicating a role for HSF1 in this tumorigenic pathway.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA 02215 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Univ Utah, Ctr Hlth Sci, Dept Internal Med, Salt Lake City, UT 84132 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston University; Utah System of Higher Education; University of Utah	Calderwood, SK (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, 21-27 Burlington Ave, Boston, MA 02215 USA.	scalderw@bidmc.harvard.edu		Bharti, Ajit/0000-0001-7972-6688; Gong, Jianlin/0000-0003-0910-014X; Khaleque, Md Abdul/0000-0002-6873-9165	NATIONAL CANCER INSTITUTE [R01CA047407, R01CA050642, P01CA031303] Funding Source: NIH RePORTER; NCI NIH HHS [CA31303, CA47407, CA50642] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Beere HM, 2004, J CELL SCI, V117, P2641, DOI 10.1242/jcs.01284; Bhat-Nakshatri P, 2002, ONCOGENE, V21, P2066, DOI 10.1038/sj.onc.1205243; Blagosklonny MV, 2001, J NATL CANCER I, V93, P239, DOI 10.1093/jnci/93.3.239-a; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Chen CM, 1997, J BIOL CHEM, V272, P26803, DOI 10.1074/jbc.272.43.26803; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Chu BY, 1998, J BIOL CHEM, V273, P18640, DOI 10.1074/jbc.273.29.18640; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570; Cornford PA, 2000, CANCER RES, V60, P7099; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; deFazio A, 2000, INT J CANCER, V87, P487, DOI 10.1002/1097-0215(20000815)87:4<487::AID-IJC5>3.0.CO;2-J; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; FADOK VA, 1992, J IMMUNOL, V148, P2207; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; GREEN M, 1995, MOL CELL BIOL, V15, P3354; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoang AT, 2000, AM J PATHOL, V156, P857, DOI 10.1016/S0002-9440(10)64954-1; Jackson JG, 2004, CANCER RES, V64, P2601, DOI 10.1158/0008-5472.CAN-03-3106; Karim RZ, 2004, PATHOLOGY, V36, P120, DOI 10.1080/00313020410001671957; Kim SO, 1999, J BIOL CHEM, V274, P36015, DOI 10.1074/jbc.274.50.36015; Klapper LN, 1997, ONCOGENE, V14, P2099, DOI 10.1038/sj.onc.1201029; Li YW, 2001, MOL CELL NEUROSCI, V17, P761, DOI 10.1006/mcne.2000.0967; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; Newton EM, 1996, MOL CELL BIOL, V16, P839; Nylandsted J, 2000, ANN NY ACAD SCI, V926, P122; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Rubin I, 2001, ANN ONCOL, V12, P3, DOI 10.1023/A:1011195320446; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SCHILLER P, 1988, J MOL BIOL, V203, P97, DOI 10.1016/0022-2836(88)90094-0; Schulze-Bergkamen H, 2004, SEMIN ONCOL, V31, P90, DOI 10.1053/j.seminoncol.2003.11.006; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Stoica GE, 2003, ONCOGENE, V22, P2073, DOI 10.1038/sj.onc.1206311; Tang D, 2005, CELL STRESS CHAPERON, V10, P46, DOI 10.1379/CSC-44R.1; Tsai MS, 2003, ONCOGENE, V22, P761, DOI 10.1038/sj.onc.1206130; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Venkateswarlu S, 2002, ONCOGENE, V21, P78, DOI 10.1038/sj.onc.1205011; Viatour P, 2004, MOL CELL, V16, P35, DOI 10.1016/j.molcel.2004.09.004; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; Wang L, 2004, J BIOL CHEM, V279, P32444, DOI 10.1074/jbc.M313963200; Wang XZ, 2004, J BIOL CHEM, V279, P49460, DOI 10.1074/jbc.M406059200; Wang XZ, 2003, MOL CELL BIOL, V23, P6013, DOI 10.1128/MCB.23.17.6013-6026.2003; Wang YQ, 2004, J BIOL CHEM, V279, P32651, DOI 10.1074/jbc.M401475200; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cb.11.110195.002301; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang Y, 2002, J CELL BIOCHEM, V86, P376, DOI 10.1002/jcb.10232	54	86	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6564	6573		10.1038/sj.onc.1208798	http://dx.doi.org/10.1038/sj.onc.1208798			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16007186				2022-12-17	WOS:000232204100010
J	Yamamichi, N; Yamamichi-Nishina, M; Mizutani, T; Watanabe, H; Minoguchi, S; Kobayashi, N; Kimura, S; Ito, T; Yahagi, N; Ichinose, M; Omata, M; Iba, H				Yamamichi, N; Yamamichi-Nishina, M; Mizutani, T; Watanabe, H; Minoguchi, S; Kobayashi, N; Kimura, S; Ito, T; Yahagi, N; Ichinose, M; Omata, M; Iba, H			The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potential	ONCOGENE			English	Article						Brm; SWI/SNF complex; HDAC inhibitors; post-transcriptional regulation; retroviral gene silencing	HISTONE DEACETYLASE INHIBITOR; MAMMALIAN SWI/SNF COMPLEXES; CHROMATIN REMODELING FACTOR; TUMOR-SUPPRESSOR; RHABDOID TUMORS; CYCLE ARREST; LUNG-CANCER; SNF COMPLEX; EXPRESSION; PROTEIN	The mammalian SWI/SNF chromatin remodeling complex is composed of more than 10 protein subunits, and plays important roles in epigenetic regulation. Each complex includes a single BRG1 or Brm molecule as the catalytic subunit. We previously reported that loss of Brm, but not BRG1, causes transcriptional gene silencing of murine leukemia virus-based retrovirus vectors. To understand the biological function and biogenesis of Brm protein, we examined seven cell lines derived from various human tumors that do not produce Brm protein. We show here that these Brm-deficient cell lines transcribe the Brm genes efficiently as detected by nuclear run-on transcription assay, whereas Brm mRNA and Brm hnRNA were undetectable by reverse transcription-polymerase c am reaction analysis. These results indicate that expression of Brm is strongly and promptly suppressed at the posttranscriptional level, through processing and transport of the primary transcript or through stability of mature Brm mRNA. This suppression was attenuated by transient treatment of these cell tines with HDAC inhibitors probably through indirect mechanism. Importantly, all of the treated cells showed prolonged induction of Brm expression after the removal of HDAC inhibitors, and acquired the ability to maintain retroviral gene expression. These results indicate that these Brm-deficient human tumor cell tines carry a functional Brm gene. Treatment with HDAC inhibitors or introduction of exogenous Brm into Brm-deficient cell lines significantly reduced the oncogenic potential as assessed by colony-forming activity in soft agar or invasion into collagen gel, indicating that, like BRG1, Brm is involved in tumor suppression.	Univ Tokyo, Inst Med Sci, Div Host Parasite Interact, Dept Microbiol & Immunol,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Fac Med, Dept Gastroenterol, Tokyo 113, Japan; Wakayama Med Coll, Dept Internal Med, Wakayama 640, Japan	University of Tokyo; University of Tokyo; Wakayama Medical University	Iba, H (corresponding author), Univ Tokyo, Inst Med Sci, Div Host Parasite Interact, Dept Microbiol & Immunol,Minato Ku, 4-6-1,Shirokanedai, Tokyo 1088639, Japan.	iba@ims.u-tokyo.ac.jp	Ichinose, Masao/HAB-1645-2022					Arai T, 1998, J VIROL, V72, P1115, DOI 10.1128/JVI.72.2.1115-1121.1998; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Biegel JA, 1999, CANCER RES, V59, P74; Bourachot B, 2003, EMBO J, V22, P6505, DOI 10.1093/emboj/cdg621; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; DeCristofaro MF, 1999, ONCOGENE, V18, P7559, DOI 10.1038/sj.onc.1203168; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; Doan DN, 2004, ONCOGENE, V23, P3462, DOI 10.1038/sj.onc.1207472; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Furumai R, 2002, CANCER RES, V62, P4916; Geng FQ, 2001, MOL CELL BIOL, V21, P4311, DOI 10.1128/MCB.21.13.4311-4320.2001; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Iba H, 2003, REV MED VIROL, V13, P99, DOI 10.1002/rmv.378; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; Jia LQ, 1997, MOL CARCINOGEN, V19, P243, DOI 10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Komatsu Y, 2001, CANCER RES, V61, P4459; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; LeGouy E, 1998, DEV DYNAM, V212, P38, DOI 10.1002/(SICI)1097-0177(199805)212:1<38::AID-AJA4>3.0.CO;2-3; Mizutani T, 2002, J BIOL CHEM, V277, P15859, DOI 10.1074/jbc.M112421200; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Reisman DN, 2003, CANCER RES, V63, P560; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; SHIMIZU E, 1994, ONCOGENE, V9, P2441; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Ui M, 2000, BIOCHEM BIOPH RES CO, V278, P97, DOI 10.1006/bbrc.2000.3777; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Wong AKC, 2000, CANCER RES, V60, P6171; Yamamichi-Nishina M, 2003, J BIOL CHEM, V278, P7422, DOI 10.1074/jbc.M208458200; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	40	86	86	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5471	5481		10.1038/sj.onc.1208716	http://dx.doi.org/10.1038/sj.onc.1208716			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	16007216				2022-12-17	WOS:000231222300007
J	Wu, XM; Shell, SM; Zou, Y				Wu, XM; Shell, SM; Zou, Y			Interaction and colocalization of Rad9/Rad1/Hus1 checkpoint complex with replication protein A in human cells	ONCOGENE			English	Article						Rad9/Rad1/Hus1; replication protein A ( RPA); interaction of 9-1-1 with RPA; DNA damage checkpiont	SINGLE-STRANDED-DNA; DAMAGE CHECKPOINT; HUMAN RAD9; BINDING PROTEIN; G2/M ARREST; S-PHASE; RPA; PHOSPHORYLATION; ATR; KINASE	Replication protein A (RPA) is a eukaryotic single-stranded DNA-binding protein consisting of three subunits of 70-, 32-, and 14-kDa (RPA70, RPA32, RPA14, respectively). It is a protein essential for most cellular DNA metabolic pathways. Checkpoint proteins Rad9, Rad1, and Hus1 form a clamp-like complex which plays a central role in the DNA damage-induced checkpoint response. In this report, we presented the evidence that Rad9-Rad1-Hus1 (9-1-1) complex directly interacted with RPA in human cells, and this interaction was mediated by the binding of Rad9 protein to both RPA70 and RPA32 subunits. In addition, the cellular interaction of 9-1-1 with RPA or hyperphosphorylated RPA was stimulated by UV irradiation or camptothecin treatment in a dose-dependent manner. Such treatments also resulted in the colocalization of the nuclear foci formed with the two complexes. Consistently, knockdown of the RPA expression in cells by the small interference RNA ( siRNA) blocked the DNA damage-dependent chromatin association of 9-1-1, and also inhibited the 9-1-1 complex formation. Taken together, our results suggest that 9-1-1 and RPA complexes collaboratively function in DNA damage responses, and that the RPA may serve as a regulator for the activity of 9-1-1 complex in the cellular checkpoint network.	E Tennessee State Univ, James H Quillen Coll Med, Dept Biochem & Mol Biol, Johnson City, TN 37614 USA	East Tennessee State University	Zou, Y (corresponding author), E Tennessee State Univ, James H Quillen Coll Med, Dept Biochem & Mol Biol, Johnson City, TN 37614 USA.	zouy@etsu.edu	Zou, Yue/ABA-8429-2020		NCI NIH HHS [R56 CA086927, R01 CA086927, CA86927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086927, R56CA086927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bao SL, 2004, ONCOGENE, V23, P5586, DOI 10.1038/sj.onc.1207753; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Binz SK, 2004, DNA REPAIR, V3, P1015, DOI 10.1016/j.dnarep.2004.03.028; Bochkarev A, 2004, CURR OPIN STRUC BIOL, V14, P36, DOI 10.1016/j.sbi.2004.01.001; Bochkareva E, 2002, EMBO J, V21, P1855, DOI 10.1093/emboj/21.7.1855; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Ellison V, 2003, PLOS BIOL, V1, P231, DOI 10.1371/journal.pbio.0000033; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Lindsey-Boltz LA, 2004, NUCLEIC ACIDS RES, V32, P4524, DOI 10.1093/nar/gkh789; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Liu YY, 2005, BIOCHEM J, V385, P519, DOI 10.1042/BJ20041151; Longhese MP, 1996, NUCLEIC ACIDS RES, V24, P3533, DOI 10.1093/nar/24.18.3533; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; PAN ZQ, 1995, P NATL ACAD SCI USA, V92, P4636, DOI 10.1073/pnas.92.10.4636; PARRILLACASTELLAR, 2004, DNA REPAIR, V3, P1009; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Robison JG, 2004, J BIOL CHEM, V279, P34802, DOI 10.1074/jbc.M404750200; Roos-Mattjus P, 2003, J BIOL CHEM, V278, P24428, DOI 10.1074/jbc.M301544200; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Shell SM, 2005, BIOCHEMISTRY-US, V44, P971, DOI 10.1021/bi048208a; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Vassin VM, 2004, MOL CELL BIOL, V24, P1930, DOI 10.1128/MCB.24.5.1930-1943.2004; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Wang L, 2004, MOL CELL BIOL, V24, P2202, DOI 10.1128/MCB.24.5.2202-2213.2004; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Yang ZG, 2002, BIOCHEMISTRY-US, V41, P13012, DOI 10.1021/bi026064z; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, P NATL ACAD SCI USA, V100, P13827, DOI 10.1073/pnas.2336100100; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	48	86	93	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2005	24	29					4728	4735		10.1038/sj.onc.1208674	http://dx.doi.org/10.1038/sj.onc.1208674			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15897895	Green Submitted, Green Accepted			2022-12-17	WOS:000230304500011
J	Freund, A; Jolivel, V; Durand, S; Kersual, N; Chalbos, D; Chavey, C; Vignon, F; Lazennec, G				Freund, A; Jolivel, V; Durand, S; Kersual, N; Chalbos, D; Chavey, C; Vignon, F; Lazennec, G			Mechanisms underlying differential expression of interleukin-8 in breast cancer cells	ONCOGENE			English	Article						estrogen receptor; breast; cancer; interleukin-8	NF-KAPPA-B; GENE-EXPRESSION; CONSTITUTIVE ACTIVATION; PROSTATE-CANCER; GROWTH-FACTOR; ANGIOGENESIS; BINDING; BETA; PROLIFERATION; MELANOMA	We have recently reported that interleukin-8 (IL-8) expression was inversely correlated to estrogen receptor (ER) status and was overexpressed in invasive breast cancer cells. In the present study, we show that IL-8 overexpression in breast cancer cells involves a higher transcriptional activity of IL-8 gene promoter. Cloning of IL-8 promoter from MDA-MB-231 and MCF-7 cells expressing high and low levels of IL-8, respectively, shows the integrity of the promoter in both cell lines. Deletion and site-directed mutagenesis of the promoter demonstrate that NF-kappaB and AP-1 and to a lesser extent C/EBP binding sites play a crucial role in the control of IL-8 promoter activity in MDA-MB-231 cells. Knock-down of NF-kappaB and AP-1 activities by adenovirus-mediated expression of an NF-kappaB super-repressor and RNA interference, respectively, decreased IL-8 expression in MDA-MB-231 cells. On the contrary, restoration of Fra-1, Fra-2, c-Jun, p50, p65, C/EBPalpha and C/EBPbeta expression levels in MCF-7 cells led to a promoter activity comparable to that observed in MDA-MB-231 cells. Our data constitute the first extensive study of IL-8 gene overexpression in breast cancer cells and suggest that the high expression of IL-8 in invasive cancer cells requires a complex cooperation between NF-kappaB, AP-1 and C/EBP transcription factors.	INSERM, U540, F-34090 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Lazennec, G (corresponding author), INSERM, U540, 60 Rue Navacelles, F-34090 Montpellier, France.	lazennec@montp.inserm.fr	Jolivel, Valérie/ABB-1136-2021; Jolivel, Valerie/A-6810-2017; Durand, Sebastien/Q-2138-2019	Jolivel, Valérie/0000-0002-4114-4559; Jolivel, Valerie/0000-0002-4114-4559; Durand, Sebastien/0000-0002-9960-9099; Chavey, Carine/0000-0002-5267-5638; Lazennec, Gwendal/0000-0002-8522-1763				Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; Brew R, 1996, EUR J CANCER, V32A, P2142, DOI 10.1016/S0959-8049(96)00221-3; BROWN PH, 1993, ONCOGENE, V8, P877; Ferrer FA, 1998, UROLOGY, V51, P161, DOI 10.1016/S0090-4295(97)00491-3; Freund A, 2003, ONCOGENE, V22, P256, DOI 10.1038/sj.onc.1206113; Fujioka S, 2003, CLIN CANCER RES, V9, P346; Gilmore T, 2002, CANCER LETT, V181, P1, DOI 10.1016/S0304-3835(01)00795-9; Haller D, 2002, J BIOL CHEM, V277, P38168, DOI 10.1074/jbc.M205737200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; KUNSCH C, 1994, J IMMUNOL, V153, P153; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Le XD, 2000, J INTERF CYTOK RES, V20, P935, DOI 10.1089/10799900050198372; Lin Y, 2004, INT J CANCER, V109, P507, DOI 10.1002/ijc.11724; Masuya D, 2001, CANCER, V92, P2628, DOI 10.1002/1097-0142(20011115)92:10<2628::AID-CNCR1616>3.0.CO;2-F; Milde-Langosch K, 2003, BREAST CANCER RES TR, V79, P175, DOI 10.1023/A:1023929504884; Milligan L, 2000, ONCOGENE, V19, P5810, DOI 10.1038/sj.onc.1203965; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; Nurnberg W, 1999, J PATHOL, V189, P546, DOI 10.1002/(SICI)1096-9896(199912)189:4<546::AID-PATH487>3.0.CO;2-L; Osborne CK, 1998, BREAST CANCER RES TR, V51, P227, DOI 10.1023/A:1006132427948; Patel PS, 2002, J INTERF CYTOK RES, V22, P427, DOI 10.1089/10799900252952217; Philips A, 1998, MOL ENDOCRINOL, V12, P973, DOI 10.1210/me.12.7.973; Roebuck KA, 1999, J INTERF CYTOK RES, V19, P429, DOI 10.1089/107999099313866; SHEIKH MS, 1994, INVAS METAST, V14, P329; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Wardell SE, 2002, MOL CELL BIOL, V22, P5451, DOI 10.1128/MCB.22.15.5451-5466.2002; Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359-6101(01)00016-8; Xu L, 2000, ONCOL RES, V12, P97, DOI 10.3727/096504001108747567; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; Zerbini LF, 2003, CANCER RES, V63, P2206	33	86	91	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6105	6114		10.1038/sj.onc.1207815	http://dx.doi.org/10.1038/sj.onc.1207815			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208657	Green Accepted, Green Submitted			2022-12-17	WOS:000223261000010
J	Vaidyanathan, G; Cismowski, MJ; Wang, GS; Vincent, TS; Brown, KD; Lanier, SM				Vaidyanathan, G; Cismowski, MJ; Wang, GS; Vincent, TS; Brown, KD; Lanier, SM			The Ras-related protein AGS1/RASD1 suppresses cell growth	ONCOGENE			English	Article						AGS1; RASD1; Dexras1; G-protein; apoptosis; cancer	SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; BINDING PROTEIN; GENE; IDENTIFICATION; DEXRAS1; INTEGRATION; ACTIVATION; HORMONE	AGS1/RASD1 is a Ras-related protein identified as a dexamethasone-inducible cDNA and as a signal regulator in various functional and protein-interaction screens. As an initial approach to define the role of AGS1/RASD1 as a Ras-family member, we determined its influence on cell growth/survival. In clonogenic assays with NIH-3T3 murine fibroblast cells, the MCF-7 human breast cancer cell line and the human lung adenocarcinoma cell line A549, AGS1/RASD1 markedly diminished the number of G418-resistant colonies, whereas the Ras subgroup member K-Ras was without effect. A549 cell infection with adenovirus engineered to express AGS1/RASD1 (Ad.AGS1) inhibited log phase growth in vitro and increased the percentage of cells undergoing apoptosis. The anti-growth action was also observed in vivo as the expression of AGS1/RASD1 inhibited the subcutaneous tumor growth of A549 cells in athymic nude mice. These data indicate that AGS1/RASD1, a member of the Ras superfamily of small G-proteins that often promotes cell growth and tumor expansion, plays an active role in preventing aberrant cell growth.	Louisiana State Univ, Ctr Hlth Sci, Dept Pharmacol & Expt Therapeut, New Orleans, LA 70112 USA; NE Ohio Univ, Coll Med, Dept Physiol & Pharmacol, Rootstown, OH 44272 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Med & Genet, Baton Rouge, LA 70803 USA; W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA; Louisiana State Univ, Ctr Hlth Sci, Stanley S Scott Canc Ctr, Baton Rouge, LA 70803 USA	Louisiana State University System; Northeast Ohio Medical University (NEOMED); Louisiana State University System; Louisiana State University; Louisiana State University Health Sciences Center at Shreveport; West Virginia University; Louisiana State University System; Louisiana State University	Lanier, SM (corresponding author), Louisiana State Univ, Ctr Hlth Sci, Dept Pharmacol & Expt Therapeut, 1901 Perdido St, New Orleans, LA 70112 USA.	slanie@lsuhsc.edu	Cismowski, Mary/E-2897-2011	Lanier, Stephen/0000-0002-2740-7607	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821, R29NS024821] Funding Source: NIH RePORTER; NIMH NIH HHS [MH90531] Funding Source: Medline; NINDS NIH HHS [NS24821] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Cismowski MJ, 2000, J BIOL CHEM, V275, P23421, DOI 10.1074/jbc.C000322200; Cismowski MJ, 1999, NAT BIOTECHNOL, V17, P878, DOI 10.1038/12867; Der C J, 1989, Cancer Treat Res, V47, P73; Ellis CA, 2002, P NATL ACAD SCI USA, V99, P9876, DOI 10.1073/pnas.142193799; Fang M, 2000, NEURON, V28, P183, DOI 10.1016/S0896-6273(00)00095-7; Finlin BS, 2001, J BIOL CHEM, V276, P42259, DOI 10.1074/jbc.M105888200; Foster R, 1996, MOL CELL BIOL, V16, P2689; Graham TE, 2001, ENDOCRINOLOGY, V142, P2631, DOI 10.1210/en.142.6.2631; Graham TE, 2002, J BIOL CHEM, V277, P10876, DOI 10.1074/jbc.M110397200; Gudermann T, 2000, N-S ARCH PHARMACOL, V361, P345, DOI 10.1007/s002109900208; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Jaffrey SR, 2002, CHEM BIOL, V9, P1329, DOI 10.1016/S1074-5521(02)00293-4; Kemppainen RJ, 2003, BBA-GENE STRUCT EXPR, V1627, P85, DOI 10.1016/S0167-4781(03)00079-4; Kemppainen RJ, 1998, J BIOL CHEM, V273, P3129, DOI 10.1074/jbc.273.6.3129; Koga T, 2002, CANCER GENET CYTOGEN, V136, P113, DOI 10.1016/S0165-4608(02)00527-7; LANIER SM, 1991, J BIOL CHEM, V266, P10470; Lanson NA, 2003, CANCER RES, V63, P7936; Luo RZ, 2003, ONCOGENE, V22, P2897, DOI 10.1038/sj.onc.1206380; Soenen V, 1998, BLOOD, V91, P1008, DOI 10.1182/blood.V91.3.1008.1008_1008_1015; Stacey MW, 1999, GENE CHROMOSOME CANC, V25, P191, DOI 10.1002/(SICI)1098-2264(199906)25:2<191::AID-GCC16>3.0.CO;2-8; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Takesono A, 2002, J BIOL CHEM, V277, P13827, DOI 10.1074/jbc.M201064200; Tu YZ, 1999, BBA-GENE STRUCT EXPR, V1489, P452, DOI 10.1016/S0167-4781(99)00197-9; Vargiu P, 2004, ONCOGENE, V23, P559, DOI 10.1038/sj.onc.1207161	25	86	91	3	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5858	5863		10.1038/sj.onc.1207774	http://dx.doi.org/10.1038/sj.onc.1207774			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15184869				2022-12-17	WOS:000222629800016
J	Schlegel, BP; Starita, LM; Parvin, JD				Schlegel, BP; Starita, LM; Parvin, JD			Overexpression of a protein fragment of RNA helicase A causes inhibition of endogenous BRCA1 function and defects in ploidy and cytokinesis in mammary epithelial cells	ONCOGENE			English	Article						BRCA1; RNA helicase A; aneuploidy; centrosome; PARP-1	POLYMERASE-II HOLOENZYME; TRANSCRIPTION IN-VITRO; POLY(ADP-RIBOSE) POLYMERASE; DNA-DAMAGE; HOMOLOGOUS RECOMBINATION; GENETIC INSTABILITY; BREAST-CANCER; EXPRESSION; CYCLE; ACTIVATION	The breast- and ovarian-specific tumor suppressor, BRCA1, has been implicated to function in many nuclear processes, including DNA damage repair, recombination, transcription, ubiquitination, cell cycle checkpoint enforcement, and centrosome regulation. Utilizing a previously described interaction between BRCA1 and RNA helicase A (RHA), we have developed a dominant-negative approach to block BRCA1 function in human breast epithelial cells. Overexpression of a truncated RHA peptide that can bind to the BRCA1 carboxy-terminus prevents normal BRCA1 function, such as BRCA1 association with nuclear foci following DNA damage. Overexpression of this dominant-negative protein induces pleomorphic nuclei, aberrant mitoses with extra centrosomes, and tetraploidy. This model system allows us to observe changes to mammary epithelial cells that occur acutely following loss of BRCA1 function. Furthermore, inhibition of BRCA1 via overexpressing the RHA fragment coincides with a reduction in PARP-1 protein expression, suggesting a possible mechanism for BRCA1 in the maintenance of genomic integrity.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Parvin, JD (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA.		Parvin, Jeffrey D/C-8955-2009		NCI NIH HHS [CA90281] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090281] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; BENJAMIN RC, 1980, J BIOL CHEM, V255, P1502; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hsu LC, 2001, CANCER RES, V61, P7713; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Lafarge S, 2001, ONCOGENE, V20, P6597, DOI 10.1038/sj.onc.1204812; Larson JS, 1997, CANCER RES, V57, P3351; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; OHGUSHI H, 1980, J BIOL CHEM, V255, P6205; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Simbulan-Rosenthal CM, 2000, P NATL ACAD SCI USA, V97, P11274, DOI 10.1073/pnas.200285797; Simbulan-Rosenthal CM, 1999, P NATL ACAD SCI USA, V96, P13191, DOI 10.1073/pnas.96.23.13191; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; TANIGUCHI T, 1982, J BIOL CHEM, V257, P4027; Tomlinson GE, 1998, CANCER RES, V58, P3237; Vispe S, 2000, P NATL ACAD SCI USA, V97, P9886, DOI 10.1073/pnas.170280397; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	39	86	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 20	2003	22	7					983	991		10.1038/sj.onc.1206195	http://dx.doi.org/10.1038/sj.onc.1206195			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592385				2022-12-17	WOS:000180926100004
J	Piccolo, E; Innominato, PF; Mariggio, MA; Maffucci, T; Iacobelli, S; Falasca, M				Piccolo, E; Innominato, PF; Mariggio, MA; Maffucci, T; Iacobelli, S; Falasca, M			The mechanism involved in the regulation of phospholipase C gamma 1 activity in cell migration	ONCOGENE			English	Article						cell motility; epidermal growth factor; phosphoinositide 3-kinase; phospholipase C; pleckstrin homology domain	FOCAL ADHESION KINASE; C-GAMMA; GROWTH-FACTOR; TUMOR-SUPPRESSOR; ACTIVATION; MOTILITY; DOMAIN; OVEREXPRESSION; IDENTIFICATION; INHIBITION	Activation of the enzyme phospholipase C (PLC) leads to the formation of second messengers inositol 1,4,5-trisphosphate and diacylglycerol. Tyrosine kinase receptors activate this reaction through PLCgamma isoenzymes. PLCgamma activity involves its activation with, and phosphorylation by, receptor tyrosine kinases. Recently, it has been shown that phosphoinositide 3-kinase (PI 3-K) may regulate PLCgamma activity through the interaction of the PI 3-K product phosphatidylinositol 3,4,5-trisphosphate (PtdIns-3,4,5-P-3) and the PLCgamma pleckstrin homology (PH) domain. In an effort to understand the signalling pathway that involves PI 3-K regulation of PLCgamma, we found that EGF induces a PI 3-K-dependent translocation of PLCgamma1 at the leading edge of migrating cells in a wound healing assay. Similarly, the isolated PH, but not the Src-homology (SH) domains, N-SH2 or SH3, of PLCgamma1, translocates at the leading edge. Our experiments also showed that stable PH PLCgamma1 expression blocks epidermal growth factor (EGF)- and serum-induced cell motility and increases cell adhesion in MDA-MB-231 cells. This may suggest that influence of PI 3-K on PLCgamma1 could be relevant in cell migration, where PLCgamma1 seems to play a key role by modulating a series of events involved in actin polymerization.	Univ G DAnnunzio, Dept Oncol & Neurosci, Sect Med Oncol, I-66100 Chieti, Italy; Univ G DAnnunzio, Dept Drug Sci, Lab Cellular Physiol, I-66100 Chieti, Italy; UCL, Sackler Inst, London WC1E 6JJ, England	G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; University of London; University College London	Falasca, M (corresponding author), Univ G DAnnunzio, Dept Oncol & Neurosci, Sect Med Oncol, Via Vestini 1, I-66100 Chieti, Italy.	m.falasca@ucl.ac.uk	Mariggiò, Maria Addolorata/T-9047-2017; Falasca, Marco/S-4020-2016	Mariggiò, Maria Addolorata/0000-0001-5306-7143; Falasca, Marco/0000-0002-9801-7235; Mariggio, Maria Addolorata/0000-0002-3508-8706				Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Carloni V, 1997, GASTROENTEROLOGY, V112, P522, DOI 10.1053/gast.1997.v112.pm9024306; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; Chang JS, 1997, CANCER RES, V57, P5465; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Khoshyomn S, 1999, NEUROSURGERY, V44, P568, DOI 10.1097/00006123-199903000-00073; LI J, 1997, SCIENCE, V275, P1876; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Maffucci T, 2001, FEBS LETT, V506, P173, DOI 10.1016/S0014-5793(01)02909-X; Matsuda M, 2001, J CELL BIOL, V153, P599, DOI 10.1083/jcb.153.3.599; Mizushima H, 1997, CELL GROWTH DIFFER, V8, P979; Morimoto AM, 2000, ONCOGENE, V19, P200, DOI 10.1038/sj.onc.1203288; Nakamura I, 2001, J CELL BIOL, V152, P361, DOI 10.1083/jcb.152.2.361; NOMOTO K, 1995, MOL CARCINOGEN, V12, P146, DOI 10.1002/mc.2940120306; Polk DB, 1998, GASTROENTEROLOGY, V114, P493, DOI 10.1016/S0016-5085(98)70532-3; Price JT, 1999, CANCER RES, V59, P5475; Razzini G, 2000, J BIOL CHEM, V275, P14873, DOI 10.1074/jbc.275.20.14873; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Smith MR, 1998, CARCINOGENESIS, V19, P177, DOI 10.1093/carcin/19.1.177; SODERQUIST AM, 1992, CANCER RES, V52, P4526; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Turner T, 1997, CLIN CANCER RES, V3, P2275; Wells A, 2000, ADV CANCER RES, V78, P31; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021	32	86	93	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2002	21	42					6520	6529		10.1038/sj.onc.1205821	http://dx.doi.org/10.1038/sj.onc.1205821			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226755				2022-12-17	WOS:000177925300012
J	Antonyak, MA; Kenyon, LC; Godwin, AK; James, DC; Emlet, DR; Okamoto, I; Tnani, M; Holgado-Madruga, M; Moscatello, DK; Wong, AJ				Antonyak, MA; Kenyon, LC; Godwin, AK; James, DC; Emlet, DR; Okamoto, I; Tnani, M; Holgado-Madruga, M; Moscatello, DK; Wong, AJ			Elevated JNK activation contributes to the pathogenesis of human brain tumors	ONCOGENE			English	Article						apoptosis; brain tumor; glioblastoma multiforme; EGF receptor; JNK; MAP kinase	EPIDERMAL GROWTH-FACTOR; N-TERMINAL KINASE; LUNG-CARCINOMA CELLS; C-JUN; PROTEIN-KINASE; SIGNALING PATHWAY; CONSTITUTIVE ACTIVATION; SUPPRESSES GROWTH; HA-RAS; TRANSFORMATION	The ERK pathway is typically associated with activation of the EGF receptor and has been shown to play a major role in promoting several tumor phenotypes. An analogous signaling module, the JNK pathway, has not been shown to be consistently activated by the EGF receptor but is instead more uniformly stimulated by cellular stresses and cytokines. The function of the JNK pathway in primary tumors is unclear as it has been implicated in both promoting apoptosis and cell growth in vitro, which may be a reflection of the cell lines chosen. Primary human brain tumors frequently show overexpression of the EGF receptor. To clarify the role of JNK in tumorigenesis, we have investigated the role of JNK in a large panel of primary human brain tumors and tumor derived cell lines. Here we present evidence that JNK has a major role in promoting tumorigenesis both in vivo and in vitro. Western blot analysis demonstrated that 86% (18 of 21) of primary brain tumors showed evidence of JNK activation but only 38% (8 of 21) showed evidence of ERK activation. Kinase assays revealed that 77% of brain tumor cell lines activated JNK in response to EGF (7 of 13) or had high levels of basal activity (3 of 13), whereas none of six normal cell lines analysed, including astrocytes, had these properties. Of several growth factors examined, EGF produced the highest level of JNK induction in tumor cell lines and the duration of activation was greater than that seen for ERK. Expression of a dominant-negative (dn) form of JNK potently inhibited EGF mediated anchorage independent growth and protection from cell death in two glial tumor cell lines. These findings demonstrate that enhanced JNK activation is frequently found in primary brain tumors and that this activation contributes to phenotypes related to transformation.	Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA; Mayo Clin & Res Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Coriell Inst Med Res, Differenciat Cell Lab, Camden, NJ 08103 USA	Jefferson University; Jefferson University; Fox Chase Cancer Center; Mayo Clinic; Coriell Institute for Medical Research	Wong, AJ (corresponding author), 233 S 10th St,BLSB 1002, Philadelphia, PA 19107 USA.		James, Charles D/E-2721-2012	James, Charles D/0000-0002-1027-203X; Kenyon, Lawrence/0000-0002-3719-9565				Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Bost F, 1999, MOL CELL BIOL, V19, P1938; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Chen NY, 2001, CANCER RES, V61, P3908; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Hashimoto A, 1999, J BIOL CHEM, V274, P20139, DOI 10.1074/jbc.274.29.20139; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; Mandell JW, 1998, AM J PATHOL, V153, P1411, DOI 10.1016/S0002-9440(10)65728-8; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; McClellan M, 1999, EXP CELL RES, V246, P471, DOI 10.1006/excr.1998.4328; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Moscatello DK, 1996, ONCOGENE, V13, P85; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Potapova O, 2001, J BIOL CHEM, V276, P28546, DOI 10.1074/jbc.M102075200; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tan PBO, 1999, TRENDS GENET, V15, P145, DOI 10.1016/S0168-9525(99)01694-7; Teng DHF, 1997, CANCER RES, V57, P4177; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WONG AJ, 1994, SEMIN ONCOL, V21, P139; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xing C, 1999, CARCINOGENESIS, V20, P1201, DOI 10.1093/carcin/20.7.1201; Xu X, 1997, P NATL ACAD SCI USA, V94, P12655, DOI 10.1073/pnas.94.23.12655	40	86	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5038	5046		10.1038/sj.onc.1205593	http://dx.doi.org/10.1038/sj.onc.1205593			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140754				2022-12-17	WOS:000176975900002
J	Imamura, O; Fujita, K; Itoh, C; Takeda, S; Furuichi, Y; Matsumoto, T				Imamura, O; Fujita, K; Itoh, C; Takeda, S; Furuichi, Y; Matsumoto, T			Werner and Bloom helicases are involved in DNA repair in a complementary fashion	ONCOGENE			English	Article							SYNDROME GENE-PRODUCT; SISTER-CHROMATID EXCHANGES; LYMPHOBLASTOID CELL-LINES; SYNDROME PROTEIN; ULTRAVIOLET-LIGHT; HOMOLOGOUS RECOMBINATION; FUNCTIONAL INTERACTION; EXONUCLEASE ACTIVITY; SYNDROME FIBROBLASTS; MOLECULAR-CLONING	Werner syndrome (WS) is a recessive disorder characterized by premature senescence. Bloom syndrome (BS) is a recessive disorder characterized by short stature and immunodeficiency. A common characteristic of both syndromes is genomic instability leading to tumorigenesis. WRN and BLM genes causing WS and BS, encode proteins that are closely related to the RecQ helicase. We produced WRN-/-, BLM-/- and WRN-/-/BLM-/- mutants in the chicken B-cell line DT40. WRN-/- cells showed hypersensitivities to genotoxic agents, such as 4-nitroquinoline 1-oxide, camptothecin and methyl methanesulfonate. They also showed a threefold increase in targeted integration rate of exogenous DNAs, but not in sister chromatid exchange (SCE) frequency. BLM-/- cells showed hypersensitivities to the genotoxic agents as well as ultraviolet (UV) light, in addition to a 10-fold increase in targeted integration rate and an 11-fold increase in SCE frequency. In WRN-/-/BLM-/- cells, synergistically increased hypersensitivities to the genotoxic agents were observed whereas both SCE frequencies and targeted integration rates were partially diminished compared to the single mutants. Chromosomal aberrations were also synergistically increased in WRN-/-/ BLM-/- cells when irradiated with UV light in late S to G(2) phases. These results suggest that both WRN and BLM may be involved in DNA repair in a complementary fashion.	AGENE Res Inst, Kanagawa 2470063, Japan; Kyoto Univ, Grad Sch Med, Dept Radiat Genet, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Matsumoto, T (corresponding author), Japanese Fdn Canc Res, Genome Ctr, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.	takehisa.matsumoto@jfcr.or.jp		Takeda, Shunichi/0000-0002-7924-7991				Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Brosh RM, 2001, J BIOL CHEM, V276, P3024, DOI 10.1074/jbc.M006784200; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; CHAGANTI RS, 1974, P NATL ACAD SCI USA, V71, P4508, DOI 10.1073/pnas.71.11.4508; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cooper MP, 2000, GENE DEV, V14, P907; Elli R, 1996, CANCER GENET CYTOGEN, V87, P112, DOI 10.1016/0165-4608(95)00294-4; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FARAGHER RGA, 1993, P NATL ACAD SCI USA, V90, P12030, DOI 10.1073/pnas.90.24.12030; FUJIWARA Y, 1977, J CELL PHYSIOL, V92, P365, DOI 10.1002/jcp.1040920305; Fukagawa T, 1999, NUCLEIC ACIDS RES, V27, P1966, DOI 10.1093/nar/27.9.1966; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GALIEGUEZOUITINA S, 1984, ANAL BIOCHEM, V138, P454, DOI 10.1016/0003-2697(84)90839-X; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; HEARTLEIN MW, 1987, EXP CELL RES, V169, P245; HIGASHIKAWA T, 1978, EXP CELL RES, V113, P438, DOI 10.1016/0014-4827(78)90386-5; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Imamura O, 2001, ONCOGENE, V20, P1143, DOI 10.1038/sj.onc.1204195; KADYK LC, 1993, GENETICS, V133, P469; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; KREPINSKY AB, 1979, HUM GENET, V50, P151, DOI 10.1007/BF00390236; KREPINSKY AB, 1980, MUTAT RES, V69, P357, DOI 10.1016/0027-5107(80)90100-1; KURIHARA T, 1987, MUTAT RES, V183, P197, DOI 10.1016/0167-8817(87)90062-9; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Machwe A, 2000, NUCLEIC ACIDS RES, V28, P2762, DOI 10.1093/nar/28.14.2762; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; NAKAYAMA K, 1985, MOL GEN GENET, V200, P266, DOI 10.1007/BF00425434; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; Okada M, 1998, BIOL PHARM BULL, V21, P235; Onoda F, 2001, MOL GEN GENET, V264, P702, DOI 10.1007/s004380000358; Orren DK, 2001, NUCLEIC ACIDS RES, V29, P1926, DOI 10.1093/nar/29.9.1926; Poot M, 1999, HUM GENET, V104, P10, DOI 10.1007/s004390050903; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; ROSIN MP, 1985, HUM GENET, V71, P187, DOI 10.1007/BF00284570; SALK D, 1985, ADV EXP MED BIOL, V190, P305; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; Shen JC, 2000, NUCLEIC ACIDS RES, V28, P3260, DOI 10.1093/nar/28.17.3260; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Shimamoto A, 2000, NUCLEIC ACIDS RES, V28, P1647, DOI 10.1093/nar/28.7.1647; SHIRAISHI Y, 1985, P NATL ACAD SCI USA, V82, P5102, DOI 10.1073/pnas.82.15.5102; SMITH GJ, 1983, MUTAT RES, V111, P405, DOI 10.1016/0027-5107(83)90036-2; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Sonoda E, 2001, P NATL ACAD SCI USA, V98, P8388, DOI 10.1073/pnas.111006398; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Suzuki N, 1999, NUCLEIC ACIDS RES, V27, P2361, DOI 10.1093/nar/27.11.2361; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Takao N, 1999, ONCOGENE, V18, P7002, DOI 10.1038/sj.onc.1203172; Tornaletti S, 1996, BIOESSAYS, V18, P221, DOI 10.1002/bies.950180309; TSAO YP, 1993, CANCER RES, V53, P5908; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WOOD RD, 1989, BIOCHEMISTRY-US, V28, P8287, DOI 10.1021/bi00447a005; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yamaguchi-Iwai Y, 1999, EMBO J, V18, P6619, DOI 10.1093/emboj/18.23.6619; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; ZHANG YL, 1992, J NAT PROD, V55, P1100, DOI 10.1021/np50086a011	69	86	88	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2002	21	6					954	963		10.1038/sj.onc.1205143	http://dx.doi.org/10.1038/sj.onc.1205143			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840341				2022-12-17	WOS:000173427100011
J	Schwarze, SR; Shi, Y; Fu, VX; Watson, PA; Jarrard, DF				Schwarze, SR; Shi, Y; Fu, VX; Watson, PA; Jarrard, DF			Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells	ONCOGENE			English	Article						cyclin-dependent kinase; p57; senescence; prostate; epithelial	CELLULAR SENESCENCE; TUMOR-SUPPRESSOR; RETINOBLASTOMA PROTEIN; REPLICATIVE SENESCENCE; P57(KIP2); PROLIFERATION; EXPRESSION; CANCER; E7; IMMORTALIZATION	Cellular senescence has been proposed to be an in vitro and in vivo block that cells must overcome in order to immortalize and become tumorigenic. To characterize these pathways, we focused on changes in the cyclin-dependent kinase inhibitors and their binding partners that underlie the cell cycle arrest at senescence. As a model, we utilized normal human prostate epithelial cell (HPEC) and human uroepithelial cell (HUC) cultures. After 30-40 population doublings cells became growth-arrested in G0/1 with a threefold decrease in Cdk2-associated activity, a point defined as pre-senescence. Temporally following this growth arrest, the cells develop a senescence morphology and express senescence-associated beta -galactosidase (SA-beta -gal). Levels of p16(INK4a) and p57(KIP2) rise in HUCs during progressive passages, whereas only p16 increases in HPEC cultures. The induced expression of p57, similar to p16, produces a senescent-like phenotype. pRB, cyclin D, p19(INK4d) and p27(KIP1) decrease in both cell types. We find that p53, p21(CIP1) and p15(INK4b) are transiently elevated in HPECs and HUCs at the pre-senescent growth arrest, then return to low proliferating levels at terminal senescence. Analysis of p53, p21(CIP1), P15(INK4b), p16(INK4a), and p57(KIP2) reveals altered expression in immortalized, non-tumorigenic HPV16 E6 and E7 prostate lines and in tumorigenic prostate cancer cells. These results indicate: (i) the existence of a subset of growth inhibiting genes elevated at the onset of the senescence, (ii) a distinct class of genes involved in the maintenance of senescence, and (iii) the frequent inactivation of these pathways during immortalization.	Univ Wisconsin, Ctr Comprehens Canc, Dept Surg, Madison, WI 53972 USA; Univ Wisconsin, Sch Med, Madison, WI 53972 USA; Univ Wisconsin, Ctr Comprehens Canc, Dept Oncol, Madison, WI 53972 USA; Univ Wisconsin, Ctr Comprehens Canc, Dept Environm Toxicol Ctr, Madison, WI 53972 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Jarrard, DF (corresponding author), Univ Wisconsin, Ctr Comprehens Canc, Dept Surg, Madison, WI 53972 USA.				NATIONAL CANCER INSTITUTE [K08CA076184] Funding Source: NIH RePORTER; NCI NIH HHS [CA76184-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belair CD, 1997, P NATL ACAD SCI USA, V94, P13677, DOI 10.1073/pnas.94.25.13677; Bright RK, 1997, CANCER RES, V57, P995; Burkhart BA, 1999, EXP CELL RES, V247, P168, DOI 10.1006/excr.1998.4345; Campisi J, 2000, IN VIVO, V14, P183; Chang BD, 1999, CANCER RES, V59, P3761; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Choi J, 2000, UROLOGY, V56, P160, DOI 10.1016/S0090-4295(00)00538-0; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dyer MA, 2000, DEVELOPMENT, V127, P3593; England NL, 1996, CARCINOGENESIS, V17, P1567, DOI 10.1093/carcin/17.8.1567; Fanton CP, 2001, J BIOL CHEM, V276, P18871, DOI 10.1074/jbc.M011514200; Fink JR, 2001, EXP HEMATOL, V29, P490, DOI 10.1016/S0301-472X(01)00619-1; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Hara E, 1996, MOL CELL BIOL, V16, P859; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Herman JG, 1996, CANCER RES, V56, P722; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; Jarrard DF, 1999, CANCER RES, V59, P2957; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Lissy NA, 1998, IMMUNITY, V8, P57, DOI 10.1016/S1074-7613(00)80458-6; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; Nagahama H, 2001, ANAT EMBRYOL, V203, P77, DOI 10.1007/s004290000146; Nijjar T, 1999, CANCER RES, V59, P5112; Oya M, 2000, BRIT J CANCER, V83, P626, DOI 10.1054/bjoc.2000.1298; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Ran QT, 2000, EXP GERONTOL, V35, P7, DOI 10.1016/S0531-5565(99)00080-7; Reynaud EG, 2000, J BIOL CHEM, V275, P18767, DOI 10.1074/jbc.M907412199; REZNIKOFF CA, 1987, J CELL PHYSIOL, V131, P285, DOI 10.1002/jcp.1041310302; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; Reznikoff CA, 1996, CANCER RES, V56, P2886; REZNIKOFF CA, 1983, IN VITRO CELL DEV B, V19, P326; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Sandhu C, 2000, CANCER RES, V60, P2616; Sarkar S, 2000, CANCER RES, V60, P3862; SASAKI M, 1994, CANCER RES, V54, P6090; Savelieva E, 1997, ONCOGENE, V14, P551, DOI 10.1038/sj.onc.1200868; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Solomon M J, 1998, Results Probl Cell Differ, V22, P79; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Tanaka H, 1998, GENE CHROMOSOME CANC, V23, P123, DOI 10.1002/(SICI)1098-2264(199810)23:2<123::AID-GCC5>3.0.CO;2-4; Taniguchi T, 1997, ONCOGENE, V14, P1201, DOI 10.1038/sj.onc.1200934; Tsugu A, 2000, AM J PATHOL, V157, P919, DOI 10.1016/S0002-9440(10)64605-6; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wittwer CT, 1997, BIOTECHNIQUES, V22, P130, DOI 10.2144/97221bi01; Xiong Y, 1996, J VIROL, V70, P999, DOI 10.1128/JVI.70.2.999-1008.1996; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163; Young JI, 2001, J BIOL CHEM, V276, P19610, DOI 10.1074/jbc.M009470200; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0	57	86	89	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2001	20	57					8184	8192		10.1038/sj.onc.1205049	http://dx.doi.org/10.1038/sj.onc.1205049			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	498KC	11781834				2022-12-17	WOS:000172507800003
J	Mende, I; Malstrom, S; Tsichlis, PN; Vogt, PK; Aoki, M				Mende, I; Malstrom, S; Tsichlis, PN; Vogt, PK; Aoki, M			Oncogenic transformation induced by membrane-targeted Akt2 and Akt3	ONCOGENE			English	Article						Akt; transformation; serine/threonine kinase	PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; MOLECULAR-CLONING; CATALYTIC SUBUNIT; TUMOR-SUPPRESSOR; B-GAMMA; ACTIVATION; EXPRESSION; OVARIAN	The kinases Akt2, Akt3 and their myristylated variants, Myr-Akt2 and Myr-Akt3 were expressed by the RCAS vector in chicken embryo fibroblasts (CEF), Myr-Akt2 and Myr-Akt3 were strongly oncogenic, inducing multilayered foci of transformed cells. In contrast, wild-type Akt2 and Akt3 were only poorly transforming, their efficiencies of focus formation were more than 100-fold lower; foci appeared later and showed less multilayering, Addition of the myristylation signal not only enhanced oncogenic potential hut also increased kinase activities. Myr-Akt2 and Myr-Akt3 also induced hemangiosarcomas in the animal, whereas wild type Akt2 and Akt3 were not oncogenic in vivo. Furthermore, Akt2, driven by the lck (lymphocyte specific kinase) promoter in transgenic mice, induced lymphomas, The oncogenic effects of Akt2 and Akt3 described here are indistinguishable from those of Akt1, The downstream targets relevant to oncogenic transformation are therefore probably shared by the three Akt kinases.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Scripps Research Institute; Jefferson University	Vogt, PK (corresponding author), 10550 N Torrey Pines Rd,BCC-239, La Jolla, CA 92037 USA.		Vogt, Peter K./R-7547-2019; Aoki, Masahiro/A-5149-2016	Vogt, Peter K./0000-0002-4519-7500; Aoki, Masahiro/0000-0003-4316-9490	NCI NIH HHS [CA 79616, CA 42564, CA 78230] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042564, R01CA079616, R01CA078230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Altomare DA, 1998, ONCOGENE, V16, P2407, DOI 10.1038/sj.onc.1201750; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Aoki M, 2000, J BIOL CHEM, V275, P6267, DOI 10.1074/jbc.275.9.6267; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Brodbeck D, 1999, J BIOL CHEM, V274, P9133, DOI 10.1074/jbc.274.14.9133; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; CECI JD, 1989, GENOMICS, V5, P699, DOI 10.1016/0888-7543(89)90111-0; CECI JD, 1991, ONCOGENE, V6, P323; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1997, ONCOGENE, V14, P2793, DOI 10.1038/sj.onc.1201121; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Coffer PJ, 1998, BIOCHEM J, V335, P1; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Liu AX, 1998, CANCER RES, V58, P2973; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Masure S, 1999, EUR J BIOCHEM, V265, P353, DOI 10.1046/j.1432-1327.1999.00774.x; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; OSBORN L, 1987, MOL CELL BIOL, V7, P326, DOI 10.1128/MCB.7.1.326; PELES E, 1992, J BIOL CHEM, V267, P12266; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Ruggeri BA, 1998, MOL CARCINOGEN, V21, P81, DOI 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SIRACUSA LD, 1987, GENETICS, V117, P85; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8	48	86	91	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2001	20	32					4419	4423		10.1038/sj.onc.1204486	http://dx.doi.org/10.1038/sj.onc.1204486			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466625				2022-12-17	WOS:000169912600018
J	Berger, SL				Berger, SL			An embarrassment of niches: the many covalent modifications of histones in transcriptional regulation	ONCOGENE			English	Review						chromatin; transcription; histone acetylation; histone phosphorylation; histone methylation; histone ubiquitination	MITOTIC CHROMOSOME CONDENSATION; H3 PHOSPHORYLATION; IN-VIVO; ACETYLTRANSFERASE ACTIVITY; GENE ACTIVATION; YEAST GCN5P; DNA-DAMAGE; ACETYLATION; COMPLEX; DOMAIN		Wistar Inst, Mol Genet Program, Philadelphia, PA 19104 USA	The Wistar Institute	Berger, SL (corresponding author), Wistar Inst, Mol Genet Program, Philadelphia, PA 19104 USA.			Berger, Shelley/0000-0001-5398-4400				Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Annunziato AT, 2000, GENE EXPRESSION, V9, P37; Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Belotserkovskaya R, 2000, MOL CELL BIOL, V20, P634, DOI 10.1128/MCB.20.2.634-647.2000; Berger SL, 2000, NATURE, V408, P412, DOI 10.1038/35044160; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Crosio C, 2000, NAT NEUROSCI, V3, P1241, DOI 10.1038/81767; de la Barre AE, 2000, EMBO J, V19, P379, DOI 10.1093/emboj/19.3.379; De Souza CPC, 2000, CELL, V102, P293, DOI 10.1016/S0092-8674(00)00035-0; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Dudley AM, 1999, GENE DEV, V13, P2940, DOI 10.1101/gad.13.22.2940; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Mizzen CA, 2000, SCIENCE, V289, P2290, DOI 10.1126/science.289.5488.2290; Nowak SJ, 2000, GENE DEV, V14, P3003, DOI 10.1101/gad.848800; Pham AD, 2000, SCIENCE, V289, P2357, DOI 10.1126/science.289.5488.2357; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Sauve DM, 1999, J CELL BIOL, V145, P225, DOI 10.1083/jcb.145.2.225; SOLOW S, 2000, IN PRESS BIOL CHEM; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Van Hooser A, 1998, J CELL SCI, V111, P3497; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155	60	86	94	1	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	2001	20	24					3007	3013		10.1038/sj.onc.1204324	http://dx.doi.org/10.1038/sj.onc.1204324			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442WT	11420715				2022-12-17	WOS:000169308500003
J	Gil, J; Esteban, M				Gil, J; Esteban, M			The interferon-induced protein kinase (PKR), triggers apoptosis through FADD-mediated activation of caspase 8 in a manner independent of Fas and TNF-alpha receptors	ONCOGENE			English	Article						PKR; apoptosis; FADD; caspases	TUMOR-SUPPRESSOR P53; EUKARYOTIC TRANSLATION INITIATION-FACTOR-2; INFLUENZA-VIRUS INFECTION; NF-KAPPA-B; CELL-DEATH; DEPENDENT PATHWAY; ANTICANCER DRUGS; EXPRESSION; LIGAND; DOMAIN	The interferon-induced dsRNA-dependent protein kinase (PKR) induces apoptosis of mammalian cells. Apoptosis induction bq PKR involves phosphorylation of the translational factor eIF-2 alpha and activation of the transcriptional factor NF-kappa B, but caspase pathways activated by PKR are not known. Upregulation of Fas mRNA by PKR has been suggested to play a role in PKR-induced apoptosis. To learn how PKR induces apoptosis, we have analysed the role of molecules in death receptor pathways. We showed the involvement of the FADD-caspase 8 pathway on PKR-induced apoptosis based on four experimental findings: upregulation of caspase 8 activity during PKR-induced apoptosis, blocking of PKR-induced apoptosis by the use of a chemical inhibitor of caspase 8, and inhibition of PKR-induced apoptosis by expression of both a FADD dominant negative or a viral FLIP molecule. Significantly, despite the PKR-mediated upregulation of Fas mRSA expression, the Fas receptor-ligand pathway is not needed for PKR-induced apoptosis. Antibodies that inhibit TNF alpha-TNFR1 or Fas-FasL interactions were not able to block PKR-induced apoptosis. Taken together, our observations establish the involvement of caspase 8 in PKR-induced apoptosis and suggest that death receptors other than Fas or TNFR1 or, alternatively, a novel mechanism involving FADD independently of death receptors, are responsible for PKR-induced apoptosis.	CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Madrid 28049, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Esteban, M (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Campus Univ Autonoma, Madrid 28049, Spain.		Gil, Jesus/C-7739-2012; Esteban, Mariano/ABG-5375-2020	Gil, Jesus/0000-0002-4303-6260; Esteban, Mariano/0000-0003-0846-2827				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Beltinger C, 1999, P NATL ACAD SCI USA, V96, P8699, DOI 10.1073/pnas.96.15.8699; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Brun A, 1996, VIROLOGY, V225, P227, DOI 10.1006/viro.1996.0592; Castelli JC, 1997, J EXP MED, V186, P967, DOI 10.1084/jem.186.6.967; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Choi KB, 1998, J BIOL CHEM, V273, P20185, DOI 10.1074/jbc.273.32.20185; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DiazGuerra M, 1997, VIROLOGY, V236, P354, DOI 10.1006/viro.1997.8719; Donze O, 1999, VIROLOGY, V256, P322, DOI 10.1006/viro.1999.9618; Gil J, 2000, ONCOGENE, V19, P1369, DOI 10.1038/sj.onc.1203448; Gil J, 1999, MOL CELL BIOL, V19, P4653; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P715; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Hu SM, 1997, J BIOL CHEM, V272, P9621; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Lee SB, 1996, J INTERF CYTOK RES, V16, P1073, DOI 10.1089/jir.1996.16.1073; Lee SB, 1997, VIROLOGY, V231, P81, DOI 10.1006/viro.1997.8494; LEE SB, 1993, VIROLOGY, V192, P380, DOI 10.1006/viro.1993.1048; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; MACKETT M, 1984, J VIROL, V49, P857, DOI 10.1128/JVI.49.3.857-864.1984; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nunez A, 1996, J MED VIROL, V50, P342, DOI 10.1002/(SICI)1096-9071(199612)50:4&lt;342::AID-JMV10&gt;3.0.CO;2-K; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; PIMENTELMUINOS FX, 1994, J IMMUNOL, V152, P5714; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Senkevich TG, 1996, SCIENCE, V273, P813, DOI 10.1126/science.273.5276.813; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Suarez P, 1996, J VIROL, V70, P2876; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Takizawa T, 1996, J VIROL, V70, P8128, DOI 10.1128/JVI.70.11.8128-8132.1996; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Tschopp J, 1998, CURR OPIN GENET DEV, V8, P82, DOI 10.1016/S0959-437X(98)80066-X; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vazquez MI, 1998, J VIROL, V72, P10126; WADA N, 1995, J BIOL CHEM, V270, P18007, DOI 10.1074/jbc.270.30.18007; WATANABE FR, 1992, NATURE, V356, P314; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeung MC, 1998, J BIOL CHEM, V273, P25198, DOI 10.1074/jbc.273.39.25198; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	74	86	91	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3665	3674		10.1038/sj.onc.1203710	http://dx.doi.org/10.1038/sj.onc.1203710			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951573				2022-12-17	WOS:000088568300013
J	Cormier, RT; Bilger, A; Lillich, AJ; Halberg, RB; Hong, KH; Gould, KA; Borenstein, N; Lander, ES; Dove, WF				Cormier, RT; Bilger, A; Lillich, AJ; Halberg, RB; Hong, KH; Gould, KA; Borenstein, N; Lander, ES; Dove, WF			The Mom1(AKR) intestinal tumor resistance region consists of Pla2g2a and a locus distal to D4Mit64	ONCOGENE			English	Article						Mom1; tumor resistance; Apc; Min mouse; goblet cell; Pla2g2a	FAMILIAL ADENOMATOUS POLYPOSIS; SECRETORY PHOSPHOLIPASE A(2); NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CARCINOMA CELL-LINES; LOW-MOLECULAR-WEIGHT; COLON-CANCER CELLS; TRANSGENIC MICE; MURINE MODEL; MIN MOUSE; CHROMOSOME 1P35-36	The Mom1 (Modifier of Min-1) region of distal chromosome 4 was identified during a screen for polymorphic modifiers of intestinal tumorigenesis in Apc(Min/+) mice. Here, we demonstrate that the Mom1(AKR) allele consists of two genetic components. These include the secretory phospholipase Pla2g2a, whose candidacy as a Mom1 resistance modifier has now been tested with several transgenic Lines. A second region, distal to Pla2g2a, has also been identified using fine structure recombinants. Pla2g2a(AKR) transgenic mice demonstrate a modest resistance to tumorigenesis in the small intestine and a ver! robust resistance in the large intestine, Moreover, the tumor resistance in the colon of Pla2g2a(AKR) animals is dosage-dependent, a finding that is consistent with our observation that Pla2g2a is expressed in goblet cells, By contrast, mice carrying the distal Mom1 modifier demonstrate a modest tumor resistance that is confined to the small intestine. Thus. the phenotypes of these two modifier loci are complementary, both in their quantitative and regional effects. The additive effects and tight Linkage of these modifiers may have been necessary for the initial identification of the Mom1 region.	Univ Wisconsin, Mcardle Lab Canc Res, Madison, WI 53706 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Univ Wisconsin, Genet Lab, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); University of Wisconsin System; University of Wisconsin Madison	Dove, WF (corresponding author), Univ Wisconsin, Mcardle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.				NCI NIH HHS [CA07075, CA63677, CA50585] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063677, R37CA063677] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; BeazerBarclay Y, 1996, CARCINOGENESIS, V17, P1757, DOI 10.1093/carcin/17.8.1757; Boolbol SK, 1996, CANCER RES, V56, P2556; Charalambous D, 1998, J GASTROEN HEPATOL, V13, P1195; Chiu CH, 1997, CANCER RES, V57, P4267; Cohn SM, 1997, J CLIN INVEST, V99, P1367, DOI 10.1172/JCI119296; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Cupillard L, 1999, J BIOL CHEM, V274, P7043, DOI 10.1074/jbc.274.11.7043; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Dobbie Z, 1997, HUM GENET, V99, P653, DOI 10.1007/s004390050423; DOVE WF, 1994, COLD SPRING HARB SYM, V59, P501, DOI 10.1101/SQB.1994.059.01.055; Dragani TA, 1997, NAT GENET, V17, P7, DOI 10.1038/ng0997-7; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Engle SJ, 1999, CANCER RES, V59, P3379; Erickson BA, 1999, J SURG RES, V81, P101, DOI 10.1006/jsre.1998.5511; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Fukushima K, 1999, J GASTROENTEROL, V34, P54, DOI 10.1007/s005350050216; Garabedian EM, 1997, J BIOL CHEM, V272, P23729, DOI 10.1074/jbc.272.38.23729; Gould KA, 1997, P NATL ACAD SCI USA, V94, P5848, DOI 10.1073/pnas.94.11.5848; Gould KA, 1996, GENETICS, V144, P1769; Gould KA, 1996, GENETICS, V144, P1777; Gould KA, 1998, EXP LUNG RES, V24, P437, DOI 10.3109/01902149809087379; Gould KA, 1996, CELL GROWTH DIFFER, V7, P1361; Grass DS, 1996, J CLIN INVEST, V97, P2233, DOI 10.1172/JCI118664; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HALBERG R, 1992, J MOL BIOL, V228, P840, DOI 10.1016/0022-2836(92)90868-K; Halberg RB, 2000, P NATL ACAD SCI USA, V97, P3461, DOI 10.1073/pnas.050585597; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; HARWIG SSL, 1995, J CLIN INVEST, V95, P603, DOI 10.1172/JCI117704; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HERZOG CR, 1995, ONCOGENE, V11, P1811; Ikegami T, 1998, CANCER LETT, V134, P129, DOI 10.1016/S0304-3835(98)00248-1; Ishizaki J, 1999, J BIOL CHEM, V274, P24973, DOI 10.1074/jbc.274.35.24973; Itoh H, 1999, J CLIN INVEST, V104, P1539, DOI 10.1172/JCI6211; Jacoby RF, 1996, CANCER RES, V56, P710; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Laine VJO, 1999, J IMMUNOL, V162, P7402; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Legare ME, 2000, GENOME RES, V10, P42; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Mahmoud NN, 1998, CARCINOGENESIS, V19, P87, DOI 10.1093/carcin/19.1.87; McCracken JD, 1996, J CLIN PHARMACOL, V36, P540, DOI 10.1002/j.1552-4604.1996.tb05043.x; Moorghen M, 1998, CELL PROLIFERAT, V31, P59, DOI 10.1046/j.1365-2184.1998.00111.x; Morel L, 1999, MAMM GENOME, V10, P176; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MULHERKAR R, 1991, HISTOCHEMISTRY, V96, P367, DOI 10.1007/BF00271358; MULHERKAR R, 1993, FEBS LETT, V317, P263, DOI 10.1016/0014-5793(93)81289-C; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Nakatsugi S, 1997, JPN J CANCER RES, V88, P1117, DOI 10.1111/j.1349-7006.1997.tb00337.x; Nevalainen TJ, 1997, J HISTOCHEM CYTOCHEM, V45, P1109, DOI 10.1177/002215549704500808; Newberry RD, 1999, NAT MED, V5, P900, DOI 10.1038/11341; Nimmrich I, 1997, HUM GENET, V100, P345, DOI 10.1007/s004390050514; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Ouellette AJ, 1997, GASTROENTEROLOGY, V113, P1779, DOI 10.1053/gast.1997.v113.pm9352884; PAULUS U, 1993, J CELL SCI, V106, P473; PIAZZA GA, 1995, CANCER RES, V55, P3110; Podolin PL, 1998, MAMM GENOME, V9, P283, DOI 10.1007/s003359900749; Podolin PL, 1997, J IMMUNOL, V159, P1835; POTTER M, 1994, CANCER RES, V54, P969; PRAML C, 1995, CANCER RES, V55, P5504; Praml C, 1998, ONCOGENE, V17, P2009, DOI 10.1038/sj.onc.1202121; Qu XD, 1998, INFECT IMMUN, V66, P2791, DOI 10.1128/IAI.66.6.2791-2797.1998; Quesada CF, 1998, JPN J CANCER RES, V89, P392, DOI 10.1111/j.1349-7006.1998.tb00576.x; RAO CV, 1995, CANCER RES, V55, P1464; Rao CV, 1996, CANCER RES, V56, P532; Reddy BS, 1999, CANCER RES, V59, P3387; RIGGINS GJ, 1995, CANCER RES, V55, P5184; Ritland SR, 1999, CARCINOGENESIS, V20, P51, DOI 10.1093/carcin/20.1.51; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Shoemaker AR, 1997, BBA-REV CANCER, V1332, pF25, DOI 10.1016/S0304-419X(96)00041-8; Spirio LN, 1996, CANCER RES, V56, P955; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Taketo MM, 1998, INFLAMM RES, V47, pS112; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126; Tomlinson IPM, 1996, ANN HUM GENET, V60, P369, DOI 10.1111/j.1469-1809.1996.tb00434.x; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Weinrauch Y, 1998, J CLIN INVEST, V102, P633, DOI 10.1172/JCI3121; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; Yang ZY, 1998, CANCER LETT, V124, P187, DOI 10.1016/S0304-3835(97)00476-X; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	89	86	90	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 29	2000	19	28					3182	3192		10.1038/sj.onc.1203646	http://dx.doi.org/10.1038/sj.onc.1203646			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918573				2022-12-17	WOS:000088019200007
J	Margue, CM; Bernasconi, M; Barr, FG; Schafer, BW				Margue, CM; Bernasconi, M; Barr, FG; Schafer, BW			Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3/FKHR	ONCOGENE			English	Article						apoptosis; BCL-XL; PAX transcription factors; rhabdomyosarcoma	PAX3-FKHR FUSION PROTEIN; ALVEOLAR RHABDOMYOSARCOMA; MUSCLE DEVELOPMENT; CELL-SURVIVAL; GENES; EXPRESSION; DIFFERENTIATION; DOMAIN; MYOD; DNA	The aberrant expression of the transcription factors PAN3 and PAX3/FKHR associated with rhabdomyosarcoma (RMS), solid tumors displaying muscle cell features, suggests that these proteins play an important role in the pathogenesis of RMS. We could previously demonstrate that one of the oncogenic functions of PAS3 and PAX3/FKHR in RMS is protection from apoptosis, BCL-XL is a prominent anti-apoptotic protein present in normal skeletal muscle and RMS cells. In the present study, we establish that BCL-XL is transcriptionally modulated bai PAX3 and PAX3/FMHR, since enhanced expression of both PAX proteins stimulates transcription of endogenous BCL-XL mRNA in a cell type specific manner. Further, we present evidence that both PAX3 and PAX3/FKHR can transcriptionally activate the Bcl-x gene promoter in cotransfection assays. Using electrophoretic mobility shift assays, an ATTA binding site for PAX3 and PAX3/FKHR could be localized in the upstream promoter region (position -42 to -39), Finally, ectopic overexpression of either PAY3, PAX3/FKHR or BCL-XL can rescue tumor cells from apoptosis induced by antisense treatment. These results suggest that at least part of the anti-apoptotic effect of PAX3 and PAX3/FKHR is mediated through direct transcriptional modulation of the prominent anti-apoptotic protein BCL-XL.	Univ Zurich, Div Clin Chem & Biochem, CH-8032 Zurich, Switzerland; Swiss Fed Inst Technol, Inst Biochem, Zurich, Switzerland; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Pennsylvania	Schafer, BW (corresponding author), Univ Zurich, Div Clin Chem & Biochem, Steinwiesstr 75, CH-8032 Zurich, Switzerland.		Bernasconi, Michele/CAG-2492-2022; Bernasconi, Michele/GOH-1815-2022; Bernasconi, Michele/C-6734-2008; Bernasconi, Michele/A-1588-2008	Bernasconi, Michele/0000-0002-5746-8806; Bernasconi, Michele/0000-0002-5746-8806; Bernasconi, Michele/0000-0002-5746-8806; Bernasconi, Michele/0000-0002-5746-8806; Schafer, Beat/0000-0001-5988-2915				ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Borycki AG, 1999, DEVELOPMENT, V126, P1665; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; Daston G, 1996, DEVELOPMENT, V122, P1017; DAVIS RJ, 1994, CANCER RES, V54, P2969; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; Dibbert B, 1998, BLOOD, V92, P778, DOI 10.1182/blood.V92.3.778.415k38_778_783; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; FRANZ T, 1993, ANAT EMBRYOL, V187, P371; Frascella E, 1998, CANCER GENET CYTOGEN, V102, P104, DOI 10.1016/S0165-4608(97)00352-X; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Ginsberg JP, 1998, CANCER RES, V58, P3542; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Mansouri A, 1996, CURR OPIN CELL BIOL, V8, P851, DOI 10.1016/S0955-0674(96)80087-1; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Phelan SA, 1997, DIABETES, V46, P1189, DOI 10.2337/diabetes.46.7.1189; SCHAFER BW, 1994, NUCLEIC ACIDS RES, V22, P4574, DOI 10.1093/nar/22.22.4574; SCHAFER BW, 1998, GEN PHYSL BIOPHYS, V17, P1; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; Wang W, 1998, CANCER RES, V58, P4426; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Wiggan O, 1998, ONCOGENE, V16, P227, DOI 10.1038/sj.onc.1201534; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120	42	86	94	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2000	19	25					2921	2929		10.1038/sj.onc.1203607	http://dx.doi.org/10.1038/sj.onc.1203607			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323BG	10871843				2022-12-17	WOS:000087544500006
J	Bilanges, B; Varrault, A; Basyuk, E; Rodriguez, C; Mazumdar, A; Pantaloni, C; Bockaert, J; Theillet, C; Spengler, D; Journot, L				Bilanges, B; Varrault, A; Basyuk, E; Rodriguez, C; Mazumdar, A; Pantaloni, C; Bockaert, J; Theillet, C; Spengler, D; Journot, L			Loss of expression of the candidate tumor suppressor gene ZAC in breast cancer cell lines and primary tumors	ONCOGENE			English	Article						ZAC; breast tumors; tumor suppressor gene; methylation; 6q25	ZINC-FINGER PROTEIN; MAMMARY EPITHELIAL-CELLS; ESTROGEN-RECEPTOR GENE; DNA METHYLATION; CHROMOSOME 6Q; E-CADHERIN; FAMILIAL MELANOMA; GROWTH INHIBITOR; CPG METHYLATION; SOLID TUMORS	Loss of chromosome 6q21-qter is the second most frequent loss of chromosomal material in sporadic breast neoplasms suggesting the presence of at least one tumor suppressor gene on 6q, We recently isolated a cDNA encoding a new Zinc finger protein which we named ZAC according to its functional properties, namely induction of apoptosis and control of cell cycle progression. ZAC is expressed in normal mammary gland and maps to 6q24-q25, a recognized breast cancer hot spot on 6q, In the present report, we investigated the possible inactivation of ZAC in breast cancer cell lines and primary tumors, We detected no mutation in ZAC coding region in a panel of 45 breast tumors with allelic imbalance of 6q24-q25, However, a survey of eight breast cancer cell lines showed a deeply reduced (three cell lines) or complete loss of (five cell lines) ZAC expression. Treatment of three of these cell lines with the methylation-interfering agent 5-azacytidine induced ZAC re-expression, In addition, Northern blot and RNase protection assay analysis of ZAC expression in 23 unselected primary breast tumors showed a reduced expression in several samples. Together with its functional properties and chromosomal localization, these findings substantiate ZAC as a good candidate for the tumor suppressor gene on 6q24-q25.	CCIPE, CNRS, UPR 9023, F-34094 Montpellier 05, France; Ctr Rech CRLC Val Aurelle Paul Lamarque, CNRS, UMR 5535, Equipe Genome & Canc, F-34098 Montpellier 05, France; Max Planck Inst Psychiat, D-80804 Munich, Germany	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Max Planck Society	Journot, L (corresponding author), CCIPE, CNRS, UPR 9023, 141 Rue Cardonille, F-34094 Montpellier 05, France.		Journot, Laurent/T-9652-2018; Bilanges, Benoit/AAP-6078-2020; Theillet, Charles/O-7634-2018	Journot, Laurent/0000-0003-3499-8887; Theillet, Charles/0000-0001-5555-2759; Basyuk, Eugenia/0000-0001-9768-4557; Bilanges, Benoit/0000-0003-4400-3716				Abdollahi A, 1997, CANCER RES, V57, P2029; Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; Astrom AK, 1999, CANCER RES, V59, P918; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Bose S, 1998, ONCOGENE, V17, P123, DOI 10.1038/sj.onc.1201940; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; Chappell SA, 1997, BRIT J CANCER, V75, P1324, DOI 10.1038/bjc.1997.224; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; DEVILEE P, 1991, ONCOGENE, V6, P1705; Dhingra K, 1996, SEMIN ONCOL, V23, P436; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dobrovic A, 1997, CANCER RES, V57, P3347; Ellisen LW, 1998, ANNU REV MED, V49, P425; FERGUSON AT, 1995, CANCER RES, V55, P2279; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GRAFF JR, 1995, CANCER RES, V55, P5195; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hankins GR, 1996, ONCOGENE, V12, P2003; HENDERSON BE, 1988, CANCER RES, V48, P246; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Huynh H, 1996, CANCER RES, V56, P4865; HUYNH HT, 1995, CANCER RES, V55, P2225; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; KNUDSON AG, 1985, CANCER RES, V45, P1437; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; Malzahn K, 1998, VIRCHOWS ARCH, V433, P119, DOI 10.1007/s004280050226; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mertens F, 1997, CANCER RES, V57, P2765; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; NEGRINI M, 1994, CANCER RES, V54, P1331; Nishizaki T, 1997, GENE CHROMOSOME CANC, V19, P267, DOI 10.1002/(SICI)1098-2264(199708)19:4<267::AID-GCC9>3.0.CO;2-V; Noviello C, 1996, CLIN CANCER RES, V2, P1601; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Pagotto U, 1999, ENDOCRINOLOGY, V140, P987, DOI 10.1210/en.140.2.987; PETRANGELI E, 1995, BRIT J CANCER, V72, P973, DOI 10.1038/bjc.1995.444; Rejthar A, 1997, NEOPLASMA, V44, P370; Rhei E, 1997, CANCER RES, V57, P3657; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; Stirzaker C, 1997, CANCER RES, V57, P2229; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TAYLORPAPADIMITRIOU J, 1989, J CELL SCI, V94, P403; Teng DHF, 1997, CANCER RES, V57, P5221; Theile M, 1996, ONCOGENE, V13, P677; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Voz ML, 1998, ONCOGENE, V16, P1409, DOI 10.1038/sj.onc.1201660; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	69	86	89	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	1999	18	27					3979	3988		10.1038/sj.onc.1202933	http://dx.doi.org/10.1038/sj.onc.1202933			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435621				2022-12-17	WOS:000081327800008
J	Pereira, R; Quang, CT; Lesault, I; Dolznig, H; Beug, H; Ghysdael, J				Pereira, R; Quang, CT; Lesault, I; Dolznig, H; Beug, H; Ghysdael, J			FLI-1 inhibits differentiation and induces proliferation of primary erythroblasts	ONCOGENE			English	Article						friend erythroleukemia; FLI-1; erythroid differentiation; erythropoietin; cell proliferation; apoptosis	ERYTHROPOIETIN RECEPTOR; ERYTHROID-DIFFERENTIATION; TERMINAL DIFFERENTIATION; ECTOPIC EXPRESSION; DNA-BINDING; F-MULV; GENE; ACTIVATION; ERYTHROLEUKEMIA; VIRUS	Friend virus-induced erythroleukemia involves two members of the ETS family of transcriptional regulators, both activated via proviral insertion in the corresponding loci. Spi-1/PU.1 is expressed in the disease induced by the original Friend virus SFFV(F-MuLV) complex in adult mice. In contrast, FLI-1 is overexpressed in about 75% of the erythroleukemias induced by the F-MuLV helper virus in newborn mice, To analyse the consequences of the enforced expression of FLI-1 on erythroblast differentiation and proliferation and to compare its activity to that of PU.1/Spi-1, we used a heterologous system of avian primary erythroblasts previously described to study the cooperation between Spi-1/PU.1 and the other molecular alterations observed in SFFV-induced disease, FLI-1 was found: (i) to inhibit the apoptotic cell death program normally activated in erythroblasts following Epo deprivation; (ii) to inhibit the terminal differentiation program induced in these cells in response to Epo and; (iii) to induce their proliferation, However, in contrast to Spi-1/PU.1, the effects of FLI-1 on erythroblast, differentiation and proliferation did not require its cooperation with an abnormally activated form of the EpoR, Enhanced survival of FLI-1 expressing erythroblasts correlated with the upregulation of bcl2 expression, FLI-1 also prevented the rapid downregulation of cyclin D2 and D3 expression normally observed during Epo-induced differentiation and delayed the downregulation of several other genes involved in cell cycle or cell proliferation control, Our results show that overexpression of FLI-1 profoundly deregulates the normal balance between differentiation and proliferation in primary erythroblasts, Thus, the activation of FLI-1 expression observed at the onset of F-MuLV-induced erythroleukemia may provide a proliferative advantage to virus infected cells that would otherwise undergo terminal differentiation or cell death.	Ctr Univ Orsay, Inst Curie, Sect Rech, CNRS,UMR 146, F-91405 Orsay, France; Univ Vienna, Vienna Bioctr, Inst Mol Biol, A-1030 Vienna, Austria; Univ Vienna, Vienna Bioctr, Inst Mol Pathol, A-1030 Vienna, Austria	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); University of Vienna; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Pereira, R (corresponding author), Ctr Univ Orsay, Inst Curie, Sect Rech, CNRS,UMR 146, Bat 110, F-91405 Orsay, France.		Dolznig, Helmut/L-7005-2015; QUANG, christine TRAN/G-7508-2016; GHYSDAEL, Jacques/F-3377-2013	Dolznig, Helmut/0000-0002-6063-3585; 				AIZAWA S, 1990, EMBO J, V9, P2107, DOI 10.1002/j.1460-2075.1990.tb07379.x; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1977, EXP CELL RES, V107, P417, DOI 10.1016/0014-4827(77)90363-9; BOEHMELT G, 1994, CELL GROWTH DIFFER, V5, P221; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DELGADO MD, 1994, ONCOGENE, V9, P1723; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; FUERSTENBERG S, 1990, J VIROL, V64, P5891, DOI 10.1128/JVI.64.12.5891-5902.1990; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, V1, P29; HOATLIN ME, 1990, P NATL ACAD SCI USA, V87, P9985, DOI 10.1073/pnas.87.24.9985; HOWARD JC, 1993, ONCOGENE, V8, P2721; Howard JC, 1996, ONCOGENE, V12, P1405; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; Quang CT, 1997, EMBO J, V16, P5639, DOI 10.1093/emboj/16.18.5639; QUANG CT, 1995, ONCOGENE, V11, P1229; RABAULT B, 1994, J BIOL CHEM, V269, P28143; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SETH A, 1993, ONCOGENE, V8, P1783; STEINLEIN P, 1994, GROWTH FACTORS, V10, P1, DOI 10.3109/08977199409019599; Tarr K, 1997, J BIOL CHEM, V272, P9099; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	36	86	86	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1597	1608		10.1038/sj.onc.1202534	http://dx.doi.org/10.1038/sj.onc.1202534			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102630				2022-12-17	WOS:000078770700010
J	Reichel, M; Gillert, E; Nilson, I; Siegler, G; Greil, J; Fey, GH; Marschalek, R				Reichel, M; Gillert, E; Nilson, I; Siegler, G; Greil, J; Fey, GH; Marschalek, R			Fine structure of translocation breakpoints in leukemic blasts with chromosomal translocation t(4;11): the DNA damage-repair model of translocation	ONCOGENE			English	Article						ALL-1/MLL/HRX gene; AF4/FEL gene; chromosomal translocation t(4 ; 11); recombination	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; TOPOISOMERASE-II INHIBITORS; CLUSTER REGION; ALL-1 GENE; HOMOLOGOUS RECOMBINATION; 11Q23 TRANSLOCATIONS; CELL-LINE; EXON/INTRON STRUCTURE; DROSOPHILA-TRITHORAX	Chromosomal translocations t(4;11) are regularly associated with a specific type of acute leukemias and probably initiate the development of this disease. It has been proposed by others, that these translocations are mediated by recombinases of the immune system. The breakpoints on both derivative chromosomes for three t(4;11) leukemia-derived cell lines and primary blasts from two patients have been analysed here in detail. The results revealed that: (a) multiple double- or single-stranded DNA breaks must have occured near the translocation breakpoints on both participating chromosomes; and (b) DNA fragments flanked by these breaks must have either been deleted, inverted or duplicated during the translocation process. We found no evidence for the involvement of specific target sequences and recombinases of the immune system. Similar characteristic features were observed by re-interpretation of published t(6;11) and t(9;22) translocation data. Therefore we present a new model for the generation of these translocations which poses, that these translocations are reciprocal but not balanced at the fine structure level and that the DNA damage-repair machinery is likely involved in producing the final structure of the translocation breakpoint.	Univ Erlangen Nurnberg, Chair Genet, D-91058 Erlangen, Germany; Univ Erlangen Nurnberg, Childrens Hosp, D-91054 Erlangen, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg	Marschalek, R (corresponding author), Univ Erlangen Nurnberg, Chair Genet, Staudtstr 15, D-91058 Erlangen, Germany.		Siegler, Gabriele/AAE-4614-2019; Marschalek, Rolf/D-3404-2011	Marschalek, Rolf/0000-0003-4870-3445; Reichel, Martin/0000-0001-7886-2784				ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; Aplan PD, 1996, BLOOD, V87, P2649, DOI 10.1182/blood.V87.7.2649.bloodjournal8772649; BAER R, 1987, CELL, V50, P97, DOI 10.1016/0092-8674(87)90666-0; BAER R, 1985, CELL, V43, P705, DOI 10.1016/0092-8674(85)90243-0; BERNARD OA, 1995, LEUKEMIA, V9, P1487; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; CHEN CS, 1993, BLOOD, V82, P1080; CIMINO G, 1993, BLOOD, V82, P544; COFFIN JM, 1992, DEV BIOLOGICALS, V76, P141; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; DOMER PH, 1995, LEUKEMIA, V9, P1305; FELIX CA, 1993, CANCER RES, V53, P2954; GARCIA IS, 1991, ONCOGENE, V6, P577; GILLSUPER H, 1997, GENES CHROMOSOM CANC, V20, P185; GILLSUPER HJ, 1993, BLOOD, V82, P3705; GREIL J, 1994, BRIT J HAEMATOL, V86, P275, DOI 10.1111/j.1365-2141.1994.tb04726.x; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1994, CANCER RES, V54, P2327; GU Y, 1992, P NATL ACAD SCI USA, V89, P10464, DOI 10.1073/pnas.89.21.10464; HARRIMAN W, 1993, ANNU REV IMMUNOL, V11, P361, DOI 10.1146/annurev.iy.11.040193.002045; HARTL P, 1987, MOL CELL BIOL, V7, P2037, DOI 10.1128/MCB.7.6.2037; HUNGER SP, 1993, BLOOD, V81, P3197; IIDA S, 1992, LEUKEMIA RES, V16, P1155, DOI 10.1016/0145-2126(92)90113-L; KANEKO Y, 1986, BLOOD, V67, P484; KATZ F, 1988, BLOOD, V71, P1438; LAITINEN J, 1994, BIOTECHNIQUES, V17, P316; LANGE B, 1987, BLOOD, V70, P192; LITZ CE, 1993, BLOOD, V81, P1567; Marschalek R, 1997, LEUKEMIA LYMPHOMA, V27, P417, DOI 10.3109/10428199709058308; MARSCHALEK R, 1995, BRIT J HAEMATOL, V90, P308, DOI 10.1111/j.1365-2141.1995.tb05151.x; MURNANE JP, 1990, NUCLEIC ACIDS RES, V18, P2733, DOI 10.1093/nar/18.9.2733; Nilson I, 1996, BRIT J HAEMATOL, V93, P966, DOI 10.1046/j.1365-2141.1996.d01-1748.x; Nilson I, 1997, BRIT J HAEMATOL, V98, P157, DOI 10.1046/j.1365-2141.1997.1522966.x; PEDERSENBJERGAARD J, 1992, LEUKEMIA RES, V16, P733, DOI 10.1016/0145-2126(92)90150-6; PLESNER P, 1987, P NATL ACAD SCI USA, V84, P1936, DOI 10.1073/pnas.84.7.1936; PUI CH, 1990, BLOOD, V76, P1449; PUI CH, 1991, BLOOD, V77, P440; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; PUI CH, 1987, BLOOD, V69, P1289; PUI CH, 1990, LANCET, V336, P417, DOI 10.1016/0140-6736(90)91956-B; RABITTS TH, 1994, NATURE, V372, P143; Rasio D, 1996, CANCER RES, V56, P1766; ROTH DB, 1991, NUCLEIC ACIDS RES, V19, P7201, DOI 10.1093/nar/19.25.7201; SCHICHMAN SA, 1994, CANCER RES, V54, P4277; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; So CW, 1997, CANCER RES, V57, P117; Stanulla M, 1997, LEUKEMIA, V11, P490, DOI 10.1038/sj.leu.2400632; Stanulla M, 1997, MOL CELL BIOL, V17, P4070, DOI 10.1128/MCB.17.7.4070; Strout MP, 1998, P NATL ACAD SCI USA, V95, P2390, DOI 10.1073/pnas.95.5.2390; Strout MP, 1996, GENE CHROMOSOME CANC, V16, P204, DOI 10.1002/(SICI)1098-2264(199607)16:3<204::AID-GCC8>3.0.CO;2-2; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VANDERPOEL SZ, 1991, P NATL ACAD SCI USA, V88, P10735; Varmus H., 1989, MOBILE DNA; ZHANG JG, 1995, BRIT J HAEMATOL, V90, P138, DOI 10.1111/j.1365-2141.1995.tb03392.x	56	86	89	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	1998	17	23					3035	3044		10.1038/sj.onc.1202229	http://dx.doi.org/10.1038/sj.onc.1202229			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881706				2022-12-17	WOS:000077427800011
J	Chappuis-Flament, S; Pasini, A; De Vita, G; Segouffin-Cariou, C; Fusco, A; Attie, T; Lenoir, GM; Santoro, M; Billaud, M				Chappuis-Flament, S; Pasini, A; De Vita, G; Segouffin-Cariou, C; Fusco, A; Attie, T; Lenoir, GM; Santoro, M; Billaud, M			Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines	ONCOGENE			English	Article						MEN 2; Hirschsprung disease; RET receptor; tyrosine kinase	MEDULLARY-THYROID CARCINOMA; ENDOCRINE NEOPLASIA TYPE-2; TYROSINE KINASE DOMAIN; HIRSCHSPRUNGS-DISEASE; PROTOONCOGENE MUTATIONS; POINT MUTATION; BIOLOGICAL PROPERTIES; GERMLINE MUTATION; RESPONSE GENES; PHENOTYPE	The RET gene encodes a receptor tyrosine kinase whose function is essential during the development of kidney and the intestinal nervous system, Germline mutations affecting one of five cysteines (Cys609, 611, 618, 620 and 634) located in the juxtamembrane domain of the RET receptor are responsible for the vast majority of two cancer-prone disorders, multiple endocrine neoplasia type 2A (MEN 2A) and familial medullary thyroid carcinoma (FMTC). These mutations lead to the replacement of a cysteine by an alternate amino acid, Mutations of the RET gene are also the underlying genetic cause of Hirschsprung disease (HSCR), a congenital aganglionosis of the hindgut, In a fraction of kindreds, MEN 2A cosegregate with HSCR and affected individuals carry a single mutation at codons 609, 618 or 620, To examine the consequences of cysteine substitution on RET function, we have introduced a Cys to Arg mutation into the wild-type RET at either codons 609, 618, 620, 630 or 634, We now report that each mutation induces a constitutive catalytic activity due to the aberrant disulfide homodimerization of RET, However, mutations 630 and 634 activate RET more strongly than mutations 609, 618 or 620 as demonstrated by quantitative assays in rodent fibroblasts and pheochromocytoma PC12 cells, Biochemical analysis revealed that mutations 618 and 620, and to a lesser extent mutation 609, result in a marked reduction of the level of RET at the cell surface and as a consequence decrease the amount of RET covalent dimer, These findings provide a molecular basis explaining the range of phenotype engendered by alterations of RET cysteines and suggest a novel mechanism whereby mutations of cysteines 609, 618 and 620 exert both activating and inactivating effects.	CNRS UMR 5641, Genet Lab, F-69373 Lyon 08, France; Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Reggio Calabria, Fac Med & Chirurg Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; Hop Necker Enfants Malad, Unite Rech Handicaps Genet Enfant, INSERM U393, F-75743 Paris, France; Hop Necker Enfants Malad, Dept Genet, F-75743 Paris, France	Centre National de la Recherche Scientifique (CNRS); University of Naples Federico II; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Billaud, M (corresponding author), CNRS UMR 5641, Genet Lab, 8 Ave Rockefeller, F-69373 Lyon 08, France.		Billaud, Marc N/M-6954-2013; ATTIE-BITACH, Tania/K-1453-2017; De Vita, Gabriella/H-4422-2011	ATTIE-BITACH, Tania/0000-0002-1155-3626; De Vita, Gabriella/0000-0002-7302-1174; Fusco, Alfredo/0000-0003-3332-5197				ANGRIST M, 1995, HUM MOL GENET, V4, P821, DOI 10.1093/hmg/4.5.821; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Berndt I, 1998, J CLIN ENDOCR METAB, V83, P770, DOI 10.1210/jc.83.3.770; Blank RD, 1996, CANCER, V78, P1996, DOI 10.1002/(SICI)1097-0142(19961101)78:9<1996::AID-CNCR22>3.3.CO;2-5; BOLINO A, 1995, ONCOGENE, V10, P2415; BORST MJ, 1995, SURGERY, V117, P386, DOI 10.1016/S0039-6060(05)80057-1; Bugalho MJ, 1997, EUR J ENDOCRINOL, V136, P423, DOI 10.1530/eje.0.1360423; CALIFANO D, 1995, ONCOGENE, V11, P107; Carlomagno F, 1997, CANCER RES, V57, P391; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Caron P, 1996, J CLIN ENDOCR METAB, V81, P2731, DOI 10.1210/jc.81.7.2731; Chakravarti A, 1996, HUM MOL GENET, V5, P303; Decker RA, 1998, HUM MOL GENET, V7, P129, DOI 10.1093/hmg/7.1.129; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; Fink M, 1996, INT J CANCER, V69, P312, DOI 10.1002/(SICI)1097-0215(19960822)69:4<312::AID-IJC13>3.0.CO;2-7; FrankRaue K, 1996, J CLIN ENDOCR METAB, V81, P1780, DOI 10.1210/jc.81.5.1780; Gershon MD, 1997, CURR OPIN NEUROBIOL, V7, P101, DOI 10.1016/S0959-4388(97)80127-4; GOODFELLOW PJ, 1995, J NATL CANCER I, V87, P1515, DOI 10.1093/jnci/87.20.1515; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Hofstra RMW, 1997, J CLIN ENDOCR METAB, V82, P4176, DOI 10.1210/jc.82.12.4176; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; Isidoro C, 1996, J BIOL CHEM, V271, P26138, DOI 10.1074/jbc.271.42.26138; Ito S, 1997, CANCER RES, V57, P2870; Iwashita T, 1996, HUM MOL GENET, V5, P1577, DOI 10.1093/hmg/5.10.1577; JANSSENTIMMEN U, 1989, GENE, V80, P325, DOI 10.1016/0378-1119(89)90296-5; Kitamura Y, 1997, ONCOGENE, V14, P3103, DOI 10.1038/sj.onc.1201102; KOMMINOTH P, 1995, CANCER, V76, P479; Lindsay RM, 1996, NEURON, V17, P571, DOI 10.1016/S0896-6273(00)80189-0; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; Moers AMJ, 1996, AM J MED, V101, P635, DOI 10.1016/S0002-9343(96)00330-0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, HUM MOL GENET, V3, P2163, DOI 10.1093/hmg/3.12.2163; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; MULLIGAN LM, 1995, J CLIN ENDOCR METAB, V80, P1989, DOI 10.1210/jc.80.7.1989; Pasini A, 1997, ONCOGENE, V15, P393, DOI 10.1038/sj.onc.1201199; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pelet A, 1998, J CLIN INVEST, V101, P1415, DOI 10.1172/JCI375; POSSENTI R, 1992, P NATL ACAD SCI USA, V89, P3815, DOI 10.1073/pnas.89.9.3815; Reynolds Lucinda F., 1995, Current Opinion in Pediatrics, V7, P702; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROSSEL M, 1995, HUM GENET, V95, P403; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUFFENECKER I, 1994, HUM MOL GENET, V3, P1939, DOI 10.1093/hmg/3.11.1939; Smith DP, 1997, ONCOGENE, V15, P1213, DOI 10.1038/sj.onc.1201481; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TANIGUCHI M, 1991, BIOCHEM BIOPH RES CO, V181, P416, DOI 10.1016/S0006-291X(05)81435-4; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; Wada M, 1996, BIOCHEM BIOPH RES CO, V218, P606, DOI 10.1006/bbrc.1996.0107	61	86	87	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	1998	17	22					2851	2861		10.1038/sj.onc.1202202	http://dx.doi.org/10.1038/sj.onc.1202202			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	143ZA	9879991				2022-12-17	WOS:000077286400005
J	Davison, TS; Yin, P; Nie, E; Kay, C; Arrowsmith, CH				Davison, TS; Yin, P; Nie, E; Kay, C; Arrowsmith, CH			Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome	ONCOGENE			English	Article						p53; oligomerization; Li-Fraumeni syndrome; DNA binding	TUMOR-SUPPRESSOR P53; TETRAMERIZATION DOMAIN; DNA-BINDING; MUTATIONS; GENE; INHIBITOR; KINASES; SYSTEM; P21	Recently two germline mutations in the oligomerization domain of p53 have been identified in patients with Li-Fraumeni and Li-Fraumeni-like Syndromes. We have used biophysical and biochemical methods to characterize these two mutants in order to better understand their functional defects and the role of the p53 oligomerization domain (residues 325 -355) in oncogenesis, We find that residues 310-360 of the L344P mutant are monomeric, apparently unfolded and cannot interact with wild-type (WT) p53. The full length L344P protein is unable to bind sequence specifically to DNA and is therefore an inactive, but not a dominant negative mutant, R337C, on the other hand, can form dimers and tetramers, can hetero-oligomerize with WTp53 and can bind to a p53 consensus element. However, the thermal stability of R337C is much lower than that of M'Tp53 and at physiological temperatures more than half of this mutant is less than tetrameric, Thus, the R337C mutant retains some functional activity yet leads to a predisposition to cancer, suggesting that even partial inactivation of p53 oligomerization is sufficient for accelerated tumour progression.	Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Alberta	Arrowsmith, CH (corresponding author), Univ Toronto, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Arrowsmith, Cheryl/0000-0002-4971-3250				CARIELLO NF, 1994, CANCER RES, V54, P4454; Casey G, 1996, ONCOGENE, V13, P1971; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1995, ONCOGENE, V10, P1485; Ishioka C, 1997, BIOCHEM BIOPH RES CO, V232, P54, DOI 10.1006/bbrc.1997.6216; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lomax ME, 1997, ONCOGENE, V14, P1869, DOI 10.1038/sj.onc.1201133; LOMAX ME, 1998, IN PRESS ONCOGENE; MIYASHITA T, 1995, CELL, V80, P293; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Sambrook J., 1989, MOL CLONING; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TARUNINA M, 1993, ONCOGENE, V8, P3165; Varley JM, 1996, ONCOGENE, V12, P2437; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Wagner P, 1995, FEBS LETT, V377, P155, DOI 10.1016/0014-5793(95)01329-6; Wagner P, 1998, ONCOGENE, V16, P105, DOI 10.1038/sj.onc.1201510; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	32	86	87	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					651	656		10.1038/sj.onc.1202062	http://dx.doi.org/10.1038/sj.onc.1202062			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704931				2022-12-17	WOS:000075195300013
J	Mandal, M; Bandyopadhyay, D; Goepfert, TM; Kumar, R				Mandal, M; Bandyopadhyay, D; Goepfert, TM; Kumar, R			Interferon-induces expression of cyclin-dependent kinase-inhibitors p21(WAF1) and p27(Kip1) that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK)	ONCOGENE			English	Article						interferons; cell cycle; CDK; CDK-inhibitors; CDK-activating kinase	SENSITIVE HEMATOPOIETIC-CELLS; DAUDI CELLS; RETINOBLASTOMA PROTEIN; ALPHA-INTERFERON; INTERLEUKIN-6 SUPPRESS; GROWTH ARREST; 3T3 CELLS; GENES; P21; G1	To understand the mechanism of interferon (IFN)-mediated suppression of cell cycle progression, we have earlier shown that IFN-alpha enhances the expression of underphosphorylated retinoblastoma protein by inhibiting the cyclin-dependent kinase-2 (CDK-2) activity (Kumar and Atlas, Proc. Natl, Acad, Sci. 89, 6599-6603, 1992; Zhang and Kumar, Biochem. Biophysi. Res. Comm., 200, 522-528, 1994), In the studies presented here, we investigated the mechanism of inhibition of CDKs in IFN-treated cells by delineating the potential role(s) of CDK-inhibitors (CKIs) and CDK-activating kinase (CAK). We report that IFN-alpha inhibits the H-1 kinase activity associated with CDK-4 or CDK-2 due to induction of expression of CDK-inhibitor p21(WAF1) (but not p27(Kip1)) as its immunodepletion from IFN-treated extracts restored the CDK-associated H-1 kinase activity, In addition, we also show that IFN-gamma induces expression of CDK-inhibitors p21(WAF1) and p27(Kip1) and inhibited the H-1 kinase activity associated with CDK-2 or CDK-4, The observed IFN-gamma-mediated inhibition of CDK-2 and CDK-4 kinase activity was due to enhanced interactions with p21(WAF1) and p27(Kip1), respectively, We also demonstrated that IFN-induced CKIs prevent CAK from activating the CDK-2 as immunodepletion of induced CKIs from the inhibitory extracts resulted in the restoration of CAK-mediated activation of CDK-2.	Univ Texas, Md Anderson Canc Ctr, Dept Clin Invest, Cell Growth Regulat Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Clin Invest, Cell Growth Regulat Lab, Cell Growth Regulat Lab, Houston, TX 77030 USA.		Mandal, Mahitosh/GMW-6195-2022	Mandal, Mahitosh/0000-0003-3861-3323	NCI NIH HHS [CA56564] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; BURKE LC, 1992, ONCOGENE, V7, P783; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; CLARKE PR, 1995, CURR BIOL, V5, P40, DOI 10.1016/S0960-9822(95)00013-3; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; HALL M, 1995, ONCOGENE, V11, P1581; HARPER JW, 1993, CELL, V75, P805; Harvat BL, 1996, CELL GROWTH DIFFER, V7, P289; Hobeika AC, 1997, ONCOGENE, V14, P1165, DOI 10.1038/sj.onc.1200939; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Korutla L, 1996, ANTICANCER RES, V16, P2789; KUMAR R, 1994, J BIOL CHEM, V269, P25437; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; KUMAR R, 1989, CANCER RES, V49, P5180; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; MOORE RN, 1984, SCIENCE, V223, P178, DOI 10.1126/science.6606850; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Peng D, 1996, CANCER RES, V56, P3666; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.bi.56.070187.003455; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; SEROZ T, 1995, CURR OPIN GENET DEV, V5, P217, DOI 10.1016/0959-437X(95)80011-5; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SOKAWA Y, 1977, NATURE, V268, P236, DOI 10.1038/268236a0; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAMADA H, 1994, MOL CELL BIOCHEM, V136, P117, DOI 10.1007/BF00926071; Yamada H, 1995, MOL CELL BIOCHEM, V152, P149, DOI 10.1007/BF01076077; ZHANG KR, 1994, BIOCHEM BIOPH RES CO, V200, P522, DOI 10.1006/bbrc.1994.1479; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1	42	86	89	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					217	225		10.1038/sj.onc.1201529	http://dx.doi.org/10.1038/sj.onc.1201529			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464540				2022-12-17	WOS:000071427100009
J	Barboule, N; Chadebech, P; Baldin, V; Vidal, S; Valette, A				Barboule, N; Chadebech, P; Baldin, V; Vidal, S; Valette, A			Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line	ONCOGENE			English	Article						p21; paclitaxel; p34(cdc2) activity; mitotic exit	CYCLIN-DEPENDENT KINASES; HUMAN OVARIAN-CARCINOMA; TAXOL-INDUCED APOPTOSIS; LEUKEMIA-CELLS; GROWTH ARREST; DNA-DAMAGE; EXPRESSION; ACTIVATION; P53; DIFFERENTIATION	It has been shown recently that expression of p21 is enhanced by paclitaxel, This cytotoxic compound induces mitotic spindle damage resulting in blockade of the mitotic cell cycle associated or not with apoptotic cell death, In the present study, we showed that, in MCF-7 cells, paclitaxel induced accumulation of p21 in cells with a G2/M DNA content, corresponding to cells either in abnormal mitosis or in an interphase-like state (decondensed chromatin) with multiple nuclei, In MCF-7 cells, the increase in p21 was subsequent to the mitotic arrest and was associated with the exit from abnormal mitosis leading to formation of cells with micronuclei. In this cell line, we noted a relationship between the elevation of p21 expression and the inhibition of p34(cdc2) activity, High levels of p21 protein were also found to be associated with inactive p34(cdc2)/cyclin B protein complex after treatment with paclitaxel, Treatment with p21 antisense oligonucleotide partially blocked induction of p21 expression by paclitaxel and significantly reduced survival of MCF-7 cells exposed to this agent, In NIH-OVCAR-3 cells, which are deficient in basal and paclitaxel-induced p21 expression, paclitaxel led to a prolonged activation of p34(cdc2) and a delayed mitotic exit associated with apoptotic cell death, These observations suggest that p21 is not required for the mitotic arrest in response to paclitaxel, but argue in favor of a role for this inhibitor in facilitating the exit from abnormal mitosis, This effectively enhances cell survival after paclitaxel-induced spindle-damage.	IPBS,CNRS,F-31077 TOULOUSE,FRANCE	Centre National de la Recherche Scientifique (CNRS)			BALDIN, Véronique/Y-8397-2019; CHADEBECH, Philippe/ABB-4423-2020	BALDIN, Véronique/0000-0001-8523-0494; CHADEBECH, Philippe/0000-0003-0757-4309				ANDREASSEN PR, 1994, J CELL BIOL, V127, P789, DOI 10.1083/jcb.127.3.789; BARBOULE N, 1995, INT J CANCER, V63, P611, DOI 10.1002/ijc.2910630502; BHALLA K, 1993, LEUKEMIA, V7, P563; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Chen J, 1996, ONCOGENE, V13, P1395; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P421; Debernardis D, 1997, CANCER RES, V57, P870; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONALDSON KL, 1994, CELL GROWTH DIFFER, V5, P1041; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Gorospe M, 1996, CANCER RES, V56, P475; Gorospe M, 1996, MOL CELL BIOL, V16, P762; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; JIANG HP, 1994, ONCOGENE, V9, P3397; Jordan MA, 1996, CANCER RES, V56, P816; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Lafon C, 1996, CELL GROWTH DIFFER, V7, P1095; LEVEDAKOU EN, 1995, CANCER RES, V55, P2500; LI Y, 1994, ONCOGENE, V9, P2261; LIEBMANN JE, 1993, BRIT J CANCER, V68, P1104, DOI 10.1038/bjc.1993.488; LONG BH, 1994, CANCER RES, V54, P4355; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAZARS P, 1995, FEBS LETT, V362, P295, DOI 10.1016/0014-5793(95)00247-7; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; ROWINSKY EK, 1988, CANCER RES, V48, P4093; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIMIZU T, 1995, CANCER RES, V55, P228; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TANG C, 1994, LEUKEMIA, V8, P1960; TISHLER RB, 1995, CANCER RES, V55, P6021; TRIELLI MO, 1996, J CELL BIOL, V3, P689; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359	45	86	90	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2867	2875		10.1038/sj.onc.1201469	http://dx.doi.org/10.1038/sj.onc.1201469			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419978				2022-12-17	WOS:A1997YJ80300013
J	McCormack, SJ; Brazinski, SE; Moore, JL; Werness, BA; Goldstein, DJ				McCormack, SJ; Brazinski, SE; Moore, JL; Werness, BA; Goldstein, DJ			Activation of the focal adhesion kinase signal transduction pathway in cervical carcinoma cell lines and human genital epithelial cells immortalized with human papillomavirus type 18	ONCOGENE			English	Article						cell adhesion molecules; focal adhesion kinase; papillomaviruses; protein-tyrosine kinases; signal transduction	PAXILLIN TYROSINE PHOSPHORYLATION; RETINOBLASTOMA GENE-PRODUCT; GROWTH-FACTOR; HUMAN KERATINOCYTES; EXTRACELLULAR-MATRIX; PROTEIN; TRANSFORMATION; BINDING; DOMAIN; DNA	The inappropriate activation of protein-tyrosine kinases (PTKs) has been associated with initiation and progression of several types of human cancers. We therefore postulated that immortalization by DNA tumor viruses results in the induction of PTKs fundamental to these processes. An RT-PCR-based screen was thus used to identify PTKs that were abundantly expressed in HPV-18-immortalized epithelial cells and HPV-containing carcinoma cell lines. One of the genes isolated in this screen was the focal adhesion kinase (FAK; pp125(FAK)), a cytoplasmic protein kinase that is activated in v-src transformed cells or by stimulation with mitogenic polypeptides. FAK also becomes catalytically active upon integrin engagement with extracellular matrix proteins, such as fibronectin. We found that FAK expression and activity were significantly elevated in HPV-18 E6/E7-immortalized human genital epithelial cells relative to their primary cell counterparts. Protein expression and tyrosine phosphorylation of the putative FAK substrate, paxillin, were also notably increased upon HPV-18 immortalization of genital epithelial cells and in HPV-containing cervical carcinoma cell lines. Most significantly, these cells expressed markedly higher levels of both intracellular and extracellular fibronectin, thus providing a mechanism for activation of FAK and increased tyrosine phosphorylation of paxillin. These findings suggest a role for the integrin/FAK-mediated signaling pathway in cervical carcinogenesis and represent one of the first demonstrations of a tyrosine kinase whose activity is elevated following viral immortalization.	GEORGETOWN UNIV, MED CTR, VINCENT T LOMBARDI CANC RES CTR, WASHINGTON, DC 20007 USA; UNIV MISSISSIPPI, MED CTR, DEPT OB GYN, JACKSON, MS 39216 USA; ROSWELL PK CANC INST, DEPT PATHOL, BUFFALO, NY USA	Georgetown University; University of Mississippi; University of Mississippi Medical Center; Roswell Park Cancer Institute					NATIONAL CANCER INSTITUTE [R29CA063044, P50CA058185] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA-63044, IP50CA58185] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BARBOSA MS, 1989, ONCOGENE, V4, P1529; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; DAGNINO L, 1995, CELL GROWTH DIFFER, V6, P191; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DURST M, 1987, ONCOGENE, V1, P251; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FERENCZY A, 1987, CERVIVAL INTRAEPITHE, P177; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1994, J VIROL, V68, P4432, DOI 10.1128/JVI.68.7.4432-4441.1994; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HANKS SK, 1991, METHOD ENZYMOL, V200, P525; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; IMAI Y, 1991, J VIROL, V65, P4966, DOI 10.1128/JVI.65.9.4966-4972.1991; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MORRIS JDH, 1993, ONCOGENE, V8, P893; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; OWENS LV, 1995, CANCER RES, V55, P2752; PARSONS JT, 1994, J CELL SCI, P109; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; RANKIN S, 1994, J BIOL CHEM, V269, P704; RHIM JS, 1994, P NATL ACAD SCI USA, V91, P11874, DOI 10.1073/pnas.91.25.11874; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SHEIBANI N, 1991, CANCER RES, V51, P5967; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; STOPPLER H, 1994, INTERVIROLOGY, V37, P168; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1994, J CELL SCI, V107, P1583; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILKS AF, 1991, METHOD ENZYMOL, V200, P533; WOODWORTH CD, 1988, CANCER RES, V48, P4620; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; YANKASKAS JR, 1993, AM J PHYSIOL, V264, pC1219, DOI 10.1152/ajpcell.1993.264.5.C1219; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	54	86	87	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	1997	15	3					265	274		10.1038/sj.onc.1201186	http://dx.doi.org/10.1038/sj.onc.1201186			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233761				2022-12-17	WOS:A1997XK99900003
J	Berner, JM; MezaZepeda, LA; Kools, PFJ; Forus, A; Schoenmakers, EFPM; VandeVen, WJM; Fodstad, O; Myklebost, O				Berner, JM; MezaZepeda, LA; Kools, PFJ; Forus, A; Schoenmakers, EFPM; VandeVen, WJM; Fodstad, O; Myklebost, O			HMGIC, the gene for an architectural transcription factor, is amplified and rearranged in a subset of human sarcomas	ONCOGENE			English	Article						chromosome 12q13-15; amplicon; MAR; MDM2; HMGIC	GENOMIC HYBRIDIZATION ANALYSIS; MULTIPLE-ABERRATION REGION; SOFT-TISSUE SARCOMAS; MESSENGER-RNA; SOLID TUMORS; AMPLIFICATION; PROTEIN; MDM2; EXPRESSION; GLI	Amplified segments of the long arm of chromosome 12 are frequently observed in human sarcomas, In most cases there are separate amplified regions around the MDM2 and CDK4 genes, Here we show recurrent amplification of a third region encompassing HMGIC, a human architectural transcription factor gene, Reduced amplification frequency of sequences flanking the gene was observed, indicating that inclusion of this third region in the amplicons is also selected for, In three samples only the 5' part of HMGIC was amplified, suggesting preferential loss of the 3' part of the gene preceding or during amplification, In several other samples rearrangement of the gene was observed, Expression analysis showed transcripts of aberrant sizes, lacking 3' sequences, and 3' RACE of one sample revealed replacement of exons 4 and 5 with ectopic sequences, This truncation of HMGIC resembles that reported for translocations of HMGIC in benign tumors, including Lipomas, and it is striking that the gene was frequently amplified or rearranged in web differentiated Liposarcomas, the malignant counterpart of lipomas, It seems conceivable that high levels of either full length or truncated hmgic could be relevant for the etiology of these tumors.	NORWEGIAN RADIUM HOSP, DEPT TUMOR BIOL, B-3000 OSLO, NORWAY; CATHOLIC UNIV LEUVEN VIB, CTR HUMAN GENET, MOL ONCOL LAB, LOUVAIN, BELGIUM	Flanders Institute for Biotechnology (VIB); KU Leuven			Meza-Zepeda, Leonardo Andres/CAG-5229-2022; Myklebost, Ola/E-9335-2010	Meza-Zepeda, Leonardo Andres/0000-0003-3056-212X; Myklebost, Ola/0000-0002-2866-3223				ASHAR HR, 1995, CELL, V82, P57; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; DALCIN P, 1993, CANCER GENET CYTOGEN, V68, P85, DOI 10.1016/0165-4608(93)90001-3; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P15, DOI 10.1002/gcc.2870140104; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P8, DOI 10.1002/gcc.2870140103; FORUS A, 1994, CANCER GENET CYTOGEN, V78, P165, DOI 10.1016/0165-4608(94)90085-X; FORUS A, 1991, CYTOGENET CELL GENET, V58, P1977; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HUANG LS, 1985, P NATL ACAD SCI USA, V82, P6825, DOI 10.1073/pnas.82.20.6825; KAZMIERCZAK B, 1995, CANCER RES, V55, P6038; Kazmierczak B, 1996, ONCOGENE, V12, P515; KHATIB ZA, 1993, CANCER RES, V53, P5535; Kools PFJ, 1996, CANCER GENET CYTOGEN, V91, P1, DOI 10.1016/S0165-4608(96)00109-4; MAELANDSMO GM, 1995, BRIT J CANCER, V72, P393, DOI 10.1038/bjc.1995.344; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PATEL UA, 1994, BIOCHEM BIOPH RES CO, V201, P63, DOI 10.1006/bbrc.1994.1669; PEDEUTOUR F, 1994, GENE CHROMOSOME CANC, V10, P85, DOI 10.1002/gcc.2870100203; REEVES R, 1990, J BIOL CHEM, V265, P8573; ROBERTS WM, 1989, CANCER RES, V49, P5407; SCHAJOWICH F, 1993, HISTOLOGICAL TYPING; SCHOENMAKERS EFPM, 1995, GENOMICS, V29, P665, DOI 10.1006/geno.1995.9952; SCHOENMAKERS EFPM, 1994, GENOMICS, V20, P210, DOI 10.1006/geno.1994.1155; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; SMITH SH, 1992, CANCER RES, V52, P3746; VANDEVEN WJM, 1995, GENE CHROMOSOME CANC, V12, P296; WANSCHURA S, 1995, GENE CHROMOSOME CANC, V14, P68, DOI 10.1002/gcc.2870140112; Weiss SW, 1994, WHO HISTOLOGICAL CLA, V2nd; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	35	86	89	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	1997	14	24					2935	2941		10.1038/sj.onc.1201135	http://dx.doi.org/10.1038/sj.onc.1201135			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205100				2022-12-17	WOS:A1997XF55500007
J	Ogretmen, B; Safa, AR				Ogretmen, B; Safa, AR			Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells	ONCOGENE			English	Article						deleted p53; multidrug resistance; MCF-7/Adr	ADRIAMYCIN-RESISTANT; GROWTH SUPPRESSION; P-GLYCOPROTEIN; GENE; MUTATIONS; BCL-2; TRANSACTIVATION; MECHANISMS; PROMOTER; MUTANTS	Multidrug resistance in MCF-7/Adr human breast cancer cells is mediated by several mechanisms including overexpression of the MDR1 gene product, P-glycoprotein and glutathion-related detoxifying enzymes. Mutations in the p53 tumor suppressor protein have been reported to play a role in the development of resistance to DNA damaging agents in several human cancer cells, In the present study we have assessed the mutational status of the p53 protein and its expression levels, degree of stability and cellular localization to investigate whether it is involved in modulating multidrug resistance in MCF-7/Adr cells compared to sensitive MCF-7 cells, As revealed by immunofluorescence microscopy using the anti-p53 mouse monoclonal antibody DO-1, wild-type p53 is sequestered in the cytoplasm of MCF-7 cells, whereas in MCF-7/Adr cells, the protein is localized in the nucleus, The sequencing of full-length p53 cDNA revealed a 21 bp deletion in its one of the four conserved regions within the conformational domain, spanning codons 126-133 at exon five, in MCF-7/Adr cells, Moreover, detection of ThaI polymorphism of codon 72 showed that MCF-7 cells predominantly express wild-type p53 with proline, while mutated p53 in MCF-7/Adr cells contains an arginine residue at codon 72, In addition, we demonstrate that the half-life of p53 in MCF-7 cells is less than 30 min while the mutated protein is more stable; its half-life is about 4 h in MCF-7/Adr cells, Thus, this study demonstrates that the deletion of codons 126-133 in p53 causes increased stability, overexpression and nuclear localization of the protein in multidrug resistant MCF-7/Adr cells, and further suggests that mutated p53 might be involved in the development of multidrug resistance in this cell line.	MED UNIV S CAROLINA,HOLLINGS CANC CTR,DEPT EXPT ONCOL,CHARLESTON,SC 29424	Medical University of South Carolina					NATIONAL CANCER INSTITUTE [R01CA056078] Funding Source: NIH RePORTER; NCI NIH HHS [CA-56078] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARA S, 1990, NUCLEIC ACIDS RES, V18, P4961, DOI 10.1093/nar/18.16.4961; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; FAIRCHILD CR, 1990, MOL PHARMACOL, V37, P801; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FAN SJ, 1995, CANCER RES, V55, P1649; FAN SJ, 1994, CANCER RES, V54, P5824; FUCHS B, 1995, ONCOGENE, V10, P789; GANT TW, 1992, NUCLEIC ACIDS RES, V20, P2841, DOI 10.1093/nar/20.11.2841; GOLDSMITH ME, 1995, J BIOL CHEM, V270, P1894, DOI 10.1074/jbc.270.4.1894; HALDAR S, 1994, CANCER RES, V54, P2095; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LANDESMAN Y, 1994, ONCOGENE, V9, P1241; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MARTIN TE, 1987, J CELL BIOL, V105, P2069, DOI 10.1083/jcb.105.5.2069; MAXWELL SA, 1994, CRIT REV ONCOGENESIS, V5, P23, DOI 10.1615/CritRevOncog.v5.i1.20; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; NEGRINI M, 1994, CANCER RES, V54, P1818; NGUYEN KT, 1994, ONCOL RES, V6, P71; OCONNOR PM, 1993, CANCER RES, V53, P4776; OGRETMEN B, 1995, BIOTECHNIQUES, V19, P374; OGRETMEN B, 1996, INT J CANCER, V67, P1; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROUBY SE, 1993, BLOOD, V82, P3452; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SAFA AR, 1994, BIOCHEMISTRY-US, V33, P256, DOI 10.1021/bi00167a034; SEGAWA K, 1993, FEBS LETT, V329, P283, DOI 10.1016/0014-5793(93)80238-P; SHAY JW, 1992, MUTAT RES, V277, P163, DOI 10.1016/0165-1110(92)90003-R; TAKAHASHI K, 1993, MOL CARCINOGEN, V8, P58, DOI 10.1002/mc.2940080112; TAKAHASHI T, 1991, BIOTECHNIQUES, V11, P166; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; WELLS WW, 1995, FREE RADICAL BIO MED, V18, P699, DOI 10.1016/0891-5849(94)00188-P; WOSIKOWSKI K, 1995, CELL GROWTH DIFFER, V6, P1395; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529	39	86	88	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 30	1997	14	4					499	506		10.1038/sj.onc.1200855	http://dx.doi.org/10.1038/sj.onc.1200855			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053847				2022-12-17	WOS:A1997WE36400013
J	Chung, GTY; Sundaresan, V; Hasleton, P; Rudd, R; Taylor, R; Rabbitts, PH				Chung, GTY; Sundaresan, V; Hasleton, P; Rudd, R; Taylor, R; Rabbitts, PH			Sequential molecular genetic changes in lung cancer development	ONCOGENE			English	Article						chromosome 3; p53; LOH; pre-neoplasia; dysplasia; tumour progression	SMALL-CELL; SHORT ARM; P53 PROTEIN; DELETION; ABNORMALITIES; CHROMOSOME-3; EXPRESSION; CARCINOMA; HETEROZYGOSITY; ACCUMULATION	Epithelial tumours develop through a sequence of preinvasive lesions of increasing disarray driven by underlying somatic genetic changes, We have studied the occurrence of the two most common somatic genetic changes associated with lung cancer in a series of premalignant bronchial lesions representing different stages in lung tumorigenesis, We present evidence that allele loss on chromosome 3 precedes damage to the p53 gene, Damage to chromosome 3 itself appears to be sequential in that the pattern of allele loss seen in dysplasia is often much more discrete than in invasive tumours, This implies that preneoplastic lesions may be a useful source of material for deletion mapping studies aimed at localising the position of tumour suppressor genes, We illustrate this by the comparison of an interstitial deletion described in this study with a homozygous deletion we have described previously, which has resulted in a better definition of the localisation of a tumour suppressor gene believed to be involved in lung cancer development.	MRC, CLIN ONCOL & RADIOTHERAPEUT UNIT, MRC CTR, CAMBRIDGE CB2 2QH, ENGLAND; WYTHENSHAWE HOSP, REG CARDIOTHORAC CTR, DEPT PATHOL, MANCHESTER M23 9LT, LANCS, ENGLAND; LONDON CHEST HOSP, LONDON E2 9JX, ENGLAND	MRC Laboratory Molecular Biology; University of Cambridge; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of London; Queen Mary University London								BENNETT WP, 1993, CANCER RES, V53, P4817; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; DALY MC, 1991, GENOMICS, V9, P113, DOI 10.1016/0888-7543(91)90227-6; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DODSON MK, 1993, CANCER RES, V53, P4456; ELDER PA, 1994, ONCOGENE, V9, P3433; GANLY PS, 1992, GENOMICS, V12, P221, DOI 10.1016/0888-7543(92)90369-4; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HIBI K, 1992, ONCOGENE, V7, P445; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KLEIN N, 1993, LAB INVEST, V68, P26; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; LUBINSKI J, 1994, CANCER RES, V54, P3710; MARCHETTI A, 1993, CANCER RES, V53, P2846; MATHEW S, 1994, CANCER RES, V54, P6265; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NUORVA K, 1993, AM J PATHOL, V142, P725; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; RABBITTS PH, 1994, BRIT MED BULL, V50, P688, DOI 10.1093/oxfordjournals.bmb.a072917; RODENHUIS S, 1992, CANCER RES, V52, pS2665; RUBIO MP, 1993, CANCER RES, V53, P3465; SATO S, 1994, CANCER RES, V54, P5652; SATO T, 1991, CANCER RES, V51, P5794; SOZZI G, 1991, CANCER RES, V51, P400; SUGIO K, 1994, CANCER RES, V54, P5811; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; SUNDARESAN V, 1995, IN PRESS ANNALS ONCO; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VIEL A, 1992, BRIT J CANCER, V66, P1030, DOI 10.1038/bjc.1992.405; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WALKER C, 1994, BRIT J CANCER, V70, P297, DOI 10.1038/bjc.1994.296; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; WU CL, 1994, CANCER RES, V54, P6484; YOKOYAMA S, 1992, CANCER RES, V52, P873	36	86	88	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2591	2598						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545116				2022-12-17	WOS:A1995TP18800015
J	SQUIRE, JA; THORNER, PS; WEITZMAN, S; MAGGI, JD; DIRKS, P; DOYLE, J; HALE, M; GODBOUT, R				SQUIRE, JA; THORNER, PS; WEITZMAN, S; MAGGI, JD; DIRKS, P; DOYLE, J; HALE, M; GODBOUT, R			COAMPLIFICATION OF MYCN AND A DEAD BOX GENE (DDX1) IN PRIMARY NEUROBLASTOMA	ONCOGENE			English	Article						GENE AMPLIFICATION; NEUROBLASTOMA; MYCN; RNA HELICASE; PROGNOSIS	HUMAN NEURO-BLASTOMA; N-MYC; CELL-LINES; HUMAN SARCOMAS; DNA-SEQUENCES; EXPRESSION; ONCOGENE; PROTEIN; REGION; FAMILY	DEAD box proteins are putative RNA helicases that have been implicated in cellular processes involving alteration of RNA secondary structure, such as translation initiation and splicing. These proteins share eight conserved amino acid motifs, including Asp(D)-Glu-(E)-Ala(A)-Asp(D) which is part of a more extended motif. Recently, we have shown that the novel DDX1 gene containing a DEAD box motif maps to the same chromosome band as MYCN at 2p24 and is co-amplified with MYCN in retinoblastoma cell lines. Here, we show that the DDX1 gene is co-amplified with the MYCN gene in 2 of three neuroblastoma cell lines and that DDX1 RNA levels correlate with DDX1 gene copy number. Since amplification of MYCN is an indicator of poor prognosis in neuroblastoma, it was of interest to determine whether co-amplification with DDX1 occurred in clinical samples of neuroblastoma and whether such a finding carried any additional prognostic significance, We determined the gene copy number of DDX1 in 32 neuroblastoma patient samples (representative of all stages): 13 were MYCN amplified and 19 had normal copy numbers of the MYCN gene. Of the 13 neuroblastomas that were MYCN amplified, seven were also DDX1 amplified, Of the 19 that were not MYCN amplified, none were DDX1 amplified. This is the first example of a gene that is co-amplified with MYCN at a high frequency in neuroblastoma. While there was a trend towards a worse clinical outcome with co-amplification, the numbers were too small to reach significance.	UNIV ALBERTA, CROSS CANC INST, DEPT ONCOL, EDMONTON, AB T6G 1Z2, CANADA; HOSP SICK CHILDREN, DEPT PATHOL, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, DEPT PEDIAT, DIV ONCOL, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, DEPT SURG, DIV NEUROSURG, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, TORONTO, ON M5G 1X8, CANADA	University of Alberta; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto			Godbout, Roseline/I-4639-2016; Squire, Jeremy/A-9352-2012	Godbout, Roseline/0000-0002-4779-9265; Squire, Jeremy/0000-0002-9863-468X				AKIYAMA K, 1991, NUCLEIC ACIDS RES, V19, P6887, DOI 10.1093/nar/19.24.6887; ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; AMLER LC, 1992, ONCOGENE, V7, P807; Biedler JL, 1983, ADV CELL NEUROBIOL, V4, P268; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1986, CANCER GENET CYTOGEN, V19, P101, DOI 10.1016/0165-4608(86)90377-8; BRODEUR GM, 1988, J CLIN ONCOL, V6, P1874, DOI 10.1200/JCO.1988.6.12.1874; COHN SL, 1991, PROG CLIN BIOL RES, V366, P21; COLE MD, 1991, CELL, V65, P715, DOI 10.1016/0092-8674(91)90377-B; COWELL JK, 1982, ANNU REV GENET, V16, P21, DOI 10.1146/annurev.ge.16.120182.000321; DEPINHO R, 1987, J CELL BIOCHEM, V33, P257, DOI 10.1002/jcb.240330404; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; GODBOUT R, 1993, P NATL ACAD SCI USA, V90, P7578, DOI 10.1073/pnas.90.16.7578; GODBOUT R, 1994, GENE, V138, P243, DOI 10.1016/0378-1119(94)90816-8; GODBOUT R, 1992, GENE, V123, P195; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KHATIB ZA, 1993, CANCER RES, V53, P5535; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; Maniatis T, 1989, MOL CLONING; MONTGOMERY KT, 1988, ADV NEUROBLASTOMA RE, V2, P71; REIFENBERGER G, 1994, CANCER RES, V54, P4299; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SCHNEIDER SH, 1991, ADV NEUROBLASTOMA RE, V3, P71; SCHNEIDER SS, 1992, MOL CELL BIOL, V12, P5563, DOI 10.1128/MCB.12.12.5563; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHILOH Y, 1986, CANCER RES, V46, P5297; SHIMADA H, 1984, J NATL CANCER I, V73, P406; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; TONIN PN, 1989, ONCOGENE, V4, P1117; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; ZEHNBAUER BA, 1988, MOL CELL BIOL, V8, P522, DOI 10.1128/MCB.8.2.522	42	86	89	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1417	1422						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731693				2022-12-17	WOS:A1995QR65100020
J	CHLICHLIA, K; MOLDENHAUER, G; DANIEL, PT; BUSSLINGER, M; GAZZOLO, L; SCHIRRMACHER, V; KHAZAIE, K				CHLICHLIA, K; MOLDENHAUER, G; DANIEL, PT; BUSSLINGER, M; GAZZOLO, L; SCHIRRMACHER, V; KHAZAIE, K			IMMEDIATE EFFECTS OF REVERSIBLE HTLV-1 TAX FUNCTION - T-CELL ACTIVATION AND APOPTOSIS	ONCOGENE			English	Article						HTLV-1 TAX; CD3; CD28; ESTROGEN RECEPTOR; T-CELL ACTIVATION; APOPTOSIS	VIRUS TYPE-I; LEUKEMIA-VIRUS; IL-2 RECEPTOR; MONOCLONAL-ANTIBODIES; TRANSGENIC MICE; GENE-EXPRESSION; BINDING DOMAINS; B-CELLS; INTERLEUKIN-2; INDUCTION	The tax protein of Human T-cell leukemia virus type 1 (HTLV-1) is important for the transforming properties of this virus in vitro and is considered to be responsible for the early stages of leukemogenesis in infected hosts. To address the early consequences of HTLV-1 tax function, we have constructed fusion proteins containing tax sequence either aminoterminal (taxER) or carboxyterminal (ERtax) of the hormone binding domain of the human estrogen receptor (ER). Addition of estrogen or the antagonist hydroxytamoxifen to Jurkat T-cells expressing these constructs led to the trans-activation or responsive promoters and upregulation of cell surface markers CD28, CD69 and CD5 but not CD25 (IL2R-alpha subunit) or B7 (ligand for CD28). Additional stimulation of the T-cell receptor CD3 complex, led to the upregulation of CD25. B7 was upregulated by concomittent activation of ERtax and CD3 or CD28 pathways, These events were in part reversible upon withdrawal of hormone and inactivation of ERtax. Severe inhibition of proliferation, and apoptosis was observed with cells which had been subjected to short term (3 days) activation of the tax fusion proteins and the CD3 complex, Induction of ERtax activity for longer than 3 days promoted cell death independently of CD3 stimulation. Co-stimulation through the CD28 cell surface molecule did not suppress induction of apoptosis.	GERMAN CANC RES CTR,DEPT TUMOR IMMUNOL,D-69120 HEIDELBERG,GERMANY; MAX DELBRUCK CTR MOLEC MED,D-13122 BERLIN,GERMANY; RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA; ALEXIS CARREL MED SCH,MOLEC & CELLULAR IMMUNOVIROL LAB,CNRS,UMR 30,LYON,FRANCE	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; Max Delbruck Center for Molecular Medicine; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Centre National de la Recherche Scientifique (CNRS)			Chlichlia, Katerina/Q-3948-2019; Busslinger, Meinrad J./J-1249-2016	Busslinger, Meinrad J./0000-0002-9111-9351; Chlichlia, Katerina/0000-0003-4952-0675				AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BIEBERICH CJ, 1993, VIROLOGY, V196, P309, DOI 10.1006/viro.1993.1481; BOULTER CA, 1987, NUCLEIC ACIDS RES, V15, P7194, DOI 10.1093/nar/15.17.7194; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DEPPER JM, 1984, J IMMUNOL, V133, P1691; DOI T, 1989, EMBO J, V8, P1953, DOI 10.1002/j.1460-2075.1989.tb03600.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; FRANCHINI G, 1984, P NATL ACAD SCI-BIOL, V81, P6207, DOI 10.1073/pnas.81.19.6207; FUJII M, 1991, ONCOGENE, V6, P1023; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; FURUTA Y, 1989, J VIROL, V63, P3185, DOI 10.1128/JVI.63.7.3185-3189.1989; GILLIS S, 1980, J EXP MED, V152, P1709, DOI 10.1084/jem.152.6.1709; GOUGEON ML, 1993, AIDS RES HUM RETROV, V9, P287, DOI 10.1089/aid.1993.9.287; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; HAFAR OK, 1993, P NATL ACAD SCI USA, V90, P11094; HATTORI T, 1981, BLOOD, V58, P645; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HOLLSBERG P, 1992, J IMMUNOL, V148, P3256; HOSHINO H, 1983, P NATL ACAD SCI-BIOL, V80, P7337, DOI 10.1073/pnas.80.23.7337; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; KELLY K, 1992, ONCOGENE, V7, P1463; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LINSLEY PS, 1993, J IMMUNOL, V150, P3161; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MCGUIRE KL, 1993, J VIROL, V67, P1590, DOI 10.1128/JVI.67.3.1590-1599.1993; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NERENBERG MI, 1991, J VIROL, V65, P3349, DOI 10.1128/JVI.65.6.3349-3353.1991; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; PUNT JA, 1994, J EXP MED, V179, P709, DOI 10.1084/jem.179.2.709; RUBEN S M, 1990, New Biologist, V2, P894; SANSOM DM, 1993, EUR J IMMUNOL, V23, P295, DOI 10.1002/eji.1830230148; SCHWARTING R, 1989, CLUSTER REPORT CD69, P428; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SUGAMURA K, 1984, INT J CANCER, V34, P221, DOI 10.1002/ijc.2910340213; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; TENDLER CL, 1990, P NATL ACAD SCI USA, V87, P5218, DOI 10.1073/pnas.87.13.5218; TSUDA H, 1984, BRIT J CANCER, V50, P843, DOI 10.1038/bjc.1984.266; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; VALLE A, 1990, IMMUNOLOGY, V69, P531; VANLIER RAW, 1988, EUR J IMMUNOL, V18, P167; VANLIER RAW, 1989, LEUKOCYTE TYPING, V4, P353; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WEISS RA, 1990, CANCER CELL-MON REV, V2, P281; WESSELBORG S, 1993, J IMMUNOL, V150, P4338; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; YODOI J, 1992, IMMUNOL TODAY, V13, P405, DOI 10.1016/0167-5699(92)90091-K; YODOI J, 1986, IMMUNOL REV, V92, P135, DOI 10.1111/j.1600-065X.1986.tb01498.x; YOSHIDA M, 1986, AIDS RES, V2, pS17	61	86	86	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					269	277						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838527				2022-12-17	WOS:A1995QC62400006
J	BOUSSET, K; HENRIKSSON, M; LUSCHERFIRZLAFF, JM; LITCHFIELD, DW; LUSCHER, B				BOUSSET, K; HENRIKSSON, M; LUSCHERFIRZLAFF, JM; LITCHFIELD, DW; LUSCHER, B			IDENTIFICATION OF CASEIN KINASE-II PHOSPHORYLATION SITES IN MAX - EFFECTS ON DNA-BINDING KINETICS OF MAX HOMODIMER AND MYC/MAX HETERODIMERS	ONCOGENE			English	Article							SERUM RESPONSE FACTOR; C-MYC ONCOPROTEIN; PROTEIN-PHOSPHORYLATION; RAS COTRANSFORMATION; SEQUENCE; CELLS; TRANSCRIPTION; ACTIVATION; INCREASES; P34CDC2	Myc proteins have been implicated in the regulation of cell growth and differentiation. The identification of Max, a basic region/helix-loop-helix/leucine zipper protein, as a partner for Myc has provided insights into Myc's molecular function as a transcription factor. Recent evidence indicates that the relative abundance of Myc and Max is important to determine the level of specific gene transcription; In this report we have identified two major in vivo phosphorylation sites in Max (Ser-2 and -11) which can be modified in vitro by casein kinase II (CKII). Phosphorylation of these sites modulates DNA-binding by increasing both the on- and off-rates of Max homo- as well as Myc/Max heterodimers. In addition, our data indicate that the steady state binding of the shorter version of Max (p21) to DNA was similar yet its rate of dissociation faster than that of the longer version of Max (p22). These data argue that different Max complexes have different kinetic properties and that these can be modified by CKII phosphorylation. We propose this as an important biological mechanism by which different dimeric complexes can exchange with varying efficiencies on DNA, thereby responding to changes in cell growth conditions.	HANNOVER MED SCH,INST MOLEC BIOL,D-30623 HANNOVER,GERMANY; UNIV MANITOBA,MANITOBA INST CELL BIOL,WINNIPEG R3E 0V9,MB,CANADA	Hannover Medical School; University of Manitoba			Henriksson, Marie Arsenian/F-5010-2015; Litchfield, David/E-4636-2015; Luscher, Bernhard/A-7330-2011	Litchfield, David/0000-0002-2425-6620; Luscher, Bernhard/0000-0002-9622-8709				ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMATI B, 1993, CELL, V72, P235; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; HENRIKSSON M, 1993, IN PRESS ONCOGENE; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LITCHFIELD DW, 1993, IN PRESS MOL CHEM BI; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; LUSCHER B, 1991, EMBO J, V10, P865, DOI 10.1002/j.1460-2075.1991.tb08019.x; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MEEK DW, 1992, BIOCHEM J, V287, P1; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PINNA LA, 1981, BIOCHEM BIOPH RES CO, V100, P449, DOI 10.1016/S0006-291X(81)80117-9; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; SETH A, 1991, J BIOL CHEM, V266, P23521; SETH A, 1992, J BIOL CHEM, V267, P24796; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STREET AJ, 1990, CURR TOP MICROBIOL, V166, P251; VASTRIK I, 1993, ONCOGENE, V8, P503; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	46	86	87	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3211	3220						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247525				2022-12-17	WOS:A1993MG78200003
J	FINNERTY, H; KELLEHER, K; MORRIS, GE; BEAN, K; MERBERG, DM; KRIZ, R; MORRIS, JC; SOOKDEO, H; TURNER, KJ; WOOD, CR				FINNERTY, H; KELLEHER, K; MORRIS, GE; BEAN, K; MERBERG, DM; KRIZ, R; MORRIS, JC; SOOKDEO, H; TURNER, KJ; WOOD, CR			MOLECULAR-CLONING OF MURINE FLT AND FLT4	ONCOGENE			English	Note							RECEPTOR TYROSINE KINASE; CHROMOSOMAL LOCALIZATION; SEQUENCE-ANALYSIS; GROWTH-FACTOR; FAMILY; GENE; IDENTIFICATION	A wide range of growth and differentiation processes are regulated by the signalling of receptor tyrosine kinases (RTKs). We have developed a nested polymerase chain reaction (PCR) procedure with degenerate primers, and used it to identify RTKs expressed in murine fetal thymus. A novel RTK, called FLT4, and the murine homologue of FLT were found, and their PCR fragment sequences were used to isolate larger cDNA clones spanning the complete coding regions of these receptors. FLT4 was found to contain an extracellular region similar to the corresponding sequences of FLT and Flk-1, containing seven immunoglobulin domains.			FINNERTY, H (corresponding author), GENET INST INC, 87 CAMBRIDGE PK DR, CAMBRIDGE, MA 02140 USA.							APRELIKOVA O, 1992, CANCER RES, V52, P746; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; GALLAND F, 1992, GENOMICS, V13, P475, DOI 10.1016/0888-7543(92)90277-Y; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HUNTER T, 1991, METHOD ENZYMOL, P3; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAUL SR, 1992, INT J CELL CLONING, V10, P309, DOI 10.1002/stem.5530100509; PONCZ M, 1982, P NATL ACAD SCI-BIOL, V79, P4298, DOI 10.1073/pnas.79.14.4298; RAZ V, 1991, ONCOGENE, V6, P753; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBUYA M, 1990, ONCOGENE, V5, P519; TERMAN BI, 1991, ONCOGENE, V6, P1677; VONHEIJNE G, 1987, SEQUENCE ANAL MOL BI, P113; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YOSHIDA MC, 1987, CYTOGENET CELL GENET, V46, P724	22	86	100	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2293	2298						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393164				2022-12-17	WOS:A1993LP17100032
J	BARDELLI, A; MAINA, F; GOUT, I; FRY, MJ; WATERFIELD, MD; COMOGLIO, PM; PONZETTO, C				BARDELLI, A; MAINA, F; GOUT, I; FRY, MJ; WATERFIELD, MD; COMOGLIO, PM; PONZETTO, C			AUTOPHOSPHORYLATION PROMOTES COMPLEX-FORMATION OF RECOMBINANT HEPATOCYTE GROWTH-FACTOR RECEPTOR WITH CYTOPLASMIC EFFECTORS CONTAINING SH2 DOMAINS	ONCOGENE			English	Article							TYROSINE KINASE-ACTIVITY; FACTOR SCATTER FACTOR; C-MET; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; BINDING-SITE; PROTEINS; PHOSPHOTYROSINE; IDENTIFICATION; PEPTIDE	Hepatocyte growth factor (HGF), also known as scatter factor (SF), is a polypeptide which induces motility and/or mitogenesis in epithelial cells. The receptor for HGF/SF, p190MET, is a two-chain transmembrane tyrosine kinase encoded by the MET proto-oncogene. To identify the cytoplasmic effectors involved in signal transduction we have produced the human HGF/SF receptor in insect cells (Sf9) by means of a recombinant baculovirus. Two 170-kDa forms of the receptor were synthesized in Sf9 cells: the uncleaved single-chain precursor (which is by far the more abundant) and the proteolytically processed two-chain molecule. Both receptor species are phosphorylated on tyrosine in vivo and are active kinases in vitro. The recombinant receptor binds and phosphorylates in vitro four known cytoplasmic transducers containing src homology region 2 (SH2) domains: the 85-kDa subunit of phosphatidylinositol 3-kinase (Pl 3-kinase), rasGAP, phospholipase-C-gamma (PLC-gamma), and p59Fyn, a tyrosine kinase of the src family. In all cases the association is strictly dependent on tyrosine phosphorylation of the receptor, indicating that it occurs via specific interaction with the SH2 domains. These results show that the HGF/SF receptor has the sequence requirements for binding a spectrum of cytoplasmic transducers whose different combinations in target cells may result in the observed pleiotropic biological response.	UNIV TURIN,DEPT BIOMED SCI & ONCOL,CSO MASSIMO AZEGLIO 52,I-10126 TURIN,ITALY; LUDWIG INST CANC RES,LONDON,ENGLAND	University of Turin; Ludwig Institute for Cancer Research			Maina, Flavio/J-9962-2019; BARDELLI, Alberto/J-9721-2018	Maina, Flavio/0000-0001-6100-4695; BARDELLI, Alberto/0000-0003-1647-5070; Comoglio, Paolo/0000-0002-7056-5328; Fry, Michael/0000-0001-8518-1370				BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COMOGLIO PM, 1984, EMBO J, V3, P483, DOI 10.1002/j.1460-2075.1984.tb01834.x; DOWNING JR, 1991, MOL CELL BIOL, V11, P2489, DOI 10.1128/MCB.11.5.2489; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GREENFIELD C, 1988, EMBO J, V7, P139, DOI 10.1002/j.1460-2075.1988.tb02793.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MAEDA S, 1990, FEBS LETT, V269, P386, DOI 10.1016/0014-5793(90)81199-X; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PONZETTO C, 1991, ONCOGENE, V6, P553; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780	24	86	88	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1973	1978						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1328986				2022-12-17	WOS:A1992JP42400010
J	HOSONO, S; LEE, CS; CHOU, MJ; YANG, CS; SHIH, C				HOSONO, S; LEE, CS; CHOU, MJ; YANG, CS; SHIH, C			MOLECULAR ANALYSIS OF THE P53 ALLELES IN PRIMARY HEPATOCELLULAR CARCINOMAS AND CELL-LINES	ONCOGENE			English	Article							HEPATITIS-B VIRUS; TUMOR SUPPRESSOR GENES; SV40-TRANSFORMED CELLS; INTEGRATION SITES; ANTI-ONCOGENE; DNA; EXPRESSION; PROTEIN; PRODUCT; CANCER	We have examined p53 oncogene/anti-oncogene alleles in 10 different human heptoma cell lines and 18 primary hepatocellular carcinomas. The p53 allele in these hepatoma cell lines appears to be a frequent target of mutation as demonstrated by Southern and Northern blotting, immunoprecipitation and Western blot analysis. In general, the steady state level of p53 specific RNA or protein in these hepatoma cell lines is higher than in normal liver. However, in three out of ten cell lines, normal-sized p53 mRNA cannot be detected. In contrast, the involvement of the p53 allele in primary hepatocellular carcinoma appears to be an exceedingly rare event. Steady state levels of p53 specific RNA in primary hepatomas are practically indistinguishable from those in normal adult liver. Using the polymerase chain reaction technique, we have amplified and subcloned exons 5, 6, 7 and 8 of p53 from 10 different hepatoma samples. DNA sequence analysis of these exon subclones reveals no apparent structural alterations. Finally, synthesis of p53 specific mRNA or protein in a HepG2 human hepatoblastoma cell line does not appear to be affected by gene expression and replication of human hepatitus B virus. Surprisingly, unlike many other kinds of human solid tumors, point mutations in p53 do not appear to be important in primary tumors of hepatocellular carcinomas.	UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; NATL TAIWAN UNIV,COLL MED,TAIPEI,TAIWAN	University of Pennsylvania; National Taiwan University			Shih, Chiaho/S-7017-2018		NCI NIH HHS [R01 CA 48198] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048198] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BEASLEY RP, 1981, LANCET, V2, P1129; BLUMBERG BS, 1981, NEW ENGL J MED, V304, P782, DOI 10.1056/NEJM198103263041312; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; CANNIZARO LA, 1989, AM J HUM GENET, V38, P812; CHANG C, 1983, MOL CELL BIOL, V3, P1133, DOI 10.1128/MCB.3.6.1133; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEJEAN A, 1984, P NATL ACAD SCI-BIOL, V81, P5350, DOI 10.1073/pnas.81.17.5350; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GRIMM J, 1976, INT J BIOCHEM, V64, P249; HARLOW E, 1988, ANTIBODIES LABORATOR; HARRIS CC, 1990, CANCER CELL-MON REV, V2, P146; HE L, 1984, IN VITRO CELL DEV B, V20, P493, DOI 10.1007/BF02619623; HINO O, 1989, J VIROL, V63, P2638, DOI 10.1128/JVI.63.6.2638-2643.1989; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; KNUDSON AG, 1985, CANCER RES, V45, P1437; KORNBLUTH J, 1985, J IMMUNOL, V134, P728; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MACNAB GM, 1976, BRIT J CANCER, V34, P509, DOI 10.1038/bjc.1976.205; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; NAGAYA T, 1987, GENE DEV, V1, P773, DOI 10.1101/gad.1.8.773; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; NEEL BG, 1981, CELL, V23, P323, DOI 10.1016/0092-8674(81)90128-8; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OCHIYA T, 1986, P NATL ACAD SCI USA, V83, P4993, DOI 10.1073/pnas.83.14.4993; PAYNE GS, 1981, CELL, V23, P311, DOI 10.1016/0092-8674(81)90127-6; Robinson W.S., 1990, VIROLOGY, P2137; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SHIH CH, 1987, J VIROL, V61, P3491, DOI 10.1128/JVI.61.11.3491-3498.1987; SLAGLE BL, 1990, J CELL BIOCHEM, V14, P276; SOUSSI T, 1987, ONCOGENE, V1, P71; STANBRIDGE EJ, 1990, SCIENCE, V247, P12, DOI 10.1126/science.2403692; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZHANG WD, 1990, JPN J CANCER RES, V81, P108, DOI 10.1111/j.1349-7006.1990.tb02534.x; ZHOU YZ, 1988, J VIROL, V62, P4224, DOI 10.1128/JVI.62.11.4224-4231.1988	56	86	87	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					237	243						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1847999				2022-12-17	WOS:A1991FZ13400009
J	PAL, N; WADEY, RB; BUCKLE, B; YEOMANS, E; PRITCHARD, J; COWELL, JK				PAL, N; WADEY, RB; BUCKLE, B; YEOMANS, E; PRITCHARD, J; COWELL, JK			PREFERENTIAL LOSS OF MATERNAL ALLELES IN SPORADIC WILMS-TUMOR	ONCOGENE			English	Article									INST CHILD HLTH,DEPT HAEMATOL & ONCOL,IMPERIAL CANC RES FUND,MOLEC GENET LAB,LONDON WC1N 1EH,ENGLAND; GREAT ORMOND ST HOSP SICK CHILDREN,DEPT HAEMATOL & ONCOL,LONDON WC1,ENGLAND	Cancer Research UK; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust				Cowell, John/0000-0002-2079-5950				ALLISON J, 1981, BIOCHEM J, V199, P725, DOI 10.1042/bj1990725; ANTONARAKIS SE, 1983, P NATL ACAD SCI-BIOL, V80, P6615, DOI 10.1073/pnas.80.21.6615; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; COUILLIN P, 1989, HUM GENET, V82, P171, DOI 10.1007/BF00284053; COWELL JK, 1989, HUM GENET, V82, P123, DOI 10.1007/BF00284042; DAO DD, 1987, AM J HUM GENET, V41, P202; DRYJA TP, 1989, NATURE, V339, P556, DOI 10.1038/339556a0; ECCLES MR, 1984, HUM GENET, V67, P190, DOI 10.1007/BF00272999; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HENDY GN, 1981, P NATL ACAD SCI-BIOL, V78, P7365, DOI 10.1073/pnas.78.12.7365; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HOPPENER JWM, 1984, HUM GENET, V66, P309, DOI 10.1007/BF00287635; JEFFREYS AJ, 1979, CELL, V18, P1, DOI 10.1016/0092-8674(79)90348-9; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; Maniatis T., 1982, MOL CLONING; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; NICHOLLS RD, 1989, AM J MED GENET, V33, P66, DOI 10.1002/ajmg.1320330109; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; QUAN F, 1985, NUCLEIC ACIDS RES, V13, P8288, DOI 10.1093/nar/13.22.8288; RAIZIS AM, 1985, HUM GENET, V70, P344, DOI 10.1007/BF00295375; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; RICCARDI VM, 1978, PEDIATRICS, V61, P604; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPARKES RS, 1983, SCIENCE, V219, P971, DOI 10.1126/science.6823558; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; VANDERMEY AGL, 1989, LANCET, V2, P1291; VANHEYNINGEN V, 1985, P NATL ACAD SCI USA, V82, P8592; WADEY RB, 1989, NUCLEIC ACIDS RES, V17, P3332, DOI 10.1093/nar/17.8.3332; WADEY RB, 1990, IN PRESS ONCOGENE; WATKINS PC, 1987, DNA-J MOLEC CELL BIO, V6, P205, DOI 10.1089/dna.1987.6.205; WILLIAMS JC, 1989, LANCET, V1, P283; WILSON JT, 1978, NUCLEIC ACIDS RES, V5, P563, DOI 10.1093/nar/5.2.563; ZHU XP, 1989, NATURE, V340, P312, DOI 10.1038/340312a0	40	86	86	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1990	5	11					1665	1668						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EL401	1980007				2022-12-17	WOS:A1990EL40100008
J	VERSNEL, MA; HAGEMEIJER, A; BOUTS, MJ; VANDERKWAST, TH; HOOGSTEDEN, HC				VERSNEL, MA; HAGEMEIJER, A; BOUTS, MJ; VANDERKWAST, TH; HOOGSTEDEN, HC			EXPRESSION OF C-SIS (PDGF B-CHAIN) AND PDGF A-CHAIN GENES IN 10 HUMAN-MALIGNANT MESOTHELIOMA CELL-LINES DERIVED FROM PRIMARY AND METASTATIC TUMORS	ONCOGENE			English	Article									ERASMUS UNIV, DEPT PATHOL, 3000 DR ROTTERDAM, NETHERLANDS; ERASMUS UNIV, DEPT PULM MED, 3000 DR ROTTERDAM, NETHERLANDS; ACAD HOSP DIJKZIGT, ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC	VERSNEL, MA (corresponding author), ERASMUS UNIV, DEPT CELL BIOL IMMUNOL & GENET, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.			Van der Kwast, Theodorus/0000-0001-8640-5786				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARRETT TB, 1984, P NATL ACAD SCI-BIOL, V81, P6772, DOI 10.1073/pnas.81.21.6772; BENHAM FJ, 1984, EMBO J, V3, P2635, DOI 10.1002/j.1460-2075.1984.tb02186.x; BETSHOLTZ C, 1984, CELL, V39, P447, DOI 10.1016/0092-8674(84)90452-5; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BETSHOLTZ C, 1983, BIOCHEM BIOPH RES CO, V117, P176, DOI 10.1016/0006-291X(83)91557-7; DEUEL TF, 1983, SCIENCE, V221, P1348, DOI 10.1126/science.6310754; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; FAVERA RD, 1982, SCIENCE, V218, P686; GERWIN B, 1987, J CELL BIOCHEM, P58; GERWIN BI, 1987, EUR J CANCER CLIN ON, V23, P1752, DOI 10.1016/0277-5379(87)90552-9; GOUSTIN AS, 1985, CELL, V41, P301, DOI 10.1016/0092-8674(85)90083-2; GRAVES DT, 1984, SCIENCE, V226, P972, DOI 10.1126/science.6209798; GROFFEN J, 1983, J EXP MED, V158, P9, DOI 10.1084/jem.158.1.9; Harnden DG, 1985, INT SYSTEM HUMAN CYT; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HOLLEY RW, 1975, NATURE, V258, P487, DOI 10.1038/258487a0; JEFFREYS AJ, 1977, CELL, V12, P429, DOI 10.1016/0092-8674(77)90119-2; Maniatis T, 1982, MOL CLONING LABORATO; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; MORTON CC, 1987, HGM, V9, P98; NISTER M, 1984, P NATL ACAD SCI-BIOL, V81, P926, DOI 10.1073/pnas.81.3.926; PANTAZIS P, 1985, P NATL ACAD SCI USA, V82, P2404, DOI 10.1073/pnas.82.8.2404; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; SWAN DC, 1982, P NATL ACAD SCI-BIOL, V79, P4691, DOI 10.1073/pnas.79.15.4691; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TODARO GJ, 1978, CANCER RES, V38, P4147; WAGNER J C, 1960, Br J Ind Med, V17, P260; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WESTERMARK B, 1986, P NATL ACAD SCI USA, V83, P7197, DOI 10.1073/pnas.83.19.7197; WHITAKER D, 1984, J PATHOL, V143, P147, DOI 10.1002/path.1711430303	32	86	86	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1988	2	6					601	605						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	3290807				2022-12-17	WOS:A1988N841500011
J	MARUYAMA, K; SCHIAVI, SC; HUSE, W; JOHNSON, GL; RULEY, HE				MARUYAMA, K; SCHIAVI, SC; HUSE, W; JOHNSON, GL; RULEY, HE			MYC-ONCOGENE AND E1A-ONCOGENE ALTER THE RESPONSES OF PC12-CELLS TO NERVE GROWTH-FACTOR AND BLOCK DIFFERENTIATION	ONCOGENE			English	Article									MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM,WORCESTER,MA 01605; STRATAGENE CLONING SYST,SAN DIEGO,CA 92121	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of Massachusetts System; University of Massachusetts Worcester					NATIONAL CANCER INSTITUTE [P01CA013106, R01CA040602] Funding Source: NIH RePORTER; NCI NIH HHS [CA 13106, CA 40602] Funding Source: Medline; NIADDK NIH HHS [9R01-AM37871] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BELL E, 1978, SCIENCE, V202, P1158, DOI 10.1126/science.725592; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BOONSTRA J, 1983, J CELL BIOL, V97, P92, DOI 10.1083/jcb.97.1.92; BURSTEIN DE, 1982, DEV BIOL, V94, P477, DOI 10.1016/0012-1606(82)90364-5; BUXSER SE, 1983, J BIOL CHEM, V258, P3741; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DURNAM DM, 1980, P NATL ACAD SCI-BIOL, V77, P6511, DOI 10.1073/pnas.77.11.6511; FEINSTEIN SC, 1985, P NATL ACAD SCI USA, V82, P5761, DOI 10.1073/pnas.82.17.5761; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1978, NATURE, V276, P191, DOI 10.1038/276191a0; GREENE LA, 1980, ANNU REV NEUROSCI, V3, P353, DOI 10.1146/annurev.ne.03.030180.002033; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUROFF G, 1981, J NEUROCHEM, V37, P342, DOI 10.1111/j.1471-4159.1981.tb00461.x; HATANAKA H, 1978, FEBS LETT, V92, P313, DOI 10.1016/0014-5793(78)80777-7; HEBY O, 1981, DIFFERENTIATION, V19, P1, DOI 10.1111/j.1432-0436.1981.tb01123.x; HEUMANN R, 1981, NATURE, V292, P838, DOI 10.1038/292838a0; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LILLIEN LE, 1985, NATURE, V317, P632, DOI 10.1038/317632a0; MARTIN G M, 1975, P67; MARTIN GM, 1974, AM J PATHOL, V74, P137; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; RULEY HE, 1984, CANCER CELL, V2, P481; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P4055, DOI 10.1073/pnas.74.9.4055; SEELEY PJ, 1983, J NEUROSCI, V3, P1488; SHIROKI K, 1979, VIROLOGY, V95, P127, DOI 10.1016/0042-6822(79)90407-0; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; VANDOREN K, 1984, J VIROL, V50, P606, DOI 10.1128/JVI.50.2.606-614.1984; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	37	86	87	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	1	4					361	367						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	K7483	2838784				2022-12-17	WOS:A1987K748300004
J	Li, BZ; Xu, HX; Han, HY; Song, S; Zhang, XJ; Ouyang, L; Qian, CA; Hong, YT; Qiu, YC; Zhou, WQ; Huang, ML; Zhuang, WZ				Li, Bingzong; Xu, Hongxia; Han, Huiying; Song, Sha; Zhang, Xiaojuan; Ouyang, Lu; Qian, Chen'ao; Hong, Yating; Qiu, Yingchun; Zhou, Wenqi; Huang, Moli; Zhuang, Wenzhuo			Exosome-mediated transfer of IncRUNX2-AS1 from multiple myeloma cells to MSCs contributes to osteogenesis	ONCOGENE			English	Article							LONG NONCODING RNA; MESENCHYMAL STEM-CELLS; NATURAL ANTISENSE; SECRETED EXOSOMES; CANCER METASTASIS; BONE-DISEASE; TRANSCRIPTION; EXPRESSION; DIFFERENTIATION; INHIBITION	Multiple myeloma (MM) is characterized by the decreased osteogenic potential of mesenchymal stem cells (MSCs). Communication between cancer cells and cancer stromal cells is a driving factor in tumor progression. Understanding the myeloma-stroma interactions is critical to the development of effective strategies that can reverse bone diseases. Here we identified that bioactive lncRNA RUNX2-AS1 in myeloma cells could be packed into exosomes and transmitted to MSCs, thus repressing the osteogenesis of MSCs. RUNX2-AS1, which arises from the antisense strand of RUNX2, was enriched in MSCs derived from MM patients (MM-MSCs). RUNX2-AS1 was capable of forming an RNA duplex with RUNX2 pre-mRNA at overlapping regions and this duplex transcriptionally repressed RUNX2 expression by reducing the splicing efficiency, resulting in decreased osteogenic potential of MSCs. In vivo mouse models, administered an inhibitor of exosome secretion, GW4869, was found to be effective in preventing bone loss, sustained by both bone formation and anticatabolic activities. Therefore, exosomal lncRNA RUNX2-AS1 may serve as a potential therapeutic target for bone lesions in MM. In summary, our results indicated a key role of exosomal lncRUNX2-AS1 in transferring from MM cells to MSCs in osteogenic differentiation, through a unique exosomal lncRUNX2-AS1/RUNX2 pathway.	[Li, Bingzong; Hong, Yating] Soochow Univ, Affiliated Hosp 2, Dept Haematol, Suzhou, Peoples R China; [Xu, Hongxia; Han, Huiying; Song, Sha; Zhang, Xiaojuan; Ouyang, Lu; Qiu, Yingchun; Zhou, Wenqi; Zhuang, Wenzhuo] Soochow Univ, Dept Cell Biol, Sch Biol & Basic Med Sci, Suzhou, Peoples R China; [Qian, Chen'ao; Huang, Moli] Soochow Univ, Dept Bioinformat, Sch Biol & Basic Med Sci, Suzhou, Peoples R China	Soochow University - China	Zhuang, WZ (corresponding author), Soochow Univ, Dept Cell Biol, Sch Biol & Basic Med Sci, Suzhou, Peoples R China.; Huang, ML (corresponding author), Soochow Univ, Dept Bioinformat, Sch Biol & Basic Med Sci, Suzhou, Peoples R China.	huangml@suda.edu.cn; zhuangwenzhuo@suda.edu.cn	li, bz/GVR-7133-2022; li, bing/GWQ-9617-2022	Huang, Moli/0000-0001-5543-9334	National Natural Science Foundation of China [81673448, 81670191]; Natural Science Foundation of Jiangsu Province China [BK 20161218, BK20161223]; Applied Basic Research Programs of Suzhou City [SYS201546]; Priority Academic Program Development of Jiangsu Higher Education Institutions	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province China(Natural Science Foundation of Jiangsu Province); Applied Basic Research Programs of Suzhou City; Priority Academic Program Development of Jiangsu Higher Education Institutions	This work was supported in part by National Natural Science Foundation of China (81673448, 81670191), Natural Science Foundation of Jiangsu Province China (BK 20161218, BK20161223), The Applied Basic Research Programs of Suzhou City (SYS201546), and A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions.	Boelens MC, 2014, CELL, V159, P499, DOI 10.1016/j.cell.2014.09.051; Carrieri C, 2012, NATURE, V491, P454, DOI 10.1038/nature11508; Challagundla KB, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv135; Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109; Faghihi MA, 2009, NAT REV MOL CELL BIO, V10, P637, DOI 10.1038/nrm2738; Franceschi RT, 2003, CONNECT TISSUE RES, V44, P109, DOI 10.1080/03008200390152188; Gezer U, 2014, CELL BIOL INT, V38, P1076, DOI 10.1002/cbin.10301; Giuliani N, 2006, BLOOD, V108, P3992, DOI 10.1182/blood-2006-05-026112; Guo JH, 2009, CELL, V138, P1236, DOI 10.1016/j.cell.2009.06.043; He CS, 2016, MOL CELL, V64, P416, DOI 10.1016/j.molcel.2016.09.034; He YP, 2008, SCIENCE, V322, P1855, DOI 10.1126/science.1163853; Hsu YL, 2017, ONCOGENE, V36, P4929, DOI 10.1038/onc.2017.105; Huang XY, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-319; Hudson WH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6395; Katayama S, 2005, SCIENCE, V309, P1564, DOI 10.1126/science.1112009; Komori T, 2005, J CELL BIOCHEM, V95, P445, DOI 10.1002/jcb.20420; Koppers-Lalic D, 2014, CELL REP, V8, P1649, DOI 10.1016/j.celrep.2014.08.027; Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821; Lee JT, 2012, SCIENCE, V338, P1435, DOI 10.1126/science.1231776; Li BZ, 2007, STEM CELLS DEV, V16, P921, DOI 10.1089/scd.2007.0074; Li Q, 2015, TUMOR BIOL, V36, P2007, DOI 10.1007/s13277-014-2807-y; Lister N, 2017, P NATL ACAD SCI USA, V114, P9942, DOI 10.1073/pnas.1621490114; Liu BD, 2015, CANCER CELL, V27, P370, DOI 10.1016/j.ccell.2015.02.004; Lokody I, 2014, NAT REV GENET, V15, P362, DOI 10.1038/nrg3741; Luga V, 2013, CANCER RES, V73, P6843, DOI 10.1158/0008-5472.CAN-13-1791; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Mohankumar S, 2016, BRIEF FUNCT GENOMICS, V15, P249, DOI 10.1093/bfgp/elv058; Qu L, 2016, CANCER CELL, V29, P653, DOI 10.1016/j.ccell.2016.03.004; Raje N, 2011, CLIN CANCER RES, V17, P1278, DOI 10.1158/1078-0432.CCR-10-1804; Roccaro AM, 2013, J CLIN INVEST, V123, P1542, DOI 10.1172/JCI66517; Saldana-Meyer R, 2014, GENE DEV, V28, P723, DOI 10.1101/gad.236869.113; Scarola M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8631; Shah S, 2014, GENE DEV, V28, P231, DOI 10.1101/gad.230177.113; Shao HL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7999; Shurtleff MJ, 2016, ELIFE, V5, DOI 10.7554/eLife.19276; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takahashi K, 2014, MOL CANCER RES, V12, P1377, DOI 10.1158/1541-7786.MCR-13-0636; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Wahlestedt C, 2006, DRUG DISCOV TODAY, V11, P503, DOI 10.1016/j.drudis.2006.04.013; Wang P, 2014, SCIENCE, V344, P310, DOI 10.1126/science.1251456; Wang YY, 2015, CELL STEM CELL, V16, P413, DOI 10.1016/j.stem.2015.03.003; Xin HQ, 2012, STEM CELLS, V30, P1556, DOI 10.1002/stem.1129; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007; Zhuang WZ, 2015, STEM CELLS, V33, P1985, DOI 10.1002/stem.1989	45	85	90	4	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2018	37	41					5508	5519		10.1038/s41388-018-0359-0	http://dx.doi.org/10.1038/s41388-018-0359-0			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GW5QO	29895968				2022-12-17	WOS:000446991200003
J	Ruscetti, M; Dadashian, EL; Guo, W; Quach, B; Mulholland, DJ; Park, JW; Tran, LM; Kobayashi, N; Bianchi-Frias, D; Xing, Y; Nelson, PS; Wu, H				Ruscetti, M.; Dadashian, E. L.; Guo, W.; Quach, B.; Mulholland, D. J.; Park, J. W.; Tran, L. M.; Kobayashi, N.; Bianchi-Frias, D.; Xing, Y.; Nelson, P. S.; Wu, H.			HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer	ONCOGENE			English	Article							ANDROGEN RECEPTOR; DNA-BINDING; INCREASED SURVIVAL; HMGI-C; ACETYLATION; ACTIVATION; CELLS; P53; SENSITIVITY; TRANSITION	PI3K (phosphoinositide 3-kinase)/AKT and RAS/MAPK (mitogen-activated protein kinase) pathway coactivation in the prostate epithelium promotes both epithelial-mesenchymal transition (EMT) and metastatic castration-resistant prostate cancer (mCRPC), which is currently incurable. To study the dynamic regulation of the EMT process, we developed novel genetically defined cellular and in vivo model systems from which epithelial, EMT and mesenchymal-like tumor cells with Pten deletion and Kras activation can be isolated. When cultured individually, each population has the capacity to regenerate all three tumor cell populations, indicative of epithelial-mesenchymal plasticity. Despite harboring the same genetic alterations, mesenchymal-like tumor cells are resistant to PI3K and MAPK pathway inhibitors, suggesting that epigenetic mechanisms may regulate the EMT process, as well as dictate the heterogeneous responses of cancer cells to therapy. Among differentially expressed epigenetic regulators, the chromatin remodeling protein HMGA2 is significantly upregulated in EMT and mesenchymal-like tumors cells, as well as in human mCRPC. Knockdown of HMGA2, or suppressing HMGA2 expression with the histone deacetylase inhibitor LBH589, inhibits epithelial-mesenchymal plasticity and stemness activities in vitro and markedly reduces tumor growth and metastasis in vivo through successful targeting of EMT and mesenchymal-like tumor cells. Importantly, LBH589 treatment in combination with castration prevents mCRPC development and significantly prolongs survival following castration by enhancing p53 and androgen receptor acetylation and in turn sensitizing castration-resistant mesenchymal-like tumor cells to androgen deprivation therapy. Taken together, these findings demonstrate that cellular plasticity is regulated epigenetically, and that mesenchymal-like tumor cell populations in mCRPC that are resistant to conventional and targeted therapies can be effectively treated with the epigenetic inhibitor LBH589.	[Ruscetti, M.; Wu, H.] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA; [Ruscetti, M.; Dadashian, E. L.; Quach, B.; Mulholland, D. J.; Tran, L. M.; Kobayashi, N.; Wu, H.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA; [Guo, W.; Wu, H.] Peking Univ, Sch Life Sci, Room 106,Jin Guang Life Sci Bldg,5 Yiheyuan Rd, Beijing 100871, Peoples R China; [Park, J. W.; Xing, Y.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA USA; [Bianchi-Frias, D.; Nelson, P. S.] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98104 USA; [Bianchi-Frias, D.; Nelson, P. S.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA; [Ruscetti, M.] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10021 USA; [Mulholland, D. J.] Mt Sinai Hosp, Icahn Sch Med, Div Hematol & Med Oncol, New York, NY 10029 USA; [Park, J. W.] Univ Louisville, KBRIN Bioinformat Core, Comp Engn & Comp Sci, Louisville, KY 40292 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Peking University; University of California System; University of California Los Angeles; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; Memorial Sloan Kettering Cancer Center; Icahn School of Medicine at Mount Sinai; University of Louisville	Wu, H (corresponding author), Peking Univ, Sch Life Sci, Room 106,Jin Guang Life Sci Bldg,5 Yiheyuan Rd, Beijing 100871, Peoples R China.	hongwu@pku.edu.cn	Guo, Weilong/AAP-2880-2021	Guo, Weilong/0000-0001-5199-1359; Ruscetti, Marcus/0000-0002-4394-2087	NIH [T32 CA009056, F32 CA112988-01, P50 CA097186, P01 CA163227, P50 CA092131, R01 CA107166, RO1 CA121110, U01 CA164188]; General Financial Grant from the China Postdoctoral Science Foundation [2015M570010]; Peking-Tsinghua Center for Life Sciences; CIRM [TG2-01169]; Prostate Cancer Foundation Young Investigator Award; Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE [R01CA121110, P50CA097186, P01CA163227, U01CA164188, R01CA107166, T32CA009056, F32CA112988, P50CA092131] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); General Financial Grant from the China Postdoctoral Science Foundation; Peking-Tsinghua Center for Life Sciences; CIRM(California Institute for Regenerative Medicine); Prostate Cancer Foundation Young Investigator Award; Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Hong Wu lab for their critical comments and suggestions. We also thank Drs Yang Zong and Owen Witte for generously supplying us with HMGA2 antibodies, and Dr Shumin Wu for supplying protein lysates from mouse ES cells. MR was supported by NIH T32 CA009056. WG was supported by a General Financial Grant from the China Postdoctoral Science Foundation (2015M570010), and in part by the Postdoctoral Fellowship of Peking-Tsinghua Center for Life Sciences. DJM was supported by NIH F32 CA112988-01, CIRM TG2-01169 and a Prostate Cancer Foundation Young Investigator Award. This work has been supported, in part, by awards from the Prostate Cancer Foundation (to HW), and grants from the NIH (P50 CA097186 and P01 CA163227 to PSN, P50 CA092131 to YX and HW, and R01 CA107166, RO1 CA121110 and U01 CA164188 to HW).	Armstrong AJ, 2011, MOL CANCER RES, V9, P997, DOI 10.1158/1541-7786.MCR-10-0490; Attard G, 2011, CLIN CANCER RES, V17, P3867, DOI 10.1158/1078-0432.CCR-11-0943; Baca Sylvan C, 2012, Front Endocrinol (Lausanne), V3, P69, DOI 10.3389/fendo.2012.00069; Bitting RL, 2014, CANCER METAST REV, V33, P441, DOI 10.1007/s10555-013-9483-z; Bradley D, 2009, CANCER-AM CANCER SOC, V115, P5541, DOI 10.1002/cncr.24597; Brannon AR, 2013, J CLIN INVEST, V123, P4568, DOI 10.1172/JCI70935; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Ferguson M, 2003, NUCLEIC ACIDS RES, V31, P3123, DOI 10.1093/nar/gkg403; Fu MF, 2003, MOL CELL BIOL, V23, P8563, DOI 10.1128/MCB.23.23.8563-8575.2003; Fusco A, 2007, NAT REV CANCER, V7, P899, DOI 10.1038/nrc2271; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gu L, 2015, NAT GENET, V47, P22, DOI 10.1038/ng.3165; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Haelens A, 2007, CANCER RES, V67, P4514, DOI 10.1158/0008-5472.CAN-06-1701; Haffner MC, 2013, J CLIN INVEST, V123, P4918, DOI 10.1172/JCI70354; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Langelotz C, 2003, BRIT J CANCER, V88, P1406, DOI 10.1038/sj.bjc.6600935; Lee S, 2011, CELL MOL LIFE SCI, V68, P325, DOI 10.1007/s00018-010-0457-9; Lei QY, 2006, CANCER CELL, V9, P367, DOI 10.1016/j.ccr.2006.03.031; Li O, 2006, GENESIS, V44, P523, DOI 10.1002/dvg.20242; Liu XM, 2010, PROSTATE, V70, P179, DOI 10.1002/pros.21051; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Luo YZ, 2013, ONCOL LETT, V5, P1353, DOI 10.3892/ol.2013.1193; Marin-Aguilera M, 2014, MOL CANCER THER, V13, P1270, DOI 10.1158/1535-7163.MCT-13-0775; Molife LR, 2010, ANN ONCOL, V21, P109, DOI 10.1093/annonc/mdp270; Mulholland DJ, 2012, CANCER RES, V72, P1878, DOI 10.1158/0008-5472.CAN-11-3132; Mulholland DJ, 2009, CANCER RES, V69, P8555, DOI 10.1158/0008-5472.CAN-08-4673; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; Nishino J, 2008, CELL, V135, P227, DOI 10.1016/j.cell.2008.09.017; Rathkopf D, 2010, CANCER CHEMOTH PHARM, V66, P181, DOI 10.1007/s00280-010-1289-x; Rathkopf DE, 2013, CANCER CHEMOTH PHARM, V72, P537, DOI 10.1007/s00280-013-2224-8; Rescigno P, 2012, CURR DRUG TARGETS, V13, P1676, DOI 10.2174/138945012803529956; Rommel B, 1997, LEUKEMIA LYMPHOMA, V26, P603, DOI 10.3109/10428199709050896; Ruscetti M, 2015, CANCER RES, V75, P2149; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Sun M, 2013, P NATL ACAD SCI USA, V110, P9920, DOI 10.1073/pnas.1305172110; Sun YT, 2012, CANCER RES, V72, P527, DOI 10.1158/0008-5472.CAN-11-3004; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Tanaka H, 2010, NAT MED, V16, P1414, DOI 10.1038/nm.2236; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Watanabe S, 2009, AM J PATHOL, V174, P854, DOI 10.2353/ajpath.2009.080523; Welsbie DS, 2009, CANCER RES, V69, P958, DOI 10.1158/0008-5472.CAN-08-2216; Winslow MM, 2011, NATURE, V473, P101, DOI 10.1038/nature09881; Zha L, 2012, MOL CELL BIOCHEM, V364, P243, DOI 10.1007/s11010-012-1224-z; Zong Y, 2012, P NATL ACAD SCI USA, V109, pE3395, DOI 10.1073/pnas.1217982109	50	85	86	2	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2016	35	29					3781	3795		10.1038/onc.2015.444	http://dx.doi.org/10.1038/onc.2015.444			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS4LS	26640144	Green Accepted			2022-12-17	WOS:000380753200004
J	Chen, HH; Yu, HI; Cho, WC; Tarn, WY				Chen, H-H; Yu, H-I; Cho, W-C; Tarn, W-Y			DDX3 modulates cell adhesion and motility and cancer cell metastasis via Rac1-mediated signaling pathway	ONCOGENE			English	Article							RNA HELICASE DDX3; PROTEIN; BETA; TRANSLATION; REQUIREMENT; REVEALS; TARGET; GROWTH; YEAST; RAC1	The DEAD-box RNA helicase DDX3 is a versatile protein involved in multiple steps of gene expression and various cellular signaling pathways. DDX3 mutations have been implicated in the wingless (Wnt) type of medulloblastoma. We show here that small interfering RNA-mediated DDX3 knockdown in various cell lines increased cell-cell adhesion but decreased cell-extracellular matrix adhesion. Moreover, DDX3 depletion suppressed cell motility and impaired directional migration in the wound-healing assay. Accordingly, DDX3-depleted cells exhibited reduced invasive capacities in vitro as well as reduced metastatic potential in mice. We also examined the mechanism underlying DDX3-regulated cell migration. DDX3 knockdown reduced the levels of both Rac1 and beta-catenin proteins, and consequentially downregulated the expression of several beta-catenin target genes. Moreover, we demonstrated that DDX3-regulated Rac1 mRNA translation, possibly through an interaction with its 5'-untranslated region, and affected beta-catenin protein stability in an Rac1-dependent manner. Taken together, our results indicate the DDX3-Rac1-beta-catenin regulatory axis in modulating the expression of Wnt/beta-catenin target genes. Therefore, this report provides a mechanistic context for the role of DDX3 in Wnt-type tumors.	[Chen, H-H; Yu, H-I; Cho, W-C; Tarn, W-Y] Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Tarn, WY (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Acad Rd,Sect 2, Taipei 11529, Taiwan.	wtarn@ibms.sinica.edu.tw	Tarn, Woan-Yuh/N-8464-2018		National Health Research Institutes of Taiwan [NHRI-EX101-10046NI]	National Health Research Institutes of Taiwan(National Health Research Institutes - Taiwan)	We thank Dr Yi-Shing Shieh for the TOPflash and FOPflash vectors, and Cho-Ying Chiang for technical assistance. This work was supported by a grant (NHRI-EX101-10046NI to WYT) from the National Health Research Institutes of Taiwan.	Akhtar N, 2001, MOL BIOL CELL, V12, P847, DOI 10.1091/mbc.12.4.847; Botlagunta M, 2008, ONCOGENE, V27, P3912, DOI 10.1038/onc.2008.33; Chang FM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028587; Chen BD, 2011, CELL MOL NEUROBIOL, V31, P251, DOI 10.1007/s10571-010-9615-8; Cheon SS, 2006, FASEB J, V20, P692, DOI 10.1096/fj.05-4759com; Chuang RY, 1997, SCIENCE, V275, P1468, DOI 10.1126/science.275.5305.1468; Cruciat CM, 2013, SCIENCE, V339, P1436, DOI 10.1126/science.1231499; Fukumura J, 2003, J BIOCHEM, V134, P71, DOI 10.1093/jb/mvg126; Grallert B, 2000, J CELL SCI, V113, P1447; Hao J, 2006, DEV BIOL, V290, P81, DOI 10.1016/j.ydbio.2005.11.011; Huang JS, 2004, BIOCHEM BIOPH RES CO, V315, P950, DOI 10.1016/j.bbrc.2004.01.151; Jones DTW, 2012, NATURE, V488, P100, DOI 10.1038/nature11284; Kang DW, 2010, CANCER RES, V70, P4233, DOI 10.1158/0008-5472.CAN-09-3470; Koshio J, 2013, CANCER IMMUNOL IMMUN, V62, P1619, DOI 10.1007/s00262-013-1467-x; Lai MC, 2008, MOL BIOL CELL, V19, P3847, DOI 10.1091/mbc.E07-12-1264; Lai MC, 2010, MOL CELL BIOL, V30, P5444, DOI 10.1128/MCB.00560-10; Lee CH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-64; Li JS, 2004, AM J PHYSIOL-ENDOC M, V286, pE818, DOI 10.1152/ajpendo.00307.2003; Marsden S, 2006, J MOL BIOL, V361, P327, DOI 10.1016/j.jmb.2006.06.016; Miao XY, 2013, INT J CLIN EXP PATHO, V6, P179; Muller T, 2002, EXP CELL RES, V280, P119, DOI 10.1006/excr.2002.5630; Parri M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-23; Pugh TJ, 2012, NATURE, V488, P106, DOI 10.1038/nature11329; Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213; Schlessinger K, 2009, GENE DEV, V23, P265, DOI 10.1101/gad.1760809; Schroder M, 2008, EMBO J, V27, P2147, DOI 10.1038/emboj.2008.143; Soto-Rifo R, 2013, NUCLEIC ACIDS RES, V41, P6286, DOI 10.1093/nar/gkt306; Soto-Rifo R, 2012, EMBO J, V31, P3745, DOI 10.1038/emboj.2012.220; Soulat D, 2008, EMBO J, V27, P2135, DOI 10.1038/emboj.2008.126; Sun MN, 2011, BBA-MOL CELL RES, V1813, P438, DOI 10.1016/j.bbamcr.2011.01.003; Tarn WY, 2009, RNA BIOL, V6, P17, DOI 10.4161/rna.6.1.7440; Vidali L, 2006, MOL BIOL CELL, V17, P2377, DOI 10.1091/mbc.E05-10-0955; Wu DW, 2014, ONCOGENE, V33, P1515, DOI 10.1038/onc.2013.107; Yang QS, 2005, BIOCHEMISTRY-US, V44, P13591, DOI 10.1021/bi0508946; Yedavalli VSRK, 2004, CELL, V119, P381, DOI 10.1016/j.cell.2004.09.029; Zavarella S, 2009, J NEUROSURG-PEDIATR, V4, P97, DOI 10.3171/2009.4.PEDS08322; Zhu G, 2012, ONCOGENE, V31, P1001, DOI 10.1038/onc.2011.294	37	85	89	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2790	2800		10.1038/onc.2014.190	http://dx.doi.org/10.1038/onc.2014.190			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25043297				2022-12-17	WOS:000354979500011
J	Zhang, LH; Yin, AA; Cheng, JX; Huang, HY; Li, XM; Zhang, YQ; Han, N; Zhang, X				Zhang, L-H; Yin, A-A; Cheng, J-X; Huang, H-Y; Li, X-M; Zhang, Y-Q; Han, N.; Zhang, X.			TRIM24 promotes glioma progression and enhances chemoresistance through activation of the PI3K/Akt signaling pathway	ONCOGENE			English	Article						glioblastoma; TRIM24; TIF1 alpha; PI3K; Akt; MGMT	GENE-EXPRESSION; MYELOID-LEUKEMIA; P53; TUMORS; VIRUS; CELLS; CHEMOTHERAPY; TEMOZOLOMIDE; INDUCTION; TARGETS	The tripartite motif protein TRIM24 (tripartite motif-containing 24) has been found to play distinct roles in tumor development and progression, according to different tumor contexts. However, it remains elusive whether TRIM24 plays a role in malignant gliomas that are the most common and deadly primary brain tumors in adults. We report here that TRIM24 expression is positively correlated with glioma malignancy and is negatively associated with prognosis of patients with newly diagnosed glioblastoma, which is the most malignant form of gliomas but displays highly heterogeneous clinical outcome. The multivariate Cox regression analysis demonstrates the independent predictive value of TRIM24 expression level for overall and progression-free survival. Knockdown of TRIM24 suppresses cell proliferation, cell cycle progression, clone formation and in vivo tumor development, whereas overexpression of TRIM24 promotes cell growth. Chromatin immunoprecipitation, real-time reverse transcription-PCR and mutation analyses demonstrate that TRIM24 binds to the PIK3CA promoter via its PHD-Bromo domain to activate the transcription of PIK3CA gene, thus enhancing phosphatidylinositide 3-kinase (PI3K)/Akt signaling. The pan-PI3K inhibitor LY294002 and small interfering RNA targeting PIK3CA both abrogate the growth-promoting effect of TRIM24. Moreover, TRIM24 regulates the expression of DNA repair enzyme O-6-methylguanine-DNA methyltransferase (MGMT) through PI3K/Akt/nuclear factor-kappa B signaling transduction and enhances resistance to temozolomide, the standard chemotherapeutic agent for glioblastoma. Finally, glioblastoma patients with low TRIM24 expression benefit from chemotherapy, whereas those with high TRIM24 expression do not have such benefit. Our results suggest that TRIM24 might serve as a potential prognostic marker and therapeutic target for the management of malignant gliomas.	[Zhang, L-H; Yin, A-A; Cheng, J-X; Huang, H-Y; Li, X-M; Zhang, Y-Q; Han, N.; Zhang, X.] Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, Xian 710032, Shaanxi Provinc, Peoples R China	Air Force Military Medical University	Zhang, X (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, Changle West Rd 127, Xian 710032, Shaanxi Provinc, Peoples R China.	zhangluhua211@163.com		Yin, An-An/0000-0002-1888-5551	National Natural Science Foundation of China [30870843, 81171087]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Xiao-Liang Yang, Xi-Qiang Cai and Juan Li for helpful assistance. This work was supported by the National Natural Science Foundation of China (no. 30870843 and no. 81171087) to X Zhang. The funding body does not play any role in the design of the study, collection and analysis of data and decision to publish.	Aghi M, 2008, ONCOGENE, V27, P4249, DOI 10.1038/onc.2008.53; Aghi M, 2006, JNCI-J NATL CANCER I, V98, P38, DOI 10.1093/jnci/djj003; Allton K, 2009, P NATL ACAD SCI USA, V106, P11612, DOI 10.1073/pnas.0813177106; Barbus S, 2011, JNCI-J NATL CANCER I, V103, P598, DOI 10.1093/jnci/djr036; Chambon M, 2011, AM J PATHOL, V178, P1461, DOI 10.1016/j.ajpath.2010.12.026; Chen J, 2012, CELL, V149, P36, DOI 10.1016/j.cell.2012.03.009; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chowdhry S, 2013, ONCOGENE, V32, P3765, DOI 10.1038/onc.2012.388; Danam RP, 2005, MOL CANCER THER, V4, P61; Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218; Fritsch R, 2013, CELL, V153, P1050, DOI 10.1016/j.cell.2013.04.031; Gandini D, 2002, LEUKEMIA, V16, P886, DOI 10.1038/sj.leu.2402452; Hatakeyama S, 2011, NAT REV CANCER, V11, P792, DOI 10.1038/nrc3139; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Herquel B, 2013, NAT STRUCT MOL BIOL, V20, P339, DOI 10.1038/nsmb.2496; Herquel B, 2011, TRANSCR-AUSTIN, V2, P231, DOI 10.4161/trns.2.5.17725; Herquel B, 2011, P NATL ACAD SCI USA, V108, P8212, DOI 10.1073/pnas.1101544108; Hui RCY, 2008, MOL CELL BIOL, V28, P5886, DOI 10.1128/MCB.01265-07; Ignat M, 2008, P NATL ACAD SCI USA, V105, P2598, DOI 10.1073/pnas.0712030105; Ikegami D, 2011, DEVELOPMENT, V138, P1507, DOI 10.1242/dev.057802; Jain AK, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001268; Jain AK, 2009, CELL CYCLE, V8, P3668, DOI 10.4161/cc.8.22.9979; Josset L, 2012, J VIROL, V86, P7192, DOI 10.1128/JVI.00563-12; Kaina B, 2007, DNA REPAIR, V6, P1079, DOI 10.1016/j.dnarep.2007.03.008; Kanai R, 2012, JNCI-J NATL CANCER I, V104, P42, DOI 10.1093/jnci/djr509; Khetchoumian K, 2007, NAT GENET, V39, P1500, DOI 10.1038/ng.2007.15; Kikuchi M, 2009, BBA-MOL CELL RES, V1793, P1828, DOI 10.1016/j.bbamcr.2009.11.001; Ledda-Columbano GM, 2004, CARCINOGENESIS, V25, P2061, DOI 10.1093/carcin/bgh221; Li HY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037657; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Ou HD, 2012, CELL, V151, P304, DOI 10.1016/j.cell.2012.08.035; Quintas-Cardama A, 2012, CANCER-AM CANCER SOC, V118, P5283, DOI 10.1002/cncr.27568; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Tisserand J, 2011, J BIOL CHEM, V286, P33369, DOI 10.1074/jbc.M111.225680; Tolcher AW, 2003, BRIT J CANCER, V88, P1004, DOI 10.1038/sj.bjc.6600827; Tsai WW, 2010, NATURE, V468, P927, DOI 10.1038/nature09542; Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Worster DT, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2001986	41	85	89	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					600	610		10.1038/onc.2013.593	http://dx.doi.org/10.1038/onc.2013.593			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24469053				2022-12-17	WOS:000348853500007
J	He, Y; Jiang, X; Chen, J				He, Y.; Jiang, X.; Chen, J.			The role of miR-150 in normal and malignant hematopoiesis	ONCOGENE			English	Review						miR-150; hematopoiesis; hematopoietic malignancies; expression profiles; gene regulation; target genes	B-CELL DEVELOPMENT; C-MYB; MICRORNA EXPRESSION; MEDIATED CONTROL; MLL; LEUKEMIA; IDENTIFICATION; LYMPHOMA; LINEAGE; DIFFERENTIATION	MicroRNAs are a class of small non-coding RNAs that have been implicated to mediate gene regulation in virtually all important biological processes. Recently there is accumulating evidence showing that miR-150 has essential regulatory roles in both normal and malignant hematopoiesis and holds great potential as a therapeutic target in treating various types of hematopoietic malignancies. The purpose of this review is to summarize our current knowledge about the expression patterns, biological functions and regulatory mechanisms of miR-150 in normal and malignant hematopoiesis, and to highlight the important questions to be answered in this burgeoning field.	[He, Y.; Jiang, X.; Chen, J.] Univ Chicago, Comm Canc Biol, Chicago, IL 60637 USA; [Jiang, X.; Chen, J.] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Chen, J (corresponding author), Univ Chicago, Dept Med, Hematol Oncol Sect, 900 E 57th St,Room 7134, Chicago, IL 60637 USA.	jchen@bsd.uchicago.edu			National Institutes of Health (NIH) [CA127277]; American Cancer Society (ACS); University of Chicago Committee on Cancer Biology (CCB); Gabrielle's Angel Foundation for Cancer Research; NATIONAL CANCER INSTITUTE [R01CA127277] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society (ACS)(American Cancer Society); University of Chicago Committee on Cancer Biology (CCB); Gabrielle's Angel Foundation for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the National Institutes of Health (NIH) R01 grant CA127277 (JC), American Cancer Society (ACS) Research Scholar grant (JC), The University of Chicago Committee on Cancer Biology (CCB) Fellowship Program (YH; XJ), and Gabrielle's Angel Foundation for Cancer Research (JC; XJ).	Adams BD, 2012, CELL REP, V2, P1048, DOI 10.1016/j.celrep.2012.09.014; Agirre X, 2008, MOL CANCER RES, V6, P1830, DOI 10.1158/1541-7786.MCR-08-0167; Barroga CF, 2008, EXP HEMATOL, V36, P1585, DOI 10.1016/j.exphem.2008.07.001; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Behm FG, 1996, BLOOD, V87, P2870, DOI 10.1182/blood.V87.7.2870.bloodjournal8772870; Bender TP, 2004, NAT IMMUNOL, V5, P721, DOI 10.1038/ni1085; Bezman NA, 2011, J EXP MED, V208, P2717, DOI 10.1084/jem.20111386; Bousquet M, 2013, MOL CANCER RES, V11, P912, DOI 10.1158/1541-7786.MCR-13-0002-T; Bruchova H, 2007, EXP HEMATOL, V35, P1657, DOI 10.1016/j.exphem.2007.08.021; Cai JP, 2012, GRAEF ARCH CLIN EXP, V250, P523, DOI 10.1007/s00417-011-1885-4; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chang TC, 2009, P NATL ACAD SCI USA, V106, P3384, DOI 10.1073/pnas.0808300106; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen JJ, 2010, NAT REV CANCER, V10, P23, DOI 10.1038/nrc2765; Chen SH, 2013, CANCER SCI, V104, P826, DOI 10.1111/cas.12156; Emambokus N, 2003, EMBO J, V22, P4478, DOI 10.1093/emboj/cdg434; Faber J, 2009, BLOOD, V113, P2375, DOI 10.1182/blood-2007-09-113597; Fang J, 2012, CURR PHARM DESIGN, V18, P3170, DOI 10.2174/1381612811209023170; Fayyad-Kazan H, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-31; Fulci V, 2007, BLOOD, V109, P4944, DOI 10.1182/blood-2006-12-062398; Garzon R, 2008, CURR OPIN HEMATOL, V15, P352, DOI 10.1097/MOH.0b013e328303e15d; Ghisi M, 2011, BLOOD, V117, P7053, DOI 10.1182/blood-2010-12-326629; Gibcus JH, 2009, NEOPLASIA, V11, P167, DOI 10.1593/neo.08980; Guo YS, 2009, BLOOD, V114, P2097, DOI 10.1182/blood-2009-01-197947; HE L, 2004, NAT REV GENET, V5, P522; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Hussein K, 2010, LEUKEMIA RES, V34, P328, DOI 10.1016/j.leukres.2009.06.014; Jiang X, 2012, ONCOTARGET, V3, P1268; Jiang X, 2012, CANCER CELL, V22, P524, DOI 10.1016/j.ccr.2012.08.028; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Lawrie CH, 2013, BRIT J HAEMATOL, V160, P571, DOI 10.1111/bjh.12157; Li ZJ, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1681; Lu J, 2008, DEV CELL, V14, P843, DOI 10.1016/j.devcel.2008.03.012; Machova Polakova K, 2011, MOL CANCER, V10, P41, DOI DOI 10.1186/1476-4598-10-41; Marcucci G, 2011, BLOOD, V117, P1121, DOI 10.1182/blood-2010-09-191312; Marcucci Guido, 2009, Curr Hematol Malig Rep, V4, P83, DOI 10.1007/s11899-009-0012-7; Mi SL, 2010, P NATL ACAD SCI USA, V107, P3710, DOI 10.1073/pnas.0914900107; Monticelli S, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-r71; Moussay E, 2011, P NATL ACAD SCI USA, V108, P6573, DOI 10.1073/pnas.1019557108; Mullighan CG, 2009, SEMIN HEMATOL, V46, P3, DOI 10.1053/j.seminhematol.2008.09.005; Muntean AG, 2012, ANNU REV PATHOL-MECH, V7, P283, DOI 10.1146/annurev-pathol-011811-132434; Newman MA, 2010, GENE DEV, V24, P1086, DOI 10.1101/gad.1919710; Ntziachristos P, 2013, ADV IMMUNOL, V117, P1, DOI 10.1016/B978-0-12-410524-9.00001-3; Orkin SH, 2008, CELL, V132, P631, DOI 10.1016/j.cell.2008.01.025; Patel JP, 2012, NEW ENGL J MED, V366, P1079, DOI 10.1056/NEJMoa1112304; Popovic R, 2009, BLOOD, V113, P3314, DOI 10.1182/blood-2008-04-154310; Rowley JD, 2008, BLOOD, V112, P2183, DOI 10.1182/blood-2008-04-097931; Schotte D, 2009, LEUKEMIA, V23, P313, DOI 10.1038/leu.2008.286; Siomi H, 2010, MOL CELL, V38, P323, DOI 10.1016/j.molcel.2010.03.013; Thomas MD, 2005, IMMUNITY, V23, P275, DOI 10.1016/j.immuni.2005.08.005; Vegiopoulos A, 2006, BLOOD, V107, P4703, DOI 10.1182/blood-2005-07-2968; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wang M, 2008, J PATHOL, V215, P13, DOI 10.1002/path.2333; Wang Y, 2006, CURR CANCER THER REV, V2, P271, DOI 10.2174/157339406777934717; Wang YG, 2010, BLOOD CELL MOL DIS, V44, P191, DOI 10.1016/j.bcmd.2009.12.010; Watanabe A, 2011, LEUKEMIA, V25, P1324, DOI 10.1038/leu.2011.81; Xiao CC, 2007, CELL, V131, P146, DOI 10.1016/j.cell.2007.07.021; Xiao CC, 2009, CELL, V136, P26, DOI 10.1016/j.cell.2008.12.027; Xu Ling, 2011, Zhonghua Xue Ye Xue Za Zhi, V32, P178; Zanette DL, 2007, BRAZ J MED BIOL RES, V40, P1435, DOI 10.1590/S0100-879X2007001100003; Zeisig BB, 2004, MOL CELL BIOL, V24, P617, DOI 10.1128/MCB.24.2.617-628.2004; Zhang H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007826; Zhao JJ, 2010, BLOOD, V115, P2630, DOI 10.1182/blood-2009-09-243147; Zheng QH, 2012, J IMMUNOL, V188, P2118, DOI 10.4049/jimmunol.1103342; Zhou BY, 2007, P NATL ACAD SCI USA, V104, P7080, DOI 10.1073/pnas.0702409104; Zuber J, 2011, GENE DEV, V25, P1628, DOI 10.1101/gad.17269211	67	85	93	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2014	33	30					3887	3893		10.1038/onc.2013.346	http://dx.doi.org/10.1038/onc.2013.346			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8NA	23955084				2022-12-17	WOS:000339394700001
J	D'Assoro, AB; Liu, T; Quatraro, C; Amato, A; Opyrchal, M; Leontovich, A; Ikeda, Y; Ohmine, S; Lingle, W; Suman, V; Ecsedy, J; Iankov, I; Di Leonardo, A; Ayers-Ringler, J; Degnim, A; Billadeau, D; McCubrey, J; Ingle, J; Salisbury, JL; Galanis, E				D'Assoro, A. B.; Liu, T.; Quatraro, C.; Amato, A.; Opyrchal, M.; Leontovich, A.; Ikeda, Y.; Ohmine, S.; Lingle, W.; Suman, V.; Ecsedy, J.; Iankov, I.; Di Leonardo, A.; Ayers-Ringler, J.; Degnim, A.; Billadeau, D.; McCubrey, J.; Ingle, J.; Salisbury, J. L.; Galanis, E.			The mitotic kinase Aurora-A promotes distant metastases by inducing epithelial-to-mesenchymal transition in ER alpha(+) breast cancer cells	ONCOGENE			English	Article						breast cancer; stemness; metastases	P53 FUNCTION LEADS; CENTROSOME AMPLIFICATION; STEM-CELLS; ERBB2; PROGRESSION; OVEREXPRESSION; PROLIFERATION; TUMORIGENESIS; EXPRESSION; RESISTANCE	In this study, we demonstrate that constitutive activation of Raf-1 oncogenic signaling induces stabilization and accumulation of Aurora-A mitotic kinase that ultimately drives the transition from an epithelial to a highly invasive mesenchymal phenotype in estrogen receptor alpha-positive (ER alpha(+)) breast cancer cells. The transition from an epithelial- to a mesenchymal-like phenotype was characterized by reduced expression of ER alpha, HER-2/Neu overexpression and loss of CD24 surface receptor (CD24(-/low)). Importantly, expression of key epithelial-to-mesenchymal transition (EMT) markers and upregulation of the stemness gene SOX2 was linked to acquisition of stem cell-like properties such as the ability to form mammospheres in vitro and tumor self-renewal in vivo. Moreover, aberrant Aurora-A kinase activity induced phosphorylation and nuclear translocation of SMAD5, indicating a novel interplay between Aurora-A and SMAD5 signaling pathways in the development of EMT, stemness and ultimately tumor progression. Importantly, pharmacological and molecular inhibition of Aurora-A kinase activity restored a CD24(+) epithelial phenotype that was coupled to ER alpha expression, downregulation of HER-2/Neu, inhibition of EMT and impaired self-renewal ability, resulting in the suppression of distant metastases. Taken together, our findings show for the first time the causal role of Aurora-A kinase in the activation of EMT pathway responsible for the development of distant metastases in ER alpha(+) breast cancer cells. Moreover, this study has important translational implications because it highlights the mitotic kinase Aurora-A as a novel promising therapeutic target to selectively eliminate highly invasive cancer cells and improve the disease-free and overall survival of ER alpha(+) breast cancer patients resistant to conventional endocrine therapy.	[D'Assoro, A. B.; Liu, T.; Quatraro, C.; Amato, A.; Ayers-Ringler, J.; Salisbury, J. L.] Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; [D'Assoro, A. B.; Opyrchal, M.; Suman, V.; Billadeau, D.; Ingle, J.; Galanis, E.] Mayo Clin, Coll Med, Dept Med Oncol, Rochester, MN 55905 USA; [Amato, A.; Di Leonardo, A.] Dept Cellular & Dev Biol, Palermo, Italy; [Opyrchal, M.; Ikeda, Y.; Ohmine, S.; Iankov, I.; Galanis, E.] Mayo Clin, Coll Med, Dept Mol Med, Rochester, MN 55905 USA; [Leontovich, A.] Mayo Clin, Coll Med, Dept Biomed Stat & Informat, Rochester, MN 55905 USA; [Lingle, W.] Mayo Clin, Coll Med, Dept Expt Pathol, Rochester, MN 55905 USA; [Ecsedy, J.] Millennium Pharmaceut Inc, Dept Oncol, Cambridge, MA USA; [Degnim, A.] Mayo Clin, Coll Med, Dept Gen Surg, Rochester, MN 55905 USA; [McCubrey, J.] E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Mayo Clinic; University of North Carolina; East Carolina University	D'Assoro, AB (corresponding author), Mayo Clin, Coll Med, Dept Biochem & Mol Biol, 200 First St SW, Rochester, MN 55905 USA.	Dassoro.antonio@mayo.edu	Di Leonardo, Aldo/F-9833-2012; Amato, Angela/T-1221-2019; Di Leonardo, Aldo/AAQ-4009-2021	Di Leonardo, Aldo/0000-0003-4760-7179; Di Leonardo, Aldo/0000-0003-4760-7179; McCubrey, James/0000-0001-6027-3156; Salisbury, Jeffrey/0000-0001-9257-4578	NCI [CA72836]; USAMRMC [BC022276]; Intramural RECDA Award; Italian Association for Cancer Research (AIRC); Mayo Clinic Breast Cancer Specialized Program of Research Excellence NIH [CA116201]; Mayo Clinic School of Medicine; Atwater Foundation; NATIONAL CANCER INSTITUTE [R01CA072836, P30CA015083, P50CA116201] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); USAMRMC(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); Intramural RECDA Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Mayo Clinic Breast Cancer Specialized Program of Research Excellence NIH; Mayo Clinic School of Medicine; Atwater Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NCI CA72836 to JLS, USAMRMC BC022276 and Intramural RECDA Award to ABD, the Italian Association for Cancer Research (AIRC) to AA, the Mayo Clinic Breast Cancer Specialized Program of Research Excellence NIH CA116201 to JI and the Mayo Clinic School of Medicine. This study was also supported by the Atwater Foundation. We also wish to acknowledge the Cytogenetic Shared Resource and TACMA core facilities of the Mayo Clinic Comprehensive Cancer Center for performing SKY, routine cytogenetic and immunohistochemistry analysis and assisting us with the interpretation of the results.	Abraham BK, 2005, CLIN CANCER RES, V11, P1154; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; Basaran G, 2011, MED ONCOL, V28, P726, DOI 10.1007/s12032-010-9516-1; Basto R, 2008, CELL, V133, P1032, DOI 10.1016/j.cell.2008.05.039; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035; Chang H, 2009, ANN ONCOL, V20, P272, DOI 10.1093/annonc/mdn624; D'Assoro AB, 2008, ONCOGENE, V27, P3901, DOI 10.1038/onc.2008.18; D'Assoro AB, 2004, ONCOGENE, V23, P4068, DOI 10.1038/sj.onc.1207568; D'Assoro AB, 2002, BREAST CANCER RES TR, V75, P25, DOI 10.1023/A:1016550619925; D'Assoro AB, 2010, INT J ONCOL, V37, P1167, DOI 10.3892/ijo_00000768; Davis JM, 2003, CLIN CANCER RES, V9, P1161; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Eralp Y, 2008, ANN ONCOL, V19, P669, DOI 10.1093/annonc/mdm522; Ghayad SE, 2010, INT J CANCER, V126, P545, DOI 10.1002/ijc.24750; Giatromanolaki A, 2011, MED ONCOL, V28, P745, DOI 10.1007/s12032-010-9530-3; Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914; Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108; Hwang-Verslues WW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008377; Jin W, 2003, BRIT J CANCER, V89, P185, DOI 10.1038/sj.bjc.6601048; Kerkhoff E, 2000, CELL GROWTH DIFFER, V11, P185; Kim ES, 2005, CYTOKINE, V29, P84, DOI 10.1016/j.cyto.2004.10.001; Kim IY, 2009, CANCER LETT, V275, P227, DOI 10.1016/j.canlet.2008.10.013; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Korkaya H, 2010, NAT CELL BIOL, V12, P419, DOI 10.1038/ncb0510-419; Lu J, 2009, CANCER CELL, V16, P195, DOI 10.1016/j.ccr.2009.08.010; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marampon F, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-31; Murohashi M, 2010, BRIT J CANCER, V102, P206, DOI 10.1038/sj.bjc.6605468; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Roesler R, 2010, LANCET ONCOL, V11, P225, DOI 10.1016/S1470-2045(09)70404-8; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Strathdee G, 2002, SEMIN CANCER BIOL, V12, P373, DOI 10.1016/S1044-579X(02)00057-3; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Turley EA, 2008, NAT CLIN PRACT ONCOL, V5, P280, DOI 10.1038/ncponc1089; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Wendt MK, 2010, ONCOGENE, V29, P6485, DOI 10.1038/onc.2010.377; Whyte J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2361; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Yu DH, 2000, BIOESSAYS, V22, P673, DOI 10.1002/1521-1878(200007)22:7<673::AID-BIES10>3.0.CO;2-A; Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538	44	85	86	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					599	610		10.1038/onc.2012.628	http://dx.doi.org/10.1038/onc.2012.628			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23334326	Green Accepted			2022-12-17	WOS:000331125100008
J	Inaguma, S; Kasai, K; Ikeda, H				Inaguma, S.; Kasai, K.; Ikeda, H.			GLI1 facilitates the migration and invasion of pancreatic cancer cells through MUC5AC-mediated attenuation of E-cadherin	ONCOGENE			English	Article						GLI1; MUC5AC; E-cadherin; beta-catenin; invasion; pancreatic cancer	GENE-EXPRESSION; MUC5AC MUCIN; HEDGEHOG; PROGNOSIS; TARGET; GROWTH; ASSOCIATION; REQUIREMENT; PROTEIN; CHOLANGIOCARCINOMA	The Kruppel-like zinc-finger protein GLI1 functions as a downstream transcription factor of Hedgehog signaling and plays a pivotal role in the cellular proliferation of many types of tumors, including pancreatic ductal adenocarcinoma (PDA). PDA develops from dysplastic lesions called pancreatic intraepithelial neoplasia (PanIN) through a multistep carcinogenesis process that changes its cellular characteristics, including a mucin expression profile. Increased expression of a gel-forming mucin, MUC5AC, was previously revealed as a major biomarker for the poor prognosis of PDA patients, but the molecular mechanisms responsible for its expression and correlation with poor prognosis are not fully understood. Here we show that MUC5AC is a direct transcriptional target of GLI1 in PDA cells. Overexpression of GLI1 enhanced MUC5AC expression, and a double knockdown of GLI1 and GLI2 suppressed endogenous MUC5AC expression in PDA cells. Luciferase reporter assays revealed that GLI1 and GLI2 can activate the MUC5AC promoter through its conserved CACCC-box-like cis-regulatory elements. We also found that GLI1-upregulated MUC5AC was expressed in the intercellular junction between cultured PDA cells and interfered with the membrane localization of E-cadherin, leading to decreased E-cadherin-dependent cell-cell adhesion and promoting the migration and invasion of PDA cells. Consistently, GLI1 induced the nuclear accumulation and target gene expression of beta-catenin in a MUC5AC-dependent manner. Finally, immunohistochemical analysis revealed that GLI1 expression statistically correlated with MUC5AC expression and also with altered subcellular localization of E-cadherin and beta-catenin in PanIN lesions and PDA. This evidence revealed a new aspect of GLI1 function in modulating E-cadherin/beta-catenin-regulated cancer cell properties through the expression of a gel-forming mucin. Oncogene (2011) 30, 714-723; doi:10.1038/onc.2010.459; published online 25 October 2010	[Inaguma, S.; Kasai, K.; Ikeda, H.] Aichi Med Univ, Dept Pathol, Sch Med, Aichi 4801195, Japan	Aichi Medical University	Kasai, K (corresponding author), Aichi Med Univ, Dept Pathol, Sch Med, 21 Karimata, Aichi 4801195, Japan.	kkasai@aichi-med-u.ac.jp	Kasai, Kenji/K-6382-2019	Kasai, Kenji/0000-0001-6566-9483	Japan Society for the Promotion of Science	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	We thank Yukiko Matsubara, Motoyasu Takeuchi and Naoki Igari (Aichi Medical University) for their expert technical assistance. We also thank Dr Akiko Tamakoshi (Aichi Medical University) for advice on statistical analyses and Dr Masahide Takahashi (Nagoya University) for comments on the manuscript. This research was supported in part by a Grant-in-Aid for Scientific Research (C) (to KK) and for Young Scientists (B) (to SI) from the Japan Society for the Promotion of Science.	Agren M, 2004, GENE, V330, P101, DOI 10.1016/j.gene.2004.01.010; Aishima S, 2006, HISTOPATHOLOGY, V49, P35, DOI 10.1111/j.1365-2559.2006.02414.x; Al-Aynati MM, 2004, CLIN CANCER RES, V10, P1235, DOI 10.1158/1078-0432.CCR-03-0087; Bafna S, 2010, ONCOGENE, V29, P2893, DOI 10.1038/onc.2010.87; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Boonla C, 2003, CANCER, V98, P1438, DOI 10.1002/cncr.11652; Briggs CD, 2009, EUR J CANCER, V45, P33, DOI 10.1016/j.ejca.2008.08.024; di Magliano MP, 2006, GENE DEV, V20, P3161, DOI 10.1101/gad.1470806; Eichberger T, 2006, GENOMICS, V87, P616, DOI 10.1016/j.ygeno.2005.12.003; Gkretsi V, 2005, J CELL SCI, V118, P697, DOI 10.1242/jcs.01638; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Jepson S, 2002, ONCOGENE, V21, P7524, DOI 10.1038/sj.onc.1205970; Kasai K, 2004, GENES CELLS, V9, P49, DOI 10.1111/j.1356-9597.2004.00701.x; Kasai K, 2008, CANCER RES, V68, P7723, DOI 10.1158/0008-5472.CAN-07-6661; Kasper M, 2006, MOL CELL BIOL, V26, P6283, DOI 10.1128/MCB.02317-05; Lee HS, 2001, CANCER, V92, P1427, DOI 10.1002/1097-0142(20010915)92:6<1427::AID-CNCR1466>3.0.CO;2-L; Li DZ, 1998, J BIOL CHEM, V273, P6812, DOI 10.1074/jbc.273.12.6812; Nolan-Stevaux O, 2009, GENE DEV, V23, P24, DOI 10.1101/gad.1753809; Park ET, 2008, INT J CANCER, V122, P1253, DOI 10.1002/ijc.23225; Prasad NB, 2005, CANCER RES, V65, P1619, DOI 10.1158/0008-5472.CAN-04-1413; Sanada Y, 2006, PANCREAS, V32, P164, DOI 10.1097/01.mpa.0000202947.80117.a0; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Senapati S, 2008, HISTOL HISTOPATHOL, V23, P1541, DOI 10.14670/HH-23.1541; Shimokawa T, 2003, CANCER RES, V63, P6116; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Singh AP, 2008, LANCET ONCOL, V9, P1076, DOI 10.1016/S1470-2045(08)70277-8; Takikita M, 2009, CANCER RES, V69, P2950, DOI 10.1158/0008-5472.CAN-08-3879; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Truant S, 2003, INT J CANCER, V104, P683, DOI 10.1002/ijc.11011; Vincent A, 2007, ONCOGENE, V26, P6566, DOI 10.1038/sj.onc.1210479; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; Yauch RL, 2008, NATURE, V455, P406, DOI 10.1038/nature07275; Yoon JW, 2002, J BIOL CHEM, V277, P5548, DOI 10.1074/jbc.M105708200; Yu CJ, 1996, INT J CANCER, V69, P457, DOI 10.1002/(SICI)1097-0215(19961220)69:6<457::AID-IJC7>3.0.CO;2-3; Yu CJ, 2005, LUNG CANCER, V47, P59, DOI 10.1016/j.lungcan.2004.05.018	35	85	90	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	6					714	723		10.1038/onc.2010.459	http://dx.doi.org/10.1038/onc.2010.459			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	719GY	20972463				2022-12-17	WOS:000287192000008
J	Zibat, A; Missiaglia, E; Rosenberger, A; Pritchard-Jones, K; Shipley, J; Hahn, H; Fulda, S				Zibat, A.; Missiaglia, E.; Rosenberger, A.; Pritchard-Jones, K.; Shipley, J.; Hahn, H.; Fulda, S.			Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma	ONCOGENE			English	Article						rhabdomyosarcoma; hedgehog; ERMS; ARMS	SIGNALING PATHWAY; EXPRESSION; GLI; MEDULLOBLASTOMA; CANCER; CLASSIFICATION; IDENTIFICATION; AMPLIFICATION; INHIBITION; SARCOMA	Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and comprises two major histological subtypes: alveolar rhabdomyosarcoma (ARMS) and embryonal rhabdomyosarcoma (ERMS). Seventy-five percent of ARMS harbor reciprocal chromosomal translocations leading to fusion genes of the forkhead transcription factor FOXO1 and PAX3 or PAX7. The hedgehog (Hh) pathway has been implied in tumor formation and progression of various cancers including RMS. However, whether Hh pathway activation presents a general feature of RMS or whether it is restricted to specific subgroups has not yet been addressed. Here, we report that marker genes of active Hh signaling, that is, Patched1 (Ptch1), Gli1, Gli3 and Myf5, are expressed at significantly higher levels in ERMS and fusion gene-negative ARMS compared with fusion gene-positive ARMS in two distinct cohorts of RMS patients. Consistently, Gli1 expression correlates with Ptch1 expression in ERMS and fusion gene-negative ARMS, but not in fusion gene-positive ARMS. In addition, expression levels of MyoD1 are significantly lower in ERMS and fusion gene-negative ARMS, pointing to an inverse association of Hh activation and early muscle differentiation. Moreover, Myf5 is identified as a novel excellent class predictor for RMS by receiver operating characteristic analysis. Importantly, high expression of Ptch1 or low MyoD1 expression significantly correlate with reduced cumulative survival in fusion gene-negative RMS underscoring the clinical relevance of these findings. By showing that Hh signaling is preferentially activated in specific subgroups of RMS, our study has important implications for molecular targeted therapies, such as small molecule Hh inhibitors, in RMS. Oncogene (2010) 29, 6323-6330; doi:10.1038/onc.2010.368; published online 6 September 2010	[Zibat, A.; Hahn, H.] Univ Goettingen, Inst Human Genet, Gottingen, Germany; [Missiaglia, E.; Pritchard-Jones, K.; Shipley, J.] Inst Canc Res, Dept Mol Cytogenet, Sutton, Surrey, England; [Rosenberger, A.] Univ Goettingen, Dept Genet Epidemiol, Gottingen, Germany; [Fulda, S.] Univ Childrens Hosp, Dept Hematol Oncol, Ulm, Baden Wuerttemb, Germany	University of Gottingen; University of London; Institute of Cancer Research - UK; University of Gottingen; Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3A, D-60528 Frankfurt, Germany.	simone.fulda@kgu.de	Pritchard-Jones, Kathy/F-4286-2014; Fulda, Simone/D-5864-2011	Pritchard-Jones, Kathy/0000-0002-2384-9475; missiaglia, edoardo/0000-0001-9221-0117; Fulda, Simone/0000-0002-0459-6417; Shipley, Janet/0000-0001-6748-8678	Deutsche Forschungsgemeinschaft; Bundesministerium fur Bildung und Forschung; European Community; Wilhelm-Sander-Stiftung [2003.112.3]; Chris Lucas Trust;  [IAP6/18]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); European Community(European Commission); Wilhelm-Sander-Stiftung; Chris Lucas Trust; 	This work has been supported by grants from the Deutsche Forschungsgemeinschaft, the Bundesministerium fur Bildung und Forschung, the European Community (ApopTrain, APOSYS) and IAP6/18 (to SF), and from the Wilhelm-Sander-Stiftung 2003.112.3 (to HH). We would like to thank the Chris Lucas Trust for their support (to EM) and the Children's Cancer and Leukemia Group for providing tumor material and clinical information. La Ligue Nationale Contre Le Cancer in collaboration with Olivier Delattre kindly supported the expression profiling of tumors.	Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Barr FG, 2002, CANCER RES, V62, P4704; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bijlsma MF, 2006, PLOS BIOL, V4, P1397, DOI 10.1371/journal.pbio.0040232; Dagher R, 1999, Oncologist, V4, P34; Dantonello TM, 2009, J CLIN ONCOL, V27, P1446, DOI 10.1200/JCO.2007.15.0466; Davicioni E, 2006, CANCER RES, V66, P6936, DOI 10.1158/0008-5472.CAN-05-4578; Davicioni E, 2009, AM J PATHOL, V174, P550, DOI 10.2353/ajpath.2009.080631; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Gerber AN, 2007, ONCOGENE, V26, P1122, DOI 10.1038/sj.onc.1209891; Gustafsson MK, 2002, GENE DEV, V16, P114, DOI 10.1101/gad.940702; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Hayes-Jordan A, 2009, CURR OPIN PEDIATR, V21, P373, DOI 10.1097/MOP.0b013e32832b4171; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Kappler R, 2004, ONCOGENE, V23, P8785, DOI 10.1038/sj.onc.1208133; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; KHATIB ZA, 1993, CANCER RES, V53, P5535; Koleva M, 2005, CELL MOL LIFE SCI, V62, P1863, DOI 10.1007/s00018-005-5072-9; Langenau DM, 2007, GENE DEV, V21, P1382, DOI 10.1101/gad.1545007; McDermott A, 2005, DEVELOPMENT, V132, P345, DOI 10.1242/dev.01537; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Missiaglia E, 2009, GENE CHROMOSOME CANC, V48, P455, DOI 10.1002/gcc.20655; Nicol K, 2007, PEDIATR DEVEL PATHOL, V10, P89, DOI 10.2350/06-03-0068.1; Oue T, 2010, J PEDIATR SURG, V45, P387, DOI 10.1016/j.jpedsurg.2009.10.081; Ragazzini P, 2004, HISTOL HISTOPATHOL, V19, P401, DOI 10.14670/HH-19.401; ROBERTS WM, 1989, CANCER RES, V49, P5407; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Scales SJ, 2009, TRENDS PHARMACOL SCI, V30, P303, DOI 10.1016/j.tips.2009.03.007; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Tomczak KK, 2003, FASEB J, V17, P403, DOI 10.1096/f.03-0568fje; Tostar U, 2006, J PATHOL, V208, P17, DOI 10.1002/path.1882; Von Hoff DD, 2009, NEW ENGL J MED, V361, P1164, DOI 10.1056/NEJMoa0905360; Wachtel M, 2006, J CLIN ONCOL, V24, P816, DOI 10.1200/JCO.2005.03.4934; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Williamson D, 2010, J CLIN ONCOL, V28, P2151, DOI 10.1200/JCO.2009.26.3814	39	85	93	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	48					6323	6330		10.1038/onc.2010.368	http://dx.doi.org/10.1038/onc.2010.368			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	688SW	20818440				2022-12-17	WOS:000284874700003
J	Maniati, E; Soper, R; Hagemann, T				Maniati, E.; Soper, R.; Hagemann, T.			Up for Mischief? IL-17/Th17 in the tumour microenvironment	ONCOGENE			English	Review						IL-17; Th17; cancer; inflammation; tumour microenvironment	REGULATORY T-CELLS; GROWTH-FACTOR-BETA; ROR-GAMMA-T; CANCER-RELATED INFLAMMATION; BRONCHIAL EPITHELIAL-CELLS; COLONY-STIMULATING FACTOR; AIRWAYS IN-VIVO; TH17 CELLS; CUTTING EDGE; TGF-BETA	The role of interleukin (IL)-17 and the IL-17-producing T helper (Th)17 cells in cancer has recently become the focus of extensive investigation. An expanding body of literature implicates Th17 cells and their hallmark cytokine in both pro-and anti-tumourigenic processes. In this review we describe their biological activities and outline the reciprocal interactions between Th17 cells and other cells of the immune system. We also discuss the evidence regarding their dual role in the tumour microenvironment. An understanding of the processes that regulate the pro-or anti-tumour activities of Th17 cell and IL-17 will allow the development of more effective means for cancer immunotherapy. Oncogene (2010) 29, 5653-5662; doi:10.1038/onc.2010.367; published online 23 August 2010	[Maniati, E.; Soper, R.; Hagemann, T.] Queen Mary Univ London, Ctr Canc & Inflammat, Inst Canc, Barts & London Sch Med & Dent, London EC1M 6BQ, England	University of London; Queen Mary University London	Hagemann, T (corresponding author), Queen Mary Univ London, Ctr Canc & Inflammat, Inst Canc, Barts & London Sch Med & Dent, Charterhouse Sq, London EC1M 6BQ, England.	t.hagemann@qmul.ac.uk	Maniati, Eleni/ABC-4551-2020		Medical Research Council; Cancer Research UK; MRC [G0601867] Funding Source: UKRI; Medical Research Council [G0601867] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the Medical Research Council (to T Hagemann and R Soper) and Cancer Research UK (to T Hagemann and E Maniati).	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Aggarwal S, 2002, J LEUKOCYTE BIOL, V71, P1; Aspord C, 2007, J EXP MED, V204, P1037, DOI 10.1084/jem.20061120; Ayyoub M, 2009, P NATL ACAD SCI USA, V106, P8635, DOI 10.1073/pnas.0900621106; Balkwill F, 2006, CANCER METAST REV, V25, P409, DOI 10.1007/s10555-006-9005-3; Benchetrit F, 2002, BLOOD, V99, P2114, DOI 10.1182/blood.V99.6.2114; Bending D, 2009, J CLIN INVEST, V119, P565, DOI 10.1172/JCI37865; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Beyer M, 2006, BLOOD, V108, P804, DOI 10.1182/blood-2006-02-002774; Boon T, 2006, ANNU REV IMMUNOL, V24, P175, DOI 10.1146/annurev.immunol.24.021605.090733; Chang SH, 2006, J BIOL CHEM, V281, P35603, DOI 10.1074/jbc.C600256200; Charles KA, 2009, J CLIN INVEST, V119, P3011, DOI 10.1172/JCI39065; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Deknuydt F, 2009, CLIN IMMUNOL, V131, P298, DOI 10.1016/j.clim.2008.12.008; DeNardo DG, 2009, CANCER CELL, V16, P91, DOI 10.1016/j.ccr.2009.06.018; Derhovanessian E, 2009, INT J CANCER, V125, P1372, DOI 10.1002/ijc.24497; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Ferretti S, 2003, J IMMUNOL, V170, P2106, DOI 10.4049/jimmunol.170.4.2106; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Gaffen SL, 2004, ARTHRITIS RES THER, V6, P240, DOI 10.1186/ar1444; Ghadjar P, 2009, INT J CANCER, V125, P741, DOI 10.1002/ijc.24468; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haqqani AS, 2000, NEOPLASIA, V2, P561, DOI 10.1038/sj.neo.7900110; Haudenschild D, 2002, J BIOL CHEM, V277, P4309, DOI 10.1074/jbc.M109372200; He DG, 2010, J IMMUNOL, V184, P2281, DOI 10.4049/jimmunol.0902574; Hinrichs CS, 2009, BLOOD, V114, P596, DOI 10.1182/blood-2009-02-203935; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; Horlock C, 2009, BRIT J CANCER, V100, P1061, DOI 10.1038/sj.bjc.6604963; Hoshino H, 1999, AM J RESP CRIT CARE, V159, P1423, DOI 10.1164/ajrccm.159.5.9806008; Hoshino H, 2000, J ALLERGY CLIN IMMUN, V105, P143, DOI 10.1016/S0091-6749(00)90189-1; Houghton AM, 2010, NAT MED, V16, P219, DOI 10.1038/nm.2084; Huang SH, 2004, ALLERGY ASTHMA PROC, V25, P17; Huang XM, 2003, FRONT BIOSCI-LANDMRK, V8, pS740, DOI 10.2741/1093; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Jones CE, 2002, AM J RESP CELL MOL, V26, P748, DOI 10.1165/ajrcmb.26.6.4757; Jovanovic DV, 1998, J IMMUNOL, V160, P3513; Kawaguchi M, 2001, J ALLERGY CLIN IMMUN, V108, P804, DOI 10.1067/mai.2001.119027; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Kolls JK, 2003, AM J RESP CELL MOL, V28, P9, DOI 10.1165/rcmb.2002-0255PS; Kortylewski M, 2009, CANCER CELL, V15, P114, DOI 10.1016/j.ccr.2008.12.018; Kryczek I, 2005, CANCER RES, V65, P465; Kryczek I, 2008, J IMMUNOL, V181, P4733, DOI 10.4049/jimmunol.181.7.4733; Kryczek I, 2007, J IMMUNOL, V178, P6730, DOI 10.4049/jimmunol.178.11.6730; Kryczek I, 2009, BLOOD, V114, P1141, DOI 10.1182/blood-2009-03-208249; Kryczek I, 2009, BLOOD, V114, P357, DOI 10.1182/blood-2008-09-177360; Laan M, 2003, EUR RESPIR J, V21, P387, DOI 10.1183/09031936.03.00303503; Laan M, 2001, BRIT J PHARMACOL, V133, P200, DOI 10.1038/sj.bjp.0704063; Laan M, 1999, J IMMUNOL, V162, P2347; Langowski JL, 2006, NATURE, V442, P461, DOI 10.1038/nature04808; Leveque L, 2009, J IMMUNOTHER, V32, P101, DOI 10.1097/CJI.0b013e318195b59e; Liu SJ, 2007, J LEUKOCYTE BIOL, V82, P354, DOI 10.1189/jlb.0207111; Lockhart E, 2006, J IMMUNOL, V177, P4662, DOI 10.4049/jimmunol.177.7.4662; Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Martin-Orozco N, 2009, IMMUNITY, V31, P787, DOI 10.1016/j.immuni.2009.09.014; Martin-Orozco N, 2009, CURR OPIN INVEST DR, V10, P543; McAllister F, 2005, J IMMUNOL, V175, P404, DOI 10.4049/jimmunol.175.1.404; Miyahara Y, 2008, P NATL ACAD SCI USA, V105, P15505, DOI 10.1073/pnas.0710686105; Miyamoto M, 2003, J IMMUNOL, V170, P4665, DOI 10.4049/jimmunol.170.9.4665; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Moseley TA, 2003, CYTOKINE GROWTH F R, V14, P155, DOI 10.1016/S1359-6101(03)00002-9; Muranski P, 2008, BLOOD, V112, P362, DOI 10.1182/blood-2007-11-120998; Murdoch C, 2004, BLOOD, V104, P2224, DOI 10.1182/blood-2004-03-1109; Ngiow SF, 2010, BLOOD, V115, P2554, DOI 10.1182/blood-2009-11-254607; Nozawa H, 2006, P NATL ACAD SCI USA, V103, P12493, DOI 10.1073/pnas.0601807103; Numasaki M, 2003, BLOOD, V101, P2620, DOI 10.1182/blood-2002-05-1461; Nurieva R, 2009, J IMMUNOL, V182, P2565, DOI 10.4049/jimmunol.0803931; Pelletier M, 2010, BLOOD, V115, P335, DOI 10.1182/blood-2009-04-216085; Prause O, 2004, THORAX, V59, P313, DOI 10.1136/thx.2003.008854; Roberts SJ, 2007, P NATL ACAD SCI USA, V104, P6770, DOI 10.1073/pnas.0604982104; Rubie C, 2006, SCAND J IMMUNOL, V63, P468, DOI 10.1111/j.1365-3083.2006.001766.x; Schwandner R, 2000, J EXP MED, V191, P1233, DOI 10.1084/jem.191.7.1233; Sfanos KS, 2008, CLIN CANCER RES, V14, P3254, DOI 10.1158/1078-0432.CCR-07-5164; Shalom-Barak T, 1998, J BIOL CHEM, V273, P27467, DOI 10.1074/jbc.273.42.27467; Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422; Siveen KS, 2009, IMMUNOL LETT, V123, P97, DOI 10.1016/j.imlet.2009.02.011; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Starnes T, 2002, J IMMUNOL, V169, P642, DOI 10.4049/jimmunol.169.2.642; Starnes T, 2001, J IMMUNOL, V167, P4137, DOI 10.4049/jimmunol.167.8.4137; Steiner GE, 2003, PROSTATE, V56, P171, DOI 10.1002/pros.10238; Su XM, 2010, J IMMUNOL, V184, P1630, DOI 10.4049/jimmunol.0902813; Tartour E, 1999, CANCER RES, V59, P3698; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Volpe E, 2008, NAT IMMUNOL, V9, P650, DOI 10.1038/ni.1613; von Euw E, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-35; Voo KS, 2009, P NATL ACAD SCI USA, V106, P4793, DOI 10.1073/pnas.0900408106; Wang L, 2009, J EXP MED, V206, P1457, DOI 10.1084/jem.20090207; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Wu SG, 2009, NAT MED, V15, P1016, DOI 10.1038/nm.2015; Xu LL, 2007, J IMMUNOL, V178, P6725, DOI 10.4049/jimmunol.178.11.6725; Yang XO, 2008, IMMUNITY, V29, P44, DOI 10.1016/j.immuni.2008.05.007; Yang XXO, 2008, J EXP MED, V205, P1063, DOI 10.1084/jem.20071978; Yang ZZ, 2009, CANCER RES, V69, P5522, DOI 10.1158/0008-5472.CAN-09-0266; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang B, 2008, BIOCHEM BIOPH RES CO, V374, P533, DOI 10.1016/j.bbrc.2008.07.060; Zhang JP, 2009, J HEPATOL, V50, P980, DOI 10.1016/j.jhep.2008.12.033; Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488; Zhou Q, 2005, INFECT IMMUN, V73, P935, DOI 10.1128/IAI.73.2.935-943.2005; Zou WP, 2010, NAT REV IMMUNOL, V10, P248, DOI 10.1038/nri2742; Zou WP, 2001, NAT MED, V7, P1339, DOI 10.1038/nm1201-1339; Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806	106	85	92	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	42					5653	5662		10.1038/onc.2010.367	http://dx.doi.org/10.1038/onc.2010.367			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	668IT	20729908	Green Accepted			2022-12-17	WOS:000283262500001
J	Nasarre, C; Roth, M; Jacob, L; Roth, L; Koncina, E; Thien, A; Labourdette, G; Poulet, P; Hubert, P; Cremel, G; Roussel, G; Aunis, D; Bagnard, D				Nasarre, C.; Roth, M.; Jacob, L.; Roth, L.; Koncina, E.; Thien, A.; Labourdette, G.; Poulet, P.; Hubert, P.; Cremel, G.; Roussel, G.; Aunis, D.; Bagnard, D.			Peptide-based interference of the transmembrane domain of neuropilin-1 inhibits glioma growth in vivo	ONCOGENE			English	Article						neuropilin; glioma; angiogenesis; peptide; tumour growth	POINT MUTATION; BREAST-CANCER; MOUSE MODEL; CELLS; RECEPTORS; BINDING; ANGIOGENESIS; ACTIVATION; PROTEIN; PROGRESSION	Angiogenesis in glioblastoma is largely dependent on vascular endothelial growth factor (VEGF) signalling. Consistently, the VEGF coreceptor NRP1 promotes angiogenesis and tumour growth in gliomas. Here, we provide data showing that an innovative peptidic tool targeting the transmembrane domain of NRP1 efficiently blocks rat and human glioma growth in vivo. We show both in vivo and in vitro that the antitumour effect results from the anti-proliferative, anti-migratory and anti-angiogenic properties of the compound. The proposed NRP1 antagonizing peptide is therefore a promising novel class of anti-angiogenic drugs that might prolong glioma patient survival. Our results finally show for the first time that the transmembrane domain of important signalling receptors can be antagonized in vivo thereby providing a new avenue towards the development of atypical antagonists with strong therapeutic potential. Oncogene (2010) 29, 2381-2392; doi:10.1038/onc.2010.9; published online 8 February 2010	[Nasarre, C.; Roth, M.; Jacob, L.; Roth, L.; Koncina, E.; Thien, A.; Labourdette, G.; Cremel, G.; Roussel, G.; Aunis, D.; Bagnard, D.] INSERM, U575, F-67200 Strasbourg, France; [Poulet, P.] Inst Phys Biol, Lab Neuroimagerie & Neurosci Cognit, Strasbourg, France; [Hubert, P.] CNRS, LISM, UPR 9027, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Bagnard, D (corresponding author), INSERM, U682, 3 Ave Moliere, F-67200 Strasbourg, France.	dominique.bagnard@inserm.u-strasbg.fr	Hubert, Pierre/C-6678-2013; Poulet, Patrick/AAD-1438-2020; Poulet, Patrick/A-2001-2012; Poulet, Patrick/AAG-7783-2021; Dominique, Aunis/W-1419-2019; Bagnard, Dominique/I-6535-2013	Hubert, Pierre/0000-0002-7549-8910; JACOB, Laurent/0000-0003-4767-0442; Poulet, Patrick/0000-0001-7998-9672; Roth, Lise/0000-0001-7555-2916; Bagnard, Dominique/0000-0002-5261-902X	INSERM; ACI JC [5327]; ARC; ANR Emergence bio; FRC/Rotary international; Pharmaxon; La Ligue Contre le Cancer	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); ACI JC; ARC(Australian Research Council); ANR Emergence bio(French National Research Agency (ANR)); FRC/Rotary international; Pharmaxon; La Ligue Contre le Cancer(Ligue nationale contre le cancer)	We thank Dr Sophie Reibel-Foisset and Mr Nicolas Lethenet for excellent assistance with in vivo experiments and animal care. This work was supported by INSERM, ACI JC (No. 5327), ARC, ANR Emergence bio, FRC/Rotary international to Dominique Bagnard. Cecile Nasarre was supported by Pharmaxon and La Ligue Contre le Cancer.	Bagci T, 2009, ONCOGENE, V28, P3537, DOI 10.1038/onc.2009.204; Bagri A, 2002, ADV EXP MED BIOL, V515, P13; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; Barr MP, 2005, BRIT J CANCER, V92, P328, DOI 10.1038/sj.bjc.6602308; Bedjeguelal K, 2006, BIOORG MED CHEM LETT, V16, P3998, DOI 10.1016/j.bmcl.2006.05.014; Bennasroune A, 2004, CRIT REV ONCOL HEMAT, V50, P23, DOI 10.1016/j.critrevonc.2003.08.004; Forbes LV, 2002, ONCOGENE, V21, P5981, DOI 10.1038/sj.onc.1205767; Gamse JT, 2002, NAT GENET, V30, P117, DOI 10.1038/ng793; Garcia-Verdugo J, 1998, J NEUROBIOL, V36, P234, DOI 10.1002/(SICI)1097-4695(199808)36:2<234::AID-NEU10>3.0.CO;2-E; Giordano RJ, 2005, CHEM BIOL, V12, P1075, DOI 10.1016/j.chembiol.2005.07.008; Goldbrunner RH, 2000, J NEURO-ONCOL, V50, P53, DOI 10.1023/A:1006462504447; Grobben B, 2002, CELL TISSUE RES, V310, P257, DOI 10.1007/s00441-002-0651-7; Guttmann-Raviv N, 2006, CANCER LETT, V231, P1, DOI 10.1016/j.canlet.2004.12.047; Hong TM, 2007, CLIN CANCER RES, V13, P4759, DOI 10.1158/1078-0432.CCR-07-0001; Hu B, 2007, ONCOGENE, V26, P5577, DOI 10.1038/sj.onc.1210348; Jain RK, 2007, NAT REV NEUROSCI, V8, P610, DOI 10.1038/nrn2175; Jain RK, 2006, NAT CLIN PRACT ONCOL, V3, P24, DOI 10.1038/ncponc0403; Jia HY, 2006, J BIOL CHEM, V281, P13493, DOI 10.1074/jbc.M512121200; JOCIC Z, 1993, BRAIN COGNITION, V23, P222, DOI 10.1006/brcg.1993.1056; Kelland LR, 2004, EUR J CANCER, V40, P827, DOI 10.1016/j.ejca.2003.11.028; Kienlen-Campard P, 2008, J BIOL CHEM, V283, P7733, DOI 10.1074/jbc.M707142200; KLOSEN P, 1993, J HISTOCHEM CYTOCHEM, V41, P455, DOI 10.1177/41.3.8429209; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; Marchesi VT, 2005, P NATL ACAD SCI USA, V102, P9093, DOI 10.1073/pnas.0503181102; MEYERS GA, 1995, NAT GENET, V11, P462, DOI 10.1038/ng1295-462; Nasarre C, 2009, CELL ADHES MIGR, V3, P383, DOI 10.4161/cam.3.4.9934; Nasarre P, 2005, NEOPLASIA, V7, P180, DOI 10.1593/neo.04481; Orian-Rousseau V, 2008, ADV CANCER RES, V101, P63, DOI 10.1016/S0065-230X(08)00404-1; Roth L, 2008, MOL BIOL CELL, V19, P646, DOI 10.1091/mbc.E07-06-0625; Senes A, 2004, CURR OPIN STRUC BIOL, V14, P465, DOI 10.1016/j.sbi.2004.07.007; Slimani H, 2006, J DRUG TARGET, V14, P694, DOI 10.1080/10611860600947607; Starzec A, 2006, LIFE SCI, V79, P2370, DOI 10.1016/j.lfs.2006.08.005; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Tessitore A, 1999, J CLIN ENDOCR METAB, V84, P3522, DOI 10.1210/jc.84.10.3522; Tirand L, 2006, J CONTROL RELEASE, V111, P153, DOI 10.1016/j.jconrel.2005.11.017; Uitenbroek, 1997, BINOMIAL SISA; Uzzan B, 2004, CANCER RES, V64, P2941, DOI 10.1158/0008-5472.CAN-03-1957; Wang ACC, 2001, AM J RESP CELL MOL, V24, P688, DOI 10.1165/ajrcmb.24.6.4376; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Williams G, 2005, J NEUROCHEM, V92, P1180, DOI 10.1111/j.1471-4159.2004.02950.x; Xu L, 2009, CANCER RES, V69, P7905, DOI 10.1158/0008-5472.CAN-09-2099	42	85	90	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	16					2381	2392		10.1038/onc.2010.9	http://dx.doi.org/10.1038/onc.2010.9			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	586YK	20140015				2022-12-17	WOS:000276951500007
J	Worthley, DL; Whitehall, VLJ; Buttenshaw, RL; Irahara, N; Greco, SA; Ramsnes, I; Mallitt, KA; Le Leu, RK; Winter, J; Hu, Y; Ogino, S; Young, GP; Leggett, BA				Worthley, D. L.; Whitehall, V. L. J.; Buttenshaw, R. L.; Irahara, N.; Greco, S. A.; Ramsnes, I.; Mallitt, K-A; Le Leu, R. K.; Winter, J.; Hu, Y.; Ogino, S.; Young, G. P.; Leggett, B. A.			DNA methylation within the normal colorectal mucosa is associated with pathway-specific predisposition to cancer	ONCOGENE			English	Article						DNA methylation; epigenetics; colorectal cancer; carcinogenesis	NORMAL COLONIC-MUCOSA; MICROSATELLITE INSTABILITY; ULCERATIVE-COLITIS; BRAF MUTATION; CHROMOSOMAL INSTABILITY; PROMOTER METHYLATION; SERRATED ADENOMAS; MOLECULAR-ORIGINS; PHENOTYPE; POLYPS	There are two major molecular pathways to sporadic colorectal cancer, the chromosomal instability (CIN) and the CpG island methylator phenotype (CIMP) pathways. This study recruited 166 patients undergoing colonoscopy. Biopsy samples were collected from the cecum, transverse colon, sigmoid colon and rectum. DNA methylation was quantified at 'type A' (ESR1, GATA5, HIC1, HPP1, SFRP1) and 'type C' markers (MGMT, MLH1, CDKN2A, MINT2, MINT31, IGF2, CACNA1G, NEU-ROG1, SOCS1, RUNX3), and LINE-1. 'Type A' genes are frequently methylated in normal and neoplastic tissues, proportional to tissue age. 'Type C' methylation is more specific for neoplasia. The last five 'type C' markers comprise a CIMP panel. The mean 'type A' and CIMP-panel methylation Z-scores were calculated. In all, 88 patients had adenomatous lesions, 32 had proximal serrated polyps (PSPs) and 50 were normal. Most 'type A' genes showed direct correlations between methylation and age (ESR1, rho = 0.66, P < 0.0001), with higher methylation distally (ESR1, P < 0.0001). On multivariate analysis, 'type A' methylation was inversely associated with colorectal adenomas (odds ratio 0.23, P < 0.001), the precursor to CIN cancers. CIMP-panel methylation was significantly associated with advanced PSPs (odds ratio = 5.1, P = 0.009), the precursor to CIMP cancers. DNA methylation in normal mucosa varied with age and region and was associated with pathway-specific pathology. In the future, the colorectal field could yield important information and potentially inform clinical practice. Oncogene (2010) 29, 1653-1662; doi:10.1038/onc.2009.449; published online 7 December 2009	[Worthley, D. L.; Whitehall, V. L. J.; Buttenshaw, R. L.; Greco, S. A.; Ramsnes, I.; Leggett, B. A.] Queensland Inst Med Res, Bancroft Ctr, Conjoint Gastroenterol Lab, Herston, Qld 4029, Australia; [Worthley, D. L.; Whitehall, V. L. J.; Buttenshaw, R. L.; Greco, S. A.; Ramsnes, I.; Leggett, B. A.] Royal Brisbane & Womens Hosp, Res Fdn Clin Res Ctr, Brisbane, Qld, Australia; [Irahara, N.; Ogino, S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Mallitt, K-A] Queensland Inst Med Res, Stat Unit, Herston, Qld 4029, Australia; [Le Leu, R. K.; Winter, J.; Hu, Y.; Young, G. P.] Flinders Univ S Australia, Flinders Ctr Canc Prevent & Control, Adelaide, SA, Australia; [Ogino, S.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Ogino, S.] Harvard Univ, Sch Med, Boston, MA USA	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; QIMR Berghofer Medical Research Institute; Flinders University South Australia; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Worthley, DL (corresponding author), Queensland Inst Med Res, Bancroft Ctr, Conjoint Gastroenterol Lab, Rm H07,PO RBH, Herston, Qld 4029, Australia.	daniel.worthley@uqconnect.edu.au	Mallitt, Kylie-Ann/GPF-9322-2022; Whitehall, Vicki L/B-6262-2013; Le Leu, Richard K/H-4555-2013; Whitehall, Vicki/E-5414-2019; Mallitt, Kylie-Ann/E-2240-2011; Leggett, Barbara A/D-3579-2011	Mallitt, Kylie-Ann/0000-0002-5722-7287; Whitehall, Vicki L/0000-0002-8285-2391; Le Leu, Richard K/0000-0003-4704-4943; Mallitt, Kylie-Ann/0000-0002-5722-7287; Leggett, Barbara/0000-0003-2062-7380; Young, Graeme/0000-0001-9458-8383; Winter, Jean/0000-0002-2041-8602	National Health and Medical Research Council [442965]; Gastroenterological Society of Australia; Royal Australasian College of Physicians Cottrell Fellowship; Royal Brisbane and Women's Hospital Foundation; Queensland Smart State PhD award	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Gastroenterological Society of Australia; Royal Australasian College of Physicians Cottrell Fellowship; Royal Brisbane and Women's Hospital Foundation; Queensland Smart State PhD award	We thank the gastroenterologists and gastroenterology nurses who helped to collect samples. This study was funded by a National Health and Medical Research Council project grant (442965), a Gastroenterological Society of Australia post-graduate medical scholarship (DLW), the Royal Australasian College of Physicians Cottrell Fellowship (DLW), a Royal Brisbane and Women's Hospital Foundation Research Grant (VLW, DLW, BAL) and a Queensland Smart State PhD award (DLW).	Ahuja N, 1998, CANCER RES, V58, P5489; Ahuja N, 2000, HISTOL HISTOPATHOL, V15, P835, DOI 10.14670/HH-15.835; Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Al-Ghnaniem R, 2007, AM J CLIN NUTR, V86, P1064, DOI 10.1093/ajcn/86.4.1064; Ally MS, 2009, CANCER EPIDEM BIOMAR, V18, P922, DOI 10.1158/1055-9965.EPI-08-0703; Australian Cancer Network Colorectal Cancer Guidelines Revision Committee, 2005, GUID PREV EARL DET M; Belshaw NJ, 2008, BRIT J CANCER, V99, P136, DOI 10.1038/sj.bjc.6604432; Botteri E, 2008, GASTROENTEROLOGY, V134, P388, DOI 10.1053/j.gastro.2007.11.007; Chen TP, 2007, NAT GENET, V39, P391, DOI 10.1038/ng1982; Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030; East JE, 2008, GASTROENTEROL CLIN N, V37, P25, DOI 10.1016/j.gtc.2007.12.014; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Figueiredo JC, 2009, CANCER EPIDEM BIOMAR, V18, P1041, DOI 10.1158/1055-9965.EPI-08-0926; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Giovannucci E, 2005, JNCI-J NATL CANCER I, V97, P1317, DOI 10.1093/jnci/dji305; Goel A, 2007, GASTROENTEROLOGY, V132, P127, DOI 10.1053/j.gastro.2006.09.018; Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076; Hoeijmakers JHJ, 2009, NEW ENGL J MED, V361, P1475, DOI 10.1056/NEJMra0804615; Horii J, 2008, CLIN BIOCHEM, V41, P1440, DOI 10.1016/j.clinbiochem.2008.08.089; Hornsby PJ, 2007, J CLIN ONCOL, V25, P1852, DOI 10.1200/JCO.2006.10.3101; IRAHARA N, 2009, J MOL DIAGN IN PRESS; Ishikawa F, 2003, CANCER SCI, V94, P944, DOI 10.1111/j.1349-7006.2003.tb01382.x; Issa JP, 2008, CLIN CANCER RES, V14, P5939, DOI 10.1158/1078-0432.CCR-08-1596; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Issa JPJ, 2001, CANCER RES, V61, P3573; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Jass JR, 2007, HISTOPATHOLOGY, V50, P113, DOI 10.1111/j.1365-2559.2006.02549.x; Jass JR, 2002, GASTROENTEROLOGY, V123, P862, DOI 10.1053/gast.2002.35392; Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671; Kim JY, 2005, P NATL ACAD SCI USA, V102, P17739, DOI 10.1073/pnas.0503976102; Konishi K, 2007, GASTROENTEROLOGY, V132, P1254, DOI 10.1053/j.gastro.2007.01.035; Menigatti M, 2009, ONCOGENE, V28, P899, DOI 10.1038/onc.2008.444; Minoo P, 2006, GUT, V55, DOI 10.1136/gut.2005.082859; Nakagawa H, 2001, CANCER RES, V61, P6991; Nuovo GJ, 2006, DIAGN MOL PATHOL, V15, P17, DOI 10.1097/00019606-200603000-00003; Ogino S, 2008, INT J CANCER, V122, P2767, DOI 10.1002/ijc.23470; Ogino S, 2009, GUT, V58, P90, DOI 10.1136/gut.2008.155473; Preston SL, 2003, CANCER RES, V63, P3819; Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404; Sandborn WJ, 1997, ANN INTERN MED, V126, P364, DOI 10.7326/0003-4819-126-5-199703010-00004; Shen LL, 2007, P NATL ACAD SCI USA, V104, P18654, DOI 10.1073/pnas.0704652104; Shen L, 2007, CLIN CANCER RES, V13, P6093, DOI 10.1158/1078-0432.CCR-07-1011; Shen LL, 2005, JNCI-J NATL CANCER I, V97, P1330, DOI 10.1093/jnci/dji275; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Spring KJ, 2006, GASTROENTEROLOGY, V131, P1400, DOI 10.1053/j.gastro.2006.08.038; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Tycko B, 2003, ANN NY ACAD SCI, V983, P43, DOI 10.1111/j.1749-6632.2003.tb05961.x; VANMUNSTER IP, 1994, DIGEST DIS SCI, V39, P834, DOI 10.1007/BF02087431; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Ye CZ, 2006, ONCOL REP, V16, P429; Young J, 2001, P NATL ACAD SCI USA, V98, P265, DOI 10.1073/pnas.011415298	57	85	92	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	2010	29	11					1653	1662		10.1038/onc.2009.449	http://dx.doi.org/10.1038/onc.2009.449			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	19966864				2022-12-17	WOS:000275694700010
J	Baudot, AD; Jeandel, PY; Mouska, X; Maurer, U; Tartare-Deckert, S; Raynaud, SD; Cassuto, JP; Ticchioni, M; Deckert, M				Baudot, A. D.; Jeandel, P. Y.; Mouska, X.; Maurer, U.; Tartare-Deckert, S.; Raynaud, S. D.; Cassuto, J. P.; Ticchioni, M.; Deckert, M.			The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKC delta and proteasome-dependent regulation of Mcl-1 expression	ONCOGENE			English	Article						B-CLL; Syk; survival; PKCdelta; Mcl-1; proteasome	ACUTE LYMPHOBLASTIC-LEUKEMIA; GLYCOGEN-SYNTHASE KINASE-3; RECEPTOR-TYPE-O; ANTIGEN-RECEPTOR; IN-VITRO; C-DELTA; APOPTOSIS; ACTIVATION; PHOSPHORYLATION; PATHWAY	B-cell chronic lymphocytic leukemia (B-CLL) is characterized by accumulation of mature monoclonal CD5+ B cells. The disease results mainly from a failure of cells to undergo apoptosis, a process largely influenced by the existence of constitutively activated components of B-cell receptor signaling and the deregulated expression of antiapoptotic molecules. Recent evidence pointing to a critical role of spleen tyrosine kinase (Syk) in ligand-independent BCR signaling prompted us to examine its role in primary B-CLL cell survival. We demonstrate that pharmacological inhibition of constitutive Syk activity and silencing by siRNA led to a dramatic decrease of cell viability in CLL samples (n = 44), regardless of clinical and biological status and induced typical apoptotic cell death with mitochondrial failure followed by caspase 3-dependent cell death. We also provide functional and biochemical evidence that Syk regulated B-CLL cell survival through a novel pathway involving PKC delta and a proteasome-dependent regulation of the anti-apoptotic protein Mcl-1. Together, our observations are consistent with a model wherein PKC delta downstream of Syk stabilizes Mcl-1 through inhibitory phosphorylation of GSK3 by Akt. We conclude that Syk constitutes a key regulator of B-CLL cell survival, emphasizing the clinical utility of Syk inhibition in hematopoietic malignancies. Oncogene (2009) 28, 3261-3273; doi:10.1038/onc.2009.179; published online 6 July 2009	[Baudot, A. D.; Mouska, X.; Ticchioni, M.; Deckert, M.] Hop Archet, INSERM, UMR576, F-06202 Nice 3, France; [Baudot, A. D.; Jeandel, P. Y.; Tartare-Deckert, S.; Deckert, M.] Univ Nice Sophia Antipolis, Nice, France; [Jeandel, P. Y.] CHU Nice, Dept Internal Med, Nice, France; [Maurer, U.] Univ Freiburg, Inst Mol Med & Cell Res, D-7800 Freiburg, Germany; [Tartare-Deckert, S.] INSERM, UMR895, Nice, France; [Raynaud, S. D.] CHU Nice, Genet Lab, Nice, France; [Cassuto, J. P.] CHU Nice, Dept Clin Hematol, Nice, France; [Ticchioni, M.] CHU Nice, Immunol Lab, Nice, France	CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; University of Freiburg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; CHU Nice; CHU Nice	Deckert, M (corresponding author), Hop Archet, INSERM, UMR576, 1 Route St Antoine Ginestiere, F-06202 Nice 3, France.	deckert@unice.fr	TARTARE-DECKERT, Sophie/P-6057-2015; Jeandel, Pierre-Yves/ABD-6658-2020; Ticchioni, Michel/P-8095-2016; Deckert, Marcel/M-4998-2016; Deckert, Marcel/T-3566-2019	TARTARE-DECKERT, Sophie/0000-0001-8680-5720; Deckert, Marcel/0000-0003-2094-559X; Mouska, Xavier/0000-0002-4263-543X	INSERM; ARC [3111]; INCa [PL-06-026]; TxCell (Valbonne, France)	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); ARC(Australian Research Council); INCa(Institut National du Cancer (INCA) France); TxCell (Valbonne, France)	This work was supported by INSERM, ARC (Grant No 3111), and INCa (Grant PL-06-026). ADB is a recipient of an INSERM-Region Provence Alpes Cote d'Azur PhD fellowship in partnership with TxCell (Valbonne, France). M Deckert is a recipient of a Contrat d'Interface Clinique with the Department of Clinical Hematology, CHU de Nice. We thank P Gounon (CCMA, Faculte des Sciences, Nice) for electron microscopy analysis, and M. Ciosi (INRA-CNRS, SophiaAntipolis) for statistical analysis.	Barragan M, 2002, BLOOD, V99, P2969, DOI 10.1182/blood.V99.8.2969; Caligaris-Cappio F, 1999, J CLIN ONCOL, V17, P399, DOI 10.1200/JCO.1999.17.1.399; Chen LG, 2005, BLOOD, V105, P2036, DOI 10.1182/blood-2004-05-1715; Chen LG, 2002, BLOOD, V100, P4609, DOI 10.1182/blood-2002-06-1683; Chen LF, 2008, BLOOD, V111, P2230, DOI 10.1182/blood-2007-07-100115; Chen LF, 2006, BLOOD, V108, P3428, DOI 10.1182/blood-2006-03-013821; Chiorazzi N, 2003, ANNU REV IMMUNOL, V21, P841, DOI 10.1146/annurev.immunol.21.120601.141018; Contri A, 2005, J CLIN INVEST, V115, P369, DOI 10.1172/JC1200522094; Crespo M, 2006, CLIN CANCER RES, V12, P726, DOI 10.1158/1078-0432.CCR-05-1531; Cuni S, 2004, LEUKEMIA, V18, P1391, DOI 10.1038/sj.leu.2403398; Deglesne PA, 2006, CANCER RES, V66, P7158, DOI 10.1158/0008-5472.CAN-06-0085; Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099-2110.2002; Feldman AL, 2008, LEUKEMIA, V22, P1139, DOI 10.1038/leu.2008.77; Gauld SB, 2005, NAT IMMUNOL, V6, P1160, DOI 10.1038/ni1256; Gobessi S, 2009, LEUKEMIA, V23, P686, DOI 10.1038/leu.2008.346; Goodman PA, 2001, ONCOGENE, V20, P3969, DOI 10.1038/sj.onc.1204515; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; Holler C, 2009, BLOOD, V113, P2791, DOI 10.1182/blood-2008-06-160713; Kipps TJ, 2003, CURR OPIN HEMATOL, V10, P312, DOI 10.1097/00062752-200307000-00010; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Lanham S, 2003, BLOOD, V101, P1087, DOI 10.1182/blood-2002-06-1822; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Leseux L, 2006, BLOOD, V108, P4156, DOI 10.1182/blood-2006-05-026203; Longo PG, 2008, BLOOD, V111, P846, DOI 10.1182/blood-2007-05-089037; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Messmer BT, 2004, J EXP MED, V200, P519, DOI 10.1084/jem.20040544; Monroe JG, 2006, NAT REV IMMUNOL, V6, P283, DOI 10.1038/nri1808; Moon KD, 2005, J BIOL CHEM, V280, P1543, DOI 10.1074/jbc.M407805200; Moshynska O, 2004, JNCI-J NATL CANCER I, V96, P673, DOI 10.1093/jnci/djh122; Motiwala T, 2007, CLIN CANCER RES, V13, P3174, DOI 10.1158/1078-0432.CCR-06-1720; Muzio M, 2008, BLOOD, V112, P188, DOI 10.1182/blood-2007-09-111344; Niiro H, 2002, NAT REV IMMUNOL, V2, P945, DOI 10.1038/nri955; Pepper C, 2008, BLOOD, V112, P3807, DOI 10.1182/blood-2008-05-157131; Petlickovski A, 2005, BLOOD, V105, P4820, DOI 10.1182/blood-2004-07-2669; Plate JMD, 2004, LEUKEMIA LYMPHOMA, V45, P1519, DOI 10.1080/10428190410001683642; Refaeli Y, 2008, PLOS BIOL, V6, P1208, DOI 10.1371/journal.pbio.0060152; Reyland ME, 2007, BIOCHEM SOC T, V35, P1001, DOI 10.1042/BST0351001; Ringshausen I, 2002, BLOOD, V100, P3741, DOI 10.1182/blood-2002-02-0539; Saxena A, 2004, AM J HEMATOL, V75, P22, DOI 10.1002/ajh.10453; Semichon M, 1997, LEUKEMIA, V11, P1921, DOI 10.1038/sj.leu.2400832; Steinberg SF, 2004, BIOCHEM J, V384, P449, DOI 10.1042/BJ20040704; Stevenson FK, 2004, BLOOD, V103, P4389, DOI 10.1182/blood-2003-12-4312; Ticchioni M, 2007, ONCOGENE, V26, P7081, DOI 10.1038/sj.onc.1210519; TOKER A, 1994, J BIOL CHEM, V269, P32358; Veldurthy A, 2008, BLOOD, V112, P1443, DOI 10.1182/blood-2007-11-123984; Wong BR, 2004, EXPERT OPIN INV DRUG, V13, P743, DOI 10.1517/13543784.13.7.743; Wossning T, 2006, J EXP MED, V203, P2829, DOI 10.1084/jem.20060967; Yamamoto N, 2003, J PHARMACOL EXP THER, V306, P1174, DOI 10.1124/jpet.103.052316	48	85	88	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2009	28	37					3261	3273		10.1038/onc.2009.179	http://dx.doi.org/10.1038/onc.2009.179			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495LS	19581935				2022-12-17	WOS:000269893700001
J	Lopez-Soto, A; Folgueras, AR; Seto, E; Gonzalez, S				Lopez-Soto, A.; Folgueras, A. R.; Seto, E.; Gonzalez, S.			HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer	ONCOGENE			English	Article						ULBPs; NKG2D; HDAC3; tumour immunosurveillance	HISTONE DEACETYLASE INHIBITORS; I-RELATED CHAIN; NK CELLS; T-CELLS; RECEPTOR; SP3; CYTOTOXICITY; ACTIVATION; PROMOTER; SUSCEPTIBILITY	The expression of the NKG2D ligands on cancer cells leads to their recognition and elimination by host immune responses mediated by natural killer and T cells. UL160-binding proteins (ULBPs) are NKG2D ligands, which are scarcely expressed in epithelial tumours, favouring their evasion from the immune system. Herein, we investigated the epigenetic mechanisms underlying the repression of ULBPs in epithelial cancer cells. We show that ULBP1-3 expression is increased in tumour cells after exposure to the inhibitor of histone deacetylases (HDACs) trichostatin A (TSA), which enhances the natural killer cell-mediated cytotoxicity of HeLa cells. Our experiments showed that the transcription factor Sp3 is crucial in the activation of the ULBP1 promoter by TSA. Furthermore, by small interfering RNA-mediated knockdown and overexpression of HDAC1-3, we showed that HDAC3 is a repressor of ULBPs expression in epithelial cancer cells. Remarkably, TSA treatment caused the complete release of HDAC3 from the ULBP1-3 promoters. HDAC3 is recruited to the ULBP1 promoter through its interaction with Sp3 and TSA treatment interfered with this association. Together, we describe a new mechanism by which cancer cells may evade the immune response through the epigenetic modulation of the ULBPs expression and provide a model in which HDAC inhibitors may favour the elimination of transformed cells by increasing the immunogenicity of epithelial tumours. Oncogene (2009) 28, 2370-2382; doi:10.1038/onc.2009.117; published online 11 May 2009	[Gonzalez, S.] Univ Oviedo, Dept Biol Func, IUOPA, Fac Med, E-33006 Oviedo, Spain; [Folgueras, A. R.] Univ Oviedo, Dept Bioquim & Biol Mol, IUOPA, E-33006 Oviedo, Spain; [Seto, E.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA	University of Oviedo; Instituto Universitario de Oncologia de Asturias; University of Oviedo; Instituto Universitario de Oncologia de Asturias; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Gonzalez, S (corresponding author), Univ Oviedo, Dept Biol Func, IUOPA, Fac Med, Julian Claveria S-N, E-33006 Oviedo, Spain.	segundog@uniovi.es	Folgueras, Alicia/B-3281-2017; López-Soto, Alejandro/A-9779-2018; Gonzalez, Segundo/AAK-8719-2021	Folgueras, Alicia/0000-0003-3426-9502; López-Soto, Alejandro/0000-0002-6360-5205; Gonzalez, Segundo/0000-0003-4631-9255	Spanish grants of Fondo de Investigaciones Sanitarias [PI-06/0841]; FICYT of Asturias [BP06-99]	Spanish grants of Fondo de Investigaciones Sanitarias; FICYT of Asturias	We thank Dr Spies and Amgen for kindly providing ULBP antibodies, Dr Garcia de Herreros for providing HT-29 M6 cells, Banco de Tumores del Hospital Universitario Central de Asturias for providing human tumour samples, Dr G Gill for providing the pBS/U6-Scrambled plasmid, Dr A Astudillo for histopathological evaluation, Dr C Lopez-Otin for helpful comments and A Vallina and MS Pitiot for technical assistance. This work was supported by the Spanish grants of Fondo de Investigaciones Sanitarias PI-06/0841. ALS holds a predoctoral fellowship from FICYT of Asturias (BP06-99).	Ammanamanchi S, 2003, J BIOL CHEM, V278, P35775, DOI 10.1074/jbc.M305961200; Andresen L, 2007, J IMMUNOL, V179, P8235, DOI 10.4049/jimmunol.179.12.8235; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Armeanu S, 2005, CANCER RES, V65, P6321, DOI 10.1158/0008-5472.CAN-04-4252; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Cosman D, 2001, IMMUNITY, V14, P123, DOI 10.1016/S1074-7613(01)00095-4; Diermayr S, 2008, BLOOD, V111, P1428, DOI 10.1182/blood-2007-07-101311; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Fischle W, 2001, J BIOL CHEM, V276, P35826, DOI 10.1074/jbc.M104935200; Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610; Gonzalez S, 2008, TRENDS IMMUNOL, V29, P397, DOI 10.1016/j.it.2008.04.007; Groh V, 2002, NATURE, V419, P734, DOI 10.1038/nature01112; Kaiser BK, 2007, NATURE, V447, P482, DOI 10.1038/nature05768; Karagianni P, 2007, ONCOGENE, V26, P5439, DOI 10.1038/sj.onc.1210612; Kato N, 2007, LEUKEMIA, V21, P2103, DOI 10.1038/sj.leu.2404862; Knutson SK, 2008, EMBO J, V27, P1017, DOI 10.1038/emboj.2008.51; Kottilil S, 2006, J IMMUNOL, V176, P1107, DOI 10.4049/jimmunol.176.2.1107; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lopez-Larrea C, 2008, TRENDS MOL MED, V14, P179, DOI 10.1016/j.molmed.2008.02.004; Lopez-Soto A, 2006, J BIOL CHEM, V281, P30419, DOI 10.1074/jbc.M604868200; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Maio M, 2003, ONCOGENE, V22, P6484, DOI 10.1038/sj.onc.1206956; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Nausch N, 2008, ONCOGENE, V27, P5944, DOI 10.1038/onc.2008.272; Pende D, 2002, CANCER RES, V62, P6178; Ropero S, 2008, ONCOGENE, V27, P4008, DOI 10.1038/onc.2008.31; Salih HR, 2003, BLOOD, V102, P1389, DOI 10.1182/blood-2003-01-0019; Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616; Skov S, 2005, CANCER RES, V65, P11136, DOI 10.1158/0008-5472.CAN-05-0599; Smyth MJ, 2005, J EXP MED, V202, P583, DOI 10.1084/jem.20050994; Sowa Y, 1999, CANCER RES, V59, P4266; Sun JM, 2002, J BIOL CHEM, V277, P35783, DOI 10.1074/jbc.C200378200; Sutherland CL, 2006, BLOOD, V108, P1313, DOI 10.1182/blood-2005-11-011320; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Waldhauer I, 2008, ONCOGENE, V27, P5932, DOI 10.1038/onc.2008.267; Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200; Wooten-Blanks LG, 2007, FASEB J, V21, P3386, DOI 10.1096/fj.07-8621com; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yang WM, 2002, J BIOL CHEM, V277, P9447, DOI 10.1074/jbc.M105993200; Yokota T, 2004, ONCOGENE, V23, P5340, DOI 10.1038/sj.onc.1207689	45	85	89	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	25					2370	2382		10.1038/onc.2009.117	http://dx.doi.org/10.1038/onc.2009.117			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462HS	19430493				2022-12-17	WOS:000267342400002
J	Javier, RT				Javier, R. T.			Cell polarity proteins: common targets for tumorigenic human viruses	ONCOGENE			English	Review						virus; polarity; tumor suppressor; PDZ; migration	LARGE TUMOR-SUPPRESSOR; TIGHT JUNCTION PROTEIN; HUMAN-PAPILLOMAVIRUS E6; PDZ DOMAIN PROTEIN; ADENOVIRUS TYPE 9; LATE GENE-EXPRESSION; PROTEASOME-MEDIATED DEGRADATION; DISTINCT ACTIVITIES CONTRIBUTE; ADENOMATOUS POLYPOSIS-COLI; MAMMALIAN EPITHELIAL-CELLS	Loss of polarity and disruption of cell junctions are common features of epithelial-derived cancer cells, and mounting evidence indicates that such defects have a direct function in the pathology of cancer. Supporting this idea, results with several different human tumor viruses indicate that their oncogenic potential depends in part on a common ability to inactivate key cell polarity proteins. For example, adenovirus (Ad) type 9 is unique among human Ads by causing exclusively estrogen-dependent mammary tumors in experimental animals and in having E4 region-encoded open reading frame 1 (E4-ORF1) as its primary oncogenic determinant. The 125-residue E4-ORF1 protein consists of two separate protein-interaction elements, one of which defines a PDZ domain-binding motif (PBM) required for E4-ORF1 to induce both cellular transformation in vitro and tumorigenesis in vivo. Most notably, the E4-ORF1 PBM mediates interactions with a selected group of cellular PDZ proteins, three of which include the cell polarity proteins Dlg1, PATJ and ZO-2. Data further indicate that these interactions promote disruption of cell junctions and a loss of cell polarity. In addition, one or more of the E4-ORF1-interacting cell polarity proteins, as well as the cell polarity protein Scribble, are common targets for the high-risk human papillomavirus (HPV) E6 or human T-cell leukemia virus type 1 (HTLV-1) Tax oncoproteins. Underscoring the significance of these observations, in humans, high-risk HPV and HTLV-1 are causative agents for cervical cancer and adult T-cell leukemia, respectively. Consequently, human tumor viruses should serve as powerful tools for deciphering mechanisms whereby disruption of cell junctions and loss of cell polarity contribute to the development of many human cancers. This review article discusses evidence supporting this hypothesis, with an emphasis on the human Ad E4-ORF1 oncoprotein.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine	Javier, RT (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.	rjavier@bcm.edu			NCI NIH HHS [R01 CA058541] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058541] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdelilah-Seyfried S, 2003, DEVELOPMENT, V130, P1927, DOI 10.1242/dev.00420; Adriance MC, 2005, BREAST CANCER RES, V7, P190, DOI 10.1186/bcr1286; ANKERST J, 1974, INT J CANCER, V13, P286, DOI 10.1002/ijc.2910130303; ANKERST J, 1989, J NATL CANCER I, V81, P294, DOI 10.1093/jnci/81.4.294; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; Arpin-Andre C, 2007, J BIOL CHEM, V282, P33132, DOI 10.1074/jbc.M702279200; Balasubramanian S, 2007, J BIOL CHEM, V282, P4162, DOI 10.1074/jbc.M607695200; Balda MS, 2003, J CELL BIOL, V160, P423, DOI 10.1083/jcb.200210020; Barnard AL, 2005, BLOOD, V106, P988, DOI 10.1182/blood-2004-07-2850; Barritt DS, 2000, J CELL BIOCHEM, V79, P213, DOI 10.1002/1097-4644(20001101)79:2<213::AID-JCB50>3.0.CO;2-G; Beatch M, 1996, J BIOL CHEM, V271, P25723, DOI 10.1074/jbc.271.42.25723; Becamel C, 2001, J BIOL CHEM, V276, P12974, DOI 10.1074/jbc.M008089200; Betanzos A, 2004, EXP CELL RES, V292, P51, DOI 10.1016/j.yexcr.2003.08.007; Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020; Bilder D, 2003, CURR BIOL, V13, pR661, DOI 10.1016/S0960-9822(03)00599-2; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bissell MJ, 2003, BREAST CANCER RES, V5, P117, DOI 10.1186/bcr579; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; BRIDGE E, 1990, VIROLOGY, V174, P345, DOI 10.1016/0042-6822(90)90088-9; BRIDGE E, 1989, J VIROL, V63, P631, DOI 10.1128/JVI.63.2.631-638.1989; Cai CL, 2006, J BIOL CHEM, V281, P4267, DOI 10.1074/jbc.M505886200; Caruana G, 2001, MOL CELL BIOL, V21, P1475, DOI 10.1128/MCB.21.5.1475-1483.2001; Chetkovich DM, 2002, J NEUROSCI, V22, P6415; Chlenski A, 1999, INT J CANCER, V82, P137, DOI 10.1002/(SICI)1097-0215(19990702)82:1<137::AID-IJC23>3.0.CO;2-F; Chlenski A, 1999, INT J CANCER, V83, P349, DOI 10.1002/(SICI)1097-0215(19991029)83:3<349::AID-IJC10>3.0.CO;2-C; Chlenski A, 2000, BBA-GENE STRUCT EXPR, V1493, P319, DOI 10.1016/S0167-4781(00)00185-8; Chung SH, 2008, ONCOGENE, V27, P1412, DOI 10.1038/sj.onc.1210784; Chung SH, 2007, J VIROL, V81, P4787, DOI 10.1128/JVI.02855-06; Cochand-Priollet B, 1998, ULTRASTRUCT PATHOL, V22, P413; Crawford J.M., 1994, ROBBINS PATHOLOGIC B, V5th, P910; Curto M, 2007, J CELL BIOL, V177, P893, DOI 10.1083/jcb.200703010; CUTT JR, 1987, J VIROL, V61, P543, DOI 10.1128/JVI.61.2.543-552.1987; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Dow LE, 2007, ONCOGENE, V26, P2272, DOI 10.1038/sj.onc.1210016; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; Endo K, 2002, J VIROL, V76, P2648, DOI 10.1128/JVI.76.6.2648-2653.2002; Endter C, 2004, CURR TOP MICROBIOL, V273, P163; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Etienne-Manneville S, 2005, J CELL BIOL, V170, P895, DOI 10.1083/jcb.200412172; Etienne-Manneville S, 2003, CURR OPIN CELL BIOL, V15, P67, DOI 10.1016/S0955-0674(02)00005-4; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586; Fink C, 2006, NEOPLASIA, V8, P1019, DOI 10.1593/neo.06559; Flint SJ, 2003, CURR TOP MICROBIOL, V272, P287; FLINT SJ, 2000, PRINCIPLES VIROLOGY, P552; Frese KK, 2006, EMBO J, V25, P1406, DOI 10.1038/sj.emboj.7601030; Frese KK, 2003, ONCOGENE, V22, P710, DOI 10.1038/sj.onc.1206151; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 2002, J GEN VIROL, V83, P283, DOI 10.1099/0022-1317-83-2-283; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Gardner LA, 2007, J BIOL CHEM, V282, P5085, DOI 10.1074/jbc.M608871200; GAZZOLO L, 1987, NATURE, V326, P714, DOI 10.1038/326714a0; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Glaunsinger BA, 2001, EMBO J, V20, P5578, DOI 10.1093/emboj/20.20.5578; Gomes ER, 2005, CELL, V121, P451, DOI 10.1016/j.cell.2005.02.022; Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178; Goode S, 1997, GENE DEV, V11, P2532, DOI 10.1101/gad.11.19.2532; GRAHAM FL, 1984, ADENOVIRUSES, P339; GREEN M, 1979, VIROLOGY, V93, P481, DOI 10.1016/0042-6822(79)90251-4; Gudjonsson T, 2002, GENE DEV, V16, P693, DOI 10.1101/gad.952602; Gudjonsson T, 2002, J CELL SCI, V115, P39; Gudjonsson T, 2005, J MAMMARY GLAND BIOL, V10, P261, DOI 10.1007/s10911-005-9586-4; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; Hamazaki Y, 2002, J BIOL CHEM, V277, P455, DOI 10.1074/jbc.M109005200; Harris BZ, 2001, J CELL SCI, V114, P3219; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; HERISSE J, 1981, NUCLEIC ACIDS RES, V9, P4023, DOI 10.1093/nar/9.16.4023; Hernandez S, 2007, EXP CELL RES, V313, P1533, DOI 10.1016/j.yexcr.2007.01.026; Heydecke D, 2006, J ANDROL, V27, P390, DOI 10.2164/jandrol.05166; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Higuchi M, 2007, J VIROL, V81, P11900, DOI 10.1128/JVI.00532-07; Hirabayashi S, 2003, MOL CELL BIOL, V23, P4267, DOI 10.1128/MCB.23.12.4267-4282.2003; Hirata A, 2004, VIROLOGY, V318, P327, DOI 10.1016/j.virol.2003.10.006; HOGENKAMP T, 1990, NUCLEIC ACIDS RES, V18, P3065, DOI 10.1093/nar/18.10.3065; HORWITZ MS, 2001, FIELDS VIROLOGY, P2301; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; HUANG MM, 1989, J VIROL, V63, P2605, DOI 10.1128/JVI.63.6.2605-2615.1989; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Humbert PO, 2006, TRENDS CELL BIOL, V16, P622, DOI 10.1016/j.tcb.2006.10.005; Iizuka-Kogo A, 2007, DEVELOPMENT, V134, P1799, DOI 10.1242/dev.02830; Inoue M, 2006, MOL BIOL CELL, V17, P2303, DOI 10.1091/mbc.E06-01-0030; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Ishioka K, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-71; James MA, 2006, J VIROL, V80, P5301, DOI 10.1128/JVI.01942-05; Javier R, 1996, BREAST CANCER RES TR, V39, P57, DOI 10.1007/BF01806078; JAVIER R, 1991, J VIROL, V65, P3192, DOI 10.1128/JVI.65.6.3192-3202.1991; JAVIER R, 1992, SCIENCE, V257, P1267, DOI 10.1126/science.1519063; JAVIER RT, 1994, J VIROL, V68, P3917, DOI 10.1128/JVI.68.6.3917-3924.1994; Jeansonne B, 2003, CELL MOL BIOL, V49, P13; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; Kimber WA, 2002, BIOCHEM J, V361, P525, DOI 10.1042/0264-6021:3610525; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Kondo R, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-88; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kotelevets L, 2004, FASEB J, V18, P115, DOI 10.1096/fj.04-1942fje; Krummel MF, 2006, NAT IMMUNOL, V7, P1143, DOI 10.1038/ni1404; Kuballa P, 2007, J BIOL CHEM, V282, P65, DOI 10.1074/jbc.M605117200; Kuhne C, 2000, ONCOGENE, V19, P5884, DOI 10.1038/sj.onc.1203988; Lakhani S, 2005, J MAMMARY GLAND BIOL, V10, P197, DOI 10.1007/s10911-005-9580-x; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; Laprise P, 2004, J BIOL CHEM, V279, P10157, DOI 10.1074/jbc.M309843200; Latorre IJ, 2005, J CELL SCI, V118, P4283, DOI 10.1242/jcs.02560; Laura RP, 2002, EXP CELL RES, V275, P155, DOI 10.1006/excr.2002.5475; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee CH, 2004, J VIROL, V78, P12366, DOI 10.1128/JVI.78.22.12366-12377.2004; Lee OK, 2003, NAT CELL BIOL, V5, P987, DOI 10.1038/ncb1055; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Lemmers C, 2002, J BIOL CHEM, V277, P25408, DOI 10.1074/jbc.M202196200; Leonoudakis D, 2004, J BIOL CHEM, V279, P19051, DOI 10.1074/jbc.M400284200; Levin ER, 2002, STEROIDS, V67, P471, DOI 10.1016/S0039-128X(01)00179-9; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; Luconi M, 2002, J STEROID BIOCHEM, V80, P369, DOI 10.1016/S0960-0760(02)00041-9; Ludford-Menting MJ, 2005, IMMUNITY, V22, P737, DOI 10.1016/j.immuni.2005.04.009; Mahieux Renaud, 2003, Rev Clin Exp Hematol, V7, P336; Mahoney ZX, 2006, P NATL ACAD SCI USA, V103, P19872, DOI 10.1073/pnas.0609326103; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Marcello E, 2007, J NEUROSCI, V27, P1682, DOI 10.1523/JNEUROSCI.3439-06.2007; Martin TA, 2004, EUR J CANCER, V40, P2717, DOI 10.1016/j.ejca.2004.08.008; Massimi P, 2006, ONCOGENE, V25, P4276, DOI 10.1038/sj.onc.1209457; Massimi P, 2004, ONCOGENE, V23, P8033, DOI 10.1038/sj.onc.1207977; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Matsumoto Y, 2006, J MED VIROL, V78, P501, DOI 10.1002/jmv.20568; Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; Mauceri D, 2007, J NEUROCHEM, V100, P1032, DOI 10.1111/j.1471-4159.2006.04267.x; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; MECHTERSHEIMER G, 1990, PATHOL RES PRACT, V186, P427, DOI 10.1016/S0344-0338(11)80460-7; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Michel D, 2005, J CELL SCI, V118, P4049, DOI 10.1242/jcs.02528; Mimori-Kiyosue Y, 2007, GENES CELLS, V12, P219, DOI 10.1111/j.1365-2443.2007.01045.x; Mol CD, 1996, STRUCTURE, V4, P1077, DOI 10.1016/S0969-2126(96)00114-1; Moore M, 1996, P NATL ACAD SCI USA, V93, P11295, DOI 10.1073/pnas.93.21.11295; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; MULLER U, 1992, J VIROL, V66, P5867; Murata M, 2005, CELL TISSUE RES, V319, P341, DOI 10.1007/s00441-004-1017-0; Naim E, 2005, KIDNEY INT, V68, P955, DOI 10.1111/j.1523-1755.2005.00489.x; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Nevels M, 1997, P NATL ACAD SCI USA, V94, P1206, DOI 10.1073/pnas.94.4.1206; Nevels M, 1999, ONCOGENE, V18, P9, DOI 10.1038/sj.onc.1202284; Nevels M, 1999, J VIROL, V73, P1591, DOI 10.1128/JVI.73.2.1591-1600.1999; Nevels M, 2001, J VIROL, V75, P3089, DOI 10.1128/JVI.75.7.3089-3094.2001; Nevels M, 2000, J VIROL, V74, P5168, DOI 10.1128/JVI.74.11.5168-5181.2000; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Nguyen MM, 2003, MOL CELL BIOL, V23, P8970, DOI 10.1128/MCB.23.24.8970-8981.2003; Nunbhakdi-Craig V, 2003, J VIROL, V77, P2807, DOI 10.1128/JVI.77.5.2807-2818.2003; Nunbhakdi-Craig V, 2002, J CELL BIOL, V158, P967, DOI 10.1083/jcb.200206114; O'Shea C, 2005, EMBO J, V24, P1211, DOI 10.1038/sj.emboj.7600597; O'Shea CC, 2005, CELL CYCLE, V4, P883, DOI 10.4161/cc.4.7.1791; Ohashi M, 2004, VIROLOGY, V320, P52, DOI 10.1016/j.virol.2003.11.014; Onishi K, 2007, GENES CELLS, V12, P535, DOI 10.1111/j.1365-2443.2007.01071.x; Osmani N, 2006, CURR BIOL, V16, P2395, DOI 10.1016/j.cub.2006.10.026; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Patrie KM, 2002, J BIOL CHEM, V277, P30183, DOI 10.1074/jbc.M203072200; Pechoux C, 1999, DEV BIOL, V206, P88, DOI 10.1006/dbio.1998.9133; Philipp S, 1997, FEBS LETT, V413, P243, DOI 10.1016/S0014-5793(97)00877-6; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; Pim D, 2002, ONCOGENE, V21, P8140, DOI 10.1038/sj.onc.1206026; Polyak K, 2005, J MAMMARY GLAND BIOL, V10, P231, DOI 10.1007/s10911-005-9584-6; PRASAD R, 1993, CANCER RES, V53, P5624; Primo L, 2007, J CELL BIOL, V176, P1035, DOI 10.1083/jcb.200607053; Procko E, 2005, BIOESSAYS, V27, P153, DOI 10.1002/bies.20157; Qin Y, 2005, J CELL BIOL, V171, P1061, DOI 10.1083/jcb.200506094; Rebeaud F, 2007, TRENDS IMMUNOL, V28, P196, DOI 10.1016/j.it.2007.03.004; Reuver SM, 1998, J CELL SCI, V111, P1071; Rincon M, 2007, NAT IMMUNOL, V8, P126, DOI 10.1038/ni0207-126; Round JL, 2005, J EXP MED, V201, P419, DOI 10.1084/jem.20041428; Round JL, 2007, NAT IMMUNOL, V8, P154, DOI 10.1038/ni1422; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Sakurai A, 2006, MOL BIOL CELL, V17, P966, DOI 10.1091/mbc.E05-07-0647; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Sato N, 2003, CANCER RES, V63, P3735; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Schaley J, 2000, J VIROL, V74, P2084, DOI 10.1128/JVI.74.5.2084-2093.2000; Shai A, 2007, CANCER RES, V67, P1626, DOI 10.1158/0008-5472.CAN-06-3344; Sheng M, 1996, CURR OPIN NEUROBIOL, V6, P602, DOI 10.1016/S0959-4388(96)80091-2; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SHENK T, 1991, ADV CANCER RES, V57, P47; Shenk T, 2001, FIELDS VIROLOGY, V2, P2265; Shin K, 2005, J CELL BIOL, V168, P705, DOI 10.1083/jcb.200408064; Shin K, 2007, EMBO REP, V8, P158, DOI 10.1038/sj.embor.7400890; Shin K, 2006, ANNU REV CELL DEV BI, V22, P207, DOI 10.1146/annurev.cellbio.22.010305.104219; Siegrist SE, 2007, GENE DEV, V21, P483, DOI 10.1101/gad.1511207; Simonson SJS, 2005, CANCER RES, V65, P8266, DOI 10.1158/0008-5472.CAN-05-1651; Soler AP, 1999, CARCINOGENESIS, V20, P1425, DOI 10.1093/carcin/20.8.1425; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STILLMAN B, 1986, CANCER SURV, V5, P389; Storrs CH, 2007, J VIROL, V81, P4080, DOI 10.1128/JVI.02545-06; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Stucke VM, 2007, MOL BIOL CELL, V18, P1744, DOI 10.1091/mbc.E06-11-0980; Sugihara-Mizuno Y, 2007, GENES CELLS, V12, P473, DOI 10.1111/j.1365-2443.2007.01066.x; Suzuki A, 2006, J CELL SCI, V119, P979, DOI 10.1242/jcs.02898; Suzuki T, 1999, ONCOGENE, V18, P5967, DOI 10.1038/sj.onc.1203008; Thomas DL, 1999, J VIROL, V73, P3071, DOI 10.1128/JVI.73.4.3071-3079.1999; Thomas DL, 2001, J VIROL, V75, P557, DOI 10.1128/JVI.75.2.557-568.2001; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 2008, ONCOGENE, V27, P7018, DOI 10.1038/onc.2008.351; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; TRENTIN JJ, 1962, SCIENCE, V137, P835, DOI 10.1126/science.137.3533.835; Tsubata C, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-46; Umeda K, 2006, CELL, V126, P741, DOI 10.1016/j.cell.2006.06.043; Valiente M, 2005, J BIOL CHEM, V280, P28936, DOI 10.1074/jbc.M504761200; VANDENELSEN P, 1983, VIROLOGY, V128, P377; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Wada H, 2005, DEVELOPMENT, V132, P2273, DOI 10.1242/dev.01810; Wang TG, 2000, AIDS RES HUM RETROV, V16, P1661, DOI 10.1089/08892220050193119; Watson RA, 2003, J CELL SCI, V116, P4925, DOI 10.1242/jcs.00809; Weiss RS, 1996, J VIROL, V70, P862, DOI 10.1128/JVI.70.2.862-872.1996; Weiss RS, 1997, J VIROL, V71, P7873, DOI 10.1128/JVI.71.10.7873-7880.1997; Weiss RS, 1997, J VIROL, V71, P1857, DOI 10.1128/JVI.71.3.1857-1870.1997; Weitzman MD, 2005, ONCOGENE, V24, P7686, DOI 10.1038/sj.onc.1209063; Weitzman MD, 2005, FRONT BIOSCI-LANDMRK, V10, P1106, DOI 10.2741/1604; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Wodarz A, 2006, CELL, V124, P1121, DOI 10.1016/j.cell.2006.03.004; Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433; WOODS DF, 1989, DEV BIOL, V134, P222, DOI 10.1016/0012-1606(89)90092-4; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Wu HJ, 2002, J BIOL CHEM, V277, P30928, DOI 10.1074/jbc.M203735200; Wu HJ, 1998, J CELL SCI, V111, P2365; Xavier R, 2004, J CELL BIOL, V166, P173, DOI 10.1083/jcb.200309044; Xie L, 2006, BLOOD, V107, P1980, DOI 10.1182/blood-2005-03-1333; Yamada KM, 2001, J CELL SCI, V114, P2375; Yamano S, 1999, J VIROL, V73, P10095, DOI 10.1128/JVI.73.12.10095-10103.1999; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J	233	85	90	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2008	27	55					7031	7046		10.1038/onc.2008.352	http://dx.doi.org/10.1038/onc.2008.352			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029943	Green Accepted			2022-12-17	WOS:000261108200014
J	Motrescu, ER; Blaise, S; Etique, N; Messaddeq, N; Chenard, MP; Stoll, I; Tomasetto, C; Rio, MC				Motrescu, E. R.; Blaise, S.; Etique, N.; Messaddeq, N.; Chenard, M-P; Stoll, I.; Tomasetto, C.; Rio, M-C			Matrix metalloproteinase-11/stromelysin-3 exhibits collagenolytic function against collagen VI under normal and malignant conditions	ONCOGENE			English	Article						matrix metalloproteinase-11/stromelysin-3; collagen VI; adipocyte; fat tissue; breast cancer	STROMAL CELL-INTERACTIONS; BREAST-CANCER; IN-VIVO; HUMAN STROMELYSIN-3; C5 DOMAIN; DIFFERENTIATION; IDENTIFICATION; METALLOPROTEINASES; PROGRESSION; ADIPOCYTES	The substrate of matrix metalloproteinase 11 (MMP11) remains unknown. We have recently shown that MMP11 is a negative regulator of adipogenesis, able to reduce and even to revert mature adipocyte differentiation. Here, we have used mouse 3T3L1 cells and human U87MG and SaOS cells to show that MMP11 cleaves the native alpha 3 chain of collagen VI, which is an adipocyte-related extracellular matrix component. It is known that extracellular proteolytic processing of this chain is required for correct collagen VI folding. Interestingly, MMP11-deficient fat tissue is less cohesive and exhibits collagen VI alteration, dramatic adipocyte plasma and basement membrane abnormalities and lipid leakage. MMP11 is thus required for correct collagen VI folding and therefore for fat tissue cohesion and adipocyte function. Both MMP11 and collagen VI favor tumor progression. Similar spatio-temporal overexpression at the adipocyte-cancer cell interface has been reported for the two proteins. MMP11-dependent collagen VI processing might therefore be expected to occur during malignancy. Accordingly, collagen VI no longer delineates adipocytes located at the invasive front of breast carcinomas. In conclusion, the native a3 chain of collagen VI constitutes a specific MMP11 substrate. This MMP11 collagenolytic activity is functional in fat tissue ontogenesis as well as during cancer invasive steps.	[Motrescu, E. R.; Blaise, S.; Etique, N.; Messaddeq, N.; Stoll, I.; Tomasetto, C.; Rio, M-C] Univ Strasbourg 1, INSERM, Dept Canc Biol, Inst Genet & Biol Mol & Cellulaire,UMR 7104,U596, F-67404 Illkirch Graffenstaden, France; [Chenard, M-P] Ctr Hosp Univ Hautepierre, Serv Anat Pathol Gen, Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg	Rio, MC (corresponding author), Univ Strasbourg 1, INSERM, Dept Canc Biol, Inst Genet & Biol Mol & Cellulaire,UMR 7104,U596, BP 10142, F-67404 Illkirch Graffenstaden, France.	rio@igbmc.u-strasbg.fr	etique, nicolas/J-4159-2017; BLAISE, Sebastien/AAS-1022-2020; Chenard, Marie-Pierre/O-2373-2016; Tomasetto, Catherine Laure/J-2783-2014	etique, nicolas/0000-0001-6613-9257; BLAISE, Sebastien/0000-0003-3012-1500; Tomasetto, Catherine Laure/0000-0002-1811-5848	Institut National de la Sante et de la Recherche Medicale; Centre National de la Recherche Scientifique; Hopital Universitaire de Strasbourg; Association pour la Recherche sur le Cancer; Ligue Nationale Francaise contre le Cancer and the Comites du Haut-Rhin et du Bas-Rhin; European Commission [FP6 LSHC-CT-2003-503297]; Cancer Degradome Project; Institut National du Cancer; Fond National pour la Sante [ACI 2004]; Canceropole Grand-Est and the 'Ruban Rose' prize	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Hopital Universitaire de Strasbourg; Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue Nationale Francaise contre le Cancer and the Comites du Haut-Rhin et du Bas-Rhin; European Commission(European CommissionEuropean Commission Joint Research Centre); Cancer Degradome Project(European Commission); Institut National du Cancer(Institut National du Cancer (INCA) France); Fond National pour la Sante; Canceropole Grand-Est and the 'Ruban Rose' prize	We thank Takako Sasaki from the Max-Planck-Institute for Biochemistry, Munich, Germany for his help. This study was supported by funds from the Institut National de la Sante et de la Recherche Medicale, the Centre National de la Recherche Scientifique, the Hopital Universitaire de Strasbourg, the Association pour la Recherche sur le Cancer, the Ligue Nationale Francaise contre le Cancer and the Comites du Haut-Rhin et du Bas-Rhin (equipe labellisee), the European Commission (FP6 LSHC-CT-2003-503297; Cancer Degradome Project), the Institut National du Cancer, Fond National pour la Sante ACI 2004 Canceropole Grand-Est and the 'Ruban Rose' prize. EM was a recipient of an EU fellowship.	Aigner T, 2002, BIOCHEM BIOPH RES CO, V290, P743, DOI 10.1006/bbrc.2001.6227; Andarawewa KL, 2005, CANCER RES, V65, P10862, DOI 10.1158/0008-5472.CAN-05-1231; Basset P, 1997, MATRIX BIOL, V15, P535, DOI 10.1016/S0945-053X(97)90028-7; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; Boulay A, 2001, CANCER RES, V61, P2189; Celis JE, 2005, MOL CELL PROTEOMICS, V4, P492, DOI 10.1074/mcp.M500030-MCP200; Dieudonne MN, 2006, BIOCHEM BIOPH RES CO, V345, P271, DOI 10.1016/j.bbrc.2006.04.076; Gregoire FM, 2001, EXP BIOL MED, V226, P997, DOI 10.1177/153537020122601106; HAN J, 1995, CONNECT TISSUE RES, V31, P161, DOI 10.3109/03008209509028404; Iyengar P, 2003, ONCOGENE, V22, P6408, DOI 10.1038/sj.onc.1206737; Iyengar P, 2005, J CLIN INVEST, V115, P1163, DOI 10.1172/JCI200523424; Kannan R, 1999, PROTEIN EXPRES PURIF, V16, P76, DOI 10.1006/prep.1999.1068; KIELTY CM, 1993, BIOCHEM BIOPH RES CO, V191, P1230, DOI 10.1006/bbrc.1993.1349; Kuo HJ, 1997, J BIOL CHEM, V272, P26522, DOI 10.1074/jbc.272.42.26522; Lamande SR, 2006, J BIOL CHEM, V281, P16607, DOI 10.1074/jbc.M510192200; Manabe Y, 2003, J PATHOL, V201, P221, DOI 10.1002/path.1430; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; MOTRESCU ER, 2008, BIOL CHEM, V389; Myint E, 1996, CORNEA, V15, P490; Nakajima I, 2002, DIFFERENTIATION, V70, P84, DOI 10.1046/j.1432-0436.2002.700203.x; NOEL A, 1995, J BIOL CHEM, V270, P22866, DOI 10.1074/jbc.270.39.22866; Noel A, 2000, ONCOGENE, V19, P1605, DOI 10.1038/sj.onc.1203465; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PEI DQ, 1994, J BIOL CHEM, V269, P25849; RIO MC, 2002, STROMELYSIN 3 PARTIC; Ruhl M, 1999, EXP CELL RES, V250, P548, DOI 10.1006/excr.1999.4540; Schaffler A, 2007, NAT CLIN PRACT ENDOC, V3, P345, DOI 10.1038/ncpendmet0456	29	85	87	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2008	27	49					6347	6355		10.1038/onc.2008.218	http://dx.doi.org/10.1038/onc.2008.218			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363JK	18622425				2022-12-17	WOS:000260263400004
J	Bertucci, F; Orsetti, B; Negre, V; Finetti, P; Rouge, C; Ahomadegbe, JC; Bibeau, F; Mathieu, MC; Treilleux, I; Jacquemier, J; Ursule, L; Martinec, A; Wang, Q; Benard, J; Puisieux, A; Birnbaum, D; Theillet, C				Bertucci, F.; Orsetti, B.; Negre, V.; Finetti, P.; Rouge, C.; Ahomadegbe, J-C; Bibeau, F.; Mathieu, M-C; Treilleux, I.; Jacquemier, J.; Ursule, L.; Martinec, A.; Wang, Q.; Benard, J.; Puisieux, A.; Birnbaum, D.; Theillet, C.			Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles	ONCOGENE			English	Article						breast cancer; DNA microarray; genetic profiles; array-CGH	MICROARRAY ANALYSIS; CANCER; PATTERNS; HYBRIDIZATION; DIFFERENTIATION; IDENTIFICATION; ASSOCIATION; SUBCLASSES; SURVIVAL; SUBTYPES	Invasive ductal carcinomas (IDCs) and invasive lobular carcinomas (ILCs) are the two major pathological types of breast cancer. Epidemiological and histoclinical data suggest biological differences, but little is known about the molecular alterations involved in ILCs. We undertook a comparative large-scale study by both array-compared genomic hybridization and cDNA microarray of a set of 50 breast tumors (21 classic ILCs and 29 IDCs) selected on homogeneous histoclinical criteria. Results were validated on independent tumor sets, as well as by quantitative RT-PCR. ILCs and IDCs presented differences at both the genomic and expression levels with ILCs being less rearranged and heterogeneous than IDCs. Supervised analysis defined a 75-BACs signature discriminating accurately ILCs from IDCs. Expression profiles identified two subgroups of ILCs: typical ILCs (similar to 50%), which were homogeneous and displayed a normal-like molecular pattern, and atypical ILCs, more heterogeneous with features intermediate between ILCs and IDCs. Supervised analysis identified a 75-gene expression signature that discriminated ILCs from IDCs, with many genes involved in cell adhesion, motility, apoptosis, protein folding, extracellular matrix and protein phosphorylation. Although ILCs and IDCs share common alterations, our data show that ILCs and IDCs could be distinguished on the basis of their genomic and expression profiles suggesting that they evolve along distinct genetic pathways.	[Bertucci, F.; Finetti, P.; Jacquemier, J.; Birnbaum, D.] Inst J Paoli I Calmettes, Ctr Cancerol Marseille, INSERM, UMR891, F-13009 Marseille, France; [Orsetti, B.; Negre, V.; Rouge, C.; Bibeau, F.; Ursule, L.; Theillet, C.] INSERM, CRLC Val Aurelle Paul Lamarque, IRCM, U896, F-34298 Montpellier 5, France; [Ahomadegbe, J-C] Univ Paris 11, UPRES 3535, Inst Gustave Roussy, Villejuif, France; [Bibeau, F.] CRLC Val Aurelle Paul Larmarque, Lab Anatomopathol, Montpellier, France; [Mathieu, M-C] Inst Gustave Roussy, Dept Biopathol, Villejuif, France; [Treilleux, I.] Ctr Leon Berard, Lab Anatomopathol, F-69373 Lyon, France; [Martinec, A.] Ipsogen SA, Marseille Luminy, France; [Wang, Q.; Puisieux, A.] Ctr Leon Berard, Oncol Mol Lab, F-69373 Lyon, France; [Benard, J.] CNRS, Inst Gustave Roussy, UMR 8126, Villejuif, France; [Puisieux, A.] Ctr Leon Berard, INSERM, U590, F-69373 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); UNICANCER; Gustave Roussy; UNICANCER; Centre Leon Berard; UNICANCER; Centre Leon Berard; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Theillet, C (corresponding author), INSERM, CRLC Val Aurelle Paul Lamarque, IRCM, U896, Rue Croix Verte, F-34298 Montpellier 5, France.	theillet@valdorel.fnclcc.fr	Theillet, Charles/O-7634-2018; Finetti, Pascal/O-8669-2017	Birnbaum, Daniel/0000-0001-7920-9883; Bertucci, Francois/0000-0002-0157-0959; PUISIEUX, Alain/0000-0002-9938-3798; Finetti, Pascal/0000-0002-2674-3123; Theillet, Charles/0000-0001-5555-2759	INSERM; Association de Recherche sur le Cancer (ARC) [5102]; Institut National du Cancer; Canceropoles PACA; Grand Sud Ouest	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Association de Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Institut National du Cancer(Institut National du Cancer (INCA) France); Canceropoles PACA; Grand Sud Ouest	This study was developed as part of a joint program Developpement d'outils de diagnostic moleculaire en Cancerologie: Applications aux cancers du sein' Ministere de l'Enseignement Superieur, de la Recherche et de la Technologie and Federation Nationale des Centres de Lutte Contre le Cancer and was supported by funds from INSERM, the Association de Recherche sur le Cancer (ARC), grant 5102, Institut National du Cancer, Canceropoles PACA and Grand Sud Ouest. The help of the Genopole Montpellier Languedoc-Roussillon is gratefully acknowledged. We thank Pr Dominique Maraninchi and Dr Claude Mawas for setting up this work and Mrs Sophie Tourpin for technical help.	Bertucci F, 2004, ONCOGENE, V23, P2564, DOI 10.1038/sj.onc.1207361; Bertucci F, 2006, OMICS, V10, P429, DOI 10.1089/omi.2006.10.429; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Flagiello D, 1998, GENE CHROMOSOME CANC, V23, P300, DOI 10.1002/(SICI)1098-2264(199812)23:4<300::AID-GCC4>3.0.CO;2-N; Fridlyand J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-96; Gunther K, 2001, J PATHOL, V193, P40, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH745>3.0.CO;2-N; Hicks J, 2006, GENOME RES, V16, P1465, DOI 10.1101/gr.5460106; Jacquemier J, 2005, CANCER RES, V65, P767; Katz A, 2007, LANCET ONCOL, V8, P55, DOI 10.1016/S1470-2045(06)71011-7; Korkola JE, 2003, CANCER RES, V63, P7167; LAMOVEC J, 1991, J SURG ONCOL, V48, P28, DOI 10.1002/jso.2930480106; Li CI, 2003, JAMA-J AM MED ASSOC, V289, P1421, DOI 10.1001/jama.289.11.1421; Loo LWM, 2004, CANCER RES, V64, P8541, DOI 10.1158/0008-5472.CAN-04-1992; Loveday RL, 2000, INT J CANCER, V86, P494, DOI 10.1002/(SICI)1097-0215(20000515)86:4<494::AID-IJC8>3.3.CO;2-F; Orsetti B, 2006, BRIT J CANCER, V95, P1439, DOI 10.1038/sj.bjc.6603433; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; SastreGarau X, 1996, CANCER, V77, P113, DOI 10.1002/(SICI)1097-0142(19960101)77:1<113::AID-CNCR19>3.0.CO;2-8; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stange DE, 2006, CLIN CANCER RES, V12, P345, DOI 10.1158/1078-0432.CCR-05-1633; Toikkanen S, 1997, BRIT J CANCER, V76, P1234, DOI 10.1038/bjc.1997.540; Turashvili G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-55; Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786	24	85	87	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2008	27	40					5359	5372		10.1038/onc.2008.158	http://dx.doi.org/10.1038/onc.2008.158			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	346UW	18490921	Green Accepted, Green Submitted			2022-12-17	WOS:000259096100009
J	Espinosa, JM				Espinosa, J. M.			Mechanisms of regulatory diversity within the p53 transcriptional network	ONCOGENE			English	Review						p21; ASPP; HZF; hCAS; serine 46; lysine 120	RNA-POLYMERASE-II; IN-VIVO; P53-DEPENDENT APOPTOSIS; DNA-DAMAGE; TUMOR-SUPPRESSOR; BINDING-SITES; GENE-EXPRESSION; MESSENGER-RNAS; CORE PROMOTER; TARGET GENES	p53 is arguably the most intensively studied protein to date, yet there is much that we ignore about its function as a transcription factor. The p53-dependent transcriptional program is remarkably flexible, as it varies with the nature of p53-activating stimuli, the cell type and the duration of the activation signal. This flexibility may allow cells to mount alternative responses to p53 activation, such as cell cycle arrest or apoptosis. Here, I organize the available data into two alternative models to explain how this regulatory diversity is achieved.	Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Espinosa, JM (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA.	joaquin.espinosa@colorado.edu			NATIONAL CANCER INSTITUTE [R01CA117907] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA117907-03, R01-CA117907, R01 CA117907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Alves NL, 2006, IMMUNITY, V24, P703, DOI 10.1016/j.immuni.2006.03.018; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Bergamaschi D, 2006, NAT GENET, V38, P1133, DOI 10.1038/ng1879; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Brunkhorst A, 2004, BIOCHEM BIOPH RES CO, V325, P574, DOI 10.1016/j.bbrc.2004.10.078; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Butler JEF, 2001, GENE DEV, V15, P2515, DOI 10.1101/gad.924301; Butler JEF, 2002, GENE DEV, V16, P2583, DOI 10.1101/gad.1026202; Cain C, 2000, J BIOL CHEM, V275, P39944, DOI 10.1074/jbc.M002509200; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Das S, 2007, CELL, V130, P624, DOI 10.1016/j.cell.2007.06.013; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; Donner AJ, 2007, CELL CYCLE, V6, P2594, DOI 10.4161/cc.6.21.4893; Donner AJ, 2007, MOL CELL, V27, P121, DOI 10.1016/j.molcel.2007.05.026; Efeyan A, 2007, CANCER RES, V67, P7350, DOI 10.1158/0008-5472.CAN-07-0200; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Fei PW, 2002, CANCER RES, V62, P7316; Figueroa A, 2003, MOL CELL BIOL, V23, P4991, DOI 10.1128/MCB.23.14.4991-5004.2003; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Garneau NL, 2007, NAT REV MOL CELL BIO, V8, P113, DOI 10.1038/nrm2104; Gohler T, 2002, J BIOL CHEM, V277, P41192, DOI 10.1074/jbc.M202344200; Gomes NP, 2006, GENE DEV, V20, P601, DOI 10.1101/gad.1398206; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; Hermeking H, 2007, CANCER CELL, V12, P414, DOI 10.1016/j.ccr.2007.10.028; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Horvath MM, 2007, PLOS GENET, V3, P1284, DOI 10.1371/journal.pgen.0030127; Jett SD, 2000, J MOL BIOL, V299, P585, DOI 10.1006/jmbi.2000.3759; Jiang M, 2003, GENE DEV, V17, P832, DOI 10.1101/gad.252603; Johannessen LE, 1999, BIOCHEM J, V337, P599, DOI 10.1042/0264-6021:3370599; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kojima K, 2005, BLOOD, V106, P3150, DOI 10.1182/blood-2005-02-0553; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a; Loncle N, 2007, EMBO J, V26, P1045, DOI 10.1038/sj.emboj.7601566; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Luecke HF, 2005, GENE DEV, V19, P1116, DOI 10.1101/gad.1297105; Mattia M, 2007, MOL CELL BIOL, V27, P1309, DOI 10.1128/MCB.01520-06; Mo XM, 2004, MOL CELL, V13, P241, DOI 10.1016/S1097-2765(03)00521-5; Moll UM, 2004, MOL CANCER RES, V2, P371; OBRIEN T, 1991, MOL CELL BIOL, V11, P5285, DOI 10.1128/MCB.11.10.5285; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Perez CA, 2007, ONCOGENE, V26, P7363, DOI 10.1038/sj.onc.1210561; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Senoo M, 2004, CANCER CELL, V6, P85, DOI 10.1016/j.ccr.2004.06.005; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Shi LF, 2005, J BIOL CHEM, V280, P18981, DOI 10.1074/jbc.M411034200; Shu LM, 2006, GENE DEV, V20, P2961, DOI 10.1101/gad.1463306; Slee EA, 2003, TOXICOL LETT, V139, P81, DOI 10.1016/S0378-4274(02)00421-6; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Tanaka T, 2007, CELL, V130, P638, DOI 10.1016/j.cell.2007.08.001; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Thompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; Truong AB, 2006, GENE DEV, V20, P3185, DOI 10.1101/gad.1463206; van de Peppel J, 2005, MOL CELL, V19, P511, DOI 10.1016/j.molcel.2005.06.033; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vives V, 2006, GENE DEV, V20, P1262, DOI 10.1101/gad.374006; Vives V, 2006, CELL CYCLE, V5, P2187, DOI 10.4161/cc.5.19.3266; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Wang G, 2005, MOL CELL, V17, P683, DOI 10.1016/j.molcel.2005.02.010; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang XP, 2004, DALTON T, P1787, DOI 10.1039/b405981f; Zhang XT, 2005, MOL CELL, V19, P89, DOI 10.1016/j.molcel.2005.05.015; Zhao RB, 2000, GENE DEV, V14, P981; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	77	85	86	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2008	27	29					4013	4023		10.1038/onc.2008.37	http://dx.doi.org/10.1038/onc.2008.37			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18278067	Green Accepted			2022-12-17	WOS:000257325100001
J	Liu, X; Mazanek, P; Dam, V; Wang, Q; Zhao, H; Guo, R; Jagannathan, J; Cnaan, A; Maris, JM; Hogarty, MD				Liu, X.; Mazanek, P.; Dam, V.; Wang, Q.; Zhao, H.; Guo, R.; Jagannathan, J.; Cnaan, A.; Maris, J. M.; Hogarty, M. D.			Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification	ONCOGENE			English	Article						neuroblastoma; CTNNB1/beta-catenin; MYC; MYCN; embryonal cancer	BETA-CATENIN; C-MYC; WNT; EXPRESSION; GENE; TARGET; ACTIVATION; MUTATIONS; MECHANISM; PATHWAY	Neuroblastoma (NB) is a frequently lethal tumor of childhood. MYCN amplification accounts for the aggressive phenotype in a subset while the majority have no consistently identified molecular aberration but frequently express MYC at high levels. We hypothesized that activated Wnt/beta-catenin (CTNNB1) signaling might account for this as MYC is a beta-catenin transcriptional target and multiple embryonal and neural crest malignancies have oncogenic alterations in this pathway. NB cell lines without MYCN amplification express higher levels of MYC and beta-catenin (with aberrant nuclear localization) than MYCN amplified cell lines. Evidence for aberrant beta-catenin-TCF transcriptional activity was demonstrated using expression profiles from 73 primary NBs. Findings included increased WNT ligands (WNT1, WNT6, WNT7A, WNT10B), DVL1 and TCF7 expression in high-risk NBs without MYCN amplification, consistent with canonical beta-catenin signaling. More directly, Patterns of Gene Expression and Gene Set Enrichment Analyses demonstrated beta-catenin target genes (for example, MYC, PPARD, NRCAM, CD44, TCF7) as coordinately upregulated in high-risk NBs without MYCN amplification in comparison to high-risk MYCN-amplified or intermediate-risk NBs, supporting pathway activation in this subset. Thus, high-risk NBs without MYCN amplification may deregulate MYC and other oncogenic genes via altered beta-catenin signaling providing a potential candidate pathway for therapeutic inhibition.	[Liu, X.; Mazanek, P.; Dam, V.; Wang, Q.; Jagannathan, J.; Cnaan, A.; Maris, J. M.; Hogarty, M. D.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; [Zhao, H.; Guo, R.; Cnaan, A.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Maris, J. M.; Hogarty, M. D.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania	Hogarty, MD (corresponding author), Childrens Hosp Philadelphia, Div Oncol, 9 N ARC 902C,3516 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	hogartym@email.chop.edu			NCI NIH HHS [P01-CA97323] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA097323] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Bellmeyer A, 2003, DEV CELL, V4, P827, DOI 10.1016/S1534-5807(03)00160-6; Blanc E, 2005, ONCOGENE, V24, P1277, DOI 10.1038/sj.onc.1208255; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; COHN SL, 1990, ONCOGENE, V5, P1821; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Eggert A, 2000, BIOTECHNIQUES, V28, P681, DOI 10.2144/00284st04; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Kleber M, 2005, J CELL BIOL, V169, P309, DOI 10.1083/jcb.200411095; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; Kolligs FT, 2002, CANCER CELL, V1, P145, DOI 10.1016/S1535-6108(02)00035-1; Lee HY, 2004, SCIENCE, V303, P1020, DOI 10.1126/science.1091611; Manduchi E, 2000, BIOINFORMATICS, V16, P685, DOI 10.1093/bioinformatics/16.8.685; Maris JM, 2002, CANCER CELL, V2, P447, DOI 10.1016/S1535-6108(02)00206-4; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; SADEE W, 1987, CANCER RES, V47, P5207; Sinner D, 2004, DEVELOPMENT, V131, P3069, DOI 10.1242/dev.01176; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Thompson PM, 2001, CANCER RES, V61, P679; Voeller HJ, 1998, CANCER RES, V58, P2520; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618; Zechner D, 2003, DEV BIOL, V258, P406, DOI 10.1016/S0012-1606(03)00123-4	34	85	88	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2008	27	10					1478	1488		10.1038/sj.onc.1210769	http://dx.doi.org/10.1038/sj.onc.1210769			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17724465				2022-12-17	WOS:000253548200015
J	Chan, KS; Sano, S; Kataoka, K; Abel, E; Carbajal, S; Beltran, L; Clifford, J; Peavey, M; Shen, J; DiGiovanni, J				Chan, K. S.; Sano, S.; Kataoka, K.; Abel, E.; Carbajal, S.; Beltran, L.; Clifford, J.; Peavey, M.; Shen, J.; DiGiovanni, J.			Forced expression of a constitutively active form of Stat3 in mouse epidermis enhances malignant progression of skin tumors induced by two-stage carcinogenesis	ONCOGENE			English	Article						stat3; epithelial carcinogenesis; malignant progression; angiogenesis and epithelial mesenchymal transition	GROWTH-FACTOR RECEPTOR; EPITHELIAL-MESENCHYMAL TRANSITIONS; E-CADHERIN; ALTERED EXPRESSION; P-CADHERIN; MICE; ONCOGENESIS; METASTASIS; INITIATION; CANCER	Recently, our laboratory demonstrated that Stat3 is required for the de novo development of chemically-induced skin tumors. We have further investigated the role of Stat3 in epithelial carcinogenesis using mice in which the expression of a constitutively active/ dimerized form of Stat3 ( Stat3C) is targeted to the proliferative compartment of epidermis ( referred to as K5.Stat3C transgenic mice). Keratinocytes from K5. Stat3C mice showed increased survival following exposure to 7,12-dimethyl-benz[ a] anthracene ( DMBA) and enhanced proliferation following exposure to 12-O-tetradecanoylphorbol-13-acetate ( TPA). In two-stage chemical carcinogenesis experiments using DMBA as the tumor initiator and TPA as the promoter, K5. Stat3C mice developed skin tumors witha shorter latency and in much greater number compared to non-transgenic littermates. Remarkably, 100% of the skin tumors that developed in K5. Stat3C transgenic mice bypassed the premalignant stage and were initially diagnosed as carcinoma in situ which rapidly progressed to squamous cell carcinoma ( SCC). These tumors were highly vascularized, poorly differentiated and invasive and loss of expression of K10, filaggrin and E-cadherin was observed by 20 weeks. Finally, overexpression of Stat3C in a papilloma cell line led to enhanced cell migration and enhanced invasion through Matrigel in both the absence and presence of growth factors. In addition to its critical role in early stages of epithelial carcinogenesis, the current study reveals a novel role for Stat3 in driving malignant progression of skin tumors in vivo.	[Chan, K. S.; Sano, S.; Kataoka, K.; Abel, E.; Carbajal, S.; Beltran, L.; Peavey, M.; Shen, J.; DiGiovanni, J.] Univ Texas Dallas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, Smithville, TX 78957 USA; [Clifford, J.] Louisiana State Univ, Hlth Sci Ctr, Dept Biochem, Shreveport, LA 71105 USA	University of Texas System; University of Texas Dallas; UTMD Anderson Cancer Center; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	DiGiovanni, J (corresponding author), Univ Texas Dallas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, 1808 Pk Rd 1C,POB 389, Smithville, TX 78957 USA.	jdigiova@mdanderson.org	KATAOKA, Ken/B-1607-2011	Abel, Erika/0000-0001-8791-825X	NCI NIH HHS [CA16672, UO1 CA05345] Funding Source: Medline; NHLBI NIH HHS [R01 HL074352] Funding Source: Medline; NIEHS NIH HHS [U01 ES11047, ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES011047, P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Cai SQ, 2005, J DERMATOL, V32, P354, DOI 10.1111/j.1346-8138.2005.tb00906.x; Cano A, 1996, INT J CANCER, V65, P254; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; Dauer DJ, 2005, ONCOGENE, V24, P3397, DOI 10.1038/sj.onc.1208469; Faraldo MLM, 1997, MOL CARCINOGEN, V20, P33, DOI 10.1002/(SICI)1098-2744(199709)20:1<33::AID-MC5>3.0.CO;2-J; Fuchs E, 1994, Princess Takamatsu Symp, V24, P290; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kiguchi K, 1998, MOL CARCINOGEN, V22, P73, DOI 10.1002/(SICI)1098-2744(199806)22:2<73::AID-MC2>3.3.CO;2-B; Kortylewski M, 2005, CANCER METAST REV, V24, P315, DOI 10.1007/s10555-005-1580-1; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Ling XY, 2005, CANCER RES, V65, P2532, DOI 10.1158/0008-5472.CAN-04-2425; MILLER DR, 1987, CANCER RES, V47, P1935; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; RHO OY, 1994, MOL CARCINOGEN, V11, P19, DOI 10.1002/mc.2940110105; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; RUGGERI B, 1992, AM J PATHOL, V140, P1179; Sano S, 2005, NAT MED, V11, P43, DOI 10.1038/nm1162; Tang MS, 2000, CANCER RES, V60, P5688; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Yamashita S, 2004, NATURE, V429, P298, DOI 10.1038/nature02545; Yang J, 2006, CANCER RES, V66, P4549, DOI 10.1158/0008-5472.CAN-05-3850; YUSPA SH, 1994, CANCER RES, V54, P1178; Zeigler ME, 1996, INVAS METAST, V16, P3	29	85	86	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1087	1094		10.1038/sj.onc.1210726	http://dx.doi.org/10.1038/sj.onc.1210726			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700521				2022-12-17	WOS:000253136700008
J	Pabst, T; Mueller, BU				Pabst, T.; Mueller, B. U.			Transcriptional dysregulation during myeloid transformation in AML	ONCOGENE			English	Review						CEBPA; RUNX1; PU.1; myeloid differentiation; AML	BINDING-PROTEIN-ALPHA; ACUTE-LYMPHOBLASTIC-LEUKEMIA; ACUTE-MYELOBLASTIC-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; FACTOR-C/EBP-ALPHA; CEBPA MUTATIONS; GRANULOCYTIC DIFFERENTIATION; POINT MUTATIONS; AML1/PEBP2-ALPHA-B GENE; PU.1 EXPRESSION	The current paradigm on leukemogenesis indicates that leukemias are propagated by leukemic stem cells. The genomic events and pathways involved in the transformation of hematopoietic precursors into leukemic stem cells are increasingly understood. This concept is based on genomic mutations or functional dysregulation of transcription factors in malignant cells of patients with acute myeloid leukemia ( AML). Loss of the CCAAT/ enhancer binding protein-alpha ( CEBPA) function in myeloid cells in vitro and in vivo leads to a differentiation block, similar to that observed in blasts from AML patients. CEBPA alterations in specific subgroups of AML comprise genomic mutations leading to dominant- negative mutant proteins, transcriptional suppression by leukemic fusion proteins, translational inhibition by activated RNA-binding proteins, and functional inhibition by phosphorylation or increased proteasomal- dependent degradation. The PU. 1 gene can be mutated or its expression or function can be blocked by leukemogenic fusion proteins in AML. Point mutations in the RUNX1/ AML1 gene are also observed in specific subtypes of AML, in addition to RUNX1 being the most frequent target for chromosomal translocation in AML. These data are persuasive evidence that impaired function of particular transcription factors contributes directly to the development of human AML, and restoring their function represents a promising target for novel therapeutic strategies in AML.	Univ Hosp Bern, Inst Med Oncol, CH-3010 Bern, Switzerland; Univ Hosp Bern, Dept Internal Med, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern	Pabst, T (corresponding author), Univ Hosp Bern, Inst Med Oncol, CH-3010 Bern, Switzerland.	thomas.pabst@insel.ch						Akasaka T, 2007, BLOOD, V109, P3451, DOI 10.1182/blood-2006-08-041012; Barjesteh van Waalwijk van Doorn-Khosrovani S, 2003, HEMATOL J, V4, P31; Behre G, 2002, J BIOL CHEM, V277, P26293, DOI 10.1074/jbc.M202301200; Bienz M, 2005, CLIN CANCER RES, V11, P1416, DOI 10.1158/1078-0432.CCR-04-1552; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Chapiro E, 2006, BLOOD, V108, P3560, DOI 10.1182/blood-2006-03-010835; Chim CS, 2002, BRIT J HAEMATOL, V119, P988, DOI 10.1046/j.1365-2141.2002.03952.x; Cook WD, 2004, BLOOD, V104, P3437, DOI 10.1182/blood-2004-06-2234; Duprez E, 2003, EMBO J, V22, P5806, DOI 10.1093/emboj/cdg556; Ferrari-Amorotti G, 2006, BLOOD, V108, P1353, DOI 10.1182/blood-2006-01-011833; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Frohling S, 2005, GENE CHROMOSOME CANC, V42, P427, DOI 10.1002/gcc.20152; Frohling S, 2004, J CLIN ONCOL, V22, P624, DOI 10.1200/JCO.2004.06.060; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Harada H, 2003, BLOOD, V101, P673, DOI 10.1182/blood-2002-04-1010; Healy J, 2007, BLOOD, V109, P683, DOI 10.1182/blood-2006-02-003236; Heath V, 2004, BLOOD, V104, P1639, DOI 10.1182/blood-2003-11-3963; Helbling D, 2005, BLOOD, V106, P1369, DOI 10.1182/blood-2004-11-4392; Helbling D, 2004, P NATL ACAD SCI USA, V101, P13312, DOI 10.1073/pnas.0404731101; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Keeshan K, 2006, CANCER CELL, V10, P401, DOI 10.1016/j.ccr.2006.09.012; Langabeer SE, 2002, GENE CHROMOSOME CANC, V34, P24, DOI 10.1002/gcc.10031; Lee YJ, 2006, BLOOD, V108, P2416, DOI 10.1182/blood-2006-02-003582; Lin LI, 2005, CLIN CANCER RES, V11, P1372, DOI 10.1158/1078-0432.CCR-04-1816; Liu HT, 2003, BLOOD, V101, P3885, DOI 10.1182/blood-2002-07-2212; Matsuno N, 2003, LEUKEMIA, V17, P2492, DOI 10.1038/sj.leu.2403160; McFie PJ, 2006, J BIOL CHEM, V281, P18069, DOI 10.1074/jbc.M512734200; Metcalf D, 2006, P NATL ACAD SCI USA, V103, P1486, DOI 10.1073/pnas.0510616103; Mizuki M, 2003, BLOOD, V101, P3164, DOI 10.1182/blood-2002-06-1677; Mueller BU, 2006, BRIT J CANCER, V94, P1918, DOI 10.1038/sj.bjc.6603198; Mueller BU, 2006, BLOOD, V107, P3330, DOI 10.1182/blood-2005-07-3068; Mueller BU, 2006, CURR OPIN HEMATOL, V13, P7, DOI 10.1097/01.moh.0000190110.08156.96; Mueller BU, 2002, BLOOD, V100, P998, DOI 10.1182/blood.V100.3.998; Nagata C, 1999, Climacteric, V2, P6, DOI 10.3109/13697139909025557; Nanri T, 2006, BLOOD, V108, p543A, DOI 10.1182/blood.V108.11.1916.1916; Osato M, 2004, ONCOGENE, V23, P4284, DOI 10.1038/sj.onc.1207779; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Pabst T, 2006, BRIT J HAEMATOL, V133, P400, DOI 10.1111/j.1365-2141.2006.06057.x; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Parkin SE, 2002, J BIOL CHEM, V277, P23563, DOI 10.1074/jbc.M202184200; Pastinen T, 2004, SCIENCE, V306, P647, DOI 10.1126/science.1101659; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Porse BT, 2005, J EXP MED, V202, P85, DOI 10.1084/jem.20050067; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; Preudhomme C, 2002, BLOOD, V100, P2717, DOI 10.1182/blood-2002-03-0990; Radomska HS, 2006, J EXP MED, V203, P371, DOI 10.1084/jem.20052242; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Rosenbauer F, 2007, NAT REV IMMUNOL, V7, P105, DOI 10.1038/nri2024; Rosmarin AG, 2005, EXP HEMATOL, V33, P131, DOI 10.1016/j.exphem.2004.08.015; Ross SE, 2004, MOL CELL BIOL, V24, P675, DOI 10.1128/MCB.24.2.675-686.2004; Roumier C, 2003, BLOOD, V101, P1277, DOI 10.1182/blood-2002-05-1474; Sellick G, 2005, LEUKEMIA, V19, P1276, DOI 10.1038/sj.leu.2403788; Shih LY, 2006, LEUKEMIA, V20, P604, DOI 10.1038/sj.leu.2404124; Silva FPG, 2003, ONCOGENE, V22, P538, DOI 10.1038/sj.onc.1206141; Skokowa J, 2006, NAT MED, V12, P1191, DOI 10.1038/nm1484; Smith ML, 2005, BRIT J HAEMATOL, V128, P318, DOI 10.1111/j.1365-2141.2004.05324.x; Smith ML, 2004, NEW ENGL J MED, V351, P2403, DOI 10.1056/NEJMoa041331; Snaddon J, 2003, GENE CHROMOSOME CANC, V37, P72, DOI 10.1002/gcc.10185; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Suraweera N, 2005, ONCOGENE, V24, P3678, DOI 10.1038/sj.onc.1208422; Tada T, 2006, JNCI-J NATL CANCER I, V98, P396, DOI 10.1093/jnci/djj093; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Timchenko LT, 2002, MOL CELL BIOL, V22, P7242, DOI 10.1128/MCB.22.20.7242-7257.2002; Truong BTH, 2003, BLOOD, V101, P1141, DOI 10.1182/blood-2002-05-1374; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Wagner K, 2006, P NATL ACAD SCI USA, V103, P6338, DOI 10.1073/pnas.0508143103; Walter MJ, 2005, P NATL ACAD SCI USA, V102, P12513, DOI 10.1073/pnas.0504247102; Wang D, 2006, BLOOD, V108, P1223, DOI 10.1182/blood-2005-12-008763; Wang GL, 2004, GENE DEV, V18, P912, DOI 10.1101/gad.1183304; Wouters BJ, 2007, BLOOD, V109, P389, DOI 10.1182/blood-2006-08-042325; Xie HF, 2004, CELL, V117, P663, DOI 10.1016/S0092-8674(04)00419-2; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang P, 2004, IMMUNITY, V21, P853, DOI 10.1016/j.immuni.2004.11.006; Zheng R, 2004, BLOOD, V103, P1883, DOI 10.1182/blood-2003-06-1978	78	85	90	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	47					6829	6837		10.1038/sj.onc.1210765	http://dx.doi.org/10.1038/sj.onc.1210765			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934489				2022-12-17	WOS:000250147000013
J	Perks, CM; Vernon, EG; Rosendahl, AH; Tonge, D; Holly, JMP				Perks, C. M.; Vernon, E. G.; Rosendahl, A. H.; Tonge, D.; Holly, J. M. P.			IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells	ONCOGENE			English	Article						IGF-II; IGFBP-2; PTEN	FACTOR-BINDING PROTEIN-2; TUMOR-SUPPRESSOR PTEN; GROWTH-FACTOR-I; EPITHELIAL-CELLS; MAP KINASE; EXPRESSION; PHOSPHATASE; INHIBITION; PROLIFERATION; TUMORIGENESIS	The dual-function phosphatase and tensin homolog deleted on chromosome 10 ( PTEN) is the second most frequently mutated gene in human cancers. PTEN counteracts the functions of many growth factors, the most prevalent of which is insulin-like growth factor II ( IGF-II). PTEN expression is stimulated by IGF-II forming a feedback loop. Investigating IGF-binding protein ( IGFBP) modulation of IGF-II actions on MCF-7 breast cancer cells, we found that IGFBP-2 also regulates PTEN. The MCF-7 cells were not responsive to high doses of IGF-II due to induction of PTEN, which was not observed with an IGF-II-analog that does not bind to IGFBPs or in the presence of an inhibitor that prevents IGFs associating with IGFBPs. These cells predominantly produce IGFBP-2: blocking IGFBP-2 with a specific antibody, or preventing IGFBP-2 binding to integrins, restored the induction of PTEN and the cells were non-responsive to high doses of the IGF-II-analog. Our. findings indicate that breast cancer cells do not respond to high doses of IGF-II due to induction of PTEN, but IGFBP-2, when free from IGF-II can suppress PTEN. Levels of IGFBP-2 are elevated frequently in human tumors: its ability to regulate PTEN could have important implications in relation to therapeutic strategies targeting growth factor pathways.	Univ Bristol, Southmead Hosp, Sch Med, Dept Clin Sci N Bristol,IMEG,IGF & Metab Endocrin, Bristol BS10 5NB, Avon, England; Lund Univ, Dept Oncol Clin Sci, Lund, Sweden; AstraZeneca UK, Macclesfield, Cheshire, England	Southmead Hospital; University of Bristol; Lund University; AstraZeneca	Perks, CM (corresponding author), Univ Bristol, Southmead Hosp, Sch Med, Dept Clin Sci N Bristol,IMEG,IGF & Metab Endocrin, Bristol BS10 5NB, Avon, England.	Claire.m.perks@bristol.ac.uk		Perks, Claire/0000-0003-1562-891X; Vernon, Ellen/0000-0002-8344-1025				Busund LT, 2005, J CLIN PATHOL, V58, P361, DOI 10.1136/jcp.2004.020834; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Clark AS, 2002, MOL CANCER THER, V1, P707; Clark MA, 2005, INT J CANCER, V116, P506, DOI 10.1002/ijc.21029; COULSON VJ, 1991, GROWTH REGULAT, V1, P119; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; DUBOIS V, 1995, EUR J BIOCHEM, V232, P47, DOI 10.1111/j.1432-1033.1995.tb20779.x; Dupont J, 2002, J CLIN INVEST, V110, P815, DOI [10.1172/JCI200213829, 10.1172/JCI0213829]; Dupont JL, 2003, J BIOL CHEM, V278, P37256, DOI 10.1074/jbc.M302355200; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Hoeflich A, 2001, CANCER RES, V61, P8601; Hwang PH, 2005, EXP MOL MED, V37, P391, DOI 10.1038/emm.2005.49; Kang-Park S, 2003, FEBS LETT, V545, P203, DOI 10.1016/S0014-5793(03)00535-0; Levitt RJ, 2005, BIOCHEM BIOPH RES CO, V336, P1056, DOI 10.1016/j.bbrc.2005.08.229; Li Y, 2001, BMC Mol Biol, V2, P2, DOI 10.1186/1471-2199-2-2; Liu XJ, 2001, J BIOL CHEM, V276, P32419, DOI 10.1074/jbc.C100299200; Maile LA, 1999, ENDOCRINOLOGY, V140, P4040, DOI 10.1210/en.140.9.4040; McCaig C, 2002, J CELL SCI, V115, P4293, DOI 10.1242/jcs.00097; Moorehead RA, 2003, J BIOL CHEM, V278, P50422, DOI 10.1074/jbc.M306894200; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Schmid AC, 2004, FEBS LETT, V566, P35, DOI 10.1016/j.febslet.2004.03.102; Schutt BS, 2004, J MOL ENDOCRINOL, V32, P859, DOI 10.1677/jme.0.0320859; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Stokoe D, 2005, P NATL ACAD SCI USA, V102, P2677, DOI 10.1073/pnas.0500089102; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Weng LP, 2002, HUM MOL GENET, V11, P1687, DOI 10.1093/hmg/11.15.1687; White ES, 2003, AM J RESP CRIT CARE, V168, P436, DOI 10.1164/rccm.200301-041OC; Wu RC, 2000, MOL CELL BIOCHEM, V203, P59, DOI 10.1023/A:1007024624967	32	85	87	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2007	26	40					5966	5972		10.1038/sj.onc.1210397	http://dx.doi.org/10.1038/sj.onc.1210397			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17369847				2022-12-17	WOS:000249123100014
J	Kreimann, EL; Morales, FC; de Orbeta-Cruz, J; Takahashi, Y; Adams, H; Liu, TJ; McCrea, PD; Georgescu, MM				Kreimann, E. L.; Morales, F. C.; de Orbeta-Cruz, J.; Takahashi, Y.; Adams, H.; Liu, T-J; McCrea, P. D.; Georgescu, M-M			Cortical stabilization of beta-catenin contributes to NHERF1/EBP50 tumor suppressor function	ONCOGENE			English	Article						NHERF1/EBP50; beta-catenin; E-cadherin; transformation; colon cancer; mouse embryonic fibroblasts (MEFs)	E-CADHERIN; NHERF; PROTEINS; COMPLEX; IDENTIFICATION; INHIBITION; MEMBRANE; ADHESIVE; FAMILY; GROWTH	Anchorage-independent growth is a hallmark of tumor growth and results from enhanced proliferation and altered cell-cell and cell-matrix interactions. By using gene-deficient mouse embryonic fibroblasts ( MEFs), we showed for the first time that NHERF1/EBP50 (Na/H exchanger regulator factor 1/ezrin-radixin-moesin binding phosphoprotein 50), an adapter protein with membrane localization under physiological conditions, inhibits cell motility and is required to suppress anchorage-independent growth. Both NHERF1 PDZ domains are necessary for the tumor suppressor effect. NHERF1 associates directly through the PDZ2 domain with beta-catenin and is required for beta-catenin localization at the cell- cell junctions in MEFs. Mechanistically, the absence of NHERF1 selectively decreased the interaction of beta-catenin with E-cadherin, but not with N-cadherin. The ensuing disorganization of E-cadherinmediated adherens junctions as well as the observed moderate increase in beta-catenin transcriptional activity contributed most likely to the anchorage-independent growth of NHERF1-deficient MEFs. In vivo, NHERF1 is specifically localized at the apical brush-border membrane in intestinal epithelial cells and is required to maintain a fraction of the cortical beta-catenin at this level. Thus, NHERF1 emerges as a cofactor essential for the integrity of epithelial tissues by maintaining the proper localization and complex assembly of beta-catenin.	Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Georgescu, MM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, 6767 Bertner Ave, Houston, TX 77030 USA.	mgeorges@mdanderson.org	Georgescu, Maria-Magdalena/AAJ-6359-2020; Kreimann, Erica/W-2082-2019; Adams, Henry/AAV-6870-2021		NIGMS NIH HHS [R01 GM052112] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brembeck FH, 2004, GENE DEV, V18, P2225, DOI 10.1101/gad.317604; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; Dai JL, 2004, ONCOGENE, V23, P8681, DOI 10.1038/sj.onc.1207962; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gottardi CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153; MCCREA PD, 1991, J BIOL CHEM, V266, P4514; Morales FC, 2004, P NATL ACAD SCI USA, V101, P17705, DOI 10.1073/pnas.0407974101; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Shenolikar S, 2004, PHYSIOLOGY, V19, P362, DOI 10.1152/physiol.00020.2004; Shibata T, 2003, HEPATOLOGY, V38, P178, DOI 10.1053/jhep.2003.50270; Suzuki J, 2004, ONCOGENE, V23, P8527, DOI 10.1038/sj.onc.1207894; Takahashi Y, 2006, EMBO J, V25, P910, DOI 10.1038/sj.emboj.7600979; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Voltz JW, 2001, ONCOGENE, V20, P6309, DOI 10.1038/sj.onc.1204774; Weinman EJ, 2003, BIOCHEMISTRY-US, V42, P12662, DOI 10.1021/bi035244l	21	85	91	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2007	26	36					5290	5299		10.1038/sj.onc.1210336	http://dx.doi.org/10.1038/sj.onc.1210336			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17325659				2022-12-17	WOS:000248674200012
J	Wang, ZH; Shen, B; Yao, HL; Jia, Y; Ren, J; Feng, Y; Wang, YZ				Wang, Z. H.; Shen, B.; Yao, H. L.; Jia, Y. C.; Ren, J.; Feng, Y. J.; Wang, Y. Z.			Blockage of intermediate-conductance-Ca2(+)-activated K+ channels inhibits progression of human endometrial cancer	ONCOGENE			English	Article						endometrial cancer; proliferation; intermediate-conductance Ca2+-activated K+ (IKCa1) channel; electrophysiology	INTERMEDIATE-CONDUCTANCE; CELL-PROLIFERATION; UP-REGULATION; POTASSIUM CHANNELS; GROWTH-FACTOR; INVOLVEMENT; CYCLE; MECHANISM; LINE; IDENTIFICATION	Potassium ( K+) channels have been implicated in proliferation of some tumor cells. However, whether K+ channels are important to the pathogenesis of endometrial cancer ( EC) remains unknown. In the present study, we report that intermediate-conductance Ca2+ activated K+ ( IKCa1) channels play a critical role in the development of EC. The expression of IKCa1 at both mRNA and protein levels in EC tissues was greatly increased than that in atypical hyperplasia and normal tissues. Treatment of EC cells with clotrimazole and TRAM-34, two agents kn own to inhibit IKCa1 channels, suppressed the proliferation of EC cells a nd blocked EC cell cycle at G(0)/G(1) phase. Similarly, downregulation of IKCa1 by siRNA against IKCa1 inhibited EC cell proliferation and arrested its cell cycle at G0/G1 phase. A clotrimazole-sensitive K+ current was induced in EC cells in response to the increased Ca2+. The current density induced by Ca2+ was great ly reduced by clotrimazole, TRAM-34, charybdotoxin or downregulation of IKCa1 by the siRNA against IKCa1. Furthermore, TRAM-34 and clotrimazole slowed the formation in nude mice of tumor generated by injection of EC cells. Our results suggest that increased activity of IKCa1 channel is necessary for the development of EC.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, Shanghai 200031, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Mat Med, Shanghai 200031, Peoples R China; Fudan Univ, Med Ctr, Obstet & Gynecol Hosp, Shanghai 200433, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Shanghai Institutes for Biological Sciences, CAS; Fudan University	Wang, YZ (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	fengyj4806@sohu.com; yzwang@ion.ac.cn						Ahn SC, 2004, PFLUG ARCH EUR J PHY, V447, P426, DOI 10.1007/s00424-003-1201-1; Begenisich T, 2004, J BIOL CHEM, V279, P47681, DOI 10.1074/jbc.M409627200; Chittajallu R, 2002, P NATL ACAD SCI USA, V99, P2350, DOI 10.1073/pnas.042698399; Dunn PM, 1998, J MEMBRANE BIOL, V165, P133, DOI 10.1007/s002329900427; Farias LMB, 2004, CANCER RES, V64, P6996, DOI 10.1158/0008-5472.CAN-04-1204; Fraser SP, 2003, PFLUG ARCH EUR J PHY, V446, P559, DOI 10.1007/s00424-003-1077-0; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; Jager H, 2004, MOL PHARMACOL, V65, P630, DOI 10.1124/mol.65.3.630; Lang F, 2003, CELL PHYSIOL BIOCHEM, V13, P41, DOI 10.1159/000070248; Legrand G, 2001, J BIOL CHEM, V276, P47608, DOI 10.1074/jbc.M107011200; Levine DA, 2002, CANCER J, V8, pS31; Lu XH, 1999, J GEN PHYSIOL, V113, P81, DOI 10.1085/jgp.113.1.81; Mork HK, 2005, ACTA PHYSIOL SCAND, V184, P141, DOI 10.1111/j.1365-201X.2005.01441.x; Nehrke K, 2003, AM J PHYSIOL-CELL PH, V284, pC535, DOI 10.1152/ajpcell.00044.2002; NILIUS B, 1992, J PHYSIOL-LONDON, V445, P537, DOI 10.1113/jphysiol.1992.sp018938; Ouadid-Ahidouch H, 2001, RECEPTOR CHANNEL, V7, P345; Ouadid-Ahidouch H, 2000, BIOCHEM BIOPH RES CO, V278, P272, DOI 10.1006/bbrc.2000.3790; Pardo LA, 1999, EMBO J, V18, P5540, DOI 10.1093/emboj/18.20.5540; Parihar AS, 2003, EUR J PHARMACOL, V471, P157, DOI 10.1016/S0014-2999(03)01825-9; Pena TL, 2000, J BIOL CHEM, V275, P13677, DOI 10.1074/jbc.275.18.13677; Rane SG, 1999, ADV SEC MESS PHOSPH, V33, P107; Rane SG, 2000, BIOCHEM BIOPH RES CO, V269, P457, DOI 10.1006/bbrc.2000.2309; Rouzaire-Dubois B, 1998, J PHYSIOL-LONDON, V510, P93, DOI 10.1111/j.1469-7793.1998.093bz.x; Ryan AJ, 2005, CELL TISSUE RES, V322, P53, DOI 10.1007/s00441-005-1109-5; Schneider JJ, 2005, GYNECOL ONCOL, V97, P246, DOI 10.1016/j.ygyno.2004.12.016; Skryma RN, 1997, PROSTATE, V33, P112, DOI 10.1002/(SICI)1097-0045(19971001)33:2<112::AID-PROS5>3.0.CO;2-M; Smith GAM, 2002, J BIOL CHEM, V277, P18528, DOI 10.1074/jbc.M200592200; Wang J, 2003, AM J PHYSIOL-CELL PH, V284, pC77, DOI 10.1152/ajpcell.00132.2002; Wang SY, 1998, J CELL PHYSIOL, V176, P456, DOI 10.1002/(SICI)1097-4652(199809)176:3<456::AID-JCP2>3.0.CO;2-N; WONDERLIN WF, 1995, J CELL PHYSIOL, V165, P177, DOI 10.1002/jcp.1041650121	30	85	98	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2007	26	35					5107	5114		10.1038/sj.onc.1210308	http://dx.doi.org/10.1038/sj.onc.1210308			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310992				2022-12-17	WOS:000248487400009
J	Pochampalli, MR; el Bejjani, RM; Schroeder, JA				Pochampalli, M. R.; el Bejjani, R. M.; Schroeder, J. A.			MUC1 is a novel regulator of erbB1 receptor trafficking	ONCOGENE			English	Article						erbB1; MUC1; phosphorylation; ubiquitination; breast cancer	GROWTH-FACTOR RECEPTOR; EGF RECEPTOR; C-SRC; TYROSINE KINASES; MAMMARY-GLAND; CANCER; CELLS; OVEREXPRESSION; SUPPRESSION; C-CBL/SLI-1	ErbB receptors are key regulators of cell survival and growth in normal and transformed tissues. The oncogenic glycoprotein MUC1 is a binding partner and substrate for erbB1 and MUC1 expression can potentiate erbB-dependent signal transduction. After receptor activation, erbB1 is typically downregulated via an endocytic pathway that results in receptor degradation or recycling. We report here that MUC1 expression inhibits the degradation of ligand-activated erbB1. Through the use of both RNAi-mediated knock down and overexpression constructs of MUC1, we show that MUC1 expression inhibits erbB1 degradation after ligand treatment in breast epithelial cells. This MUC1-mediated protection against erbB1 degradation can increase total cellular pools of erbB1 over time. Biotinylation of surface proteins demonstrates that cell-surface associated erbB1 receptor is protected by MUC1 against ligand-induced degradation, although this is accompanied by an increase in erbB1 internalization. The MUC1-mediated protection against degradation occurs with a decrease in EGF-stimulated ubiquitination of erbB1, and an increase in erbB1 recycling. These data indicate that MUC1 expression is a potent regulator of erbB1 receptor stability upon activation and may promote transformation through the inhibition of erbB1 degradation.	Univ Arizona, Arizona Canc Ctr, Dept Mol & Cellular Biol, Tucson, AZ 85724 USA; Univ Arizona, Bio5 Inst, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona; University of Arizona	Schroeder, JA (corresponding author), Univ Arizona, Arizona Canc Ctr, Dept Mol & Cellular Biol, Tucson, AZ 85724 USA.	jschroeder@azcc.arizona.edu		El Bejjani, Rachid/0000-0003-2328-0773; schroeder, joyce/0000-0003-1277-5172	NATIONAL CANCER INSTITUTE [R01CA102113] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA102113, R01 CA102113-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Bivona TG, 2003, CURR OPIN CELL BIOL, V15, P136, DOI 10.1016/S0955-0674(03)00016-4; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Hanisch FG, 2000, GLYCOBIOLOGY, V10, P439, DOI 10.1093/glycob/10.5.439; HILKENS J, 1995, CANCER LETT, V90, P27, DOI 10.1016/0304-3835(94)03674-8; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Kowanetz K, 2004, MOL BIOL CELL, V15, P3155, DOI 10.1091/mbc.E03-09-0683; Kuwada SK, 1998, AM J PHYSIOL-CELL PH, V275, pC1419, DOI 10.1152/ajpcell.1998.275.6.C1419; LAN MS, 1990, J BIOL CHEM, V265, P15294; Lee FT, 2005, CLIN CANCER RES, V11, p7080S, DOI 10.1158/1078-0432.CCR-1004-0019; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li XJ, 2005, CANCER BIOL THER, V4, P968, DOI 10.4161/cbt.4.9.1913; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LITVINOV SV, 1993, J BIOL CHEM, V268, P21364; McDermott KM, 2001, INT J CANCER, V94, P783, DOI 10.1002/ijc.1554; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Puertollano R, 2004, NAT CELL BIOL, V6, P244, DOI 10.1038/ncb1106; Reinheckel T, 2005, J CELL SCI, V118, P3387, DOI 10.1242/jcs.02469; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Schroeder JA, 2004, ONCOGENE, V23, P5739, DOI 10.1038/sj.onc.1207713; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Schroeder JA, 1997, J MAMMARY GLAND BIOL, V2, P119, DOI 10.1023/A:1026347629876; Shtiegman K, 2003, SEMIN CANCER BIOL, V13, P29, DOI 10.1016/S1044-579X(02)00097-4; Strachan L, 2001, J BIOL CHEM, V276, P18265, DOI 10.1074/jbc.M006935200; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Wang Y, 2002, MOL CELL BIOL, V22, P7279, DOI 10.1128/MCB.22.20.7279-7290.2002; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Yan Q, 2005, EXP CELL RES, V304, P265, DOI 10.1016/j.yexcr.2004.11.003; ZOTTER S, 1988, Cancer Reviews, V11-12, P55	37	85	89	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1693	1701		10.1038/sj.onc.1209976	http://dx.doi.org/10.1038/sj.onc.1209976			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16983337				2022-12-17	WOS:000244955600003
J	An, J; Chervin, AS; Nie, A; Ducoff, HS; Huang, Z				An, J.; Chervin, A. S.; Nie, A.; Ducoff, H. S.; Huang, Z.			Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor	ONCOGENE			English	Article						Bcl-2; HA14-1; p53; radiosensitization; apoptosis; ROS; JNK	N-TERMINAL KINASE; CYTOCHROME-C RELEASE; INDUCED APOPTOSIS; TUMOR-CELLS; DNA-DAMAGE; RADIATION; DEATH; ACTIVATION; JNK; BAX	Bcl-2 overexpression is an important mechanism underlying the aggressive behavior of prostate cancer cells and their resistance to radio- or chemotherapy. HA14-1, a recently discovered organic Bcl-2 inhibitor, potently induces apoptosis in various human cancer cells. Sequential exposure of radioresistant LNCaP (wild-type (wt) p53), LNCaP/Bcl-2 (wt p53) and PC3 (mutant p53) prostate cancer cells to a minimally cytotoxic concentration of 10 mu M HA14-1 for 1 h followed by 1-6 Gy gamma radiation, resulted in a highly synergistic (combination index < 1.0) induction of cell death as determined by an apoptosis assay at 72 h, and a clonogenicity assay at 12 days, after the initial treatment. The reverse treatment sequence did not cause a synergistic induction of cell death. When compared to individual treatments, cell death induced by the combined treatment was associated with dramatically increased reactive oxygen species (ROS) generation, c-Jun N-terminal kinase (JNK) activation, Bcl-2 phosphorylation, cytochrome c release, caspase-3 activation and DNA fragmentation. Exposure to either 200 mu g/ml of the antioxidant alpha-tocopherol or 10 mu M JNK inhibitor SP600125 before the combined treatment resulted in decreased activation of JNK and caspase-3 as well as decreased DNA fragmentation. However, treatment with the pancaspase inhibitor carbobenzoxyl-valyl-alanyl-aspartyl-[O-methyl]-fuoromethylketone before the combined treatment inhibited apoptosis without affecting JNK activation, and this inhibitory effect was enhanced in the presence of alpha-tocopherol or SP600125. Taken together, our results indicate that HA14-1 potently sensitizes radioresistant LNCaP and PC3 cells to gamma radiation, regardless of the status of p53. ROS and JNK are important early signals that trigger both caspase-dependent and -independent cell death pathways and contribute to the apoptotic synergy induced by the combined treatments.	Burnham Inst Med Res, La Jolla, CA 92037 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA	Sanford Burnham Prebys Medical Discovery Institute; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	An, J (corresponding author), Burnham Inst Med Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jingan@burnham.org						Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; An J, 2004, J BIOL CHEM, V279, P19133, DOI 10.1074/jbc.M400295200; Autorino R, 2003, UROL INT, V70, P1, DOI 10.1159/000067704; Bauer JJ, 1996, J UROLOGY, V156, P1511, DOI 10.1016/S0022-5347(01)65641-6; Belka C, 2004, INT J RADIAT ONCOL, V58, P542, DOI 10.1016/j.ijrobp.2003.09.067; Catz SD, 2003, APOPTOSIS, V8, P29, DOI 10.1023/A:1021692801278; Chaudhary KS, 2001, J PATHOL, V193, P522, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH821>3.0.CO;2-Y; Chendil D, 2004, ONCOGENE, V23, P1599, DOI 10.1038/sj.onc.1207284; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Denmeade SR, 1996, PROSTATE, V28, P251; DEWEY WC, 1971, P NATL ACAD SCI USA, V68, P667, DOI 10.1073/pnas.68.3.667; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Garzotto M, 1999, CANCER RES, V59, P5194; Hahn P, 1996, INT J RADIAT ONCOL, V34, P41, DOI 10.1016/0360-3016(95)02024-1; Hering F L, 2001, Sao Paulo Med J, V119, P138; Higuchi Y, 2003, BIOCHEM PHARMACOL, V66, P1527, DOI 10.1016/S0006-2952(03)00508-2; Kimura K, 1999, CANCER RES, V59, P1606; Kolesnick R, 2003, ONCOGENE, V22, P5897, DOI 10.1038/sj.onc.1206702; Krajewska M, 1996, AM J PATHOL, V148, P1567; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Lickliter JD, 2003, LEUKEMIA, V17, P2074, DOI 10.1038/sj.leu.2403102; Lin AN, 2002, AGING CELL, V1, P112, DOI 10.1046/j.1474-9728.2002.00014.x; Lin X, 2003, CANCER RES, V63, P3413; Marchal S, 2004, BIOCHEMISTRY-MOSCOW+, V69, P45, DOI 10.1023/B:BIRY.0000016350.61894.be; McConkey DJ, 1996, CANCER RES, V56, P5594; Mikkelsen RB, 2003, ONCOGENE, V22, P5734, DOI 10.1038/sj.onc.1206663; Milella M, 2002, BLOOD, V99, P3461, DOI 10.1182/blood.V99.9.3461; Mishra KP, 2004, J ENVIRON PATHOL TOX, V23, P61, DOI 10.1615/JEnvPathToxOncol.v23.i1.60; Ortiz MA, 2001, CANCER RES, V61, P8504; Park J, 1997, J BIOL CHEM, V272, P16725, DOI 10.1074/jbc.272.27.16725; Phillips DC, 2002, ARCH BIOCHEM BIOPHYS, V407, P15, DOI 10.1016/S0003-9861(02)00496-4; RAFFO AJ, 1995, CANCER RES, V55, P4438; Reed JC, 1996, ADV EXP MED BIOL, V406, P99; Rosser CJ, 2003, INT J RADIAT ONCOL, V56, P1, DOI 10.1016/S0360-3016(02)04468-1; Scherr DS, 1999, J UROLOGY, V162, P12, DOI 10.1097/00005392-199907000-00003; Scott SL, 2002, CANCER BIOTHER RADIO, V17, P647, DOI 10.1089/108497802320970253; Shaffer DR, 2003, LANCET ONCOL, V4, P407, DOI 10.1016/S1470-2045(03)01138-0; Szostak MJ, 2000, ONCOL REP, V7, P699; Tang DG, 1997, PROSTATE, V32, P284; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Todaro M, 2002, J CELL BIOCHEM, V86, P162, DOI 10.1002/jcb.10203; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Vivo C, 2003, J BIOL CHEM, V278, P25461, DOI 10.1074/jbc.M302161200; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Xiao D, 2004, ONCOGENE, V23, P5594, DOI 10.1038/sj.onc.1207747; Yamaguchi H, 2002, CANCER RES, V62, P466; Yu NF, 2000, TETRAHEDRON LETT, V41, P6993, DOI 10.1016/S0040-4039(00)01195-3; Zhan QM, 1999, ONCOGENE, V18, P297, DOI 10.1038/sj.onc.1202310	49	85	92	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					652	661		10.1038/sj.onc.1209830	http://dx.doi.org/10.1038/sj.onc.1209830			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16909121				2022-12-17	WOS:000243902200003
J	James, SR; Link, PA; Karpf, AR				James, S. R.; Link, P. A.; Karpf, A. R.			Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b	ONCOGENE			English	Article						cancer/germline antigens; cancer-testis antigens; DNMT1; DNMT3b; gene expression; DNA methylation; histone modifications	CYTOLYTIC T-LYMPHOCYTES; DE-NOVO METHYLATION; DNA METHYLATION; CANCER-CELLS; CANCER/TESTIS ANTIGENS; CPG METHYLATION; GERM-LINE; METHYLTRANSFERASES; EXPRESSION; TUMOR	We examined the function of two key DNA methyltransferase (DNMT) enzymes in epigenetic regulation of X-linked cancer/germline (CG-X) antigen genes in human cancer cells, using MAGE-A1, NY-ESO-1, and XAGE-1 as models. In HCT116 cells, genetic knockout of DNMT1 caused moderate activation of CG-X genes, DNMT3b knockout had a negligible effect, and double knockout of both enzymes caused robust gene induction. Similarly, dual DNMT knockout caused dramatic hypomethylation of the MAGE-A1 and NY-ESO-1 promoters, DNMT1 knockout showed moderate hypomethylation, and DNMT3b knockout elicited only slight methylation changes. In contrast, both single and double knockout cells showed significant hypomethylation of the XAGE-1 promoter. RNA interference (RNAi) targeting of DNMT1 in HCT116 cells validated the results seen using genetic knockout cells; however, RNAi targeting of DNMT1 in a different colorectal cancer cell line revealed a greater independent role for DNMT1 in mediating CG-X gene repression and promoter methylation in other cell types. Notably, the histone H3 modi. cation pattern at CG-X promoters was altered following DNMT knockout. DNMT1 or DNMT3b knockout reduced dimethylated lysine-9 (diMe-H3K9) levels, but did not significantly affect dimethylated lysine-4 (diMe-H3K4) or acetylated lysine-9 (Ac-H3-K9) levels. In contrast, dual DNMT1/3b knockout reduced the level of diMe-H3K9 and dramatically increased the levels of diMe-H3K4 and Ac-H3K9 at CG-X gene loci. In summary, DNMT1 and DNMT3b were found to perform both redundant and independent functions in epigenetic regulation of CG-X antigen genes in human cancer cells.	New York State Dept Hlth, Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Canc Drug Ctr, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Karpf, AR (corresponding author), New York State Dept Hlth, Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Canc Drug Ctr, Elm & Carlton St, Buffalo, NY 14263 USA.	adam.karpf@roswellpark.org		Karpf, Adam/0000-0002-0866-0666	NCI NIH HHS [R01 CA116674-01A1, CA16056, R01 CA116674] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA116674, P30CA016056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cheng JC, 2004, CANCER CELL, V6, P151, DOI 10.1016/j.ccr.2004.06.023; Chomez P, 2001, CANCER RES, V61, P5544; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; DE SC, 1996, P NATL ACAD SCI USA, V93, P7149, DOI DOI 10.1073/PNAS.93.14.7149; De Smet C, 2004, MOL CELL BIOL, V24, P4781, DOI 10.1128/MCB.24.11.4781-4790.2004; De Smet C, 1999, MOL CELL BIOL, V19, P7327; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gillespie AM, 1999, CANCER TREAT REV, V25, P219, DOI 10.1053/ctrv.1999.0126; Guo ZS, 2006, CANCER RES, V66, P1105, DOI 10.1158/0008-5472.CAN-05-3020; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jiang GC, 2004, J CELL BIOCHEM, V93, P286, DOI 10.1002/jcb.20146; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; Karpf AR, 2004, MOL PHARMACOL, V65, P18, DOI 10.1124/mol.65.1.18; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; Koslowski M, 2004, CANCER RES, V64, P5988, DOI 10.1158/0008-5472.CAN-04-1187; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311; Maio M, 2003, ONCOGENE, V22, P6484, DOI 10.1038/sj.onc.1206956; Odunsi K, 2003, CANCER RES, V63, P6076; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Qian Feng, 2004, Cancer Immun, V4, P12; Reynolds SR, 2003, CLIN CANCER RES, V9, P657; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Rozen S, 2000, Methods Mol Biol, V132, P365; Shi HD, 2003, CANCER RES, V63, P2164; Sigalotti L, 2004, CANCER RES, V64, P9167, DOI 10.1158/0008-5472.CAN-04-1442; Sigalotti L, 2002, J IMMUNOTHER, V25, P16, DOI 10.1097/00002371-200201000-00002; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Song LG, 2005, ANAL CHEM, V77, P504, DOI 10.1021/ac0489420; Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046; Tachibana M, 2005, GENE DEV, V19, P815, DOI 10.1101/gad.1284005; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Ting AH, 2006, CANCER RES, V66, P729, DOI 10.1158/0008-5472.CAN-05-1537; Ting AH, 2004, NAT GENET, V36, P582, DOI 10.1038/ng1365; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; WEBER J, 1994, CANCER RES, V54, P1766; Weiser TS, 2001, J IMMUNOTHER, V24, P151, DOI 10.1097/00002371-200103000-00010	53	85	91	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	52					6975	6985		10.1038/sj.onc.1209678	http://dx.doi.org/10.1038/sj.onc.1209678			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16715135				2022-12-17	WOS:000241732300008
J	Narod, SA				Narod, S. A.			Modifiers of risk of hereditary breast cancer	ONCOGENE			English	Review						BRCA1; BRCA2; penetrance; risk factors; genetic counseling; breast cancer	BRCA2 MUTATION CARRIERS; BILATERAL PROPHYLACTIC OOPHORECTOMY; SURGICAL ADJUVANT BREAST; OVARIAN-CANCER; ORAL-CONTRACEPTIVES; INHERITED MUTATIONS; WOMEN; PENETRANCE; PREVENTION; TAMOXIFEN	Mutations in the BRCA1 and BRCA2 genes confer a high lifetime risk of breast and ovarian cancer. The risk varies from individual to individual, and it appears that the risk has increased in recent generations. These observations imply that non-genetic factors may modify the inherited risk. To date, the factors that appear most strongly to modify the risk include reproductive histories and exogenous hormones. Oral contraceptives are associated with a profound reduction in the risk of ovarian cancer, and with little or no increase in the risk of breast cancer. Other modifying factors include age of menarche, parity, breastfeeding and oophorectomy. The effect of parity is different in BRCA1 and BRCA2 carriers. Multiparity appears to be protective in BRCA1 carriers, but is associated with an increase in risk in BRCA2 carriers. Oophorectomy has been associated with reductions in both the risk of breast and ovarian cancer. Knowledge of these risk factors will be useful for managing risk and for developing prevention strategies.	Univ Toronto, Womens Coll Hosp, Ctr Res Womens Hlth, Toronto, ON M5G 1N8, Canada	University of Toronto; University Toronto Affiliates; Womens College Hospital	Narod, SA (corresponding author), Univ Toronto, Womens Coll Hosp, Ctr Res Womens Hlth, 790 Bay St,Room 750A, Toronto, ON M5G 1N8, Canada.	steven.narod@wchospital.ca	Narod, Steven A/AAA-6112-2022					Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; Clarke M, 1998, LANCET, V351, P1451; Cullinane CA, 2005, INT J CANCER, V117, P988, DOI 10.1002/ijc.21273; Eisen A, 2005, J CLIN ONCOL, V23, P7491, DOI 10.1200/JCO.2004.00.7138; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Friedman E, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1387; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; Gronwald J, 2006, INT J CANCER, V118, P2281, DOI 10.1002/ijc.21536; Jernstrom H, 2003, CARCINOGENESIS, V24, P991, DOI 10.1093/carcin/bgg047; JERNSTROM H, 2004, JNCI-J NATL CANCER I, V96, P209; Kauff ND, 2002, NEW ENGL J MED, V346, P1609, DOI 10.1056/NEJMoa020119; King MC, 2001, JAMA-J AM MED ASSOC, V286, P2251, DOI 10.1001/jama.286.18.2251; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Kotsopoulos J, 2005, CANCER CAUSE CONTROL, V16, P125, DOI 10.1007/s10552-004-2593-8; Kotsopoulos J, 2005, CANCER CAUSE CONTROL, V16, P667, DOI 10.1007/s10552-005-1724-1; KOTSOPOULOS J, 2006, UNPUB AGE 1 BRITH RI; Kowalska E, 2005, CANCER EPIDEM BIOMAR, V14, P1302, DOI 10.1158/1055-9965.EPI-03-0448; LevyLahad E, 1997, AM J HUM GENET, V60, P1059; Mazoyer S, 1996, NAT GENET, V14, P253, DOI 10.1038/ng1196-253; Meijers-Heijboer H, 2001, NEW ENGL J MED, V345, P159, DOI 10.1056/NEJM200107193450301; NAROD S, 1993, LANCET, V341, P1101, DOI 10.1016/0140-6736(93)92468-9; Narod SA, 2002, JNCI-J NATL CANCER I, V94, P1773, DOI 10.1093/jnci/94.23.1773; Narod SA, 1998, NEW ENGL J MED, V339, P424, DOI 10.1056/NEJM199808133390702; NKONDJOCK A, 2006, INT J CANCER, V18, P1852; Phelan CM, 1996, NAT GENET, V12, P309, DOI 10.1038/ng0396-309; Rebbeck TR, 1999, AM J HUM GENET, V64, P1371, DOI 10.1086/302366; Rebbeck TR, 1999, J NATL CANCER I, V91, P1475, DOI 10.1093/jnci/91.17.1475; Rebbeck TR, 2005, J CLIN ONCOL, V23, P7804, DOI 10.1200/JCO.2004.00.8151; Rebbeck TR, 2001, CANCER RES, V61, P5420; Risch HA, 2001, AM J HUM GENET, V68, P700, DOI 10.1086/318787; Runnebaum IB, 2001, PHARMACOGENETICS, V11, P635, DOI 10.1097/00008571-200110000-00010; RUSSO J, 1992, BREAST CANCER RES TR, V23, P211, DOI 10.1007/BF01833517; RUSSO J, 2001, BREAST J, V7, P277; Thompson D, 2001, AM J HUM GENET, V68, P410, DOI 10.1086/318181; Thorlacius S, 1997, AM J HUM GENET, V60, P1079; Tryggvadottir L, 2006, JNCI-J NATL CANCER I, V98, P116, DOI 10.1093/jnci/djj012; Weitzel JN, 2005, CANCER EPIDEM BIOMAR, V14, P1534, DOI 10.1158/1055-9965.EPI-05-0070	39	85	90	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2006	25	43					5832	5836		10.1038/sj.onc.1209870	http://dx.doi.org/10.1038/sj.onc.1209870			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TS	16998497				2022-12-17	WOS:000240765900003
J	Kato, Y; Ying, H; Zhao, L; Furuya, F; Araki, O; Willingham, MC; Cheng, SY				Kato, Y; Ying, H; Zhao, L; Furuya, F; Araki, O; Willingham, MC; Cheng, SY			PPAR gamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappa B signaling pathway	ONCOGENE			English	Article						thyroid cancer; mutant thyroid hormone receptor; PPAR gamma; NF-kappa B; mouse model; apoptosis	HORMONE RECEPTOR-BETA; HUMAN PROSTATE-CANCER; INHIBITS CELL-GROWTH; MOUSE MODEL; TRANSCRIPTIONAL ACTIVITY; GENERALIZED RESISTANCE; LIPOPROTEIN-LIPASE; TARGETED MUTATION; CARCINOMA CELLS; TRANSGENIC MICE	The molecular genetic events underlying thyroid carcinogenesis are poorly understood. Mice harboring a knock-in dominantly negative mutant thyroid hormone receptor beta (TR beta(PV/PV) mouse) spontaneously develop follicular thyroid carcinoma similar to human thyroid cancer. Using this mutant mouse, we tested the hypothesis that the peroxisome proliferator-activated receptor gamma (PPAR gamma) could function as a tumor suppressor in thyroid cancer in vivo. Using the offspring from the cross of TR beta(PV/+) and PPAR gamma(+/-) mice, we found that thyroid carcinogenesis progressed significantly faster in TRbPV/PV mice with PPAR gamma insufficiency from increased cell proliferation and reduced apoptosis. Reduced PPAR gamma protein abundance led to the activation of the nuclear factor-kappa B signaling pathway, resulting in the activation of cyclin D1 and repression of critical genes involved in apoptosis. Treatment of TR beta PV/PV mice with a PPAR gamma agonist, rosiglitazone, delayed the progression of thyroid carcinogenesis by decreasing cell proliferation and activation of apoptosis. These results suggest that PPAR gamma is a critical modi. er in thyroid carcinogenesis and could be tested as a therapeutic target in thyroid follicular carcinoma.	NCI, Mol Biol Lab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC 27109 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Wake Forest University	Cheng, SY (corresponding author), NCI, Mol Biol Lab, Canc Res Ctr, NIH, 37 Convent Dr,Room 5128, Bethesda, MD 20892 USA.	chengs@mail.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC008752, ZIABC008752] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama TE, 2002, MOL CELL BIOL, V22, P2607, DOI 10.1128/MCB.22.8.2607-2619.2002; Asou H, 1999, INT J ONCOL, V15, P1027; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Cheung L, 2003, J CLIN ENDOCR METAB, V88, P354, DOI 10.1210/jc.2002-021020; Chevillard S, 2004, CLIN CANCER RES, V10, P6586, DOI 10.1158/1078-0432.CCR-04-0053; COOPER DS, 1981, J CLIN ENDOCR METAB, V52, P294, DOI 10.1210/jcem-52-2-294; Demetri GD, 1999, P NATL ACAD SCI USA, V96, P3951, DOI 10.1073/pnas.96.7.3951; Fan WQ, 2005, ENDOCRINOLOGY, V146, P85, DOI 10.1210/en.2004-1046; FLEISS JL, 1981, STAT METHODS RATES; Furumoto H, 2005, MOL CELL BIOL, V25, P124, DOI 10.1128/MCB.25.1.124-135.2005; Goldberg IJ, 2001, FRONT BIOSCI-LANDMRK, V6, pD388, DOI 10.2741/Goldberg; Guan You-Fei, 1999, Neoplasia (New York), V1, P330, DOI 10.1038/sj.neo.7900050; Gustafson KS, 2003, AM J CLIN PATHOL, V120, P175, DOI 10.1309/2E6QGJRGGETVT8K9; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Jeker LT, 1999, BIOCHEM BIOPH RES CO, V257, P511, DOI 10.1006/bbrc.1999.0468; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kaneshige M, 2000, P NATL ACAD SCI USA, V97, P13209, DOI 10.1073/pnas.230285997; Kato Y, 2004, ENDOCRINOLOGY, V145, P4430, DOI 10.1210/en.2004-0612; Keelan JA, 1999, BIOCHEM BIOPH RES CO, V262, P579, DOI 10.1006/bbrc.1999.1257; Klopper JP, 2004, MOL CANCER THER, V3, P1011; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Kubota T, 1998, CANCER RES, V58, P3344; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; Lee E, 2013, STAT METHODS SURVIVA; MAZZAFERRI EL, 1993, NEW ENGL J MED, V328, P553; MEIER CA, 1992, MOL ENDOCRINOL, V6, P248, DOI 10.1210/me.6.2.248; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; Motomura W, 2000, CANCER RES, V60, P5558; Mueller E, 2000, P NATL ACAD SCI USA, V97, P10990, DOI 10.1073/pnas.180329197; Nikiforova MN, 2002, AM J SURG PATHOL, V26, P1016, DOI 10.1097/00000478-200208000-00006; Nishida K, 2002, BRIT J CANCER, V86, P1303, DOI 10.1038/sj.bjc.6600241; Ohta K, 2001, J CLIN ENDOCR METAB, V86, P2170, DOI 10.1210/jc.86.5.2170; ONO S, 1991, J CLIN ENDOCR METAB, V73, P990, DOI 10.1210/jcem-73-5-990; Park JW, 2005, THYROID, V15, P222, DOI 10.1089/thy.2005.15.222; PARRILLA R, 1991, J CLIN INVEST, V88, P2123, DOI 10.1172/JCI115542; Rivas M, 2003, MOL CELL ENDOCRINOL, V213, P31, DOI 10.1016/j.mce.2003.10.029; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Setoguchi K, 2001, J CLIN INVEST, V108, P1667; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; Suzuki H, 2003, MOL ENDOCRINOL, V17, P1647, DOI 10.1210/me.2003-0114; Suzuki H, 2003, MOL ENDOCRINOL, V17, P895, DOI 10.1210/me.2002-0326; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; SYLVIA L, 2004, MOL BASIS THYROID CA, P23; Takahashi N, 1999, FEBS LETT, V455, P135, DOI 10.1016/S0014-5793(99)00871-6; Tsubouchi Y, 2000, BIOCHEM BIOPH RES CO, V270, P400, DOI 10.1006/bbrc.2000.2436; Wang NP, 2002, J BIOL CHEM, V277, P34176, DOI 10.1074/jbc.M203436200; Yen PM, 2003, TRENDS ENDOCRIN MET, V14, P327, DOI 10.1016/S1043-2760(03)00114-0; Ying H, 2003, CANCER RES, V63, P5274; Ying H, 2003, CARCINOGENESIS, V24, P1467, DOI 10.1093/carcin/bgg111; Zeiger MA, 1997, ENDOCRINOLOGY, V138, P3133, DOI 10.1210/en.138.8.3133	53	85	90	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2006	25	19					2736	2747		10.1038/sj.onc.1209299	http://dx.doi.org/10.1038/sj.onc.1209299			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	039AW	16314832				2022-12-17	WOS:000237272900005
J	Javelaud, D; Delmas, V; Moller, M; Sextius, P; Andre, J; Menashi, S; Larue, L; Mauviel, A				Javelaud, D; Delmas, V; Moller, M; Sextius, P; Andre, J; Menashi, S; Larue, L; Mauviel, A			Stable overexpression of Smad7 in human melanoma cells inhibits their tumorigenicity in vitro and in vivo	ONCOGENE			English	Article						TGF-ss; Smad; melanoma; tumor progression; metalloproteinases; angiogenesis	GROWTH-FACTOR-BETA; TGF-BETA; MATRIX METALLOPROTEINASES	We previously identified constitutive Smad signaling in human melanoma cells despite resistance to transforming growth factor-beta (TGF-beta) control of cell proliferation. This led us to investigate the effect of inhibitory Smad7 overexpression on melanoma cell behavior. Using the highly metastatic cell line, 1205-Lu, we thus generated melanoma cell clones constitutively expressing Smad7, and their mock-transfected counterparts. Stable expression of Smad7 resulted in an inhibition of constitutive Smad2/3 phosphorylation, and in a reduced TGF-beta response of Smad3/Smad4- driven gene transactivation, as measured using transfected Smad3/4-specific reporter gene constructs. Smad7 overexpression, however, did not alter their proliferative capacity and resistance to TGF-beta-driven growth inhibition. On the other hand, expression of Smad7 efficiently reduced the capacity of human melanoma cells to invade Matrigel in Boyden migration chambers, while not affecting their motility and adhesion to collagen and laminin. Gelatin zymography identified reduced MMP-2 and MMP-9 secretion by Smad7-expressing melanoma cells as compared with their control counterparts. Smad7-expressing melanoma cells exhibited a dramatically reduced capacity to form colonies under anchorage-independent culture conditions, and, when injected subcutaneously into nude mice, were largely delayed in their ability to form tumors. These results suggest that TGF-beta production by melanoma cells not only affects the tumor environment but also directly contributes to tumor cell aggressiveness through autocrine activation of Smad signaling.	Hop St Louis, INSERM, U697, F-75010 Paris, France; Inst Curie, CNRS, UMR 146, F-91405 Orsay, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Mauviel, A (corresponding author), Hop St Louis, INSERM, U697, Pavillon Bazin,1 Ave Claude Vellefaux, F-75010 Paris, France.	alain.mauviel@stlouis.inserm.fr	; javelaud, delphine/B-1129-2019	Delmas, veronique/0000-0001-7368-3664; SEXTIUS, PEGGY/0000-0002-8710-6582; Mauviel, Alain/0000-0002-0438-2793; javelaud, delphine/0000-0002-7674-7739				Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Berking C, 2001, CANCER RES, V61, P8306; Daniels CE, 2004, J CLIN INVEST, V114, P1308, DOI 10.1175/JCI200419603; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Hofmann UB, 2000, J INVEST DERMATOL, V115, P337, DOI 10.1046/j.1523-1747.2000.00068.x; Javelaud D, 2004, INT J BIOCHEM CELL B, V36, P1161, DOI 10.1016/S1357-2725(03)00255-3; Javelaud D, 2003, J BIOL CHEM, V278, P24624, DOI 10.1074/jbc.M301942200; Komuro A, 2004, ONCOGENE, V23, P6914, DOI 10.1038/sj.onc.1207885; Ludwig T, 2002, AM J PHYSIOL-RENAL, V283, pF319, DOI 10.1152/ajprenal.00327.2001; MacDougall John R., 1993, Molecular and Cellular Differentiation, V1, P21; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 2002, TRENDS MOL MED, V8, P361, DOI 10.1016/S1471-4914(02)02376-6; Reed JA, 2001, CANCER RES, V61, P8074; Rodeck U, 1999, CANCER RES, V59, P547; RODECK U, 1994, CANCER RES, V54, P575; Shi WB, 2004, J CELL BIOL, V164, P291, DOI 10.1083/jcb.200307151; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Xavier S, 2004, J BIOL CHEM, V279, P15167, DOI 10.1074/jbc.M309798200	23	85	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7624	7629		10.1038/sj.onc.1208900	http://dx.doi.org/10.1038/sj.onc.1208900			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16007121	Green Submitted			2022-12-17	WOS:000233333800012
J	Gupta, M; Gupta, SK; Balliet, AG; Hollander, MC; Fornace, AJ; Hoffman, B; Liebermann, DA				Gupta, M; Gupta, SK; Balliet, AG; Hollander, MC; Fornace, AJ; Hoffman, B; Liebermann, DA			Hematopoietic cells from Gadd45a- and Gadd45b-deficient mice are sensitized to genotoxic-stress-induced apoptosis	ONCOGENE			English	Article						gadd45-deficient mice; apoptosis; hematopoietic cells; genotoxic stress; DNA damage	NEGATIVE GROWTH-CONTROL; P53-REGULATED PROTEIN GADD45; RESPONSE GENE MYD118; NUCLEAR ANTIGEN; DNA-REPAIR; ARREST; EXPRESSION; ACTIVATION; INDUCTION; RADIATION	Gadd45a, gadd45b and gadd45g (Gadd45/MyD118/CR6) are genes that are rapidly induced by genotoxic stress. However, the exact function of Gadd45 proteins in the response of mammalian cells to genotoxic stress is unclear. Here, advantage was taken of gadd45a- and gadd45b-deficient mice to determine the role gadd45a- and gadd45b play in the response of bone marrow ( BM) cells to genotoxic stress. BM cells from gadd45a- and gadd45b-deficient mice were observed to be more sensitive to ultraviolet radiation chemotherapy (UVC), VP-16 and daunorubicin (DNR)-induced apoptosis compared to wildtype (wt) cells. The increased apoptosis in gadd45a- and gadd45b-deficient cells was evident also by enhanced activation of caspase-3 and poly-ADP-ribose polymerase cleavage and decreased expression of c-inhibitor of apoptotic protein-1, Bcl-2, Bcl-xL compared to wt cells. Reintroduction of gadd45 into gadd45-deficient BM cells restored the wt apoptotic phenotype. Both gadd45a- and gadd45b-deficient BM cells also displayed defective G2/M arrest following exposure to UVC and VP-16, but not to DNR, indicating the existence of different G2/M checkpoints that are either dependent or independent of gadd45. Taken together, these findings identify gadd45a and gadd45b as antiapoptotic genes that increase the survival of hematopoietic cells following exposure to UV radiation and certain anticancer drugs.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; NCI, Canc Res Ctr, NIH, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Liebermann, DA (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Room 331,3307 N Broad St, Philadelphia, PA 19140 USA.	lieberma@temple.edu	Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	NATIONAL CANCER INSTITUTE [R01CA089718] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070530] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA89718-02] Funding Source: Medline; NHLBI NIH HHS [R01 HL 70530-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Azam N, 2001, J BIOL CHEM, V276, P2766, DOI 10.1074/jbc.M005626200; Balliet AG, 2001, DNA CELL BIOL, V20, P239, DOI 10.1089/104454901750219125; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; KASTAN MB, 1992, CELL, V274, P29592; Krishnaraju K, 2001, BLOOD, V97, P1298, DOI 10.1182/blood.V97.5.1298; Maeda T, 2002, J INVEST DERMATOL, V119, P22, DOI 10.1046/j.1523-1747.2002.01781.x; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Vairapandi M, 2002, J CELL PHYSIOL, V192, P327, DOI 10.1002/jcp.10140; Vairapandi M, 1996, ONCOGENE, V12, P2579; Vairapandi M, 2000, J BIOL CHEM, V275, P16810, DOI 10.1074/jbc.275.22.16810; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Yang JF, 2001, NAT IMMUNOL, V2, P157, DOI 10.1038/84264; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Zazzeroni F, 2003, BLOOD, V102, P3270, DOI 10.1182/blood-2003-03-0689; Zerbini LF, 2004, P NATL ACAD SCI USA, V101, P13618, DOI 10.1073/pnas.0402069101; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885; Zhang W, 2001, INT J ONCOL, V18, P749	27	85	92	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7170	7179		10.1038/sj.onc.1208847	http://dx.doi.org/10.1038/sj.onc.1208847			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16170381				2022-12-17	WOS:000232990100006
J	Kehn, K; de la Fuente, C; Strouss, K; Berro, R; Jiang, H; Brady, J; Mahieux, R; Pumfery, A; Bottazzi, ME; Kashanchi, F				Kehn, K; de la Fuente, C; Strouss, K; Berro, R; Jiang, H; Brady, J; Mahieux, R; Pumfery, A; Bottazzi, ME; Kashanchi, F			The HTLV-I Tax oncoprotein targets the retinoblastoma protein for proteasomal degradation	ONCOGENE			English	Review						tax; HTLV-I; Rb; proteasome; cell cycle; tumorigenesis	T-CELL LEUKEMIA; VIRUS TYPE-1 TAX; TUMOR-SUPPRESSOR PROTEIN; ONCOGENE PRODUCT TAX; KAPPA-B-ALPHA; CYCLE PROGRESSION; ADENOVIRUS E1A; RB FAMILY; TRANSCRIPTIONAL ACTIVATION; HUMAN-LYMPHOCYTES	Human T-cell leukemia virus type-I (HTLV-I), the etiologic agent of adult T-cell leukemia (ATL), is estimated to affect 10 - 20 million people worldwide. The transforming ability of HTLV-I has been largely attributed to the viral protein Tax, which modulates the activity of several well-known cell cycle regulators. An important cell cycle regulator, the retinoblastoma (Rb) protein, is often inactivated in many cancers including virally induced cancers. Upon examination of Rb status, we observed a decrease in Rb protein expression in HTLV-1-infected cell lines as well as in ex vivo ATL patient samples. Transient transfection assays indicated that decreased Rb protein levels were Tax dependent. Here, we demonstrate for the first time that Tax directly associates with Rb. This interaction was localized within the B pocket of Rb and the C-terminus of Tax (aa 245 - 353). Within the C-terminus of Tax, we have identified an LXCXE-like motif, that when mutated resulted in the loss of Tax/Rb interaction. Furthermore, through the use of proteasome inhibitors, such as MG-132, in vivo and proteasome degradation assays in vitro, we found that Tax destabilizes the hypo-phosphorylated( active) form of Rb via the proteasome pathway. Therefore, we propose a model whereby Tax targets Rb to the proteasome by acting as a molecular bridge bringing Rb into contact with the proteasome for degradation.	George Washington Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20037 USA; NCI, Virus Tumor Biol Sect, Basic Res Lab, NIH, Bethesda, MD 20892 USA; Inst Pasteur, Dept SIDA & Retrovirus, Unite Epidemiol & Physiopathol Virus Oncogenes, F-75724 Paris 15, France; George Washington Univ, Med Ctr, Dept Microbiol & Trop Med, Washington, DC 20037 USA; Inst Genom Res TIGR, Rockville, MD 20850 USA	George Washington University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; George Washington University; J. Craig Venter Institute	Kashanchi, F (corresponding author), George Washington Univ, Sch Med, Dept Biochem & Mol Biol, 2300 Eye St NW,Ross Hall,Rm 552, Washington, DC 20037 USA.	bcmfxk@gwumc.edu	Kehn-Hall, Kylene/I-5752-2013	Bottazzi, Maria Elena/0000-0002-8429-0476; mahieux, renaud/0000-0002-5129-6804	NIAID NIH HHS [AI44357, AI43894, AI061560] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005691] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI061560, R01AI043894, R29AI044357] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016/S0305-7372(03)00081-1; Akagi T, 1996, ONCOGENE, V12, P1645; Almond JB, 2002, LEUKEMIA, V16, P433, DOI 10.1038/sj.leu.2402417; Antelman D, 1997, ONCOGENE, V15, P2855, DOI 10.1038/sj.onc.1201465; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Blagosklonny MV, 2002, CELL CYCLE, V1, P103, DOI 10.4161/cc.1.2.108; Boyer SN, 1996, CANCER RES, V56, P4620; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Chen WJ, 2004, J BIOL CHEM, V279, P13496, DOI 10.1074/jbc.M212390200; Darnell GA, 2003, MOL CELL BIOL, V23, P6520, DOI 10.1128/MCB.23.18.6520-6532.2003; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; de la Fuente C, 2003, MOL CELL BIOCHEM, V245, P99, DOI 10.1023/A:1022866027585; Dunaief JL, 2002, CURR EYE RES, V24, P392, DOI 10.1076/ceyr.24.5.392.8524; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; Fan SJ, 2001, ONCOGENE, V20, P4827, DOI 10.1038/sj.onc.1204666; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; FUJII M, 1991, ONCOGENE, V6, P1023; Gatza ML, 2003, ONCOGENE, V22, P5141, DOI 10.1038/sj.onc.1206549; GITLIN SD, 1991, J VIROL, V65, P2612, DOI 10.1128/JVI.65.5.2612-2621.1991; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; Gottesfeld JM, 1996, MOL CELL BIOL, V16, P1777; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Grossman WJ, 1996, J ACQ IMMUN DEF SYND, V13, pS162, DOI 10.1097/00042560-199600001-00025; Haller K, 2002, MOL CELL BIOL, V22, P3327, DOI 10.1128/MCB.22.10.3327-3338.2002; Hangaishi A, 1996, BLOOD, V87, P4949, DOI 10.1182/blood.V87.12.4949.bloodjournal87124949; Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Hatta Y, 1997, LEUKEMIA, V11, P984, DOI 10.1038/sj.leu.2400686; He Q, 2004, ONCOGENE, V23, P2554, DOI 10.1038/sj.onc.1207351; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; Hemelaar J, 2001, J VIROL, V75, P11106, DOI 10.1128/JVI.75.22.11106-11115.2001; Hollsberg P, 1999, MICROBIOL MOL BIOL R, V63, P308; Iha H, 2000, AIDS RES HUM RETROV, V16, P1633, DOI 10.1089/08892220050193074; ISHIDA S, 1995, CELL GROWTH DIFFER, V6, P229; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; Jiang H, 1999, MOL CELL BIOL, V19, P8136; Johnson David G., 1998, Frontiers in Bioscience, V3, pD447; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Kalejta RF, 2003, P NATL ACAD SCI USA, V100, P3263, DOI 10.1073/pnas.0538058100; Kalejta RF, 2003, MOL CELL BIOL, V23, P1885, DOI 10.1128/MCB.23.6.1885-1895.2003; Kashanchi F, 1996, J VIROL, V70, P5503, DOI 10.1128/JVI.70.8.5503-5510.1996; Kehn Kylene, 2004, Retrovirology, V1, P6, DOI 10.1186/1742-4690-1-6; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; Lee JY, 1998, BIOCHEM J, V334, P457, DOI 10.1042/bj3340457; Lenz HJ, 2003, CANCER TREAT REV, V29, P41, DOI 10.1016/S0305-7372(03)00082-3; Li JN, 2003, BIOCHEMISTRY-US, V42, P6921, DOI 10.1021/bi034369n; Liu BY, 2003, MOL CELL BIOL, V23, P5269, DOI 10.1128/MCB.23.15.5269-5281.2003; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Mori N, 1997, EUR J HAEMATOL, V58, P114; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nakayama K, 2000, LEUKEMIA RES, V24, P299, DOI 10.1016/S0145-2126(99)00186-1; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Ohtani K, 2000, J BIOL CHEM, V275, P11154, DOI 10.1074/jbc.275.15.11154; Pajonk F, 2001, RADIAT RES, V156, P447, DOI 10.1667/0033-7587(2001)156[0447:TPICBA]2.0.CO;2; Pan WJ, 2001, CANCER RES, V61, P2885; PATRICK DR, 1994, J BIOL CHEM, V269, P6842; Petropoulos L, 1998, VIROLOGY, V252, P189, DOI 10.1006/viro.1998.9430; Plath T, 2002, J NATL CANCER I, V94, P129, DOI 10.1093/jnci/94.2.129; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; Ruemmele FM, 2002, BIOCHEM BIOPH RES CO, V290, P1308, DOI 10.1006/bbrc.2002.6348; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Salcedo M, 1995, ARCH MED RES, V26, pS157; Sambrook J, 2001, MOL CLONING LAB MANU; Santiago F, 1999, J VIROL, V73, P9917, DOI 10.1128/JVI.73.12.9917-9927.1999; Schmitt I, 1998, J VIROL, V72, P633, DOI 10.1128/JVI.72.1.633-640.1998; Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; SEMMES OJ, 1992, VIROLOGY, V188, P754, DOI 10.1016/0042-6822(92)90530-3; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Song S, 2000, VIROLOGY, V267, P141, DOI 10.1006/viro.1999.0106; SUZUKI T, 1995, ONCOGENE, V10, P1199; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Suzuki Takeshi, 1997, Leukemia (Basingstoke), V11, P14; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; Wang HT, 2004, J VIROL, V78, P1503, DOI 10.1128/JVI.78.3.1503-1512.2004; Wang J, 2001, ONCOGENE, V20, P4740, DOI 10.1038/sj.onc.1204655; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; Wu KL, 2004, J BIOL CHEM, V279, P495, DOI 10.1074/jbc.M310069200; YAMAOKA S, 1992, ONCOGENE, V7, P433; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0	101	85	87	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					525	540		10.1038/sj.onc.1208105	http://dx.doi.org/10.1038/sj.onc.1208105			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580311				2022-12-17	WOS:000226420400001
J	Lim, JH; Lee, ES; You, HJ; Lee, JW; Park, JW; Chun, YS				Lim, JH; Lee, ES; You, HJ; Lee, JW; Park, JW; Chun, YS			Ras-dependent induction of HIF-1a(785) via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion	ONCOGENE			English	Article						HIF-1 alpha isoform; Ras signaling; phobol ester; EGF	INDUCIBLE FACTOR 1-ALPHA; OVEREXPRESSION; STABILIZATION; HIF-1-ALPHA; EXPRESSION; PROTEIN; TARGET; CELLS	Hypoxia-inducible factor-1alpha (HIF-1alpha) plays crucial roles in tumor promotion by transactivating approximately 60 kinds of its target genes. Recently, we reported a novel splice variant HIF-1alpha(785), which is regulated primarily by phorbol ester. This variant can be stabilized under normoxic conditions because it loses an acetylation site Lys532. Its expression was found to promote xenografted tumor growth in nude mice. We here found that the Ras oncogene regulates HIF-1alpha(785) expression via the Raf/MEK/ERK pathway, and that both phorbol ester and epidermal growth factor also induced HIF-1alpha(785) via the same pathway. We also identified the nonhypoxic regulatory domain responsible for phorbol ester-induced HIF-1alpha(785) expression. These results imply that HIF-1alpha(785) may play an important role in tumor promotion mediated by the Ras oncogene, phorbol ester or tumor growth factors.	Seoul Natl Univ, Coll Med, Human Genome Res Inst, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 110799, South Korea; Chosun Univ, Coll Med, Dept Pharmacol, Kwangju 501759, South Korea; Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 110799, South Korea	Seoul National University (SNU); Seoul National University (SNU); Chosun University; Seoul National University (SNU)	Chun, YS (corresponding author), Seoul Natl Univ, Coll Med, Human Genome Res Inst, 28 Yongon Dong, Seoul 110799, South Korea.	chunys@snu.ac.kr	Park, Jong-Wan/J-2758-2012; Lee, Jung Weon/AAC-1146-2020; Chun, Yang Sook/J-2789-2012; Lee, Jung Weon/F-9149-2012	Lee, Jung Weon/0000-0003-2722-8200; 				Alahari SK, 2000, J CELL BIOL, V151, P1141, DOI 10.1083/jcb.151.6.1141; Birner P, 2000, CANCER RES, V60, P4693; Cho HJ, 2002, J BIOL CHEM, V277, P19358, DOI 10.1074/jbc.M200933200; Chun YS, 2003, CANCER RES, V63, P8700; Chun YS, 2002, J KOREAN MED SCI, V17, P581, DOI 10.3346/jkms.2002.17.5.581; Chun YS, 2001, J CELL SCI, V114, P4051; Feldser D, 1999, CANCER RES, V59, P3915; Gothie E, 2000, J BIOL CHEM, V275, P6922, DOI 10.1074/jbc.275.10.6922; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Liu XH, 2002, J BIOL CHEM, V277, P50081, DOI 10.1074/jbc.M201095200; Rak J, 1995, CANCER METAST REV, V14, P263, DOI 10.1007/BF00690598; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Shapiro P, 2002, CRIT REV CL LAB SCI, V39, P285, DOI 10.1080/10408360290795538; Yeo EJ, 2003, J NATL CANCER I, V95, P516, DOI 10.1093/jnci/95.7.516; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 1999, CANCER RES, V59, P5830; Zhong H, 2000, CANCER RES, V60, P1541	20	85	91	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9427	9431		10.1038/sj.onc.1208003	http://dx.doi.org/10.1038/sj.onc.1208003			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15543236				2022-12-17	WOS:000225764100014
J	Singh, V; Miranda, TB; Jiang, W; Frankel, A; Roemer, ME; Robb, VA; Gutmann, DH; Herschman, HR; Clarke, S; Newsham, IF				Singh, V; Miranda, TB; Jiang, W; Frankel, A; Roemer, ME; Robb, VA; Gutmann, DH; Herschman, HR; Clarke, S; Newsham, IF			DAL-1/4.1B tumor suppressor interacts with protein arginine N-methyltransferase 3 (PRMT3) and inhibits its ability to methylate substrates in vitro and in vivo	ONCOGENE			English	Article						PRMT3; DAL-1/4.1B; tumor suppressor; protein methylation	N-METHYLTRANSFERASE; SUBCELLULAR-LOCALIZATION; BINDING; DOMAIN; SPECIFICITY; GROWTH; CD44; TRANSCRIPTION; MEMBRANE; RECEPTOR	DAL-1 (differentially expressed in adenocarcinoma of the lung)/4.1B is a tumor suppress-or gene on human chromosome 18p11.3 whose expression is lost in >50% of primary non-small-cell lung carcinomas. Based on sequence similarity, DAL-1/4.1B has been assigned to the Protein 4.1 superfamily whose members interact with plasma membrane proteins through their N-terminal FERM (4.1/Ezrin/Radixin/Moesin) domain, and cytoskeletal components via their C-terminal SAB (spectrin-actin binding) region. Using the DAL-1/4.1B FERM domain as bait for yeast two-hybrid interaction cloning, we identified protein arginine N-methyltransferase 3 (PRMT3) as a specific DAL-1/4.1B-interacting protein. PRMT3 catalyses the post-translational transfer of methyl groups from S-adenosyl-L-methionine to arginine residues of proteins. Coimmunoprecipitation experiments using lung and breast cancer cell lines confirmed this interaction in mammalian cells in vivo. In vitro binding assays demonstrated that this was an interaction occurring via the C-terminal catalytic core domain of PRMT3. DAL-1/4.1B was determined not to be a substrate for PRMT3-mediated methylation but its presence inhibits the in vitro methylation of a glycine-rich and arginine-rich methyl-accepting protein, GST (glutathione-S-transferase-GAR (glycine- and arginine-rich), which contains 14 'RGG' consensus methylation sites. In addition, induced expression of DAL-1/4.1B in MCF-7 breast cancer cells showed that the DAL-1/4.1B protein significantly inhibits PRMT3 methylation of cellular substrates. These findings suggest that modulation of post-translational methylation may be an important mechanism through which DAL-1/ 4.1B affects tumor cell growth.	Henry Ford Hosp, Hermelin Brain Tumor Ctr, Dept Neurosurg, David & Doreen Hermelin Lab Mol Oncogenet, Detroit, MI 48202 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	Henry Ford Health System; Henry Ford Hospital; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Washington University (WUSTL); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Newsham, IF (corresponding author), Henry Ford Hosp, Hermelin Brain Tumor Ctr, Dept Neurosurg, David & Doreen Hermelin Lab Mol Oncogenet, E&R Bldg,Room 3096,2799 W Grand Blvd, Detroit, MI 48202 USA.	irene@bogler.net		Gutmann, David/0000-0002-3127-5045	NATIONAL CANCER INSTITUTE [F32CA097816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026020, R01GM026020, T32GM007185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041520] Funding Source: NIH RePORTER; NCI NIH HHS [CA77030, F32-CA-097816-01] Funding Source: Medline; NIGMS NIH HHS [GM26020, T32 GM07185] Funding Source: Medline; NINDS NIH HHS [NS41520] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aleta JM, 1998, TRENDS BIOCHEM SCI, V23, P89, DOI 10.1016/S0968-0004(98)01185-2; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bachand F, 2004, EMBO J, V23, P2641, DOI 10.1038/sj.emboj.7600265; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Berthet C, 2002, GENES CELLS, V7, P29, DOI 10.1046/j.1356-9597.2001.00497.x; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; Charboneau AL, 2002, INT J CANCER, V100, P181, DOI 10.1002/ijc.10470; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Frankel A, 2002, J BIOL CHEM, V277, P3537, DOI 10.1074/jbc.M108786200; Frankel A, 2000, J BIOL CHEM, V275, P32974, DOI 10.1074/jbc.M006445200; Frankel A, 1999, BIOCHEM BIOPH RES CO, V259, P391, DOI 10.1006/bbrc.1999.0779; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Goutebroze L, 2000, MOL CELL BIOL, V20, P1699, DOI 10.1128/MCB.20.5.1699-1712.2000; Gutmann DH, 2001, NEUROBIOL DIS, V8, P266, DOI 10.1006/nbdi.2000.0376; Gutmann DH, 2000, HUM MOL GENET, V9, P1495, DOI 10.1093/hmg/9.10.1495; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; Kittiniyom K, 2004, GENE CHROMOSOME CANC, V40, P190, DOI 10.1002/gcc.20034; Kittiniyom K, 2001, BREAST CANCER RES, V3, P192, DOI 10.1186/bcr294; KUMAR A, 1986, J BIOL CHEM, V261, P1266; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; Miranda TB, 2004, J BIOL CHEM, V279, P22902, DOI 10.1074/jbc.M312904200; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(01)00269-0; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Perry A, 2000, J NEUROPATH EXP NEUR, V59, P872, DOI 10.1093/jnen/59.10.872; Robb VA, 2004, ONCOGENE, V23, P3589, DOI 10.1038/sj.onc.1207445; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; Tang J, 2000, J BIOL CHEM, V275, P19866, DOI 10.1074/jbc.M000023200; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; Tran Y, 1998, ONCOGENE, V17, P3499, DOI 10.1038/sj.onc.1202258; Tran YK, 1999, CANCER RES, V59, P35; Trofatter J A, 1993, Cell, V75, P826; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yu TX, 2002, BIOCHEM J, V365, P783, DOI 10.1042/BJ20020060	45	85	104	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7761	7771		10.1038/sj.onc.1208057	http://dx.doi.org/10.1038/sj.onc.1208057			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15334060	Bronze			2022-12-17	WOS:000224331600002
J	Buscemi, G; Perego, P; Carenini, N; Nakanishi, M; Chessa, L; Chen, JJ; Khanna, K; Delia, D				Buscemi, G; Perego, P; Carenini, N; Nakanishi, M; Chessa, L; Chen, JJ; Khanna, K; Delia, D			Activation of ATM and Chk2 kinases in relation to the amount of DNA strand breaks	ONCOGENE			English	Article						ATM; Chk2; DNA double-strand breaks; checkpoints	ATAXIA-TELANGIECTASIA; CELL-CYCLE; IONIZING-RADIATION; DEPENDENT PHOSPHORYLATION; CHECKPOINT KINASE-2; DAMAGE CHECKPOINT; TUMOR-SUPPRESSOR; PROTEIN-KINASE; IN-VIVO; REPAIR	The diverse checkpoint responses to DNA damage may reflect differential sensitivities by molecular components of the damage-signalling network to the type and amount of lesions. Here, we determined the kinetics of activation of the checkpoint kinases ATM and Chk2 ( the latter substrate of ATM) in relation to the initial yield of genomic DNA single-strand (SSBs) and double-strand breaks (DSBs). We show that doses of gamma-radiation (IR) as low as 0.25 Gy, which generate vast numbers of SSBs but only a few DSBs per cell (<8), promptly activate ATM kinase and induce the phosphorylation of the ATM substrates p53 - Ser15, Nbs1 - Ser343 and Chk2 - Thr68. The full activation of Chk2 kinase, however, is triggered by treatments inflicting >19 DSBs per cell (e.g. 1 Gy), which cause Chk2 autophosphorylation on Thr387, Chk2-dependent accumulation of p21(waf1) and checkpoint arrest in the S phase. Our results indicate that, in contrast to ATM, Chk2 activity is triggered by a greater number of DSBs, implying that, below a certain threshold level of lesions (<19 DSBs), DNA repair can occur through ATM, without enforcing Chk2-dependent checkpoints.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Nagoya City Univ, Sch Med, Dept Biochem, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Osped S Andrea, I-00189 Rome, Italy; Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Pediat, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Adolescent Med, Rochester, MN 55905 USA; Queensland Inst Med Res, Mol & Cellular Biol Div, Brisbane, Qld 4006, Australia	Fondazione IRCCS Istituto Nazionale Tumori Milan; Nagoya City University; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; Mayo Clinic; Mayo Clinic; Mayo Clinic; QIMR Berghofer Medical Research Institute	Delia, D (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.	delia@istitutotumori.mi.it	Buscemi, Giacomo/ABI-1170-2020; Perego, Paola/J-7647-2016	Buscemi, Giacomo/0000-0002-8404-7142; Perego, Paola/0000-0003-2806-7269; Khanna, Kum Kum/0000-0001-8650-5381	Telethon [GP0205Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ahn JW, 2003, J BIOL CHEM, V278, P20480, DOI 10.1074/jbc.M213185200; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Birnboim HC, 1997, J CELL BIOCHEM, V66, P219, DOI 10.1002/(SICI)1097-4644(19970801)66:2<219::AID-JCB9>3.0.CO;2-T; Brodsky MH, 2004, MOL CELL BIOL, V24, P1219, DOI 10.1128/MCB.24.3.1219-1231.2004; Brosh RM, 1999, MOL BIOL CELL, V10, P3583, DOI 10.1091/mbc.10.11.3583; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; CAPRANICO G, 1987, CANCER RES, V47, P3752; Chehab NH, 2000, GENE DEV, V14, P278; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Delia D, 2000, BRIT J CANCER, V82, P1938; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Girard PM, 2002, ONCOGENE, V21, P4191, DOI 10.1038/sj.onc.1205596; GOLOS B, 1991, NEOPLASMA, V38, P559; Guidarelli A, 1997, FREE RADICAL RES, V26, P537, DOI 10.3109/10715769709097825; Guo ZJ, 2000, MOL BIOL CELL, V11, P1535, DOI 10.1091/mbc.11.5.1535; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; HUE YK, 1994, CANCER RES, V54, P2544; Jakob B, 2003, RADIAT RES, V159, P676, DOI 10.1667/0033-7587(2003)159[0676:BIOHCT]2.0.CO;2; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; KOHN KW, 1981, MEASUREMENT DNA STRA, P370; Kraakman-van der Zwet M, 1999, MUTAT RES-DNA REPAIR, V434, P17, DOI 10.1016/S0921-8777(99)00009-9; Kuhne M, 2004, CANCER RES, V64, P500, DOI 10.1158/0008-5472.CAN-03-2384; Lavin LF, 1999, INT J RADIAT BIOL, V75, P1201; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Leroy C, 2001, EMBO J, V20, P2896, DOI 10.1093/emboj/20.11.2896; MacQueen AJ, 2001, GENE DEV, V15, P1674, DOI 10.1101/gad.902601; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; McDonald ER, 2001, ANN MED, V33, P113, DOI 10.3109/07853890109002066; Mirzayans R, 1999, CARCINOGENESIS, V20, P941, DOI 10.1093/carcin/20.6.941; Mochan TA, 2003, CANCER RES, V63, P8586; NUNEZ MI, 1995, BRIT J CANCER, V71, P311, DOI 10.1038/bjc.1995.62; Perego P, 2000, INT J CANCER, V87, P343, DOI 10.1002/1097-0215(20000801)87:3<343::AID-IJC6>3.0.CO;2-8; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Plumb MA, 1999, INT J RADIAT BIOL, V75, P553, DOI 10.1080/095530099140195; Prise KM, 2001, RADIAT RES, V156, P572, DOI 10.1667/0033-7587(2001)156[0572:AROSOI]2.0.CO;2; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Shackelford RE, 2000, FREE RADICAL BIO MED, V28, P1387, DOI 10.1016/S0891-5849(00)00224-0; Shieh SY, 2000, GENE DEV, V14, P289; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Taylor AMR, 2001, BEST PRACT RES CL HA, V14, P631, DOI 10.1053/beha.2001.0158; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Walworth NC, 2000, CURR OPIN CELL BIOL, V12, P697, DOI 10.1016/S0955-0674(00)00154-X; Wang HC, 2001, ONCOGENE, V20, P2212, DOI 10.1038/sj.onc.1204350; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Wu XL, 2003, J BIOL CHEM, V278, P36163, DOI 10.1074/jbc.M303795200; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	63	85	93	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7691	7700		10.1038/sj.onc.1207986	http://dx.doi.org/10.1038/sj.onc.1207986			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15361830				2022-12-17	WOS:000224306700010
J	Giraud, S; Hurlstone, A; Avril, S; Coqueret, O				Giraud, S; Hurlstone, A; Avril, S; Coqueret, O			Implication of BRG1 and cdk9 in the STAT3-mediated activation of the p21waf1 gene	ONCOGENE			English	Article						STAT3; chromatin; acetylation; p21waf1	RNA-POLYMERASE-II; TRANSCRIPTION ELONGATION; COMPLEX; STAT3; PHOSPHORYLATION; RECRUITMENT; ACETYLATION; INTERACTS; PROMOTER; PROTEIN	STAT transcription factors ( signal transducers and activators of transcription) are cytoplasmic proteins that induce gene activation in response to cytokine receptor stimulation. Following tyrosine phosphorylation, STAT proteins translocate into the nucleus and activate specific target genes. We have previously reported that STAT3 activates the expression of the p21waf1 gene through its association with the NcoA/SRC1a and CBP coactivators. In this study, we explore the role of BRG1, a component of the SWI/SNF chromatin-remodeling complex, and the role of cdk9, a component of the elongation factor P-TEFb, in the STAT3-mediated expression of p21waf1. We found using pull-down experiments and co-immunoprecipitation assays that both proteins associate with STAT3. Chromatin immunoprecipitation (ChIP) experiments indicate that STAT3 DNA binding results in histone H3 acetylation and BRG1 recruitment. Using Southern blot analysis, we found that the loading of BRG1 is followed by an increased accessibility of the proximal p21waf1 promoter and by the association of RNA polymerase II. As a next step, STAT3 then recruits the cdk9 kinase to phosphorylate the carboxy-terminal domain of the RNA polymerase at serine 2. Accordingly, the elongating form of the polymerase can be detected by ChIP experiments on the coding region of the gene, probably initiating mRNA synthesis. Therefore, STAT3 not only promotes the initiation of transcription but also regulates chromatin remodeling and transcription elongation through its interaction with BRG1 and cdk9.	CHU Angers, INSERM, U564, F-49033 Angers, France; Univ Med Ctr Utrecht, Dept Immunol, Utrecht, Netherlands; Univ Med Ctr Utrecht, Ctr Biomed Genet, Utrecht, Netherlands	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Coqueret, O (corresponding author), CHU Angers, INSERM, U564, 4 Rue Larrey, F-49033 Angers, France.	olivier.coqueret@univ-angers.fr	AVRIL, sylvie/K-6024-2015; Coqueret, Olivier/K-9660-2015	Coqueret, Olivier/0000-0002-2843-7867; Hurlstone, Adam/0000-0001-5260-9457; Avril, Sylvie/0000-0003-0574-6752				Ahn SH, 2004, MOL CELL, V13, P67, DOI 10.1016/S1097-2765(03)00492-1; Barre B, 2003, J BIOL CHEM, V278, P2990, DOI 10.1074/jbc.M210422200; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buratowski S, 2003, NAT STRUCT BIOL, V10, P679, DOI 10.1038/nsb0903-679; Calvo O, 2003, GENE DEV, V17, P1321, DOI 10.1101/gad.1093603; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; Corey LL, 2003, GENE DEV, V17, P1392, DOI 10.1101/gad.1071803; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Giraud S, 2002, J BIOL CHEM, V277, P8004, DOI 10.1074/jbc.M111486200; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Huang M, 2002, NAT CELL BIOL, V4, P774, DOI 10.1038/ncb855; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Morillon A, 2003, CELL, V115, P425, DOI 10.1016/S0092-8674(03)00880-8; Simic R, 2003, EMBO J, V22, P1846, DOI 10.1093/emboj/cdg179; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; VAQUERO A, 2003, SCI AGING KNOWLEDGE, pRE4, DOI DOI 10.1126/SAGEKE.2003.14.RE4; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000	22	85	86	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7391	7398		10.1038/sj.onc.1207972	http://dx.doi.org/10.1038/sj.onc.1207972			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15286705				2022-12-17	WOS:000224021400009
J	Wang, L; Pan, Y; Dai, JL				Wang, L; Pan, Y; Dai, JL			Evidence of MKK4 pro-oncogenic activity in breast and pancreatic tumors	ONCOGENE			English	Article						MKK4; MAP kinase; oncogenes; apoptosis	METASTASIS SUPPRESSOR GENE; JUN NH2-TERMINAL KINASE; LUNG-CARCINOMA CELLS; N-TERMINAL KINASE; SIGNAL-TRANSDUCTION; PROTEIN-KINASES; CANCER; GROWTH; JNK; TRANSFORMATION	MKK4, located in close proximity to p53 gene, is thought to be a tumor suppressor and a metastasis suppressor gene. A low-rate MKK4 gene alteration has been found in a few tumor types, including breast and pancreatic. A suppressor activity for prostate and ovarian tumor metastasis has also been suggested. To understand the pathobiologic roles of MKK4 in tumorigenesis, we examined the phenotypic changes in response to perturbation of the MKK4 expression in breast and pancreatic cancer cell lines. Ectopic expression of MKK4 by adenoviral delivery in MKK4-negative cancer lines stimulated the cell proliferation and invasion, whereas knockdown of MKK4 expression by small interference RNA in an MKK4-positive breast cancer cell line, MDA-MB-231, resulted in decreased anchorage-independent growth, suppressed tumor growth in mouse xenograft model, and increased cell susceptibility to apoptosis brought by stress signals such as serum deprivation. These results argue that MKK4 functions as a pro-oncogenic molecule instead of a suppressor in breast and pancreatic tumors.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Dai, JL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Unit 089,1515 Holcombe Blvd, Houston, TX 77030 USA.	jldai@mdanderson.org						Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Chae KS, 2002, EUR J CANCER, V38, P2048, DOI 10.1016/S0959-8049(02)00147-8; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cuenda A, 2000, INT J BIOCHEM CELL B, V32, P581, DOI 10.1016/S1357-2725(00)00003-0; Dai JL, 1999, MOL CARCINOGEN, V26, P37, DOI 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6; Dai JL, 1999, P NATL ACAD SCI USA, V96, P1427, DOI 10.1073/pnas.96.4.1427; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; Kim HL, 2001, CANCER RES, V61, P2833; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee HY, 2003, J BIOL CHEM, V278, P23630, DOI 10.1074/jbc.M300997200; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; ROCKWELL SC, 1972, J NATL CANCER I, V49, P735; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Su GH, 1998, CANCER RES, V58, P2339; Su Gloria H, 2002, Hum Mutat, V19, P81, DOI 10.1002/humu.9002; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Teng DHF, 1997, CANCER RES, V57, P4177; Wang L, 2003, CANCER RES, V63, P4724; Wu CW, 2000, AM J PATHOL, V156, P2007, DOI 10.1016/S0002-9440(10)65073-0; Xiao L, 2000, CANCER RES, V60, P400; Yamada SD, 2002, CANCER RES, V62, P6717; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yang YM, 2003, CLIN CANCER RES, V9, P391; Yoshida BA, 1999, CANCER RES, V59, P5483	35	85	93	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	2004	23	35					5978	5985		10.1038/sj.onc.1207802	http://dx.doi.org/10.1038/sj.onc.1207802			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15184866				2022-12-17	WOS:000222941100012
J	Distelhorst, CW; Shore, GC				Distelhorst, CW; Shore, GC			Bcl-2 and calcium: controversy beneath the surface	ONCOGENE			English	Review						Bcl-2; calcium; endoplasmic reticulum	CYTOCHROME-C RELEASE; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; ENDOPLASMIC-RETICULUM CA2+; INTRACELLULAR CA2+; CELL-DEATH; OXIDATIVE STRESS; APOPTOSIS; HOMEOSTASIS; STORES; BAX	The function of Bcl-2 family members on the endoplasmic reticulum has received increasing attention in recent years. The endoplasmic reticulum is the major organelle involved in intracellular calcium homeostasis and calcium signaling, including calcium signals that mediate apoptosis induction by anticancer drugs. But currently a controversy exists regarding reported effects of Bcl-2 on the calcium concentration within the lumen of the endoplasmic reticulum. Although several prominent reports indicate that Bcl-2 overexpression is associated with a decrease in luminal calcium, there are a large number of reports indicating that Bcl-2 either does not decrease luminal calcium or actually increases luminal calcium. This review summarizes this vast array of conflicting findings, and analyses potential reasons why different conclusions have been reached by different laboratories. Future directions are emphasized that might bring clarity to this important area of apoptosis biology.	Case Western Reserve Univ, Sch Med, Div Hematol Oncol, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Ctr Comprehens Canc, Div Hematol Oncol, Cleveland, OH 44106 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	Case Western Reserve University; University Hospitals of Cleveland; McGill University; McGill University	Distelhorst, CW (corresponding author), Case Western Reserve Univ, Sch Med, Div Hematol Oncol, BRB329,10900 Euclid Ave, Cleveland, OH 44106 USA.	cwd@case.edu						BAFFY G, 1993, J BIOL CHEM, V268, P6511; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bian XP, 1997, AM J PHYSIOL-CELL PH, V272, pC1241, DOI 10.1152/ajpcell.1997.272.4.C1241; Bootman MD, 2001, J CELL SCI, V114, P2213; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Breckenridge DG, 2002, P NATL ACAD SCI USA, V99, P4331, DOI 10.1073/pnas.072088099; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628; Distelhorst CW, 1996, CELL CALCIUM, V19, P473, DOI 10.1016/S0143-4160(96)90056-1; Distelhorst CW, 2003, BIOCHEM SOC T, V31, P958; Distelhorst CW, 1996, ONCOGENE, V12, P2051; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Germain M, 2002, J BIOL CHEM, V277, P18053, DOI 10.1074/jbc.M201235200; GERMAIN M, 2003, SCI STKE, pPE10; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Ichimiya M, 1998, AM J PHYSIOL-CELL PH, V275, pC832, DOI 10.1152/ajpcell.1998.275.3.C832; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Li C, 2002, P NATL ACAD SCI USA, V99, P9830, DOI 10.1073/pnas.152571899; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; LODISH HF, 1992, J BIOL CHEM, V267, P12753; MAGNELLI L, 1994, BIOCHEM BIOPH RES CO, V204, P84, DOI 10.1006/bbrc.1994.2429; Mathai JP, 2002, ONCOGENE, V21, P2534, DOI 10.1038/sj.onc.1205340; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Oakes SA, 2003, BIOCHEM PHARMACOL, V66, P1335, DOI 10.1016/S0006-2952(03)00482-9; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Pan Z, 2000, J BIOL CHEM, V275, P19978, DOI 10.1074/jbc.M908329199; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Petersen OH, 2002, BIOL RES, V35, P177, DOI 10.4067/S0716-97602002000200008; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Putney JW, 2001, J CELL SCI, V114, P2223; Rizzuto R, 2003, ONCOGENE, V22, P8619, DOI 10.1038/sj.onc.1207105; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shirane M, 2003, NAT CELL BIOL, V5, P28, DOI 10.1038/ncb894; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Thomenius MJ, 2003, J BIOL CHEM, V278, P6243, DOI 10.1074/jbc.M208878200; Thrower EC, 2001, TRENDS PHARMACOL SCI, V22, P580, DOI 10.1016/S0165-6147(00)01809-5; Uhlmann EJ, 1998, J BIOL CHEM, V273, P17926, DOI 10.1074/jbc.273.28.17926; Vanden Abeele F, 2002, CANCER CELL, V1, P169; Wang NS, 2001, J BIOL CHEM, V276, P44117, DOI 10.1074/jbc.M101958200; Wei HF, 1998, J NEUROCHEM, V70, P2305; Williams SS, 2000, CANCER RES, V60, P4358; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533; Zhu LP, 1999, J BIOL CHEM, V274, P33267, DOI 10.1074/jbc.274.47.33267; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	54	85	91	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2004	23	16					2875	2880		10.1038/sj.onc.1207519	http://dx.doi.org/10.1038/sj.onc.1207519			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	15077150				2022-12-17	WOS:000220799600014
J	Fishman, P; Bar-Yehuda, S; Ohana, G; Barer, F; Ochaion, A; Erlanger, A; Madi, L				Fishman, P; Bar-Yehuda, S; Ohana, G; Barer, F; Ochaion, A; Erlanger, A; Madi, L			An agonist to the A(3) adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B	ONCOGENE			English	Article						A(3) adenosine receptor; CF101; colon carcinoma; beta-catenin; GSK-3 beta	BIOCHEMICAL-CHARACTERIZATION; PROGNOSTIC MARKER; SIGNALING PATHWAY; CANCER-THERAPY; CELL GROWTH; MELANOMA; TUMOR; PHOSPHORYLATION; OVEREXPRESSION; ACTIVATION	A(3) adenosine receptor (A(3)AR) activation with the specific agonist CF101 has been shown to inhibit the development of colon carcinoma growth in syngeneic and xenograft murine models. In the present study, we looked into the effect of CF101 on the molecular mechanisms involved in the inhibition of HCT-116 colon carcinoma in mice. In tumor lesions derived from CF101-treated mice, a decrease in the expression level of protein kinase A (PKA) and an increase in glycogen synthase kinase-3beta (GSK-3beta) was observed. This gave rise to downregulation of beta-catenin and its transcriptional gene products cyclin D1 and c-Myc. Further mechanistic studies in vitro revealed that these responses were counteracted by the selective A(3)AR antagonist MRS 1523 and by the GSK-3beta inhibitors lithium and SB216763, confirming that the observed effects were A(3)AR and GSK-3beta mediated. CF101 downregulated PKB/Akt expression level, resulting in a decrease in the level and DNA-binding capacity of NF-kappaB, both in vivo and in vitro. Furthermore, the PKA and PKB/Akt inhibitors H89 and Worthmannin mimicked the effect of CF101, supporting their involvement in mediating the response to the agonist. This is the first demonstration that A(3)AR activation induces colon carcinoma growth inhibition via the modulation of the key proteins GSK-3beta and NF-kappaB.	Can Fite Biopharma Ltd, IL-49170 Kiryat Matalon, Petach Tikva, Israel; Tel Aviv Univ, Sackler Fac Med, Rabin Med Ctr, Felsenstein Med Res Ctr,Lab Clin & Tumor Immunol, Petah Tiqwa, Israel	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Fishman, P (corresponding author), Can Fite Biopharma Ltd, IL-49170 Kiryat Matalon, Petach Tikva, Israel.	pnina@canfite.co.il						Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Chana JS, 2002, BRIT J PLAST SURG, V55, P623, DOI 10.1054/bjps.2002.3964; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Ferkey DM, 2000, DEV BIOL, V225, P471, DOI 10.1006/dbio.2000.9816; Fishman P, 2003, ANTICANCER RES, V23, P2077; Fishman P, 2002, ANTI-CANCER DRUG, V13, P437, DOI 10.1097/00001813-200206000-00001; Fishman P, 2002, ONCOGENE, V21, P4060, DOI 10.1038/sj.onc.1205531; Fishman P, 2001, EXP CELL RES, V269, P230, DOI 10.1006/excr.2001.5327; Gessi S, 2001, BRIT J PHARMACOL, V134, P116, DOI 10.1038/sj.bjp.0704254; Hosokawa Y, 1998, GENE CHROMOSOME CANC, V22, P66, DOI 10.1002/(SICI)1098-2264(199805)22:1<66::AID-GCC9>3.0.CO;2-5; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kolligs FT, 2002, DIGESTION, V66, P131, DOI 10.1159/000066755; Lovig T, 2002, SCAND J GASTROENTERO, V37, P1184, DOI 10.1080/003655202760373407; Madi L, 2003, J BIOL CHEM, V278, P42121, DOI 10.1074/jbc.M301243200; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Masuda M, 2002, CANCER RES, V62, P3351; Merighi S, 2001, BRIT J PHARMACOL, V134, P1215, DOI 10.1038/sj.bjp.0704352; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Nguyen DC, 2003, INT J ONCOL, V22, P1285; Ohana G, 2003, BRIT J CANCER, V89, P1552, DOI 10.1038/sj.bjc.6601315; Ohana G, 2001, J CELL PHYSIOL, V186, P19, DOI 10.1002/1097-4652(200101)186:1<19::AID-JCP1011>3.0.CO;2-3; Olah ME, 2000, PHARMACOL THERAPEUT, V85, P55, DOI 10.1016/S0163-7258(99)00051-0; Parrella P, 2001, INVEST OPHTH VIS SCI, V42, P1679; Poulsen SA, 1998, BIOORGAN MED CHEM, V6, P619, DOI 10.1016/S0968-0896(98)00038-8; Schulte G, 2002, MOL PHARMACOL, V62, P1137, DOI 10.1124/mol.62.5.1137; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Suh BC, 2001, BRIT J PHARMACOL, V134, P132, DOI 10.1038/sj.bjp.0704218; Trincavelli ML, 2002, MOL PHARMACOL, V62, P1373, DOI 10.1124/mol.62.6.1373; Trincavelli ML, 2002, BBA-MOL CELL RES, V1591, P55, DOI 10.1016/S0167-4889(02)00248-3; VanWardenburg RCAM, 1997, INT J CANCER, V73, P544, DOI 10.1002/(SICI)1097-0215(19971114)73:4<544::AID-IJC15>3.0.CO;2-9	33	85	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2465	2471		10.1038/sj.onc.1207355	http://dx.doi.org/10.1038/sj.onc.1207355			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14691449				2022-12-17	WOS:000220558000004
J	Denkert, C; Furstenberg, A; Daniel, PT; Koch, I; Kobel, M; Weichert, W; Siegert, A; Hauptmann, S				Denkert, C; Furstenberg, A; Daniel, PT; Koch, I; Kobel, M; Weichert, W; Siegert, A; Hauptmann, S			Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference	ONCOGENE			English	Article						cyclooxygenase; ovarian carcinoma; NS-398; RNA interference	COLON-CANCER CELLS; CULTURED-MAMMALIAN-CELLS; CYCLOOXYGENASE-2 EXPRESSION; CHEMOTHERAPY RESISTANCE; PROGNOSTIC-SIGNIFICANCE; GROWTH-INHIBITION; BREAST-CANCER; UP-REGULATION; COX-2; APOPTOSIS	Cyclooxygenases, particularly COX-2, play an important role in tumor development and progression. We have previously shown that COX-2 expression is an independent prognostic factor in human ovarian carcinoma. In this study, we investigated the effects of the inhibition of COX isoforms by the NSAID NS-398 as well as by COX-isoform-specific RNA interference (RNAi) in the human ovarian carcinoma cell lines OVCAR-3 and SKOV-3. OVCAR-3 cells showed a constitutive expression of COX-1 and an induction of high levels of COX-2 and PGE(2) after stimulation with interleukin-1beta. In contrast, SKOV-3 cells were negative for both COX isoforms. In OVCAR-3 cells, PGE(2) production was inhibited by NS-398 in concentrations of 1 muM and by a COX-2-specific silencing RNA ( siRNA), while a COX-1-specific siRNA did not have an effect. This suggests that COX-2 is the major source of PGE(2) in this cell line. To dissociate COX-2-specific and non-COX-2-specific effects on cell proliferation, a proliferation assay was performed after incubation of cells with NS-398 and COX siRNAs. NS-398 induced an inhibition of cell proliferation at concentrations of 50-500 muM, which are above the concentrations needed for the inhibition of PGE(2) production. This inhibitory effect was present in the COX-positive cell line OVCAR-3 as well as in the COX-negative cell line SKOV-3 and could not be reverted by addition of exogenous PGE(2). Neither COX-1- nor COX-2-specific siRNAs had an effect on cell proliferation of OVCAR-3 cells. Cell cycle analysis showed an increased accumulation of cells in the G0/G1 phase after treatment with NS-398, but not with COX siRNAs. These experiments suggest that NS-398 reduced cell proliferation in ovarian carcinoma cells by induction of G0/G1 cell cycle arrest independent of COX-2 inhibition. Our study shows that specific inhibition of COX isoforms by RNAi could be used to dissociate effects of NSAIDs. Furthermore, our results suggest that cell cycle arrest is one of the primary mechanisms responsible for the antiproliferative effects of NS-398 on ovarian carcinoma cells.	Humboldt Univ, Charite Hosp, Inst Pathol, D-10117 Berlin, Germany; Humboldt Univ, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Univ Halle Wittenberg, Inst Pathol, Halle Saale, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin; Martin Luther University Halle Wittenberg	Denkert, C (corresponding author), Humboldt Univ, Charite Hosp, Inst Pathol, Campus Mitte,Schumannstr 20-21, D-10117 Berlin, Germany.		Köbel, Martin/A-7373-2011; Denkert, Carsten/AHE-2675-2022	Denkert, Carsten/0000-0002-2249-0982; Kobel, Martin/0000-0002-6615-2037				Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Denkert C, 2002, AM J PATHOL, V160, P893, DOI 10.1016/S0002-9440(10)64912-7; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Ferrandina G, 2002, J CLIN ONCOL, V20, P973, DOI 10.1200/JCO.20.4.973; Ferrandina G, 2002, ANN ONCOL, V13, P1205, DOI 10.1093/annonc/mdf207; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fogh J., 1975, HUMAN TUMOR CELLS IN, VVolume 1, P115, DOI [10.1007/978-1-4757-1647-4_5, DOI 10.1007/978-1-4757-1647-4_5]; Goldberg Y, 1996, ONCOGENE, V12, P893; HAMILTON TC, 1983, CANCER RES, V43, P5379; Harborth J, 2001, J CELL SCI, V114, P4557; Huang M, 1998, CANCER RES, V58, P1208; Hung WC, 2000, MOL PHARMACOL, V58, P1398, DOI 10.1124/mol.58.6.1398; Khuder SA, 2001, BRIT J CANCER, V84, P1188, DOI 10.1054/bjoc.2000.1709; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Ristimaki A, 2002, CANCER RES, V62, P632; Rodriguez-Burford C, 2002, CLIN CANCER RES, V8, P202; Shono T, 2001, CANCER RES, V61, P4375; THOMPSON HJ, 1995, J NATL CANCER I, V87, P1259; THUN MJ, 1994, CANCER METAST REV, V13, P269, DOI 10.1007/BF00666097; Toyoshima T, 2002, BRIT J CANCER, V86, P1150, DOI 10.1038/sj/bcj/6600183; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Yip-Schneider MT, 2001, J PHARMACOL EXP THER, V298, P976; Yip-Schneider MT, 2000, CARCINOGENESIS, V21, P139, DOI 10.1093/carcin/21.2.139; Yoshimura R, 2000, CANCER-AM CANCER SOC, V89, P589, DOI 10.1002/1097-0142(20000801)89:3<589::AID-CNCR14>3.0.CO;2-C	31	85	98	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8653	8661		10.1038/sj.onc.1206920	http://dx.doi.org/10.1038/sj.onc.1206920			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647459				2022-12-17	WOS:000186844900002
J	Sugioka, R; Shimizu, S; Funatsu, T; Tamagawa, H; Sawa, Y; Kawakami, T; Tsujimoto, Y				Sugioka, R; Shimizu, S; Funatsu, T; Tamagawa, H; Sawa, Y; Kawakami, T; Tsujimoto, Y			BH4-domain peptide from Bcl-x(L) exerts anti-apoptotic activity in vivo	ONCOGENE			English	Article						Bcl-x(L); BH4 domain; apoptosis; mitochondria; TAT	DEPENDENT ANION CHANNEL; BCL-2 PROTEIN FAMILY; CYTOCHROME-C; CELL-DEATH; BH4 DOMAIN; CASPASE ACTIVATION; GENE TRANSFECTION; CONSERVED DOMAINS; BAX; MITOCHONDRIA	The Bcl-2 family of proteins regulates apoptosis chiefly by controlling mitochondrial membrane permeability. It has previously been shown that the BH4 domain of Bcl-2/Bcl-x(L) is essential for the prevention of apoptotic mitochondrial changes, including the release of cytochrome c and apoptotic cell death. We have previously reported that BH4 peptide fused to the protein transduction domain of HIV-1 TAT protein (TAT-BH4) significantly inhibits etoposide-induced apoptosis in a cell line. This time, we investigated whether TAT-BH4 peptide was cytoprotective in ex vivo and in vivo rodent models. Intraperitoneal injection of TAT-BH4 peptide greatly inhibited X-ray-induced apoptosis in the small intestine of mice and partially suppressed Fas-induced fulminant hepatitis. In addition, this peptide markedly suppressed heart failure after ischemia-reperfusion injury in isolated rat heart, probably by preventing mitochondrial dysfunction. These findings demonstrate that TAT-BH4 peptide exerts antiapoptotic activity both in vivo and ex vivo, and imply that it may be a useful therapeutic agent for diseases involving mitochondrial dysfunction and apoptosis.	Osaka Univ, Lab Prot Architecton, Res Ctr Struct Biol, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Surg, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, JST, SORST, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, JST, CREST, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Tsujimoto, Y (corresponding author), Osaka Univ, Sch Med, Mol Genet Lab, Dept Postgenomics & Dis, 2-2 Yamadaoka,Room B8, Suita, Osaka 5650871, Japan.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hirotani M, 1999, J BIOL CHEM, V274, P20415, DOI 10.1074/jbc.274.29.20415; Hockenbery D M, 1992, Semin Immunol, V4, P413; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lee LC, 1996, J BIOL CHEM, V271, P23284, DOI 10.1074/jbc.271.38.23284; Macho A, 1999, ONCOGENE, V18, P7543, DOI 10.1038/sj.onc.1203095; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Park IW, 2001, J IMMUNOL, V167, P2766, DOI 10.4049/jimmunol.167.5.2766; Saikumar P, 1998, ONCOGENE, V17, P3341, DOI 10.1038/sj.onc.1202579; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; SHIMIZU S, 1994, TRANSPLANTATION, V57, P144, DOI 10.1097/00007890-199401000-00022; Shimizu S, 1996, CANCER RES, V56, P2161; Shimizu S, 1996, ONCOGENE, V12, P2251; SOLEM LE, 1993, TOXICOL APPL PHARM, V121, P50, DOI 10.1006/taap.1993.1128; Suzuki K, 1997, J CLIN INVEST, V99, P1645, DOI 10.1172/JCI119327; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2000, GENE DEV, V14, P2060; Yamabe K, 1998, BIOCHEM BIOPH RES CO, V243, P217, DOI 10.1006/bbrc.1997.7925; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073	41	85	91	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8432	8440		10.1038/sj.onc.1207180	http://dx.doi.org/10.1038/sj.onc.1207180			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627984				2022-12-17	WOS:000186650300007
J	Duda, DG; Sunamura, M; Lefter, LP; Furukawa, T; Yokoyama, T; Yatsuoka, T; Abe, T; Inoue, H; Motoi, F; Egawa, S; Matsuno, S; Horii, A				Duda, DG; Sunamura, M; Lefter, LP; Furukawa, T; Yokoyama, T; Yatsuoka, T; Abe, T; Inoue, H; Motoi, F; Egawa, S; Matsuno, S; Horii, A			Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells	ONCOGENE			English	Article						SMAD4; invasion; angiogenesis; TGF-beta; ETS-1	TRANSCRIPTION FACTOR ETS-1; VASCULAR ENDOTHELIAL-CELLS; MATRIX METALLOPROTEINASES; CANCER-CELLS; DUCTAL TUMORIGENESIS; EXPRESSION; ANGIOGENESIS; APOPTOSIS; SUPPRESSION; CARCINOMA	SMAD4 is a critical cofactor in signal transduction pathways activated in response to transforming growth factor-beta (TGF-beta)-related ligands, regulating cell growth and differentiation. The roles played by SMAD4 inactivation in tumours highlighted it as a tumour-suppressor gene. However, restoration of the TGF-beta antiproliferative pathway following SMAD4 gene transfer in null-tumour cell lines is controversial. Herein, we report the inhibitory effects of SMAD4 on pancreatic tumour invasion and angiogenesis. Adenoviral transfer of this gene in a panel of SMAD4 homozygous-deleted human pancreatic tumour cell lines restored SMAD4 protein expression and function. Although it did not affect proliferation significantly in vitro, SMAD4 inhibited in vivo tumour growth in immunodeficient mice. In this xenograft setting, differential suppression of tumour growth in vivo was mediated, at least in part, through downregulation of vascular endothelial growth factor and expression of gelatinases. We documented the reduced invasion and angiogenesis histologically and by intravital microscopy, and gained mechanistic insight at the messenger and protein level. Finally, we found a negative reciprocal regulation between SMAD4 and ETS-1. ETS-1 is considered a marker for tumour invasion. Upon SMAD4 deletion, we detected high expression levels of ETS-1 in pancreatic tumour cells, suggesting the shift of the pancreatic tumour toward an invasive phenotype.	Tohoku Univ, Grad Sch Med, Div Gastroenterol Surg, Sendai, Miyagi 9808574, Japan; Tohoku Univ, Grad Sch Med, Dept Mol Pathol, Sendai, Miyagi 9808575, Japan	Tohoku University; Tohoku University	Sunamura, M (corresponding author), 1-1 Seiryomachi,Aoba Ku, Sendai, Miyagi 9808574, Japan.	msun-thk@umin.ac.jp	Egawa, Shinichi/S-4055-2019; Lefter, Liviu Paul/A-2395-2009; Duda, Dan G/H-8523-2014; Furukawa, Toru/AAF-5596-2021; Horii, Akira/AAW-2839-2021	Egawa, Shinichi/0000-0002-1115-4932; Duda, Dan G/0000-0001-7065-8797; Furukawa, Toru/0000-0002-1083-2324; Horii, Akira/0000-0002-3967-3291				Attiga FA, 2000, CANCER RES, V60, P4629; Behrens P, 2001, INT J MOL MED, V8, P149; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bramhall SR, 1997, INT J PANCREATOL, V21, P1; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Dai JL, 1999, MOL CARCINOGEN, V26, P37, DOI 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6; Dai JL, 1999, P NATL ACAD SCI USA, V96, P1427, DOI 10.1073/pnas.96.4.1427; Davidson B, 2001, CLIN CANCER RES, V7, P551; Duda DG, 2000, CANCER RES, V60, P1111; Elvert G, 2003, J BIOL CHEM, V278, P7520, DOI 10.1074/jbc.M211298200; Eskinazi R, 1998, GASTROENTEROLOGY, V114, P1211, DOI 10.1016/S0016-5085(98)70427-5; Fink SP, 2001, CANCER RES, V61, P256; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Fukushige S, 1998, CANCER RES, V58, P4222; Furukawa T, 1996, AM J PATHOL, V148, P1763; Inoue H, 2001, GENE CHROMOSOME CANC, V31, P295, DOI 10.1002/gcc.1147; Ito T, 1998, MODERN PATHOL, V11, P209; Itoh T, 1998, CANCER RES, V58, P1048; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Jiang YF, 2000, BLOOD, V95, P3945; JIAO SS, 1993, BIO-TECHNOL, V11, P497, DOI 10.1038/nbt0493-497; Kita D, 2001, CANCER RES, V61, P7985; Kondo E, 1999, J BIOCHEM-TOKYO, V125, P818; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lefter LP, 2002, GENE CHROMOSOME CANC, V34, P234, DOI 10.1002/gcc.10060; Nakayama T, 2001, MODERN PATHOL, V14, P415, DOI 10.1038/modpathol.3880328; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nishikawa A, 2000, GYNECOL ONCOL, V79, P256, DOI 10.1006/gyno.2000.5944; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Peng BL, 2002, CLIN CANCER RES, V8, P3628; Ramachandra M, 2002, CANCER RES, V62, P6045; Reisdorff J, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015617.39974.FB; Sato Y, 2001, ANN NY ACAD SCI, V947, P117; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Span PN, 2002, ONCOGENE, V21, P8506, DOI 10.1038/sj.onc.1206040; St Croix B, 2000, SCIENCE, V289, P1197; Sun CL, 2001, ONCOL REP, V8, P89; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Taniguchi N, 1999, BBA-MOL BASIS DIS, V1455, P287, DOI 10.1016/S0925-4439(99)00066-6; Teruyama K, 2001, J CELL PHYSIOL, V188, P243, DOI 10.1002/jcp.1112; Thant AA, 1999, ONCOGENE, V18, P6555, DOI 10.1038/sj.onc.1203049; Valter MM, 1999, CANCER RES, V59, P5608; Vlaykova T, 1997, INT J CANCER, V74, P326, DOI 10.1002/(SICI)1097-0215(19970620)74:3<326::AID-IJC16>3.0.CO;2-9; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wilentz RE, 2000, CANCER RES, V60, P2002; Yang X, 1999, DEVELOPMENT, V126, P1571; Yatsuoka T, 2000, AM J GASTROENTEROL, V95, P2080	48	85	92	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2003	22	44					6857	6864		10.1038/sj.onc.1206751	http://dx.doi.org/10.1038/sj.onc.1206751			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534532				2022-12-17	WOS:000185843400006
J	Morris, MR; Hesson, LB; Wagner, KJ; Morgan, NV; Astuti, D; Lees, RD; Cooper, WN; Lee, JA; Gentle, D; Macdonald, F; Kishida, T; Grundy, R; Yao, M; Latif, F; Maher, ER				Morris, MR; Hesson, LB; Wagner, KJ; Morgan, NV; Astuti, D; Lees, RD; Cooper, WN; Lee, JA; Gentle, D; Macdonald, F; Kishida, T; Grundy, R; Yao, M; Latif, F; Maher, ER			Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma	ONCOGENE			English	Article						Wilms' tumour; renal cell carcimona; methylation; profile; epigenetics	ABERRANT PROMOTER METHYLATION; E-CADHERIN GENE; HYPERMETHYLATION-ASSOCIATED INACTIVATION; HYPOXIA-INDUCIBLE FACTORS; FAMILIAL GASTRIC-CANCER; RECEPTOR-BETA GENE; SUPPRESSOR GENE; CPG ISLAND; COLORECTAL-CANCER; DNA METHYLATION	To investigate the role of epigenetic gene silencing in the pathogenesis of Wilms' tumour and renal cell carcinoma (RCC), we determined their methylation pro. le using a candidate gene approach. Thus, 40 Wilms' tumours and up to 49 adult RCC were analysed by methylation-specific PCR for promoter methylation at CASP8, CDH1, CDH13, DAPK, MGMT, NORE1A, p14(ARF) and RARB2 in primary Wilms' tumours and CASP8, CDH1, CDH13, CRBP1, DAPK, MGMT, MT1G, NORE1A, p16(INK4a), SDHB and RARB2 in primary RCC. Both tumour sample sets had previously been analysed for RASSF1A promoter methylation, and p16(INK4a) methylation results were also available for the Wilms' tumour samples. Wilms' tumours demonstrated a high incidence of methylation at CASP8 (43%) and MGMT (30%), intermediate frequencies at NORE1A (15%), p14(ARF) (15%), p16(INK4a) (10%), DAPK (11%) and CRBP1 (9%), but promoter methylation was rare or absent at RARB2 (0%), CDH13 ( 0%) and CDH1 (3%). No association was detected between methylation of RASSF1A, CASP8 or MGMT in individual tumours. The frequency of MGMT methylation was higher in stage 1 and 2 tumours (50%) than in stage 3 and 4 tumours (17%) but this did not reach statistical significance ( P = 0.06). RCC were most frequently methylated at DAPK (24%), MT1G ( 20%), NORE1A (19%), CDH1 (16%) and MGMT ( 9%) and not or rarely at SDHB (4%), RARB2 ( 0%), p16(INK4a) ( 0%) and CDH13 ( 3%). There were no associations between methylation of RASSF1A, DAPK and CDH1 in individual tumours. Papillary RCC demonstrated a higher frequency of DAPK methylation ( 43%) than clear cell tumours ( 19%) ( P = 0.14). We have demonstrated that de novo promoter methylation is frequent in Wilms' tumour and RCC, and these data enable methylation profiles to be constructed for each tumour type. Thus, combining our results with data published previously, it appears that promoter methylation occurs frequently (greater than or equal to20% of primary tumours) at CASP8, SLIT2 and RASSF1A in Wilms' tumour and at RASSF1A, TIMP3, DAPK, SLIT2, MT1G and GSTP1 in RCC.	Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Canc Res UK Renal Mol Oncol Grp, Birmingham B15 2TT, W Midlands, England; Birmingham Womens Hosp, W Midlands Reg Genet Serv, Birmingham B15 2TG, W Midlands, England; Birmingham Childrens Hosp, Dept Paediat Oncol, Birmingham, W Midlands, England; Yokohama City Univ, Sch Med, Yokohama, Kanagawa 232, Japan	University of Birmingham; University of Birmingham; Birmingham Women's Hospital; University of Birmingham; Yokohama City University	Maher, ER (corresponding author), Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.		Morris, Mark/C-6413-2008; MAHER, EAMONN R/A-9507-2008; Hesson, Luke/HDM-0311-2022; Morgan, Neil V/A-5475-2009	MAHER, EAMONN R/0000-0002-6226-6918; Morgan, Neil V/0000-0001-6433-5692; Morris, Mark/0000-0002-0700-355X; Astuti, Dewi/0000-0003-4205-6160				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Arcellana-Panlilio MY, 2000, GENE CHROMOSOME CANC, V29, P63, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1006>3.0.CO;2-L; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; AUSTRUY E, 1995, GENE CHROMOSOME CANC, V14, P285, DOI 10.1002/gcc.2870140407; Baylin SB, 1998, ADV CANCER RES, V72, P141; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Burrow CR, 2000, EXP NEPHROL, V8, P219; Caca K, 2002, INT J CANCER, V97, P481, DOI 10.1002/ijc.1639; Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; Cote S, 1998, ANTI-CANCER DRUG, V9, P743; Dallol A, 2003, CANCER RES, V63, P1054; Dallol A, 2002, CANCER RES, V62, P5874; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Eggert A, 2001, CANCER RES, V61, P1314; Esteller M, 2000, CANCER RES, V60, P129; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2001, CANCER RES, V61, P3225; Esteller M, 2002, CANCER RES, V62, P5902; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; Gimenez-Roqueplo AP, 2002, J CLIN ENDOCR METAB, V87, P4771, DOI 10.1210/jc.2002-020525; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816; Grundy P, 1996, MED PEDIATR ONCOL, V27, P429, DOI 10.1002/(SICI)1096-911X(199611)27:5<429::AID-MPO7>3.0.CO;2-O; Grundy RG, 1998, BRIT J CANCER, V78, P1181, DOI 10.1038/bjc.1998.651; Harada K, 2002, CANCER RES, V62, P5897; Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Huang Y, 2003, INT J CANCER, V104, P735, DOI 10.1002/ijc.11006; Huebner K, 2001, P NATL ACAD SCI USA, V98, P14763, DOI 10.1073/pnas.261586598; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Kawakami M, 1999, INT J ONCOL, V15, P715; Keller G, 1999, AM J PATHOL, V155, P337, DOI 10.1016/S0002-9440(10)65129-2; Klamt B, 1998, GENE CHROMOSOME CANC, V22, P287, DOI 10.1002/(SICI)1098-2264(199808)22:4<287::AID-GCC4>3.0.CO;2-R; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lee SW, 1996, NAT MED, V2, P776, DOI 10.1038/nm0796-776; Lo KW, 2001, CANCER RES, V61, P3877; Maruyama R, 2002, CLIN CANCER RES, V8, P514; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Morrissey C, 2001, CANCER RES, V61, P7277; Nguyen A, 2000, CANCER LETT, V160, P133, DOI 10.1016/S0304-3835(00)00534-6; Nojima D, 2001, MOL CARCINOGEN, V32, P19, DOI 10.1002/mc.1060; Richards FM, 1999, HUM MOL GENET, V8, P607, DOI 10.1093/hmg/8.4.607; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Sato M, 1998, HUM GENET, V103, P96, DOI 10.1007/s004390050790; Schulz S, 2000, J PATHOL, V191, P162; Shivapurkar N, 2002, CANCER BIOL THER, V1, P65, DOI 10.4161/cbt.1.1.45; Skotnicka-Klonowicz G, 2000, EUR J SURG ONCOL, V26, P61, DOI 10.1053/ejso.1999.0742; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; STORKEL S, 1995, WORLD J UROL, V13, P153; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Toyooka KO, 2002, AM J PATHOL, V161, P629, DOI 10.1016/S0002-9440(10)64218-6; Toyooka KO, 2001, CANCER RES, V61, P4556; Toyooka S, 2002, CANCER RES, V62, P3382; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Turner KJ, 2002, CANCER RES, V62, P2957; Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462; van der Velden PA, 2001, CANCER RES, V61, P5303; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Wagner KJ, 2002, ONCOGENE, V21, P7277, DOI 10.1038/sj.onc.1205922; Wheeler JMD, 2001, GUT, V48, P367, DOI 10.1136/gut.48.3.367; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466; Zbar B, 2000, SEMIN CANCER BIOL, V10, P313, DOI 10.1006/scbi.2000.0151; Zochbauer-Muller S, 2001, CANCER RES, V61, P249; Zuzak TJ, 2002, EUR J CANCER, V38, P83, DOI 10.1016/S0959-8049(01)00355-0	77	85	90	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 2	2003	22	43					6794	6801		10.1038/sj.onc.1206914	http://dx.doi.org/10.1038/sj.onc.1206914			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555992				2022-12-17	WOS:000185799300014
J	Bai, YQ; Miyake, S; Iwai, T; Yuasa, Y				Bai, YQ; Miyake, S; Iwai, T; Yuasa, Y			CDX2, a homeobox transcription factor, upregulates transcription of the p21/WAF1/CIP1 gene	ONCOGENE			English	Article						CDX2; transcription; p21/WAF1/CIP1	HEPATOCYTE NUCLEAR FACTOR-1-ALPHA; HOMEODOMAIN PROTEIN CDX2; CYCLIN-DEPENDENT KINASES; INTESTINAL METAPLASIA; CELL-LINE; P21(WAF1/CIP1) GENE; ECTOPIC EXPRESSION; DNA-REPLICATION; TRANSGENIC MICE; DOWN-REGULATION	The CDX2 homeobox transcription factor plays key roles in intestinal development and homeostasis. CDX2 is downregulated during colorectal carcinogenesis, whereas overexpression of CDX2 results in growth inhibition and differentiation of colon carcinoma and intestinal cells. However, the means by which CDX2 functions remain poorly understood. p21/WAF1/CIP1 is one of the cyclin-dependent kinase inhibitors. In addition to its role in cell cycle control, p21 plays critical roles in differentiation and tumor suppression. The overlapping in both the expression and function of CDX2 and p21 in the small intestine and colon strongly suggests a link between these two genes. By means of luciferase reporter and electrophoretic mobility shift assays, we show here that CDX2 transactivated and physically interacted with the promoter of p21 in a p53-independent manner. Moreover, overexpression of CDX2 increased the mRNA expression of p21 in HT-29 colon carcinoma cells, as demonstrated by reverse transcription-polymerase chain reaction. These data suggest that p21 is a transcriptional target of CDX2. Our results may thus provide a new mechanism underlying the functions of CDX2.	Tokyo Med & Dent Univ, Grad Sch Med & Dent, Dept Mol Oncol, Bunkyo Ku, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Grad Sch Med & Dent, Dept Surg, Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Yuasa, Y (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med & Dent, Dept Mol Oncol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.							Allan LA, 2000, MOL CELL BIOL, V20, P1291, DOI 10.1128/MCB.20.4.1291-1298.2000; Bai YQ, 2000, MOL CARCINOGEN, V28, P184, DOI 10.1002/1098-2744(200007)28:3<184::AID-MC7>3.0.CO;2-6; Bai YQ, 2002, CANCER LETT, V176, P47, DOI 10.1016/S0304-3835(01)00753-4; Boudreau F, 2002, J BIOL CHEM, V277, P31909, DOI 10.1074/jbc.M204622200; Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bukholm IK, 2000, VIRCHOWS ARCH, V436, P224, DOI 10.1007/s004280050034; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; EE HC, 1995, AM J PATHOL, V147, P586; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gartel AL, 2000, ONCOGENE, V19, P5182, DOI 10.1038/sj.onc.1203900; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; HARPER JW, 1993, CELL, V75, P805; Hinoi T, 2002, GASTROENTEROLOGY, V123, P1565, DOI 10.1053/gast.2002.36598; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; JAMES R, 1994, J BIOL CHEM, V269, P15229; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; Krasinski SD, 2001, AM J PHYSIOL-GASTR L, V281, pG69, DOI 10.1152/ajpgi.2001.281.1.G69; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lickert H, 2000, DEVELOPMENT, V127, P3805; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Lorentz O, 1999, ONCOGENE, V18, P87, DOI 10.1038/sj.onc.1202280; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Moucadel V, 2002, BIOCHEM BIOPH RES CO, V297, P607, DOI 10.1016/S0006-291X(02)02250-7; Mutoh H, 2002, BIOCHEM BIOPH RES CO, V294, P470, DOI 10.1016/S0006-291X(02)00480-1; Perlman H, 1998, J BIOL CHEM, V273, P13713, DOI 10.1074/jbc.273.22.13713; Polyak K, 1996, AM J PATHOL, V149, P381; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Silberg DG, 2002, GASTROENTEROLOGY, V122, P689, DOI 10.1053/gast.2002.31902; Smith RC, 1997, GENE DEV, V11, P1674, DOI 10.1101/gad.11.13.1674; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; Subramanian V, 1998, DIFFERENTIATION, V64, P11, DOI 10.1046/j.1432-0436.1998.6410011.x; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; van Wering HM, 2002, J BIOL CHEM, V277, P27659, DOI 10.1074/jbc.M203645200; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	47	85	89	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7942	7949		10.1038/sj.onc.1206634	http://dx.doi.org/10.1038/sj.onc.1206634			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970742				2022-12-17	WOS:000185388200009
J	Henshall, SM; Afar, DEH; Rasiah, KK; Horvath, LG; Gish, K; Caras, I; Ramakrishnan, V; Wong, M; Jeffry, U; Kench, JG; Quinn, DI; Turner, JJ; Delprado, W; Lee, CS; Golovsky, D; Brenner, PC; O'Neill, GF; Kooner, R; Stricker, PD; Grygiel, JJ; Mack, DH; Sutherland, RL				Henshall, SM; Afar, DEH; Rasiah, KK; Horvath, LG; Gish, K; Caras, I; Ramakrishnan, V; Wong, M; Jeffry, U; Kench, JG; Quinn, DI; Turner, JJ; Delprado, W; Lee, CS; Golovsky, D; Brenner, PC; O'Neill, GF; Kooner, R; Stricker, PD; Grygiel, JJ; Mack, DH; Sutherland, RL			Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer	ONCOGENE			English	Article						ZnT4; prostate cancer; zinc transporter; oligonucleotide microarrray; hyperplasia	FUNCTIONAL-CHARACTERIZATION; MONOCLONAL-ANTIBODY; CONFERS RESISTANCE; GERMLINE MUTATIONS; EPITHELIAL-CELLS; GENE; CLONING; MICROARRAYS; THERAPY; TISSUE	We have utilized oligonucleotide microarrays to identify novel genes of potential clinical and biological importance in prostate cancer. RNA from 74 prostate cancers and 164 normal body samples representing 40 different tissues were analysed using a customized Affymetrix GeneChip(R) oligonucleotide microarray representative of over 90% of the expressed human genome. The gene for the zinc transporter ZnT4 was one of several genes that displayed significantly higher expression in prostate cancer compared to normal tissues from other organs. A polyclonal antipeptide antibody was used to demonstrate ZnT4 expression in the epithelium of all 165 elements of benign and 326 elements of localized prostate cancers examined and in nine of 10 advanced prostate cancer specimens by immunohistochemistry. Interestingly, decreased intensity of ZnT4 immunoreactivity occurred in the progression from benign to invasive localized prostate cancer and to metastatic disease. Immunofluorescence analysis and surface biotinylation studies of cells expressing ZnT4 localised the protein to intracellular vesicles and to the plasma membrane. These findings are consistent with a role for ZnT4 in vesicular transport of zinc to the cell membrane and potentially in efflux of zinc in the prostate.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia; Eos Biotechnol, Genom Res, San Francisco, CA 94080 USA; St Vincents Hosp, Dept Anat Pathol, Darlinghurst, NSW 2010, Australia; Douglass Hanly Moir Pathol, N Ryde, NSW 2113, Australia; Royal Prince Alfred Hosp, Dept Anat Pathol, Camperdown, NSW 2050, Australia; Univ Sydney, Dept Pathol, Camperdown, NSW 2050, Australia; St Vincents Hosp, Dept Urol, Darlinghurst, NSW 2010, Australia; St Vincents Hosp, Dept Med Oncol, Darlinghurst, NSW 2010, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; St Vincents Hospital Sydney; University of Sydney; University of Sydney; St Vincents Hospital Sydney; St Vincents Hospital Sydney	Sutherland, RL (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	r.sutherland@garvan.org.au	Quinn, David/N-3730-2019; Sutherland, Robert L/A-8378-2008; Quinn, David I/F-4343-2015	Quinn, David/0000-0002-1411-0417; Quinn, David I/0000-0002-1411-0417; Lee, C. Soon/0000-0003-1058-5826; Turner, Jennifer/0000-0001-5550-3375; Horvath, Lisa/0000-0001-6842-9223; Caras, Ingrid/0000-0002-8902-808X; Kench, James Geoffrey/0000-0001-8687-4988				Bubendorf L, 1999, J NATL CANCER I, V91, P1758, DOI 10.1093/jnci/91.20.1758; Carpten J, 2002, NAT GENET, V30, P181, DOI 10.1038/ng823; Cho YH, 2002, INT J ANTIMICROB AG, V19, P576, DOI 10.1016/S0924-8579(02)00115-2; Costello LC, 1999, J BIOL CHEM, V274, P17499, DOI 10.1074/jbc.274.25.17499; Costello LC, 1997, J BIOL CHEM, V272, P28875, DOI 10.1074/jbc.272.46.28875; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Feng P, 2000, MOL UROL, V4, P31; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; Huang LP, 2002, J BIOL CHEM, V277, P26389, DOI 10.1074/jbc.M200462200; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; Inoue K, 2002, HUM MOL GENET, V11, P1775, DOI 10.1093/hmg/11.15.1775; Kambe T, 2002, J BIOL CHEM, V277, P19049, DOI 10.1074/jbc.M200910200; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Liang JY, 1999, PROSTATE, V40, P200; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; MCMAHON RJ, 1998, J NUTR, V128; MCNEAL JE, 1997, HISTOLOGY PATHOLOGIS; Michalczyk AA, 2002, BIOCHEM J, V364, P105, DOI 10.1042/bj3640105; Murgia C, 1999, AM J PHYSIOL-GASTR L, V277, pG1231, DOI 10.1152/ajpgi.1999.277.6.G1231; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Quinn DI, 2001, J CLIN ONCOL, V19, P3692, DOI 10.1200/JCO.2001.19.16.3692; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Uzzo RG, 2002, CLIN CANCER RES, V8, P3579; Xu JF, 2002, NAT GENET, V32, P321, DOI 10.1038/ng994; Zaichick V. Ye., 1997, International Urology and Nephrology, V29, P565, DOI 10.1007/BF02552202	28	85	87	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6005	6012		10.1038/sj.onc.1206797	http://dx.doi.org/10.1038/sj.onc.1206797			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955079				2022-12-17	WOS:000185137800009
J	Rosner, M; Hofer, K; Kubista, M; Hengstschlager, M				Rosner, M; Hofer, K; Kubista, M; Hengstschlager, M			Cell size regulation by the human TSC tumor suppressor proteins depends on PI3K and FKBP38	ONCOGENE			English	Article						TSC1; TSC2; tuberin; hamartin; tuberous sclerosis; cell cycle; cell size	SCLEROSIS GENE-2 PRODUCT; C-MYC; EMBRYONIC LETHALITY; GENETIC-CONTROL; KINASE-ACTIVITY; TUBERIN; HAMARTIN; GROWTH; IDENTIFICATION; ACTIVATION	TSC1 and TSC2 are responsible for the tumor suppressor gene syndrome tuberous sclerosis (TSC). Mammalian TSC genes have been shown to be involved in cell cycle regulation. Recently, in Drosophila, these data have been confirmed and TSC genes have further been demonstrated to affect cell size control. Here we provide supporting data for the fact that the latter function is conserved in mammals. Human TSC1 and TSC2 trigger mammalian cell size reduction and a dominant-negative TSC2 mutant induces increased size. These effects occur in all cell cycle phases, are dependent on the activity of the phosphoinositide-3-kinase and are abolished by co-overexpression of a dominant-negative Akt mutant. Two independent naturally occurring and disease-causing mutations within the TSC2 gene eliminate tuberin's capacity to affect cell size control, emphasizing the relevance of this function for the development of the disease. The same mutations have earlier been shown not to affect tuberin's antiproliferative capacity. That the consequences of modulated TSC gene expression on cell proliferation and on cell size can be assigned to separable functions is further supported by two findings: A mutation within the TSC1 gene, earlier shown to still harbor anti-proliferative effects, was found to eliminate the cell size regulating functions. An important mammalian cell size regulator, c-Myc, was found to inhibit tuberin's antiproliferative capacity, but to have no effects on tuberin-dependent cell size control. To obtain further mechanistical insights, microarray screens for genes involved in TSC1- or TSC2-mediated cell size effects were performed. Antisense experiments revealed that the so observed regulation of the FK506-binding protein, FKBP38, plays a role in TSC gene-dependent cell size regulation. These data provide new insights into mammalian cell size regulation and allow a better understanding of the function of human TSC genes.	Univ Vienna, A-1090 Vienna, Austria	University of Vienna	Hengstschlager, M (corresponding author), Univ Vienna, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	markus.hengstschlaeger@akh-wien.ac.at	Kubista, Mikael/A-5689-2008	Kubista, Mikael/0000-0002-2940-352X				Aghdasi B, 2001, P NATL ACAD SCI USA, V98, P2425, DOI 10.1073/pnas.041614198; Aicher LD, 2001, J BIOL CHEM, V276, P21017, DOI 10.1074/jbc.C100136200; Backman SA, 2002, CURR OPIN NEUROBIOL, V12, P516, DOI 10.1016/S0959-4388(02)00354-9; Beier R, 2000, EMBO J, V19, P5813, DOI 10.1093/emboj/19.21.5813; Benvenuto G, 2000, ONCOGENE, V19, P6306, DOI 10.1038/sj.onc.1204009; Cheadle JP, 2000, HUM GENET, V107, P97, DOI 10.1007/s004390000348; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Gomez M. R., 1999, TUBEROUS SCLEROSIS C; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Jaeschke A, 2002, J CELL BIOL, V159, P217, DOI 10.1083/jcb.jcb.200206108; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; Klettner A, 2001, MOL BRAIN RES, V97, P21, DOI 10.1016/S0169-328X(01)00286-8; Kleymenova E, 2001, MOL CELL, V7, P823, DOI 10.1016/S1097-2765(01)00226-X; Kobayashi T, 1999, CANCER RES, V59, P1206; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; Kwan KM, 2002, GENESIS, V32, P49, DOI 10.1002/gene.10068; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; LAM E, 1995, GENE, V160, P297, DOI 10.1016/0378-1119(95)00216-S; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lou Dingyuan, 2001, Molecular Cell Biology Research Communications, V4, P374, DOI 10.1006/mcbr.2001.0307; Maheshwar MM, 1997, HUM MOL GENET, V6, P1991, DOI 10.1093/hmg/6.11.1991; Mak BC, 2003, J BIOL CHEM, V278, P5947, DOI 10.1074/jbc.C200473200; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Miloloza A, 2002, J NEUROPATH EXP NEUR, V61, P154, DOI 10.1093/jnen/61.2.154; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; Montagne J, 2001, Sci STKE, V2001, ppe36, DOI 10.1126/stke.2001.105.pe36; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; NELLIST M, 1993, CELL, V75, P1305; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Orimoto K, 1996, BIOCHEM BIOPH RES CO, V219, P70, DOI 10.1006/bbrc.1996.0183; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Pasumarthi KBS, 2000, CIRC RES, V86, P1069, DOI 10.1161/01.RES.86.10.1069; Plank TL, 1998, CANCER RES, V58, P4766; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Prober DA, 2001, CURR OPIN GENET DEV, V11, P19, DOI 10.1016/S0959-437X(00)00151-9; Pusch O, 1997, ONCOGENE, V15, P649, DOI 10.1038/sj.onc.1201236; Radimerski T, 2002, GENE DEV, V16, P2627, DOI 10.1101/gad.239102; Schiene-Fischer C, 2001, FEBS LETT, V495, P1, DOI 10.1016/S0014-5793(01)02326-2; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; Schuldiner O, 2001, ONCOGENE, V20, P4984, DOI 10.1038/sj.onc.1204459; Shirane M, 2003, NAT CELL BIOL, V5, P28, DOI 10.1038/ncb894; Soucek T, 1998, ONCOGENE, V16, P2197, DOI 10.1038/sj.onc.1201743; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Soucek T, 2001, ONCOGENE, V20, P4904, DOI 10.1038/sj.onc.1204627; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Tsuchiya H, 1996, CANCER RES, V56, P429; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0	66	85	87	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4786	4798		10.1038/sj.onc.1206776	http://dx.doi.org/10.1038/sj.onc.1206776			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894220				2022-12-17	WOS:000184344600002
J	Bhattacharya, S; Garriga, J; Calbo, J; Yong, T; Haines, DS; Grana, X				Bhattacharya, S; Garriga, J; Calbo, J; Yong, T; Haines, DS; Grana, X			SKP2 associates with p130 and accelerates p130 ubiquitylation and degradation in human cells	ONCOGENE			English	Article						adenoviruses; cyclin D1; cyclin E; CDK; E2F1	DEPENDENT KINASE INHIBITORS; HUMAN PROSTATE-CANCER; LIGASE SUBUNIT SKP2; BOX PROTEIN SKP2; RETINOBLASTOMA PROTEIN; S-PHASE; ADIPOCYTE DIFFERENTIATION; CYCLIN-E; PHOSPHORYLATION; P107	p130 is a member of the retinoblastoma family of pocket proteins, which includes pRB and p107. Unlike pRB and p107, p130 protein levels decrease dramatically following its hyperphosphorylation starting in the mid-G1 phase of the cell cycle. However, the mechanism leading to p130 downregulation is unknown. We have found that the proteasome inhibitor, lactacystin, inhibited p130 downregulation in T98G cells progressing through the G1/S transition and S phase and that p130 is multiubiquitylated in 293 cells. We have previously shown that ectopic expression of both cyclin D and E induces phosphorylation and downregulation of p130. Since the SKP1/Cul1/SKP2 E3 ubiquitin ligase complex mediates ubiquitylation of substrates previously phosphorylated by cyclin-dependent kinases, we investigated the potential role of this ubiquitin ligase in mediating p130 downregulation. We found that p130 interacts with SKP1, Cul-1 and SKP2 in human 293 cells. We also found that ectopic coexpression of SKP2 and p130 leads to dose-dependent downregulation of p130, reduces p130 protein half-life and induces p130 ubiquitylation in these cells. Moreover, adenoviral-mediated expression of SKP2 accelerates downregulation of endogenous hyperphosphorylated p130 in mitogen-stimulated T98G cells and primary W138 fibroblasts. We conclude that p130 is a substrate of the SCFSKP2 ubiquitin ligase and this E3 ligase regulates p130 abundance during the cell cycle.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Univ Barcelona, Dept Biochem & Mol Biol, Barcelona, Spain	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Barcelona	Grana, X (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, AHP Bldg,Room 308,3307 N Broad St, Philadelphia, PA 19140 USA.			Grana, Xavier/0000-0001-7134-0473	NATIONAL CANCER INSTITUTE [R24CA088261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045450, K02AI001823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054894] Funding Source: NIH RePORTER; NCI NIH HHS [R24 CA88261-01] Funding Source: Medline; NIAID NIH HHS [R01 AI45450, K02 AI01823] Funding Source: Medline; NIGMS NIH HHS [R29 GM54894] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1996, MOL CELL BIOL, V16, P6623; Ausubel FM., 1988, CURRENT PROTOCOLS MO; Calbo J, 2002, J BIOL CHEM, V277, P50263, DOI 10.1074/jbc.M209181200; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; Cheng LY, 2000, J BIOL CHEM, V275, P30317, DOI 10.1074/jbc.M005707200; Chiarle R, 2002, AM J PATHOL, V160, P1457, DOI 10.1016/S0002-9440(10)62571-0; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; DeSalle LM, 2001, FEBS LETT, V490, P179, DOI 10.1016/S0014-5793(01)02121-4; Garriga J, 1996, BIOCHEM J, V319, P293, DOI 10.1042/bj3190293; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; GRANA X, 1995, ONCOGENE, V11, P211; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; Hershko D, 2001, CANCER, V91, P1745, DOI 10.1002/1097-0142(20010501)91:9<1745::AID-CNCR1193>3.0.CO;2-H; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Lim MS, 2002, BLOOD, V100, P2950, DOI 10.1182/blood.V100.8.2950; Lu LF, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-22; Masuda T, 2002, CANCER RES, V62, P3819; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; MAYOL X, 1998, FRONT BIOSCI, V3, P11; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Parreno M, 2000, J VIROL, V74, P3166, DOI 10.1128/JVI.74.7.3166-3176.2000; Parreno M, 2001, ONCOGENE, V20, P4793, DOI 10.1038/sj.onc.1204644; Penin RM, 2002, MODERN PATHOL, V15, P1227, DOI 10.1097/01.MP.0000036589.99516.D6; Prince AM, 2002, BIOCHEM BIOPH RES CO, V290, P1066, DOI 10.1006/bbrc.2001.6291; Richon VM, 1997, J BIOL CHEM, V272, P10117, DOI 10.1074/jbc.272.15.10117; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Yang G, 2002, CLIN CANCER RES, V8, P3419; Yew PR, 2001, J CELL PHYSIOL, V187, P1, DOI 10.1002/1097-4652(2001)9999:9999<1::AID-JCP1049>3.0.CO;2-O; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408	43	85	86	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2003	22	16					2443	2451		10.1038/sj.onc.1206339	http://dx.doi.org/10.1038/sj.onc.1206339			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717421				2022-12-17	WOS:000182383500007
J	Unoki, M; Nakamura, Y				Unoki, M; Nakamura, Y			EGR2 induces apoptosis in various cancer cell lines by direct transactivation of BNIP3L and BAK	ONCOGENE			English	Article						EGR2; BNIP3L; BAK; apoptosis; PTEN	BCL-2 HOMOLOG; GROWTH SUPPRESSION; MEDIATED TRANSFER; GENE; MUTATIONS; PROTEIN; DEATH; PTEN; IDENTIFICATION; MODULATION	EGR2 plays a key role in the PTEN-induced apoptotic pathway. Using adenovirus-mediated gene transfer to 39 cancer cell lines, we found that EGR2 could induce apoptosis in a large proportion of these lines by altering the permeability of mitochondrial membranes, releasing cytochrome c and activating caspase-3, -8, and -9. Analysis by cDNA microarray and subsequent functional studies revealed that EGR2 directly transactivates expression of BNIP3L and BAK. Our results helped to clarify the molecular mechanism of the apoptotic pathway induced by PTEN-EGR2, and suggested that EGR2 may be an excellent target molecule for gene therapy to treat a variety of cancers.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Unoki, Motoko/X-3285-2019	Unoki, Motoko/0000-0002-9629-3818				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; Imazu T, 1999, ONCOGENE, V18, P4523, DOI 10.1038/sj.onc.1202722; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Kruidering M, 2000, IUBMB LIFE, V50, P85, DOI 10.1080/713803693; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MacEwan DJ, 1996, FEBS LETT, V379, P77, DOI 10.1016/0014-5793(95)01495-0; Matsushima M, 1998, GENE CHROMOSOME CANC, V21, P230, DOI 10.1002/(SICI)1098-2264(199803)21:3<230::AID-GCC7>3.0.CO;2-0; Matsushima-Nishiu M, 2001, CANCER RES, V61, P3741; Minaguchi T, 1999, CANCER RES, V59, P6063; Mittelstadt PR, 1999, J BIOL CHEM, V274, P3222, DOI 10.1074/jbc.274.5.3222; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; Obata K, 1998, CANCER RES, V58, P2095; Ono K, 2000, CANCER RES, V60, P5007; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Risinger JI, 1997, CANCER RES, V57, P4736; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; Unoki M, 2001, ONCOGENE, V20, P4457, DOI 10.1038/sj.onc.1204608; Warner LE, 1998, NAT GENET, V18, P382, DOI 10.1038/ng0498-382; Wei MC, 2000, GENE DEV, V14, P2060; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zorick TS, 1996, MOL CELL NEUROSCI, V8, P129, DOI 10.1006/mcne.1996.0052	36	85	89	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2172	2185		10.1038/sj.onc.1206222	http://dx.doi.org/10.1038/sj.onc.1206222			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687019				2022-12-17	WOS:000182066900011
J	Wang, Q; Moyret-Lalle, C; Couzon, F; Surbiguet-Clippe, C; Saurin, JC; Lorca, T; Navarro, C; Puisieux, A				Wang, Q; Moyret-Lalle, C; Couzon, F; Surbiguet-Clippe, C; Saurin, JC; Lorca, T; Navarro, C; Puisieux, A			Alterations of anaphase-promoting complex genes in human colon cancer cells	ONCOGENE			English	Article						APC/C; cyclosome; ubiquitination; colon cancer; cyclin B1	APC-DEPENDENT PROTEOLYSIS; HUMAN COLORECTAL CANCERS; B-TYPE CYCLINS; MITOTIC EXIT; OVEREXPRESSION; CHECKPOINT; MUTATIONS; PROTEINS; MITOSIS; KINASE	Ubiquitin-mediated proteolysis of cell cycle regulators is a major element of the cell cycle control. The anaphase-promoting complex (APC/C) is a large multisubunit ubiquitin-protein ligase required for the ubiquitination and degradation of G1 and mitotic checkpoint regulators. APC/C-dependent proteolysis regulates cyclin levels in G1, and triggers the separation of sister chromatids at the metaphase-anaphase transition and the destruction of mitotic cyclins at the end of mitosis. Furthermore, it was recently shown that APC/C regulates the degradation of crucial regulators of signal transduction pathways. We report here gene alterations in several components of this complex in human colon cancer cells, including APC6/CDC16 and APC8/CDC23 which are known to be key function elements. The experimental expression of a truncation mutant of APC8/CDC23 subunit (CDC23DeltaTPR) leads to abnormal levels of APC/C targets such as cyclin B1 and disturbs the cell cycle progression of colon epithelial cells through mitosis. Overall, these data support the hypothesis of a deleterious role of these mutations during colorectal carcinogenesis.	INSERM, Ctr Leon Berard, Ctr Oncol Genet, U453, F-69008 Lyon 08, France; Fac Pharm Lyon, F-69373 Lyon, France; Hop Edouard Herriot, Federat Special Digest, F-69437 Lyon 03, France; CNRS, UPR 1086, Ctr Rech Biochim Macromol, F-34293 Montpellier 5, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Puisieux, A (corresponding author), INSERM, Ctr Leon Berard, Ctr Oncol Genet, U453, 28 Rue Laennec, F-69008 Lyon 08, France.		Moyret-Lalle, Caroline/G-2742-2013	Moyret-Lalle, Caroline/0000-0002-8359-2018; Lorca, Thierry/0000-0003-2007-8924; PUISIEUX, Alain/0000-0002-9938-3798				Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; COMBARET V, 1995, INT J CANCER, V61, P185, DOI 10.1002/ijc.2910610208; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Gieffers C, 2001, MOL CELL, V7, P907, DOI 10.1016/S1097-2765(01)00234-9; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Irniger S, 1997, J CELL SCI, V110, P1523; Kawasaki A, 2001, J CELL BIOL, V152, P275, DOI 10.1083/jcb.152.2.275; Noton E, 2000, MOL CELL, V5, P85, DOI 10.1016/S1097-2765(00)80405-0; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Sarafan-Vasseur N, 2002, ONCOGENE, V21, P2051, DOI 10.1038/sj.onc.1205257; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Soria JC, 2000, CANCER RES, V60, P4000; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wang AJ, 1997, J CANCER RES CLIN, V123, P124, DOI 10.1007/BF01269891; Wang Q, 1999, HUM GENET, V105, P79, DOI 10.1007/s004390051067; Wasch R, 2002, NATURE, V418, P556, DOI 10.1038/nature00856; Yin XY, 2001, CANCER RES, V61, P6487; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791; Zhang YK, 2001, MOL CELL BIOL, V21, P5190, DOI 10.1128/MCB.21.15.5190-5199.2001; Zhao ND, 1998, GENOMICS, V53, P184, DOI 10.1006/geno.1998.5473	22	85	91	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2003	22	10					1486	1490		10.1038/sj.onc.1206224	http://dx.doi.org/10.1038/sj.onc.1206224			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629511	Bronze			2022-12-17	WOS:000181411900005
J	Nishino, T; Morikawa, K				Nishino, T; Morikawa, K			Structure and function of nucleases in DNA repair: shape, grip and blade of the DNA scissors	ONCOGENE			English	Article						DNA repair; nuclease; metal-dependent cleavage; protein-DNA interaction; structure-function relationships	NUCLEOTIDE EXCISION-REPAIR; X-RAY-STRUCTURE; COLI RNASE HI; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; MISMATCH REPAIR; APURINIC/APYRIMIDINIC ENDONUCLEASE; PROTEIN MUTS; ACTIVE-SITE; METAL-IONS	DNA nucleases catalyze the cleavage of phosphodiester bonds. These enzymes play crucial roles in various DNA repair processes, which involve DNA replication, base excision repair, nucleotide excision repair, mismatch repair, and double strand break repair. In recent years, new nucleases involved in various DNA repair processes have been reported, including the Mus81 : Mms4 (Eme1) complex, which functions during the meiotic phase and the Artemis: DNA-PK complex, which processes a V(D)J recombination intermediate. Defects of these nucleases cause genetic instability or severe immunodeficiency. Thus, structural biology on various nuclease actions is essential for the elucidation of the molecular mechanism of complex DNA repair machinery. Three-dimensional structural information of nucleases is also rapidly accumulating, thus providing important insights into the molecular architectures, as well as the DNA recognition and cleavage mechanisms. This review focuses on the three-dimensional structure-function relationships of nucleases crucial for DNA repair processes.	BERI, Dept Biol Struct, Suita, Osaka 5650874, Japan		Morikawa, K (corresponding author), BERI, Dept Biol Struct, 6-2-3 Furuedai, Suita, Osaka 5650874, Japan.	morikawa@beri.or.jp		nishino, tatsuya/0000-0001-8017-8762				Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P17, DOI 10.1016/S0968-0004(97)01162-6; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P3746, DOI 10.1093/nar/26.16.3746; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Beernink PT, 2001, J MOL BIOL, V307, P1023, DOI 10.1006/jmbi.2001.4529; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Boddy MN, 2001, CELL, V107, P537, DOI 10.1016/S0092-8674(01)00536-0; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; Fijalkowska IJ, 1996, P NATL ACAD SCI USA, V93, P2856, DOI 10.1073/pnas.93.7.2856; Galburt EA, 1999, NAT STRUCT BIOL, V6, P1096, DOI 10.1038/70027; Goedken ER, 2001, J BIOL CHEM, V276, P7266, DOI 10.1074/jbc.M009626200; Goldsby RE, 2001, NAT MED, V7, P638, DOI 10.1038/88963; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Hadden JM, 2002, EMBO J, V21, P3505, DOI 10.1093/emboj/cdf337; Hamdan S, 2002, STRUCTURE, V10, P535, DOI 10.1016/S0969-2126(02)00738-4; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; Interthal H, 2000, MOL GEN GENET, V263, P812, DOI 10.1007/s004380000241; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P111; Kaliraman V, 2001, GENE DEV, V15, P2730, DOI 10.1101/gad.932201; KATAYANAGI K, 1993, PROTEINS, V17, P337, DOI 10.1002/prot.340170402; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; LEVIN JD, 1991, J BIOL CHEM, V266, P22893; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; Mol CD, 2000, MUTAT RES-DNA REPAIR, V460, P211, DOI 10.1016/S0921-8777(00)00028-8; MORRISON A, 1993, EMBO J, V12, P1467, DOI 10.1002/j.1460-2075.1993.tb05790.x; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Mullen JR, 2001, GENETICS, V157, P103; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; Parikh SS, 2000, MUTAT RES-DNA REPAIR, V460, P183, DOI 10.1016/S0921-8777(00)00026-4; Petit C, 1999, BIOCHIMIE, V81, P15, DOI 10.1016/S0300-9084(99)80034-0; Pingoud A, 2001, NUCLEIC ACIDS RES, V29, P3705, DOI 10.1093/nar/29.18.3705; Prakash S, 2000, MUTAT RES-FUND MOL M, V451, P13, DOI 10.1016/S0027-5107(00)00037-3; Raaijmakers H, 1999, EMBO J, V18, P1447, DOI 10.1093/emboj/18.6.1447; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Sharples GJ, 2001, MOL MICROBIOL, V39, P823, DOI 10.1046/j.1365-2958.2001.02284.x; Shevelev IV, 2002, NAT REV MOL CELL BIO, V3, P364, DOI 10.1038/nrm804; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; Tsutakawa SE, 1999, MOL CELL, V3, P621, DOI 10.1016/S1097-2765(00)80355-X; Tsutakawa SE, 1999, CELL, V99, P615, DOI 10.1016/S0092-8674(00)81550-0; Tsutakawa SE, 2001, NUCLEIC ACIDS RES, V29, P3775, DOI 10.1093/nar/29.18.3775; Vassylyev DG, 1997, CURR OPIN STRUC BIOL, V7, P103, DOI 10.1016/S0959-440X(97)80013-9; Wilson DM, 1997, P NATL ACAD SCI USA, V94, P12754, DOI 10.1073/pnas.94.24.12754; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Yamagata A, 2002, P NATL ACAD SCI USA, V99, P5908, DOI 10.1073/pnas.092547099; Yang W, 2000, MUTAT RES-DNA REPAIR, V460, P245, DOI 10.1016/S0921-8777(00)00030-6; Yoshikawa M, 2001, J BIOL CHEM, V276, P10432, DOI 10.1074/jbc.M010138200	62	85	87	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2002	21	58					9022	9032		10.1038/sj.onc.1206135	http://dx.doi.org/10.1038/sj.onc.1206135			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	626TP	12483517				2022-12-17	WOS:000179889500012
J	Pane, F; Intrieri, M; Quintarelli, C; Izzo, B; Muccioli, GC; Salvatore, F				Pane, F; Intrieri, M; Quintarelli, C; Izzo, B; Muccioli, GC; Salvatore, F			BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations	ONCOGENE			English	Review						Philadelphia chromosome; Ph positive leukemias; molecular pathogenesis; phenotype of leukemia	CHRONIC MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; ABL TYROSINE KINASE; CHRONIC MYELOCYTIC-LEUKEMIA; POLYMERASE CHAIN-REACTION; HYBRID MESSENGER-RNA; CHRONIC MYELOMONOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC-LEUKEMIA; IN-SITU HYBRIDIZATION	The Philadelphia chromosome (Ph), a minute chromosome that derives from the balanced translocation between chromosomes 9 and 22, was first described in 1960 and was for a long time the only genetic lesion consistently associated with human cancer. This chromosomal translocation results in the fusion between the 5' part of BCR gene, normally located on chromosome 22, and the 3' part of the ABL gene on chromosome 9 giving origin to a BCR/ABL fusion gene which is transcribed and then translated into a hybrid protein. Three main variants of the BCR/ABL gene have been described, that, depending on the length of the sequence of the BCR gene included, encode for the p190(BCR/ABL), P210(BCR/ABL), and P230(BCR/ABL) proteins. These three main variants are associated with distinct clinical types of human leukemias. Herein we review the data on the correlations between the type of BCR/ABL gene and the corresponding leukemic clinical features. Lastly, drawing on experimental data, we provide insight into the different transforming power of the three hybrid BCR/ABL proteins.	Univ Naples Federico II, CEINGE Biotechnol Avanzate, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; Univ Molise, Fac Sci MFN, Dipartimento STAT, Isernia, Italy	CEINGE Biotecnologie Avanzate; University of Naples Federico II; University of Naples Federico II; University of Molise	Pane, F (corresponding author), Univ Naples Federico II, CEINGE Biotechnol Avanzate, Via 5 Pansini 5, I-80131 Naples, Italy.		Quintarelli, Concetta/K-6056-2016; Pierantoni, Giovanna Maria/O-7527-2015; Schepis, Filippo/H-9417-2014; Salvatore, Francesco/A-1966-2011	Quintarelli, Concetta/0000-0002-4343-9705; Pierantoni, Giovanna Maria/0000-0003-4078-8528; Schepis, Filippo/0000-0001-6549-5102; Salvatore, Francesco/0000-0002-2346-3564				AHMED S, 1994, J BIOL CHEM, V269, P17642; ALIMENA G, 1995, LEUKEMIA, V9, P1483; ANNINO L, 1994, LEUKEMIA, V8, P664; Arico M, 2000, NEW ENGL J MED, V342, P998, DOI 10.1056/NEJM200004063421402; BACCARANI M, 1995, LEUKEMIA, V9, P1648; BENNETT JM, 1994, BRIT J HAEMATOL, V87, P746, DOI 10.1111/j.1365-2141.1994.tb06734.x; Blickstein D, 1997, BLOOD, V90, P2768, DOI 10.1182/blood.V90.7.2768.2768_2768_2771; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Briz M, 1997, BLOOD, V90, P5024, DOI 10.1182/blood.V90.12.5024.5024_5024_5024; Cervantes F, 1996, LEUKEMIA, V10, P1241; CHISSOE SL, 1995, GENOMICS, V27, P67, DOI 10.1006/geno.1995.1008; Chopra R, 1999, BLOOD REV, V13, P211, DOI 10.1054/blre.1999.0119; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; CLARKSON B, 1993, LEUKEMIA, V7, P1683; Cobaleda C, 2000, BLOOD, V95, P1007, DOI 10.1182/blood.V95.3.1007.003k35_1007_1013; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DAVIS RL, 1985, MOL CELL BIOL, V5, P204, DOI 10.1128/MCB.5.1.204; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; Delforge M, 1999, BLOOD, V93, P284, DOI 10.1182/blood.V93.1.284.401k31_284_292; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DHINGRA K, 1991, LEUKEMIA, V5, P191; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; EISENBERG A, 1988, LEUKEMIA, V2, P642; ERIKSON J, 1986, P NATL ACAD SCI USA, V83, P1807, DOI 10.1073/pnas.83.6.1807; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016/0002-9343(77)90124-3; Fioretos T, 1999, BLOOD, V94, P225, DOI 10.1182/blood.V94.1.225.413k24_225_232; FIORETOS T, 1993, LEUKEMIA, V7, P1225; FUTAKI M, 1992, LEUKEMIA RES, V16, P1071, DOI 10.1016/0145-2126(92)90045-9; GALE RP, 1984, P NATL ACAD SCI-BIOL, V81, P5648, DOI 10.1073/pnas.81.18.5648; Gleissner B, 2002, BLOOD, V99, P1536, DOI 10.1182/blood.V99.5.1536; Goldman JM, 2001, BLOOD, V98, P2039, DOI 10.1182/blood.V98.7.2039; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GROFFEN J, 1983, J EXP MED, V158, P9, DOI 10.1084/jem.158.1.9; Gross AW, 1999, MOL CELL BIOL, V19, P6918; Gross AW, 2000, ONCOGENE, V19, P6286, DOI 10.1038/sj.onc.1204023; Haferlach T, 1997, BRIT J HAEMATOL, V99, P452, DOI 10.1046/j.1365-2141.1997.4203237.x; Haskovec C, 1998, BRIT J HAEMATOL, V103, P1104, DOI 10.1046/j.1365-2141.1998.01098.x; HEISTERKAMP N, 1982, NATURE, V299, P747, DOI 10.1038/299747a0; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hochhaus A, 2000, BLOOD, V95, P62; Hochhaus A, 1996, BLOOD, V88, P2236, DOI 10.1182/blood.V88.6.2236.bloodjournal8862236; Holyoake T, 1999, BLOOD, V94, P2056, DOI 10.1182/blood.V94.6.2056; Holyoake TL, 2001, BLOOD, V97, P720, DOI 10.1182/blood.V97.3.720; Holyoake TL, 2001, BRIT J HAEMATOL, V113, P11, DOI 10.1046/j.1365-2141.2001.02558.x; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; How GF, 1999, BRIT J HAEMATOL, V105, P434, DOI 10.1111/j.1365-2141.1999.01372.x; How GF, 1998, LEUKEMIA, V12, P1166, DOI 10.1038/sj.leu.2401055; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Huntly BJP, 2002, BLOOD, V99, P4547, DOI 10.1182/blood.V99.12.4547; Huntly BJP, 2001, BLOOD, V98, P1732, DOI 10.1182/blood.V98.6.1732; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; INOKUCHI K, 1991, BLOOD, V78, P3125; INUKAI T, 1993, BRIT J HAEMATOL, V85, P823; IWATA S, 1994, LEUKEMIA, V8, P1696; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JAUBERT J, 1990, BRIT J HAEMATOL, V74, P30, DOI 10.1111/j.1365-2141.1990.tb02534.x; JONAS D, 1992, BLOOD, V79, P1017; KANTARJIAN HM, 1991, BLOOD, V78, P2411, DOI 10.1182/blood.V78.9.2411.bloodjournal7892411; Kasprzyk A, 1999, LEUKEMIA, V13, P2000, DOI 10.1038/sj.leu.2401580; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; Kin Y, 2001, J BIOL CHEM, V276, P39462, DOI 10.1074/jbc.M105484200; Kojima K, 1999, BRIT J HAEMATOL, V106, P720, DOI 10.1046/j.1365-2141.1999.01588.x; Kolomietz E, 2001, BLOOD, V97, P3581, DOI 10.1182/blood.V97.11.3581; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KURZROCK R, 1987, BLOOD, V70, P1584; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; Lee SJ, 2000, BRIT J HAEMATOL, V111, P993, DOI 10.1046/j.1365-2141.2000.02216.x; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Ma GZ, 1997, ONCOGENE, V14, P2367, DOI 10.1038/sj.onc.1201053; MaguerSatta V, 1996, BLOOD, V88, P1796; Mancini M, 2001, Hematol J, V2, P54, DOI 10.1038/sj.thj.6200079; Martinelli G, 2002, HAEMATOLOGICA, V87, P688; Martinelli G, 2000, BONE MARROW TRANSPL, V25, P729, DOI 10.1038/sj.bmt.1702207; Martinez-Mancilla M, 2002, HAEMATOLOGICA, V87, P666; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MAURER J, 1991, LANCET, V337, P1055, DOI 10.1016/0140-6736(91)91706-Z; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; McWhirter JR, 1997, ONCOGENE, V15, P1625, DOI 10.1038/sj.onc.1201342; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MELO JV, 1994, LEUKEMIA, V8, P208; MELO JV, 1993, BLOOD, V81, P2488; MELO JV, 1993, BLOOD, V81, P158; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; Miao YJ, 1996, J BIOL CHEM, V271, P22823, DOI 10.1074/jbc.271.37.22823; MILLS KI, 1991, LEUKEMIA, V5, P731; Mittre H, 1997, BLOOD, V89, P4239, DOI 10.1182/blood.V89.11.4239; Moreno MD, 2001, BLOOD, V97, P3668; MORRIS CM, 1991, BLOOD, V78, P1078; NEGRINI M, 1992, CANCER GENET CYTOGEN, V61, P11, DOI 10.1016/0165-4608(92)90363-D; NOWELL PC, 1960, SCIENCE, V132, P1497; NUCIFORA G, 1995, BLOOD, V86, P1; Okamoto K, 1997, BRIT J HAEMATOL, V96, P611, DOI 10.1046/j.1365-2141.1997.d01-2066.x; Olson MF, 1996, J MOL MED-JMM, V74, P563, DOI 10.1007/s001090050060; OPALKA B, 1992, BLOOD, V80, P1854; Pajor L, 2000, LEUKEMIA, V14, P1122, DOI 10.1038/sj.leu.2401794; Pane F, 1999, BLOOD, V94, P2200, DOI 10.1182/blood.V94.7.2200.419a33_2200_2207; Pane F, 1996, LEUKEMIA, V10, P741; Pane F, 1996, BLOOD, V88, P2410, DOI 10.1182/blood.V88.7.2410.bloodjournal8872410; Paulsson K, 2001, CANCER GENET CYTOGEN, V130, P160, DOI 10.1016/S0165-4608(01)00486-1; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; Polak J, 2000, BONE MARROW TRANSPL, V25, P1109, DOI 10.1038/sj.bmt.1702412; PREUDHOMME C, 1992, BRIT J HAEMATOL, V82, P623, DOI 10.1111/j.1365-2141.1992.tb06480.x; Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907; Quackenbush RC, 2000, BLOOD, V95, P2913, DOI 10.1182/blood.V95.9.2913.009k32_2913_2921; Radich J, 1997, BLOOD, V89, P2602, DOI 10.1182/blood.V89.7.2602; RADICH JP, 1994, LEUKEMIA, V8, P1688; Rotoli B, 2000, BRIT J HAEMATOL, V110, P493; Roumier C, 1999, HAEMATOLOGICA, V84, P1075; ROWLEY JD, 1973, NEW ENGL J MED, V289, P220; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Saglio G, 1997, LEUKEMIA LYMPHOMA, V26, P281, DOI 10.3109/10428199709051777; SAGLIO G, 1988, BLOOD, V72, P1203; Saglio G, 1996, BLOOD, V87, P1075, DOI 10.1182/blood.V87.3.1075.bloodjournal8731075; SAGLIO G, 1990, BLOOD, V76, P1819; Saglio G, 1999, LEUKEMIA, V13, pS96, DOI 10.1038/sj.leu.2401321; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHAEFERREGO K, 1987, BLOOD, V70, P448; Schenk TM, 1998, LEUKEMIA, V12, P666, DOI 10.1038/sj.leu.2400986; Schoch C, 1997, BRIT J HAEMATOL, V99, P605, DOI 10.1046/j.1365-2141.1997.4473257.x; Schrappe M, 1998, BLOOD, V92, P2730; SECKERWALKER LM, 1992, CANCER GENET CYTOGEN, V58, P29, DOI 10.1016/0165-4608(92)90129-V; SHEPHERD P, 1995, BRIT J HAEMATOL, V89, P546, DOI 10.1111/j.1365-2141.1995.tb08362.x; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Sinclair PB, 2000, BLOOD, V95, P738, DOI 10.1182/blood.V95.3.738.003k21_738_743; SOEKARMAN D, 1990, LEUKEMIA, V4, P397; STAM K, 1985, NEW ENGL J MED, V313, P1429, DOI 10.1056/NEJM198512053132301; STEWART MJ, 1994, J BIOL CHEM, V269, P10820; SURYANARAYAN K, 1991, BLOOD, V77, P324; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Takahashi N, 1998, BLOOD, V92, P4758, DOI 10.1182/blood.V92.12.4758; Takeda N, 1999, P NATL ACAD SCI USA, V96, P203, DOI 10.1073/pnas.96.1.203; TUSZYNSKI A, 1993, LEUKEMIA, V7, P1504; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; VANDERPLAS DC, 1991, LEUKEMIA, V5, P457; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; vanRhee F, 1996, BLOOD, V87, P5213, DOI 10.1182/blood.V87.12.5213.bloodjournal87125213; VERSCHRAEGEN CF, 1995, CANCER-AM CANCER SOC, V76, P992, DOI 10.1002/1097-0142(19950915)76:6<992::AID-CNCR2820760612>3.0.CO;2-L; Verstovsek S, 2002, CANCER, V94, P2416, DOI 10.1002/cncr.10490; WADA H, 1995, CANCER RES, V55, P3192; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WESTBROOK CA, 1992, BLOOD, V80, P2983; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Wilson G, 1997, BLOOD, V89, P3064, DOI 10.1182/blood.V89.8.3064; Wilson GA, 2000, BRIT J HAEMATOL, V111, P1109, DOI 10.1046/j.1365-2141.2000.02471.x; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamagata T, 1996, BRIT J HAEMATOL, V94, P370, DOI 10.1046/j.1365-2141.1996.d01-1798.x; ZACCARIA A, 1993, LEUKEMIA LYMPHOMA, V11, P81, DOI 10.3109/10428199309047869; ZACCARIA A, 1993, BRIT J HAEMATOL, V84, P265, DOI 10.1111/j.1365-2141.1993.tb03062.x	164	85	98	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	2002	21	56					8652	8667		10.1038/sj.onc.1206094	http://dx.doi.org/10.1038/sj.onc.1206094			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476311				2022-12-17	WOS:000179734300014
J	Nishimori, H; Sasaki, Y; Yoshida, K; Irifune, H; Zembutsu, H; Tanaka, T; Aoyama, T; Hosaka, T; Kawaguchi, S; Wada, T; Hata, J; Toguchida, J; Nakamura, Y; Tokino, T				Nishimori, H; Sasaki, Y; Yoshida, K; Irifune, H; Zembutsu, H; Tanaka, T; Aoyama, T; Hosaka, T; Kawaguchi, S; Wada, T; Hata, J; Toguchida, J; Nakamura, Y; Tokino, T			The Id2 gene is a novel target of transcriptional activation by EWS-ETS fusion proteins in Ewing family tumors	ONCOGENE			English	Article						ld2; EWS-ETS; Ewing family tumor	DNA-BINDING; CHROMOSOME-TRANSLOCATION; SARCOMA TRANSLOCATION; MOLECULAR ANALYSIS; CDNA MICROARRAY; CELLS; EXPRESSION; CANCER; FUSES; ERG	We report here that the Id2 (inhibitor of DNA binding 2) gene is a novel target of transcriptional activation by EWS-FLI1 and EWS-ERG, two fusion proteins that characterize Ewing family tumors (EFTs). To identify downstream targets of these EWS-ETS fusion proteins, we introduced EWS-ETS fusion constructs into a human fibrosarcoma cell line by retroviral transduction. cDNA microarray analysis revealed that Id2 expression was up-regulated by introducing the EWS-ETS fusion gene but not by the normal full-length ETS gene. An Id2 promoter-luciferase reporter assay showed that transactivation by EWS-ETS involves the minimal Id2 promoter and may function in cooperation with c-Myc within the full-length regulatory region. A chromatin immunoprecipitation assay revealed direct interaction between the Id2 promoter and EWS-FLI1 fusion protein in vivo. Significantly higher expression of Id2 and c-Myc was observed in all of the six EFT cell lines examined compared to six other sarcoma cell lines. Moreover, high levels of Id2 expression were also observed in five of the six primary tumors examined. Id2 is generally thought to affect the balance between cell differentiation and proliferation in development and is highly expressed in several cancer types. Considering these previous studies, our data suggest that the oncogenic effect of EWS-ETS may be mediated in part by up-regulating Id2 expression.	Sapporo Med Univ, Sch Med, Inst Canc Res, Dept Mol Biol,Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Med, Dept Orthoped Surg, Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Univ Tokyo, Inst Med Sci, Mol Med Lab, Ctr Human Genome,Minato Ku, Tokyo 1088639, Japan; Kyoto Univ, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Fac Med, Dept Orthoped Surg, Sakyo Ku, Kyoto 6068507, Japan; Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1608582, Japan	Sapporo Medical University; Sapporo Medical University; University of Tokyo; Kyoto University; Kyoto University; Keio University	Tokino, T (corresponding author), Sapporo Med Univ, Sch Med, Inst Canc Res, Dept Mol Biol,Chuo Ku, S-1,W-17, Sapporo, Hokkaido 0608556, Japan.		Tanaka, Toshihiro/J-9310-2014; Sasaki, Yasushi/AAA-3079-2019; Tokino, Takashi/AAI-9887-2021	Tanaka, Toshihiro/0000-0001-6201-9784; Sasaki, Yasushi/0000-0002-3500-8059; 				Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; de Alava E, 2000, CANCER-AM CANCER SOC, V89, P783, DOI 10.1002/1097-0142(20000815)89:4<783::AID-CNCR10>3.0.CO;2-Q; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Ishida S, 2000, JPN J CANCER RES, V91, P174, DOI 10.1111/j.1349-7006.2000.tb00929.x; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; Kihara C, 2001, CANCER RES, V61, P6474; Kleeff J, 1998, CANCER RES, V58, P3769; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lopez-Guerrero JA, 2001, LAB INVEST, V81, P803, DOI 10.1038/labinvest.3780290; MAO XH, 1994, J BIOL CHEM, V269, P18216; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Morimoto I, 2002, GENE CHROMOSOME CANC, V33, P270, DOI 10.1002/gcc.10020; Ono K, 2000, CANCER RES, V60, P5007; OUCHIDA M, 1995, ONCOGENE, V11, P1049; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; Rockman SP, 2001, J BIOL CHEM, V276, P45113, DOI 10.1074/jbc.M107742200; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Thompson AD, 1996, ONCOGENE, V13, P2649; Urano F, 1998, JPN J CANCER RES, V89, P703, DOI 10.1111/j.1349-7006.1998.tb03274.x; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; WEI G, 2000, CANCER, V89, P783; Yokota Y, 2001, ONCOGENE, V20, P8290, DOI 10.1038/sj.onc.1205090; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	38	85	88	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8302	8309		10.1038/sj.onc.1206025	http://dx.doi.org/10.1038/sj.onc.1206025			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447693				2022-12-17	WOS:000179323900008
J	Humar, B; Graziano, F; Cascinu, S; Catalano, V; Ruzzo, AM; Magnani, M; Toro, T; Burchill, T; Futschik, ME; Merriman, T; Guilford, P				Humar, B; Graziano, F; Cascinu, S; Catalano, V; Ruzzo, AM; Magnani, M; Toro, T; Burchill, T; Futschik, ME; Merriman, T; Guilford, P			Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer	ONCOGENE			English	Article						diffuse gastric cancer; E-cadherin; CDH1; polymorphism; genetics	E-CADHERIN GENE; LINKAGE DISEQUILIBRIUM; EPIDEMIOLOGY; CARCINOMA; MUTATIONS	Truncating mutations in the gene for the cell to cell adhesion protein E-cadherin are the most consistent genetic alterations observed in sporadic and hereditary diffuse gastric cancer (DGC). In addition to these inactivating mutations, a CDH1 promoter polymorphism at position -160 has been reported to lead to transcriptional downregulation of the gene in vitro. We therefore performed a case-control study to investigate whether this variant is associated with an increased susceptibility to DGC. The frequency of the - 160A allele was significantly higher (P < 0.005) in 53 diffuse gastric cancer cases compared to 70 matched controls. The odds ratio associated with the A-allele was 2.27 for CA-heterozygotes (95% CI 1.16-4.44) and 7.84 for AA-homozygotes (95% CI 2.89-21.24). Two additional polymorphisms (the 48+6T-->C and the 2076C-->T variant) were genotyped and shown to be equally distributed among cases and controls. Haplotype analysis with the three polymorphisms confirmed an association with disease (P < 0.004). However, this analysis suggested the -160C --> A CDH1 promoter polymorphism may be in linkage disequilibrium with a distinct aetiological locus or acts in combination with other functional variants in or near the C-DH1 region.	Univ Otago, Dept Biochem, Canc Genet Lab, Dunedin, Aotearoa, New Zealand; Hosp Urbino, Div Med Oncol, I-61029 Urbino, Italy; Hosp Parma, I-43100 Parma, Italy; Hosp Pesaro, I-61100 Pesaro, Italy; Univ Urbino, G Fornaini Inst Biochem & Mol Biol, I-61029 Urbino, Italy; Univ Otago, Knowledge Engn Lab, Dunedin, Aotearoa, New Zealand; Univ Otago, Biochem Lab, Dunedin, Aotearoa, New Zealand	University of Otago; University of Parma; University Hospital of Parma; University of Urbino; University of Otago; University of Otago	Guilford, P (corresponding author), Univ Otago, Dept Biochem, Canc Genet Lab, POB 56, Dunedin, Aotearoa, New Zealand.		Ruzzo, Annamaria/Q-2155-2016; Magnani, Mauro/A-1919-2008; Futschik, Matthias/AAK-8837-2020; Cascinu, Stefano/AAN-1923-2020; Cascinu, Stefano/G-2399-2017	Ruzzo, Annamaria/0000-0003-2815-1890; Futschik, Matthias/0000-0002-6245-8071; Cascinu, Stefano/0000-0003-2215-0731; Guilford, Parry/0000-0002-7256-9576; Merriman, Tony/0000-0003-0844-8726; Magnani, Mauro/0000-0001-6456-6626				Avizienyte E, 2001, J MED GENET, V38, P49, DOI 10.1136/jmg.38.1.49; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Borch K, 2000, BRIT J SURG, V87, P618, DOI 10.1046/j.1365-2168.2000.01425.x; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003; Dunbier A, 2001, ADV CANCER RES, V83, P55, DOI 10.1016/S0065-230X(01)83002-5; FISHER RA, 1951, DESIGN EXPT, P1; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; HOWSON CP, 1986, EPIDEMIOL REV, V8, P1; Humar B, 2002, HUM MUTAT, V19, P518, DOI 10.1002/humu.10067; Koeleman BPC, 2000, ANN HUM GENET, V64, P207, DOI 10.1017/S0003480000008095; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; LAUREN PA, 1993, CANCER-AM CANCER SOC, V71, P2926, DOI 10.1002/1097-0142(19930515)71:10<2926::AID-CNCR2820711007>3.0.CO;2-X; Lei HX, 2002, INT J CANCER, V98, P199, DOI 10.1002/ijc.10176; Li LC, 2000, CANCER RES, V60, P873; Porter TR, 2002, ONCOGENE, V21, P1928, DOI 10.1038/sj.onc.1205245; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Wu MS, 2002, CANCER-AM CANCER SOC, V94, P1443, DOI 10.1002/cncr.10371	19	85	93	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 21	2002	21	53					8192	8195		10.1038/sj.onc.1205921	http://dx.doi.org/10.1038/sj.onc.1205921			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615DW	12444556				2022-12-17	WOS:000179231400014
J	Fusaro, G; Wang, S; Chellappan, S				Fusaro, G; Wang, S; Chellappan, S			Differential regulation of Rb family proteins and prohibitin during camptothecin-induced apoptosis	ONCOGENE			English	Article						Rb; E2F; prohibitin; apoptosis; cell cycle	RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; TRANSCRIPTIONAL ACTIVITY; REPRESS TRANSCRIPTION; CELL-LINES; E2F-1; P53; PHOSPHORYLATION; PROLIFERATION; RECEPTOR	Prohibitin, a potential tumor suppressor, is known to induce growth suppression and repress E2F-mediated transcription. These growth regulatory functions of prohibitin require a physical interaction with the Rb protein. We now find that prohibitin protects cells from apoptosis mediated by camptothecin, a topoisomerase I inhibitor. Camptothecin treatment of Ramos B cells leads to the degradation of Rb protein and phosphorylation of its family members, p107 and p130. This correlates with an increase in the levels of cyclin E as well as the kinase activity associated with it. Inactivation of Rb leads to the dissociation and release of free E2F. We find also that E2F activity is induced upon camptothecin treatment, but this increase is absent in prohibitin overexpressing cells. It thus appears that prohibitin may be inhibiting apoptosis by downregulating E2F activity when Rb family members are inactive.	H Lee Moffit Canc Ctr & Res Inst, Dept Interdiscilinary Oncol, Tampa, FL 33612 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	Columbia University	Chellappan, S (corresponding author), H Lee Moffit Canc Ctr & Res Inst, Dept Interdiscilinary Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.				NATIONAL CANCER INSTITUTE [R01CA077301] Funding Source: NIH RePORTER; NCI NIH HHS [CA77301] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Berger KH, 1998, MOL CELL BIOL, V18, P4043, DOI 10.1128/MCB.18.7.4043; Blagosklonny MV, 1999, BIOESSAYS, V21, P704, DOI 10.1002/(SICI)1521-1878(199908)21:8<704::AID-BIES10>3.0.CO;2-5; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; Coates PJ, 2001, EXP CELL RES, V265, P262, DOI 10.1006/excr.2001.5166; Delage-Mourroux R, 2000, J BIOL CHEM, V275, P35848, DOI 10.1074/jbc.M001327200; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HSEIH JK, 1997, GENE DEV, V11, P1840; Hunt KK, 1997, CANCER RES, V57, P4722; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; JUPE ER, 1995, EXP CELL RES, V218, P577, DOI 10.1006/excr.1995.1194; KITAGAWA M, 1995, ONCOGENE, V10, P229; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; Nip J, 1997, MOL CELL BIOL, V17, P1049, DOI 10.1128/MCB.17.3.1049; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 2001, APOPTOSIS, V6, P173, DOI 10.1023/A:1011332625740; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Steglich G, 1999, MOL CELL BIOL, V19, P3435; TERASHIMA M, 1994, EMBO J, V13, P3782, DOI 10.1002/j.1460-2075.1994.tb06689.x; Wang S, 1999, MOL CELL BIOL, V19, P7447; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	40	85	103	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 4	2002	21	29					4539	4548		10.1038/sj.onc.1205551	http://dx.doi.org/10.1038/sj.onc.1205551			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085232				2022-12-17	WOS:000176476700008
J	Chieffi, P; Battista, S; Barchi, M; Di Agostino, S; Pierantoni, GM; Fedele, M; Chiariotti, L; Tramontano, D; Fusco, A				Chieffi, P; Battista, S; Barchi, M; Di Agostino, S; Pierantoni, GM; Fedele, M; Chiariotti, L; Tramontano, D; Fusco, A			HMGA1 and HMGA2 protein expression in mouse spermatogenesis	ONCOGENE			English	Article						HMGA proteins; testis; spermatogenesis; fertility	IFN-BETA GENE; SERTOLI CELLS; HMGI(Y) PROTEINS; TRANSGENIC MICE; MESSENGER-RNA; DNA-BINDING; PROMOTER; RECEPTOR; I(Y); IDENTIFICATION	The high-mobility group A (HMGA) nonhistone chromosomal proteins HMGA1 and HMGA2 play a role in determining chromatin structure and in regulating the transcription of several genes. High levels of these proteins are characteristic of rapidly dividing cells in embryonic tissue and in tumors. The aim of this study was to determine the role of HMGA1 and HMGA2 throughout mouse spermatogenesis. Northern blot analysis and immunocytochemistry showed HMGA1 and HMGA2 expression during the progression from spermatocyte to spermatid. Interestingly, Western blot analysis with antibodies against the HMGA1 gene product revealed only the HMG1c isoform (27 kDa) in the testis; HMGA1a and HMGA1b were undetectable. These three isoforms are encoded by the HMGA1 gene through alternative splicing. Finally, few spermatids and complete absence of spermatozoa were observed in the testes of HMGA2-null mice, which suggests that the HMGA2 gene plays a critical role in male fertility.	Univ Naples Federico II, CNR,Ctr Endocrinol & Oncol Sperimentale, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Naples 2, Dipartimento Med Sperimentale, I-80138 Naples, Italy; Univ Roma Tor Vergata, Sezione Anat, Dipartimento Biol Cellulare & Sanita Publ, Rome, Italy; Univ Catanzaro, Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; Univ Sannio, Fac Sci MM FF NN, Benevento, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita della Campania Vanvitelli; University of Rome Tor Vergata; Magna Graecia University of Catanzaro; University of Sannio	Chieffi, P (corresponding author), Univ Naples Federico II, CNR,Ctr Endocrinol & Oncol Sperimentale, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.		Battista, Sabrina/AAY-2981-2020; Di Agostino, Silvia/H-1121-2018; Tramontano, Donatella/AAS-1740-2020; Chiariotti, Lorenzo/AAC-5262-2022; Fedele, Monica/C-1417-2015; Pierantoni, Giovanna Maria/O-7527-2015; Di Agostino, Silvia/S-8566-2019; Chieffi, Paolo/ABA-7892-2020; Barchi, Marco/Q-9378-2019	Battista, Sabrina/0000-0001-5899-9759; Di Agostino, Silvia/0000-0003-3730-1125; Fedele, Monica/0000-0002-9171-1312; Pierantoni, Giovanna Maria/0000-0003-4078-8528; Barchi, Marco/0000-0003-1104-6234; CHIARIOTTI, Lorenzo/0000-0001-6097-4171; Fusco, Alfredo/0000-0003-3332-5197; Tramontano, Donatella/0000-0002-9308-034X; chieffi, paolo/0000-0001-8483-5635				Abe N, 1999, CANCER RES, V59, P1169; Abe N, 2000, CANCER RES, V60, P3117; Albanesi C, 1996, DEVELOPMENT, V122, P1291; Anand A, 2000, NAT GENET, V24, P377, DOI 10.1038/74207; Arlotta P, 2000, J BIOL CHEM, V275, P14394, DOI 10.1074/jbc.M000564200; ASHAR HR, 1995, CELL, V82, P57; Bandiera A, 1998, CANCER RES, V58, P426; Battista S, 1999, CANCER RES, V59, P4793; Bellve A.R., 1979, Oxford Reviews of Reproductive Biology, V1, P159; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BOOCKFOR FR, 1991, ENDOCRINOLOGY, V129, P256, DOI 10.1210/endo-129-1-256; Chiappetta G, 1998, CANCER RES, V58, P4193; Chiappetta G, 1996, ONCOGENE, V13, P2439; Chiappetta G, 2001, INT J CANCER, V91, P147, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1033>3.3.CO;2-M; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; Chiariotti L, 1998, GENOMICS, V47, P258, DOI 10.1006/geno.1997.5105; CHUBB C, 1985, ENDOCRINOLOGY, V117, P338, DOI 10.1210/endo-117-1-338; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; DEKRETSER DM, 1995, BASIC ENDOCRINOLOGY, P2307; DU W, 1994, P NATL ACAD SCI USA, V91, P11318, DOI 10.1073/pnas.91.24.11318; Eddy EM, 1998, SEMIN CELL DEV BIOL, V9, P451, DOI 10.1006/scdb.1998.0201; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; Fedele M, 2000, J BIOL CHEM, V275, P7894, DOI 10.1074/jbc.275.11.7894; Fedele M, 2001, CARCINOGENESIS, V22, P1583, DOI 10.1093/carcin/22.10.1583; Fedele M, 1996, CANCER RES, V56, P1896; GERARD N, 1991, MOL CELL ENDOCRINOL, V82, pR13, DOI 10.1016/0303-7207(91)90019-O; GRIMALDI P, 1993, MOL ENDOCRINOL, V7, P1217, DOI 10.1210/me.7.9.1217; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Hess JL, 1998, AM J CLIN PATHOL, V109, P251, DOI 10.1093/ajcp/109.3.251; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; LEGER H, 1995, MOL CELL BIOL, V15, P3738; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; McCarrey J, 1993, CELL MOL BIOL TESTIS, P58; Meistrich M L, 1977, Methods Cell Biol, V15, P15, DOI 10.1016/S0091-679X(08)60207-1; Nagpal S, 1999, J BIOL CHEM, V274, P22563, DOI 10.1074/jbc.274.32.22563; OKUDA Y, 1994, ENDOCRINE, V2, P1163; Pero R, 2001, AM J PATHOL, V159, P1225, DOI 10.1016/S0002-9440(10)62508-4; Rommel B, 1997, LEUKEMIA LYMPHOMA, V26, P603, DOI 10.3109/10428199709050896; ROSSI P, 1993, DEV BIOL, V155, P68, DOI 10.1006/dbio.1993.1007; Sambrook J, 1989, MOL CLONING LAB MANU; Sette C, 1997, DEVELOPMENT, V124, P2267; Sharpe RM, 1994, REGULATION SPERMATOG, P1363; TAMIMI Y, 1993, CANCER RES, V53, P5512; TAMURA TA, 1992, J BIOL CHEM, V267, P4327; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; vanWert JM, 1998, BIOL REPROD, V59, P704, DOI 10.1095/biolreprod59.3.704; WISNIEWSKI J, 1993, EUR J BIOCHEM, V212, P137, DOI 10.1111/j.1432-1033.1993.tb17643.x; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	50	85	89	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 16	2002	21	22					3644	3650		10.1038/sj/onc/1205501	http://dx.doi.org/10.1038/sj/onc/1205501			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032866				2022-12-17	WOS:000175793700015
J	He, Q; Lee, DI; Rong, R; Yu, M; Luo, X; Klein, M; El-Deiry, WS; Huang, Y; Hussain, A; Sheikh, MS				He, Q; Lee, DI; Rong, R; Yu, M; Luo, X; Klein, M; El-Deiry, WS; Huang, Y; Hussain, A; Sheikh, MS			Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway	ONCOGENE			English	Article						ER-stress; thapsigargin; death receptors; caspases; apoptosis; TRAIL	GENE-EXPRESSION; GENOTOXIC STRESS; KILLER/DR5 GENE; RELEASE; PROTEIN; INHIBITOR; LIGAND	Thapsigargin (TG), by inducing perturbations in cellular Ca2+ homeostasis, has been shown to induce apoptosis. The molecular mechanisms of Ca2+ perturbation-induced apoptosis are not fully understood. In this study, we demonstrate for the first time that TG-mediated perturbations in Ca2+ homeostasis are coupled with activation of the death receptor 5 (DR5)-dependent apoptotic pathway in human cancer cells. TG selectively upregulated DR5 but had no effect on the expression 4 the other TRAIL receptor, DR4. TG also upregulated the expression of the DR5 ligand TRAIL (tumor necrosis factor-related apoptosis inducing ligand), albeit in a cell-type specific manner. TG-induced apoptosis has been shown to be associated with activation of the mitochondrial pathway. We found that TG upregulation of DR5 and TRAIL was coupled with caspase 8 activation and Bid cleavage, suggesting that the TG-regulated DR5 pathway could be linked to the mitochondrial pathway. TG enhanced not only DR5 mRNA stability but also increased induction of the DR5 genomic promoter-reporter gene. The TG-induced increase in DR5 expression appeared to occur as a consequence of TG-induced endoplasmic reticulum (ER) Ca2+ pool depletion. Thus, we report our novel findings that ER Ca2+ pool depletion-induced apoptotic signals are mediated, at least in part, via a DR5-dependent apoptotic pathway and there appears to be a cross-talk between the death receptor and mitochondrial pathways.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA; Univ Maryland, Sch Med, Dept Biochem, Greenebaum Canc Ctr,Vet Affairs Med Ctr, Baltimore, MD 21201 USA; Univ Penn, Howard Hughes Med Inst, Lab Mol Oncol & Cell Cycle Regulat, Sch Med, Philadelphia, PA 19104 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); Howard Hughes Medical Institute; University of Pennsylvania	Sheikh, MS (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA.	sheikhm@mail.upstate.edu	El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266	NCI NIH HHS [CA89043] Funding Source: Medline; NHLBI NIH HHS [P01HL27867] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA089043] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; FURUYA Y, 1994, CANCER RES, V54, P6167; Griffith TS, 1999, J IMMUNOL, V162, P2597; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Huang Y, 2001, CANCER RES, V61, P6918; JACKMAN J, 1994, CANCER RES, V54, P5656; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Krebs J, 1998, BIOMETALS, V11, P375, DOI 10.1023/A:1009226316146; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LI WWF, 1993, J BIOL CHEM, V268, P12003; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Ruth JH, 1999, AM J RESP CELL MOL, V21, P621, DOI 10.1165/ajrcmb.21.5.3694; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; SHEIKH MS, 1994, ONCOGENE, V9, P3407; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheikh MS, 2000, LEUKEMIA, V14, P1509, DOI 10.1038/sj.leu.2401865; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Waser M, 1997, J CELL BIOL, V138, P547, DOI 10.1083/jcb.138.3.547; Wei MC, 2000, GENE DEV, V14, P2060; Wertz IE, 2000, J BIOL CHEM, V275, P11470, DOI 10.1074/jbc.275.15.11470; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805	28	85	88	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2623	2633		10.1038/sj.onc.1205345	http://dx.doi.org/10.1038/sj.onc.1205345			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965535				2022-12-17	WOS:000174996500002
J	Guzzi, F; Zanchetta, D; Cassoni, P; Guzzi, V; Francolini, M; Parenti, M; Chini, B				Guzzi, F; Zanchetta, D; Cassoni, P; Guzzi, V; Francolini, M; Parenti, M; Chini, B			Localization of the human oxytocin receptor in caveolin-1 enriched domains turns the receptor-mediated inhibition of cell growth into a proliferative response	ONCOGENE			English	Article						cell growth; oxytocin receptor; G-protein coupled receptor; caveolin; MDCK cells	SIGNAL-TRANSDUCTION; ADENYLYL-CYCLASE; CHOLESTEROL; VASOPRESSIN; SEQUESTRATION; MECHANISMS; COMPLEXES; PROTEINS	In this study, we investigated the functional role of the localization of human OTR in caveolin-1 enriched membrane domains. Biochemical fractionation of MDCK cells stably expressing the WT OTR-GFP indicated that only minor quantities of receptor are partitioned in caveolin-1 enriched domains. However, when fused to caveolin-2, the OTR protein proved to be exclusively localized in caveolin-1 enriched fractions, where it bound the agonist with increased affinity and efficiently coupled to Galpha(q/11). Interestingly, the chimeric protein was unable to undergo agonist-induced internalization and remained confined to the plasma membrane even after prolonged agonist exposure (120 min). A striking difference in receptor stimulation was observed when the OT-induced effect on cell proliferation was analysed: stimulation of the human WT OTR inhibited cell growth, whereas the chimeric protein had a proliferative effect. These data indicate that the localization of human OTR in caveolin-1 enriched microdomains radically alters its regulatory effects on cell growth; the fraction of OTR residing in caveolar structures may therefore play a crucial role in regulating cell proliferation.	CNR, Cellular & Mol Pharmacol Ctr, I-20129 Milan, Italy; Univ Milan, Dept Expt & Environm Med, I-20052 Monza, Italy; Univ Turin, Dept Biomed Sci & Oncol, I-10126 Turin, Italy; Univ Milan, Dept Pharmacol, I-20129 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Milan; University of Turin; University of Milan	Chini, B (corresponding author), CNR, Cellular & Mol Pharmacol Ctr, I-20129 Milan, Italy.	B.Chini@csfic.mi.cnr.it	Cassoni, Paola/I-8544-2018	Chini, Bice/0000-0002-1686-284X; FRANCOLINI, MAURA/0000-0002-3126-1575				ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Cassoni P, 2001, ENDOCRINOLOGY, V142, P1130, DOI 10.1210/en.142.3.1130; Cassoni P, 1997, INT J CANCER, V72, P340, DOI 10.1002/(SICI)1097-0215(19970717)72:2<340::AID-IJC23>3.0.CO;2-I; Cassoni P, 1998, INT J CANCER, V77, P695, DOI 10.1002/(SICI)1097-0215(19980831)77:5<695::AID-IJC6>3.0.CO;2-Q; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; Chini B, 1996, FEBS LETT, V397, P201, DOI 10.1016/S0014-5793(96)01135-0; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dessy C, 2000, EMBO J, V19, P4272, DOI 10.1093/emboj/19.16.4272; ELANDS J, 1988, AM J PHYSIOL, V254, pE31, DOI 10.1152/ajpendo.1988.254.1.E31; Gimpl G, 2000, EUR J BIOCHEM, V267, P2483, DOI 10.1046/j.1432-1327.2000.01280.x; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hailstones D, 1998, J LIPID RES, V39, P369; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; Hoare S, 1999, J BIOL CHEM, V274, P28682, DOI 10.1074/jbc.274.40.28682; KIRK CJ, 1986, BIOCHEM J, V240, P197, DOI 10.1042/bj2400197; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; OHMICHI M, 1995, ENDOCRINOLOGY, V136, P2082, DOI 10.1210/en.136.5.2082; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Ostrom RS, 2000, MOL PHARMACOL, V57, P1075; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; STRAKOVA Z, 1997, AM J PHYSIOL, V272, P870; STRAKOVA Z, 1998, AM J PHYSL SE, V274, P634; THIBONNIER M, 1994, J BIOL CHEM, V269, P3304	34	85	85	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1658	1667		10.1038/sj.onc.1205219	http://dx.doi.org/10.1038/sj.onc.1205219			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896597				2022-12-17	WOS:000174214200004
J	Bishop, PC; Myers, T; Robey, R; Fry, DW; Liu, ET; Blagosklonny, MV; Bates, SE				Bishop, PC; Myers, T; Robey, R; Fry, DW; Liu, ET; Blagosklonny, MV; Bates, SE			Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family	ONCOGENE			English	Article						oncogenes; HER1/HER2 inhibitors; EGF; NCI drug screen; signal transduction	ANTICANCER DRUG SCREEN; BREAST-CANCER; PROGNOSTIC FACTOR; TUMOR-SUPPRESSOR; ONCOGENE; THERAPY; GENE; P53; AMPLIFICATION; EXPRESSION	Clinical responses to the HER1 (EGF receptor) inhibitors and HER2/neu/ErbB2 inhibitors correlate with high levels of receptor expression. However, a significant subset of patients with high receptor levels appear to be refractory to treatment. We have observed similar results in the 60 cell lines of the NCI Anti-Cancer Drug Screen using a panel of 11 selective HER1 inhibitors. As expected, low HER1-expressing cell lines were insensitive to HER1 inhibitors. In cell lines with high HER1 expression, low concentrations of HER1 inhibitors potently inhibit both HER1 phosphorylation and the mitogen-activated protein kinase (MAPK) pathway. However, this inhibition did not always correlate with cellular arrest. High HER1-expressing cell lines can be subdivided into two groups based on their sensitivity to HER1 inhibitors. In the sensitive group, receptor and growth inhibition was concordant and occurred at submicromolar concentrations of HER1 inhibitors. In the insensitive group, receptor inhibition occurred at a low concentration (<1 mum) but concentrations that were ten times or higher were required for growth inhibition. Also, neither induction of p21 and cyclin D1 nor p53 status could explain the difference between sensitive and insensitive cells. Although EGF activated the MAPK pathway in all cell lines, only drug-sensitive cell lines responded to EGF (accelerated entry from G1 to S) and to HER1 inhibitors (GI arrest) by changes in cell cycling. Furthermore, an EGF-dependent immortalized mammary epithelial cell line was extremely sensitive to a panel of HER1 inhibitors. We infer that independence from mitogen-mediated signaling confers insensitivity to HER1 inhibitors in a large subset of cancer cell lines.	NCI, Med Branch, DCS, MB,NIH, Bethesda, MD 20892 USA; US FDA, CBER, OTRR, DCTDA,Oncol Branch, Rockville, MD 20852 USA; NCI, DTP, Rockville, MD USA; Parke Davis Pharmaceut, Ann Arbor, MI USA; Natl Univ Singapore, Singapore Genom Programme, Singapore, Singapore; New York Med Coll, Dept Med, Valhalla, NY 10595 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pfizer; National University of Singapore; New York Medical College	Bates, SE (corresponding author), NCI, Med Branch, DCS, MB,NIH, Bldg 10,Room 12N226,9000 Rockville Pike, Bethesda, MD 20892 USA.		Liu, Edison/C-4141-2008; Bates, Susan/AFP-9514-2022	Myers, Timothy Gene/0000-0002-7059-5906; Robey, Rob/0000-0002-0857-3650				BISHOP PC, 1999, SEMINARS BREAST DIS, V2, P200; Blagosklonny MV, 2000, CANCER RES, V60, P3425; BLAGOSKLONNY MV, 2001, CELL CYCLE CHECKPOIN, P52; Bridges AJ, 1996, J MED CHEM, V39, P267, DOI 10.1021/jm9503613; DARZYNKIEWICZ Z, 1995, J CELL BIOCHEM, V58, P151, DOI 10.1002/jcb.240580204; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Fan Zhen, 1998, Current Opinion in Oncology, V10, P67, DOI 10.1097/00001622-199801000-00011; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; Gabrilove J, 1990, Curr Opin Oncol, V2, P163; Gibbs JB, 2000, J CLIN INVEST, V105, P9, DOI 10.1172/JCI9084; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; Klohs Wayne D., 1997, Current Opinion in Oncology, V9, P562, DOI 10.1097/00001622-199711000-00012; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MONKS A, 1991, J NATL CANCER I, V83, P757, DOI 10.1093/jnci/83.11.757; Monks A, 1997, ANTI-CANCER DRUG DES, V12, P533; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pegram MD, 1998, BREAST CANCER RES TR, V52, P65, DOI 10.1023/A:1006111117877; Ritland SR, 2000, CANCER RES, V60, P4678; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; Ross JS, 1999, AM J CLIN PATHOL, V112, pS53; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOULE HD, 1990, CANCER RES, V50, P6075; STINSON SF, 1992, ANTICANCER RES, V12, P1035; Thor AD, 1998, JNCI-J NATL CANCER I, V90, P1346, DOI 10.1093/jnci/90.18.1346; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Weinstein-Oppenheimer CR, 2000, PHARMACOL THERAPEUT, V88, P229, DOI 10.1016/S0163-7258(00)00085-1; Wosikowski K, 1997, JNCI-J NATL CANCER I, V89, P1505, DOI 10.1093/jnci/89.20.1505; Zeng YX, 1996, ONCOGENE, V12, P1557	33	85	97	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2002	21	1					119	127		10.1038/sj.onc.1205028	http://dx.doi.org/10.1038/sj.onc.1205028			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791182				2022-12-17	WOS:000172887800012
J	Rohn, TA; Wagenknecht, B; Roth, W; Naumann, U; Gulbins, E; Krammer, PH; Walczak, H; Weller, M				Rohn, TA; Wagenknecht, B; Roth, W; Naumann, U; Gulbins, E; Krammer, PH; Walczak, H; Weller, M			CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release	ONCOGENE			English	Article						brain; apoptosis; neuroimmunology; cytokines; immunotherapy	MALIGNANT GLIOMA; CD95 LIGAND; LETHAL WEAPON; APO2 LIGAND; IN-VIVO; DEATH; EXPRESSION; CYTOTOXICITY; MODULATION; RECEPTORS	Death ligands such as CD95 ligand (CD95L) or tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand (TRAIL/Apo2L) induce apoptosis in radiochemotherapy-resistant human malignant glioma cell lines. The death-signaling TRAIL receptors 2 (TRAIL-R2/death receptor (DR) 5) and TRAIL-R1/ DR4 were expressed more abundantly than the non-death-inducing (decoy) receptors TRAIL-R3/DcR1 and TRAIL-R4/DcR2 in 12 human glioma cell lines. Four of the 12 cell lines were TRAIL/Apo2L-sensitive in the absence of a protein synthesis inhibitor, cycloheximide (CHX), Three of the 12 cell lines were still TRAIL/ Apo2L-resistant in the presence of CHX, TRAIL-R2 expression predicted sensitivity to apoptosis. Coexposure to TRAIL/Apo2L and cytotoxic drugs such as topotecan, lomustine (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, CCNU) or temozolomide resulted in synergistic killing. Synergistic killing was more often observed in cell lines retaining wild-type p53 activity (U87MG, LN-229) than in p53 mutant cell lines (LN-18, T98G, U373MG). Drug exposure resulted in enhanced TRAIL-R2 expression, but decreased TRAIL-R4 expression in U87MG cells. Ectopic expression of dominant-negative p53(V135A) abrogated the drug-induced changes in TRAIL-R2 and TRAIL-R4 expression, but had no effect on synergy. Thus, neither wildtype p53 function nor changes in TRAIL receptor expression were required for synergy, In contrast, synergy resulted possibly from drug-induced cytochrome c release from mitochondria, serving as an amplifier of the TRAIL/Apo2L-mediated cascade of caspase activation. These data provide novel insights into the role of the TRAIL/Apo2L system in malignant gliomas and illustrate that TRAIL/Apo2L-based immunochemotherapy may be an effective therapeutic strategy for these lethal neoplasms.	Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72076 Tubingen, Germany; Univ Tubingen, Sch Med, Inst Physiol, D-72076 Tubingen, Germany; German Canc Res Ctr, Dept Immunogenet, D-6900 Heidelberg, Germany; German Canc Res Ctr, Dept Apoptosis Regulat, D-6900 Heidelberg, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Weller, M (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.		Walczak, Henning/AAV-2214-2020; Gulbins, Erich/L-6989-2014	Walczak, Henning/0000-0002-6312-4591; Gulbins, Erich/0000-0002-3117-1342; Weller, Michael/0000-0002-1748-174X				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BERENBAUM MC, 1981, ADV CANCER RES, V35, P269, DOI 10.1016/S0065-230X(08)60912-4; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Glaser T, 1999, ONCOGENE, V18, P5044, DOI 10.1038/sj.onc.1202882; GLASER T, 2001, IN PRESS ONCOGENE; Griffith TS, 1999, J IMMUNOL, V162, P2597; Hermisson M, 2000, ONCOGENE, V19, P2338, DOI 10.1038/sj.onc.1203554; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Keane MM, 1999, CANCER RES, V59, P734; Nagane M, 2000, CANCER RES, V60, P847; Naumann U, 1998, ONCOGENE, V17, P1567, DOI 10.1038/sj.onc.1202071; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Roth W, 1999, BIOCHEM BIOPH RES CO, V265, P479, DOI 10.1006/bbrc.1999.1693; Roth W, 1997, CANCER IMMUNOL IMMUN, V44, P55, DOI 10.1007/s002620050355; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Schmidt F, 2001, EUR J PHARMACOL, V412, P21, DOI 10.1016/S0014-2999(00)00923-7; Sheikh MS, 1998, CANCER RES, V58, P1593; VAN MEIR EG, 1994, CANCER RES, V54, P649; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Weller M, 1998, BRAIN PATHOL, V8, P285; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; Weller M, 1998, INT J CANCER, V79, P640; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8	27	85	90	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4128	4137		10.1038/sj.onc.1204534	http://dx.doi.org/10.1038/sj.onc.1204534			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464279				2022-12-17	WOS:000169857200003
J	Shigemitsu, K; Sekido, Y; Usami, N; Mori, S; Sato, M; Horio, Y; Hasegawa, Y; Bader, SA; Gazdar, AF; Minna, JD; Hida, T; Yoshioka, H; Imaizumi, M; Ueda, Y; Takahashi, M; Shimokata, K				Shigemitsu, K; Sekido, Y; Usami, N; Mori, S; Sato, M; Horio, Y; Hasegawa, Y; Bader, SA; Gazdar, AF; Minna, JD; Hida, T; Yoshioka, H; Imaizumi, M; Ueda, Y; Takahashi, M; Shimokata, K			Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion	ONCOGENE			English	Article						beta-catenin; lung cancer; malignant mesothelioma; chromosome 3; homozygous deletion; breakpoint cloning	CELL-LINES; HEPATOCELLULAR CARCINOMAS; GROWTH SUPPRESSION; HUMAN SEMAPHORIN; E-CADHERIN; MUTATIONS; EXPRESSION; ACTIVATION; REGION; CHROMOSOME-3	The beta -catenin gene (CTNNB1) has been shown to be genetically mutated in various human malignancies. To determine whether the beta -catenin gene is responsible for oncogenesis in thoracic malignancies, we searched for the mutation in 166 lung cancers (90 primary tumors and 76 cell lines), one blastoma and 10 malignant mesotheliomas (two primary tumors and eight cell lines). Among the lung cancers, including 43 small cell lung cancers (SCLCs) and 123 non-small cell lung cancers (NSCLCs), we identified four alterations in exon 3, which is the target region of mutation for stabilizing beta -catenin. One primary adenocarcinoma had a somatic mutation from C to G, leading to an amino acid substitution from Ser to Cys at codon 37. Among the cell lines, SCLC NCI-H1092 had a mutation from A to G, leading to an Asp to Cry substitution at codon 6, NSCLC HCC15 had a mutation from C to T, leading to a Ser to Phe substitution at codon 45, and NSCLC NCI-H358 had a mutation from A to G, leading to a Thr to Ala substitution at codon 75. One blastoma also had a somatic mutation from C to C, leading to a Ser to Cys substitution at codon 37. Among the 10 malignant mesotheliomas, we identified a homozygous deletion in the NCI-H28 cell line. Cloning of the rearranged fragment from NCI-H28 indicated that all the exons except exon 1 of the beta -catenin gene are deleted and that the deletion junction is 13 kb downstream from exon 1. Furthermore, Northern blot analysis of 26 lung cancer and eight mesothelioma cell line RNAs detected ubiquitous expression of the beta -catenin messages except NCI-H28, although Western blot analysis showed that relatively less amounts of protein products were expressed in some of lung cancer cell lines, Our findings suggest that the beta -catenin gene is infrequently mutated in lung cancer and that the NCI-H28 homozygous deletion of the beta -catenin gene might indicate the possibility of a new tumor suppressor gene residing in this region at 3p21.3, where various types of human cancers show frequent allelic loss.	Nagoya Univ, Sch Med, Dept Clin Prevent Med, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Thorac Surg, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Internal Med 1, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Pathol 2, Nagoya, Aichi 4668550, Japan; Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; Aichi Canc Ctr, Dept Internal Med, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Nagoya University; Nagoya University; Nagoya University; Nagoya University; Aichi Cancer Center	Sekido, Y (corresponding author), Nagoya Univ, Sch Med, Dept Clin Prevent Med, Nagoya, Aichi 4668550, Japan.		Sekido, Yoshitaka/P-9756-2015; Hasegawa, Yoshinori/I-1277-2012; Sato, MITSUO/I-7280-2014; Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014	Sato, MITSUO/0000-0001-5458-9576; Takahashi, Masahide/0000-0002-2803-2683; Horio, Yoshitsugu/0000-0003-4661-6399; Sekido, Yoshitaka/0000-0002-2428-3848	NATIONAL CANCER INSTITUTE [R01CA071618, P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [CA71618, P50 CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bell DW, 1997, CANCER RES, V57, P4057; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Calvo R, 2000, P NATL ACAD SCI USA, V97, P12776, DOI 10.1073/pnas.97.23.12776; CHENG JQ, 1994, CANCER RES, V54, P5547; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; FLEJTER WL, 1989, GENE CHROMOSOME CANC, V1, P148, DOI 10.1002/gcc.2870010207; Fukuchi T, 1998, CANCER RES, V58, P3526; Gao BN, 2000, J BIOL CHEM, V275, P12237, DOI 10.1074/jbc.275.16.12237; Garcia-Rostan G, 1999, CANCER RES, V59, P1811; GIBAS Z, 1986, CANCER GENET CYTOGEN, V20, P191, DOI 10.1016/0165-4608(86)90074-9; HAGEMEIJER A, 1990, CANCER GENET CYTOGEN, V47, P1, DOI 10.1016/0165-4608(90)90258-C; Hidaka N, 1998, MODERN PATHOL, V11, P1039; Iwao K, 1998, CANCER RES, V58, P1021; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Kase S, 2000, CLIN CANCER RES, V6, P4789; LU YY, 1994, GENE CHROMOSOME CANC, V9, P76, DOI 10.1002/gcc.2870090114; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nawrocki B, 1998, AM J PATHOL, V153, P1521, DOI 10.1016/S0002-9440(10)65740-9; Palacios J, 1998, CANCER RES, V58, P1344; Park WS, 1999, CANCER RES, V59, P4257; POPESCU NC, 1988, CANCER RES, V48, P142; Retera JMAM, 1998, J CLIN PATHOL, V51, P891, DOI 10.1136/jcp.51.12.891; Roche J, 1996, ONCOGENE, V12, P1289; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sambrook J, 1989, MOL CLONING LAB MANU; Sato M, 2000, JPN J CANCER RES, V91, P504, DOI 10.1111/j.1349-7006.2000.tb00974.x; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; SEKIDO Y, 1994, CANCER RES, V54, P4988; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; SEKIDO Y, 1995, CANCER RES, V55, P1227; Sekido Y, 1998, BBA-REV CANCER, V1378, pF21, DOI 10.1016/S0304-419X(98)00010-9; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Smythe WR, 1999, LUNG CANCER-J IASLC, V24, P157, DOI 10.1016/S0169-5002(99)00032-X; Sparks AB, 1998, CANCER RES, V58, P1130; Sunaga N, 2001, GENE CHROMOSOME CANC, V30, P316, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1097>3.0.CO;2-9; TAGUCHI T, 1993, CANCER RES, V53, P4349; TIAINEN M, 1989, BRIT J CANCER, V60, P618, DOI 10.1038/bjc.1989.326; Voeller HJ, 1998, CANCER RES, V58, P2520; Xiang RH, 1996, GENOMICS, V32, P39, DOI 10.1006/geno.1996.0074; YAMAKAWA K, 1993, ONCOGENE, V8, P327; Zhurinsky J, 2000, MOL CELL BIOL, V20, P4238, DOI 10.1128/MCB.20.12.4238-4252.2000	45	85	88	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2001	20	31					4249	4257		10.1038/sj.onc.1204557	http://dx.doi.org/10.1038/sj.onc.1204557			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	452KQ	11464291				2022-12-17	WOS:000169857200015
J	Verrecchia, F; Tacheau, C; Schorpp-Kistner, M; Angel, P; Mauviel, A				Verrecchia, F; Tacheau, C; Schorpp-Kistner, M; Angel, P; Mauviel, A			Induction of the AP-1 members c-Jun and JunB by TGF-beta/Smad suppresses early Smad-driven gene activation	ONCOGENE			English	Article						TGF-zeta; signaling; Smad; AP-1; Jun; gene expression	GROWTH-FACTOR-BETA; TRANSCRIPTIONAL ACTIVATION; COACTIVATOR P300; BINDING SEQUENCE; COL7A1 PROMOTER; DNA-BINDING; FOS; EXPRESSION; COMPLEX; IDENTIFICATION	Smad proteins transduce signals from TGF-beta receptors and regulate transcription of target genes, Among the latter are c-jun and junB, which encode members of the AP-I family of transcription factors. In this study, we have investigated the functional interactions of the Smad and AP-1 transcription factors in the context of Smad-specific gene transactivation in both fibroblasts and keratinocytes. We demonstrate that overexpression of either junB or c-jun prevents TGF-beta- or Smad3-induced transactivation of the Smad-specific promoter construct (SBE)(4)-Lux. Inversely, Smad-driven promoter transactivation by TGF-beta /Smad is significantly enhanced when c-jun expression is abolished in HaCaT keratinocytes, and when junB expression is prevented in fibroblasts, consistent with the cell-type specific induction of jun members by TGF-beta, We also demonstrate that Smad-specific gene transactivation in junB(-/-) mouse embryonic fibroblasts is significantly higher than in embryonic fibroblasts from the control parental mouse line, and that this difference is abolished by rescuing junB expression in junB(-/-) cells. Finally, we have determined that off-DNA interactions between Smad3 and both c-jun and JunB result in the reduction of Smad3/ DNA interactions, From these results, we provide a model in which jun expression in response to the initial Smad cascade represents a negative feed-back mechanism counteracting Smad-driven gene transactivation.	Hop St Louis, INSERM, U532, F-75010 Paris, France; Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, D-69120 Heidelberg, Germany	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Helmholtz Association; German Cancer Research Center (DKFZ)	Mauviel, A (corresponding author), Hop St Louis, Inst Rech Peau, INSERM, U532, Pavillon Bazin,1 Ave Claude Vellefaux, F-75475 Paris 10, France.		Verrecchia, Franck/G-5535-2018; MAUVIEL, Alain/F-6251-2013	Verrecchia, Franck/0000-0003-4920-2554; Mauviel, Alain/0000-0002-0438-2793				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Letterio JJ, 1997, CLIN IMMUNOL IMMUNOP, V84, P244, DOI 10.1006/clin.1997.4409; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Maggirwar SB, 2000, J NEUROCHEM, V74, P527, DOI 10.1046/j.1471-4159.2000.740527.x; MARINKOVICH MP, 1993, DEV DYNAM, V197, P255, DOI 10.1002/aja.1001970404; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Tang WL, 1998, J BIOL CHEM, V273, P5506, DOI 10.1074/jbc.273.10.5506; Verrecchia F, 2000, J BIOL CHEM, V275, P30226, DOI 10.1074/jbc.M005310200; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Wong C, 1999, MOL CELL BIOL, V19, P1821; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	39	85	87	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2001	20	18					2205	2211		10.1038/sj.onc.1204347	http://dx.doi.org/10.1038/sj.onc.1204347			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402315				2022-12-17	WOS:000168404500002
J	Kasten, M; Giordano, A				Kasten, M; Giordano, A			Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity	ONCOGENE			English	Article						Cdk; Ets2; transcription; cell cycle	CYCLIN-DEPENDENT KINASES; CELL-CYCLE; PROSTATE-CANCER; PROTEIN-KINASE; FAMILY; ACTIVATION; EXPRESSION; PISSLRE; GROWTH; DOMAIN	Cdk10 is a Cdc2-related kinase that may play a role in regulating the G2/M phase of the cell cycle. However little is known about the proteins that interact with this putative kinase and contribute to its function in the cell. We report in this study that Cdk10 interacts with the N-terminus of the Ets2 transcription factor, which contains the highly conserved Pointed domain and transactivation domain. The Pointed domain has been implicated in protein-protein interactions and we find that Ets2 requires an intact Pointed domain to bind Cdk10, The Pointed domain of Ets1 is highly similar to Ets2, however Cdk10 does not recognize Ets1 in a two-hybrid assay thereby demonstrating significant binding specificity on the part of Cdk10, We find that Cdk10 binds full length Ets2 in vitro and in vivo and inhibits Ets2 transactivation in mammalian cells.	Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Anat, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Cell Biol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University	Giordano, A (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA.		Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X	NATIONAL CANCER INSTITUTE [T32CA009137] Funding Source: NIH RePORTER; NCI NIH HHS [5 T32 CA 09137] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; BRAMBILLA R, 1994, ONCOGENE, V9, P3037; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; CHUMAKOV AM, 1993, J VIROL, V67, P2421, DOI 10.1128/JVI.67.4.2421-2425.1993; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Dohrmann PR, 1996, MOL CELL BIOL, V16, P1746; GOLEMIS EA, 1997, CURRENT PROTOCOLS MO; GRANA X, 1994, ONCOGENE, V9, P2097; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; LI S, 1995, CANCER RES, V55, P3992; Liu AY, 1997, PROSTATE, V30, P145, DOI 10.1002/(SICI)1097-0045(19970215)30:3<145::AID-PROS1>3.0.CO;2-L; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; MacLachlan TK, 1998, J CELL BIOCHEM, V71, P467, DOI 10.1002/(SICI)1097-4644(19981215)71:4<467::AID-JCB2>3.3.CO;2-7; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Puri PL, 2000, GENE DEV, V14, P574; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; Sementchenko VI, 1998, ONCOGENE, V17, P2883, DOI 10.1038/sj.onc.1202220; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Simpson S, 1997, ONCOGENE, V14, P2149, DOI 10.1038/sj.onc.1201058; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; Watson MA, 1996, BIOTECHNIQUES, V21, P255; WEN SC, 1995, EXP CELL RES, V217, P8, DOI 10.1006/excr.1995.1057; Yang BS, 1996, MOL CELL BIOL, V16, P538	31	85	89	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2001	20	15					1832	1838		10.1038/sj.onc.1204295	http://dx.doi.org/10.1038/sj.onc.1204295			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313931				2022-12-17	WOS:000167908400004
J	Llovera, M; Pichard, C; Bernichtein, S; Jeay, S; Touraine, P; Kelly, PA; Goffin, V				Llovera, M; Pichard, C; Bernichtein, S; Jeay, S; Touraine, P; Kelly, PA; Goffin, V			Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation	ONCOGENE			English	Article						prolactin; prolactin receptor; breast cancer; antagonist; signaling; proliferation	GROWTH-HORMONE RECEPTOR; PROTEIN-KINASE-C; CARCINOMA CELLS; EXPRESSION; BINDING; GENE; INDUCTION; APOPTOSIS; FAMILY; STAT3	The involvement of human prolactin (hPRL) in breast cancer has been recently reconsidered based on its autocrine/paracrine proliferative effect described in human mammary tumor epithelial cells. Therefore, there is growing interest in the development of potent hPRL antagonists that may inhibit this effect. We previously designed hPRL analogs displaying antagonistic properties in a human transcriptional bioassay. We now report that the most potent of those analogs, G129R-hPRL, antagonizes all hPRL-induced effects analysed in various breast cancer cell lines, including cell proliferation. The analog per sc lacks intrinsic agonistic activity on PRL receptor-activated signaling cascades, cell proliferation and apoptosis, indicating that its mode of action only occurs through competitive inhibition of hPRL. We provide some molecular basis of this antagonistic effect by demonstrating that G129R-hPRL competitively inhibits hPRL-activation of the JAK-STAT and MAPK pathways, two signaling cascades involved in the mitogenic effect of hPRL in mammary epithelial cells. This competitive inhibition persists for at least 48 h, as evidenced by long term analysis of STAT5b activation or of progression through cell cycle. These results are the first demonstration at the molecular level that hPRL antagonists interfering with receptor dimerization disrupt signaling events in breast cancer cells, which prevents hPRL-induced cell proliferation.	Fac Med Necker Enfants Malad, INSERM, U344, F-75730 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Goffin, V (corresponding author), Fac Med Necker Enfants Malad, INSERM, U344, 156 Rue Vaugirard, F-75730 Paris 15, France.		Llovera, Marta/AAE-4230-2021; Llovera, Marta/B-5585-2009; GOFFIN, Vincent/G-3322-2013; Kelly, Paul/A-7951-2008	Llovera, Marta/0000-0001-8399-6867; GOFFIN, Vincent/0000-0002-8021-3086; JEAY, SEBASTIEN/0000-0001-7476-3340				BANERJEE R, 1992, MOL CELL ENDOCRINOL, V90, P61, DOI 10.1016/0303-7207(92)90102-C; BenJonathan N, 1996, ENDOCR REV, V17, P639, DOI 10.1210/edrv-17-6-639; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; Canbay E, 1997, BIOCHEM J, V324, P231, DOI 10.1042/bj3240231; Chen WY, 1999, CLIN CANCER RES, V5, P3583; Clevenger CV, 1997, J MAMMARY GLAND BIOL, V2, P59, DOI 10.1023/A:1026325630359; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; Das R, 1996, BREAST CANCER RES TR, V40, P141, DOI 10.1007/BF01806209; Das R, 1996, ONCOGENE, V13, P1139; Das R, 1997, J MAMMARY GLAND BIOL, V2, P29, DOI 10.1023/A:1026369412612; DaSilva L, 1996, MOL CELL ENDOCRINOL, V117, P131, DOI 10.1016/0303-7207(95)03738-1; Dickson C, 2000, ONCOGENE, V19, P1097, DOI 10.1038/sj.onc.1203267; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; FUH G, 1995, J BIOL CHEM, V270, P13133, DOI 10.1074/jbc.270.22.13133; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; GINSBURG E, 1995, CANCER RES, V55, P2591; GOFFIN V, 1994, J BIOL CHEM, V269, P32598; GOFFIN V, 1992, MOL ENDOCRINOL, V6, P1381, DOI 10.1210/me.6.9.1381; Goffin V, 1999, ENDOCRINOLOGY, V140, P3853, DOI 10.1210/en.140.8.3853; Goffin V, 1996, ENDOCR REV, V17, P385, DOI 10.1210/er.17.4.385; Goffin V, 1996, J BIOL CHEM, V271, P16573, DOI 10.1074/jbc.271.28.16573; Goffin V, 1999, MOL CELL ENDOCRINOL, V151, P79, DOI 10.1016/S0303-7207(99)00023-4; GORDON KE, 2000, BREAST CANCER RES, V2, P1; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Hankinson SE, 1999, J NATL CANCER I, V91, P629, DOI 10.1093/jnci/91.7.629; HORWITZ KB, 1985, ENDOCRINOLOGY, V116, P2236, DOI 10.1210/endo-116-6-2236; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; Kinet S, 1999, J BIOL CHEM, V274, P26033, DOI 10.1074/jbc.274.37.26033; Kirken RA, 1997, J BIOL CHEM, V272, P14098, DOI 10.1074/jbc.272.22.14098; Krumenacker JS, 1998, ENDOCRINE, V9, P163, DOI 10.1385/ENDO:9:2:163; Llovera M, 2000, EXP GERONTOL, V35, P41, DOI 10.1016/S0531-5565(99)00078-9; Lou W, 2000, PROSTATE, V42, P239, DOI 10.1002/(SICI)1097-0045(20000215)42:3<239::AID-PROS10>3.0.CO;2-G; Maus MV, 1999, ENDOCRINOLOGY, V140, P5447, DOI 10.1210/en.140.11.5447; Melck D, 2000, ENDOCRINOLOGY, V141, P118, DOI 10.1210/en.141.1.118; Nicholson RI, 1999, ENDOCR-RELAT CANCER, V6, P373, DOI 10.1677/erc.0.0060373; PARIS N, 1990, BIOTECHNOL APPL BIOC, V12, P436; Price DT, 1999, J UROLOGY, V162, P1537, DOI 10.1016/S0022-5347(05)68354-1; Saraste A, 1999, HERZ, V24, P189, DOI 10.1007/BF03044961; Schaber JD, 1998, CANCER RES, V58, P1914; ShawBruha CM, 1997, BREAST CANCER RES TR, V44, P243, DOI 10.1023/A:1005879103367; Touraine P, 1998, J CLIN ENDOCR METAB, V83, P667, DOI 10.1210/jc.83.2.667; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Vomachka AJ, 2000, ONCOGENE, V19, P1077, DOI 10.1038/sj.onc.1203348; Vonderhaar BK, 1998, PHARMACOL THERAPEUT, V79, P169, DOI 10.1016/S0163-7258(98)00017-5; WATERS SB, 1989, MOL CELL ENDOCRINOL, V63, P159, DOI 10.1016/0303-7207(89)90092-0; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; Wennbo H, 2000, ONCOGENE, V19, P1072, DOI 10.1038/sj.onc.1203349; Wennbo H, 1997, J CLIN INVEST, V100, P2744, DOI 10.1172/JCI119820; Wingo PA, 1998, CANCER-AM CANCER SOC, V82, P1197, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1197::AID-CNCR26>3.0.CO;2-0; Zhou JN, 1998, MOL CARCINOGEN, V21, P234, DOI 10.1002/(SICI)1098-2744(199804)21:4<234::AID-MC2>3.0.CO;2-K	54	85	87	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2000	19	41					4695	4705		10.1038/sj.onc.1203846	http://dx.doi.org/10.1038/sj.onc.1203846			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032019				2022-12-17	WOS:000089528800003
J	Zoumpourlis, V; Papassava, P; Linardopoulos, S; Gillespie, D; Balmain, A; Pintzas, A				Zoumpourlis, V; Papassava, P; Linardopoulos, S; Gillespie, D; Balmain, A; Pintzas, A			High levels of phosphorylated c-Jun, Fra-1, Fra-2 and ATF-2 proteins correlate with malignant phenotypes in the multistage mouse skin carcinogenesis model	ONCOGENE			English	Article						jun; fos; ATF-2; mouse skin; AP-1; carcinogenesis	DNA-BINDING ACTIVITY; HA-RAS; CYCLIN D1; V-JUN; TRANSCRIPTIONAL ACTIVATION; CHEMICAL CARCINOGENESIS; CELLULAR-TRANSFORMATION; HETERODIMER FORMATION; ONCOGENE ACTIVATION; IN-VITRO	Analysis of the functions of AP-1 transcription factor in cellular systems has shown its key role as a mediator of oncogenic signals. The employment of suitable animal model systems greatly facilitates the study of changes in the composition and activity of the AP-1 complex. Here, we have analysed the quantitative and qualitative changes of AP-1 at different stages of carcinogenesis in mouse skin cell lines, derived from tumours induced by chemical mutagens. The findings of this study suggest that elevated AP-1 DNA binding and transactivation activity characterize the carcinoma cell lines, most notably the highly malignant spindle carcinomas. In addition, increased amounts and post-translational modifications of c-Jun, Fra-1, Fra-2 and ATF-2 proteins account for a high percentage of the increased AP-1 activity. Remarkably, high levels of phosphorylated ATF-2 protein were detected in malignant cell lines, indicating a novel role of ATF-2 in tumour progression. c-Jun and ATF-2 proteins are phosphorylated by highly active JNK kinases present in tumour cells. Finally, our results indicate distinct functions for different AP-1 components in the promotion and progression of mouse skin tumours.	Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, GR-11635 Athens, Greece; Onyx Pharmaceut, Richmond, CA 94806 USA; CRC Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94143 USA	National Hellenic Research Foundation; Beatson Institute; University of California System; University of California San Francisco	Pintzas, A (corresponding author), Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, 48 Vas Constantinou Ave, GR-11635 Athens, Greece.			Gillespie, David/0000-0002-6338-0544; Linardopoulos, Spiros/0000-0002-6600-400X				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BENBROOK DM, 1990, ONCOGENE, V5, P295; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACK EJ, 1994, ONCOGENE, V9, P2363; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOWDEN GT, 1994, CANCER RES, V54, pS1882; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BUCHMANN A, 1991, CANCER RES, V51, P4097; BURLEY SK, 1994, CURR OPIN STRUC BIOL, V4, P3, DOI 10.1016/S0959-440X(94)90053-1; BURNS PA, 1991, ONCOGENE, V6, P2363; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOMANN FE, 1994, MOL CARCINOGEN, V9, P61, DOI 10.1002/mc.2940090202; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FILMUS J, 1994, ONCOGENE, V9, P3627; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GRUDA MC, 1994, ONCOGENE, V9, P2537; HANKINS WD, 1981, CELL, V26, P91, DOI 10.1016/0092-8674(81)90036-2; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Lallemand D, 1998, EMBO J, V17, P5615, DOI 10.1093/emboj/17.19.5615; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OEHLER T, 1993, ONCOGENE, V8, P1141; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QUINTANILLA M, 1991, CARCINOGENESIS, V12, P1875, DOI 10.1093/carcin/12.10.1875; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STOLER AB, 1993, J CELL BIOL, V122, P1103, DOI 10.1083/jcb.122.5.1103; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Vandel L, 1996, MOL CELL BIOL, V16, P1881; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; YUSPA SH, 1988, ADV CANCER RES, V50, P25, DOI 10.1016/S0065-230X(08)60434-0; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	65	85	92	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2000	19	35					4011	4021		10.1038/sj.onc.1203732	http://dx.doi.org/10.1038/sj.onc.1203732			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962557				2022-12-17	WOS:000088825300006
J	Willers, H; McCarthy, EE; Wu, B; Wunsch, H; Tang, W; Taghian, DG; Xia, F; Powell, SN				Willers, H; McCarthy, EE; Wu, B; Wunsch, H; Tang, W; Taghian, DG; Xia, F; Powell, SN			Dissociation of p53-mediated suppression of homologous recombination from G1/S cell cycle checkpoint control	ONCOGENE			English	Article						p53; homologous recombination; G1/S cell cycle checkpoint; genomic stability	TEMPERATURE-SENSITIVE MUTANT; WILD-TYPE P53; DNA-BINDING; NUCLEAR-LOCALIZATION; GAMMA-IRRADIATION; TERMINAL DOMAIN; MAMMALIAN-CELLS; PROTEIN; EXPRESSION; GROWTH	The tumor suppressor p53 is considered as the guardian of the genome which is activated following genotoxic stress. In many cell types, p53 mediates G1 cell cycle arrest as the predominant cellular response. Inactivation of wild-type p53 leads to loss of G1/S checkpoint control and to genomic instability, including increased spontaneous homologous recombination (HR), To determine whether regulation of the G1/S checkpoint is required for suppression of HR, we assessed recombination events using a plasmid substrate that stably integrated into the genome of p53-null mouse fibroblasts. Exogenous expression of a temperature-sensitive p53 protein (Ala135 to Val), which had lost trans-activation function and could not regulate G1/S transition,when in mutant conformation, reduced HR rates to the same extent as wild-type p53. Furthermore, a p53 construct with an alternatively-spliced carboxy terminus also retained this ability in the absence of both activities, G1/S control and non-sequence specific DNA binding as mediated by the carboxy terminus. Our data dissociate regulation of HR by p53 from its role as a cell cycle checkpoint protein. The results support a model which extends p53's role as a guardian of the genome to include transactivation-independent regulatory functions in DNA repair, replication and recombination.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol,Lab Mol & Cellulare Radiat Biol, Charlestown, MA 02129 USA; Univ Hamburg, Hosp Eppendorf, Dept Radiat Oncol, D-20246 Hamburg, Germany; Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA	Harvard University; Massachusetts General Hospital; University of Hamburg; Eli Lilly	Powell, SN (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Dept Radiat Oncol, Cox 3,100 Blossom St, Boston, MA 02114 USA.		Xia, Fen/G-3708-2013		NATIONAL CANCER INSTITUTE [R01CA058985] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58985] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EYFJORD JE, 1995, CANCER RES, V55, P646; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HAMILTON AA, 1987, MOL CELL BIOL, V7, P1409, DOI 10.1128/MCB.7.4.1409; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HIRANO Y, 1995, ONCOGENE, V10, P1879; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Isaacs JS, 1997, CANCER RES, V57, P2986; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Janus F, 1999, MOL CELL BIOL, V19, P2155; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; Kachnic LA, 1999, J BIOL CHEM, V274, P13111, DOI 10.1074/jbc.274.19.13111; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Leiter LM, 1996, ONCOGENE, V12, P2661; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Martinez JD, 1997, ONCOGENE, V14, P2511, DOI 10.1038/sj.onc.1201095; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; MEYN MS, 1994, INT J RADIAT BIOL, V66, pS141; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLIGAN RC, 1980, SCIENCE, V209, P1422, DOI 10.1126/science.6251549; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; PARDO FS, 1994, RADIAT RES, V140, P180, DOI 10.2307/3578901; POWELL SN, 1995, CANCER RES, V55, P1643; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; Schwartz D, 1997, ONCOGENE, V15, P2597, DOI 10.1038/sj.onc.1201436; SHAULSKY G, 1990, ONCOGENE, V5, P1707; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STEWART N, 1995, ONCOGENE, V10, P109; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Tang W, 1999, CANCER RES, V59, P2562; Wiesmuller L, 1996, J VIROL, V70, P737; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; XIA F, 1994, MOL CELL BIOL, V14, P5850, DOI 10.1128/MCB.14.9.5850; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	53	85	87	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2000	19	5					632	639		10.1038/sj.onc.1203142	http://dx.doi.org/10.1038/sj.onc.1203142			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZU	10698508				2022-12-17	WOS:000085192000005
J	Huntsman, DG; Chin, SF; Muleris, M; Batley, SJ; Collins, VP; Wiedemann, LM; Aparicio, S; Caldas, C				Huntsman, DG; Chin, SF; Muleris, M; Batley, SJ; Collins, VP; Wiedemann, LM; Aparicio, S; Caldas, C			MLL2, the second human homolog of the Drosophila trithorax gene, maps to 19q13.1 and is amplified in solid tumor cell lines	ONCOGENE			English	Article						MLL2; MLL; amplification; tumor; cell lines	BREAKPOINT CLUSTER REGION; ALL-1 GENE; ACUTE-LEUKEMIA; TANDEM DUPLICATION; TRANSLOCATIONS; AMPLIFICATION; EXPRESSION; 11Q23; REARRANGEMENTS; INVOLVEMENT	The Mixed Lineage Leukemia (MLL) gene is commonly involved in translocations in infantile leukemia and is amplified in some cases of adult myeloid leukemia. A homolog of MLL denoted MLL2, which represents the second human homolog of the Drosophila trithorax gene, was characterized by assembling ESTs, the KIAA0304 cDNA clone, RT-PCR fragments and a new clone isolated from a cDNA phage library and compared to the available genomic sequence. The MLL2 gene maps to 19q13.1, a region of frequent rearrangement or amplification in solid tumors. MLL2 consists of an 8.5-9 kb transcript and spans 20 kb of genomic DNA, The predicted MLL2 protein possesses all of the major domains defined in MLL and the two genes have a similar genomic structure. We find that MLL2 is amplified in two of 14 pancreatic carcinoma cell lines and one of five glioblastoma cell lines and is a likely critical gene in 19q13.1 amplifications. It is also a candidate for chromosomal rearrangements involving this chromosome locus, MLL2 is one additional mammalian trithorax-group gene with involvement in human cancer.	Univ Cambridge, Addenbrookes Hosp, CRC Dept Oncol, Cambridge CB2 2XY, England; Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Inst Curie, CNRS, UMR 147, F-75248 Paris, France; Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Div Histopathol, Cambridge CB2 2QQ, England; Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England; Wellcome CRC Inst Canc Res & Dev Biol, Cambridge CB2 1QR, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Cite; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Caldas, C (corresponding author), Univ Cambridge, Addenbrookes Hosp, CRC Dept Oncol, Wellcome Trust MRC Bldg, Cambridge CB2 2XY, England.		Caldas, Carlos/U-7250-2019; Wiedemann, Leanne/E-3316-2010; Caldas, Carlos/A-7543-2008; Huntsman, David/ABE-6082-2020	Caldas, Carlos/0000-0003-3547-1489; chin, suet-feung/0000-0001-5697-1082; Wiedemann, Leanne/0000-0002-0964-4676; Aparicio, Samuel/0000-0002-0487-9599	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allen RJ, 1998, LEUKEMIA, V12, P1119, DOI 10.1038/sj.leu.2401002; Ariyama Y, 1998, GENE CHROMOSOME CANC, V23, P267, DOI 10.1002/(SICI)1098-2264(199811)23:3<267::AID-GCC10>3.3.CO;2-0; BAFFA R, 1995, P NATL ACAD SCI USA, V92, P4922, DOI 10.1073/pnas.92.11.4922; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BREEN TR, 1993, DEVELOPMENT, V117, P119; BREEN TR, 1995, MECH DEVELOP, V52, P89, DOI 10.1016/0925-4773(95)00393-F; Caldas C, 1998, ONCOGENE, V16, P3233, DOI 10.1038/sj.onc.1201873; CALDAS C, 1999, IN PRESS CANC MET RE; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Chernova OB, 1998, ONCOGENE, V17, P2873, DOI 10.1038/sj.onc.1202481; Cui XM, 1998, NAT GENET, V18, P331, DOI 10.1038/ng0498-331; Curtis LJ, 1998, GENOMICS, V53, P42, DOI 10.1006/geno.1998.5405; DJABALI M, 1992, NAT GENET, V2, P112; DOMER PH, 1993, P NATL ACAD SCI USA, V90, P7884, DOI 10.1073/pnas.90.16.7884; Felix CA, 1998, BLOOD, V91, P4451; Ferbus D, 1999, INT J CANCER, V80, P369; FitzGerald KT, 1999, GENOMICS, V59, P187, DOI 10.1006/geno.1999.5860; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; GOULD AP, 1990, NATURE, V348, P308, DOI 10.1038/348308a0; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1994, CANCER RES, V54, P2327; Hoglund M, 1998, GENE CHROMOSOME CANC, V21, P8; Lochner K, 1996, CANCER RES, V56, P2171; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MARSCHALEK R, 1995, BRIT J HAEMATOL, V90, P308, DOI 10.1111/j.1365-2141.1995.tb05151.x; Michaux L, 1998, BLOOD, V92, p78A; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; MULERIS M, 1994, CYTOGENET CELL GENET, V65, P82, DOI 10.1159/000133605; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Nilson I, 1996, BRIT J HAEMATOL, V93, P966, DOI 10.1046/j.1365-2141.1996.d01-1748.x; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; Rasio D, 1996, CANCER RES, V56, P1766; ROWLEY JD, 1993, SEMIN CANCER BIOL, V4, P377; SCHICHMAN SA, 1994, CANCER RES, V54, P4277; SCHICHMAN SA, 1994, P NATL ACAD SCI USA, V91, P6236, DOI 10.1073/pnas.91.13.6236; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; Tanaka K, 1997, BLOOD, V89, P596, DOI 10.1182/blood.V89.2.596; Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.3.CO;2-C; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Wiedemann LM, 1999, BRIT J HAEMATOL, V105, P256, DOI 10.1111/j.1365-2141.1999.01291.x; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	44	85	94	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					7975	7984		10.1038/sj.onc.1203291	http://dx.doi.org/10.1038/sj.onc.1203291			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637508				2022-12-17	WOS:000084634600006
J	Soufir, N; Moles, JP; Vilmer, C; Moch, C; Verola, O; Rivet, J; Tesniere, A; Dubertret, L; Basset-Seguin, N				Soufir, N; Moles, JP; Vilmer, C; Moch, C; Verola, O; Rivet, J; Tesniere, A; Dubertret, L; Basset-Seguin, N			P16UV mutations in human skin epithelial tumors	ONCOGENE			English	Article						INKA-ARF locus; p16 gene; p53 gene; Cdk4 gene; non melanoma skin cancers; tandem mutation	SQUAMOUS-CELL CARCINOMAS; P53 GENE-MUTATIONS; SUPPRESSOR GENE; INK4A LOCUS; ULTRAVIOLET-IRRADIATION; GERMLINE MUTATIONS; HUMAN CANCERS; CYCLE ARREST; CDKN2 GENE; MELANOMA	The p16 gene expresses two alternative transcripts (p16 alpha and p16 beta) involved in tumor suppression via the retinoblastoma (Rb) or p53 pathways. Disruption of these pathways can occur through inactivation of p16 or p53, or activating mutations of cyclin dependant kinase 4 gene (Cdk4). We searched for p16, Cdk4 and p53 gene mutations in 20 squamous cell carcinomas (SSCs), 1 actinic keratosis (AK), and 28 basal cell carcinomas (BCCs), using PCR-SSCP. A deletion and methylation analysis of p16 was also performed. Six different mutations (12%) were detected in exon 2 of p16 (common to p16 alpha and p16 beta), in five out of 21 squamous lesions (24%) (one AK and four SCCs) and one out of 28 BCCs (3.5%), These included four (66%) ultraviolet (UV)-type mutations (two tandems CC : GC to TT : AA transitions and two C : G to T : A transitions at dipyrimidic site) and two transversions, P53 mutations were present in 18 samples (37%), mostly of UV type. Of these, only two (one BCC and one AK) harboured simultaneously mutations of p16, but with no consequence on p16 beta transcript. Our data demonstrate for the first time the presence of p16 UV induced mutations in non melanoma skin cancer, particularly in the most aggressive SCC type, and support that p16 and p53 are involved in two independent pathways in skin carcinogenesis.	Hop St Louis, Inst Rech Peau, INSERM, U312, F-75010 Paris, France; IURC, Lab Dermatol Mol, Montpellier, France; Hop St Louis, Serv Anatomopathol, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Basset-Seguin, N (corresponding author), Hop St Louis, Inst Rech Peau, INSERM, U312, Pavillon Bazin,1 Ave Claude Vellefaux, F-75010 Paris, France.		Molès, Jean-Pierre/M-2286-2017	Molès, Jean-Pierre/0000-0002-6863-6350; Moch, Clara/0000-0002-8674-3440				BASSETSEGUIN N, 1994, J INVEST DERMATOL, V103, pS102, DOI 10.1111/1523-1747.ep12399372; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Chang TG, 1997, BIOCHEM BIOPH RES CO, V230, P85, DOI 10.1006/bbrc.1996.5891; Chaubert P, 1996, MOL CELL PROBE, V10, P467, DOI 10.1006/mcpr.1996.0064; Coleman KG, 1997, J BIOL CHEM, V272, P18869, DOI 10.1074/jbc.272.30.18869; Enders GH, 1996, ONCOGENE, V12, P1239; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GRUIS NA, 1995, AM J PATHOL, V146, P1199; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Healy E, 1996, J INVEST DERMATOL, V107, P318, DOI 10.1111/1523-1747.ep12363118; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Jares P, 1997, ONCOGENE, V15, P1445, DOI 10.1038/sj.onc.1201309; Kubo Y, 1997, BIOCHEM BIOPH RES CO, V232, P38, DOI 10.1006/bbrc.1997.6217; LAMB A, 1994, SCIENCE, V264, P436; Lilischkis R, 1996, INT J CANCER, V66, P249, DOI 10.1002/(SICI)1097-0215(19960410)66:2<249::AID-IJC19>3.0.CO;2-7; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; LIU Q, 1995, ONCOGENE, V10, P1061; LO KW, 1995, CANCER RES, V55, P2039; MAESTRO R, 1995, SCIENCE, V267, P15, DOI 10.1126/science.7809600; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MOLES JP, 1993, ONCOGENE, V8, P583; Muzeau F, 1997, INT J CANCER, V72, P27, DOI 10.1002/(SICI)1097-0215(19970703)72:1<27::AID-IJC3>3.0.CO;2-6; NATARAJ AJ, 1995, PHOTOCHEM PHOTOBIOL, V62, P218, DOI 10.1111/j.1751-1097.1995.tb05262.x; NISHIGORI C, 1994, P NATL ACAD SCI USA, V91, P7189, DOI 10.1073/pnas.91.15.7189; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; POLLOCK PM, 1995, ONCOGENE, V11, P663; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; QUINN AG, 1994, J INVEST DERMATOL, V102, P300, DOI 10.1111/1523-1747.ep12371786; QUINN AG, 1994, CANCER RES, V54, P4756; Rehman I, 1996, ONCOGENE, V12, P2483; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; Wang XQ, 1996, CANCER RES, V56, P2510; WHELAN AJ, 1995, NEW ENGL J MED, V333, P975, DOI 10.1056/NEJM199510123331505; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yang R, 1996, BIOCHEM BIOPH RES CO, V218, P254, DOI 10.1006/bbrc.1996.0045; Yarbrough WG, 1996, J NATL CANCER I, V88, P1489, DOI 10.1093/jnci/88.20.1489; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	48	85	87	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5477	5481		10.1038/sj.onc.1202915	http://dx.doi.org/10.1038/sj.onc.1202915			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498902				2022-12-17	WOS:000082718600013
J	Kodama, A; Takaishi, K; Nakano, K; Nishioka, H; Takai, Y				Kodama, A; Takaishi, K; Nakano, K; Nishioka, H; Takai, Y			Involvement of Cdc42 small G protein in cell-cell adhesion, migration and morphology of MDCK cells	ONCOGENE			English	Article						Cdc42Hs; G25K; cadherin; cell adhesion; cell migration; cell morphology	FILAMENT-BINDING PROTEIN; RAC1 SMALL GTPASES; ADHERENS-TYPE JUNCTIONS; FOCAL ADHESIONS; TIGHT JUNCTIONS; ACTIN-CYTOSKELETON; MOLECULAR CHARACTERIZATION; CA2+-DEPENDENT EXOCYTOSIS; SACCHAROMYCES-CEREVISIAE; CYTOPLASMIC DOMAIN	The Rho small G protein family consists of the Rho, Rac, and Cdc42 subfamilies and regulates various cell functions through reorganization of the actin cytoskeleton. We previously showed that the Rho subfamily regulates the formation of stress fibers and focal adhesions whereas the Rac subfamily regulates the E-cadherin-based cell-cell adhesion in MDCK cells, We studied here tbe function of the Cdc42 subfamily, consisting of two members, Cdc42Hs and G25k, in cell adhesion, migration, and morphology of MDCK cells. For this purpose, we made and used MDCK cell lines stably expressing each of dominant active mutants of Cdc42Hs (sMDCK-Cdc42HsDA)and G25K (sMDCK-G25KDA). Actin filaments at the cell-cell adhesion sites increased in both sMDCK-Cdc42HsDA and -G25KDA cells. Both E-cadherin and beta-catenin, adherens junctional proteins, at the cell-cell adhesion sites also increased in both sMDCK-Cdc42HsDA and -G25KDA cells. Electron microscopic analysis revealed that sMDCK-Cdc42NsDA cells tightly contacted with each other throughout the lateral membranes. Moreover, both the HGF- and TPA-induced disruption of the cadherin-based cell-cell adhesion and the subsequent cell migration were inhibited in both sMDCK-Cdc42HsDA and -G25KDA cells. Go-expression of the dominant negative mutant of Rad, a member of the Rac subfamily, with the dominant active mutant of Cdc42Hs did not inhibit the increased accumulation of actin filaments at the cell-cell adhesion sites. These results suggest that the Cdc42 subfamily is involved in the cadherin-based cell-cell adhesion in a manner independent of the Rac subfamily. Furthermore, the cells were frequently enveloped by the large multinuclear cells in both sMDCK-Gdc42HsDA and -G25KDA cells. Video microscopic analysis revealed that the cells were engulfed by the large cells during cytokinesis.	Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project,Nishi Ku, Kobe, Hyogo 6512241, Japan	Osaka University; Japan Science & Technology Agency (JST)	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; ANDERSON JM, 1995, AM J PHYSIOL, V269, P467; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CITI S, 1988, NATURE, V333, P272, DOI 10.1038/333272a0; DRECHSEL DN, 1996, CURR BIOL, V7, P12; Dutartre H, 1996, J CELL SCI, V109, P367; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GEIGER B, 1991, CELL MOTIL CYTOSKEL, V20, P1, DOI 10.1002/cm.970200102; GUMBINER BM, 1993, J CELL BIOL, V123, P1631, DOI 10.1083/jcb.123.6.1631; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Imamura H, 1998, MOL BIOL CELL, V9, P2561, DOI 10.1091/mbc.9.9.2561; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; JOCKUSCH BM, 1995, REV CELL DEV BIOL, V11, P379; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Keon BH, 1996, J CELL BIOL, V134, P1003, DOI 10.1083/jcb.134.4.1003; Komuro R, 1996, GENES CELLS, V1, P943, DOI 10.1046/j.1365-2443.1996.760276.x; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; Ohtsuka T, 1998, J CELL BIOL, V143, P1227, DOI 10.1083/jcb.143.5.1227; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PEYRIERAS N, 1985, P NATL ACAD SCI USA, V82, P8067, DOI 10.1073/pnas.82.23.8067; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schneeberger EE, 1992, AM J PHYSIOL, V262, P647; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Stoffler HE, 1998, J CELL SCI, V111, P2779; STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81, DOI 10.1016/0304-419X(91)90008-9; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, ONCOGENE, V11, P39; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VESTWEBER D, 1984, CELL DIFFER DEV, V15, P269, DOI 10.1016/0045-6039(84)90084-8; WILKINS JA, 1986, J CELL BIOL, V103, P1483, DOI 10.1083/jcb.103.4.1483; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; ZAHRAOUI A, 1994, J CELL BIOL, V124, P101, DOI 10.1083/jcb.124.1.101; ZHONG Y, 1993, J CELL BIOL, V120, P477, DOI 10.1083/jcb.120.2.477	64	85	85	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	1999	18	27					3996	4006		10.1038/sj.onc.1202773	http://dx.doi.org/10.1038/sj.onc.1202773			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435623				2022-12-17	WOS:000081327800010
J	Yue, JB; Frey, RS; Mulder, KM				Yue, JB; Frey, RS; Mulder, KM			Cross-talk between the Smad1 and Ras/MEK signaling pathways for TGF beta	ONCOGENE			English	Article						Ras/MEK; TGF beta; Smad1	GROWTH-FACTOR-BETA; FAMILY MEDIATOR SMAD1; BREAST-CANCER CELLS; EPITHELIAL-CELLS; PROTEIN; KINASE; MAD; ACTIVATION; PHOSPHORYLATION; BMP	Our previous data demonstrated that Ras activation was necessary and sufficient for transforming growth factor-p (TGF beta)-mediated Erk1 activation, and,vas required for TGF beta up-regulation of the Cdk inhibitors (CKI's) p27(Kip1) and p21(Cip1) (KM Mulder and SL Morris, J, Biol, Chem., 267, 5029-5031, 1992; MT Hartsough and KM Mulder, J, Biol, Chem., 270, 7117-7124, 1995; MT Hartsough ef nl,, J, Biol, Chem., 271, 22368-22375, 1996 and J Yue et al., Oncogene, 17, 47-55, 1998), Here we examined the role of Res in TGF beta-mediated effects on a rat homolog of Smad1 (termed RSmad1), We demonstrate that both TGF beta and bone morphogenetic protein (BMP) can induce endogenous Smad1 phosphorylation in intestinal epithelial cells (IECs), The combination of transient expression of RSmad1 and TGF beta treatment had an additive effect on induction of the TGF beta-responsive reporter 3TP-lux, Either inactivation of Ras by stable, inducible expression of a dominant-negative mutant of Ras (RasN17) or addition of MAP and ERK kinase (MEK) inhibitor PD98059 to cells significantly decreased the ability of both TGF beta and BMP to induce phosphorylation of endogenous Smad1 in IECs, Moreover, either inactivation of Ras or addition of PD98059 to IEC 4-1 cells inhibited the ability of RSmad1 to regulate 3TP luciferase activity in both the presence and absence of TGF beta, Collectively, our data indicate that TGF beta can regulate RSmad1 function in epithelial cells, and that the Ras/MEK pathway is partially required for TGF beta-mediated regulation of RSmad1.	Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Mulder, KM (corresponding author), Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA.		Yue, Jianbo/AAC-4588-2019; Yue, Jianbo/C-4463-2009; Yue, Jianbo/K-8002-2015	Yue, Jianbo/0000-0001-6384-5447	NCI NIH HHS [CA51425, CA68444, CA54816] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068444, R01CA051425, R01CA054816] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; CHEN Y, 1997, P NATL ACAD SCI USA, V94, P12939; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; Frey RS, 1997, CANCER LETT, V117, P41, DOI 10.1016/S0304-3835(97)00211-5; Frey RS, 1997, CANCER RES, V57, P628; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MULDER KM, 1993, J CELL PHYSIOL, V154, P162, DOI 10.1002/jcp.1041540120; MULDER KM, 1992, J BIOL CHEM, V267, P5029; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; RAFTERY LA, 1995, GENETICS, V139, P241; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; Xu RH, 1996, P NATL ACAD SCI USA, V93, P834, DOI 10.1073/pnas.93.2.834; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; YUE J, 1999, IN PRESS J CELL PHYS; Yue JB, 1998, ONCOGENE, V17, P47, DOI 10.1038/sj.onc.1201903	29	85	92	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					2033	2037		10.1038/sj.onc.1202521	http://dx.doi.org/10.1038/sj.onc.1202521			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208426	Bronze			2022-12-17	WOS:000079191300014
J	Krynska, B; Otte, J; Franks, R; Khalili, K; Croul, S				Krynska, B; Otte, J; Franks, R; Khalili, K; Croul, S			Human ubiquitous JCV(CY) T-antigen gene induces brain tumors in experimental animals	ONCOGENE			English	Article						human virus; brain tumors; transgenic mice	PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; JC VIRUS-DNA; HUMAN NEUROTROPIC POLYOMAVIRUS; HUMAN PAPOVAVIRUS JC; TRANSGENIC MICE; EARLY PROTEIN; BK-VIRUS; TISSUE; URINE; EXPRESSION	JCV is a papovavirus which is widespread in the human population. The prototype Mad-1 variant of JCV induces a fatal demyelinating disease of the central nervous system (CNS) called Progressive Multifocal Leukoencephalopathy (PML) in immunosuppressed individuals. The unique tropism of JCV (Mad-l) to the CNS is attributed to the tissue-specific regulation of the viral early promoter which is responsible for the production of the viral regulatory protein, T-antigen, The archetype form of this virus, JCV(CY), which has been repeatedly isolated from the urine of PML and non-PML individuals, is distinct from JCV(Mad-1) in the structural organization of the regulatory sequence. To characterize the tissue specific expression of JCV(CY) and to investigate its potential in inducing disease, transgenic mice containing the early region of JCV(CY) were generated. Some of these mice between 9-13 months of age exhibited signs of illness as manifested by paralysis of rear limbs, hunched posture, and poor grooming. Neuropathological examination indicated no sign of hypomyelination of the brain, but surprisingly, revealed the presence of primitive tumors originating from the cerebellum and the surrounding brain stem. The tumor masses also infiltrated the surrounding tissue. Results from RNA and protein studies revealed a high level of T-antigen mRNA expression in hindbrains of clinically normal and affected transgenic mice. However, higher levels of T-antigen RNA and protein were detected in brains of the animals exhibiting severe illness. The close resemblance of JCV(CY) induced tumor in transgenic mice to the human medulloblastoma/primitive neuroectodermal tumor (PNETs) in location, histologic appearance, and expression of marker proteins strongly suggests the utility of this novel animal model for the study of human brain tumors.	Allegheny Univ Hlth Sci, Ctr Neurovirol & Neurooncol, Philadelphia, PA 19102 USA; Univ Illinois, Coll Med, Dept Genet, Chicago, IL 60612 USA; Allegheny Univ Hlth Sci, Dept Pathol & Lab Med, Philadelphia, PA 19102 USA	Drexel University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Drexel University	Khalili, K (corresponding author), Allegheny Univ Hlth Sci, Ctr Neurovirol & Neurooncol, Broad & Vine,MS 406, Philadelphia, PA 19102 USA.			Croul, Sidney/0000-0002-2224-5485				ARTHUR RR, 1989, PROG MED VIROL, V36, P42; ARTHUR RR, 1989, J CLIN MICROBIOL, V27, P1174, DOI 10.1128/JCM.27.6.1174-1179.1989; ASTROM KE, 1958, BRAIN, V81, P93, DOI 10.1093/brain/81.1.93; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; CASTAIGNE P, 1974, REV NEUROL-FRANCE, V130, P379; COLEMAN DV, 1980, J INFECT DIS, V142, P1, DOI 10.1093/infdis/142.1.1; DORRIES K, 1994, VIROLOGY, V198, P59, DOI 10.1006/viro.1994.1008; EGAN JD, 1980, TRANSPLANTATION, V29, P84, DOI 10.1097/00007890-198001000-00021; FEIGENBAUM L, 1992, J VIROL, V66, P1176, DOI 10.1128/JVI.66.2.1176-1182.1992; Franks RR, 1996, ONCOGENE, V12, P2573; FRIDQUE RJ, 1992, MOL NEUROVIROLOGY, P25; FRISQUE RJ, 1980, J VIROL, V35, P265, DOI 10.1128/JVI.35.1.265-269.1980; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; FUNG KM, 1995, J NEUROPATH EXP NEUR, V54, P285, DOI 10.1097/00005072-199505000-00001; GARDNER SD, 1984, J CLIN PATHOL, V37, P578, DOI 10.1136/jcp.37.5.578; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; HO K, 1980, ACTA NEUROPATHOL, V52, P81, DOI 10.1007/BF00687233; ISHAQ M, 1994, P NATL ACAD SCI USA, V91, P8283, DOI 10.1073/pnas.91.17.8283; Krynska B, 1997, J CELL BIOCHEM, V67, P223, DOI 10.1002/(SICI)1097-4644(19971101)67:2<223::AID-JCB7>3.0.CO;2-Z; LIBERSKI PP, 1982, NEUROPATOL POL, V20, P3; LOEBER G, 1988, J VIROL, V62, P1730, DOI 10.1128/JVI.62.5.1730-1735.1988; Matsushima T, 1997, NEUROLOGY, V48, P279, DOI 10.1212/WNL.48.1.279; MYERS C, 1989, J VIROL, V63, P4445, DOI 10.1128/JVI.63.10.4445-4449.1989; OHASHI T, 1978, J NEUROPATH EXP NEUR, V37, P667, DOI 10.1097/00005072-197809000-00301; PADGETT BL, 1971, LANCET, V1, P1257; RAJ GV, 1995, INT J ONCOL, V7, P801; RAJ GV, 1995, VIROLOGY, V213, P283, DOI 10.1006/viro.1995.0001; Rencic A, 1996, P NATL ACAD SCI USA, V93, P7352, DOI 10.1073/pnas.93.14.7352; RHEIN GMZ, 1965, SCIENCE, V148, P1477, DOI 10.1126/science.148.3676.1477; SIMA AAF, 1983, ANN NEUROL, V14, P183, DOI 10.1002/ana.410140205; SMALL JA, 1986, CELL, V46, P13, DOI 10.1016/0092-8674(86)90855-X; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; SURI C, 1993, J NEUROSCI, V13, P1280; TORNATORE C, 1992, ANN NEUROL, V31, P454, DOI 10.1002/ana.410310426; Vago L, 1996, J ACQ IMMUN DEF SYND, V12, P139, DOI 10.1097/00042560-199606010-00006; VARAKIS J, 1978, CANCER RES, V38, P1718; WALKER DL, 1973, SCIENCE, V181, P674, DOI 10.1126/science.181.4100.674; WEINER LP, 1972, NEW ENGL J MED, V286, P385, DOI 10.1056/NEJM197202242860801; WHITE FA, 1992, J VIROL, V66, P5726, DOI 10.1128/JVI.66.10.5726-5734.1992; YOGO Y, 1991, J VIROL, V65, P2422, DOI 10.1128/JVI.65.5.2422-2428.1991; ZURHEIN GM, 1983, POLYOMAVIRUSES HUMAN, P205; ZURHEIN GM, 1987, CANC CAMPAIGN EXPT N, V10, P19; ZURHEIN GM, 1975, P 7 INT C NEUR, V1, P479	43	85	89	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					39	46		10.1038/sj.onc.1202278	http://dx.doi.org/10.1038/sj.onc.1202278			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926918	Bronze			2022-12-17	WOS:000078166000005
J	McKay, BC; Ljungman, M; Rainbow, AJ				McKay, BC; Ljungman, M; Rainbow, AJ			Persistent DNA damage induced by ultraviolet light inhibits p21(waf1) and bax expression: implications for DNA repair, UV sensitivity and the induction of apoptosis	ONCOGENE			English	Article						apoptosis; DNA repair; E2F-1; E2F-4; viral tumour antigens; p21(waf1)	TRANSCRIPTION-COUPLED REPAIR; CYCLIN-DEPENDENT KINASES; LI-FRAUMENI SYNDROME; PIGMENTOSUM GROUP-C; LARGE T-ANTIGEN; CELL-CYCLE; XERODERMA-PIGMENTOSUM; EXCISION-REPAIR; G(1) ARREST; P53-DEPENDENT APOPTOSIS	Ultraviolet light (UV) induced DNA lesions efficiently block transcript elongation and induce the p53 response. Although p53 contributes to transcriptional activation of the p21(WAF1) and bax genes, accumulation of these proteins requires that these genes are free of UV induced pyrimidine dimers. We assessed the level of expression of p53 and the p53 regulated p21(WAF1) and bax gene products in normal diploid fibroblasts (NDF) and several nucleotide excision repair deficient fibroblasts following UV-irradiation. At low UV fluences, increased expression of p53, p21(WAF1) and bax was only observed in fibroblasts deficient in transcription coupled repair (TCR). Whereas p53 protein levels increased in all cell types at high UV fluences, p21(WAF1) levels initially decreased and then recovered in a manner dependent on TCR. At later times, expression of p21(WAF1) and bax was only elevated in TCR-proficient cells. The lack of TCR strongly correlated with an enhanced induction of apoptosis. Furthermore, we assessed the effect of modulation of the p53/p21(WAF1)/pRb pathway on clonogenic survival following UV irradiation. Expression of E2F-1, E2F-4, and the large tumour antigens of SV40 and Polyomavirus conferred UV sensitivity to NDF whereas p21(WAF1) protected cells against UV treatment. We propose that the fluence dependent attenuation of protective functions of p53 by blockage of transcription favours apoptosis following UV exposure.	McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada; Univ Michigan, Ctr Comprehens Canc, Div Canc Biol, Dept Radiat Oncol, Ann Arbor, MI 48109 USA	McMaster University; University of Michigan System; University of Michigan	Rainbow, AJ (corresponding author), McMaster Univ, Dept Biol Life Sci, Bldg 218A,1280 Main St W, Hamilton, ON L8S 4K1, Canada.		McKay, Bruce C/I-4081-2013	McKay, Bruce C/0000-0002-7921-1331				Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CARREAU M, 1992, MUTAT RES, V274, P57, DOI 10.1016/0921-8777(92)90043-3; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; deLaat A, 1996, PHOTOCHEM PHOTOBIOL, V63, P492; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Doherty J, 1997, ONCOGENE, V14, P1923, DOI 10.1038/sj.onc.1201025; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; EASTHAM JA, 1995, CANCER RES, V55, P5151; EVANS MK, 1993, J BIOL CHEM, V268, P4839; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; Gluzman Y., 1982, EUKARYOTIC VIRAL VEC, P187; GomezManzano C, 1997, J NATL CANCER I, V89, P1036, DOI 10.1093/jnci/89.14.1036; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GRAHAM F, 1991, GENE TRANSFER EXPRES, V7; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, ONCOGENE, V10, P1563; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IMRAY P, 1983, MUTAT RES, V112, P301, DOI 10.1016/0167-8817(83)90005-6; KARENTZ D, 1986, MUTAT RES, V165, P165, DOI 10.1016/0167-8817(86)90051-9; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN WK, 1994, MUTAT RES, V314, P67, DOI 10.1016/0921-8777(94)90062-0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Ljungman M, 1996, ONCOGENE, V13, P823; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu X, 1996, ONCOGENE, V13, P413; Luna RMDO, 1996, GENOMICS, V33, P352, DOI 10.1006/geno.1996.0210; MASSIE B, 1986, MOL CELL BIOL, V6, P2872, DOI 10.1128/MCB.6.8.2872; MAYNE LV, 1982, CANCER RES, V42, P1473; McDonald E, 1996, CANCER RES, V56, P2250; McKay BC, 1997, PHOTOCHEM PHOTOBIOL, V66, P659, DOI 10.1111/j.1751-1097.1997.tb03203.x; McKay BC, 1997, CARCINOGENESIS, V18, P245, DOI 10.1093/carcin/18.2.245; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Mirzayans R, 1996, CARCINOGENESIS, V17, P691, DOI 10.1093/carcin/17.4.691; MIYASHITA T, 1995, CELL, V80, P293; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MORSY MA, 1993, J CLIN INVEST, V92, P1580, DOI 10.1172/JCI116739; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; Reinke V, 1997, RADIAT RES, V148, P115, DOI 10.2307/3579567; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SAUERBIER W, 1978, ANNU REV GENET, V12, P329, DOI 10.1146/annurev.ge.12.120178.001553; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SMITH ML, 1995, ONCOGENE, V10, P1053; Tolbert DM, 1996, CANCER RES, V56, P3324; Tu YQ, 1997, J BIOL CHEM, V272, P20747, DOI 10.1074/jbc.272.33.20747; VANHOFFEN A, 1995, EMBO J, V14, P360, DOI 10.1002/j.1460-2075.1995.tb07010.x; vanLaar T, 1995, BIOCHEM BIOPH RES CO, V217, P769, DOI 10.1006/bbrc.1995.2839; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Weissinger EM, 1997, MOL CELL BIOL, V17, P3229, DOI 10.1128/MCB.17.6.3229; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; ZEIGLER A, 1994, NATURE, V372, P773	73	85	87	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					545	555		10.1038/sj.onc.1201963	http://dx.doi.org/10.1038/sj.onc.1201963			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704920				2022-12-17	WOS:000075195300002
J	Asakura, T; Sasaki, T; Nagano, F; Satoh, A; Obaishi, H; Nishioka, H; Imamura, H; Hotta, K; Tanaka, K; Nakanishi, H; Takai, Y				Asakura, T; Sasaki, T; Nagano, F; Satoh, A; Obaishi, H; Nishioka, H; Imamura, H; Hotta, K; Tanaka, K; Nakanishi, H; Takai, Y			Isolation and characterization of a novel actin filament-binding protein from Saccharomyces cerevisiae	ONCOGENE			English	Article						F-actin; F-actin-binding protein; yeast; ABP140	YEAST SACCHAROMYCES; MEMBRANE INTERACTIONS; CELL-ADHESION; BUD FORMATION; F-ACTIN; CYTOSKELETON; RHO; GTP; MORPHOGENESIS; GENE	We purified a novel actin filament (F-actin)-binding protein from the soluble fraction of Saccharomyces cerevisiae by successive column chromatographies by use of the I-125-labeled F-actin blot overlay method. The purified protein showed a minimum M-r of about 140 kDa on SDS-polyacrylamide gel electrophoresis and we named it ABP140. A search with the partial amino acid sequences of ABP140 against the Saccharomyces Genome Database revealed that the open reading frame of the ABP140 gene (ABP140) corresponded to YOR239W fused with YOR240W by the +1 translational frame shift. The encoded protein consisted of 628 amino acids with a calculated M-r of 71,484. The recombinant protein interacted with F-actin and showed the activity to crosslink F-actin into a bundle. Indirect immunofluorescence study demonstrated that ABP140 was colocalized with both cortical actin patches and cytoplasmic actin cables in intact cells. However, elimination of ABP140 by gene disruption did not show a deleterious effect on cell growth or affect the organization of F-actin. These results indicate that ABP140 is not required for cell growth but may be involved in the reorganization of F-actin in the budding yeast.	Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 565, Japan; JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project,Nishi Ku, Kobe, Hyogo 65122, Japan	Osaka University; Japan Science & Technology Agency (JST)	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 565, Japan.			Nakanishi, Hiroyuki/0000-0002-9765-0266				ADAMS AEM, 1989, SCIENCE, V243, P231, DOI 10.1126/science.2643162; ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; AMATRUDA JF, 1992, J CELL BIOL, V119, P1151, DOI 10.1083/jcb.119.5.1151; BELCOURT MF, 1990, CELL, V62, P339, DOI 10.1016/0092-8674(90)90371-K; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURRIDGE K, 1981, NATURE, V294, P565, DOI 10.1038/294565a0; CHIA CP, 1991, CELL MOTIL CYTOSKEL, V18, P164, DOI 10.1002/cm.970180303; COOPER JA, 1982, METHOD ENZYMOL, V85, P182; Cowin P, 1996, CURR OPIN CELL BIOL, V8, P56, DOI 10.1016/S0955-0674(96)80049-4; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gips Sanford J., 1994, Seminars in Cell Biology, V5, P201, DOI 10.1006/scel.1994.1025; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; IMAZUMI K, 1994, BIOCHEM BIOPH RES CO, V205, P1409, DOI 10.1006/bbrc.1994.2822; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; Kato M, 1996, J BIOL CHEM, V271, P31775, DOI 10.1074/jbc.271.50.31775; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; Madden K, 1992, Trends Cell Biol, V2, P22, DOI 10.1016/0962-8924(92)90140-I; MASUDA T, 1994, J BIOL CHEM, V269, P19713; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; POLLARD TD, 1982, METHOD ENZYMOL, V85, P211; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; SHEMATEK EM, 1980, J BIOL CHEM, V255, P895; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, ONCOGENE, V11, P39; TAKAISHI K, 1997, IN PRESS J CELL BIOL; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; Vandekerckhove J, 1990, CURR OPIN CELL BIOL, V2, P41, DOI 10.1016/S0955-0674(05)80029-8; WELCH MD, 1994, CURR OPIN CELL BIOL, V6, P110, DOI 10.1016/0955-0674(94)90124-4; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; Zahner JE, 1996, MOL CELL BIOL, V16, P1857	50	85	92	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	1998	16	1					121	130		10.1038/sj.onc.1201487	http://dx.doi.org/10.1038/sj.onc.1201487			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YP056	9467951				2022-12-17	WOS:000071236800015
J	CherbonnelLasserre, C; Gauny, S; Kronenberg, A				CherbonnelLasserre, C; Gauny, S; Kronenberg, A			Suppression of apoptosis by Bcl-2 or Bcl-x(L) promotes susceptibility to mutagenesis	ONCOGENE			English	Article						Bcl-2; Bcl-x(L); apoptosis; mutagenesis; ionizing radiation	PROGRAMMED CELL-DEATH; DIPLOID HUMAN-LYMPHOBLASTS; DNA FRAGMENTATION; INDUCED MUTATION; HPRT LOCUS; P53 STATUS; BAX GENE; B-CELLS; IN-VIVO; PROTEIN	Bcl-2 appears to contribute to neoplasia primarily by promoting cell survival, rather than by stimulating cellular proliferation. Bcl-2, and the related protein Bcl-x(L) each suppress apoptosis induced by a wide variety of stimuli in many different cell types. Here we report that suppression of apoptosis by Bcl-2 or Bcl-x(L) markedly elevates the levels of radiation-induced mutations. This enhanced mutagenesis is the result of an increase in mutation frequency (mutations per survivor) together with a moderate increase in viability. Ectopic expression of either Bcl-2 or Bcl-x(L) enhances radiation mutagenesis in cells with wtp53. Surprisingly, we found that ectopic expression of Bcl-x(L) also promotes mutagenesis in p53(-) cells. These results support the hypothesis that apoptosis plays a crucial role in maintaining genomic integrity by selectively eliminating highly mutated cells from the population.	UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DIV LIFE SCI, BERKELEY, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley					NATIONAL CANCER INSTITUTE [R01CA062364] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-62364] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMUNDSON SA, 1992, MUTAT RES, V267, P89, DOI 10.1016/0027-5107(92)90113-G; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; CHEN G, 1995, EXP CELL RES, V221, P55, DOI 10.1006/excr.1995.1351; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DOLE MG, 1995, CANCER RES, V55, P2576; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FUKUNAGAJOHNSON N, 1995, CARCINOGENESIS, V16, P1761, DOI 10.1093/carcin/16.8.1761; FURTH EE, 1981, ANAL BIOCHEM, V110, P1, DOI 10.1016/0003-2697(81)90103-2; Gauthier ER, 1996, CANCER RES, V56, P1451; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; Han ZY, 1996, CANCER RES, V56, P1621; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HAVRE PA, 1995, CANCER RES, V55, P4420; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KAN ZY, 1995, MOL CELL BIOL, V15, P5849; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; KRONENBERG A, 1989, MUTAT RES, V211, P215, DOI 10.1016/0027-5107(89)90004-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBER HL, 1982, MUTAT RES, V94, P467, DOI 10.1016/0027-5107(82)90308-6; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1992, CANCER RES, V52, P5407; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NELSON SL, 1995, RADIAT RES, V141, P2, DOI 10.2307/3579083; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PHILLIPS EN, 1995, RADIAT RES, V143, P255, DOI 10.2307/3579211; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1994, COLD SPRING HARB SYM, V59, P403, DOI 10.1101/SQB.1994.059.01.045; XIA F, 1994, MOL CELL BIOL, V14, P5850, DOI 10.1128/MCB.14.9.5850; XIA F, 1995, CANCER RES, V55, P12; YANDELL DW, 1990, MUTAT RES, V229, P89, DOI 10.1016/0027-5107(90)90011-R; Yin DX, 1996, P NATL ACAD SCI USA, V93, P3394, DOI 10.1073/pnas.93.8.3394; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JL, 1995, CARCINOGENESIS, V16, P2295, DOI 10.1093/carcin/16.10.2295; ZHAN QM, 1994, ONCOGENE, V9, P3743	46	85	86	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1489	1497						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875987				2022-12-17	WOS:A1996VL38400014
J	Jannot, CB; Beerli, RR; Mason, S; Gullick, WJ; Hynes, NE				Jannot, CB; Beerli, RR; Mason, S; Gullick, WJ; Hynes, NE			Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells	ONCOGENE			English	Article						ErbB receptor tyrosine kinases; single-chain antibody	HUMAN-BREAST-CANCER; NEU DIFFERENTIATION FACTOR; FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; PROTEINS; ERBB-2; HEREGULIN; SH2; DOMAINS; P185NEU	A gene encoding a single-chain antibody (scFv) which specifically binds the epidermal growth factor receptor (EGFR) has been constructed from hybridoma cells producing the R1 monoclonal antibody. The gene, designated scFv-R1R, was introduced into EGFR transformed NIH3T3 cells via retroviral infection. scFv-R1R was directed to the lumen of the endoplasmic reticulum (ER) where it bound the extracellular domain of the receptor inhibiting its appearance on the plasma membrane. In these cells, EGF induced tyrosine phosphorylation of the EGFR and several substrates was greatly reduced. Furthermore, intracellular retention of EGFR caused a partial inhibition in the transformed growth of the cells. Intracellular expression of receptor tyrosine kinase directed scFvs is a novel approach for affecting tumor cell growth. We have recently shown that scFv-5R directed to ErbB2, another member of the ErbB family, blocks the anchorage independent growth of ErbB2 transformed cells. In order to examine the effects of scFv-R1R and scFv-5R on the long-term growth of tumor cells overexpressing either EGFR or ErbB2, retroviruses encoding the two scFvs were used to infect various human tumor cell lines. Intracellular expression of the scFvs resulted in a marked inhibition of stable colony formation in some of the cell lines. In general, inhibition was observed when overexpressed receptor was targeted. However, in some cases expression of both scFvs was incompatible with long term cell growth suggesting that heterodimers of ErbB2 and EGFR are essential for the growth of some human tumor cell lines.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND; HAMMERSMITH HOSP,IMPERIAL CANC RES FUND,MOL ONCOL UNIT,LONDON W12 0NN,ENGLAND	Friedrich Miescher Institute for Biomedical Research; Cancer Research UK; Imperial College London								BARRETTLEE P, 1990, BRIT J CANCER, V61, P612, DOI 10.1038/bjc.1990.136; BEERLI RR, 1994, BIOCHEM BIOPH RES CO, V204, P666, DOI 10.1006/bbrc.1994.2511; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BEERLI RR, 1996, J BIOL CHEM, V271, P3071; BIOCCA S, 1995, BIO-TECHNOL, V13, P1110, DOI 10.1038/nbt1095-1110; DESHANE J, 1994, GENE THER, V1, P332; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; DUAN LX, 1994, P NATL ACAD SCI USA, V91, P5075, DOI 10.1073/pnas.91.11.5075; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GULLICK WJ, 1984, ANAL BIOCHEM, V141, P253, DOI 10.1016/0003-2697(84)90454-8; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; MARTE BM, 1995, ONCOGENE, V10, P167; MHASHILKAR AM, 1995, EMBO J, V14, P1542, DOI 10.1002/j.1460-2075.1995.tb07140.x; Murphy L C, 1990, Semin Cancer Biol, V1, P305; MURRAY PA, 1993, BRIT J CANCER, V67, P1408, DOI 10.1038/bjc.1993.261; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; RICHARDSON JH, 1995, P NATL ACAD SCI USA, V92, P3137, DOI 10.1073/pnas.92.8.3137; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; WELS W, 1995, INT J CANCER, V60, P137, DOI 10.1002/ijc.2910600120; WELS W, 1992, BIO-TECHNOL, V10, P1128, DOI 10.1038/nbt1092-1128; WILDENHAIN Y, 1990, ONCOGENE, V5, P879; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179	37	85	91	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					275	282						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710366				2022-12-17	WOS:A1996VA25200006
J	Jakus, J; Yeudall, WA				Jakus, J; Yeudall, WA			Growth inhibitory concentrations of EGF induce p21 (WAF1/Cip1) and alter cell cycle control in squamous carcinoma cells	ONCOGENE			English	Article						epidermal growth factor; p21; WAF1; Cip1; PCNA; cyclin dependent kinase	HUMAN EPIDERMOID CARCINOMA; DEPENDENT KINASES; A431 CELLS; RECEPTOR; CULTURE; PROTEIN; HEAD; NECK; DIFFERENTIATION; OVEREXPRESSION	Previous studies have reported inhibition of A431 squamous carcinoma cell growth by nanomolar concentrations of epidermal growth factor (EGF), a potent mitogen for cells of epithelial origin, In this study, we examined potential mechanisms through which inhibition of keratinocyte growth mediated by EGF might occur by analysing components of the cell cycle regulatory machinery in A431, HN6 and HN30 keratinocytes in the presence of growth inhibitory or growth stimulatory doses of EGF, Treatment of cells with 25 pM EGF produced an increase in [H-3]thymidine incorporation in A431, HN6 and HN30 cells, with respect to control cultures, Exposure to 2.5 nM EGF reduced [H-3]thymidine incorporation in A431 cells and HN6 cells to 11% and 70% of control levels, respectively, whereas HN30 cells continued to proliferate in the presence of EGF, [H-3]thymidine incorporation assays carried out over 24 h revealed repression of DNA synthesis in A431 cells after 12 h exposure to 2.5 nM EGF compared to untreated cells, Flow cytometry studies demonstrated accumulation of cells in G(0)/G(1) after addition of 2.5 nM, but not 25 pM EGF, Western blot analysis revealed elevation of p21 (WAF1/CIP1/SDI1) protein levels in A431 and HN6 cells under growth-inhibitory conditions, Stimulatory doses of EGF did not induce p21 in these cells, Northern blot hybridization demonstrated elevated levels of p21 mRNA within 4 h of exposure of A431 cells to 2.5 nM EGF, which remained elevated above basal levels at 24 h, In vitro kinase assays demonstrated temporal differences in CDK2, and CDK6 activities which were related to EGF concentration, Immunocomplex Western blotting demonstrated increased association of p21 with CDK2 and CDK6 in A431 cells treated with 2.5 nM EGF, Furthermore, temporal alterations in the association of PCNA with p21 and with CDK6 were observed, The data indicate that p21 is a likely mediator of EGF-induced growth-inhibition, probably through mechanisms involving sequestration of PCNA and inhibition of CDK activity.	NIDR,CELLULAR DEV & ONCOL LAB,MOLEC CARCINOGENESIS GRP,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								BARNES DW, 1982, J CELL BIOL, V93, P1, DOI 10.1083/jcb.93.1.1; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSS JE, 1982, P NATL ACAD SCI-BIOL, V79, P2574, DOI 10.1073/pnas.79.8.2574; CARDINALI M, 1995, INT J CANCER, V61, P98, DOI 10.1002/ijc.2910610117; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; GAME SM, 1992, INT J CANCER, V52, P461, DOI 10.1002/ijc.2910520322; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Harlow E., 1989, ANTIBODIES LAB MANUA; HARPER JW, 1993, CELL, V75, P805; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; ISHITOYA J, 1989, BRIT J CANCER, V59, P559, DOI 10.1038/bjc.1989.113; JIANG HP, 1994, ONCOGENE, V9, P3397; KEARSLEY JH, 1990, BRIT J CANCER, V61, P821, DOI 10.1038/bjc.1990.184; KONGER RL, 1993, J CELL PHYSIOL, V156, P515, DOI 10.1002/jcp.1041560310; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI Y, 1994, ONCOGENE, V9, P2261; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; MICHIELI P, 1994, CANCER RES, V54, P3391; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OZANNE B, 1986, J PATHOL, V149, P9, DOI 10.1002/path.1711490104; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PRIME SS, 1994, BRIT J CANCER, V69, P8, DOI 10.1038/bjc.1994.2; RHEINWALD JG, 1977, NATURE, V265, P421, DOI 10.1038/265421a0; ROSDY M, 1988, IN VITRO CELL DEV, V22, P295; SACHS L, 1987, CANCER RES, V47, P1981; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SOMERS KD, 1992, CANCER RES, V52, P5997; STANTON P, 1994, BRIT J CANCER, V70, P427, DOI 10.1038/bjc.1994.322; STEINMAN RA, 1994, ONCOGENE, V9, P3389; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WIRTH PJ, 1987, CANCER RES, V47, P2831; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YEUDALL WA, 1994, CARCINOGENESIS, V15, P2683, DOI 10.1093/carcin/15.12.2683	42	85	86	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2369	2376						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649777				2022-12-17	WOS:A1996UQ22000014
J	ROSENBERG, AR; ZINDY, F; LEDEIST, F; MOULY, H; METEZEAU, P; BRECHOT, C; LAMAS, E				ROSENBERG, AR; ZINDY, F; LEDEIST, F; MOULY, H; METEZEAU, P; BRECHOT, C; LAMAS, E			OVEREXPRESSION OF HUMAN CYCLIN-A ADVANCES ENTRY INTO S-PHASE	ONCOGENE			English	Article						CELL CYCLE; CYCLIN A; G1-S TRANSITION; S-PHASE CONTROL; SCANNING LASER CYTOMETRY	HUMAN CELL-CYCLE; SEA-URCHIN EGGS; DNA-REPLICATION; PROTEIN-KINASE; MESSENGER-RNA; MAMMALIAN FIBROBLASTS; TRANSCRIPTION FACTOR; VIRAL ONCOPROTEINS; RESTRICTION POINT; DEPENDENT KINASES	Cyclin A is a cell cycle regulatory protein that functions in mitotic and S-phase control in mammalian cells. Using a genomic construction corresponding to the human cyclin A gene under the control of its own promoter, we have established stable transfectants overexpressing cyclin A protein, Experiments assisted by laser scanning image cytometry showed that this overexpression begins from late G1 phase onwards and is therefore cell cycle-regulated in this model. We demonstrated that this overexpression advances entry into S phase, leading to a contraction of the overall cell generation time. These results provide evidence that cyclin A can be a rate-limiting factor with respect to the control of the transition to S phase in mammalian cells.	CHU NECKER ENFANTS MALAD, INSERM, U132, F-75743 PARIS 15, FRANCE; INST PASTEUR, CYTOMETRIE ANALYT & PREPARAT LAB, UNITE BIOCHIM CELLULAIRE, F-75724 PARIS 15, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	ROSENBERG, AR (corresponding author), INST NECKER, INSERM, U370, 156 RUE VAUGIRARD, F-75730 PARIS 15, FRANCE.		Lamas, Eugenia/L-9654-2018	Lamas, Eugenia/0000-0001-7677-9442; Rosenberg, Arielle/0000-0003-2085-8146				ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BATES S, 1994, ONCOGENE, V9, P71; CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; DOU QP, 1993, CANCER RES, V53, P1493; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HUNT T, 1991, NATURE, V350, P462, DOI 10.1038/350462a0; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JIANG W, 1993, ONCOGENE, V8, P3447; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEVINS JR, 1992, SCIENCE, V258, P424; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; ROY LM, 1991, J CELL BIOL, V113, P507, DOI 10.1083/jcb.113.3.507; SOBCZAKTHEPOT J, 1993, EXP CELL RES, V206, P43, DOI 10.1006/excr.1993.1118; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WIMMEL A, 1994, ONCOGENE, V9, P995; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	59	85	88	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1501	1509						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731704				2022-12-17	WOS:A1995QU68100005
J	WASYLYK, C; MAIRA, SM; SOBIESZCZUK, P; WASYLYK, B				WASYLYK, C; MAIRA, SM; SOBIESZCZUK, P; WASYLYK, B			REVERSION OF RAS TRANSFORMED-CELLS BY ETS TRANSDOMINANT MUTANTS	ONCOGENE			English	Article							MATRIX-DEGRADING METALLOPROTEINASES; TRANSCRIPTION FACTORS; PROTEIN-KINASE; SIGNAL TRANSDUCTION; ACTIVATION DOMAIN; GENE FAMILY; PHOSPHORYLATION; PHOTORECEPTOR; DROSOPHILA; CASCADE	Considerable progress has been made in elucidating the components of the Ras signalling pathway, from both biochemical and genetic investigations. However little is known about the nuclear targets of the pathway, and in particular those that mediate the long-term changes in gene expression resulting from Ras transformation. Ets family members may be involved in these processes since Ras stimulates transcription through ets-DNA binding sites. We show that a mutated Ets protein, Delta PU.1, inhibits Ras activation of transcription. Stable expression of Delta PU.1 in Ras transformed NIH3T3 fibroblasts reverts the transformed phenotype by many characteristics, including morphology, anchorage independent growth, saturation density, growth in low serum, tumour formation in nude mice and to some extent sensitivity to apoptotic cell death. Similar trans-dominant mutants of c-Ets-1 and c-Ets-2, the most divergent members of the Ets-family to PU.1, also revert Ras transformed cells, as indicated by morphology, anchorage-independent growth, saturation density and doubling time in low serum. Reversion may result from a shared property of the mutants, such as binding to ets motifs in promoters. These results provide evidence for an important role for Ets proteins in Ras transformation.	FAC MED STRASBOURG, INST CHIM BIOL, CNRS, LGME, INSERM, U184, F-67085 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Wasylyk, Bohdan/ABG-6778-2020	Wasylyk, Bohdan/0000-0002-1718-1237				ADLER V, 1992, J BIOL CHEM, V267, P17001; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BRENNER CA, 1989, GENE DEV, V3, P848, DOI 10.1101/gad.3.6.848; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; ELION EA, 1991, P NATL ACAD SCI USA, V88, P9392, DOI 10.1073/pnas.88.21.9392; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; HANCOCK JF, 1993, CURR BIOL, V3, P770, DOI 10.1016/0960-9822(93)90027-L; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; NEIMAN AM, 1993, TRENDS GENET, V9, P390, DOI 10.1016/0168-9525(93)90139-9; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; THOMAS JH, 1993, TRENDS GENET, V9, P395, DOI 10.1016/0168-9525(93)90140-D; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK B, 1993, EUR J BIOCHEM, V21, P523; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1992, CELL GROWTH DIFFER, V3, P617; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WHARTON W, 1989, CELL GROWTH DIVISION, P139	37	85	85	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3665	3673						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970725				2022-12-17	WOS:A1994PT39200030
J	SAEZ, R; CHAN, AML; MIKI, T; AARONSON, SA				SAEZ, R; CHAN, AML; MIKI, T; AARONSON, SA			ONCOGENIC ACTIVATION OF HUMAN R-RAS BY POINT MUTATIONS ANALOGOUS TO THOSE OF PROTOTYPE H-RAS ONCOGENES	ONCOGENE			English	Article							GROWTH-FACTOR; NIH3T3 FIBROBLASTS; GENE-PRODUCT; KINASE; RAF-1; TRANSFORMATION; EXPRESSION; CELLS; PROTEINS	R-ras, K-rev-1/rap and TC21, are more closely related to prototype H-vas than any other known members of the vas superfamily. We recently isolated a mutationally activated TC21 oncogene from a human ovarian carcinoma cell line. Based upon these observations, we sought to re-examine the transforming potential of R-ras, which was reported earlier to lack transforming capacity. Mutations were introduced into the R-uas gene at codons 38 or 87, analogous to positions 12 and 61, respectively, responsible for H-ras oncogene activation. While both mutations resulted in acquisition of R-ras transforming capacity for NIH3T3 cells the position 61 was shown to be more active. Transfectants expressing either R-ras mutant formed colonies in soft agar and were tumorigenic in vivo. As has been reported for H-ras, R-ras cooperated with c-raf-1 in inducing transformation of NIH3T3 cells. These results imply interactions in R-ras and c-raf-1 signaling pathways. We observed R-ras transcripts of 4.6 and 1.2 kb ubiquitously expressed in each of a variety of tissues examined. All these findings raise the possibility that R-ras, like prototype vas genes, may be mutationally activated as an oncogene in some human malignancies.	MT SINAI MED CTR,DERALD H RUTTENBERG CANC CTR,NEW YORK,NY 10029; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Chan, Andrew Man-Lok/J-9497-2013; Chan, Andrew/AAC-1145-2020	Chan, Andrew Man-Lok/0000-0001-9923-5464; Chan, Andrew/0000-0001-9923-5464				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CHAN AML, 1994, IN PRESS P NATL ACAD; CHARDIN P, 1991, CANCER CELL-MON REV, V3, P117; CUADRADO A, 1993, ONCOGENE, V8, P2443; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HEIDARAN MA, 1990, ONCOGENE, V5, P1265; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; LACAL JC, 1986, P NATL ACAD SCI USA, V83, P5400, DOI 10.1073/pnas.83.15.5400; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; REY I, 1994, ONCOGENE, V9, P685; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4648; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	30	85	86	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2977	2982						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084601				2022-12-17	WOS:A1994PG82200024
J	HERBER				HERBER			INDUCIBLE REGULATORY ELEMENTS IN THE HUMAN CYCLIN-D1 PROMOTER (VOL 9, PG 1295, 1994)	ONCOGENE			English	Correction, Addition													Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				HERBER, 1994, ONCOGENE, V9, P1295	1	85	89	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					2105	2107						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208558				2022-12-17	WOS:A1994NR68500038
J	CARLESSO, N; GRIFFIN, JD; DRUKER, BJ				CARLESSO, N; GRIFFIN, JD; DRUKER, BJ			USE OF A TEMPERATURE-SENSITIVE MUTANT TO DEFINE THE BIOLOGICAL EFFECTS OF THE P210(BCR-ABL) TYROSINE KINASE ON PROLIFERATION OF A FACTOR-DEPENDENT MURINE MYELOID CELL-LINE	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; COLONY-STIMULATING FACTOR; MIDDLE-T-ANTIGEN; V-ABL ONCOGENE; BCR-ABL; INTERLEUKIN-3 DEPENDENCE; PHILADELPHIA-CHROMOSOME; INVITRO TRANSFORMATION; HEMATOPOIETIC-CELLS; PROTEIN-KINASE	The Philadelphia chromosome, detected in virtually all cases of chronic myelogenous leukemia, is formed by a reciprocal translocation between chromosomes 9 and 22 that fuses BCR encoded sequences upstream of exon 2 of c-ABL. This oncogene produces a fusion protein, p210(BCR-ABL), in which the ABL tyrosine kinase activity is elevated. This elevated kinase activity is essential for transformation, but the mechanisms involved are unknown. To investigate p210(BCR-ABL) function we constructed a model system in which the tyrosine kinase activity of p210(BCR-ABL) was inducible. Two amino acid substitutions, Arg to His at amino acid 457 and Tyr to His at amino acid 469 of c-abl, modeled on mutations known to render v-src temperature-sensitive for tyrosine kinase activity, were introduced into p210(BCR-ABL). This mutant was characterized in an IL-3 growth factor dependent murine myeloid cell line, 32Dc13. Cell lines expressing the temperature-sensitive mutant remained factor dependent at the non-permissive temperature, but at the permissive temperature displayed a marked reduction in cell death in the absence of growth factor and an exaggerated proliferative response to low levels of IL-3. Both the kinase activity of the mutant and the levels of tyrosine phosphorylated proteins are increased in the temperature-sensitive mutant at the permissive temperature. Further, tyrosine phosphorylation of potential substrates of the p210(BCR-ABL) tyrosine kinase, p120 rasGAP and its associated proteins of p190 and p62, only occurs at the permissive temperature in cells expressing the temperature-sensitive mutant.	DANA FARBER CANC INST, DIV TUMOR IMMUNOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV TURIN, DEPT EXPTL MED & ONCOL, HEMATOL SECT, TURIN, ITALY; DANA FARBER CANC INST, DIV CELLULAR & MOLEC BIOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; University of Turin; Harvard University; Dana-Farber Cancer Institute				Druker, Brian/0000-0001-8331-8206	NCI NIH HHS [CA01422, CA36167] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA036167, K08CA001422, R01CA036167] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNETT MJ, 1989, BONE MARROW TRANSPL, V4, P345; BEDI A, 1992, BLOOD S, V80, pA154; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BROXMEYER HE, 1987, J CLIN INVEST, V79, P721, DOI 10.1172/JCI112877; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; COULOMBEL L, 1983, NEW ENGL J MED, V308, P1493, DOI 10.1056/NEJM198306233082502; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DONAHUE RE, 1988, SCIENCE, V241, P1820, DOI 10.1126/science.3051378; DRUKER B, 1992, BLOOD, V79, P2215; DRUKER BJ, 1991, NUCLEIC ACIDS RES, V19, P6855, DOI 10.1093/nar/19.24.6855; DRUKER BJ, 1992, J VIROL, V66, P5770, DOI 10.1128/JVI.66.10.5770-5776.1992; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; ENGELMAN A, 1987, P NATL ACAD SCI USA, V84, P8021, DOI 10.1073/pnas.84.22.8021; ENGELMAN A, 1990, J VIROL, V64, P4242, DOI 10.1128/JVI.64.9.4242-4251.1990; ENGELMAN A, 1990, MOL CELL BIOL, V10, P4365, DOI 10.1128/MCB.10.8.4365; EVANS CA, 1993, CANCER RES, V53, P1735; FINCHAM VJ, 1986, J VIROL, V58, P694, DOI 10.1128/JVI.58.2.694-699.1986; Gishizky M L, 1992, Curr Top Microbiol Immunol, V182, P65; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GREENBERGER JS, 1983, P NATL ACAD SCI USA, V80, P2391; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Hariharan I K, 1988, Oncogene Res, V3, P387; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HONMA Y, 1992, LEUKEMIA, V6, P229; HURLEY TR, 1992, J VIROL, V66, P7406, DOI 10.1128/JVI.66.12.7406-7413.1992; KANAKURA Y, 1990, BLOOD, V76, P706; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KIPREOS ET, 1987, P NATL ACAD SCI USA, V84, P1345, DOI 10.1073/pnas.84.5.1345; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LANEUVILLE P, 1992, BLOOD, V80, P1788; LANEUVILLE P, 1991, ONCOGENE, V6, P275; MANDANAS RA, 1992, LEUKEMIA, V6, P796; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MATULONIS U, 1993, IN PRESS EXP HEMATOL; MAYER BJ, 1986, J VIROL, V60, P858, DOI 10.1128/JVI.60.3.858-867.1986; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; METCALF D, 1986, BLOOD, V68, P46; MOORE MAS, 1977, CLIN HAEMATOL, V6, P97; NOWELL PC, 1960, SCIENCE, V132, P1497; RISSER R, 1978, J EXP MED, V148, P714, DOI 10.1084/jem.148.3.714; ROSENBERG N, 1975, P NATL ACAD SCI USA, V72, P1932, DOI 10.1073/pnas.72.5.1932; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SEFTON BM, 1981, P NATL ACAD SCI-BIOL, V78, P1552, DOI 10.1073/pnas.78.3.1552; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798	49	85	88	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					149	156						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302574				2022-12-17	WOS:A1994MW24700018
J	ZHANG, LQ; LEMARCHANDEL, V; ROMEO, PH; BENDAVID, Y; GREER, P; BERNSTEIN, A				ZHANG, LQ; LEMARCHANDEL, V; ROMEO, PH; BENDAVID, Y; GREER, P; BERNSTEIN, A			THE FLI-1 PROTOONCOGENE, INVOLVED IN ERYTHROLEUKEMIA AND EWINGS-SARCOMA, ENCODES A TRANSCRIPTIONAL ACTIVATOR WITH DNA-BINDING SPECIFICITIES DISTINCT FROM OTHER ETS FAMILY MEMBERS	ONCOGENE			English	Article							MURINE LEUKEMIA-VIRUS; PUTATIVE ONCOGENE; GENE FAMILY; C-ETS; CELLS; EXPRESSION; IDENTIFICATION; ENHANCER; CONTAINS; PROTEINS	The late stages of the erythroleukemias induced by either the replication-defective Friend spleen focus-forming virus (SFFV) or the Friend murine leukemia virus (FMuLV) are associated with the insertional activation of one of two members (Spi-1 or Fli-1) of the Ets protooncogene family of transcriptional factors. Fli-1 is not rearranged or activated in the erythroleukemias induced by SFFV, and similarly Spi-1 is not rearranged or activated in the leukemic cell clones induced by F-MuLV. This strict specificity of integration sites suggests that Fli-1 and Spi-1 may be functionally distinct and transactivate different downstream genes during the progression of multistage Friend erythroleukemia. In this study, we show that the Fli-1 protein, like other Ets proteins, has DNA-binding activity and can act as a sequence-specific transcriptional activator. We also show that the Fli-1 and Spi-1 proteins are functionally distinct in that they recognize and transactivate through distinct DNA binding sites. Furthermore, we have identified an octanucleotide core sequence that is required in vitro for optimal binding of Fli-1 to the Drosophila E74 target and the promoter sequence of the human GPIIb gene.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,INST MED SCI,TORONTO M5S 1A1,ONTARIO,CANADA; HOP HENRI MONDOR,INSERM,U91,F-94010 CRETEIL,FRANCE; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M5S 1A1,ONTARIO,CANADA; SUNNYBROOK HLTH SCI CTR,DIV CANC RES,TORONTO M4N 3M5,ON,CANADA; QUEENS UNIV,DEPT PATHOL,KINGSTON K7L 3N6,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Queens University - Canada; University of Toronto			Romeo, Paul-Henri/L-5989-2017	Romeo, Paul-Henri/0000-0002-8294-0367				ATCHISON ML, 1988, EMBO J, V7, P4213, DOI 10.1002/j.1460-2075.1988.tb03318.x; AURIGEMMA RE, 1992, J VIROL, V66, P3056, DOI 10.1128/JVI.66.5.3056-3061.1992; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BHAT NK, 1987, P NATL ACAD SCI USA, V86, P7495; BOULOUKOS KE, 1988, MOL CELL BIOL, V9, P5718; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOERNER TJ, 1990, IN PRESS METHODS ENZ; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PRIBYL LJ, 1991, ONCOGENE, V6, P1175; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	41	85	87	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1621	1630						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502483				2022-12-17	WOS:A1993LE06400026
J	SHAW, P; TARDY, S; BENITO, E; OBRADOR, A; COSTA, J				SHAW, P; TARDY, S; BENITO, E; OBRADOR, A; COSTA, J			OCCURRENCE OF KI-RAS AND P53 MUTATIONS IN PRIMARY COLORECTAL TUMORS	ONCOGENE			English	Article							CHROMOSOME-5 ALLELE LOSS; FAMILIAL POLYPOSIS COLI; SHORT ARM; GENE-MUTATIONS; LONG ARM; CARCINOMAS; ANTIGEN; ONCOGENE; DNA; TRANSFORMATION	Twenty-four colorectal tumors and their paired mucosa were examined for allele loss on chromosomes 5 and 17, using polymerase chain reaction-amplified DNA, and for mutations in the Ki-ras and p53 genes. In addition, 19 benign polyps were analysed for mutations in the p53 gene. RFLP analysis of the long arm of chromosome 5 indicated an allele loss frequency of 47% for malignant tumors, a value somewhat higher than previously observed. Examination of the short arm of chromosome 17 indicated an allele loss of 60%. Sequence analysis of the p53 gene in colorectal tumors indicated that 64% contained a mutation. All tumors showing allele loss on chromosome 17 were mutant for p53, suggesting that mutation of one p53 allele precedes the hemizygotic loss of the wild-type allele. Sequence analysis of the p53 gene in 19 benign polyps, devoid of severe dysplasia, did not reveal any mutants, suggesting that the mutation of one p53 allele is an event that takes place after polyp formation. Ki-ras mutations were observed in 48% of the tumors examined. All tumors which were mutant for Ki-ras, except for one, were also mutant for p53.	EPIDEMIOL UNIT,E-07012 MALLORCA,SPAIN; TUMOR REGISTRY MALLORCA,E-07012 MALLORCA,SPAIN; HOSP SON DURETA ANDREA DORIA,GASTROENTEROL UNIT,E-07014 MALLORCA,SPAIN	Hospital Universitari Son Espases; Hospital Universitari Son Dureta	SHAW, P (corresponding author), UNIV LAUSANNE,INST PATHOL,DIV ONCOL EXPTL,RUE BUGNON 25,CH-1011 LAUSANNE,SWITZERLAND.			Benito Oliver, Enrique/0000-0002-0489-4668				ASHTONRICKARDT PG, 1989, ONCOGENE, V4, P1169; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BENITO E, 1990, INT J CANCER, V45, P69, DOI 10.1002/ijc.2910450114; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINDLAY CA, 1989, CELL, V57, P1083; FORESTER K, 1987, NATURE, V327, P298; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; KHAN PM, 1988, HUMAN GENETICS; KLINGER H, 1987, CYTOGENET CELL GENET, V46, P1; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Maniatis T., 1982, MOL CLONING; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MILLER C, 1986, NATURE, V319, P783, DOI 10.1038/319783a0; MITCHELL LG, 1989, ANAL BIOCHEM, V178, P239, DOI 10.1016/0003-2697(89)90631-3; MONPEZAT JP, 1988, INT J CANCER, V41, P404, DOI 10.1002/ijc.2910410315; MULERIS M, 1985, CR ACAD SCI III-VIE, P315; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; SAHLI R, 1985, NUCLEIC ACIDS RES, V13, P3617, DOI 10.1093/nar/13.10.3617; SCHIBLER U, 1980, J MOL BIOL, V142, P93, DOI 10.1016/0022-2836(80)90208-9; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; STEWART GD, 1987, NUCLEIC ACIDS RES, V15, P3939, DOI 10.1093/nar/15.9.3939; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WILDRICK DM, 1988, BIOCHEM BIOPH RES CO, V150, P591, DOI 10.1016/0006-291X(88)90434-2	37	85	86	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2121	2128						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1945416				2022-12-17	WOS:A1991GX11900024
J	GLINEUR, C; BAILLY, M; GHYSDAEL, J				GLINEUR, C; BAILLY, M; GHYSDAEL, J			THE C-ERBA ALPHA-ENCODED THYROID-HORMONE RECEPTOR IS PHOSPHORYLATED IN ITS AMINO TERMINAL DOMAIN BY CASEIN KINASE-II	ONCOGENE			English	Article											GLINEUR, C (corresponding author), INST PASTEUR,CNRS,UA 1160,INSERM,U186,1 RUE CALMETTE,F-59019 LILLE,FRANCE.		GHYSDAEL, Jacques/F-3377-2013					ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; BENBROOK D, 1987, SCIENCE, V238, P788, DOI 10.1126/science.3672126; BIGLER J, 1988, MOL CELL BIOL, V8, P4155, DOI 10.1128/MCB.8.10.4155; BREATHNACH R, 1983, NUCLEIC ACIDS RES, V11, P7110; DAHMUS ME, 1981, J BIOL CHEM, V256, P3332; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DRAPEAU GR, 1980, J BIOL CHEM, V255, P839; DURBAN E, 1985, EMBO J, V4, P2921, DOI 10.1002/j.1460-2075.1985.tb04024.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GILMORE T, 1985, CELL, V40, P609, DOI 10.1016/0092-8674(85)90209-0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOROWITZ ZD, 1989, MOL ENDOCRINOL, V3, P148, DOI 10.1210/mend-3-1-148; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; JANSSON M, 1987, ONCOGENE, V1, P167; JANSSON M, 1983, EMBO J, V2, P561, DOI 10.1002/j.1460-2075.1983.tb01463.x; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P479, DOI 10.1210/mend-2-6-479; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MIESFELD R, 1987, SCIENCE, V236, P423, DOI 10.1126/science.3563519; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; MUNOZ A, 1988, EMBO J, V6, P375; NAKAI A, 1988, MOL ENDOCRINOL, V2, P1087, DOI 10.1210/mend-2-11-1087; NAKAI A, 1988, P NATL ACAD SCI USA, V85, P2781, DOI 10.1073/pnas.85.8.2781; PINNA LA, 1979, BIOCHEM BIOPH RES CO, V87, P114, DOI 10.1016/0006-291X(79)91654-1; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; SOMMERCORN J, 1987, J BIOL CHEM, V262, P3839; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; TUAZON PT, 1979, EUR J BIOCHEM, V94, P497, DOI 10.1111/j.1432-1033.1979.tb12918.x; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; WALTON GM, 1983, J BIOL CHEM, V258, P4440; WEINBERGER C, 1985, NATURE, V318, P670, DOI 10.1038/318670a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	54	85	87	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1989	4	10					1247	1254						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AU508	2552374				2022-12-17	WOS:A1989AU50800013
J	LIFSHITZ, B; FAINSTEIN, E; MARCELLE, C; SHTIVELMAN, E; AMSON, R; GALE, RP; CANAANI, E				LIFSHITZ, B; FAINSTEIN, E; MARCELLE, C; SHTIVELMAN, E; AMSON, R; GALE, RP; CANAANI, E			BCR GENES AND TRANSCRIPTS	ONCOGENE			English	Article									WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024	Weizmann Institute of Science; University of California System; University of California Los Angeles					NCI NIH HHS [CA-38569] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038569] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CANAANI E, 1984, LANCET, V1, P593; CHAMPLIN RE, 1985, BLOOD, V65, P1039; COLLINS SJ, 1984, SCIENCE, V225, P72, DOI 10.1126/science.6587568; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; FINK GR, 1986, CELL, V45, P155, DOI 10.1016/0092-8674(86)90378-8; FROMM M, 1983, Journal of Molecular and Applied Genetics, V2, P127; GALE RP, 1984, P NATL ACAD SCI US, V81, P5548; GREENBERG ME, 1983, CELL, V33, P767, DOI 10.1016/0092-8674(83)90019-3; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1985, BIOCHIM BIOPHYS ACTA, V823, P1, DOI 10.1016/0304-419X(85)90012-5; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; NOWELL PC, 1960, SCIENCE, V132, P1197; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984	27	85	87	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1988	2	2					113	117						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	3285291				2022-12-17	WOS:A1988M086000003
J	VANTVEER, LJ; HERMENS, R; VANDENBERGBAKKER, LAM; CHENG, NC; FLEUREN, GJ; BOS, JL; CLETON, FJ; SCHRIER, PI				VANTVEER, LJ; HERMENS, R; VANDENBERGBAKKER, LAM; CHENG, NC; FLEUREN, GJ; BOS, JL; CLETON, FJ; SCHRIER, PI			RAS ONCOGENE ACTIVATION IN HUMAN OVARIAN-CARCINOMA	ONCOGENE			English	Article									UNIV HOSP LEIDEN,DEPT CLIN ONCOL,POB 9600,2300 RC LEIDEN,NETHERLANDS; UNIV HOSP LEIDEN,DEPT PATHOL,2300 RC LEIDEN,NETHERLANDS; STATE UNIV LEIDEN,DEPT MED BIOCHEM,SYLVIUS LABS,2312 AV LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University - Excl LUMC			Hermens, Rosella P.M.G./N-3581-2014	Hermens, Rosella P.M.G./0000-0001-7624-7120				ANDERSON SJ, 1982, J VIROL, V44, P696, DOI 10.1128/JVI.44.2.696-702.1982; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOS JL, 1987, BLOOD, V69, P1237; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1986, NUCLEIC ACIDS RES, V14, P1209, DOI 10.1093/nar/14.3.1209; BOS JL, 1987, IN PRESS MUT RES; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FEIG LA, 1984, SCIENCE, V223, P698, DOI 10.1126/science.6695178; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FILMUS JE, 1985, CANCER RES, V45, P4468; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FUJITA J, 1985, P NATL ACAD SCI USA, V82, P3849, DOI 10.1073/pnas.82.11.3849; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALLICK GE, 1985, P NATL ACAD SCI USA, V82, P1795, DOI 10.1073/pnas.82.6.1795; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUSELLA J, 1979, P NATL ACAD SCI USA, V76, P5239, DOI 10.1073/pnas.76.10.5239; HOFKER MH, 1986, AM J HUM GENET, V39, P438; JANSSEN JWG, 1987, ONCOGENE, V1, P175; JELINEK WR, 1980, P NATL ACAD SCI-BIOL, V77, P1398, DOI 10.1073/pnas.77.3.1398; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; KURZROCK R, 1986, CANCER RES, V46, P1530; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OHUCHI N, 1987, CANCER RES, V47, P1413; OHUCHI N, 1986, CANCER RES, V46, P2511; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; PULCIANI S, 1982, NATURE, V300, P539, DOI 10.1038/300539a0; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; RIOU G, 1984, CR ACAD SCI III-VIE, V299, P575; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SHEN VWP, 1987, ONCOGENE, V1, P157; SHIH TY, 1979, VIROLOGY, V96, P64, DOI 10.1016/0042-6822(79)90173-9; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; TANAKA T, 1986, CANCER RES, V46, P1465; TAYA Y, 1984, EMBO J, V3, P2943, DOI 10.1002/j.1460-2075.1984.tb02236.x; THEILLET C, 1986, CANCER RES, V46, P4776; THOR A, 1984, NATURE, V311, P562, DOI 10.1038/311562a0; VANTVEER LJ, 1984, MOL CELL BIOL, V4, P2532, DOI 10.1128/MCB.4.11.2532; VARMUS HE, 1984, ANNU REV GENET, V18, P533; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; VERWEIJ CL, 1985, NUCLEIC ACIDS RES, V13, P4699, DOI 10.1093/nar/13.13.4699; VIOLA MV, 1985, J EXP MED, V161, P1213, DOI 10.1084/jem.161.5.1213; VIOLA MV, 1986, NEW ENGL J MED, V314, P133, DOI 10.1056/NEJM198601163140301; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	61	85	87	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1988	2	2					157	165						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M0860	3285294				2022-12-17	WOS:A1988M086000009
J	Panagopoulou, M; Karaglani, M; Balgkouranidou, I; Biziota, E; Koukaki, T; Karamitrousis, E; Nena, E; Tsamardinos, I; Kolios, G; Lianidou, E; Kakolyris, S; Chatzaki, E				Panagopoulou, Maria; Karaglani, Makrina; Balgkouranidou, Ioanna; Biziota, Eirini; Koukaki, Triantafillia; Karamitrousis, Evaggelos; Nena, Evangelia; Tsamardinos, Ioannis; Kolios, George; Lianidou, Evi; Kakolyris, Stylianos; Chatzaki, Ekaterini			Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers	ONCOGENE			English	Article							SOX17 PROMOTER METHYLATION; TUMOR DNA; DIAGNOSTIC MARKER; LIQUID BIOPSY; NUCLEIC-ACIDS; PLASMA DNA; EXPRESSION; BLOOD; INTEGRITY; BIOMARKER	Blood circulating cell-free DNA (ccfDNA) is a suggested biosource of valuable clinical information for cancer, meeting the need for a minimally-invasive advancement in the route of precision medicine. In this paper, we evaluated the prognostic and predictive potential of ccfDNA parameters in early and advanced breast cancer. Groups consisted of 150 and 16 breast cancer patients under adjuvant and neoadjuvant therapy respectively, 34 patients with metastatic disease and 35 healthy volunteers. Direct quantification of ccfDNA in plasma revealed elevated concentrations correlated to the incidence of death, shorter PFS, and non-response to pharmacotherapy in the metastatic but not in the other groups. The methylation status of a panel of cancer-related genes chosen based on previous expression and epigenetic data (KLK10, SOX17, WNT5A, MSH2, GATA3) was assessed by quantitative methylation-specific PCR. All but the GATA3 gene was more frequently methylated in all the patient groups than in healthy individuals (all p < 0.05). The methylation of WNT5A was statistically significantly correlated to greater tumor size and poor prognosis characteristics and in advanced stage disease with shorter OS. In the metastatic group, also SOX17 methylation was significantly correlated to the incidence of death, shorter PFS, and OS. KLK10 methylation was significantly correlated to unfavorable clinicopathological characteristics and relapse, whereas in the adjuvant group to shorter DFI. Methylation of at least 3 or 4 genes was significantly correlated to shorter OS and no pharmacotherapy response, respectively. Classification analysis by a fully automated, machine learning software produced a single-parametric linear model using ccfDNA plasma concentration values, with great discriminating power to predict response to chemotherapy (AUC 0.803, 95% CI [0.606, 1.000]) in the metastatic group. Two more multi-parametric signatures were produced for the metastatic group, predicting survival and disease outcome. Finally, a multiple logistic regression model was constructed, discriminating between patient groups and healthy individuals. Overall, ccfDNA emerged as a highly potent predictive classifier in metastatic breast cancer. Upon prospective clinical evaluation, all the signatures produced could aid accurate prognosis.	[Panagopoulou, Maria; Karaglani, Makrina; Balgkouranidou, Ioanna; Kolios, George; Chatzaki, Ekaterini] Democritus Univ Thrace, Med Sch, Lab Pharmacol, Alexandroupolis 68100, Greece; [Balgkouranidou, Ioanna; Biziota, Eirini; Koukaki, Triantafillia; Karamitrousis, Evaggelos; Kakolyris, Stylianos] Democritus Univ Thrace, Med Sch, Dept Oncol, Alexandroupolis 68100, Greece; [Nena, Evangelia] Democritus Univ Thrace, Lab Hyg & Environm Protect, Med Sch, Alexandroupolis 68100, Greece; [Tsamardinos, Ioannis] Univ Crete, Dept Comp Sci, Voutes, Greece; [Tsamardinos, Ioannis] Gnosis Data Anal, Voutes 70013, Crete, Greece; [Lianidou, Evi] Univ Athens, Dept Chem, Lab Analyt Chem, Anal Circulating Tumor Cells, Athens, Greece; [Chatzaki, Ekaterini] Fdn Res & Technol Hellas, Voutes 70013, Crete, Greece	Democritus University of Thrace; Democritus University of Thrace; Democritus University of Thrace; University of Crete; National & Kapodistrian University of Athens; Foundation for Research & Technology - Hellas (FORTH)	Chatzaki, E (corresponding author), Democritus Univ Thrace, Med Sch, Lab Pharmacol, Alexandroupolis 68100, Greece.; Chatzaki, E (corresponding author), Fdn Res & Technol Hellas, Voutes 70013, Crete, Greece.	achatzak@med.duth.gr	Chatzaki, Ekaterini/AAW-9507-2020; Nena, Evangelia/AAD-9385-2019; Chatzaki, Ekaterini/CAF-7645-2022; Kolios, George/N-6641-2013	Chatzaki, Ekaterini/0000-0002-5832-4257; Nena, Evangelia/0000-0003-0381-4715; Kolios, George/0000-0002-2066-4782; Karaglani, Makrina/0000-0002-9853-3571; Lianidou, Evi/0000-0002-7796-5914	Act: "PROGRAM FOR THE GRANTING OF SCHOLARSHIPS FOR POSTGRADUATE STUDIES OF SECOND CYCLE STUDIES"; State Scholarship Foundation in Greece (IKY) (Operational Program "Human Resources Development-Education and Lifelong Learning", Partnership Agreement PA 2014-2020)	Act: "PROGRAM FOR THE GRANTING OF SCHOLARSHIPS FOR POSTGRADUATE STUDIES OF SECOND CYCLE STUDIES"; State Scholarship Foundation in Greece (IKY) (Operational Program "Human Resources Development-Education and Lifelong Learning", Partnership Agreement PA 2014-2020)	Ms Maria Panagopoulou received a scholarship for the implementation of her PhD Thesis, co-funded through the Act: "PROGRAM FOR THE GRANTING OF SCHOLARSHIPS FOR POSTGRADUATE STUDIES OF SECOND CYCLE STUDIES". State Scholarship Foundation in Greece (IKY) (Operational Program "Human Resources Development-Education and Lifelong Learning", Partnership Agreement PA 2014-2020).	Agassi R, 2015, AM J CLIN PATHOL, V143, P18, DOI 10.1309/AJCPI5YHG0OGFAHM; Alix-Panabieres C, 2016, CANCER DISCOV, V6, P479, DOI 10.1158/2159-8290.CD-15-1483; ANKER P, 1975, CANCER RES, V35, P2375; Balgkouranidou I, 2016, CLIN CHEM LAB MED, V54, P1385, DOI 10.1515/cclm-2015-0776; Boser B. E., 1992, Proceedings of the Fifth Annual ACM Workshop on Computational Learning Theory, P144, DOI 10.1145/130385.130401; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Breiman L, 2017, CLASSIFICATION REGRE; Catarino R, 2008, DNA CELL BIOL, V27, P415, DOI 10.1089/dna.2008.0744; Chimonidou M, 2013, CLIN CHEM, V59, P270, DOI 10.1373/clinchem.2012.191551; Cooper SJ, 2010, ONCOGENE, V29, P2905, DOI 10.1038/onc.2010.64; Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Elshimali YI, 2013, INT J MOL SCI, V14, P18925, DOI 10.3390/ijms140918925; Fu DY, 2010, BREAST CANCER RES TR, V119, P601, DOI 10.1007/s10549-009-0339-8; Fu DY, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000637; Hattermann K, 2008, ANAL BIOCHEM, V377, P62, DOI 10.1016/j.ab.2008.03.014; HOERL AE, 1970, TECHNOMETRICS, V12, P55, DOI 10.1080/00401706.1970.10488634; Jiang PY, 2015, P NATL ACAD SCI USA, V112, pE1317, DOI 10.1073/pnas.1500076112; Jonsson M, 2002, CANCER RES, V62, P409; Kappil MA, 2016, ANTICANCER RES, V36, P4039; Kioulafa M, 2009, ANN ONCOL, V20, P1020, DOI 10.1093/annonc/mdn733; Laktionov PP, 2004, NUCLEOS NUCLEOT NUCL, V23, P879, DOI 10.1081/NCN-200026035; Lamb YN, 2017, MOL DIAGN THER, V21, P225, DOI 10.1007/s40291-017-0259-y; LEON SA, 1977, CANCER RES, V37, P646; Leris ACA, 2005, ANTICANCER RES, V25, P731; Li B, 2001, CANCER RES, V61, P8014; LI Y, 2015, BMC CANCER, V15; List M, 2014, J INTEGR BIOINFORMAT, V11, pCP4, DOI 10.2390/biecoll-jib-2014-236; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu Jun-Liang, 2016, Chronic Dis Transl Med, V2, P223, DOI 10.1016/j.cdtm.2016.12.001; Madhavan D, 2014, BREAST CANCER RES TR, V146, P163, DOI 10.1007/s10549-014-2946-2; Markaki M, 2018, EBIOMEDICINE, V31, P36, DOI 10.1016/j.ebiom.2018.03.027; Mastoraki S, 2018, CLIN CANCER RES, V24, P1500, DOI 10.1158/1078-0432.CCR-17-1181; Matthaios D, 2016, ONCOL LETT, V12, P748, DOI 10.3892/ol.2016.4649; McCleskey BC, 2015, AM J CLIN PATHOL, V144, P756, DOI 10.1309/AJCP5MMR1FJVVTPK; Miao F, 2014, DIABETES, V63, P1748, DOI 10.2337/db13-1251; Mouliere F, 2015, P NATL ACAD SCI USA, V112, P3178, DOI 10.1073/pnas.1501321112; Olsson E, 2015, EMBO MOL MED, V7, P1034, DOI 10.15252/emmm.201404913; Orfanoudaki G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03557-4; Pantel K, 2013, CANCER RES, V73, P6384, DOI 10.1158/0008-5472.CAN-13-2030; Salvi S, 2016, ONCOTARGETS THER, V9, P6549, DOI 10.2147/OTT.S100901; Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066; Stroun M, 2001, CLIN CHIM ACTA, V313, P139, DOI 10.1016/S0009-8981(01)00665-9; Tan GQ, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010197; Tangvarasittichai O, 2015, INDIAN J CLIN BIOCHE, V30, P55, DOI 10.1007/s12291-013-0407-z; Trifa F, 2013, TUMOR BIOL, V34, P1625, DOI 10.1007/s13277-013-0694-2; Tsamardinos I, 2018, MACH LEARN, V107, P1895, DOI 10.1007/s10994-018-5714-4; Umetani N, 2006, J CLIN ONCOL, V24, P4270, DOI 10.1200/JCO.2006.05.9493; Underhill HR, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006162; van der Meide WF, 2011, GYNECOL ONCOL, V123, P116, DOI 10.1016/j.ygyno.2011.06.015; Yousef GM, 2004, BRIT J CANCER, V90, P167, DOI 10.1038/sj.bjc.6601451; 2008, BIOCELL, V32, P237	53	84	90	2	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3387	3401		10.1038/s41388-018-0660-y	http://dx.doi.org/10.1038/s41388-018-0660-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30643192				2022-12-17	WOS:000466610000005
J	Hua, SN; Lei, L; Deng, L; Weng, X; Liu, CD; Qi, XL; Wang, S; Zhang, DY; Zou, XJ; Cao, CH; Liu, L; Wu, DH				Hua, Shengni; Lei, Ling; Deng, Ling; Weng, Xie; Liu, Chengdong; Qi, Xiaolong; Wang, Shuang; Zhang, Dongyan; Zou, Xuejing; Cao, Chuanhui; Liu, Li; Wu, Dehua			miR-139-5p inhibits aerobic glycolysis, cell proliferation, migration, and invasion in hepatocellular carcinoma via a reciprocal regulatory interaction with ETS1	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR ETS1; TUMOR-SUPPRESSOR; DIFFERENTIAL EXPRESSION; GASTRIC-CANCER; PROTOONCOGENE; METASTASIS; MICRORNAS; HYPOXIA; NETWORK	Cancer cells have metabolic features that allow them to preferentially metabolize glucose through aerobic glycolysis, providing them with a progression advantage. However, microRNA (miRNA) regulation of aerobic glycolysis in cancer cells has not been extensively investigated. We addressed this in the present study by examining the regulation of miR-139-5p on aerobic glycolysis of hepatocellular carcinoma (HCC) using clinical specimens, HCC cells, and a mouse xenograft model. We found that overexpressing miR-139-5p restrained aerobic glycolysis, suppressing proliferation, migration, and invasion in HCC cells. miR-139-5p regulated hexokinase 1 (HK1) and 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) expression by directly targeting the transcription factor ETS1, which bound to the promoters of the HK1 and PFKFB3 genes. miR-139-5p-induced aerobic glycolysis, proliferation, migration, and invasion were reversed by ETS1 overexpression, while ETS1 silencing induced the expression of miR-139-5p via a post-transcriptional regulation mode involving Drosha. miR-139-5p expression was reduced in HCC compared to para-carcinoma tissue, which was confirmed in The Cancer Genome Atlas and GSE54751 HCC cohorts. Notably, the lower expression of mir-139 was correlated with worse prognosis. These outcomes indicate that reciprocal regulatory interactions between miR-139-5p and ETS1 modulate aerobic glycolysis, proliferation, and metastasis in HCC cells, suggesting new targets for HCC treatment.	[Hua, Shengni; Lei, Ling; Deng, Ling; Liu, Chengdong; Zhang, Dongyan; Cao, Chuanhui; Wu, Dehua] Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou, Guangdong, Peoples R China; [Weng, Xie; Zou, Xuejing; Liu, Li] Southern Med Univ, Nanfang Hosp, Hepatol Unit, Guangzhou, Guangdong, Peoples R China; [Weng, Xie; Zou, Xuejing; Liu, Li] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, Guangzhou, Guangdong, Peoples R China; [Qi, Xiaolong] Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Guangzhou, Guangdong, Peoples R China; [Wang, Shuang] Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou, Guangdong, Peoples R China	Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China	Wu, DH (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou, Guangdong, Peoples R China.; Liu, L (corresponding author), Southern Med Univ, Nanfang Hosp, Hepatol Unit, Guangzhou, Guangdong, Peoples R China.; Liu, L (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Infect Dis, Guangzhou, Guangdong, Peoples R China.	liuli.fimmu@gmail.com; wudehua.gd@gmail.com	hua, shengni/HDN-5084-2022	Liu, Li/0000-0002-5265-4159; Zou, Xuejing/0000-0001-6360-204X; Wu, De-Hua/0000-0003-0560-0016	Nation's Nature Science Foundation of China [81472711, 91540111, 81672756, 81401180, 81372283]; Guangdong Province Nature Science Foundation [2014A030311013]	Nation's Nature Science Foundation of China; Guangdong Province Nature Science Foundation	This work was supported by Nation's Nature Science Foundation of China (Grant nos. 81472711, 91540111, 81672756, 81401180, and 81372283) and the Guangdong Province Nature Science Foundation (Grant no. 2014A030311013).	Adam M, 2003, EUR UROL, V44, P329, DOI 10.1016/S0302-2838(03)00262-8; Au SLK, 2012, HEPATOLOGY, V56, P622, DOI 10.1002/hep.25679; Bao W, 2011, GASTROENTEROLOGY, V141, P2076, DOI 10.1053/j.gastro.2011.08.050; Chabre O, 2013, ENDOCR-RELAT CANCER, V20, P579, DOI 10.1530/ERC-13-0051; Corbetta S, 2010, ENDOCR-RELAT CANCER, V17, P135, DOI 10.1677/ERC-09-0134; Dittmer J, 2015, SEMIN CANCER BIOL, V35, P20, DOI 10.1016/j.semcancer.2015.09.010; Dong Z, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004299; Emmrich S, 2016, ONCOGENE, V35, P1822, DOI 10.1038/onc.2015.247; Endig J, 2016, CANCER CELL, V30, P308, DOI 10.1016/j.ccell.2016.06.009; Findlay VJ, 2013, ADV CANCER RES, V119, P1, DOI 10.1016/B978-0-12-407190-2.00001-0; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Guo JM, 2009, J GASTROEN HEPATOL, V24, P652, DOI 10.1111/j.1440-1746.2008.05666.x; Guo WJ, 2015, HEPATOLOGY, V62, P1132, DOI 10.1002/hep.27929; Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838; Haakensen VD, 2016, INT J CANCER, V139, P1117, DOI 10.1002/ijc.30142; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He GF, 2015, NUCLEIC ACIDS RES, V43, P4322, DOI 10.1093/nar/gkv267; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hiroki E, 2010, CANCER SCI, V101, P241, DOI 10.1111/j.1349-7006.2009.01385.x; Hu J, 2016, CANCER CELL, V29, P49, DOI 10.1016/j.ccell.2015.12.005; Huang Y, 2012, NUCLEIC ACIDS RES, V40, P10478, DOI 10.1093/nar/gks789; Li L, 2017, CANCER LETT, V400, P89, DOI 10.1016/j.canlet.2017.04.034; Li QG, 2016, SCI REP-UK, V6, DOI 10.1038/srep27157; Liu L, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.20; Ma XY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6212; Nie HZ, 2015, HEPATOLOGY, V62, P1145, DOI 10.1002/hep.27940; Nucera S, 2016, CANCER CELL, V29, P905, DOI 10.1016/j.ccell.2016.05.007; Pichiorri F, 2016, CANCER CELL, V30, P349, DOI 10.1016/j.ccell.2016.07.007; Rayner KJ, 2010, SCIENCE, V328, P1570, DOI 10.1126/science.1189862; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Rupaimoole R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6202; Shen J, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0105-1; Shen K, 2014, FEBS J, V281, P3609, DOI 10.1111/febs.12880; Tsoulfas G, 2011, J GASTROENTEROL, V46, P249, DOI 10.1007/s00535-010-0302-9; Wang CD, 2015, J BIOL CHEM, V290, P21925, DOI 10.1074/jbc.M115.644864; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228; Wong CCL, 2011, GASTROENTEROLOGY, V140, P322, DOI 10.1053/j.gastro.2010.10.006; Xu K, 2016, ONCOTARGET, V7, P75118, DOI 10.18632/oncotarget.12611; Zeng S, 2017, CANCER LETT, V390, P67, DOI 10.1016/j.canlet.2016.12.042; Zhang Y, 2011, CANCER RES, V71, P3552, DOI 10.1158/0008-5472.CAN-10-2435; Zhao J, 2008, HEPATOLOGY, V48, P265, DOI 10.1002/hep.22280	42	84	86	2	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	12					1624	1636		10.1038/s41388-017-0057-3	http://dx.doi.org/10.1038/s41388-017-0057-3			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA8YC	29335523				2022-12-17	WOS:000428626700006
J	Xue, J; Chi, Y; Chen, Y; Huang, S; Ye, X; Niu, J; Wang, W; Pfeffer, LM; Shao, ZM; Wu, ZH; Wu, J				Xue, J.; Chi, Y.; Chen, Y.; Huang, S.; Ye, X.; Niu, J.; Wang, W.; Pfeffer, L. M.; Shao, Z-m; Wu, Z-H; Wu, J.			MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; PATHOLOGICAL COMPLETE RESPONSE; NEOADJUVANT CHEMOTHERAPY; GENE-EXPRESSION; PACLITAXEL; MICRORNAS; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDICTOR; PROMOTES	MicroRNAs (miRNAs) have been demonstrated to have critical roles in regulating cancer cell proliferation, survival and sensitivity to chemotherapy. The potential application of using miRNAs to predict therapeutic response to cancer treatment holds high promise, but miRNAs with predictive value remain to be identified and underlying mechanisms have not been completely understood. Here, we show a strong correlation between miR-621 expression and chemosensitivity to paclitaxel plus carboplatin (PTX/CBP) regimen, an effective neoadjuvant chemotherapy for breast cancer patients. High level of miR-621 predicts better response to PTX/CBP regimen neoadjuvant chemotherapy in breast cancer patients, who also tend to achieve pathological complete response. Ectopic overexpression of miR-621 promoted apoptosis and increased chemosensitivity to PTX and CBP both in cultured breast cancer cells and in xenograft tumor model. We further show that FBXO11 is a direct functional target of miR-621 and miR-621 level is negatively correlated with FBXO11 expression in breast cancer patients. Ectopic expression of FBXO11 attenuated increased apoptosis in breast cancer cells overexpressing miR-621 upon PTX or CBP treatment. Consistently, high FBXO11 expression significantly correlated with poor survival in breast cancer patients. Mechanistically, we found in breast cancer cells FBXO11 interacts with p53 and promotes its neddylation, which suppressed the p53 transactivity. Accordingly, miR-621-dependent FBXO11 suppression enhanced p53 activity and increased apoptosis in breast cancer cells exposed to chemotherapeutics. Taken together, our data suggest that miR-621 enhances chemosensitivity of breast cancer cells to PTX/CBP chemotherapy by suppressing FBXO11depedent inhibition of p53. miR-621 may serve as a predictive biomarker and a potential therapeutic target in breast cancer treatment.	[Xue, J.; Chi, Y.; Chen, Y.; Huang, S.; Shao, Z-m; Wu, J.] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, 270 Dong An Rd, Shanghai 200032, Peoples R China; [Xue, J.; Chi, Y.; Chen, Y.; Huang, S.; Shao, Z-m; Wu, J.] Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai 200433, Peoples R China; [Xue, J.; Niu, J.; Wang, W.; Pfeffer, L. M.; Wu, Z-H] Univ Tennessee, Ctr Hlth Sci, Ctr Canc Res, 19 S Manassas St, Memphis, TN 38163 USA; [Chen, Y.] Wenzhou Med Coll, Dept Surg Oncol, Affiliated Hosp 1, Wenzhou, Zhejiang, Peoples R China; [Ye, X.] Fudan Univ, Inst Merieux Lab, Shanghai Canc Ctr, Shanghai 200433, Peoples R China; [Niu, J.; Wang, W.; Pfeffer, L. M.; Wu, Z-H] Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, Memphis, TN 38163 USA	Fudan University; Fudan University; University of Tennessee System; University of Tennessee Health Science Center; Wenzhou Medical University; Fudan University; University of Tennessee System; University of Tennessee Health Science Center	Wu, J (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, 270 Dong An Rd, Shanghai 200032, Peoples R China.; Wu, ZH (corresponding author), Univ Tennessee, Ctr Hlth Sci, Ctr Canc Res, 19 S Manassas St, Memphis, TN 38163 USA.	zwu6@uthsc.edu; wujiong1122@vip.sina.com		Pfeffer, Lawrence/0000-0003-2809-1234	National Natural Science Foundation of China (NSFC) [81272924]; National Cancer Institute [R01 CA149251]; American Cancer Society [RSG-13-186-01-CSM]; NATIONAL CANCER INSTITUTE [R01CA149251] Funding Source: NIH RePORTER	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Bert Vogelstein (Johns Hopkins University) for wild-type, DICER<SUP>-/-</SUP> and p53<SUP>-/-</SUP> HCT116 cells. This work was supported in part by the National Natural Science Foundation of China (NSFC) (81272924 to JW), National Cancer Institute (R01 CA149251 to ZW), and American Cancer Society (RSG-13-186-01-CSM to ZW).	Abbas T, 2013, MOL CELL, V49, P1147, DOI 10.1016/j.molcel.2013.02.003; Abida WM, 2007, J BIOL CHEM, V282, P1797, DOI 10.1074/jbc.M609001200; Balko JM, 2014, CANCER DISCOV, V4, P232, DOI 10.1158/2159-8290.CD-13-0286; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Berry DA, 2005, NEW ENGL J MED, V353, P1784, DOI 10.1056/NEJMoa050518; Blower PE, 2008, MOL CANCER THER, V7, P1, DOI 10.1158/1535-7163.MCT-07-0573; Bonnefoi H, 2014, ANN ONCOL, V25, P1128, DOI 10.1093/annonc/mdu118; Borst P, 2010, CELL CYCLE, V9, P4836, DOI 10.4161/cc.9.24.14326; Chang XZ, 2008, BREAST CANCER RES TR, V111, P65, DOI 10.1007/s10549-007-9761-y; Chen XS, 2010, ANN ONCOL, V21, P961, DOI 10.1093/annonc/mdq041; Chen YZ, 2011, CANCER LETT, V302, P63, DOI 10.1016/j.canlet.2010.12.014; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Dhami GK, 2013, MOL CELL, V50, P565, DOI 10.1016/j.molcel.2013.04.028; Dieras V, 2004, J CLIN ONCOL, V22, P4958, DOI 10.1200/JCO.2004.02.122; Duan S, 2012, NATURE, V481, P90, DOI 10.1038/nature10688; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022; Harris L, 2007, J CLIN ONCOL, V25, P5287, DOI 10.1200/JCO.2007.14.2364; Hatzis C, 2011, JAMA-J AM MED ASSOC, V305, P1873, DOI 10.1001/jama.2011.593; Hess KR, 2006, J CLIN ONCOL, V24, P4236, DOI 10.1200/JCO.2006.05.6861; Iwata H, 2011, JPN J CLIN ONCOL, V41, P867, DOI 10.1093/jjco/hyr081; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lawrence G, 2002, J CLIN ONCOL, V20, P2905, DOI 10.1200/JCO.2002.20.12.2905; Lee JK, 2010, CLIN CANCER RES, V16, P711, DOI 10.1158/1078-0432.CCR-09-2247; Li JY, 2012, BREAST CANCER RES TR, V131, P837, DOI 10.1007/s10549-011-1502-6; Li LH, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju083; Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140; Mamounas EP, 2012, J CLIN ONCOL, V30, P3960, DOI 10.1200/JCO.2011.40.8369; Mulrane L, 2013, CANCER RES, V73, P6554, DOI 10.1158/0008-5472.CAN-13-1841; Nowak AK, 2004, LANCET ONCOL, V5, P372, DOI 10.1016/S1470-2045(04)01494-9; Pan YZ, 2009, MOL PHARMACOL, V75, P1374, DOI 10.1124/mol.108.054163; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Powell E, 2014, CANCER DISCOV, V4, P405, DOI 10.1158/2159-8290.CD-13-0136; Shivdasani RA, 2006, BLOOD, V108, P3646, DOI 10.1182/blood-2006-01-030015; Skaar JR, 2013, NAT REV MOL CELL BIO, V14, P369, DOI 10.1038/nrm3582; Skawran B, 2008, MODERN PATHOL, V21, P1479, DOI 10.1038/modpathol.2008.147; Smith IC, 2002, J CLIN ONCOL, V20, P1456, DOI 10.1200/JCO.20.6.1456; Tabchy A, 2010, CLIN CANCER RES, V16, P5351, DOI 10.1158/1078-0432.CCR-10-1265; Thuerigen O, 2006, J CLIN ONCOL, V24, P1839, DOI 10.1200/JCO.2005.04.7019; Walerych D, 2012, CARCINOGENESIS, V33, P2007, DOI 10.1093/carcin/bgs232; Wang H, 2012, PLOS ONE, V7, P34210, DOI DOI 10.1371/J0URNAL.P0NE.0034210; Weigelt B, 2012, NAT REV CLIN ONCOL, V9, P58, DOI 10.1038/nrclinonc.2011.125; Wu X, 2009, BIOINFORMATICS, V25, P832, DOI 10.1093/bioinformatics/btp059; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yang CH, 2015, J BIOL CHEM, V290, P6037, DOI 10.1074/jbc.M114.632125; Yang F, 2012, EMBO J, V31, P110, DOI 10.1038/emboj.2011.364; Yerushalmi R, 2010, LANCET ONCOL, V11, P174, DOI 10.1016/S1470-2045(09)70262-1; Zheng HQ, 2014, CANCER CELL, V26, P358, DOI 10.1016/j.ccr.2014.07.022; Zhou M, 2010, J BIOL CHEM, V285, P21496, DOI 10.1074/jbc.M109.083337	50	84	86	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2016	35	4					448	458		10.1038/onc.2015.96	http://dx.doi.org/10.1038/onc.2015.96			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OT	25867061	hybrid, Green Accepted, Green Published			2022-12-17	WOS:000369056700005
J	Zhao, D; Besser, AH; Wander, SA; Sun, J; Zhou, W; Wang, B; Ince, T; Durante, MA; Guo, W; Mills, G; Theodorescu, D; Slingerland, J				Zhao, D.; Besser, A. H.; Wander, S. A.; Sun, J.; Zhou, W.; Wang, B.; Ince, T.; Durante, M. A.; Guo, W.; Mills, G.; Theodorescu, D.; Slingerland, J.			Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation	ONCOGENE			English	Article							KINASE INHIBITOR P27(KIP1); GROWTH-FACTOR-BETA; CELL-CYCLE; DEPENDENT KINASE; BREAST-CANCER; CDK INHIBITOR; TARGETED THERAPIES; ONCOGENIC FUNCTION; MAMMALIAN-CELLS; MICE LACKING	p27 restrains normal cell growth, but PI3K-dependent C-terminal phosphorylation of p27 at threonine 157 (T157) and T198 promotes cancer cell invasion. Here, we describe an oncogenic feedforward loop in which p27pT157pT198 binds Janus kinase 2 (JAK2) promoting STAT3 (signal transducer and activator of transcription 3) recruitment and activation. STAT3 induces TWIST1 to drive a p27-dependent epithelial-mesenchymal transition (EMT) and further activates AKT contributing to acquisition and maintenance of metastatic potential. p27 knockdown in highly metastatic PI3K-activated cells reduces STAT3 binding to the TWIST1 promoter, TWIST1 promoter activity and TWIST1 expression, reverts EMT and impairs metastasis, whereas activated STAT3 rescues p27 knockdown. Cell cycle-defective phosphomimetic p27T157DT198D (p27CK-DD) activates STAT3 to induce a TWIST1-dependent EMT in human mammary epithelial cells and increases breast and bladder cancer invasion and metastasis. Data support a mechanism in which PI3K-deregulated p27 binds JAK2, to drive STAT3 activation and EMT through STAT3-mediated TWIST1 induction. Furthermore, STAT3, once activated, feeds forward to further activate AKT.	[Zhao, D.; Besser, A. H.; Wander, S. A.; Sun, J.; Zhou, W.; Wang, B.; Ince, T.; Durante, M. A.; Slingerland, J.] Univ Miami, Miller Sch Med, Braman Family Breast Canc Inst, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; [Zhao, D.; Besser, A. H.; Wander, S. A.; Durante, M. A.] Univ Miami, Miller Sch Med, Sheila & David Fuente Grad Program Canc Biol, Miami, FL 33136 USA; [Zhou, W.; Wang, B.; Slingerland, J.] Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA; [Ince, T.] Univ Miami, Miller Sch Med, Stem Cell Res Inst, Dept Pathol, Miami, FL 33136 USA; [Guo, W.; Mills, G.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Guo, W.; Mills, G.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Theodorescu, D.] Univ Colorado, Ctr Canc, Aurora, CO USA; [Slingerland, J.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA	University of Miami; University of Miami; University of Miami; University of Miami; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Miami	Slingerland, J (corresponding author), Univ Miami, Miller Sch Med, Braman Family Breast Canc Inst, Sylvester Comprehens Canc Ctr, 1501 NW 10th Ave,BRB708, Miami, FL 33136 USA.	jslingerland@med.miami.edu	Durante, Michael/ABH-8217-2020; Zhou, Wen/A-5763-2010; Zhao, Dekuang/H-5671-2015	Durante, Michael/0000-0003-3137-6847; Zhou, Wen/0000-0002-5496-5815; Ince, Tan/0000-0003-0315-6425; Zhao, Dekuang/0000-0002-7251-2481	UMSCCC Analytical Imaging Core Facility; Doris Duke Charitable Foundation;  [NCI-2R01CA105118-05A]; NATIONAL CANCER INSTITUTE [R01CA105118, R01CA075115, P50CA083639] Funding Source: NIH RePORTER	UMSCCC Analytical Imaging Core Facility; Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge the support of lab members, the UMSCCC Analytical Imaging Core Facility and Grant NCI-2R01CA105118-05A. A grant from the Doris Duke Charitable Foundation supported AB, SW and JMS.	Ansieau S, 2010, ONCOGENE, V29, P3173, DOI 10.1038/onc.2010.92; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Besson A, 2004, NAT REV CANCER, V4, P948, DOI 10.1038/nrc1501; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Cheng GZ, 2008, J BIOL CHEM, V283, P14665, DOI 10.1074/jbc.M707429200; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Denicourt C, 2007, CANCER RES, V67, P9238, DOI 10.1158/0008-5472.CAN-07-1375; Devarajan E, 2009, CURR MOL MED, V9, P626, DOI 10.2174/156652409788488720; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Fujita N, 2003, J BIOL CHEM, V278, P49254, DOI 10.1074/jbc.M306614200; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hennessy Bryan T, 2010, Clin Proteomics, V6, P129, DOI 10.1007/s12014-010-9055-y; Hidaka T, 2009, ANTICANCER RES, V29, P597; Hong F, 2008, MOL CELL, V30, P701, DOI 10.1016/j.molcel.2008.04.027; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Jakel H, 2011, ONCOGENE, V30, P3502, DOI 10.1038/onc.2011.68; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; Kossatz U, 2006, EMBO J, V25, P5159, DOI 10.1038/sj.emboj.7601388; Kruck S, 2012, BJU INT, V109, P1565, DOI 10.1111/j.1464-410X.2011.10649.x; Larreaa MD, 2009, P NATL ACAD SCI USA, V106, P9268, DOI 10.1073/pnas.0805057106; Li H, 2012, CELL STEM CELL, V11, P845, DOI 10.1016/j.stem.2012.09.014; Li R, 2006, J UROLOGY, V175, P528, DOI 10.1016/S0022-5347(05)00151-5; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liang J, 2002, COLD SPRING HARB CEL, V3; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Lieblein JC, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-302; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Menchon C, 2011, CELL CYCLE, V10, P1435, DOI 10.4161/cc.10.9.15421; Micalizzi DS, 2010, J MAMMARY GLAND BIOL, V15, P117, DOI 10.1007/s10911-010-9178-9; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Motti ML, 2004, CELL CYCLE, V3, P1074; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nitz MD, 2008, METHOD ENZYMOL, V439, P219, DOI 10.1016/S0076-6879(07)00417-X; Pippa R, 2012, ONCOGENE, V31, P4207, DOI 10.1038/onc.2011.582; Piva R, 1999, J NEUROPATH EXP NEUR, V58, P691, DOI 10.1097/00005072-199907000-00002; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Serres MP, 2011, ONCOGENE, V30, P2846, DOI 10.1038/onc.2011.9; Sethi N, 2011, NAT REV CANCER, V11, P735, DOI 10.1038/nrc3125; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wander SA, 2013, BREAST CANCER RES TR, V138, P369, DOI 10.1007/s10549-012-2389-6; Wander SA, 2011, CLIN CANCER RES, V17, P12, DOI 10.1158/1078-0432.CCR-10-0752; Xiong H, 2012, J BIOL CHEM, V287, P5819, DOI 10.1074/jbc.M111.295964; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	60	84	89	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2015	34	43					5447	5459		10.1038/onc.2014.473	http://dx.doi.org/10.1038/onc.2014.473			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EM	25684140	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000363479700005
J	Zhang, Z; Liu, X; Feng, B; Liu, N; Wu, Q; Han, Y; Nie, Y; Wu, K; Shi, Y; Fan, D				Zhang, Z.; Liu, X.; Feng, B.; Liu, N.; Wu, Q.; Han, Y.; Nie, Y.; Wu, K.; Shi, Y.; Fan, D.			STIM1, a direct target of microRNA-185, promotes tumor metastasis and is associated with poor prognosis in colorectal cancer	ONCOGENE			English	Article							STROMAL INTERACTION MOLECULE-1; ACTIVATES CRAC CHANNELS; CA2+ INFLUX; MESENCHYMAL TRANSITION; CALCIUM; GROWTH; MIR-185; STORE; MIGRATION; SENSOR	STIM1 (stromal interaction molecule 1), an endoplasmic reticulum Ca2+ sensor that triggers the store-operated Ca2+ entry activation, has recently been implicated in cancer progression. However, the role of STIM1 in the progression and metastasis of colorectal cancer (CRC) has not been addressed. In this study, we confirmed increased expression of STIM1 in highly invasive CRC cell lines. Enhanced expression of STIM1 promoted CRC cell metastasis in vitro and in vivo, whereas silencing of STIM1 with small interfering RNA resulted in reduced metastasis. Ectopic expression of STIM1 in CRC cells induced epithelial-to-mesenchymal transition (EMT), whereas silencing of STIM1 had the opposite effect. Furthermore, STIM1 expression was markedly higher in CRC tissues than in adjacent noncancerous tissues. STIM1 overexpression correlated with poor differentiation and higher tumor node metastasis stage. CRC patients with positive STIM1 expression had poorer prognoses than those with negative STIM1 expression. Moreover, STIM1 was found to be a direct target of miR-185, a microRNA (miRNA) that has not previously been reported to be involved in EMT, in both CRC tissues and cell lines. Taken together, these findings demonstrate for the first time that STIM1 promotes metastasis and is associated with cancer progression and poor prognosis in patients with CRC. In addition, we show that expression of STIM1 is regulated by a posttranscriptional regulatory mechanism mediated by a new EMT-related miRNA. This novel miR-185-STIM1 axis promotes CRC metastasis and may be a candidate biomarker for prognosis and a target for new therapies.	[Zhang, Z.; Liu, X.; Feng, B.; Liu, N.; Wu, Q.; Han, Y.; Nie, Y.; Wu, K.; Shi, Y.; Fan, D.] Fourth Mil Med Univ, State Key Lab Canc Biol, 127 Chang Le West Rd, Xian 710032, Shaanxi, Peoples R China; [Zhang, Z.; Liu, X.; Feng, B.; Liu, N.; Wu, Q.; Han, Y.; Nie, Y.; Wu, K.; Shi, Y.; Fan, D.] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian 710032, Shaanxi, Peoples R China	Air Force Military Medical University; Air Force Military Medical University	Shi, Y (corresponding author), Fourth Mil Med Univ, State Key Lab Canc Biol, 127 Chang Le West Rd, Xian 710032, Shaanxi, Peoples R China.; Shi, Y (corresponding author), Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian 710032, Shaanxi, Peoples R China.	shiyquan@fmmu.edu.cn; daimingfan@fmmu.edu.cn	Shi, Yongquan/AAE-3954-2020		National Basic Research Program of China [2010CB732405, 2010CB529300]; National Natural Science Foundation of China [81030044, 81272343, 81070326, 81172096, 81472300, 81472301, 81201632, 30900675]; National Science and Technology Projects of China [2014ZX09508002]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Projects of China	This work was supported by National Basic Research Program of China (Grant nos: 2010CB732405 and 2010CB529300), National Natural Science Foundation of China (Grant nos: 81030044, 81272343, 81070326, 81172096, 81472300, 81472301, 81201632 and 30900675) and National Science and Technology Projects of China (Grant no.: 2014ZX09508002).	Akcakaya P, 2011, INT J ONCOL, V39, P311, DOI 10.3892/ijo.2011.1043; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Center MM, 2009, CA-CANCER J CLIN, V59, P366, DOI 10.3322/caac.20038; Chen YF, 2011, P NATL ACAD SCI USA, V108, P15225, DOI 10.1073/pnas.1103315108; Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872; Duranton B, 2003, AMINO ACIDS, V24, P63, DOI 10.1007/s00726-002-0333-5; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Gregory PA, 2008, CELL CYCLE, V7, P3112, DOI 10.4161/cc.7.20.6851; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058; Guo RW, 2009, CARDIOVASC RES, V81, P660, DOI 10.1093/cvr/cvn338; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hu JJ, 2011, BIOCHEM BIOPH RES CO, V411, P786, DOI 10.1016/j.bbrc.2011.07.025; Imam JS, 2010, ONCOGENE, V29, P4971, DOI 10.1038/onc.2010.233; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kraljevic Pavelic S., 2011, MOL CANCER, V10, P22, DOI DOI 10.1186/1476-4598-10-22; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lioudyno MI, 2008, P NATL ACAD SCI USA, V105, P2011, DOI 10.1073/pnas.0706122105; Liu M, 2011, CANCER LETT, V301, P151, DOI 10.1016/j.canlet.2010.11.009; Liu XQ, 2011, CARCINOGENESIS, V32, P1798, DOI 10.1093/carcin/bgr213; Loboda A, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-9; Lu WJ, 2009, AM J PHYSIOL-LUNG C, V297, pL17, DOI 10.1152/ajplung.00063.2009; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Okabe H, 1999, INT J IMPOT RES, V11, P133, DOI 10.1038/sj.ijir.3900394; Parekh AB, 2010, NAT REV DRUG DISCOV, V9, P399, DOI 10.1038/nrd3136; Park CY, 2009, CELL, V136, P876, DOI 10.1016/j.cell.2009.02.014; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Prevarskaya N, 2011, NAT REV CANCER, V11, P609, DOI 10.1038/nrc3105; Putney JW, 2005, J CELL BIOL, V169, P381, DOI 10.1083/jcb.200503161; Ritchie MF, 2011, FRONT BIOSCI-LANDMRK, V16, P2402, DOI 10.2741/3862; Roberts-Thomson SJ, 2010, PHARMACOL THERAPEUT, V127, P121, DOI 10.1016/j.pharmthera.2010.04.016; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Stanisz H, 2014, PIGM CELL MELANOMA R, V27, P442, DOI 10.1111/pcmr.12222; Suyama E, 2004, J BIOL CHEM, V279, P38083, DOI 10.1074/jbc.C400313200; Takahashi Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006677; Tan ZQ, 2014, MOL CELL BIOCHEM, V386, P223, DOI 10.1007/s11010-013-1860-y; Tang HL, 2012, CURR CANCER DRUG TAR, V12, P1032, DOI 10.2174/156800912803251180; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Varga-Szabo D, 2008, J EXP MED, V205, P1583, DOI 10.1084/jem.20080302; Wang ZW, 2010, DRUG RESIST UPDATE, V13, P109, DOI 10.1016/j.drup.2010.07.001; Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019; Yang SY, 2005, J BIOL CHEM, V280, P27130, DOI 10.1074/jbc.M501625200; Yoon JH, 2013, CLIN CANCER RES, V19, P4599, DOI 10.1158/1078-0432.CCR-12-3675; Zhang H, 2010, ONCOGENE, V29, P937, DOI 10.1038/onc.2009.406; Zhang SL, 2006, P NATL ACAD SCI USA, V103, P9357, DOI 10.1073/pnas.0603161103; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147; Zhao LA, 2010, GUT, V59, P1226, DOI 10.1136/gut.2009.202739; Zhi QM, 2013, BIOMED PHARMACOTHER, V67, P393, DOI 10.1016/j.biopha.2013.03.022; Zhuang R, 2013, NUCLEIC ACIDS RES, V41, P7905, DOI 10.1093/nar/gkt565	51	84	88	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2015	34	37					4808	4820		10.1038/onc.2014.404	http://dx.doi.org/10.1038/onc.2014.404			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR0YP	25531324	Green Published, hybrid			2022-12-17	WOS:000361050000002
J	Du, W; Elemento, O				Du, W.; Elemento, O.			Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies	ONCOGENE			English	Review							CELL LUNG-CANCER; BREAST-CANCER; CLONAL EVOLUTION; DNA METHYLATION; IN-VIVO; INTRATUMOR HETEROGENEITY; TUMOR HETEROGENEITY; GENOMIC INSTABILITY; GENE; RESISTANCE	The transformation of normal cells into cancer cells and maintenance of the malignant state and phenotypes are associated with genetic and epigenetic deregulations, altered cellular signaling responses and aberrant interactions with the microenvironment. These alterations are constantly evolving as tumor cells face changing selective pressures induced by the cells themselves, the microenvironment and drug treatments. Tumors are also complex ecosystems where different, sometime heterogeneous, subclonal tumor populations and a variety of nontumor cells coexist in a constantly evolving manner. The interactions between molecules and between cells that arise as a result of these alterations and ecosystems are even more complex. The cancer research community is increasingly embracing this complexity and adopting a combination of systems biology methods and integrated analyses to understand and predictively model the activity of cancer cells. Systems biology approaches are helping to understand the mechanisms of tumor progression and design more effective cancer therapies. These approaches work in tandem with rapid technological advancements that enable data acquisition on a broader scale, with finer accuracy, higher dimensionality and higher throughput than ever. Using such data, computational and mathematical models help identify key deregulated functions and processes, establish predictive biomarkers and optimize therapeutic strategies. Moving forward, implementing patient-specific computational and mathematical models of cancer will significantly improve the specificity and efficacy of targeted therapy, and will accelerate the adoption of personalized and precision cancer medicine.	[Elemento, O.] Weill Cornell Med Coll, Lab Canc Syst Biol, Sandra & Edward Meyer Canc Ctr, Dept Physiol & Biophys,Inst Computat Biomed, New York, NY 10021 USA; Weill Cornell Med Coll, Inst Precis Med, New York, NY 10021 USA	Cornell University; Cornell University	Elemento, O (corresponding author), Weill Cornell Med Coll, Lab Canc Syst Biol, Sandra & Edward Meyer Canc Ctr, Dept Physiol & Biophys,Inst Computat Biomed, 1305 York Ave, New York, NY 10021 USA.	ole2001@med.cornell.edu			NIH; CAREER Grant from National Science Foundation; Starr Cancer Consortium; Hirschl Trust	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CAREER Grant from National Science Foundation; Starr Cancer Consortium; Hirschl Trust	We gratefully acknowledge insightful comments from Dr Yanwen Jiang (Elemento lab) and our anonymous reviewer. We also thank other members in the laboratory and Physiology, Biophysics and Systems Biology program of Weill Cornell Graduate School for helpful discussions. This work was supported by NIH, CAREER Grant from National Science Foundation, Starr Cancer Consortium and Hirschl Trust.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Almendro V, 2014, CELL REP, V6, P514, DOI 10.1016/j.celrep.2013.12.041; Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650; [Anonymous], 2013, NATURE, V499, P43, DOI [10.1038/nature12222, DOI 10.1038/NATURE12222, DOI 10.1038/nature12222]; Ashworth A, 2011, CELL, V145, P30, DOI 10.1016/j.cell.2011.03.020; Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Basanta D, 2012, MOL PHARMACEUT, V9, P914, DOI 10.1021/mp200458e; Bashashati A, 2013, J PATHOL, V231, P21, DOI 10.1002/path.4230; Bendall SC, 2011, SCIENCE, V332, P687, DOI 10.1126/science.1198704; Berger MF, 2012, NATURE, V485, P502, DOI 10.1038/nature11071; Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Booth MJ, 2012, SCIENCE, V336, P934, DOI 10.1126/science.1220671; Burstein HJ, 2005, NEW ENGL J MED, V353, P1652, DOI 10.1056/NEJMp058197; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Casado P, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003573; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cheng WY, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005974; Choe SC, 2011, SCI REP-UK, V1, DOI 10.1038/srep00031; Choi Jae Duk, 2013, Genomics & Informatics, V11, P164, DOI 10.5808/GI.2013.11.4.164; Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Cleary AS, 2014, NATURE, V508, P113, DOI 10.1038/nature13187; Costello JC, 2014, NAT BIOTECHNOL; Dalerba P, 2011, NAT BIOTECHNOL, V29, P1120, DOI 10.1038/nbt.2038; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Palma M, 2013, CANCER CELL, V23, P277, DOI 10.1016/j.ccr.2013.02.013; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Eikenberry S, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000362; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Eswaran J, 2013, SCI REP-UK, V3, DOI 10.1038/srep01689; Eswaran J, 2012, SCI REP-UK, V2, DOI 10.1038/srep00264; Faratian D, 2009, CANCER RES, V69, P6713, DOI 10.1158/0008-5472.CAN-09-0777; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696; Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Greger JG, 2012, MOL CANCER THER, V11, P909, DOI 10.1158/1535-7163.MCT-11-0989; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865; Harris TJR, 2010, NAT REV CLIN ONCOL, V7, P251, DOI 10.1038/nrclinonc.2010.41; Hay M, 2014, NAT BIOTECHNOL, V32, P40, DOI 10.1038/nbt.2786; Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111; Horvath A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02256; Hou Y, 2012, CELL, V148, P873, DOI 10.1016/j.cell.2012.02.028; Hu J, 2013, NAT BIOTECHNOL, V31, P522, DOI 10.1038/nbt.2530; Jahchan NS, 2013, CANCER DISCOV, V3, P1364, DOI 10.1158/2159-8290.CD-13-0183; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Johnson BE, 2014, SCIENCE, V343, P189, DOI 10.1126/science.1239947; Jones S, 2009, SCIENCE, V324, P217, DOI 10.1126/science.1171202; Kahlert C, 2014, BRIT J CANCER, V110, P441, DOI 10.1038/bjc.2013.745; Karr JR, 2012, CELL, V150, P389, DOI 10.1016/j.cell.2012.05.044; Kenny HA, 2007, INT J CANCER, V121, P1463, DOI 10.1002/ijc.22874; Keutgen XM, 2012, CLIN CANCER RES, V18, P2032, DOI 10.1158/1078-0432.CCR-11-2487; Kim JH, 2011, GENOME RES, V21, P1028, DOI 10.1101/gr.119347.110; Kirouac DC, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004008; Klinger B, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.29; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Korolev KS, 2014, NAT REV CANCER, V14, P371, DOI 10.1038/nrc3712; Kreso A, 2013, SCIENCE, V339, P543, DOI 10.1126/science.1227670; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Landan G, 2012, NAT GENET, V44, P1207, DOI 10.1038/ng.2442; Landau DA, 2013, CELL, V152, P714, DOI 10.1016/j.cell.2013.01.019; Leder K, 2014, CELL, V156, P603, DOI 10.1016/j.cell.2013.12.029; Lee W, 2010, NATURE, V465, P473, DOI 10.1038/nature09004; Ley TJ, 2008, NATURE, V456, P66, DOI 10.1038/nature07485; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lohr JG, 2014, CANCER CELL, V25, P91, DOI 10.1016/j.ccr.2013.12.015; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Lu Y, 2011, ONCOGENE, V30, P4567, DOI 10.1038/onc.2011.164; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Maher CA, 2009, NATURE, V458, P97, DOI 10.1038/nature07638; Mao ML, 2013, CLIN CANCER RES, V19, P657, DOI 10.1158/1078-0432.CCR-11-1446; Margolin AA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006112; Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261; McFarland CD, 2013, P NATL ACAD SCI USA, V110, P2910, DOI 10.1073/pnas.1213968110; Metzker ML, 2010, NAT REV GENET, V11, P31, DOI 10.1038/nrg2626; Moritz A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000998; Muller FL, 2012, NATURE, V488, P337, DOI 10.1038/nature11331; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Nakasone ES, 2012, CANCER CELL, V21, P488, DOI 10.1016/j.ccr.2012.02.017; Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Niepel M, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004379; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Ojesina AI, 2014, NATURE, V506, P371, DOI 10.1038/nature12881; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Oved K, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.15; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Pan H, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.634.634; Park ES, 2011, P NATL ACAD SCI USA, V108, P17456, DOI 10.1073/pnas.1114210108; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Pierobon M, 2015, ONCOGENE, V34, P805, DOI 10.1038/onc.2014.16; Pike BL, 2008, LEUKEMIA, V22, P1035, DOI 10.1038/leu.2008.18; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Poon SL, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006086; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Reth M, 2004, NAT REV IMMUNOL, V4, P269, DOI 10.1038/nri1335; Roychowdhury S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003161; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Sheehan KM, 2008, ONCOGENE, V27, P323, DOI 10.1038/sj.onc.1210647; Shih AH, 2012, NAT REV CANCER, V12, P599, DOI 10.1038/nrc3343; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sottoriva A, 2013, P NATL ACAD SCI USA, V110, P4009, DOI 10.1073/pnas.1219747110; Spurrier B, 2008, NAT PROTOC, V3, P1796, DOI 10.1038/nprot.2008.179; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Suva ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184; Tamborero D, 2013, SCI REP-UK, V3, DOI 10.1038/srep02650; Vakoc BJ, 2009, NAT MED, V15, P1219, DOI 10.1038/nm.1971; Van Allen EM, 2014, NAT MED, V20, P682, DOI 10.1038/nm.3559; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vandin F, 2011, J COMPUT BIOL, V18, P507, DOI 10.1089/cmb.2010.0265; Vaske CJ, 2010, BIOINFORMATICS, V26, pi237, DOI 10.1093/bioinformatics/btq182; Venkatasubramanian R, 2010, BRIT J CANCER, V103, P486, DOI 10.1038/sj.bjc.6605773; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wagner JP, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003994; Wang K, 2009, NAT BIOTECHNOL, V27, P829, DOI 10.1038/nbt.1563; Wang YG, 2014, NAT MATER, V13, P204, DOI [10.1038/nmat3819, 10.1038/NMAT3819]; Wargo AR, 2007, P NATL ACAD SCI USA, V104, P19914, DOI 10.1073/pnas.0707766104; Wistuba II, 2011, NAT REV CLIN ONCOL, V8, P135, DOI 10.1038/nrclinonc.2011.2; Wright G, 2003, P NATL ACAD SCI USA, V100, P9991, DOI 10.1073/pnas.1732008100; Wu YM, 2013, SCI REP-UK, V3, P1, DOI [10.1038/srep02326, 10.1038/srep03248]; Wu Y, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002355; Xu X, 2012, CELL, V148, P886, DOI 10.1016/j.cell.2012.02.025; Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67	139	84	84	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	25					3215	3225		10.1038/onc.2014.291	http://dx.doi.org/10.1038/onc.2014.291			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK9XH	25220419				2022-12-17	WOS:000356592300001
J	Miow, QH; Tan, TZ; Ye, J; Lau, JA; Yokomizo, T; Thiery, JP; Mori, S				Miow, Q. H.; Tan, T. Z.; Ye, J.; Lau, J. A.; Yokomizo, T.; Thiery, J-P; Mori, S.			Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer	ONCOGENE			English	Article							NF-KAPPA-B; PLATINUM-BASED CHEMOTHERAPY; GERM-CELL TUMORS; TRANSCRIPTION FACTORS SNAIL; BREAST-CANCER; DRUG-RESISTANCE; MOLECULAR SUBTYPES; CYCLE PROGRESSION; INDUCED APOPTOSIS; OXIDATIVE STRESS	Chemoresistance to platinums, such as cisplatin, is of critical concern in the treatment of ovarian cancer. Recent evidence has linked epithelial-mesenchymal transition (EMT) as a contributing mechanism. The current study explored the connection between cellular responses to cisplatin and EMT in ovarian cancer. Expression microarrays were utilized to estimate the EMT status as a binary phenotype, and the transcriptional responses of 46 ovarian cancer cell lines to cisplatin were measured at dosages equivalent to 50% growth inhibition. Phenotypic responses to cisplatin were quantified with respect to cell number, proliferation rate and apoptosis, and then compared with the epithelial or mesenchymal status. Ovarian cancer cell lines with an epithelial status exhibited higher resistance to cisplatin treatment in the MTS assay than those with a mesenchymal status. Pathway analyses revealed the induction of G1/S- and S-phase genes (P = 0.001) and the activation of multiple NF-kappa B (nuclear factor kappa-light-chain-enhancer of activated B cells) downstream genes (P = 0.0016) by cisplatin selectively in epithelial-like cell lines. BrdU incorporation and Caspase-3/7 release assays confirmed impaired apoptosis in epithelial-like ovarian cancer cells. In clinical samples, we observed resistance to single platinum treatment and the selective activation of the NF-kappa B pathway by platinum in ovarian cancers with an epithelial status. Overall, our results suggest that, in epithelial-like ovarian cancer cells, NF-kappa B activation by cisplatin may lead to defective apoptosis, preferential proliferation arrest and a consequential decreased sensitivity to cisplatin.	[Miow, Q. H.; Tan, T. Z.; Lau, J. A.; Thiery, J-P; Mori, S.] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117548, Singapore; [Miow, Q. H.] Natl Univ Singapore, Grad Sch Integrat Sci & Engn, Singapore, Singapore; [Ye, J.] Natl Univ Singapore, Yong Loo Lin Sch Med, Deans Off, Singapore, Singapore; [Yokomizo, T.; Mori, S.] Japanese Fdn Canc Res, Inst Canc, Div Canc Genom, Tokyo 1358550, Japan; [Thiery, J-P] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore; [Thiery, J-P] Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore	National University of Singapore; National University of Singapore; National University of Singapore; Japanese Foundation for Cancer Research; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Mori, S (corresponding author), Japanese Fdn Canc Res, Inst Canc, Div Canc Genom, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.	seiichi.mori@jfcr.or.jp	Tan, Tuan Zea/I-9227-2019; Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Tan, Tuan Zea/0000-0001-6624-1593; Miow, Qing Hao/0000-0001-8029-8238; Thiery, Jean Paul/0000-0003-0478-5020; Ye, Jieru/0000-0002-5776-9385	Cancer Science Institute of Singapore; Institute of Molecular and Cell Biology at A*STAR, Singapore; Vehicle Racing Commemorative Foundation in Japan; Princess Takamatsu Cancer Research Fund	Cancer Science Institute of Singapore; Institute of Molecular and Cell Biology at A*STAR, Singapore; Vehicle Racing Commemorative Foundation in Japan; Princess Takamatsu Cancer Research Fund	We thank Drs K Yamaguchi, N Matsumura and S Murphy for kindly providing us with a panel of ovarian cancer cell lines. We thank Dr R Jackson for her careful editing of the English language. This work was supported in part through a grant from the Cancer Science Institute of Singapore, the Institute of Molecular and Cell Biology at A*STAR, Singapore, the Vehicle Racing Commemorative Foundation in Japan and the Princess Takamatsu Cancer Research Fund.	Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123; Ahmed AA, 2007, CANCER CELL, V12, P514, DOI 10.1016/j.ccr.2007.11.014; Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bentires-Alj M, 2003, ONCOGENE, V22, P90, DOI 10.1038/sj.onc.1206056; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bremmer F, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-19; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Coleman RL, 2013, NAT REV CLIN ONCOL, V10, P211, DOI 10.1038/nrclinonc.2013.5; Davidson B, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00033; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; Du FF, 2013, ONCOL REP, V30, P1113, DOI 10.3892/or.2013.2567; Escarcega RO, 2007, CLIN ONCOL-UK, V19, P154, DOI 10.1016/j.clon.2006.11.013; Gatti L, 2002, CELL DEATH DIFFER, V9, P1352, DOI 10.1038/sj.cdd.4401109; Godwin P, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00120; Gupta N, 2013, GYNECOL ONCOL, V130, P200, DOI 10.1016/j.ygyno.2013.03.019; Haslehurst AM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-91; Helleman J, 2010, GYNECOL ONCOL, V117, P170, DOI 10.1016/j.ygyno.2010.01.010; Huang RYJ, 2012, CURR DRUG TARGETS, V13, P1649; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Kajiyama H, 2007, INT J ONCOL, V31, P277; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kang J, 2012, JNCI-J NATL CANCER I, V104, P670, DOI 10.1093/jnci/djs177; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Kondoh E, 2010, INT J CANCER, V126, P2448, DOI 10.1002/ijc.24919; Kurrey NK, 2005, GYNECOL ONCOL, V97, P155, DOI 10.1016/j.ygyno.2004.12.043; Latifi A, 2011, J CELL BIOCHEM, V112, P2850, DOI 10.1002/jcb.23199; Leitao MM, 2009, SEMIN ONCOL, V36, P106, DOI 10.1053/j.seminoncol.2008.12.002; Li QQ, 2009, CLIN CANCER RES, V15, P2657, DOI 10.1158/1078-0432.CCR-08-2372; Lin-Chao S., 1994, J Biomed Sci, V1, P131, DOI 10.1007/BF02257987; Liu GH, 2006, INT J GYNECOL CANCER, V16, P1777, DOI 10.1111/j.1525-1438.2006.00652.x; Mabuchi S, 2004, J BIOL CHEM, V279, P23477, DOI 10.1074/jbc.M313709200; Marchini S, 2013, EUR J CANCER, V49, P520, DOI 10.1016/j.ejca.2012.06.026; Masters JRW, 2003, NAT REV CANCER, V3, P517, DOI 10.1038/nrc1120; Matsumura N, 2011, GENOME RES, V21, P74, DOI 10.1101/gr.108803.110; MIETTINEN M, 1985, AM J PATHOL, V120, P402; Mizuno H, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-137; Mueller S, 2006, INT J ONCOL, V29, P471; Nakamura Y, 2004, CANCER SCI, V95, P7, DOI 10.1111/j.1349-7006.2004.tb03163.x; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; OSTROW S, 1980, CANCER CLIN TRIALS, V3, P23; Parajuli B, 2013, CANCER EPIDEMIOL, V37, P512, DOI 10.1016/j.canep.2013.02.008; PARKER RJ, 1991, J CLIN INVEST, V87, P772, DOI 10.1172/JCI115080; Perez RP, 1998, EUR J CANCER, V34, P1535, DOI 10.1016/S0959-8049(98)00227-5; Qin LF, 2002, CANCER LETT, V175, P27, DOI 10.1016/S0304-3835(01)00720-0; Rosano L, 2011, CLIN CANCER RES, V17, P2350, DOI 10.1158/1078-0432.CCR-10-2325; Rustin GJS, 2006, J CLIN ONCOL, V24, P45, DOI 10.1200/JCO.2005.01.2757; Samanta AK, 2004, J BIOL CHEM, V279, P7576, DOI 10.1074/jbc.M311659200; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Shah MA, 2001, CLIN CANCER RES, V7, P2168; Shen DW, 2012, PHARMACOL REV, V64, P706, DOI 10.1124/pr.111.005637; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725; Simons AL, 2007, CANCER RES, V67, P3364, DOI 10.1158/0008-5472.CAN-06-3717; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Solomon LA, 2008, J OVARIAN RES, V1, DOI 10.1186/1757-2215-1-9; SORENSON CM, 1988, CANCER RES, V48, P4484; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tan TZ, 2013, EMBO MOL MED, V5, P1051, DOI 10.1002/emmm.201201823; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tomaskovic-Crook E, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2416; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Troester MA, 2004, CANCER RES, V64, P4218, DOI 10.1158/0008-5472.CAN-04-0107; Verhaak RGW, 2013, J CLIN INVEST, V123, P517, DOI 10.1172/JCI65833; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Weir NM, 2007, CANCER BIOL THER, V6, P178, DOI 10.4161/cbt.6.2.3577; Wintzell M, 2012, CANCER BIOL THER, V13, P1454, DOI 10.4161/cbt.22007; Xiao GT, 2011, AM J CANCER RES, V1, P192; Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038; Yang D, 2013, CANCER CELL, V23, P186, DOI 10.1016/j.ccr.2012.12.020; Yip HT, 2006, ARCH OTOLARYNGOL, V132, P317, DOI 10.1001/archotol.132.3.317; Yue P, 2012, ONCOGENE, V31, P2309, DOI 10.1038/onc.2011.409	76	84	87	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					1899	1907		10.1038/onc.2014.136	http://dx.doi.org/10.1038/onc.2014.136			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24858042				2022-12-17	WOS:000352725600004
J	Di Giandomenico, S; Frapolli, R; Bello, E; Uboldi, S; Licandro, SA; Marchini, S; Beltrame, L; Brich, S; Mauro, V; Tamborini, E; Pilotti, S; Casali, PG; Grosso, F; Sanfilippo, R; Gronchi, A; Mantovani, R; Gatta, R; Galmarini, CM; Sousa-Faro, JMF; D'Incalci, M				Di Giandomenico, S.; Frapolli, R.; Bello, E.; Uboldi, S.; Licandro, S. A.; Marchini, S.; Beltrame, L.; Brich, S.; Mauro, V.; Tamborini, E.; Pilotti, S.; Casali, P. G.; Grosso, F.; Sanfilippo, R.; Gronchi, A.; Mantovani, R.; Gatta, R.; Galmarini, C. M.; Sousa-Faro, J. M. F.; D'Incalci, M.			Mode of action of trabectedin in myxoid liposarcomas	ONCOGENE			English	Article						trabectedin; myxoid liposarcoma; xenografts; differentiation; transcription regulation	NUCLEOTIDE-EXCISION-REPAIR; ROUND-CELL LIPOSARCOMA; CHOP FUSION PROTEIN; ANTITUMOR-ACTIVITY; SOFT-TISSUE; TRANSCRIPTIONAL ACTIVATION; ADIPOCYTE DIFFERENTIATION; ECTEINASCIDIN 743; BINDING PROTEIN; MINOR-GROOVE	To elucidate the mechanisms behind the high sensitivity of myxoid/round cell liposarcoma (MRCL) to trabectedin and the suggested selectivity for specific subtypes, we have developed and characterized three MRCL xenografts, namely ML017, ML015 and ML004 differing for the break point of the fusion gene FUS-CHOP, respectively of type I, II and III. FUS-CHOP binding to the promoters of some target genes such as Pentraxin 3 or Fibronectin 1, assessed by chromatin immunoprecipitation, was strongly reduced in the tumor 24 h after the first or the third weekly dose of trabectedin, indicating that the drug at therapeutic doses causes a detachment of the FUS-CHOP chimera from its target promoters as previously shown in vitro. Moreover, the higher sensitivity of MRCL types I and II appears to be related to a more prolonged block of the transactivating activity of the fusion protein. Doxorubicin did not affect the binding of FUS-CHOP to target promoters. Histologically, the response to trabectedin in ML017 and ML015 was associated with a marked depletion of non-lipogenic tumoral cells and vascular component, as well as lipidic maturation as confirmed by PPAR gamma 2 expression in western Blot. By contrast, in ML004 no major changes either in the cellularity or in the amount of mature were found, and consistently PPAR gamma 2 was null. In conclusion, the data support the view that the selective mechanism of action of trabectedin in MRCL is specific and related to its ability to cause a functional inactivation of the oncogenic chimera with consequent derepression of the adypocytic differentiation.	[Di Giandomenico, S.; Frapolli, R.; Bello, E.; Uboldi, S.; Licandro, S. A.; Marchini, S.; Beltrame, L.; D'Incalci, M.] Ist Ric Farmacol Mario Negri, IRCCS, Dept Oncol, I-20156 Milan, Italy; [Brich, S.; Mauro, V.; Tamborini, E.; Pilotti, S.] Fdn IRCCS Ist Nazl Tumori, Dept Pathol, Milan, Italy; [Casali, P. G.; Sanfilippo, R.] Fdn IRCCS Ist Nazl Tumori, Dept Canc Med, Adult Sarcoma Med Treatment Unit, Milan, Italy; [Grosso, F.] SS Antonio & Biagio Gen Hosp, Dept Oncol, Alessandria, Italy; [Gronchi, A.] Fdn IRCCS Ist Nazl Tumori, Dept Surg, Milan, Italy; [Mantovani, R.; Gatta, R.] Univ Milan, Dipartimento Biosci, Milan, Italy; [Galmarini, C. M.; Sousa-Faro, J. M. F.] PharmaMar SA, Madrid, Spain	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Azienda Ospedaliera SS Antonio Biagio Cesare Arrigo; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milan; PharmaMar	D'Incalci, M (corresponding author), Ist Ric Farmacol Mario Negri, IRCCS, Dept Oncol, Via La Masa 19, I-20156 Milan, Italy.	maurizio.dincalci@marionegri.it	Marchini, sergio/J-3968-2018; Sanfilippo, Roberta/E-2123-2017; Beltrame, Luca/AAB-1998-2020; Gronchi, Alessandro/O-6589-2016; Bello, Ezia/AAB-2210-2020; D'Incalci, Maurizio/AAA-9021-2020; Brich, Silvia/AAC-1283-2019; Tamborini, Elena/C-3307-2017; brich, silvia/K-4049-2016; Frapolli, Roberta/AAA-6729-2020; casali, Paolo Giovanni/D-1524-2017	Marchini, sergio/0000-0003-1783-7651; Sanfilippo, Roberta/0000-0002-9704-0521; Beltrame, Luca/0000-0003-3631-6544; Gronchi, Alessandro/0000-0002-4703-3534; Bello, Ezia/0000-0001-5116-0758; D'Incalci, Maurizio/0000-0001-8784-1360; Brich, Silvia/0000-0002-6359-1712; Tamborini, Elena/0000-0002-3819-8687; brich, silvia/0000-0002-6359-1712; Frapolli, Roberta/0000-0003-2907-273X; casali, Paolo Giovanni/0000-0003-4056-8023; Licandro, Simonetta Andrea/0000-0001-7597-7084; Galmarini, Carlos Maria/0000-0001-5494-6617; Uboldi, Sarah/0000-0002-6430-0323	AIRC grants	AIRC grants(Fondazione AIRC per la ricerca sul cancro)	The study was supported by two AIRC grants to MD and SP.	Adelmant G, 1998, J BIOL CHEM, V273, P15574, DOI 10.1074/jbc.273.25.15574; [Anonymous], 2002, PATHOLOGY GENETICS T; Antonescu CR, 2001, CLIN CANCER RES, V7, P3977; Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; Bode-Lesniewska B, 2007, GENE CHROMOSOME CANC, V46, P961, DOI 10.1002/gcc.20478; Bonfanti M, 1999, ANTI-CANCER DRUG DES, V14, P179; BROGGINI M, 1994, ANTI-CANCER DRUG DES, V9, P373; BROGGINI M, 1995, NUCLEIC ACIDS RES, V23, P81, DOI 10.1093/nar/23.1.81; Charytonowicz E, 2012, J CLIN INVEST, V122, P886, DOI 10.1172/JCI60015; CHIANG SY, 1994, BIOCHEMISTRY-US, V33, P7033, DOI 10.1021/bi00189a003; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; D'Incalci A, 2003, EXPERT OPIN INV DRUG, V12, P1843; D'Incalci M, 2010, MOL CANCER THER, V9, P2157, DOI 10.1158/1535-7163.MCT-10-0263; Damia G, 1996, INT J CANCER, V66, P779, DOI 10.1002/(SICI)1097-0215(19960611)66:6<779::AID-IJC12>3.0.CO;2-Z; Demicco EG, 2012, MODERN PATHOL, V25, P212, DOI 10.1038/modpathol.2011.148; Dervan PB, 1999, CURR OPIN CHEM BIOL, V3, P688, DOI 10.1016/S1367-5931(99)00027-7; Erba E, 2001, EUR J CANCER, V37, P97, DOI 10.1016/S0959-8049(00)00357-9; Forni C, 2009, MOL CANCER THER, V8, P449, DOI 10.1158/1535-7163.MCT-08-0848; Frapolli R, 2010, CLIN CANCER RES, V16, P4958, DOI 10.1158/1078-0432.CCR-10-0317; Friedman D, 2002, CANCER RES, V62, P3377; Gajate C, 2002, J BIOL CHEM, V277, P41580, DOI 10.1074/jbc.M204644200; Germano G, 2013, CANCER CELL, V23, P249, DOI 10.1016/j.ccr.2013.01.008; Germano G, 2010, CANCER RES, V70, P2235, DOI 10.1158/0008-5472.CAN-09-2335; Goransson M, 2002, EXP CELL RES, V278, P125, DOI 10.1006/excr.2002.5566; Gronchi A, 2012, ANN ONCOL, V23, P771, DOI 10.1093/annonc/mdr265; Grosso F, 2009, ANN ONCOL, V20, P1439, DOI 10.1093/annonc/mdp004; Grosso F, 2007, LANCET ONCOL, V8, P595, DOI 10.1016/S1470-2045(07)70175-4; Hendriks HR, 1999, ANN ONCOL, V10, P1233, DOI 10.1023/A:1008364727071; Hurley LH, 2002, NAT REV CANCER, V2, P188, DOI 10.1038/nrc749; Izbicka E, 1998, ANN ONCOL, V9, P981, DOI 10.1023/A:1008224322396; Jin S, 2000, P NATL ACAD SCI USA, V97, P6775, DOI 10.1073/pnas.97.12.6775; KNIGHT JC, 1995, CANCER RES, V55, P24; Kuroda M, 1997, AM J PATHOL, V151, P735; Li WW, 2001, CLIN CANCER RES, V7, P2908; Licitra L, 2006, J CLIN ONCOL, V24, P5630, DOI 10.1200/JCO.2005.04.6136; Minuzzo M, 2005, MOL PHARMACOL, V68, P1496, DOI 10.1124/mol.105.013615; Minuzzo M, 2000, P NATL ACAD SCI USA, V97, P6780, DOI 10.1073/pnas.97.12.6780; Negri T, 2010, CLIN CANCER RES, V16, P3581, DOI 10.1158/1078-0432.CCR-09-2912; PANAGOPOULOS I, 1994, CANCER RES, V54, P6500; Perez-Losada J, 2000, ONCOGENE, V19, P2413, DOI 10.1038/sj.onc.1203572; Perez-Mancera PA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002569; Pommier Y, 1996, BIOCHEMISTRY-US, V35, P13303, DOI 10.1021/bi960306b; Powers MP, 2010, MODERN PATHOL, V23, P1307, DOI 10.1038/modpathol.2010.118; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Riggi N, 2006, CANCER RES, V66, P7016, DOI 10.1158/0008-5472.CAN-05-3979; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; Sandberg AA, 2004, CANCER GENET CYTOGEN, V155, P1, DOI 10.1016/j.cancergencyto.2004.08.005; Takebayashi Y, 2001, NAT MED, V7, P961, DOI 10.1038/91008; Tavecchio M, 2008, EUR J CANCER, V44, P609, DOI 10.1016/j.ejca.2008.01.003; Valoti G, 1998, CLIN CANCER RES, V4, P1977; van Roggen JFG, 1999, HISTOPATHOLOGY, V35, P291; Wang WL, 2012, CLIN SARCOMA RES, V2, DOI 10.1186/2045-3329-2-25; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zewail-Foote M, 1999, J MED CHEM, V42, P2493, DOI 10.1021/jm990241l	60	84	85	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2014	33	44					5201	5210		10.1038/onc.2013.462	http://dx.doi.org/10.1038/onc.2013.462			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR9RZ	24213580				2022-12-17	WOS:000343914900007
J	Park, JY; Singh, TR; Nassar, N; Zhang, F; Freund, M; Hanenberg, H; Meetei, AR; Andreassen, PR				Park, J-Y; Singh, T. R.; Nassar, N.; Zhang, F.; Freund, M.; Hanenberg, H.; Meetei, A. R.; Andreassen, P. R.			Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair	ONCOGENE			English	Article						PALB2; RAD51C; BRCA2; homologous recombination; BRCA genes; DNA repair	HOMOLOGOUS RECOMBINATION REPAIR; CAUSE FANCONI-ANEMIA; SUSCEPTIBILITY GENE; GERMLINE MUTATIONS; CHROMOSOMAL BREAKS; PROTEIN COMPLEX; PATHWAY; XRCC3; IDENTIFICATION; DEFICIENCY	Heterozygous carriers of germ-line mutations in the BRCA2/FANCD1, PALB2/FANCN and RAD51C/FANCO DNA repair genes have an increased lifetime risk of developing breast, ovarian and other cancers; bi-allelic mutations in these genes clinically manifest as Fanconi anemia (FA). Here, we demonstrate that RAD51C is part of a novel protein complex that contains PALB2 and BRCA2. Further, the PALB2 WD40 domain can directly and independently bind RAD51C and BRCA2. To understand the role of these homologous recombination (HR) proteins in DNA repair, we functionally characterize effects of missense mutants of the PALB2 WD40 domain that have been reported in breast cancer patients. In contrast to large truncations of PALB2, which display a complete loss of interaction, the L939W, T1030I and L1143P missense mutants/variants of the PALB2 WD40 domain are associated with altered patterns of direct binding to the RAD51C, RAD51 and BRCA2 HR proteins in biochemical assays. Further, the T1030I missense mutant is unstable, whereas the L939W and L1143P proteins are stable but partially disrupt the PALB2-RAD51C-BRCA2 complex in cells. Functionally, the L939W and L1143P mutants display a decreased capacity for DNA double-strand break-induced HR and an increased cellular sensitivity to ionizing radiation. As further evidence for the functional importance of the HR complex, RAD51C mutants that are associated with cancer susceptibility and FA also display decreased complex formation with PALB2. Together, our results suggest that three different cancer susceptibility and FA proteins function in a DNA repair pathway based upon the PALB2 WD40 domain binding to RAD51C and BRCA2.	[Park, J-Y; Singh, T. R.; Nassar, N.; Zhang, F.; Meetei, A. R.; Andreassen, P. R.] Cincinnati Childrens Res Fdn, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA; [Nassar, N.; Meetei, A. R.; Andreassen, P. R.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Freund, M.; Hanenberg, H.] Univ Dusseldorf, Dept Otorhinolaryngol & Head Neck Surg, Sch Med, Dusseldorf, Germany; [Hanenberg, H.] Indiana Univ Sch Med, Riley Hosp, Dept Pediat, Unit Pediat Hematol Oncol,Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; [Hanenberg, H.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Heinrich Heine University Dusseldorf; Indiana University System; Indiana University Bloomington; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University Bloomington	Meetei, AR (corresponding author), Cincinnati Childrens Res Fdn, 3333 Burnet Ave ML S7-203, Cincinnati, OH 45229 USA.	Ruhikanta.Meetei@cchmc.org; Paul.Andreassen@cchmc.org	Nassar, Natasha/K-3918-2019	singh, thiyam/0000-0002-0441-6818	BMBF; NIH [R01 CA138237, CA155294, R01 HL084082, R01 HL085587]; NATIONAL CANCER INSTITUTE [R01CA155294, R01CA138237] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085587, R01HL084082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK090971] Funding Source: NIH RePORTER	BMBF(Federal Ministry of Education & Research (BMBF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We are grateful to Dr Hans Joenje (Vrije Universiteit Medical Center), Dr Youngho Kim (Wonkwang University), Dr James Lessard (Cincinnati Children's Research Foundation), Dr Yoshihiro Nakatani (Dana-Farber Cancer Institute) and Drs Maria Jasin and Koji Nakanishi (Memorial Sloan-Kettering Cancer Center) for EUFA1341 fibroblasts, the human RAD51 cDNA, anti-actin antibodies, pOZ vectors, and U2OS-DR cells and pCBASce, respectively. This work was supported by the BMBF networks of 'Inherited bone marrow failure syndromes' and 'Foamyvirus-mediated genetic therapy for FNACA (FoneFA) and NIH R01 CA138237 and CA155294 (HH), NIH R01 HL084082 (ARM) and NIH R01 HL085587 (PRA).	Abbott DW, 1998, J NATL CANCER I, V90, P978, DOI 10.1093/jnci/90.13.978; Adank MA, 2011, BREAST CANCER RES TR, V127, P357, DOI 10.1007/s10549-010-1001-1; Ali AM, 2012, BLOOD, V119, P3285, DOI 10.1182/blood-2011-10-385963; Andreassen PR, 2009, CURR CANCER DRUG TAR, V9, P101, DOI 10.2174/156800909787314011; Balia C, 2010, FAM CANCER, V9, P531, DOI 10.1007/s10689-010-9382-1; Bogdanova N, 2011, BREAST CANCER RES TR, V126, P545, DOI 10.1007/s10549-010-1290-4; Bogliolo M, 2013, AM J HUM GENET, V92, P800, DOI 10.1016/j.ajhg.2013.04.002; Buisson R, 2010, NAT STRUCT MOL BIOL, V17, P1247, DOI 10.1038/nsmb.1915; Carreira A, 2009, CELL, V136, P1032, DOI 10.1016/j.cell.2009.02.019; Casadei S, 2011, CANCER RES, V71, P2222, DOI 10.1158/0008-5472.CAN-10-3958; Catucci I, 2012, FAM CANCER, V11, P483, DOI 10.1007/s10689-012-9540-8; Chun J, 2013, MOL CELL BIOL, V33, P387, DOI 10.1128/MCB.00465-12; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Ding YC, 2011, BREAST CANCER RES TR, V126, P227, DOI 10.1007/s10549-010-1271-7; Dray E, 2010, NAT STRUCT MOL BIOL, V17, P1255, DOI 10.1038/nsmb.1916; Erkko H, 2007, NATURE, V446, P316, DOI 10.1038/nature05609; Hayakawa T, 2010, J CELL SCI, V123, P1124, DOI 10.1242/jcs.060178; Hellebrand H, 2011, HUM MUTAT, V32, pE2176, DOI 10.1002/humu.21478; Hofstatter EW, 2011, FAM CANCER, V10, P225, DOI 10.1007/s10689-011-9426-1; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Huang J, 2009, NAT CELL BIOL, V11, P592, DOI 10.1038/ncb1865; Kee Y, 2012, J CLIN INVEST, V122, P3799, DOI 10.1172/JCI58321; Lio YC, 2003, J BIOL CHEM, V278, P2469, DOI 10.1074/jbc.M211038200; Liu YL, 2007, J BIOL CHEM, V282, P1973, DOI 10.1074/jbc.M609066200; Makde RD, 2010, NATURE, V467, P562, DOI 10.1038/nature09321; Masson JY, 2001, GENE DEV, V15, P3296, DOI 10.1101/gad.947001; Meindl A, 2010, NAT GENET, V42, P410, DOI 10.1038/ng.569; Miller KA, 2004, NUCLEIC ACIDS RES, V32, P169, DOI 10.1093/nar/gkg925; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Oliver AW, 2009, EMBO REP, V10, P990, DOI 10.1038/embor.2009.126; Rahman N, 2007, NAT GENET, V39, P165, DOI 10.1038/ng1959; Reid S, 2007, NAT GENET, V39, P162, DOI 10.1038/ng1947; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Singh TR, 2010, MOL CELL, V37, P879, DOI 10.1016/j.molcel.2010.01.036; Somyajit K, 2012, J BIOL CHEM, V287, P3366, DOI 10.1074/jbc.M111.311241; Stark JM, 2002, J BIOL CHEM, V277, P20185, DOI 10.1074/jbc.M112132200; Stirnimann CU, 2010, TRENDS BIOCHEM SCI, V35, P565, DOI 10.1016/j.tibs.2010.04.003; Sy SMH, 2009, P NATL ACAD SCI USA, V106, P7155, DOI 10.1073/pnas.0811159106; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; Tischkowitz M, 2007, P NATL ACAD SCI USA, V104, P6788, DOI 10.1073/pnas.0701724104; Tischkowitz M, 2012, HUM MUTAT, V33, P674, DOI 10.1002/humu.22022; Turnbull C, 2008, ANNU REV GENOM HUM G, V9, P321, DOI 10.1146/annurev.genom.9.081307.164339; Vaz F, 2010, NAT GENET, V42, P406, DOI 10.1038/ng.570; Vuorela M, 2011, BREAST CANCER RES TR, V130, P1003, DOI 10.1007/s10549-011-1677-x; Walsh T, 2007, CANCER CELL, V11, P103, DOI 10.1016/j.ccr.2007.01.010; Wilson JB, 2008, ONCOGENE, V27, P3641, DOI 10.1038/sj.onc.1211034; Wong MW, 2011, BREAST CANCER RES TR, V127, P853, DOI 10.1007/s10549-011-1443-0; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xia B, 2007, NAT GENET, V39, P159, DOI 10.1038/ng1942; Xia B, 2006, MOL CELL, V22, P719, DOI 10.1016/j.molcel.2006.05.022; Yoshihara T, 2004, EMBO J, V23, P670, DOI 10.1038/sj.emboj.7600087; Zhang F, 2009, MOL CANCER RES, V7, P1110, DOI 10.1158/1541-7786.MCR-09-0123; Zhang F, 2009, CURR BIOL, V19, P524, DOI 10.1016/j.cub.2009.02.018; Zheng YL, 2012, CANCER-AM CANCER SOC, V118, P1362, DOI 10.1002/cncr.26388	56	84	91	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	2014	33	40					4803	4812		10.1038/onc.2013.421	http://dx.doi.org/10.1038/onc.2013.421			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0EH	24141787	Green Accepted, Green Submitted			2022-12-17	WOS:000343240100002
J	Khongkow, P; Karunarathna, U; Khongkow, M; Gong, C; Gomes, AR; Yague, E; Monteiro, LJ; Kongsema, M; Zona, S; Man, EPS; Tsang, JWH; Coombes, RC; Wu, KJ; Khoo, US; Medema, RH; Freire, R; Lam, EWF				Khongkow, P.; Karunarathna, U.; Khongkow, M.; Gong, C.; Gomes, A. R.; Yague, E.; Monteiro, L. J.; Kongsema, M.; Zona, S.; Man, E. P. S.; Tsang, J. W-H; Coombes, R. C.; Wu, K-J; Khoo, U-S; Medema, R. H.; Freire, R.; Lam, E. W-F			FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance	ONCOGENE			English	Article						FOXM1; senescence; DNA damage; NBS1; epirubicin; resistance; breast cancer	STRAND BREAK REPAIR; ATR-DEPENDENT PHOSPHORYLATION; CANCER; ACTIVATION; EXPRESSION; LINKAGE; CELLS; P53	FOXM1 is implicated in genotoxic drug resistance but its mechanism of action remains elusive. We show here that FOXM1-depletion can sensitize breast cancer cells and mouse embryonic fibroblasts (MEFs) into entering epirubicin-induced senescence, with the loss of long-term cell proliferation ability, the accumulation of gamma H2AX foci, and the induction of senescence-associated beta-galactosidase activity and cell morphology. Conversely, reconstitution of FOXM1 in FOXM1-deficient MEFs alleviates the accumulation of senescence-associated gamma H2AX foci. We also demonstrate that FOXM1 regulates NBS1 at the transcriptional level through an forkhead response element on its promoter. Like FOXM1, NBS1 is overexpressed in the epirubicin-resistant MCF-7Epi(R) cells and its expression level is low but inducible by epirubicin in MCF-7 cells. Consistently, overexpression of FOXM1 augmented and FOXM1 depletion reduced NBS1 expression and epirubicin-induced ataxia-telangiectasia mutated (ATM)phosphorylation in breast cancer cells. Together these findings suggest that FOXM1 increases NBS1 expression and ATM phosphorylation, possibly through increasing the levels of the MRN(MRE11/RAD50/NBS1) complex. Consistent with this idea, the loss of P-ATM induction by epirubicin in the NBS1-deficient NBS1-LBI fibroblasts can be rescued by NBS1 reconstitution. Resembling FOXM1, NBS1 depletion also rendered MCF-7 and MCF-7Epi(R) cells more sensitive to epirubicin-induced cellular senescence. In agreement, the DNA repair-defective and senescence phenotypes in FOXM1-deficent cells can be effectively rescued by overexpression of NBS1. Moreover, overexpression of NBS1 and FOXM1 similarly enhanced and their depletion downregulated homologous recombination (HR) DNA repair activity. Crucially, overexpression of FOXM1 failed to augment HR activity in the background of NBS1 depletion, demonstrating that NBS1 is indispensable for the HR function of FOXM1. The physiological relevance of the regulation of NBS1 expression by FOXM1 is further underscored by the strong and significant correlation between nuclear FOXM1 and total NBS1 expression in breast cancer patient samples, further suggesting that NBS1 as a key FOXM1 target gene involved in DNA damage response, genotoxic drug resistance and DNA damage-induced senescence.	[Khongkow, P.; Karunarathna, U.; Khongkow, M.; Gong, C.; Gomes, A. R.; Yague, E.; Monteiro, L. J.; Kongsema, M.; Zona, S.; Coombes, R. C.; Lam, E. W-F] Imperial Coll London, Dept Surg & Canc, London W12 0NN, England; [Gong, C.; Man, E. P. S.; Khoo, U-S] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Tsang, J. W-H] Univ Hong Kong, Li Ka Shing Fac Med, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; [Wu, K-J] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan; [Medema, R. H.] Netherlands Canc Inst, Div Cell Biol, Amsterdam, Netherlands; [Freire, R.] Hosp Univ Canarias, Inst Tecnol Biomed, Unidad Invest, San Cristobal la Laguna, Spain	Imperial College London; University of Hong Kong; University of Hong Kong; National Yang Ming Chiao Tung University; Netherlands Cancer Institute; Universidad de la Laguna	Lam, EWF (corresponding author), Imperial Coll London, Dept Surg & Canc, Hammersmith Hosp Campus,Cane Rd, London W12 0NN, England.	eric.lam@imperial.ac.uk	Khoo, Ui Soon/C-4293-2009; Lam, Eric W-F/AAW-8566-2020; Wu, Kou-Juey/P-4654-2015; Kongsema, Mesayamas/H-3063-2017; Khoo, Ui Soon/C-1345-2014; Freire, Raimundo/Q-7660-2019; Khoo, Ui Soon/K-2041-2019; Monteiro, Lara J/AAU-8518-2020	Khoo, Ui Soon/0000-0003-2200-7505; Lam, Eric W-F/0000-0003-1274-3576; Khoo, Ui Soon/0000-0003-2200-7505; Freire, Raimundo/0000-0003-4473-8894; Coombes, Raoul Charles/0000-0002-4811-1100; Kongsema, Mesayamas/0000-0001-7146-9349; Khongkow, Mattaka/0000-0002-4424-8898; Medema, Rene/0000-0002-6754-0381; Khongkow, Pasarat/0000-0003-3068-2412	Cancer Research UK; Breast Cancer Campaign; Fundacao para a Ciencia e a Tecnologia; Royal Thai Government Scholarships; Biotechnology and Biological Sciences Research Council [1243234] Funding Source: researchfish; Cancer Research UK [12011] Funding Source: researchfish; Breast Cancer Campaign [2012NovPhD016, 2012MayPR070] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Breast Cancer Campaign; Fundacao para a Ciencia e a Tecnologia(Portuguese Foundation for Science and TechnologyEuropean Commission); Royal Thai Government Scholarships; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Breast Cancer Campaign	EW-F Lam, AR Gomes, RC Coombes were supported by grants from Cancer Research UK, EW-F Lam and S Zona by grants from Breast Cancer Campaign, LJ Monteiro grants from Fundacao para a Ciencia e a Tecnologia, and P Khongkow, M Khongkow and M Kongsema from the Royal Thai Government Scholarships. We also thank Julie Millour for initiating the study and help with this work.	Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012293; Chiang YC, 2003, J BIOL CHEM, V278, P19286, DOI 10.1074/jbc.M212043200; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; de Olano N, 2012, MOL CANCER RES, V10, P1189, DOI 10.1158/1541-7786.MCR-11-0559; Delacote F, 2002, NUCLEIC ACIDS RES, V30, P3454, DOI 10.1093/nar/gkf452; Dupre A, 2006, NAT STRUCT MOL BIOL, V13, P451, DOI 10.1038/nsmb1090; Gorospe M, 2008, TRENDS CELL BIOL, V18, P77, DOI 10.1016/j.tcb.2007.11.007; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Helleday T, 2007, DNA REPAIR, V6, P923, DOI 10.1016/j.dnarep.2007.02.006; Kang J, 2005, MOL CELL BIOL, V25, P661, DOI 10.1128/MCB.25.2.661-670.2005; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Kobayashi J, 2004, DNA REPAIR, V3, P855, DOI 10.1016/j.dnarep.2004.03.023; Kuo LJ, 2008, IN VIVO, V22, P305; Kwok JMM, 2010, MOL CANCER RES, V8, P24, DOI 10.1158/1541-7786.MCR-09-0432; Kwok JMM, 2008, MOL CANCER THER, V7, P2022, DOI 10.1158/1535-7163.MCT-08-0188; Lam EWF, 2013, NAT REV CANCER, V13, P482, DOI 10.1038/nrc3539; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; McGovern UB, 2009, MOL CANCER THER, V8, P582, DOI 10.1158/1535-7163.MCT-08-0805; Millour J, 2010, ONCOGENE, V29, P2983, DOI 10.1038/onc.2010.47; Millour J, 2011, MOL CANCER THER, V10, P1046, DOI 10.1158/1535-7163.MCT-11-0024; Monteiro LJ, 2013, ONCOGENE, V32, P4634, DOI 10.1038/onc.2012.491; NERI B, 1989, INT J CLIN PHARM TH, V27, P388; Nowak DE, 2005, BIOTECHNIQUES, V39, P715, DOI 10.2144/000112014; Riches LC, 2008, MUTAGENESIS, V23, P331, DOI 10.1093/mutage/gen039; Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Seviour EG, 2010, AGING-US, V2, P900, DOI 10.18632/aging.100248; So SR, 2009, J CELL BIOL, V187, P977, DOI 10.1083/jcb.200906064; Stearns V, 2004, PHARMACOGENOMICS J, V4, P143, DOI 10.1038/sj.tpj.6500242; Stiff T, 2005, EMBO J, V24, P199, DOI 10.1038/sj.emboj.7600504; Stiff T, 2006, EMBO J, V25, P5775, DOI 10.1038/sj.emboj.7601446; Weinstock David M, 2007, Nat Cell Biol, V9, P978; Weinstock DM, 2006, METHOD ENZYMOL, V409, P524, DOI 10.1016/S0076-6879(05)09031-2	36	84	85	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2014	33	32					4144	4155		10.1038/onc.2013.457	http://dx.doi.org/10.1038/onc.2013.457			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YK	24141789	Green Accepted, hybrid, Green Published			2022-12-17	WOS:000340595700005
J	Barbarulo, A; Iansante, V; Chaidos, A; Naresh, K; Rahemtulla, A; Franzoso, G; Karadimitris, A; Haskard, DO; Papa, S; Bubici, C				Barbarulo, A.; Iansante, V.; Chaidos, A.; Naresh, K.; Rahemtulla, A.; Franzoso, G.; Karadimitris, A.; Haskard, D. O.; Papa, S.; Bubici, C.			Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma	ONCOGENE			English	Article						PARP14; c-Jun N-terminal kinase; survival; multiple myeloma; apoptosis	N-TERMINAL KINASE; GENE-EXPRESSION; CELL-LINES; APOPTOSIS; JNK; LYMPHOMA; PROLIFERATION; SUPPRESSION; ACTIVATION; CARCINOMA	Regulation of cell survival is a key part of the pathogenesis of multiple myeloma (MM). Jun N-terminal kinase (JNK) signaling has been implicated in MM pathogenesis, but its function is unclear. To elucidate the role of JNK in MM, we evaluated the specific functions of the two major JNK proteins, JNK1 and JNK2. We show here that JNK2 is constitutively activated in a panel of MM cell lines and primary tumors. Using loss-of-function studies, we demonstrate that JNK2 is required for the survival of myeloma cells and constitutively suppresses JNK1-mediated apoptosis by affecting expression of poly(ADP-ribose) polymerase (PARP) 14, a key regulator of B-cell survival. Strikingly, we found that PARP14 is highly expressed in myeloma plasma cells and associated with disease progression and poor survival. Overexpression of PARP14 completely rescued myeloma cells from apoptosis induced by JNK2 knockdown, indicating that PARP14 is critically involved in JNK2-dependent survival. Mechanistically, PARP14 was found to promote the survival of myeloma cells by binding and inhibiting JNK1. Moreover, inhibition of PARP14 enhances the sensitization of MM cells to anti-myeloma agents. Our findings reveal a novel regulatory pathway in myeloma cells through which JNK2 signals cell survival via PARP14, and identify PARP14 as a potential therapeutic target in myeloma.	[Barbarulo, A.; Franzoso, G.; Bubici, C.] Univ London Imperial Coll Sci Technol & Med, Dept Med, Sect Inflammat & Signal Transduct, London, England; [Iansante, V.; Papa, S.] Fdn Liver Res, Inst Hepatol, Cell Signalling & Canc Lab, London WC1E 6HX, England; [Chaidos, A.; Rahemtulla, A.; Karadimitris, A.] Imperial Coll Healthcare NHS Trust, Ctr Haematol, London, England; [Chaidos, A.; Naresh, K.; Rahemtulla, A.; Karadimitris, A.; Haskard, D. O.] Univ London Imperial Coll Sci Technol & Med, London, England; [Naresh, K.] Imperial Coll Healthcare NHS Trust, Dept Histopathol, London, England; [Haskard, D. O.] Imperial Coll Healthcare NHS Trust, Natl Heart & Lung Inst, British Heart Fdn, Vasc Sci Unit, London, England	Imperial College London; University of London; University College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; University of London; University College London	Papa, S (corresponding author), Fdn Liver Res, Inst Hepatol, Cell Signalling & Canc Lab, 69-75 Chenies Mews, London WC1E 6HX, England.	s.papa@researchinliver.org.uk; c.bubici@imperial.ac.uk	Franzoso, Guido/GRR-8628-2022; Papa, Salvatore/J-9413-2012	Papa, Salvatore/0000-0002-8369-6538; Bubici, Concetta/0000-0002-8074-4661; Franzoso, Guido/0000-0002-0778-988X; Iansante, Valeria/0000-0002-4369-3375; Naresh, Kikkeri N/0000-0003-3807-3638; Chaidos, Aristeidis/0000-0003-1453-8576	NIH [R01 CA084040, R01 CA098583]; Cancer Research UK [C26587/A8839]; Kay Kendall Leukemia Fund [KKL443]; Italian Association for Cancer Research [8557]; Foundation for Liver Research; Cancer Research UK [15115] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [R01CA084040, R01CA098583] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Research UK(Cancer Research UK); Kay Kendall Leukemia Fund; Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); Foundation for Liver Research; Cancer Research UK(Cancer Research UK); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to S Chokshi, R Williams and J Dyson for critical comments on the manuscript. We also thank D Trono (Ecole Polytechnique Federale de Lausanne, Switzerland) for the pWPI lentiviral vector and M Johns (Imperial College) for the human PARP14 cDNA; H Cooksley, A Riva (Institute of Hepatology), and PM Choy, MH Lam and V Patel (MSc students) for technical support. GF receives funding from NIH grants R01 CA084040 and R01 CA098583 and Cancer Research UK grant C26587/A8839. DOH receives professorial support from the British Heart Foundation. This study was primarily supported by a research grant from Kay Kendall Leukemia Fund (KKL443) to CB, and in part by grants from Italian Association for Cancer Research (Start-up 8557) and the Foundation for Liver Research to S.P.	Ahmed SU, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007305; Anbalagan M, 2012, INT J CANCER, V130, P1967, DOI 10.1002/ijc.26207; Anderson KC, 2011, ANNU REV PATHOL-MECH, V6, P249, DOI 10.1146/annurev-pathol-011110-130249; Aravind L, 2001, TRENDS BIOCHEM SCI, V26, P273, DOI 10.1016/S0968-0004(01)01787-X; Bardwell AJ, 2009, J BIOL CHEM, V284, P13165, DOI 10.1074/jbc.M900080200; Blonska M, 2007, IMMUNITY, V26, P55, DOI 10.1016/j.immuni.2006.11.008; Bogoyevitch MA, 2006, MICROBIOL MOL BIOL R, V70, P1061, DOI 10.1128/MMBR.00025-06; Bogoyevitch MA, 2010, BBA-PROTEINS PROTEOM, V1804, P463, DOI 10.1016/j.bbapap.2009.11.002; Bost F, 1999, MOL CELL BIOL, V19, P1938; Brune V, 2008, J EXP MED, V205, P2251, DOI 10.1084/jem.20080809; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; Chen NY, 2001, CANCER RES, V61, P3908; Cho SH, 2011, P NATL ACAD SCI USA, V108, P15972, DOI 10.1073/pnas.1017082108; Cho SH, 2009, BLOOD, V113, P2416, DOI 10.1182/blood-2008-03-144121; Cui J, 2005, J BIOL CHEM, V280, P9913, DOI 10.1074/jbc.M412165200; Cui J, 2006, CANCER RES, V66, P10024, DOI 10.1158/0008-5472.CAN-06-0136; Ford J, 2008, CELL CYCLE, V7, P3091, DOI 10.4161/cc.7.19.6799; Gangopadhyay NN, 2011, CANCER INVEST, V29, P608, DOI 10.3109/07357907.2011.621916; Geest CR, 2009, J LEUKOCYTE BIOL, V86, P237, DOI 10.1189/jlb.0209097; Goenka S, 2006, P NATL ACAD SCI USA, V103, P4210, DOI 10.1073/pnas.0506981103; Goenka S, 2007, J BIOL CHEM, V282, P18732, DOI 10.1074/jbc.M611283200; Gururajan M, 2005, BLOOD, V106, P1382, DOI 10.1182/blood-2004-10-3819; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Hideshima T, 2003, ONCOGENE, V22, P8797, DOI 10.1038/sj.onc.1206919; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hideshima T, 2003, BLOOD, V101, P703, DOI 10.1182/blood-2002-06-1874; Hui LJ, 2008, J CLIN INVEST, V118, P3943, DOI 10.1172/JCI37156; Kajiguchi T, 2006, CANCER SCI, V97, P540, DOI 10.1111/j.1349-7006.2006.00199.x; Ke HN, 2010, CANCER RES, V70, P3080, DOI 10.1158/0008-5472.CAN-09-2923; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; Kim KH, 2010, BIOMAT PROP PROD DEV, P149; Liu J, 2004, MOL CELL BIOL, V24, P10844, DOI 10.1128/MCB.24.24.10844-10856.2004; Naresh KN, 2006, J CLIN PATHOL, V59, P903, DOI 10.1136/jcp.2004.020610; Nitta RT, 2011, ONCOGENE, V30, P234, DOI 10.1038/onc.2010.414; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; Pham CG, 2007, MOL CELL BIOL, V27, P3920, DOI 10.1128/MCB.01219-06; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040; Raab MS, 2009, LANCET, V374, P324, DOI 10.1016/S0140-6736(09)60221-X; Rajkumar SV, 2011, NAT REV CLIN ONCOL, V8, P479, DOI 10.1038/nrclinonc.2011.63; Raman M, 2007, ONCOGENE, V26, P3100, DOI 10.1038/sj.onc.1210392; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Spanoudakis E, 2009, BLOOD, V113, P2498, DOI 10.1182/blood-2008-06-161281; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Witzig TE, 1999, BRIT J HAEMATOL, V104, P131, DOI 10.1046/j.1365-2141.1999.01136.x; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Yanagawa T, 2007, CANCER RES, V67, P8682, DOI 10.1158/0008-5472.CAN-07-1586; Yang YM, 2003, CLIN CANCER RES, V9, P391; Yoon CH, 2012, ONCOGENE, V31, P4655, DOI 10.1038/onc.2011.634; Zazzeroni F, 2003, BLOOD, V102, P3270, DOI 10.1182/blood-2003-03-0689; Zhan FH, 2007, BLOOD, V109, P1692, DOI 10.1182/blood-2006-07-037077; Zhan F, 2006, BLOOD, V108, P2020, DOI 10.1182/blood-2005-11-013458	53	84	92	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2013	32	36					4231	4242		10.1038/onc.2012.448	http://dx.doi.org/10.1038/onc.2012.448			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23045269	Green Accepted			2022-12-17	WOS:000324168000005
J	Alberti, C; Pinciroli, P; Valeri, B; Ferri, R; Ditto, A; Umezawa, K; Sensi, M; Canevari, S; Tomassetti, A				Alberti, C.; Pinciroli, P.; Valeri, B.; Ferri, R.; Ditto, A.; Umezawa, K.; Sensi, M.; Canevari, S.; Tomassetti, A.			Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer	ONCOGENE			English	Article						epithelial ovarian cancer; EGFR; IL-6; PAI-1; NFkB	GROWTH-FACTOR-RECEPTOR; KAPPA-B; BREAST-CANCER; PLASMINOGEN-ACTIVATOR; CELLS; TUMOR; EXPRESSION; OVEREXPRESSION; MACROPHAGES; PROGRESSION	The epidermal growth factor receptor (EGFR), a member of the ErbB family of receptor tyrosine kinases, is expressed in up to 70% of epithelial ovarian cancers (EOCs), where it correlates with poor prognosis. The majority of EOCs are diagnosed at an advanced stage, and at least 50% present malignant ascites. High levels of IL-6 have been found in the ascites of EOC patients and correlate with shorter survival. Herein, we investigated the signaling cascade led by EGFR activation in EOC and assessed whether EGFR activation could induce an EOC microenvironment characterized by pro-inflammatory molecules. In vitro analysis of EOC cell lines revealed that ligand-stimulated EGFR activated NFkB-dependent transcription and induced secretion of IL-6 and plasminogen activator inhibitor (PAI-1). IL-6/PAI-1 expression and secretion were strongly inhibited by the tyrosine kinase inhibitor AG1478 and EGFR silencing. A significant reduction of EGF-stimulated IL-6/PAI-1 secretion was also obtained with the NFkB inhibitor dehydroxymethylepoxyquinomicin. Of 23 primary EOC tumors from advanced-stage patients with malignant ascites at surgery, 12 co-expressed membrane EGFR, IL-6 and PAI-1 by immunohistochemistry; both IL-6 and PAI-1 were present in 83% of the corresponding ascites. Analysis of a publicly available gene-expression data set from 204 EOCs confirmed a significant correlation between IL-6 and PAI-1 expression, and patients with the highest IL-6 and PAI-1 co-expression showed a significantly shorter progression-free survival time (P = 0.028). This suggests that EGFR/NFkB/IL-6-PAI-1 may have a significant impact on the therapy of a particular subset of EOC, and that IL-6/PAI-1 co-expression may be a novel prognostic marker. Oncogene (2012) 31, 4139-4149; doi:10.1038/onc.2011.572; published online 12 December 2011	[Canevari, S.; Tomassetti, A.] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Unit Mol Therapies, Milan, Italy; [Valeri, B.] Fdn IRCCS Ist Nazl Tumori, Dept Pathol, Milan, Italy; [Ditto, A.] Fdn IRCCS Ist Nazl Tumori, Dept Gynecol Oncol, Milan, Italy; [Umezawa, K.] Keio Univ, Fac Sci & Technol, Dept Appl Chem, Kohoku Ku, Tokyo 108, Japan; [Sensi, M.] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Unit Human Tumor Immunobiol, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Keio University; Fondazione IRCCS Istituto Nazionale Tumori Milan	Canevari, S (corresponding author), Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Unit Mol Therapies, Milan, Italy.	silvana.canevari@istitutotumori.mi.it; antonella.tomassetti@istitutotumori.mi.it	Ditto, Antonino/H-2219-2017; Valeri, Barbara/C-1986-2017; Sensi, Marialuisa/K-5631-2014; Tomassetti, Antonella/G-7906-2015; Ferri, Raffaele/B-5439-2013	Ditto, Antonino/0000-0002-5684-8225; Valeri, Barbara/0000-0001-9143-7280; Sensi, Marialuisa/0000-0002-7643-0248; Tomassetti, Antonella/0000-0001-6772-9937; Ferri, Raffaele/0000-0001-6937-3065	Italian Association for Cancer Research [IG4608]; Italian Ministry of Health	Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health(Ministry of Health, Italy)	We thank the gynecologic clinical staff and the biorepository personnel at the Fondazione IRCCS Istituto Nazionale dei Tumori, whose activity made this study possible; we thank Dr. Patrick Moore for English editing of the manuscript. Financial Support: Italian Association for Cancer Research (IG4608 to SC) and Italian Ministry of Health (Grant Alleanza contro il Cancro, ACC and Progetto Oncologico di Medicina Molecolare: i Tumori Femminili to SC).	Anglesio MS, 2008, MOL CANCER RES, V6, P1678, DOI 10.1158/1541-7786.MCR-08-0193; Ass K, 2008, CANCER TREAT REV, V34, P122, DOI 10.1016/j.ctrv.2007.10.005; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Berchuck A, 2009, CLIN CANCER RES, V15, P2448, DOI 10.1158/1078-0432.CCR-08-2430; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Braun AH, 2005, CLIN CANCER RES, V11, P4639, DOI 10.1158/1078-0432.CCR-05-0973; Carey MS, 2010, CLIN CANCER RES, V16, P2852, DOI 10.1158/1078-0432.CCR-09-2502; Castellano G, 2006, CANCER RES, V66, P10709, DOI 10.1158/0008-5472.CAN-06-1327; Colomiere M, 2009, BRIT J CANCER, V100, P134, DOI 10.1038/sj.bjc.6604794; Conti M, 2006, MOL ENDOCRINOL, V20, P715, DOI 10.1210/me.2005-0185; De Santis G, 2009, ONCOGENE, V28, P1206, DOI 10.1038/onc.2008.470; Degl'Innocenti D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012701; Guo YQ, 2010, CLIN CANCER RES, V16, P5759, DOI 10.1158/1078-0432.CCR-10-1095; Hagemann T, 2005, J IMMUNOL, V175, P1197, DOI 10.4049/jimmunol.175.2.1197; Hagemann T, 2006, J IMMUNOL, V176, P5023, DOI 10.4049/jimmunol.176.8.5023; Hartman ZC, 2011, CANCER RES, V71, P4380, DOI 10.1158/0008-5472.CAN-11-0308; Hudson LG, 2009, CANCER TREAT RES, V149, P203, DOI 10.1007/978-0-387-98094-2_10; Jiang T, 2011, CANCER RES, V71, P2183, DOI 10.1158/0008-5472.CAN-10-3626; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kryczek I, 2000, BRIT J CANCER, V82, P621; Leissner P, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-216; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Look MP, 2002, JNCI-J NATL CANCER I, V94, P116, DOI 10.1093/jnci/94.2.116; Paugh BS, 2008, FASEB J, V22, P455, DOI 10.1096/fj.07-8276com; Penson RT, 2000, INT J GYNECOL CANCER, V10, P33, DOI 10.1046/j.1525-1438.2000.00003.x; Sheng Q, 2011, BRIT J CANCER, V104, P1241, DOI 10.1038/bjc.2011.62; Siwak DR, 2010, J ONCOL, V2010, DOI 10.1155/2010/568938; Sternlicht MD, 2006, CANCER EPIDEM BIOMAR, V15, P2107, DOI 10.1158/1055-9965.EPI-06-0351; Tomassetti A, 2008, NEOPLASIA, V10, P1481, DOI 10.1593/neo.81004; TOSI E, 1995, INT J CANCER, V62, P643, DOI 10.1002/ijc.2910620525; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Umezawa K, 2006, CANCER SCI, V97, P990, DOI 10.1111/j.1349-7006.2006.00285.x; Van Laere SJ, 2007, BRIT J CANCER, V97, P659, DOI 10.1038/sj.bjc.6603906; Yamamoto M, 2008, J MED CHEM, V51, P5780, DOI 10.1021/jm8006245	35	84	87	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	37					4139	4149		10.1038/onc.2011.572	http://dx.doi.org/10.1038/onc.2011.572			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NR	22158046	hybrid			2022-12-17	WOS:000308688900006
J	Anastas, JN; Biechele, TL; Robitaille, M; Muster, J; Allison, KH; Angers, S; Moon, RT				Anastas, J. N.; Biechele, T. L.; Robitaille, M.; Muster, J.; Allison, K. H.; Angers, S.; Moon, R. T.			A protein complex of SCRIB, NOS1AP and VANGL1 regulates cell polarity and migration, and is associated with breast cancer progression	ONCOGENE			English	Article						SCRIB; NOS1AP; VANGL1; migration; PCP	NITRIC-OXIDE SYNTHASE; NEURAL-TUBE DEFECTS; EXTENSION MOVEMENTS; E-CADHERIN; LOCALIZATION; INTERACTS; ADHESION; PATHWAY; CAPON; DEGRADATION	By analyzing public data sets of gene expression in human breast cancers we observed that increased levels of transcripts encoding the planar cell polarity (PCP) proteins SCRIB and VANGL1 correlate with increased risk of patient relapse. Experimentally, we found that reducing expression of SCRIB by short-hairpin RNAs (shRNAs) reduces the growth of human breast cancer cells in xenograft assays. To investigate SCRIB-associated proteins that might participate in the responses of breast cancer cells to altered levels of SCRIB, we used mass spectrometry and confocal microscopy. These studies reveal that SCRIB is present in at least two unique protein complexes: (1) a complex of SCRIB, ARHGEF, GIT and PAK (p21-activated kinase), and (2) a complex of SCRIB, NOS1AP and VANGL. Focusing on NOS1AP, we observed that NOS1AP colocalizes with both SCRIB and VANGL1 along cellular protrusions in metastatic breast cancer cells, but does not colocalize with either SCRIB or VANGL1 at cell junctions in normal breast cells. We investigated the effects of shRNA-mediated knockdown of NOS1AP and SCRIB in vitro, and found that reducing NOS1AP and SCRIB slows breast cancer cell migration and prevents the establishment of leading-trailing polarity. We also find that reduction of NOS1AP enhances anchorage-independent growth. Collectively these data point to the relevance of NOS1AP and SCRIB protein complexes in breast cancer. Oncogene (2012) 31, 3696-3708; doi:10.1038/onc.2011.528; published online 19 December 2011	[Anastas, J. N.; Biechele, T. L.; Muster, J.; Moon, R. T.] Univ Washington, Sch Med, Inst Stem Cell & Regenerat Med, Seattle, WA 98109 USA; [Anastas, J. N.] Univ Washington, Sch Med, Mol & Cellular Biol Grad Program, Seattle, WA 98109 USA; [Biechele, T. L.; Muster, J.; Moon, R. T.] Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98109 USA; [Biechele, T. L.; Muster, J.; Moon, R. T.] Univ Washington, Sch Med, Howard Hughes Med Inst, Seattle, WA 98109 USA; [Robitaille, M.; Angers, S.] Univ Toronto, Dept Pharmaceut Sci, Toronto, ON, Canada; [Robitaille, M.; Angers, S.] Univ Toronto, Dept Biochem, Toronto, ON, Canada; [Allison, K. H.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Toronto; University of Toronto; University of Washington; University of Washington Seattle	Moon, RT (corresponding author), Univ Washington, Sch Med, Inst Stem Cell & Regenerat Med, Campus Box 358056,815 Mercer St,Room S524, Seattle, WA 98109 USA.	rtmoon@uw.edu	Moon, Randall T/B-1743-2014; Robitaille, Melanie/ABA-5861-2020; Angers, Stephane/E-1432-2014; Moon, Randall/M-5605-2019	Moon, Randall T/0000-0002-9352-1408; Robitaille, Melanie/0000-0001-9354-5162; Angers, Stephane/0000-0001-7241-9044; Moon, Randall/0000-0002-9352-1408; Muster, Jeanot/0000-0002-1972-6851	US Department of Defense Breast Cancer Research Award [W81XWH-070100367]; Canadian Breast Cancer Foundation-Ontario Region	US Department of Defense Breast Cancer Research Award; Canadian Breast Cancer Foundation-Ontario Region	Funding for this research was provided by the US Department of Defense Breast Cancer Research Award (Grant W81XWH-070100367). RTM is an investigator of the Howard Hughes Medical Institute. MR holds a postdoctoral fellowship from the Canadian Breast Cancer Foundation-Ontario Region. Special thanks to Allison Adams for providing the GFP viruses, and Ron Steifert and the Lynn and Mike Garvey Imaging Center for their assistance.	Angers S, 2006, NAT CELL BIOL, V8, P348, DOI 10.1038/ncb1381; Audebert S, 2004, CURR BIOL, V14, P987, DOI 10.1016/j.cub.2004.05.051; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Carrel D, 2009, J NEUROSCI, V29, P8248, DOI 10.1523/JNEUROSCI.5287-08.2009; Cordero JB, 2010, DEV CELL, V18, P999, DOI 10.1016/j.devcel.2010.05.014; Courbard JR, 2009, DEV BIOL, V333, P67, DOI 10.1016/j.ydbio.2009.06.024; Dow LE, 2007, ONCOGENE, V26, P2272, DOI 10.1038/sj.onc.1210016; Fang M, 2000, NEURON, V28, P183, DOI 10.1016/S0896-6273(00)00095-7; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Ivanov AI, 2010, AM J PATHOL, V176, P134, DOI 10.2353/ajpath.2010.090220; Jaffrey SR, 2002, P NATL ACAD SCI USA, V99, P3199, DOI 10.1073/pnas.261705799; Jaffrey SR, 1998, NEURON, V20, P115, DOI 10.1016/S0896-6273(00)80439-0; Major MB, 2007, SCIENCE, V316, P1043, DOI 10.1126/science/1141515; Metais JY, 2005, FEBS LETT, V579, P3725, DOI 10.1016/j.febslet.2005.05.062; Montcouquiol M, 2003, NATURE, V423, P173, DOI 10.1038/nature01618; Moreau MM, 2010, J NEUROSCI, V30, P9738, DOI 10.1523/JNEUROSCI.6007-09.2010; Murdoch JN, 2003, HUM MOL GENET, V12, P87, DOI 10.1093/hmg/ddg014; Murdoch JN, 2001, GENOMICS, V78, P55, DOI 10.1006/geno.2001.6638; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Nola S, 2008, HUM MOL GENET, V17, P3552, DOI 10.1093/hmg/ddn248; Osmani N, 2006, CURR BIOL, V16, P2395, DOI 10.1016/j.cub.2006.10.026; Petit MM, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-1; Petit MMR, 2005, FEBS LETT, V579, P5061, DOI 10.1016/j.febslet.2005.08.012; Phua DCY, 2009, MOL BIOL CELL, V20, P2841, DOI 10.1091/mbc.E08-02-0199; Qin Y, 2005, J CELL BIOL, V171, P1061, DOI 10.1083/jcb.200506094; Richier L, 2010, J NEUROSCI, V30, P4796, DOI 10.1523/JNEUROSCI.3726-09.2010; Vervenne HBVK, 2008, DEV BIOL, V320, P267, DOI 10.1016/j.ydbio.2008.05.529; Wada H, 2005, DEVELOPMENT, V132, P2273, DOI 10.1242/dev.01810; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045	34	84	84	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	32					3696	3708		10.1038/onc.2011.528	http://dx.doi.org/10.1038/onc.2011.528			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	990TF	22179838	Green Published, hybrid			2022-12-17	WOS:000307653800004
J	Arpaia, E; Blaser, H; Quintela-Fandino, M; Duncan, G; Leong, HS; Ablack, A; Nambiar, SC; Lind, EF; Silvester, J; Fleming, CK; Rufini, A; Tusche, MW; Brustle, A; Ohashi, PS; Lewis, JD; Mak, TW				Arpaia, E.; Blaser, H.; Quintela-Fandino, M.; Duncan, G.; Leong, H. S.; Ablack, A.; Nambiar, S. C.; Lind, E. F.; Silvester, J.; Fleming, C. K.; Rufini, A.; Tusche, M. W.; Bruestle, A.; Ohashi, P. S.; Lewis, J. D.; Mak, T. W.			The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and Erk	ONCOGENE			English	Article						Rho-GTPase; caveolin-1; alpha5-integrin; Src; cancer; intravital microscopy	CELL-MIGRATION; IN-VIVO; PROSTATE-CANCER; ACTIN CYTOSKELETON; SIGNALING PATHWAY; TUMOR PROGRESSION; INTEGRIN ALPHA-5; CARCINOMA-CELLS; MELANOMA-CELLS; KINASE	Proteins containing a caveolin-binding domain (CBD), such as the Rho-GTPases, can interact with caveolin-1 (Cav1) through its caveolin scaffold domain. Rho-GTPases are important regulators of p130(Cas), which is crucial for both normal cell migration and Src kinase-mediated metastasis of cancer cells. However, although Rho-GTPases (particularly RhoC) and Cav1 have been linked to cancer progression and metastasis, the underlying molecular mechanisms are largely unknown. To investigate the function of Cav1-Rho-GTPase interaction in metastasis, we disrupted Cav1-Rho-GTPase binding in melanoma and mammary epithelial tumor cells by overexpressing CBD, and examined the loss-of-function of RhoC in metastatic cancer cells. Cancer cells overexpressing CBD or lacking RhoC had reduced p130(Cas) phosphorylation and Rac1 activation, resulting in an inhibition of migration and invasion in vitro. The activity of Src and the activation of its downstream targets FAK, Pyk2, Ras and extracellular signal-regulated kinase (Erk) 1/2 were also impaired. A reduction in alpha 5-integrin expression, which is required for binding to fibronectin and thus cell migration and survival, was observed in CBD-expressing cells and cells lacking RhoC. As a result of these defects, CBD-expressing melanoma cells had a reduced ability to metastasize in recipient mice, and impaired extravasation and survival in secondary sites in chicken embryos. Our data indicate that interaction between Cav1 and Rho-GTPases (most likely RhoC but not RhoA) promotes metastasis by stimulating alpha 5-integrin expression and regulating the Src-dependent activation of p130(Cas)/Rac1, FAK/Pyk2 and Ras/Erk1/2 signaling cascades. Oncogene (2012) 31, 884-896; doi: 10.1038/onc.2011.288; published online 18 July 2011	[Arpaia, E.; Blaser, H.; Quintela-Fandino, M.; Duncan, G.; Lind, E. F.; Silvester, J.; Fleming, C. K.; Rufini, A.; Tusche, M. W.; Bruestle, A.; Ohashi, P. S.; Mak, T. W.] Univ Hlth Network, Campbell Family Inst Breast Canc Res, Toronto, ON M5G 2M9, Canada; [Arpaia, E.; Ohashi, P. S.; Mak, T. W.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Arpaia, E.; Ohashi, P. S.; Mak, T. W.] Univ Toronto, Dept Immunol, Toronto, ON, Canada; [Quintela-Fandino, M.] Spain Spanish Natl Canc Ctr CNIO, Clin Invest Unit, Breast Canc Grp, Madrid, Spain; [Leong, H. S.; Ablack, A.; Nambiar, S. C.; Lewis, J. D.] London Reg Canc Program, Translat Prostate Canc Res Grp, London, England; [Rufini, A.] Univ Leicester, Lab Apoptosis Canc, MRC, Toxicol Unit, Lancaster, England	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Leicester	Mak, TW (corresponding author), Univ Hlth Network, Campbell Family Inst Breast Canc Res, 620 Univ Ave,Suite 706, Toronto, ON M5G 2M9, Canada.	tmak@uhnresearch.ca		Lind, Evan/0000-0001-7026-2012; quintela-fandino, miguel/0000-0003-1648-1964; Leong, Hon/0000-0001-7801-1402; Silvester, Jennifer/0000-0001-6087-4066; Ohashi, Pamela S./0000-0003-2915-9317	Canadian Institutes of Health Research [179815]; National Cancer Institute of Canada/Terry Fox Foundation [18176]; Canadian Breast Cancer Foundation	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Cancer Institute of Canada/Terry Fox Foundation; Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS))	We thank Dr Marc Pellegrini for helpful discussions and Dr Mary Saunders for insightful scientific editing. This work was supported by Grant # 179815 from the Canadian Institutes of Health Research to TWM, and Grant # 18176 from the National Cancer Institute of Canada/Terry Fox Foundation to JDL. HSL is funded by a Canadian Breast Cancer Foundation Post-Doctoral fellowship.	Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Bosco EE, 2009, CELL MOL LIFE SCI, V66, P370, DOI 10.1007/s00018-008-8552-x; Brabek J, 2005, MOL CANCER RES, V3, P307, DOI 10.1158/1541-7786.MCR-05-0015; Campbell L, 2008, BRIT J CANCER, V98, P931, DOI 10.1038/sj.bjc.6604243; Capozza F, 2003, AM J PATHOL, V162, P2029, DOI 10.1016/S0002-9440(10)64335-0; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cokakli M, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-65; Couet J, 2001, ADV DRUG DELIVER REV, V49, P223, DOI 10.1016/S0169-409X(01)00139-9; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Fecchi K, 2012, INT J CANCER, V130, P1273, DOI 10.1002/ijc.26092; Felicetti F, 2009, INT J CANCER, V125, P1514, DOI 10.1002/ijc.24451; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; Giehl K, 2005, BIOL CHEM, V386, P193, DOI 10.1515/BC.2005.025; Goetz JG, 2008, J CELL BIOL, V180, P1261, DOI 10.1083/jcb.200709019; Grande-Garcia A, 2007, J CELL BIOL, V177, P683, DOI 10.1083/jcb.200701006; Haenssen KK, 2010, J CELL SCI, V123, P1373, DOI 10.1242/jcs.050906; Hakem A, 2005, GENE DEV, V19, P1974, DOI 10.1101/gad.1310805; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Ho CC, 2002, AM J PATHOL, V161, P1647, DOI 10.1016/S0002-9440(10)64442-2; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Kidera Yasuhiro, 2010, J Exp Clin Cancer Res, V29, P127, DOI 10.1186/1756-9966-29-127; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Kinbara K, 2003, NAT REV MOL CELL BIO, V4, P767, DOI 10.1038/nrm1229; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; Lewis JD, 2006, NAT MED, V12, P354, DOI 10.1038/nm1368; Li LK, 2001, CANCER RES, V61, P4386; Lim ST, 2008, MOL CELL, V29, P9, DOI 10.1016/j.molcel.2007.11.031; Lim ST, 2010, J BIOL CHEM, V285, P1743, DOI 10.1074/jbc.M109.064212; Lin M, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-21; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; Mebratu Y, 2009, CELL CYCLE, V8, P1168, DOI 10.4161/cc.8.8.8147; Meenderink LM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013412; Mierke CT, 2011, J CELL SCI, V124, P369, DOI 10.1242/jcs.071985; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nam JM, 2010, CANCER RES, V70, P5238, DOI 10.1158/0008-5472.CAN-09-2319; Narumiya S, 2009, CANCER METAST REV, V28, P65, DOI 10.1007/s10555-008-9170-7; NATALI PG, 1995, BRIT J CANCER, V71, P1243, DOI 10.1038/bjc.1995.240; OBrien V, 1996, EXP CELL RES, V224, P208, DOI 10.1006/excr.1996.0130; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Qian F, 2005, BIOCHEM BIOPH RES CO, V333, P1269, DOI 10.1016/j.bbrc.2005.06.039; Quest AFG, 2008, J CELL MOL MED, V12, P1130, DOI 10.1111/j.1582-4934.2008.00331.x; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112; Sharma A, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-50; Shaul YD, 2007, BBA-MOL CELL RES, V1773, P1213, DOI 10.1016/j.bbamcr.2006.10.005; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Thompson TC, 1999, APOPTOSIS, V4, P233, DOI 10.1023/A:1009612708099; Timpson P, 2001, CURR BIOL, V11, P1836, DOI 10.1016/S0960-9822(01)00583-8; Torii S, 2006, CANCER SCI, V97, P697, DOI 10.1111/j.1349-7006.2006.00244.x; Wheeler DL, 2009, ONCOLOGIST, V14, P667, DOI 10.1634/theoncologist.2009-0009; Williams TM, 2005, J BIOL CHEM, V280, P25134, DOI 10.1074/jbc.M501186200; Williams TM, 2003, MOL BIOL CELL, V14, P1027, DOI 10.1091/mbc.E02-08-0503; Williams TM, 2004, J BIOL CHEM, V279, P51630, DOI 10.1074/jbc.M409214200; Wu L, 2008, ONCOGENE, V27, P1439, DOI 10.1038/sj.onc.1210770; Yamamoto T, 1999, J BIOCHEM-TOKYO, V126, P799, DOI 10.1093/oxfordjournals.jbchem.a022519; Yamana N, 2006, MOL CELL BIOL, V26, P6844, DOI 10.1128/MCB.00283-06; Yip SC, 2007, J CELL SCI, V120, P3138, DOI 10.1242/jcs.005298; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zijlstra A, 2002, CANCER RES, V62, P7083; Zijlstra A, 2008, CANCER CELL, V13, P221, DOI 10.1016/j.ccr.2008.01.031	68	84	87	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	7					884	896		10.1038/onc.2011.288	http://dx.doi.org/10.1038/onc.2011.288			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	897BL	21765460	hybrid, Green Published			2022-12-17	WOS:000300615800007
J	Xiong, X; Zhao, Y; He, H; Sun, Y				Xiong, X.; Zhao, Y.; He, H.; Sun, Y.			Ribosomal protein S27-like and S27 interplay with p53-MDM2 axis as a target, a substrate and a regulator	ONCOGENE			English	Article						MDM2; p53; protein interplays; ribosomal proteins; ubiquitination	TUMOR-CELL GROWTH; SACCHAROMYCES-CEREVISIAE; ACTIVATES P53; MDM2 BINDING; IN-VIVO; INHIBITION; CARCINOMA; GENE; METALLOPANSTIMULIN; APOPTOSIS	Several ribosomal proteins regulate p53 function by modulating MDM2. We recently found that RPS27L, a RPS27-like protein, is a direct p53-inducible target. Here we showed that RPS27 itself is a p53-repressible target. Furthermore, the N-terminal region of either RPS27L or RPS27 binds to MDM2 on the central acidic domain of MDM2. RPS27L or RPS27 forms an in vivo triplex with MDM2-p53 and competes with p53 for MDM2 binding. Similar to p53, RPS27L, but not RPS27, is a short-lived protein and a novel MDM2 substrate. Degradation of RPS27L requires the RING or acidic domain of MDM2. Ectopic expression of RPS27L or RPS27 inhibits MDM-2-mediated p53 ubiquitination and increases p53 levels by extending p53 protein half-life, whereas siRNA silencing of RPS27L decreases p53 levels by shortening p53 half-life, with a corresponding reduction in p53 transcription activity. RPS27L is mainly localized in the cytoplasm, but upon p53-activating signals, a portion of RPS27L shuttled to the nucleoplasm where it colocalizes with MDM2. Both the cytoplasmic and the nuclear p53, induced by ribosomal stress, were reduced upon RPS27L silencing. Our study reveals a multilevel interplay between RPS27L/S27 and p53-MDM2 axis, with RPS27L functioning as a p53 target, a MDM2 substrate and a p53 regulator. Oncogene (2011) 30, 1798-1811; doi:10.1038/onc.2010.569; published online 20 December 2010	[Xiong, X.; Zhao, Y.; He, H.; Sun, Y.] Univ Michigan, Dept Radiat Oncol, Div Radiat & Canc Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Sun, Y (corresponding author), Univ Michigan, Dept Radiat Oncol, Div Radiat & Canc Biol, 4424B MS-1,1301 Catherine St, Ann Arbor, MI 48109 USA.	sunyi@umich.edu	Sun, Yi/K-1025-2014	Sun, Yi/0000-0002-5841-4287; Xiong, Xiufang/0000-0001-6842-3673	National Cancer Institute [CA111554, CA118762]; University of Michigan Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE [R01CA111554, R01CA118762] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of Michigan Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by the National Cancer Institute grants (CA111554 and CA118762), and in part by a grant from the Seth Bonder Endowed Research Fund of the University of Michigan Comprehensive Cancer Center to YS.	Atsuta Y, 2002, CANCER LETT, V182, P101, DOI 10.1016/S0304-3835(02)00068-X; Balasubramanian S, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-1-r2; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Burch LR, 2000, FEBS LETT, V472, P93, DOI 10.1016/S0014-5793(00)01427-7; CHAN YL, 1993, NUCLEIC ACIDS RES, V21, P649, DOI 10.1093/nar/21.3.649; Chen D, 2007, ONCOGENE, V26, P5029, DOI 10.1038/sj.onc.1210327; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; FernandezPol JA, 1997, ANTICANCER RES, V17, P1519; FERNANDEZPOL JA, 1993, J BIOL CHEM, V268, P21198; FERNANDEZPOL JA, 1994, CELL GROWTH DIFFER, V5, P811; FernandezPol JA, 1996, ANTICANCER RES, V16, P2177; Ganger DR, 1997, ANTICANCER RES, V17, P1993; Ganger DR, 2001, CANCER DETECT PREV, V25, P231; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Gu QY, 2007, CANCER RES, V67, P3616, DOI 10.1158/0008-5472.CAN-06-4020; He H, 2007, ONCOGENE, V26, P2707, DOI 10.1038/sj.onc.1210073; Jia LJ, 2009, CANCER RES, V69, P4974, DOI 10.1158/0008-5472.CAN-08-4671; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Kulikov R, 2006, J BIOL CHEM, V281, P28575, DOI 10.1074/jbc.M513311200; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lee WJ, 2004, OTOLARYNG HEAD NECK, V131, P466, DOI 10.1016/j.otohns.2004.03.011; Li J, 2007, CANCER RES, V67, P11317, DOI 10.1158/0008-5472.CAN-07-1088; Lindstrom MS, 2007, CELL CYCLE, V6, P434, DOI 10.4161/cc.6.4.3861; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Ofir-Rosenfeld Y, 2008, MOL CELL, V32, P180, DOI 10.1016/j.molcel.2008.08.031; Peng YH, 2003, ONCOGENE, V22, P4478, DOI 10.1038/sj.onc.1206777; Robinson M, 2003, CANCER BIOL THER, V2, P406, DOI 10.4161/cbt.2.4.437; Shangary S, 2008, P NATL ACAD SCI USA, V105, P3933, DOI 10.1073/pnas.0708917105; Shimizu H, 2002, J BIOL CHEM, V277, P28446, DOI 10.1074/jbc.M202296200; Sonnichsen B, 2005, NATURE, V434, P462, DOI 10.1038/nature03353; Stack Brendan C Jr, 2004, World J Surg Oncol, V2, P45, DOI 10.1186/1477-7819-2-45; Sun SH, 2008, CANCER BIOL THER, V7, P845, DOI 10.4161/cbt.7.6.5841; Swaroop M, 2003, ANTICANCER RES, V23, P3167; Tan M, 2008, ONCOGENE, V27, P1404, DOI 10.1038/sj.onc.1210780; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Wang YW, 2006, CLIN CANCER RES, V12, P4965, DOI 10.1158/1078-0432.CCR-05-2316; WONG JM, 1993, CANCER RES, V53, P1916; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhu Y, 2009, MOL CELL, V35, P316, DOI 10.1016/j.molcel.2009.07.014	44	84	85	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	15					1798	1811		10.1038/onc.2010.569	http://dx.doi.org/10.1038/onc.2010.569			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	749ZM	21170087	Green Accepted			2022-12-17	WOS:000289512200007
J	Al-Souhibani, N; Al-Ahmadi, W; Hesketh, JE; Blackshear, PJ; Khabar, KSA				Al-Souhibani, N.; Al-Ahmadi, W.; Hesketh, J. E.; Blackshear, P. J.; Khabar, K. S. A.			The RNA-binding zinc-finger protein tristetraprolin regulates AU-rich mRNAs involved in breast cancer-related processes	ONCOGENE			English	Article						posttranscriptional control; AU-rich elements; RNA-binding proteins; RNA stability; tristetraprolin	UROKINASE PLASMINOGEN-ACTIVATOR; ENDOTHELIAL GROWTH-FACTOR; POSTTRANSCRIPTIONAL REGULATION; PROGNOSTIC-FACTOR; GENE-EXPRESSION; HUR; RECEPTOR; ELEMENTS; CELL; CYCLOOXYGENASE-2	Tristetraprolin (TTP or ZFP36) is a tandem CCCH zinc-finger RNA-binding protein that regulates the stability of certain AU-rich element (ARE) mRNAs. Recent work suggests that TTP is deficient in cancer cells when compared with normal cell types. In this study we found that TTP expression was lower in invasive breast cancer cells (MDAMB231) compared with normal breast cell lines MCF12A and MCF-10. TTP targets were probed using a novel approach by expressing the C124R zinc-finger TTP mutant that functions as dominant negative and increases target mRNA expression. In contrast to wild-type TTP, C124R TTP was able to increase certain ARE-mRNA expressions in serum-stimulated breast cancer cells. Using an ARE-gene microarray, novel targets of TTP regulation were identified, namely, urokinase plasminogen activator (uPA), uPA receptor and matrix metalloproteinase-1, all known to have prominent roles in breast cancer invasion and metastasis. Expression of these targets was upregulated in tumorigenic types, particularly in highly invasive MDAMB231. The mRNA half-lives of these TTP-regulated genes were increased in TTP-knockout embryonic mouse fibroblasts, as assessed using real-time polymerase chain reaction, whereas forced restoration of TTP by transfection led to a reduction in their mRNA levels. RNA immunoprecipitation confirmed an association of TTP, but not C124R, with these target transcripts. Moreover, TTP reduced, whereas the mutant C124R TTP increased, the activity of reporter constructs fused to target ARE. As a result of TTP regulation, invasiveness of MDAMB231 cells was reduced. The data suggest that TTP, in a 30 untranslated region- and ARE-dependent manner, regulates an important subset of cancer-related genes that are involved in cellular growth, invasion and metastasis. Oncogene ( 2010) 29, 4205-4215; doi: 10.1038/onc.2010.168; published online 24 May 2010	[Al-Souhibani, N.; Al-Ahmadi, W.; Khabar, K. S. A.] King Faisal Specialist Hosp & Res Ctr, Program BioMol Res, Riyadh 11211, Saudi Arabia; [Hesketh, J. E.] Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Blackshear, P. J.] NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC USA	King Faisal Specialist Hospital & Research Center; Newcastle University - UK; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Khabar, KSA (corresponding author), King Faisal Specialist Hosp & Res Ctr, Program BioMol Res, P3354, Riyadh 11211, Saudi Arabia.	khabar@kfshrc.edu.sa	Khabar, Khalid/AAG-3487-2019; Blackshear, Perry J./C-6206-2019	Khabar, Khalid/0000-0003-1003-9788; Blackshear, Perry J./0000-0002-9561-8529	King Khalid Foundation, Riyadh; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090080] Funding Source: NIH RePORTER	King Khalid Foundation, Riyadh; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This study is a part of the Newcastle University doctoral thesis requirements of NA-S. NA-S was supported by a PhD scholarship from King Khalid Foundation, Riyadh. We acknowledge Dr Wi S Lai for TTP plasmids and for the knockout MEF line. We also acknowledge Mr Maher Al-Saif for his technical assistance.	Al-Ahmadi W, 2009, ONCOGENE, V28, P1782, DOI 10.1038/onc.2009.16; Al-Ahmadi W, 2009, NUCLEIC ACIDS RES, V37, P3612, DOI 10.1093/nar/gkp223; Ass K, 2008, CANCER TREAT REV, V34, P122, DOI 10.1016/j.ctrv.2007.10.005; Asyali MH, 2004, NUCLEIC ACIDS RES, V32, P2323, DOI 10.1093/nar/gkh544; Bacac M, 2008, ANNU REV PATHOL-MECH, V3, P221, DOI 10.1146/annurev.pathmechdis.3.121806.151523; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; Brennan SE, 2009, CANCER RES, V69, P5168, DOI 10.1158/0008-5472.CAN-08-4238; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Christensen L, 1996, INT J CANCER, V66, P441; de Silanes IL, 2003, ONCOGENE, V22, P7146, DOI 10.1038/sj.onc.1206862; Denkert C, 2004, CANCER RES, V64, P189, DOI 10.1158/0008-5472.CAN-03-1987; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; Essafi-Benkhadir K, 2007, MOL BIOL CELL, V18, P4648, DOI 10.1091/mbc.E07-06-0570; FINI ME, 1987, BIOCHEMISTRY-US, V26, P6156, DOI 10.1021/bi00393a032; Fisher JL, 2000, BREAST CANCER RES TR, V61, P1, DOI 10.1023/A:1006445129195; Gebeshuber CA, 2009, EMBO REP, V10, P400, DOI 10.1038/embor.2009.9; Heinonen M, 2007, CLIN CANCER RES, V13, P6959, DOI 10.1158/1078-0432.CCR-07-1432; Iwata H, 1996, JPN J CANCER RES, V87, P602, DOI 10.1111/j.1349-7006.1996.tb00266.x; Khabar KSA, 2004, J MOL BIOL, V342, P833, DOI 10.1016/j.jmb.2004.07.065; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; Lai WS, 2006, MOL CELL BIOL, V26, P9196, DOI 10.1128/MCB.00945-06; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lai WS, 2002, J BIOL CHEM, V277, P9606, DOI 10.1074/jbc.M110395200; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; LIOTTA LA, 1986, CANCER RES, V46, P1; McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624; Mrena J, 2005, CLIN CANCER RES, V11, P7362, DOI 10.1158/1078-0432.CCR-05-0764; Nanbu R, 1997, EUR J BIOCHEM, V247, P169, DOI 10.1111/j.1432-1033.1997.00169.x; NANBU R, 1994, MOL CELL BIOL, V14, P4920, DOI 10.1128/MCB.14.7.4920; QUAX PHA, 1990, CANCER RES, V50, P1488; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; Sawaoka H, 2003, J BIOL CHEM, V278, P13928, DOI 10.1074/jbc.M300016200; Shetty S, 1997, MOL CELL BIOL, V17, P1075, DOI 10.1128/MCB.17.3.1075; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; Stoecklin G, 2008, J BIOL CHEM, V283, P11689, DOI 10.1074/jbc.M709657200; Suswam E, 2008, CANCER RES, V68, P674, DOI 10.1158/0008-5472.CAN-07-2751; Tran H, 2003, MOL CELL BIOL, V23, P7177, DOI 10.1128/MCB.23.20.7177-7188.2003; VINCENTI MP, 1994, NUCLEIC ACIDS RES, V22, P4818, DOI 10.1093/nar/22.22.4818; Vincenti MP, 2002, ARTHRITIS RES, V4, P157, DOI 10.1186/ar401; Vlasova IA, 2008, MOL CELL, V29, P263, DOI 10.1016/j.molcel.2007.11.024; Wang GJ, 1998, P NATL ACAD SCI USA, V95, P6296, DOI 10.1073/pnas.95.11.6296; Young LE, 2009, GASTROENTEROLOGY, V136, P1669, DOI 10.1053/j.gastro.2009.01.010	45	84	86	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2010	29	29					4205	4215		10.1038/onc.2010.168	http://dx.doi.org/10.1038/onc.2010.168			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	628VL	20498646	Green Accepted			2022-12-17	WOS:000280151500008
J	Ribeiro, AS; Albergaria, A; Sousa, B; Correia, AL; Bracke, M; Seruca, R; Schmitt, FC; Paredes, J				Ribeiro, A. S.; Albergaria, A.; Sousa, B.; Correia, A. L.; Bracke, M.; Seruca, R.; Schmitt, F. C.; Paredes, J.			Extracellular cleavage and shedding of P-cadherin: a mechanism underlying the invasive behaviour of breast cancer cells	ONCOGENE			English	Article						P-cadherin; migration; invasion; MMPs; sP-cad	EPITHELIAL-MESENCHYMAL TRANSITION; MATRIX METALLOPROTEINASE-1; GASTRIC-CANCER; EXPRESSION; ADHESION; LINES; CARCINOMA; MOTILITY; METASTASIS; PHENOTYPE	Cell-cell adhesion is an elementary process in normal epithelial cellular architecture. Several studies have shown the role mediated by cadherins in this process, besides their role in the maintenance of cell polarity, differentiation and cell growth. However, during tumour progression, these molecules are frequently altered. In breast cancer, tumours that overexpress P-cadherin usually present a high histological grade, show decreased cell polarity and are associated with worse patient survival. However, little is known about how this protein dictates the very aggressive behaviour of these tumours. To achieve this goal, we set up two breast cancer cell models, where P-cadherin expression was differently modulated and analysed in terms of cell invasion, motility and migration. We show that P-cadherin overexpression, in breast cancer cells with wild-type E-cadherin, promotes cell invasion, motility and migration. Moreover, we found that the overexpression of P-cadherin induces the secretion of matrix metalloproteases, specifically MMP-1 and MMP-2, which then lead to P-cadherin ectodomain cleavage. Further, we showed that soluble P-cadherin fragment is able to induce in vitro invasion of breast cancer cells. Overall, our results contribute to elucidate the mechanism underlying the invasive behaviour of P-cadherin expressing breast tumours. Oncogene (2010) 29, 392-402; doi:10.1038/onc.2009.338; published online 9 November 2009	[Ribeiro, A. S.; Albergaria, A.; Sousa, B.; Correia, A. L.; Seruca, R.; Schmitt, F. C.; Paredes, J.] Univ Porto IPATIMUP, Inst Mol Pathol & Immunol, Canc Genet Grp, P-4200465 Oporto, Portugal; [Albergaria, A.] Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, Braga, Portugal; [Bracke, M.] Ghent Univ Hosp, Dept Radiotherapy & Nucl Med, Lab Expt Canc Res, Ghent, Belgium; [Schmitt, F. C.] Univ Porto, Fac Med, P-4100 Oporto, Portugal	Universidade do Porto; Universidade do Minho; Ghent University; Ghent University Hospital; Universidade do Porto	Paredes, J (corresponding author), Univ Porto IPATIMUP, Inst Mol Pathol & Immunol, Canc Genet Grp, Rua Dr Roberto Frias S-N, P-4200465 Oporto, Portugal.	jparedes@ipatimup.pt	Schmitt, Fernando/A-5270-2008; Paredes, Joana/F-8224-2011; Ribeiro, Ana/J-7334-2013; seruca, raquel/F-8187-2011; Correia, Ana Luisa/E-9738-2012; Sousa, Bárbara/K-8854-2014; Albergaria, André/J-6162-2013	Schmitt, Fernando/0000-0002-3711-8681; Paredes, Joana/0000-0002-1076-1343; Ribeiro, Ana/0000-0002-9698-9233; Sousa, Bárbara/0000-0002-0990-022X; Albergaria, André/0000-0002-2315-2360; Seruca, Raquel/0000-0002-8851-4166; Schmitt, Fernando/0000-0003-1006-6946; Correia, Ana Luisa/0000-0003-2414-0131	Portuguese Science and Technology Foundation (FCT) [POCI/BIA-BCM/59252/2004, SFRH/BD/36096/2007, SFRH/BD/15316/2005]	Portuguese Science and Technology Foundation (FCT)(Portuguese Foundation for Science and Technology)	The work presented was mainly supported by a scientific project (POCI/BIA-BCM/59252/2004) financed by the Portuguese Science and Technology Foundation (FCT). FCT also provided research grants as follows: Programa Ciencia 2007 (FCT) for Joana Paredes, and PhD research grants for Ana Sofia Ribeiro (SFRH/BD/36096/2007) and Andre Albergaria (SFRH/BD/15316/2005).	Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Chen HY, 1997, J CELL SCI, V110, P345; Chhabra ES, 2007, NAT CELL BIOL, V9, P1110, DOI 10.1038/ncb1007-1110; De Paul AL, 2005, J ANDROL, V26, P44; Fenteany G, 2000, CURR BIOL, V10, P831, DOI 10.1016/S0960-9822(00)00579-0; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Fujimoto D, 2008, ANTICANCER RES, V28, P847; Gamallo C, 2001, MODERN PATHOL, V14, P650, DOI 10.1038/modpathol.3880367; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Ito T, 1999, MODERN PATHOL, V12, P669; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; Longatto Filho A, 2005, CYTOPATHOLOGY, V16, P88, DOI 10.1111/j.1365-2303.2004.00226.x; Mannello F, 2008, CANCER SCI, V99, P2160, DOI 10.1111/j.1349-7006.2008.00921.x; Murray GI, 1998, GUT, V43, P791, DOI 10.1136/gut.43.6.791; Murray GI, 1998, J PATHOL, V185, P256; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Noe V, 2001, J CELL SCI, V114, P111; Okuyama N, 2008, ONCOL REP, V20, P1497, DOI 10.3892/or_00000171; Oliveira MJ, 2003, EMBO J, V22, P6161, DOI 10.1093/emboj/cdg586; Paredes J, 2008, J CLIN PATHOL, V61, P856, DOI 10.1136/jcp.2007.052704; Paredes J, 2005, CLIN CANCER RES, V11, P5869, DOI 10.1158/1078-0432.CCR-05-0059; Paredes J, 2004, CANCER RES, V64, P8309, DOI 10.1158/0008-5472.CAN-04-0795; Paredes J, 2002, PATHOL RES PRACT, V198, P795, DOI 10.1078/0344-0338-00338; Paredes J, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1774; Paredes J, 2007, CELL ONCOL, V29, P467; Remacle AG, 1998, BRIT J CANCER, V77, P926, DOI 10.1038/bjc.1998.153; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Simpson KJ, 2008, NAT CELL BIOL, V10, P1027, DOI 10.1038/ncb1762; Soler AP, 1999, CANCER-AM CANCER SOC, V86, P1263, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1263::AID-CNCR23>3.3.CO;2-U; Soler AP, 2002, J CELL BIOCHEM, V85, P180, DOI 10.1002/jcb.10126; Stefansson IM, 2004, J CLIN ONCOL, V22, P1242, DOI 10.1200/JCO.2004.09.034; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; Taniuchi K, 2005, CANCER RES, V65, P3092, DOI 10.1158/0008.5472.CAN-04-3646; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Van Marck V, 2005, CANCER RES, V65, P8774, DOI 10.1158/0008-5472.CAN-04-4414; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Yamazaki D, 2005, CANCER SCI, V96, P379, DOI 10.1111/j.1349-7006.2005.00062.x	42	84	84	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					392	402		10.1038/onc.2009.338	http://dx.doi.org/10.1038/onc.2009.338			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19901964	Green Published			2022-12-17	WOS:000273793200008
J	Wasch, R; Robbins, JA; Cross, FR				Waesch, R.; Robbins, J. A.; Cross, F. R.			The emerging role of APC/C-Cdh1 in controlling differentiation, genomic stability and tumor suppression	ONCOGENE			English	Review						anaphase-promoting complex; ubiquitin; proteasome; differentiation; genomic instability; tumor suppression	ANAPHASE-PROMOTING COMPLEX; APC-DEPENDENT PROTEOLYSIS; XENOPUS EGG EXTRACTS; CELL-CYCLE ARREST; S-PHASE ENTRY; AURORA-A; MITOTIC SPINDLE; UBIQUITIN LIGASE; D-BOX; SACCHAROMYCES-CEREVISIAE	Deregulation of the G1/G0 phase of the cell cycle can lead to cancer. During G1, most cells commit alternatively to DNA replication and division, or to cell-cycle exit and differentiation. The anaphase-promoting complex or cyclosome (APC/C) activated by Cdh1 coordinately eliminates positive cell-cycle regulators as well as inhibitors of differentiation, thereby coupling cell-cycle exit and differentiation. Misregulation of Cdh1 thus has the potential to promote both cell-cycle re-entry and either perturbed differentiation or dedifferentiation. In addition, APC/C-Cdh1 is required to maintain genomic stability. As a result, loss of Cdh1 can contribute to tumorigenesis in the form of proliferation of poorly differentiated and genetically unstable cells.	[Waesch, R.] Univ Med Ctr, Dept Hematol & Oncol, D-79106 Freiburg, Germany; [Robbins, J. A.; Cross, F. R.] Rockefeller Univ, Lab Yeast Mol Genet, New York, NY 10021 USA	University of Freiburg; Rockefeller University	Wasch, R (corresponding author), Univ Med Ctr, Dept Hematol & Oncol, Hugstetterstr 55, D-79106 Freiburg, Germany.	ralph.waesch@uniklinik-freiburg.de	Waesch, Ralph/F-6282-2019	Robbins, Jonathan/0000-0001-9690-4976	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047238, T32GM007739] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM047238-14, R01 GM047238, R01 GM047238-10, R01 GM047238-05A2, R01 GM047238-09, R01 GM047238-08, R01 GM047238-06, R01 GM047238-07, R01 GM047238-16, T32 GM007739, R01 GM047238-12, R01 GM047238-13, R01 GM047238-15, R01 GM047238-11] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Araki M, 2003, EMBO J, V22, P6115, DOI 10.1093/emboj/cdg573; Archambault V, 2009, NAT REV MOL CELL BIO, V10, P265, DOI 10.1038/nrm2653; Barr AR, 2007, J CELL SCI, V120, P2987, DOI 10.1242/jcs.013136; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bassermann F, 2008, CELL, V134, P256, DOI 10.1016/j.cell.2008.05.043; Benmaamar R, 2005, CELL CYCLE, V4, P1230, DOI 10.4161/cc.4.9.2048; Binne UK, 2007, NAT CELL BIOL, V9, P225, DOI 10.1038/ncb1532; Bloom J, 2007, NAT REV MOL CELL BIO, V8, P149, DOI 10.1038/nrm2105; Carroll CW, 2002, NAT CELL BIOL, V4, P880, DOI 10.1038/ncb871; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Castro A, 2003, MOL CELL BIOL, V23, P4126, DOI 10.1128/MCB.23.12.4126-4138.2003; Castro A, 2002, EMBO REP, V3, P1209, DOI 10.1093/embo-reports/kvf241; Chaudhary J, 2005, BIOL REPROD, V72, P1205, DOI 10.1095/biolreprod.104.035717; Crasta K, 2008, NAT CELL BIOL, V10, P665, DOI 10.1038/ncb1729; Crasta K, 2006, EMBO J, V25, P2551, DOI 10.1038/sj.emboj.7601136; Cross FR, 2003, DEV CELL, V4, P741, DOI 10.1016/S1534-5807(03)00119-9; Cuende J, 2008, ONCOGENE, V27, P3339, DOI 10.1038/sj.onc.1210987; Diffley JFX, 2004, CURR BIOL, V14, pR778, DOI 10.1016/j.cub.2004.09.019; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Engelbert D, 2008, ONCOGENE, V27, P907, DOI 10.1038/sj.onc.1210703; Enquist-Newman M, 2008, MOL CELL, V30, P437, DOI 10.1016/j.molcel.2008.04.004; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; Floyd S, 2008, CURR BIOL, V18, P1649, DOI 10.1016/j.cub.2008.09.058; Fujita T, 2008, AM J PATHOL, V173, P217, DOI 10.2353/ajpath.2008.070957; Fujita T, 2008, CLIN CANCER RES, V14, P1966, DOI 10.1158/1078-0432.CCR-07-1585; Garcia-Higuera I, 2008, NAT CELL BIOL, V10, P802, DOI 10.1038/ncb1742; Gieffers C, 1999, P NATL ACAD SCI USA, V96, P11317, DOI 10.1073/pnas.96.20.11317; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Hayes MJ, 2006, NAT CELL BIOL, V8, P607, DOI 10.1038/ncb1410; Hildebrandt ER, 2001, MOL BIOL CELL, V12, P3402, DOI 10.1091/mbc.12.11.3402; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Jacobs HW, 2002, CURR BIOL, V12, P1435, DOI 10.1016/S0960-9822(02)01074-6; Jaquenoud M, 2002, EMBO J, V21, P6515, DOI 10.1093/emboj/cdf634; Ji M, 2008, BLOOD, V112, P1068, DOI 10.1182/blood-2008-01-133504; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; Keppler A, 2003, NAT BIOTECHNOL, V21, P86, DOI 10.1038/nbt765; Konishi Y, 2004, SCIENCE, V303, P1026, DOI 10.1126/science.1093712; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Lapenna S, 2009, NAT REV DRUG DISCOV, V8, P547, DOI 10.1038/nrd2907; Lasorella A, 2006, NATURE, V442, P471, DOI 10.1038/nature04895; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Lehman NL, 2007, AM J PATHOL, V170, P1793, DOI 10.2353/ajpath.2007.060767; Lengronne A, 2002, MOL CELL, V9, P1067, DOI 10.1016/S1097-2765(02)00513-0; Li M, 2008, NAT CELL BIOL, V10, P1083, DOI 10.1038/ncb1768; Li M, 2009, CELL DIV, V4, DOI 10.1186/1747-1028-4-2; Li WQ, 2007, FASEB J, V21, P3606, DOI 10.1096/fj.07-8159com; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Listovsky T, 2004, EMBO J, V23, P1619, DOI 10.1038/sj.emboj.7600149; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Liu WJ, 2007, MOL CELL BIOL, V27, P2967, DOI 10.1128/MCB.01830-06; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Lwin T, 2007, BLOOD, V110, P1631, DOI 10.1182/blood-2006-11-060350; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Passmore LA, 2003, EMBO J, V22, P786, DOI 10.1093/emboj/cdg084; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Pesin JA, 2008, ANNU REV CELL DEV BI, V24, P475, DOI 10.1146/annurev.cellbio.041408.115949; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Pfleger CM, 2000, GENE DEV, V14, P655; Rape M, 2006, CELL, V124, P89, DOI 10.1016/j.cell.2005.10.032; Rape M, 2004, NATURE, V432, P588, DOI 10.1038/nature03023; Reis A, 2006, EMBO REP, V7, P1040, DOI 10.1038/sj.embor.7400772; Ross KE, 2003, GENETICS, V165, P489; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Shirayama M, 1999, NATURE, V402, P203, DOI 10.1038/46080; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Skotheim JM, 2008, NATURE, V454, P291, DOI 10.1038/nature07118; Sorensen CS, 2001, MOL CELL BIOL, V21, P3692, DOI 10.1128/MCB.21.11.3692-3703.2001; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Stegmuller J, 2008, J NEUROSCI, V28, P1961, DOI 10.1523/JNEUROSCI.3061-07.2008; Stegmuller J, 2006, NEURON, V50, P389, DOI 10.1016/j.neuron.2006.03.034; Steigemann P, 2009, CELL, V136, P473, DOI 10.1016/j.cell.2008.12.020; Stewart S, 2005, MOL CELL BIOL, V25, P10516, DOI 10.1128/MCB.25.23.10516-10527.2005; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Stroschein SL, 2001, GENE DEV, V15, P2822; Sudo T, 2001, EMBO J, V20, P6499, DOI 10.1093/emboj/20.22.6499; Suh HC, 2008, ONCOGENE, V27, P5612, DOI 10.1038/onc.2008.175; Sullivan M, 2007, J BIOL CHEM, V282, P19710, DOI 10.1074/jbc.M701507200; Takahashi C, 2006, CANCER RES, V66, P9345, DOI 10.1158/0008-5472.CAN-06-1250; Taylor S, 2008, CURR OPIN CELL BIOL, V20, P77, DOI 10.1016/j.ceb.2007.11.008; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wang CX, 2000, BLOOD, V96, P259, DOI 10.1182/blood.V96.1.259.013k36_259_263; Wasch R, 2005, ONCOGENE, V24, P1, DOI 10.1038/sj.onc.1208017; Wasch R, 2002, NATURE, V418, P556, DOI 10.1038/nature00856; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Wirth KG, 2004, GENE DEV, V18, P88, DOI 10.1101/gad.285404; Wu G, 2007, MOL BIOL CELL, V18, P1018, DOI 10.1091/mbc.E06-09-0809; Yamano H, 2004, MOL CELL, V13, P137, DOI 10.1016/S1097-2765(03)00480-5; Yeong FM, 2000, MOL CELL, V5, P501, DOI 10.1016/S1097-2765(00)80444-X; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721; Zhao WM, 2005, J BIOL CHEM, V280, P33516, DOI 10.1074/jbc.M504657200; Zhou Y, 2003, J BIOL CHEM, V278, P12530, DOI 10.1074/jbc.M212853200; Zielke N, 2008, GENE DEV, V22, P1690, DOI 10.1101/gad.469108	100	84	85	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	2010	29	1					1	10		10.1038/onc.2009.325	http://dx.doi.org/10.1038/onc.2009.325			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19826416	Green Accepted			2022-12-17	WOS:000273373500001
J	Lakshmikuttyamma, A; Scott, SA; DeCoteau, JF; Geyer, CR				Lakshmikuttyamma, A.; Scott, S. A.; DeCoteau, J. F.; Geyer, C. R.			Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition	ONCOGENE			English	Article						p15INK4B; SUV39H1; chaetocin; histone methylation; DNA methylation	HISTONE METHYLTRANSFERASE SUV39H1; ACUTE MYELOID-LEUKEMIA; DNA METHYLATION; DEACETYLASE INHIBITION; CPG ISLAND; E-CADHERIN; HETEROCHROMATIN FORMATION; LYSINE-9 METHYLATION; POOR-PROGNOSIS; PROMOTER DNA	Reexpression of hypermethylated tumor suppressor genes using DNA methyltransferase (DNMT) and histone deacetylase inhibitors occurs by a mechanism whereby promoter demethylation is the dominant event. In support of this model, we found in acute myeloid leukemia cells with hypermethylated p15INK4B and E-cadherin promoters that the DNMT inhibitor, 5-aza-20-deoxycytidine, induced p15INK4B and E-cadherin expression, and decreased levels of DNA methylation, histone H3 lysine 9 (H3K9) methylation and SUV39H1 associated with p15INK4B and E-cadherin promoters. On the basis of these observations, we examined whether promoter demethylation was dominant to H3K9 demethylation in p15INK4B and E-cadherin reexpression. We observed that SUV39H1 short hairpin RNA and chaetocin, a SUV39H1 inhibitor, induced p15INK4B and E-cadherin expression and H3K9 demethylation without promoter demethylation. Reexpression of hypermethylated p15INK4B and E-cadherin required histone H3K9 demethylation that was achieved directly by inhibiting SUV39H1 expression or activity, or indirectly by decreasing the amount of SUV39H1 associated with the p15INK4B and E-cadherin promoters using 5-aza-20-deoxycytidine. The results from this study highlight the potential of H3K9 methyltransferases as therapeutic targets for reactivating expression of hypermethylated genes. Oncogene (2010) 29, 576-588; doi: 10.1038/onc.2009.361; published online 2 November 2009	[Geyer, C. R.] Univ Saskatchewan, Dept Pathol, Saskatchewan Canc Agcy, Canc Stem Cell Res Grp, Saskatoon, SK S7N 4H4, Canada; [Geyer, C. R.] Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 4H4, Canada	University of Saskatchewan; University of Saskatchewan	Geyer, CR (corresponding author), Univ Saskatchewan, Dept Pathol, Saskatchewan Canc Agcy, Canc Stem Cell Res Grp, 20 Campus Dr, Saskatoon, SK S7N 4H4, Canada.	ron.geyer@usask.ca	Lakshmikuttyamma, Ashakumary/K-7164-2019	Lakshmikuttyamma, Ashakumary/0000-0001-8580-7855; Scott, Stuart/0000-0001-5720-1864	Canadian Institutes of Health Research; Canada Foundation for Innovation; Saskatchewan Health Research Foundation	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); Saskatchewan Health Research Foundation	This work was supported by grants from the Canadian Institutes of Health Research, Canada Foundation for Innovation, and the Saskatchewan Health Research Foundation. CRG is a CIHR-RPP New Investigator. AL is a Rethink Breast Cancer PDF.	Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Boultwood J, 2007, BRIT J HAEMATOL, V138, P3, DOI 10.1111/j.1365-2141.2007.06604.x; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Carbone R, 2006, MOL CELL BIOL, V26, P1288, DOI 10.1128/MCB.26.4.1288-1296.2006; Cattaneo F, 2008, J CELL BIOCHEM, V105, P344, DOI 10.1002/jcb.21869; Chakraborty S, 2003, ONCOGENE, V22, P5229, DOI 10.1038/sj.onc.1206600; Christiansen DH, 2003, LEUKEMIA, V17, P1813, DOI 10.1038/sj.leu.2403054; Coombes MM, 2003, ONCOGENE, V22, P8902, DOI 10.1038/sj.onc.1207050; Dodge JE, 2001, LEUKEMIA RES, V25, P917, DOI 10.1016/S0145-2126(01)00053-4; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Egger G, 2007, CANCER RES, V67, P346, DOI 10.1158/0008-5472.CAN-06-2845; Fahrner JA, 2002, CANCER RES, V62, P7213; Fujita N, 2003, J BIOL CHEM, V278, P24132, DOI 10.1074/jbc.M302283200; Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Galm O, 2006, BLOOD REV, V20, P1, DOI 10.1016/j.blre.2005.01.006; Gilbert J, 2004, CLIN CANCER RES, V10, P4589, DOI 10.1158/1078-0432.CCR-03-0297; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Gore Steven D, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS30, DOI 10.1038/ncponc0346; Greiner D, 2005, NAT CHEM BIOL, V1, P143, DOI 10.1038/nchembio721; Guldberg P, 2002, METHODS, V27, P121, DOI 10.1016/S1046-2023(02)00063-4; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1997, CANCER RES, V57, P837; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Issa Jean-Pierre, 2003, Current Opinion in Oncology, V15, P446, DOI 10.1097/00001622-200311000-00007; Jang H, 2007, J BIOL CHEM, V282, P11172, DOI 10.1074/jbc.M611199200; Jiemjit A, 2008, ONCOGENE, V27, P3615, DOI 10.1038/sj.onc.1211018; Kamoi K, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-5; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; Li YH, 2002, P NATL ACAD SCI USA, V99, P16462, DOI 10.1073/pnas.162371699; Liu YN, 2005, ONCOGENE, V24, P8277, DOI 10.1038/sj.onc.1208991; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; Mal AK, 2006, EMBO J, V25, P3323, DOI 10.1038/sj.emboj.7601229; McGarvey KM, 2007, CANCER RES, V67, P5097, DOI 10.1158/0008-5472.CAN-06-2029; Melki JR, 2000, BLOOD, V95, P3208; Melki JR, 1999, CANCER RES, V59, P3730; Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nguyen CT, 2002, CANCER RES, V62, P6456; Nicolas E, 2003, MOL CELL BIOL, V23, P1614, DOI 10.1128/MCB.23.5.1614-1622.2003; Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Ogawa M, 2007, LEUKEMIA RES, V31, P611, DOI 10.1016/j.leukres.2006.09.023; Pastural E, 2007, ONCOGENE, V26, P1586, DOI 10.1038/sj.onc.1209959; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; Preisler HD, 2001, LEUKEMIA, V15, P1589, DOI 10.1038/sj.leu.2402211; Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Scott SA, 2006, LEUKEMIA RES, V30, P69, DOI 10.1016/j.leukres.2005.05.010; Scott SA, 2007, EXP HEMATOL, V35, P263, DOI 10.1016/j.exphem.2006.10.005; Shimamoto T, 2005, LEUKEMIA RES, V29, P653, DOI 10.1016/j.leukres.2004.11.014; Spensberger D, 2008, FEBS LETT, V582, P2761, DOI 10.1016/j.febslet.2008.06.056; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Teofili L, 2003, LEUKEMIA, V17, P919, DOI 10.1038/sj.leu.2402907; Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Wozniak RJ, 2007, ONCOGENE, V26, P77, DOI 10.1038/sj.onc.1209763; Wu R, 2005, MOL BIOL CELL, V16, P2872, DOI 10.1091/mbc.e04-11-0997; Yu WQ, 2008, NATURE, V451, P202, DOI 10.1038/nature06468; Zhang C, 2007, J PATHOL, V212, P134, DOI 10.1002/path.2173; Zinn RL, 2007, CANCER RES, V67, P194, DOI 10.1158/0008-5472.CAN-06-3396	72	84	92	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					576	588		10.1038/onc.2009.361	http://dx.doi.org/10.1038/onc.2009.361			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19881540				2022-12-17	WOS:000274084600010
J	Nalbandian, A; Yan, BS; Pichugin, A; Bronson, RT; Kramnik, I				Nalbandian, A.; Yan, B-S; Pichugin, A.; Bronson, R. T.; Kramnik, I.			Lung carcinogenesis induced by chronic tuberculosis infection: the experimental model and genetic control	ONCOGENE			English	Article						Mycobacterium tuberculosis; sst1; chronic inflammation; squamous cell carcinoma; macrophages; epiregulin	MITOSIS-SPECIFIC PHOSPHORYLATION; GROWTH-FACTOR FAMILY; PULMONARY TUBERCULOSIS; CHRONIC INFLAMMATION; HISTONE H3; CANCER; EPIREGULIN; CARCINOMA; PATHOGENESIS; TUMORS	Coexistence of pulmonary tuberculosis (TB) and lung cancer in clinic poses significant challenges for the diagnostic and treatment of both diseases. Although association of chronic inflammation and cancer is well-documented, causal relationship between TB infection and lung cancer are not understood. We present experimental evidence that chronic TB infection induces cell dysplasia and squamous cell carcinoma (SCC) in a lung-specific manner. First, squamous cell aggregates consistently appeared within the lung tissue associated with chronic TB lesions, and in some cases resembled SCCs. A transplantable tumor was established after the transfer of cells isolated from TB lung lesions into syngeneic recipients. Second, the (Mycobacterium tuberculosis) MTB-infected macrophages play a pivotal role in TB-induced carcinogenesis by inducing DNA damage in their vicinity and by the production of a potent epidermal growth factor epiregulin, which may serve as a paracrine survival and growth factor responsible for squamous metaplasia and tumorigenesis. Third, lung carcinogenesis during the course of chronic TB infection was more pronounced in animals with severe lung tissue damage mediated by TB-susceptibility locus sst1. Together, our experimental findings showed a causal link between pulmonary TB and lung tumorigenesis and established a genetic model for further analysis of carcinogenic mechanisms activated by TB infection.	[Nalbandian, A.; Yan, B-S; Pichugin, A.; Kramnik, I.] Harvard Univ, Sch Med, Dept Immunol & Infect Dis, Boston, MA 02115 USA; [Yan, B-S] Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 112, Taiwan; [Bronson, R. T.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; National Yang Ming Chiao Tung University; Harvard University; Harvard Medical School	Kramnik, I (corresponding author), Harvard Univ, Sch Med, Dept Immunol & Infect Dis, 665 Huntington Ave, Boston, MA 02115 USA.	ikramnik@hsph.harvard.edu		Yan, Bo-Shiun/0000-0002-9613-4788; Pichugin, Alexander/0000-0002-2577-7284; Kramnik, Igor/0000-0001-6511-9246	NHLBI NIH HHS [R01 HL059836] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059836] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ardies C Murray, 2003, Integr Cancer Ther, V2, P238, DOI 10.1177/1534735403256332; Azad N, 2008, J TOXICOL ENV HEAL B, V11, P1, DOI 10.1080/10937400701436460; Baba I, 2000, CANCER RES, V60, P6886; Bewersdorf J, 2006, P NATL ACAD SCI USA, V103, P18137, DOI 10.1073/pnas.0608709103; CAGLE PT, 1985, CANCER, V56, P2031, DOI 10.1002/1097-0142(19851015)56:8<2031::AID-CNCR2820560824>3.0.CO;2-K; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dacosta N A, 1991, J Postgrad Med, V37, P185; Dalgleish AG, 2002, ADV CANCER RES, V84, P231, DOI 10.1016/S0065-230X(02)84008-8; Fujiwara Nagatoshi, 2005, Current Drug Targets - Inflammation and Allergy, V4, P281, DOI 10.2174/1568010054022024; GOPALAKRISHNAN P, 1975, AM SURGEON, V41, P405; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Inagaki N, 1997, J BIOL CHEM, V272, P25195, DOI 10.1074/jbc.272.40.25195; Jin DY, 2007, FRONT BIOSCI-LANDMRK, V12, P222, DOI 10.2741/2060; Karin M, 2006, CELL, V124, P823, DOI 10.1016/j.cell.2006.02.016; Klein G, 2005, IMMUNOL LETT, V100, P29, DOI 10.1016/j.imlet.2005.06.024; Komarova EA, 2005, FASEB J, V19, P1030, DOI 10.1096/fj.04-3213fje; Kramnik I, 2000, P NATL ACAD SCI USA, V97, P8560, DOI 10.1073/pnas.150227197; Kurasawa T, 1998, Nihon Rinsho, V56, P3167; Lawrence T, 2007, INT J EXP PATHOL, V88, P85, DOI 10.1111/j.1365-2613.2006.00507.x; Lawrence T, 2007, TRENDS PHARMACOL SCI, V28, P162, DOI 10.1016/j.tips.2007.02.003; Lee D, 2004, MOL CELL BIOL, V24, P8907, DOI 10.1128/MCB.24.20.8907-8916.2004; Melnikova VO, 2005, MUTAT RES-FUND MOL M, V571, P91, DOI 10.1016/j.mrfmmm.2004.11.015; Mohan VP, 2001, INFECT IMMUN, V69, P1847, DOI 10.1128/IAI.69.3.1847-1855.2001; Moutsopoulos NM, 2008, CURR OPIN IMMUNOL, V20, P234, DOI 10.1016/j.coi.2008.04.003; Naito Y, 2002, FREE RADICAL BIO MED, V33, P323, DOI 10.1016/S0891-5849(02)00868-7; Nelson CM, 2006, ANNU REV CELL DEV BI, V22, P287, DOI 10.1146/annurev.cellbio.22.010305.104315; Nussenzweig A, 2006, NATURE, V439, P406, DOI 10.1038/439406a; Oka K, 2005, ACTA BIOCHIM POL, V52, P311; Pastore S, 2006, EUR J DERMATOL, V16, P125; Preuss U, 2003, NUCLEIC ACIDS RES, V31, P878, DOI 10.1093/nar/gkg176; Russell DG, 2007, NAT REV MICROBIOL, V5, P39, DOI 10.1038/nrmicro1538; Sakuraba Motoki, 2006, Ann Thorac Cardiovasc Surg, V12, P53; SAKURAI R, 1989, JPN J MED, V28, P471; Saunders BM, 2007, IMMUNOL CELL BIOL, V85, P103, DOI 10.1038/sj.icb.7100027; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; Shirakata Y, 2000, J BIOL CHEM, V275, P5748, DOI 10.1074/jbc.275.8.5748; Shirasawa S, 2004, P NATL ACAD SCI USA, V101, P13921, DOI 10.1073/pnas.0404217101; Takahashi M, 2003, CIRCULATION, V108, P2524, DOI 10.1161/01.CIR.0000096482.02567.8C; Tan TT, 2007, CURR OPIN IMMUNOL, V19, P209, DOI 10.1016/j.coi.2007.01.001; TING YM, 1976, RADIOLOGY, V119, P307, DOI 10.1148/119.2.307; Toyoda H, 1997, BIOCHEM J, V326, P69, DOI 10.1042/bj3260069; Ulrichs T, 2006, J PATHOL, V208, P261, DOI 10.1002/path.1906; Ulrichs T, 2004, J PATHOL, V204, P217, DOI 10.1002/path.1628; van Kempen LCL, 2006, EUR J CANCER, V42, P728, DOI 10.1016/j.ejca.2006.01.004; Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248; Wang Y, 2004, CANCER RES, V64, P1647, DOI 10.1158/0008-5472.CAN-03-3273	48	84	96	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2009	28	17					1928	1938		10.1038/onc.2009.32	http://dx.doi.org/10.1038/onc.2009.32			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PX	19330024				2022-12-17	WOS:000265640600005
J	Komatsu, D; Kato, M; Nakayama, J; Miyagawa, S; Kamata, T				Komatsu, D.; Kato, M.; Nakayama, J.; Miyagawa, S.; Kamata, T.			NADPH oxidase 1 plays a critical mediating role in oncogenic Ras-induced vascular endothelial growth factor expression	ONCOGENE			English	Article						Nox1; Ras; VEGF; ER K; Sp1	PROTEIN-TYROSINE-PHOSPHATASE; MAP KINASE PHOSPHATASES; REACTIVE OXYGEN; FACTOR GENE; ACTIVATION; CELLS; SUPEROXIDE; CANCER; NOX1; ADENOCARCINOMA	Reactive oxygen species (ROS)-generating enzyme Nox1 is important in the induction of oncogenic Ras transformation phenotypes, but it is not defined whether Nox1 is involved in Ras-induced upregulation of vascular endothelial growth factor (VEGF), a potent stimulator of tumor angiogenesis. Here we describe that ablation of the Nox1 activity by Nox1 small-interference RNAs (siRNAs) or diphenylene iodonium (DPI) inhibited synthesis of both VEGF proteins and VEGF mRNAs in K-Ras transformed normal rat kidney (KNRK) cells. Nox1siRNAs and DPI suppressed extracellular signal-regulated kinase (ERK)dependent phosphorylation of a transcription factor Sp1 and Sp1 binding to a VEGF promoter. Furthermore, tumors derived from Nox1siRNA-transfected KNRK cells markedly decreased neovascularization. The Nox1 activity was required for VEGF production in human colon cancer CaCO-2 cells, as in the case of KNRK cells. However, since overexpression of Nox1 in normal rat kidney cells failed to induce VEGF, the Nox1 activity alone was not sufficient to upregulate VEGF expression, which suggests that unlike the previously proposed model, Nox1 may act in concert with other effectors integrated into the Ras network. We propose that Nox1 mediates oncogenic Ras-induced upregulation of VEGF and angiogenesis by activating Sp1 through Ras-ERK-dependent phosphorylation of Sp1.	[Komatsu, D.; Kato, M.; Kamata, T.] Shinshu Univ, Grad Sch Med, Dept Mol Biol & Biochem, Nagano 3908621, Japan; [Komatsu, D.; Miyagawa, S.] Shinshu Univ, Grad Sch Med, Dept Surg, Nagano 3908621, Japan; [Nakayama, J.] Shinshu Univ, Grad Sch Med, Inst Organ Transplantat Reconstruct Med & Tissue, Nagano 3908621, Japan	Shinshu University; Shinshu University; Shinshu University	Kamata, T (corresponding author), Shinshu Univ, Sch Med, Dept Mol Biol & Biochem, 3-1-1 Asahi, Nagano 3908621, Japan.	kamatat@sch.md.shinshu-u.ac.jp						Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Carnesecchi S, 2006, EXP CELL RES, V312, P3413, DOI 10.1016/j.yexcr.2006.07.003; Cheng GJ, 2004, J BIOL CHEM, V279, P34250, DOI 10.1074/jbc.M400660200; Chiarugi P, 2001, J BIOL CHEM, V276, P33478, DOI 10.1074/jbc.M102302200; Chupreta S, 2000, AM J PHYSIOL-CELL PH, V278, pC697, DOI 10.1152/ajpcell.2000.278.4.C697; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fu XY, 2006, J BIOL CHEM, V281, P20368, DOI 10.1074/jbc.M603353200; Geiszt M, 2003, J IMMUNOL, V171, P299, DOI 10.4049/jimmunol.171.1.299; Gioeli D, 1999, CANCER RES, V59, P279; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kondoh K, 2007, BBA-MOL CELL RES, V1773, P1227, DOI 10.1016/j.bbamcr.2006.12.002; Kranenburg O, 2004, BBA-REV CANCER, V1654, P23, DOI 10.1016/j.bbcan.2003.09.004; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Mitsushita J, 2004, CANCER RES, V64, P3580, DOI 10.1158/0008-5472.CAN-03-3909; Mochizuki T, 2006, ONCOGENE, V25, P3699, DOI 10.1038/sj.onc.1209406; Omachi T, 2007, CANCER LETT, V246, P167, DOI 10.1016/j.canlet.2006.02.013; Rhee SG, 2003, J AM SOC NEPHROL, V14, pS211, DOI 10.1097/01.ASN.0000077404.45564.7E; Sambrook J., 2001, MOL CLONING; Sen CK, 2002, J BIOL CHEM, V277, P33284, DOI 10.1074/jbc.M203391200; Shinohara M, 2007, J BIOL CHEM, V282, P17640, DOI 10.1074/jbc.M609450200; Shukla S, 2004, NEOPLASIA, V6, P390, DOI 10.1593/neo.04112; Szanto I, 2005, J PATHOL, V207, P164, DOI 10.1002/path.1824; Vaquero EC, 2004, J BIOL CHEM, V279, P34643, DOI 10.1074/jbc.M400078200; Wang FS, 2004, J BIOL CHEM, V279, P10331, DOI 10.1074/jbc.M308013200; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6	30	84	86	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2008	27	34					4724	4732		10.1038/onc.2008.102	http://dx.doi.org/10.1038/onc.2008.102			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18454179				2022-12-17	WOS:000258236300010
J	Peng, SL				Peng, S. L.			Foxo in the immune system	ONCOGENE			English	Review						transcription factors; autoimmunity; T cells; B cells; arthritis; lupus	FORKHEAD TRANSCRIPTION FACTOR; OXIDATIVE-STRESS; NUCLEAR EXCLUSION; INFLAMMATORY ARTHRITIS; NEUTROPHIL APOPTOSIS; CELL PROLIFERATION; SIGNALING PATHWAY; TUMOR SUPPRESSION; FACTOR FKHR; DNA-DAMAGE	In addition to their key roles in cellular survival, death, proliferation and metabolism, the Foxo subfamily of forkhead (Fox) transcription factors play critical roles in the homeostasis of immune-relevant cells, including T cells, B cells, neutrophils and other non-lymphoid lineages that modulate inflammation in disease states such as inflammatory arthritis and systemic lupus erythematosus. This review summarizes such current and expanding knowledge of the Foxo family members in immunity, and their potential as therapeutic targets in inflammatory disease.	Clin Res & Exploratory Dev, Palo Alto, CA 94304 USA		Peng, SL (corresponding author), Clin Res & Exploratory Dev, LLC 3431 Hillview Ave,M-S A2-259, Palo Alto, CA 94304 USA.	stanford.peng@roche.com	Peng, Stanford/S-6723-2019					Asada S, 2007, CELL SIGNAL, V19, P519, DOI 10.1016/j.cellsig.2006.08.015; Asselin-Labat ML, 2004, BLOOD, V104, P215, DOI 10.1182/blood-2003-12-4295; Aud D, 2006, NAT CLIN PRACT RHEUM, V2, P434, DOI 10.1038/ncprheum0222; Behzad H, 2007, CYTOKINE, V38, P74, DOI 10.1016/j.cyto.2007.05.004; Birkenkamp KU, 2007, J BIOL CHEM, V282, P2211, DOI 10.1074/jbc.M606669200; Bosque A, 2007, BLOOD, V109, P1627, DOI 10.1182/blood-2006-05-022319; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Charvet C, 2006, J IMMUNOL, V177, P5024, DOI 10.4049/jimmunol.177.8.5024; Chen J, 2006, J IMMUNOL, V176, P2711, DOI 10.4049/jimmunol.176.5.2711; Coffer PJ, 2004, NAT REV IMMUNOL, V4, P889, DOI 10.1038/nri1488; Crellin NK, 2007, BLOOD, V109, P2014, DOI 10.1182/blood-2006-07-035279; Crossley LJ, 2003, J LEUKOCYTE BIOL, V74, P583, DOI 10.1189/jlb.0103020; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; De Ruiter ND, 2001, MOL CELL BIOL, V21, P8225, DOI 10.1128/MCB.21.23.8225-8235.2001; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Fabre S, 2005, J IMMUNOL, V174, P4161, DOI 10.4049/jimmunol.174.7.4161; FABRE S, 2006, FOXOS B CANC, V93, pE36; Fallarino F, 2004, J EXP MED, V200, P1051, DOI 10.1084/jem.20040942; Fosbrink M, 2006, J BIOL CHEM, V281, P19009, DOI 10.1074/jbc.M602055200; Georgiades SN, 2005, ORG LETT, V7, P4091, DOI 10.1021/ol0513286; Hinman RM, 2007, J IMMUNOL, V178, P740, DOI 10.4049/jimmunol.178.2.740; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Huang HJ, 2006, SCIENCE, V314, P294, DOI 10.1126/science.1130512; HUGHES LB, 2006, ANN M AM COLL RHE WA; Jacobsen EA, 2006, J IMMUNOL, V176, P6831, DOI 10.4049/jimmunol.176.11.6831; Jonsson H, 2005, NAT MED, V11, P666, DOI 10.1038/nm1248; Jonsson H, 2005, CELL MOL LIFE SCI, V62, P397, DOI 10.1007/s00018-004-4365-8; Kau TR, 2003, CANCER CELL, V4, P463, DOI 10.1016/S1535-6108(03)00303-9; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Lam EWF, 2006, BIOCHEM SOC T, V34, P722, DOI 10.1042/BST0340722; Lehtinen MK, 2006, CELL, V125, P987, DOI 10.1016/j.cell.2006.03.046; Lin L, 2004, IMMUNITY, V21, P203, DOI 10.1016/j.immuni.2004.06.016; Ludikhuize J, 2007, ARTHRITIS RHEUM-US, V56, P2180, DOI 10.1002/art.22653; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Matsuzaki H, 2005, P NATL ACAD SCI USA, V102, P11278, DOI 10.1073/pnas.0502738102; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nakae J, 2006, J CLIN INVEST, V116, P2473, DOI 10.1172/JCI25518; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Pandiyan P, 2004, J EXP MED, V199, P831, DOI 10.1084/jem.20031058; Peng SL, 2007, AUTOIMMUNITY, V40, P462, DOI 10.1080/08916930701464913; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Reedquist KA, 2006, BIOCHEM SOC T, V34, P727, DOI 10.1042/BST0340727; Rena G, 2004, EMBO REP, V5, P60, DOI 10.1038/sj.embor.7400048; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Riou C, 2007, J EXP MED, V204, P79, DOI 10.1084/jem.20061681; Schroeder FC, 2005, J NAT PROD, V68, P574, DOI 10.1021/np049624z; Sela U, 2006, EUR J IMMUNOL, V36, P2971, DOI 10.1002/eji.200636137; So CW, 2003, BLOOD, V101, P633, DOI 10.1182/blood-2002-06-1785; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; Tsuchida K, 2006, J MED CHEM, V49, P80, DOI 10.1021/jm050550d; van der Heide LP, 2005, TRENDS BIOCHEM SCI, V30, P81, DOI 10.1016/j.tibs.2004.12.002; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; van der Horst A, 2006, NAT CELL BIOL, V8, P1064, DOI 10.1038/ncb1469; Wijchers PJEC, 2006, BIOCHEM J, V397, P233, DOI 10.1042/BJ20060387; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Yamamura Y, 2006, J BIOL CHEM, V281, P5267, DOI 10.1074/jbc.M512151200; Yang KY, 2003, CELL SIGNAL, V15, P225, DOI 10.1016/S0898-6568(02)00063-3; Yau CYF, 2005, CANCER RES, V65, P1497, DOI 10.1158/0008-5472.CAN-04-2940; You H, 2004, P NATL ACAD SCI USA, V101, P14057, DOI 10.1073/pnas.0406286101; You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353; You H, 2006, P NATL ACAD SCI USA, V103, P9051, DOI 10.1073/pnas.0600889103; Yusuf I, 2004, BLOOD, V104, P784, DOI 10.1182/blood-2003-09-3071; Zhuang YL, 2006, NEUROENDOCRINOL LETT, V27, P53	70	84	86	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 7	2008	27	16					2337	2344		10.1038/onc.2008.26	http://dx.doi.org/10.1038/onc.2008.26			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	285NE	18391975				2022-12-17	WOS:000254782700008
J	Lufei, C; Koh, TH; Uchida, T; Cao, X				Lufei, C.; Koh, T. H.; Uchida, T.; Cao, X.			Pin1 is required for the Ser727 phosphorylation-dependent Stat3 activity	ONCOGENE			English	Article						Pin1; serine phosphorylation; Stat3; transcriptional activity	PROLYL ISOMERASE PIN1; SERINE PHOSPHORYLATION; CARCINOMA CELLS; BREAST-CANCER; ACTIVATION; ISOMERIZATION; TRANSCRIPTION; DETACHMENT; ONCOGENE; PROTEINS	Signal transducer and activator of transcription 3 (Stat3) belongs to a family of latent cytoplasmic transcription factors important for cytokine signaling. Stat3 is constitutively activated in various tumors, and activated Stat3 itself also acts as an oncogene. Transcriptional activity of Stat3 is controlled by Tyr-phosphorylation, followed by dimerization and nuclear translocation. However, phosphorylation on Ser727 is indispensable for its maximal transcriptional activity with unclear mechanism. Here, we report that peptidyl-prolyl cis/trans isomerase 1 (Pin1), which specifically recognizes the pSer/Thr-Pro motifs on its target proteins, interacts with Stat3 upon cytokine/growth factor stimulation. Overexpression of Pin1 promotes Stat3 transcriptional activity and target gene expression, as well as recruitment of transcription coactivator, p300. These effects, however, were compromised in the Pin1-deficient cells, and were totally dependent on the Ser727 phosphorylation site. Finally, we showed that Pin1 enhances Stat3-mediated epithelial mesenchymal transition in breast cancer cells induced by oncostatin M. Our data reveal a novel, Ser727 phosphorylation-dependent, post-translational regulation mechanism for Stat3.	[Lufei, C.; Koh, T. H.; Cao, X.] Inst Mol & Cell Biol, Signal Transduct Lab, Singapore, Singapore; [Uchida, T.] Tohoku Univ, Grad Sch Agr Sci, Sendai, Miyagi 980, Japan	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Tohoku University	Cao, X (corresponding author), Inst Mol & Cell Biol, Cell Signaling Lab, 61 Proteos Bldg,61 Biopolis Dr, Singapore 138673, Singapore.	mcbcaoxm@imcb.a-star.edu.sg		Uchida, Takafumi/0000-0003-3665-4906				Bao L, 2004, AM J PATHOL, V164, P1727, DOI 10.1016/S0002-9440(10)63731-5; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736; Holzer RG, 2004, CLIN EXP METASTAS, V21, P167, DOI 10.1023/B:CLIN.0000024760.02667.db; Jorcyk CL, 2006, CYTOKINE, V33, P323, DOI 10.1016/j.cyto.2006.03.004; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Lu KP, 1996, NATURE, V380, P544; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135; Ng DCH, 2006, J CELL BIOL, V172, P245, DOI 10.1083/jcb.200503021; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WINKLER S, 2000, P SOC PHOTO-OPT INS, V1, P287; Wulf G, 2004, EMBO J, V23, P3397, DOI 10.1038/sj.emboj.7600323; Wulf G, 2003, BREAST CANCER RES, V5, P76, DOI 10.1186/bcr572; Wulf G, 2005, NAT CELL BIOL, V7, P435, DOI 10.1038/ncb0505-435; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zhanel George G, 2002, Expert Opin Pharmacother, V3, P277; Zhang F, 2003, ONCOGENE, V22, P894, DOI 10.1038/sj.onc.1206158; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	32	84	85	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2007	26	55					7656	7664		10.1038/sj.onc.1210567	http://dx.doi.org/10.1038/sj.onc.1210567			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17563747				2022-12-17	WOS:000251537800007
J	Kobel, M; Weidensdorfer, D; Reinke, C; Lederer, M; Schmitt, WD; Zeng, K; Thomssen, C; Hauptmann, S; Huettelmaier, S				Koebel, M.; Weidensdorfer, D.; Reinke, C.; Lederer, M.; Schmitt, W. D.; Zeng, K.; Thomssen, C.; Hauptmann, S.; Huettelmaier, S.			Expression of the RNA-binding protein IMP1 correlates with poor prognosis in ovarian carcinoma	ONCOGENE			English	Article						IMP1; ovarian carcinoma; c-myc	MYC MESSENGER-RNA; C-MYC; CRD-BP; FAMILY; CANCER; TUMORS; OVEREXPRESSION; TRANSLATION; CELLS; ZBP1	The IMP (IGFII mRNA-binding protein) family comprises a group of three RNA-binding proteins involved in the regulation of cytoplasmic mRNA-fate. Recent studies identified IMP proteins as oncofetal factors in various neoplasias, but knowledge of a potential role in ovarian carcinomas is still lacking. The immunohistochemical analysis of 107 ovarian carcinomas, 30 serous borderline tumors of the ovary and five normal ovaries revealed de novo synthesis of IMP1 in 69% of ovarian carcinomas. Elevated IMP1 expression was observed preferentially in high-grade and high-stage cases and was a significant prognostic indicator for reduced recurrence-free and overall survival. Phenotypic studies in ovarian carcinoma-derived ES-2 cells demonstrated that IMP1 knockdown affects proliferation and cell survival. Reduced proliferation was associated with decreased c-myc mRNA half-life, suggesting IMP1 as an oncogenic factor that is involved in promoting elevated proliferation by stabilizing the c-myc mRNA in ovarian carcinoma cells.	Univ Halle Wittenberg, Dept Med, D-06120 Halle, Germany; Univ Halle Wittenberg, Inst Pathol, Dept Med, Halle, Germany; Univ Halle Wittenberg, Dept Gynecol, Halle, Germany	Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg	Huettelmaier, S (corresponding author), Univ Halle Wittenberg, Dept Med, Halle-Wittenberg Heinrich-Damerow-St 1, D-06120 Halle, Germany.	hauptmann@medizin.uni-halle.de; stefan.huettelmaier@medizin.uni-halle.de	Hüttelmaier, Stefan/AAQ-1203-2021; Köbel, Martin/A-7373-2011; Thomssen, Christoph/ABC-3102-2021; Schmitt, Wolfgang D/B-4729-2008	Schmitt, Wolfgang D/0000-0002-7870-138X; Kobel, Martin/0000-0002-6615-2037				Chen CH, 2005, INT J GYNECOL CANCER, V15, P878, DOI 10.1111/j.1525-1438.2005.00150.x; Dimova I, 2006, EUR J CANCER, V42, P674, DOI 10.1016/j.ejca.2005.11.022; Farina KL, 2003, J CELL BIOL, V160, P77, DOI 10.1083/jcb.200206003; Gu LJ, 2004, INT J ONCOL, V24, P671; Hansen TVO, 2004, MOL CELL BIOL, V24, P4448, DOI 10.1128/MCB.24.10.4448-4464.2004; Huttelmaier S, 2005, NATURE, V438, P512, DOI 10.1038/nature04115; Ioannidis P, 2005, J BIOL CHEM, V280, P20086, DOI 10.1074/jbc.M410036200; Ioannidis P, 2004, CANCER LETT, V209, P245, DOI 10.1016/j.canlet.2003.12.015; Ioannidis P, 2003, ANTICANCER RES, V23, P2179; Ioannidis P, 2001, INT J CANCER, V94, P480, DOI 10.1002/ijc.1512; Kobel M, 2006, INT J GYNECOL PATHOL, V25, P121, DOI 10.1097/01.pgp.0000185410.39050.ac; Lemm I, 2002, MOL CELL BIOL, V22, P3959, DOI 10.1128/MCB.22.12.3959-3969.2002; Liao BS, 2004, J BIOL CHEM, V279, P48716, DOI 10.1074/jbc.M405853200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mueller-Pillasch F, 1999, MECH DEVELOP, V88, P95, DOI 10.1016/S0925-4773(99)00160-4; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; Noubissi FK, 2006, NATURE, V441, P898, DOI 10.1038/nature04839; Ross J, 2001, ONCOGENE, V20, P6544, DOI 10.1038/sj.onc.1204838; Shih IM, 2004, AM J PATHOL, V164, P1511, DOI 10.1016/S0002-9440(10)63708-X; Sparanese D, 2007, NUCLEIC ACIDS RES, V35, P1209, DOI 10.1093/nar/gkl1148; Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039; Yaniv K, 2003, DEVELOPMENT, V130, P5649, DOI 10.1242/dev.00810; Yaniv K, 2002, GENE, V287, P49, DOI 10.1016/S0378-1119(01)00866-6; Yisraeli JK, 2005, BIOL CELL, V97, P87	24	84	86	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2007	26	54					7584	7589		10.1038/sj.onc.1210563	http://dx.doi.org/10.1038/sj.onc.1210563			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17546046				2022-12-17	WOS:000251282100011
J	Sethi, G; Ahn, KS; Chaturvedi, MM; Aggarwal, BB				Sethi, G.; Ahn, K. S.; Chaturvedi, M. M.; Aggarwal, B. B.			Epidermal growth factor (EGF) activates nuclear factor-kappa B through I kappa B alpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of I kappa B alpha	ONCOGENE			English	Article						NF; kappa B; EGF; TNF; IKK; AKT	TUMOR-NECROSIS-FACTOR; CELL LUNG-CANCER; GENE-EXPRESSION; DEGRADATION; INHIBITION; APOPTOSIS; INDUCTION; GEFITINIB; PATHWAY; COMPLEX	Overexpression of epidermal growth factor (EGF) receptor and constitutive activation of nuclear factor-kappa B (NF-kappa B) are frequently encountered in tumor cells. Although EGF has been shown to induce NF-kappa B activation, the mechanism is poorly understood. EGF activated NF-kappa B DNA binding, induced NF-kappa B reporter activity and the expression of antiapoptotic and cell-proliferative gene products. Interestingly, non-small cell lung adenocarcinoma cell lines (HCC827 and H3255), which exhibit EGFR amplification, showed ligand-independent activation of NF-kappa B. Unlike tumor-necrosis factor (TNF), however, EGF failed to induce I kappa B alpha phosphorylation and ubiquitination and the activation of I kappa B alpha kinase (IKK). Although DN-IKK beta inhibited TNF-induced NF-kappa B activity, DN-IKK beta had no effect on EGF-induced NF-kappa B activation, suggesting that EGF-induced NF-kappa B activation is IKK independent. Using dominant-negative plasmids, we also demonstrated the role of TRADD, TRAF2, NIK and Ras in EGF-induced NF-kappa B activation. By using specific antibodies and I kappa B alpha plasmid, which is mutated at tyrosine 42 to phenylalanine, we show that EGF induced the tyrosine phosphorylation of I kappa B alpha at residue 42. Furthermore, EGF receptor kinase inhibitor blocked I kappa B alpha phosphorylation and consequent NF-kappa B activation. Overall, our results indicate that tyrosine phosphorylation of I kappa B alpha at residue 42 is critical for EGF-induced NF-kappa B activation pathway.	Univ Texas, MD Anderson Canc Ctr, Cytokine Res Lab, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Delhi, Dept Zool, Delhi 110007, India.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013; Ahn, Kwang Seok/G-4249-2013; Sethi, Gautam/F-2372-2011	Sethi, Gautam/0000-0002-8677-8475	NCI NIH HHS [P01 CA91844] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA091844] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Amann J, 2005, CANCER RES, V65, P226; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FINCO TS, 1993, J BIOL CHEM, V268, P17676; Habib AA, 1998, J BIOL CHEM, V273, P6885, DOI 10.1074/jbc.273.12.6885; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; Haussler U, 2005, AM J PHYSIOL-RENAL, V289, pF808, DOI 10.1152/ajprenal.00434.2003; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Mukhopadhyay A, 2000, J BIOL CHEM, V275, P8549, DOI 10.1074/jbc.275.12.8549; Obata H, 1996, BIOCHEM BIOPH RES CO, V224, P27, DOI 10.1006/bbrc.1996.0979; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; Sun L, 1998, ONCOGENE, V16, P2095, DOI 10.1038/sj.onc.1201731; Takada Y, 2004, J BIOL CHEM, V279, P39541, DOI 10.1074/jbc.M403449200; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Tracy S, 2004, CANCER RES, V64, P7241, DOI 10.1158/0008-5472.CAN-04-1905; Traxler P, 2004, CANCER RES, V64, P4931, DOI 10.1158/0008-5472.CAN-03-3681; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014	29	84	90	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2007	26	52					7324	7332		10.1038/sj.onc.1210544	http://dx.doi.org/10.1038/sj.onc.1210544			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17533369				2022-12-17	WOS:000250955700004
J	Beke, L; Nuytten, M; Van Eynde, A; Beullens, M; Bollen, M				Beke, L.; Nuytten, M.; Van Eynde, A.; Beullens, M.; Bollen, M.			The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2	ONCOGENE			English	Article						EZH2; tumor suppressor; Polycomb group proteins; prostate cancer PSP94; epigenetics	SECRETORY PROTEIN; CANCER; METHYLATION; EXPRESSION; GROWTH; HYPERCALCEMIA; PROGRESSION; MALIGNANCY	PSP94, for prostatic secretory protein of 94 amino acids, is secreted by the prostate gland and functions as a suppressor of tumor growth and metastasis. The expression of PSP94 is lost in advanced, hormone-refractory prostate cancer and this correlates with an increased expression of the Polycomb protein EZH2 (enhancer of zeste homolog 2), which represses transcription via trimethylation of histone H3 on Lys27 (H3K27). We show here that these events are causally related and that the MSMB gene, which encodes PSP94, is trimethylated on H3K27 in androgen-refractory, but not in androgen-sensitive prostate cancer cells. Chromatin immunoprecipitation experiments confirmed an association of EZH2 with the MSMB gene. The RNAi-mediated knockdown of EZH2 resulted in a loss of H3K27 trimethylation and an increased expression of the MSMB gene. Conversely, the overexpression of EZH2 was associated with a decreased expression of the MSMB gene. We also demonstrate that MSMB is additionally repressed in androgen-refractory prostate cancer cells by the hypoacetylation of histone H3K9 and the hypermethylation of a CpG island in the promoter region. Our data disclose a hitherto unexplored link between the putative oncogene EZH2 and the tumor suppressor PSP94, and show that MSMB is silenced by EZH2 in advanced prostate cancer cells.	Katholieke Univ Leuven, Fac Med, Dept Mol Cell Biol, Lab Biosignaling & Therapeut, Louvain, Belgium	KU Leuven	Van Eynde, A (corresponding author), Afdeling Biochem, Campus Gasthuisberg,O&N1,Herestr 49,Bus 901, B-3000 Louvain, Belgium.	Aleyde.VanEynde@med.kuleuven.be						Annabi B, 2005, CLIN EXP METASTAS, V22, P429, DOI 10.1007/s10585-005-2669-1; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020; Garde SV, 1999, PROSTATE, V38, P118, DOI 10.1002/(SICI)1097-0045(19990201)38:2<118::AID-PROS5>3.0.CO;2-G; Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204; Lamy S, 2006, INT J CANCER, V118, P2350, DOI 10.1002/ijc.21615; LaTulippe E, 2002, CANCER RES, V62, P4499; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Saramaki OR, 2006, GENE CHROMOSOME CANC, V45, P639, DOI 10.1002/gcc.20327; Shukeir N, 2004, CANCER RES, V64, P5370, DOI 10.1158/0008-5472.CAN-04-0788; Shukeir N, 2003, CANCER RES, V63, P2072; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; Vanaja DK, 2003, CANCER RES, V63, P3877; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431	18	84	88	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	31					4590	4595		10.1038/sj.onc.1210248	http://dx.doi.org/10.1038/sj.onc.1210248			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17237810				2022-12-17	WOS:000247836100013
J	Vakifahmetoglu, H; Olsson, M; Orrenius, S; Zhivotovsky, B				Vakifahmetoglu, H.; Olsson, M.; Orrenius, S.; Zhivotovsky, B.			Functional connection between p53 and caspase-2 is essential for apoptosis induced by DNA damage	ONCOGENE			English	Article						apoptosis; caspase-2; PIDDosome complex; p53; 5-FU	CYTOCHROME-C RELEASE; CELL-DEATH; ACTIVATION; PROTEIN; PIDD; TRANSCRIPTION; LOCALIZATION; MITOCHONDRIA; REQUIREMENT; INHIBITOR	Recent findings have established caspase-2 as an important apical regulator in apoptotic pathways leading from DNA damage to release of mitochondrial cytochrome c and subsequent activation of effector caspases. Yet, the molecular map connecting the embarking stimuli of genotoxic stress with caspase-2 activation remains to be elucidated. Here, we address the question of potential caspase-2 regulators by examining 5-fluorouracil (5-FU)-induced apoptosis in wild-type and p53-deficient human colon carcinoma cells. Apoptosis was observed only in p53(+/+) cells and was preceded by caspase-2 activation. Hence, although no direct interaction between p53 and caspase-2 was observed in the cell system used, our data clearly demonstrate that a functional connection between these two proteins is essential for initiation of the 5-FU-induced apoptotic process. Proposed mediators of caspase-2 activation include PIDDosome complex proteins PIDD and RAIDD. Surprisingly, the presence of a complex encompassing at least RAIDD, PIDD and caspase-2 was verified in both p53(+/+) and p53(-/-) cells, also in the absence of 5-FU treatment. Thus, our results confirm the participation of PIDD and RAIDD in PIDDosome complex formation but question their role as sole mediators of caspase-2 activation. This assumption was further supported by siRNA transfections targeting PIDD or RAIDD. In conclusion, our findings support the hypothesis of p53 as an upstream regulator of caspase activity and provide data concerning caspase-2 processing mechanisms. As suppression of caspase-2 expression in 5-FU-treated cells also affects the level of the p53 protein, possibilities of a reciprocal interaction between these proteins are discussed.	Karolinska Inst, Inst Environm Med, Div Toxicol, SE-17177 Stockholm, Sweden	Karolinska Institutet	Zhivotovsky, B (corresponding author), Karolinska Inst, Inst Environm Med, Div Toxicol, Box 210, SE-17177 Stockholm, Sweden.	Boris.Zhivotovsky@imm.ki.se	Zhivotovsky, Boris/A-4346-2014; Olsson, Magnus/E-3140-2012	Zhivotovsky, Boris/0000-0002-2238-3482; Olsson, Magnus/0000-0002-6370-8423				Baliga BC, 2004, CELL DEATH DIFFER, V11, P1234, DOI 10.1038/sj.cdd.4401492; Baliga BC, 2003, J BIOL CHEM, V278, P4899, DOI 10.1074/jbc.M211512200; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Berube C, 2005, P NATL ACAD SCI USA, V102, P14314, DOI 10.1073/pnas.0506475102; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; Enoksson M, 2004, J BIOL CHEM, V279, P49575, DOI 10.1074/jbc.C400374200; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; Ho PK, 2005, FEBS J, V272, P1401, DOI 10.1111/j.1742-4658.2005.04573.x; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Jiang M, 2003, GENE DEV, V17, P832, DOI 10.1101/gad.252603; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Levav-Cohen Y, 2005, BIOCHEM BIOPH RES CO, V331, P737, DOI 10.1016/j.bbrc.2005.03.152; Lin CF, 2005, J BIOL CHEM, V280, P23758, DOI 10.1074/jbc.M412292200; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Marsden VS, 2004, J CELL BIOL, V165, P775, DOI 10.1083/jcb.200312030; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Park HH, 2006, J MOL BIOL, V357, P358, DOI 10.1016/j.jmb.2005.12.082; Paroni G, 2001, J BIOL CHEM, V276, P21907, DOI 10.1074/jbc.M011565200; Ren JY, 2005, P NATL ACAD SCI USA, V102, P565, DOI 10.1073/pnas.0408744102; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Robertson JD, 2004, EMBO REP, V5, P643, DOI 10.1038/sj.embor.7400153; Rotter B, 2004, BIOCHEM J, V378, P161, DOI 10.1042/BJ20030955; Scholz C, 2005, ONCOGENE, V24, P1904, DOI 10.1038/sj.onc.1208233; Schuler M, 2005, TRENDS GENET, V21, P182, DOI 10.1016/j.tig.2005.01.001; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Seth R, 2005, J BIOL CHEM, V280, P31230, DOI 10.1074/jbc.M503305200; Shearwin-Whyatt LM, 2000, CELL DEATH DIFFER, V7, P155, DOI 10.1038/sj.cdd.4400632; Shikama Y, 2001, EXP CELL RES, V264, P315, DOI 10.1006/excr.2000.5153; Tang J, 2005, CANCER BIOL THER, V4, P645, DOI 10.4161/cbt.4.6.1729; Telliez JB, 2000, BBA-PROTEIN STRUCT M, V1478, P280, DOI 10.1016/S0167-4838(00)00029-7; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Troy CM, 2001, J NEUROSCI, V21, P5007, DOI 10.1523/JNEUROSCI.21-14-05007.2001; Wang Q, 2006, CELL DEATH DIFFER, V13, P75, DOI 10.1038/sj.cdd.4401690; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378	44	84	89	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2006	25	41					5683	5692		10.1038/sj.onc.1209569	http://dx.doi.org/10.1038/sj.onc.1209569			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16652156				2022-12-17	WOS:000240599100010
J	Balmer, A; Zografos, L; Munier, F				Balmer, A.; Zografos, L.; Munier, F.			Diagnosis and current management of retinoblastoma	ONCOGENE			English	Review						retinoblastoma; tumor suppressor gene; diagnosis; management	DIFFUSE INFILTRATING RETINOBLASTOMA; TRANSGENIC MURINE RETINOBLASTOMA; RISK-FACTORS; SUBCONJUNCTIVAL CARBOPLATIN; HEREDITARY RETINOBLASTOMA; BILATERAL RETINOBLASTOMA; NONOCULAR TUMORS; PARENTAL AGE; SURVIVORS; RETINOCYTOMA	Retinoblastoma represents the prototypic model for inherited cancers. The RB1 gene was the first tumor suppressor gene to be identified. It represents the most frequent primary eye cancer in children under 15 years old, habitually occurring in infancy, even in utero, but can be observed in older children or young adults. Many other retinal lesions may also simulate retinoblastoma. The two major presenting signs are leukocoria and strabismus, but other ocular or general signs may be observed. A highly malignant tumor, retinoblastoma can nowadays be cured. The heritable form, however, carries a high risk of second nonocular tumors. Treatment in the early stages of disease holds a good prognosis for survival and salvage of visual function. In very late stages, however, the prognosis for ocular function and even survival is jeopardized.	Jules Gonin Univ Eye Hosp, Ocular Oncol Serv, Lausanne, Switzerland		Balmer, A (corresponding author), Hop Ophtalmique Jules Gonin, Ave France 15, CH-1004 Lausanne, Switzerland.	aubin.balmer@bluewin.ch						Abramson D H, 1989, Acta Ophthalmol Suppl, V194, P3; Abramson D H, 1999, Ophthalmic Genet, V20, P193, DOI 10.1076/opge.20.3.193.2284; Abramson DH, 1998, OPHTHALMOLOGY, V105, P573, DOI 10.1016/S0161-6420(98)94006-4; Abramson DH, 2001, OPHTHALMOLOGY, V108, P1868, DOI 10.1016/S0161-6420(01)00713-8; Abramson DH, 1996, RETINA-J RET VIT DIS, V16, P232, DOI 10.1097/00006982-199616030-00009; AERTS I, 2005, INT RET S INT SOC GE; BALMER A, 1993, OPHTHALMIC PAED GEN, V14, P33, DOI 10.3109/13816819309087621; BALMER A, 1991, OPHTHALMIC PAED GEN, V12, P131, DOI 10.3109/13816819109029394; BALMER A, 2002, TUMEURS INTRAOCULAIR, P587; Balmer A, 2002, TUMEURS INTRAOCULAIR, P485; Balmer A, 2002, TUMEURS INTRAOCULAIR, P481; BEAVERSON K, 2001, 10 INT C OC ONC AMST, P202; BINDER PS, 1974, AM J OPHTHALMOL, V77, P674, DOI 10.1016/0002-9394(74)90530-3; Chan Helen S L, 2005, Ophthalmol Clin North Am, V18, P55, DOI 10.1016/j.ohc.2004.11.002; Chantada G L, 1999, Ophthalmic Genet, V20, P133, DOI 10.1076/opge.20.3.133.2277; Chevez-Barrios P, 2005, J CLIN ONCOL, V23, P7927, DOI 10.1200/JCO.2004.00.1883; Conway R Max, 2005, Ophthalmol Clin North Am, V18, P25, DOI 10.1016/j.ohc.2004.08.006; DERKINDEREN DJ, 1990, AM J OPHTHALMOL, V110, P605, DOI 10.1016/S0002-9394(14)77056-4; Fletcher O, 2004, JNCI-J NATL CANCER I, V96, P357, DOI 10.1093/jnci/djh058; GALLIE BL, 1984, OPHTHALMOLOGY, V91, P666; GALLIE BL, 1982, OPHTHALMOLOGY, V89, P1393; GIRARD B, 1989, J FR OPHTALMOL, V12, P369; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Khelfaoui F, 1996, CANCER-AM CANCER SOC, V77, P1206, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1206::AID-CNCR30>3.0.CO;2-3; Kivela T, 1999, J CLIN ONCOL, V17, P1829, DOI 10.1200/JCO.1999.17.6.1829; KOPELMAN JE, 1987, OPHTHALMOLOGY, V94, P371; Linn Murphree A, 2005, Ophthalmol Clin North Am, V18, P41; MAATKIEVIT JA, 1993, PRENATAL DIAG, V13, P377, DOI 10.1002/pd.1970130510; MAHONEY MC, 1990, OPHTHALMOLOGY, V97, P1143; MARGO C, 1983, ARCH OPHTHALMOL-CHIC, V101, P1519, DOI 10.1001/archopht.1983.01040020521003; MATSUNAGA E, 1990, HUM GENET, V84, P155; MESSMER EP, 1991, OPHTHALMOLOGY, V98, P136; MILLER RW, 1969, J PEDIATR, V75, P685, DOI 10.1016/S0022-3476(69)80466-X; MORGAN G, 1971, BRIT J OPHTHALMOL, V55, P600, DOI 10.1136/bjo.55.9.600; MUNIER F, 2002, TUMEURS INTRAOCULAIR, P466; Murray TG, 1997, ARCH OPHTHALMOL-CHIC, V115, P1286, DOI 10.1001/archopht.1997.01100160456013; REESE A B, 1963, Trans Am Acad Ophthalmol Otolaryngol, V67, P164; Scat Y, 1996, J FR OPHTALMOL, V19, P83; Shields CL, 1997, J PEDIAT OPHTH STRAB, V34, P165; SHIELDS CL, 1993, BRIT J OPHTHALMOL, V77, P544, DOI 10.1136/bjo.77.9.544; Shields CL, 1999, ARCH OPHTHALMOL-CHIC, V117, P885; SHIELDS CL, 1991, OPHTHALMOLOGY, V98, P395; SHIELDS CL, 1993, OPHTHALMOLOGY, V100, P216; Simpson Joe Leigh, 2005, J Natl Cancer Inst Monogr, P87; Singh AD, 2000, ARCH OPHTHALMOL-CHIC, V118, P199; Uusitalo MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P41; Van Quill KR, 2005, OPHTHALMOLOGY, V112, P1151, DOI 10.1016/j.ophtha.2004.11.060; Xu Hong-Ji, 2003, Ophthalmol Clin North Am, V16, P621, DOI 10.1016/S0896-1549(03)00065-8; Xu KP, 2004, AM J OPHTHALMOL, V137, P18, DOI 10.1016/S0002-9394(03)00872-9; ZOGRAFOS L, 2002, TUMEURS INTRAOCULAIR, P21	50	84	95	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5341	5349		10.1038/sj.onc.1209622	http://dx.doi.org/10.1038/sj.onc.1209622			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936756				2022-12-17	WOS:000240064100021
J	Zuo, X; Wu, Y; Morris, JS; Stimmel, JB; Leesnitzer, LM; Fischer, SM; Lippman, SM; Shureiqi, I				Zuo, X; Wu, Y; Morris, JS; Stimmel, JB; Leesnitzer, LM; Fischer, SM; Lippman, SM; Shureiqi, I			Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity	ONCOGENE			English	Article						15-lipoxygenase-1; PPAR-gamma; PPAR-delta; colon cancer	PROLIFERATOR-ACTIVATED RECEPTOR; COLORECTAL-CANCER CELLS; ADIPOCYTE DIFFERENTIATION; COLON CARCINOGENESIS; NUCLEAR RECEPTORS; DELTA; APOPTOSIS; LIGANDS; 15-LIPOXYGENASE-1; EXPRESSION	Peroxisome proliferator-activated receptors (PPARs) are transcription factors that strongly influence molecular events in normal and cancer cells. PPAR-beta/delta (PPAR-b/d) overexpression suppresses the activity of PPAR-gamma (PPAR-g) and PPAR-alpha. This interaction has been questioned, however, by studies with synthetic ligands of PPARs in PPAR-b/d-null cells, and it is not known whether an interaction between PPAR-b/d and PPAR-g exists, especially in relation to the signaling by natural PPAR ligands. Oxidative metabolites of linoleic and arachidonic acids are natural ligands of PPARs. 13-S-hydroxyoctadecadienoic acid (13-S-HODE), the main product of 15-lipoxygenase-1 (15-LOX-1) metabolism of linoleic acid, downregulates PPAR-b/d. We tested (a) whether PPAR-b/d expression modulates PPAR-g activity in experimental models of the loss and gain of PPAR-b/d function in colon cancer cells and (b) whether 15-LOX-1 formation of 13-S-HODE influences the interaction between PPAR-b/d and PPAR-g. We found that (a) 15-LOX-1 formation of 13-S-HODE promoted PPAR-gactivity, (b) PPAR-b/d expression suppressed PPAR-gactivity in models of both loss and gain of PPAR-b/d function, (c) 15-LOX-1 activated PPAR-g by downregulating PPAR-b/d, and (d) 15-LOX-1 expression induced apoptosis in colon cancer cells via modulating PPAR-b/d suppression of PPAR-g. These findings elucidate a novel mechanism of the signaling by natural ligands of PPARs, which involves modulating the interaction between PPAR-b/d and PPAR-g.	Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77230 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX USA; GlaxoSmithKline Inc, Dept Screening & Cmpd Profiling, Res Triangle Pk, NC USA; Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Houston, TX USA; Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; GlaxoSmithKline; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Shureiqi, I (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Unit 1360,1515 Holcombe Blvd, Houston, TX 77230 USA.	ishureiqi@mdanderson.org	Shureiqi, imad/T-6214-2019	Shureiqi, Imad/0000-0003-2019-938X; Zuo, Xiangsheng/0000-0002-8593-1132	NCI NIH HHS [R01 CA104278] Funding Source: Medline; NIEHS NIH HHS [P30 ES007784, ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bull AW, 2003, CARCINOGENESIS, V24, P1717, DOI 10.1093/carcin/bgg131; CALNEK D, 1993, DIFFERENTIATION, V53, P95, DOI 10.1111/j.1432-0436.1993.tb00649.x; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Fajas L, 2002, DEV CELL, V3, P903, DOI 10.1016/S1534-5807(02)00360-X; Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534-5807(02)00190-9; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI14006; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; Girnun GD, 2002, P NATL ACAD SCI USA, V99, P13771, DOI 10.1073/pnas.162480299; Gupta RA, 2001, J BIOL CHEM, V276, P29681, DOI 10.1074/jbc.M103779200; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Matsusue K, 2004, FASEB J, V18, P1477, DOI 10.1096/fj.04-1944fje; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; MOLL R, 1993, DIFFERENTIATION, V53, P75, DOI 10.1111/j.1432-0436.1993.tb00648.x; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nixon JB, 2004, PROSTAG LEUKOTR ESS, V70, P7, DOI 10.1016/j.plefa.2003.06.001; Nixon JB, 2003, PROSTAG LEUKOTR ESS, V68, P323, DOI 10.1016/S0952-3278(03)00023-1; Osawa E, 2003, GASTROENTEROLOGY, V124, P361, DOI 10.1053/gast.2003.50067; Park BH, 2001, P NATL ACAD SCI USA, V98, P2598, DOI 10.1073/pnas.051630998; Peters JM, 2003, BBA-MOL CELL BIOL L, V1632, P80, DOI 10.1016/S1388-1981(03)00065-9; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Renard P, 2001, Nucleic Acids Res, V29, pE21, DOI 10.1093/nar/29.4.e21; Rusinol AE, 2000, J BIOL CHEM, V275, P7296, DOI 10.1074/jbc.275.10.7296; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Shi YH, 2002, P NATL ACAD SCI USA, V99, P2613, DOI 10.1073/pnas.052707099; Shureiqi I, 2000, J NATL CANCER I, V92, P1136, DOI 10.1093/jnci/92.14.1136; Shureiqi I, 1999, CARCINOGENESIS, V20, P1985, DOI 10.1093/carcin/20.10.1985; Shureiqi I, 2003, P NATL ACAD SCI USA, V100, P9968, DOI 10.1073/pnas.1631086100; Shureiqi I, 2001, CANCER RES, V61, P6307; Stephen RL, 2004, CANCER RES, V64, P3162, DOI 10.1158/0008-5472.CAN-03-2760; Yu JS, 2003, CANCER RES, V63, P6170	36	84	87	5	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 23	2006	25	8					1225	1241		10.1038/sj.onc.1209160	http://dx.doi.org/10.1038/sj.onc.1209160			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16288226	Green Accepted			2022-12-17	WOS:000235537500010
J	Wang, J; Zhang, X; Thomas, SM; Grandis, JR; Wells, A; Chen, Z; Ferris, RL				Wang, J; Zhang, X; Thomas, SM; Grandis, JR; Wells, A; Chen, Z; Ferris, RL			Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR	ONCOGENE			English	Article						CCR7; EGFR; PI3K; Akt; PLC gamma-1	GASTRIN-RELEASING-PEPTIDE; GROWTH-FACTOR RECEPTOR; UP-REGULATION; DENDRITIC CELLS; CARCINOMA; PROTEIN; 3-KINASE; SIGNAL; EXPRESSION; AKT	Chemokine receptor 7 (CCR7) upregulation, which mediates immune cell survival and migration to lymph nodes, has recently been associated with nodal metastasis of squamous cell carcinoma of the head and neck (SCCHN). However, the mechanism of CCR7 in tumor progression, its downstream signaling mediators, and interactions with other pathways contributing to metastasis of SCCHN have not been determined. We hypothesized that inflammatory chemokine-mediated signals could also promote tumor proliferation and mitogenic effects. Functional assays showed that chemotaxis and invasion of metastatic SCCHN cells were dependent on phosphoinositide-3 kinase (PI3K) and its substrate, activated phospholipase C gamma-1. In addition, treatment of CCR7(+) metastatic SCCHN cells with CCL19 (MIP-3 beta) showed rapid activation of the prosurvival, PI3K/Akt pathway. Transactivation of EGFR-mediated and mitogen-activated protein kinase signaling pathways, which can promote migration and survival in parallel, did not appear to contribute to the functional or biochemical effects of CCR7 stimulation. Thus, proinflammatory chemokine signals that mediate activation, trafficking and survival of tumor-infiltrating immune cells in the tumor microenvironment actually appear to induce signals for progression of cancer cells. The CCR7-mediated pathway in metastatic SCCHN cells functions independently of EGFR signal transduction and therefore may represent an additional target for therapeutic intervention to prevent tumor progression and metastasis.	Univ Pittsburgh, Inst Canc, Dept Otolaryngol, Sch Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Dept Immunol, Sch Med, Pittsburgh, PA 15213 USA; Emory Univ, Winship Canc Ctr, Dept Hematol & Oncol, Atlanta, GA 30332 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Emory University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Ferris, RL (corresponding author), Univ Pittsburgh, Inst Canc, Dept Otolaryngol, Sch Med, Res Wing,Room 1-19D,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	ferrisrl@upmc.edu	Thomas, Sufi/O-1487-2018; Thomas, Sufi Mary/AFR-1642-2022	Thomas, Sufi/0000-0001-5370-0842; Thomas, Sufi Mary/0000-0001-5370-0842; Wells, Alan/0000-0002-1637-8150				Amornphimoltham P, 2004, CLIN CANCER RES, V10, P4029, DOI 10.1158/1078-0432.CCR-03-0249; Benistant C, 2000, ONCOGENE, V19, P5083, DOI 10.1038/sj.onc.1203871; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Biswas SK, 2002, J INTERF CYTOK RES, V22, P527, DOI 10.1089/10799900252982007; Curnock AP, 2003, J IMMUNOL METHODS, V273, P29, DOI 10.1016/S0022-1759(02)00416-7; Curnock AP, 2002, IMMUNOLOGY, V105, P125, DOI 10.1046/j.1365-2567.2002.01345.x; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Ellis CA, 1999, J BIOL CHEM, V274, P13718, DOI 10.1074/jbc.274.19.13718; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Grandis JR, 1998, J CELL BIOCHEM, V69, P55, DOI 10.1002/(SICI)1097-4644(19980401)69:1<55::AID-JCB6>3.0.CO;2-U; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; HEO DS, 1989, CANCER RES, V49, P5167; Kane LP, 2001, NAT IMMUNOL, V2, P37, DOI 10.1038/83144; Lango MN, 2002, J NATL CANCER I, V94, P375; Li XX, 2000, P NATL ACAD SCI USA, V97, P10489, DOI 10.1073/pnas.160265197; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; Lui VWY, 2003, ONCOGENE, V22, P6183, DOI 10.1038/sj.onc.1206720; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Mailliard RB, 2004, CANCER RES, V64, P5934, DOI 10.1158/0008-5472.CAN-04-1261; Mills GB, 2001, SEMIN ONCOL, V28, P125, DOI 10.1053/sonc.2001.28554; Murakami T, 2003, J EXP MED, V198, P1337, DOI 10.1084/jem.20030593; Pilkington KR, 2004, J BIOL CHEM, V279, P40276, DOI 10.1074/jbc.M405808200; Sanchez-Sanchez N, 2004, BLOOD, V104, P619, DOI 10.1182/blood-2003-11-3943; Sotsios Y, 2000, IMMUNOL REV, V177, P217, DOI 10.1034/j.1600-065X.2000.17712.x; Thomas SM, 2003, CANCER RES, V63, P5629; Tosi L, 2005, HEAD NECK-J SCI SPEC, V27, P130, DOI 10.1002/hed.20120; Uchida D, 2003, EXP CELL RES, V290, P289, DOI 10.1016/S0014-4827(03)00344-6; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Wang H, 2002, AM J PHYSIOL-CELL PH, V283, pC1351, DOI 10.1152/ajpcell.00001.2002; Wang J, 2004, CANCER RES, V64, P1861, DOI 10.1158/0008-5472.CAN-03-2968; WELLS A, 2004, SCI STKE, V253, P47	31	84	91	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5897	5904		10.1038/sj.onc.1208740	http://dx.doi.org/10.1038/sj.onc.1208740			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	16007209				2022-12-17	WOS:000231590400012
J	Benini, S; Perbal, B; Zambelli, D; Colombo, MP; Manara, MC; Serra, M; Parenza, M; Martinez, V; Picci, P; Scotlandi, K				Benini, S; Perbal, B; Zambelli, D; Colombo, MP; Manara, MC; Serra, M; Parenza, M; Martinez, V; Picci, P; Scotlandi, K			In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type	ONCOGENE			English	Article						Ewing's sarcoma; CCN3; migration; tumorigenicity	TISSUE GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; CCN FAMILY; PROGNOSTIC IMPACT; GENE NOV; EXPRESSION; TUMORS; MATRIX-METALLOPROTEINASE-9; SURFACE; OVEREXPRESSION	Altered expression of CCN3 has been observed in a variety of musculoskeletal tumours, including Ewing's sarcoma (ES). Despite its widespread distribution, very little is known about its biological functions and molecular mechanisms of action. We transfected CCN3 gene into a CCN3-negative ES cell line and analysed the in vitro and in vivo behaviours of stably transfected clones. Forced expression of CCN3 significantly reduced cell proliferation in vitro, growth in anchorage-independent conditions, and tumorigenicity in nude mice. Despite the antiproliferative effect, CCN3-transfected ES cells displayed increased migration and invasion of Matrigel. The decreased expression of alpha 2 beta 1 integrin receptor and the increased amount of cell surface-associated matrix metalloproteinase (MMP)-9 following the expression of CCN3 may be the basis for the increased migratory abilities of transfected cells. Cells lacking a2b1 are less facilitated to have stable anchorage since the predominant collagen extracted from ES tissue is indeed type I collagen, and proMMP-9 was recently found to provide a cellular switch between stationary and migratory ES cell phase. Our findings are in line with those recently obtained in glioblastoma. However, the underlying molecular mechanisms appear to be different, further highlighting the importance of the cellular context in the regulation of function of CCN proteins.	Ist Otroped Rizzoli, Lab Ric Oncol, I-40136 Bologna, Italy; Univ Paris 07, Lab Oncol Virale & Mol, UFR Biochem, F-75005 Paris, France; Ist Nazl Studio & Cura Tumori, Immunotherapy & Gene Therapy Unit, I-20133 Milan, Italy	UDICE-French Research Universities; Universite Paris Cite; Fondazione IRCCS Istituto Nazionale Tumori Milan	Scotlandi, K (corresponding author), Ist Otroped Rizzoli, Lab Ric Oncol, Via Barbiano 1-10, I-40136 Bologna, Italy.	katia.scotlandi@ior.it	Manara, Maria Cristina/K-3366-2018; Serra, Massimo/J-4878-2016; Colombo, Mario P./V-7166-2017; Scotlandi, Katia/J-9009-2016; BENINI, STEFANIA/D-1804-2019; Picci, Piero/J-5979-2016	Manara, Maria Cristina/0000-0001-5686-720X; Serra, Massimo/0000-0003-0742-1177; Colombo, Mario P./0000-0003-0042-7955; Scotlandi, Katia/0000-0001-6114-9499; BENINI, STEFANIA/0000-0003-0958-9088; Picci, Piero/0000-0002-8519-4101				AARONSON SA, 1968, SCIENCE, V162, P1024, DOI 10.1126/science.162.3857.1024; Bacci G, 2000, J CLIN ONCOL, V18, P4, DOI 10.1200/JCO.2000.18.1.4; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Chevalier G, 1998, AM J PATHOL, V152, P1563; de Alava E, 1998, J CLIN ONCOL, V16, P1248, DOI 10.1200/JCO.1998.16.4.1248; de Alava E, 2000, CANCER-AM CANCER SOC, V89, P783, DOI 10.1002/1097-0142(20000815)89:4<783::AID-CNCR10>3.0.CO;2-Q; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Ellis PD, 2000, ARTERIOSCL THROM VAS, V20, P1912, DOI 10.1161/01.ATV.20.8.1912; Fan WH, 2002, J BIOL CHEM, V277, P9800, DOI 10.1074/jbc.M111213200; Fridman R, 2003, CANCER METAST REV, V22, P153, DOI 10.1023/A:1023091214123; Glukhova L, 2001, CANCER GENET CYTOGEN, V130, P105, DOI 10.1016/S0165-4608(01)00477-0; Gupta N, 2001, J CLIN PATHOL-MOL PA, V54, P293, DOI 10.1136/mp.54.5.293; HARVEY W, 1982, BRIT J CANCER, V46, P848, DOI 10.1038/bjc.1982.294; Hattinger CM, 2002, BRIT J CANCER, V86, P1763, DOI 10.1038/sj.bjc.6600332; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Lake A. C., 2003, CELL COMMUN SIGNAL, V1, P1, DOI DOI 10.1186/1478-811X-1-5; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Laurent M, 2003, FASEB J, V17, P1919, DOI 10.1096/fj.02-1023fje; Lin CG, 2003, J BIOL CHEM, V278, P24200, DOI 10.1074/jbc.M302028200; Liu CL, 1999, GENE, V238, P471, DOI 10.1016/S0378-1119(99)00364-9; Lopez-Guerrero JA, 2001, LAB INVEST, V81, P803, DOI 10.1038/labinvest.3780290; Maillard M, 2001, J CLIN PATHOL-MOL PA, V54, P275, DOI 10.1136/mp.54.4.275; Manara MC, 2002, AM J PATHOL, V160, P849, DOI 10.1016/S0002-9440(10)64908-5; Ohali A, 2003, J CLIN ONCOL, V21, P3836, DOI 10.1200/JCO.2003.05.059; Ozaki T, 2001, GENE CHROMOSOME CANC, V32, P164, DOI 10.1002/gcc.1178; Perbal B, 1999, P NATL ACAD SCI USA, V96, P869, DOI 10.1073/pnas.96.3.869; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140-6736(03)15172-0; Perbal B., 1988, PRACTICAL GUIDE MOL; Perri T, 2001, PEDIATR HEMAT ONCOL, V18, P325, DOI 10.1080/088800101300312591; Planque N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-15; Sanceau J, 2003, J BIOL CHEM, V278, P36537, DOI 10.1074/jbc.M304300200; Scholz G, 1996, MOL CELL BIOL, V16, P481; Scotlandi K, 2000, J ORTHOPAED RES, V18, P959, DOI 10.1002/jor.1100180616; Soon LL, 2003, J BIOL CHEM, V278, P11465, DOI 10.1074/jbc.M210945200; STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157; VANVALEN F, 1994, EUR J CANCER, V30A, P2119, DOI 10.1016/0959-8049(94)00346-7; Wei G, 2000, CANCER-AM CANCER SOC, V89, P793, DOI 10.1002/1097-0142(20000815)89:4<793::AID-CNCR11>3.0.CO;2-M; Yabe H, 2002, BIOCHEM BIOPH RES CO, V293, P61, DOI 10.1016/S0006-291X(02)00129-8; Yu CY, 2003, J PATHOL, V201, P609, DOI 10.1002/path.1468; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zielenska M, 2001, CANCER, V91, P2156, DOI 10.1002/1097-0142(20010601)91:11<2156::AID-CNCR1244>3.0.CO;2-I	45	84	93	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4349	4361		10.1038/sj.onc.1208620	http://dx.doi.org/10.1038/sj.onc.1208620			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15824736				2022-12-17	WOS:000229976900004
J	Ledl, A; Schmidt, D; Muller, S				Ledl, A; Schmidt, D; Muller, S			Viral oncoproteins E1A and E7 and cellular LxCxE proteins repress SUMO modification of the retinoblastoma tumor suppressor	ONCOGENE			English	Article						SUMO; pRB; viral oncoproteins; LxCxE	LARGE T-ANTIGEN; HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; STRUCTURAL BASIS; GENE-EXPRESSION; CYCLE ARREST; P53 ACTIVITY; C-JUN; RB; PRB	The retinoblastoma tumor suppressor protein (pRB) is a major regulator of cell-cycle progression and cellular differentiation. Central to pRB function is the pocket domain, which serves as the main binding region for cellular regulators. In tumors pRB is frequently inactivated by mutations in the pocket domain or by binding of viral oncoproteins to this region. A characteristic feature of these viral oncoproteins and many cellular pRB-binding partners is an LxCxE sequence motif, which interacts with pRB's pocket domain. Here, we show that the ubiquitin-like modi. er SUMO is covalently attached to a distinct residue (K720) of pRB within the B-box of the pocket region that binds LxCxE-motif proteins. We provide evidence that SUMO preferentially targets the active, hypophosphorylated form of pRB and show that tumorigenic mutations of pRB in the pocket domain lead to a loss of SUMOylation. Notably, the level of pRB SUMOylation is controlled by the interaction of pRB with viral and cellular LxCxE-motif proteins. Inhibitors of pRB function, including the viral oncoproteins E1A and E7 and the cellular E1A-like inhibitor of differentiation EID-1, completely abolish SUMO modi. cation of pRB. Conversely, pRB mutants deficient in binding of LxCxE-motif proteins exhibit a drastically enhanced modification by SUMO. Finally, we provide evidence that SUMOylation can influence pRB function, as the SUMO-deficient pRB(K720R) mutant exerts a slightly higher repressive potential on an E2F-responsive reporter gene than wildtype pRB. Taken together, these data identify SUMO modification as a novel post-translational modification of pRB that may control pRB activity by modulating LxCxE - pocket interactions.	Max Planck Inst Biochem, Dept Mol Cell Biol, D-82152 Martinsried, Germany	Max Planck Society	Muller, S (corresponding author), Max Planck Inst Biochem, Dept Mol Cell Biol, Klopferspitz 18A, D-82152 Martinsried, Germany.	stmuelle@biochem.mpg.de		Muller, Stefan/0000-0002-8792-7700				Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brown VD, 2002, MOL CELL BIOL, V22, P1390, DOI 10.1128/MCB.22.5.1390-1401.2002; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chan HM, 2001, ONCOGENE, V20, P6152, DOI 10.1038/sj.onc.1204793; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; Dick FA, 2000, MOL CELL BIOL, V20, P3715, DOI 10.1128/MCB.20.10.3715-3727.2000; Dick FA, 2002, J VIROL, V76, P6224, DOI 10.1128/JVI.76.12.6224-6234.2002; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kim HY, 2001, EMBO J, V20, P295, DOI 10.1093/emboj/20.1.295; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Lee C, 2002, GENE DEV, V16, P3199, DOI 10.1101/gad.1046102; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Liu HP, 2004, CURR OPIN GENET DEV, V14, P55, DOI 10.1016/j.gde.2003.11.005; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MacLellan WR, 2000, MOL CELL BIOL, V20, P8903, DOI 10.1128/MCB.20.23.8903-8915.2000; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Miyake S, 2000, MOL CELL BIOL, V20, P8889, DOI 10.1128/MCB.20.23.8889-8902.2000; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Takaki T, 2004, BIOCHEM BIOPH RES CO, V316, P252, DOI 10.1016/j.bbrc.2004.02.044; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Wen H, 2001, GENE, V263, P85, DOI 10.1016/S0378-1119(00)00585-0; Xiao B, 2003, P NATL ACAD SCI USA, V100, P2363, DOI 10.1073/pnas.0436813100; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	49	84	87	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3810	3818		10.1038/sj.onc.1208539	http://dx.doi.org/10.1038/sj.onc.1208539			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15806172				2022-12-17	WOS:000229346300011
J	Vellon, L; Menendez, JA; Lupu, R				Vellon, L; Menendez, JA; Lupu, R			alpha(v)beta(3) integrin regulates Heregulin (HRG)-induced cell proliferation and survival in breast cancer	ONCOGENE			English	Article						Heregulin; alpha(v)beta(3); integrins; S-247; breast cancer	ANGIOGENIC FACTOR; CYR61; METASTASIS; ANTAGONIST; ACTIVATION; EXPRESSION; GROWTH; TUMORIGENICITY; APOPTOSIS; MIGRATION	alpha(v)beta(3) integrin-overexpression in tumor associated vasculature is a marker of poor prognosis in breast cancer. A positive correlation between alpha(v)beta(3) integrin and overexpression of Heregulin (HRG), a growth factor associated with breast cancer aggressiveness was recently demonstrated. Here, we addressed the role of alpha(v)beta(3) in the proliferation and survival of HRG-overexpressing breast cancer models. Expression of the RGD-binding integrins alpha(v)beta(3), alpha(v)beta(5) and alpha(v)beta(6) was assessed in the HRG-overexpressing breast cancer cells MDA-MB-231, Hs578T (231/WT and Hs578T/WT, respectively) and derived cells transfected with the antisense orientation of the HRG-beta 2 full-length cDNA (231/ASPOOL, 231/AS31 and Hs578T/AS15). Interestingly, only alpha(v)beta(3) expression was noticeably decreased by blockade of HRG expression in the 231/ ASPOOL, 231/AS31 and Hs578T/AS15 cells. Small RGD-based peptidomimetic alpha(v)beta(3) antagonists significantly decreased cell viability and anchorage-dependent cell growth of HRG- overexpressing cells, while the low-HRG-expressing 231/AS31 cells did not show a significant response. Mechanistically, functional blockade of alpha(v)beta(3) impaired HRG- promoted hyperactivation of ERK1/ ERK2 MAPK without altering the activation of AKT. Flow cytometric analysis of the cell cycle demonstrated that alpha(v)beta(3) antagonists significantly decreased S- and G2/ M-phase subpopulations of 231/WT and control 231/ VEC cells. Comparable, this effect was linked to an increase in the levels and nuclear translocation of the CDKs inhibitor p27(Kip1). Besides downregulating alpha(v)beta(3) and its driven signaling, HRG blockade led to decreased levels of CYR61 in 231/ASPOOL and 231/AS31 cells. Considering that CYR61 is sufficient to upregulate the expression of alpha(v)beta(3), we then assessed alpha(v)beta(3) levels in MDA-MB-231 cell derivatives expressing the antisense orientation of the CYR61 cDNA (231/CYR61AS-5 and 231/CYR61AS-8). Remarkably, downregulation of CYR61 drastically decreased the levels of alpha(v)beta(3) in the 231/ CYR61-5 and 231/CYR61-8 cells, providing further evidence of a key role for CYR61 in HRG- dependent alpha(v)beta(3) overexpression. Moreover, blockade of CYR61 expression impaired the HRG- induced hyperactivation of ERK1/ ERK2 MAPK without altering the activation status of AKT in MDA-MB-231 cells, thus resembling the effects exerted by the downregulation of HRG expression as well as by functional blockade of alpha(v)beta(3). These results indicate that HRG is regulating alpha(v)beta(3) levels as well as alpha(v)beta(3)-triggered signaling through its downstream effector, CYR61, in highly invasive breast cancer cells. Altogether, the data presented here provide evidence of a CYR61-regulatory role on alpha(v)beta(3) integrin expression in the modulation of uncontrolled growth of HRG-overexpressing breast carcinomas. This work supports additional studies concerning the use of integrin antagonists as dual therapeutic agents in breast cancer, targeting both, endothelial and tumor cells.	Evanston Northwestern Healthcare Res Inst, Dept Med, Breast Canc Translat Res Lab, Evanston, IL 60201 USA; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Lupu, R (corresponding author), Evanston Northwestern Healthcare Res Inst, Dept Med, Breast Canc Translat Res Lab, 1001 Univ Pl, Evanston, IL 60201 USA.	r-lupu@northwestern.edu	MENENDEZ, JAVIER A/C-6148-2016	MENENDEZ, JAVIER A/0000-0001-8733-4561	PHS HHS [R01-0490490] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Atlas E, 2003, MOL CANCER RES, V1, P165; Buerkle MA, 2002, BRIT J CANCER, V86, P788, DOI 10.1038/sj.bjc.6600141; Butler B, 2003, J BIOL CHEM, V278, P5264, DOI 10.1074/jbc.M206997200; Carron CP, 1998, CANCER RES, V58, P1930; CRAIG WS, 1995, BIOPOLYMERS, V37, P157, DOI 10.1002/bip.360370209; Cruet-Hennequart S, 2003, ONCOGENE, V22, P1688, DOI 10.1038/sj.onc.1206347; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; Gasparini G, 1998, CLIN CANCER RES, V4, P2625; Griggs David William, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P263; Harms JF, 2004, CLIN EXP METASTAS, V21, P119, DOI 10.1023/B:CLIN.0000024763.69809.64; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Janssen ML, 2002, CANCER RES, V62, P6146; Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576; Leu SJ, 2004, J BIOL CHEM, V279, P44177, DOI 10.1074/jbc.M407850200; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; Levkau B, 2002, CELL DEATH DIFFER, V9, P1360, DOI 10.1038/sj.cdd.4401106; Lin MT, 2004, J BIOL CHEM, V279, P24015, DOI 10.1074/jbc.M402305200; Martin KH, 2002, SCIENCE, V296, P1652, DOI 10.1126/science.296.5573.1652; Menendez JA, 2003, ENDOCR-RELAT CANCER, V10, P141, DOI 10.1677/erc.0.0100141; MENENDEZ JA, 2004, ONCOGENE        1213; Meyer Debra Mary, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P825; PERCHEUR I, 2002, FASEB J, V16, P1266; Pereira JJ, 2004, CANCER RES, V64, P977, DOI 10.1158/0008-5472.CAN-03-3056; Reinmuth N, 2003, CANCER RES, V63, P2079; Roberts MS, 2003, J BIOL CHEM, V278, P1975, DOI 10.1074/jbc.M208607200; Rolli M, 2003, P NATL ACAD SCI USA, V100, P9482, DOI 10.1073/pnas.1633689100; Ruegg C, 2004, BBA-REV CANCER, V1654, P51, DOI 10.1016/j.bbcan.2003.09.003; Schaffner P, 2003, CELL MOL LIFE SCI, V60, P119, DOI 10.1007/s000180300008; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Shannon KE, 2004, CLIN EXP METASTAS, V21, P129, DOI 10.1023/B:CLIN.0000024764.93092.5f; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Stupack DG, 2003, ONCOGENE, V22, P9022, DOI 10.1038/sj.onc.1207110; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; Tang CK, 1996, CANCER RES, V56, P3350; Tsai MS, 2003, ONCOGENE, V22, P761, DOI 10.1038/sj.onc.1206130; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Tsai MS, 2000, CANCER RES, V60, P5603	38	84	88	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3759	3773		10.1038/sj.onc.1208452	http://dx.doi.org/10.1038/sj.onc.1208452			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782133				2022-12-17	WOS:000229346300007
J	Jones, AM; Douglas, EJ; Halford, SER; Fiegler, H; Gorman, PA; Roylance, RR; Carter, NP; Tomlinson, IPM				Jones, AM; Douglas, EJ; Halford, SER; Fiegler, H; Gorman, PA; Roylance, RR; Carter, NP; Tomlinson, IPM			Array-CGH analysis of microsatellite-stable, near-diploid bowel cancers and comparison with other types of colorectal carcinoma	ONCOGENE			English	Article						colorectal cancer; CGH; microsatellite; chromosomal instability; genetic pathways	COMPARATIVE GENOMIC HYBRIDIZATION; HIGH-RESOLUTION ANALYSIS; PTEN MUTATIONS; AMPLIFICATION; INSTABILITY; MALIGNANCIES; MICROARRAYS; PHENOTYPE; DISTINCT; PATHWAY	Microsatellite-stable, near-diploid (MSI-CIN-) colorectal carcinomas have been reported, but it is not clear as to whether these tumours form a discrete group or represent one end of the distribution of MSI-CIN+ cancers. In order to address this question, we screened 23 MSI-CIN- colorectal cancers for gains and losses using array-based comparative genomic hybridization (aCGH) based on large-insert clones at about 1 Mb density. We compared our findings with those from a small set of MSI+CIN+ cancers, and with our reported data from MSI-CIN+ and MSI+CIN- cancers. We found no evidence of any form of genomic instability in MSI-CIN- cancers. At the level of the chromosome arm, the MSI-CIN- cancers had significantly fewer gains and losses than MSI-CIN+ tumours, but more than the MSI+CIN- and MSI+CIN+ lesions. The chromosomal-scale changes found in MSI-CIN- cancers generally involved the same sites as those in MSI-CIN+ tumours, and in both cancer groups, the best predictor of a specific change was the total number of such changes in that tumour. A few chromosomal-scale changes did, however, differ between the MSI-CIN- and MSI-CIN+ pathways. MSI-CIN- cancers showed: low frequencies of gain of 9p and 19p; infrequent loss of 5q and a high frequency of 20p gain. Overall, our data suggested that the MSI-CIN- group is heterogeneous, one type of MSI-CIN- cancer having few (less than or equal to6) chromosomal-scale changes and the other with more (greater than or equal to10) changes resembling MSI-CIN+ cancers. At the level of individual clones, frequent and/or discrete gains or losses were generally located within regions of chromosomal-scale changes in both MSI-CIN- and MSI-CIN+ cancers, and fewer losses and gains were present in MSI-CIN- than MSI-CIN+ tumours. No changes by clone, which were specific to the MSI-CIN- cancers, were found. In addition to indicating differences among the cancer groups, our results also detected over 50 sites (amplifications, potential homozygous deletion and gains or losses which extended over only a few megabases) which might harbour uncharacterized oncogenes or tumour suppressor loci. In conclusion, our data support the suggestion that some MSI-CIN- carcinomas form a qualitatively different group from the other cancer types, and also suggest that the MSI-CIN- group is itself heterogeneous.	Canc Res UK, Mol & Populat Genet Lab, London WC2A 3PX, England; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; St Marks Hosp, Canc Res UK, Colorectal Canc Unit, Harrow HA1 3UJ, Middx, England	Cancer Research UK; Wellcome Trust Sanger Institute; Cancer Research UK; Imperial College London	Tomlinson, IPM (corresponding author), Canc Res UK, Mol & Populat Genet Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	ian.tomlinson@cancer.org.uk		Davison, Ellie/0000-0003-0927-932X				Curtis LJ, 2000, J PATHOL, V192, P440; Douglas EJ, 2004, CANCER RES, V64, P4817, DOI 10.1158/0008-5472.CAN-04-0328; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Georgiades IB, 1999, ONCOGENE, V18, P7933, DOI 10.1038/sj.onc.1203368; Giaretti W, 2003, GENE CHROMOSOME CANC, V37, P207, DOI 10.1002/gcc.10203; Gill N, 2002, GASTROENTEROLOGY, V122, P248, DOI 10.1053/gast.2002.30917; Guanti G, 2000, HUM MOL GENET, V9, P283, DOI 10.1093/hmg/9.2.283; Hawkins NJ, 2001, BRIT J CANCER, V84, P232, DOI 10.1054/bjoc.2000.1554; Iino H, 1999, J CLIN PATHOL, V52, P5, DOI 10.1136/jcp.52.1.5; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Jass JR, 2002, GASTROENTEROLOGY, V123, P862, DOI 10.1053/gast.2002.35392; LEACH FS, 1993, CANCER RES, V53, P1986; Lipton L, 2003, CANCER RES, V63, P7595; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Nakao K, 2004, CARCINOGENESIS, V25, P1345, DOI 10.1093/carcin/bgh134; Nassif NT, 2004, ONCOGENE, V23, P617, DOI 10.1038/sj.onc.1207059; Pedowitz SD, 2003, GASTROENTEROLOGY, V125, P1915, DOI 10.1053/j.gastro.2003.04.016; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Yamashita K, 2003, CANCER CELL, V4, P121, DOI 10.1016/S1535-6108(03)00190-9	20	84	85	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					118	129		10.1038/sj.onc.1208194	http://dx.doi.org/10.1038/sj.onc.1208194			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15531920				2022-12-17	WOS:000226125800014
J	Satoh, A; Toyota, M; Ikeda, H; Morimoto, Y; Akino, K; Mita, H; Suzuki, H; Sasaki, Y; Kanaseki, T; Takamura, Y; Soejima, H; Urano, T; Yanagihara, K; Endo, T; Hinoda, Y; Fujita, M; Hosokawa, M; Sato, N; Tokino, T; Imai, K				Satoh, A; Toyota, M; Ikeda, H; Morimoto, Y; Akino, K; Mita, H; Suzuki, H; Sasaki, Y; Kanaseki, T; Takamura, Y; Soejima, H; Urano, T; Yanagihara, K; Endo, T; Hinoda, Y; Fujita, M; Hosokawa, M; Sato, N; Tokino, T; Imai, K			Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells	ONCOGENE			English	Article						DNA methylation; chromatin; gene expression	CPG ISLAND HYPERMETHYLATION; GENE-EXPRESSION; DNA METHYLATION; TUMOR-CELLS; HISTONE MODIFICATIONS; GOOD PROGNOSIS; PROMOTER-IV; LARGE-BOWEL; CARCINOMAS; PROTEIN	Tightly regulated at the level of transcription, expression of MHC class II molecules varies significantly among gastrointestinal cancers. High levels of MHC class II expression are often associated with a better prognosis, which is indicative of the involvement of CD4(+) lymphocytes in tumor suppression, but the molecular mechanism by which MHC class II expression is regulated remains unclear. In the present study, we investigated the expression of one inducible MHC class II molecule, HLA-DR, and its coactivators in a panel of colorectal and gastric cancer cell lines. Interferon-gamma induced expression of HLA-DR in 14 of 20 cell lines tested; the remaining six cell lines did not express HLA-DR. Analysis of the expression of transcription factors and coactivators associated with HLA-DR revealed that the loss of CIITA expression was closely associated with the absence of HLA-DR induction. Moreover, DNA methylation of the 50 CpG island of CIITA-PIV was detected in all cancer cells that lacked CIITA. The methylation and resultant silencing of CIITA-PIV depended on the activities of two DNA methyltransferases, DNMT1 and DNMT3B, and their genetic inactivation restored CIITA-PIV expression. It thus appears that CIITA methylation is a key mechanism that enables some gastrointestinal cancer cells to escape immune surveillance.	Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608543, Japan; Sapporo Med Univ, Dept Mol Biol, Canc Res Inst, Sapporo, Hokkaido 0608543, Japan; PRESTO JST, Kawaguchi 3320012, Japan; Sapporo Med Univ, Dept Pathol, Sapporo, Hokkaido 0608556, Japan; Saga Med Sch, Div Mol Biol & Genet, Saga 8498501, Japan; Nagoya Univ, Sch Med, Dept Biochem 2, Nagoya, Aichi 4660065, Japan; Natl Canc Ctr, Res Inst, Cent Anim Lab, Tokyo 1040045, Japan; Yamaguchi Univ, Sch Med, Dept Clin Lab Sci, Yamaguchi 7558505, Japan; Keiyukai Sapporo Hosp, Sapporo, Hokkaido 0030027, Japan	Sapporo Medical University; Sapporo Medical University; Japan Science & Technology Agency (JST); Sapporo Medical University; Saga University; Nagoya University; National Cancer Center - Japan; Yamaguchi University	Toyota, M (corresponding author), Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0608543, Japan.	mtoyota@sapmed.ac.jp	Sasaki, Yasushi/AAA-3079-2019; Tokino, Takashi/AAI-9887-2021	Sasaki, Yasushi/0000-0002-3500-8059; Soejima, Hidenobu/0000-0001-5076-6563; Urano, Takeshi/0000-0003-3383-3554; Kanaseki, Takayuki/0000-0001-7294-6880				Abril E, 1998, CANCER IMMUNOL IMMUN, V47, P113, DOI 10.1007/s002620050511; ANDERSEN SN, 1993, BRIT J CANCER, V68, P80, DOI 10.1038/bjc.1993.290; Armstrong TD, 1998, J IMMUNOL, V160, P661; Armstrong TD, 1997, P NATL ACAD SCI USA, V94, P6886, DOI 10.1073/pnas.94.13.6886; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Croce M, 2003, ONCOGENE, V22, P7848, DOI 10.1038/sj.onc.1207054; Fahrner JA, 2002, CANCER RES, V62, P7213; Garrido F, 2001, ADV CANCER RES, V83, P117, DOI 10.1016/S0065-230X(01)83005-0; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; KAKLAMANIS L, 1992, CANCER SURV, V13, P155; Kanaseki T, 2003, J IMMUNOL, V170, P4980, DOI 10.4049/jimmunol.170.10.4980; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Lennon AM, 1997, IMMUNOGENETICS, V45, P266, DOI 10.1007/s002510050202; Liang GN, 2000, CANCER RES, V60, P4907; Lovig T, 2002, BRIT J CANCER, V87, P756, DOI 10.1038/sj.bjc.6600507; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; MCDOUGALL CJ, 1990, CANCER RES, V50, P8023; Meazza R, 2003, EUR J IMMUNOL, V33, P1183, DOI 10.1002/eji.200323712; Morris AC, 2000, J IMMUNOL, V164, P4143, DOI 10.4049/jimmunol.164.8.4143; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Nakagawachi T, 2003, ONCOGENE, V22, P8835, DOI 10.1038/sj.onc.1207183; Neugut AI, 1996, SEMIN ONCOL, V23, P281; Nguyen CT, 2002, CANCER RES, V62, P6456; Ossendorp F, 2000, IMMUNOL LETT, V74, P75, DOI 10.1016/S0165-2478(00)00252-2; Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Sengupta PK, 2003, CANCER RES, V63, P1789; Suzuki H, 2000, CANCER RES, V60, P4353; Takamura Y, 2004, GLIA, V45, P392, DOI 10.1002/glia.10343; Ting JPY, 2002, CELL, V109, pS21, DOI 10.1016/S0092-8674(02)00696-7; Toes REM, 1999, J EXP MED, V189, P753, DOI 10.1084/jem.189.5.753; Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100; van den Elsen PJ, 2001, J REPROD IMMUNOL, V52, P129, DOI 10.1016/S0165-0378(01)00115-2; Waldburger JM, 2001, J EXP MED, V194, P393, DOI 10.1084/jem.194.4.393; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yazawa T, 2002, AM J PATHOL, V161, P291, DOI 10.1016/S0002-9440(10)64181-8	39	84	92	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8876	8886		10.1038/sj.onc.1208144	http://dx.doi.org/10.1038/sj.onc.1208144			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15467734				2022-12-17	WOS:000225354600003
J	Sevilla, A; Santos, CR; Barcia, R; Vega, FM; Lazo, PA				Sevilla, A; Santos, CR; Barcia, R; Vega, FM; Lazo, PA			c-Jun phosphorylation by the human vaccinia-related kinase 1 (VRK1) and its cooperation with the N-terminal kinase of c-Jun (JNK)	ONCOGENE			English	Article						VRK1; c-Jun; JNK; transcription	CELL LUNG CARCINOMAS; TRANSCRIPTION FACTORS; GENE-EXPRESSION; ACTIVATION; FAMILY; CANCER; ATF2; PROLIFERATION; AP-1	The VRK1 kinase is a novel Ser-Thr kinase in the human kinome that diverged from the casein kinase 1 branch. These kinases phosphorylate transcription factors related to stress responses, such as p53. In this report we have studied the phosphorylation of the transcription factor c-Jun in its N-terminal region. The VRK1 protein phosphorylates c-Jun with a Km of 0.4 muM, and is not inhibited by SP600125. VRK1 phosphorylates c-Jun in Ser63 and Ser73 in vitro, the same residues targeted by the N-terminal kinase of c-Jun (JNK). This phosphorylation induces the stabilization and accumulation of the c-Jun protein. VRK1 phosphorylates the endogenous c-Jun in Ser63. VRK1 activates c-Jun dependent transcription, which is dependent on phosphorylation of Ser63 and Ser73. The c-Jun with Ser63Ala and Ser73Ala substitutions is not transcriptionally active when cotransfected with VRK1. VRK1 interacts with c-Jun but not with JNK. The cotransfection of VRK1 and JNK has an additive effect on the transcriptional activation of c-Jun indicating that they can cooperate when both are at suboptimal dose; otherwise, maximum effect by one of them prevents the effect of the other. The VRK1-c-Jun connection represents a component of a new signaling pathway whose upstream elements remain to be identified.	Univ Salamanca, CSIC, Ctr Invest Canc, IBMCC, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Lazo, PA (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, IBMCC, Campus Miguel Unamuno, E-37007 Salamanca, Spain.	plazozbi@usal.es	Lazo, Pedro A./M-6435-2014; Vega, Francisco M./C-4678-2008; Sevilla, Ana/N-8579-2017	Lazo, Pedro A./0000-0001-8997-3025; Vega, Francisco M./0000-0002-9015-864X; Sevilla, Ana/0000-0002-9251-4759				ADLER V, 1995, CELL GROWTH DIFFER, V6, P1437; Antonyak MA, 2002, ONCOGENE, V21, P5038, DOI 10.1038/sj.onc.1205593; Aoyagi K, 1998, CLIN CANCER RES, V4, P2153; Barcia R, 2002, ARCH BIOCHEM BIOPHYS, V399, P1, DOI 10.1006/abbi.2001.2746; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Clerk A, 1997, BIOCHEM J, V325, P801, DOI 10.1042/bj3250801; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dlakic M, 2001, EMBO J, V20, P828, DOI 10.1093/emboj/20.4.828; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Dunn C, 2002, CELL SIGNAL, V14, P585, DOI 10.1016/S0898-6568(01)00275-3; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Hall MC, 2003, J BIOL CHEM, V278, P10304, DOI 10.1074/jbc.M212334200; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI200112466; Hernandez-Torres J, 2001, J BIOL CHEM, V276, P35405, DOI 10.1074/jbc.M104723200; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Lopez-Borges S, 2000, ONCOGENE, V19, P3656, DOI 10.1038/sj.onc.1203709; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Meggiato T, 2003, PANCREAS, V26, P65, DOI 10.1097/00006676-200301000-00011; Neyns B, 1996, ONCOGENE, V12, P1247; Nezu J, 1997, GENOMICS, V45, P327, DOI 10.1006/geno.1997.4938; Nichols RJ, 2004, J BIOL CHEM, V279, P7934, DOI 10.1074/jbc.M310813200; Sevilla A, 2004, J BIOL CHEM, V279, P27458, DOI 10.1074/jbc.M401009200; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shuman JD, 1997, J BIOL CHEM, V272, P12793, DOI 10.1074/jbc.272.19.12793; Szabo E, 1996, CANCER RES, V56, P305; TINIAKOS DG, 1994, BRIT J UROL, V74, P757, DOI 10.1111/j.1464-410X.1994.tb07121.x; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Vega FM, 2003, FEBS LETT, V544, P176, DOI 10.1016/S0014-5793(03)00501-5; Volm M, 2002, CLIN CANCER RES, V8, P1843; Weiss L, 2000, J EXP MED, V191, P139, DOI 10.1084/jem.191.1.139; WODRICH W, 1993, CARCINOGENESIS, V14, P1121, DOI 10.1093/carcin/14.6.1121; Yunta M, 2002, EUR J BIOCHEM, V269, P1012, DOI 10.1046/j.0014-2956.2001.02741.x	38	84	84	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8950	8958		10.1038/sj.onc.1208015	http://dx.doi.org/10.1038/sj.onc.1208015			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15378002	Green Submitted, Bronze			2022-12-17	WOS:000225354600010
J	Silva, J; Chang, K; Hannon, GJ; Rivas, FV				Silva, J; Chang, K; Hannon, GJ; Rivas, FV			RNA-interference-based functional genomics in mammalian cells: reverse genetics coming of age	ONCOGENE			English	Article						RNAi; high throughput screening; functional genomics; cancer; apoptosis; synthetic lethality	DOUBLE-STRANDED-RNA; SACCHAROMYCES-CEREVISIAE; CAENORHABDITIS-ELEGANS; PROTEIN-KINASE; SCREENS; DESIGN; ART; IDENTIFICATION; MICROARRAYS; GENES	Sequencing of complete genomes has provided researchers with a wealth of information to study genome organization, genetic instability, and polymorphisms, as well as a knowledge of all potentially expressed genes. The identification of all genes encoded in the human genome opens the door for large-scale systematic gene silencing using small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs). With the recent development of siRNA and shRNA expression libraries, the application of RNAi technology to assign function to cancer genes and to delineate molecular pathways in which these genes affect in normal and transformed cells, will contribute significantly to the knowledge necessary to develop new and also improve existing cancer therapy.	Cold Spring Harbor Lab, Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Hannon, GJ (corresponding author), Cold Spring Harbor Lab, Watson Sch Biol Sci, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	hannon@cshl.edu	Hannon, Gregory/AAB-3568-2019					Aravind L, 2001, SCIENCE, V291, P1279, DOI 10.1126/science.291.5507.1279; Aza-Blanc P, 2003, MOL CELL, V12, P627, DOI 10.1016/S1097-2765(03)00348-4; BASSON ME, 1987, GENETICS, V117, P645; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Boutros M, 2004, SCIENCE, V303, P832, DOI 10.1126/science.1091266; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Chen Z, 2000, BIOESSAYS, V22, P503, DOI 10.1002/(SICI)1521-1878(200006)22:6&lt;503::AID-BIES2&gt;3.0.CO;2-7; Chuaqui RF, 2002, NAT GENET, V32, P509, DOI 10.1038/ng1034; Churchill GA, 2002, NAT GENET, V32, P490, DOI 10.1038/ng1031; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Dujon B, 2004, NATURE, V430, P35, DOI 10.1038/nature02579; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Forsburg SL, 2001, NAT REV GENET, V2, P659, DOI 10.1038/35088500; Forster T, 2003, J ENDOCRINOL, V178, P195, DOI 10.1677/joe.0.1780195; GLASS B, 1954, ADV GENET, V6, P95, DOI 10.1016/S0065-2660(08)60128-5; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Harborth J, 2001, J CELL SCI, V114, P4557; Hsieh AC, 2004, NUCLEIC ACIDS RES, V32, P893, DOI 10.1093/nar/gkh238; Huang QH, 2004, P NATL ACAD SCI USA, V101, P3456, DOI 10.1073/pnas.0308562100; Jorgensen EM, 2002, NAT REV GENET, V3, P356, DOI 10.1038/nrg794; Kumar R, 2003, GENOME RES, V13, P2333, DOI 10.1101/gr.1575003; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; Michiels F, 2002, NAT BIOTECHNOL, V20, P1154, DOI 10.1038/nbt746; Mikkers H, 2003, ADV CANCER RES, V88, P53, DOI 10.1016/S0065-230X(03)88304-5; MINKS MA, 1979, J BIOL CHEM, V254, P180; Montgomery Mary K, 2004, Methods Mol Biol, V265, P3; Mousses S, 2003, GENOME RES, V13, P2341, DOI 10.1101/gr.1478703; Paddison PJ, 2003, CURR OPIN MOL THER, V5, P217; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; Shuman HA, 2003, NAT REV GENET, V4, P419, DOI 10.1038/nrg1087; Silva JM, 2004, P NATL ACAD SCI USA, V101, P6548, DOI 10.1073/pnas.0400165101; Somma MP, 2002, MOL BIOL CELL, V13, P2448, DOI 10.1091/mbc.01-12-0589; St Johnston D, 2002, NAT REV GENET, V3, P176, DOI 10.1038/nrg751; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Ziauddin J, 2001, NATURE, V411, P107, DOI 10.1038/35075114	42	84	101	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2004	23	51					8401	8409		10.1038/sj.onc.1208176	http://dx.doi.org/10.1038/sj.onc.1208176			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867BA	15517022				2022-12-17	WOS:000224815900011
J	Radhakrishnan, SK; Feliciano, CS; Najmabadi, F; Haegebarth, A; Kandel, ES; Tyner, AL; Gartel, AL				Radhakrishnan, SK; Feliciano, CS; Najmabadi, F; Haegebarth, A; Kandel, ES; Tyner, AL; Gartel, AL			Constitutive expression of E2F-1 leads to p21-dependent cell cycle arrest in S phase of the cell cycle	ONCOGENE			English	Article						p21; E2F-1; cell cycle; cdk2	TRANSCRIPTION FACTOR E2F1; DEPENDENT KINASES; P21; APOPTOSIS; PROGRESSION; BINDING; SUPPRESSION; REPRESSION; CHECKPOINT; ACTIVATION	p21 is a potent inhibitor of cyclin-dependent kinases capable of arresting cell cycle progression. p21 is primarily regulated at the transcriptional level by several transcription factors, including p53. Previously, we reported that certain members of the E2F family of transcription factors may activate p21 transcription via a p53-independent mechanism. To further elucidate the consequences of E2F-1-regulated induction of p21, we developed cell lines with a tamoxifen-dependent form of E2F-1. We confirmed direct interaction of E2F-1 with the proximal region of the p21 promoter. Interestingly, elevated E2F-1 activity was sufficient to arrest a substantial subset of cells in S phase and this effect was correlated to and dependent on the induction of p21 protein. Since E2F proteins control genes required for cell cycle progression and are activated by various oncogenic events, we believe that the p21-dependent arrest described in this report represents an additional mechanism that guards against unrestricted cell proliferation.	Univ Illinois, Coll Med, Dept Med, Chicago, IL 60612 USA; Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cleveland Clinic Foundation	Gartel, AL (corresponding author), Univ Illinois, Coll Med, Dept Med, 840 S Wood ,Room 1041, Chicago, IL 60612 USA.	agartel@uic.edu		Radhakrishnan, Senthil/0000-0002-5211-9498; Tyner, Angela/0000-0001-7448-8625	NCI NIH HHS [CA91146-01A1] Funding Source: Medline; NIDDK NIH HHS [DK48836, R01 DK044525, R01 DK044525-10] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA091146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044525, R01DK048836] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Farhana L, 2002, CANCER RES, V62, P3842; Gartel A L, 1998, Prog Mol Subcell Biol, V20, P43; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Gartel AL, 1998, ONCOGENE, V17, P3463, DOI 10.1038/sj.onc.1202240; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; HARPER JW, 1993, CELL, V75, P805; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LOGAN TJ, 1995, CANCER RES, V55, P2883; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Takahashi Y, 2000, GENE DEV, V14, P804; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WALDMAN T, 1995, CANCER RES, V55, P5187; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Zhang YX, 2000, CANCER RES, V60, P2025	28	84	97	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4173	4176		10.1038/sj.onc.1207571	http://dx.doi.org/10.1038/sj.onc.1207571			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15048076				2022-12-17	WOS:000221520200016
J	Gamble, SC; Odontiadis, M; Waxman, J; Westbrook, JA; Dunn, MJ; Wait, R; Lam, EWF; Bevan, CL				Gamble, SC; Odontiadis, M; Waxman, J; Westbrook, JA; Dunn, MJ; Wait, R; Lam, EWF; Bevan, CL			Androgens target prohibitin to regulate proliferation of prostate cancer cells	ONCOGENE			English	Article						androgen; prohibitin; prostate cancer	POLYACRYLAMIDE-GELS; RECEPTOR GENE; CELLULAR SENESCENCE; MASS-SPECTROMETRY; PROTEIN DATABASE; HORMONAL-THERAPY; EXPRESSION; IDENTIFICATION; REPRESSION; RB	Proteins involved in the growth response of prostate cancer cells to androgen were investigated by comparing the proteomes of LNCaP cells treated with vehicle or androgen. Whole-cell lysates were separated by two-dimensional PAGE, and HPLC-MS/MS was used to identify androgen-regulated proteins. Prohibitin, a protein with cell-cycle regulatory activity, was shown to be downregulated by 50% following androgen stimulation. Western blot and reverse transcription-PCR experiments confirmed the result and showed that regulation occurs at the level of transcription. To determine the importance of prohibitin in androgen-stimulated growth, we used transient transfection to overexpress the protein and RNA interference to knock down the protein. Subsequent FACS analysis showed that cells with reduced levels of prohibitin showed a slight but reproducible increase in the percentage of population in cell cycle, while cells with increased prohibitin levels showed a clear reduction in the percentage entering cell cycle, following dihydrotestosterone stimulation, when compared to untransfected controls. Confocal microscopy showed localization of prohibitin in the nucleus as well as the mitochondria of LNCaP cells. It therefore seems that the regulation of prohibitin is a vital part of the cellular growth response to androgen stimulation in LNCaPs and prohibitin may have a nuclear regulatory role in cell-cycle progression.	Hammersmith Hosp, Imperial Coll London, Dept Canc Med, London W12 0NN, England; Harefield Hosp, Imperial Coll Sch Med, Heart Sci Ctr, Harefield UB9 6JH, Middx, England; Inst Psychiat, Dept Neurosci, London SE5 8AF, England; Univ London Imperial Coll Sci & Technol, Fac Med, Kennedy Inst Rheumatol Div, London W6 8LH, England	Imperial College London; Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; University of London; King's College London; Imperial College London; University of Oxford	Bevan, CL (corresponding author), Hammersmith Hosp, Imperial Coll London, Dept Canc Med, London W12 0NN, England.	charlotte.bevan@imperial.ac.uk	Bevan, Charlotte L/K-2276-2012; Lam, Eric W-F/AAW-8566-2020; Bevan, Charlotte/T-7769-2019	Bevan, Charlotte L/0000-0002-7533-0552; Lam, Eric W-F/0000-0003-1274-3576; 				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Coates PJ, 2001, EXP CELL RES, V265, P262, DOI 10.1006/excr.2001.5166; Coates PJ, 1997, CURR BIOL, V7, P607, DOI 10.1016/S0960-9822(06)00261-2; CORBETT JM, 1994, ELECTROPHORESIS, V15, P1459, DOI 10.1002/elps.11501501209; Dixit VD, 2003, ENDOCRINOLOGY, V144, P1496, DOI 10.1210/en.2002-220955; Fellenberg J, 2003, INT J CANCER, V105, P636, DOI 10.1002/ijc.11135; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.3.CO;2-Y; Gottlieb B, 1997, NUCLEIC ACIDS RES, V25, P158, DOI 10.1093/nar/25.1.158; GRAYHACK JT, 1987, CANCER, V60, P589, DOI 10.1002/1097-0142(19870801)60:3+<589::AID-CNCR2820601526>3.0.CO;2-R; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; IKONEN E, 1995, FEBS LETT, V358, P273, DOI 10.1016/0014-5793(94)01444-6; JENO P, 1995, ANAL BIOCHEM, V224, P75, DOI 10.1006/abio.1995.1010; Jupe ER, 1996, EXP CELL RES, V224, P128, DOI 10.1006/excr.1996.0120; Koivisto P, 1998, AM J PATHOL, V152, P1; KRAUSS MR, 1990, BIOTECHNIQUES, V8, P218; LIU XT, 1994, BIOCHEM BIOPH RES CO, V201, P409, DOI 10.1006/bbrc.1994.1716; Mackey AJ, 2002, MOL CELL PROTEOMICS, V1, P139, DOI 10.1074/mcp.M100004-MCP200; MCCLUNG JK, 1989, BIOCHEM BIOPH RES CO, V164, P1316, DOI 10.1016/0006-291X(89)91813-5; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Slade MJ, 1999, J CLIN ONCOL, V17, P870, DOI 10.1200/JCO.1999.17.3.870; Steglich G, 1999, MOL CELL BIOL, V19, P3435; Thompson WE, 2001, ENDOCRINOLOGY, V142, P4076, DOI 10.1210/en.142.9.4076; Thompson WE, 1999, ANAT REC, V256, P40, DOI 10.1002/(SICI)1097-0185(19990901)256:1<40::AID-AR6>3.0.CO;2-X; Vander Heiden MG, 2002, J BIOL CHEM, V277, P44870, DOI 10.1074/jbc.M204888200; Verrijdt G, 2003, MOL GENET METAB, V78, P175, DOI 10.1016/S1096-7192(03)00003-9; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wait R, 2002, ELECTROPHORESIS, V23, P3418, DOI 10.1002/1522-2683(200210)23:19&lt;3418::AID-ELPS3418&gt;3.0.CO;2-7; Wait R, 2001, ELECTROPHORESIS, V22, P3043, DOI 10.1002/1522-2683(200108)22:14<3043::AID-ELPS3043>3.0.CO;2-M; Wang S, 2002, EMBO J, V21, P3019, DOI 10.1093/emboj/cdf302; Wang S, 1999, MOL CELL BIOL, V19, P7447; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944; Weekes J, 1999, ELECTROPHORESIS, V20, P898, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<898::AID-ELPS898>3.0.CO;2-B; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Woodlock TJ, 2001, BLOOD CELL MOL DIS, V27, P27, DOI 10.1006/bcmd.2000.0348; Yan JX, 2000, ELECTROPHORESIS, V21, P3666, DOI 10.1002/1522-2683(200011)21:17<3666::AID-ELPS3666>3.0.CO;2-6	40	84	97	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					2996	3004		10.1038/sj.onc.1207444	http://dx.doi.org/10.1038/sj.onc.1207444			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	14968116				2022-12-17	WOS:000220845200003
J	Amir, RE; Haecker, H; Karin, M; Ciechanover, A				Amir, RE; Haecker, H; Karin, M; Ciechanover, A			Mechanism of processing of the NF-kappa B2 p100 precursor: identification of the specific polyubiquitin chain-anchoring lysine residue and analysis of the role of NEDD8-modification on the SCF beta-TrCP ubiquitin ligase	ONCOGENE			English	Article						ubiquitin; processing; NF-kappa B2; p100; p52; NEDD8	NF-KAPPA-B; NEDD8; PROTEIN; E3; PHOSPHORYLATION; DEGRADATION; ACTIVATION; PATHWAY; SYSTEM; ALPHA	Processing of the NF-kappaB2 precursor p100 to the mature p52 subunit is regulated via a unique pathway. NF-kappaB-inducing kinase (NIK) induces IkappaB kinase alpha (IKKalpha)-mediated phosphorylation of specific serine residues in the C-terminal domain of p100, leading to recruitment of the SCFbeta-TrCP ubiquitin ligase. We identified a single lysine residue, K855, that serves as the ubiquitin-anchoring residue required for signal-induced processing of p100. In a reconstituted system containing purified components, p100-K855R could not be ubiquitinated. In a crude extract and cells, only residual, signal-independent ubiquitination and processing were retained. Importantly, K855 is located in a site homologous to K22 that serves as an ubiquitination site in IkappaBalpha. This suggests a common recognition mechanism for the two molecules. In contrast, p105, the p100 homologue, lacks a similar Lys residue. We also demonstrate that the NEDD8 pathway is essential for the SCFbeta-TrCP activity. In a reconstituted system, efficient ubiquitination of p100 required all three components of the pathway - E1, the UBC12 E2 and NEDD8. Experiments in reconstituted systems and in cells demonstrated that SCFbeta-TrCP, which contains a mutant Cul-1 that cannot be NEDDylated, cannot stimulate ubiquitination and processing. Similarly, dominant negative UBC12 inhibits, in a reversible manner, both ubiquitination and processing of p100.	Technion Israel Inst Technol, Fac Med, Dept Biochem, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel; Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of California System; University of California San Diego	Ciechanover, A (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Biochem, POB 9649, IL-31096 Haifa, Israel.	c_tzachy@netvision.net.il	Haecker, Hans/F-6826-2013; Ciechanover, Aaron J/C-9166-2017	Haecker, Hans/0000-0001-5971-0451; 				Amir RE, 2002, J BIOL CHEM, V277, P23253, DOI 10.1074/jbc.M200967200; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; Gong LM, 2000, J BIOL CHEM, V275, P14212, DOI 10.1074/jbc.275.19.14212; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Kamitani T, 2001, J BIOL CHEM, V276, P46655, DOI 10.1074/jbc.M108636200; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Morimoto M, 2000, BIOCHEM BIOPH RES CO, V270, P1093, DOI 10.1006/bbrc.2000.2576; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Neri A, 1996, LEUKEMIA LYMPHOMA, V23, P43, DOI 10.3109/10428199609054800; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; Wu K, 2002, J BIOL CHEM, V277, P516, DOI 10.1074/jbc.M108008200; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3	29	84	88	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2540	2547		10.1038/sj.onc.1207366	http://dx.doi.org/10.1038/sj.onc.1207366			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14676825				2022-12-17	WOS:000220558000011
J	Melnikova, VO; Bolshakov, SV; Walker, C; Ananthaswamy, HN				Melnikova, VO; Bolshakov, SV; Walker, C; Ananthaswamy, HN			Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines	ONCOGENE			English	Article						melanoma; Braf; ras; ERK1/2; p53; INK4a/ARF	WILD-TYPE P53; HUMAN MELANOCYTIC LESIONS; HUMAN CUTANEOUS MELANOMA; HUMAN-MALIGNANT MELANOMA; MOUSE SKIN TUMORS; N-RAS MUTATIONS; ULTRAVIOLET-RADIATION; FAMILIAL MELANOMA; ONCOGENIC RAS; BRAF GENE	We have conducted an analysis of genetic alterations in spontaneous murine melanoma cell line B16F(0) and its two metastatic clones, B16F(1) and B16F(10) and the carcinogen-induced murine melanoma cell lines CM519, CM3205, and K1735. We found that unlike human melanomas, the murine melanoma cell lines did not have activating mutations in the Braf oncogene at exon 11 or 15. However, there were distinct patterns of alterations in the ras, Ink4a/Arf, and p53 genes in the two melanoma groups. In the spontaneous B16 melanoma cell lines, expression of p16(Ink4a) and p19(Arf) tumor suppressor proteins was lost as a consequence of a large deletion spanning Ink4a/Arf exons 1alpha, 1beta, and 2. In contrast, the carcinogen-induced melanoma cell lines expressed p16(Ink4a) but had inactivating mutations in either p19(Arf) (K1735) or p53 (CM519 and CM3205). Inactivation of p19(Arf) or p53 in carcinogen-induced melanomas was accompanied by constitutive activation of mitogen-activated protein kinases (MAPKs) and/or mutation-associated activation of N-ras. These results indicate that genetic alterations in p16(Ink4a)/p19(Arf), p53 and ras-MAPK pathways can cooperate in the development of murine melanoma.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Ananthaswamy, HN (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, POB 301402,Unit 902, Houston, TX 77030 USA.	hanantha@mdanderson.org			NATIONAL CANCER INSTITUTE [P30CA016672, R01CA046523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672, CA 46523] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBINO AP, 1989, ONCOGENE, V4, P1363; ALBINO AP, 1994, MELANOMA RES, V4, P35, DOI 10.1097/00008390-199402000-00006; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ananthaswamy H N, 1998, J Investig Dermatol Symp Proc, V3, P52; Ananthaswamy HN, 1998, PHOTOCHEM PHOTOBIOL, V67, P227, DOI 10.1562/0031-8655(1998)067<0227:MIHSHM>2.3.CO;2; Bardeesy N, 2001, MOL CELL BIOL, V21, P2144, DOI 10.1128/MCB.21.6.2144-2153.2001; Bastian BC, 1998, CANCER RES, V58, P2170; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bishop DT, 2002, J NATL CANCER I, V94, P894, DOI 10.1093/jnci/94.12.894; BOSARI S, 1995, AM J PATHOL, V147, P790; Brash DE, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P136; Brose MS, 2002, CANCER RES, V62, P6997; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dong JL, 2003, CANCER RES, V63, P3883; Elwood JM, 1997, INT J CANCER, V73, P198, DOI 10.1002/(SICI)1097-0215(19971009)73:2<198::AID-IJC6>3.0.CO;2-R; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Flores JF, 1996, CANCER RES, V56, P5023; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; FOUNTAIN JW, 1990, CANCER SURV, V9, P645; GANNON JV, 1991, NATURE, V349, P802; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; Gorden A, 2003, CANCER RES, V63, P3955; Groth A, 2000, J BIOL CHEM, V275, P27473; Gruis NA, 1999, J INVEST DERM SYMP P, V4, P50, DOI 10.1038/sj.jidsp.5640181; Haluska FG, 1998, J CLIN ONCOL, V16, P670, DOI 10.1200/JCO.1998.16.2.670; Hartmann A, 1996, INT J CANCER, V67, P313, DOI 10.1002/(SICI)1097-0215(19960729)67:3<313::AID-IJC1>3.0.CO;2-U; HERLYN M, 1993, MOL CELLULAR BIOL ME; Hewitt C, 2002, HUM MOL GENET, V11, P1273, DOI 10.1093/hmg/11.11.1273; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JAFARI M, 1995, J CANCER RES CLIN, V121, P23, DOI 10.1007/BF01202725; Jhappan C, 2003, ONCOGENE, V22, P3099, DOI 10.1038/sj.onc.1206450; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Klotzsche O, 1998, ONCOGENE, V16, P3423, DOI 10.1038/sj.onc.1202155; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KRIPKE ML, 1979, JNCI-J NATL CANCER I, V63, P541, DOI 10.1093/jnci/63.3.541; Kumar R, 1998, GENE CHROMOSOME CANC, V23, P273, DOI 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; LUBBE J, 1994, J INVEST DERMATOL, V102, P819, DOI 10.1111/1523-1747.ep12381544; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAO L, 1995, CANCER RES, V55, P2995; Melnikova VO, 2003, ONCOGENE, V22, P5958, DOI 10.1038/sj.onc.1206595; Metcalfe S, 1999, ONCOGENE, V18, P2351, DOI 10.1038/sj.onc.1202559; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Monzon J, 1998, NEW ENGL J MED, V338, P879, DOI 10.1056/NEJM199803263381305; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Noonan FP, 2001, NATURE, V413, P271, DOI 10.1038/35095108; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Omholt K, 2002, CLIN CANCER RES, V8, P3468; Osaka M, 1996, MOL CARCINOGEN, V16, P126, DOI 10.1002/(SICI)1098-2744(199607)16:3<126::AID-MC2>3.0.CO;2-F; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Papp T, 1996, J CANCER RES CLIN, V122, P541, DOI 10.1007/BF01213550; PICCININ S, 1997, CLIN LAB MED, V20, P667; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Recio JA, 2002, CANCER RES, V62, P6724; Rigel DS, 2000, CA-CANCER J CLIN, V50, P215, DOI 10.3322/canjclin.50.4.215; Rizos H, 2001, J BIOL CHEM, V276, P41424, DOI 10.1074/jbc.M105299200; ROMERDAHL CA, 1986, CANCER METAST REV, V5, P167, DOI 10.1007/BF00046429; Satyamoorthy K, 2003, CANCER RES, V63, P756; Schlamp CL, 1997, J NATL CANCER I, V89, P1530, DOI 10.1093/jnci/89.20.1530; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 2002, CANCER RES, V62, P2761; SPARROW LE, 1995, MELANOMA RES, V5, P93, DOI 10.1097/00008390-199504000-00004; STONE S, 1995, CANCER RES, V55, P2988; SUN XF, 1992, LANCET, V340, P1369, DOI 10.1016/0140-6736(92)92558-W; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; vanElsas A, 1996, AM J PATHOL, V149, P883; VANTVEER LJ, 1989, MOL CELL BIOL, V9, P3114, DOI 10.1128/MCB.9.7.3114; VOLKENANDT M, 1991, PIGM CELL RES, V4, P35, DOI 10.1111/j.1600-0749.1991.tb00311.x; Weber A, 2003, ONCOGENE, V22, P4757, DOI 10.1038/sj.onc.1206705; WEISS J, 1993, INT J CANCER, V54, P693, DOI 10.1002/ijc.2910540427; Wong AK, 2000, CANCER METAST REV, V19, P121, DOI 10.1023/A:1026537423753; Xu XL, 2003, CANCER RES, V63, P4561; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zhuang SM, 1997, CANCER RES, V57, P2710; Zhuang SM, 1998, ONCOGENE, V16, P803, DOI 10.1038/sj.onc.1201600	87	84	84	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2347	2356		10.1038/sj.onc.1207405	http://dx.doi.org/10.1038/sj.onc.1207405			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14743208				2022-12-17	WOS:000220427700009
J	Chopin, V; Toillon, RA; Jouy, N; Le Bourhis, X				Chopin, V; Toillon, RA; Jouy, N; Le Bourhis, X			P21(WAF1/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells	ONCOGENE			English	Article						apoptosis; breast cancer; butyrate; cell cycle; PCNA; P21(waf1/cip1)	HISTONE DEACETYLASE INHIBITOR; HUMAN COLON-CANCER; BINDING PROTEIN-3 PROMOTER; NUCLEOTIDE EXCISION-REPAIR; GROWTH ARREST; CARCINOMA CELLS; NUCLEAR ANTIGEN; IN-VIVO; TRANSCRIPTIONAL REPRESSION; INDUCIBLE EXPRESSION	Sodium butyrate (NaB) has been proposed as a potential anticancer agent. However, its mechanism of action is not totally elucidated. Here, we showed that NaB-induced cell cycle arrest and apoptosis were associated with an increase of P21(waf1/cip1) in MCF-7 breast cancer cells. This increase was more important in the nuclei, as revealed by immunofluorescence analysis. Transient transfections of MCF-7 cells with p21 deficient for interaction with CDK, but not with p21 deficient for interaction with PCNA <LF>(p21PCNA-), abrogated NaB-induced cell cycle arrest. This indicated that cell cycle blockage involved the interaction of P21(waf1/cip1) with CDK. However, P21(waf1/cip1) was dispensable, since p21 antisense did not modify cell cycle arrest. On the other hand, NaB-induced apoptosis was abolished by p21 antisense or p21PCNA-. In addition, NaB decreased PCNA levels, but increased the association of PCNA with P21(waf1/cip1). These results suggested that NaB-induced apoptosis required P21(waf1/cip1) and its interaction with PCNA.	Univ Sci & Technol Lille, Equipe Facteurs Croissance, Dev Biol Lab, UPRES 1033, F-59655 Villeneuve Dascq, France; Inst Rech Canc Lille, Inst Rech, Inst Med Predict & Rech Therapeut, IMPRT, F-59045 Lille, France	Universite de Lille - ISITE; Universite de Lille	Le Bourhis, X (corresponding author), Univ Sci & Technol Lille, Equipe Facteurs Croissance, Dev Biol Lab, UPRES 1033, IFR 118, F-59655 Villeneuve Dascq, France.	Xuefen.lebourhis@univ-lille1.fr	Le+Bourhis, Xuefen/AAL-5141-2021; Toillon, Robert-Alain/Q-2286-2018	Toillon, Robert-Alain/0000-0001-5483-2118				Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CHEN IT, 1995, ONCOGENE, V11, P1931; Chen ZX, 2002, CANCER LETT, V188, P127, DOI 10.1016/S0304-3835(02)00322-1; Chopin V, 2002, BRIT J PHARMACOL, V135, P79, DOI 10.1038/sj.bjp.0704456; Cooper MP, 1999, MOL BIOL CELL, V10, P2119, DOI 10.1091/mbc.10.7.2119; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Delavaine L, 1999, ONCOGENE, V18, P5381, DOI 10.1038/sj.onc.1202923; Della Ragione F, 2001, FEBS LETT, V499, P199, DOI 10.1016/S0014-5793(01)02539-X; Demary K, 2001, CANCER LETT, V163, P103, DOI 10.1016/S0304-3835(00)00676-5; Derjuga A, 2001, J BIOL CHEM, V276, P37815; Detjen KM, 2003, EXP CELL RES, V282, P78, DOI 10.1016/S0014-4827(02)00011-3; Feng XL, 2002, TRENDS CELL BIOL, V12, P532, DOI 10.1016/S0962-8924(02)02391-7; Galfi P, 2002, CANCER LETT, V188, P141, DOI 10.1016/S0304-3835(02)00347-6; Gartel AL, 2003, EXP CELL RES, V283, P17, DOI 10.1016/S0014-4827(02)00020-4; Gilbert J, 2001, CLIN CANCER RES, V7, P2292; Gregory DJ, 2002, CELL CYCLE, V1, P343, DOI 10.4161/cc.1.5.153; HALL PA, 1995, ONCOGENE, V10, P2427; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Ito N, 2001, NEUROSURGERY, V49, P430, DOI 10.1097/00006123-200108000-00031; Lallemand F, 1996, BIOCHEM BIOPH RES CO, V229, P163, DOI 10.1006/bbrc.1996.1774; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; Mandal M, 1997, CARCINOGENESIS, V18, P229, DOI 10.1093/carcin/18.1.229; Mattock H, 2001, EXP CELL RES, V265, P234, DOI 10.1006/excr.2001.5160; Mita H, 2002, MOL CELL BIOL, V22, P4544, DOI 10.1128/MCB.22.13.4544-4555.2002; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; Patnaik A, 2002, CLIN CANCER RES, V8, P2142; Pellizzaro C, 2001, INT J CANCER, V91, P654, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1117>3.0.CO;2-I; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Peschiaroli A, 2002, ONCOGENE, V21, P8114, DOI 10.1038/sj.onc.1206010; Qiao L, 2002, HEPATOLOGY, V36, P39, DOI 10.1053/jhep.2002.33899; Qin LF, 2001, CANCER LETT, V172, P7, DOI 10.1016/S0304-3835(01)00701-7; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Ritt MG, 2000, CANCER LETT, V158, P73, DOI 10.1016/S0304-3835(00)00507-3; Rousseau D, 1999, ONCOGENE, V18, P4313, DOI 10.1038/sj.onc.1202686; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Sawa H, 2001, Brain Tumor Pathol, V18, P109, DOI 10.1007/BF02479423; Schwartz B, 1998, MOL CELL BIOCHEM, V188, P21, DOI 10.1023/A:1006831330340; Scott M, 2001, J CELL SCI, V114, P3455; Shibata MA, 2001, CANCER GENE THER, V8, P23, DOI 10.1038/sj.cgt.7700275; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; Sowa Y, 1999, CANCER RES, V59, P4266; Sowa Y, 2000, BIOFACTORS, V12, P283, DOI 10.1002/biof.5520120142; Suzuki A, 2000, CELL DEATH DIFFER, V7, P721, DOI 10.1038/sj.cdd.4400706; Takahashi S, 2001, CANCER RES, V61, P1187; Terao Y, 2001, INT J CANCER, V94, P257, DOI 10.1002/ijc.1448; Tian H, 2000, CANCER RES, V60, P679; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; Tsao YP, 1999, J VIROL, V73, P4983, DOI 10.1128/JVI.73.6.4983-4990.1999; Tsubaki J, 2002, ENDOCRINOLOGY, V143, P1778, DOI 10.1210/en.143.5.1778; Tsubaki J, 2001, J ENDOCRINOL, V169, P97, DOI 10.1677/joe.0.1690097; Vaziri C, 1998, CELL GROWTH DIFFER, V9, P465; Velazquez OC, 1996, JPEN-PARENTER ENTER, V20, P243, DOI 10.1177/0148607196020004243; Walker GE, 2001, ENDOCRINOLOGY, V142, P3817, DOI 10.1210/en.142.9.3817; Wang XM, 1999, ANTICANCER RES, V19, P2901; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Xiang H, 2002, ONCOGENE, V21, P3611, DOI 10.1038/sj.onc.1205449; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	65	84	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					21	29		10.1038/sj.onc.1207020	http://dx.doi.org/10.1038/sj.onc.1207020			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712207				2022-12-17	WOS:000187895300003
J	Brummer, T; Naegele, H; Reth, M; Misawa, Y				Brummer, T; Naegele, H; Reth, M; Misawa, Y			Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf	ONCOGENE			English	Article						B-Raf; feedback phosphorylation; ERK; B-cell antigen receptor; DT40; MEK-inhibitor UO126	ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE; CELL ANTIGEN RECEPTOR; COMPLETE CODING SEQUENCE; NERVE GROWTH-FACTOR; JUN NH2-TERMINAL KINASE; NEGATIVE REGULATION; POSITIVE FEEDBACK; TYROSINE KINASES; STRUCTURAL BASIS	The extracellular signal-regulated kinase (ERK) pathway plays an important role during the development and activation of B lymphocytes. We have recently shown that B-Raf is a dominant ERK activator in B-cell antigen receptor signalling. We now show that B-Raf is hyperphosphorylated upon BCR engagement and undergoes a prominent electrophoretic mobility shift. This shift correlates with ERK activation and is prevented by the MEK inhibitor U0126. Syk-deficient DT40 B cells display neither dual ERK phosphorylation nor a mobility shift of B-Raf upon BCR engagement. The inducible expression of a constitutively active B-Raf in this mutant line restores dual ERK phosphorylation and the mobility shift of endogenous B-Raf, indicating that these two events are connected to each other. By site-directed mutagenesis studies, we demonstrate that the shift is due to an ERK2-mediated feedback phosphorylation of serine/threonine residues within an evolutionary conserved SPKTP motif at the C-terminus of B-Raf. Replacement of these residues by negatively charged amino acids causes a constitutive mobility shift and a reduction of PC12 cell differentiation. We discuss a model in which ERK-mediated phosphorylation of the SPKTP motif is involved in negative feedback regulation of B-Raf.	Univ Freiburg, Dept Mol Immunol, D-79108 Freiburg, Germany; Max Planck Inst Immunobiol, D-79108 Freiburg, Germany	University of Freiburg; Max Planck Society	Misawa, Y (corresponding author), Univ Virginia Hlth Syst, Dept Pharmacol, POB 800735,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	ym8n@virginia.edu	Brummer, Tilman/B-6218-2016; Brummer, Tilman/AAA-9428-2020	Brummer, Tilman/0000-0003-4387-7905; Brummer, Tilman/0000-0003-4387-7905				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; Brummer T, 2002, EMBO J, V21, P5611, DOI 10.1093/emboj/cdf588; Bruyns E, 1998, J EXP MED, V188, P561, DOI 10.1084/jem.188.3.561; CALOGERAKI I, 1993, BIOCHEM BIOPH RES CO, V193, P1324, DOI 10.1006/bbrc.1993.1770; Carey KD, 2003, J BIOL CHEM, V278, P3185, DOI 10.1074/jbc.M207014200; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; Ferrier AF, 1997, J BIOL CHEM, V272, P2136; Fleming HE, 2001, IMMUNITY, V15, P521, DOI 10.1016/S1074-7613(01)00216-3; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; Gold MR, 2000, CURR TOP MICROBIOL, V245, P77; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Guan KL, 2000, J BIOL CHEM, V275, P27354; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hashimoto A, 1998, J EXP MED, V188, P1287, DOI 10.1084/jem.188.7.1287; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Iritani BM, 1997, EMBO J, V16, P7019, DOI 10.1093/emboj/16.23.7019; Jaiswal RK, 1996, J BIOL CHEM, V271, P23626, DOI 10.1074/jbc.271.39.23626; Jiang A, 1998, J EXP MED, V188, P1297, DOI 10.1084/jem.188.7.1297; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; KIM KJ, 1979, J IMMUNOL, V122, P549; KLEIN G, 1975, INTERVIROLOGY, V5, P319, DOI 10.1159/000149930; KOENEN M, 1988, ONCOGENE, V2, P179; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; Lax I, 2002, MOL CELL, V10, P709, DOI 10.1016/S1097-2765(02)00689-5; LEE RM, 1992, J BIOL CHEM, V267, P1088; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; MacNicol MC, 2000, J BIOL CHEM, V275, P3803, DOI 10.1074/jbc.275.6.3803; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; Papin C, 1996, ONCOGENE, V12, P2213; Richards JD, 2001, J IMMUNOL, V166, P3855, DOI 10.4049/jimmunol.166.6.3855; Roy F, 2002, GENE DEV, V16, P427, DOI 10.1101/gad.962902; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Shirakata Y, 1999, J IMMUNOL, V163, P6589; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; SPRENGER F, 1993, MOL CELL BIOL, V13, P1163, DOI 10.1128/MCB.13.2.1163; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Toran-Allerand CD, 1999, FRONT NEUROENDOCRIN, V20, P97, DOI 10.1006/frne.1999.0177; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; UEKI K, 1994, J BIOL CHEM, V269, P15756; Wartmann M, 1997, J BIOL CHEM, V272, P3915, DOI 10.1074/jbc.272.7.3915; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; Wojnowski L, 2000, MECH DEVELOP, V91, P97, DOI 10.1016/S0925-4773(99)00276-2; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; Xu R, 1999, J IMMUNOL, V163, P1110; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0; Zhang BH, 2001, J BIOL CHEM, V276, P31620, DOI 10.1074/jbc.M102808200; Zhang Y, 1996, NUCLEIC ACIDS RES, V24, P543, DOI 10.1093/nar/24.4.543; ZHUO S, 1993, J BIOL CHEM, V268, P17754; Zimmermann S, 1997, ONCOGENE, V15, P1503, DOI 10.1038/sj.onc.1201322	67	84	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8823	8834		10.1038/sj.onc.1207185	http://dx.doi.org/10.1038/sj.onc.1207185			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654779				2022-12-17	WOS:000186982200003
J	Kioi, M; Yamamoto, K; Higashi, S; Koshikawa, N; Fujita, K; Miyazaki, K				Kioi, M; Yamamoto, K; Higashi, S; Koshikawa, N; Fujita, K; Miyazaki, K			Matrilysin (MMP-7) induces homotypic adhesion of human colon cancer cells and enhances their metastatic potential in nude mouse model	ONCOGENE			English	Article						matrilysin; matrix metalloproteinases; metastasis; colon carcinoma; E-cadherin	MATRIX-DEGRADING METALLOPROTEINASE; ANCHORAGE-INDEPENDENT GROWTH; HUMAN COLORECTAL CANCERS; E-CADHERIN; CARCINOMA-CELLS; EXTRACELLULAR-MATRIX; TUMOR INVASION; EXPRESSION; CLEAVAGE; INTEGRIN	Matrilysin (MMP-7) is thought to contribute to invasive growth and metastasis of colon carcinoma and many other human cancers. The present study demonstrates that treatment of human colon carcinoma cells with active matrilysin induces cell aggregation in vitro and promotes liver metastasis in nude mice. When two kinds of colon carcinoma cell lines were incubated with active matrilysin, this enzyme efficiently bound to the cell surface and induced loose cell aggregation, which led to E-cadherin-mediated tight cell aggregation. Synthetic MMP inhibitors inhibited both the membrane binding of matrilysin and matrilysin-induced cell aggregation, while TIMP-2 inhibited only the cell aggregation. Two other active MMPs, stromelysin and gelatinase A, neither bound to cell membrane nor induced cell aggregation. Tumor cells in loose cell aggregates could reaggregate even after they were freed from matrilysin and dispersed. When injected into the spleen of nude mice, the tumor cells in the stable aggregates produced much larger metastatic nodules in the livers than control cells and those in the loose aggregates. These results suggest that matrilysin may enhance metastatic potential of tumor cells by processing a cell surface protein(s) and thereby inducing loose and then tight aggregation of tumor cells.	Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan; Yokohama City Univ, Sch Med, Dept Oral Maxillofacial Surg, Kanazawa Ku, Yokohama, Kanagawa 2360008, Japan	Yokohama City University; Yokohama City University	Miyazaki, K (corresponding author), Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, 641-12 Maioka Cho, Yokohama, Kanagawa 2440813, Japan.		Yamamoto, Kazuhiro/AAD-9650-2019; Koshikawa, Naohiko/S-7306-2017	Koshikawa, Naohiko/0000-0002-4539-888X; Kioi, Mitomu/0000-0002-7981-3340				Abdel-Ghany M, 2001, J BIOL CHEM, V276, P25438, DOI 10.1074/jbc.M100478200; Adachi Y, 1999, GUT, V45, P252, DOI 10.1136/gut.45.2.252; Agnihotri R, 2001, J BIOL CHEM, V276, P28261, DOI 10.1074/jbc.M103608200; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Belaaouaj AA, 2000, J BIOL CHEM, V275, P27123; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BROWNER MF, 1995, BIOCHEMISTRY-US, V34, P6602, DOI 10.1021/bi00020a004; Caterson B, 2000, MATRIX BIOL, V19, P333, DOI 10.1016/S0945-053X(00)00078-0; Chen WT, 1996, ENZYME PROTEIN, V49, P59, DOI 10.1159/000468616; Davies G, 2001, CLIN CANCER RES, V7, P3289; Gearing AJH, 2002, IMMUNOL LETT, V81, P41, DOI 10.1016/S0165-2478(01)00333-9; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Hasegawa S, 1998, INT J CANCER, V76, P812, DOI 10.1002/(SICI)1097-0215(19980610)76:6<812::AID-IJC8>3.0.CO;2-0; Higashi S, 2003, J BIOL CHEM, V278, P14020, DOI 10.1074/jbc.M212264200; Higashi S, 1999, J BIOL CHEM, V274, P10497, DOI 10.1074/jbc.274.15.10497; INCH WR, 1970, GROWTH, V34, P271; Inohara H, 1996, CANCER RES, V56, P4530; Ishikawa T, 1996, CANCER LETT, V107, P5, DOI 10.1016/0304-3835(96)04336-4; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; Kondo K, 1998, CANCER RES, V58, P2014; Mitsiades N, 2001, CANCER RES, V61, P577; Miyata S, 2000, J BIOL CHEM, V275, P4592, DOI 10.1074/jbc.275.7.4592; MIYAZAKI K, 1990, CANCER RES, V50, P7758; MONZ B, 1994, ONCOL REP, V1, P1177; Mueller S, 2000, CANCER RES, V60, P156; MuellerKlieser W, 1997, AM J PHYSIOL-CELL PH, V273, pC1109, DOI 10.1152/ajpcell.1997.273.4.C1109; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nagashima Y, 1997, INT J CANCER, V72, P441, DOI 10.1002/(SICI)1097-0215(19970729)72:3<441::AID-IJC11>3.0.CO;2-F; Noe V, 2001, J CELL SCI, V114, P111; NOGUCHI P, 1979, IN VITRO CELL DEV B, V15, P401; Olive PL, 1997, CANCER RES, V57, P5528; SEMPLE TU, 1978, CANCER RES, V38, P1345; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; Takeda T, 2000, MOL BIOL CELL, V11, P3219, DOI 10.1091/mbc.11.9.3219; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; UMENISHI F, 1990, J BIOCHEM-TOKYO, V108, P537, DOI 10.1093/oxfordjournals.jbchem.a123238; vonBredow DC, 1997, EXP CELL RES, V236, P341, DOI 10.1006/excr.1997.3711; Welch AR, 1996, BIOCHEMISTRY-US, V35, P10103, DOI 10.1021/bi9601969; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; YOSHIMOTO M, 1993, INT J CANCER, V54, P614, DOI 10.1002/ijc.2910540415; Yu Q, 2000, GENE DEV, V14, P163; Yu WH, 2000, J BIOL CHEM, V275, P4183, DOI 10.1074/jbc.275.6.4183; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702	44	84	89	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8662	8670		10.1038/sj.onc.1207181	http://dx.doi.org/10.1038/sj.onc.1207181			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647460				2022-12-17	WOS:000186844900003
J	Eliopoulos, AG; Caamano, JH; Flavell, J; Reynolds, GM; Murray, PG; Poyet, JL; Young, LS				Eliopoulos, AG; Caamano, JH; Flavell, J; Reynolds, GM; Murray, PG; Poyet, JL; Young, LS			Epstein-Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-kappa B2 to p52 via an IKK gamma/NEMO-independent signalling pathway	ONCOGENE			English	Article						LMP1; EBV; NF-kappa B2; signalling	NF-KAPPA-B; MEMBRANE-PROTEIN 1; LYMPHOTOXIN-BETA-RECEPTOR; LYMPHOCYTE GROWTH TRANSFORMATION; CYCLIN D1; SPLENIC MICROARCHITECTURE; TRANSCRIPTIONAL ACTIVITY; BCL-2 EXPRESSION; IMMUNE-RESPONSES; TRANSGENIC MICE	The oncogenic Epstein - Barr virus (EBV)-encoded latent infection membrane protein 1 (LMP1) constitutively activates the 'canonical' NF-kappaB pathway that involves the phosphorylation and degradation of IkappaBalpha downstream of the IkappaB kinases (IKKs). In this study, we show that LMP1 also promotes the proteasome-mediated proteolysis of p100 NF-kappaB2 resulting in the generation of active p52, which translocates to the nucleus in complex with the p65 and RelB NF-kappaB subunits. LMP1-induced NF-kappaB transactivation is reduced in nf-kb2(-/-) mouse embryo fibroblasts, suggesting that p100 processing contributes to LMP1-mediated NF-kappaB transcriptional effects. This pathway is likely to operate in vivo, as the expression of LMP1 in primary EBV-positive Hodgkin's lymphoma and nasopharyngeal carcinoma biopsies correlates with the nuclear accumulation of p52. Interestingly, while the ability of LMP1 to activate the canonical NF-kappaB pathway is impaired in cells lacking IKKgamma/NEMO, the regulatory subunit of the IKK complex, p100 processing remains unaffected. As a result, nuclear translocation of p52, but not p65, occurs in the absence of IKKgamma. These data point to the existence of a novel signalling pathway that regulates NF-kappaB in LMP1-expressingcells, and may thereby play a role in both oncogenic transformation and the establishment of persistent EBV infection.	Univ Birmingham, Sch Med, Canc Res UK Inst Canc Studies, Birmingham B15 2TA, W Midlands, England; Univ Birmingham, Sch Med, MRC, Ctr Immune Regulat, Birmingham B15 2TA, W Midlands, England; Univ Birmingham, Sch Med, Dept Pathol, Birmingham B15 2TA, W Midlands, England; Hop St Louis, INSERM, U532, Inst Rech Peau, F-75475 Paris 10, France	Cancer Research UK; University of Birmingham; University of Birmingham; University of Birmingham; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Eliopoulos, AG (corresponding author), Univ Birmingham, Sch Med, Canc Res UK Inst Canc Studies, Birmingham B15 2TA, W Midlands, England.	A.G.Eliopoulos@bham.ac.uk	Young, Lawrence S/B-7213-2009; Caamano, Jorge/O-7530-2019; Poyet, Jean-Luc/G-7114-2017; ELIOPOULOS, ARISTIDES/ABI-6632-2020; Caamano, Jorge/I-6778-2012; Reynolds, Gary/F-8641-2014; ELIOPOULOS, ARISTIDES/R-9449-2018	Young, Lawrence S/0000-0003-3919-4298; Caamano, Jorge/0000-0003-3530-7056; Poyet, Jean-Luc/0000-0002-3747-255X; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Caamano, Jorge/0000-0003-3530-7056; Reynolds, Gary/0000-0002-3250-0582; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Damania B, 2000, J VIROL, V74, P1593, DOI 10.1128/JVI.74.4.1593-1601.2000; Dawson CW, 2003, J BIOL CHEM, V278, P3694, DOI 10.1074/jbc.M209840200; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; Eliopoulos AG, 2003, J VIROL, V77, P1316, DOI 10.1128/JVI.77.2.1316-1328.2003; Eliopoulos AG, 2002, J VIROL, V76, P4567, DOI 10.1128/JVI.76.9.4567-4579.2002; Eliopoulos AG, 2002, EMBO J, V21, P4831, DOI 10.1093/emboj/cdf478; Flavell JR, 2000, J CLIN PATHOL-MOL PA, V53, P145, DOI 10.1136/mp.53.3.145; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Garceau N, 2000, J EXP MED, V191, P381, DOI 10.1084/jem.191.2.381; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; He ZM, 2000, CANCER RES, V60, P1845; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; HUEN DS, 1995, ONCOGENE, V10, P549; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Izumi KM, 1999, MOL CELL BIOL, V19, P5759; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; Kaisho T, 2001, J EXP MED, V193, P417, DOI 10.1084/jem.193.4.417; KANNO T, 1994, P NATL ACAD SCI USA, V91, P12634, DOI 10.1073/pnas.91.26.12634; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Koike R, 1996, EUR J IMMUNOL, V26, P669, DOI 10.1002/eji.1830260324; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; Lam N, 2003, EMBO J, V22, P3027, DOI 10.1093/emboj/cdg284; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Luftig MA, 2001, J BIOL CHEM, V276, P14602, DOI 10.1074/jbc.C100103200; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Matsumoto M, 1996, SCIENCE, V271, P1289, DOI 10.1126/science.271.5253.1289; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; McFarland EDC, 1999, ONCOGENE, V18, P6959, DOI 10.1038/sj.onc.1203217; Mordmuller B, 2003, EMBO REP, V4, P82, DOI 10.1038/embor710; Murono S, 2001, P NATL ACAD SCI USA, V98, P6905, DOI 10.1073/pnas.121016998; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; Perkins ND, 1997, INT J BIOCHEM CELL B, V29, P1433, DOI 10.1016/S1357-2725(97)00088-5; Poyet JL, 2001, J BIOL CHEM, V276, P3183, DOI 10.1074/jbc.C000792200; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; Santoro MG, 2003, EMBO J, V22, P2552, DOI 10.1093/emboj/cdg267; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; Viatour P, 2003, LEUKEMIA, V17, P1349, DOI 10.1038/sj.leu.2402982; Wang YQ, 2002, NAT CELL BIOL, V4, P888, DOI 10.1038/ncb872; Westerheide SD, 2001, MOL CELL BIOL, V21, P8428, DOI 10.1128/MCB.21.24.8428-8436.2001; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453	69	84	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2003	22	48					7557	7569		10.1038/sj.onc.1207120	http://dx.doi.org/10.1038/sj.onc.1207120			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576817				2022-12-17	WOS:000186113000002
J	Frese, S; Pirnia, F; Miescher, D; Krajewski, S; Borner, MM; Reed, JC; Schmid, RA				Frese, S; Pirnia, F; Miescher, D; Krajewski, S; Borner, MM; Reed, JC; Schmid, RA			PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2	ONCOGENE			English	Article						lung cancer; resistance to apoptosis; tumor necrosis factor-related apoptosis-inducing ligand; mitogen-activated protein kinase; primary culture	TRAIL-INDUCED APOPTOSIS; SIGNAL-REGULATED KINASE; MAP KINASE; IN-VIVO; TRAIL/APO2L-INDUCED APOPTOSIS; CHEMOTHERAPEUTIC-AGENTS; INHIBITORY PROTEIN; ANTITUMOR-ACTIVITY; TUMOR-CELLS; LIGAND	Tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) belongs to the family of programmed cell death-inducing cytokines. Apo2L/TRAIL induces apoptosis in a wide variety of tumor cells. Tumor cells that are resistant to Apo2L/TRAIL-induced apoptosis can be sensitized by chemotherapeutic drugs and other agents via an unknown mechanism. Here we report that PG490 (triptolide), a diterpene triepoxide extracted from the Chinese herb Tripterygium wilfordii and used in traditional Chinese medicine, sensitizes lung cancer but not normal human bronchial epithelial cells to Apo2L/TRAIL-induced apoptosis. Sensitization was accompanied by caspase-3 and caspase-8 activation, whereas no cleavage of caspase-9 was observed. Determination of cell surface receptors by flow cytometry demonstrated no difference in Apo2L/TRAIL-R1 and -R2 expression, the two receptors with functional death domains, between resistant and sensitized cells. In cells treated with the combination of Apo2L/TRAIL and PG490, we observed activation of ERK2, a member of the mitogen-activated protein kinase family. Furthermore, sensitization could be blocked by the ERK inhibitor U0126 but not the p38 inhibitor SB203580, suggesting that activation of ERK2 is required for this effect. In addition, sensitization of lung cancer cells was also seen in ex vivo culture of lung cancer tissue from four patients who underwent surgery. Immunohistochemical staining showed a clear reduction in proliferation cell nuclear antigen (PCNA) in tissue treated with Apo2L/TRAIL and PG490. In conclusion, apoptosis induced by the combination of Apo2L/TRAIL and PG490 warrants further evaluation as a potential new strategy for the treatment of lung cancer.	Univ Hosp Bern, Dept Clin Res, Div Gen Thorac Surg, CH-3010 Bern, Switzerland; Univ Hosp Bern, Inst Med Oncol, CH-3010 Bern, Switzerland; Burnham Inst, La Jolla, CA 92037 USA	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; Sanford Burnham Prebys Medical Discovery Institute	Frese, S (corresponding author), Univ Hosp Bern, Dept Clin Res, Div Gen Thorac Surg, Murtenstr 35,Room C807, CH-3010 Bern, Switzerland.	steffen.frese@email.de	Frese, Steffen/AAL-4573-2021; Borner, Markus/B-7583-2011	Schmid, Ralph Alexander/0000-0003-0699-079X	NCI NIH HHS [CA 69381] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chang WT, 2001, J BIOL CHEM, V276, P2221, DOI 10.1074/jbc.M009713200; Cottom J, 2003, J BIOL CHEM, V278, P7167, DOI 10.1074/jbc.M203901200; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Evdokiou A, 2002, INT J CANCER, V99, P491, DOI 10.1002/ijc.10376; Faul JL, 2000, AM J RESP CRIT CARE, V162, P2252, DOI 10.1164/ajrccm.162.6.2002018; Frese S, 2002, J THORAC CARDIOV SUR, V123, P168, DOI 10.1067/mtc.2002.119694; Gliniak B, 1999, CANCER RES, V59, P6153; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Griffith TS, 2002, CANCER RES, V62, P3093; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Huynh PN, 2000, J ANDROL, V21, P689; Ishiwata N, 2000, ANTICANCER RES, V20, P1445; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Krajewska M, 1997, CANCER RES, V57, P1605; Lee KY, 2002, EXP MOL MED, V34, P462, DOI 10.1038/emm.2002.64; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Lee MW, 2002, FEBS LETT, V512, P313, DOI 10.1016/S0014-5793(02)02225-1; Lee YJ, 2001, ONCOGENE, V20, P1476, DOI 10.1038/sj.onc.1204225; Leverkus M, 2000, CANCER RES, V60, P553; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; McCullagh P, 1989, MONOGRAPHS STAT APPL, V2nd; Nam SY, 2002, ONCOGENE, V21, P337, DOI 10.1038/sj.onc.1205068; Nesterov A, 2002, ONCOGENE, V21, P1135, DOI 10.1038/sj.onc.1205151; Rohn TA, 2001, ONCOGENE, V20, P4128, DOI 10.1038/sj.onc.1204534; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Stadheim TA, 2001, CANCER RES, V61, P1533; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiang H, 2002, ONCOGENE, V21, P3611, DOI 10.1038/sj.onc.1205449; Yang YL, 1998, IMMUNOPHARMACOLOGY, V40, P139, DOI 10.1016/S0162-3109(98)00036-8; Zhang XD, 1999, CANCER RES, V59, P2747	40	84	96	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5427	5435		10.1038/sj.onc.1206842	http://dx.doi.org/10.1038/sj.onc.1206842			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934102				2022-12-17	WOS:000184735000007
J	Moynahan, ME				Moynahan, ME			The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans	ONCOGENE			English	Article						BRCA1; BRCA2; tumor suppression; genetic instability	SINGLE NUCLEOTIDE POLYMORPHISM; GENE-EXPRESSION PROFILES; FAMILIAL BREAST-CANCER; DNA-REPAIR; EMBRYONIC LETHALITY; SUSCEPTIBILITY GENE; MAMMARY-TUMORS; CENTROSOME AMPLIFICATION; OVARIAN-CANCER; MOUSE MODEL	BRCA1 and BRCA2 mutations are estimated to be responsible for the great majority of familial breast and ovarian cancers. Much progress has been made toward the understanding of the function of these proteins through genetic, biochemical, and structural studies. The embryonic lethality encountered in the knockout mouse initially hindered the development of mouse models aimed at studying tumor suppression. However, mice that harbor hypomorphic Brca1 and Brca2 alleles and cre-mediated tissue-specific deletions for Brca1 and Brca2 have been generated. Mice deficient for either Brca1 or Brca2 sustain a wide range of carcinoma and mammary epithelium deleted for Brca1 or Brca2 is highly susceptible to mammary tumorigenesis. Mammary (and other) tumors occur at long latency as compared to oncogene-induced mouse tumors. p53 deficiency is highly cooperative with both Brca1 and Brca2 in promoting tumorigenesis. Analysis of Brca1-associated mammary tumors reveals significant similarities to BRCA1-associated breast cancer in regard to high tumor grade, hormone receptor negativity, a high incidence of p53 mutations and genetic instability.	Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Moynahan, ME (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.	moynaham@mskcc.org		Moynahan, Mary Ellen/0000-0002-0167-1020				Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Basham VM, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr419; Begg CB, 2002, J NATL CANCER I, V94, P1221; Bennett LM, 2000, MOL CARCINOGEN, V28, P174, DOI 10.1002/1098-2744(200007)28:3<174::AID-MC6>3.0.CO;2-C; Bennett LM, 2001, TOXICOL PATHOL, V29, P117, DOI 10.1080/019262301301418928; Bennett LM, 2000, CANCER RES, V60, P3461; Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Brose MS, 2002, J NATL CANCER I, V94, P1365, DOI 10.1093/jnci/94.18.1365; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; Cressman VL, 1999, CELL GROWTH DIFFER, V10, P1; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; Deng CX, 2001, SEMIN CANCER BIOL, V11, P387, DOI 10.1006/scbi.2001.0394; EASTON DF, 1993, AM J HUM GENET, V52, P678; Frank TS, 2002, J CLIN ONCOL, V20, P1480, DOI 10.1200/JCO.20.6.1480; Friedman LS, 1998, CANCER RES, V58, P1338; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Greenblatt MS, 2001, CANCER RES, V61, P4092; Gruber SB, 2002, J NATL CANCER I, V94, P1344; Hakem R, 2001, ANNU REV GENET, V35, P209, DOI 10.1146/annurev.genet.35.102401.090432; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Hohenstein P, 2001, ONCOGENE, V20, P2544, DOI 10.1038/sj.onc.1204363; Janocko LE, 2001, CYTOMETRY, V46, P136, DOI 10.1002/cyto.1098; Jazaeri AA, 2002, JNCI-J NATL CANCER I, V94, P990, DOI 10.1093/jnci/94.13.990; Jones C, 2001, BRIT J CANCER, V85, P422, DOI 10.1054/bjoc.2001.1869; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Karabinis ME, 2001, CARCINOGENESIS, V22, P343, DOI 10.1093/carcin/22.2.343; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Levy-Lahad E, 2001, P NATL ACAD SCI USA, V98, P3232, DOI 10.1073/pnas.051624098; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Ludwig T, 2001, ONCOGENE, V20, P3937, DOI 10.1038/sj.onc.1204512; Ludwig T, 2001, GENE DEV, V15, P1188, DOI 10.1101/gad.879201; MacLachlan TK, 2002, MOL CELL BIOL, V22, P4280, DOI 10.1128/MCB.22.12.4280-4292.2002; Mak TW, 2000, NAT IMMUNOL, V1, P77, DOI 10.1038/76950; McAllister KA, 2002, CANCER RES, V62, P990; Medina D, 2002, ENVIRON MOL MUTAGEN, V39, P178, DOI 10.1002/em.10064; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 2002, CANCER BIOL THER, V1, P187, DOI 10.4161/cbt.66; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Moynahan ME, 2001, CANCER RES, V61, P4842; Phillips KA, 2000, J CLIN ONCOL, V18, p107S; Risch HA, 2001, AM J HUM GENET, V68, P700, DOI 10.1086/318787; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Seidman AD, 2001, J CLIN ONCOL, V19, P2587, DOI 10.1200/JCO.2001.19.10.2587; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Shin SJ, 2002, AM J SURG PATHOL, V26, P413, DOI 10.1097/00000478-200204000-00002; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Thompson D, 2002, JNCI-J NATL CANCER I, V94, P1358, DOI 10.1093/jnci/94.18.1358; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Turner BC, 2002, CANCER RES, V62, P4054; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Tutt ANJ, 2002, EMBO REP, V3, P255, DOI 10.1093/embo-reports/kvf037; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang WW, 2001, CANCER EPIDEM BIOMAR, V10, P955; Weaver Z, 2002, ONCOGENE, V21, P5097, DOI 10.1038/sj.onc.1205636; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Yu VPCC, 2000, GENE DEV, V14, P1400	77	84	84	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2002	21	58					8994	9007		10.1038/sj.onc.1206177	http://dx.doi.org/10.1038/sj.onc.1206177			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	626TP	12483515				2022-12-17	WOS:000179889500010
J	Davezac, N; Baldin, W; Blot, J; Ducommun, B; Tassan, JP				Davezac, N; Baldin, W; Blot, J; Ducommun, B; Tassan, JP			Human pEg3 kinase associates with and phosphorylates CDC25B phosphatase: a potential role for pEg3 in cell cycle regulation	ONCOGENE			English	Article						cell cycle; CDC25B; pEg3; kinase; human cells	MITOTIC INDUCER; HELA-CELLS; MITOSIS; LOCALIZATION; TYROSINE; HOMOLOG; 14-3-3-PROTEINS; THREONINE-14; ACTIVATION; TRANSITION	The pEg3 protein is a member of the evolutionarily conserved KIN1/PAR-1/MARK kinase family which is involved in cell polarity and microtubule dynamics. In Xenopus, pEg3 has been shown to be a cell cycle dependent kinase whose activity increases to a maximum level during mitosis of the first embryonic cell division. CDC25B is one of the three CDC25 phosphatase genes identified in human. It is thought to regulate the G2/M progression by dephosphorylating and activating the CDK/cyclin complexes. In the present study we show that the human pEg3 kinase is able to specifically phosphorylate CDC25B in vitro. One phosphorylation site was identified and corresponded to serine 323. This residue is equivalent to serine 216 in human CDC25C which plays an important role in the regulation of phosphatase during the cell cycle and at the G2 checkpoint. pEg3 is also able to specifically associate with CDC25B in vitro and in vivo. We show that the ectopic expression of active pEg3 in human U2OS cells induces an accumulation of cells in G2. This effect is counteracted by overexpression of CDC25B. Taken together these results suggest that pEg3 is a potential regulator of the G2/M progression and may act antagonistically to the CDC25B phosphatase.	Univ Rennes 1, IFR 97, CNRS, UMR 6061, F-35043 Rennes, France; Univ Toulouse 3, CNRS, UMR 5088, LBCMCP, F-31062 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Universite de Rennes 1; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Tassan, JP (corresponding author), Univ Rennes 1, IFR 97, CNRS, UMR 6061, 2 Ave Professeur Leon Bernard,CS34317, F-35043 Rennes, France.		BALDIN, Véronique/Y-8397-2019; DUCOMMUN, Bernard/B-3208-2008	BALDIN, Véronique/0000-0001-8523-0494; DUCOMMUN, Bernard/0000-0002-7126-8368				Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Blot J, 2002, DEV BIOL, V241, P327, DOI 10.1006/dbio.2001.0525; Cans C, 1999, ANTICANCER RES, V19, P1241; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Davezac N, 2000, ONCOGENE, V19, P2179, DOI 10.1038/sj.onc.1203545; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Escalas N, 2000, EXP CELL RES, V257, P206, DOI 10.1006/excr.2000.4878; Forrest A, 2001, ONCOGENE, V20, P4393, DOI 10.1038/sj.onc.1204574; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Lammer C, 1998, J CELL SCI, V111, P2445; LEVIN DE, 1990, P NATL ACAD SCI USA, V87, P8272, DOI 10.1073/pnas.87.21.8272; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; Mils V, 2000, ONCOGENE, V19, P1257, DOI 10.1038/sj.onc.1203419; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; NAGATA A, 1991, NEW BIOL, V3, P959; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rice RL, 1997, BIOCHEMISTRY-US, V36, P15965, DOI 10.1021/bi971338h; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Woo ES, 1999, ONCOGENE, V18, P2770, DOI 10.1038/sj.onc.1202614; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174	38	84	97	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7630	7641		10.1038/sj.onc.1205870	http://dx.doi.org/10.1038/sj.onc.1205870			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400006				2022-12-17	WOS:000178756200003
J	Lin, J; Tang, H; Jin, X; Jia, G; Hsieh, JT				Lin, J; Tang, H; Jin, X; Jia, G; Hsieh, JT			p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3	ONCOGENE			English	Article						p-53; Stat3; prostate cancer; apoptosis	WILD-TYPE P53; EPIDERMAL-GROWTH-FACTOR; SIGNAL TRANSDUCER; SUPPRESSES GROWTH; TUMOR-SUPPRESSOR; INDUCED APOPTOSIS; GENE-THERAPY; MUTANT P53; ACTIVATION; CARCINOMA	Constitutive activation of the signal transducer and activator of transcription 3 (Stat3) and mutation of the p53 are both commonly detected in human prostate cancer cells. We sought to investigate whether there is functional regulation of Stat3 by wild-type (wt) p53. Our results demonstrate that expression of wt p53 but not mutant p53 significantly reduced tyrosine phosphorylation of Stat3 and inhibited Stat3 DNA binding activity in both DU145 and Tsu prostate cancer cell lines that express constitutively active Stat3. Expression of the p53 downstream target, p21(WAF-1), did not have any inhibitory effect on Stat3 phosphorylation. Wt p53 but not p21(WAF-1) induced dramatic apoptosis in these prostate cancer cells. Expression of wt p53 did not cause a reduction of phosphorylation-independent Stat3 protein and reduction of phosphorylation of three unrelated protein kinases, ERK1, ERK2 (ERK1/2), and AKT. Interestingly, p53-dependent apoptosis occurred in the presence of high levels of phosphorylated AKT and ERK1/2 in both DU145 and Tsu prostate cancer cells. Further, we evaluated a series of established human prostate, breast, and ovarian cancer cell lines and found that all cancer cell lines expressing constitutively active Stat3, only harbor mutated or deleted p53. One implication of these results is that the anti-proliferative activities of p53 may not be compatible with the constitutive Stat3 signal in cancer cells.	Univ Michigan, Ctr Comprehens Canc, Dept Obstet & Gynecol, Div Gynecol Oncol, Ann Arbor, MI 48109 USA; Huang Si Aesthet Plast Surg Hosp, Beijing, Peoples R China; Univ Texas, SW Med Ctr, Dept Urol, Dallas, TX USA	University of Michigan System; University of Michigan; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lin, J (corresponding author), Univ Michigan, Ctr Comprehens Canc, Dept Obstet & Gynecol, Div Gynecol Oncol, Ann Arbor, MI 48109 USA.	linjia@mich.edu	Tang, Hua/K-4948-2016; Lin, Jiayuh/E-3515-2011	Tang, Hua/0000-0002-6685-6165; 				BARTEK J, 1990, ONCOGENE, V5, P893; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELSTNER E, 1995, CANCER RES, V55, P2822; Fritsche M, 1998, MOL CELL ENDOCRINOL, V143, P143, DOI 10.1016/S0303-7207(98)00140-3; Funamoto M, 2000, J BIOL CHEM, V275, P10561, DOI 10.1074/jbc.275.14.10561; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; GarciaOlivares A, 1997, ENVIRONMETRICS, V8, P1, DOI 10.1002/(SICI)1099-095X(199701)8:1<1::AID-ENV230>3.3.CO;2-2; Hall MC, 2000, J UROLOGY, V163, P1033, DOI 10.1016/S0022-5347(05)67877-9; Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931; ISAACS WB, 1991, CANCER RES, V51, P4716; Jacobberger JW, 1999, CYTOMETRY, V38, P201, DOI 10.1002/(SICI)1097-0320(19991015)38:5<201::AID-CYTO2>3.0.CO;2-F; JOVE R, 2001, 92 AACR ANN M; Katayose D, 1995, CLIN CANCER RES, V1, P889; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lin JY, 2000, CANCER RES, V60, P5895; Lin JY, 2002, CANCER RES, V62, P376; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Meyers FJ, 1998, CANCER, V83, P2534, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2534::AID-CNCR19>3.3.CO;2-M; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; NAVONE NM, 1993, J NATL CANCER I, V85, P1657, DOI 10.1093/jnci/85.20.1657; Ni Z, 2000, CANCER RES, V60, P1225; Niu GL, 1999, CANCER RES, V59, P5059; Niu GL, 2001, CANCER RES, V61, P3276; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rayanade RJ, 1998, J IMMUNOL, V161, P325; Sartor CI, 1997, CANCER RES, V57, P978; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Tagliaferri P, 1996, CLIN CANCER RES, V2, P207; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAGINUMA Y, 1992, CANCER RES, V52, P4196; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	42	84	87	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3082	3088		10.1038/sj.onc.1205426	http://dx.doi.org/10.1038/sj.onc.1205426			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082540				2022-12-17	WOS:000175262700017
J	Gasco, M; Sullivan, A; Repellin, C; Brooks, L; Farrell, PJ; Tidy, JA; Dunne, B; Gusterson, B; Evans, DJ; Crook, T				Gasco, M; Sullivan, A; Repellin, C; Brooks, L; Farrell, PJ; Tidy, JA; Dunne, B; Gusterson, B; Evans, DJ; Crook, T			Coincident inactivation of 14-3-3 sigma and p16(INK4a) is an early event in vulval squamous neoplasia	ONCOGENE			English	Article						14-3-3 sigma; p16(INK4a); vulval cancer; CpG methylation	PRIMARY HUMAN KERATINOCYTES; HUMAN-PAPILLOMAVIRUS; INTRAEPITHELIAL NEOPLASIA; 5'-CPG ISLAND; CPG ISLANDS; CARCINOMA; GENE; HYPERMETHYLATION; CLONING; CANCER	The structure and expression of 14-3-3 sigma(sigma) was analysed in squamous carcinomas (SCC) of the vulva and in the vulval pre-malignant lesion vulval intraepithetial neoplasia (VIN). Sequence analysis of the sigma coding region did not detect mutations in any case of SCC or VIN III and loss of heterozygosity (LOH) occurred in only 2 out of 27 informative cases. In contrast to the absence of genetic change, methylation-specific PCR (MSP) analysis revealed dense CpG methylation within the a gene in approximately 60% of cases of vulval SCC, but methylation was not detected in matched, normal epithelial tissue. Methylation was associated in all cases with reduced or absent expression of a mRNA. There was no correlation between sigma methylation and HPV or p53 status. Analysis of pre-malignant vulval intraepithelial neoplasia (VIN) revealed that sigma methylation was detectable early in neoplastic development. Coincident methylation, accompanied by loss of expression, of sigma and p16(INK4a) was commonly detected in both SCC and VIN 111, suggesting that epigenetic silencing of these two genes is an early and important event in vulval neoplasia.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Ludwig Inst Canc Res, London W2 1PG, England; Azienda Osped S Croce & Carle, UO Oncol Med, I-12100 Cuneo, Italy; Univ Sheffield, No Gen Hosp, Dept Gynaecol Oncol, Sheffield S5 7AU, S Yorkshire, England; Univ Glasgow, Western Infirm, Dept Pathol, Glasgow G11 6NT, Lanark, Scotland; Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Histopathol, London W2 1PG, England	Imperial College London; Ludwig Institute for Cancer Research; Northern General Hospital; University of Sheffield; University of Glasgow; Imperial College London	Crook, T (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Ludwig Inst Canc Res, St Marys Campus,Norfolk Pl, London W2 1PG, England.		gusterson, barry a/D-3752-2009	Farrell, Paul/0000-0002-6754-9351				Basta A, 1999, EUR J GYNAECOL ONCOL, V20, P111; Brooks LA, 2000, CANCER RES, V60, P6875; CRUM CP, 1992, OBSTET GYNECOL, V79, P448, DOI 10.1097/00006250-199203000-00025; Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117; Dhar S, 2000, MOL CELL BIOL, V20, P7764, DOI 10.1128/MCB.20.20.7764-7772.2000; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GREER CE, 1991, AM J CLIN PATHOL, V95, P117, DOI 10.1093/ajcp/95.2.117; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898; Jones RW, 2000, OBSTET GYNECOL, V96, P470, DOI 10.1016/S0029-7844(00)00949-2; JONES RW, 1994, OBSTET GYNECOL, V84, P741; Kagie MJ, 1997, GYNECOL ONCOL, V67, P178, DOI 10.1006/gyno.1997.4834; LEE YY, 1994, ONCOGENE, V9, P1655; LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346; Munro J, 1999, CANCER RES, V59, P2516; O'Nions J, 2001, BRIT J CANCER, V85, P1551, DOI 10.1054/bjoc.2001.2138; Pinto AP, 1999, AM J PATHOL, V154, P1009, DOI 10.1016/S0002-9440(10)65353-9; PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507; RESNICK RM, 1990, JNCI-J NATL CANCER I, V82, P1477, DOI 10.1093/jnci/82.18.1477; SMITS HL, 1992, J GEN VIROL, V73, P3263, DOI 10.1099/0022-1317-73-12-3263; Suzuki H, 2000, CANCER RES, V60, P4353; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; Vellucci VF, 1995, GENE, V166, P213, DOI 10.1016/0378-1119(95)00543-9	26	84	87	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2002	21	12					1876	1881		10.1038/sj.onc.1205256	http://dx.doi.org/10.1038/sj.onc.1205256			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896620				2022-12-17	WOS:000174284500010
J	Dajee, M; Tarutani, M; Deng, H; Cai, T; Khavari, PA				Dajee, M; Tarutani, M; Deng, H; Cai, T; Khavari, PA			Epidermal Ras blockade demonstrates spatially localized Ras promotion of proliferation and inhibition of differentiation	ONCOGENE			English	Article						epithelium; growth control; Ras; differentiation; skin	CELL-CYCLE ARREST; H-RAS; ONCOGENIC RAS; N-RAS; MONOCLONAL-ANTIBODIES; TRANSGENIC MICE; GENE-TRANSFER; STEM-CELLS; EXPRESSION; SKIN	While important in carcinogenesis, the role of Ras in normal self-renewing tissues such as epidermis is unclear. To address this, we altered Ras function in undifferentiated and differentiating epidermal layers. Ras blockade within undifferentiated basal epidermal cells leads to decreased integrin expression, diminished growth capacity and induction of differentiation. Ras blockade in post-mitotic suprabasal epidermis exerts no effect. In contrast, regulated Ras and Raf activation inhibits differentiation. These findings indicate that spatially restricted Ras/Raf signaling divides epidermis into an undifferentiated proliferative compartment and a differentiating post-mitotic compartment and suggest a new role for Ras in tissue homeostasis.	VA Palo Alto Healthcare Syst, Menlo Pk, CA 94025 USA; Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Khavari, PA (corresponding author), 269 Campus Dr,Room 2145, Stanford, CA 94305 USA.	khavari@CMGM.stanford.edu			NIAMS NIH HHS [AR43799, AR45192] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043799, R01AR045192, R29AR043799] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; Brown K, 1998, CURR BIOL, V8, P516, DOI 10.1016/S0960-9822(98)70203-9; Choate KA, 1996, HUM GENE THER, V7, P2247, DOI 10.1089/hum.1996.7.18-2247; Choate KA, 1996, NAT MED, V2, P1263, DOI 10.1038/nm1196-1263; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; DALE BA, 1987, J INVEST DERMATOL, V88, P306, DOI 10.1111/1523-1747.ep12466185; Deng H, 1998, BIOTECHNIQUES, V25, P274, DOI 10.2144/98252gt02; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DLUGOSZ AA, 1994, CANCER RES, V54, P6413; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; Ewen M E, 2000, Prog Cell Cycle Res, V4, P1; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Ferbeyre G, 2000, GENE DEV, V14, P2015; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; GREENHALGH DA, 1993, CANCER RES, V53, P5071; GREENHALGH DA, 1993, MOL CARCINOGEN, V7, P99, DOI 10.1002/mc.2940070208; Haase I, 2001, J CLIN INVEST, V108, P527, DOI 10.1172/JCI200112153; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Halfar K, 2001, DEVELOPMENT, V128, P1687; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; IVANYI D, 1989, J PATHOL, V159, P7, DOI 10.1002/path.1711590105; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; KONIECZNY SF, 1989, ONCOGENE, V4, P473; KOZMA L, 1993, P NATL ACAD SCI USA, V90, P4460, DOI 10.1073/pnas.90.10.4460; Li A, 1998, P NATL ACAD SCI USA, V95, P3902, DOI 10.1073/pnas.95.7.3902; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; Marshall CJ, 1999, BIOCHEM SOC T, V27, P363, DOI 10.1042/bst0270363; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Robbins PB, 2001, P NATL ACAD SCI USA, V98, P5193, DOI 10.1073/pnas.091484998; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Roper E, 2001, EMBO REP, V2, P145, DOI 10.1093/embo-reports/kve020; Ruiz-Hidalgo MJ, 1999, INT J ONCOL, V14, P777; Schmidt M, 2000, J BIOL CHEM, V275, P41011, DOI 10.1074/jbc.M003716200; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shi B, 2000, BIOCHEM CELL BIOL, V78, P469, DOI 10.1139/bcb-78-4-469; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Stewart S, 2000, J BIOL CHEM, V275, P8854, DOI 10.1074/jbc.275.12.8854; STOCKSCHLADER MAR, 1994, GENE THER, V1, P317; Takahashi H, 2001, J BIOL CHEM, V276, P36632, DOI 10.1074/jbc.M102021200; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; Watt FM, 1998, PHILOS T R SOC B, V353, P831, DOI 10.1098/rstb.1998.0247; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YUSPA SH, 1983, CANCER RES, V43, P6021; YUSPA SH, 1994, CANCER RES, V54, P1178; Zhu AJ, 1999, P NATL ACAD SCI USA, V96, P6728, DOI 10.1073/pnas.96.12.6728	59	84	84	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1527	1538		10.1038/sj.onc.1205287	http://dx.doi.org/10.1038/sj.onc.1205287			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896581				2022-12-17	WOS:000173956800008
J	Klein, G; Powers, A; Croce, C				Klein, G; Powers, A; Croce, C			Association of SV40 with human tumors	ONCOGENE			English	Article						SV40; mesothelioma; brain tumors; bone tumors	MALIGNANT PLEURAL MESOTHELIOMA; HUMAN BRAIN-TUMORS; T-ANTIGEN; SV40-LIKE SEQUENCES; SIMIAN-VIRUS-40; EXPRESSION; DNA; CELLS; GENE; MEDULLOBLASTOMAS	In 1994, PCR and protein studies suggested that SV40 DNA sequences and proteins were present in 29/48 (60%) USA human mesothelioma samples. Sequence analysis confirmed that the sequences were homologous to SV40. One year later, SV40 was also found in 5/9 human mesotheliomas, and in 1996 SV40 was also reported to be present in 1/3 of the tumor specimens examined. These reports, in combination with an earlier study in 1992 which had detected SV40 in human brain tumors, raised concerns that SV40 was associated with certain types of human tumors, specifically mesothelioma, bone, and brain tumors. These findings raised concerns, because these tumor types are the same malignancies that had been observed in animals injected with SV40. However, a study in 1996 and a presentation made at the International Mesothelioma Interest Group, IMIG in 1997 failed to detect SV40 in mesotheliomas, suggesting the possibility that laboratory artifacts, such as PCR contamination, had caused the previous positive findings. In 1997, the FDA, the NIH, and the CDC organized an international conference in Bethesda to review the literature and to address the possibility that SV40 was present in, and was possibly the cause of, some human tumors. The results of that conference were reported the same year in a meeting review in Oneogene by Carbone and colleagues. Briefly, the consensus was that before accepting the possibility that SV40 was present in human tumors, a multilaboratory study needed to be conducted. It was recommended that a blinded multi-laboratory study be directed by an independent scientist not previously associated with the controversial reports of SV40 in human specimens. It was also recommended that this study include laboratories that had reported positive findings as well as laboratories that had failed to detect SV40 in human specimens. Since 1997, about 30 independent reports have been published on this topic, including the multi-laboratory study. Evidence in favor and against a possible association of SV40 with human cancer was reviewed at an international concensus meeting at the University of Chicago on 20, 21 April 2001, entitled 'Malignant Mesothelioma: Therapeutic Options and the Role of SV40, 2001'. The main focus was the association of SV40 with mesothelioma and other human tumors. At the end of the meeting, a panel discussion, which included independent experts who had not published on this topic, critically reviewed the evidence presented at the meeting. The results of the meeting and of the final panel discussion are outlined below.	Loyola Univ Chicago, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA; Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Thomas Jefferson Univ, Sch Med, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Loyola University Chicago; Karolinska Institutet; Jefferson University	Powers, A (corresponding author), Loyola Univ Chicago, Cardinal Bernardin Canc Ctr, Room 205,2160 S 1st Ave, Maywood, IL 60153 USA.	apower@lumc.edu	Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Bocchetta M, 2000, P NATL ACAD SCI USA, V97, P10214, DOI 10.1073/pnas.170207097; Cacciotti P, 2001, P NATL ACAD SCI USA, V98, P12032, DOI 10.1073/pnas.211026798; Carbone M, 1996, ONCOGENE, V13, P527; Carbone M, 1997, ONCOGENE, V15, P1877, DOI 10.1038/sj.onc.1201375; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; CARBONE M, 1991, MOL BASIS HUMAN CANC, P191; CICALA C, 1993, AM J PATHOL, V142, P1524; Cristaudo A., 1995, Journal of Environmental Pathology Toxicology and Oncology, V14, P29; Cristaudo A, 2000, ANTICANCER RES, V20, P895; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; DIAMANDOPOULOUS GT, 1972, SCIENCE, V40, P73; EDDY BE, 1961, P SOC EXP BIOL MED, V107, P65; Emri S, 2000, ANTICANCER RES, V20, P891; Fisher SG, 1999, ANTICANCER RES, V19, P2173; Gamberi G, 2000, GENE CHROMOSOME CANC, V28, P23, DOI 10.1002/(SICI)1098-2264(200005)28:1<23::AID-GCC3>3.0.CO;2-W; GEISSLER E, 1990, PROG MED VIROL, V37, P211; GERBER P, 1962, VIROLOGY, V18, P582, DOI 10.1016/0042-6822(62)90061-2; HEINONEN OP, 1973, INT J EPIDEMIOL, V2, P229, DOI 10.1093/ije/2.3.229; Hirvonen A, 1999, MOL CARCINOGEN, V26, P93, DOI 10.1002/(SICI)1098-2744(199910)26:2<93::AID-MC4>3.3.CO;2-Q; Imperiale MJ, 2001, SEMIN CANCER BIOL, V11, P81, DOI 10.1006/scbi.2000.0349; INNIS MD, 1968, NATURE, V219, P972, DOI 10.1038/219972a0; Jasani B, 2001, SEMIN CANCER BIOL, V11, P49, DOI 10.1006/scbi.2000.0346; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; Lednicky JA, 1997, INT J CANCER, V72, P791; MALKIN D, 2001, IN PRESS ONCOGENE; Mayall FG, 1999, J CLIN PATHOL, V52, P291, DOI 10.1136/jcp.52.4.291; MORTIMER EA, 1981, NEW ENGL J MED, V305, P1517, DOI 10.1056/NEJM198112173052507; Pilatte Y, 2000, AM J RESP CELL MOL, V23, P788, DOI 10.1165/ajrcmb.23.6.4251; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Procopio A, 2000, GENE CHROMOSOME CANC, V29, P173, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1019>3.0.CO;2-B; Ramael M, 1999, EUR RESPIR J, V14, P1381, DOI 10.1183/09031936.99.14613819; Roushdy-Hammady I, 2001, LANCET, V357, P444, DOI 10.1016/S0140-6736(00)04013-7; Rundell K, 2001, SEMIN CANCER BIOL, V11, P5, DOI 10.1006/scbi.2000.0341; Schrump DS, 2001, SEMIN CANCER BIOL, V11, P73, DOI 10.1006/scbi.2000.0348; Shivapurkar N, 2000, J CELL BIOCHEM, V76, P181; Strickler HD, 1996, CANCER EPIDEM BIOMAR, V5, P473; Strickler HD, 2001, CANCER EPIDEM BIOMAR, V10, P523; Testa JR, 1998, CANCER RES, V58, P4505; Testa JR, 2001, SEMIN CANCER BIOL, V11, P31, DOI 10.1006/scbi.2000.0344; Toyooka S, 2001, CANCER RES, V61, P5727; Waheed I, 1999, CANCER RES, V59, P6068; Weggen S, 2000, BRAIN PATHOL, V10, P85; Yamamoto H, 2000, BRIT J CANCER, V82, P1677; Zhen HN, 1999, CANCER, V86, P2124, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2124::AID-CNCR34>3.0.CO;2-D	45	84	85	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1141	1149		10.1038/sj.onc.1205173	http://dx.doi.org/10.1038/sj.onc.1205173			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850833	Green Submitted			2022-12-17	WOS:000173729400001
J	Lin, JL; Chen, HC; Fang, HI; Robinson, D; Kung, HJ; Shih, HM				Lin, JL; Chen, HC; Fang, HI; Robinson, D; Kung, HJ; Shih, HM			MST4, a new Ste20-related kinase that mediates cell growth and transformation via modulating ERK pathway	ONCOGENE			English	Article						Ste20 kinase; cell transformation; kinase signaling	N-TERMINAL KINASE; STE20-LIKE PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; SIGNALING COMPONENTS; ADAPTER PROTEINS; CARCINOMA-CELLS; FAMILY MEMBERS; OXIDANT STRESS; ACTIVATION; APOPTOSIS	In this study, we report the cloning and characterization of a novel human Ste20-related kinase that we designated MST4 (accession number AF231012). The 416 amino acid full-length MST4 contains an aminoterminal kinase domain, which is highly homologous to MST3 and SOK, and a unique carboxy-terminal domain. Northern blot analysis indicated that MST4 is highly expressed in placenta, thymus, and peripheral blood leukocytes. Wild-type but not kinase-dead MST4 can phosphorylate myelin basic protein in an in vitro kinase assay. MST4 specifically activates ERK but not JNK or p38 MAPK in transient transfected cells or in stable cell lines. Overexpression of dominant negative MEK1 or treatment with PD98059 abolishes MST4-induced ERK activity, whereas dominant-negative Ras or c-Raf-1 mutants failed to do so, indicating MST4 activates MEK1/ERK via a Ras/Raf-1 independent pathway. HeLa and Phoenix cell lines overexpressing wild-type, but not kinase-dead, MST4 exhibit increased growth rate and form aggressive soft-agar colonies. These phenotypes can be inhibited by PD98059. These results provide the first evidence that MST4 is biologically active in the activation of MEK/ERK pathway and in mediating cell growth and transformation.	Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 11529, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA	National Health Research Institutes - Taiwan; National Defense Medical Center; University of California System; University of California Davis	Shih, HM (corresponding author), Natl Hlth Res Inst, Div Mol & Genom Med, 128,Sec2,Yen Chiu Yuan RD, Taipei 11529, Taiwan.	shihh@nhri.org.tw	Kung, Hsing-Jien/C-7651-2013; Shih, Hsiu-Ming/S-7023-2018					ARNOLD R, 2001, J BIOL CHEM, V29, P29; Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; Blalock WL, 2000, ONCOGENE, V19, P526, DOI 10.1038/sj.onc.1203337; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BRUNET A, 1994, ONCOGENE, V9, P3379; Chen HC, 1998, J BIOMED SCI, V5, P86, DOI 10.1007/BF02258361; Chen Y. R., 1999, GENE THER MOL BIOL, V4, P83; Chen YR, 1999, ONCOGENE, V18, P7370, DOI 10.1038/sj.onc.1203116; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; Dan I, 2000, FEBS LETT, V469, P19, DOI 10.1016/S0014-5793(00)01247-3; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; Endo J, 2000, FEBS LETT, V468, P234, DOI 10.1016/S0014-5793(00)01219-9; Feng YY, 1998, CURR BIOL, V8, P267, DOI 10.1016/S0960-9822(98)70108-3; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Fu CA, 1999, J BIOL CHEM, V274, P30729, DOI 10.1074/jbc.274.43.30729; Gilbreth M, 1996, P NATL ACAD SCI USA, V93, P13802, DOI 10.1073/pnas.93.24.13802; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; GRAVES JD, 2001, J BIOL CHEM, V13, P13; Greulich H, 1998, J BIOL CHEM, V273, P13280, DOI 10.1074/jbc.273.21.13280; Greulich H, 1996, ONCOGENE, V12, P1689; HANKS SK, 1991, METHOD ENZYMOL, V200, P525; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; Johnston AM, 2000, ONCOGENE, V19, P4290, DOI 10.1038/sj.onc.1203784; Kakeya H, 1998, CANCER RES, V58, P4888; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Leberer E, 1996, P NATL ACAD SCI USA, V93, P13217, DOI 10.1073/pnas.93.23.13217; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lee BN, 1999, P NATL ACAD SCI USA, V96, P12679, DOI 10.1073/pnas.96.22.12679; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; LEE KK, 2001, J BIOL CHEM, V7, P7; LING P, 2001, J BIOL CHEM, V13, P13; Ljungdahl S, 1998, CELL GROWTH DIFFER, V9, P565; Moore TM, 2000, J BIOL CHEM, V275, P4311, DOI 10.1074/jbc.275.6.4311; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; Nakano K, 2000, J BIOL CHEM, V275, P20533, DOI 10.1074/jbc.M001009200; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Osada S, 1997, FEBS LETT, V404, P227, DOI 10.1016/S0014-5793(97)00139-7; Plattner R, 1999, ONCOGENE, V18, P1807, DOI 10.1038/sj.onc.1202482; Pombo CM, 1997, J BIOL CHEM, V272, P29372, DOI 10.1074/jbc.272.46.29372; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; QIAN Z, 2001, J BIOL CHEM, V16, P16; Raitt DC, 2000, EMBO J, V19, P4623, DOI 10.1093/emboj/19.17.4623; Rimerman RA, 2000, J BIOL CHEM, V275, P14736, DOI 10.1074/jbc.M910241199; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sabourin LA, 1999, ONCOGENE, V18, P7566, DOI 10.1038/sj.onc.1203119; Schramek H, 1997, J BIOL CHEM, V272, P11426; Schrick K, 1997, GENETICS, V147, P19; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Shi CS, 2000, BLOOD, V95, P776, DOI 10.1182/blood.V95.3.776.003k23_776_782; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Tassi E, 1999, J BIOL CHEM, V274, P33287, DOI 10.1074/jbc.274.47.33287; Tsutsumi T, 2000, J BIOL CHEM, V275, P9157, DOI 10.1074/jbc.275.13.9157; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Verheijen MHG, 1999, J BIOL CHEM, V274, P1487, DOI 10.1074/jbc.274.3.1487; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yustein JT, 2000, ONCOGENE, V19, P710, DOI 10.1038/sj.onc.1203342; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133; Zhou TH, 2000, J BIOL CHEM, V275, P2513, DOI 10.1074/jbc.275.4.2513	65	84	87	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6559	6569		10.1038/sj.onc.1204818	http://dx.doi.org/10.1038/sj.onc.1204818			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641781				2022-12-17	WOS:000171404200009
J	Dunkern, TR; Fritz, G; Kaina, B				Dunkern, TR; Fritz, G; Kaina, B			Ultraviolet light-induced DNA damage triggers apoptosis in nucleotide excision repair-deficient cells via Bcl-2 decline and caspase-3/-8 activation	ONCOGENE			English	Article						apoptosis; UV light; Bcl-2; nucleotide excision repair; DNA-damage; caspases	DRUG-INDUCED APOPTOSIS; BREAST-CANCER CELLS; CD95 FAS/APO-1; MITOCHONDRIAL CONTROL; SIGNAL-TRANSDUCTION; MUTATION-INDUCTION; ALKYLATING-AGENTS; MOLECULAR-CLONING; MISMATCH REPAIR; LEUKEMIA-CELLS	Ultraviolet (UV) light is a potent mutagenic and genotoxic agent. Whereas DNA damage induced by UV light is known to be responsible for UV-induced genotoxicity, its role in triggering apoptosis is still unclear. We addressed this issue by comparing nucleotide excision repair (NER) deficient 27-1 and 43-3B Chinese hamster (CHO) cells with the corresponding wild-type and ERCC-1 complemented cells. It is shown that NER deficient cells are dramatically hypersensitive to UV-C induced apoptosis, indicating that DNA damage is the major stimulus for the apoptotic response. Apoptosis triggered by UV-C induced DNA damage is related to caspase- and proteosome-dependent degradation of Bcl-2 protein. The expression of other members of the Bcl-2 family such as Bax, Bcl-x(L) and Bak were not affected. Bcl-2 decline is causally involved in UV-C induced apoptosis since overexpression of Bcl-2 protected NER deficient cells against apoptosis. We also demonstrate that caspase-8, caspase-9 and caspase-3 are activated and PARP is cleaved in response to unrepaired UV-C induced DNA damage. Caspase-8 activation occurred independently of CD95 receptor activation since CD95R/ FasR and CD95L/FasL were not altered in expression, and transfection of transdominant negative FADD failed to block apoptosis. Overall, the data demonstrate that UV-C induced non-repaired DNA damage triggers apoptosis in NER deficient fibroblasts involving components of the intrinsic mitochondrial damage pathway.	Univ Mainz, Inst Toxicol, Div Appl Toxicol, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz	Kaina, B (corresponding author), Univ Mainz, Inst Toxicol, Div Appl Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.							Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Belka C, 1999, INT J RADIAT BIOL, V75, P1257, DOI 10.1080/095530099139412; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; CADET J, 1992, J PHOTOCH PHOTOBIO B, V15, P277, DOI 10.1016/1011-1344(92)85135-H; Canman CE, 1996, NATURE, V384, P213, DOI 10.1038/384213a0; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; COSSARIZZA A, 1994, EXP CELL RES, V214, P323, DOI 10.1006/excr.1994.1264; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Ferreira CG, 2000, CLIN CANCER RES, V6, P203; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HALDAR S, 1994, CANCER RES, V54, P2095; Hayashi T, 1998, MUTAT RES-DNA REPAIR, V407, P269, DOI 10.1016/S0921-8777(98)00013-5; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Hu T, 1999, MUTAT RES-FUND MOL M, V426, P51, DOI 10.1016/S0027-5107(99)00077-9; Ioannou YA, 1996, NUCLEIC ACIDS RES, V24, P992; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kaina B, 1997, MUTAT RES-FUND MOL M, V381, P227, DOI 10.1016/S0027-5107(97)00187-5; Kim DK, 2000, EXP CELL RES, V257, P82, DOI 10.1006/excr.2000.4868; Kim JW, 2000, J BIOL CHEM, V275, P8121, DOI 10.1074/jbc.275.11.8121; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; Kurokawa H, 1999, ONCOL REP, V6, P33; Lackinger D, 2000, MUTAT RES-FUND MOL M, V457, P113, DOI 10.1016/S0027-5107(00)00133-0; LARMINAT F, 1994, NUCLEIC ACIDS RES, V22, P3005, DOI 10.1093/nar/22.15.3005; Lee HY, 1997, GENE, V184, P177, DOI 10.1016/S0378-1119(96)00592-6; LEE KB, 1993, CARCINOGENESIS, V14, P2177, DOI 10.1093/carcin/14.10.2177; Lips J, 2001, CARCINOGENESIS, V22, P579, DOI 10.1093/carcin/22.4.579; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Mansukhani A, 2000, J CELL BIOL, V149, P1297, DOI 10.1083/jcb.149.6.1297; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Ochs K, 2000, CANCER RES, V60, P5815; Pizer ES, 1996, CANCER RES, V56, P745; REED JC, 1989, ONCOGENE RES, V4, P271; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Richardson DS, 1999, ADV EXP MED BIOL, V457, P259; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Schwarz T, 1998, J PHOTOCH PHOTOBIO B, V44, P91, DOI 10.1016/S1011-1344(98)00126-2; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; STEFANINI M, 1986, MUTAT RES, V174, P155, DOI 10.1016/0165-7992(86)90108-9; Tatsuta T, 1996, J IMMUNOL, V157, P3949; Tomicic MT, 2001, BIOCHEM BIOPH RES CO, V281, P404, DOI 10.1006/bbrc.2001.4367; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; WEEDA G, 1990, MOL CELL BIOL, V10, P2570, DOI 10.1128/MCB.10.6.2570; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; WESTERVELD A, 1984, NATURE, V310, P425, DOI 10.1038/310425a0; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; WOOD RD, 1982, MUTAT RES, V95, P505, DOI 10.1016/0027-5107(82)90281-0; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; YIN DX, 1995, CANCER RES, V55, P4922; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343	63	84	85	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2001	20	42					6026	6038		10.1038/sj.onc.1204754	http://dx.doi.org/10.1038/sj.onc.1204754			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593410				2022-12-17	WOS:000171056300010
J	Knight, MJ; Riffkin, CD; Muscat, AM; Ashley, DM; Hawkins, CJ				Knight, MJ; Riffkin, CD; Muscat, AM; Ashley, DM; Hawkins, CJ			Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells	ONCOGENE			English	Article						apoptosis; glioma; resistance; TRAIL; Fas; Bcl-2	INHIBITORY PROTEIN EXPRESSION; HUMAN-MELANOMA CELLS; MEDIATED APOPTOSIS; MALIGNANT GLIOMA; DECOY RECEPTOR; DEATH PATHWAY; LIGAND TRAIL; CASPASE-8; GENE; AMPLIFICATION	FasL and TNF-related apoptosis-inducing ligand (TRAIL) belong to a subgroup of the TNF superfamily which induce apoptosis by binding to their death domain containing receptors. In the present study we have utilized a panel of seven cell lines derived from human malignant gliomas to characterize molecular pathways through which FasL and TRAIL induce apoptosis in sensitive glioma cells and the mechanisms of resistance in cell lines which survive the death stimuli. Our findings indicate that FADD and Caspase-8 are essential for FasL and TRAIL mediated apoptosis in glioma cells. One sensitive cell line (D270) can be protected from FasL and TRAIL induced death by anti-apoptotic Bcl-2 family members while another (D645) cannot, implying that these lines may represent glioma examples of type II and type I cells respectively. For the first time we demonstrate resistance to FasL but not to TRAIL within the one glioma cell line. Furthermore, we report distinct mechanisms of resistance within different glioma lines, including downregulation of Caspase-8 in U373MG. Cycloheximide sensitized four of the resistant cell lines suggesting the presence of labile inhibitors. None of the known apoptosis inhibitors examined accounted for the observed resistance, suggesting novel inhibitors may exist in glioma cells.	Royal Childrens Hosp, Dept Haematol & Oncol, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia; Univ Melbourne, Royal Melbourne Hosp, Dept Surg, Parkville, Vic, Australia	Royal Children's Hospital Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; Royal Melbourne Hospital; University of Melbourne	Hawkins, CJ (corresponding author), Royal Childrens Hosp, Dept Haematol & Oncol, Flemington Rd, Parkville, Vic 3052, Australia.		Hawkins, Christine/B-8769-2011	Hawkins, Christine/0000-0001-8120-1071				Bai C, 2000, P NATL ACAD SCI USA, V97, P1230, DOI 10.1073/pnas.97.3.1230; BIGNER DD, 1981, J NEUROPATH EXP NEUR, V40, P201, DOI 10.1097/00005072-198105000-00001; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Coultas L, 2000, APOPTOSIS, V5, P491, DOI 10.1023/A:1009617727938; DELEEUW WJF, 1989, NUCLEIC ACIDS RES, V17, P10137, DOI 10.1093/nar/17.23.10137; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Griffith TS, 1998, J IMMUNOL, V161, P2833; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hao CH, 2001, CANCER RES, V61, P1162; Hawkins CJ, 1999, P NATL ACAD SCI USA, V96, P2885, DOI 10.1073/pnas.96.6.2885; Hawkins CJ, 1996, P NATL ACAD SCI USA, V93, P13786, DOI 10.1073/pnas.93.24.13786; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; Hopkins-Donaldson S, 2000, CANCER RES, V60, P4315; Hosli P, 1998, ANN ONCOL, V9, P589; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jenkins M, 2000, J BIOL CHEM, V275, P7988, DOI 10.1074/jbc.275.11.7988; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Keane MM, 1999, CANCER RES, V59, P734; Kim EJ, 2001, INT J ONCOL, V18, P187; Kim KH, 2000, CLIN CANCER RES, V6, P335; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kitsberg D, 1999, J NEUROSCI, V19, P8244; Leverkus M, 2000, CANCER RES, V60, P553; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Myc A, 1999, ENDOCRINOLOGY, V140, P5431, DOI 10.1210/en.140.11.5431; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Perlman H, 1999, J EXP MED, V190, P1679, DOI 10.1084/jem.190.11.1679; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Roth W, 1999, CELL MOL LIFE SCI, V56, P481, DOI 10.1007/s000180050447; Roth W, 2001, CANCER RES, V61, P2759; Sambrook J, 1989, MOL CLONING LAB MANU; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Shin MS, 1999, AM J PATHOL, V154, P1785, DOI 10.1016/S0002-9440(10)65434-X; Somia NV, 1999, P NATL ACAD SCI USA, V96, P12667, DOI 10.1073/pnas.96.22.12667; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Truneh A, 2000, J BIOL CHEM, V275, P23319, DOI 10.1074/jbc.M910438199; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Wrone-Smith T, 2001, EXP HEMATOL, V29, P572, DOI 10.1016/S0301-472X(01)00627-0; Wu M, 2000, J NEUROSCI RES, V61, P464, DOI 10.1002/1097-4547(20000815)61:4<464::AID-JNR14>3.3.CO;2-7; Yanagisawa J, 1997, J BIOL CHEM, V272, P8539, DOI 10.1074/jbc.272.13.8539; Yu KY, 1999, J BIOL CHEM, V274, P13733, DOI 10.1074/jbc.274.20.13733; Zhang XD, 2000, J IMMUNOL, V164, P3961, DOI 10.4049/jimmunol.164.8.3961; Zhang XD, 1999, CANCER RES, V59, P2747; Zhang XJ, 2000, BIOCHEM BIOPH RES CO, V277, P487, DOI 10.1006/bbrc.2000.3699; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	64	84	88	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5789	5798		10.1038/sj.onc.1204810	http://dx.doi.org/10.1038/sj.onc.1204810			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593384				2022-12-17	WOS:000171037200002
J	Takita, J; Yang, HW; Chen, YY; Hanada, R; Yamamoto, K; Teitz, T; Kidd, V; Hayashi, Y				Takita, J; Yang, HW; Chen, YY; Hanada, R; Yamamoto, K; Teitz, T; Kidd, V; Hayashi, Y			Allelic imbalance on chromosome 2q and alterations of the caspase 8 gene in neuroblastoma	ONCOGENE			English	Article						allelic imbalance; chromosome 2q; neuroblastoma; caspase 8; caspase 10	TUMOR-SUPPRESSOR GENES; CELL LUNG-CARCINOMA; N-MYC AMPLIFICATION; P16 CDKN2A GENE; P73 GENE; HETEROZYGOSITY; APOPTOSIS; EXPRESSION; DELETION; CANCER	We previously reported a high incidence of loss of heterozygosity (LOH) on chromosome 2q33 in neuroblastoma (NB), observed in various types of human cancers including lung cancer, head and neck cancer and follicular thyroid carcinoma. To better elucidate the role of chromosome 20 aberrations in NE, we examined common allelic imbalance (AI) regions on chromosome 20 in 82 NE patients using 10 polymorphic microsatellite markers. AI on 20 was detected in 26 (32%) of 82 NE cases. There was a distinct common AI region between the D2S115 and D2S307 markers on 2q33, The distance between these markers was about 2.0 cM, Recently, the caspase 8 and caspase 10 genes, both of which encode cystein protease, were mapped to chromosome 2q33, Since the common AI region on 2q33 includes the caspase 8 and caspase 10 genes, the alterations of these genes were examined further. Absent or reduced expression of caspase 8 and caspase 10 were found in 19 (70%) of 27 and two (7%) of 27 NE cell lines by reverse transcription-polymerase chain reaction, respectively. A missense mutation was detected at codon 96, GCT (Alanine) to GTT (Valine), of the caspase 8 gene in one of the NE cell lines lacking caspase 8 expression. Thirteen (68%) of 19 cell lines lacking caspase 8 expression displayed methylation of the CpG island of the caspase 8 gene, whereas only one (13%) of eight cell lines with caspase 8 expression showed caspase 8 methylation (P=0.031), Furthermore, there was significant association between Al at 2q33 and loss of caspase 8 expression (P=0.026), These results indicated that there was a tumor suppressor gene in the common AI region on chromosome 2q33 involved in the pathogenesis of a subset of NE. It is possible that the caspase 8 gene is one of the candidate tumor suppressor genes for NE and inactivation of this gene plays an important role in the tumorigenesis of NE through mainly its methylation.	Univ Tokyo, Grad Sch Med, Dept Pediat, Bunkyo Ku, Tokyo 1138655, Japan; Saitama Childrens Med Ctr, Div Hematol Oncol, Iwatsuki, Saitama 3390077, Japan; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38101 USA	University of Tokyo; Saitama Children's Medical Center; St Jude Children's Research Hospital	Hayashi, Y (corresponding author), Univ Tokyo, Grad Sch Med, Dept Pediat, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	hayashiy-tky@umin.ac.jp	Chen, Yuyan/V-7279-2019	Chen, Yuyan/0000-0002-2894-1430	NCI NIH HHS [2RD1 CA67938] Funding Source: Medline; PHS HHS [21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA067938, R01CA067938] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CEYNS V, 1998, GENE DEV, V12, P1551; Chen QY, 1998, NATURE, V392, P293, DOI 10.1038/32675; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; FERNANDESALNEMR.T, 1909, P NATL ACAD SCI USA, V93, P7464; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FONG CT, 1992, CANCER RES, V52, P1780; Fulda S, 1999, ONCOGENE, V18, P1479, DOI 10.1038/sj.onc.1202435; Grenet J, 1999, GENE, V226, P225, DOI 10.1016/S0378-1119(98)00565-4; Herman JG, 1996, CANCER RES, V56, P722; Inoue A, 1997, INT J CANCER, V72, P1070, DOI 10.1002/(SICI)1097-0215(19970917)72:6<1070::AID-IJC23>3.0.CO;2-7; Kaneko M, 1998, MED PEDIATR ONCOL, V31, P1, DOI 10.1002/(SICI)1096-911X(199807)31:1<1::AID-MPO1>3.0.CO;2-H; Kawano S, 1999, BLOOD, V94, P1113; KOHNO T, 1994, ONCOGENE, V9, P103; Kong XT, 1997, CANCER RES, V57, P3772; Kong XT, 1997, EUR J CANCER, V33, P1962, DOI 10.1016/S0959-8049(97)00209-8; Kukita Y, 1997, HUM MUTAT, V10, P400, DOI 10.1002/(SICI)1098-1004(1997)10:5<400::AID-HUMU11>3.3.CO;2-1; Lutz W, 1998, ONCOGENE, V17, P339, DOI 10.1038/sj.onc.1200201; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Muliokandov MR, 1996, CANCER RES, V56, P197; Nishizuka S, 1998, J PATHOL, V185, P38, DOI 10.1002/(SICI)1096-9896(199805)185:1<38::AID-PATH58>3.0.CO;2-T; Otsuka T, 1996, GENE CHROMOSOME CANC, V16, P113, DOI 10.1002/(SICI)1098-2264(199606)16:2<113::AID-GCC5>3.0.CO;2-2; Ransom DT, 1998, HEAD NECK-J SCI SPEC, V20, P404; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SAWAGUCHI S, 1990, CANCER, V66, P1879, DOI 10.1002/1097-0142(19901101)66:9<1879::AID-CNCR2820660905>3.0.CO;2-L; Schor NF, 1999, J NEURO-ONCOL, V41, P159, DOI 10.1023/A:1006171406740; SCHWAB M, 1993, SEMIN CANCER BIOL, V4, P13; Schwemmler W, 1996, ENDOCYT CELL RES, V11, P219; SHISEKI M, 1994, CANCER RES, V54, P5643; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; TAKITA J, 1995, ONCOGENE, V11, P1829; Takita J, 1997, CANCER RES, V57, P907; Takita J, 1998, ONCOGENE, V17, P3137, DOI 10.1038/sj.onc.1202232; Takita J, 2000, EUR J CANCER, V36, P508, DOI 10.1016/S0959-8049(99)00342-1; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tung WS, 1997, GENE CHROMOSOME CANC, V19, P43, DOI 10.1002/(SICI)1098-2264(199705)19:1<43::AID-GCC7>3.0.CO;2-0; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Yang HW, 2000, INT J MOL MED, V5, P379; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488	45	84	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2001	20	32					4424	4432		10.1038/sj.onc.1204521	http://dx.doi.org/10.1038/sj.onc.1204521			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466626				2022-12-17	WOS:000169912600019
J	Richard, DE; Vouret-Craviari, V; Pouyssegur, J				Richard, DE; Vouret-Craviari, V; Pouyssegur, J			Angiogenesis and G-protein-coupled receptors: signals that bridge the gap	ONCOGENE			English	Article						angiogenesis; thrombin; angiotensin II; hypoxia inducible factor 1; p42/p44; MAP kinase; ROS	ENDOTHELIAL GROWTH-FACTOR; INDUCIBLE FACTOR 1-ALPHA; SMOOTH-MUSCLE; THROMBIN RECEPTOR; ANGIOTENSIN-II; ACTIN CYTOSKELETON; TUMOR ANGIOGENESIS; FACTOR EXPRESSION; TYROSINE KINASE; CELL-ACTIVATION	Angiogenesis is a mechanism that has repercussions in a number of physiological and pathological situations. Vascular endothelial growth factor and basic fibroblast growth factor have understandably received enormous research coverage for being the major mediators of new blood vessel growth, often overshadowing other agonist that also have strong angiogenic potential. We wish to put the spotlight on GPCR agonists that undoubtedly have their word to say on the subject of angiogenesis. In this short review, we will discuss our findings along with the work from other groups on the mechanisms by which GPCR agonists, like thrombin and angiotensin II, control a number of angiogenic signals. A complete understanding of these mechanisms could, by the design of new therapeutic strategies, have a strong impact in clinical oncology.	Ctr Antoine Lacassagne, Inst Signaling Dev Biol & Canc Res, CNRS, UMR 6543, F-06189 Nice, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	Pouyssegur, J (corresponding author), Ctr Antoine Lacassagne, Inst Signaling Dev Biol & Canc Res, CNRS, UMR 6543, 33 Ave Valombrose, F-06189 Nice, France.		Richard, Darren E./K-6760-2019	Richard, Darren/0000-0003-2690-0480				Bae GU, 1999, J BIOL CHEM, V274, P32596, DOI 10.1074/jbc.274.46.32596; BARSHAVIT R, 1990, CELL REGUL, V1, P453, DOI 10.1091/mbc.1.6.453; BARSHAVIT R, 1983, SCIENCE, V220, P728, DOI 10.1126/science.6836310; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Biggerstaff JP, 1999, CLIN EXP METASTAS, V17, P723, DOI 10.1023/A:1006763827882; Brar SS, 1999, J BIOL CHEM, V274, P20017, DOI 10.1074/jbc.274.28.20017; Browder T, 2000, J BIOL CHEM, V275, P1521, DOI 10.1074/jbc.275.3.1521; Brower V, 1999, NAT BIOTECHNOL, V17, P963, DOI 10.1038/13654; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CARNEY DH, 1992, THROMBIN STRUCTURE F, P351; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DuhamelClerin E, 1997, ARTERIOSCL THROM VAS, V17, P1931, DOI 10.1161/01.ATV.17.10.1931; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Feldser D, 1999, CANCER RES, V59, P3915; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gallacher B, 1997, ANN SAUDI MED, V17, P489, DOI 10.5144/0256-4947.1997.489a; GARCIA JGN, 1995, BLOOD COAGUL FIBRIN, V6, P609, DOI 10.1097/00001721-199510000-00001; GARCIA JGN, 1995, J INVEST MED, V43, P117; GRECO NJ, 1992, THROMBIN STRUCTURE F, P275; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HERBERT JM, 1994, BIOCHEM J, V303, P227, DOI 10.1042/bj3030227; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Inoue M, 1998, CIRCULATION, V98, P2108, DOI 10.1161/01.CIR.98.20.2108; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jackson JR, 1997, FASEB J, V11, P457, DOI 10.1096/fasebj.11.6.9194526; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; Maragoudakis ME, 2000, ADV EXP MED BIOL, V476, P47; MARI B, 1994, J BIOL CHEM, V269, P8517; Martin M, 1996, INT J CANCER, V65, P796, DOI 10.1002/(SICI)1097-0215(19960315)65:6<796::AID-IJC16>3.0.CO;2-2; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McCarthy MJ, 1999, J VASC SURG, V30, P261, DOI 10.1016/S0741-5214(99)70136-9; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Nguyen M, 1999, LAB INVEST, V79, P467; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; OBRIEN ER, 1994, AM J PATHOL, V145, P883; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Otani A, 2000, INVEST OPHTH VIS SCI, V41, P1192; PANKONIN G, 1991, BIOMED BIOCHIM ACTA, V50, P1073; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; Rabiet MJP, 1996, ARTERIOSCL THROM VAS, V16, P488, DOI 10.1161/01.ATV.16.3.488; Richard DE, 2000, J BIOL CHEM, V275, P26765; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Schmidt VA, 1998, J BIOL CHEM, V273, P15061, DOI 10.1074/jbc.273.24.15061; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Senger DR, 1996, AM J PATHOL, V149, P293; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Sodhi A, 2000, CANCER RES, V60, P4873; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tsopanoglou NE, 1999, J BIOL CHEM, V274, P23969, DOI 10.1074/jbc.274.34.23969; TSOPANOGLOU NE, 1993, AM J PHYSIOL, V264, pC1302, DOI 10.1152/ajpcell.1993.264.5.C1302; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; Vouret-Craviari V, 1999, INFECT IMMUN, V67, P3002, DOI 10.1128/IAI.67.6.3002-3008.1999; Vouret-Craviari V, 1998, MOL BIOL CELL, V9, P2639, DOI 10.1091/mbc.9.9.2639; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wang HS, 1997, J SURG RES, V68, P139, DOI 10.1006/jsre.1997.5044; Wenger RH, 1997, BIOL CHEM, V378, P609; WILLIAMS B, 1995, HYPERTENSION, V25, P913, DOI 10.1161/01.HYP.25.5.913; Zain J, 2000, BLOOD, V95, P3133; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 2000, CANCER RES, V60, P1541; ZUCKER S, 1995, J BIOL CHEM, V270, P23730, DOI 10.1074/jbc.270.40.23730; Zucker S, 1998, INT J CANCER, V75, P780, DOI 10.1002/(SICI)1097-0215(19980302)75:5<780::AID-IJC19>3.3.CO;2-N; Zundel W, 2000, GENE DEV, V14, P391	79	84	89	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2001	20	13					1556	1562		10.1038/sj.onc.1204193	http://dx.doi.org/10.1038/sj.onc.1204193			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313902				2022-12-17	WOS:000168089800005
J	Ciullo, I; Diez-Roux, G; Di Domenico, M; Migliaccio, A; Avvedimento, EV				Ciullo, I; Diez-Roux, G; Di Domenico, M; Migliaccio, A; Avvedimento, EV			cAMP signaling selectively influences Ras effectors pathways	ONCOGENE			English	Article						transduction; cAMP-dependent kinase; Ras and GTP binding proteins; PI3-kinases; growth; thyroid differentiation	DEPENDENT PROTEIN-KINASE; CYCLIC-AMP; THYROTROPIN RECEPTOR; THYROID-CELLS; DNA-SYNTHESIS; CELLULAR RAS; INHIBITION; ACTIVATION; PROLIFERATION; GROWTH	Thyrotropin (TSH) stimulates survival and growth of thyroid cells via a seven transmembrane G protein-coupled receptor. TSH elevates the intracellular cyclic AMP (cAMP) levels activating protein kinase A (PKA), Recent evidence indicates that p21 Ras is required for TSH-induced mitogenesis, but the molecular mechanism(s) is not known. Here we report that Ras p21 activity is necessary for the Go- G1 transition in TSH induced cycle and that the downstream effector of Ras upon TSH signaling is p85-p110 PI3K, We show that PI3K inhibitors block TSH-induced DNA synthesis, cAMP-PKA stimulate the formation of the complex PI3K-p21 Ras and reduce the complex Ras-Raf1 in thyroid and other cells types. Moreover, PKA phosphorylates immunoprecipitated p85 and PKA phosphorylation of cell extracts significantly stimulates the formation of the complex PI3K-Ras, We suggest that PKA phosphorylates p85 and stabilizes the complex p110-p85, enhancing the interaction PI3K and p21 Ras, Simultaneously, cAMP inhibits Raf-1-ERK signaling by decreasing Raf1 availability to Ras, Under these circumstances PI3K signaling is favored. These results indicate that PI3K is an important mediator of Ras effects in cAMP-induced proliferation and illustrates how cAMP can selectively influence Ras effector pathways.	Univ Naples Federico II, Fac Med,Policlin 2, Dipartimento Biol & Patol Mol & Cellulare, CNR, I-80131 Naples, Italy; Univ Catanzaro, Fac Med, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; Univ Naples 2, Ist Patol Gen, I-80138 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro; Universita della Campania Vanvitelli	Avvedimento, EV (corresponding author), Univ Naples Federico II, Fac Med,Policlin 2, Dipt Biol & Patol Mol & Cell, CNR, Via S Pansini 5, I-80131 Naples, Italy.		Migliaccio, Antimo/AAB-3376-2019	Di Domenico, Marina/0000-0002-6201-4200; Migliaccio, Antimo/0000-0002-4197-2055				ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BONAPACE IM, 1990, MOL CELL BIOL, V10, P1033, DOI 10.1128/MCB.10.3.1033; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Cass LA, 2000, ONCOGENE, V19, P924, DOI 10.1038/sj.onc.1203393; Cass LA, 1999, MOL CELL BIOL, V19, P5882; CHEATHAM B, 1997, MOL CELL BIOL, V14, P4902; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DEVITA G, 2000, IN PRESS CANC RES; Feliciello A, 2000, J BIOL CHEM, V275, P303, DOI 10.1074/jbc.275.1.303; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; INDOLFI C, 1995, NAT MED, V1, P541, DOI 10.1038/nm0695-541; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; MEINKOTH JL, 1992, J BIOL CHEM, V267, P13239; MEINKOTH JL, 1991, THYROIDOLOGY, V3, P97; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Paolillo M, 1999, J BIOL CHEM, V274, P6546, DOI 10.1074/jbc.274.10.6546; PORCELLINI A, 1995, ONCOGENE, V11, P1089; PORCELLINI A, 1997, ONCOGENE, V14, P2233; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; THOMPSON MA, 1995, J BIOL CHEM, V270, P4224, DOI 10.1074/jbc.270.9.4224; TRAMONTANO D, 1988, ENDOCRINOLOGY, V122, P133, DOI 10.1210/endo-122-1-133; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; Weissinger EM, 1997, MOL CELL BIOL, V17, P3229, DOI 10.1128/MCB.17.6.3229; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	36	84	86	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1186	1192		10.1038/sj.onc.1204219	http://dx.doi.org/10.1038/sj.onc.1204219			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313862				2022-12-17	WOS:000167570100005
J	Chen, XB; Zheng, YM; Zhu, JH; Jiang, JY; Wang, J				Chen, XB; Zheng, YM; Zhu, JH; Jiang, JY; Wang, J			p73 is transcriptionally regulated by DNA damage, p53, and p73	ONCOGENE			English	Article						p53; p73; DNA damage; transcriptional regulation	KINASE C-ABL; APOPTOTIC RESPONSE; INDUCE APOPTOSIS; IDENTIFICATION; PROTEIN; DOMAIN; CELLS; GENES	p73 is a member of the p53 family, Recent studies have shown that DNA damage can stabilize p73 protein and enhance p73-mediated apoptosis in a c-Abl dependent manner. To determine what regulates p73 transcriptionally, we analysed the expression of p73 in several cell lines following genotoxic stresses. We found that p73 is induced in certain cell lines when treated with therapeutic DNA damaging agents. We also found that p53 and p73, but not mutant p53(R249S) and p73 beta 292, directly induce the expression of the p73 gene. In addition, we found one potential p53-binding site in the promoter of the p73 gene. This binding site is responsive to p53, p73, and DIVA damage. Taken together, these data suggest that p73 is transcriptionally regulated by DNA damage and p53, and is autoregulated.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Chen, XB (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA.				NCI NIH HHS [R01 CA81237, CA76069] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081237, R29CA076069, R01CA076069] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gong JG, 1999, NATURE, V399, P806; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 1999, CANCER RES, V59, P3257; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 1998, CANCER RES, V58, P5061; Zhu KC, 1999, ONCOGENE, V18, P7740, DOI 10.1038/sj.onc.1203235	23	84	86	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2001	20	6					769	774		10.1038/sj.onc.1204149	http://dx.doi.org/10.1038/sj.onc.1204149			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314010				2022-12-17	WOS:000166806000012
J	Elliott, K; Ge, K; Du, W; Prendergast, GC				Elliott, K; Ge, K; Du, W; Prendergast, GC			The c-Myc-interacting adaptor protein Bin1 activates a caspase-independent cell death program	ONCOGENE			English	Article						transformation; apoptosis; cancer; amphiphysin-like protein/amph1	TUMOR-SUPPRESSOR BIN1; ABL TYROSINE KINASE; INDUCED APOPTOSIS; GENE-EXPRESSION; SCHIZOSACCHAROMYCES-POMBE; MEDIATED ENDOCYTOSIS; AMPHIPHYSIN ISOFORM; EMBRYO FIBROBLASTS; PROSTATE-CANCER; SPLICE VARIANTS	Cell death processes are progressively inactivated during malignant development, in part by loss of tumor suppressors that can promote cell death. The Bin1 gene encodes a nucleocytosolic adaptor protein with tumor suppressor properties, initially identified through its ability to interact with and inhibit malignant transformation by c-Myc and other oncogenes, Bin1 is frequently missing or functionally inactivated in breast and prostate cancers and in melanoma, In this study, we show that Bin1 engages a caspase-independent cell death process similar to type II apoptosis, characterized by cell shrinkage, substratum detachment, vacuolated cytoplasm, and DNA degradation. Cell death induction was relieved by mutation of the BAR domain, a putative effector domain, or by a missplicing event that occurs in melanoma and inactivates suppressor activity. Cells in all phases of the cell cycle were susceptible to death and p53 and Rb were dispensable. Notably, Bin1 did not activate caspases and the broad spectrum caspase inhibitor ZVAD,fmk did not block cell death. Consistent with the lack of caspase involvement, dying cells lacked nucleosomal DNA cleavage and nuclear lamina degradation. Moreover, neither Bcl-2 or dominant inhibition of the Pas pathway had any effect. In previous work, we showed that Bin1 could not suppress cell transformation by SV40 large T antigen. Consistent with this finding, we observed that T antigen suppressed the death program engaged by Bin1, This observation was interesting in light of emerging evidence that T antigen has roles in cell immortalization and human cell transformation beyond Rb and p53 inactivation. In support of a link to c-Myc-induced death processes, AEBSF, a serine protease inhibitor that inhibits apoptosis by c-Myc, potently suppressed DNA degradation by Bin1, Our findings suggest that the tumor suppressor activity of Bin1 reflects engagement of a unique cell death program, We propose that loss of Bin1 may promote malignancy by blunting death penalties associated with oncogene activation.	Dupont Merck Pharmaceut Co, Glenolden Lab, Glenolden, PA 19036 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	DuPont; The Wistar Institute	Prendergast, GC (corresponding author), Dupont Merck Pharmaceut Co, Glenolden Lab, Glenolden, PA 19036 USA.		Ge, Kai/H-2810-2019	Ge, Kai/0000-0002-7442-5138				ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; Amarante-Mendes GP, 1998, CELL DEATH DIFFER, V5, P298, DOI 10.1038/sj.cdd.4400354; ANTON M, 1995, J VIROL, V69, P4600, DOI 10.1128/JVI.69.8.4600-4606.1995; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barbieri MA, 1998, J BIOL CHEM, V273, P19367, DOI 10.1074/jbc.273.31.19367; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Bowen C, 1998, CANCER RES, V58, P3275; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; Conzen SD, 1995, ONCOGENE, V11, P2295; Crouch DH, 1996, ONCOGENE, V12, P2689; Dang CV, 1999, MOL CELL BIOL, V19, P1; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; Davis RA, 1996, ECONOMET THEOR, V12, P1, DOI 10.1017/S0266466600006423; Day ML, 1997, J BIOL CHEM, V272, P8125, DOI 10.1074/jbc.272.13.8125; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Ding HF, 1998, J BIOL CHEM, V273, P28378, DOI 10.1074/jbc.273.43.28378; Elliott K, 1999, ONCOGENE, V18, P3564, DOI 10.1038/sj.onc.1202670; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fearnhead HO, 1997, GENE DEV, V11, P1266, DOI 10.1101/gad.11.10.1266; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GARTE SJ, 1993, CRIT REV ONCOGENESIS, V4, P435; Ge K, 2000, INT J CANCER, V86, P155, DOI 10.1002/(SICI)1097-0215(20000415)86:2<155::AID-IJC2>3.0.CO;2-M; Ge K, 1999, P NATL ACAD SCI USA, V96, P9689, DOI 10.1073/pnas.96.17.9689; Ge K, 2000, INT J CANCER, V85, P376; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GUSSE M, 1989, MOL CELL BIOL, V9, P5395, DOI 10.1128/MCB.9.12.5395; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Harlow E, 1998, ANTIBODIES LAB MANUA; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Ink B, 1997, MOL CELL BIOL, V17, P2468, DOI 10.1128/MCB.17.5.2468; James C, 1997, CURR BIOL, V7, P246, DOI 10.1016/S0960-9822(06)00120-5; Jenkins RB, 1997, CANCER RES, V57, P524; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Jurgensmeier JM, 1997, MOL BIOL CELL, V8, P325; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; Kangas AL, 1998, ONCOGENE, V16, P387, DOI 10.1038/sj.onc.1201779; KYPRIANOU N, 1990, CANCER RES, V50, P3748; KYPRIANOU N, 1991, CANCER RES, V51, P162; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LEMAITRE JM, 1995, MOL CELL BIOL, V15, P5054; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Mao NC, 1999, GENOMICS, V56, P51, DOI 10.1006/geno.1998.5709; Mateo V, 1999, NAT MED, V5, P1277, DOI 10.1038/15233; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Powell AJ, 1999, ONCOGENE, V18, P7343, DOI 10.1038/sj.onc.1203154; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Sakamuro D, 1995, ONCOGENE, V11, P2411; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Trudel M, 1997, J EXP MED, V186, P1873, DOI 10.1084/jem.186.11.1873; Tsuneoka M, 2000, ONCOGENE, V19, P115, DOI 10.1038/sj.onc.1203232; Tsutsui K, 1997, BIOCHEM BIOPH RES CO, V236, P178, DOI 10.1006/bbrc.1997.6927; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wechsler-Reya RJ, 1998, MOL CELL BIOL, V18, P566, DOI 10.1128/MCB.18.1.566; WechslerReya R, 1997, CANCER RES, V57, P3258; WechslerReya R, 1997, J BIOL CHEM, V272, P31453, DOI 10.1074/jbc.272.50.31453; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Wixler V, 1999, FEBS LETT, V445, P351, DOI 10.1016/S0014-5793(99)00151-9; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wright SC, 1997, J EXP MED, V186, P1107, DOI 10.1084/jem.186.7.1107; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; YANG BS, 1991, MOL CELL BIOL, V11, P2291, DOI 10.1128/MCB.11.4.2291; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhang P, 2000, INT J CANCER, V85, P599, DOI 10.1002/(SICI)1097-0215(20000301)85:5<599::AID-IJC1>3.0.CO;2-#	97	84	92	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2000	19	41					4669	4684		10.1038/sj.onc.1203681	http://dx.doi.org/10.1038/sj.onc.1203681			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032017				2022-12-17	WOS:000089528800001
J	Katoh, I; Aisaki, K; Kurata, S; Ikawa, S; Ikawa, Y				Katoh, I; Aisaki, K; Kurata, S; Ikawa, S; Ikawa, Y			p51A (TAp63 gamma), a p53 homolog, accumulates in response to DNA damage for cell regulation	ONCOGENE			English	Article						p51; p63; p53; p21(wafI); Bax; DNA damage	TEMPERATURE-SENSITIVE MUTANT; KINASE C-ABL; MUTATIONAL ANALYSIS; IONIZING-RADIATION; APOPTOTIC RESPONSE; IN-VIVO; GENE; P63; PHOSPHORYLATION; PROLIFERATION	p51A, or TAp63 gamma, a translation product of gene p51, or p63, was identified as a homolog of p53 in its primary structure and transactivating function. p53 plays a decision-making role in inducing either cell cycle arrest or apoptosis in response to DNA damage, and thereby preserves genome integrity of living cells, To compare the biological activities between p51A and p53, cell lines with low-level, constitutive expression of each protein were obtained by cDNA transfection of mouse erythroleukemic cells. Production of p51A with an apparent molecular mass of 57-kilodalton (kD) accompanied induction of p21(wafl) and appearance of hemoglobin-producing cells. After DNA-damaging treatment either with ultraviolet light (UV) irradiation or with actinomycin D, the p51A protein accumulated in time courses corresponding to those of wild-type p53, and caused an increase in the hemoglobin-positive cell count. In contrast, p53-accumulated cells underwent apoptosis without exhibiting the feature of erythroid differentiation, The mode of p21(wafl) and Bax-alpha upregulations varied between p51A- and p53-expressing cells and between the types of DNA damage. These results suggest the possibility that p51A induces differentiation under genotoxic circumstances. There may be cellular factors that control p51A protein stability and transactivating ability.	Tokyo Med & Dent Univ, Div Med Res, Dept Retroviral Regulat, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Human Gene Sci Ctr, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Med Res Inst, Tokyo 1138510, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Cell Biol, Sendai, Miyagi 9808575, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tohoku University	Ikawa, Y (corresponding author), Tokyo Med & Dent Univ, Div Med Res, Dept Retroviral Regulat, Tokyo 1138519, Japan.		井川, 俊太郎/L-5911-2015					Agami R, 1999, NATURE, V399, P809; AIZAWA S, 1990, EMBO J, V9, P2107, DOI 10.1002/j.1460-2075.1990.tb07379.x; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gong JG, 1999, NATURE, V399, P806; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Haapajarvi T, 1997, MOL CELL BIOL, V17, P3074, DOI 10.1128/MCB.17.6.3074; Hagiwara K, 1999, CANCER RES, V59, P4165; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kato MV, 1997, BLOOD, V90, P1373, DOI 10.1182/blood.V90.4.1373.1373_1373_1378; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lu X, 1996, ONCOGENE, V13, P413; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MIYASHITA T, 1995, CELL, V80, P293; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shimada A, 1999, CANCER RES, V59, P2781; Sunahara M, 1999, ONCOGENE, V18, P3761, DOI 10.1038/sj.onc.1202972; White E, 1999, NATURE, V399, P734, DOI 10.1038/21539; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; XU X, 1995, JPN J CANCER RES, V86, P284, DOI 10.1111/j.1349-7006.1995.tb03052.x; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	34	84	86	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2000	19	27					3126	3130		10.1038/sj.onc.1203644	http://dx.doi.org/10.1038/sj.onc.1203644			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871867				2022-12-17	WOS:000087903900012
J	Zimmermann, J; Erdmann, D; Lalande, I; Grossenbacher, R; Noorani, M; Furst, P				Zimmermann, J; Erdmann, D; Lalande, I; Grossenbacher, R; Noorani, M; Furst, P			Proteasome inhibitor induced gene expression profiles reveal overexpression of transcriptional regulators ATF3, GADD153 and MAD1	ONCOGENE			English	Article						proteasome; cDNA microarray; gene expression; ATF3; GADD153; MAD1	PROGRAMMED CELL-DEATH; ENDOPLASMIC-RETICULUM; UBIQUITIN/PROTEASOME PATHWAY; DNA MICROARRAY; CANCER-CELLS; PROTEIN; STRESS; APOPTOSIS; GROWTH; MYC	The ubiquitin/proteasome pathway has been implicated in a wide variety of cellular processes and the number of substrates degraded by the proteasome is impressive. Most prominently, the stability of a large number of transcription factors is regulated by ubiquitination. To elucidate pathways regulated by the proteasome, gene expression profiles were generated, comparing changes of mRNA expression of 7900 genes from the UniGene collection upon exposure of cells to the proteasome inhibitors Lactacystin, Lactacystin-beta-lactone or MG132 by means of microarray based cDNA hybridization, The three profiles were very similar, but differed significantly from a gene expression profile generated with the histone deacetylase inhibitor Trapoxin A, indicating that the observed alterations were indeed due to proteasome inhibition, Two of the most prominently induced genes encoded the growth arrest and DNA damage inducible protein Gadd153 and the activating transcription factor ATF3, both transcription factors of the CCAAT/enhancer binding protein (C/EBP) family. ii third gene encoded for the transcriptional repressor and c-Myc antagonist Mad1. Our results suggest that proteasome inhibition leads to upregulation of specific members of transcription factor families controlling cellular stress response and proliferation.	Novartis Pharma AG, Oncol Res, CH-4002 Basel, Switzerland	Novartis	Furst, P (corresponding author), Novartis Pharma AG, Oncol Res, WKL-125-13-14, CH-4002 Basel, Switzerland.							Adams J, 1999, CANCER RES, V59, P2615; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BAI JPF, 1995, J PHARM PHARMACOL, V47, P674, DOI 10.1111/j.2042-7158.1995.tb05858.x; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Bogyo M, 1997, BIOPOLYMERS, V43, P269, DOI 10.1002/(SICI)1097-0282(1997)43:4<269::AID-BIP2>3.0.CO;2-T; Bonvini P, 1998, ONCOGENE, V16, P1131, DOI 10.1038/sj.onc.1201625; Bush KT, 1997, J BIOL CHEM, V272, P9086; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Chang DD, 1998, ONCOGENE, V16, P1921, DOI 10.1038/sj.onc.1201715; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Chen CH, 1996, ONCOGENE, V13, P1659; Drexler HCA, 1998, APOPTOSIS, V3, P1, DOI 10.1023/A:1009604900979; Eymin B, 1997, CANCER RES, V57, P686; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; Firestein R, 1998, J BIOL CHEM, V273, P5892, DOI 10.1074/jbc.273.10.5892; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Goodbourn S, 1997, BIOCHEM SOC T, V25, P498, DOI 10.1042/bst0250498; Han S, 1999, ONCOL REP, V6, P569; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Herrmann JL, 1998, ONCOGENE, V17, P2889, DOI 10.1038/sj.onc.1202221; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; ICHIHARA A, 1995, MOL BIOL REP, V21, P49, DOI 10.1007/BF00990970; ImajohOhmi S, 1995, BIOCHEM BIOPH RES CO, V217, P1070, DOI 10.1006/bbrc.1995.2878; Kawazoe Y, 1998, EUR J BIOCHEM, V255, P356, DOI 10.1046/j.1432-1327.1998.2550356.x; Kitagawa H, 1999, FEBS LETT, V443, P181, DOI 10.1016/S0014-5793(98)01709-8; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Machiels BM, 1997, CYTOMETRY, V28, P243; MASUMOTO M, 1996, FEBS LETT, V395, P143; Miller G, 1997, GENOME RES, V7, P1027, DOI 10.1101/gr.7.10.1027; Outinen PA, 1998, BIOCHEM J, V332, P213, DOI 10.1042/bj3320213; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; *PE APPL BIOS, US B ABI PRISM 7700, V2; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; Tchernitsa OI, 1999, ONCOGENE, V18, P5448, DOI 10.1038/sj.onc.1202987; VanLint C, 1996, GENE EXPRESSION, V5, P245; Wang X, 1998, J IMMUNOL, V160, P788; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Wolfe B, 1997, ISSUES SCI TECHNOL, V13, P17; YOSHIDA H, 1992, JPN J CANCER RES, V83, P324, DOI 10.1111/j.1349-7006.1992.tb00109.x; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	52	84	86	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2000	19	25					2913	2920		10.1038/sj.onc.1203606	http://dx.doi.org/10.1038/sj.onc.1203606			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	323BG	10871842				2022-12-17	WOS:000087544500005
J	Brandvold, KA; Neiman, P; Ruddell, A				Brandvold, KA; Neiman, P; Ruddell, A			Angiogenesis is an early event in the generation of myc-induced lymphomas	ONCOGENE			English	Article						angiogenesis; lymphoma; c-myc; v-myc oncogene; avian retrovirus	NON-HODGKINS-LYMPHOMAS; C-MYC; TUMOR ANGIOGENESIS; CELL; VIRUS; FABRICIUS; BURSA; GENE; IDENTIFICATION; TRANSFORMATION	Angiogenesis was identified as an early consequence of myc gene overexpression in two models of retroviral lymphomagenesis. Avian leukosis virus (ALV) induces bursal lymphoma in chickens after proviral c-myc gene integration, while the HB-1 retrovirus carries a v-myc oncogene and also induces metastatic lymphoma. Immunohistochemical studies of the effects of increased c-myc or v-myc overexpression revealed early angiogenesis within myc-transformed bursal follicles, which persisted in lymphomas and metastases. Abnormal vessel growth was consistently detected within 13 days after transplantation of a few myc-overexpressing progenitors into ablated bursal follicles, suggesting that these angiogenic changes may support the initial expansion of tumor precursors, as well as later stage lymphomagenesis, Conditioned media from myc-overexpressing B cell lines promoted proliferation of vascular endothelium in vitro, while media from B cells expressing low myc levels showed little effect. Moreover, ectopic myc overexpression in the low myc B cell lines increased production of the endothelial growth activity, indicating that myc induces secretion of angiogenic factors from B cells. These findings demonstrate that myc overexpression in lymphocytes generates an angiogenic phenotype in vitro as well as in vivo.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Dept Med, Seattle, WA 98109 USA; Univ Washington, Dept Pathol, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Ruddell, A (corresponding author), Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA.			Ruddell, Alanna/0000-0002-0195-5576	NCI NIH HHS [R01 CA20068, R01 CA68328] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA020068, R01CA068328] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISTER K, 1983, J VIROL, V46, P337, DOI 10.1128/JVI.46.2.337-346.1983; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Bowers WJ, 1996, J VIROL, V70, P3051, DOI 10.1128/JVI.70.5.3051-3059.1996; COOPER MD, 1968, JNCI-J NATL CANCER I, V41, P373; EWERT DL, 1989, VIROLOGY, V170, P433, DOI 10.1016/0042-6822(89)90434-0; EWERT DL, 1988, ADV VET SCI COMP MED, V32, P37; Gong M, 1998, J VIROL, V72, P5517, DOI 10.1128/JVI.72.7.5517-5525.1998; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HENRIKSSON M, 1996, ADV CANCER RES, V68, P110; Holash J, 1999, ONCOGENE, V18, P5356, DOI 10.1038/sj.onc.1203035; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Kerbel RS, 1998, MOL MED, V4, P286, DOI 10.1007/BF03401737; Kraemer M, 1999, CELL GROWTH DIFFER, V10, P193; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; NEIMAN P, 1985, P NATL ACAD SCI USA, V82, P222, DOI 10.1073/pnas.82.1.222; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NEIMAN PE, 1994, ADV IMMUNOL, V56, P467, DOI 10.1016/S0065-2776(08)60457-5; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; PerezAtayde AR, 1997, AM J PATHOL, V150, P815; Ribatti D, 1998, BRIT J CANCER, V77, P1900, DOI 10.1038/bjc.1998.316; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; Vacca A, 1999, BRIT J CANCER, V79, P965, DOI 10.1038/sj.bjc.6690154; Vacca A, 1998, INT J CLIN LAB RES, V28, P55, DOI 10.1007/s005990050018	26	84	87	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2000	19	23					2780	2785		10.1038/sj.onc.1203589	http://dx.doi.org/10.1038/sj.onc.1203589			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851079				2022-12-17	WOS:000087318500007
J	Kratzer, F; Rosorius, O; Heger, P; Hirschmann, N; Dobner, T; Hauber, J; Stauber, RH				Kratzer, F; Rosorius, O; Heger, P; Hirschmann, N; Dobner, T; Hauber, J; Stauber, RH			The adenovirus type 5 E1B-55K oncoprotein is a highly active shuttle protein and shuttling is independent of E4orf6, p53 and Mdm2	ONCOGENE			English	Article						adenovirus; nucleo-cytoplasmic transport; oncoproteins; GFP	REGION-4 34-KILODALTON PROTEIN; NUCLEAR EXPORT; 55-KILODALTON PROTEIN; MESSENGER-RNAS; INFECTED-CELLS; TRANSFORMED-CELLS; TUMOR-ANTIGEN; LIVING CELLS; REV PROTEIN; SEQUENCE	The E1B-55K and E4orf6 oncoproteins of adenovirus type 5 are involved in the export of viral mRNAs, Previously, it cr as suggested that a complex composed of E1B-55K and E4orf6 serves as a nucleocytoplasmic transporter for viral mRNAs in which the E4orf6 protein directs both nuclear import and export, We now demonstrate that the E1B-55K protein itself shuttles efficiently in the absence of E4orf6, In addition, E1B-55K trafficking was independent of the defined shuttle proteins Mdm2 or p53, which interacts with E1B-55K, The identified N-terminal E1B-55K leucine-rich nuclear-export signal (NES) conferred rapid nuclear export even in a heterologous system in contrast to the postulated E4orf6NES, Interestingly, although shuttling was blocked by inhibitors of the CRM1 mediated export pathway, E1B-55K inhibited neither the activity nor the trafficking of the retroviral shuttle proteins HIV-1 Rev and HTLV-1 Rex, In contrast, Rev or Rex blocked the nuclear export of E1B-55K, most likely by competing for essential export factors, Our results provide new insights into the regulation of the adenovirus mRNA export system and the processes of adenovirus mediated transformation.	Univ Erlangen Nurnberg, Inst Clin & Mol Virol, D-91054 Erlangen, Germany; Univ Regensburg, Inst Med Mikrobiol & Hyg, D-93053 Regensburg, Germany	University of Erlangen Nuremberg; University of Regensburg	Stauber, RH (corresponding author), Univ Erlangen Nurnberg, Inst Clin & Mol Virol, Schlossgarten 4, D-91054 Erlangen, Germany.			Stauber, Roland/0000-0002-1341-4523; Heger, Peter/0000-0003-2583-2981				Aranda M, 1998, VIROLOGY, V243, P261, DOI 10.1006/viro.1998.9032; BABICH A, 1983, MOL CELL BIOL, V3, P1212, DOI 10.1128/MCB.3.7.1212; Bevec D, 1997, BIOL SIGNAL, V6, P124; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; DAGOSTINO DM, 1992, MOL CELL BIOL, V12, P1375, DOI 10.1128/MCB.12.3.1375; DIX I, 1993, J VIROL, V67, P3226, DOI 10.1128/JVI.67.6.3226-3231.1993; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; Felber BK, 1997, MOD CELL B, V17, P323; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; FUJITA A, 1995, J VIROL, V69, P6180, DOI 10.1128/JVI.69.10.6180-6190.1995; Ginsberg HS, 1999, P NATL ACAD SCI USA, V96, P10409, DOI 10.1073/pnas.96.18.10409; Goodrum FD, 1999, J VIROL, V73, P7474, DOI 10.1128/JVI.73.9.7474-7488.1999; Goodrum FD, 1996, J VIROL, V70, P6323, DOI 10.1128/JVI.70.9.6323-6335.1996; Goodrum FD, 1997, J VIROL, V71, P548, DOI 10.1128/JVI.71.1.548-561.1997; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Grand RJA, 1999, ONCOGENE, V18, P955, DOI 10.1038/sj.onc.1202358; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; Harada JN, 1999, J VIROL, V73, P5333, DOI 10.1128/JVI.73.7.5333-5344.1999; Heger P, 1999, ONCOGENE, V18, P4080, DOI 10.1038/sj.onc.1202762; Heger P, 1998, J VIROL, V72, P8659, DOI 10.1128/JVI.72.11.8659-8668.1998; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hope TJ, 1997, CHEM BIOL, V4, P335, DOI 10.1016/S1074-5521(97)90124-1; Horridge JJ, 1998, J VIROL, V72, P9374, DOI 10.1128/JVI.72.11.9374-9379.1998; Huang W, 1998, J VIROL, V72, P225, DOI 10.1128/JVI.72.1.225-235.1998; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; Kirn D, 1998, NAT MED, V4, P1341, DOI 10.1038/3902; Kirn D, 1999, NAT MED, V5, P991, DOI 10.1038/12426; Konig C, 1999, J VIROL, V73, P2253; Leppard KN, 1998, SEMIN VIROL, V8, P301, DOI 10.1006/smvy.1997.0132; Leppard KN, 1999, J GEN VIROL, V80, P997, DOI 10.1099/0022-1317-80-4-997; LEPPARD KN, 1993, J GEN VIROL, V74, P575, DOI 10.1099/0022-1317-74-4-575; Liao DQ, 1999, VIROLOGY, V254, P11, DOI 10.1006/viro.1998.9512; Logan J, 1984, CANCER CELL, V2, P527; Maheswaran S, 1998, ONCOGENE, V16, P2041, DOI 10.1038/sj.onc.1201741; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Moore M, 1996, P NATL ACAD SCI USA, V93, P11295, DOI 10.1073/pnas.93.21.11295; Nevels M, 1997, P NATL ACAD SCI USA, V94, P1206, DOI 10.1073/pnas.94.4.1206; NORDQVIST K, 1994, MOL CELL BIOL, V14, P437, DOI 10.1128/MCB.14.1.437; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Rosorius O, 1999, J CELL SCI, V112, P2369; Rosorius O, 1999, BIOTECHNIQUES, V27, P350, DOI 10.2144/99272rr02; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Rubenwolf S, 1997, J VIROL, V71, P1115, DOI 10.1128/JVI.71.2.1115-1123.1997; SARNOW P, 1984, J VIROL, V49, P692, DOI 10.1128/JVI.49.3.692-700.1984; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHENK T, 1996, VIROLOGY, P2111; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400; Stauber RH, 1998, BIOTECHNIQUES, V24, P462, DOI 10.2144/98243rr01; Stauber RH, 1998, VIROLOGY, V251, P38, DOI 10.1006/viro.1998.9295; Steegenga WT, 1998, ONCOGENE, V16, P349, DOI 10.1038/sj.onc.1201540; Stewart AK, 1999, GENE THER, V6, P350, DOI 10.1038/sj.gt.3300833; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Yang UC, 1996, J VIROL, V70, P4071, DOI 10.1128/JVI.70.6.4071-4080.1996; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0	60	84	85	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2000	19	7					850	857		10.1038/sj.onc.1203395	http://dx.doi.org/10.1038/sj.onc.1203395			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702793				2022-12-17	WOS:000085567700002
J	Newman, SP; Bates, NP; Vernimmen, D; Parker, MG; Hurst, HC				Newman, SP; Bates, NP; Vernimmen, D; Parker, MG; Hurst, HC			Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer	ONCOGENE			English	Article						ERBB2; oestrogen receptor; SRC-1; breast cancer; transcriptional repression	DEPENDENT TRANSCRIPTIONAL ACTIVATION; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; MEDIATED TRANSACTIVATIONS; COACTIVATOR-1 INTERACTS; PROTEIN EXPRESSION; MAMMARY-CARCINOMA; NEU ONCOGENE; CELLS; GROWTH	Overexpression of the ERBB2 proto oncogene in breast tumours, which occurs in 25-30% of patients, correlates with poor prognosis, In oestrogen receptor (ER) positive breast epithelial cells oestrogens reduce ERBB2 mRNA and protein levels, an effect that is reversed in the presence of anti-oestrogens such as tamoxifen and ICI 182780. Our previous studies have shown that the major effect of oestrogen on ERBB2 expression is at the level of transcription and that this is mediated through a region within the EXBB2 first intron which can act as an oestrogen-suppressible enhancer in ER positive breast cells. in vitro footprinting of the smallest DNA fragment that retained full activity revealed four transcription factor binding sites. We report here that two of these sites are recognized by AP-2 proteins and the other two are bound by a variety of bZIP factors, including CREB and ATF1, with a major complex containing ATFa/JunD. However, by using ER mutants it is clear that repression occurs essentially off the DNA. Indeed, the essential domain of the ER responsible for repression of the ERBB2 enhancer is a region termed AF2 which is required for the ligand-dependent association of non-DNA binding cofactors, We further demonstrate that one of these ER cofactors, SRC-1, can relieve oestrogen repression of the ERBB2 enhancer and conclude that these data fit with a model whereby the ER and the ERBB2 enhancer compete for this limiting, non-DNA binding cofactor, Thus, in oestrogenic conditions SRC-1 preferentially binds to the ER which effectively sequesters it thereby reducing enhancer activity, but in antioestrogenic media the cofactor is released from the ER and is therefore available to activate the EXBB2 enhancer.	Hammersmith Hosp, Imperial Canc Res Fund, Mol Oncol Unit, ICSM, London W12 0NN, England; Imperial Canc Res Fund, London WC2A 3PX, England	Cancer Research UK; Imperial College London; Cancer Research UK	Hurst, HC (corresponding author), Hammersmith Hosp, Imperial Canc Res Fund, Mol Oncol Unit, ICSM, London W12 0NN, England.							ANTONIOTTI S, 1994, BRIT J CANCER, V70, P1095, DOI 10.1038/bjc.1994.454; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bates NP, 1997, ONCOGENE, V15, P473, DOI 10.1038/sj.onc.1201368; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; Berns EMJJ, 1998, BREAST CANCER RES TR, V48, P87, DOI 10.1023/A:1005903226483; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Bocco JL, 1996, ONCOGENE, V12, P1971; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; CHATTON B, 1994, ONCOGENE, V9, P375; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DATI C, 1990, ONCOGENE, V5, P1001; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DSOUZA B, 1993, ONCOGENE, V8, P1797; Gee JMW, 1999, J PATHOL, V189, P514, DOI 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; HURST HC, 1996, PROTEIN PROFILES, V3; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; LAHOOTI H, 1994, MOL ENDOCRINOL, V8, P182, DOI 10.1210/me.8.2.182; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MARCHIONNI MA, 1995, NATURE, V378, P334, DOI 10.1038/378334a0; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Nass SJ, 1998, NAT MED, V4, P761, DOI 10.1038/nm0798-761; Newby JC, 1997, CLIN CANCER RES, V3, P1643; ONATE SA, 1995, SCIENCE, V270, P1354; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; READ LD, 1990, CANCER RES, V50, P3947; Revillion F, 1998, EUR J CANCER, V34, P791, DOI 10.1016/S0959-8049(97)10157-5; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Turner BC, 1998, CANCER RES, V58, P5466; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WARRI AM, 1991, INT J CANCER, V49, P616, DOI 10.1002/ijc.2910490425	46	84	86	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 27	2000	19	4					490	497		10.1038/sj.onc.1203416	http://dx.doi.org/10.1038/sj.onc.1203416			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	280LL	10698518				2022-12-17	WOS:000085104200002
J	Nagata, Y; Anan, T; Yoshida, T; Mizukami, T; Taya, Y; Fujiwara, T; Kato, H; Saya, H; Nakao, M				Nagata, Y; Anan, T; Yoshida, T; Mizukami, T; Taya, Y; Fujiwara, T; Kato, H; Saya, H; Nakao, M			The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association	ONCOGENE			English	Article						p53; ubiquitin-proteasome; mdm2; hsp90; conformation; phosphorylation	TUMOR-SUPPRESSOR GENE; HEAT-SHOCK-PROTEIN; DNA-DAMAGE; CELL-LINE; MOLECULAR CHAPERONE; PROTEASOME PATHWAY; CRYSTAL-STRUCTURE; DEGRADATION; MDM2; PHOSPHORYLATION	Mutant-type p53 (mt p53) is largely accumulated in cancer cells due to its increased stability, To elucidate the mechanism of mt p53 stabilization, we analysed the turnover of p53 mutated at codon 248 whose alteration is most frequently found in human cancers. Proteasome inhibition induced the accumulation of ubiquitinated mt p53, indicating that the ubiquitinated forms were essentially unstable and degraded by the proteasome, The presence of a small amount of the ubiquitinated mt p53 relative to the abundant non-ubiquitinated form suggested that the mt p53 ubiquitination was a rate-limiting process in the slow turnover, Two phenomena destabilizing mt p53 via the ubiquitin-proteasome degradation were proved to be independent, First, the coexpression of wild-type p53 (wt p53) promoted mt p53 destabilization as feedback regulation. Second, geldanamycin also induced mt p53 destabilization through the dissociation of the protein from hsp90 but not through the restoration of wt p53 function. Neither the mutant-specific conformation nor the N-terminal phosphorylation seemed to contribute directly to the mt p53 stabilization, Further, a two-dimensional gel electrophoresis revealed that most of the post-translationally modified mt p53 was equally subjected to ubiquitination and subsequent proteasomal degradation, These findings are evidence that mt p53 stabilization depends on the impaired ubiquitination due to both the loss of wt p53 function and the hsp90 association.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Kurume Univ, Sch Med, Dept Pediat & Child Hlth, Kurume, Fukuoka 8300011, Japan; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Tokyo 1940023, Japan; Ctr Canc, Res Inst, Chuo Ku, Tokyo 1040045, Japan; Okayama Univ, Sch Med, Dept Surg 1, Okayama 7000914, Japan	Kumamoto University; Kurume University; Kyowa Kirin Ltd; Okayama University	Nakao, M (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 8600811, Japan.		Saya, Hideyuki/J-4325-2013					AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; BROWN JP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CORDONCARDO C, 1994, CANCER RES, V54, P794; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRITSCHE M, 1993, ONCOGENE, V8, P307; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Hall PA, 1996, J PATHOL, V180, P1; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; KASTAN MB, 1991, CANCER RES, V51, P6304; KONDO S, 1995, ONCOGENE, V10, P2001; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Landers JE, 1997, CANCER RES, V57, P3562; LEGROS Y, 1994, ONCOGENE, V9, P3689; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Maki CG, 1996, CANCER RES, V56, P2649; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYAJI H, 1990, CYTOTECHNOLOGY, V3, P133, DOI 10.1007/BF00143675; Miyake H, 1998, ONCOGENE, V16, P933, DOI 10.1038/sj.onc.1201602; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Pagano M, 1997, FASEB J, V11, P1067, DOI 10.1096/fasebj.11.13.9367342; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Roth JA, 1997, J NATL CANCER I, V89, P21, DOI 10.1093/jnci/89.1.21; Save V, 1998, J PATHOL, V184, P348; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Selkirk James K., 1994, Applied and Theoretical Electrophoresis, V4, P11; Sharma SV, 1998, ONCOGENE, V16, P2639, DOI 10.1038/sj.onc.1201790; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; VOJTESEK B, 1995, ONCOGENE, V10, P389; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	53	84	86	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 28	1999	18	44					6037	6049		10.1038/sj.onc.1202978	http://dx.doi.org/10.1038/sj.onc.1202978			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557093				2022-12-17	WOS:000083359100010
J	Philipp, J; Vo, K; Gurley, KE; Seidel, K; Kemp, CJ				Philipp, J; Vo, K; Gurley, KE; Seidel, K; Kemp, CJ			Tumor suppression by p27(Kip1) and p21(Cip1) during chemically induced skin carcinogenesis	ONCOGENE			English	Article						p27(Kip1); p21(Cip1); p53; H-ras; tumor promotion; intestinal neoplasia	DEPENDENT KINASE INHIBITOR; CELL-CYCLE ARREST; MOUSE SKIN; POTENTIAL MEDIATOR; BREAST-CANCER; RAS; EXPRESSION; DIFFERENTIATION; P21; P53	p27(Kip1)and p21(Cip1) are cyclin dependent kinase inhibitors which can arrest cell proliferation and p27 is a tumor suppressor gene. To address the mechanism of tumor suppression by p27 and to determine if p21 has a tumor suppressor phenotype, we utilized the two stage skin carcinogenesis model on p27 and p21 knockout mice. In this model, initiation, which involves mutation of H-ras induced by DMBA, can be distinguished from promotion induced by TPA, and progression to carcinoma. The mean number of papillomas did not differ between p27 - / - and control littermates, but papilloma growth rate was increased and carcinomas developed earlier. Thus, p27 deficiency did not enhance initiation, but resulted in more rapid clonal expansion of initiated cells during promotion. TPA treatment reduced p27 expression in keratinocytes also supporting a role for p27 during promotion. Tumors from p27 - / - mice contained mutant H-ras indicating that p27 deficiency did not substitute for mutant ras and further, that during ras driven tumor growth, p27 is partially antagonistic since its removal led to faster growth. The treated p27 - / - mice also developed intestinal adenomas, p21 - / - mice did not display a significant increase in tumor numbers, growth rate or progression to carcinomas and these tumors also had mutated H-rns. Carcinomas from p21 - / - mice were more poorly differentiated with a high frequency of anaplastic spindle cell carcinomas. Thus p21 deficiency mainly resulted in higher grade undifferentiated tumors.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Kemp, CJ (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview N, Seattle, WA 98109 USA.							Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCHMANN A, 1991, CANCER RES, V51, P4097; BURNS PA, 1991, ONCOGENE, V6, P2363; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Esposito V, 1997, CANCER RES, V57, P3381; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; Harvat BL, 1998, J CELL SCI, V111, P1185; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1994, ONCOGENE, V9, P3397; Kalbfleish J., 1980, STAT ANAL FAILURE TI; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KLEINSZANTO AJP, 1989, SKIN TUMORS EXPT CLI, P19; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PIETENPOL JA, 1995, CANCER RES, V55, P1206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RUGGERI B, 1991, CANCER RES, V51, P6615; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P419; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; Singh SP, 1998, CANCER RES, V58, P1730; StCroix B, 1996, NAT MED, V2, P1204; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tikoo R, 1997, J BIOL CHEM, V272, P442; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsihlias J, 1998, CANCER RES, V58, P542; Weinberg WC, 1997, ONCOGENE, V15, P685, DOI 10.1038/sj.onc.1201230; WINBERG LD, 1995, SKIN CANC MECH HUMAN, P113; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	62	84	86	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	1999	18	33					4689	4698		10.1038/sj.onc.1202840	http://dx.doi.org/10.1038/sj.onc.1202840			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467416				2022-12-17	WOS:000082154400006
J	Rousseau, D; Cannella, D; Boulaire, J; Fitzgerald, P; Fotedar, A; Fotedar, R				Rousseau, D; Cannella, D; Boulaire, J; Fitzgerald, P; Fotedar, A; Fotedar, R			Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway	ONCOGENE			English	Article						p21(WAF1,Cip1); CDK; cell cycle; ubiquitination; proteasome; PCNA	DEPENDENT KINASE INHIBITOR; NUCLEOTIDE EXCISION-REPAIR; CELL NUCLEAR ANTIGEN; DNA-REPLICATION; RETINOBLASTOMA PROTEIN; POTENTIAL MEDIATOR; MAMMALIAN-CELLS; P21(CIP1); SUBUNIT; CLONING	The CDK inhibitor, p21(WAF1/Cip1) blocks cell cycle progression. In vitro, the N-terminus of p21 binds and inhibits CDK-cyclin kinase activity, whereas the C-terminus binds and inhibits PCNA (proliferating cell nuclear antigen) function. PCNA is essential for processivity of both DNA polymerase delta and epsilon. We have performed a detailed analysis of growth inhibition by the N- and C-terminal regions of p21, and determined whether the N- and C-terminal regions mediate this effect by different mechanisms. Expression of either the N- or the C-terminal region of p21 inhibits DNA synthesis and cell growth, but not as efficiently as full length p21, The effectiveness of the two p21 domains is dependent on their stability which is determined by the ubiquitin-proteasome pathway. The stabilization of the N- and C-terminal region of p21 increases their effectiveness as inhibitors of DNA synthesis to levels comparable to full length p21, Inhibition of DNA synthesis by the N-terminal region of p21 involves suppression of E2F activity. In contrast, inhibition by the C-terminal region of p21 is not accompanied by suppression of E2F activity, but is mediated via PCNA binding. The C-terminal region of p21 therefore inhibits cell growth by a mechanism distinct from that of the N-terminal region containing the CDK-cyclin inhibitory domain.	Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA; Inst Biol Struct JP Ebel, F-38027 Grenoble 1, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Fotedar, A (corresponding author), Sidney Kimmel Canc Ctr, 10835 Altman Rd, San Diego, CA 92121 USA.		Boulaire, Jerome/A-5954-2009; Cannella, Dominique/F-4879-2019	Cannella, Dominique/0000-0002-1665-9833	NATIONAL CANCER INSTITUTE [R01CA074435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031453] Funding Source: NIH RePORTER; NCI NIH HHS [CA74435] Funding Source: Medline; NIAID NIH HHS [AI31453] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams PD, 1996, MOL CELL BIOL, V16, P6623; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; BRENOTBOSC F, 1995, CHROMOSOMA, V103, P517, DOI 10.1007/BF00355316; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chen IT, 1996, ONCOGENE, V12, P595; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Fotedar A, 1996, J BIOL CHEM, V271, P31627, DOI 10.1074/jbc.271.49.31627; FOTEDAR R, 1991, COLD SH Q B, V56, P325; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; Fotedar R, 1996, ONCOGENE, V12, P2155; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOUBIN F, 1995, ONCOGENE, V10, P2281; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Lukas J, 1996, MOL CELL BIOL, V16, P1047; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; ROBERTS JM, 1994, COLD SPRING HARB SYM, V59, P31, DOI 10.1101/SQB.1994.059.01.006; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	57	84	85	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	1999	18	30					4313	4325		10.1038/sj.onc.1202686	http://dx.doi.org/10.1038/sj.onc.1202686			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439039				2022-12-17	WOS:000081732700004
J	Soulez, M; Saurin, AJ; Freemont, PS; Knight, JC				Soulez, M; Saurin, AJ; Freemont, PS; Knight, JC			SSX and the synovial-sarcoma-specific chimaeric protein SYT-SSX co-localize with the human Polycomb group complex	ONCOGENE			English	Article						chromosome translocation; SSX; SYT; polycomb; chromatin; nucleus	MYC TRANSGENIC MICE; TRANSCRIPTIONAL REPRESSOR; NUCLEAR-BODIES; GROUP GENES; IDENTIFICATION; DROSOPHILA; TRANSLOCATION; CHROMATIN; HOMOLOG; FUSION	Chromosome translocation t(X;18)(p11.2;q11.2) is unique to synovial sarcomas and results in an 'in frame' fusion of the SYT gene with the SSX1 or closely-related SSX2 gene. Wild-type SYT and SSX proteins, and the SYT-SSX chimaeric proteins, can modulate transcription in gene reporter assays. To help elucidate the role of these proteins in cell function and neoplasia we have performed immunolabeliing experiments to determine their subcellular localization in three cell types. Transient expression of epitope-tagged proteins produced distinctive nuclear staining patterns, The punctate staining of SYT and SYT-SSX proteins showed some similarities. We immunolabelled a series of endogenous nuclear antigens and excluded the SYT and SYT-SSX focal staining from association with these domains (e.g. sites of active transcription, snRNPs), In further experiments we immunolabelled the Polycomb group (PcG) proteins RING1 or BMI-1 and showed that SSX and SYT-SSX proteins, but not SYT, co-localized with these markers. Consistent with this we show that SSX and SYT-SSX associate with chromatin, and also associate with condensed chromatin at metaphase, Noteably, SSX produced a dense signal over the surface of metaphase chromosomes whereas SYT-SSX produced discrete focal staining, Our data indicate that SSX and SYT-SSX proteins are recruited to nuclear domains occupied by PcG complexes, and this provides us with a new insight into the possible function of wild-type SSX and the mechanism by which the aberrant SYT-SSX protein might disrupt fundamental mechanisms controlling cell division and cell fate.	Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Imperial Canc Res Fund Labs, London W12 0NN, England; Imperial Canc Res Fund, Mol Struct & Funct Lab, London WC2A 3PX, England	Imperial College London; Cancer Research UK; Imperial College London; Cancer Research UK	Freemont, PS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.			Freemont, Paul/0000-0002-5658-8486; Saurin, Andrew/0000-0001-5162-003X				Alkema MJ, 1997, J MOL BIOL, V273, P993, DOI 10.1006/jmbi.1997.1372; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; BIENZ L, 1995, BIOESSAYS, V17, P775, DOI 10.1002/bies.950170907; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; Bridge JA, 1994, CYTOGENETICS BONE SO; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Core N, 1997, DEVELOPMENT, V124, P721; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; deBruijn DRH, 1996, ONCOGENE, V13, P643; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; dosSantos NR, 1997, HUM MOL GENET, V6, P1549, DOI 10.1093/hmg/6.9.1549; Enzinger FM, 1995, SOFT TISSUE TUMORS, V3rd; FISHER C, 1986, HUM PATHOL, V17, P996, DOI 10.1016/S0046-8177(86)80083-1; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; Gure AO, 1997, INT J CANCER, V72, P965, DOI 10.1002/(SICI)1097-0215(19970917)72:6<965::AID-IJC8>3.0.CO;2-N; Hashimoto N, 1998, BIOCHEM BIOPH RES CO, V245, P356, DOI 10.1006/bbrc.1998.8438; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Huang S, 1997, J CELL BIOL, V137, P965, DOI 10.1083/jcb.137.5.965; LIM FL, 1998, IN PRESS ONCOGENE; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; RENWICK PJ, 1995, CYTOGENET CELL GENET, V70, P58, DOI 10.1159/000133992; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; Saurin AJ, 1998, J CELL BIOL, V142, P887, DOI 10.1083/jcb.142.4.887; Schoorlemmer J, 1997, EMBO J, V16, P5930, DOI 10.1093/emboj/16.19.5930; Schumacher A, 1997, TRENDS GENET, V13, P167, DOI 10.1016/S0168-9525(97)01133-5; STUURMAN N, 1992, J CELL SCI, V101, P773; van Lohuizen M, 1998, CELL MOL LIFE SCI, V54, P71, DOI 10.1007/s000180050126; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Wang G, 1997, CYTOGENET CELL GENET, V78, P50, DOI 10.1159/000134626; WANSINK DG, 1994, J CELL SCI, V107, P1449	34	84	87	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	1999	18	17					2739	2746		10.1038/sj.onc.1202613	http://dx.doi.org/10.1038/sj.onc.1202613			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348348				2022-12-17	WOS:000080124900009
J	Eymin, B; Haugg, M; Droin, N; Sordet, O; Dimanche-Boitrel, MT; Solary, E				Eymin, B; Haugg, M; Droin, N; Sordet, O; Dimanche-Boitrel, MT; Solary, E			p27(Kip1) induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells	ONCOGENE			English	Article						p27(Kip1); drug resistance; apoptosis; caspases; cytochrome c	ANTICANCER AGENTS; TOPOISOMERASE-II; CYCLE ARREST; MITOCHONDRIA; PROTEASE; CASPASES; DEATH; BCL-2; INHIBITORS; ETOPOSIDE	The cyclin-dependent kinase inhibitor p27(Kip1) has been implicated as a drug resistance factor in tumor cells grown as spheroids or confluent monolayers. Here, we show that p27(Kip1) overexpression also induces resistance to drug-induced apoptosis and cytotoxicity in human leukemic cells growing in suspension, The anti-apoptotic effect of p27(Kip1) is not restricted to DNA-damaging agents but extends to the tubulin poison vinblastin, agonistic anti-Fas antibodies and macromolecule synthesis inhibitors. To further identify at which level this protein interferes with the cell death pathway, we investigated its influence on caspase activation and mitochondrial changes. Exposure df mock-transfected U937 cells to 50 mu M etoposide activates procaspase-3 and the long isoform of procaspase-2 and induces mitochondrial potential decrease and cytochrome c release from mitochondria to the cytosol, All these events are prevented by p27(KiP1) overexpression. p27(Kip1) does not modulate BcL-2, BcL-X-L, Mel-1 and Bar protein level in leukemic cells but suppresses Mel-1 expression decrease observed in mock-transfected U937 cells undergoing etoposide-induced cell death. We conclude that p27(Kip1) prevents cell death upstream of the final pathway common to many apoptotic stimuli that involves cytochrome c release from mitochondria and activation of downstream caspases.	Fac Med & Pharm, CJF,Lab Oncohematol & Pharmacol, INSERM 94-08, Grp Biol & Therapie Canc JE515, F-21033 Dijon, France; CHU Le Bocoge, F-21033 Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Solary, E (corresponding author), Fac Med & Pharm, CJF,Lab Oncohematol & Pharmacol, INSERM 9408, Grp Biol & Therapie Canc JE515, 7 Blvd Jeanne Arc, F-21033 Dijon, France.		Sordet, Olivier/M-3271-2014; Droin, Nathalie M/Y-5506-2018; eymin, beatrice/U-4670-2019; Dimanche-Boitrel, Marie-Therese M/I-4642-2015; Eymin, Beatrice/M-1962-2013	Sordet, Olivier/0000-0001-6027-4925; Droin, Nathalie M/0000-0002-6099-5324; eymin, beatrice/0000-0002-7311-3810; Eymin, Beatrice/0000-0002-7311-3810; Dimanche-Boitrel, Marie-Therese/0000-0002-8038-7780; Solary, Eric/0000-0002-8629-1341				BERTRAND R, 1995, DRUG DEVELOP RES, V34, P138, DOI 10.1002/ddr.430340206; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; DIMANCHEBOITREL MT, 1998, IN PRESS INT J CANC; DROIN N, 1998, IN PRESS ONCOGENE; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; Duttaroy A, 1997, J CELL BIOCHEM, V64, P434; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; Eymin B, 1997, CANCER RES, V57, P686; EYMIN B, 1995, INT J CANCER, V63, P268, DOI 10.1002/ijc.2910630221; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Han ZY, 1997, J BIOL CHEM, V272, P13432, DOI 10.1074/jbc.272.20.13432; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Katayose Y, 1997, CANCER RES, V57, P5441; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lu YJ, 1998, ONCOGENE, V16, P705, DOI 10.1038/sj.onc.1201585; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SOLARY E, 1993, BLOOD, V81, P1359; Solary E, 1998, CELL BIOL TOXICOL, V14, P121, DOI 10.1023/A:1007481921502; StCroix B, 1996, NAT MED, V2, P1204; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang W, 1995, CLIN CANCER RES, V1, P1051	41	84	87	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1411	1418		10.1038/sj.onc.1202437	http://dx.doi.org/10.1038/sj.onc.1202437			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050878				2022-12-17	WOS:000078651600003
J	Lu, YJ; Yamagishi, N; Yagi, T; Takebe, H				Lu, YJ; Yamagishi, N; Yagi, T; Takebe, H			Mutated p21(WAF1/CIP1/SDI1) lacking CDK-inhibitory activity fails to prevent apoptosis in human colorectal carcinoma cells	ONCOGENE			English	Article						adriamycin; apoptosis; CDK; p21; X-ray	CYCLIN-DEPENDENT KINASES; P53-MEDIATED G(1) ARREST; HUMAN CANCER-CELLS; TUMOR SUPPRESSION; DNA-REPLICATION; P21; P53; IDENTIFICATION; GENE; PCNA	Human colorectal tumor cell lines were established which express wildtype p21 or p21 with a mutation at codon 46 (Cys) or 140 (Gly) on IPTG treatment (LacSwitch). The IPTG-induced windtype p21 bound to CDK2 and PCNA and inhibited CDK activity in the cells and reduced cell growth rate; whereas, both IPTG-induced mutated p21 proteins neither bound to CDK2 nor affected the CDK activity but did bind to PCNA, and they did not affect the cell growth rate, Wildtype p21 suppressed apoptosis and enhanced survival of X-ray-irradiated or adriamycin-treated cells; but, mutated p21 neither suppressed apoptosis nor affected cell survival, When cells were treated with mimosine, a p53-independent p21-inducer, or butyrolactone I, a specific inhibitor of CDK, cellular endogenous p21 was induced and X-ray or adriamycin-induced apoptosis was blocked, These results suggest that CDK-binding or CDK-inhibitory activity of p21 is required to prevent apoptosis, i.,e.,, CDK is required for apoptosis in human tumor cells.	Kyoto Univ, Grad Sch Med, Dept Radiat Genet, Sakyo Ku, Kyoto 60601, Japan	Kyoto University	Lu, YJ (corresponding author), Kyoto Univ, Grad Sch Med, Dept Radiat Genet, Sakyo Ku, Yoshida-konoe-cho, Kyoto 60601, Japan.							Adams PD, 1996, MOL CELL BIOL, V16, P6623; Alpan RS, 1996, CELL GROWTH DIFFER, V7, P893; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Balbin M, 1996, J BIOL CHEM, V271, P15782, DOI 10.1074/jbc.271.26.15782; BHATIA K, 1995, CANCER RES, V55, P1431; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHEN YQ, 1995, CANCER RES, V55, P4536; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GOUBIN F, 1995, ONCOGENE, V10, P2281; HARPER JW, 1993, CELL, V75, P805; KITAGAWA M, 1993, ONCOGENE, V8, P2425; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI YJ, 1995, ONCOGENE, V10, P599; LU YJ, 1996, CARCINOGENESIS, V17, P2243; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; McDonald E, 1996, CANCER RES, V56, P2250; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PEEPER DS, 1994, BBA-REV CANCER, V1198, P215, DOI 10.1016/0304-419X(94)90015-9; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAKUT R, 1995, ONCOGENE, V11, P393	38	84	87	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 12	1998	16	6					705	712		10.1038/sj.onc.1201585	http://dx.doi.org/10.1038/sj.onc.1201585			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488034				2022-12-17	WOS:000071931800002
J	Gayther, SA; Barski, P; Batley, SJ; Li, LM; deFoy, KAF; Cohen, SN; Ponder, BAJ; Caldas, C				Gayther, SA; Barski, P; Batley, SJ; Li, LM; deFoy, KAF; Cohen, SN; Ponder, BAJ; Caldas, C			Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours	ONCOGENE			English	Article						TSG101; FHIT; splicing; tumour	BREAKPOINT; CANCER; 3P14.2; CELLS	Intragenic deletions of TSG101, the human homolog of a mouse gene (tsg101) that acts to suppress malignant cell growth, were reported in human breast tumours, We screened TSG101 for somatic mutations in DNA and RNA samples isolated from a variety of common human malignancies, EBV-immortalised B-cells, and normal lung parenchyma, Intragenic TSG101 deletions in RNA transcripts were frequently found in all types of samples, Analysis of DNA failed to show genomic rearrangements corresponding to transcripts containing deletions in the same samples, The breakpoints of most transcript deletions coincide with genuine or cryptic splice site sequences, suggesting that they result from alternative or aberrant splicing, A similar spectrum of transcript deletions has previously been described in the putative tumour suppressor gene FHIT. We analysed FHIT in the same series of RNA samples and detected truncated FHIT transcripts frequently in both tumour and normal tissues, In addition, transcripts from TSG101, FHIT and seven other genes were analysed in RNA isolated from normal peripheral blood lymphocytes, Large TSC101 and FHIT intragenic transcript deletions were detected and these appeared to be the predominant transcript in 'aged' lymphocytes. Similar alterations were not detected in transcripts of the other genes which were analysed, Our findings demonstrate that truncated TSG101 and FHIT transcripts are commonly detected in both normal and malignant tissues and that a significant fraction of these are likely to be the result of aberrant splicing, While we cannot exclude that alterations in TSG101 and FHIT occur during cancer development, our data indicate that in this context the commonly observed transcript abnormalities are misleading.	ADDENBROOKES HOSP,CRC,HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 2QQ,ENGLAND; UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN MED,ACAD DEPT ONCOL,CRC,CAMBRIDGE CB2 2QQ,ENGLAND; STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305; STANFORD UNIV,SCH MED,DEPT MED,STANFORD,CA 94305	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Stanford University; Stanford University			Caldas, Carlos/A-7543-2008; Caldas, Carlos/U-7250-2019	Caldas, Carlos/0000-0003-3547-1489; BARSKI, PIOTR/0000-0002-2002-6748				Druck T, 1997, CANCER RES, V57, P504; Flaman JM, 1996, ONCOGENE, V12, P813; Fong KM, 1997, CANCER RES, V57, P2256; Foster KA, 1996, CANCER RES, V56, P3622; Gayther SA, 1997, NAT GENET, V15, P103, DOI 10.1038/ng0197-103; Hayashi S, 1997, CANCER RES, V57, P1981; Huebner K, 1997, BBA-REV CANCER, V1332, pM65, DOI 10.1016/S0304-419X(97)00009-7; Lee MP, 1997, CANCER RES, V57, P3131; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Lochner K, 1996, CANCER RES, V56, P2171; Luan XD, 1997, ONCOGENE, V15, P79, DOI 10.1038/sj.onc.1201164; Nam DK, 1996, GENE, V178, P169, DOI 10.1016/0378-1119(96)00364-2; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Steiner P, 1997, NAT GENET, V16, P332, DOI 10.1038/ng0897-332; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770	17	84	86	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2119	2126		10.1038/sj.onc.1201591	http://dx.doi.org/10.1038/sj.onc.1201591			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366528				2022-12-17	WOS:A1997YC28400012
J	Agarwal, ML; Agarwal, A; Taylor, WR; Wang, ZQ; Wagner, EF; Stark, GR				Agarwal, ML; Agarwal, A; Taylor, WR; Wang, ZQ; Wagner, EF; Stark, GR			Defective induction but normal activation and function of p53 in mouse cells lacking poly-ADP-ribose polymerase	ONCOGENE			English	Article						growth arrest; DNA damage; N-(phosphonacetyl)-L-aspartate; spindle checkpoint; mouse embryo fibroblasts	WILD-TYPE P53; DNA-BINDING FUNCTION; ANTISENSE RNA EXPRESSION; TUMOR-SUPPRESSOR PROTEIN; POLY(ADP-RIBOSE) POLYMERASE; GENE AMPLIFICATION; CYCLE CHECKPOINT; ATAXIA-TELANGIECTASIA; CELLULAR-RESPONSE; GENOMIC STABILITY	Poly-ADP-ribose polymerase (PARP) and p53 are bath induced by DNA damage and each has been proposed to mediate the normal cellular response to damage, We find that embryo fibroblasts from PARP-null mice have a similar to twofold lower basal level of p53 and that the induction of p53 in response to DNA damage or nucleotide depletion is more than twofold less than in normal mouse cells, These factors combine to decrease the induced level of the p53 protein in PARP-deficient cells by 4-5-fold, compared to normal cells, However, there is virtually no decrease in the induction of p53 activity in PARP-deficient cells, as assayed with a p53-responsive promoter, Furthermore, cells lacking PARP arrest normally in G(1) after DNA damage, in contrast to cells lacking p53, where this checkpoint is absent, Other p53-dependent properties, such as the mitotic spindle checkpoint and permissivity for gene amplification, are also normal in PARP-deficient cells, We conclude that the induced level of the p53 protein is governed by a combination of PARP-dependent and PARP-independent pathways and that the activation of p53 is largely PARP-independent, The results are consistent with a model in which the regulation of gene expression by p53 involves both increases in the amount of the protein and activation of p53 as a transcription factor.	CLEVELAND CLIN FDN,RES INST,DEPT MOL BIOL,CLEVELAND,OH 44195; INT AGCY RES CANC,F-69372 LYON 08,FRANCE; RES INST MOL PATHOL,A-1030 VIENNA,AUSTRIA	Cleveland Clinic Foundation; World Health Organization; International Agency for Research on Cancer (IARC); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)				Wagner, Erwin F/0000-0001-7872-0196	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049345] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49345] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BENJAMIN RC, 1980, J BIOL CHEM, V255, P493; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DING RC, 1994, CANCER RES, V54, P4627; DING RC, 1992, J BIOL CHEM, V267, P12804; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; DURKACZ BW, 1980, NATURE, V283, P595; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIZAKA Y, 1995, P NATL ACAD SCI USA, V92, P3224, DOI 10.1073/pnas.92.8.3224; JUAREZSALINAS H, 1979, NATURE, V282, P740, DOI 10.1038/282740a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Kupper JH, 1996, CANCER RES, V56, P2715; KUPPER JH, 1995, MOL CELL BIOL, V15, P3154; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PERRY ME, 1992, P NATL ACAD SCI USA, V89, P8112, DOI 10.1073/pnas.89.17.8112; SATOH MS, 1993, J BIOL CHEM, V268, P5480; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; STEWART N, 1995, ONCOGENE, V10, P109; STRAIN AJ, 1985, EXP CELL RES, V159, P531, DOI 10.1016/S0014-4827(85)80026-4; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TLSTY TD, 1990, P NATL ACAD SCI USA, V87, P3132, DOI 10.1073/pnas.87.8.3132; TSENG A, 1987, P NATL ACAD SCI USA, V84, P1107, DOI 10.1073/pnas.84.4.1107; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WHITACRE CM, 1995, CANCER RES, V55, P3697; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	54	84	84	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1035	1041		10.1038/sj.onc.1201274	http://dx.doi.org/10.1038/sj.onc.1201274			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285557	Bronze			2022-12-17	WOS:A1997XT16100004
J	ElAshry, D; Miller, DL; Kharbanda, S; Lippman, ME; Kern, FG				ElAshry, D; Miller, DL; Kharbanda, S; Lippman, ME; Kern, FG			Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis	ONCOGENE			English	Article						breast cancer; apoptosis; Raf-1 kinase; estrogen-independence	HUMAN MAMMARY TISSUES; PROTEIN-KINASE; MCF-7 CELLS; IN-VITRO; MAP KINASE; SIGNAL-TRANSDUCTION; DEPLETED CONDITIONS; PROGNOSTIC FACTORS; FACTOR SECRETION; RECEPTOR	Overexpression of many growth factor receptors, as well as growth factors, has been shown to confer varying degrees of estrogen-independent growth on estrogen receptor (ER) positive breast cancer cells. The protooncogene Raf-1 is a key intermediate in the signal transduction pathway of many of these growth factor receptors, and when constitutively activated in fibroblasts is transforming. To examine the effects of Raf-1 kinase activity on the estrogen-dependent growth of human breast cancer cells, ER+ MCF-7 breast cancer cells were stably transfected with an expression construct directing the expression of an amino-truncated protein having constitutive kinase activity. Expression of constitutively activated Raf in MCF-7 cells is incompatible with growth in the presence of estrogen; that is, cells down-regulate expression of the transfected Raf. Constitutive Raf activity does allow for growth of the cells in the absence of estrogen, suggesting that activation of growth factor signaling pathways through Raf may confer a selective advantage for growth of breast cancer cells under estrogen-deprived conditions. In addition, the high levels of Raf activity induce apoptosis in cells grown under either condition. This is a novel activity for Raf, and may occur because the levels of the constitutive Raf are extremely high in these cells.	GEORGETOWN UNIV,MED CTR,DEPT BIOCHEM & MOL BIOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT MED,WASHINGTON,DC 20007	Georgetown University; Georgetown University	ElAshry, D (corresponding author), GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007, USA.				NCI NIH HHS [CA50376, 2P30-CA-51008, CA71465] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA071465, P30CA051008, R01CA050376] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROPOULOS K, 1992, CELL GROWTH DIFFER, V3, P731; ARMSTRONG DK, 1994, CANCER RES, V54, P5280; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1996, CANCER RES, V56, P1851; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BRACEY TS, 1995, ONCOGENE, V10, P2391; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CANMAN CE, 1995, SEMIN CANCER BIOL, V6, P17, DOI 10.1006/scbi.1995.0003; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARK GM, 1988, SEMIN ONCOL, V15, P20; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DESOMBRE ER, 1986, CANCER RES, V46, P4256; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; HEERDT BG, 1994, CANCER RES, V54, P3288; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JAMAL S, 1995, ONCOGENE, V10, P2095; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; KASID A, 1987, CANCER RES, V47, P5733; KNIGHT WA, 1977, CANCER RES, V37, P4669; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYPRIANOU N, 1991, CANCER RES, V51, P162; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LIPPMAN ME, 1989, J STEROID BIOCHEM, V34, P107, DOI 10.1016/0022-4731(89)90071-X; LIU YL, 1995, BREAST CANCER RES TR, V34, P97, DOI 10.1007/BF00665783; MAGNUSON NS, 1994, SEMIN CANCER BIOL, V5, P247; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MCGUIRE WL, 1990, J NATL CANCER I, V82, P1006, DOI 10.1093/jnci/82.12.1006; MCLESKEY SW, 1993, CANCER RES, V53, P2168; MILLER DL, 1994, CELL GROWTH DIFFER, V5, P1263; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OHUCHI N, 1986, CANCER RES, V46, P2511; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SIEGFRIED Z, 1990, MOL CELL BIOL, V10, P6073, DOI 10.1128/MCB.10.11.6073; SOMMERS CL, 1990, CANCER RES, V50, P67; STRANGE R, 1992, DEVELOPMENT, V115, P49; SUKUMAR S, 1988, SCIENCE, V240, P524, DOI 10.1126/science.3282307; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOR A, 1986, LAB INVEST, V55, P603; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; WANG HG, 1994, ONCOGENE, V9, P2751; WANG TTY, 1995, CANCER RES, V55, P2487; WARRI AM, 1993, JNCI-J NATL CANCER I, V85, P1412, DOI 10.1093/jnci/85.17.1412; WHITE E, 1994, COLD SPRING HARB SYM, V59, P395, DOI 10.1101/SQB.1994.059.01.044; WILSON JW, 1995, INT J CANCER, V61, P502, DOI 10.1002/ijc.2910610413; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	62	84	86	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					423	435		10.1038/sj.onc.1201198	http://dx.doi.org/10.1038/sj.onc.1201198			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242379				2022-12-17	WOS:A1997XM23800007
J	Varley, JM; Thorncroft, M; McGown, G; Appleby, J; Kelsey, AM; Tricker, KJ; Evans, DGR; Birch, JM				Varley, JM; Thorncroft, M; McGown, G; Appleby, J; Kelsey, AM; Tricker, KJ; Evans, DGR; Birch, JM			A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene	ONCOGENE			English	Article						chromosome 17; LOH; Li-Fraumeni; tumours	GERMLINE P53 MUTATIONS; CANCER FAMILY SYNDROME; BREAST-OVARIAN CANCER; WILD-TYPE CHROMOSOME; SUPPRESSOR GENE; SPLICING MUTATION; BRAIN-TUMORS; YOUNG-ADULTS; PRONE FAMILY; ALLELE LOSS	We have studied a total of 36 tumours from 28 patients with germline mutations to the TP53 gene for loss of heterozygosity at TP53 using techniques of both direct sequencing and restriction fragment length polymorphism analysis. All patients were from families conforming to the definition of classical Li-Fraumeni syndrome (LFS) or were Li-Frammeni-like (LFL). The data we have obtained show that loss of the wild-type TP53 gene is observed in under half (44%) of all tumours, and that the pattern of LOH at TP53 may be mutation specific, LOH has been observed in premalignant as web as invasive tumours. Two tumours (6%) show loss of the mutant allele and retention of the wild-type, To confirm that TP53 is indeed the target for LOH events on chromosome 17, we have used additional microsatellite repeats to examine patterns of allelic imbalance along the length of chromosome 17. Data from this analysis indicate that TP53 is the target of loss, but reveal some other interesting patterns of allelic imbalance at other loci on chromosome 17.	ROYAL MANCHESTER CHILDRENS HOSP,CRC,PAEDIAT & FAMILIAL CANC RES GRP,MANCHESTER M27 4HA,LANCS,ENGLAND	Royal Manchester Children's Hospital	Varley, JM (corresponding author), PATERSON INST CANC RES,DEPT CANC GENET,CRC,WILMSLOW RD,MANCHESTER M20 9BX,LANCS,ENGLAND.		Evans, D Gareth/AAB-4308-2022	Evans, D Gareth/0000-0002-8482-5784				BIRCH JM, 1994, CANCER RES, V54, P1298; BIRCH JM, 1990, J PATHOL, V161, P1, DOI 10.1002/path.1711610102; BORRESEN AL, 1992, CANCER RES, V52, P3234; BOWCOCK AM, 1993, AM J HUM GENET, V52, P718; BRUGIERES L, 1993, CANCER RES, V53, P452; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CAVENEE WK, 1990, GENETIC BASIS FOR CARCINOGENESIS, P33; CHEN PC, 1995, CANCER GENET CYTOGEN, V82, P106, DOI 10.1016/0165-4608(94)00213-U; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHUNG R, 1991, GENE CHROMOSOME CANC, V3, P323, DOI 10.1002/gcc.2870030502; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; CORNELIS RS, 1994, CANCER RES, V54, P4200; DILLER L, 1995, J CLIN INVEST, V95, P1606, DOI 10.1172/JCI117834; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; EELES RA, 1993, ONCOGENE, V8, P1269; FELIX CA, 1995, MED PEDIATR ONCOL, V25, P431, DOI 10.1002/mpo.2950250603; FELIX CA, 1993, ONCOGENE, V8, P1203; FELIX CA, 1992, J CLIN INVEST, V89, P640, DOI 10.1172/JCI115630; FREBOURG T, 1995, AM J HUM GENET, V56, P608; GARBER JE, 1991, CANCER RES, V51, P6094; GERKEN SC, 1995, AM J HUM GENET, V56, P484; GRAYSON GH, 1994, AM J PEDIAT HEMATOL, V16, P341; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; GUTIERREZ MI, 1994, HUM MOL GENET, V3, P2247, DOI 10.1093/hmg/3.12.2247; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAMELIN R, 1994, HUM GENET, V94, P88, DOI 10.1007/BF02272849; Heim S, 1995, CANC CYTOGENETICS; HOGGARD N, 1995, GENE CHROMOSOME CANC, V12, P24, DOI 10.1002/gcc.2870120105; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HORIO Y, 1994, ONCOGENE, V9, P1231; IAVARONE A, 1992, P NATL ACAD SCI USA, V89, P4207, DOI 10.1073/pnas.89.9.4207; Ichii Shigetoshi, 1992, Human Molecular Genetics, V1, P387, DOI 10.1093/hmg/1.6.387; JOLLY KW, 1994, ONCOGENE, V9, P97; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOVAR H, 1992, ONCOGENE, V7, P2169; KYRITSIS AP, 1994, JNCI-J NATL CANCER I, V86, P344, DOI 10.1093/jnci/86.5.344; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; Li YJ, 1995, INT J CANCER, V64, P383, DOI 10.1002/ijc.2910640606; LUBBE J, 1995, BRAIN PATHOL, V5, P15, DOI 10.1111/j.1750-3639.1995.tb00572.x; MACKAY J, 1988, LANCET, V2, P1384; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MCINTYRE JF, 1994, J CLIN ONCOL, V12, P925, DOI 10.1200/JCO.1994.12.5.925; METZGER AK, 1991, P NATL ACAD SCI USA, V88, P7825, DOI 10.1073/pnas.88.17.7825; MUKHOPADHYAY T, 1993, CANCER RES, V53, P4362; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PLUMMER SJ, 1994, ONCOGENE, V9, P3273; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; PROSSER J, 1992, BRIT J CANCER, V65, P527, DOI 10.1038/bjc.1992.109; SAMESHIMA Y, 1992, J NATL CANCER I, V84, P703, DOI 10.1093/jnci/84.9.703; SCOTT RJ, 1993, SCHWEIZ MED WSCHR, V123, P1287; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; STACK M, 1995, HUM MOL GENET, V4, P2047, DOI 10.1093/hmg/4.11.2047; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; TORY K, 1989, J NATL CANCER I, V81, P1097, DOI 10.1093/jnci/81.14.1097; Varley JM, 1996, ONCOGENE, V12, P2437; VARLEY JM, 1997, UNPUB MANUSCRIPT; WAGNER J, 1994, JNCI-J NATL CANCER I, V86, P1707, DOI 10.1093/jnci/86.22.1707; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839; WILLIAMS KJ, 1996, IN PRESS ONCOGENE; ZHU X, 1992, CYTOGENET CELL GENET, V59, P248, DOI 10.1159/000133261	66	84	85	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					865	871		10.1038/sj.onc.1201041	http://dx.doi.org/10.1038/sj.onc.1201041			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047394				2022-12-17	WOS:A1997WJ11200013
J	Florenes, VA; Bhattacharya, N; Bani, MR; BenDavid, Y; Kerbel, RS; Slingerland, JM				Florenes, VA; Bhattacharya, N; Bani, MR; BenDavid, Y; Kerbel, RS; Slingerland, JM			TGF-beta mediated G(1) arrest in a human melanoma cell line lacking p15(INK4B): Evidence for cooperation between p21(Cip1/WAF1) and p27	ONCOGENE			English	Article						G(1) arrest; TGF-beta; p15(INK4B)-negative; p27(Kip1); p21(Cip1/WAF1); melanoma	GROWTH-FACTOR-BETA; DEPENDENT KINASE INHIBITOR; RETINOBLASTOMA GENE-PRODUCT; CYCLE ARREST; CDK INHIBITOR; DNA-REPLICATION; MAMMALIAN-CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; EPITHELIAL-CELLS; PROTEIN	We have studied TGF-beta mediated G(1) arrest in WM35, an early stage human melanoma cell line. These cells have lost p15(INK4B) expression through loss of one chromosome 9 and rearrangement of the other. In asynchronously growing WM35, TGF-beta caused reductions in cyclin D1, cyclin A and cdk4 proteins and their associated kinase activities and an increase in both p21(Cip1/WAF1) and p27(Kip1). These findings were confirmed in cells released from quiescence in the presence of TGF-beta, in which TGF-beta inhibited or delayed the reduction in the cdk inhibitors that normally occurs in late G(1). In contrast to observations in other cell types, there was an increased association of both p21(Cip1/WAF1) and p27(Kip1) with cyclin D1/cdk4 and with cyclin E/cdk2 during TGF-beta mediated arrest of asynchronously growing cells. Upregulation of p21(Cip1/WAF1) preceded that of p27(Kip1). Furthermore, p21(Cip1/WAF1) and p27(Kip1) were not present in the same cdk complexes but bound distinct populations of target cdk molecules. Both p21(Cip1/WAF1) and p27(Kip1) immunoprecipitates from asynchronously growing cells contained active kinase complexes. These KIP-associated kinase activities were reduced in TGF-beta arrested cells. It has been proposed that in TGF-beta arrested epithelial cells, up-regulation of p15(INK4B) and of p15(INK4B) binding to cdk4 serves to destabilize the association of p27(Kip1) with cyclin D1/cdk4, promoting p27(Kip1) binding and inhibition of cyclin E/cdk2. Our findings demonstrate that this is not a universal mechanism of G(1) arrest by TGF-beta, In TGF-beta arrested WM35, which lack p15(INK4B), the increased p21(Cip1/WAF1) may serve a similar function to that of p15(INK4B): initiating kinase inhibition and providing an additional mechanism to supplement the effect of p27(Kip1) on G(1) cyclin/cdks.	UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DEPT MED BIOPHYS, DIV CANC BIOL, TORONTO, ON M4N 3M5, CANADA; UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DEPT MED, TORONTO, ON M4N 3M5, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center					NCI NIH HHS [CA41233] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041233] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Bani MR, 1996, CANCER RES, V56, P3075; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CORNIL I, 1991, P NATL ACAD SCI USA, V88, P6028, DOI 10.1073/pnas.88.14.6028; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; Enders GH, 1996, ONCOGENE, V12, P1239; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jiang HP, 1996, MOL CELL DIFFER, V4, P67; JIANG HP, 1995, ONCOGENE, V10, P1855; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KO TC, 1995, ONCOGENE, V10, P177; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KRAMER IM, 1994, J CELL SCI, V107, P3469; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIU L, 1995, ONCOGENE, V11, P405; LIU L, 1995, UNPUB ONCOGENE; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MacDougall John R., 1993, Molecular and Cellular Differentiation, V1, P21; MAELANDSMO GM, IN PRESS AM J PATHOL; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEI WQ, 1996, CANCER RES, V56, P264; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOSES HL, 1992, MOL REPROD DEV, V32, P179, DOI 10.1002/mrd.1080320215; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OTSUKI T, 1995, CANCER RES, V55, P1436; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; Petrocelli T, 1996, ONCOGENE, V12, P1387; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REED SI, 1994, J CELL SCI, P69; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RODECK U, 1994, CANCER RES, V54, P575; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SLINGERLAND J, 1996, UNPUB; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Welch DR, 1996, MOL CELL DIFFER, V4, P91; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	80	84	88	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	1996	13	11					2447	2457						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957087				2022-12-17	WOS:A1996VX10800018
J	Willumsen, BM; Cox, AD; Solski, PA; Der, CJ; Buss, JE				Willumsen, BM; Cox, AD; Solski, PA; Der, CJ; Buss, JE			Novel determinants of H-Ras plasma membrane localization and transformation	ONCOGENE			English	Article						palmitoylation; lipid modification; Ras transformation	POLYBASIC DOMAIN; CAAX MOTIF; PROTEINS; P21RAS; PALMITOYLATION; PALMITATE; ONCOGENE; PRODUCT; CYCLASE; SIGNAL	Although it is well-established that modification of Ras by farnesol is a critical step for its membrane association and transforming activity, the contribution of other C-terminal sequences and palmitate modification to Ras localization and function remains unclear, We have characterized H-Ras mutant proteins with alterations in the palmitoylated cysteines or in sequences flanking these residues, We found that non-palmitoylated proteins were impaired not only in membrane association but also in transforming activity, Mutations which drastically altered residues adjacent to the palmitoylated cysteine did not abolish palmitoylation, However, despite continued lipid modification the mutant proteins failed to bind to plasma membranes and instead accumulated on internal membranes and, importantly, were not transforming, Addition of an N-terminal myristoylation signal to these defective mutants, or to proteins entirely lacking the C-terminal 25 residues restored both plasma membrane association and transforming activity, Thus, H-Ras does not absolutely require prenylation or palmitoylation nor indeed its hypervariable domain in order to interact with effecters that ultimately cause transformation, However, in this native state, the C-terminus appears to provide a combination of lipids and a previously unrecognized signal for specific plasma membrane targeting that are essential for the correct localization and biological function of H-Ras.	UNIV N CAROLINA,DEPT RADIAT ONCOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; IOWA STATE UNIV SCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Iowa State University	Willumsen, BM (corresponding author), UNIV COPENHAGEN,DEPT MOL CELL BIOL,OSTER FARIMAGSGADE 2A,DK-1353 COPENHAGEN,DENMARK.		Willumsen, Berthe M/H-1903-2012	Willumsen, Berthe M/0000-0002-2277-6999; Cox, Adrienne D./0000-0002-4901-2454; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA052072, R29CA061951, R01CA042978] Funding Source: NIH RePORTER; NCI NIH HHS [CA52072, CA61951, CA42978] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Dudler T, 1996, J BIOL CHEM, V271, P11541, DOI 10.1074/jbc.271.19.11541; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GUTIERREZ L, 1991, BIOCHIM BIOPHYS ACTA, V1078, P147, DOI 10.1016/0167-4838(91)99003-B; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HORIUCHI H, 1992, MOL CELL BIOL, V12, P4515, DOI 10.1128/MCB.12.10.4515; JHAPPAN C, 1986, J VIROL, V60, P750, DOI 10.1128/JVI.60.2.750-753.1986; Kato K, 1992, Semin Cancer Biol, V3, P179; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LACAL PM, 1988, ONCOGENE, V2, P533; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LOWY DR, 1988, CELLULAR MOL BIOL TU, P203; LU JY, 1995, J BIOL CHEM, V270, P7251, DOI 10.1074/jbc.270.13.7251; NEWMAN CMH, 1992, J BIOL CHEM, V267, P12329; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1991, MOL CELL BIOL, V11, P6026, DOI 10.1128/MCB.11.12.6026; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WILLUMSEN BM, 1985, EMBO J, V4, P2893, DOI 10.1002/j.1460-2075.1985.tb04019.x; WILLUMSEN BM, 1995, METHODS ENZYMOL LIPI, V220, P269; WILSON PT, 1995, J BIOL CHEM, V270, P9967	27	84	85	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1901	1909						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934536				2022-12-17	WOS:A1996VR79500009
J	Gurniak, CB; Berg, LJ				Gurniak, CB; Berg, LJ			A new member of the Eph family of receptors that lacks protein tyrosine kinase activity	ONCOGENE			English	Article						Eph family tyrosine kinase; catalytically inactive tyrosine kinase; alternatively spliced receptor; thymus; brain	T-CELL DEVELOPMENT; SIGNAL-TRANSDUCTION; IL-2 RECEPTOR; JANUS KINASE; GAMMA-CHAIN; ZETA-CHAIN; IDENTIFICATION; ASSOCIATION; EXPRESSION; ACTIVATION	Using a PCR-based screen to identify tyrosine kinases involved in T cell development, we have cloned a new member of the Eph-family of receptor tyrosine kinases (Mep, for murine eph-family protein). At the amino acid level Mep is 60% identical to the chicken embyronic kinase Cek9. Sequence analysis indicates that the predicted extracellular portion of Mep bears an Ig-like domain, a cysteine-rich region, and sequences homologous to fibronectin type III. The transmembrane region of Mep is followed by a kinase domain. Surprisingly, this kinase domain carries amino acid substitutions in the highly conserved consensus motifs found in all protein tyrosine kinases and known to be crucial for kinase activity. We demonstrate that a bacterial fusion protein of the Mep kinase domain does not have protein tyrosine kinase activity. Analysis of Mep mRNA levels in a variety of mouse tissues shows that Mep is highly expressed in thymus and brain. We have also isolated two additional Mep cDNA clones from thymocytes which are predicted to encode secreted forms of the Mep extracellular domain; mRNAs encoding these secreted isoforms are also expressed in mouse brain.	HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSON G, 1993, NATURE, V362, P70, DOI 10.1038/362070a0; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; BURGESS KE, 1992, P NATL ACAD SCI USA, V89, P9311, DOI 10.1073/pnas.89.19.9311; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DRESCHER U, 1995, CELL, V82; Gurniak CB, 1996, BLOOD, V87, P3151, DOI 10.1182/blood.V87.8.3151.bloodjournal8783151; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARRIS WA, 1995, NEURON, V15, P241, DOI 10.1016/0896-6273(95)90000-4; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HOZUMI K, 1994, INT IMMUNOL, V6, P1451, DOI 10.1093/intimm/6.9.1451; HUEBER AO, 1994, BRAZ J MED BIOL RES, V27, P275; IHLE JN, 1994, P SOC EXP BIOL MED, V206, P268; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KIRKEN RA, 1994, J BIOL CHEM, V269, P19136; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1988, ONCOGENE, V3, P629; LU YL, 1992, J IMMUNOL, V149, P24; MACNEIL I, 1993, J IMMUNOL, V151, P6913; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MOTT R, 1992, B MATH BIOL, V54, P59, DOI 10.1007/BF02458620; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; SAMELSON LE, 1990, J IMMUNOL, V145, P2448; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHAO HN, 1995, J BIOL CHEM, V270, P5636, DOI 10.1074/jbc.270.10.5636; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; TAYLOR V, 1994, NEUROSCIENCE, V63, P163, DOI 10.1016/0306-4522(94)90014-0; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VONBOEHMER H, 1988, IMMUNOL REV, V101, P21; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057	57	84	90	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					777	786						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761299				2022-12-17	WOS:A1996VD43300013
J	Sakano, S; Serizawa, R; Inada, T; Iwama, A; Itoh, A; Kato, C; Shimizu, Y; Shinkai, F; Shimizu, R; Kondo, S; Ohno, M; Suda, T				Sakano, S; Serizawa, R; Inada, T; Iwama, A; Itoh, A; Kato, C; Shimizu, Y; Shinkai, F; Shimizu, R; Kondo, S; Ohno, M; Suda, T			Characterization of a ligand for receptor protein-tyrosine kinase HTK expressed in immature hematopoietic cells	ONCOGENE			English	Article						receptor tyrosine kinase; HTK; HTK ligand; BIAcore; hematopoietic cells	MOLECULAR-CLONING; GROWTH-FACTOR; EPH; FAMILY; GENE; B61; SIGNAL; ALPHA; ELF-1; MEK4	HTK is a receptor tyrosine kinase that belongs to the Eph subfamily. An extensive screening using BIAcore system revealed that a colon cancer cell line, C-l, expressed the ligand for HTK. From the conditioned medium of C-l cells, a soluble form of ligand was purified by receptor affinity chromatography, and the isolation of full-length cDNA revealed that this ligand is identical to the human HTK ligand (HTKL) previously reported. HTK receptor tyrosine phosphorylation was induced by membrane-bound or clustered soluble HTKL but not by unclustered soluble HTKL, indicating that HTKL requires cell-to-cell interaction for receptor activation. Binding analysis demonstrated that HTKL binds to HTK with a much higher affinity (K-d: 1.23 nM) than the other transmembrane-type ligand for Eph family, LERK-2/ELKL (K-d: 135 nM). The expression of HTK in cord blood cells was upregulated after the culture in the presence of stem cell factor. Clustered soluble HTKL stimulated the proliferation of sorted HTK+ cord blood cells and a hematopoietic cell line, UT-7/EPO from which HTK was isolated. These findings suggest the involvement of HTK-HTKL system in the proliferation of HTK+ hematopoietic progenitor cells in the hematopoietic environment.	KUMAMOTO UNIV,SCH MED,INST MOL EMBRYOL & GENET,DEPT CELL DIFFERENTIAT,KUMAMOTO 860,JAPAN; ASAHI CHEM IND CO LTD,FUNDAMENTAL RES LAB LIFE SCI,FUJI,SHIZUOKA 416,JAPAN; ASAHI CHEM IND CO LTD,LIFE SCI RES INST,BIOL RES LAB,FUJI,SHIZUOKA 416,JAPAN	Kumamoto University			Shinkai-ouchi, Fumiko/E-3207-2010; Suda, Toshio/H-6761-2013	Shinkai-ouchi, Fumiko/0000-0002-0095-941X; Suda, Toshio/0000-0001-7540-1771				BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1994, J BIOL CHEM, V269, P14211; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; EASTY DJ, 1995, CANCER RES, V55, P2528; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; KOMATSU N, 1993, BLOOD, V82, P456; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SAKANO S, 1994, ONCOGENE, V9, P1155; SHAO HN, 1994, J BIOL CHEM, V269, P26606; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; ZETTLMEISSL G, 1990, DNA CELL BIOL, V9, P347, DOI 10.1089/dna.1990.9.347	29	84	91	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					813	822						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761303				2022-12-17	WOS:A1996VD43300017
J	Chen, IT; Akamatsu, M; Smith, ML; Lung, FDT; Duba, D; Roller, PP; Fornace, AJ; OConnor, PM				Chen, IT; Akamatsu, M; Smith, ML; Lung, FDT; Duba, D; Roller, PP; Fornace, AJ; OConnor, PM			Characterization of p21(Cip1/Waf1) peptide domains required for cyclin E/Cdk2 and PCNA interaction	ONCOGENE			English	Article						Cip1; cyclin E/Cdk2; GADD45; PCNA; peptide; p53; Waf1	REPLICATION; INHIBITOR; KINASES	The cyclin-dependent kinase inhibitor p21(Cip1/Waf1) is responsible for the p53-dependent growth arrest of cells in G1 phase following DNA damage, In the present study we investigated regions of p21 involved in inhibition of the G(1)/S phase cyclin-dependent kinase, cyclin E/Cdk2, as well as regions of p21 important for binding to this kinase and recombinant PCNA, To perform these studies we synthesized a series of overlapping peptides spanning the entire p21 sequence and used them in in vitro assays with cyclin E/Cdk2-immune complexes and with recombinant p21 and PCNA proteins, One amino-terminal p21 peptide spanning amino acids 15-40, antagonized p21 binding and inhibition of cyclin E/Cdk2 kinase, Antagonism of p21 binding was, however, lost in a similar peptide lacking amino acids 15-20, or in a peptide in which cysteine-18 was substituted for a serine, These results suggest that this peptide region is important for p21 interaction with cyclin E/Cdk2, A second peptide (amino acids 58-77) also antagonized p21-activity, but this peptide did not affect the ability of p21 to interact with cyclin E/Cdk2, A region in p21 larger than 26 amino acids is presumably required for Cdk-inhibition because none of the peptides we tested inhibited cyclin E/Cdk2, We also found that a peptide spanning amino acids 21-45 bound recombinant p21 in ELISA assays, and additional studies revealed a requirement for amino acids 26 through 45 for this interaction, A p21 peptide spanning amino acids 139-164 was found to bind PCNA in a filter binding assay and this peptide suppressed recombinant p21-PCNA interaction, Conformational analysis revealed that peptides spanning amino acids 21-45 and 139-164 tended towards an alpha-helical conformation in trifluoroethanol buffer, indicating that these regions are probably in a coiled conformation in the native protein, Taken together, our results provide an insight into domains of p21 that are involved in cyclin E/Cdk2 and PCNA interaction, Our results also suggest that a potential p21 dimerization domain may lie in the amino-terminus of p21, Continued exploration of these domains could prove useful in assessing p21-mimetic strategies for cancer treatment.	NCI, MOLEC PHARMACOL LAB, NIH, BETHESDA, MD 20892 USA; NCI, MED CHEM LAB, DIV BASIC SCI, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X				BAE IS, 1995, CANCER RES, V55, P2387; BHATIA K, 1995, CANCER RES, V55, P1431; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHEN IT, 1995, IN PRESS ONCOGENE; CHEN J, 1995, UNPUB; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Draetta Giulio, 1993, Trends in Cell Biology, V3, P287, DOI 10.1016/0962-8924(93)90001-H; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GOUBIN F, 1995, ONCOGENE, V10, P2281; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALL PA, 1995, ONCOGENE, V10, P2427; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUPPI K, 1994, ONCOGENE, V9, P3017; JIANG HP, 1994, ONCOGENE, V9, P3397; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MICHIELI P, 1994, CANCER RES, V54, P3391; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER M, 1995, CELL, V267, P1024; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; SCHULZ GE, 1990, PRINCIPLE PROTEIN ST, P102; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAKUT R, 1995, ONCOGENE, V11, P393; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHAN QM, 1995, INT J ONCOL, V6, P937; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG W, 1995, CANCER RES, V55, P668; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x	53	84	89	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					595	607						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637717				2022-12-17	WOS:A1996TV59700017
J	PASINI, B; HOFSTRA, RMW; YIN, L; BOCCIARDI, R; SANTAMARIA, G; GROOTSCHOLTEN, PM; CECCHERINI, I; PATRONE, G; PRIOLO, M; BUYS, CHCM; ROMEO, G				PASINI, B; HOFSTRA, RMW; YIN, L; BOCCIARDI, R; SANTAMARIA, G; GROOTSCHOLTEN, PM; CECCHERINI, I; PATRONE, G; PRIOLO, M; BUYS, CHCM; ROMEO, G			THE PHYSICAL MAP OF THE HUMAN RET PROTOONCOGENE	ONCOGENE			English	Article						RET PROTOONCOGENE; GENE STRUCTURE; MEN 2; HIRSCHSPRUNG DISEASE; CHROMOSOME 10	C-KIT GENE; TYROSINE KINASE; SEQUENCE SIMILARITY; PROTOONCOGENE RET; TRANSFORMING GENE; CDNA CLONING; CELL-LINE; LONG ARM; DNA; RECEPTOR	The RET proto-oncogene, a transmembrane tyrosine kinase receptor, is involved in the development of at least five different disease phenotypes. RET is activated through somatic rearrangements in a number of cases of papillary thyroid carcinoma while germ-line point mutations are associated with three inherited cancer syndromes MEN 2A, MEN 2B and FMTC. Moreover, point mutations or heterozygous deletions of RET are found in the dominant form of Hirschsprung disease or congenital colonic aganglionosis. We cloned the entire RET genomic sequence in a contig of cosmids encompassing 150 kb, from the CA repeat sTCL-2 to the region upstream the RET promoter, and established the position of the 20 exons of the RET gene with respect to a detailed restriction map based on eight endonucleases. A new highly polymorphic CA repeat sequence was identified within intron 5 of RET (RET-INT5). Finally the orientation of RET on chromosome 10q11.2 made it possible to orientate three other genes rearranged with RET in papillary thyroid carcinomas, namely H4/D10S170 on 10q21, R1 alpha on 17q23 and RFG2/Ele1 on 10q11.2.	IST GIANNINA GASLINI, GENET MOLEC LAB, I-16147 GENOA, ITALY; UNIV GRONINGEN, DEPT MED GENET, 9713 AW GRONINGEN, NETHERLANDS	University of Genoa; IRCCS Istituto Giannina Gaslini; University of Groningen			Ceccherini, Isabella/P-8195-2014; Bocciardi, Renata/J-8577-2016; Pasini, Barbara/AHI-2004-2022; Santamaria, Giuseppe/AAB-4185-2021	Ceccherini, Isabella/0000-0001-8732-1955; Bocciardi, Renata/0000-0001-8415-3802; Pasini, Barbara/0000-0002-4373-1212; Santamaria, Giuseppe/0000-0002-7686-6703; Hofstra, Robert/0000-0001-7498-3829				ANDRE C, 1992, ONCOGENE, V7, P685; ANGRIST M, 1995, HUM MOL GENET, V4, P821, DOI 10.1093/hmg/4.5.821; ASAI N, 1995, MOL CELL BIOL, V15, P1613; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V9, P244; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; CARLSON KM, 1994, HUM MOL GENET, V3, P1207; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CECCHERINI I, 1994, ONCOGENE, V9, P3025; CECCHERINI I, 1993, BIOCHEM BIOPH RES CO, V196, P1288, DOI 10.1006/bbrc.1993.2392; CONSALEZ GG, 1992, GENOMICS, V14, P557, DOI 10.1016/S0888-7543(05)80151-X; DAUWERSE HG, 1989, NUCLEIC ACIDS RES, V17, P3603, DOI 10.1093/nar/17.9.3603; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, J MED GENET, V31, P602, DOI 10.1136/jmg.31.8.602; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, GENE CHROMOSOME CANC, V12, P209, DOI 10.1002/gcc.2870120308; GARDNER E, 1994, HUM MOL GENET, V3, P1771, DOI 10.1093/hmg/3.10.1771; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ITOH F, 1992, ONCOGENE, V7, P1201; IWAMOTO T, 1993, ONCOGENE, V8, P1087; KUMA K, 1993, MOL BIOL EVOL, V10, P539; LAIRMORE TC, 1993, P NATL ACAD SCI USA, V90, P492, DOI 10.1073/pnas.90.2.492; LINDOR NM, 1995, J CLIN ENDOCR METAB, V80, P627, DOI 10.1210/jc.80.2.627; LORENZO MJ, 1995, ONCOGENE, V10, P1377; LYONNET S, 1993, NAT GENET, V4, P346, DOI 10.1038/ng0893-346; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MINOLETTI F, 1994, GENE CHROMOSOME CANC, V11, P51, DOI 10.1002/gcc.2870110108; MOLE SE, 1993, HUM MOL GENET, V2, P247, DOI 10.1093/hmg/2.3.247; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SANTORO M, 1994, ONCOGENE, V9, P509; SCHNEIDER C, 1991, CLONIGN YAC VECTORS; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCHUFFENECKER I, 1994, HUM MOL GENET, V3, P1939, DOI 10.1093/hmg/3.11.1939; SCHUSTER MK, 1994, HUM MOL GENET, V3, P677, DOI 10.1093/hmg/3.4.677; SCOTT A F, 1987, Genomics, V1, P113, DOI 10.1016/0888-7543(87)90003-6; SHERR CJ, 1990, BLOOD, V75, P1; SMITH CL, 1988, GENOME ANAL PRACTICA; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SOZZI G, 1994, GENE CHROMOSOME CANC, V9, P244, DOI 10.1002/gcc.2870090404; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TSUZUKI T, 1995, ONCOGENE, V10, P191; VANDENBARK GR, 1992, ONCOGENE, V7, P1259; XING SH, 1994, BIOCHEM BIOPH RES CO, V205, P1526, DOI 10.1006/bbrc.1994.2840; YIN L, 1993, HUM MOL GENET, V2, P1803; Yin Luo, 1994, European Journal of Human Genetics, V2, P272	61	84	92	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	1995	11	9					1737	1743						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478601				2022-12-17	WOS:A1995TD09400008
J	LANDGREN, E; BLUMEJENSEN, P; COURTNEIDGE, SA; CLAESSONWELSH, L				LANDGREN, E; BLUMEJENSEN, P; COURTNEIDGE, SA; CLAESSONWELSH, L			FIBROBLAST GROWTH-FACTOR RECEPTOR-1 REGULATION OF SRC FAMILY KINASES	ONCOGENE			English	Article						FGF RECEPTOR; SRC FAMILY KINASES; REGULATION	PROTEIN-TYROSINE KINASE; B-TYPE RECEPTOR; SIGNAL-TRANSDUCTION; C-SRC; PDGF RECEPTOR; SH2 DOMAIN; PHOSPHOLIPASE C-GAMMA-1; BETA-RECEPTOR; CDNA CLONING; PHOSPHORYLATION	Fibroblast growth factors (FGFs) induce proliferation and differentiation of a wide variety of cells by stimulation of cell surface expressed high affinity-binding receptor tyrosine kinases. Members of the Src family of cytoplasmic tyrosine kinases are substrates for certain growth factor receptors, We have examined interactions between FGF receptor-1 (FGFR-1) and Src, Fyn and Yes. In lung capillary endothelial cells and murine fibroblasts, bFGF stimulation led to increased autophosphorylation of Src family members, In contrast, in porcine aortic endothelial cells (FGFR-1/PAE) and lung fibroblasts from chinese hamster (CCL 39), activation of FGFR caused reduced autophosphorylation of Src and Fyn. In neither case could complex-formation between Src members and FGFR be seen, Analysis of a panel of mutated FGFR-1 expressed in PAE cells showed that FGFR-1/Y766F mediated an increased autophosphorylation of Src members and upregulation of their kinase activities, Y766 in FGFR-1 has been shown to serve as a binding site for phospholipase C-gamma, which regulates Ca2+ fluxes and protein kinase C (PKC) activity. The negative effect on Src kinase activity upon FGFR stimulation was mimicked by activation of PKC in FGFR-1/PAE or CCL 39 cells using phorbol 12-myristate 13-acetate (PMA) and Src was phosphorylated in vitro by purified recombinant PKC alpha. Moreover, inhibition of PBC attenuated the bFGF induced decrease in autophosphorylation of Src family members, These data indicate a negative regulatory role for PRC on Src kinase activity in certain cell types.	EUROPEAN MOLEC BIOL LAB, DIFFERENTIAT PROGRAMME, W-6900 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)	LANDGREN, E (corresponding author), BIOMED CTR, LUDWIG INST CANC RES, UPPSALA BRANCH, BOX 595, S-75124 UPPSALA, SWEDEN.			Claesson-Welsh, Lena/0000-0003-4275-2000				ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CASSEL D, 1983, P NATL ACAD SCI-BIOL, V80, P6224, DOI 10.1073/pnas.80.20.6224; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CHINKERS M, 1986, J BIOL CHEM, V261, P8295; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COCHET C, 1984, J BIOL CHEM, V259, P2553; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; FARESE RV, 1992, CELL SIGNAL, V4, P133, DOI 10.1016/0898-6568(92)90077-L; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GANDINO L, 1990, ONCOGENE, V5, P721; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HOU JZ, 1993, PROTEIN SCI, V2, P86; IWASHITA S, 1992, CELL SIGNAL, V4, P123, DOI 10.1016/0898-6568(92)90076-K; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MIYAZONO K, 1987, J BIOL CHEM, V262, P4098; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MOYERS JS, 1993, MOL CELL BIOL, V13, P2391, DOI 10.1128/MCB.13.4.2391; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OKADA M, 1993, J BIOL CHEM, V268, P18070; OKADA M, 1991, J BIOL CHEM, V266, P24249; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SOROKIN A, 1994, J BIOL CHEM, V269, P17056; STABEL S, 1991, METHOD ENZYMOL, V200, P670; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WENNSTROM S, 1992, J BIOL CHEM, V267, P13749; Wennstrom S, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104816; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; ZHAN X, 1994, J BIOL CHEM, V269, P20221	51	84	86	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	1995	10	10					2027	2035						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761103				2022-12-17	WOS:A1995QZ92600017
J	RENZING, J; LANE, DP				RENZING, J; LANE, DP			P53-DEPENDENT GROWTH ARREST FOLLOWING CALCIUM PHOSPHATE-MEDIATED TRANSFECTION OF MURINE FIBROBLASTS	ONCOGENE			English	Note						P53; GROWTH ARREST; CALCIUM PHOSPHATE TRANSFECTION	P53 PROTEIN; DNA; INDUCTION; UV	A variety of genotoxic agents can induce an accumulation of p53 protein in the nuclei of mammalian cells and lead to either growth arrest or apoptosis in a p53-dependent manner. Recently, the induction of the p53 pathway has also been reported for non-genotoxic agents such as heat shock and hypoxia, rendering it likely that p53 activity might be triggered by a wider range of cellular stress factors. Here we report the effect of calcium phosphate-mediated transfection, a technique commonly used in studies of transient gene expression in mammalian cells, on fibroblasts containing wild-type p53. Incubation with a calcium phosphate precipitate results in a transient growth arrest in the presence or absence of plasmid DNA. The effect is accompanied by a rise in p53 protein levels and increased transcription of a p53-dependent reporter construct and is not observed in fibroblasts derived from p53 knockout mice.	UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DOVER R, 1994, J CELL SCI, V107, P1181; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FREBOURG T, 1992, CANCER RES, V52, P6976; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HALL PA, 1993, ONCOGENE, V8, P203; HARVEY M, 1993, ONCOGENE, V8, P2457; KASTAN MB, 1991, CANCER RES, V51, P6304; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MANIATIS T, 1990, MOL CLONING; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	16	84	87	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1865	1868						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753562				2022-12-17	WOS:A1995QX46900020
J	BARKER, KT; MARTINDALE, JE; MITCHELL, PJ; KAMALATI, T; PAGE, MJ; PHIPPARD, DJ; DALE, TC; GUSTERSON, BA; CROMPTON, MR				BARKER, KT; MARTINDALE, JE; MITCHELL, PJ; KAMALATI, T; PAGE, MJ; PHIPPARD, DJ; DALE, TC; GUSTERSON, BA; CROMPTON, MR			EXPRESSION PATTERNS OF THE NOVEL RECEPTOR-LIKE TYROSINE KINASE, DDR, IN HUMAN BREAST-TUMORS	ONCOGENE			English	Article						DDR (DISCOIDIN DOMAIN RECEPTOR); PROTEIN TYROSINE KINASE; BREAST TUMOR; IN SITU HYBRIDIZATION	GROWTH-FACTOR RECEPTORS; HUMAN INSULIN-RECEPTOR; PROTEIN OVEREXPRESSION; SIGNAL TRANSDUCTION; DISCOIDIN-I; CANCER; ONCOGENE; FAMILY; AMPLIFICATION; DISEASE	Using a reverse transcriptase-polymerase chain reaction based differential screening procedure, Rie have identified the discoidin domain receptor as a protein tyrosine kinase that is expressed in lymph nodes containing breast tumour metastases. By Northern blotting and in situ hybridisation we have demonstrated the expression of the discoidin domain receptor in human primary breast tumour samples, metastasis-containing lymph nodes and a numb;er of normal tissues. Direct comparison of malignant breast and adjacent normal epithelial tissue revealed over expression in the tumour cells.	INST CANC RES,CELL BIOL & EXPTL PATHOL SECT,SUTTON SM2 5NG,SURREY,ENGLAND; WELLCOME RES LABS,DEPT CELL BIOL,BECKENHAM BR3 3BS,KENT,ENGLAND	University of London; Institute of Cancer Research - UK; GlaxoSmithKline; Wellcome Research Laboratories			gusterson, barry a/D-3752-2009; Dale, Trevor C/D-3749-2009; Mitchell, Philip J/F-6393-2013	Dale, Trevor C/0000-0002-4880-9963; 				ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; BOLEN JB, 1993, ONCOGENE, V8, P2025; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FOX SB, 1994, BREAST CANCER RES TR, V29, P41, DOI 10.1007/BF00666180; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GASPARINI G, 1994, BREAST CANCER RES TR, V29, P59, DOI 10.1007/BF00666182; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HENNIPMAN A, 1989, CANCER RES, V49, P516; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; KARN T, 1993, ONCOGENE, V8, P3433; KLIJN JGM, 1994, BREAST CANCER RES TR, V29, P73, DOI 10.1007/BF00666183; LAI C, 1994, ONCOGENE, V9, P877; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LATHE R, 1989, IN SITU HYBRIDISATIO, P71; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; MARSHALL E, 1993, SCIENCE, V259, P618, DOI 10.1126/science.8430308; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PATERSON MC, 1991, CANCER RES, V51, P556; PEREZ R, 1984, BREAST CANCER RES TR, V4, P189, DOI 10.1007/BF01806484; RAJKUMAR T, 1994, BREAST CANCER RES TR, V29, P3, DOI 10.1007/BF00666177; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SAINSBURY JRC, 1985, LANCET, V1, P364; Sambrook J., 1989, MOL CLONING LAB MANU; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPRINGER WR, 1984, CELL, V39, P557, DOI 10.1016/0092-8674(84)90462-8; TOI M, 1994, BREAST CANCER RES TR, V29, P51, DOI 10.1007/BF00666181; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YIE Y, 1993, NUCLEIC ACIDS RES, V21, P361, DOI 10.1093/nar/21.2.361; ZERLIN M, 1993, ONCOGENE, V8, P2731	48	84	92	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					569	575						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845682				2022-12-17	WOS:A1995QF64800018
J	LIU, QY; YAN, YX; MCCLURE, M; NAKAGAWA, H; FUJIMURA, F; RUSTGI, AK				LIU, QY; YAN, YX; MCCLURE, M; NAKAGAWA, H; FUJIMURA, F; RUSTGI, AK			MTS-1 (CDKN2) TUMOR-SUPPRESSOR GENE DELETIONS ARE A FREQUENT EVENT IN ESOPHAGUS SQUAMOUS CANCER AND PANCREATIC ADENOCARCINOMA CELL-LINES	ONCOGENE			English	Note						TUMOR SUPPRESSOR GENE; ESOPHAGUS CANCER; PANCREAS CANCER	BLADDER-CANCER; CHROMOSOME-9; EXPRESSION; RETINOBLASTOMA; MUTATION; RECEPTOR; REGION	MTS-1 is a candidate tumor suppressor gene on chromosome 9p21-22, a region frequently observed to have loss of heterozygosity in esophagus squamous cell carcinomas and pancreatic ductal adenocarcinomas. In order to determine whether MTS-1 sequences are deleted or mutated in cell lines derived from these cancers, we performed PCR amplification of MTS-1 exons 1 and 2. In this fashion, we found that 67% of esophagus squamous cancer cell lines have deletions of both exons 1 and 2, and 50% of pancreatic cancer cell lines have similar deletions. Furthermore, an additional 30% of pancreatic cancer cell lines harbored point mutations or microdeletions based on DNA sequencing. MTS-1 encodes p16, an inhibitor of cyclin-dependent kinase 4 (cdk4) which complexes with cyclin D1. Our data suggest that MTS-1 deletions and mutations may play an important role in the molecular pathogenesis of esophagus squamous cell and pancreatic cancers.	HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, GASTROINTESTINAL UNIT, BOSTON, MA 02114 USA; MYRIAD GENET INC, SALT LAKE CITY, UT 84108 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Myriad Genetics, Inc								ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARTON CM, 1991, BRIT J CANCER, V64, P1076, DOI 10.1038/bjc.1991.467; CAIRNS P, 1993, CANCER RES, V53, P1230; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; HOHNE MW, 1992, CANCER RES, V52, P2616; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HORII A, 1992, CANCER RES, V52, P6696; HUANG Y, 1992, CANCER RES, V52, P6525; JAMES CD, 1993, CANCER RES, V53, P3674; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1992, CANCER RES, V52, P2980; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KORC M, 1986, P NATL ACAD SCI USA, V83, P5141, DOI 10.1073/pnas.83.14.5141; LU SH, 1988, INT J CANCER, V42, P502, DOI 10.1002/ijc.2910420406; MERLO A, 1994, CANCER RES, V54, P640; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; REDSTON MS, 1994, CANCER RES, V54, P3025; RODRIGUEZ E, 1994, CANCER RES, V54, P3398; RUPPERT JM, 1993, CANCER RES, V53, P5093; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SEYMOUR AB, 1994, CANCER RES, V54, P2761; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; VANDERRIET P, 1994, CANCER RES, V54, P1156	26	84	88	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	1995	10	3					619	622						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845688				2022-12-17	WOS:A1995QF64800024
J	HAINAUT, P; ROLLEY, N; DAVIES, M; MILNER, J				HAINAUT, P; ROLLEY, N; DAVIES, M; MILNER, J			MODULATION BY COPPER OF P53 CONFORMATION AND SEQUENCE-SPECIFIC DNA-BINDING - ROLE FOR CU(II) CU(I) REDOX MECHANISM	ONCOGENE			English	Article						P53; REGULATION; REDOX; COPPER; DNA BINDING	TUMOR-SUPPRESSOR P53; GENE-EXPRESSION; WILD-TYPE; MALTOSE-BINDING; METAL-IONS; PROTEIN; FORMS; HYDROQUINONE; COMPLEXES; OXIDATION	The tumor suppressor protein p53 is a metal-binding transcription factor whose conformation and function are altered by mutation in cancers. Using murine p53 translated in vitro, we report here that concentrations of copper within the physiological range (< 30 mu M) alter the conformation of wild-type p53 and inhibit sequence-specific DNA-binding. Direct binding of copper to p53 in the form of Cu(I) was demonstrated by Electron Spin Resonance using a purified recombinant protein containing residues 1-343 of murine wild-type p53 fused to E. coli maltose binding protein. Moreover, protection against the effect of Cu(II) sulfate was achieved by the Cu(I)-specific chelator bathocuproinedisulfonic acid but not by scavengers of reactive oxygen species, suggesting that alteration of p53 by copper depends upon a Cu(II)/Cu(I) redox mechanism, but does not require the production of reactive oxygen species. Thus copper at physiological concentrations can interact with wild-type p53 and affect its DNA-binding capacity.	UNIV YORK,DEPT CHEM,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK	HAINAUT, P (corresponding author), UNIV YORK,DEPT BIOL,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Davies, Michael/AGX-9184-2022; Davies, Michael J/H-4939-2011; Davies, Michael/GWV-2527-2022; Hainaut, Pierre/B-6018-2012	Davies, Michael/0000-0002-5196-6919; Davies, Michael J/0000-0002-5196-6919; Hainaut, Pierre/0000-0002-1303-1610				ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BUTCHER S, 1994, BIOCHEM J, V298, P513, DOI 10.1042/bj2980513; CANTOR KP, 1966, P NATL ACAD SCI USA, V55, P642, DOI 10.1073/pnas.55.3.642; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DUPLAY P, 1984, J BIOL CHEM, V259, P606; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRANKEL AD, 1987, P NATL ACAD SCI USA, V84, P4841, DOI 10.1073/pnas.84.14.4841; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GIEDROC DP, 1986, P NATL ACAD SCI USA, V83, P8452, DOI 10.1073/pnas.83.22.8452; GIEDROC DP, 1986, BIOCHEMISTRY-US, V25, P4969, DOI 10.1021/bi00365a037; Goodman BA, 1970, ADV INORG CHEM RAD, V13, P135, DOI DOI 10.1016/S0065-2792(08)60336-2; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1994, ONCOGENE, V8, P299; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HASSAPOGLIDOU S, 1993, ONCOGENE, V8, P1501; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; Jameson R. F, 1981, MET IONS BIOL SYST, V12, P1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LI YB, 1993, CARCINOGENESIS, V14, P1303, DOI 10.1093/carcin/14.7.1303; LI YB, 1993, ARCH BIOCHEM BIOPHYS, V300, P346, DOI 10.1006/abbi.1993.1047; MARGALIOTH EJ, 1983, CANCER, V52, P868, DOI 10.1002/1097-0142(19830901)52:5<868::AID-CNCR2820520521>3.0.CO;2-K; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; OHALLORAN TV, 1989, MET IONS BIOL SYST, V25, P105; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; POSWILLO DE, 1971, NATURE, V231, P447, DOI 10.1038/231447a0; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; SRINIVASAN R, 1993, CANCER RES, V53, P5361; WACKER WEC, 1959, J BIOL CHEM, V234, P3257; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575	38	84	84	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					27	32						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824276				2022-12-17	WOS:A1995QA98000004
J	HOLLAND, EA; BEATON, SC; EDWARDS, BG; KEFFORD, RF; MANN, GJ				HOLLAND, EA; BEATON, SC; EDWARDS, BG; KEFFORD, RF; MANN, GJ			LOSS OF HETEROZYGOSITY AND HOMOZYGOUS DELETIONS ON 9P21-22 IN MELANOMA	ONCOGENE			English	Article							CYTOGENETIC ANALYSIS; LINKAGE MAP; SHORT ARM; CHROMOSOME-9; REGION; LOCUS; GENES	Recent studies have implicated chromosome 9p21-22 as a location for a gene involved in cutaneous melanoma (CM). Deletion mapping in 35 matched tumour-constitutional DNA pairs from metastatic melanomas (including one melanoma cell line) and one dysplastic naevus has been performed using six short tandem repeat polymorphic (STRP) markers (D9S157-D9S162-LFNA-D9S171-D9S126-D9S104) which span approximately 19 cM across the 9p21-22 region. Both heterozygous and homozygous deletions were observed across the region in melanomas from both sporadic and familial cases. Overall 57% (20/35) of the samples displayed some form of loss. A deletion map identifies two areas of common loss either side of the interferon gene cluster. Familial CM has previously been shown to link to the more proximal of these regions. The deleted region distal to IFNA has not been previously described in melanoma. The results imply the involvement of more than one tumour suppressor gene on 9p in CM.			HOLLAND, EA (corresponding author), UNIV SYDNEY,WESTMEAD CTR,DEPT MED ONCOL,WESTMEAD,NSW 2145,AUSTRALIA.		Mann, Graham J/G-4758-2014	Mann, Graham J/0000-0003-1301-405X; Kefford, Richard/0000-0001-9251-9229				ANDERSEN TI, 1992, GENE CHROMOSOME CANC, V4, P113, DOI 10.1002/gcc.2870040203; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CENTER R, 1993, GENE CHROMOSOME CANC, V7, P47, DOI 10.1002/gcc.2870070108; COLEMAN A, 1993, AM J HUM GENET S, V53, pA287; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; DRACOPOLI NC, 1985, P NATL ACAD SCI USA, V82, P1470, DOI 10.1073/pnas.82.5.1470; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOUNTAIN JW, 1990, CANCER SURV, V9, P645; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; FOUNTAIN JW, 1992, GENOMICS, V14, P105, DOI 10.1016/S0888-7543(05)80290-3; FOUNTAIN JW, 1993, AM J HUM GENET S, V53, pA170; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; Greene MH, 1979, HUMAN MALIGNANT MELA, P139; HALUSKA FG, 1993, AM J HUM GENET S, V53, pA306; JAMES CD, 1993, CANCER RES, V53, P3674; JONASSON J, 1977, J CELL SCI, V24, P217; KARLBOM AE, 1993, HUM GENET, V92, P169; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KWIATKOWSKI DJ, 1992, HUM MOL GENET, V1, P658, DOI 10.1093/hmg/1.8.658-a; KWIATKOWSKI DJ, 1993, CYTOGENET CELL GENET, V64, P94; LINDBLOM A, 1993, HUM GENET, V91, P6; MACLENNAN R, 1992, J NATL CANCER I, V84, P1427, DOI 10.1093/jnci/84.18.1427; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; NANCARROW DJ, 1993, AM J HUM GENET, V53, P936; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; OLOPADE OI, 1993, CANCER RES, V53, P2410; OLOPADE OI, 1992, CANCER RES, V52, P2523; PETTY EM, 1993, AM J HUM GENET, V53, P96; RUSTGI AK, 1992, ANNU REV MED, V43, P61, DOI 10.1146/annurev.me.43.020192.000425; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWECHHEIMER K, 1993, CLIN INVESTIGATOR, V71, P488; TAGUCHI T, 1993, CANCER RES, V53, P4349; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WILKIE PJ, 1992, GENOMICS, V12, P607, DOI 10.1016/0888-7543(92)90456-3; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488	37	84	86	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1361	1365						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152796				2022-12-17	WOS:A1994NH40100007
J	BARE, DJ; LAUDER, JM; WILKIE, MB; MANESS, PF				BARE, DJ; LAUDER, JM; WILKIE, MB; MANESS, PF			P59(FYN) IN RAT-BRAIN IS LOCALIZED IN DEVELOPING AXONAL TRACTS AND SUBPOPULATIONS OF ADULT NEURONS AND GLIA	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; NERVE GROWTH CONE; SRC GENE-PRODUCT; CEREBRAL-CORTEX; MOUSE; RECEPTOR; PROTOONCOGENE; PP60C-SRC; FAMILY	Expression of the c-fyn proto-oncogene was analysed in the developing and adult rat brain by subcellular fractionation and immunocytochemistry using polyclonal antibodies specific for its protein product (p59fyn). Immunoperoxidase staining revealed widespread localization of p59fyn in developing axonal tracts throughout the fetal (E18) rat brain. fyn immunoreactivity was not observed in most axon-rich regions of the adult brain, but continued to be expressed at elevated levels in the adult olfactory and vomeronasal systems. At other sites in the adult rat brain, fyn immunoreactivity was restricted to cell bodies of neuronal subpopulations, especially those in brain stem and hypothalamic nuclei, and to subpopulations of glial cells along axonal tracts in the medulla, optic nerve and white matter of the spinal cord. In the peripheral nervous system, fyn staining was also prominent in Schwann cells. Subcellular fractionation of fetal and adult rat brain confirmed the immunocytochemical localization, demonstrating an enrichment of p59fyn in membranes from a fetal brain fraction containing nerve growth cones, and lower levels in adult brain where there was only a small enrichment in synaptosomal membranes. The developmental regulation of p59fyn suggests that the fyn tyrosine kinase may serve separate cellular roles in axonal growth and specialized functions of mature neurons and glia.	UNIV N CAROLINA, SCH MED, DEPT CELL BIOL & ANAT, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NEI NIH HHS [EY06336] Funding Source: Medline; NINDS NIH HHS [NS26620] Funding Source: Medline; NATIONAL EYE INSTITUTE [F32EY006336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026620] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATASHI JR, 1992, NEURON, V8, P831, DOI 10.1016/0896-6273(92)90197-L; BARBER PC, 1978, BRAIN RES, V147, P297, DOI 10.1016/0006-8993(78)90841-7; BISCARDI JS, 1993, IN PRESS EXP EYE RES; COHEN RS, 1977, J CELL BIOL, V74, P181, DOI 10.1083/jcb.74.1.181; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; FENTRESS JC, 1981, ANAT EMBRYOL, V163, P275, DOI 10.1007/BF00315705; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; GRAZIADEI PPC, 1978, NEURONAL PLASTICITY; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IGNELZI MA, 1992, J COMP NEUROL, V315, P171, DOI 10.1002/cne.903150205; IGNELZI MA, 1992, SOC NEUR ABSTR, V4614, P1095; INGRAHAM CA, 1992, ONCOGENE, V7, P95; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBEAU JM, 1991, J NEUROSCI RES, V28, P299, DOI 10.1002/jnr.490280217; LIUZZI FJ, 1987, BRAIN RES, V403, P385, DOI 10.1016/0006-8993(87)90081-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MEIRI KF, 1986, P NATL ACAD SCI USA, V83, P3537, DOI 10.1073/pnas.83.10.3537; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PFENNINGER KH, 1983, CELL, V35, P573, DOI 10.1016/0092-8674(83)90191-5; POMEROY SL, 1990, J NEUROSCI, V10, P1952; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SIMKOWITZ P, 1989, J NEUROSCI, V9, P1004; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWLE AC, 1984, J HISTOCHEM CYTOCHEM, V32, P766, DOI 10.1177/32.7.6145741; UNGER JW, 1991, NEUROSCIENCE, V42, P853, DOI 10.1016/0306-4522(91)90049-T; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WOODHAMS PL, 1981, ANAT EMBRYOL, V163, P331, DOI 10.1007/BF00315709; ZHAO YH, 1991, ONCOGENE, V6, P1725	38	84	85	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1993	8	6					1429	1436						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502471				2022-12-17	WOS:A1993LE06400005
J	WONG, S; REYNOLDS, AB; PAPKOFF, J				WONG, S; REYNOLDS, AB; PAPKOFF, J			PLATELET ACTIVATION LEADS TO INCREASED C-SRC KINASE-ACTIVITY AND ASSOCIATION OF C-SRC WITH AN 85-KDA TYROSINE PHOSPHOPROTEIN	ONCOGENE			English	Article							GLYCOPROTEIN-IIB-IIIA; CELL ANTIGEN RECEPTOR; AMINO-TERMINAL DOMAIN; PROTEIN-KINASE; MONOCLONAL-ANTIBODIES; RAPID PHOSPHORYLATION; SIGNAL TRANSDUCTION; CYTOPLASMIC DOMAINS; STABLE ASSOCIATION; MEMBRANE SKELETON	We have used platelets as a model system to study the function of c-src in signal transduction and cell adhesion. Numerous proteins were found to be phosphorylated on tyrosine in response to thrombin-induced platelet activation and aggregation. Two phases of phosphorylation were observed, with the second phase, but not the first, being inhibited by blocking platelet aggregation with an Arg-Gly-Asp-Ser tetrapeptide. As a first step towards identifying those proteins phosphorylated on tyrosine and to determine the specific role of p60src during platelet activation, we looked for changes in p60src kinase activity and for associations of p60src with other tyrosine phosphoproteins. The data presented here demonstrate an increase in p60src kinase activity within 1 min of thrombin-induced activation. Furthermore, p60src transiently associates with a tyrosine phosphoprotein during platelet activation and aggregation. This tyrosine phosphoprotein, p80/85, is a previously characterized cytoskeletal substrate for v-src in transformed cells. The data presented here suggest a model in which p60src functions in platelets to link upstream events, such as cell-surface adhesive interactions, with changes in platelet shape and cytoskeletal organization.	SYNTEX INC, S3-1, 3401 HILLVIEW AVE, PALO ALTO, CA 94304 USA; ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38105 USA	Syntex Corporation; St Jude Children's Research Hospital								AIKEN ML, 1990, BLOOD, V76, P2501; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHALUPNY NJ, 1991, EMBO J, V10, P121; DEGROOT PG, 1990, BRIT J HAEMATOL, V75, P308; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FERRELL JE, 1990, ONCOGENE, V5, P1033; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FINDIK D, 1988, FEBS LETT, V235, P51, DOI 10.1016/0014-5793(88)81232-8; FOX JEB, 1988, BIOESSAYS, V8, P14, DOI 10.1002/bies.950080105; FOX JEB, 1990, J CELL BIOL, V111, P483, DOI 10.1083/jcb.111.2.483; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; HARRIS AS, 1990, P NATL ACAD SCI USA, V87, P3009, DOI 10.1073/pnas.87.8.3009; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORAK ID, 1990, ONCOGENE, V5, P597; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; ISHIHARA N, 1985, THROMB HAEMOSTASIS, V54, P579; KAMPS MP, 1988, ONCOGENE, V2, P305; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KIEFFER N, 1990, ANNU REV CELL BIOL, V6, P329; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KROLL MH, 1989, BLOOD, V74, P1181; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEUNG LLK, 1984, J CLIN INVEST, V74, P1764, DOI 10.1172/JCI111595; LING E, 1988, J BIOL CHEM, V263, P2209; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MCGREGOR JL, 1989, J BIOL CHEM, V264, P501; MOSHER DF, 1990, ANNU REV MED, V41, P85; NAKAMURA S, 1985, FEBS LETT, V184, P56, DOI 10.1016/0014-5793(85)80652-9; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; NAKAMURA S, 1988, EUR J BIOCHEM, V174, P471, DOI 10.1111/j.1432-1033.1988.tb14122.x; NIEVELSTEIN PFEM, 1988, HAEMOSTASIS, V18, P342; OCKENHOUSE CF, 1989, J CLIN INVEST, V84, P468, DOI 10.1172/JCI114188; RENDU F, 1989, BLOOD, V73, P1545; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; TREZZINI C, 1990, IMMUNOLOGY, V71, P29; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; TUY FPD, 1983, NATURE, V305, P435; VARSHNEY GC, 1986, FEBS LETT, V205, P97, DOI 10.1016/0014-5793(86)80873-0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; VEILLETTE A, 1989, NATURE, V338, P275; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; ZHAO YH, 1990, ONCOGENE, V5, P1629	57	84	86	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2407	2415						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1281303				2022-12-17	WOS:A1992KA85600005
J	POGNONEC, P; BOULUKOS, KE; GHYSDAEL, J				POGNONEC, P; BOULUKOS, KE; GHYSDAEL, J			THE C-ETS-1 PROTEIN IS CHROMATIN ASSOCIATED AND BINDS TO DNA INVITRO	ONCOGENE			English	Article											POGNONEC, P (corresponding author), INST PASTEUR,CNRS,UA 041160,INSERM,U186,F-59019 LILLE,FRANCE.		GHYSDAEL, Jacques/F-3377-2013					BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHEN JH, 1988, ONCOGENE RES, V2, P371; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; ELGIN SCR, 1984, NATURE, V309, P213, DOI 10.1038/309213a0; FUJIWARA S, 1988, ONCOGENE, V2, P99; GEGONNE A, 1987, MOL CELL BIOL, V7, P806, DOI 10.1128/MCB.7.2.806; GHYSDAEL J, 1986, EMBO J, V5, P2251, DOI 10.1002/j.1460-2075.1986.tb04492.x; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GRAF T, 1979, VIROLOGY, V99, P431, DOI 10.1016/0042-6822(79)90024-2; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KAUFMANN Y, 1987, J EXP MED, V166, P810, DOI 10.1084/jem.166.3.810; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; MULLER R, 1987, ONCOGENE RES, V2, P19; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; RENZ M, 1987, NUCLEIC ACIDS RES, V15, P277, DOI 10.1093/nar/15.1.277; ROUSSEL M, 1979, NATURE, V281, P453; SAMBUCETTI LC, 1986, SCIENCE, V234, P1417, DOI 10.1126/science.3491427; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0	35	84	84	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1989	4	6					691	697						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2660071				2022-12-17	WOS:A1989AA66000004
J	HURLEY, TR; SEFTON, BM				HURLEY, TR; SEFTON, BM			ANALYSIS OF THE ACTIVITY AND PHOSPHORYLATION OF THE LCK PROTEIN IN LYMPHOID-CELLS	ONCOGENE			English	Article											HURLEY, TR (corresponding author), SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,POB 85800,SAN DIEGO,CA 92138, USA.				NCI NIH HHS [CA 42350, CA 14195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014195, R01CA042350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER HT, 1988, J VIROL, V62, P4113, DOI 10.1128/JVI.62.11.4113-4122.1988; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1985, MOL CELL BIOL, V5, P2647, DOI 10.1128/MCB.5.10.2647; CASNELLIE JE, 1984, P NATL ACAD SCI-BIOL, V81, P6676, DOI 10.1073/pnas.81.21.6676; CASNELLIE JE, 1982, J BIOL CHEM, V257, P3877; CASNELLIE JE, 1983, J BIOL CHEM, V258, P738; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COUSSENS PM, 1985, MOL CELL BIOL, V5, P2753, DOI 10.1128/MCB.5.10.2753; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; GLYNN JP, 1964, CANCER RES, V24, P502; GORER PA, 1950, BRIT J CANCER, V4, P372, DOI 10.1038/bjc.1950.36; HARRIS AW, 1973, J IMMUNOL, V110, P431; HORIBATA K, 1970, EXP CELL RES, V60, P61, DOI 10.1016/0014-4827(70)90489-1; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HYMAN R, 1972, J NATL CANCER I, V48, P173; HYMAN R, 1974, J NATL CANCER I, V52, P429, DOI 10.1093/jnci/52.2.429; HYMAN R, 1980, IMMUNOGENETICS, V10, P261, DOI 10.1007/BF01561574; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KAMPS MP, 1988, ONCOGENE RES, V3, P105; KAMPS MP, 1988, ONCOGENE, V2, P305; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1986, NATURE, V324, P674, DOI 10.1038/324674a0; SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505; SEFTON BM, 1980, J VIROL, V33, P220, DOI 10.1128/JVI.33.1.220-229.1980; THOM RE, 1987, FEBS LETT, V222, P104, DOI 10.1016/0014-5793(87)80200-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREVILLYAN JM, 1986, BIOCHIM BIOPHYS ACTA, V888, P286, DOI 10.1016/0167-4889(86)90228-4; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; VOGT M, 1979, VIROLOGY, V93, P226, DOI 10.1016/0042-6822(79)90290-3; VORONOVA AF, 1987, MOL CELL BIOL, V7, P4407, DOI 10.1128/MCB.7.12.4407; VORONOVA AF, 1984, MOL CELL BIOL, V4, P2705, DOI 10.1128/MCB.4.12.2705; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WONG TW, 1983, J BIOL CHEM, V258, P1022	43	84	84	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1989	4	3					265	272						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5676	2468122				2022-12-17	WOS:A1989U567600001
J	EHRHART, JC; DUTHU, A; ULLRICH, S; APPELLA, E; MAY, P				EHRHART, JC; DUTHU, A; ULLRICH, S; APPELLA, E; MAY, P			SPECIFIC INTERACTION BETWEEN A SUBSET OF THE P53-PROTEIN FAMILY AND HEAT-SHOCK PROTEINS HSP72/HSC73 IN A HUMAN OSTEO-SARCOMA CELL-LINE	ONCOGENE			English	Article									NCI,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	EHRHART, JC (corresponding author), INST RECH SCI CANC,UNITE ONCOL MOLEC,BP 8,F-94802 VILLEJUIF,FRANCE.							BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; CHO HY, 1976, SCIENCE, V194, P951, DOI 10.1126/science.62397; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CRAWFORD LV, 1982, ADV VIRAL ONCOL, P3; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; DUTHU A, 1985, VIROLOGY, V147, P275, DOI 10.1016/0042-6822(85)90130-8; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; Franza BR, 1984, CANC CELLS, V1, P137; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KLEIN G, 1982, ADV VIRAL ONCOLOGY, V2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1987, ONCOGENE, V1, P241; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATLASHEWSKI G, 1987, ONCOGENE RES, V1, P77; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MCALLISTER RM, 1971, CANCER-AM CANCER SOC, V27, P397, DOI 10.1002/1097-0142(197102)27:2<397::AID-CNCR2820270224>3.0.CO;2-X; MCCORMICK F, 1980, J VIROL, V34, P213, DOI 10.1128/JVI.34.1.213-224.1980; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; MORRISON B, 1983, J VIROL, V47, P106, DOI 10.1128/JVI.47.1.106-114.1983; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; RHIM JS, 1977, INT J CANCER, V19, P505, DOI 10.1002/ijc.2910190411; RHIM JS, 1975, INT J CANCER, V16, P840, DOI 10.1002/ijc.2910160516; RHIM JS, 1975, NATURE, V256, P751, DOI 10.1038/256751a0; ROGERS MJ, 1979, P NATL ACAD SCI USA, V76, P1415, DOI 10.1073/pnas.76.3.1415; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SEFTON BM, 1982, J VIROL, V44, P467, DOI 10.1128/JVI.44.2.467-474.1982; STURZBECHER HW, 1987, ONCOGENE, V1, P201; TAINSKY MA, 1987, MOL CELL BIOL, V7, P1280, DOI 10.1128/MCB.7.3.1280; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; THOMAS R, 1983, VIROLOGY, V131, P502, DOI 10.1016/0042-6822(83)90516-0; ULLRICH SJ, 1986, P NATL ACAD SCI USA, V83, P3121, DOI 10.1073/pnas.83.10.3121; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; YANG YHJ, 1979, J GEN VIROL, V43, P447	57	84	86	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					595	603						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	2978869				2022-12-17	WOS:A1988R516300017
J	Gilbert, SM; Oliphant, CJ; Hassan, S; Peille, AL; Bronsert, P; Falzoni, S; Di Virgilio, F; McNulty, S; Lara, R				Gilbert, S. M.; Oliphant, C. J.; Hassan, S.; Peille, A. L.; Bronsert, P.; Falzoni, S.; Di Virgilio, F.; McNulty, S.; Lara, R.			ATP in the tumour microenvironment drives expression of nfP2X(7), a key mediator of cancer cell survival	ONCOGENE			English	Article							P2X(7) RECEPTOR; P2X7 RECEPTOR; P-2Z RECEPTOR; ACTIVATION; INCREASES; PHARMACOLOGY; LYMPHOCYTES; RELEASE; MOUSE	The ATP-gated receptor P2X(7) is expressed in multiple malignant tumours including neuroblastoma, melanoma, prostate, lung and breast. P2X(7) has a significant role in mediating diverse cell responses, which upon dysregulation are associated with tumour initiation and development. The rapid, ATP-mediated activation of P2X(7) induces a fast-inward cation current in cells. However, prolonged ATP-mediated activation of P2X(7) leads to formation of a pore that increases membrane permeability and eventually causes cell death. This presents a potential paradox, as the tumour microenvironment contains extracellular ATP at levels sufficient to activate the P2X(7) pore and trigger cell death. However, P2X(7) expression is associated with enhanced cancer cell survival, proliferation and metastatic potential. At least one distinct conformational form of P2X(7), termed non-pore functional P2X(7) (nfP2X(7)), has been described, which is not able to form a functional pore. We demonstrate for the first time in this study that exposure to a high ATP concentration, equivalent to those measured in the tumour microenvironment, drives nfP2X(7) expression and also that nfP2X(7) is essential for tumour cell survival. We show that monoclonal antibodies raised against a P2X(7) amino acid sequence (200-216), whose conformation is distinct from that of wild-type (WT) P2X(7), bind specifically to nfP2X(7) expressed on the surface of tumour cells. We also show that nfP2X(7) is broadly expressed in patient-derived tumour sections from a wide range of cancers. Therefore, antibodies raised against E200 provide tools that can differentiate between forms of the P2X(7) receptor that have a key role in cancer.	[Gilbert, S. M.; Oliphant, C. J.; McNulty, S.; Lara, R.] Queen Mary Univ London, Blizard Inst, Babraham Res Campus, Cambridge, England; [Hassan, S.] Queen Mary Univ London, Blizard Inst, Ctr Cutaneous Res, London, England; [Peille, A. L.] Charles River Discovery Res Serv Germany GmbH, Freiburg, Germany; [Bronsert, P.] Univ Freiburg, Med Ctr, Inst Surg Pathol, Freiburg, Germany; [Bronsert, P.] Univ Freiburg, Med Ctr, Comprehens Canc Ctr Freiburg, Freiburg, Germany; [Bronsert, P.] Univ Freiburg, Fac Med, Freiburg, Germany; [Falzoni, S.; Di Virgilio, F.] Univ Ferrara, Dept Morphol Surg & Expt Med, Sect Pathol Oncol & Expt Biol, Ferrara, Italy	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of London; Queen Mary University London; University of London; Queen Mary University London; University of Freiburg; University of Freiburg; University of Freiburg; University of Ferrara	Lara, R (corresponding author), Queen Mary Univ London, Blizard Inst, Babraham Res Campus, Cambridge, England.	romain.lara@biosceptre.com	Lara, Romain/AAE-8108-2020; Di Virgilio, Francesco/J-3754-2018; DI VIRGILIO, Francesco/O-4634-2019	Di Virgilio, Francesco/0000-0003-3566-1362; DI VIRGILIO, Francesco/0000-0003-3566-1362; Falzoni, Simonetta/0000-0002-6594-0357	Innovate UK SMART Proof of Concept award [710832]	Innovate UK SMART Proof of Concept award(UK Research & Innovation (UKRI)Innovate UK)	This work was supported by Innovate UK SMART Proof of Concept award (Grant number 710832). We thank Julian A Barden and Angus Gidley-Baird for their support and critical review of the manuscript.	Adinolfi E, 2005, MOL BIOL CELL, V16, P3260, DOI 10.1091/mbc.E04-11-1025; Adinolfi E, 2002, BLOOD, V99, P706, DOI 10.1182/blood.V99.2.706; Adinolfi E, 2012, CANCER RES, V72, P2957, DOI 10.1158/0008-5472.CAN-11-1947; Adinolfi E, 2009, J BIOL CHEM, V284, P10120, DOI 10.1074/jbc.M805805200; Allard B, 2017, IMMUNOL REV, V276, P121, DOI 10.1111/imr.12528; Amoroso F, 2015, ONCOGENE, V34, P5240, DOI 10.1038/onc.2014.444; Amoroso F, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.105; Amoroso F, 2016, ONCOTARGET, V7, P49664, DOI 10.18632/oncotarget.10430; Auger R, 2005, J BIOL CHEM, V280, P28142, DOI 10.1074/jbc.M501290200; Barden J. A., 2014, J CLIN CELL IMMUNOL, V5, P237, DOI [10.4172/2155-9899.1000237, DOI 10.4172/2155-9899.1000237]; Barden JA, 2003, FEBS LETT, V538, P159, DOI 10.1016/S0014-5793(03)00172-8; Barden JA, 2011, Patent No. [WO2011020155 A1, 2011020155A1]; Baricordi OR, 1996, BLOOD, V87, P682, DOI 10.1182/blood.V87.2.682.bloodjournal872682; Baricordi OR, 1999, J BIOL CHEM, V274, P33206, DOI 10.1074/jbc.274.47.33206; Buell G, 1998, BLOOD, V92, P3521, DOI 10.1182/blood.V92.10.3521.422k50_3521_3528; BUISMAN HP, 1988, P NATL ACAD SCI USA, V85, P7988, DOI 10.1073/pnas.85.21.7988; Burnstock G, 2006, BRIT J PHARMACOL, V147, pS172, DOI 10.1038/sj.bjp.0706429; Di Virgilio F, 2017, ONCOGENE, V36, P293, DOI 10.1038/onc.2016.206; Di Virgilio F, 2017, IMMUNITY, V47, P15, DOI 10.1016/j.immuni.2017.06.020; DIVIRGILIO F, 1989, J IMMUNOL, V143, P1955; Donnelly-Roberts DL, 2009, BRIT J PHARMACOL, V157, P1203, DOI 10.1111/j.1476-5381.2009.00233.x; FALZONI S, 1995, J CLIN INVEST, V95, P1207, DOI 10.1172/JCI117770; Feng YH, 2006, J BIOL CHEM, V281, P17228, DOI 10.1074/jbc.M602999200; Ferrari D, 1999, J BIOL CHEM, V274, P13205, DOI 10.1074/jbc.274.19.13205; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028; Gilbert SM, 2017, BRIT J DERMATOL, V177, P117, DOI 10.1111/bjd.15364; Gu BJ, 2000, AM J PHYSIOL-CELL PH, V279, pC1189, DOI 10.1152/ajpcell.2000.279.4.C1189; Jelassi B, 2011, ONCOGENE, V30, P2108, DOI 10.1038/onc.2010.593; Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008; Lohman AW, 2012, CARDIOVASC RES, V95, P269, DOI 10.1093/cvr/cvs187; North RA, 2000, ANNU REV PHARMACOL, V40, P563, DOI 10.1146/annurev.pharmtox.40.1.563; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Pellegatti P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002599; Qiu Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114371; Raffaghello L, 2006, CANCER RES, V66, P907, DOI 10.1158/0008-5472.CAN-05-3185; Robert R, 2008, MOL PHARMACOL, V73, P478, DOI 10.1124/mol.107.040725; Slater M, 2004, HISTOPATHOLOGY, V44, P206, DOI 10.1111/j.0309-0167.2004.01798.x; Slater M, 2004, BREAST CANCER RES TR, V83, P1, DOI 10.1023/B:BREA.0000010670.85915.0f; Slater M, 2003, MELANOMA RES, V13, P137, DOI 10.1097/00008390-200304000-00005; Sluyter R, 2017, ADV EXP MED BIOL, V1051, P17, DOI 10.1007/5584_2017_59; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Tan C, 2015, EXP THER MED, V10, P1472, DOI 10.3892/etm.2015.2705; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wiley JS, 2011, TISSUE ANTIGENS, V78, P321, DOI 10.1111/j.1399-0039.2011.01780.x; Worthington RA, 2002, FEBS LETT, V512, P43, DOI 10.1016/S0014-5793(01)03311-7; Zhang XJ, 2004, LEUKEMIA RES, V28, P1313, DOI 10.1016/j.leukres.2004.04.001	47	83	84	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2019	38	2					194	208		10.1038/s41388-018-0426-6	http://dx.doi.org/10.1038/s41388-018-0426-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG9XX	30087439	hybrid, Green Published			2022-12-17	WOS:000455366700004
J	Ruan, H; Zhan, YY; Hou, J; Xu, B; Chen, B; Tian, Y; Wu, D; Zhao, Y; Zhang, Y; Chen, X; Mi, P; Zhang, L; Zhang, S; Wang, X; Cao, H; Zhang, W; Wang, H; Li, H; Su, Y; Zhang, XK; Hu, T				Ruan, H.; Zhan, Y. Y.; Hou, J.; Xu, B.; Chen, B.; Tian, Y.; Wu, D.; Zhao, Y.; Zhang, Y.; Chen, X.; Mi, P.; Zhang, L.; Zhang, S.; Wang, X.; Cao, H.; Zhang, W.; Wang, H.; Li, H.; Su, Y.; Zhang, X. K.; Hu, T.			Berberine binds RXR alpha to suppress beta-catenin signaling in colon cancer cells	ONCOGENE			English	Article							RETINOID-X-RECEPTOR; ADENOMATOUS-POLYPOSIS-COLI; COLORECTAL-CANCER; NUCLEAR RECEPTORS; DOWN-REGULATION; C-CBL; WNT; IDENTIFICATION; GROWTH; INHIBITION	Berberine, an isoquinoline alkaloid, is a traditional oriental medicine used to treat diarrhea and gastroenteritis. Recently, we reported that it could inhibit the growth of intestinal polyp in animals and in patients with the familial adenomatous polyposis by downregulating beta-catenin signaling. However, the intracellular target mediating the effects of berberine remains elusive. Here, we provide evidence that berberine inhibits beta-catenin function via directly binding to a unique region comprising residues Gln275, Arg316 and Arg371 in nuclear receptor retinoid X receptor alpha (RXR alpha), where berberine concomitantly binding to and synergistically activating RXR alpha with 9-cis-retinoic acid (9-cis-RA), a natural ligand binding to the classical ligand-binding pocket of RXR alpha. Berberine binding promotes RXR alpha interaction with nuclear beta-catenin, leading to c-Cbl mediated degradation of beta-catenin, and consequently inhibits the proliferation of colon cancer cells. Furthermore, berberine suppresses the growth of human colon carcinoma xenograft in nude mice in an RXR alpha-dependent manner. Together, our study not only identifies RXRa as a direct protein target for berberine but also dissects their binding mode and validates that berberine indeed suppresses beta-catenin signaling and cell growth in colon cancer via binding RXR alpha, which provide new strategies for the design of new RXR alpha-based antitumor agents and drug combinations.	[Ruan, H.; Zhan, Y. Y.; Hou, J.; Xu, B.; Chen, B.; Tian, Y.; Wu, D.; Zhao, Y.; Zhang, Y.; Chen, X.; Mi, P.; Cao, H.; Zhang, W.; Hu, T.] Xiamen Univ, Canc Res Ctr, Med Coll, 315 Chengyi Bldg,Xiangan Campus, Xiamen 361102, Fujian, Peoples R China; [Zhang, L.] Xiamen Univ, Sch Life Sci, Xiamen, Peoples R China; [Zhang, S.; Wang, X.; Wang, H.; Li, H.] Tsinghua Univ, Sch Life Sci, Beijing, Peoples R China; [Su, Y.; Zhang, X. K.] Xiamen Univ, Sch Pharmaceut Sci, Xiamen, Peoples R China; [Zhang, X. K.] Sanford Burnham Med Res Inst, Canc Ctr, La Jolla, CA USA	Xiamen University; Xiamen University; Tsinghua University; Xiamen University; Sanford Burnham Prebys Medical Discovery Institute	Zhan, YY; Hu, T (corresponding author), Xiamen Univ, Canc Res Ctr, Med Coll, 315 Chengyi Bldg,Xiangan Campus, Xiamen 361102, Fujian, Peoples R China.; Zhang, XK (corresponding author), Sanford Burnham Med Res Inst, Canc Ctr, La Jolla, CA USA.	yyzhan@xmu.edu.cn; xkzhang@xmu.edu.cn; thu@xmu.edu.cn	; Li, Haitao/B-2668-2012	Yujie, Zhao/0000-0002-7028-2408; Li, Haitao/0000-0001-6741-293X	National Natural Science Foundation of China [U1405228, 81472568, 81572589]; Natural Science Foundation of Fujian [2014J07010, 2017J06020, 2015R1036-1, 2017R1036-4, 2016R1034-1, 2016R1034-4]; Fundamental Research Funds for the Central Universities [20720150058]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Fujian(Natural Science Foundation of Fujian Province); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by the grants from the National Natural Science Foundation of China (U1405228, 81472568 and 81572589), the Natural Science Foundation of Fujian grant (2014J07010, 2017J06020, 2015R1036-1, 2017R1036-4, 2016R1034-1 and 2016R1034-4) and the Fundamental Research Funds for the Central Universities (20720150058).	Albring KF, 2013, BIOFACTORS, V39, P652, DOI 10.1002/biof.1133; Beildeck ME, 2010, EXP CELL RES, V316, P1763, DOI 10.1016/j.yexcr.2010.02.001; Casimiro MC, 2014, EXPERT OPIN INV DRUG, V23, P295, DOI 10.1517/13543784.2014.867017; Cesario RM, 2006, CANCER LETT, V240, P225, DOI 10.1016/j.canlet.2005.09.010; Chai YS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090850; Chen LQ, 2014, CHEM BIOL, V21, P596, DOI 10.1016/j.chembiol.2014.02.017; Chitalia V, 2013, J BIOL CHEM, V288, P23505, DOI 10.1074/jbc.M113.473801; Corson TW, 2007, CELL, V130, P769, DOI 10.1016/j.cell.2007.08.021; Dawson MI, 2002, CURR MED CHEM, V9, P623, DOI 10.2174/0929867023370789; de Lera AR, 2007, NAT REV DRUG DISCOV, V6, P811, DOI 10.1038/nrd2398; Delfosse V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9089; Dillard AC, 2008, NUTR CANCER, V60, P97, DOI 10.1080/01635580701586754; Duvic M, 2001, J CLIN ONCOL, V19, P2456, DOI 10.1200/JCO.2001.19.9.2456; Egan JB, 2010, CANCER RES, V70, P1496, DOI 10.1158/0008-5472.CAN-09-3264; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; Gampe RT, 2000, GENE DEV, V14, P2229, DOI 10.1101/gad.802300; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; Guldenschuh L, 2001, DIS COLON RECTUM, V44, P1090, DOI 10.1007/BF02234627; Gwyn K, 2002, AM J GASTROENTEROL, V97, P13, DOI 10.1111/j.1572-0241.2002.05435.x; Han AJ, 2008, CANCER BIOL THER, V7, P454, DOI 10.4161/cbt.7.3.5455; Imanshahidi M, 2008, PHYTOTHER RES, V22, P999, DOI 10.1002/ptr.2399; Jacobs ET, 2010, CARCINOGENESIS, V31, P1412, DOI 10.1093/carcin/bgq127; Janakiram NB, 2013, CANCER PREV RES, V6, P1251, DOI 10.1158/1940-6207.CAPR-13-0249; Kersten S, 1998, J MOL BIOL, V284, P21, DOI 10.1006/jmbi.1998.2168; Kolluri SK, 2005, P NATL ACAD SCI USA, V102, P2525, DOI 10.1073/pnas.0409721102; Kong WJ, 2004, NAT MED, V10, P1344, DOI 10.1038/nm1135; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Mak PA, 2002, J LIPID RES, V43, P2037, DOI 10.1194/jlr.C200014-JLR200; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; Mulholland DJ, 2005, ENDOCR REV, V26, P898, DOI 10.1210/er.2003-0034; Park JJ, 2012, BIOCHEM BIOPH RES CO, V426, P461, DOI 10.1016/j.bbrc.2012.08.091; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Perez E, 2012, BBA-MOL CELL BIOL L, V1821, P57, DOI 10.1016/j.bbalip.2011.04.003; Rayasam GV, 2010, PHYTOTHER RES, V24, P1260, DOI 10.1002/ptr.3165; Saha SK, 2014, EUR J PHARMACOL, V744, P132, DOI 10.1016/j.ejphar.2014.09.048; Sekiya T, 2002, CANCER RES, V62, P3322; Seo HS, 2015, MOL MED REP, V12, P800, DOI 10.3892/mmr.2015.3480; Shivanna S, 2015, J BIOL CHEM, V290, P12537, DOI 10.1074/jbc.M114.616623; Tang H, 2014, CANCER BIOMARK, V14, P313, DOI 10.3233/CBM-140409; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Volate SR, 2009, MOL CARCINOGEN, V48, P920, DOI 10.1002/mc.20542; Wang LH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056666; Wang LH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036418; Wang W, 2011, CELL RES, V21, P730, DOI 10.1038/cr.2011.30; Wu K, 2012, INT J ONCOL, V41, P292, DOI 10.3892/ijo.2012.1423; Xiao JH, 2003, J BIOL CHEM, V278, P29954, DOI 10.1074/jbc.M304761200; Yamazaki K, 2007, GUT, V56, P1557, DOI 10.1136/gut.2007.129858; Yu ML, 2014, MOL MED REP, V9, P249, DOI 10.3892/mmr.2013.1762; Zhang HT, 2011, J MOL BIOL, V407, P13, DOI 10.1016/j.jmb.2011.01.032; Zhang H, 2010, METABOLISM, V59, P285, DOI 10.1016/j.metabol.2009.07.029; Zhang JF, 2013, J CELL MOL MED, V17, P1484, DOI 10.1111/jcmm.12119; Zhang XK, 2015, ACTA PHARMACOL SIN, V36, P102, DOI 10.1038/aps.2014.109; Zhang ZG, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6493; Zhou H, 2010, CANCER CELL, V17, P560, DOI 10.1016/j.ccr.2010.04.023; Zuo F, 2006, DRUG METAB DISPOS, V34, P2064, DOI 10.1124/dmd.106.011361	55	83	90	3	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2017	36	50					6906	6918		10.1038/onc.2017.296	http://dx.doi.org/10.1038/onc.2017.296			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FQ0JM	28846104	Green Published, hybrid			2022-12-17	WOS:000418041800007
J	Lin, Y; Yang, X; Liu, W; Li, B; Yin, W; Shi, Y; He, R				Lin, Y.; Yang, X.; Liu, W.; Li, B.; Yin, W.; Shi, Y.; He, R.			Chemerin has a protective role in hepatocellular carcinoma by inhibiting the expression of IL-6 and GM-CSF and MDSC accumulation	ONCOGENE			English	Article							NATURAL-KILLER-CELLS; NF-KAPPA-B; SUPPRESSOR-CELLS; ENDOTHELIAL-CELLS; CANCER-CELLS; TUMOR MICROENVIRONMENT; DENDRITIC CELLS; RECEPTOR CCRL2; POOR-PROGNOSIS; T-CELLS	Hepatocellular carcinoma (HCC) is linked to inflammation and immunosuppression. Chemerin is highly expressed in the liver and implicated in the regulation of inflammation. However, the role of chemerin in HCC remains unclear. In this study, we aimed to investigate whether chemerin is able to influence HCC progression by regulating tumor-associated inflammation. Here we demonstrated that chemerin significantly decreased in blood and tumor tissues of HCC patients, and tumor chemerin levels were inversely associated with the prognosis. In an orthotopic mouse model of HCC, Rarres2(-/-)mice exhibited aggressive tumor growth and lung metastasis, whereas chemerin overexpression greatly inhibited tumor growth. The tumor-inhibitory effect of chemerin was accompanied by a shift in tumor-infiltrating immune cells from myeloid-derived suppressive cells (MDSCs) to interferon-gamma'T cells and decreased tumor angiogenesis. Furthermore, we demonstrated that the tumor-inhibitory effect of chemerin was partly dependent on T cells, as chemerin overexpression could inhibit tumor growth, albeit to a lesser extent, in Rag1(-/-) mice when compared with wild-type controls. Mechanistically, chemerin inhibited nuclear factor-.B activation and the expression of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-6) by tumor cells and tumor-associated endothelial cell, respectively, via its receptors, and consequently, MDSC induction was impaired, leading to restoration of antitumor T-cell response and decreased tumor angiogenesis. Clinically, systemic and tumor levels of chemerin were found to inversely correlate with circulating concentrations of GM-CSF or IL-6 and tumor-infiltrating myeloid cells, respectively, in HCC patients. Moreover, neutralization of GM-CSF and IL-6 abrogated HCC progression and MDSC accumulation in Rarres2(-/-) mice. In conclusion, our study reveals the tumor-inhibitory effect of chemerin by suppressing inflammatory tumor microenvironment with therapeutic implications for inflammation-associated cancer-like HCC.	[Lin, Y.; Yang, X.; Li, B.; Yin, W.; He, R.] Minist Educ, Dept Immunol, Sch Basic Med Sci, Shanghai, Peoples R China; [Lin, Y.; Yang, X.; Li, B.; Yin, W.; He, R.] Minist Educ, Key Lab Med Mol Virol, Sch Basic Med Sci, Shanghai, Peoples R China; [Lin, Y.; Yang, X.; Li, B.; Yin, W.; He, R.] Minist Hlth, Dept Immunol, Sch Basic Med Sci, Shanghai, Peoples R China; [Lin, Y.; Yang, X.; Li, B.; Yin, W.; He, R.] Minist Hlth, Key Lab Med Mol Virol, Sch Basic Med Sci, Shanghai, Peoples R China; [Liu, W.; Shi, Y.] Zhongshan Hosp, Liver Canc Inst, Dept Liver Surg, Key Lab Carcinogenesis & Canc Invas,Minist Educ, 180 FengLin Rd, Shanghai 200032, Peoples R China; [He, R.] Fudan Univ, Biotherapy Res Ctr, Dept Immunol, Shanghai, Peoples R China	Fudan University; Fudan University	Shi, Y (corresponding author), Zhongshan Hosp, Liver Canc Inst, Dept Liver Surg, Key Lab Carcinogenesis & Canc Invas,Minist Educ, 180 FengLin Rd, Shanghai 200032, Peoples R China.; He, R (corresponding author), Fudan Univ, Shanghai Med Sch, Dept Immunol, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China.	shi.yinghong@zs-hospital.sh.cn; ruihe@fudan.edu.cn	Lin, Yuli/GNP-4999-2022; Yang, Xuguang/GNP-2847-2022; He, Rui/P-7302-2019	Lin, Yuli/0000-0002-8779-2471; Yang, Xuguang/0000-0002-6198-6008; He, Rui/0000-0001-5288-9786	National Natural Science Foundation of China [813220437, 81471555, 31600715, 81272389, 81472674]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Dr Yongjun Dang (Department of Biochemistry and Molecular Biology, Fudan University) for the assistance with pulldown assay. This work is supported by National Natural Science Foundation of China grant 813220437, 81471555 (to RH), 31600715 (to YL) and 81272389, 81472674 (to YS).	Albanesi C, 2009, J EXP MED, V206, P249, DOI 10.1084/jem.20080129; Arihara F, 2013, CANCER IMMUNOL IMMUN, V62, P1421, DOI 10.1007/s00262-013-1447-1; Barnea G, 2008, P NATL ACAD SCI USA, V105, P64, DOI 10.1073/pnas.0710487105; Bondue B, 2011, CYTOKINE GROWTH F R, V22, P331, DOI 10.1016/j.cytogfr.2011.11.004; Bondue B, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002358; Chen MF, 2014, ONCOTARGET, V5, P8716, DOI 10.18632/oncotarget.2368; Condamine T, 2015, ANNU REV MED, V66, P97, DOI 10.1146/annurev-med-051013-052304; Condamine T, 2011, TRENDS IMMUNOL, V32, P19, DOI 10.1016/j.it.2010.10.002; Corzo CA, 2010, J EXP MED, V207, P2439, DOI 10.1084/jem.20100587; Dolcetti L, 2010, EUR J IMMUNOL, V40, P22, DOI 10.1002/eji.200939903; Fisher DT, 2014, SEMIN IMMUNOL, V26, P38, DOI 10.1016/j.smim.2014.01.008; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gao Q, 2007, J CLIN ONCOL, V25, P2586, DOI 10.1200/JCO.2006.09.4565; Goralski KB, 2007, J BIOL CHEM, V282, P28175, DOI 10.1074/jbc.M700793200; He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183; Hoechst B, 2008, GASTROENTEROLOGY, V135, P234, DOI 10.1053/j.gastro.2008.03.020; Hoechst B, 2009, HEPATOLOGY, V50, P799, DOI 10.1002/hep.23054; Imai K, 2014, INT J MOL SCI, V15, P11294, DOI 10.3390/ijms150711294; Kaur J, 2010, BIOCHEM BIOPH RES CO, V391, P1762, DOI 10.1016/j.bbrc.2009.12.150; Lin W, 2011, CLIN LAB, V57, P879; Lin YL, 2014, CELL MOL IMMUNOL, V11, P355, DOI 10.1038/cmi.2014.15; Makarova-Rusher OV, 2015, J HEPATOL, V62, P1420, DOI 10.1016/j.jhep.2015.02.038; Monnier J, 2012, J IMMUNOL, V189, P956, DOI 10.4049/jimmunol.1102871; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740; Pachynski RK, 2012, J EXP MED, V209, P1427, DOI 10.1084/jem.20112124; Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519; Parolini S, 2007, BLOOD, V109, P3625, DOI 10.1182/blood-2006-08-038844; Su SC, 2014, CANCER CELL, V25, P605, DOI 10.1016/j.ccr.2014.03.021; Teijaro JR, 2011, CELL, V146, P980, DOI 10.1016/j.cell.2011.08.015; Tian ZG, 2013, HEPATOLOGY, V57, P1654, DOI 10.1002/hep.26115; Tsuyada A, 2012, CANCER RES, V72, P2768, DOI 10.1158/0008-5472.CAN-11-3567; Wanninger J, 2012, MOL CELL ENDOCRINOL, V349, P248, DOI 10.1016/j.mce.2011.10.032; Wittamer V, 2003, J EXP MED, V198, P977, DOI 10.1084/jem.20030382; Wong VWS, 2009, INT J CANCER, V124, P2766, DOI 10.1002/ijc.24281; Yang S, 2014, IMMUNITY, V41, P973, DOI 10.1016/j.immuni.2014.11.013; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791; Zabel BA, 2008, J EXP MED, V205, P2207, DOI 10.1084/jem.20080300; Zhang JP, 2009, J HEPATOL, V50, P980, DOI 10.1016/j.jhep.2008.12.033; Zhao L, 2014, ALLERGY, V69, P763, DOI 10.1111/all.12408; Zhu AX, 2011, NAT REV CLIN ONCOL, V8, P292, DOI 10.1038/nrclinonc.2011.30; Zhu XD, 2008, J CLIN ONCOL, V26, P2707, DOI 10.1200/JCO.2007.15.6521	42	83	86	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3599	3608		10.1038/onc.2016.516	http://dx.doi.org/10.1038/onc.2016.516			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28166197				2022-12-17	WOS:000403878600009
J	Ciamporcero, E; Shen, H; Ramakrishnan, S; Ku, SY; Chintala, S; Shen, L; Adelaiye, R; Miles, KM; Ullio, C; Pizzimenti, S; Daga, M; Azabdaftari, G; Attwood, K; Johnson, C; Zhang, J; Barrera, G; Pili, R				Ciamporcero, E.; Shen, H.; Ramakrishnan, S.; Ku, S. Yu; Chintala, S.; Shen, L.; Adelaiye, R.; Miles, K. M.; Ullio, C.; Pizzimenti, S.; Daga, M.; Azabdaftari, G.; Attwood, K.; Johnson, C.; Zhang, J.; Barrera, G.; Pili, R.			YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage	ONCOGENE			English	Article							YES-ASSOCIATED PROTEIN; INVASIVE BLADDER-CANCER; INDEPENDENT PROGNOSTIC MARKER; BREAST-CANCER; HIPPO PATHWAY; CONFERS RESISTANCE; RADICAL CYSTECTOMY; UP-REGULATION; CISPLATIN; APOPTOSIS	Current standard of care for muscle-invasive urothelial cell carcinoma (UCC) is surgery along with perioperative platinum-based chemotherapy. UCC is sensitive to cisplatin-based regimens, but acquired resistance eventually occurs, and a subset of tumors is intrinsically resistant. Thus, there is an unmet need for new therapeutic approaches to target chemotherapy-resistant UCC. Yes-associated protein (YAP) is a transcriptional co-activator that has been associated with bladder cancer progression and cisplatin resistance in ovarian cancer. In contrast, YAP has been shown to induce DNA damage associated apoptosis in non-small cell lung carcinoma. However, no data have been reported on the YAP role in UCC chemo-resistance. Thus, we have investigated the potential dichotomous role of YAP in UCC response to chemotherapy utilizing two patient-derived xenograft models recently established. Constitutive expression and activation of YAP inversely correlated with in vitro and in vivo cisplatin sensitivity. YAP overexpression protected while YAP knockdown sensitized UCC cells to chemotherapy and radiation effects via increased accumulation of DNA damage and apoptosis. Furthermore, pharmacological YAP inhibition with verteporfin inhibited tumor cell proliferation and restored sensitivity to cisplatin. In addition, nuclear YAP expression was associated with poor outcome in UCC patients who received perioperative chemotherapy. In conclusion, these results suggest that YAP activation exerts a protective role and represents a pharmacological target to enhance the anti-tumor effects of DNA damaging modalities in the treatment of UCC.	[Ciamporcero, E.; Ramakrishnan, S.; Ku, S. Yu; Chintala, S.; Shen, L.; Adelaiye, R.; Miles, K. M.; Johnson, C.; Pili, R.] Roswell Pk Canc Inst, Dept Med, Genitourinary Program, Buffalo, NY 14263 USA; [Ciamporcero, E.; Ullio, C.; Pizzimenti, S.; Daga, M.; Barrera, G.] Univ Turin, Dept Clin & Biol Sci, Turin, Italy; [Shen, H.; Zhang, J.] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; [Ramakrishnan, S.; Ku, S. Yu; Adelaiye, R.] Roswell Pk Canc Inst, Dept Canc Pathol & Prevent, Buffalo, NY 14263 USA; [Chintala, S.; Johnson, C.] Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; [Azabdaftari, G.] Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA; [Attwood, K.] Roswell Pk Canc Inst, Dept Biostat & Bioinformat, Buffalo, NY 14263 USA; [Pili, R.] Indiana Univ, Dept Med, Indianapolis, IN USA	Roswell Park Cancer Institute; University of Turin; Roswell Park Cancer Institute; Roswell Park Cancer Institute; Roswell Park Cancer Institute; Roswell Park Cancer Institute; Roswell Park Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis	Barrera, G (corresponding author), Univ Turin, Dept Clin & Biol Sci, Turin, Italy.; Pili, R (corresponding author), Indiana Univ, Dept Med, Simon Canc Ctr, Indianapolis, IN USA.; Pili, R (corresponding author), Roswell Pk Canc Inst, Elm&Carlton St, Buffalo, NY 14263 USA.	giuseppina.barrera@unito.it; rpili@iu.edu	Pizzimenti, Stefania/AAB-8250-2022; Ramakrishnan, Swathi/O-5054-2019; Ciamporcero, Eric/M-6580-2017; Zhang, Jianmin/AAN-2931-2020	Pizzimenti, Stefania/0000-0001-6937-8632; Ciamporcero, Eric/0000-0002-3856-6435; 	National Cancer Institute [P30 CA016056, R21 CA179693]; American Cancer Society [127226-RSG-14-214-01-TBE]; NATIONAL CANCER INSTITUTE [P30CA016056, R21CA179693] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was in part supported by the National Cancer Institute P30 CA016056 (RP), R21 CA179693 (JZ), the American Cancer Society 127226-RSG-14-214-01-TBE (JZ) and a research donation from Richard Di Vita and family (RP). We thank the MTMR and Pathology Core Facilities at Roswell Park Cancer Institute for processing the tissue samples.	Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Belyanskaya LL, 2005, INT J CANCER, V117, P755, DOI 10.1002/ijc.21242; Bressler NM, 2000, INVEST OPHTH VIS SCI, V41, P624; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Ciamporcero E, 2015, MOL CANCER THER, V14, P101, DOI 10.1158/1535-7163.MCT-14-0094; Cote RJ, 1997, NATURE, V385, P123, DOI 10.1038/385123b0; Damrauer JS, 2014, P NATL ACAD SCI USA, V111, P3110, DOI 10.1073/pnas.1318376111; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Ehsanian R, 2010, ONCOGENE, V29, P6160, DOI 10.1038/onc.2010.339; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Fernandez A, 2012, ONCOGENE, V31, P1923, DOI 10.1038/onc.2011.379; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Grossman HB, 2003, NEW ENGL J MED, V349, P859, DOI 10.1056/NEJMoa022148; Hall CA, 2010, CANCER RES, V70, P8517, DOI 10.1158/0008-5472.CAN-10-1242; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Huang JM, 2013, ONCOGENE, V32, P2220, DOI 10.1038/onc.2012.231; Imanaka Y, 2011, J HUM GENET, V56, P270, DOI 10.1038/jhg.2011.1; Jiang N, 2015, ONCOGENE, V34, P2764, DOI 10.1038/onc.2014.206; Lai D, 2011, CANCER RES, V71, P2728, DOI 10.1158/0008-5472.CAN-10-2711; Liao WJ, 2009, METHODS, V48, P46, DOI 10.1016/j.ymeth.2009.02.016; Lin MT, 2004, J BIOL CHEM, V279, P24015, DOI 10.1074/jbc.M402305200; Liu JY, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-349; Liu XF, 2012, AM J PATHOL, V180, P599, DOI 10.1016/j.ajpath.2011.10.036; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Madersbacher S, 2003, J CLIN ONCOL, V21, P690, DOI 10.1200/JCO.2003.05.101; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pollack A, 1997, CLIN CANCER RES, V3, P1823; PROCTOR AJ, 1991, ONCOGENE, V6, P789; Reichert S, 2011, RADIOTHER ONCOL, V101, P51, DOI 10.1016/j.radonc.2011.06.037; Roos WP, 2013, CANCER LETT, V332, P237, DOI 10.1016/j.canlet.2012.01.007; Shah JB, 2011, CLIN CANCER RES, V17, P2608, DOI 10.1158/1078-0432.CCR-10-2770; Sheen-Chen SM, 2012, ANTICANCER RES, V32, P3321; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Stein JP, 2001, J CLIN ONCOL, V19, P666, DOI 10.1200/JCO.2001.19.3.666; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Sun XP, 2014, FEBS J, V281, P115, DOI 10.1111/febs.12577; Todorovic V, 2005, J CELL BIOL, V171, P559, DOI 10.1083/jcb.200504015; Torti D, 2011, EMBO MOL MED, V3, P623, DOI 10.1002/emmm.201100176; Tsai HC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090159; von der Maase H, 2000, J CLIN ONCOL, V18, P3068, DOI 10.1200/JCO.2000.18.17.3068; Wang MY, 2009, CANCER RES, V69, P3482, DOI 10.1158/0008-5472.CAN-08-2524; Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495; Yu FX, 2014, CANCER CELL, V25, P822, DOI 10.1016/j.ccr.2014.04.017; Yuan M, 2008, CELL DEATH DIFFER, V15, P1752, DOI 10.1038/cdd.2008.108; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zhang JM, 2009, NAT CELL BIOL, V11, P1444, DOI 10.1038/ncb1993; Zhang X, 2011, ONCOGENE, V30, P2810, DOI 10.1038/onc.2011.8; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhao YL, 2014, CANCER RES, V74, P4493, DOI 10.1158/0008-5472.CAN-13-2712; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	53	83	83	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2016	35	12					1541	1553		10.1038/onc.2015.219	http://dx.doi.org/10.1038/onc.2015.219			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RJ	26119935	Green Accepted			2022-12-17	WOS:000373063600007
J	Morton, JJ; Bird, G; Keysar, SB; Astling, DP; Lyons, TR; Anderson, RT; Glogowska, MJ; Estes, P; Eagles, JR; Le, PN; Gan, G; McGettigan, B; Fernandez, P; Padilla-Just, N; Varella-Garcia, M; Song, JI; Bowles, DW; Schedin, P; Tan, AC; Roop, DR; Wang, XJ; Refaeli, Y; Jimeno, A				Morton, J. J.; Bird, G.; Keysar, S. B.; Astling, D. P.; Lyons, T. R.; Anderson, R. T.; Glogowska, M. J.; Estes, P.; Eagles, J. R.; Le, P. N.; Gan, G.; McGettigan, B.; Fernandez, P.; Padilla-Just, N.; Varella-Garcia, M.; Song, J. I.; Bowles, D. W.; Schedin, P.; Tan, A-C; Roop, D. R.; Wang, X-J; Refaeli, Y.; Jimeno, A.			XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; LARGE GENE LISTS; PANCREATIC-CANCER; STEM-CELLS; NUDE-MICE; RNA-SEQ; TUMOR; RECEPTOR; THERAPY; LYMPHANGIOGENESIS	The limitations of cancer cell lines have led to the development of direct patient-derived xenograft models. However, the interplay between the implanted human cancer cells and recruited mouse stromal and immune cells alters the tumor microenvironment and limits the value of these models. To overcome these constraints, we have developed a technique to expand human hematopoietic stem and progenitor cells (HSPCs) and use them to reconstitute the radiation-depleted bone marrow of a NOD/SCID/IL2rg(-/-) (NSG) mouse on which a patient's tumor is then transplanted (XactMice). The human HSPCs produce immune cells that home into the tumor and help replicate its natural microenvironment. Despite previous passage on nude mice, the expression of epithelial, stromal and immune genes in XactMice tumors aligns more closely to that of the patient tumor than to those grown in nonhumanized mice-an effect partially facilitated by human cytokines expressed by both the HSPC progeny and the tumor cells. The human immune and stromal cells produced in the XactMice can help recapitulate the microenvironment of an implanted xenograft, reverse the initial genetic drift seen after passage on non-humanized mice and provide a more accurate tumor model to guide patient treatment.	[Morton, J. J.; Keysar, S. B.; Astling, D. P.; Lyons, T. R.; Anderson, R. T.; Glogowska, M. J.; Eagles, J. R.; Le, P. N.; McGettigan, B.; Padilla-Just, N.; Varella-Garcia, M.; Bowles, D. W.; Schedin, P.; Tan, A-C; Jimeno, A.] Univ Colorado, Sch Med, Div Med Oncol, Dept Med, Aurora, CO USA; [Bird, G.; Estes, P.; Roop, D. R.; Refaeli, Y.] Univ Colorado, Sch Med, Dept Dermatol, 12800 E 19th Ave,MS-8320, Aurora, CO 80045 USA; [Astling, D. P.; Tan, A-C] Univ Colorado, Sch Med, Dept Biostat & Informat, Aurora, CO USA; [Gan, G.] Univ Colorado, Sch Med, Dept Radiat Oncol, Aurora, CO USA; [Fernandez, P.; Wang, X-J] Univ Colorado, Sch Med, Dept Pathol, Aurora, CO USA; [Song, J. I.; Jimeno, A.] Univ Colorado, Sch Med, Dept Otolaryngol, Aurora, CO USA; [Roop, D. R.; Wang, X-J; Refaeli, Y.; Jimeno, A.] Univ Colorado, Sch Med, Charles C Gates Ctr Regenerat Med & Stem Cell Bio, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Refaeli, Y (corresponding author), Univ Colorado, Sch Med, Dept Dermatol, 12800 E 19th Ave,MS-8320, Aurora, CO 80045 USA.; Jimeno, A (corresponding author), Univ Colorado, Sch Med, Dept Med Oncol & Otolaryngol, 12801 E 17th Ave,MS-8117, Aurora, CO 80045 USA.	Yosef.Refaeli@ucdenver.edu; Antonio.Jimeno@ucdenver.edu	Schedin, Pepper/C-2532-2009; Tan, Aik Choon/A-3135-2011; McGettigan, Brett/AAT-2828-2021	Tan, Aik Choon/0000-0003-2955-8369; Astling, David/0000-0001-8179-0304	Department of Defense Award [W81XWN-10-1-0798]; Charles C Gates Center for Regenerative Medicine and Stem Cell Biology; National Institutes of Health Cancer Center [P30 CA046934]; NIH [R21 DE019712, R01 CA149456, R01 CA117802-06, P30 AR057212-02, P01 AI022295-24, T32 CA174648]; Janet Mordecai Foundation; Peter and Rhonda Grant Foundation; Translational Research Award from the Leukemia and Lymphoma Society; NATIONAL CANCER INSTITUTE [R21CA156114, P30CA046934, R01CA149456, R01CA117802, T32CA174648] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR057212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015953, R01DE024371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R21DE019712] Funding Source: NIH RePORTER	Department of Defense Award(United States Department of Defense); Charles C Gates Center for Regenerative Medicine and Stem Cell Biology; National Institutes of Health Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Janet Mordecai Foundation; Peter and Rhonda Grant Foundation; Translational Research Award from the Leukemia and Lymphoma Society; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank the patients and normal subjects for their time and generous tissue and blood donations. This work was primarily supported by Department of Defense Award W81XWN-10-1-0798 (principal investigator AJ; co-investigator YR), the Charles C Gates Center for Regenerative Medicine and Stem Cell Biology, and National Institutes of Health Cancer Center Support Grant P30 CA046934 (AJ, YR). Additionally supported by NIH R21 DE019712 (AJ), NIH R01 CA149456 (AJ), the Janet Mordecai Foundation (AJ), the Peter and Rhonda Grant Foundation (AJ), NIH R01 CA117802-06 (YR), NIH P30 AR057212-02 (YR), NIH P01 AI022295-24 (YR), NIH T32 CA174648 (principal investigator XJW; co-investigator PNL) and a Translational Research Award from the Leukemia and Lymphoma Society (YR).	Abate-Daga D, 2014, HUM GENE THER, V25, P1003, DOI 10.1089/hum.2013.209; Al-Lazikani B, 2012, NAT BIOTECHNOL, V30, P679, DOI 10.1038/nbt.2284; Bankert RB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024420; Bird GA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105525; Christiansen Ailsa, 2011, Genes Cancer, V2, P1146, DOI 10.1177/1947601911423028; Dadras SS, 2003, AM J PATHOL, V162, P1951, DOI 10.1016/S0002-9440(10)64328-3; DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; ENGELHOLM SA, 1985, EUR J CANCER CLIN ON, V21, P815, DOI 10.1016/0277-5379(85)90221-4; Fullar A, 2012, EXP CELL RES, V318, P1517, DOI 10.1016/j.yexcr.2012.03.023; Garrido-Laguna I, 2011, CLIN CANCER RES, V17, P5793, DOI 10.1158/1078-0432.CCR-11-0341; Geary SM, 2008, EXP CELL RES, V314, P2165, DOI 10.1016/j.yexcr.2008.04.011; Gomes FG, 2013, LIFE SCI, V92, P101, DOI 10.1016/j.lfs.2012.10.008; Hausser HJ, 2005, BIOCHEM BIOPH RES CO, V333, P216, DOI 10.1016/j.bbrc.2005.05.097; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Iorns E, 2012, BREAST CANCER RES TR, V131, P321, DOI 10.1007/s10549-011-1784-8; Jackson DG, 2003, TRENDS CARDIOVAS MED, V13, P1, DOI 10.1016/S1050-1738(02)00189-5; Keysar SB, 2013, MOL ONCOL, V7, P776, DOI 10.1016/j.molonc.2013.03.004; Keysar SB, 2013, CANCER RES, V73, P3381, DOI 10.1158/0008-5472.CAN-12-4047; Kidd S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030563; Kimple RJ, 2013, CLIN CANCER RES, V19, P855, DOI 10.1158/1078-0432.CCR-12-2746; Lan P, 2006, BLOOD, V108, P487, DOI 10.1182/blood-2005-11-4388; Lee HJ, 2009, ARTHRITIS RHEUM-US, V60, P2325, DOI 10.1002/art.24786; Leskov I, 2013, ONCOGENE, V32, P1066, DOI 10.1038/onc.2012.117; Lui VWY, 2013, CANCER DISCOV, V3, P761, DOI 10.1158/2159-8290.CD-13-0103; McBride WH, 2004, RADIAT RES, V162, P1, DOI 10.1667/RR3196; Ozer H, 2000, J CLIN ONCOL, V18, P3558, DOI 10.1200/JCO.2000.18.20.3558; Pallasch CP, 2014, CELL, V156, P590, DOI 10.1016/j.cell.2013.12.041; Redon Richard, 2009, V529, P267, DOI 10.1007/978-1-59745-538-1_17; Rong ZL, 2014, CELL STEM CELL, V14, P121, DOI 10.1016/j.stem.2013.11.014; Rongvaux A, 2014, NAT BIOTECHNOL, V32, P364, DOI 10.1038/nbt.2858; Ruitberg CM, 2001, NUCLEIC ACIDS RES, V29, P320, DOI 10.1093/nar/29.1.320; Suggitt M, 2005, CLIN CANCER RES, V11, P971; Tawada M, 2012, J GASTROENTEROL, V47, P1057, DOI 10.1007/s00535-012-0638-4; Tentler JJ, 2012, NAT REV CLIN ONCOL, V9, P338, DOI 10.1038/nrclinonc.2012.61; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Tsuyada A, 2012, CANCER RES, V72, P2768, DOI 10.1158/0008-5472.CAN-11-3567; Wege AK, 2011, INT J CANCER, V129, P2194, DOI 10.1002/ijc.26159; Wels J, 2008, GENE DEV, V22, P559, DOI 10.1101/gad.1636908; WENNERBERG J, 1983, ACTA OTO-LARYNGOL, V95, P183, DOI 10.3109/00016488309130933; Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271; Zhou QJ, 2014, CANCER LETT, V344, P13, DOI 10.1016/j.canlet.2013.10.015	45	83	89	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2016	35	3					290	300		10.1038/onc.2015.94	http://dx.doi.org/10.1038/onc.2015.94			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OF	25893296	Green Accepted			2022-12-17	WOS:000369055300003
J	Ahn, J; Konno, H; Barber, GN				Ahn, J.; Konno, H.; Barber, G. N.			Diverse roles of STING-dependent signaling on the development of cancer	ONCOGENE			English	Article							INNATE; TUMORIGENESIS; INFLAMMATION; ADAPTER; CELLS; TOLL	Stimulator of interferon genes (STING) is a cellular sensor that controls cytosolic DNA-activated innate immune signaling. We have previously demonstrated that STING-deficient mice are resistant to carcinogen-induced skin cancer, similar to myeloid differentiation primary response gene 88 (MyD88) deficient mice, since the production of STING-dependent DNA-damage-induced proinflammatory cytokines, that likely require MyD88 signaling to exert their growth-promoting activity, are prevented. In contrast, MyD88-deficient mice are sensitive to colitis-associated cancer (CAC), since selected cytokines generated following DNA-damage also activate repair pathways, which can help prevent tumor development. Here, we demonstrate that STING signaling facilitates wound repair processes and that analogous to MyD88-deficient mice, STING-deficient mice (SKO) are prone to CAC induced by DNA-damaging agents. SKO mice harboring tumors exhibited low levels of tumor-suppressive interleukin-22 binding protein (IL-22BP) compared to normal mice, a cytokine considered critical for preventing colon-related cancer. Our data indicate that STING constitutes a critical component of the host early response to intestinal damage and is essential for invigorating tissue repair pathways that may help prevent tumorigenesis.	[Barber, G. N.] Univ Miami, Sch Med, Dept Cell Biol, Miami, FL 33136 USA; [Barber, G. N.] Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA	University of Miami; University of Miami	Barber, GN (corresponding author), Univ Miami, Sch Med, Dept Cell Biol, 511 Papanicolaou Bldg,1550 NW 10th Ave, Miami, FL 33136 USA.	gbarber@med.miami.edu			NATIONAL CANCER INSTITUTE [R01CA194404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI079336] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA194404] Funding Source: Medline; NIAID NIH HHS [R01 AI079336] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahn J, 2014, J IMMUNOL, V193, P4634, DOI 10.4049/jimmunol.1401337; Ahn J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6166; Ahn J, 2012, P NATL ACAD SCI USA, V109, P19386, DOI 10.1073/pnas.1215006109; Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050; Burdette DL, 2011, NATURE, V478, P515, DOI 10.1038/nature10429; Cai X, 2014, MOL CELL, V54, P289, DOI 10.1016/j.molcel.2014.03.040; Cataisson C, 2012, J EXP MED, V209, P1689, DOI 10.1084/jem.20101355; De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279; Elinav E, 2011, CELL, V145, P745, DOI 10.1016/j.cell.2011.04.022; Fukata M, 2009, SEMIN IMMUNOL, V21, P242, DOI 10.1016/j.smim.2009.06.005; Gall A, 2012, IMMUNITY, V36, P120, DOI 10.1016/j.immuni.2011.11.018; Goldszmid RS, 2012, NAT IMMUNOL, V13, P932, DOI 10.1038/ni.2422; Huber S, 2012, NATURE, V491, P259, DOI 10.1038/nature11535; Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317; Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476; JACOBY RF, 1991, J CLIN INVEST, V87, P624, DOI 10.1172/JCI115039; Liu Y, 2014, NEW ENGL J MED, V371, P507, DOI 10.1056/NEJMoa1312625; Namjou B, 2011, GENES IMMUN, V12, P270, DOI 10.1038/gene.2010.73; Nowarski R, 2013, CANCER IMMUNOL RES, V1, P77, DOI 10.1158/2326-6066.CIR-13-0081; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; Salcedo R, 2013, TRENDS IMMUNOL, V34, P379, DOI 10.1016/j.it.2013.03.008; Salcedo R, 2010, J EXP MED, V207, P1625, DOI 10.1084/jem.20100199; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Swann JB, 2008, P NATL ACAD SCI USA, V105, P652, DOI 10.1073/pnas.0708594105; Zenewicz LA, 2008, IMMUNITY, V29, P947, DOI 10.1016/j.immuni.2008.11.003; Zhu QF, 2014, J IMMUNOL, V193, P4779, DOI 10.4049/jimmunol.1402051	26	83	87	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2015	34	41					5302	5308		10.1038/onc.2014.457	http://dx.doi.org/10.1038/onc.2014.457			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CT1QL	25639870	Green Accepted			2022-12-17	WOS:000362575400010
J	Lee, IH; Sohn, M; Lim, HJ; Yoon, S; Oh, H; Shin, S; Shin, JH; Oh, SH; Kim, J; Lee, DK; Noh, DY; Bae, DS; Seong, JK; Bae, YS				Lee, I. H.; Sohn, M.; Lim, H. J.; Yoon, S.; Oh, H.; Shin, S.; Shin, J. H.; Oh, S-H; Kim, J.; Lee, D. K.; Noh, D. Y.; Bae, D. S.; Seong, J. K.; Bae, Y. S.			Ahnak functions as a tumor suppressor via modulation of TGF beta/Smad signaling pathway	ONCOGENE			English	Article							MAMMARY-GLAND DEVELOPMENT; C-MYC; BETA; PROTEIN; IDENTIFICATION; TARGET; GENE; PHOSPHATASE; COMPLEX	We provide detailed mechanisms of Ahnak-mediated potentiation of transforming growth factor beta (TGF beta) signaling, which leads to a negative regulation of cell growth. We show that Smad3 interacts with Ahnak through MH2 domain and that Ahnak stimulates Smad3 localization into nucleus leading to potentiating TGF beta-induced transcriptional activity of R-Smad. Moreover, overexpression of Ahnak resulted in growth retardation and cell cycle arrest through downregulation of c-Myc and cyclin D1/D2. We describe results from analyses of Ahnak(-/-) mouse model expressing middle T antigen in a mammary gland-specific manner (MMTVTg/+ Ahnak(-/-)), which showed significantly progressed hyperplasia of mammary glands compared with MMTVTg/+ Ahnak(+/+). Finally, we screened multiple human breast cancer tissues and showed that the expression of Ahnak in cancer tissues is lower than that in control tissues by 50%. Taken together, these data indicate that Ahnak mediates a negative regulation of cell growth and acts as novel tumor suppressor through potentiation of TGF beta signaling.	[Lee, I. H.; Sohn, M.; Lim, H. J.; Yoon, S.; Oh, H.; Shin, S.; Kim, J.; Lee, D. K.; Bae, Y. S.] Ewha Womans Univ, Dept Life Sci, Seoul, South Korea; [Lee, I. H.; Sohn, M.; Lim, H. J.; Yoon, S.; Oh, H.; Shin, S.; Kim, J.; Lee, D. K.; Bae, Y. S.] Ewha Womans Univ, GT5 program, Seoul, South Korea; [Shin, J. H.; Seong, J. K.] Seoul Natl Univ, Coll Vet Med, Lab Dev Biol & Genom, Seoul 151742, South Korea; [Oh, S-H] Gachon Univ, Coll Pharm, Inchon, South Korea; [Noh, D. Y.] Seoul Natl Univ, Sch Med, Dept Surg, Seoul 151742, South Korea; [Bae, D. S.] Sungkyunkwan Univ, Samsung Hosp, Dept Obstet & Gynecol, Seoul, South Korea	Ewha Womans University; Ewha Womans University; Seoul National University (SNU); Gachon University; Seoul National University (SNU); Sungkyunkwan University (SKKU); Samsung Medical Center	Seong, JK (corresponding author), Seoul Natl Univ, Coll Vet Med, Lab Dev Biol & Genom, Seoul 151742, South Korea.	snumouse@snu.ac.kr; baeys@ewha.ac.kr	LEE, IN HYE/T-2714-2019	LEE, IN HYE/0000-0003-2334-3594; Lee, Daekee/0000-0001-8130-2059; Seong, Je Kyung/0000-0003-1177-6958	National Research Foundation of Korea (NRF) grant [2012R1A5A1048236]; Drug Target Validation program [20090093987]; Bio & Medical Technology Development Program [2012M3A9B4028785]; Redoxomics grant - Ministry of Science, ICT & Future Planning [2012M3A9C5048708]; Ewha Womans University Research Grant	National Research Foundation of Korea (NRF) grant; Drug Target Validation program; Bio & Medical Technology Development Program; Redoxomics grant - Ministry of Science, ICT & Future Planning; Ewha Womans University Research Grant	This work was supported by the National Research Foundation of Korea (NRF) grant (No. 2012R1A5A1048236), by the Drug Target Validation program (No. 20090093987), by the Bio & Medical Technology Development Program (No. 2012M3A9B4028785) and by Redoxomics grant (No. 2012M3A9C5048708) funded by Ministry of Science, ICT & Future Planning, and the Ewha Womans University Research Grant of 2013 (to I.H.L.).	Briones-Orta Marco A, 2011, Curr Mol Pharmacol, V4, P141; Conidi A, 2011, CYTOKINE GROWTH F R, V22, P287, DOI 10.1016/j.cytogfr.2011.11.006; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Drabsch Y, 2012, CANCER METAST REV, V31, P553, DOI 10.1007/s10555-012-9375-7; Florenes VA, 1996, ONCOGENE, V13, P2447; Forrester E, 2005, CANCER RES, V65, P2296, DOI 10.1158/0008-5472.CAN-04-3272; Gentil BJ, 2001, J BIOL CHEM, V276, P23253, DOI 10.1074/jbc.M010655200; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Haase H, 1999, FASEB J, V13, P2161, DOI 10.1096/fasebj.13.15.2161; HASHIMOTO T, 1995, EXP CELL RES, V217, P258, DOI 10.1006/excr.1995.1085; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heldin CH, 2012, CELL TISSUE RES, V347, P21, DOI 10.1007/s00441-011-1190-x; Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021; Hohaus A, 2002, FASEB J, V16, DOI 10.1096/fj.01-0855com; Jackson R, 2013, VIROLOGY, V435, P425, DOI 10.1016/j.virol.2012.09.032; Kang JS, 2009, TRENDS CELL BIOL, V19, P385, DOI 10.1016/j.tcb.2009.05.008; Lee IH, 2004, J BIOL CHEM, V279, P26645, DOI 10.1074/jbc.M311525200; Lee IH, 2008, J BIOL CHEM, V283, P6312, DOI 10.1074/jbc.M706878200; Lim HJ, 2013, CARDIOVASC RES, V97, P302, DOI 10.1093/cvr/cvs311; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Morikawa M, 2013, ONCOGENE, V32, P1609, DOI 10.1038/onc.2012.191; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Scollen S, 2011, CANCER EPIDEM BIOMAR, V20, P1112, DOI 10.1158/1055-9965.EPI-11-0062; SEEDORF K, 1987, EMBO J, V6, P139, DOI 10.1002/j.1460-2075.1987.tb04731.x; Sekiya F, 1999, J BIOL CHEM, V274, P13900, DOI 10.1074/jbc.274.20.13900; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; SHTIVELMAN E, 1993, J CELL BIOL, V120, P625, DOI 10.1083/jcb.120.3.625; SHTIVELMAN E, 1992, P NATL ACAD SCI USA, V89, P5472, DOI 10.1073/pnas.89.12.5472; Sundqvist A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3066; Tarasewicz E, 2012, CELL CYCLE, V11, P2443, DOI 10.4161/cc.20546; Wang CG, 2011, CELL CYCLE, V10, P57, DOI 10.4161/cc.10.1.14449; Zhang SP, 2007, MOL CELL BIOL, V27, P4488, DOI 10.1128/MCB.01636-06; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	35	83	84	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2014	33	38					4675	4684		10.1038/onc.2014.69	http://dx.doi.org/10.1038/onc.2014.69			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3VX	24662814	Green Published, hybrid			2022-12-17	WOS:000342007200006
J	Michels, J; Vitale, I; Saparbaev, M; Castedo, M; Kroemer, G				Michels, J.; Vitale, I.; Saparbaev, M.; Castedo, M.; Kroemer, G.			Predictive biomarkers for cancer therapy with PARP inhibitors	ONCOGENE			English	Review						PAR; base excision repair; homologous recombination; BRCAness; synthetic lethality	POLY(ADP-RIBOSE) POLYMERASE INHIBITOR; HOMOLOGOUS RECOMBINATION REPAIR; DOUBLE-STRAND BREAKS; POLYMERASE-1-DEPENDENT CELL-DEATH; PEGYLATED LIPOSOMAL DOXORUBICIN; NUCLEOTIDE EXCISION-REPAIR; APOPTOSIS-INDUCING FACTOR; DEPENDENT PROTEIN-KINASE; REFRACTORY SOLID TUMORS; ADP-RIBOSE POLYMERASE-1	Poly(ADP-ribose) polymerase (PARP) inhibitors have raised high expectations for the treatment of multiple malignancies. PARP inhibitors, which can be used as monotherapies or in combination with DNA-damaging agents, are particularly efficient against tumors with defects in DNA repair mechanisms, in particular the homologous recombination pathway, for instance due to BRCA mutations. Thus, deficient DNA repair provides a framework for the success of PARP inhibitors in medical oncology. Here, we review encouraging results obtained in recent clinical trials investigating the safety and efficacy of PARP inhibitors as anticancer agents. We discuss emerging mechanisms of regulation of homologous recombination and how inhibition of DNA repair might be used in cancer therapy. We surmise that the identification of patients that are likely to benefit from PARP inhibition will improve the clinical use of PARP inhibitors in a defined target population. Thus, we will place special emphasis on biomarker discovery.	[Michels, J.; Castedo, M.; Kroemer, G.] INSERM, U848, F-94805 Villejuif, France; [Michels, J.; Saparbaev, M.; Castedo, M.; Kroemer, G.] Inst Gustave Roussy, Villejuif, France; [Michels, J.; Saparbaev, M.; Castedo, M.; Kroemer, G.] Univ Paris Sud, Villejuif, France; [Vitale, I.] Regina Elena Inst Canc Res, Rome, Italy; [Vitale, I.] Natl Inst Hlth, Rome, Italy; [Saparbaev, M.] CNRS, UMR 8200, Villejuif, France; [Kroemer, G.] Inst Gustave Roussy, Metabol Platform, Villejuif, France; [Kroemer, G.] Ctr Rech Cordeliers, Paris, France; [Kroemer, G.] Hosp Europe Georges Pompidou, AP HP, Pole Biol, Paris, France; [Kroemer, G.] Univ Paris 05, Fac Med, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Istituto Superiore di Sanita (ISS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Castedo, M (corresponding author), Inst Gustave Roussy, INSERM U848, 114 Rue Edouard Vaillant, F-94805 Villejuif, France.	castedo@igr.fr	KROEMER, Guido/B-4263-2013; Vitale, Ilio/M-3960-2017; Kroemer, Guido/AAY-9859-2020; Saparbaev, Murat K/N-3225-2015; Michels, Judith/Q-5693-2018; Saparbaev, Murat/AAC-5478-2020	KROEMER, Guido/0000-0002-9334-4405; Vitale, Ilio/0000-0002-5918-1841; Saparbaev, Murat K/0000-0002-4630-1074; Michels, Judith/0000-0002-9640-0222; Saparbaev, Murat/0000-0002-4630-1074	Ligue contre le Cancer (equipe labellisee); Agence National de la Recherche; AXA Chair for Longevity Research; Association pour la Recherche sur le Cancer; Associazione Italiana per la Ricerca sul Cancro (AIRC); Canceropole Ile-de-France; Institut National du Cancer (INCa); Fondation Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche Medicale; European Commission (ArtForce); European Research Council; LabEx Immuno-Oncology; Action Lions 'Vaincre le Cancer', Luxembourg; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (Socrate); Cancer Research and Personalized Medicine (Carpem); Paris Alliance of Cancer Research Institutes	Ligue contre le Cancer (equipe labellisee); Agence National de la Recherche(French National Research Agency (ANR)); AXA Chair for Longevity Research(AXA Research Fund); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Canceropole Ile-de-France(Region Ile-de-France); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Fondation Bettencourt-Schueller; Fondation de France(Fondation de France); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); European Commission (ArtForce)(European CommissionEuropean Commission Joint Research Centre); European Research Council(European Research Council (ERC)European Commission); LabEx Immuno-Oncology; Action Lions 'Vaincre le Cancer', Luxembourg; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (Socrate); Cancer Research and Personalized Medicine (Carpem); Paris Alliance of Cancer Research Institutes	The authors would like to thank Lorenzo Galluzzi (Universite Paris Descartes, Paris, France) for assistance with manuscript preparation. The authors are supported by the Ligue contre le Cancer (equipe labellisee), Agence National de la Recherche, AXA Chair for Longevity Research, Association pour la Recherche sur le Cancer, Associazione Italiana per la Ricerca sul Cancro (AIRC), Canceropole Ile-de-France, Institut National du Cancer (INCa), Fondation Bettencourt-Schueller, Fondation de France, Fondation pour la Recherche Medicale, the European Commission (ArtForce), the European Research Council, the LabEx Immuno-Oncology, Action Lions 'Vaincre le Cancer', Luxembourg, the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (Socrate) and Cancer Research and Personalized Medicine (Carpem) and the Paris Alliance of Cancer Research Institutes.	Abeti R, 2011, BRAIN, V134, P1658, DOI 10.1093/brain/awr104; Abkevich V, 2012, BRIT J CANCER, V107, P1776, DOI 10.1038/bjc.2012.451; Adams SF, 2011, GYNECOL ONCOL, V123, P486, DOI 10.1016/j.ygyno.2011.08.032; Andressoo JO, 2005, ADV EXP MED BIOL, V570, P45, DOI 10.1007/1-4020-3764-3_3; Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8; Aurelius J, 2012, BLOOD, V119, P5832, DOI 10.1182/blood-2011-11-391722; Ba XQ, 2011, AM J PATHOL, V178, P946, DOI 10.1016/j.ajpath.2010.12.004; Bai P, 2012, CELL METAB, V16, P290, DOI 10.1016/j.cmet.2012.06.016; Baker KM, 2003, J BIOL CHEM, V278, P17876, DOI 10.1074/jbc.M209480200; Bedikian AY, 2009, CANCER INVEST, V27, P756, DOI 10.1080/07357900802709159; Birkbak NJ, 2012, CANCER DISCOV, V2, P366, DOI 10.1158/2159-8290.CD-11-0206; Boiteux S, 2000, ARCH BIOCHEM BIOPHYS, V377, P1, DOI 10.1006/abbi.2000.1773; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; Brenner JC, 2011, CANCER CELL, V19, P664, DOI 10.1016/j.ccr.2011.04.010; Brenner JC, 2009, BBA-REV CANCER, V1796, P201, DOI 10.1016/j.bbcan.2009.04.005; Bryant HE, 2006, NUCLEIC ACIDS RES, V34, P1685, DOI 10.1093/nar/gkl108; Bryant HE, 2009, EMBO J, V28, P2601, DOI 10.1038/emboj.2009.206; Bullrich F, 1999, CANCER RES, V59, P24; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Campalans A, 2013, NUCLEIC ACIDS RES, V41, P3115, DOI 10.1093/nar/gkt025; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Carbone M, 2008, ONCOGENE, V27, P6083, DOI 10.1038/onc.2008.221; Cavallo F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051563; Cazales M, 2005, CELL CYCLE, V4, P1233, DOI 10.4161/cc.4.9.1964; Cerbinskaite A, 2012, CANCER TREAT REV, V38, P89, DOI 10.1016/j.ctrv.2011.04.015; CHAMBON P, 1963, BIOCHEM BIOPH RES CO, V11, P39, DOI 10.1016/0006-291X(63)90024-X; Choudhury A, 2009, MOL CANCER THER, V8, P203, DOI 10.1158/1535-7163.MCT-08-0959; Cousineau I, 2011, MOL GENET GENOMICS, V285, P325, DOI 10.1007/s00438-011-0612-5; Couto CAM, 2011, J CELL BIOL, V194, P367, DOI 10.1083/jcb.201012132; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Daniel RA, 2009, CLIN CANCER RES, V15, P1241, DOI 10.1158/1078-0432.CCR-08-1095; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206; De Vos M, 2012, BIOCHEM PHARMACOL, V84, P137, DOI 10.1016/j.bcp.2012.03.018; Dean E, 2012, BRIT J CANCER, V106, P468, DOI 10.1038/bjc.2011.555; Dedes KJ, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001538; Delaney CA, 2000, CLIN CANCER RES, V6, P2860; di Fagagna FD, 1999, NAT GENET, V23, P76; Drew Y, 2011, JNCI-J NATL CANCER I, V103, P334, DOI 10.1093/jnci/djq509; Dungey FA, 2008, INT J RADIAT ONCOL, V72, P1188, DOI 10.1016/j.ijrobp.2008.07.031; Dungey FA, 2009, MOL CANCER THER, V8, P2243, DOI 10.1158/1535-7163.MCT-09-0201; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548; Ethier C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047978; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fong PC, 2010, J CLIN ONCOL, V28, P2512, DOI 10.1200/JCO.2009.26.9589; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Fraser M, 2012, CLIN CANCER RES, V18, P1015, DOI 10.1158/1078-0432.CCR-11-2189; Fraser M, 2011, CELL CYCLE, V10, P2218, DOI 10.4161/cc.10.13.16305; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Gambi N, 2008, BIOCHEM PHARMACOL, V75, P2356, DOI 10.1016/j.bcp.2008.03.015; Gelmon KA, 2011, LANCET ONCOL, V12, P852, DOI 10.1016/S1470-2045(11)70214-5; Gonzalez-Angulo AM, 2011, CLIN CANCER RES, V17, P1082, DOI 10.1158/1078-0432.CCR-10-2560; Gordon AN, 2001, J CLIN ONCOL, V19, P3312, DOI 10.1200/JCO.2001.19.14.3312; Gottipati P, 2010, CANCER RES, V70, P5389, DOI 10.1158/0008-5472.CAN-09-4716; Graeser M, 2010, CLIN CANCER RES, V16, P6159, DOI 10.1158/1078-0432.CCR-10-1027; Gros L, 2003, MUTAT RES-FUND MOL M, V531, P219, DOI 10.1016/j.mrfmmm.2003.07.008; Gros L, 2002, ONCOGENE, V21, P8905, DOI 10.1038/sj.onc.1206005; Gudmundsdottir K, 2006, ONCOGENE, V25, P5864, DOI 10.1038/sj.onc.1209874; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Haince JF, 2008, J BIOL CHEM, V283, P1197, DOI 10.1074/jbc.M706734200; Hassa PO, 2006, MICROBIOL MOL BIOL R, V70, P789, DOI 10.1128/MMBR.00040-05; Helleday T, 2011, MOL ONCOL, V5, P387, DOI 10.1016/j.molonc.2011.07.001; Herceg Z, 1999, MOL CELL BIOL, V19, P5124; Hochegger H, 2006, EMBO J, V25, P1305, DOI 10.1038/sj.emboj.7601015; Hong DS, 2013, CANCER TREAT REV, V39, P375, DOI 10.1016/j.ctrv.2012.10.001; Horton TM, 2009, MOL CANCER THER, V8, P2232, DOI 10.1158/1535-7163.MCT-09-0142; Hottiger MO, 2010, TRENDS BIOCHEM SCI, V35, P208, DOI 10.1016/j.tibs.2009.12.003; Huang Q, 2009, CELL DEATH DIFFER, V16, P264, DOI 10.1038/cdd.2008.151; Huang Q, 2009, AUTOPHAGY, V5, P273, DOI 10.4161/auto.5.2.7640; Huang SH, 2008, ONCOL REP, V20, P567, DOI 10.3892/or_00000043; Hughes-Davies L, 2003, CELL, V115, P523, DOI 10.1016/S0092-8674(03)00930-9; Ibrahim YH, 2012, CANCER DISCOV, V2, P1036, DOI 10.1158/2159-8290.CD-11-0348; Jacinto FV, 2007, MUTAGENESIS, V22, P247, DOI 10.1093/mutage/gem009; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jankevicius G, 2013, NAT STRUCT MOL BIOL, V20, P508, DOI 10.1038/nsmb.2523; Johnson N, 2011, NAT MED, V17, P875, DOI 10.1038/nm.2377; Johnson N, 2009, MOL CELL, V35, P327, DOI 10.1016/j.molcel.2009.06.036; Jouan-Lanhouet S, 2012, CELL DEATH DIFFER, V19, P2003, DOI 10.1038/cdd.2012.90; Juvekar A, 2012, CANCER DISCOV, V2, P1048, DOI 10.1158/2159-8290.CD-11-0336; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kashima L, 2012, J BIOL CHEM, V287, P12975, DOI 10.1074/jbc.M111.321828; Kashiwaya K, 2009, CANCER SCI, V100, P457, DOI 10.1111/j.1349-7006.2008.01058.x; Kaye SB, 2012, J CLIN ONCOL, V30, P372, DOI 10.1200/JCO.2011.36.9215; Khan OA, 2011, BRIT J CANCER, V104, P750, DOI 10.1038/bjc.2011.8; King BS, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.393504; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Krishnakumar R, 2010, MOL CELL, V39, P8, DOI 10.1016/j.molcel.2010.06.017; Kumar A, 2010, P NATL ACAD SCI USA, V107, P7491, DOI 10.1073/pnas.0914242107; Kummar S, 2012, CLIN CANCER RES, V18, P1726, DOI 10.1158/1078-0432.CCR-11-2821; Kummar S, 2011, CANCER RES, V71, P5626, DOI 10.1158/0008-5472.CAN-11-1227; Langelier MF, 2012, SCIENCE, V336, P728, DOI 10.1126/science.1216338; Lavin MF, 2008, NAT REV MOL CELL BIO, V9, P759, DOI 10.1038/nrm2514; Ledermann J, 2012, NEW ENGL J MED, V366, P1382, DOI 10.1056/NEJMoa1105535; Li LP, 2008, CANCER RES, V68, P9141, DOI 10.1158/0008-5472.CAN-08-1127; Liu LF, 2000, ANN NY ACAD SCI, V922, P1; Luo X, 2012, GENE DEV, V26, P417, DOI 10.1101/gad.183509.111; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maeta Y, 2005, TUMOR BIOL, V26, P300, DOI 10.1159/000089288; Magan N, 2012, ANTI-CANCER DRUG, V23, P627, DOI 10.1097/CAD.0b013e328350900f; Mansour WY, 2010, NUCLEIC ACIDS RES, V38, P6065, DOI 10.1093/nar/gkq387; Rodriguez-Vargas JM, 2012, CELL RES, V22, P1181, DOI 10.1038/cr.2012.70; Marsit CJ, 2004, ONCOGENE, V23, P1000, DOI 10.1038/sj.onc.1207256; McEllin B, 2010, CANCER RES, V70, P5457, DOI 10.1158/0008-5472.CAN-09-4295; Mendes-Pereira AM, 2009, EMBO MOL MED, V1, P315, DOI 10.1002/emmm.200900041; Menissier-de Murcia J, 2001, MOL CELL BIOL, V21, P1828; Merkhofer EC, 2010, ONCOGENE, V29, P1238, DOI 10.1038/onc.2009.410; Michels J, 2013, CANCER RES, V73, P2271, DOI 10.1158/0008-5472.CAN-12-3000; Michels J, 2013, CELL CYCLE, V12, P877, DOI 10.4161/cc.24034; Modi S, 2011, CLIN CANCER RES, V17, P5132, DOI 10.1158/1078-0432.CCR-11-0072; Montoni A, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00018; Moroni F, 2012, BRIT J PHARMACOL, V165, P1487, DOI 10.1111/j.1476-5381.2011.01666.x; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Moynahan ME, 2001, CANCER RES, V61, P4842; Mukhopadhyay A, 2010, CLIN CANCER RES, V16, P2344, DOI 10.1158/1078-0432.CCR-09-2758; Munoz-Gamez JA, 2011, CANCER LETT, V301, P47, DOI 10.1016/j.canlet.2010.10.026; Munoz-Gomez JA, 2009, AUTOPHAGY, V5, P61, DOI 10.4161/auto.5.1.7272; Narayan G, 2004, CANCER RES, V64, P2994, DOI 10.1158/0008-5472.CAN-04-0245; Noguchi M, 2006, BIOCHEM BIOPH RES CO, V351, P658, DOI 10.1016/j.bbrc.2006.10.094; Noren Hooten N, 2011, J BIOL CHEM, V286, P44679, DOI 10.1074/jbc.M111.255869; Nowsheen S, 2012, CANCER RES, V72, P4796, DOI 10.1158/0008-5472.CAN-12-1287; Nowsheen S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024148; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; O'Connor KW, 2013, CANCER RES, V73, P2529, DOI 10.1158/0008-5472.CAN-12-3313; Ocampo MTA, 2002, MOL CELL BIOL, V22, P6111, DOI 10.1128/MCB.22.17.6111-6121.2002; Pacher P, 2007, CARDIOVASC DRUG REV, V25, P235, DOI 10.1111/j.1527-3466.2007.00018.x; Palma JP, 2009, CLIN CANCER RES, V15, P7277, DOI 10.1158/1078-0432.CCR-09-1245; Pan Q, 2012, CELL BIOCHEM BIOPHYS, V62, P185, DOI 10.1007/s12013-011-9280-7; Park SY, 2005, CANCER RES, V65, P3894, DOI 10.1158/0008-5472.CAN-04-4014; Patel AG, 2012, CLIN CANCER RES, V18, P1655, DOI 10.1158/1078-0432.CCR-11-2890; Patel AG, 2011, P NATL ACAD SCI USA, V108, P3406, DOI 10.1073/pnas.1013715108; PEGG AE, 1990, CANCER RES, V50, P6119; Piao L, 2011, GENE CHROMOSOME CANC, V50, P13, DOI 10.1002/gcc.20828; Pines A, 2012, J CELL BIOL, V199, P235, DOI 10.1083/jcb.201112132; Plummer R, 2013, CANCER CHEMOTH PHARM, V71, P1191, DOI 10.1007/s00280-013-2113-1; Plummer R, 2008, CLIN CANCER RES, V14, P7917, DOI 10.1158/1078-0432.CCR-08-1223; Press JZ, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-17; Rajan A, 2012, CLIN CANCER RES, V18, P2344, DOI 10.1158/1078-0432.CCR-11-2425; Riffell JL, 2012, NAT REV DRUG DISCOV, V11, P923, DOI 10.1038/nrd3868; Robu M, 2013, P NATL ACAD SCI USA, V110, P1658, DOI 10.1073/pnas.1209507110; Rosado MM, 2013, IMMUNOLOGY, V139, P428, DOI 10.1111/imm.12099; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; Rulten SL, 2011, MOL CELL, V41, P33, DOI 10.1016/j.molcel.2010.12.006; Russo AL, 2009, CLIN CANCER RES, V15, P607, DOI 10.1158/1078-0432.CCR-08-2079; Sahaboglu A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015495; Sakai W, 2008, NATURE, V451, P1116, DOI 10.1038/nature06633; Sakata KI, 2011, CANCER SCI, V102, P1712, DOI 10.1111/j.1349-7006.2011.02004.x; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Samol J, 2012, INVEST NEW DRUG, V30, P1493, DOI 10.1007/s10637-011-9682-9; Samper E, 2001, J CELL BIOL, V154, P49, DOI 10.1083/jcb.200103049; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; Schaffner C, 2000, P NATL ACAD SCI USA, V97, P2773, DOI 10.1073/pnas.050400997; Schultz N, 2003, NUCLEIC ACIDS RES, V31, P4959, DOI 10.1093/nar/gkg703; Sedgwick B, 2004, NAT REV MOL CELL BIO, V5, P148, DOI 10.1038/nrm1312; Seki A, 2008, SCIENCE, V320, P1655, DOI 10.1126/science.1157425; Senra JM, 2011, MOL CANCER THER, V10, P1949, DOI 10.1158/1535-7163.MCT-11-0278; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sourisseau T, 2010, EMBO MOL MED, V2, P130, DOI 10.1002/emmm.201000068; Spagnolo L, 2012, NUCLEIC ACIDS RES, V40, P4168, DOI 10.1093/nar/gkr1231; Stefansson OA, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2334; Strom CE, 2011, NUCLEIC ACIDS RES, V39, P3166, DOI 10.1093/nar/gkq1241; Strosznajder JB, 2012, MOL NEUROBIOL, V46, P78, DOI 10.1007/s12035-012-8258-9; Strosznajder RP, 2010, MOL NEUROBIOL, V41, P187, DOI 10.1007/s12035-010-8124-6; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Sugimura K, 2008, J CELL BIOL, V183, P1203, DOI 10.1083/jcb.200806068; Sultana R, 2013, CANCER RES, V73, P1621, DOI 10.1158/0008-5472.CAN-12-2929; Szabo C, 2005, PHARMACOL RES, V52, P60, DOI 10.1016/j.phrs.2005.02.015; Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852; Taverna P, 2000, CANCER CHEMOTH PHARM, V46, P507, DOI 10.1007/s002800000186; TAVERNA P, 1992, ANTI-CANCER DRUG, V3, P401, DOI 10.1097/00001813-199208000-00014; Tentori L, 2010, CURR CANCER DRUG TAR, V10, P368, DOI 10.2174/156800910791208571; Tentori L, 1999, LEUKEMIA, V13, P901, DOI 10.1038/sj.leu.2401423; Thomas HD, 2007, MOL CANCER THER, V6, P945, DOI 10.1158/1535-7163.MCT-06-0552; Tsutsumi M, 2001, CARCINOGENESIS, V22, P1, DOI 10.1093/carcin/22.1.1; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; Verweij J, 2004, LANCET, V364, P1127, DOI 10.1016/S0140-6736(04)17098-0; Veuger SJ, 2009, ONCOGENE, V28, P832, DOI 10.1038/onc.2008.439; Veuger SJ, 2003, CANCER RES, V63, P6008; Veuger SJ, 2004, ONCOGENE, V23, P7322, DOI 10.1038/sj.onc.1207984; Virag L, MOL ASPECTS MED, VS0098-2997; Vodenicharov MD, 2005, J CELL SCI, V118, P589, DOI 10.1242/jcs.01636; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang ML, 2006, NUCLEIC ACIDS RES, V34, P6170, DOI 10.1093/nar/gkl840; Wang YF, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2000902; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Wesierska-Gadek J, 2012, BIOCHEM PHARMACOL, V84, P1318, DOI 10.1016/j.bcp.2012.07.024; Weston VJ, 2010, BLOOD, V116, P4578, DOI 10.1182/blood-2010-01-265769; Williamson CT, 2010, MOL CANCER THER, V9, P347, DOI 10.1158/1535-7163.MCT-09-0872; Wilson DM, 2001, MUTAT RES-DNA REPAIR, V485, P283, DOI 10.1016/S0921-8777(01)00063-5; Wooster R, 2003, NEW ENGL J MED, V348, P2339, DOI 10.1056/NEJMra012284; Yang G, 2010, CLIN CANCER RES, V16, P3171, DOI 10.1158/1078-0432.CCR-09-3171; Yang YG, 2004, ONCOGENE, V23, P3872, DOI 10.1038/sj.onc.1207491; Ying SM, 2012, CANCER RES, V72, P2814, DOI 10.1158/0008-5472.CAN-11-3417; Yoon JH, 2012, BIOCHEM PHARMACOL, V83, P747, DOI 10.1016/j.bcp.2011.12.029; Yu SW, 2006, P NATL ACAD SCI USA, V103, P18314, DOI 10.1073/pnas.0606528103; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799; Zaremba T, 2009, BRIT J CANCER, V101, P256, DOI 10.1038/sj.bjc.6605166; Zhang JX, 2012, HEPATOLOGY, V55, P1840, DOI 10.1002/hep.25566; Zhou J, 2013, FEBS LETT, V587, P170, DOI 10.1016/j.febslet.2012.11.018; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	207	83	83	1	41	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2014	33	30					3894	3907		10.1038/onc.2013.352	http://dx.doi.org/10.1038/onc.2013.352			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8NA	24037533				2022-12-17	WOS:000339394700002
J	Qian, X; Anzovino, A; Kim, S; Suyama, K; Yao, J; Hulit, J; Agiostratidou, G; Chandiramani, N; McDaid, HM; Nagi, C; Cohen, HW; Phillips, GR; Norton, L; Hazan, RB				Qian, X.; Anzovino, A.; Kim, S.; Suyama, K.; Yao, J.; Hulit, J.; Agiostratidou, G.; Chandiramani, N.; McDaid, H. M.; Nagi, C.; Cohen, H. W.; Phillips, G. R.; Norton, L.; Hazan, R. B.			N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties	ONCOGENE			English	Article						ErbB2; N-cadherin; FGFR; mammospheres; metastasis	BREAST-CANCER; STEM-CELLS; GROWTH; MIGRATION; FGF; POPULATION; INVASION; SUBPOPULATIONS; PROLIFERATION; ESTABLISHMENT	N-cadherin and HER2/neu were found to be co-expressed in invasive breast carcinomas. To test the contribution of N-cadherin and HER2 in mammary tumor metastasis, we targeted N-cadherin expression in the mammary epithelium of the MMTV-Neu mouse. In the context of ErbB2/Neu, N-cadherin stimulated carcinoma cell invasion, proliferation and metastasis. N-cadherin caused fibroblast growth factor receptor (FGFR) upmodulation, resulting in epithelial-to-mesenchymal transition (EMT) and stem/progenitor like properties, involving Snail and Slug upregulation, mammosphere formation and aldehyde dehydrogenase activity. N-cadherin potentiation of the FGFR stimulated extracellular signal regulated kinase (ERK) and protein kinase B (AKT) phosphorylation resulting in differential effects on metastasis. Although ERK inhibition suppressed cyclin D1 expression, cell proliferation and stem/progenitor cell properties, it did not affect invasion or EMT. Conversely, AKT inhibition suppressed invasion through Akt 2 attenuation, and EMT through Snail inhibition, but had no effect on cyclin D1 expression, cell proliferation or mammosphere formation. These findings suggest N-cadherin/FGFR has a pivotal role in promoting metastasis through differential regulation of ERK and AKT, and underscore the potential for targeting the FGFR in advanced ErbB2-amplified breast tumors.	[Qian, X.; Anzovino, A.; Kim, S.; Suyama, K.; Yao, J.; Agiostratidou, G.; Chandiramani, N.; Hazan, R. B.] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; [Hulit, J.] Univ Manchester, Manchester Breast Ctr, Manchester, Lancs, England; [Hulit, J.] Univ Manchester, Paterson Inst Canc Res, Breakthrough Breast Canc Res Unit, Manchester, Lancs, England; [McDaid, H. M.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; [Nagi, C.] Mt Sinai Sch Med, Dept Pathol, New York, NY USA; [Cohen, H. W.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10461 USA; [Phillips, G. R.] Mt Sinai Sch Med, Dept Neurosci, New York, NY USA; [Norton, L.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA	Yeshiva University; Albert Einstein College of Medicine; University of Manchester; Paterson Institute for Cancer Research; University of Manchester; Yeshiva University; Albert Einstein College of Medicine; Icahn School of Medicine at Mount Sinai; Yeshiva University; Albert Einstein College of Medicine; Icahn School of Medicine at Mount Sinai; Memorial Sloan Kettering Cancer Center	Hazan, RB (corresponding author), Albert Einstein Coll Med, Dept Pathol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	Rachel.hazan@einstein.yu.edu		Emmanuel, Natasha/0000-0003-0130-1094; Cohen, Hillel/0000-0002-4524-0898; Norton, Larry/0000-0003-3701-9250	Breast Cancer Research Foundation; National Cancer Institute [1R01 CA135061-01A1]; CTSA from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [UL1RR025750, KL2RR025749, TL1RR025748]; NIH roadmap for Medical Research; NATIONAL CANCER INSTITUTE [R01CA077263, P30CA013330, R01CA135061] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001073] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [TL1RR025748, KL2RR025749, UL1RR025750] Funding Source: NIH RePORTER	Breast Cancer Research Foundation; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CTSA from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NIH roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Dr Jeffrey Segall for providing the wild-type MMTV-ErbB2 mouse. We thank Dr Peng Guo for expert assistance in confocal imaging and the imaging facility at Albert Einstein College of Medicine. This work was supported by grants from the Breast Cancer Research Foundation (RB Hazan and Larry Norton) and the National Cancer Institute grant (1R01 CA135061-01A1; RB Hazan). This publication was also supported in part by the CTSA Grant UL1RR025750, KL2RR025749 and TL1RR025748 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) and NIH roadmap for Medical Research.	BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Chin YR, 2009, CELL SIGNAL, V21, P470, DOI 10.1016/j.cellsig.2008.11.015; Chung S, 2013, ONCOGENE, V32, P422, DOI 10.1038/onc.2012.65; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Dontu G, 2003, CELL PROLIFERAT, V36, P59, DOI 10.1046/j.1365-2184.36.s.1.6.x; Eceles SA, 2001, J MAMMARY GLAND BIOL, V6, P393, DOI 10.1023/A:1014730829872; Eirew P, 2012, STEM CELLS, V30, P344, DOI 10.1002/stem.1001; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Giordano A, 2012, MOL CANCER THER, V11, P2526, DOI 10.1158/1535-7163.MCT-12-0460; Gotoh N, 2009, CURR STEM CELL RES T, V4, P9, DOI 10.2174/157488809787169048; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hulit J, 2007, CANCER RES, V67, P3106, DOI 10.1158/0008-5472.CAN-06-3401; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Issa A, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3379; Knudsen KA, 2005, J CELL BIOCHEM, V95, P1093, DOI 10.1002/jcb.20469; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Koziczak M, 2004, J BIOL CHEM, V279, P50004, DOI 10.1074/jbc.M404252200; Koziczak M, 2004, ONCOGENE, V23, P3501, DOI 10.1038/sj.onc.1207331; Larocca D, 1998, HYBRIDOMA, V17, P21, DOI 10.1089/hyb.1998.17.21; Lelievre EC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033206; Liao MJ, 2007, CANCER RES, V67, P8131, DOI 10.1158/0008-5472.CAN-06-4493; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Nagi C, 2005, BREAST CANCER RES TR, V94, P225, DOI 10.1007/s10549-005-7727-5; Nahta R, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1612; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Qian BZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006562; Qian X, 2013, ONCOGENE, V32, P2292, DOI 10.1038/onc.2012.249; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Sharpe R, 2011, CLIN CANCER RES, V17, P5275, DOI 10.1158/1078-0432.CCR-10-2727; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smalley MJ, 2012, J MAMMARY GLAND BIOL, V17, P91, DOI 10.1007/s10911-012-9257-1; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Toker A, 2006, CANCER RES, V66, P3963, DOI 10.1158/0008-5472.CAN-06-0743; Tomaskovic-Crook E, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2416; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Walsh MM, 2001, HUM PATHOL, V32, P583, DOI 10.1053/hupa.2001.24988; Warzecha CC, 2009, RNA BIOL, V6, P546, DOI 10.4161/rna.6.5.9606; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Xue GD, 2013, JNCI-J NATL CANCER I, V105, P393, DOI 10.1093/jnci/djs648; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033	47	83	92	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3411	3421		10.1038/onc.2013.310	http://dx.doi.org/10.1038/onc.2013.310			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	23975425	Green Accepted			2022-12-17	WOS:000338779300008
J	Raja, R; Kale, S; Thorat, D; Soundararajan, G; Lohite, K; Mane, A; Karnik, S; Kundu, GC				Raja, R.; Kale, S.; Thorat, D.; Soundararajan, G.; Lohite, K.; Mane, A.; Karnik, S.; Kundu, G. C.			Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1 alpha-mediated VEGF-dependent angiogenesis	ONCOGENE			English	Article						osteopontin; hypoxia; HIF1 alpha; angiogenesis	LINKED KINASE ILK; NF-KAPPA-B; INDUCIBLE FACTOR 1-ALPHA; CANCER-CELLS; PROSTATE-CANCER; GENE-EXPRESSION; MALIGNANT PROGRESSION; UP-REGULATION; ACTIVATION; HIF-1-ALPHA	Hypoxia is a salient feature of most solid tumors, and hypoxic adaptation of cancer cells has crucial implications in propagation of malignant clonal cell population. Osteopontin (OPN) has been identified as a hypoxia-responsive gene, but the mechanistic and regulatory role of OPN under hypoxia is less characterized. The present study identifies the existence of a positive inter-regulatory loop between hypoxia and OPN. We have shown that hypoxia induces OPN expression in breast cancer cells; however, the expression was found to be HIF1 alpha independent. OPN enabled transcriptional upregulation of HIF1 alpha expression both under normoxia and hypoxia, whereas stability of HIF1 alpha protein in breast cancer cells remained unaffected. Moreover, we have shown that OPN induces integrin-linked kinase (ILK)/Akt-mediated nuclear factor (NF)-kappa B p65 activation leading to HIF1 alpha-dependent vascular endothelial growth factor (VEGF) expression and angiogenesis in response to hypoxia. These in vitro data are biologically important as OPN expressing cells induce greater tumor growth and angiogenesis through enhanced expressions of proangiogenic molecules as compared with control. Immunohistochemical analysis of human breast cancer specimens revealed significant correlation between OPN and HIF1 alpha but not HIF2 alpha. Elevated expression of HIF1 alpha and OPN was observed in pre-neoplastic and early stage infiltrating ductal carcinoma implicating the role of these proteins in neoplastic progression of breast cancer. Together, our results substantiate the prime role of OPN in cellular adaptation through ILK and NF-kappa B-mediated HIF1 alpha-dependent VEGF expression in response to hypoxia that ultimately controls breast cancer progression and angiogenesis. Our study reinforces the fact that targeting OPN and its regulated signaling network hold important therapeutic implications.	[Raja, R.; Kale, S.; Thorat, D.; Soundararajan, G.; Kundu, G. C.] Natl Ctr Cell Sci, Lab Tumor Biol Angiogenesis & Nanomed Res, Pune 411007, Maharashtra, India; [Lohite, K.; Mane, A.; Karnik, S.] Ruby Hall Clin, Grant Med Fdn, Pune, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Kundu, GC (corresponding author), Natl Ctr Cell Sci, Lab Tumor Biol Angiogenesis & Nanomed Res, NCCS Complex, Pune 411007, Maharashtra, India.	kundu@nccs.res.in	Kundu, Gopal C./ABA-9897-2020; Raja, Remya/GXM-8598-2022	Raja, Remya/0000-0002-7576-6778	Council of Scientific and Industrial Research (CSIR); Indian Council of Medical Research (ICMR); CSIR; ICMR; NCCS, Government of India	Council of Scientific and Industrial Research (CSIR)(Council of Scientific & Industrial Research (CSIR) - India); Indian Council of Medical Research (ICMR)(Indian Council of Medical Research (ICMR)); CSIR(Council of Scientific & Industrial Research (CSIR) - India); ICMR(Indian Council of Medical Research (ICMR)); NCCS, Government of India	We thank Dr B. Ramanamurthy, In-charge, Experimental Animal Facility (EAF), NCCS, India for breeding and maintaining NOD-SCID and OPN KO mice. We also thank Dr S. Ghaskabdi, Department of Zoology, University of Pune, India for providing the facility for CAM assay. This work was supported by grants from Council of Scientific and Industrial Research (CSIR) (to GCK, SK and GS) and Indian Council of Medical Research (ICMR) (to RR). This project was funded by CSIR, ICMR and NCCS, Government of India.	Ahmed M, 2011, EXPERT OPIN THER TAR, V15, P1113, DOI 10.1517/14728222.2011.594438; Ahmed M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-101; Behera R, 2010, CARCINOGENESIS, V31, P192, DOI 10.1093/carcin/bgp289; Bendinelli P, 2009, MOL CANCER RES, V7, P1328, DOI 10.1158/1541-7786.MCR-08-0548; Bos R, 2003, CANCER, V97, P1573, DOI 10.1002/cncr.11246; Brahimi Horn C, 2005, CELL SIGNAL, V17, P1; Chakraborty G, 2008, CANCER RES, V68, P152, DOI 10.1158/0008-5472.CAN-07-2126; Chakraborty G, 2006, CURR MOL MED, V6, P819, DOI 10.2174/156652406779010803; Chan DA, 2010, BRIT J CANCER, V103, P1, DOI 10.1038/sj.bjc.6605682; Chen R, 2011, ONCOGENE, V30, P2570, DOI 10.1038/onc.2010.623; Cook AC, 2005, MOL CARCINOGEN, V43, P225, DOI 10.1002/mc.20105; Dahl KDC, 2005, MOL BIOL CELL, V16, P1901; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; Denko NC, 2003, ONCOGENE, V22, P5907, DOI 10.1038/sj.onc.1206703; Doe MR, 2012, CANCER RES, V72, P949, DOI 10.1158/0008-5472.CAN-11-2371; Fedarko NS, 2001, CLIN CANCER RES, V7, P4060; Gu T, 2009, LUNG CANCER, V66, P176, DOI 10.1016/j.lungcan.2009.02.004; Hammond EM, 2006, CLIN CANCER RES, V12, P5007, DOI 10.1158/1078-0432.CCR-06-0613; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hockel M, 2001, SEMIN ONCOL, V28, P36, DOI 10.1016/S0093-7754(01)90211-8; Hockel M, 1996, CANCER RES, V56, P4509; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jain A, 2009, CLIN CANCER RES, V15, P5199, DOI 10.1158/1078-0432.CCR-09-0783; Jain S, 2008, CANCER RES, V68, P7750, DOI 10.1158/0008-5472.CAN-07-6689; Janji B, 2000, ONCOGENE, V19, P3069, DOI 10.1038/sj.onc.1203640; Kaidi A, 2006, CANCER RES, V66, P6683, DOI 10.1158/0008-5472.CAN-06-0425; Kim HK, 2009, J AM COLL CARDIOL, V53, P2009, DOI 10.1016/j.jacc.2009.01.066; Kumar V, 2010, CANCER RES, V70, P10381, DOI 10.1158/0008-5472.CAN-10-1470; Kuo HP, 2009, BIOCHEM BIOPH RES CO, V389, P640, DOI 10.1016/j.bbrc.2009.09.042; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Le QT, 2003, CLIN CANCER RES, V9, P59; Lech M, 2009, J IMMUNOL, V183, P4109, DOI 10.4049/jimmunol.0900118; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Loboda A, 2010, MOL CELLS, V29, P435, DOI 10.1007/s10059-010-0067-2; Lu ZH, 2005, MOL CELL BIOL, V25, P4625, DOI 10.1128/MCB.25.11.4625-4637.2005; Machado-Linde F, 2012, REPROD SCI, V19, P1018, DOI 10.1177/1933719112446080; McAllister SS, 2008, CELL, V133, P994, DOI 10.1016/j.cell.2008.04.045; Mihai LG, 2012, FARMACIA, V60, P49; Miller RL, 1998, J LAB CLIN MED, V131, P45, DOI 10.1016/S0022-2143(98)90076-2; Mukundan H, 2004, J CARDIOVASC PHARM, V44, P93, DOI 10.1097/00005344-200407000-00013; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Pore N, 2006, MOL CANCER RES, V4, P471, DOI 10.1158/1541-7786.MCR-05-0234; Rangaswami H, 2006, TRENDS CELL BIOL, V16, P79, DOI 10.1016/j.tcb.2005.12.005; Rittling SR, 2004, BRIT J CANCER, V90, P1877, DOI 10.1038/sj.bjc.6601839; Rohwer N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012038; Said HM, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-55; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Sharma P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-178; Singhal H, 1997, CLIN CANCER RES, V3, P605; Skuli N, 2009, CANCER RES, V69, P3308, DOI 10.1158/0008-5472.CAN-08-2158; Sliwa M, 2007, BRAIN, V130, P476, DOI 10.1093/brain/awl263; Song G, 2009, J CELL MOL MED, V13, P1706, DOI 10.1111/j.1582-4934.2008.00540.x; Stasinopoulos I, 2009, CANCER BIOL THER, V8, P31, DOI 10.4161/cbt.8.1.7079; Subarsky P, 2003, CLIN EXP METASTAS, V20, P237, DOI 10.1023/A:1022939318102; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; van Uden P, 2008, BIOCHEM J, V412, P477, DOI 10.1042/BJ20080476; Vaupel P, 2004, ONCOLOGIST, V9, P4, DOI 10.1634/theoncologist.9-90005-4; Vaupel P, 2003, CANCER RES, V63, P7634; Vaupel P., 2010, Experimental Oncology, V32, P125; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wai PY, 2004, J SURG RES, V121, P228, DOI 10.1016/j.jss.2004.03.028; Wong CCL, 2011, P NATL ACAD SCI USA, V108, P16369, DOI 10.1073/pnas.1113483108; Yang L, 2012, CHINESE MED J-PEKING, V125, P293, DOI 10.3760/cma.j.issn.0366-6999.2012.02.024; Zhong H, 1999, CANCER RES, V59, P5830; Zhu YH, 2005, ONCOGENE, V24, P6555, DOI 10.1038/sj.onc.1208800	66	83	90	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2014	33	16					2053	2064		10.1038/onc.2013.171	http://dx.doi.org/10.1038/onc.2013.171			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF3GH	23728336				2022-12-17	WOS:000334599100005
J	Wu, MH; Huang, CY; Lin, JA; Wang, SW; Peng, CY; Cheng, HC; Tang, CH				Wu, M-H; Huang, C-Y; Lin, J-A; Wang, S-W; Peng, C-Y; Cheng, H-C; Tang, C-H			Endothelin-1 promotes vascular endothelial growth factor-dependent angiogenesis in human chondrosarcoma cells	ONCOGENE			English	Article						ET-1; VEGF; angiogenesis; chondrosarcoma	INTEGRIN-LINKED KINASE; FACTOR-I ACTIVATION; ANTIANGIOGENIC AGENTS; TUMOR ANGIOGENESIS; OVARIAN-CARCINOMA; B-RECEPTOR; EXPRESSION; PATHWAYS; CANCER; OSTEOBLASTS	Chondrosarcoma is the second most common sarcoma in bone malignancy and is characterized by a high metastatic potential. Angiogenesis is essential for the cancer metastasis. Endothelin-1 (ET-1) has been implicated in tumor angiogenesis and metastasis. However, the relationship of ET-1 with vascular endothelial growth factor (VEGF) expression and angiogenesis in human chondrosarcoma cells is mostly unknown. Here, we found that the expression of ET-1 and VEGF were correlated with tumor stage and were significantly higher than that in the normal cartilage. Exogenous ET-1 with chondrosarcoma cells promoted VEGF expression and subsequently increased migration and tube formation in endothelial progenitor cells. ET-1 increased VEGF expression and angiogenesis through ETAR, integrin-linked kinase (ILK), Akt and hypoxia-inducible factor-1 alpha (HIF-1 alpha) signaling cascades. Knockdown of ET-1 decreased VEGF expression and also abolished chondrosarcoma conditional medium-mediated angiogenesis in vitro as well as angiogenesis effects in the chick chorioallantoic membrane and Matrigel plug nude mice model in vivo. In addition, in the xenograft tumor angiogenesis model, knockdown of ET-1 significantly reduced tumor growth and tumor-associated angiogenesis. Taken together, these results indicate that ET-1 occurs through ETAR, ILK and Akt, which in turn activates HIF-1 alpha, resulting in the activation of VEGF expression and contributing to the angiogenesis and tumor growth of human chondrosarcoma cells.	[Wu, M-H; Huang, C-Y; Lin, J-A; Tang, C-H] China Med Univ, Sch Med, Grad Inst Basic Med Sci, Taichung 404, Taiwan; [Huang, C-Y; Peng, C-Y] China Med Univ, Dept Chinese Med, Taichung 404, Taiwan; [Huang, C-Y] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung, Taiwan; [Wang, S-W] Mackay Med Coll, Dept Med, New Taipei City, Taiwan; [Peng, C-Y] China Med Univ Hosp, Nat Med Prod Res Ctr, Taichung, Taiwan; [Cheng, H-C] Natl Chung Hsing Univ, Dept Life Sci, Taichung 40227, Taiwan; [Tang, C-H] China Med Univ, Sch Med, Dept Pharmacol, Taichung 404, Taiwan; [Tang, C-H] Asia Univ, Coll Hlth Sci, Dept Biotechnol, Taichung, Taiwan	China Medical University Taiwan; China Medical University Taiwan; Asia University Taiwan; Mackay Medical College; China Medical University Taiwan; China Medical University Hospital - Taiwan; National Chung Hsing University; China Medical University Taiwan; Asia University Taiwan	Tang, CH (corresponding author), China Med Univ, Sch Med, Dept Pharmacol, 91 Hsueh Shih Rd, Taichung 404, Taiwan.	chtang@mail.cmu.edu.tw	吳, 旻寰/ABG-2574-2020; Wang, Shih-Wei/AAH-1967-2020	吳, 旻寰/0000-0002-6579-1515; Wang, Shih-Wei/0000-0001-7522-6352; Cheng, Hsu-Chen/0000-0002-6586-6425	National Science Council of Taiwan [NSC99-2320-B-039-003-MY3, NSC100-2320-B-039-028-MY3]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan)	We thank Dr WM Fu for providing Akt mutant and HRE promoter construct. This work was supported by grants from the National Science Council of Taiwan (NSC99-2320-B-039-003-MY3 and NSC100-2320-B-039-028-MY3).	Albini A, 2012, NAT REV CLIN ONCOL, V9, P498, DOI 10.1038/nrclinonc.2012.120; Bagnato A, 2003, TRENDS ENDOCRIN MET, V14, P44, DOI 10.1016/S1043-2760(02)00010-3; Bagnato A, 2008, CAN J PHYSIOL PHARM, V86, P473, DOI 10.1139/Y08-058; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bishayee A, 2012, CURR CANCER DRUG TAR, V12, P1095; Boldrini L, 2006, VIRCHOWS ARCH, V449, P546, DOI 10.1007/s00428-006-0273-7; Camenisch G, 2001, PFLUG ARCH EUR J PHY, V443, P240, DOI 10.1007/s004240100679; Cianfrocca R, 2010, CAN J PHYSIOL PHARM, V88, P796, DOI 10.1139/Y10-052; Demunter A, 2001, VIRCHOWS ARCH, V438, P485, DOI 10.1007/s004280000362; Herrmann E, 2006, EXPERT REV ANTICANC, V6, P73, DOI 10.1586/14737140.6.1.73; Hsieh MT, 2003, LIFE SCI, V73, P1007, DOI 10.1016/S0024-3205(03)00372-2; Huang HC, 2003, J BIOL CHEM, V278, P46750, DOI 10.1074/jbc.M305216200; Kaneko Y, 2004, J CELL SCI, V117, P407, DOI 10.1242/jcs.00871; Keating AM, 2011, OCUL SURF, V9, P227, DOI 10.1016/S1542-0124(11)70035-0; Lahav R, 2004, CANCER RES, V64, P8945, DOI 10.1158/0008-5472.CAN-04-1510; Lahav R, 1999, P NATL ACAD SCI USA, V96, P11496, DOI 10.1073/pnas.96.20.11496; Lamagna C, 2006, J LEUKOCYTE BIOL, V80, P705, DOI 10.1189/jlb.1105656; Merino M, 2011, EUR J CANCER, V47, P1846, DOI 10.1016/j.ejca.2011.04.020; Nagy JA, 2007, ANNU REV PATHOL-MECH, V2, P251, DOI 10.1146/annurev.pathol.2.010506.134925; Nickols NG, 2007, ACS CHEM BIOL, V2, P561, DOI 10.1021/cb700110z; PASSANITI A, 1992, LAB INVEST, V67, P519; Rosano L, 2006, MOL CANCER THER, V5, P833, DOI 10.1158/1535-7163.MCT-05-0523; Spinella F, 2004, J BIOL CHEM, V279, P46700, DOI 10.1074/jbc.M408584200; Spinella F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011241; Storgard C, 2005, METHODS MOL BIOL, V294, P123; Tang CH, 2007, J BIOL CHEM, V282, P25406, DOI 10.1074/jbc.M701001200; Terek RM, 1998, J ORTHOPAED RES, V16, P585, DOI 10.1002/jor.1100160510; Tseng CP, 2003, FEBS LETT, V541, P21, DOI 10.1016/S0014-5793(03)00281-3; Tseng WP, 2010, J CELL PHYSIOL, V223, P810, DOI 10.1002/jcp.22104; Venuti A, 2002, CLIN SCI, V103, p310S, DOI 10.1042/CS103S310S; Villers A, 2010, PROG UROL, V20, pS77, DOI 10.1016/S1166-7087(10)70033-6; Wang HH, 2011, ACS NANO, V5, P4337, DOI 10.1021/nn102752a; Wang YC, 2003, ANAL BIOCHEM, V319, P206, DOI 10.1016/S0003-2697(03)00330-0; Weis SM, 2011, NAT MED, V17, P1359, DOI 10.1038/nm.2537; Whitman EM, 2008, AM J PHYSIOL-LUNG C, V294, pL309, DOI 10.1152/ajplung.00091.2007; Wu MH, 2012, J CELL PHYSIOL, V227, P3016, DOI 10.1002/jcp.23043; Wulfing P, 2004, CLIN CANCER RES, V10, P2393, DOI 10.1158/1078-0432.CCR-03-0115; Xia XB, 2009, P NATL ACAD SCI USA, V106, P4260, DOI 10.1073/pnas.0810067106; Yen ML, 2005, MOL PHARMACOL, V68, P1061, DOI 10.1124/mol.104.010082; Zhang HM, 2011, EXP CELL RES, V317, P2904, DOI 10.1016/j.yexcr.2011.08.012; Zhou WQ, 2008, NATL J ANDROL, V14, P987	41	83	85	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1725	1735		10.1038/onc.2013.109	http://dx.doi.org/10.1038/onc.2013.109			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23584483	Bronze			2022-12-17	WOS:000334344700012
J	Kendellen, MF; Bradford, JW; Lawrence, CL; Clark, KS; Baldwin, AS				Kendellen, M. F.; Bradford, J. W.; Lawrence, C. L.; Clark, K. S.; Baldwin, A. S.			Canonical and non-canonical NF-kappa B signaling promotes breast cancer tumor-initiating cells	ONCOGENE			English	Article						NF-kappa B; basal-like breast cancer; tumor-initiating cells; EMT; IL-6; IL-1 beta	EPITHELIAL-MESENCHYMAL TRANSITION; STEM-LIKE CELLS; KINASE-BETA; PROGRESSION; METASTASIS; ACTIVATION; CHEMOTHERAPY; RESISTANCE; INHIBITOR; RADIATION	Tumor-initiating cells (TICs) are a sub-population of cells that exhibit a robust ability to self-renew and contribute to the formation of primary tumors, the relapse of previously treated tumors and the development of metastases. TICs have been identified in various tumors including those of the breast, and are particularly enriched in the basal-like and claudin-low subtypes of breast cancer. The signaling pathways that contribute to the function and maintenance of TlCs are under intense study. We explored the potential involvement of the nuclear factor-kappa B (NF-kappa B) family of transcription factors in TICs in cell lines that are representative of basal-like and claudin-low breast cancer. NF-kappa B was found to be activated in breast cancer cells that form tumorspheres efficiently. Moreover, both canonical and non-canonical NF-kappa B signaling is required for these cells to self-renew in vitro and to form xenograft tumors efficiently in vivo using limiting dilutions of cells. Consistent with this fact, canonical and non-canonical NF-kappa B signaling is activated in TICs isolated from breast cancer cell lines. Experimental results indicate that NF-kappa B promotes the function of TICs by stimulating epithelial-to-mesenchymal transition and by upregulating the expression of the inflammatory cytokines interleukin-1 beta and interleukin-6. The results suggest the use of NE-a inhibitors for clinical therapy of certain breast cancers.	[Kendellen, M. F.; Bradford, J. W.; Lawrence, C. L.; Clark, K. S.; Baldwin, A. S.] Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Baldwin, AS (corresponding author), Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	abaldwin@med.unc.edu			T32 National Research Service Award [5-T32-CA009156-37]; F32 National Research Service Award from the National Institutes of Health [1F32CA153439-01, 1F32CA162628-01]; American Cancer Society [120296-PF-11-093-01-DDC]; National Cancer Institute [CA138937, CA73756]; Department of Defense [BC073048]; Samuel Waxman Cancer Research Foundation; NATIONAL CANCER INSTITUTE [R01CA073756, T32CA009156, F32CA153439, R01CA075080, F32CA162628, R01CA138937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035098] Funding Source: NIH RePORTER	T32 National Research Service Award; F32 National Research Service Award from the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense(United States Department of Defense); Samuel Waxman Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We would like to thank members of the Baldwin lab for helpful discussions and comments. MFK and JWB were supported by a T32 National Research Service Award (5-T32-CA009156-37) awarded to the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill. MFK was also supported by an F32 National Research Service Award (1F32CA153439-01) from the National Institutes of Health and a post-doctoral Fellowship from the American Cancer Society (120296-PF-11-093-01-DDC). JWB was also supported by an F32 National Research Service Award (1F32CA162628-01) from the National Institutes of Health. Research support was provided by National Cancer Institute, grants CA138937 and CA73756, and by Department of Defense grant BC073048. Additional research support was provided by the Samuel Waxman Cancer Research Foundation.	Abraham BK, 2005, CLIN CANCER RES, V11, P1154; Aktas B, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2333; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Bhat-Nakshatri P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-411; Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Cao YX, 2007, P NATL ACAD SCI USA, V104, P15852, DOI 10.1073/pnas.0706728104; Charafe-Jauffret E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-202; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Croker AK, 2008, J CELL MOL MED, V12, P374, DOI 10.1111/j.1582-4934.2007.00211.x; Fillmore C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1673; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; Hambardzumyan D, 2006, CANCER CELL, V10, P454, DOI 10.1016/j.ccr.2006.11.008; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Johnstone PAS, 2002, CURR PROB CANCER, V26, P282, DOI 10.1067/mcn.2002.129997; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Lawson JC, 2009, BREAST CANCER RES TR, V118, P241, DOI 10.1007/s10549-009-0524-9; Lee HE, 2011, BRIT J CANCER, V104, P1730, DOI 10.1038/bjc.2011.159; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Liu M, 2010, CANCER RES, V70, P10464, DOI 10.1158/0008-5472.CAN-10-0732; Liu SL, 2011, CANCER RES, V71, P614, DOI 10.1158/0008-5472.CAN-10-0538; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mattioli I, 2004, J IMMUNOL, V172, P6336, DOI 10.4049/jimmunol.172.10.6336; Merkhofer EC, 2010, ONCOGENE, V29, P1238, DOI 10.1038/onc.2009.410; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Nakshatri H, 2009, CURR STEM CELL RES T, V4, P50, DOI 10.2174/157488809787169110; Pastrana E, 2011, CELL STEM CELL, V8, P486, DOI 10.1016/j.stem.2011.04.007; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Rajasekhar VK, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1159; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Steinbrecher KA, 2005, MOL CELL BIOL, V25, P8444, DOI 10.1128/MCB.25.19.8444-8455.2005; Storci G, 2010, J CELL PHYSIOL, V225, P682, DOI 10.1002/jcp.22264; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wilson W, 2008, CANCER RES, V68, P8156, DOI 10.1158/0008-5472.CAN-08-1061; Yamaguchi N, 2009, CANCER SCI, V100, P1668, DOI 10.1111/j.1349-7006.2009.01228.x; Yu Y, 2008, J BIOL CHEM, V283, P24497, DOI 10.1074/jbc.M802825200; Zhou JB, 2008, BREAST CANCER RES TR, V111, P419, DOI 10.1007/s10549-007-9798-y; Ziegelbauer K, 2005, BRIT J PHARMACOL, V145, P178, DOI 10.1038/sj.bjp.0706176	56	83	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1297	1305		10.1038/onc.2013.64	http://dx.doi.org/10.1038/onc.2013.64			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23474754	Green Accepted, Green Submitted			2022-12-17	WOS:000332631100010
J	Yamaguchi, H; Chang, SS; Hsu, JL; Hung, MC				Yamaguchi, H.; Chang, S-S; Hsu, J. L.; Hung, M-C			Signaling cross-talk in the resistance to HER family receptor targeted therapy	ONCOGENE			English	Review						signaling cross-talk; EGFR; HER2; drug resistance	GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; NF-KAPPA-B; TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; BETA-CATENIN; TRASTUZUMAB RESISTANCE; PROMOTES TUMORIGENESIS; CONFERS RESISTANCE; TUBEROUS SCLEROSIS	Epidermal growth factor receptor (EGFR) and human EGFR 2 (HER2) have an important role in the initiation and progression of various types of cancer. Inhibitors targeting these receptor tyrosine kinases are some of the most successful targeted anticancer drugs widely used for cancer treatment; however, cancer cells have mechanisms of intrinsic and acquired drug resistance that pose as major obstacles in drug efficacy. Extensive studies from both clinical and laboratory research have identified several molecular mechanisms underlying resistance. Among them is the role of signaling cross-talk between the EGFR/HER2 and other signaling pathways. In this review, we focus particularly on this signaling cross-talk at the receptor, mediator and effector levels, and further discuss alternative approaches to overcome resistance. In addition to well-recognized signaling cross-talk involved in the resistance, we also introduce the cross-talk between EGFR/HER2-mediated pathways and pathways triggered by other types of receptors, including those of the Notch, Wnt and TNFR/IKK/NF-kappa B pathways, and discuss the potential role of targeting this cross-talk to sensitize cells to EGFR/HER2 inhibitors.	[Yamaguchi, H.; Chang, S-S; Hsu, J. L.; Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Chang, S-S; Hung, M-C] Univ Texas Hlth Sci Ctr Houston, Grad Sch Biomed Sci, Houston, TX 77030 USA; [Hsu, J. L.; Hung, M-C] China Med Univ, Ctr Mol Med, Taichung, Taiwan; [Hsu, J. L.; Hung, M-C] China Med Univ, Grad Inst Canc Biol, Taichung, Taiwan; [Hsu, J. L.; Hung, M-C] Asia Univ, Dept Biotechnol, Taichung, Taiwan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; China Medical University Taiwan; China Medical University Taiwan; Asia University Taiwan	Hung, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Unit 108, 1515 Holcombe Blvd, Houston, TX 77030 USA.	mhung@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	National Breast Cancer Foundation; Sister Institution Fund of China Medical University Hospital; MD Anderson Cancer Center; Patel Memorial Breast Cancer Research Fund; Center for Biological Pathways; CCSG [CA16672]; NATIONAL CANCER INSTITUTE [R01CA109311, P30CA016672] Funding Source: NIH RePORTER	National Breast Cancer Foundation; Sister Institution Fund of China Medical University Hospital; MD Anderson Cancer Center; Patel Memorial Breast Cancer Research Fund; Center for Biological Pathways; CCSG; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the National Breast Cancer Foundation, Sister Institution Fund of China Medical University Hospital and MD Anderson Cancer Center, Patel Memorial Breast Cancer Research Fund, Center for Biological Pathways, and CCSG (CA16672).	Abramson V, 2011, CLIN CANCER RES, V17, P952, DOI 10.1158/1078-0432.CCR-09-1947; Al-Hussaini H, 2011, MOL CANCER THER, V10, P9, DOI 10.1158/1535-7163.MCT-10-0677; Arkenau HT, 2011, BRIT J CANCER, V104, P392, DOI 10.1038/sj.bjc.6606030; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Balint E, 2001, BRIT J CANCER, V85, P1813, DOI 10.1054/bjoc.2001.2128; Baselga J, 2005, J CLIN ONCOL, V23, P2445, DOI 10.1200/JCO.2005.11.890; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bertotti A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000643; Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109; Biechele TL, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002274; Bivona TG, 2011, NATURE, V471, P523, DOI 10.1038/nature09870; Booy EP, 2011, ONCOGENE, V30, P2367, DOI 10.1038/onc.2010.616; Bronte Giuseppe, 2011, Front Biosci (Elite Ed), V3, P879; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgess AW, 2008, GROWTH FACTORS, V26, P263, DOI 10.1080/08977190802312844; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cappuzzo F, 2008, BRIT J CANCER, V99, P83, DOI 10.1038/sj.bjc.6604439; Carayol N, 2006, CELL SIGNAL, V18, P1941, DOI 10.1016/j.cellsig.2006.02.014; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chan CH, 2012, CELL, V149, P1098, DOI 10.1016/j.cell.2012.02.065; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen YJ, 2007, J BIOL CHEM, V282, P27215, DOI 10.1074/jbc.M700264200; Chiu HC, 2011, BIOCHEM PHARMACOL, V81, P1263, DOI 10.1016/j.bcp.2011.03.003; Cipriano R, 2012, J CLIN INVEST, V122, P3197, DOI 10.1172/JCI60517; Costa DB, 2007, PLOS MED, V4, P1669, DOI 10.1371/journal.pmed.0040315; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Dhomen Nathalie S., 2012, Critical Reviews in Oncogenesis, V17, P31; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Ding QQ, 2008, CANCER RES, V68, P6109, DOI 10.1158/0008-5472.CAN-08-0579; Ding QQ, 2007, MOL CELL BIOL, V27, P4006, DOI 10.1128/MCB.00620-06; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; Dong YY, 2010, CANCER RES, V70, P5465, DOI 10.1158/0008-5472.CAN-10-0173; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Ercan D, 2012, CANCER DISCOV, V2, P934, DOI 10.1158/2159-8290.CD-12-0103; Esteva FJ, 2010, AM J PATHOL, V177, P1647, DOI 10.2353/ajpath.2010.090885; Faber AC, 2011, CANCER DISCOV, V1, P352, DOI 10.1158/2159-8290.CD-11-0106; Faber AC, 2009, P NATL ACAD SCI USA, V106, P19503, DOI 10.1073/pnas.0905056106; Fan WW, 2011, CANCER RES, V71, P4494, DOI 10.1158/0008-5472.CAN-10-2668; Gan HK, 2009, J CLIN NEUROSCI, V16, P748, DOI 10.1016/j.jocn.2008.12.005; Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577; Harada D, 2012, CANCER SCI, V103, P1795, DOI 10.1111/j.1349-7006.2012.02363.x; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang WC, 2005, MOL CELL BIOL, V25, P6592, DOI 10.1128/MCB.25.15.6592-6602.2005; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jeong WJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002242; Ji HT, 2009, MOL CELL, V36, P547, DOI 10.1016/j.molcel.2009.09.034; Kanarek N, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000166; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kim SM, 2012, MOL CANCER THER, V11, P2254, DOI 10.1158/1535-7163.MCT-12-0311; Kolev V, 2008, NAT CELL BIOL, V10, DOI 10.1038/ncb1750; Kono SA, 2009, DRUG RESIST UPDATE, V12, P95, DOI 10.1016/j.drup.2009.05.001; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Lang JY, 2011, CANCER CELL, V20, P341, DOI 10.1016/j.ccr.2011.07.017; Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011; Lee DF, 2008, CLIN CANCER RES, V14, P5656, DOI 10.1158/1078-0432.CCR-08-0123; Lee DF, 2007, CELL, V130, P440, DOI 10.1016/j.cell.2007.05.058; Lee H, 2009, CANCER CELL, V15, P283, DOI 10.1016/j.ccr.2009.02.015; Lee SY, 2012, J CLIN INVEST, V122, P3211, DOI 10.1172/JCI60498; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Li LY, 2011, ONCOGENE, V30, P1773, DOI 10.1038/onc.2010.558; Liang K, 2010, CANCER CELL, V18, P423, DOI 10.1016/j.ccr.2010.10.025; Liska D, 2011, CLIN CANCER RES, V17, P472, DOI 10.1158/1078-0432.CCR-10-0568; Liu M, 2012, MOL CELL, V45, P171, DOI 10.1016/j.molcel.2011.11.018; Liu ZJ, 2006, CANCER RES, V66, P4182, DOI 10.1158/0008-5472.CAN-05-3589; Lo HW, 2008, CLIN CANCER RES, V14, P6042, DOI 10.1158/1078-0432.CCR-07-4923; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lu CH, 2007, CLIN CANCER RES, V13, P5883, DOI 10.1158/1078-0432.CCR-06-2837; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Malmlof M, 2007, J BIOL CHEM, V282, P2288, DOI 10.1074/jbc.M604953200; Maniati E, 2011, J CLIN INVEST, V121, P4685, DOI 10.1172/JCI45797; Maraver A, 2012, CANCER CELL, V22, P222, DOI 10.1016/j.ccr.2012.06.014; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Morgillo F, 2007, CLIN CANCER RES, V13, P2795, DOI 10.1158/1078-0432.CCR-06-2077; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Narayan M, 2009, CANCER RES, V69, P2191, DOI 10.1158/0008-5472.CAN-08-1056; Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758; Ohashi K, 2012, P NATL ACAD SCI USA, V109, pE2127, DOI 10.1073/pnas.1203530109; Osipo C, 2008, ONCOGENE, V27, P5019, DOI 10.1038/onc.2008.149; Oxnard GR, 2011, CLIN CANCER RES, V17, P5530, DOI 10.1158/1078-0432.CCR-10-2571; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Qi XJ, 2006, J BIOL CHEM, V281, P813, DOI 10.1074/jbc.M505546200; Rasola A, 2007, ONCOGENE, V26, P1078, DOI 10.1038/sj.onc.1209859; Regales L, 2009, J CLIN INVEST, V119, P3000, DOI 10.1172/JCI38746; Ren ZY, 2002, J BIOL CHEM, V277, P38486, DOI 10.1074/jbc.M112438200; Rimawi MF, 2010, CANCER-AM CANCER SOC, V116, P1234, DOI 10.1002/cncr.24816; Rouge TD, 2007, CANCER RES, V67, P6253, DOI 10.1158/0008-5472.CAN-07-0538; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Sasaki T, 2010, CANCER RES, V70, P10038, DOI 10.1158/0008-5472.CAN-10-2956; Sen M, 2012, CLIN CANCER RES, V18, P4986, DOI 10.1158/1078-0432.CCR-12-0792; Sequist LV, 2008, ANNU REV MED, V59, P429, DOI 10.1146/annurev.med.59.090506.202405; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Seshacharyulu P, 2012, EXPERT OPIN THER TAR, V16, P15, DOI 10.1517/14728222.2011.648617; Shah NP, 2003, ONCOGENE, V22, P7389, DOI 10.1038/sj.onc.1206942; Sharma MR, 2011, NAT REV CLIN ONCOL, V8, P70, DOI 10.1038/nrclinonc.2010.219; Sharma SV, 2006, CLIN CANCER RES, V12, p4392S, DOI 10.1158/1078-0432.CCR-06-0096; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Sher YP, 2009, ONCOGENE, V28, P3286, DOI 10.1038/onc.2009.187; Shigematsu H, 2006, INT J CANCER, V118, P257, DOI 10.1002/ijc.21496; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Su JL, 2011, CANCER RES, V71, P6878, DOI 10.1158/0008-5472.CAN-11-0295; Suda K, 2009, J THORAC ONCOL, V4, P1, DOI 10.1097/JTO.0b013e3181913c9f; Takezawa K, 2012, CANCER DISCOV, V2, P922, DOI 10.1158/2159-8290.CD-12-0108; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Wang Y, 2012, CANCER CELL, V21, P374, DOI 10.1016/j.ccr.2011.12.028; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Wong KK, 2010, CURR OPIN GENET DEV, V20, P87, DOI 10.1016/j.gde.2009.11.002; Xie M, 2012, J CELL BIOCHEM, V113, P1501, DOI 10.1002/jcb.24019; Xie XM, 2007, CANCER CELL, V12, P52, DOI 10.1016/j.ccr.2007.05.009; Yamaguchi H, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00015; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yang JY, 2010, CANCER RES, V70, P4709, DOI 10.1158/0008-5472.CAN-09-4524; Yang JY, 2009, CLIN CANCER RES, V15, P752, DOI 10.1158/1078-0432.CCR-08-0124; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yao Z, 2010, P NATL ACAD SCI USA, V107, P15535, DOI 10.1073/pnas.1009472107; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yen CJ, 2008, CANCER RES, V68, P2632, DOI 10.1158/0008-5472.CAN-07-5460; Yun CH, 2008, P NATL ACAD SCI USA, V105, P2070, DOI 10.1073/pnas.0709662105; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhuang GL, 2010, CANCER RES, V70, P299, DOI 10.1158/0008-5472.CAN-09-1845	143	83	85	1	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2014	33	9					1073	1081		10.1038/onc.2013.74	http://dx.doi.org/10.1038/onc.2013.74			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XT	23542173	Green Accepted			2022-12-17	WOS:000331933800001
J	Zhang, J; Espinoza, LA; Kinders, RJ; Lawrence, SM; Pfister, TD; Zhou, M; Veenstra, TD; Thorgeirsson, SS; Jessup, JM				Zhang, J.; Espinoza, L. A.; Kinders, R. J.; Lawrence, S. M.; Pfister, T. D.; Zhou, M.; Veenstra, T. D.; Thorgeirsson, S. S.; Jessup, J. M.			NANOG modulates stemness in human colorectal cancer	ONCOGENE			English	Article						NANOG; NANOGP8; stemness; colorectal cancer; cancer stem cell	TRANSCRIPTIONAL NETWORK; GENE-EXPRESSION; CELLS; PLURIPOTENCY; SOX2; INHIBITOR; PROGNOSIS; SIGNATURE; PATHWAYS; LUNG	NANOG is a stem cell transcription factor that is essential for embryonic development, reprogramming normal adult cells and malignant transformation and progression. The nearly identical retrogene NANOGP8 is expressed in multiple cancers, but generally not in normal tissues and its function is not well defined. Our postulate is that NANOGP8 directly modulates the stemness of individual human colorectal carcinoma (CRC) cells. Stemness was measured in vitro as the spherogenicity of single CRC cells in serum-free medium and the size of the side population (SP) and in vivo as tumorigenicity and experimental metastatic potential in NOD/SCID mice. We found that 80% of clinical liver metastases express a NANOG with 75% of the positive metastases containing NANOGP8 transcripts. In all, 3-62% of single cells within six CRC lines form spheroids in serum-free medium in suspension. NANOGP8 is translated into protein. The relative expression of a NANOG gene increased 8- to 122-fold during spheroid formation, more than the increase in OCT4 or SOX2 transcripts with NANOGP8 the more prevalent family member. Short hairpin RNA (shRNA) to NANOG not only inhibits spherogenicity but also reduces expression of OCT4 and SOX2, the size of the SP and tumor growth in vivo. Inhibition of NANOG gene expression is associated with inhibition of proliferation and decreased phosphorylation of G2-related cell-cycle proteins. Overexpression of NANOGP8 rescues single-cell spherogenicity when NANOG gene expression is inhibited and increases the SP in CRC. Thus, NANOGP8 can substitute for NANOG in directly promoting stemness in CRC.	[Zhang, J.; Espinoza, L. A.; Thorgeirsson, S. S.; Jessup, J. M.] NCI, Expt Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Kinders, R. J.; Lawrence, S. M.; Pfister, T. D.] SAIC Frederick Inc, Lab Human Toxicol & Pharmacol, Appl Dev Res Support Directorate, Frederick Natl Lab Canc Res, Frederick, MD USA; [Zhou, M.; Veenstra, T. D.] SAIC Frederick, Lab Prote & Analyt Technol, Frederick Natl Lab Canc Res, Frederick, MD USA; [Jessup, J. M.] Div Canc Treatment & Diag, Canc Diag Program, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Jessup, JM (corresponding author), Canc Diag Program, Diagnost Evaluat Branch, Bethesda, MD 20892 USA.	jessupj@mail.nih.gov			Center for Cancer Research of the NCI [ZIA BC 011199]; Department of Defense [W81XWH-11-1-0327]; NATIONAL CANCER INSTITUTE [ZIABC011199] Funding Source: NIH RePORTER	Center for Cancer Research of the NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge the valuable advice and support of Drs Elizabeth Conner and Valentina Factor. Also, we gratefully acknowledge the support provided by the Center for Cancer Research of the NCI for Project ZIA BC 011199 and by the Department of Defense for Grant Number W81XWH-11-1-0327. The opinions expressed in this manuscript are those of the authors and do not necessarily represent those of the National Cancer Institute, the National Institutes of Health, the Department of Health and Human Services or the Department of the Army.	Ambady S, 2010, INT J DEV BIOL, V54, P1743, DOI 10.1387/ijdb.103192sa; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Booth HAF, 2004, GENOMICS, V84, P229, DOI 10.1016/j.ygeno.2004.02.014; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chambers I, 2007, NATURE, V450, P1230, DOI 10.1038/nature06403; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Ding JJ, 2012, CELL RES, V22, P155, DOI 10.1038/cr.2011.179; Dykxhoorn DM, 2006, P NATL ACAD SCI USA, V103, P5953, DOI 10.1073/pnas.0601309103; Eberle I, 2010, NUCLEIC ACIDS RES, V38, P5384, DOI 10.1093/nar/gkq307; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Huang HJ, 2006, SCIENCE, V314, P294, DOI 10.1126/science.1130512; Huang H, 2009, NUCLEIC ACIDS RES, V37, P7560, DOI 10.1093/nar/gkp835; Ishiguro T, 2012, BIOCHEM BIOPH RES CO, V418, P199, DOI 10.1016/j.bbrc.2011.10.123; JESSUP JM, 1989, CANCER RES, V49, P6906; Jeter CR, 2011, ONCOGENE, V30, P3833, DOI 10.1038/onc.2011.114; Jeter CR, 2009, STEM CELLS, V27, P993, DOI 10.1002/stem.29; Ji J, 2010, HUM PATHOL, V41, P1438, DOI 10.1016/j.humpath.2009.11.021; Katoh M, 2011, CURR PHARM BIOTECHNO, V12, P160, DOI 10.2174/138920111794295710; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; Kinders RJ, 2010, CLIN CANCER RES, V16, P5447, DOI 10.1158/1078-0432.CCR-09-3076; Kong DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012445; Kumar SM, 2012, ONCOGENE, V31, P4898, DOI 10.1038/onc.2011.656; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Lengner CJ, 2007, CELL STEM CELL, V1, P403, DOI 10.1016/j.stem.2007.07.020; Lin KK, 2006, METHOD ENZYMOL, V420, P255, DOI 10.1016/S0076-6879(06)20011-9; Lu KP, 1996, NATURE, V380, P544; Macfarlan TS, 2012, NATURE, V487, P57, DOI 10.1038/nature11244; Meng HM, 2010, CANCER BIOL THER, V9, P295, DOI 10.4161/cbt.9.4.10666; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Miyanari Y, 2012, NATURE, V483, P470, DOI 10.1038/nature10807; Miyoshi N, 2010, P NATL ACAD SCI USA, V107, P40, DOI 10.1073/pnas.0912407107; MULDER JWR, 1994, LANCET, V344, P1470, DOI 10.1016/S0140-6736(94)90290-9; Nishi M, 2011, J BIOL CHEM, V286, P11593, DOI 10.1074/jbc.M110.187989; Park IH, 2008, CELL, V134, P877, DOI 10.1016/j.cell.2008.07.041; Po A, 2010, EMBO J, V29, P2646, DOI 10.1038/emboj.2010.131; Saiki Y, 2009, ANN SURG ONCOL, V16, P2638, DOI 10.1245/s10434-009-0567-5; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Santagata S, 2007, AM J SURG PATHOL, V31, P836, DOI 10.1097/PAS.0b013e31802e708a; Sholl LM, 2010, AM J SURG PATHOL, V34, P1193, DOI 10.1097/PAS.0b013e3181e5e024; Silva J, 2009, CELL, V138, P722, DOI 10.1016/j.cell.2009.07.039; Simkus C, 2009, IMMUNOLOGY, V128, P206, DOI 10.1111/j.1365-2567.2009.03101.x; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Utikal J, 2009, J CELL SCI, V122, P3502, DOI 10.1242/jcs.054783; Wang Q, 2009, ANTICANCER RES, V29, P1233; Xu F, 2012, DIGEST DIS SCI, V57, P2340, DOI 10.1007/s10620-012-2182-8; You JS, 2009, CANCER RES, V69, P5716, DOI 10.1158/0008-5472.CAN-08-4953; Yu JY, 2009, SCIENCE, V324, P797, DOI 10.1126/science.1172482; Zappone MV, 2000, DEVELOPMENT, V127, P2367; Zbinden M, 2010, EMBO J, V29, P2659, DOI 10.1038/emboj.2010.137; Zhang J, 2011, P 102 ANN M AM ASS C; Zhang J, 2010, J CLIN PATHOL, V63, P879, DOI 10.1136/jcp.2009.073593; Zhang JY, 2006, FEBS J, V273, P1723, DOI 10.1111/j.1742-4658.2006.05186.x; Zhang X, 2010, J GASTROINTEST SURG, V14, P1220, DOI 10.1007/s11605-010-1246-3	56	83	89	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2013	32	37					4397	4405		10.1038/onc.2012.461	http://dx.doi.org/10.1038/onc.2012.461			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23085761	Green Accepted			2022-12-17	WOS:000324404200008
J	Zhang, X; Cruz, FD; Terry, M; Remotti, F; Matushansky, I				Zhang, X.; Cruz, F. D.; Terry, M.; Remotti, F.; Matushansky, I.			Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming	ONCOGENE			English	Article						sarcoma; stem cells; induced pluripotent stem cells	MESENCHYMAL STEM-CELLS; RED-BLOOD-CELLS; HEMATOPOIETIC STEM; DIRECTED DIFFERENTIATION; HUMAN FIBROBLASTS; COPY NUMBER; IN-VITRO; GENES; GENOME; CLASSIFICATION	Pluripotent cells can be derived from various types of somatic cells by nuclear reprogramming using defined transcription factors. It is, however, unclear whether human cancer cells can be similarly reprogrammed and subsequently terminally differentiated with abrogation of tumorigenicity. Here, using sarcomas we show that human-derived complex karyotype solid tumors: (1) can be reprogrammed into a pluripotent-like state as defined by all in vitro criteria used to define pluripotent stem cells generated from somatic cells; (2) can be terminally differentiated into mature connective tissue and red blood cells; and (3) terminal differentiation is accompanied with loss of both proliferation and tumorigenicity. We go on to perform the first global DNA promoter methylation and gene expression analyses comparing human cancers to their reprogrammed counterparts and report that reprogramming/differentiation results in significant epigenetic remodeling of oncogenes and tumor suppressors, while not significantly altering the differentiation status of the reprogrammed cancer cells, in essence dedifferentiating them to a state slightly before the mesenchymal stem cell differentiation stage. Our data demonstrate that direct nuclear reprogramming can restore terminal differentiation potential to human-derived cancer cells, with simultaneous loss of tumorigenicity, without the need to revert to an embryonic state. We anticipate that our models would serve as a starting point to more fully assess how nuclear reprogramming overcomes the multitude of genetic and epigenetic aberrancies inherent in human cancers to restore normal terminal differentiation pathways. Finally, these findings suggest that nuclear reprogramming may be a broadly applicable therapeutic strategy for the treatment of cancer.	[Zhang, X.; Cruz, F. D.; Terry, M.; Remotti, F.; Matushansky, I.] Columbia Univ, Med Ctr, Dept Med, Div Med Oncol, New York, NY 10032 USA	Columbia University	Matushansky, I (corresponding author), Columbia Univ, Med Ctr, Dept Med, Div Med Oncol, 1130 St Nicholas Ave Rm 208C, New York, NY 10032 USA.	im17@columbia.edu			NCI; Gerstner CDA; Damon Runyon Cancer Research Fund; NATIONAL CANCER INSTITUTE [K08CA132986] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Gerstner CDA; Damon Runyon Cancer Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank: Timothy C Wang MD for critical discussions and manuscript review; Sara Siddiqi and Gannie Tzonove for general technical assistance; Carlos Cordo-Cardo MD PhD for assistance with solid tumor pathological review and discussion; Benjamin Tycko MD PhD for assistance with DNA methylation analysis; Bachir Alobeid MD for assistance with hematological pathological review; Pavel Sumazin PhD for bioniformatic analysis. IM receives funding from NCI, Gerstner CDA and the Damon Runyon Cancer Research Fund.; XZ performed all experiments and assisted with experimental design. MT assisted with experiments and data interpretation. FDC assisted with experiments and data interpretation. FR reviewed and interpreted all histopathology outlined. IM designed the concept and experiments, interpreted the data and wrote the manuscript. IM receives funding from NCI, Gerstner CDA and the Damon Runyon Cancer Research Fund.	BARRIOS C, 1994, AM J CLIN ONCOL-CANC, V17, P273, DOI 10.1097/00000421-199406000-00019; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bock C, 2010, NAT BIOTECHNOL, V28, P1106, DOI 10.1038/nbt.1681; Carette JE, 2010, BLOOD, V115, P4039, DOI 10.1182/blood-2009-07-231845; Chang G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010320; Charytonowicz E, 2012, J CLIN INVEST, V122, P886, DOI 10.1172/JCI60015; Huangfu DW, 2008, NAT BIOTECHNOL, V26, P1269, DOI 10.1038/nbt.1502; Eminli S, 2009, NAT GENET, V41, P968, DOI 10.1038/ng.428; Esteban MA, 2010, CELL STEM CELL, V6, P71, DOI 10.1016/j.stem.2009.12.001; Feng JF, 2011, P NATL ACAD SCI USA, V108, P6503, DOI 10.1073/pnas.1015449108; Giebel B, 2008, BIOL CHEM, V389, P813, DOI 10.1515/BC.2008.092; Glauche I, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000447; Gore A, 2011, NATURE, V471, P63, DOI 10.1038/nature09805; Han JN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012297; Higgins ME, 2007, NUCLEIC ACIDS RES, V35, pD721, DOI 10.1093/nar/gkl811; Hochedlinger K, 2004, GENE DEV, V18, P1875, DOI 10.1101/gad.1213504; Hussein SM, 2011, NATURE, V471, P58, DOI 10.1038/nature09871; Jaenisch R, 2008, CELL, V132, P567, DOI 10.1016/j.cell.2008.01.015; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Koche RP, 2011, CELL STEM CELL, V8, P96, DOI 10.1016/j.stem.2010.12.001; Krause U, 2011, METHODS MOL BIOL, V698, P215, DOI 10.1007/978-1-60761-999-4_17; Lai RC, 2011, METHODS MOL BIOL, V698, P141, DOI 10.1007/978-1-60761-999-4_11; Laurent LC, 2011, CELL STEM CELL, V8, P106, DOI 10.1016/j.stem.2010.12.003; Lengner CJ, 2010, ANN NY ACAD SCI, V1192, P38, DOI 10.1111/j.1749-6632.2009.05213.x; Lister R, 2011, NATURE, V471, P68, DOI 10.1038/nature09798; Lu SJ, 2010, METHODS MOL BIOL, V636, P105, DOI 10.1007/978-1-60761-691-7_7; Lu SJ, 2008, BLOOD, V112, P4475, DOI 10.1182/blood-2008-05-157198; Ma F, 2008, P NATL ACAD SCI USA, V105, P13087, DOI 10.1073/pnas.0802220105; Matushansky I, 2008, AM J PATHOL, V172, P1069, DOI 10.2353/ajpath.2008.070284; Matushansky I, 2007, J CLIN INVEST, V117, P3248, DOI 10.1172/JCI31377; Mayshar Y, 2010, CELL STEM CELL, V7, P521, DOI 10.1016/j.stem.2010.07.017; Merryweather-Clarke AT, 2011, BLOOD, V117, pE96, DOI 10.1182/blood-2010-07-290825; Mikkelsen TS, 2008, NATURE, V454, P49, DOI 10.1038/nature07056; Mills J, 2011, MOL CANCER THER, V10, P313, DOI 10.1158/1535-7163.MCT-10-0724; Mills J, 2009, HUM CELL, V22, P85, DOI 10.1111/j.1749-0774.2009.00073.x; Miyamoto K, 2007, CELL STEM CELL, V1, P101, DOI 10.1016/j.stem.2007.02.001; Miyoshi N, 2010, P NATL ACAD SCI USA, V107, P40, DOI 10.1073/pnas.0912407107; OGAWA M, 1983, BLOOD, V61, P823; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Okita K, 2010, NAT PROTOC, V5, P418, DOI 10.1038/nprot.2009.231; Pitha-Rowe I, 2003, LEUKEMIA, V17, P1723, DOI 10.1038/sj.leu.2403065; Pomerantz JH, 2009, J CELL SCI, V122, P1045, DOI 10.1242/jcs.041376; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Siddiqi S, 2010, CURR STEM CELL RES T, V5, P63, DOI 10.2174/157488810790442859; Silva J, 2008, PLOS BIOL, V6, P2237, DOI 10.1371/journal.pbio.0060253; Spivakov M, 2007, NAT REV GENET, V8, P263, DOI 10.1038/nrg2046; Stadtfeld M, 2010, GENE DEV, V24, P2239, DOI 10.1101/gad.1963910; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tang Y, 2005, CANCER RES, V65, P8324, DOI 10.1158/0008-5472.CAN-05-0027; Theunissen TW, 2011, CURR BIOL, V21, P65, DOI 10.1016/j.cub.2010.11.074; Utikal J, 2009, J CELL SCI, V122, P3502, DOI 10.1242/jcs.054783; Utikal J, 2009, NATURE, V460, P1145, DOI 10.1038/nature08285; Warren L, 2010, CELL STEM CELL, V7, P618, DOI 10.1016/j.stem.2010.08.012; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944; West FD, 2008, STEM CELLS, V26, P2768, DOI 10.1634/stemcells.2008-0124; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zhang B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015336	58	83	88	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2013	32	18					2249	2260		10.1038/onc.2012.237	http://dx.doi.org/10.1038/onc.2012.237			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140VF	22777357	Green Accepted			2022-12-17	WOS:000318683600002
J	Catuogno, S; Cerchia, L; Romano, G; Pognonec, P; Condorelli, G; de Franciscis, V				Catuogno, S.; Cerchia, L.; Romano, G.; Pognonec, P.; Condorelli, G.; de Franciscis, V.			miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis	ONCOGENE			English	Article						A549; p53; AP20187	TUMOR-SUPPRESSOR NETWORK; REGULATES APOPTOSIS; SPINDLE CHECKPOINT; DEATH RECEPTORS; DOWN-REGULATION; FEEDBACK LOOP; P53; MYC; MICRORNAS; EXPRESSION	MicroRNAs (miRNAs) constitute a class of small non-coding RNAs that negatively regulate the expression of their target genes. They are involved in many biological processes, including cell proliferation, apoptosis and differentiation, and are considered as promising new therapeutic targets for cancer. However, the identity of miRNAs involved in apoptosis and their respective targets remain largely unknown. Given the elevated complexity of miRNA regulation of gene expression, we performed a functional screening as an alternative strategy to identify those miRNAs that in lung cancer cells may interfere with the apoptotic process. To this aim, we generated a derivative of the non-small cell lung carcinoma A549 cell line in which caspase-8, a critical upstream initiator of apoptosis, can be activated by administration of the small dimerizer drug AP20187. We found a number of miRNAs that may rescue cell viability from caspase-8 activation. They included miRNAs already described as oncogenic such as miR-17, miR-135 and miR-520, but also some miRNAs such as miR-124-1 and miR-34c for which a tumor-suppressive role has instead been described or expected. Among them, nniR-34c-5p markedly increased resistance to paclitaxel-induced apoptosis. We demonstrate that Bmf (Bcl-2-modifying factor) is a target of miR-34c-5p, and that its silencing, together with that of c-myc, a known target of miR-34c-5p, contributes to resistance to apoptosis induced by paclitaxel through p53 downregulation. Oncogene (2013) 32, 341-351; doi:10.1038/onc.2012.51; published online 27 February 2012	[Catuogno, S.; Cerchia, L.; Condorelli, G.; de Franciscis, V.] CNR G Salvatore, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; [Catuogno, S.; Condorelli, G.] Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Naples, Italy; [Romano, G.] IRCCS Fdn SDN, Naples, Italy; [Pognonec, P.] Univ Nice Sophia Antipolis, Fac Med, CNRS, Nice 2, France	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; IRCCS Istituto di Ricerca Diagnostica e Nucleare (SDN); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	de Franciscis, V (corresponding author), CNR G Salvatore, Ist Endocrinol & Oncol Sperimentale, Via Pansini 5, I-80131 Naples, Italy.	defranci@unina.it	Condorelli, Gerolama/AAC-3472-2022; Catuogno, Silvia/AAB-9969-2019	Condorelli, Gerolama/0000-0003-0177-8829; Catuogno, Silvia/0000-0002-1653-4205; Cerchia, Laura/0000-0002-7633-7932	CNR [11-0075]; MIUR grant [MERIT RBNE08YFN3_001, 4971, 10620]; Italian Ministry of Economy and Finance; Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	CNR(Consiglio Nazionale delle Ricerche (CNR)); MIUR grant(Ministry of Education, Universities and Research (MIUR)); Italian Ministry of Economy and Finance; Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	This work was supported by funds from CNR, AICR No. 11-0075 (LC), an MIUR grant, MERIT RBNE08YFN3_001 (VdF), AIRC No. 4971 (LC) and No. 10620 (GC), and from the Italian Ministry of Economy and Finance to the CNR for the Project FaReBio di Qualita. We thank ARIAD Pharmaceuticals Inc. for providing the AP20187 dimerizer drug and Soddu for the pLuc-MDM2 expression vector. We also thank Dr Patrick Martin for help with the development of the inducible death vectors; Dr L Baraldi for technical assistance; CL Esposito, S Camorani, I laccarino and P Verde for suggestions and comments; and A Pollice for critically reading the manuscript.	Allan LA, 2007, MOL CELL, V26, P301, DOI 10.1016/j.molcel.2007.03.019; Allen TD, 2011, CANCER RES, V71, P2212, DOI 10.1158/0008-5472.CAN-10-3590; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Cannell IG, 2010, CELL CYCLE, V9, P2726, DOI 10.4161/cc.9.14.12182; Cannell IG, 2010, P NATL ACAD SCI USA, V107, P5375, DOI 10.1073/pnas.0910015107; Carlotti F, 2005, CANCER GENE THER, V12, P627, DOI 10.1038/sj.cgt.7700825; Chabalier C, 2006, CELL CYCLE, V5, P1001, DOI 10.4161/cc.5.9.2726; Chang DW, 2003, SCI STKE, V167, pPL1; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Christoffersen NR, 2010, CELL DEATH DIFFER, V17, P236, DOI 10.1038/cdd.2009.109; Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008-5472.CAN-07-1585; Corney DC, 2010, CLIN CANCER RES, V16, P1119, DOI 10.1158/1078-0432.CCR-09-2642; Dacic S, 2010, MODERN PATHOL, V23, P1577, DOI 10.1038/modpathol.2010.152; DelSal G, 1996, ONCOGENE, V12, P177; Farazi TA, 2011, J PATHOL, V223, P102, DOI 10.1002/path.2806; Garofalo M, 2011, ANNU REV PHARMACOL, V51, P25, DOI 10.1146/annurev-pharmtox-010510-100517; Guicciardi ME, 2009, FASEB J, V23, P1625, DOI 10.1096/fj.08-111005; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; He XY, 2007, CANCER RES, V67, P11099, DOI 10.1158/0008-5472.CAN-07-2672; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hermeking H, 2010, CELL DEATH DIFFER, V17, P193, DOI 10.1038/cdd.2009.56; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868; Kress TR, 2011, MOL CELL, V41, P445, DOI 10.1016/j.molcel.2011.01.023; Lee JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021300; Li YQ, 2009, CANCER RES, V69, P7569, DOI 10.1158/0008-5472.CAN-09-0529; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Lu WG, 2002, CANCER RES, V62, P1305; Maclean KH, 2003, MOL CELL BIOL, V23, P7256, DOI 10.1128/MCB.23.20.7256-7270.2003; Mellert HS, 2011, J BIOL CHEM, V286, P4264, DOI 10.1074/jbc.M110.184663; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; Nagel R, 2008, CANCER RES, V68, P5795, DOI 10.1158/0008-5472.CAN-08-0951; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Sotillo E, 2011, ONCOGENE, V30, P2587, DOI 10.1038/onc.2010.634; Soucek L, 2010, CURR OPIN GENET DEV, V20, P91, DOI 10.1016/j.gde.2009.11.001; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; van Leeuwen I, 2009, ADV CANCER RES, V102, P171, DOI 10.1016/S0065-230X(09)02005-3; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yamakuchi M, 2009, CELL CYCLE, V8, P712, DOI 10.4161/cc.8.5.7753; Zachos G, 2007, DEV CELL, V12, P247, DOI 10.1016/j.devcel.2007.01.003	45	83	87	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2013	32	3					341	351		10.1038/onc.2012.51	http://dx.doi.org/10.1038/onc.2012.51			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22370637				2022-12-17	WOS:000314736600008
J	Kesanakurti, D; Chetty, C; Dinh, DH; Gujrati, M; Rao, JS				Kesanakurti, D.; Chetty, C.; Dinh, D. H.; Gujrati, M.; Rao, J. S.			Role of MMP-2 in the regulation of IL-6/Stat3 survival signaling via interaction with alpha 5 beta 1 integrin in glioma	ONCOGENE			English	Article						MMP-2; alpha 5 beta 1; glioma; IL-6; STAT3; CyclinD1	BREAST-CARCINOMA CELLS; MATRIX METALLOPROTEINASE-2; CANCER CELLS; ALPHA(5)BETA(1) INTEGRIN; STAT3 ACTIVATION; TUMOR INVASION; KAPPA-B; EXPRESSION; GROWTH; APOPTOSIS	Matrix metalloproteinase-2 (MMP-2) has pivotal role in the degradation of extracellular matrix, and thereby enhances the invasive, proliferative and metastatic potential in cancer. Knockdown of MMP-2 using MMP-2 small interfering RNA (pM) in human glioma xenograft cell lines 4910 and 5310 decreased cell proliferation compared with mock and pSV (scrambled vector) treatments, as determined by 5-bromo-2'-deoxyuridine incorporation, Ki-67 staining and clonogenic survival assay. Cytokine array and western blotting using tumor-conditioned media displayed modulated secretory levels of various cytokines including granulocyte-macrophage colony-stimulating factor, interleukin-6 (IL-6), IL-8, IL-10, tumor necrosis factor-alpha, angiogenin, vascular endothelial growth factor and PDGF-BB in MMP-2 knockdown cells. Further, cDNA PCR array indicated potential negative regulation of Janus kinase/Stat3 pathway in pM-treated cells. Mechanistically, MMP-2 is involved in complex formation with alpha 5 and beta 1 integrins and MMP-2 downregulation inhibited alpha 5 beta 1 integrin-mediated Stat3 phosphorylation and nuclear translocation. Electrophoretic mobility shift assay and chromatin immunoprecipitation assays showed inhibited Stat3 DNA-binding activity and recruitment at CyclinD1 and c-Myc promoters in pM-treated cells. In individual experiments, IL-6 or siRNA-insensitive MMP-2 overexpression by pM-FL-A141G counteracted and restored the pM-inhibited Stat3 DNA-binding activity, suggesting IL-6/Stat3 signaling suppression in pM-treated 4910 and 5310 cells. MMP-2/alpha 5 beta 1 binding is enhanced in human recombinant MMP-2 treatments, resulting in elevated Stat3 DNA-binding activity and recruitment on CyclinD1 and c-Myc promoters. Activation of alpha 5 beta 1 signaling by Fibronectin adhesion elevated pM-inhibited Stat3 phosphorylation whereas blocking alpha 5 beta 1 abrogated constitutive Stat3 activation. In vivo experiments with orthotropic tumor model revealed the decreased tumor size in pM treatment compared with mock or pSV treatments. Innmunofluorescence studies in tumor sections corroborated our in vitro findings evidencing high expression and co-localization of MMP-2/alpha 5 beta 1, which is decreased upon pM treatment along with significantly reduced IL-6, phospho-Stat3, CyclinD1, c-Myc, Ki-67 and PCNA expression levels. Our data indicate the possible role of MMP-2/alpha 5 beta 1 interaction in the regulation of alpha 5 beta 1-mediated IL-6/Stat3 signaling activation and signifies the therapeutic potential of blocking MMP-2/alpha 5 beta 1 interaction in glioma treatment. Oncogene (2013) 32, 327-340; doi:10.1038/onc.2012.52; published online 20 February 2012	[Kesanakurti, D.; Chetty, C.; Rao, J. S.] Univ Illinois, Coll Med Peoria, Dept Canc Biol & Pharmacol, Peoria, IL 61605 USA; [Dinh, D. H.; Rao, J. S.] Univ Illinois, Coll Med Peoria, Dept Neurosurg, Peoria, IL 61605 USA; [Gujrati, M.] Univ Illinois, Coll Med Peoria, Dept Pathol, Peoria, IL 61605 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med Peoria, Dept Canc Biol & Pharmacol, 1 Illini Dr, Peoria, IL 61605 USA.	jsrao@uic.edu			National Institute of Neurological Disorders and Stroke [NS64535-01A2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS064535] Funding Source: NIH RePORTER	National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Shellee Abraham for manuscript preparation and Diana Meister and Sushma Jasti for manuscript review. This research was supported by award NS64535-01A2 (to JSR) from the National Institute of Neurological Disorders and Stroke.	Aoudjit F, 2001, ONCOGENE, V20, P4995, DOI 10.1038/sj.onc.1204554; Ara T, 2010, EUR J CANCER, V46, P1223, DOI 10.1016/j.ejca.2010.02.026; Badiga AV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020614; Bhaskar V, 2008, INVEST NEW DRUG, V26, P7, DOI 10.1007/s10637-007-9078-z; Bollrath J, 2009, EMBO REP, V10, P1314, DOI 10.1038/embor.2009.243; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Chetty C, 2006, MOL CANCER THER, V5, P2289, DOI 10.1158/1535-7163.MCT-06-0169; Chetty C, 2010, INT J CANCER, V127, P1081, DOI 10.1002/ijc.25134; Courter DL, 2005, J BIOL CHEM, V280, P12145, DOI 10.1074/jbc.M412555200; Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8; Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252; Farber K, 2008, MOL CELL NEUROSCI, V39, P579, DOI 10.1016/j.mcn.2008.08.005; Galatioto J, 2010, J CELL SCI, V123, P3789, DOI 10.1242/jcs.073387; Ganji PCN, 2011, MOL CANCER RES, V9, P51, DOI 10.1158/1541-7786.MCR-10-0399; Giannini C, 2005, NEURO-ONCOLOGY, V7, P164, DOI 10.1215/S1152851704000821; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Han X., 2010, EUR J CLIN MED ONCOL, V2, P59; Hong DS, 2007, CANCER-AM CANCER SOC, V110, P1911, DOI 10.1002/cncr.22999; Hsu CP, 2011, EUR J CLIN INVEST, V41, P277, DOI 10.1111/j.1365-2362.2010.02405.x; Huang C, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-51; Isaji T, 2009, J BIOL CHEM, V284, P12207, DOI 10.1074/jbc.M807920200; Kesanakurti D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019341; Kesanakurti D, 2009, BIOCHEM BIOPH RES CO, V390, P427, DOI 10.1016/j.bbrc.2009.09.046; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Khalili P, 2006, MOL CANCER THER, V5, P2271, DOI 10.1158/1535-7163.MCT-06-0100; Klein S, 2002, MOL CELL BIOL, V22, P5912, DOI 10.1128/MCB.22.16.5912-5922.2002; Korah R, 2004, CANCER RES, V64, P4514, DOI 10.1158/0008-5472.CAN-03-3853; Lee BH, 2005, J CELL BIOCHEM, V95, P1214, DOI 10.1002/jcb.20488; Levkau B, 2002, CELL DEATH DIFFER, V9, P1360, DOI 10.1038/sj.cdd.4401106; Levy DE, 2006, P NATL ACAD SCI USA, V103, P10151, DOI 10.1073/pnas.0604042103; Li RH, 2010, ONCOL REP, V23, P1553, DOI 10.3892/or_00000795; Louis DN, 2006, ANNU REV PATHOL-MECH, V1, P97, DOI 10.1146/annurev.pathol.1.110304.100043; Maglott A, 2006, CANCER RES, V66, P6002, DOI 10.1158/0008-5472.CAN-05-4105; Martinkova E, 2010, INT J CANCER, V127, P1240, DOI 10.1002/ijc.25187; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; Melet A, 2008, ADV EXP MED BIOL, V615, P47, DOI 10.1007/978-1-4020-6554-5_4; Mino K, 2011, CANCER SCI, V102, P1052, DOI 10.1111/j.1349-7006.2011.01901.x; Mitra Aparna, 2003, Journal of Environmental Pathology Toxicology and Oncology, V22, P167, DOI 10.1615/JEnvPathToxOncol.v22.i3.20; Morgan MR, 2004, J BIOL CHEM, V279, P26533, DOI 10.1074/jbc.M401736200; Morozevich GE, 2008, BIOCHEMISTRY-MOSCOW+, V73, P791, DOI 10.1134/S0006297908070079; Morozevich G, 2009, CELL CYCLE, V8, P2219, DOI 10.4161/cc.8.14.8980; Ogier C, 2006, GLIA, V54, P272, DOI 10.1002/glia.20349; Park CC, 2006, CANCER RES, V66, P1526, DOI 10.1158/0008-5472.CAN-05-3071; Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Rojas A, 2011, ONCOGENE, V30, P2345, DOI 10.1038/onc.2010.605; Salgado R, 2003, INT J CANCER, V103, P642, DOI 10.1002/ijc.10833; Senft C, 2011, J NEURO-ONCOL, V101, P393, DOI 10.1007/s11060-010-0273-y; Shain KH, 2009, CANCER RES, V69, P1009, DOI 10.1158/0008-5472.CAN-08-2419; Silletti S, 2001, P NATL ACAD SCI USA, V98, P119, DOI 10.1073/pnas.011343298; Song LX, 2011, MOL CANCER THER, V10, P481, DOI 10.1158/1535-7163.MCT-10-0502; Wang H, 2009, STEM CELLS, V27, P2393, DOI 10.1002/stem.188; Weissenberger J, 2004, ONCOGENE, V23, P3308, DOI 10.1038/sj.onc.1207455; Xie TX, 2004, ONCOGENE, V23, P3550, DOI 10.1038/sj.onc.1207383; Xiong H, 2008, NEOPLASIA, V10, P287, DOI 10.1593/neo.07971; Zhang XY, 2009, ANTICANCER RES, V29, P4497	59	83	88	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2013	32	3					327	340		10.1038/onc.2012.52	http://dx.doi.org/10.1038/onc.2012.52			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22349830	Green Accepted			2022-12-17	WOS:000314736600007
J	Lee, SO; Andey, T; Jin, UH; Kim, K; Sachdeva, M; Safe, S				Lee, S-O; Andey, T.; Jin, U-H; Kim, K.; Sachdeva, M.; Safe, S.			The nuclear receptor TR3 regulates mTORC1 signaling in lung cancer cells expressing wild-type p53	ONCOGENE			English	Article						TR3; Nur77; NR4A1; mTORC1; c-DIMs; lung cancer	INDUCED B-ALPHA; NUR77; ACTIVATION; APOPTOSIS; PROTECTOR; PATHWAY; TARGET; GENES; NR4A2; BCL-2	The orphan nuclear receptor TR3 (NR41A and Nur77) is overexpressed in most lung cancer patients and is a negative prognostic factor for patient survival. The function of TR3 was investigated in non-small-cell lung cancer A549 and H460 cells, and knockdown of TR3 by RNA interference (siTR3) inhibited cancer cell growth and induced apoptosis. The prosurvival activity of TR3 was due, in part, to formation of a p300/TR3/specificity protein 1 complex bound to GC-rich promoter regions of survivin and other Sp-regulated genes (mechanism 1). However, in p53 wild-type A549 and H460 cells, siTR3 inhibited the mTORC1 pathway, and this was due to activation of p53 and induction of the p53-responsive gene sestrin 2, which subsequently activated the mTORC1 inhibitor AMP-activated protein kinase alpha (AMPK alpha) (mechanism 2). This demonstrates that the pro-oncogenic activity of TR3 in lung cancer cells was due to inhibition of p53 and activation of mTORC1. 1,1-Bis(3'-indolyl)-1-(p-hydroxyphenyl) methane (DIM-C-pPhOH) is a recently discovered inhibitor of TR3, which mimics the effects of siTR3. DIM-C-pPhOH inhibited growth and induced apoptosis in lung cancer cells and lung tumors in murine orthotopic and metastatic models, and this was accompanied by decreased expression of survivin and inhibition of mTORC1 signaling, demonstrating that inactivators of TR3 represent a novel class of mTORC1 inhibitors. Oncogene (2012) 31, 3265-3276; doi:10.1038/onc.2011.504; published online 14 November 2011	[Safe, S.] Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA; [Lee, S-O; Jin, U-H; Kim, K.; Safe, S.] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX USA; [Andey, T.; Sachdeva, M.] Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Dept Pharmaceut, Tallahassee, FL 32307 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; State University System of Florida; Florida A&M University	Safe, S (corresponding author), Texas A&M Univ, Dept Vet Physiol & Pharmacol, Vet Res Bldg 410, College Stn, TX 77843 USA.	ssafe@cvm.tamu.edu		Sachdeva, Mandip/0000-0001-9192-8143; Kim, Kyounghyun/0000-0002-7240-2768; Lee, Syng-Ook/0000-0002-8958-8634	National Institutes of Health [R01-CA124998]; Texas AM AgriLife; NATIONAL CANCER INSTITUTE [R01CA124998] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003020] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Texas AM AgriLife; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported by National Institutes of Health (R01-CA124998) and the Texas A&M AgriLife.	Azoitei N, 2010, GUT, V59, P1316, DOI 10.1136/gut.2009.206813; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Bras A, 2000, CELL DEATH DIFFER, V7, P262, DOI 10.1038/sj.cdd.4400653; Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028; Chen LL, 2011, GUT, V60, P534, DOI 10.1136/gut.2010.224071; Chen LL, 2009, HEPATOLOGY, V50, P122, DOI 10.1002/hep.22933; Chintharlapalli S, 2005, J BIOL CHEM, V280, P24903, DOI 10.1074/jbc.M500107200; Cho SD, 2007, CANCER RES, V67, P674, DOI 10.1158/0008-5472.CAN-06-2907; Cho SD, 2010, MOL PHARMACOL, V77, P396, DOI 10.1124/mol.109.061143; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Ke N, 2004, CANCER RES, V64, P8208, DOI 10.1158/0008-5472.CAN-04-2134; Kolluri SK, 2008, CANCER CELL, V14, P285, DOI 10.1016/j.ccr.2008.09.002; Kolluri SK, 2003, MOL CELL BIOL, V23, P8651, DOI 10.1128/MCB.23.23.8651-8667.2003; Lee JH, 2010, SCIENCE, V327, P1223, DOI 10.1126/science.1182228; Lee SO, 2010, CANCER RES, V70, P6824, DOI 10.1158/0008-5472.CAN-10-1992; Lee SO, 2009, MOL CANCER RES, V7, P1169, DOI 10.1158/1541-7786.MCR-08-0473; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li QX, 2006, HISTOL HISTOPATHOL, V21, P533, DOI 10.14670/HH-21.533; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Liu JJ, 2010, CANCER RES, V70, P3628, DOI 10.1158/0008-5472.CAN-09-3160; MARUYAMA K, 1995, CANCER LETT, V96, P117, DOI 10.1016/0304-3835(95)03921-I; Maxwell Megan A, 2006, Nucl Recept Signal, V4, pe002; McKenna NJ, 2009, MOL ENDOCRINOL, V23, P740, DOI 10.1210/me.2009-0135; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Pearen MA, 2010, MOL ENDOCRINOL, V24, P1891, DOI 10.1210/me.2010-0015; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Wu H, 2011, FASEB J, V25, P192, DOI 10.1096/fj.10-166462; Yang Q, 2007, CELL RES, V17, P666, DOI 10.1038/cr.2007.64; Zeng HY, 2006, J EXP MED, V203, P719, DOI 10.1084/jem.20051523; Zhan YP, 2008, NAT CHEM BIOL, V4, P548, DOI 10.1038/nchembio.106; Zhang XK, 2007, EXPERT OPIN THER TAR, V11, P69, DOI 10.1517/14728222.11.1.69; Zhao BX, 2006, EMBO J, V25, P5703, DOI 10.1038/sj.emboj.7601435	35	83	85	2	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	27					3265	3276		10.1038/onc.2011.504	http://dx.doi.org/10.1038/onc.2011.504			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	970FL	22081070	Bronze, Green Accepted			2022-12-17	WOS:000306113400006
J	Orr, B; Riddick, ACP; Stewart, GD; Anderson, RA; Franco, OE; Hayward, SW; Thomson, AA				Orr, B.; Riddick, A. C. P.; Stewart, G. D.; Anderson, R. A.; Franco, O. E.; Hayward, S. W.; Thomson, A. A.			Identification of stromally expressed molecules in the prostate by tag-profiling of cancer-associated fibroblasts, normal fibroblasts and fetal prostate	ONCOGENE			English	Article						prostate; stromal/epithelial interactions; cancer-associated fibroblasts; cancer microenvironment; Tag profiling	GENE-EXPRESSION; BREAST-CANCER; TUMOR MICROENVIRONMENT; REACTIVE STROMA; GROWTH-FACTOR; CELLS; CARCINOGENESIS; PROGRESSION; MESENCHYME; BETA	The stromal microenvironment has key roles in prostate development and cancer, and cancer-associated fibroblasts (CAFs) stimulate tumourigenesis via several mechanisms including the expression of pro-tumourigenic factors. Mesenchyme (embryonic stroma) controls prostate organogenesis, and in some circumstances can re-differentiate prostate tumours. We have applied next-generation Tag profiling to fetal human prostate, normal human prostate fibroblasts (NPFs) and CAFs to identify molecules expressed in prostatic stroma. Comparison of gene expression profiles of a patient-matched pair of NPFs vs CAFs identified 671 transcripts that were enriched in CAFs and 356 transcripts whose levels were decreased, relative to NPFs. Gene ontology analysis revealed that CAF-enriched transcripts were associated with prostate morphogenesis and CAF-depleted transcripts were associated with cell cycle. We selected mRNAs to follow-up by comparison of our data sets with published prostate cancer fibroblast microarray profiles as well as by focusing on transcripts encoding secreted and peripheral membrane proteins, as well as mesenchymal transcripts identified in a previous study from our group. We confirmed differential transcript expression between CAFs and NPFs using QrtPCR, and defined protein localization using immunohistochemistry in fetal prostate, adult prostate and prostate cancer. We demonstrated that ASPN, CAV1, CFH, CTSK, DCN, FBLN1, FHL1, FN, NKTR, OGN, PARVA, S100A6, SPARC, STC1 and ZEB1 proteins showed specific and varied expression patterns in fetal human prostate and in prostate cancer. Colocalization studies suggested that some stromally expressed molecules were also expressed in subsets of tumour epithelia, indicating that they may be novel markers of EMT. Additionally, two molecules (ASPN and STC1) marked overlapping and distinct subregions of stroma associated with tumour epithelia and may represent new CAF markers. Oncogene (2012) 31, 1130-1142; doi:10.1038/onc.2011.312; published online 1 August 2011	[Orr, B.; Thomson, A. A.] Queens Med Res Inst, Med Res Council Human Reprod Sci Unit, Edinburgh EH16 4TJ, Midlothian, Scotland; [Riddick, A. C. P.; Stewart, G. D.] Western Gen Hosp, Dept Urol, Edinburgh EH4 2XU, Midlothian, Scotland; [Anderson, R. A.] Univ Edinburgh, Reprod & Dev Sci Sect, Queens Med Res Inst, Edinburgh, Midlothian, Scotland; [Franco, O. E.; Hayward, S. W.] Vanderbilt Univ, Med Ctr, Dept Urol Surg, Nashville, TN USA; [Franco, O. E.; Hayward, S. W.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN USA	University of Edinburgh; University of Edinburgh; University of Edinburgh; Vanderbilt University; Vanderbilt University	Thomson, AA (corresponding author), Queens Med Res Inst, Med Res Council Human Reprod Sci Unit, 47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland.	a.thomson@hrsu.mrc.ac.uk	Thomson, Axel/A-7893-2013	Stewart, Grant D./0000-0003-3188-9140; Hayward, Simon/0000-0002-6059-6550	MRC WBSe [1276.00.003.00004.01]; NCI [CA126505]; MRC; Prostate Cancer Charity; Medical Research Council [G1002033, MC_U127684421, G1100357, G1002118] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [U54CA126505] Funding Source: NIH RePORTER; MRC [G1002033, MC_U127684421, G1002118, G1100357] Funding Source: UKRI	MRC WBSe(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Prostate Cancer Charity; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We would like to thank Ted Pinner for help with the figure preparation, Donald Dunbar for Bio-informatic advice and Sheila Macpherson for help with colocalization. This work was funded by the MRC WBSe 1276.00.003.00004.01 to AAT and NCI CA126505 to SWH. The MRC Human Reproductive Sciences Unit closed on 31 March 2011. AAT was supported by the MRC and The Prostate Cancer Charity.	Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Ao MF, 2007, CANCER RES, V67, P4244, DOI 10.1158/0008-5472.CAN-06-3946; Augsten M, 2009, P NATL ACAD SCI USA, V106, P3414, DOI 10.1073/pnas.0813144106; Ayala G, 2003, CLIN CANCER RES, V9, P4792; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Cunha GR, 2002, DIFFERENTIATION, V70, P473, DOI 10.1046/j.1432-0436.2002.700902.x; Dakhova O, 2009, CLIN CANCER RES, V15, P3979, DOI 10.1158/1078-0432.CCR-08-1899; Di Vizio D, 2009, CELL CYCLE, V8, P2420, DOI 10.4161/cc.8.15.9116; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Franco OE, 2011, CANCER RES, V71, P1272, DOI 10.1158/0008-5472.CAN-10-3142; Gregg JL, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-165; HAYASHI N, 1991, CANCER RES, V51, P4924; Hayward SW, 1996, ANN NY ACAD SCI, V784, P50, DOI 10.1111/j.1749-6632.1996.tb16227.x; Hayward SW, 2001, CANCER RES, V61, P8135; Joensuu K, 2008, CANCER LETT, V265, P76, DOI 10.1016/j.canlet.2008.02.022; Joesting MS, 2005, CANCER RES, V65, P10423, DOI 10.1158/0008-5472.CAN-05-0824; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kiskowski MA, 2011, CANCER RES, V71, P3459, DOI 10.1158/0008-5472.CAN-10-2999; Kizawa H, 2005, NAT GENET, V37, P138, DOI 10.1038/ng1496; Lesniak W, 2009, BIOCHEM BIOPH RES CO, V390, P1087, DOI 10.1016/j.bbrc.2009.10.150; Ma XJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2222; Madar S, 2009, CARCINOGENESIS, V30, P20, DOI 10.1093/carcin/bgn232; Olumi AF, 1999, CANCER RES, V59, P5002; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pascal LE, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-317; Placencio VR, 2008, CANCER RES, V68, P4709, DOI 10.1158/0008-5472.CAN-07-6289; Pritchard C, 2009, CANCER RES, V69, P1739, DOI 10.1158/0008-5472.CAN-07-6817; Rehman I, 2005, PROSTATE, V65, P322, DOI 10.1002/pros.20302; Schaeffer EM, 2008, ONCOGENE, V27, P7180, DOI 10.1038/onc.2008.327; Stasko SE, 2001, DEV DYNAM, V220, P49, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1086>3.0.CO;2-5; Stolovitzky GA, 2005, P NATL ACAD SCI USA, V102, P1402, DOI 10.1073/pnas.0406555102; Sugimoto H, 2006, CANCER BIOL THER, V5, P1640, DOI 10.4161/cbt.5.12.3354; Thalmann GN, 2010, EUR UROL, V58, P162, DOI 10.1016/j.eururo.2009.08.026; Thomson AA, 1999, DEVELOPMENT, V126, P3693; TIMMS BG, 1995, MICROSC RES TECHNIQ, V30, P319, DOI 10.1002/jemt.1070300407; Tuxhorn JA, 2002, CANCER RES, V62, P3298; Vanpoucke G, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r213; Watson JEV, 2004, PROSTATE, V61, P192, DOI 10.1002/pros.20100; Whitaker HC, 2010, PROSTATE, V70, P333, DOI 10.1002/pros.21059; Witkiewicz AK, 2009, CELL CYCLE, V8, P1654, DOI 10.4161/cc.8.11.8544; Yanagisawa N, 2007, HUM PATHOL, V38, P1611, DOI 10.1016/j.humpath.2007.04.008; Zhao HJ, 2007, J CELL PHYSIOL, V210, P111, DOI 10.1002/jcp.20828	42	83	85	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	9					1130	1142		10.1038/onc.2011.312	http://dx.doi.org/10.1038/onc.2011.312			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	901EW	21804603	Green Published, hybrid			2022-12-17	WOS:000300945900006
J	Lemarie, A; Grimm, S				Lemarie, A.; Grimm, S.			Mitochondrial respiratory chain complexes: apoptosis sensors mutated in cancer	ONCOGENE			English	Review						apoptosis; respiratory chain; reactive oxygen species; mitochondria	ELECTRON-TRANSPORT-CHAIN; SUCCINATE-UBIQUINONE OXIDOREDUCTASE; OXYGEN SPECIES GENERATION; GASTROINTESTINAL STROMAL TUMORS; OXIDATIVELY DAMAGED PROTEINS; EHRLICH ASCITES TUMOR; CYTOCHROME-C-OXIDASE; DEPENDENT CELL-DEATH; SDHD GENE-MUTATIONS; DNA MUTATIONS	Mutations in cancer cells affecting subunits of the respiratory chain (RC) indicate a central role of oxidative phosphorylation for tumourigenesis. Recent studies have suggested that such mutations of RC complexes impact apoptosis induction. We review here the evidence for this hypothesis, which in particular emerged from work on how complex I and II mediate signals for apoptosis. Both protein aggregates are specifically inhibited for apoptosis induction through different means by exploiting with protease activation and pH change, two widespread but independent features of dying cells. Nevertheless, both converge on forming reactive oxygen species for the demise of the cell. Investigations into these mitochondrial processes will remain a rewarding area for unravelling the causes of tumourigenesis and for discovering interference options. Oncogene (2011) 30, 3985-4003; doi:10.1038/onc.2011.167; published online 30 May 2011	[Lemarie, A.] Univ Toulouse 3, INSERM CRCT U1037, Dept Expt Therapeut, Inst Claudius Regaud, F-31052 Toulouse, France; [Lemarie, A.] Univ Toulouse 3, Fac Pharmaceut Sci, F-31052 Toulouse, France; [Grimm, S.] Univ London Imperial Coll Sci Technol & Med, Dept Expt Med & Toxicol, London, England	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Imperial College London	Lemarie, A (corresponding author), Univ Toulouse 3, INSERM CRCT U1037, Dept Expt Therapeut, Inst Claudius Regaud, 20-24 Rue Pont St Pierre, F-31052 Toulouse, France.	lemarie.anthony@claudiusregaud.fr; s.grimm@imperial.ac.uk	LEMARIE, Anthony/G-4018-2017	LEMARIE, Anthony/0000-0002-6523-4962	Cancer Research UK; la Ligue Nationale Contre le Cancer (Hautes-Pyrenees and Haute-Garonne committees); Wellcome Trust; CRUK; MRC; Breast Cancer Campaign	Cancer Research UK(Cancer Research UK); la Ligue Nationale Contre le Cancer (Hautes-Pyrenees and Haute-Garonne committees); Wellcome Trust(Wellcome TrustEuropean Commission); CRUK(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Breast Cancer Campaign	We acknowledge the financial support from Cancer Research UK (to AL and SG) as well as from la Ligue Nationale Contre le Cancer (Hautes-Pyrenees and Haute-Garonne committees; to AL) and support by the Wellcome Trust, CRUK, MRC, Breast Cancer Campaign (to SG).	Abu-Amero KK, 2005, ONCOGENE, V24, P1455, DOI 10.1038/sj.onc.1208292; Akhmedov D, 2010, FASEB J, V24, P4613, DOI 10.1096/fj.10-162222; Albayrak T, 2003, MOL BIOL CELL, V14, P3082, DOI 10.1091/mbc.e02-10-0631; Amar L, 2005, J CLIN ONCOL, V23, P8812, DOI 10.1200/JCO.2005.03.1484; Amar L, 2007, J CLIN ENDOCR METAB, V92, P3822, DOI 10.1210/jc.2007-0709; Arrington DD, 2006, AM J PHYSIOL-CELL PH, V291, pC1159, DOI 10.1152/ajpcell.00207.2006; Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; Bayley JP, 2010, CURR OPIN GENET DEV, V20, P324, DOI 10.1016/j.gde.2010.02.008; Bayley JP, 2010, LANCET ONCOL, V11, P366, DOI 10.1016/S1470-2045(10)70007-3; Bayley JP, 2005, BMC MED GENET, V6, DOI 10.1186/1471-2350-6-39; Baysal BE, 2008, J MED GENET, V45, P689, DOI 10.1136/jmg.2008.058560; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Belevich I, 2008, ANTIOXID REDOX SIGN, V10, P1, DOI 10.1089/ars.2007.1705; Benit P, 2009, BBA-MOL CELL RES, V1793, P181, DOI 10.1016/j.bbamcr.2008.06.004; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Blank A, 2010, ENDOCR-RELAT CANCER, V17, P919, DOI 10.1677/ERC-09-0316; Boedeker CC, 2007, OTOLARYNG HEAD NECK, V137, P126, DOI 10.1016/j.otohns.2007.01.015; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Bonora E, 2006, CANCER RES, V66, P6087, DOI 10.1158/0008-5472.CAN-06-0171; BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144; Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607; Briere JJ, 2005, HUM MOL GENET, V14, P3263, DOI 10.1093/hmg/ddi359; Brockmann K, 2002, ANN NEUROL, V52, P38, DOI 10.1002/ana.10232; Brusque AM, 2002, NEUROCHEM INT, V40, P593, DOI 10.1016/S0197-0186(01)00130-9; Burnichon N, 2010, HUM MOL GENET, V19, P3011, DOI 10.1093/hmg/ddq206; Burnichon N, 2009, J CLIN ENDOCR METAB, V94, P2817, DOI 10.1210/jc.2008-2504; Byun HO, 2008, J CELL BIOCHEM, V104, P1747, DOI 10.1002/jcb.21741; Campanella M, 2009, TRENDS BIOCHEM SCI, V34, P343, DOI 10.1016/j.tibs.2009.03.006; Cecchini G, 2003, ANNU REV BIOCHEM, V72, P77, DOI 10.1146/annurev.biochem.72.121801.161700; Cervera AM, 2008, CANCER RES, V68, P4058, DOI 10.1158/0008-5472.CAN-07-5580; Chen CL, 2008, J BIOL CHEM, V283, P27991, DOI 10.1074/jbc.M802691200; Chen YR, 2007, J BIOL CHEM, V282, P32640, DOI 10.1074/jbc.M702294200; Chen YQ, 2007, J CELL SCI, V120, P4155, DOI 10.1242/jcs.011163; Chen Z, 2010, ONCOGENE, V29, P4362, DOI 10.1038/onc.2010.193; Choksi KB, 2008, FREE RADICAL BIO MED, V45, P826, DOI 10.1016/j.freeradbiomed.2008.06.006; Choksi KB, 2007, FREE RADICAL BIO MED, V43, P1423, DOI 10.1016/j.freeradbiomed.2007.07.027; CINO M, 1989, ARCH BIOCHEM BIOPHYS, V269, P623, DOI 10.1016/0003-9861(89)90148-3; Circu ML, 2010, FREE RADICAL BIO MED, V48, P749, DOI 10.1016/j.freeradbiomed.2009.12.022; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; Cullen SP, 2008, CELL DEATH DIFFER, V15, P251, DOI 10.1038/sj.cdd.4402244; Cuperus R, 2010, CELL MOL LIFE SCI, V67, P807, DOI 10.1007/s00018-009-0212-2; Dahia PLM, 2005, PLOS GENET, V1, P72, DOI 10.1371/journal.pgen.0010008; Dayal D, 2009, RADIAT RES, V172, P737, DOI 10.1667/RR1617.1; Dekker PBD, 2003, J PATHOL, V201, P480, DOI 10.1002/path.1461; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Di Paola M, 2000, BIOCHEMISTRY-US, V39, P6660, DOI 10.1021/bi9924415; Diaz F, 2010, BBA-MOL BASIS DIS, V1802, P100, DOI 10.1016/j.bbadis.2009.07.013; Diaz-Ruiz R, 2008, J BIOL CHEM, V283, P26948, DOI 10.1074/jbc.M800408200; Diaz-Ruiz R, 2011, BBA-BIOENERGETICS, V1807, P568, DOI 10.1016/j.bbabio.2010.08.010; Dibrov E, 1998, J BIOL CHEM, V273, P32042, DOI 10.1074/jbc.273.48.32042; Distelmaier F, 2009, BRAIN, V132, P833, DOI 10.1093/brain/awp058; Dong LF, 2008, ONCOGENE, V27, P4324, DOI 10.1038/onc.2008.69; Dong LF, 2007, CANCER RES, V67, P11906, DOI 10.1158/0008-5472.CAN-07-3034; Dong LF, 2011, FREE RADICAL BIO MED, V50, P1546, DOI 10.1016/j.freeradbiomed.2011.02.032; Dong LF, 2011, J BIOL CHEM, V286, P3717, DOI 10.1074/jbc.M110.186643; Dong LF, 2009, CLIN CANCER RES, V15, P1593, DOI 10.1158/1078-0432.CCR-08-2439; Favier J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007094; Feichtinger Rene G, 2011, Front Biosci (Elite Ed), V3, P194, DOI 10.2741/e233; Finsterer J, 2008, PEDIATR NEUROL, V39, P223, DOI 10.1016/j.pediatrneurol.2008.07.013; Fiorucci S, 2004, J IMMUNOL, V173, P874, DOI 10.4049/jimmunol.173.2.874; Frezza C, 2009, SEMIN CANCER BIOL, V19, P4, DOI 10.1016/j.semcancer.2008.11.008; Gasparre G, 2008, HUM MOL GENET, V17, P986, DOI 10.1093/hmg/ddm371; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Ghezzi D, 2009, NAT GENET, V41, P654, DOI 10.1038/ng.378; Gimenez-Roqueplo AP, 2008, CLIN EXP PHARMACOL P, V35, P376, DOI 10.1111/j.1440-1681.2008.04881.x; Gimenez-Roqueplo AP, 2003, CANCER RES, V63, P5615; Gimenez-Roqueplo AP, 2001, AM J HUM GENET, V69, P1186, DOI 10.1086/324413; Gogvadze V, 2010, MOL ASPECTS MED, V31, P60, DOI 10.1016/j.mam.2009.12.004; Gogvadze V, 2009, SEMIN CANCER BIOL, V19, P57, DOI 10.1016/j.semcancer.2008.11.007; Gottlieb E, 2005, NAT REV CANCER, V5, P857, DOI 10.1038/nrc1737; Grimm S, 2004, NAT REV GENET, V5, P179, DOI 10.1038/nrg1291; Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154; Guo J, 2003, J BIOL CHEM, V278, P47629, DOI 10.1074/jbc.M306312200; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Guzy RD, 2008, MOL CELL BIOL, V28, P718, DOI 10.1128/MCB.01338-07; Habano W, 2003, ONCOL REP, V10, P1375; HALICKA HD, 1995, CANCER RES, V55, P444; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hao HX, 2009, SCIENCE, V325, P1139, DOI 10.1126/science.1175689; He YP, 2010, NATURE, V464, P610, DOI 10.1038/nature08802; HEINZ A, 1981, J MEMBRANE BIOL, V61, P143, DOI 10.1007/BF01870520; HENSEN EF, 2011, FAM CANC; Hervouet E, 2008, CARCINOGENESIS, V29, P1528, DOI 10.1093/carcin/bgn125; Horvath R, 2006, J NEUROL NEUROSUR PS, V77, P74, DOI 10.1136/jnnp.2005.067041; Huang JZ, 2009, J MOL BIOL, V387, P559, DOI 10.1016/j.jmb.2009.02.028; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Ishii N, 2007, MITOCHONDRION, V7, P24, DOI 10.1016/j.mito.2006.11.012; Ishii T, 2005, CANCER RES, V65, P203; Ishii T, 2011, MITOCHONDRION, V11, P155, DOI 10.1016/j.mito.2010.09.006; Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906; Janeway KA, 2011, P NATL ACAD SCI USA, V108, P314, DOI 10.1073/pnas.1009199108; Kazama H, 2008, IMMUNITY, V29, P21, DOI 10.1016/j.immuni.2008.05.013; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Klanner C, 2000, FEBS LETT, V470, P365, DOI 10.1016/S0014-5793(00)01322-3; KRAHENBUHL S, 1991, J BIOL CHEM, V266, P20998; Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200; Kussmaul L, 2006, P NATL ACAD SCI USA, V103, P7607, DOI 10.1073/pnas.0510977103; Kwong JQ, 2007, J CELL BIOL, V179, P1163, DOI 10.1083/jcb.200704059; Lagadic-Gossmann D, 2004, CELL DEATH DIFFER, V11, P953, DOI 10.1038/sj.cdd.4401466; Lartigue L, 2009, MOL BIOL CELL, V20, P4871, DOI 10.1091/mbc.E09-07-0649; Le SB, 2007, J BIOL CHEM, V282, P8860, DOI 10.1074/jbc.M611777200; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Lehtonen HJ, 2007, INT J CANCER, V121, P1386, DOI 10.1002/ijc.22819; Lemarie A, 2011, CELL DEATH DIFFER, V18, P338, DOI 10.1038/cdd.2010.93; Lemarie A, 2009, MITOCHONDRION, V9, P254, DOI 10.1016/j.mito.2009.03.004; Lenaz G, 2010, ANTIOXID REDOX SIGN, V12, P961, DOI 10.1089/ars.2009.2704; Levitas A, 2010, EUR J HUM GENET, V18, P1160, DOI 10.1038/ejhg.2010.83; Liot G, 2009, CELL DEATH DIFFER, V16, P899, DOI 10.1038/cdd.2009.22; Lluis JM, 2007, CANCER RES, V67, P7368, DOI 10.1158/0008-5472.CAN-07-0515; Lu JX, 2009, CELL RES, V19, P802, DOI 10.1038/cr.2009.69; Maklashina E, 2010, BBA-BIOENERGETICS, V1797, P1877, DOI 10.1016/j.bbabio.2010.02.015; Mandavilli BS, 2005, MOL BRAIN RES, V133, P215, DOI 10.1016/j.molbrainres.2004.10.033; Martinvalet D, 2005, IMMUNITY, V22, P355, DOI 10.1016/j.immuni.2005.02.004; Martinvalet D, 2008, CELL, V133, P681, DOI 10.1016/j.cell.2008.03.032; Mason MG, 2006, P NATL ACAD SCI USA, V103, P708, DOI 10.1073/pnas.0506562103; Mast JD, 2008, DEVELOPMENT, V135, P2669, DOI 10.1242/dev.020644; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Mbaya E, 2010, CELL DEATH DIFFER, V17, P1855, DOI 10.1038/cdd.2010.51; McLaughlin BA, 1998, NEUROSCIENCE, V86, P279, DOI 10.1016/S0306-4522(97)00594-0; McLennan HR, 2000, J BIOENERG BIOMEMBR, V32, P153, DOI 10.1023/A:1005507913372; McWhinney SR, 2007, NEW ENGL J MED, V357, P1054, DOI 10.1056/NEJMc071191; Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554; Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677; Miyadera H, 2003, P NATL ACAD SCI USA, V100, P473, DOI 10.1073/pnas.0237315100; Moreira PI, 2006, J BIOL CHEM, V281, P10143, DOI 10.1074/jbc.M510249200; Muntane J, 2010, WORLD J HEPATOL, V2, P337, DOI 10.4254/wjh.v2.i9.337; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Nakamura K, 1996, J BIOL CHEM, V271, P521, DOI 10.1074/jbc.271.1.521; Neumann HPH, 2004, JAMA-J AM MED ASSOC, V292, P943, DOI 10.1001/jama.292.8.943; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; Ohta S, 2006, ONCOGENE, V25, P4768, DOI 10.1038/sj.onc.1209602; OOSTVEEN FG, 1995, J BIOL CHEM, V270, P26104, DOI 10.1074/jbc.270.44.26104; Ott M, 2007, APOPTOSIS, V12, P913, DOI 10.1007/s10495-007-0756-2; Oyedotun KS, 2007, BBA-BIOENERGETICS, V1767, P1436, DOI 10.1016/j.bbabio.2007.09.008; Paddenberg R, 2003, AM J PHYSIOL-LUNG C, V284, pL710, DOI 10.1152/ajplung.00149.2002; Pagnamenta AT, 2006, MOL GENET METAB, V89, P214, DOI 10.1016/j.ymgme.2006.05.003; Pang Z, 1997, J NEUROSCI, V17, P3064; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Parfait B, 2000, HUM GENET, V106, P236, DOI 10.1007/s004390051033; Park JS, 2009, HUM MOL GENET, V18, P1578, DOI 10.1093/hmg/ddp069; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004; Penta JS, 2001, MUTAT RES-REV MUTAT, V488, P119, DOI 10.1016/S1383-5742(01)00053-9; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; Piantadosi CA, 2008, J BIOL CHEM, V283, P10967, DOI 10.1074/jbc.M709741200; Pollard PJ, 2006, J CLIN ENDOCR METAB, V91, P4593, DOI 10.1210/jc.2006-0920; Pollard PJ, 2005, HUM MOL GENET, V14, P2231, DOI 10.1093/hmg/ddi227; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Prochazka L, 2010, APOPTOSIS, V15, P782, DOI 10.1007/s10495-010-0482-z; Puissegur MP, 2011, CELL DEATH DIFFER, V18, P465, DOI 10.1038/cdd.2010.119; Putignani L, 2008, BREAST CANCER RES TR, V110, P439, DOI 10.1007/s10549-007-9738-x; Ralph SJ, 2010, MOL ASPECTS MED, V31, P145, DOI 10.1016/j.mam.2010.02.008; Ralph SJ, 2009, MOL NUTR FOOD RES, V53, P7, DOI 10.1002/mnfr.200890054; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Ricci JE, 2003, CELL DEATH DIFFER, V10, P488, DOI 10.1038/sj.cdd.4401225; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Ricketts C, 2008, J NATL CANCER I, V100, P1260, DOI 10.1093/jnci/djn254; Rikka S, 2011, CELL DEATH DIFFER, V18, P721, DOI 10.1038/cdd.2010.146; Rodriguez-Enriquez S, 2001, EUR J BIOCHEM, V268, P2512, DOI 10.1046/j.1432-1327.2001.02140.x; Rutter J, 2010, MITOCHONDRION, V10, P393, DOI 10.1016/j.mito.2010.03.001; Ryland LK, 2011, CANCER BIOL THER, V11, P138, DOI 10.4161/cbt.11.2.14624; Schapira AHV, 2010, EXP NEUROL, V224, P331, DOI 10.1016/j.expneurol.2010.03.028; Schimke RN, 2010, AM J MED GENET A, V152A, P1531, DOI 10.1002/ajmg.a.33384; Schlisio S, 2008, GENE DEV, V22, P884, DOI 10.1101/gad.1648608; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Selak MA, 2006, BBA-BIOENERGETICS, V1757, P567, DOI 10.1016/j.bbabio.2006.05.015; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Senoo-Matsuda N, 2003, J BIOL CHEM, V278, P22031, DOI 10.1074/jbc.M211377200; Senoo-Matsuda N, 2001, J BIOL CHEM, V276, P41553, DOI 10.1074/jbc.M104718200; Shidara Y, 2005, CANCER RES, V65, P1655, DOI 10.1158/0008-5472.CAN-04-2012; Siskind LJ, 2005, J BIOENERG BIOMEMBR, V37, P143, DOI 10.1007/s10863-005-6567-7; Slane BG, 2006, CANCER RES, V66, P7615, DOI 10.1158/0008-5472.CAN-06-0833; Smith EH, 2007, HUM MOL GENET, V16, P3136, DOI 10.1093/hmg/ddm275; Solaini G, 2010, BBA-BIOENERGETICS, V1797, P1171, DOI 10.1016/j.bbabio.2010.02.011; Soller M, 2007, MOL PHARMACOL, V71, P1535, DOI 10.1124/mol.107.034371; Sun F, 2005, CELL, V121, P1043, DOI 10.1016/j.cell.2005.05.025; Szeto SSW, 2007, J BIOL CHEM, V282, P27518, DOI 10.1074/jbc.M700601200; Tran QM, 2007, P NATL ACAD SCI USA, V104, P18007, DOI 10.1073/pnas.0707732104; Tran QM, 2006, J BIOL CHEM, V281, P32310, DOI 10.1074/jbc.M607476200; Van Coster R, 2003, AM J MED GENET A, V120A, P13, DOI 10.1002/ajmg.a.10202; van Nederveen FH, 2009, LANCET ONCOL, V10, P764, DOI 10.1016/S1470-2045(09)70164-0; Vander Heiden MG, 2002, J BIOL CHEM, V277, P44870, DOI 10.1074/jbc.M204888200; Waldmann J, 2009, ENDOCRINE, V35, P347, DOI 10.1007/s12020-009-9178-y; Walker DW, 2006, P NATL ACAD SCI USA, V103, P16382, DOI 10.1073/pnas.0607918103; Wallace KB, 2000, ANNU REV PHARMACOL, V40, P353, DOI 10.1146/annurev.pharmtox.40.1.353; WINK DA, 2008, NITRIC OXIDE, V19, P192; Wojtczak L, 1996, ACTA BIOCHIM POL, V43, P361; Wojtczak L, 1999, EUR J BIOCHEM, V263, P495, DOI 10.1046/j.1432-1327.1999.00522.x; Xu RH, 2005, CANCER RES, V65, P613; Yang XL, 1997, AM J PHYSIOL-ENDOC M, V272, pE173, DOI 10.1152/ajpendo.1997.272.1.E173; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; Yeung SJ, 2008, CELL MOL LIFE SCI, V65, P3981, DOI 10.1007/s00018-008-8224-x; ZHANG Y, 1990, J BIOL CHEM, V265, P16330; Zhao ZW, 2006, BIOCHEM CELL BIOL, V84, P1013, DOI 10.1139/O06-188	196	83	85	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	38					3985	4003		10.1038/onc.2011.167	http://dx.doi.org/10.1038/onc.2011.167			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823KR	21625217	Bronze			2022-12-17	WOS:000295121600001
J	Askham, JM; Platt, F; Chambers, PA; Snowden, H; Taylor, CF; Knowles, MA				Askham, J. M.; Platt, F.; Chambers, P. A.; Snowden, H.; Taylor, C. F.; Knowles, M. A.			AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K	ONCOGENE			English	Article						AKT1; mutation; bladder cancer	PLECKSTRIN HOMOLOGY DOMAIN; CELL CARCINOMA; PH DOMAIN; IN-VIVO; KINASE; PROTEIN; ACTIVATION; DOWNSTREAM; AKT/PKB; PATHWAY	The phosphatidylinositol-3-kinase (PI3 kinase)-AKT pathway is frequently activated in cancer. Recent reports have identified a transforming mutation of AKT1 in breast, colorectal, ovarian and lung cancers. We report here the occurrence of this mutation in bladder tumours. The AKT1 G49A (E17K) mutation was found in 2/44 (4.8%) bladder cancer cell lines and 5/184 (2.7%) bladder tumours. Cell lines expressing mutant AKT1 show constitutive AKT1 activation under conditions of growth factor withdrawal. We also detected a novel AKT1 mutation G145A (E49K). This mutation also enhances AKT activation and shows transforming activity in NIH3T3 cells, though activity is weaker than that of E17K. Enhanced activation of AKT1 when E17K and E49K mutations are in tandem suggests that they can co-operate.	[Askham, J. M.; Platt, F.; Knowles, M. A.] St James Univ Hosp, Canc Res UK Clin Ctr, Leeds Inst Mol Med, Leeds LS9 7TF, W Yorkshire, England; [Chambers, P. A.; Snowden, H.; Taylor, C. F.] St James Univ Hosp, Canc Res UK Genome Variat Lab, Leeds LS9 7TF, W Yorkshire, England	Cancer Research UK; Saint James's University Hospital; University of Leeds; Saint James's University Hospital	Knowles, MA (corresponding author), St James Univ Hosp, Canc Res UK Clin Ctr, Leeds Inst Mol Med, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	m.a.knowles@leeds.ac.uk	Chambers, Philip/AAK-8549-2020	Chambers, Philip/0000-0002-0926-717X; Knowles, Margaret/0000-0002-9363-8657	Cancer Research UK [C6228/A5433]	Cancer Research UK(Cancer Research UK)	This work was funded by a Programme grant from Cancer Research UK (C6228/A5433).	Aveyard JS, 1999, BRIT J CANCER, V80, P904, DOI 10.1038/sj.bjc.6690439; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bleeker FE, 2008, ONCOGENE, V27, P5648, DOI 10.1038/onc.2008.170; Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024; Brugge J, 2007, CANCER CELL, V12, P104, DOI 10.1016/j.ccr.2007.07.014; Cairns P, 1998, ONCOGENE, V16, P3215, DOI 10.1038/sj.onc.1201855; Calleja V, 2007, PLOS BIOL, V5, P780, DOI 10.1371/journal.pbio.0050095; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Dong B, 2007, J BIOL CHEM, V282, P25131, DOI 10.1074/jbc.M702123200; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Kim MS, 2008, BRIT J CANCER, V98, P1533, DOI 10.1038/sj.bjc.6604212; Knowles MA, 2003, CANCER RES, V63, P7652; Kumar R, 2005, CANCER RES, V65, P2511, DOI 10.1158/0008-5472.CAN-05-0189; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Landgraf KE, 2008, BIOCHEMISTRY-US, V47, P12260, DOI 10.1021/bi801683k; Lopez-Knowles E, 2006, CANCER RES, V66, P7401, DOI 10.1158/0008-5472.CAN-06-1182; Malanga D, 2008, CELL CYCLE, V7, P665, DOI 10.4161/cc.7.5.5485; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Milburn CC, 2003, BIOCHEM J, V375, P531, DOI 10.1042/BJ20031229; PLATT FM, 2009, CLIN CAN RE IN PRESS; Pymar LS, 2008, HUM MOL GENET, V17, P2006, DOI 10.1093/hmg/ddn098; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; Tokuda E, 2007, CANCER RES, V67, P9666, DOI 10.1158/0008-5472.CAN-07-1050; Wang DS, 2000, INT J CANCER, V88, P620, DOI 10.1002/1097-0215(20001115)88:4<620::AID-IJC16>3.0.CO;2-Z	27	83	84	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2010	29	1					150	155		10.1038/onc.2009.315	http://dx.doi.org/10.1038/onc.2009.315			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540XE	19802009				2022-12-17	WOS:000273373500014
J	Wright, TM; Brannon, AR; Gordan, JD; Mikels, AJ; Mitchell, C; Chen, S; Espinosa, I; van de Rijn, M; Pruthi, R; Wallen, E; Edwards, L; Nusse, R; Rathmell, WK				Wright, T. M.; Brannon, A. R.; Gordan, J. D.; Mikels, A. J.; Mitchell, C.; Chen, S.; Espinosa, I.; van de Rijn, M.; Pruthi, R.; Wallen, E.; Edwards, L.; Nusse, R.; Rathmell, W. K.			Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; Ror2; tyrosine kinase; cancer; cell signaling	RECEPTOR TYROSINE KINASE; KIDNEY; CANCER; GENES; MOUSE; MICROENVIRONMENT; ANGIOGENESIS; EXPRESSION; FAMILY; TUBULE	Inappropriate kinase expression and subsequent promiscuous activity defines the transformation of many solid tumors including renal cell carcinoma (RCC). Thus, the expression of novel tumor-associated kinases has the potential to dramatically shape tumor cell behavior. Further, identifying tumor-associated kinases can lend insight into patterns of tumor growth and characteristics. Here, we report the identification of the RTK-like orphan receptor 2 (Ror2), a new tumor-associated kinase in RCC cell lines and primary tumors. Ror2 is an orphan receptor tyrosine kinase with physiological expression normally seen in the embryonic kidney. However, in RCC, Ror2 expression correlated with expression of genes involved at the extracellular matrix, including Twist and matrix metalloprotease-2 (MMP2). Expression of MMP2 in RCC cells was suppressed by Ror2 knockdown, placing Ror2 as a mediator of MMP2 regulation in RCC and a potential regulator of extracellular matrix remodeling. The suppression of Ror2 not only inhibited cell migration, but also inhibited anchorage-independent growth in soft agar and growth in an orthotopic xenograft model. These findings suggest a novel pathway of tumor-promoting activity by Ror2 within a subset of renal carcinomas, with significant implications for unraveling the tumorigenesis of RCC. Oncogene ( 2009) 28, 2513-2523; doi: 10.1038/onc.2009.116; published online 18 May 2009	[Wright, T. M.; Brannon, A. R.; Rathmell, W. K.] Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; [Wright, T. M.; Brannon, A. R.; Chen, S.; Pruthi, R.; Wallen, E.; Rathmell, W. K.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Gordan, J. D.] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Mikels, A. J.; Nusse, R.] Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; [Mikels, A. J.; Nusse, R.] Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; [Mitchell, C.; Edwards, L.] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27599 USA; [Espinosa, I.; van de Rijn, M.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Pruthi, R.; Wallen, E.] Univ N Carolina, Dept Urol, Chapel Hill, NC 27599 USA; [Rathmell, W. K.] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Pennsylvania; Pennsylvania Medicine; Stanford University; Howard Hughes Medical Institute; Stanford University; University of North Carolina; University of North Carolina Chapel Hill; Stanford University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Rathmell, WK (corresponding author), Univ N Carolina, Lineberger Canc Ctr, 450 W Dr CB 7295, Chapel Hill, NC 27599 USA.	rathmell@med.unc.edu	Edwards, Lloyd/N-2759-2019; Ariel, Pablo/AGJ-4118-2022	Edwards, Lloyd/0000-0002-7788-4575; van de Rijn, Matt/0000-0002-1909-9739	Doris Duke Charitable Fund and the V foundation (WKR); Initiative for Maximizing Student Diversity Training [NIH-R25GM055336, NCI-F31CA132543]; MSTP [T32]; UNC Tumor Procurement Facility; UNC Lineberger Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE [F31CA132543, K08CA098410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM055336] Funding Source: NIH RePORTER	Doris Duke Charitable Fund and the V foundation (WKR); Initiative for Maximizing Student Diversity Training; MSTP; UNC Tumor Procurement Facility; UNC Lineberger Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the Rathmell Lab members and the Lineberger Cancer Center community for thoughtful insights/advice. Additional thanks to the Microscopy Services Laboratory for use of their facilities, the Lineberger Animal Core Studies Facility and the Baldwin Lab for use of reagents. We also thank Dr H Shelton Earp, Dr Ian Davis and Dr Jon Serody for paper critiques. Funding for this project was provided in part by the Doris Duke Charitable Fund and the V foundation (WKR), Initiative for Maximizing Student Diversity Training Grant NIH-R25GM055336 (TMW and CM) and NCI-F31CA132543 ( TMW). Funding for JDG was provided by a MSTP grant and a T32 grant in hemostasis and thrombosis. Human tumor samples were collected by the UNC Tumor Procurement Facility, supported by the UNC Lineberger Comprehensive Cancer Center.	*AM CANC SOC INC, 2008, CANC FACTS FIG; Atkins MB, 2004, J CLIN ONCOL, V22, P909, DOI 10.1200/JCO.2004.08.185; Billiard J, 2005, MOL ENDOCRINOL, V19, P90, DOI 10.1210/me.2004-0153; Coombs GS, 2008, CURR DRUG TARGETS, V9, P513, DOI 10.2174/138945008784911796; Cowey CL, 2008, EXPERT OPIN DRUG DIS, V3, P311, DOI 10.1517/17460441.3.3.311; Davies JA, 1996, ACTA ANAT, V156, P187; de Castro-Carpeno J, 2008, CLIN TRANSL ONCOL, V10, P6, DOI 10.1007/s12094-008-0147-3; De Luca A, 2008, J CELL PHYSIOL, V214, P559, DOI 10.1002/jcp.21260; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Kurban G, 2006, CANCER RES, V66, P1313, DOI 10.1158/0008-5472.CAN-05-2560; Linehan WM, 2003, J UROLOGY, V170, P2163, DOI 10.1097/01.ju.0000096060.92397.ed; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; Matsuda T, 2001, MECH DEVELOP, V105, P153, DOI 10.1016/S0925-4773(01)00383-5; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; Oishi I, 1997, J BIOL CHEM, V272, P11916, DOI 10.1074/jbc.272.18.11916; Oldridge M, 2000, NAT GENET, V24, P275, DOI 10.1038/73495; Racusen LC, 1997, J LAB CLIN MED, V129, P318, DOI 10.1016/S0022-2143(97)90180-3; Rathmell WK, 2005, EXPERT REV ANTICANC, V5, P1031, DOI 10.1586/14737140.5.6.1031; SAXEN L, 1987, PEDIATR NEPHROL, V1, P385, DOI 10.1007/BF00849241; Schwabe GC, 2004, DEV DYNAM, V229, P400, DOI 10.1002/dvdy.10466; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Takeuchi S, 2000, GENES CELLS, V5, P71, DOI 10.1046/j.1365-2443.2000.00300.x; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van Amerongen R, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.135re9; Yoda A, 2003, J RECEPT SIG TRANSD, V23, P1, DOI 10.1081/RRS-120018757; Zhang XH, 2002, INT J UROL, V9, P509, DOI 10.1046/j.1442-2042.2002.00511.x	29	83	85	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2009	28	27					2513	2523		10.1038/onc.2009.116	http://dx.doi.org/10.1038/onc.2009.116			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468HD	19448672	Green Submitted, Green Accepted			2022-12-17	WOS:000267806800004
J	Busso, CS; Iwakuma, T; Izumi, T				Busso, C. S.; Iwakuma, T.; Izumi, T.			Ubiquitination of mammalian AP endonuclease (APE1) regulated by the p53-MDM2 signaling pathway	ONCOGENE			English	Article						APE1; p53; MDM2; DNA repair; DNA damage; ubiquitination	BASE EXCISION-REPAIR; OXIDATIVE DNA-DAMAGE; ADENOMATOUS POLYPOSIS-COLI; ABASIC SITE REPAIR; EXTRACELLULAR CALCIUM; PROTEIN APE/REF-1; CELL-DEATH; IN-VIVO; P53; MDM2	APE1/Ref-1 is an essential DNA repair/gene regulatory protein in mammals of which intracellular level significantly affects cellular sensitivity to genotoxicants. The apurinic/apyrimidinic endonuclease 1 (APE1) functions are altered by phosphorylation and acetylation. We here report that APE1 is also modified by ubiquitination. APE1 ubiquitination occurred specifically at Lys residues near the N-terminus, and was markedly enhanced by mouse double minute 2 (MDM2), the major intracellular p53 inhibitor. Moreover, DNA-damaging reagents and nutlin-3, an inhibitor of MDM2-p53 interaction, increased APE1 ubiquitination in the presence of p53. Downmodulation of MDM2 increased APE1 level, suggesting that MDM2-mediated ubiquitination can be a signal for APE1 degradation. In addition, unlike the wild-type APE1, ubiquitin-APE1 fusion proteins were predominantly present in the cytoplasm. Therefore, monoubiquitination not only is a prerequisite for degradation, but may also alter the APE1 activities in cells. These results reveal a novel regulation of APE1 through ubiquitination.	[Izumi, T.] Louisiana State Univ, Stanley S Scott Canc Ctr, Dept Otolaryngol, Hlth Sci Ctr,CSRB, New Orleans, LA 70112 USA; [Iwakuma, T.] Louisiana State Univ, Stanley S Scott Canc Ctr, Dept Genet, Hlth Sci Ctr, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Izumi, T (corresponding author), Louisiana State Univ, Stanley S Scott Canc Ctr, Dept Otolaryngol, Hlth Sci Ctr,CSRB, 533 Bolivar St, New Orleans, LA 70112 USA.	tizumi@lsuhsc.edu			NCI [CA98664]; Louisiana Cancer Research Consortium; NATIONAL CANCER INSTITUTE [R56CA098664, R01CA098664] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Louisiana Cancer Research Consortium; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank KA Kerlec, KM Lane, MWLake, MK Rogoszewicz and C Bulkin for their technical assistance, and Mr Lake for editorial help. We also thank Dr S Desai and Dr A Haas at LSUHSC, New Orleans for their critical discussion and experimental guidance. Dr Davis's excellent editorial help is much appreciated. This research was supported by NCI grant CA98664 (TI) and Louisiana Cancer Research Consortium funding.	ASOU H, 1991, BLOOD, V77, P2031; Badciong JC, 2002, J BIOL CHEM, V277, P49668, DOI 10.1074/jbc.M208593200; Balusu R, 2007, BIOCHEMISTRY-US, V46, P13961, DOI 10.1021/bi701632e; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; Bhakat KK, 2003, EMBO J, V22, P6299, DOI 10.1093/emboj/cdg595; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Cummins JM, 2004, NATURE, V428, DOI 10.1038/nature02501; Desai SD, 2006, CANCER RES, V66, P921, DOI 10.1158/0008-5472.CAN-05-1123; Di Maso V, 2007, MOL MED, V13, P89, DOI 10.2119/2006-00084.DiMaso; Fan ZS, 2003, NAT IMMUNOL, V4, P145, DOI 10.1038/ni885; Fantini D, 2008, FREE RADICAL RES, V42, P20, DOI 10.1080/10715760701765616; Fishel ML, 2007, MOL ASPECTS MED, V28, P375, DOI 10.1016/j.mam.2007.04.005; Fritz G, 1999, ONCOGENE, V18, P1033, DOI 10.1038/sj.onc.1202394; Fuchs S, 2003, J HYPERTENS, V21, P327, DOI 10.1097/00004872-200302000-00024; Fung H, 2005, MOL CELL, V17, P463, DOI 10.1016/j.molcel.2004.12.029; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Guillet M, 2002, EMBO J, V21, P2833, DOI 10.1093/emboj/21.11.2833; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Ischenko AA, 2002, NATURE, V415, P183, DOI 10.1038/415183a; Iwakuma T, 2003, MOL CANCER RES, V1, P993; Izumi T, 2005, P NATL ACAD SCI USA, V102, P5739, DOI 10.1073/pnas.0500986102; Izumi T, 2003, TOXICOLOGY, V193, P43, DOI 10.1016/S0300-483X(03)00289-0; Izumi T, 1996, BIOCHEMISTRY-US, V35, P14679, DOI 10.1021/bi961995u; Jackson EB, 2005, NUCLEIC ACIDS RES, V33, P3303, DOI 10.1093/nar/gki641; Jaiswal AS, 2008, CANCER LETT, V271, P272, DOI 10.1016/j.canlet.2008.06.024; Kakolyris S, 1997, CANCER RES, V57, P1794; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Koukourakis MI, 2001, INT J RADIAT ONCOL, V50, P27, DOI 10.1016/S0360-3016(00)01561-3; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Ludwig DL, 1998, MUTAT RES-DNA REPAIR, V409, P17, DOI 10.1016/S0921-8777(98)00039-1; Marchenko ND, 2007, EMBO J, V26, P923, DOI 10.1038/sj.emboj.7601560; MCHAFFIE GS, 1995, BONE, V17, P11, DOI 10.1016/8756-3282(95)00131-V; Meira LB, 1997, NAT GENET, V17, P145, DOI 10.1038/ng1097-145; Meira LB, 2001, CANCER RES, V61, P5552; Minsky N, 2004, MOL CELL, V16, P631, DOI 10.1016/j.molcel.2004.10.016; OKAZAKI T, 1994, J BIOL CHEM, V269, P27855; ONO Y, 1994, MUTAT RES, V315, P55, DOI 10.1016/0921-8777(94)90028-0; Robertson KA, 1997, CELL GROWTH DIFFER, V8, P443; SAPORITO SM, 1989, J BACTERIOL, V171, P2542, DOI 10.1128/jb.171.5.2542-2546.1989; Saville MK, 2004, J BIOL CHEM, V279, P42169, DOI 10.1074/jbc.M403362200; Shmueli A, 2004, MOL CELL, V13, P4, DOI 10.1016/S1097-2765(03)00529-X; Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917; Tell G, 2005, ANTIOXID REDOX SIGN, V7, P367, DOI 10.1089/ars.2005.7.367; Tell G, 2009, ANTIOXID REDOX SIGN, V11, P601, DOI 10.1089/ars.2008.2194; Uldrijan S, 2007, EMBO J, V26, P102, DOI 10.1038/sj.emboj.7601469; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; WALKER LJ, 1994, NUCLEIC ACIDS RES, V22, P4884, DOI 10.1093/nar/22.23.4884; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919; Yacoub A, 1997, CANCER RES, V57, P5457; Yang HY, 2007, ONCOGENE, V26, P7355, DOI 10.1038/sj.onc.1210540; Yang HY, 2003, MOL CELL BIOL, V23, P7096, DOI 10.1128/MCB.23.20.7096-7107.2003; Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327; Zhao JF, 2008, J BIOL CHEM, V283, P9925, DOI 10.1074/jbc.M708345200; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	57	83	88	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2009	28	13					1616	1625		10.1038/onc.2009.5	http://dx.doi.org/10.1038/onc.2009.5			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427LJ	19219073	Green Accepted			2022-12-17	WOS:000264780500006
J	Xenaki, G; Ontikatze, T; Rjaendran, R; Startford, IJ; Drive, C; Krstic-Demonacos, M; Demonacos, C				Xenaki, G.; Ontikatze, T.; Rjaendran, R.; Startford, I. J.; Drive, C.; Krstic-Demonacos, M.; Demonacos, C.			PCAF is an HIF-1 alpha cofactor that regulates p53 transcriptional activity in hypoxia	ONCOGENE			English	Article						transcription; p53; hypoxia-inducible factor; PCAF; apoptosis	HISTONE DEACETYLASE INHIBITORS; INDUCIBLE FACTOR-1 HIF-1; DNA-DAMAGE; GENE-EXPRESSION; CELLULAR-RESPONSE; INDUCED APOPTOSIS; STRUCTURAL BASIS; FACTOR 1-ALPHA; IN-VITRO; ACETYLATION	The p53 tumour suppressor is involved in several crucial cellular functions including cell-cycle arrest and apoptosis. p53 stabilization occurs under hypoxic and DNA damage conditions. However, only in the latter scenario is stabilized p53 capable of inducing the expression of its pro-apoptotic targets. Here we present evidence that under hypoxia-mimicking conditions p53 acetylation is reduced to a greater extent at K320 site targeted by P300/CBP-associated factor (PCAF) than at K382 site targeted by p300/CBP. The limited amounts of acetylated p53 at K320 are preferentially recruited to the promoter of the p21(WAF-1/CIP-1) gene, which appears to be unaffected by hypoxia, but are not recruited to the BID promoter and hence p53 is incapable of upregulating pro-apoptotic BID in hypoxic conditions. As the K320 p53 acetylation is the site predominantly affected in hypoxia, the PCAF histone acetyltransferase activity is the key regulator of the cellular fate modulated by p53 under these conditions. In addition, we provide evidence that PCAF acetylates hypoxia-inducible factor-1 alpha (HIF-1 alpha) in hypoxic conditions and that the acetylated HIF-1 alpha is recruited to a particular subset of its targets. In conclusion, PCAF regulates the balance between cell-cycle arrest and apoptosis in hypoxia by modulating the activity and protein stability of both p53 and HIF-alpha.	[Xenaki, G.; Ontikatze, T.; Rjaendran, R.; Startford, I. J.; Drive, C.; Demonacos, C.] Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PT, Lancs, England; [Drive, C.] Univ Manchester, Paterson Inst Canc Res, Manchester M13 9PT, Lancs, England; [Krstic-Demonacos, M.] Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Manchester; Paterson Institute for Cancer Research; University of Manchester; University of Manchester	Demonacos, C (corresponding author), Univ Manchester, Sch Pharm & Pharmaceut Sci, Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	cdemonacos@manchester.ac.uk	Demonacos, Constantinos/K-1277-2019	Demonacos, Constantinos/0000-0002-4515-755X; Rajendran, Ramkumar/0000-0002-3610-8430; Dive, Caroline/0000-0002-1726-8850; stratford, ian/0000-0002-5222-4765	School of Pharmacy, University of Manchester; Cancer Research UK; MRC programme [G0500366]; Wellcome Trust [069024]; Medical Research Council [G0500366] Funding Source: researchfish; MRC [G0500366] Funding Source: UKRI	School of Pharmacy, University of Manchester; Cancer Research UK(Cancer Research UK); MRC programme(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank W El-Deiry for providing the BID-p53-Luc reporter construct; I Talianidis for the Flag-PCAF and Flag-PCAF-DHAT constructs; T Halazonetis for the p53K320R expression vector; K Williams for the HIF-1 alpha-responsive reporters of VEGF-Luc, CA-IX-Luc, PGK-1-Luc and LDH-A-Luc; M Blaylock and the Paterson Institute for Cancer Research for assistance with FACS analysis. Our research was supported by the School of Pharmacy, University of Manchester (CD), Cancer Research UK (CDive), MRC programme grant (G0500366) to IJS and Wellcome Trust (069024) to MKD.	Achison M, 2003, ONCOGENE, V22, P3431, DOI 10.1038/sj.onc.1206434; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bilton R, 2006, TRENDS CELL BIOL, V16, P616, DOI 10.1016/j.tcb.2006.10.002; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Brahimi-Horn C, 2005, CELL SIGNAL, V17, P1, DOI 10.1016/j.cellsig.2004.04.010; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chao C, 2006, MOL CELL BIOL, V26, P6859, DOI 10.1128/MCB.00062-06; Chen DL, 2003, J BIOL CHEM, V278, P13595, DOI 10.1074/jbc.C200694200; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Demonacos C, 2004, NAT CELL BIOL, V6, P968, DOI 10.1038/ncb1170; Demonacos C, 2001, MOL CELL, V8, P71, DOI 10.1016/S1097-2765(01)00277-5; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erler JT, 2004, MOL CELL BIOL, V24, P2875, DOI 10.1128/MCB.24.7.2875-2889.2004; Fei PW, 2004, CANCER CELL, V6, P597, DOI 10.1016/j.ccr.2004.10.012; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Freedman SJ, 2003, NAT STRUCT BIOL, V10, P504, DOI 10.1038/nsb936; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Goda N, 2003, ANTIOXID REDOX SIGN, V5, P467, DOI 10.1089/152308603768295212; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Greijer AE, 2004, J CLIN PATHOL, V57, P1009, DOI 10.1136/jcp.2003.015032; Hammond EM, 2006, MOL CELL BIOL, V26, P3492, DOI 10.1128/MCB.26.9.3492-3504.2006; Hammond EM, 2005, BIOCHEM BIOPH RES CO, V331, P718, DOI 10.1016/j.bbrc.2005.03.154; Hansson LO, 2002, P NATL ACAD SCI USA, V99, P10305, DOI 10.1073/pnas.122347199; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Jin YT, 2002, J BIOL CHEM, V277, P30838, DOI 10.1074/jbc.M204078200; Kaelin WG, 2005, ANNU REV BIOCHEM, V74, P115, DOI 10.1146/annurev.biochem.74.082803.133142; Kasper LH, 2005, EMBO J, V24, P3846, DOI 10.1038/sj.emboj.7600846; Knights CD, 2006, J CELL BIOL, V173, P533, DOI 10.1083/jcb.200512059; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Liang DM, 2006, CELL CYCLE, V5, P2430, DOI 10.4161/cc.5.21.3409; Linares LK, 2007, NAT CELL BIOL, V9, P331, DOI 10.1038/ncb1545; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Pan Y, 2004, ONCOGENE, V23, P4975, DOI 10.1038/sj.onc.1207657; Pescador N, 2005, BIOCHEM J, V390, P189, DOI 10.1042/BJ20042121; Poux AN, 2003, BIOCHEMISTRY-US, V42, P14366, DOI 10.1021/bi035632n; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Ravi R, 2000, GENE DEV, V14, P34; Roy S, 2005, CELL DEATH DIFFER, V12, P482, DOI 10.1038/sj.cdd.4401581; Roy S, 2007, J BIOL CHEM, V282, P4765, DOI 10.1074/jbc.M609588200; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Schmid T, 2004, BIOCHEM J, V380, P289, DOI 10.1042/BJ20031299; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Tyteca S, 2006, MOL CELL, V24, P807, DOI 10.1016/j.molcel.2006.12.005; Vaupel P, 2004, ONCOLOGIST, V9, P4, DOI 10.1634/theoncologist.9-90005-4; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Vousden KH, 2005, CELL, V120, P7, DOI 10.1016/j.cell.2004.12.027; Warnecke C, 2004, FASEB J, V18, P1462, DOI 10.1096/fj.04-1640fje; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wykoff CC, 2000, CANCER RES, V60, P7075; You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353; Zhu YH, 2002, J BIOL CHEM, V277, P22909, DOI 10.1074/jbc.M200042200	59	83	87	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 2	2008	27	44					5785	5796		10.1038/onc.2008.192	http://dx.doi.org/10.1038/onc.2008.192			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	355QC	18574470	Green Accepted			2022-12-17	WOS:000259722400003
J	Wang, X; Jiang, X				Wang, X.; Jiang, X.			Post-translational regulation of PTEN	ONCOGENE			English	Review						PTEN; tumor suppressor; protein-protein interaction; post-translational modification; ubiquitination; subpopulation	TUMOR-SUPPRESSOR PTEN; LHERMITTE-DUCLOS-DISEASE; HEMATOPOIETIC STEM-CELLS; MAJOR VAULT PROTEIN; MICE LACKING PTEN; PHOSPHATASE-ACTIVITY; NUCLEAR PTEN; NEGATIVE REGULATION; CHROMOSOME-10 PTEN; PROSTATE-CANCER	PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor regulates a variety of cellular processes including cell proliferation, growth, migration and death. This master regulator itself is also under deliberative regulation. Although the evidence for PTEN regulation and its significance in normal biology and disease is overwhelming, the mechanisms and exact functional consequences of PTEN regulation are far from clear. In this review, we discuss recent advances concerning post-translational regulation of PTEN in general, and in more detail about its regulation by ubiquitination. We also discuss some unsolved questions in the field and how they might be addressed in the future. We propose that the complex regulatory mechanisms of PTEN dictate how this tumor suppressor executes its distinct biological functions.	[Wang, X.; Jiang, X.] Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center	Jiang, X (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave,Box 522, New York, NY 10065 USA.	jiangx@mskcc.org			American Cancer Society Scholar fund; Geoffrey Beene Cancer Research fund	American Cancer Society Scholar fund(American Cancer Society); Geoffrey Beene Cancer Research fund	We thank Dr Ian Ganley for critical reading and suggestions. This work was supported by an American Cancer Society Scholar fund (to XJ) and a Geoffrey Beene Cancer Research fund (to XJ).	Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Anan T, 1998, GENES CELLS, V3, P751, DOI 10.1046/j.1365-2443.1998.00227.x; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Cai ZQ, 2005, CIRC RES, V97, P1351, DOI 10.1161/01.RES.0000195656.52760.30; Chung JH, 2005, CANCER RES, V65, P4108, DOI 10.1158/0008-5472.CAN-05-0124; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dummler B, 2007, BIOCHEM SOC T, V35, P231, DOI 10.1042/BST0350231; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Georgescu MM, 2000, CANCER RES, V60, P7033; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hlobilkova A, 2000, EXP CELL RES, V256, P571, DOI 10.1006/excr.2000.4867; Iijima M, 2004, J BIOL CHEM, V279, P16606, DOI 10.1074/jbc.M312098200; Kurlawalla-Martinez C, 2005, MOL CELL BIOL, V25, P2498, DOI 10.1128/MCB.25.6.2498-2510.2005; Kwon CH, 2001, NAT GENET, V29, P404, DOI 10.1038/ng781; Kwon CH, 2006, NEURON, V50, P377, DOI 10.1016/j.neuron.2006.03.023; Kwon J, 2004, P NATL ACAD SCI USA, V101, P16419, DOI 10.1073/pnas.0407396101; Lachyankar MB, 2000, J NEUROSCI, V20, P1404; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lindsay Y, 2006, J CELL SCI, V119, P5160, DOI 10.1242/jcs.000133; Liu XM, 2007, P NATL ACAD SCI USA, V104, P2259, DOI 10.1073/pnas.0604153104; Maccario H, 2007, BIOCHEM J, V405, P439, DOI 10.1042/BJ20061837; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Minaguchi T, 2006, CANCER RES, V66, P11677, DOI 10.1158/0008-5472.CAN-06-2240; Mirmohammadsadegh A, 2006, CANCER RES, V66, P6546, DOI 10.1158/0008-5472.CAN-06-0384; Mocanu MM, 2007, BRIT J PHARMACOL, V150, P833, DOI 10.1038/sj.bjp.0707155; Odriozola L, 2007, J BIOL CHEM, V282, P23306, DOI 10.1074/jbc.M611240200; Okahara F, 2004, J BIOL CHEM, V279, P45300, DOI 10.1074/jbc.C400377200; Okumura K, 2005, P NATL ACAD SCI USA, V102, P2703, DOI 10.1073/pnas.0409370102; Okumura K, 2006, J BIOL CHEM, V281, P26562, DOI 10.1074/jbc.M605391200; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Oudit GY, 2008, CARDIOVASC RES, V78, P505, DOI 10.1093/cvr/cvn041; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; Planchon SM, 2008, J CELL SCI, V121, P249, DOI 10.1242/jcs.022459; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Reddy P, 2008, SCIENCE, V319, P611, DOI 10.1126/science.1152257; Rosivatz E, 2006, ACS CHEM BIOL, V1, P780, DOI 10.1021/cb600352f; Ross SH, 2007, CELL SIGNAL, V19, P1521, DOI 10.1016/j.cellsig.2007.01.026; Sasaoka T, 2006, PHARMACOL THERAPEUT, V112, P799, DOI 10.1016/j.pharmthera.2006.06.001; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stiles BL, 2006, MOL CELL BIOL, V26, P2772, DOI 10.1128/MCB.26.7.2772-2781.2006; Subauste MC, 2005, J BIOL CHEM, V280, P5676, DOI 10.1074/jbc.M405561200; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Takahashi Y, 2006, EMBO J, V25, P910, DOI 10.1038/sj.emboj.7600979; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Valiente M, 2005, J BIOL CHEM, V280, P28936, DOI 10.1074/jbc.M504761200; Vazquez F, 2006, P NATL ACAD SCI USA, V103, P3633, DOI 10.1073/pnas.0510570103; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Walker SM, 2004, BIOCHEM J, V379, P301, DOI 10.1042/BJ20031839; WANG X, 2008, BIOCH J; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Weng LP, 2001, HUM MOL GENET, V10, P237, DOI 10.1093/hmg/10.3.237; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Whiteman DC, 2002, INT J CANCER, V99, P63, DOI 10.1002/ijc.10294; Wiencke JK, 2007, NEURO-ONCOLOGY, V9, P271, DOI 10.1215/15228517-2007-003; Wijesekara N, 2005, MOL CELL BIOL, V25, P1135, DOI 10.1128/MCB.25.3.1135-1145.2005; Wu WD, 2003, J BIOL CHEM, V278, P28258, DOI 10.1074/jbc.M303318200; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747	73	83	86	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 15	2008	27	41					5454	5463		10.1038/onc.2008.242	http://dx.doi.org/10.1038/onc.2008.242			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KW	18794880				2022-12-17	WOS:000259280700007
J	Qi, W; Shakalya, K; Stejskal, A; Goldman, A; Beeck, S; Cooke, L; Mahadevan, D				Qi, W.; Shakalya, K.; Stejskal, A.; Goldman, A.; Beeck, S.; Cooke, L.; Mahadevan, D.			NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells	ONCOGENE			English	Article						nucleophosmin; small molecular inhibitor; NSC348884; p53; apoptosis	TUMOR-SUPPRESSOR PROTEIN; TRANSCRIPTIONAL ACTIVITY; CENTROSOME DUPLICATION; NUCLEOLAR PROTEIN-B23; DNA-DAMAGE; B23; P53; IDENTIFICATION; NUCLEAR; GROWTH	Nucleophosmin (NPM), a multifunctional nucleolar phosphoprotein is dysregulated in human malignancies leadingto anti-apoptosis and inhibition of differentiation. We evaluated the precise three-dimensional structure of NPM based on the highly conserved structure of Xenopus NO38 and its requirement to form dimers and pentamers via its N-terminal domain (residues, 1-107). We hypothesized that a small molecular inhibitor (SMI) that could disrupt the formation of dimers would inhibit aberrant NPM function(s) in cancer cells. Molecular modeling, pharmacophore design, in silico screening and interactive docking identified NSC348884 as a putative NPM SMI that disrupts a defined hydrophobic pocket required for oligomerization. NSC348884 inhibited cell proliferation at an IC50 of 1.7-4.0 mu M in distinct cancer cell lines and disrupted NPM oligomer formation by native polyacrylamide gel electrophoresis assay. Treatment of several different cancer cell types with NSC348884 upregulated p53 (increased Ser15 phosphorylation) and induced apoptosis in a dose-dependent manner that correlated with apoptotic markers: H2AX phosphorylation, poly(ADP-ribose) polymerase cleavage and Annexin V labeling. Further, NSC348884 synergized doxorubicin cytotoxicity on cancer cell viability. The data together show that NSC348884 is an SMI of NPM oligomer formation, upregulates p53, induces apoptosis and synergizes with chemotherapy. Hence, an SMI to NPM may be a useful approach to anticancer therapy.	[Qi, W.; Shakalya, K.; Stejskal, A.; Goldman, A.; Beeck, S.; Cooke, L.; Mahadevan, D.] Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona	Qi, W (corresponding author), Univ Arizona, Arizona Canc Ctr, 1515 N Campbell Ave, Tucson, AZ 85724 USA.	wenqing@email.arizona.edu; dmahadevan@azcc.arizona						Ahn JY, 2005, MOL CELL, V18, P435, DOI 10.1016/j.molcel.2005.04.010; Arkin MR, 2004, NAT REV DRUG DISCOV, V3, P301, DOI 10.1038/nrd1343; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Brady SN, 2004, MOL CELL BIOL, V24, P9327, DOI 10.1128/MCB.24.21.9327-9338.2004; Chan HJ, 2005, BIOCHEM BIOPH RES CO, V333, P396, DOI 10.1016/j.bbrc.2005.04.176; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; CHOU YH, 1995, BIOCHEM BIOPH RES CO, V217, P313, DOI 10.1006/bbrc.1995.2779; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FEUERSTEIN N, 1988, J BIOL CHEM, V263, P10608; Gjerset RA, 2006, J MOL HISTOL, V37, P239, DOI 10.1007/s10735-006-9040-y; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Herrera JE, 1996, BIOCHEMISTRY-US, V35, P2668, DOI 10.1021/bi9523320; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Kondo T, 1997, ONCOGENE, V15, P1275, DOI 10.1038/sj.onc.1201286; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Lee C, 2005, CANCER RES, V65, P9834, DOI 10.1158/0008-5472.CAN-05-1759; Li J, 2005, LEUKEMIA RES, V29, P1415, DOI 10.1016/j.leukres.2005.05.005; Li J, 2004, J BIOL CHEM, V279, P41275, DOI 10.1074/jbc.C400297200; Li YP, 1996, EUR J BIOCHEM, V237, P153, DOI 10.1111/j.1432-1033.1996.0153n.x; Lim MJ, 2006, CANCER DETECT PREV, V30, P481, DOI 10.1016/j.cdp.2006.10.008; Liu Y, 2007, CANCER RES, V67, P2685, DOI 10.1158/0008-5472.CAN-06-3497; Maiguel DA, 2004, MOL CELL BIOL, V24, P3703, DOI 10.1128/MCB.24.9.3703-3711.2004; Namboodiri VMH, 2004, STRUCTURE, V12, P2149, DOI 10.1016/j.str.2004.09.017; Naoe T, 2006, CANCER SCI, V97, P963, DOI 10.1111/j.1349-7006.2006.00270.x; Nozawa Y, 1996, J PATHOL, V178, P48; Okuda M, 2002, ONCOGENE, V21, P6170, DOI 10.1038/sj.onc.1205708; Okuwaki M, 2001, FEBS LETT, V506, P272, DOI 10.1016/S0014-5793(01)02939-8; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Oost TK, 2004, J MED CHEM, V47, P4417, DOI 10.1021/jm040037k; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; PATTERSON SD, 1995, J BIOL CHEM, V270, P9429, DOI 10.1074/jbc.270.16.9429; Qi WQ, 2003, RADIAT RES, V160, P217, DOI 10.1667/RR3038; Shields LBE, 1997, J SOC GYNECOL INVEST, V4, P298, DOI 10.1016/S1071-5576(97)00068-3; Subong ENP, 1999, PROSTATE, V39, P298; Takemura M, 1999, J BIOCHEM-TOKYO, V125, P904, DOI 10.1093/oxfordjournals.jbchem.a022367; TANAKA M, 1992, CANCER RES, V52, P3372; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; VanBelzen N, 1995, EUR J BIOCHEM, V234, P843; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; WANG DR, 1993, CELL MOL BIOL RES, V39, P33; Wang W, 2005, NAT CELL BIOL, V7, P823, DOI 10.1038/ncb1282; Ye KQ, 2005, CANCER BIOL THER, V4, P918, DOI 10.4161/cbt.4.9.2072; Yeh CW, 2006, MOL PHARMACOL, V70, P1443, DOI 10.1124/mol.106.024810; YUNG BY, 1990, CANCER RES, V50, P5987; Zhang YP, 2004, CELL CYCLE, V3, P259	49	83	90	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2008	27	30					4210	4220		10.1038/onc.2008.54	http://dx.doi.org/10.1038/onc.2008.54			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18345031				2022-12-17	WOS:000257496800008
J	Gross, I; Duluc, I; Benameur, T; Calon, A; Martin, E; Brabletz, T; Kedinger, M; Domon-Dell, C; Freund, JN				Gross, I.; Duluc, I.; Benameur, T.; Calon, A.; Martin, E.; Brabletz, T.; Kedinger, M.; Domon-Dell, C.; Freund, J-N			The intestine-specific homeobox gene Cdx2 decreases mobility and antagonizes dissemination of colon cancer cells	ONCOGENE			English	Article						Cdx; colon cancer; metastasis; migration; wound healing	MALIGNANT-TUMOR PROGRESSION; COLORECTAL-CANCER; E-CADHERIN; CHROMOSOMAL INSTABILITY; EXPRESSION SIGNATURE; DOWN-REGULATION; MUTANT MICE; DIFFERENTIATION; CARCINOMA; PROTEIN	The gravity of colorectal cancer is mainly due to the capacity of tumor cells to migrate out of the tumor mass to invade the stroma and disseminate as metastases. The acquisition of a migratory phenotype also occurs during wound healing. Here, we show that several features characterizing invasive colon tumor cells are shared by migrating cells during wound repair in vitro. In particular, the expression of the intestine-specific transcription factor Cdx2, a key gene for intestinal identity downregulated in invasive cancer cells, is reduced during wound healing in vitro. Transcription factors involved in epithelial-mesenchymal transition such as Snail and Slug are upregulated during wound healing and are able to repress Cdx2 transcription. In vitro, forced expression of Cdx2 in human colon cancer cell lines retarded wound repair and reduced migration, whereas inhibition of Cdx2 expression by RNA interference enhanced migration. In vivo, forced expression of Cdx2 opposed tumor cells spreading in nude mice xenografted at three different sites. These data provide evidence that Cdx2 antagonizes the process of tumor cell dissemination, and they suggest that this homeobox gene might represent a new therapeutic target against metastatic spreading of colon cancer.	[Gross, I.; Duluc, I.; Benameur, T.; Calon, A.; Martin, E.; Kedinger, M.; Domon-Dell, C.; Freund, J-N] INSERM, U 682, F-67200 Strasbourg, France; [Gross, I.; Duluc, I.; Benameur, T.; Calon, A.; Martin, E.; Kedinger, M.; Domon-Dell, C.; Freund, J-N] Univ Strasbourg, Fac Med, Strasbourg, France; [Brabletz, T.] Univ Freiburg, Dept Surg, Freiburg, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Freiburg	Freund, JN (corresponding author), INSERM, U 682, 3 Ave Moliere, F-67200 Strasbourg, France.	jean-noel.freund@inserm.u-strasbg.fr	Freund, Jean-Noel/R-4383-2016; DULUC, Isabelle/AAA-7062-2022; Gross, Isabelle/P-9859-2019; Duluc, Isabelle/O-1972-2017; Gross, Isabelle/I-4972-2016; Calon, Alexandre/GPK-2061-2022; Domon-Dell, Claire/P-2368-2017; BENAMEUR, TAREK/P-9053-2019	Freund, Jean-Noel/0000-0002-0971-3774; DULUC, Isabelle/0000-0001-8396-6385; Gross, Isabelle/0000-0002-2783-8773; Duluc, Isabelle/0000-0001-8396-6385; Gross, Isabelle/0000-0002-2783-8773; DOMON-DELL, Claire/0000-0002-8445-9593				Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; Beck F, 1999, P NATL ACAD SCI USA, V96, P7318, DOI 10.1073/pnas.96.13.7318; Benahmed F, 2007, AM J PATHOL, V170, P733, DOI 10.2353/ajpath.2007.060696; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; Bonhomme C, 2003, GUT, V52, P1465, DOI 10.1136/gut.52.10.1465; Brabletz T, 2004, CANCER RES, V64, P6973, DOI 10.1158/0008-5472.CAN-04-1132; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Calon A, 2007, NUCLEIC ACIDS RES, V35, P175, DOI 10.1093/nar/gkl1034; Carrio M, 2005, CANCER RES, V65, P7177, DOI 10.1158/0008-5472.CAN-04-1717; Cavallaro U, 2004, ANN NY ACAD SCI, V1014, P58, DOI 10.1196/annals.1294.006; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; CHANTRET I, 1994, J CELL SCI, V107, P213; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Diep CB, 2006, GENE CHROMOSOME CANC, V45, P31, DOI 10.1002/gcc.20261; Domon-Dell C, 2002, FEBS LETT, V518, P83, DOI 10.1016/S0014-5793(02)02650-9; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; EE HC, 1995, AM J PATHOL, V147, P586; Franci C, 2006, ONCOGENE, V25, P5134, DOI 10.1038/sj.onc.1209519; Gauthier JL, 2003, WORLD CL PARASITES, V6, P1; Gavert N, 2005, J CELL BIOL, V168, P633, DOI 10.1083/jcb.200408051; Hamada J, 2001, INT J CANCER, V93, P516, DOI 10.1002/ijc.1357; Hansen SL, 2003, AM J PATHOL, V163, P2421, DOI 10.1016/S0002-9440(10)63597-3; Hartwell KA, 2006, P NATL ACAD SCI USA, V103, P18969, DOI 10.1073/pnas.0608636103; Hazan RB, 2004, ANN NY ACAD SCI, V1014, P155, DOI 10.1196/annals.1294.016; Hinoi T, 2003, J BIOL CHEM, V278, P44608, DOI 10.1074/jbc.M307435200; Hinoi T, 2002, GASTROENTEROLOGY, V123, P1565, DOI 10.1053/gast.2002.36598; Kaimaktchiev V, 2004, MODERN PATHOL, V17, P1392, DOI 10.1038/modpathol.3800205; Keller MS, 2004, AM J PHYSIOL-GASTR L, V287, pG104, DOI 10.1152/ajpgi.00484.2003; Lorentz O, 1999, ONCOGENE, V18, P87, DOI 10.1038/sj.onc.1202280; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mesquita P, 2003, J BIOL CHEM, V278, P51549, DOI 10.1074/jbc.M309019200; Ohta H, 2006, CLIN EXP METASTAS, V23, P381, DOI 10.1007/s10585-006-9047-5; Pandrea IV, 2000, EXP MOL PATHOL, V69, P37, DOI 10.1006/exmp.2000.2309; Pedersen TX, 2003, ONCOGENE, V22, P3964, DOI 10.1038/sj.onc.1206614; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Subtil C, 2007, CANCER LETT, V247, P197, DOI 10.1016/j.canlet.2006.04.004; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Yagi OK, 1999, BRIT J CANCER, V79, P440, DOI 10.1038/sj.bjc.6690068; Zhao YW, 2005, ONCOL REP, V13, P721	41	83	97	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2008	27	1					107	115		10.1038/sj.onc.1210601	http://dx.doi.org/10.1038/sj.onc.1210601			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17599044				2022-12-17	WOS:000252118700011
J	Ghaleb, AM; Katz, JP; Kaestner, KH; Du, JX; Yang, VW				Ghaleb, A. M.; Katz, J. P.; Kaestner, K. H.; Du, J. X.; Yang, V. W.			Kruppel-like factor 4 exhibits antiapoptotic activity following gamma-radiation-induced DNA damage	ONCOGENE			English	Article						apoptosis; cell cycle; KLF4; p53; BAX; p21(WAF1/CIP1)	P53 TUMOR-SUPPRESSOR; CELL-CYCLE ARREST; APOPTOSIS; GENE; KLF4; DIFFERENTIATION; IDENTIFICATION; PROLIFERATION; EXPRESSION; PROGRESSION	In response to gamma-radiation- induced DNA damage, organisms either activate cell cycle checkpoint and repair machinery or undergo apoptosis to eliminate damaged cells. Although previous studies indicated that the tumor suppressor p53 is critically involved in mediating both responses, how a cell decides which pathway to take is not well established. The zinc-finger-containing transcription factor, Kruppel-like factor 4 (KLF4), is a crucial mediator for the checkpoint functions of p53 after gamma-irradiation and does so by inhibiting the transition from the G1 to S and G(2) to M phases of the cell cycle. Here, we determined the role of KLF4 in modulating the apoptotic response following c-irradiation. In three independent cell systems including colorectal cancer cells and mouse embryo fibroblasts in which expression of KLF4 could be manipulated, we observed that gamma-irradiated cells underwent apoptosis if KLF4 was absent. In the presence of KLF4, the degree of apoptosis was significantly reduced and cells resorted to checkpoint arrest. The mechanism by which KLF4 accomplished this antiapoptotic effect is by activating expression of the cell cycle arrest gene, p21(WAF1/CIP1), and by inhibiting the ability of p53 to transactivate expression of the proapoptotic gene, BAX. Results of our study illustrate an unexpected antiapoptotic function of KLF4, heretofore considered a tumor suppressor in colorectal cancer, and suggest that KLF4 may be an important determinant of cell fate following gamma-radiation- induced DNA damage.	Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; Univ Penn, Sch Med, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Oncol, Atlanta, GA 30322 USA	Emory University; University of Pennsylvania; University of Pennsylvania; Emory University	Yang, VW (corresponding author), Emory Univ, Sch Med, Dept Med, Div Digest Dis, 201 Whitehead Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	vyang@emory.edu			NCI NIH HHS [R01 CA084197, R01 CA084197-09, CA84197, R01 CA084197-08, R01 CA084197-07] Funding Source: Medline; NIDDK NIH HHS [R24 DK064399, R24 DK064399-03, R01 DK052230-10, R01 DK052230-11, R24 DK064399-04, R01 DK052230-09, R24 DK064399-05, DK52230, DK64399, R01 DK052230] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R24DK064399, R01DK052230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brodsky MH, 2004, MOL CELL BIOL, V24, P1219, DOI 10.1128/MCB.24.3.1219-1231.2004; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Chan TA, 2000, GENE DEV, V14, P1584; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Foster KW, 2005, ONCOGENE, V24, P1491, DOI 10.1038/sj.onc.1208307; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Jin SK, 2000, P NATL ACAD SCI USA, V97, P7301, DOI 10.1073/pnas.97.13.7301; Katz JP, 2005, GASTROENTEROLOGY, V128, P935, DOI 10.1053/j.gastro.2005.02.022; Katz JP, 2002, DEVELOPMENT, V129, P2619; Lewanski CR, 2001, LANCET ONCOL, V2, P455; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MIYASHITA T, 1995, CELL, V80, P293; Rowland BD, 2006, NAT REV CANCER, V6, P11, DOI 10.1038/nrc1780; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wei DY, 2005, CANCER RES, V65, P2746, DOI 10.1158/0008-5472.CAN-04-3619; Yoon HS, 2005, ONCOGENE, V24, P4017, DOI 10.1038/sj.onc.1208576; Yoon HS, 2004, J BIOL CHEM, V279, P5035, DOI 10.1074/jbc.M307631200; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Yu J, 2003, CANCER BIOL THER, V2, P694; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067	42	83	92	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2365	2373		10.1038/sj.onc.1210022	http://dx.doi.org/10.1038/sj.onc.1210022			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016435	Green Accepted			2022-12-17	WOS:000245466000012
J	Chin, SF; Wang, Y; Thorne, NP; Teschendorff, AE; Pinder, SE; Vias, M; Naderi, A; Roberts, I; Barbosa-Morais, NL; Garcia, MJ; Iyer, NG; Kranjac, T; Robertson, JFR; Aparicio, S; Tavare, S; Ellis, I; Brenton, JD; Caldas, C				Chin, S-F; Wang, Y.; Thorne, N. P.; Teschendorff, A. E.; Pinder, S. E.; Vias, M.; Naderi, A.; Roberts, I.; Barbosa-Morais, N. L.; Garcia, M. J.; Iyer, N. G.; Kranjac, T.; Robertson, J. F. R.; Aparicio, S.; Tavare, S.; Ellis, I.; Brenton, J. D.; Caldas, C.			Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers	ONCOGENE			English	Article						breast cancer; array-CGH; amplification; deletion	HISTOLOGICAL GRADE; GENE; MICROARRAY; IDENTIFICATION; CARCINOMAS; PATTERNS; AMPLIFICATION; SUBGROUPS; REVEALS; CGH	We analysed 148 primary breast cancers using BAC-arrays containing 287 clones representing cancer-related gene/loci to obtain genomic molecular portraits. Gains were detected in 136 tumors (91.9%) and losses in 123 tumors (83.1%). Eight tumors (5.4%) did not have any genomic aberrations in the 281 clones analysed. Common (more than 15% of the samples) gains were observed at 8q11-qtel, 1q21-qtel, 17q11-q12 and 11q13, whereas common losses were observed at 16q12-qtel, 11ptel-p15.5, 1p36-ptel, 17p11.2-p12 and 8ptel-p22. Patients with tumors registering either less than 5% (median value) or less than 11% (third quartile) total copy number changes had a better overall survival (log-rank test: P = 0.0417 and P = 0.0375, respectively). Unsupervised hierarchical clustering based on copy number changes identified four clusters. Women with tumors from the cluster with amplification of three regions containing known breast oncogenes (11q13, 17q12 and 20q13) had a worse prognosis. The good prognosis group (Nottingham Prognostic Index (NPI) <= 3.4) tumors had frequent loss of 16q24-qtel. Genes significantly associated with estrogen receptor (ER), Grade and NPI were used to build k-nearest neighbor (KNN) classifiers that predicted ER, Grade and NPI status in the test set with an average misclassification rate of 24.7, 25.7 and 35.7%, respectively. These data raise the prospect of generating a molecular taxonomy of breast cancer based on copy number pro. ling using tumor DNA, which may be more generally applicable than expression microarray analysis.	Univ Cambridge, Hutchison MRC Res Ctr, Dept Oncol, Canc Genom Program, Cambridge CB2 2XZ, Cambs, England; Addenbrookes Hosp, Dept Histopathol, Cambridge CB2 2QQ, England; Hutchison MRC, Res Ctr, Canc Cell Unit, Cambridge, England; Inst Mol Med, Lisbon, Portugal; Univ Nottingham, Nottingham NG7 2RD, England	University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Universidade de Lisboa; University of Nottingham	Caldas, C (corresponding author), Univ Cambridge, Hutchison MRC Res Ctr, Dept Oncol, Canc Genom Program, Hill Rd, Cambridge CB2 2XZ, Cambs, England.	cc234@cam.ac.uk	Caldas, Carlos/A-7543-2008; García, María J/G-1361-2016; Wang, Yanzhong/GRY-3114-2022; Barbosa-Morais, Nuno L/I-2743-2013; Brenton, James D/B-3174-2008; Caldas, Carlos/U-7250-2019	García, María J/0000-0002-2236-9912; Barbosa-Morais, Nuno L/0000-0002-1215-0538; Brenton, James D/0000-0002-5738-6683; Caldas, Carlos/0000-0003-3547-1489; Naderi, Ali/0000-0001-7142-7616; Aparicio, Samuel/0000-0002-0487-9599; /0000-0003-4167-8910; Ellis, Ian/0000-0001-5292-8474; Wang, Yanzhong/0000-0002-0768-1676; chin, suet-feung/0000-0001-5697-1082				Al-Kuraya K, 2004, CANCER RES, V64, P8534, DOI 10.1158/0008-5472.CAN-04-1945; Bogliolo M, 2002, MUTAGENESIS, V17, P529, DOI 10.1093/mutage/17.6.529; Callagy G, 2005, J PATHOL, V205, P388, DOI 10.1002/path.1694; Chin SF, 2001, BRIT J CANCER, V84, P193, DOI 10.1054/bjoc.2000.1577; Cingoz S, 2003, CANCER GENET CYTOGEN, V145, P108, DOI 10.1016/S0165-4608(03)00094-3; Daigo Y, 2001, AM J PATHOL, V158, P1623, DOI 10.1016/S0002-9440(10)64118-1; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Forozan F, 1997, TRENDS GENET, V13, P405, DOI 10.1016/S0168-9525(97)01244-4; Fridlyand J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-96; GILCHRIST KW, 1985, BREAST CANCER RES TR, V5, P3, DOI 10.1007/BF01807642; Glinsky GV, 2004, CLIN CANCER RES, V10, P2272, DOI 10.1158/1078-0432.CCR-03-0522; Gunther K, 2001, J PATHOL, V193, P40, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH745>3.0.CO;2-N; Heidenblad M, 2005, ONCOGENE, V24, P1794, DOI 10.1038/sj.onc.1208383; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; James LA, 1997, ONCOGENE, V14, P1059, DOI 10.1038/sj.onc.1200923; Jones C, 2004, CLIN CANCER RES, V10, P5988, DOI 10.1158/1078-0432.CCR-03-0731; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Kim YH, 2006, ONCOGENE, V25, P130, DOI 10.1038/sj.onc.1208997; Korsching E, 2004, BRIT J CANCER, V90, P1422, DOI 10.1038/sj.bjc.6601658; Landi MT, 2005, J NATL CANCER I, V97, P998, DOI 10.1093/jnci/dji176; Loo LWM, 2004, CANCER RES, V64, P8541, DOI 10.1158/0008-5472.CAN-04-1992; Maass N, 2002, CANCER LETT, V185, P219, DOI 10.1016/S0304-3835(02)00286-0; McShane LM, 2002, BIOINFORMATICS, V18, P1462, DOI 10.1093/bioinformatics/18.11.1462; Naylor TL, 2005, BREAST CANCER RES, V7, pR1186, DOI 10.1186/bcr1356; Nessling M, 2005, CANCER RES, V65, P439; Nupponen NN, 2000, GENE CHROMOSOME CANC, V28, P203; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; PIPER J, 2002, P 3 EUR QUANT MOL CY, P109; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Rennstam K, 2003, CANCER RES, V63, P8861; Reyal F, 2005, CANCER RES, V65, P1376, DOI 10.1158/0008-5472.CAN-04-2706; Roylance R, 1999, CANCER RES, V59, P1433; Smyth Gordon K, 2003, Methods Mol Biol, V224, P111; Soares R, 2004, MOL ENDOCRINOL, V18, P2333, DOI 10.1210/me.2003-0362; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stange DE, 2006, CLIN CANCER RES, V12, P345, DOI 10.1158/1078-0432.CCR-05-1633; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.3.CO;2-C; Tsarouha H, 1999, CANCER GENET CYTOGEN, V113, P156, DOI 10.1016/S0165-4608(99)00016-3; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang DY, 2004, MOL ENDOCRINOL, V18, P402, DOI 10.1210/me.2003-0202; WENGER CR, 1993, BREAST CANCER RES TR, V28, P9, DOI 10.1007/BF00666351; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069	44	83	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1959	1970		10.1038/sj.onc.1209985	http://dx.doi.org/10.1038/sj.onc.1209985			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17001317				2022-12-17	WOS:000245117700014
J	Morales, A; Paris, R; Villanueva, A; Llavuna, L; Garcia-Ruiz, C; Fernandez-Checa, JC				Morales, A.; Paris, R.; Villanueva, A.; Llavuna, L.; Garcia-Ruiz, C.; Fernandez-Checa, J. C.			Pharmacological inhibition or small interfering RNA targeting acid ceramidase sensitizes hepatoma cells to chemotherapy and reduces tumor growth in vivo	ONCOGENE			English	Article						cancer therapy; ceramide; sphingosine-1-phosphate; mitochondria; apoptosis	MITOCHONDRIAL PERMEABILITY TRANSITION; DAUNORUBICIN-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; SPHINGOSINE 1-PHOSPHATE; GD3 GANGLIOSIDE; SPHINGOSINE-1-PHOSPHATE; GENERATION; KINASE; DEATH; NECROSIS	Ceramidases (CDases) play a key role in cancer therapy through enhanced conversion of ceramide into sphingosine 1-phosphate (S1P), but their involvement in hepatocarcinogenesis is unknown. Here, we report that daunorubicin (DNR) activated acid CDase post-transcriptionally in established human (HepG2 cells) or mouse (Hepa1c1c7) hepatoma cell lines as well as in primary cells from murine liver tumors, but not in cultured mouse hepatocytes. Acid CDase silencing by small interfering RNA (siRNA) or pharmacological inhibition with N-oleoylethanolamine (NOE) enhanced the ceramide to S1P balance compared to DNR alone, sensitizing hepatoma cells (HepG2, Hep-3B, SK-Hep and Hepa1c1c7) to DNR-induced cell death. DNR plus NOE or acid CDase siRNA-induced cell death was preceded by ultrastructural changes in mitochondria, stimulation of reactive oxygen species generation, release of Smac/DIABLO and cytochrome c and caspase-3 activation. In addition, in vivo siRNA treatment targeting acid CDase reduced tumor growth in liver tumor xenografts of HepG2 cells and enhanced DNR therapy. Thus, acid CDase promotes hepatocarcinogenesis and its antagonism may be a promising strategy in the treatment of liver cancer.	Hosp Clin Barcelona, Liver Unit, Inst Malalties Digest, Inst Invest Biomed August Pi & Sunyer,IDIBAPS, Barcelona 08036, Spain; IDIBELL, Inst Invest Bellvitge, Inst Catala Oncol, Lab Recerca Translac, Barcelona, Spain; CSIC, Inst Invest Biomed, Dept Expt Pathol, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB)	Fernandez-Checa, JC (corresponding author), Hosp Clin Barcelona, Liver Unit, Inst Malalties Digest, Inst Invest Biomed August Pi & Sunyer,IDIBAPS, C Villarroel 170, Barcelona 08036, Spain.	checa229@yahoo.com	Garcia-Ruiz, Carmen/L-8211-2014; Fernández-Checa, José Carlos/L-8342-2014; Morales, Albert/E-2988-2013	Garcia-Ruiz, Carmen/0000-0002-2652-6102; Fernández-Checa, José Carlos/0000-0003-3422-2990; Morales, Albert/0000-0001-8702-2269	NIAAA NIH HHS [P50 AA11999, 1R21 AA014135-01] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R21AA014135, P50AA011999] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; Block TM, 2003, ONCOGENE, V22, P5093, DOI 10.1038/sj.onc.1206557; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Burek C, 2001, ONCOGENE, V20, P6493, DOI 10.1038/sj.onc.1204841; Colell Anna, 2001, FASEB Journal, V15, P1068; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 2001, BLOOD, V98, P2828, DOI 10.1182/blood.V98.9.2828; Edsall LC, 1998, BIOCHEMISTRY-US, V37, P12892, DOI 10.1021/bi980744d; Franzen R, 2001, J BIOL CHEM, V276, P35382, DOI 10.1074/jbc.M102153200; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Garcia-Ruiz C, 2003, J CLIN INVEST, V111, P197, DOI 10.1172/JCI200316010; Garcia-Ruiz C, 2002, J BIOL CHEM, V277, P36443, DOI 10.1074/jbc.M206021200; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Gilot D, 2005, CARCINOGENESIS, V26, P2086, DOI 10.1093/carcin/bgi187; Gruber C, 2004, BIOCHEM PHARMACOL, V67, P1859, DOI 10.1016/j.bcp.2004.01.026; Hara S, 2004, CELL DEATH DIFFER, V11, P853, DOI 10.1038/sj.cdd.4401428; HASSLER DF, 1993, ADV LIPID RES, V26, P49; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; Kawaguchi K, 2005, BIOCHEM BIOPH RES CO, V329, P370, DOI 10.1016/j.bbrc.2005.01.128; Kim JS, 2003, BIOCHEM BIOPH RES CO, V304, P463, DOI 10.1016/S0006-291X(03)00618-1; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Li CM, 1999, GENOMICS, V62, P223, DOI 10.1006/geno.1999.5940; Liu YY, 2001, FASEB J, V15, P719, DOI 10.1096/fj.00-0223com; Matsko CM, 2001, BIOCHEM BIOPH RES CO, V287, P1112, DOI 10.1006/bbrc.2001.5696; Monick MM, 2004, J IMMUNOL, V173, P123, DOI 10.4049/jimmunol.173.1.123; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Paris F, 2002, NAT MED, V8, P901, DOI 10.1038/nm0902-901; Paris R, 2002, J BIOL CHEM, V277, P49870, DOI 10.1074/jbc.M208303200; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; Payne SG, 2002, FEBS LETT, V531, P54, DOI 10.1016/S0014-5793(02)03480-4; Prinetti A, 2006, BIOCHEM J, V395, P311, DOI 10.1042/BJ20051184; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Selzner M, 2001, CANCER RES, V61, P1233; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Strelow A, 2000, J EXP MED, V192, P601, DOI 10.1084/jem.192.5.601; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; Suzuki E, 2004, P NATL ACAD SCI USA, V101, P14788, DOI 10.1073/pnas.0406536101; Yatomi Y, 1996, BIOCHEMISTRY-US, V35, P626, DOI 10.1021/bi9515533	46	83	87	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					905	916		10.1038/sj.onc.1209834	http://dx.doi.org/10.1038/sj.onc.1209834			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16862171				2022-12-17	WOS:000244063800011
J	Alchanati, I; Nallar, SC; Sun, P; Gao, L; Hu, J; Stein, A; Yakirevich, E; Konforty, D; Alroy, I; Zhao, X; Reddy, SP; Resnick, MB; Kalvakolanu, DV				Alchanati, I.; Nallar, S. C.; Sun, P.; Gao, L.; Hu, J.; Stein, A.; Yakirevich, E.; Konforty, D.; Alroy, I.; Zhao, X.; Reddy, S. P.; Resnick, M. B.; Kalvakolanu, D. V.			A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas	ONCOGENE			English	Article						cell growth; cancer; cytokines; tumor suppression; transcription	ACID-ACTIVATED REGULATOR; TUMOR-SUPPRESSOR GENE; RETINOIC ACID; IN-VIVO; C-MET; GROWTH-SUPPRESSION; SIGNAL TRANSDUCER; CANCER-CELLS; COMPLEX-I; IFN-BETA	Gene associated with retinoid interferon-induced mortality (GRIM)-19, an inhibitor of transcription factor STAT3, was originally identified as a critical regulatory protein in a genetic screen that was designed to identify the gene products necessary for Interferon (IFN)-beta-and retinoic acid-induced cell death. Over expression of GRIM-19 activates cell death. Conversely, inactivation of its expression promotes cell growth. STAT3 is a transcription factor that regulates gene expression in response to multiple extra cellular growth factors. In contrast to its normal feedback inhibition, a constitutive activation of STAT3 has been documented in several tumors. Although many STAT3-inhibitors are described, their relevance to human cancer is unclear. In an attempt to de. ne the molecular alterations associated with human renal cell carcinoma (RCC) using mass spectrometry, we have discovered that expression of GRIM-19 is lost or severely depressed in a number of primary RCC and in some urinogenital tumors. Using an RCC cell line, we show that down regulation of GRIM-19 promotes tumor growth via an augmentation of STAT3-dependent gene expression. These studies for the. rst time show a tumor-suppressor like activity of GRIM-19.	Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Proteol Ltd, Rehovot, Israel; Jilin Univ, Sch Basic Med, Dept Pathophysiol, Changchun 130023, Peoples R China; Carmel Hosp, Dept Urol, Haifa, Israel; Rhode Isl Hosp, Dept Pathol, Providence, RI 02902 USA; Brown Univ, Sch Med, Providence, RI 02912 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA	University System of Maryland; University of Maryland Baltimore; Jilin University; Clalit Health Services; Carmel Medical Center; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Kalvakolanu, DV (corresponding author), Univ Maryland, Sch Med, Greenebaum Canc Ctr, 660 W Redwood St,Howard Hall Room 324, Baltimore, MD 21201 USA.	dkalvako@umaryland.edu	Resnick, Murray/U-2986-2019		NATIONAL CANCER INSTITUTE [R01CA105005] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R56ES011863, R01ES011863] Funding Source: NIH RePORTER; NCI NIH HHS [CA105005, CA78286] Funding Source: Medline; NHLBI NIH HHS [HL66109] Funding Source: Medline; NIEHS NIH HHS [ES11863] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Angell JE, 2000, J BIOL CHEM, V275, P33416, DOI 10.1074/jbc.M003929200; BAGGETTO LG, 1992, BIOCHIMIE, V74, P959, DOI 10.1016/0300-9084(92)90016-8; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; Chidambaram NV, 2000, J INTERF CYTOK RES, V20, P661, DOI 10.1089/107999000414844; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; Fearnley IM, 2001, J BIOL CHEM, V276, P38345, DOI 10.1074/jbc.C100444200; Fischer J, 1998, ONCOGENE, V17, P733, DOI 10.1038/sj.onc.1201983; Gao AC, 1999, PROSTATE, V38, P46, DOI 10.1002/(SICI)1097-0045(19990101)38:1<46::AID-PROS6>3.0.CO;2-9; Gao LF, 2005, CLIN CANCER RES, V11, P6333, DOI 10.1158/1078-0432.CCR-05-0148; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gresser I, 2002, CYTOKINE GROWTH F R, V13, P111, DOI 10.1016/S1359-6101(01)00035-1; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hu JD, 2002, J INTERF CYTOK RES, V22, P1017, DOI 10.1089/107999002760624242; Huang GC, 2004, MOL CELL BIOL, V24, P8447, DOI 10.1128/MCB.24.19.8447-8456.2004; Ikeda H, 2002, CYTOKINE GROWTH F R, V13, P95, DOI 10.1016/S1359-6101(01)00038-7; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Kalvakolanu DV, 2004, CYTOKINE GROWTH F R, V15, P169, DOI 10.1016/j.cytogfr.2004.01.002; Kalvakolanu DV, 2001, MOL BASIS CANC, P503; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; Klosek SK, 2004, ONCOL REP, V12, P293; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lindner DJ, 2002, CLIN CANCER RES, V8, P3210; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Lubensky IA, 1999, AM J PATHOL, V155, P517, DOI 10.1016/S0002-9440(10)65147-4; Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135; Maximo V, 2005, BRIT J CANCER, V92, P1892, DOI 10.1038/sj.bjc.6602547; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MOORE DM, 1994, SEMIN HEMATOL, V31, P31; Morris MR, 2004, J CLIN PATHOL, V57, P706, DOI 10.1136/jcp.2003.011767; Pingoud-Meier C, 2003, CLIN CANCER RES, V9, P6401; Pollard PJ, 2003, ANN MED, V35, P632, DOI 10.1080/07853890310018458; Pollard PJ, 2005, HUM MOL GENET, V14, P2231, DOI 10.1093/hmg/ddi227; Radaeva S, 2002, GASTROENTEROLOGY, V122, P1020, DOI 10.1053/gast.2002.32388; Schmidt PR, 1997, J ANTHROPOL ARCHAEOL, V16, P73, DOI 10.1006/jaar.1997.0305; Seo T, 2002, J VIROL, V76, P8797, DOI 10.1128/JVI.76.17.8797-8807.2002; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Simpson RJ, 2003, PROTEINS PROTEOMICS; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; Thacher SM, 2000, CURR PHARM DESIGN, V6, P25, DOI 10.2174/1381612003401415; Trovato M, 2004, EUR J HISTOCHEM, V48, P291; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Xu Q, 2005, ONCOGENE, V24, P5552, DOI 10.1038/sj.onc.1208719; Yang J, 2005, CANCER RES, V65, P939; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zhang J, 2003, P NATL ACAD SCI USA, V100, P9342, DOI 10.1073/pnas.1633516100; Zhang XW, 2004, CANCER RES, V64, P2474, DOI 10.1158/0008-5472.CAN-03-3443; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727	62	83	97	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	54					7138	7147		10.1038/sj.onc.1209708	http://dx.doi.org/10.1038/sj.onc.1209708			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16732315				2022-12-17	WOS:000242046900003
J	Yang, Y; Pan, X; Lei, W; Wang, J; Song, J				Yang, Y.; Pan, X.; Lei, W.; Wang, J.; Song, J.			Transforming growth factor-beta 1 induces epithelial-to-mesenchymal transition and apoptosis via a cell cycle-dependent mechanism	ONCOGENE			English	Article						PKD; EMT; cell cycle; TGF-beta; apoptosis; signaling	PROTEIN-KINASE-D; GROWTH-FACTOR-BETA; CONFERS RESISTANCE; TRANSDIFFERENTIATION; ACTIVATION; PLASTICITY; MIGRATION; P38; HEPATOCYTES; PROGRESSION	Apoptosis and epithelial-to-mesenchymal transition (EMT) have been implicated in a variety of biological processes, such as embryonic development, fibrosis and tumor progression. Transforming growth factor-beta (TGF-beta) can induce simultaneously both EMT and apoptotic response of epithelial cells. However, the underlying mechanism of these biological events remains not well understood. In the present study, we show that TGF-beta 1 induces apoptosis and EMT in AML-12 cells in a cell cycle-related manner, in which apoptosis and EMT took place at G2/M and G1/S phases, respectively. TGF-beta 1-induced apoptosis was correlated with different extent of caspase activation at different cell cycle phases. Interestingly, increased phosphorylation of protein kinase D (PKD) can be observed in G1/S phase in response to TGF-beta 1, and inhibition of PKD by inhibitor or by small interference RNA blocked EMT but not apoptosis. Our data suggest a previously unrecognized role of cell cycle state in the regulation of TGF-beta-induced EMT and apoptosis, and demonstrate that PKD is involved in the TGF-beta 1-induced EMT.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Song, J (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	jgsong@sibs.ac.cn	Lei, Weiwei/H-4997-2012; Yang, Yanan/F-1592-2010					Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bakin AV, 2002, J CELL SCI, V115, P3193; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bollag WB, 2004, DRUG NEWS PERSPECT, V17, P117, DOI 10.1358/dnp.2004.17.2.829045; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kennett SB, 2004, J BIOL CHEM, V279, P3300, DOI 10.1074/jbc.M305734200; Lemonnier J, 2004, J BIOL CHEM, V279, P259, DOI 10.1074/jbc.M308665200; Liao JH, 2001, CELL RES, V11, P89, DOI 10.1038/sj.cr.7290072; Lu X, 2004, NEOPLASIA, V6, P603, DOI 10.1593/neo.04241; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Piek E, 1999, J CELL SCI, V112, P4557; Prigozhina NL, 2004, CURR BIOL, V14, P88, DOI 10.1016/j.cub.2004.01.003; Prindull G, 2004, BLOOD, V103, P2892, DOI 10.1182/blood-2003-08-2807; Prunier C, 2005, J BIOL CHEM, V280, P17540, DOI 10.1074/jbc.M500974200; Qiang YW, 2004, BLOOD, V103, P301, DOI 10.1182/blood-2003-06-2066; Schuster N, 2002, CELL TISSUE RES, V307, P1, DOI 10.1007/s00441-001-0479-6; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Twomey C, 2005, J CELL MOL MED, V9, P345, DOI 10.1111/j.1582-4934.2005.tb00360.x; Valdes F, 2002, MOL CANCER RES, V1, P68; Van Lint J, 2002, INT J BIOCHEM CELL B, V34, P577, DOI 10.1016/S1357-2725(01)00163-7; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Woods AJ, 2004, EMBO J, V23, P2531, DOI 10.1038/sj.emboj.7600267; Yang Y, 2004, INT J BIOCHEM CELL B, V36, P223, DOI 10.1016/S1357-2725(03)00215-2; Zhao S, 2004, J CELL PHYSIOL, V199, P47, DOI 10.1002/jcp.10453	32	83	87	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	55					7235	7244		10.1038/sj.onc.1209712	http://dx.doi.org/10.1038/sj.onc.1209712			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16799646				2022-12-17	WOS:000242244700002
J	Ito, K; Oji, Y; Tatsumi, N; Shimizu, S; Kanai, Y; Nakazawa, T; Asada, M; Jomgeow, T; Aoyagi, S; Nakano, Y; Tamaki, H; Sakaguchi, N; T Shirakata,; Nishida, S; Kawakami, M; Tsuboi, A; Oka, Y; Tsujimoto, Y; Sugiyama, H				Ito, K.; Oji, Y.; Tatsumi, N.; Shimizu, S.; Kanai, Y.; Nakazawa, T.; Asada, M.; Jomgeow, T.; Aoyagi, S.; Nakano, Y.; Tamaki, H.; Sakaguchi, N.; T Shirakata; Nishida, S.; Kawakami, M.; Tsuboi, A.; Oka, Y.; Tsujimoto, Y.; Sugiyama, H.			Antiapoptotic function of 17AA(+) WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway	ONCOGENE			English	Article						Wilms' tumor gene; WT1; anti-apoptosis; 17AA(+) WT1 isoform	PROMOTER ACTIVITY; EXPRESSION; SUPPRESSOR; OVEREXPRESSION; DIFFERENTIATION; PROLIFERATION; INVOLVEMENT; INHIBITION; REPRESSION; PRODUCT	The WT1 gene is overexpressed in human primary leukemia and a wide variety of solid cancers. The WT1 gene is alternatively spliced at two sites, yielding four isoforms: 17AA(+) KTS(+), 17AA(+) KTS(-), 17AA(-) KTS(+), and 17AA(-) KTS(-). Here, we showed that 17AA(+) WT1-specific siRNA induced apoptosis in three WT1-expressing leukemia cell lines (K562, HL-60, and Kasumi-1), but not in WT1-nonexpressing lymphoma cell line (Daudi). 17AA(+) WT1-specific siRNA activated caspase- 3 and - 9 in the intrinsic apoptosis pathway but not caspase- 8 in the extrinsic one. On the other hand, 17AA(-) WT1-specific siRNA did not induce apoptosis in the three WT1-expressing cell lines. The apoptosis was associated with activation of proapoptotic Bax, which was activated upstream of the mitochondria. Constitutive expression of 17AA(+) WT1 isoforms inhibited apoptosis of K562 leukemia cells induced by apoptosis-inducing agents, etoposide and doxorubicin, through the protection of mitochondrial membrane damages, and DNA-binding zinc-finger region of 17AA(+) WT1 isoform was essential for the antiapoptotic functions. We further studied the gene(s) whose expression was altered by the expression of 17AA(+) WT1 isoforms and showed that the expression of proapoptotic Bak was decreased by the expression of 17AA(+) KTS(-) WT1 isoform. Taken together, these results indicated that 17AA(+) WT1 isoforms played antiapoptotic roles at some points upstream of the mitochondria in the intrinsic apoptosis pathway.	Osaka Univ, Dept Funct Diagnost Sci, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Biomed Informat, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Med Genet, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Mol Med, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Canc Immunotherapy, Grad Sch Med, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University; Osaka University; Osaka University	Sugiyama, H (corresponding author), Osaka Univ, Dept Funct Diagnost Sci, Grad Sch Med, 1-7 Yamada Oka, Suita, Osaka 5650871, Japan.	sugiyama@sahs.med.osaka-u.ac.jp	Nakazawa, Tsutomu/ABF-2907-2020	Nakazawa, Tsutomu/0000-0003-4286-9356				Algar EM, 1996, ONCOGENE, V12, P1005; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Davies JA, 2004, HUM MOL GENET, V13, P235, DOI 10.1093/hmg/ddh015; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; Englert C, 1997, CANCER RES, V57, P1429; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GOODYER P, 1995, ONCOGENE, V10, P1125; Harada Y, 1999, MOL UROL, V3, P357; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; Herzer U, 1999, CURR BIOL, V9, P837, DOI 10.1016/S0960-9822(99)80369-8; Hubinger G, 2001, EXP HEMATOL, V29, P1226, DOI 10.1016/S0301-472X(01)00719-6; Inoue K, 1998, BLOOD, V91, P2969, DOI 10.1182/blood.V91.8.2969.2969_2969_2976; INOUE K, 1994, BLOOD, V84, P3071, DOI 10.1182/blood.V84.9.3071.3071; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Li H, 2003, INT J HEMATOL, V77, P463, DOI 10.1007/BF02986614; Loeb DM, 2001, CANCER RES, V61, P921; Loeb DM, 2003, LEUKEMIA, V17, P965, DOI 10.1038/sj.leu.2402906; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Miyoshi Y, 2002, CLIN CANCER RES, V8, P1167; Niksic M, 2004, HUM MOL GENET, V13, P463, DOI 10.1093/hmg/ddh040; Oji Y, 1999, JPN J CANCER RES, V90, P194, DOI 10.1111/j.1349-7006.1999.tb00733.x; Oji Y, 2002, INT J CANCER, V100, P297, DOI 10.1002/ijc.10476; Oji Y, 2004, CANCER SCI, V95, P822, DOI 10.1111/j.1349-7006.2004.tb02188.x; Oji Y, 2004, ANTICANCER RES, V24, P3103; Oji Y, 2004, CANCER SCI, V95, P583, DOI 10.1111/j.1349-7006.2004.tb02490.x; Oji Y, 2003, CANCER SCI, V94, P712, DOI 10.1111/j.1349-7006.2003.tb01507.x; Oji Y, 2003, CANCER SCI, V94, P606, DOI 10.1111/j.1349-7006.2003.tb01490.x; Oji Y, 2003, CANCER SCI, V94, P523, DOI 10.1111/j.1349-7006.2003.tb01477.x; Osaka M, 1997, INT J CANCER, V72, P696, DOI 10.1002/(SICI)1097-0215(19970807)72:4<696::AID-IJC23>3.0.CO;2-8; Reynolds PA, 2003, GENE DEV, V17, P2094, DOI 10.1101/gad.1110703; Shimizu S, 1996, ONCOGENE, V12, P2251; Siehl JM, 2004, ANN HEMATOL, V83, P745, DOI 10.1007/s00277-004-0941-0; Sugiyama H, 2001, INT J HEMATOL, V73, P177, DOI 10.1007/BF02981935; Tsuboi A, 1999, LEUKEMIA RES, V23, P499, DOI 10.1016/S0145-2126(99)00037-5; Tuna M, 2005, ONCOGENE, V24, P1648, DOI 10.1038/sj.onc.1208345; Ueda T, 2003, CANCER SCI, V94, P271, DOI 10.1111/j.1349-7006.2003.tb01432.x; Wagner KD, 2002, EMBO J, V21, P1398, DOI 10.1093/emboj/21.6.1398; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; Yamagami T, 1998, LEUKEMIA RES, V22, P383, DOI 10.1016/S0145-2126(97)00176-8; Yamagami T, 1996, BLOOD, V87, P2878, DOI 10.1182/blood.V87.7.2878.bloodjournal8772878	42	83	89	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	30					4217	4229		10.1038/sj.onc.1209455	http://dx.doi.org/10.1038/sj.onc.1209455			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16518414				2022-12-17	WOS:000239004800009
J	Gonzalez-Polo, RA; Carvalho, G; Braun, T; Decaudin, D; Fabre, C; Larochette, N; Perfettini, JL; Djavaheri-Mergny, M; Youlyouz-Marfak, I; Codogno, P; Raphael, M; Feuillard, J; Kroemer, G				Gonzalez-Polo, RA; Carvalho, G; Braun, T; Decaudin, D; Fabre, C; Larochette, N; Perfettini, JL; Djavaheri-Mergny, M; Youlyouz-Marfak, I; Codogno, P; Raphael, M; Feuillard, J; Kroemer, G			PK11195 potently sensitizes to apoptosis induction independently from the peripheral benzodiazepin receptor	ONCOGENE			English	Article						autophagy; caspase; Bcl-2; NF-kappaB	DEPENDENT ANION CHANNEL; CELL-CYCLE ARREST; MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; CANCER-CELLS; LEUKEMIA-CELLS; LIGAND; BCL-2; RESISTANCE; LONIDAMINE; INHIBITOR	1-(2-Chlorophenyl-N-methylpropyl)-3-isoquinolinecarboxamide (PK11195) is a prototypic ligand of the peripheral benzodiazepine receptor (PBR), a mitochondrial outer membrane protein. PK11195 can be used to chemosensitize tumor cells to a variety of chemotherapeutic agents, both in vitro and in vivo. PK11195 has been suggested to exert this effect via inhibition of the multiple drug resistance (MDR) pump and by direct mitochondrial effects which could be mediated by the PBR. Here, we established a model system in which PK11195 and another PBR ligand, 7-chloro-5-(4-chlorophenyl)- 1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2- one (Ro5-4864), sensitize to nutrient depletion-induced cell death. In this MDR-independent model, PK11195 and Ro5-4864 are fully active even when the PBR is knocked down by small interfering RNA. Cells that lack PBR possess low-affinity binding sites for PK11195 and Ro5-4864. The starvation-sensitizing effects of PK11195 are not due to a modulation of the adaptive response of starved cells, namely autophagy and NF-kappa B activation. Rather, it appears that the combination of PK11195 with autophagy or NF-kappa B inhibitors has a potent synergistic death-inducing effect. Starved cells treated with PK11195 exhibit characteristics of apoptosis, including loss of the mitochondrial transmembrane potential, mitochondrial cytochrome c release, caspase activation and chromatin condensation. Accordingly, stabilization of mitochondria by overexpression of Bcl-2 or expression of the viral mitochondrial inhibitor (vMIA) from cytomegalovirus inhibits cell death induced by PK11195 plus starvation. Thus, PK11195 potently sensitizes to apoptosis via a pathway that involves mitochondria, yet does not involve the PBR.	Inst Gustave Roussy, CNRS, UMR 8125, F-94805 Villejuif, France; Inst Curie, Dept Hematol, F-75005 Paris, France; Inst Andre Lwoff, INSERM, U504, F-94807 Villejuif, France; CNRS, UMR 6101, Limoges, France; Fac Med, Hematol Lab, Limoges, France; CHU Dupuytren, Limoges, France; CHU Kremlin Bicetre, U473, Serv Hematol Biol, Le Kremlin Bicetre, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CHU Limoges; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Codogno, Patrice/G-1384-2013; González-Polo, Rosa A./I-6076-2016; Djavaheri-Mergny, Mojgan/N-6315-2017; KROEMER, Guido/B-4263-2013; Braun, Thorsten/GRJ-8918-2022; LAROCHETTE, Nathanael/R-4298-2017; Djavaheri-Mergny, Mojgan/L-3890-2019; PERFETTINI, Jean-Luc/N-4699-2017; Kroemer, Guido/AAY-9859-2020; Feuillard, Jean/O-8587-2016	Codogno, Patrice/0000-0002-5492-3180; González-Polo, Rosa A./0000-0002-0163-2953; Djavaheri-Mergny, Mojgan/0000-0003-4893-6505; KROEMER, Guido/0000-0002-9334-4405; LAROCHETTE, Nathanael/0000-0002-7936-678X; Djavaheri-Mergny, Mojgan/0000-0003-4893-6505; PERFETTINI, Jean-Luc/0000-0002-2427-2604; Youlyouz-Marfak, Ibtissam/0000-0002-9853-1592; Feuillard, Jean/0000-0001-6223-2454				ANSSEAU M, 1991, PHARMACOPSYCHIATRY, V24, P8, DOI 10.1055/s-2007-1014425; Banker DE, 2002, LEUKEMIA RES, V26, P91, DOI 10.1016/S0145-2126(01)00112-6; Baran-Marszak F, 2004, BLOOD, V104, P2475, DOI 10.1182/blood-2003-10-3508; BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; Belzacq AS, 2003, CANCER RES, V63, P541; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Boitano A, 2003, CANCER RES, V63, P6870; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Boya P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622; Carayon P, 1996, BLOOD, V87, P3170, DOI 10.1182/blood.V87.8.3170.bloodjournal8783170; Casellas P, 2002, NEUROCHEM INT, V40, P475, DOI 10.1016/S0197-0186(01)00118-8; Castedo M, 2002, J EXP MED, V196, P1121, DOI 10.1084/jem.20021758; Chauhan D, 2004, BLOOD, V104, P2458, DOI 10.1182/blood-2004-02-0547; Chen J, 2002, MOL CANCER THER, V1, P981; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Decaudin D, 2004, ANTI-CANCER DRUG, V15, P737, DOI 10.1097/00001813-200409000-00001; Decaudin D, 2002, CANCER RES, V62, P1388; Fennell DA, 2001, BRIT J CANCER, V84, P1397, DOI 10.1054/bjoc.2001.1788; FERRY A, 1989, FUNDAM CLIN PHARM, V3, P383, DOI 10.1111/j.1472-8206.1989.tb00679.x; Feuillard J, 2000, BLOOD, V95, P2068, DOI 10.1182/blood.V95.6.2068.2068; Galiegue S, 2004, CLIN CANCER RES, V10, P2058, DOI 10.1158/1078-0432.CCR-03-0988; Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Harborth J, 2001, J CELL SCI, V114, P4557; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; Jakubikova J, 2002, NEOPLASMA, V49, P231; Jorda EG, 2005, APOPTOSIS, V10, P91, DOI 10.1007/s10495-005-6064-9; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Lebedeva IV, 2003, CANCER RES, V63, P8138; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Maaser K, 2005, CLIN CANCER RES, V11, P1751, DOI 10.1158/1078-0432.CCR-04-1955; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; Miccoli L, 1998, J NATL CANCER I, V90, P1400, DOI 10.1093/jnci/90.18.1400; Miccoli L, 1998, CANCER RES, V58, P5777; Muscarella DE, 2003, TOXICOL SCI, V74, P66, DOI 10.1093/toxsci/kfg052; Okaro AC, 2002, GUT, V51, P556, DOI 10.1136/gut.51.4.556; Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200; Poncet D, 2004, J BIOL CHEM, V279, P22605, DOI 10.1074/jbc.M308408200; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Rochard P, 2004, GENE EXPRESSION, V12, P13, DOI 10.3727/000000004783992170; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; SNYDER SH, 1990, NEUROCHEM RES, V15, P119, DOI 10.1007/BF00972201; Sutter AP, 2004, J HEPATOL, V41, P799, DOI 10.1016/j.jhep.2004.07.015; Sutter AP, 2003, BRIT J CANCER, V89, P564, DOI 10.1038/sj.bjc.6601125; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Walter RB, 2004, BLOOD, V103, P4276, DOI 10.1182/blood-2003-11-3825; Weisinger G, 2004, BIOCHEMISTRY-US, V43, P12315, DOI 10.1021/bi030251v	50	83	87	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7503	7513		10.1038/sj.onc.1208907	http://dx.doi.org/10.1038/sj.onc.1208907			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16091749				2022-12-17	WOS:000233333800001
J	Vandermoere, F; El Yazidi-Belkoura, I; Adriaenssens, E; Lemoine, J; Hondermarck, H				Vandermoere, F; El Yazidi-Belkoura, I; Adriaenssens, E; Lemoine, J; Hondermarck, H			The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-kappa B activation induced via interaction between Akt and I kappa B kinase-beta in breast cancer cells	ONCOGENE			English	Article						breast cancer; fibroblast growth factor; apoptosis; proteomics; signaling	INSULIN-RECEPTOR SUBSTRATE-1; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAY; DEPENDENT PATHWAY; SURVIVAL; TARGET; PROLIFERATION; PROGRESSION; METASTASIS; MODULATION	Fibroblast growth factor-2 (FGF-2) is known for its mitogenic and motogenic effects on breast cancer cells. Here, we demonstrate that FGF-2 is also a potent stimulator of breast cancer cell survival, as it counteracts the apoptotic activity of the C2 ceramide analogue and various chemotherapeutic agents (5-fluorouracil, camptothecin, etoposide) in MCF-7, T47-D and BT-20 cells. The use of pharmacological inhibitors (PD98059, wortmannin, LY294002, SN50) and transfection with negative dominants (I kappa Bm, p110(PI3K (phosphoinositide 3-kinase))*Delta K, AktND) or small interfering RNA targeted against Akt indicated that PI3K/Akt and nuclear factor-kappa B (NF-kappa B), but not p42/p44 MAP-kinases, were required to stimulate FGF-2 antiapoptotic activity. The activation of NF-kappa B was dependent on PI3K/Akt, and using a combination of approaches based on immunoprecipitation, Western blotting and proteomics (two-dimensional electrophoresis and mass spectrometry), we identified the beta form of I kappa B kinase (IKK beta) as a target of Akt signaling. The selective disruption of IKK beta using small interfering RNA induced a potent inhibition of Akt-mediated activation of NF-kappa B and cell survival, indicating the functional involvement of IKK beta in FGF-2 antiapoptotic signaling. Together, these results demonstrate Akt/IKK beta interaction in NF-kappa B pathways, thereby emphasizing the potential of these proteins as therapeutic targets in breast cancer.	INSERM, ERI8, UPRESEA 1033, F-59655 Villeneuve Dascq, France; Univ Sci & Tech Lille Flandres Artois, IFR118, CNRS, UMR 8576, Villeneuve Dascq, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille	Hondermarck, H (corresponding author), INSERM, ERI8, UPRESEA 1033, Batiment SN3, F-59655 Villeneuve Dascq, France.	hubert.hondermarck@univ-lille1.fr	lemoine, jerome/C-4272-2014; El Yazidi-Belkoura, Ikram/AAE-8805-2022	lemoine, jerome/0000-0002-5497-6880; EL YAZIDI-BELKOURA, IKRAM/0000-0002-5323-7509; VANDERMOERE, Franck/0000-0001-5724-7037				Ajenjo N, 2000, J BIOL CHEM, V275, P7189, DOI 10.1074/jbc.275.10.7189; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Bange J, 2001, NAT MED, V7, P548, DOI 10.1038/87872; Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; Bhakar AL, 1999, J BIOL CHEM, V274, P21443, DOI 10.1074/jbc.274.30.21443; Carlson CJ, 2004, BIOCHEM BIOPH RES CO, V316, P533, DOI 10.1016/j.bbrc.2004.02.082; Creedon DJ, 1996, J BIOL CHEM, V271, P20713, DOI 10.1074/jbc.271.34.20713; Descamps S, 2001, J BIOL CHEM, V276, P17864, DOI 10.1074/jbc.M010499200; Dickson C, 2000, BREAST CANCER RES, V2, P191, DOI 10.1186/bcr53; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Fenig E, 1997, CLIN CANCER RES, V3, P135; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gibbs JB, 2000, J CLIN INVEST, V105, P9, DOI 10.1172/JCI9084; Greene MW, 2003, J BIOL CHEM, V278, P8199, DOI 10.1074/jbc.M209153200; Hondermarck H, 2003, MOL CELL PROTEOMICS, V2, P281, DOI 10.1074/mcp.R300003-MCP200; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KUREBAYASHI J, 1993, CANCER RES, V53, P2178; Lawlor MA, 2001, J CELL SCI, V114, P2903; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Manetti F, 2003, CURR PHARM DESIGN, V9, P567, DOI 10.2174/1381612033391487; MCLESKEY SW, 1993, CANCER RES, V53, P2168; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Murphy PR, 2001, ENDOCRINOLOGY, V142, P81, DOI 10.1210/en.142.1.81; Nurcombe V, 2000, J BIOL CHEM, V275, P30009, DOI 10.1074/jbc.M003038200; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Ornitz DM, 2001, GENOME BIOL, V2; Ozes ON, 1999, NATURE, V401, P82; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Polnaszek N, 2003, CANCER RES, V63, P5754; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; TAKEI Y, 1994, CLIN CHEM, V40, P1980; Vercoutter-Edouart AS, 2001, CANCER RES, V61, P76; Vercoutter-Edouart AS, 2000, FEBS LETT, V478, P209, DOI 10.1016/S0014-5793(00)01855-X; Villafuerte BC, 2004, J BIOL CHEM, V279, P36650, DOI 10.1074/jbc.M404349200; Zhang LR, 1999, CANCER RES, V59, P5023	41	83	92	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 18	2005	24	35					5482	5491		10.1038/sj.onc.1208713	http://dx.doi.org/10.1038/sj.onc.1208713			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	955JN	15856005				2022-12-17	WOS:000231222300008
J	Saalbach, A; Wetzel, A; Haustein, UF; Sticherling, M; Simon, JC; Anderegg, U				Saalbach, A; Wetzel, A; Haustein, UF; Sticherling, M; Simon, JC; Anderegg, U			Interaction of human Thy-1 (CD 90) with the integrin alpha v beta 3 (CD51/CD61): an important mechanism mediating melanoma cell adhesion to activated endothelium	ONCOGENE			English	Article						Thy-1; alpha v beta 3; endothelial cell; adhesion; melanoma	IN-VITRO; MATRIX METALLOPROTEINASE-1; INTEGRIN ALPHA(V)BETA(3); ALPHA-V-BETA-3 INTEGRIN; MALIGNANT-MELANOMA; MOLECULE L1; FIBROBLASTS; EXPRESSION; METASTASIS; LYMPHOCYTES	The expression of the alpha v beta 3 integrin (CD51/CD61) on human melanoma cells has been shown to be associated most closely with tumor progression and metastases formation in melanoma. Here, we demonstrated a specific interaction of the avb3 integrin on melanoma cells with the human Thy-1, an inducible cell adhesion molecule expressed on the cell surface of activated endothelial cells (EC). The interaction was shown by the binding of purified Thy-1 protein to alpha(V)beta(3) transfected cells, to alpha v beta 3-expressing melanoma cells and to purified alpha(V)beta(3) integrin. Moreover, melanoma cells adhere specifically to Thy-1 transfectants via avb3 on melanoma cells showing the functional relevance of this interaction for cell adhesion. Finally, the importance of the alpha v beta 3/Thy-1 interaction for the adhesion of melanoma cells to the activated endothelium was confirmed under static and flow conditions by the inhibition of melanoma cell adhesion to and transmigration across activated EC by blocking the avb3/Thy-1 interaction. In conclusion, we have identified a new pair of adhesion molecules Thy-1 and avb3 mediating the interaction of melanoma cells and activated EC. These data explain at least in part the high tumorigenicity of avb3-expressing melanoma cells and the association of alpha v beta 3-positive melanoma cells with a high risk of metastasis and poor prognosis.	Saxon Acad Sci, D-04107 Leipzig, Germany; Univ Leipzig, Dept Dermatol Venerol & Allergol, D-04103 Leipzig, Germany	Leipzig University	Saalbach, A (corresponding author), Saxon Acad Sci, D-04107 Leipzig, Germany.	saalbach@medizin.uni-leipzig.de	Saalbach, Anja/ABD-4003-2021	Saalbach, Anja/0000-0002-1084-3875				Ahrens T, 2001, J INVEST DERMATOL, V116, P93, DOI 10.1046/j.1523-1747.2001.00236.x; Anasagasti MJ, 1997, J NATL CANCER I, V89, P645, DOI 10.1093/jnci/89.9.645; AUBERT C, 1993, INT J CANCER, V54, P784, DOI 10.1002/ijc.2910540513; Averbeck M, 2004, EUR J IMMUNOL, V34, P2708, DOI 10.1002/eji.200425355; BEAN MA, 1975, CANCER RES, V35, P2902; Buckley CD, 1996, J CELL SCI, V109, P437; Byzova TV, 2000, EXP CELL RES, V254, P299, DOI 10.1006/excr.1999.4765; CAREY TE, 1976, P NATL ACAD SCI USA, V73, P3278, DOI 10.1073/pnas.73.9.3278; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CRAIG W, 1993, J EXP MED, V177, P1331, DOI 10.1084/jem.177.5.1331; CRAWFORD JM, 1986, LAB INVEST, V54, P122; Duczmal A, 1997, BIOCHEM BIOPH RES CO, V232, P236, DOI 10.1006/bbrc.1997.6265; Ebeling O, 1996, EUR J IMMUNOL, V26, P2508, DOI 10.1002/eji.1830261035; Felding-Habermann B, 1997, J CELL BIOL, V139, P1567, DOI 10.1083/jcb.139.6.1567; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; Johnson JP, 1999, CANCER METAST REV, V18, P345, DOI 10.1023/A:1006304806799; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kumar CC, 2000, ADV EXP MED BIOL, V476, P169; Leyton L, 2001, CURR BIOL, V11, P1028, DOI 10.1016/S0960-9822(01)00262-7; LOCKSHIN A, 1985, J NATL CANCER I, V74, P899; Meyer T, 1998, EUR J CANCER, V34, P214, DOI 10.1016/S0959-8049(97)10129-0; MULLER D, 1991, INT J CANCER, V48, P550, DOI 10.1002/ijc.2910480412; Murray GI, 1996, NAT MED, V2, P461, DOI 10.1038/nm0496461; OROSZ P, 1995, INT J CANCER, V60, P867, DOI 10.1002/ijc.2910600624; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; Saalbach A, 1999, CELL TISSUE RES, V298, P307, DOI 10.1007/s004419900079; Saalbach A, 2000, J INVEST DERMATOL, V115, P882, DOI 10.1046/j.1523-1747.2000.00104.x; Saalbach A, 1996, J INVEST DERMATOL, V106, P1314, DOI 10.1111/1523-1747.ep12349035; Saalbach A, 2002, MICROVASC RES, V64, P86, DOI 10.1006/mvre.2002.2401; Saalbach A, 1998, ARCH DERMATOL RES, V290, P360, DOI 10.1007/s004030050318; SMITH JW, 1990, J BIOL CHEM, V265, P2168; VARNER JA, 1996, ADV ONCOL, P69; VIDAL M, 1990, EMBO J, V9, P833, DOI 10.1002/j.1460-2075.1990.tb08180.x; Voura EB, 2001, MOL BIOL CELL, V12, P2699, DOI 10.1091/mbc.12.9.2699; Wandel E, 2002, ARCH DERMATOL RES, V293, P601, DOI 10.1007/s00403-001-0289-4; Wandel E, 2000, EXP DERMATOL, V9, P34, DOI 10.1034/j.1600-0625.2000.009001034.x; Weerasinghe D, 1998, J CELL BIOL, V142, P595, DOI 10.1083/jcb.142.2.595; Wetzel A, 2004, J IMMUNOL, V172, P3850, DOI 10.4049/jimmunol.172.6.3850; WILLIAMS AF, 1982, BIOSCIENCE REP, V2, P277, DOI 10.1007/BF01115113; Yoshizaki T, 1997, CANCER, V79, P139, DOI 10.1002/(SICI)1097-0142(19970101)79:1<139::AID-CNCR20>3.0.CO;2-4	44	83	84	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4710	4720		10.1038/sj.onc.1208559	http://dx.doi.org/10.1038/sj.onc.1208559			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15897908				2022-12-17	WOS:000230304500009
J	Sun, JZ; Wang, DA; Jain, RK; Carie, A; Paquette, S; Ennis, E; Blaskovich, MA; Baldini, L; Coppola, D; Hamilton, AD; Sebti, SM				Sun, JZ; Wang, DA; Jain, RK; Carie, A; Paquette, S; Ennis, E; Blaskovich, MA; Baldini, L; Coppola, D; Hamilton, AD; Sebti, SM			Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors	ONCOGENE			English	Article						PDGF; VEGF; angiogenesis inhibitors; tumorigenesis; growth factor binders	ENDOTHELIAL GROWTH-FACTOR; TUMOR ANGIOGENESIS; ESTABLISHED TUMORS; ANTITUMOR EFFICACY; KINASE INHIBITORS; FACTOR-BB; IN-VIVO; REGRESSION; CANCER; EXPRESSION	Angiogenesis depends on vascular endothelial growth factor ( VEGF) for initiation and platelet-derived growth factor ( PDGF) for maintenance of blood vessels. We have designed a targeted library of compounds from which we identified a novel molecule, GFB-204, that binds PDGF and VEGF, blocks binding of PDGF and VEGF to their receptors (200-500 nM) and subsequently inhibits PDGFR and Flk-1 tyrosine phosphorylation and stimulation of the protein kinases Erk1, Erk2 and Akt and the signal transducer and activator of transcription STAT3. GFB204 is selective for PDGF and VEGF and does not inhibit EGF, IGF-1 and FGF stimulation of Erk1/2, Akt and STAT3. GFB-204 inhibits endothelial cell migration and capillary network formation in vitro. Finally, treatment of mice with GFB-204 suppresses human tumor growth and angiogenesis. Thus, inhibition of VEGF and PDGF receptor binding with a synthetic molecule results in potent inhibition of angiogenesis and tumorigenesis.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program,MRC DRDIS, Tampa, FL 33612 USA; Univ S Florida, Dept Interdisciplinary Oncol, Tampa, FL 33412 USA; Univ S Florida, Dept Biochem & Mol Biol, Tampa, FL 33412 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Yale University	Sebti, SM (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program,MRC DRDIS, 12902 Magnolia Dr, Tampa, FL 33612 USA.	Andew.hamilton@yale.edu; Sebti@moffitt.usf.edu	Jain, Rakesh K/I-1384-2017; Baldini, Laura/N-3588-2014	Jain, Rakesh K/0000-0001-7571-3548; Baldini, Laura/0000-0002-0985-4331; Baldini, Luca/0000-0003-2964-9981; Carie, Adam/0000-0001-7804-0465	NCI NIH HHS [CA78038] Funding Source: Medline; NIGMS NIH HHS [GM35208] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035208] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON M, 1995, GROWTH FACTORS, V12, P159, DOI 10.3109/08977199509028962; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Blaskovich MA, 2003, CANCER RES, V63, P1270; Blaskovich MA, 2000, NAT BIOTECHNOL, V18, P1065, DOI 10.1038/80257; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Erber R, 2003, FASEB J, V17, P338, DOI 10.1096/fj.03-0271fje; Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Huang JZ, 2003, P NATL ACAD SCI USA, V100, P7785, DOI 10.1073/pnas.1432908100; Jain RK, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.37265; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Laird AD, 2000, CANCER RES, V60, P4152; Miao RQ, 2002, BLOOD, V100, P3245, DOI 10.1182/blood-2002-01-0185; Morin MJ, 2000, ONCOGENE, V19, P6574, DOI 10.1038/sj.onc.1204102; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; Papadimitriou E, 2001, BIOCHEM BIOPH RES CO, V282, P306, DOI 10.1006/bbrc.2001.4574; Paris Daniel, 2004, Angiogenesis, V7, P75, DOI 10.1023/B:AGEN.0000037335.17717.bf; Relf M, 1997, CANCER RES, V57, P963; Sun JZ, 1999, CANCER RES, V59, P4919; Wedge SR, 2000, CANCER RES, V60, P970; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zhang Wei, 2002, Angiogenesis, V5, P35, DOI 10.1023/A:1021540120521	28	83	90	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2005	24	29					4701	4709		10.1038/sj.onc.1208391	http://dx.doi.org/10.1038/sj.onc.1208391			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	942TD	15897913				2022-12-17	WOS:000230304500008
J	Anastasi, S; Sala, G; Chen, HP; Caprini, E; Russo, G; Iacovelli, S; Lucini, F; Ingvarsson, S; Segatto, O				Anastasi, S; Sala, G; Chen, HP; Caprini, E; Russo, G; Iacovelli, S; Lucini, F; Ingvarsson, S; Segatto, O			Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin	ONCOGENE			English	Article						RALT; MIG-6; ErbB-2; breast cancer; Herceptin; targeted therapies	RECEPTOR TYROSINE KINASES; GROWTH-FACTOR RECEPTOR; SIGNALING NETWORK; TRANSGENIC MICE; DOWN-REGULATION; CHROMOSOME 1P; CANCER; INHIBITION; PROTEIN; RALT	An emerging paradigm holds that loss of negative signalling to receptor tyrosine kinases (RTKs) is permissive for their oncogenic activity. Herein, we have addressed tumor suppression by RALT/MIG- 6, a transcriptionally controlled feedback inhibitor of ErbB RTKs, in breast cancer cells. Knockdown of RALT expression by RNAi enhanced the EGF-dependent proliferation of normal breast epithelial cells, indicating that loss of RALT signalling in breast epithelium may represent an advantageous condition during ErbB-driven tumorigenesis. Although mutational inactivation of the RALT gene was not detected in human breast carcinomas, RALT mRNA and protein expression was strongly and selectively reduced in ERBB2-amplified breast cancer cell lines. Reconstitution of RALT expression in ERBB-2-amplified SKBr-3 and BT474 cells inhibited ErbB-2-dependent mitogenic signalling and counteracted the ability of ErbB ligands to promote resistance to the ErbB-2-targeting drug Herceptin. Thus, loss of RALT expression cooperates with ERBB2 gene amplification to drive full oncogenic signalling by the ErbB-2 receptor. Moreover, loss of RALT signalling may adversely affect tumor responses to ErbB-2-targeting agents.	Regina Elena Inst Canc Res, Immunol Lab, I-00158 Rome, Italy; Univ Iceland, Inst Expt Pathol, Reykjavik, Iceland; IDI, Mol Oncol Lab, Rome, Italy; Regina Elena Inst Canc Res, Lab Mol Oncogenesis, I-00158 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Iceland; IRCCS Istituto Dermopatico dell'Immacolata (IDI); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Segatto, O (corresponding author), Regina Elena Inst Canc Res, Immunol Lab, Via Messi Oro,156-158, I-00158 Rome, Italy.	segatto@ifo.it	Sala, Gianluca/C-2056-2017; Ingvarsson, Sigurdur/E-7448-2011; anastasi, sergio/AAB-9585-2020; Caprini, Elisabetta/AAG-8523-2020; Russo, Giandomenico/K-9566-2016	Sala, Gianluca/0000-0002-4494-915X; Ingvarsson, Sigurdur/0000-0003-4125-1714; anastasi, sergio/0000-0003-1009-6117; Russo, Giandomenico/0000-0002-7718-9687; iacovelli, stefano/0000-0003-0806-6365; Segatto, Oreste/0000-0003-2561-1142				Amatschek S, 2004, CANCER RES, V64, P844, DOI 10.1158/0008-5472.CAN-03-2361; Anastasi S, 2003, ONCOGENE, V22, P4221, DOI 10.1038/sj.onc.1206516; Bache KG, 2004, EMBO J, V23, P2707, DOI 10.1038/sj.emboj.7600292; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Bieche I, 1999, GENE CHROMOSOME CANC, V24, P255, DOI 10.1002/(SICI)1098-2264(199903)24:3<255::AID-GCC11>3.0.CO;2-2; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Farabegoli F, 1996, INT J CANCER, V69, P381, DOI 10.1002/(SICI)1097-0215(19961021)69:5<381::AID-IJC5>3.0.CO;2-1; Fiorentino L, 2000, MOL CELL BIOL, V20, P7735, DOI 10.1128/MCB.20.20.7735-7750.2000; Fiorini M, 2002, ONCOGENE, V21, P6530, DOI 10.1038/sj.onc.1205823; Fiorini M, 2001, FEBS LETT, V490, P132, DOI 10.1016/S0014-5793(01)02116-0; Hackel PO, 2001, BIOL CHEM, V382, P1649, DOI 10.1515/BC.2001.200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Kim HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400; Lo TL, 2004, CANCER RES, V64, P6127, DOI 10.1158/0008-5472.CAN-04-1207; Makkinje A, 2000, J BIOL CHEM, V275, P17838, DOI 10.1074/jbc.M909735199; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Mincione G, 1996, J CELL BIOCHEM, V60, P437, DOI 10.1002/(SICI)1097-4644(19960315)60:4<437::AID-JCB1>3.0.CO;2-T; Moghal N, 2003, EXP CELL RES, V284, P150, DOI 10.1016/S0014-4827(02)00097-6; Motoyama AB, 2002, CANCER RES, V62, P3151; MURILLAS R, 1995, EMBO J, V14, P5216, DOI 10.1002/j.1460-2075.1995.tb00206.x; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; Polo S, 2004, CURR OPIN CELL BIOL, V16, P156, DOI 10.1016/j.ceb.2004.02.003; Ragnarsson G, 1999, BRIT J CANCER, V79, P1468, DOI 10.1038/sj.bjc.6690234; Saarikoski ST, 2002, FEBS LETT, V530, P186, DOI 10.1016/S0014-5793(02)03475-0; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tsukamoto K, 1998, CANCER-AM CANCER SOC, V82, P317, DOI 10.1002/(SICI)1097-0142(19980115)82:2<323::AID-CNCR11>3.3.CO;2-P; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	36	83	95	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4540	4548		10.1038/sj.onc.1208658	http://dx.doi.org/10.1038/sj.onc.1208658			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856022	Green Published			2022-12-17	WOS:000230157100007
J	Fischer, U; Steffens, S; Frank, S; Rainov, NG; Schulze-Osthoff, KS; Kramm, CM				Fischer, U; Steffens, S; Frank, S; Rainov, NG; Schulze-Osthoff, KS; Kramm, CM			Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/5-fluorocytosine suicide gene therapy-induced cell death in glioma cells	ONCOGENE			English	Article						apoptosis; Bcl-2; CD95; cytosine deaminase; p53; thymidine kinase	INDUCED APOPTOSIS; MALIGNANT GLIOMAS; KINASE GENE; BRAIN-TUMOR; P53 GENE; VIRUS; BCL-2; ACTIVATION; GANCICLOVIR; GLIOBLASTOMA	Suicide gene transfer using thymidine kinase (TK) and ganciclovir (GCV) treatment or the cytosine deaminase (CD)/5-fluorocytosine (5-FC) system represents the most widely used approach for gene therapy of cancer. However, molecular pathways and resistance mechanisms remain controversial for GCV-mediated cytotoxicity, and are virtually unknown for the CD/5-FC system. Here, we elucidated some of the cellular pathways in glioma cell lines that were transduced to express the TK or CD gene. In wild-type p53-expressing U87 cells, exposure to GCV and 5-FC resulted in a weak p53 response, although apoptosis was efficiently induced. Cell death triggered by GCV and 5-FC was independent of death receptors, but accompanied by mitochondrial alterations. Whereas expression of Bax remained unaffected, in particular, GCV and also 5-FC caused a decline in the level of Bcl-2. Similar findings were obtained in 9L and T98G glioma cells that express mutant p53, and also underwent mitochondrial apoptosis in both the TK/GCV and CD/5-FC system. Upon treatment of 9L cells with 5-FC, Bcl-x(L) expression slowly declined, whereas exposure to GCV resulted in the rapid proapoptotic phosphorylation of Bcl-x(L). These data suggest that TK/GCV- and CD/5-FC-induced apoptosis does neither require p53 nor death receptors, but converges at a mitochondrial pathway triggered by different mechanisms of modulation of Bcl-2 proteins.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Dept Pediat Hematol Oncol & Immunol, D-40225 Dusseldorf, Germany; Univ Liverpool, Dept Neurol Sci, Liverpool L69 3BX, Merseyside, England; Walton Ctr Neurol & Neurosurg, NHS Trust, Liverpool, Merseyside, England	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; University of Liverpool; Walton Centre	Schulze-Osthoff, KS (corresponding author), Univ Dusseldorf, Inst Mol Med, Univ Str 1, D-40225 Dusseldorf, Germany.	kso@uni-duesseldorf.de	Steffens, Sabine/AAV-4551-2020; Schulze-Osthoff, Klaus/N-9025-2013	Steffens, Sabine/0000-0002-6892-9751; Schulze-Osthoff, Klaus/0000-0003-1443-2720				Aghi M, 1998, J NATL CANCER I, V90, P370, DOI 10.1093/jnci/90.5.370; ASAI A, 1994, J NEURO-ONCOL, V19, P259, DOI 10.1007/BF01053280; Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104; Beltinger C, 1999, P NATL ACAD SCI USA, V96, P8699, DOI 10.1073/pnas.96.15.8699; Beltinger C, 2000, CANCER RES, V60, P3212; Burek C, 2001, ONCOGENE, V20, P6493, DOI 10.1038/sj.onc.1204841; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; Essmann F, 2003, CELL DEATH DIFFER, V10, P1260, DOI 10.1038/sj.cdd.4401301; Fan MY, 2000, J BIOL CHEM, V275, P29980, DOI 10.1074/jbc.M003776200; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; FREEMAN SM, 1993, CANCER RES, V53, P5274; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Glaser T, 2001, GENE THER, V8, P469, DOI 10.1038/sj.gt.3301415; Hamel W, 1996, CANCER RES, V56, P2697; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Ichikawa T, 2000, CANCER GENE THER, V7, P74, DOI 10.1038/sj.cgt.7700086; KANEKO Y, 1995, CANCER LETT, V96, P105, DOI 10.1016/0304-3835(95)03919-N; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Klatzmann D, 1996, HUM GENE THER, V7, P109, DOI 10.1089/hum.1996.7.1-109; Kramm Christof M, 2003, Methods Mol Biol, V215, P137; KRAMM CM, 1995, BRAIN PATHOL, V5, P345, DOI 10.1111/j.1750-3639.1995.tb00615.x; Kramm CM, 1997, HUM GENE THER, V8, P2057, DOI 10.1089/hum.1997.8.17-2057; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; McMasters RA, 1998, HUM GENE THER, V9, P2253, DOI 10.1089/hum.1998.9.15-2253; Milosevic J, 2003, ONCOGENE, V22, P6852, DOI 10.1038/sj.onc.1206716; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOOLTEN FL, 1986, CANCER RES, V46, P5276; MULLEN CA, 1992, P NATL ACAD SCI USA, V89, P33, DOI 10.1073/pnas.89.1.33; Nanda D, 2001, CANCER RES, V61, P8743; OLDFIELD EH, 1993, HUM GENE THER, V4, P39, DOI 10.1089/hum.1993.4.1-39; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Rainov NG, 2000, HUM GENE THER, V11, P2389, DOI 10.1089/104303400750038499; Rainov Nikolai G., 2001, Current Gene Therapy, V1, P367, DOI 10.2174/1566523013348445; Schilsky RL, 1998, ONCOLOGY-NY, V12, P13; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Tomicic MT, 2002, ONCOGENE, V21, P2141, DOI 10.1038/sj.onc.1205280; Totzke G, 2003, ONCOGENE, V22, P8021, DOI 10.1038/sj.onc.1206837; VAN MEIR EG, 1994, CANCER RES, V54, P649; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wallace H, 1996, ONCOGENE, V13, P55; Wei JW, 2004, CANCER CELL, V5, P477, DOI 10.1016/S1535-6108(04)00116-3; Wei SJ, 1999, GENE THER, V6, P420, DOI 10.1038/sj.gt.3300817; Wei SJ, 1998, EXP CELL RES, V241, P66, DOI 10.1006/excr.1998.4005; WEIZSAECKER M, 1981, J NEUROL, V224, P183, DOI 10.1007/BF00313280; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; Xie YJ, 1999, CLIN CANCER RES, V5, P4224; Zimmer C, 1997, EXP NEUROL, V143, P61, DOI 10.1006/exnr.1996.6350	59	83	101	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1231	1243		10.1038/sj.onc.1208290	http://dx.doi.org/10.1038/sj.onc.1208290			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15592511				2022-12-17	WOS:000226898700010
J	Suenaga, N; Mori, H; Itoh, Y; Seiki, M				Suenaga, N; Mori, H; Itoh, Y; Seiki, M			CD44 binding through the hemopexin-like domain is critical for its shedding by membrane-type 1 matrix metalloproteinase	ONCOGENE			English	Article						MT-MMP; CD44; hemopexin-like domain	TUMOR-CELL MIGRATION; SURFACE; EXPRESSION; INVASION; MT1-MMP; MATRIX-METALLOPROTEINASE-9; ACTIVATION; CLEAVAGE	Membrane-type 1 matrix metalloproteinase (MT1-MMP) is a potent modulator of pericellular environment through its proteolytic activity and promotes migration, invasion, and proliferation of tumor cells. During cell migration, MT1-MMP binds to CD44H, a major hyaluronan receptor, through the hemopexin-like (HPX) domain and localizes at the migration front. MT1-MMP is also responsible for shedding CD44H, which supports CD44H-mediated cell migration. In this study, we asked whether the binding of MT1-MMP to CD44H is a prerequisite step for the successive shedding. Deletion of the HPX domain deprived MT1-MMP of its shedding activity. Furthermore, disruption of the CD44H/MT1-MMP complex by overexpressing the HPX fragments resulted in inhibition of the shedding. Thus, the CD44H in the complex appears to be the direct substrate of MT1-MMP for shedding. Interestingly, other members of the MT-MMP family showed varied extents of CD44H shedding. Domain swapping between MT1-MMP and other MT-MMPs revealed that the ability of the HPX domains to bind CD44H is conserved among them. However, the shedding activity was different depending on the catalytic domains. The conserved binding ability of the HPX domains suggests that CD44H may act as a core molecule assembling multiple MT-MMPs on the cell surface.	Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Seiki, M (corresponding author), Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	mseiki@ims.u-tokyo.ac.jp	Seiki, Motoharu/K-9443-2015	Itoh, Yoshifumi/0000-0002-2128-2823				Abecassis I, 2003, EXP CELL RES, V291, P363, DOI 10.1016/j.yexcr.2003.08.006; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Goebeler M, 1996, J CELL SCI, V109, P1957; Ha HY, 2001, CANCER RES, V61, P984; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kojima S, 2000, FEBS LETT, V480, P142, DOI 10.1016/S0014-5793(00)01919-0; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Murai T, 2004, J BIOL CHEM, V279, P4541, DOI 10.1074/jbc.M307356200; Nagano O, 2004, J CELL BIOL, V165, P893, DOI 10.1083/jcb.200310024; Nakamura H, 2004, CANCER RES, V64, P876, DOI 10.1158/0008-5472.CAN-03-3502; NAOT D, 1997, ADV CANCER RES, V71, P241; Okamoto I, 2002, AM J PATHOL, V160, P441, DOI 10.1016/S0002-9440(10)64863-8; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Seiki M, 2003, CANCER METAST REV, V22, P129, DOI 10.1023/A:1023087113214; Tsunezuka Y, 1996, CANCER RES, V56, P5678; Ueda J, 2003, ONCOGENE, V22, P8716, DOI 10.1038/sj.onc.1206962; Vivinus-Nebot M, 2004, J IMMUNOL, V172, P1397, DOI 10.4049/jimmunol.172.3.1397; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Yu Q, 2000, GENE DEV, V14, P163; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702	27	83	91	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					859	868		10.1038/sj.onc.1208258	http://dx.doi.org/10.1038/sj.onc.1208258			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15558018				2022-12-17	WOS:000226577100012
J	Miyazaki, H; Watabe, T; Kitamura, T; Miyazono, K				Miyazaki, H; Watabe, T; Kitamura, T; Miyazono, K			BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells	ONCOGENE			English	Article						PC-3; DU-145; p21(CIP1/WAF1); pRb	BONE MORPHOGENETIC PROTEIN; RETINOBLASTOMA PROTEIN; CANCER CELLS; II RECEPTOR; FACTOR-BETA; EXPRESSION; TGF-BETA-1; CYCLE; DIFFERENTIATION; TRANSDUCTION	Prostate cancer is one of the most common cancers in men. Several lines of evidence have suggested that bone morphogenetic protein (BMP) signals play important roles in the generation and progression of prostate cancers. In the present study, we show that BMP-7 inhibits the proliferation of androgen-insensitive PC-3 and DU-145 prostate cancer cells in a medium containing 1% fetal bovine serum, observed as decreased incorporation of [H-3] thymidine and decreased cell number. Cell cycle analysis by flow cytometry showed an increased fraction of cells in the G1 phase and subsequent decrease in both S and G2/M phase after BMP-7 stimulation. BMP-7 caused an upregulation of the cyclin-dependent kinase inhibitor (CDKI) p21(CIP1/WAF1), and decreased the activity of Cdk2, leading to hypophosphorylation of Rb proteins. Furthermore, in order to evaluate the impact of BMP signals on prostate tumor growth, we generated the PC-3 cell lines expressing a constitutively active BMP type I receptor (constitutively active (c.a.) activin receptor-like kinase (ALK)-6) in a tetracycline (Tet)-regulated manner. Tet/doxycycline-regulated expression of c.a.ALK-6 resulted in the inhibition of in vitro cell proliferation and reduction of the size of tumors derived from the PC-3 cells subcutaneously injected into immune-deficient mice. Collectively, these findings suggest that BMP signals inhibit growth and proliferation of prostate tumor cells through induction of CDKI. Furthermore, this is the first report of a role for BMP signaling in reducing growth kinetics of androgen-insensitive prostate tumors.	Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Urol, Bunkyo Ku, Tokyo 1130033, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; University of Tokyo; Japanese Foundation for Cancer Research	Miyazono, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono-ind@umin.ac.jp	Kitamura, Toshio/AAA-2071-2021					Autzen P, 1998, BRIT J CANCER, V78, P1219, DOI 10.1038/bjc.1998.658; Baron U, 1997, NUCLEIC ACIDS RES, V25, P2723, DOI 10.1093/nar/25.14.2723; Brubaker KD, 2004, J CELL BIOCHEM, V91, P151, DOI 10.1002/jcb.10679; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; Callahan JF, 2002, J MED CHEM, V45, P999, DOI 10.1021/jm010493y; Candia AF, 1997, DEVELOPMENT, V124, P4467; CLARKE NW, 1991, BRIT J UROL, V68, P74, DOI 10.1111/j.1464-410X.1991.tb15260.x; Ebisawa T, 1999, J CELL SCI, V112, P3519; Era T, 2000, P NATL ACAD SCI USA, V97, P1737, DOI 10.1073/pnas.97.4.1737; Franzen A, 2001, BIOCHEM BIOPH RES CO, V285, P773; Ghosh-Choudhury N, 2000, BIOCHEM BIOPH RES CO, V272, P705, DOI 10.1006/bbrc.2000.2844; Ghosh-Choudhury N, 2000, BBA-MOL CELL RES, V1497, P186, DOI 10.1016/S0167-4889(00)00060-4; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Guo YP, 1998, CELL GROWTH DIFFER, V9, P185; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Ide H, 1997, CANCER RES, V57, P5022; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; ISHIKAWA T, 1995, BIOCHEM BIOPH RES CO, V216, P26, DOI 10.1006/bbrc.1995.2587; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359-6101(97)00036-1; Kim IY, 2000, CANCER RES, V60, P2840; Kim IY, 1996, CANCER RES, V56, P44; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LIU F, 1995, MOL CELL BIOL, V15, P3479; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Masuda H, 2003, PROSTATE, V54, P268, DOI 10.1002/pros.10193; Miyazono K, 2000, J CELL SCI, V113, P1101; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ota T, 2002, J CELL PHYSIOL, V193, P299, DOI 10.1002/jcp.10170; Park BJ, 2000, CANCER RES, V60, P3031; Reddi AH, 1998, NAT BIOTECHNOL, V16, P247, DOI 10.1038/nbt0398-247; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; SCHER HI, 1987, AM J MED, V82, P6, DOI 10.1016/0002-9343(87)90483-9; Thomas R, 1998, PROSTATE, V37, P236, DOI 10.1002/(SICI)1097-0045(19981201)37:4<236::AID-PROS5>3.0.CO;2-C; VINDELOV LL, 1983, CYTOMETRY, V3, P328, DOI 10.1002/cyto.990030504; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wong GA, 2003, AM J PHYSIOL-ENDOC M, V284, pE972, DOI 10.1152/ajpendo.00385.2002; Wozney JM, 1998, CLIN ORTHOP RELAT R, P26	39	83	95	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9326	9335		10.1038/sj.onc.1208127	http://dx.doi.org/10.1038/sj.onc.1208127			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15531927				2022-12-17	WOS:000225764100004
J	Gallego, MA; Joseph, B; Hemstrom, TH; Tamiji, S; Mortier, L; Kroemer, G; Formstecher, P; Zhivotovsky, B; Marchetti, P				Gallego, MA; Joseph, B; Hemstrom, TH; Tamiji, S; Mortier, L; Kroemer, G; Formstecher, P; Zhivotovsky, B; Marchetti, P			Apoptosis-inducing factor determines the chemoresistance of non-small-cell lung carcinomas	ONCOGENE			English	Article						staurosporine; apoptosis; mitochondria; caspase-independent	DNA-DEGRADATION; CANCER-CELLS; DEATH; AIF; STAUROSPORINE; PROTEASES; PROTEIN; MITOCHONDRIA; EXPRESSION; ACTIVATION	Non-small-cell lung carcinomas (NSCLCs) are resistant to the induction of apoptosis by conventional anticancer treatment. However, NSCLC cell lines are sensitive to the action of the broad protein kinase inhibitor, staurosporine (STS). In the NSCLC cell line U1810, STS induced the mitochondrial release of apoptosis-inducing factor (AIF) and cytochrome c (Cyt c) followed by activation of caspases, nuclear condensation, DNA fragmentation and finally cell death. Although preincubation of U1810 cells with the broad-spectrum caspase inhibitor z-VAD.fmk delayed the occurrence of nuclear apoptosis induced by STS, it did not impede mitochondrial alterations (such as the release of Cyt c and AIF) and cell death to occur. Moreover, the microinjection of neither Cyt c nor recombinant active caspase-3 into the cytoplasm promoted nuclear apoptosis-related changes in U1810 cells. Evaluation of the role of the caspase-independent factor AIF in STS-mediated death revealed that, upon immunodepletion of AIF, cytosols from STS-treated U1810 lost their capacity to induce nuclear condensation when incubated with isolated nuclei. In addition, microinjection of an anti-AIF antibody prevented AIF from translocating to the nuclei of STS-treated U1810 cells and reduced STS-induced cell death. Finally, although the transfection-enforced overexpression of AIF was not sufficient to induce cell death, it did enhance STS-mediated cell killing. Altogether, these results indicate that activation of caspases is not sufficient to kill U1810 cells and rather suggests an important role for the AIF-mediated mitochondrial-mediated death pathway.	Fac Med Lille, INSERM, U459, F-59045 Lille, France; Karolinska Inst, Inst Environm Med, Dept Toxicol, S-17177 Stockholm, Sweden; Inst Gustave Roussy, CNRS, UMR8125, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Karolinska Institutet; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Marchetti, P (corresponding author), Fac Med Lille, INSERM, U459, 1 Pl Verdun, F-59045 Lille, France.	philippe.marchetti@lille.inserm.fr	Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013; Zhivotovsky, Boris/A-4346-2014	KROEMER, Guido/0000-0002-9334-4405; Zhivotovsky, Boris/0000-0002-2238-3482; Joseph, Bertrand/0000-0001-5655-9979; MARCHETTI, Philippe/0000-0002-4663-6800				Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; Belmokhtar CA, 2001, ONCOGENE, V20, P3354, DOI 10.1038/sj.onc.1204436; BERGH J, 1985, ACTA PATH MICRO IM A, V93, P133; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Deas O, 1998, J IMMUNOL, V161, P3375; Ekedahl J, 2003, CANCER BIOL THER, V2, P663; Ekedahl J, 2002, EXP CELL RES, V279, P277, DOI 10.1006/excr.2002.5608; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Joseph B, 2002, ONCOGENE, V21, P65, DOI 10.1038/sj/onc/1205018; Joseph B, 2001, ONCOGENE, V20, P2877, DOI 10.1038/sj.onc.1204402; Joseph B, 1999, BIOCHEM BIOPH RES CO, V262, P381, DOI 10.1006/bbrc.1999.1191; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Mathiasen IS, 2002, TRENDS MOL MED, V8, P212, DOI 10.1016/S1471-4914(02)02328-6; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Mullauer L, 2001, MUTAT RES-REV MUTAT, V488, P211, DOI 10.1016/S1383-5742(01)00057-6; Penninger JM, 2003, NAT CELL BIOL, V5, P97, DOI 10.1038/ncb0203-97; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Schmitt E, 2003, CANCER RES, V63, P8233; Sirzen F, 1998, LUNG CANCER-J IASLC, V22, P1, DOI 10.1016/S0169-5002(98)00066-X; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; van Loo G, 2001, CELL DEATH DIFFER, V8, P1136, DOI 10.1038/sj.cdd.4400944; Volm M, 2000, ANTICANCER RES, V20, P3449; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Wu M, 2002, J BIOL CHEM, V277, P25617, DOI 10.1074/jbc.M202285200; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Xue LY, 2003, EXP CELL RES, V283, P135, DOI 10.1016/S0014-4827(02)00032-0; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; ZHIVOTOVSKY B, 1994, FEBS LETT, V351, P150, DOI 10.1016/0014-5793(94)00827-2; Zhivotovsky B, 2003, SEMIN CANCER BIOL, V13, P125, DOI 10.1016/S1044-579X(02)00130-X	37	83	86	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6282	6291		10.1038/sj.onc.1207835	http://dx.doi.org/10.1038/sj.onc.1207835			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15286713				2022-12-17	WOS:000223399000012
J	Cerisano, V; Aalto, Y; Perdichizzi, S; Bernard, G; Manara, MC; Benini, S; Cenacchi, G; Preda, P; Lattanzi, G; Nagy, B; Knuutila, S; Colombo, MP; Bernard, A; Picci, P; Scotlandi, K				Cerisano, V; Aalto, Y; Perdichizzi, S; Bernard, G; Manara, MC; Benini, S; Cenacchi, G; Preda, P; Lattanzi, G; Nagy, B; Knuutila, S; Colombo, MP; Bernard, A; Picci, P; Scotlandi, K			Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators	ONCOGENE			English	Article						CD99; Ewing's sarcoma; homotypic aggregation; apoptosis; zyxin; actin	MIC2 GENE-PRODUCT; REED-STERNBERG PHENOTYPE; PSEUDOAUTOSOMAL GENE; CD99 ENGAGEMENT; NEUROECTODERMAL TUMOR; MEMBRANE-PROTEIN; DOWN-REGULATION; T-CELLS; APOPTOSIS; PHOSPHATIDYLSERINE	CD99 is a unique 32-kDa cell surface molecule with broad cellular expression but still poorly understood biological functions. In cancer cells, CD99 is highly expressed in virtually all Ewing's sarcoma (ES). Engagement of CD99 induces fast homotypic aggregation of ES cells and caspase-independent apoptosis. In this study, we analysed signal transduction after CD99 engagement on ES cells. Findings obtained with selective inhibitors indicated that only actin cytoskeleton integrity was essential for cell-cell adhesion and apoptosis of ES cells. Indeed, CD99 stimulation induced actin repolymerization, further supporting the role of cytoskeleton in CD99 signaling. Gene expression profiling of ES cells after CD99 engagement showed modulation in the expression of 32 genes. Among the pool of upregulated genes reported to be involved in cell adhesion, we chose to analyse the role of zyxin, a cytoplasmic adherens junction protein found to play a role in the regulation of the actin cytoskeleton. Overexpression of zyxin after CD99 ligation was confirmed by real-time PCR and Western blot. Treatment of ES cells with zyxin antisense otigonucleotides inhibited CD99-induced cell aggregation and apoptosis, suggesting a functional role for this protein. Therefore, our findings indicate that CD99 functions occur through reorganization of cytoskeleton and identify actin and zyxin as the early signaling events driven by CD99 engagement.	Ist Ortoped Rizzoli, Lab Ric Oncol, I-40136 Bologna, Italy; Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland; Univ Helsinki, FIN-00014 Helsinki, Finland; Hosp Archet, UMR 576, Unite INSERM, Nice 3, France; Univ Bologna, Dipartimento Clin Sci Radiol & Istocitopatol, Bologna, Italy; Ist Ortoped Rizzoli, ITOI CNR, Unit Bologna, I-40136 Bologna, Italy; Ist Nazl Studio & Cura Tumori, Immunotherapy & Gene Therapy Unit, I-20133 Milan, Italy	IRCCS Istituto Ortopedico Rizzoli; University of Helsinki; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Bologna; IRCCS Istituto Ortopedico Rizzoli; Fondazione IRCCS Istituto Nazionale Tumori Milan	Scotlandi, K (corresponding author), Ist Ortoped Rizzoli, Lab Ric Oncol, I-40136 Bologna, Italy.	katia.scotlandi@ior.it	Manara, Maria Cristina/K-3366-2018; Nagy, Balint/F-6943-2012; LATTANZI, GIOVANNA/P-8214-2015; Lattanzi, Giovanna/AAY-3186-2020; Colombo, Mario P./V-7166-2017; Scotlandi, Katia/J-9009-2016; BENINI, STEFANIA/D-1804-2019; Picci, Piero/J-5979-2016	Manara, Maria Cristina/0000-0001-5686-720X; LATTANZI, GIOVANNA/0000-0002-7103-8722; Lattanzi, Giovanna/0000-0002-7103-8722; Colombo, Mario P./0000-0003-0042-7955; Scotlandi, Katia/0000-0001-6114-9499; BENINI, STEFANIA/0000-0003-0958-9088; CENACCHI, GIOVANNA/0000-0001-5824-3118; Picci, Piero/0000-0002-8519-4101				Alberti I, 2002, FASEB J, V16, P1946, DOI 10.1096/fj.02-0049fje; AMBROS IM, 1991, CANCER, V67, P1886, DOI 10.1002/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO;2-U; AUSSEL C, 1993, BIOCHEMISTRY-US, V32, P10096, DOI 10.1021/bi00089a027; BANTING GS, 1989, MOL IMMUNOL, V26, P181, DOI 10.1016/0161-5890(89)90100-4; Beckerle MC, 1997, BIOESSAYS, V19, P949, DOI 10.1002/bies.950191104; BERNARD A, 1988, J IMMUNOL, V140, P1802; Bernard G, 2000, EUR J IMMUNOL, V30, P3061, DOI 10.1002/1521-4141(200010)30:10<3061::AID-IMMU3061>3.0.CO;2-M; Bernard G, 1997, J IMMUNOL, V158, P2543; BERNARD G, 1995, J IMMUNOL, V154, P26; Choi FY, 1998, J IMMUNOL, V161, P749; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; Dworzak MN, 1999, BRIT J HAEMATOL, V105, P690, DOI 10.1046/j.1365-2141.1999.01426.x; Fidler I.J., 1997, CANC PRINCIPLES PRAC; Fisher C, 1998, Ann Diagn Pathol, V2, P401, DOI 10.1016/S1092-9134(98)80042-7; GELIN C, 1989, EMBO J, V8, P3253, DOI 10.1002/j.1460-2075.1989.tb08485.x; GELIN C, 1995, LEUCOCYTE TYPING, V5; GOODFELLOW PJ, 1986, SCIENCE, V234, P740, DOI 10.1126/science.2877492; Granter SR, 1996, HUM PATHOL, V27, P1273, DOI 10.1016/S0046-8177(96)90336-6; Hahn JH, 1997, J IMMUNOL, V159, P2250; Hahn MJ, 2000, FEBS LETT, V470, P350, DOI 10.1016/S0014-5793(00)01330-2; Jung KC, 2002, J KOREAN MED SCI, V17, P483, DOI 10.3346/jkms.2002.17.4.483; Kasinrerk W, 2000, IMMUNOL LETT, V71, P33, DOI 10.1016/S0165-2478(99)00165-0; Kettunen E, 2001, INT J CANCER, V91, P492, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1094>3.0.CO;2-M; Kim MK, 2003, FEBS LETT, V546, P379, DOI 10.1016/S0014-5793(03)00567-2; Kim SH, 1998, BLOOD, V92, P4287, DOI 10.1182/blood.V92.11.4287.423k41_4287_4295; Kim SH, 2000, BLOOD, V95, P294; KOVAR H, 1990, ONCOGENE, V5, P1067; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mateo W, 2002, BLOOD, V100, P2882, DOI 10.1182/blood-2001-12-0217; Nix DA, 2001, J BIOL CHEM, V276, P34759, DOI 10.1074/jbc.M102820200; Nix DA, 1997, J CELL BIOL, V138, P1139, DOI 10.1083/jcb.138.5.1139; Pettersen RD, 1999, J IMMUNOL, V162, P7031; Pettersen RD, 2001, J IMMUNOL, V166, P4931, DOI 10.4049/jimmunol.166.8.4931; PREDA P, 1995, MICROSC RES TECHNIQ, V32, P75, DOI 10.1002/jemt.1070320108; RAMANI P, 1993, HISTOPATHOLOGY, V23, P557, DOI 10.1111/j.1365-2559.1993.tb01243.x; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Scotlandi K, 2000, CANCER RES, V60, P5134; Scotlandi K, 1996, CANCER RES, V56, P2434; Scotlandi K, 1996, HUM PATHOL, V27, P408, DOI 10.1016/S0046-8177(96)90115-X; Shen JC, 1998, MOL CARCINOGEN, V23, P13, DOI 10.1002/(SICI)1098-2744(199809)23:1<13::AID-MC2>3.0.CO;2-I; Sohn HW, 1998, AM J PATHOL, V153, P1937, DOI 10.1016/S0002-9440(10)65707-0; Sohn HW, 2001, J IMMUNOL, V166, P787, DOI 10.4049/jimmunol.166.2.787; Waclavicek M, 1998, J IMMUNOL, V161, P4671; Wingett D, 1999, CELL IMMUNOL, V193, P17, DOI 10.1006/cimm.1999.1470; Yoon SS, 2003, FEBS LETT, V540, P217, DOI 10.1016/S0014-5793(03)00268-0; Zen K, 1996, IMMUNOBIOLOGY, V195, P323, DOI 10.1016/S0171-2985(96)80049-0	47	83	91	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5664	5674		10.1038/sj.onc.1207741	http://dx.doi.org/10.1038/sj.onc.1207741			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184883				2022-12-17	WOS:000222629500011
J	Brennan, K; Gonzalez-Sancho, JM; Castelo-Soccio, LA; Howe, LR; Brown, AMC				Brennan, K; Gonzalez-Sancho, JM; Castelo-Soccio, LA; Howe, LR; Brown, AMC			Truncated mutants of the putative Wnt receptor LRP6/Arrow can stabilize beta-catenin independently of Frizzled proteins	ONCOGENE			English	Article						wnt signaling; beta-catenin; receptors; Frizzled; LRP6; Arrow	SIGNALING PATHWAY; SPEMANN ORGANIZER; ILLEGITIMATE TRANSCRIPTION; DROSOPHILA; WINGLESS; GENE; FAMILY; DENSITY; MECHANISM; MEMBER	Secreted signaling proteins of the Wnt family are known to regulate a diverse range of developmental processes, and their signaling pathway through beta-catenin is frequently activated in cancer. The identification of both Frizzled and LRP5/6 (LRP: low-density lipoprotein receptor-related protein) proteins as components of cell-surface receptors for Wnt proteins has raised questions about their individual functions. We have investigated this issue through a structure-function analysis of Frizzled and LRP proteins that have been implicated in Wnt1 signaling. Consistent with other reports, we find that LRP6/Arrow proteins deleted for their extracellular domain are able to activate the Wnt/beta-catenin signaling pathway. Importantly, our results demonstrate that this signaling from LRP6/Arrow derivatives can occur in a Frizzled- and ligand-independent manner. Furthermore, we show that the PPSP motifs within the intracellular domain of LRP6 are required for signaling. In contrast to results with LRP6, overexpression of Frizzled proteins did not activate the pathway. Based on evidence of ligand binding to both Frizzled and LRP6, current models suggest that both proteins are components of a Wnt receptor complex that signals to beta-catenin. In light of these models, our data imply that LRP5/6/Arrow proteins constitute the distal signal-initiating component of these receptors. The results also support the notion that LRP5/6 are candidate oncogenes.	Cornell Univ, Weill Med Coll, Dept Cell & Dev Biol, New York, NY 10021 USA; Rockefeller Univ, Strang Canc Res Lab, New York, NY 10021 USA	Cornell University; Rockefeller University	Brown, AMC (corresponding author), Cornell Univ, Weill Med Coll, Dept Cell & Dev Biol, 1300 York Ave, New York, NY 10021 USA.	amcbrown@med.cornell.edu	Gonzalez-Sancho, Jose/AAA-6010-2019	Gonzalez-Sancho, Jose/0000-0001-5875-1964; Howe, Louise/0000-0002-1468-7136; Brennan, Keith/0000-0002-9384-125X	NCI NIH HHS [CA47207, R01 CA047207] Funding Source: Medline; NIGMS NIH HHS [R01 GM067739, GM67739] Funding Source: Medline; Wellcome Trust [065994] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047207, R29CA047207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067739] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bhanot P, 1999, DEVELOPMENT, V126, P4175; Binari RC, 1997, DEVELOPMENT, V124, P2623; Boutros M, 2000, SCIENCE, V288, P1825, DOI 10.1126/science.288.5472.1825; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; Brown SD, 1998, BIOCHEM BIOPH RES CO, V248, P879, DOI 10.1006/bbrc.1998.9061; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; Chen CM, 1999, DEVELOPMENT, V126, P5441; Deardorff' MA, 1998, DEVELOPMENT, V125, P2687; Deardorff MA, 2001, DEVELOPMENT, V128, P3655; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Gazit A, 1999, ONCOGENE, V18, P5959, DOI 10.1038/sj.onc.1202985; Giarre M, 1998, ANN NY ACAD SCI, V857, P43, DOI 10.1111/j.1749-6632.1998.tb10106.x; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Holmen SL, 2002, J BIOL CHEM, V277, P34727, DOI 10.1074/jbc.M204989200; Howe LR, 2001, J BIOL CHEM, V276, P20108, DOI 10.1074/jbc.M010692200; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; Kaplan Jean-Claude, 1992, Human Mutation, V1, P357, DOI 10.1002/humu.1380010502; Karasawa T, 2002, J BIOL CHEM, V277, P37479, DOI 10.1074/jbc.M205658200; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Liu GZ, 2003, MOL CELL BIOL, V23, P5825, DOI 10.1128/MCB.23.16.5825-5835.2003; Longo KA, 2002, J BIOL CHEM, V277, P38239, DOI 10.1074/jbc.M206402200; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Nusse R, 1997, COLD SPRING HARB SYM, V62, P185; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Polakis P, 2000, GENE DEV, V14, P1837; Sato A, 1999, DEVELOPMENT, V126, P4421; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schweizer L, 2003, BMC CELL BIOL, V4, DOI 10.1186/1471-2121-4-4; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; Toyofuku T, 2000, J CELL BIOL, V150, P225, DOI 10.1083/jcb.150.1.225; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Umbhauer M, 2000, EMBO J, V19, P4944, DOI 10.1093/emboj/19.18.4944; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; Uusitalo M, 1999, EXP CELL RES, V253, P336, DOI 10.1006/excr.1999.4710; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wang YS, 1996, J BIOL CHEM, V271, P4468; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110	60	83	87	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4873	4884		10.1038/sj.onc.1207642	http://dx.doi.org/10.1038/sj.onc.1207642			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15064719	Green Accepted			2022-12-17	WOS:000222104200008
J	Hug, BA; Lazar, MA				Hug, BA; Lazar, MA			ETO interacting proteins	ONCOGENE			English	Article						ETO; MTG8; repression; corepressor; HDAC	ACUTE MYELOID-LEUKEMIA; HISTONE DEACETYLASE COMPLEX; N-COR; TRANSCRIPTIONAL REPRESSION; COREPRESSOR COMPLEX; FUSION TRANSCRIPT; RECEPTOR; SMRT; FAMILY; GENE	The 8; 21 translocation produces a fusion between the ETO gene and that encoding the myeloid transcription factor AML1. The AML1-ETO fusion substitutes the majority of the ETO protein for the coregulator recruitment domains of AML1. Biochemical analyses of ETO have led to the identification of numerous interacting proteins including many corepressors. Importantly, the proteins interacting with ETO are different from those of wild-type AML1, suggesting that altered coregulator recruitment underlies the oncogenic properties of AML1 - ETO. The list of corepressors capable of binding ETO includes histone deacetylases (HDACs) and components of distinct HDAC core complexes. These investigations have provided mechanistic insight into corepressor recruitment by ETO and clues to the leukemogenic activity of AML1 - ETO.	Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Diabet Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Lazar, MA (corresponding author), Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, 611 CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.	brucehug@mail.med.upenn.edu; lazar@mail.med.upenn.edu	Lazar, Mitchell A/AAF-3738-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK043806, R01DK045586, R01DK043806] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL004339] Funding Source: Medline; NIDDK NIH HHS [DK43806, DK45586] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Ansieau S, 2002, J BIOL CHEM, V277, P4906, DOI 10.1074/jbc.M110078200; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Davis JN, 2003, GENE, V303, P1, DOI 10.1016/S0378-1119(02)01172-1; Davis JN, 1999, ONCOGENE, V18, P1375, DOI 10.1038/sj.onc.1202412; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; ERICKSON PF, 1994, CANCER RES, V54, P1782; Espinas ML, 2000, EMBO REP, V1, P253, DOI 10.1093/embo-reports/kvd046; FEINSTEIN PG, 1995, GENETICS, V140, P573; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gottlieb PD, 2002, NAT GENET, V31, P25, DOI 10.1038/ng866; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; Guenther MG, 2000, GENE DEV, V14, P1048; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; Hug BA, 2002, CANCER RES, V62, P2906; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Hung HL, 2001, J BIOL CHEM, V276, P10715, DOI 10.1074/jbc.M007846200; Iizuka M, 2003, CURR OPIN GENET DEV, V13, P154, DOI 10.1016/S0959-437X(03)00020-0; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Kozu Tomoko, 1997, Leukemia (Basingstoke), V11, P297; Li H, 1997, MOL ENDOCRINOL, V11, P2025, DOI 10.1210/me.11.13.2025; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; Li JW, 2002, GENE DEV, V16, P687, DOI 10.1101/gad.962502; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Morohoshi F, 2000, GENE, V241, P287, DOI 10.1016/S0378-1119(99)00481-3; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Odaka R, 2000, ONCOGENE, V19, P3584, DOI 10.1038/sj.onc.1203689; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang L, 2002, GENE, V285, P119, DOI 10.1016/S0378-1119(02)00418-3; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Wolford JK, 1998, GENE, V212, P103, DOI 10.1016/S0378-1119(98)00141-3; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Yu JJ, 2003, EMBO J, V22, P3403, DOI 10.1093/emboj/cdg326; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	50	83	88	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2004	23	24					4270	4274		10.1038/sj.onc.1207674	http://dx.doi.org/10.1038/sj.onc.1207674			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156183				2022-12-17	WOS:000221586000012
J	Dong, ZZ; Liu, LH; Han, BG; Pincheira, R; Zhang, JT				Dong, ZZ; Liu, LH; Han, BG; Pincheira, R; Zhang, JT			Role of eIF3 p170 in controlling synthesis of ribonucleotide reductase M2 and cell growth	ONCOGENE			English	Article						eIF3; anchorage-independent cell growth; p170; ribonucleotide reductase; translation initiation factor; antisense cDNA	MALIGNANT-TRANSFORMATION; PROTEIN-SYNTHESIS; GENE-EXPRESSION; MESSENGER-RNA; SUBUNIT; TRANSLATION; CYCLE; R2; OVEREXPRESSION; PROLIFERATION	Translation initiation in eukaryotes is a rate-limiting step in protein synthesis. It is a complicated process that involves many eukaryotic initiation factors (eIFs). Altering the expression level or the function of eIFs may influence the synthesis of some proteins and consequently cause abnormal cell growth and malignant transformation. P170, the largest putative subunit of eIF3, has been found elevated in human breast, cervical, esophageal, and lung cancers, suggesting that p170 may have a potential role in malignant transformation and/or cell growth control. Our recent studies suggested that p170 is likely a translational regulator and it may mediate the effect of mimosine on the translation of a subset mRNAs. Mimosine, a plant nonprotein amino acid, inhibits mammalian DNA synthesis, an essential event of cell growth. The rate-limiting step in DNA synthesis is the conversion of the ribonucleotides to their corresponding deoxyribonucleotides catalysed by ribonucleotide reductase of which the activity is regulated by the level of its M2 subunit. It has been reported that inhibiting the activity of M2 also inhibits cell growth. To understand the relationship between protein and DNA synthesis and between p170 and cell growth control, we investigated in this study whether p170 regulates the synthesis of M2 and, thus, cell growth. We found that altering the expression level of p170 changes the synthesis rate of both M2 and DNA. Decreasing p170 expression in human lung cancer cell line H1299 and breast cancer cell line MCF7 significantly reversed their malignant growth phenotype. However, the overall [S-35] methionine incorporation following dramatic decrease in p170 expression was only similar to25% less than the control cells. These observations, together with our previous findings, suggest that p170 may regulate the translation of a subset mRNAs and its elevated expression level may be important for cancer cell growth and for maintaining their malignant phenotype.	Indiana Univ, Sch Med,Ctr Canc, Dept Pharmacol & Toxicol, Walther Oncol Ctr,Walther Canc Inst, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Zhang, JT (corresponding author), Indiana Univ, Sch Med,Ctr Canc, Dept Pharmacol & Toxicol, Walther Oncol Ctr,Walther Canc Inst, 1044 W Walnut St,R4-166, Indianapolis, IN 46202 USA.	jianzhan@iupui.edu	Zhang, Jian-Ting/L-8334-2015	Pincheira, Roxana/0000-0003-4277-5245	NCI NIH HHS [CA64539, CA94961] Funding Source: Medline; NIGMS NIH HHS [GM59475] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094961, R01CA064539, R29CA064539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059475] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abid MR, 1999, J BIOL CHEM, V274, P35991, DOI 10.1074/jbc.274.50.35991; AMARA FM, 1994, J BIOL CHEM, V269, P6709; Andrus L, 1998, BIOCHEM PHARMACOL, V55, P1807, DOI 10.1016/S0006-2952(98)00053-7; Bachmann F, 1997, CANCER RES, V57, P988; BENNE R, 1976, P NATL ACAD SCI USA, V73, P3005, DOI 10.1073/pnas.73.9.3005; BJORKLUND S, 1992, EMBO J, V11, P4953, DOI 10.1002/j.1460-2075.1992.tb05602.x; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; Block KL, 1998, J BIOL CHEM, V273, P31901, DOI 10.1074/jbc.273.48.31901; Buratti E, 1998, NUCLEIC ACIDS RES, V26, P3179, DOI 10.1093/nar/26.13.3179; Chaudhuri J, 1997, J BIOL CHEM, V272, P30975, DOI 10.1074/jbc.272.49.30975; Chen GP, 1999, INT J CANCER, V84, P95, DOI 10.1002/(SICI)1097-0215(19990420)84:2<95::AID-IJC1>3.0.CO;2-N; Chen SY, 2000, ANTISENSE NUCLEIC A, V10, P111, DOI 10.1089/oli.1.2000.10.111; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; Dellas A, 1998, CANCER, V83, P1376, DOI 10.1002/(SICI)1097-0142(19981001)83:7<1376::AID-CNCR15>3.0.CO;2-1; Dong ZZ, 1998, AM J PHYSIOL-GASTR L, V274, pG535, DOI 10.1152/ajpgi.1998.274.3.G535; Dong ZZ, 2003, MOL BIOL CELL, V14, P3942, DOI 10.1091/mbc.E02-12-0784; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; ENGSTROM Y, 1985, J BIOL CHEM, V260, P9114; ERIKSSON S, 1984, J BIOL CHEM, V259, P1695; Fan HZ, 1996, P NATL ACAD SCI USA, V93, P14036, DOI 10.1073/pnas.93.24.14036; Fernandez J, 2002, J BIOL CHEM, V277, P2050, DOI 10.1074/jbc.M109199200; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; GILBERT DM, 1995, J BIOL CHEM, V270, P9597, DOI 10.1074/jbc.270.16.9597; Han BG, 2002, MOL CELL BIOL, V22, P7372, DOI 10.1128/MCB.22.21.7372-7384.2002; HANAUSKEABEL HM, 1994, BBA-MOL CELL RES, V1221, P115, DOI 10.1016/0167-4889(94)90003-5; HANAUSKEABEL HM, 1995, FEBS LETT, V366, P92, DOI 10.1016/0014-5793(95)00493-S; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P637; HURTA RAR, 1995, J CELL BIOCHEM, V57, P543, DOI 10.1002/jcb.240570319; JIANG W, 1993, ONCOGENE, V8, P3447; Kalejta RF, 1997, EXP CELL RES, V231, P173, DOI 10.1006/excr.1996.3444; KANG HA, 1994, J BIOL CHEM, V269, P3934; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lee Y, 2003, CANCER RES, V63, P2802; Li Q, 1998, TOXICOL APPL PHARM, V150, P154, DOI 10.1006/taap.1998.8394; Manjeshwar S, 1999, MOL CARCINOGEN, V24, P188, DOI 10.1002/(SICI)1098-2744(199903)24:3<188::AID-MC5>3.0.CO;2-#; MANN GJ, 1988, CANCER RES, V48, P5151; Mayeur GL, 2002, FEBS LETT, V514, P49, DOI 10.1016/S0014-5793(02)02307-4; Methot N, 1996, MOL CELL BIOL, V16, P5328; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; Park JB, 2000, BIOCHEM BIOPH RES CO, V267, P651, DOI 10.1006/bbrc.1999.1980; Pincheira R, 2001, BRIT J CANCER, V84, P1520, DOI 10.1054/bjoc.2001.1828; Sambrook J., 1989, MOL CLONING; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; WRIGHT JA, 1990, BIOCHEM CELL BIOL, V68, P1364, DOI 10.1139/o90-199; YARBRO JW, 1992, SEMIN ONCOL, V19, P1; Zhou B, 2001, CYTOGENET CELL GENET, V95, P52, DOI 10.1159/000057017; ZHOU BS, 1995, CANCER RES, V55, P1328; Zhou BS, 1998, CLIN EXP METASTAS, V16, P43	50	83	97	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3790	3801		10.1038/sj.onc.1207465	http://dx.doi.org/10.1038/sj.onc.1207465			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15094776				2022-12-17	WOS:000221242500006
J	Chikumi, H; Barac, A; Behbahani, B; Gao, Y; Teramoto, H; Zheng, Y; Gutkind, JS				Chikumi, H; Barac, A; Behbahani, B; Gao, Y; Teramoto, H; Zheng, Y; Gutkind, JS			Homo- and hetero-oligomerization of PDZ-RhoGEF, LARG and p115RhoGEF by their C-terminal region regulates their in vivo Rho GEF activity and transforming potential	ONCOGENE			English	Article						Rho; guanine-nucleotide exchange factor; transformation; GTPases; G proteins	NUCLEOTIDE EXCHANGE FACTORS; VAV PROTOONCOGENE PRODUCT; HETEROTRIMERIC G-PROTEINS; LEUKEMIA-ASSOCIATED RHO; TYROSINE PHOSPHORYLATION; GUANOSINE TRIPHOSPHATASES; CELLULAR-TRANSFORMATION; DEPENDENT ACTIVATION; P115 RHOGEF; DBL FAMILY	PDZ-RhoGEF, LARG, and p115RhoGEF are members of a newly identified family of Rho-guanine nucleotide exchange factors (GEFs) exhibiting a unique structural feature consisting of the presence of an area of similarity to regulators of G protein signaling (RGS). This RGS-like (RGL) domain provides a functional motif by which Galpha(12) and Galpha(13) can bind and regulate the activity of these RhoGEFs, thus providing a direct link from these heterotrimeric G proteins to Rho. PDZ-RhoGEF and LARG can also be phosphorylated by tyrosine kinases, including FAK, and associate with Plexin B, a semaphorin receptor, which controls axon guidance during development, through their PDZ domain, thereby stimulating Rho. Interestingly, while characterizing a PDZ-RhoGEF antiserum, we found that a transfected PDZ-RhoGEF construct associated with the endogenous PDZ-RhoGEF. Indeed, we observed that PDZ-RhoGEF and LARG can form homo- and hetero-oligomers, whereas p115RhoGEF can only homo-oligomerize, and that this intermolecular interaction was mediated by their unique C-terminal regions. Deletion of the C-terminal tail of PDZ-RhoGEF had no significant effect on the GEF catalytic activity towards Rho in vitro, but resulted in a drastic increase in the ability to stimulate a serum response element reporter and the accumulation of the GTP-bound Rho in vivo. Furthermore, removal of the C-termini of each of the three RGL-containing GEFs unleashed their full transforming potential. Together, these findings suggest the existence of a novel mechanism controlling the activity of PDZ-RhoGEF, LARG, and p115RhoGEF, which involves homo- and hetero-oligomerization through their inhibitory C-terminal region.	Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Childrens Hosp Res Fdn, Cincinnati, OH 45229 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, 9000 Rockville Pike,Bldg 30,Room 211, Bethesda, MD 20892 USA.	sg39v@nih.gov	Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Zheng, Yi/J-7235-2015	Gutkind, J. Silvio/0000-0002-5150-4482; Zheng, Yi/0000-0001-7089-6074; Barac, Ana/0000-0002-9935-8904	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; Aurandt J, 2002, P NATL ACAD SCI USA, V99, P12085, DOI 10.1073/pnas.142433199; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HART MJ, 1994, J BIOL CHEM, V269, P62; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Kim S, 2001, J BIOL CHEM, V276, P10581, DOI 10.1074/jbc.C000806200; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Longenecker KL, 2001, STRUCTURE, V9, P559, DOI 10.1016/S0969-2126(01)00620-7; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Perrot V, 2002, J BIOL CHEM, V277, P43115, DOI 10.1074/jbc.M206005200; Ponting CP, 1999, J MOL MED, V77, P695, DOI 10.1007/s001099900054; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Sakabe K, 2002, FEBS LETT, V511, P15, DOI 10.1016/S0014-5793(01)03264-1; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Taya S, 2001, J CELL BIOL, V155, P809, DOI 10.1083/jcb.200106139; Teramoto H, 1997, J BIOL CHEM, V272, P10751; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zhu KJ, 2001, MOL CELL BIOL, V21, P425, DOI 10.1128/MCB.21.2.425-437.2001; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022	36	83	84	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					233	240		10.1038/sj.onc.1207012	http://dx.doi.org/10.1038/sj.onc.1207012			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712228				2022-12-17	WOS:000187895300024
J	Gallego, MI; Bierie, B; Hennighausen, L				Gallego, MI; Bierie, B; Hennighausen, L			Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways	ONCOGENE			English	Article						breast cancer; transgenic mice; HGF; scatter factor; c-Met	HEPATOCYTE GROWTH-FACTOR; MET TYROSINE KINASE; NEGATIVE BREAST-CANCER; FACTOR SCATTER FACTOR; C-MET; BETA-CATENIN; GLAND DEVELOPMENT; FACTOR/SCATTER FACTOR; RECEPTOR MET; COLORECTAL-CANCER	Overexpression of hepatocyte growth factor (HGF), also called scatter factor (SIT), and its receptor c-Met are associated with poor prognosis for cancer patients. In particular, breast cancer cells can produce HGF that acts in a paracrine as well as in an autocrine manner. Therefore, HGF and c-Met are putative targets for cancer therapy. To explore HGF/c-Met signaling in breast cancer, we have generated transgenic mice expressing HGF specifically in mammary epithelium under the transcriptional control of the whey acidic protein (WAP) gene promoter. WAP-HGF transgenic females developed hyperplastic ductal trees and multifocal invasive tumors after several pregnancies, some of which progressed to lung metastases. Tumors produced HGF and displayed phosphorylated c-Met, which correlated with increased Akt as well as c-myc activation. A high growth rate, as demonstrated by Ki67 nuclear antigen staining, and a lack of progesterone receptor were characteristic of the tumors. Immunohistochemical analysis revealed areas of osteopontin (Opn) expression in WAP-HGF tumors and lung metastases in agreement with a previously reported role for Opn in invasive growth. We suggest that these mice may serve as a new breast cancer model for the evaluation of the effects of unscheduled HGF expression in breast cancer.	Fdn Marcelino Botin, Ctr Invest Energet Medioambientales & Tecnol, Project Breast Canc, Madrid 28042, Spain; NIDDK, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Gallego, MI (corresponding author), CIEMAT, Av Complutense 22,Edificio 7, E-28040 Madrid, Spain.			Gallego, Marta I./0000-0003-0143-2553; Hennighausen, Lothar/0000-0001-8319-9841	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK061000, ZIADK061000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aulmann S, 2002, BREAST CANCER RES TR, V74, P25, DOI 10.1023/A:1016061327812; Bieche I, 1999, INT J CANCER, V82, P908, DOI 10.1002/(SICI)1097-0215(19990909)82:6<908::AID-IJC22>3.0.CO;2-N; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Boon EMJ, 2002, CANCER RES, V62, P5126; Bowers DC, 2000, CANCER RES, V60, P4277; Camp RL, 1999, CANCER, V86, P2259, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2259::AID-CNCR13>3.0.CO;2-2; Cui XJ, 2003, MOL ENDOCRINOL, V17, P575, DOI 10.1210/me.2002-0318; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Edakuni G, 2001, PATHOL INT, V51, P172, DOI 10.1046/j.1440-1827.2001.01182.x; Elliott BE, 2002, CAN J PHYSIOL PHARM, V80, P91, DOI 10.1139/y02-010; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; Gallagher RCJ, 2002, ONCOGENE, V21, P6446, DOI 10.1038/sj.onc.1205892; Ghoussoub RAD, 1998, CANCER, V82, P1513, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7; Greenberg R, 2003, BREAST CANCER RES, V5, pR71, DOI 10.1186/bcr588; Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8; HOGAN B, 1994, MANIPULATING MOUSE E; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; Kamalati T, 1999, J MAMMARY GLAND BIOL, V4, P69, DOI 10.1023/A:1018756620265; Kang JY, 2003, CANCER RES, V63, P1101; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; KORDON EC, 1995, J VIROL, V69, P8066, DOI 10.1128/JVI.69.12.8066-8069.1995; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Medico E, 2001, CANCER RES, V61, P5861; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Miyoshi K, 2002, P NATL ACAD SCI USA, V99, P219, DOI 10.1073/pnas.012414099; Monga SPS, 2002, CANCER RES, V62, P2064; Nakopoulou L, 2000, HISTOPATHOLOGY, V36, P313; Nemir M, 2000, J BIOL CHEM, V275, P969, DOI 10.1074/jbc.275.2.969; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; NIRANJAN B, 1995, DEVELOPMENT, V121, P2897; Oates AJ, 1996, ONCOGENE, V13, P97; Ocal IT, 2003, CANCER-AM CANCER SOC, V97, P1841, DOI 10.1002/cncr.11335; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; PITTIUS CW, 1988, P NATL ACAD SCI USA, V85, P5874, DOI 10.1073/pnas.85.16.5874; Pollard JW, 2001, BREAST CANCER RES, V3, P230, DOI 10.1186/bcr301; Rahimi N, 1996, CELL GROWTH DIFFER, V7, P263; Rittling SR, 1997, CELL GROWTH DIFFER, V8, P1061; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Rudland PS, 2002, CANCER RES, V62, P3417; Schlotter CM, 2003, BREAST CANCER RES, V5, pR30, DOI 10.1186/bcr568; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SORIANO JV, 1995, J CELL SCI, V108, P413; Stal O, 2003, BREAST CANCER RES, V5, pR37, DOI 10.1186/bcr569; Takeuchi H, 2003, CLIN CANCER RES, V9, P1480; Tuck AB, 2000, J CELL BIOCHEM, V78, P465, DOI 10.1002/1097-4644(20000901)78:3<465::AID-JCB11>3.0.CO;2-C; Tuck AB, 2001, J MAMMARY GLAND BIOL, V6, P419, DOI 10.1023/A:1014734930781; Tuck AB, 1996, AM J PATHOL, V148, P225; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Walter KA, 2002, MOL CELL BIOL, V22, P2703, DOI 10.1128/MCB.22.8.2703-2715.2002; Wang X, 2002, MOL CELL, V9, P411, DOI 10.1016/S1097-2765(02)00439-2; WOODROOFE C, 1992, DNA CELL BIOL, V11, P587, DOI 10.1089/dna.1992.11.587; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; YAMASHITA J, 1994, CANCER RES, V54, P1630; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Yant J, 1998, EXP CELL RES, V241, P476, DOI 10.1006/excr.1998.4028; Yoshida S, 2003, J INVEST DERMATOL, V120, P335, DOI 10.1046/j.1523-1747.2003.12039.x; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358	62	83	88	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8498	8508		10.1038/sj.onc.1207063	http://dx.doi.org/10.1038/sj.onc.1207063			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627990				2022-12-17	WOS:000186650300013
J	Gupta, A; Inaba, S; Wong, OK; Fang, GW; Liu, JW				Gupta, A; Inaba, S; Wong, OK; Fang, GW; Liu, JW			Breast cancer-specific gene 1 interacts with the mitotic checkpoint kinase BubR1	ONCOGENE			English	Article						BCSG1; BubR1; mitotic checkpoint; yeast two-hybrid; aneuploidy; multinucleation	ANAPHASE-PROMOTING COMPLEX; KINETOCHORE LOCALIZATION; SYNUCLEIN-GAMMA; ABERRANT EXPRESSION; PROTEIN BUBR1; HBUBR1; CELLS; MAD2; PHOSPHORYLATION; APOPTOSIS	The abnormal expression of breast cancer-specific gene 1 (BCSG1) in malignant mammary epithelial cells is highly associated with the development and progression of breast cancer. A series of in vitro and in vivo studies performed in our laboratory and others have demonstrated that BCSG1 expression significantly stimulates proliferation, invasion, and metastasis of breast cancer cells. However, currently little is known about how BCSG1 exerts its oncogenic functions. To elucidate the cellular mechanisms underlying the effects of BCSG1 in breast cancer cells, we used a yeast two-hybrid system to screen for proteins that could associate with BCSG1. Through this screening, we identified the mitotic checkpoint protein BubR1 as a novel binding partner of BCSG1. The specific association of BCSG1 with BubR1 in breast cancer cells was demonstrated by immunoprecipitation and GST pull-down assays. Intriguingly, experiments conducted in four different cell lines all showed that exogenous expressions of BCSG1 consistently reduce the cellular levels of the BubR1 protein without affecting BubR1 mRNA expression. The tendency of endogenous BCSG1 expression coinciding with lower BubR1 protein levels was also observed in seven out of eight breast cancer cell lines. We further showed that the reducing effect of BCSG1 on BubR1 protein expression could be prevented by treating BCSG1-transfected cells with MG-132, a selective 26S proteasome inhibitor, implying that the proteasome machinery may be involved in the BCSG1-induced reduction of the BubR1 protein. Accompanied with a reduction of BubR1 protein level, BCSG1 expression resulted in multinucleation of breast cancer cells upon treatment with spindle inhibitor nocodazole, indicating an impaired mitotic checkpoint. Taken together, our novel findings suggest that BCSG1 may accelerate the progression of breast cancer at least in part by compromising the mitotic checkpoint control through inactivation of BubR1.	VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Liu, JW (corresponding author), VA Palo Alto Hlth Care Syst, 3801 Miranda Ave, Palo Alto, CA 94304 USA.	Jingwen.Liu@med.va.gov			NCI NIH HHS [1R01CA83648-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083648] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bin OY, 2002, CLIN ENDOCRINOL, V56, P341, DOI 10.1046/j.1365-2265.2002.01475.x; Bruening W, 2000, CANCER-AM CANCER SOC, V88, P2154, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2154::AID-CNCR23>3.0.CO;2-9; Canman JC, 2002, J CELL SCI, V115, P3787, DOI 10.1242/jcs.00057; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chan GKT, 1998, J CELL BIOL, V143, P49, DOI 10.1083/jcb.143.1.49; Chen RH, 2002, J CELL BIOL, V158, P487, DOI 10.1083/jcb.200204048; Davenport JW, 1999, GENOMICS, V55, P113, DOI 10.1006/geno.1998.5629; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Fagin JA, 2002, MOL ENDOCRINOL, V16, P903, DOI 10.1210/me.16.5.903; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Gupta A, 2003, CANCER RES, V63, P664; Hoyt MA, 2001, J CELL BIOL, V154, P909, DOI 10.1083/jcb.200108010; Jablonski SA, 1998, CHROMOSOMA, V107, P386, DOI 10.1007/s004120050322; Ji HJ, 1997, CANCER RES, V57, P759; Jia TL, 1999, CANCER RES, V59, P742; Liu JW, 2000, BREAST CANCER RES TR, V62, P99, DOI 10.1023/A:1006418219012; LU A, 2002, J BIOL CHEM, V12, P12; Lu AP, 2001, ONCOGENE, V20, P5173, DOI 10.1038/sj.onc.1204668; Myrie KA, 2000, CANCER LETT, V152, P193, DOI 10.1016/S0304-3835(00)00340-2; Ohshima K, 2000, CANCER LETT, V158, P141, DOI 10.1016/S0304-3835(00)00512-7; Page AM, 1999, ANNU REV BIOCHEM, V68, P583, DOI 10.1146/annurev.biochem.68.1.583; Pan ZZ, 2002, J BIOL CHEM, V277, P35050, DOI 10.1074/jbc.M201650200; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; ROBERTS BT, 1994, MOL CELL BIOL, V14, P8282, DOI 10.1128/MCB.14.12.8282; Shannon KB, 2002, MOL BIOL CELL, V13, P3706, DOI 10.1091/mbc.E02-03-0137; Shichiri M, 2002, CANCER RES, V62, P13; Skoufias DA, 2001, P NATL ACAD SCI USA, V98, P4492, DOI 10.1073/pnas.081076898; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Surguchov A, 2001, CELL MOTIL CYTOSKEL, V49, P218, DOI 10.1002/cm.1035; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Taylor SS, 2001, J CELL SCI, V114, P4385; WANG YH, 1991, P NATL ACAD SCI USA, V88, P8779, DOI 10.1073/pnas.88.19.8779	33	83	93	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2003	22	48					7593	7599		10.1038/sj.onc.1206880	http://dx.doi.org/10.1038/sj.onc.1206880			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576821				2022-12-17	WOS:000186113000006
J	Bohm, M; Sawicka, K; Siebrasse, JP; Brehmer-Fastnacht, A; Peters, R; Klempnauer, KH				Bohm, M; Sawicka, K; Siebrasse, JP; Brehmer-Fastnacht, A; Peters, R; Klempnauer, KH			The transformation suppressor protein Pdcd4 shuttles between nucleus and cytoplasm and binds RNA	ONCOGENE			English	Article						Pdcd4; nuclear export signals; RNA-binding; Myb target gene	INITIATION-FACTOR 4G; EUKARYOTIC TRANSLATION; QUALITY-CONTROL; C-MYB; EXPORT; GENE; CRM1; IDENTIFICATION; PROMOTER; MESSAGE	The Pdcd4 gene has originally been isolated in a search for genes that are activated in cells undergoing apoptosis. Independent of these studies, the Pdcd4 gene has been implicated in the suppression of tumor-promoter-mediated transformation of keratinocytes and as a downstream target of Myb in hematopoietic cells. The Pdcd4 protein has weak homology to the eucaryotic translation initiation factor eIF4G and has been shown to interact with certain translation initiation factors. To explore the molecular function of the Pdcd4 protein, we have studied its subcellular localization. We show that the Pdcd4 protein is a predominantly nuclear protein under normal growth conditions and that it is exported from the nucleus by a leptomycin B-sensitive mechanism upon serum withdrawal. The protein contains two nuclear export signals, one of which is very potent. In addition, we demonstrate that the Pdcd4 protein has RNA-binding activity and that the sequences involved in RNA-binding are located in the amino-terminal part of the protein. Taken together, our data raise the possibility that Pdcd4 is involved in some aspect of nuclear RNA metabolism in addition to its suspected role in protein translation.	Univ Munster, Inst Biochem, D-48149 Munster, Germany; Univ Munster, Inst Med Biophys, D-48149 Munster, Germany	University of Munster; University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de	Peters, Reiner/E-7352-2011	Sawicka, Kirsty/0000-0003-4195-6327				Appl H, 2002, ONCOGENE, V21, P3076, DOI 10.1038/sj.onc.1205427; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Elfgang C, 1999, P NATL ACAD SCI USA, V96, P6229, DOI 10.1073/pnas.96.11.6229; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Goke A, 2002, BIOCHEM BIOPH RES CO, V297, P78, DOI 10.1016/S0006-291X(02)02129-0; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Kang MJ, 2002, BIOCHEM BIOPH RES CO, V293, P617, DOI 10.1016/S0006-291X(02)00264-4; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; Lykke-Andersen J, 2001, CURR BIOL, V11, pR88, DOI 10.1016/S0960-9822(01)00036-7; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; McKendrick L, 2001, MOL CELL BIOL, V21, P3632, DOI 10.1128/MCB.21.11.3632-3641.2001; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NISHI K, 1994, J BIOL CHEM, V269, P6320; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Perez-Canadillas JM, 2001, CURR OPIN STRUC BIOL, V11, P53, DOI 10.1016/S0959-440X(00)00164-0; Schell T, 2002, GENOME BIOL, V3; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; Schlichter U, 2001, BBA-GENE STRUCT EXPR, V1520, P99, DOI 10.1016/S0167-4781(01)00252-4; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Wagner C, 1998, MAR BIOL, V131, P411, DOI 10.1007/s002270050334; Weiss MA, 1998, BIOPOLYMERS, V48, P167, DOI 10.1002/(SICI)1097-0282(1998)48:2<167::AID-BIP6>3.0.CO;2-8; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Westhof E, 1999, CURR OPIN STRUC BIOL, V9, P293, DOI 10.1016/S0959-440X(99)80039-6; Weston K, 1999, ONCOGENE, V18, P3034, DOI 10.1038/sj.onc.1202728; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yoshinaga H, 1999, PATHOL INT, V49, P1067, DOI 10.1046/j.1440-1827.1999.00995.x	29	83	91	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4905	4910		10.1038/sj.onc.1206710	http://dx.doi.org/10.1038/sj.onc.1206710			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894233				2022-12-17	WOS:000184344600015
J	Henneke, G; Koundrioukoff, S; Hubscher, U				Henneke, G; Koundrioukoff, S; Hubscher, U			Phosphorylation of human Fen1 by cyclin-dependent kinase modulates its role in replication fork regulation	ONCOGENE			English	Article						replication; cell cycle; Fen1; Cdks; phosphorylation	EUKARYOTIC DNA-REPLICATION; HUMAN FLAP ENDONUCLEASE-1; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; CDC2 PHOSPHORYLATION; MOTIF PRESENT; PCNA-BINDING; YEAST; REPAIR; PROTEINS	Cyclin-dependent kinase (Cdk) Cdk1-Cyclin A can phosphorylate Flap endonuclease 1 (Fen1), a key-enzyme of the DNA replication machinery, in late S phase. Cdk1-cyclin A forms a complex in vitro and in vivo with Fen1. Furthermore, Fen1 phosphorylation is detected in vivo and depends upon Cdks activity. As a functional consequence of phosphorylation by Cdk1-Cyclin A in vitro, endo- and exonuclease activities of Fen1 are reduced whereas its DNA binding is not affected. Moreover, phosphorylation of Fen1 by Cdk1-Cyclin A abrogates its proliferating cell nuclear antigen (PCNA) binding thus preventing stimulation of Fen1 by PCNA. Concomitantly, human cells expressing the S187A mutant defective for Cdk1-Cyclin A phosphorylation accumulate in S phase consistent with a failure in cell cycle regulation through DNA replication. Our results suggest a novel regulatory role of Cdks onto the end of S phase by targeting directly a key enzyme involved in DNA replication.	Univ Zurich, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland	University of Zurich	Hubscher, U (corresponding author), Univ Zurich, Inst Vet Biochem & Mol Biol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	hubscher@vetbio.unizh.ch		Henneke, Ghislaine/0000-0002-2985-5526				ABRAHAM RT, 1995, BIOL CELL, V83, P105, DOI 10.1016/0248-4900(96)81298-6; Adams PD, 1996, MOL CELL BIOL, V16, P6623; Bae SH, 2000, J BIOL CHEM, V275, P38022, DOI 10.1074/jbc.M006513200; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Biswas EE, 1997, BIOCHEMISTRY-US, V36, P5955, DOI 10.1021/bi962890u; Brosh RM, 2001, EMBO J, V20, P5791; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; Dahm K, 2002, ONCOGENE, V21, P7710, DOI 10.1038/sj.onc.1205872; Donaldson AD, 1999, CURR OPIN GENET DEV, V9, P62, DOI 10.1016/S0959-437X(99)80009-4; Ducoux M, 2001, J BIOL CHEM, V276, P49258, DOI 10.1074/jbc.M106990200; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; Fotedar R, 1995, Prog Cell Cycle Res, V1, P73; Frouin I, 2002, EMBO J, V21, P2485, DOI 10.1093/emboj/21.10.2485; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Hasan S, 2001, MOL CELL, V7, P1221, DOI 10.1016/S1097-2765(01)00272-6; Henneke G, 2003, EMBO REP, V4, P252, DOI 10.1038/sj.embor.embor774; Henricksen LA, 2000, J BIOL CHEM, V275, P16420, DOI 10.1074/jbc.M909635199; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; Johnston L H, 2000, Prog Cell Cycle Res, V4, P61; Johnston LH, 1999, TRENDS CELL BIOL, V9, P249, DOI 10.1016/S0962-8924(99)01586-X; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kang HY, 2000, GENETICS, V155, P1055; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Koundrioukoff S, 2000, J BIOL CHEM, V275, P22882, DOI 10.1074/jbc.M001850200; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Lin XH, 1998, P NATL ACAD SCI USA, V95, P14693, DOI 10.1073/pnas.95.25.14693; Matsuzaki Y, 2002, NUCLEIC ACIDS RES, V30, P3273, DOI 10.1093/nar/gkf440; MCVEY D, 1993, J VIROL, V67, P5206, DOI 10.1128/JVI.67.9.5206-5215.1993; Morgan DO, 1996, CURR OPIN CELL BIOL, V8, P767, DOI 10.1016/S0955-0674(96)80076-7; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Nurse P, 2000, CELL, V100, P71, DOI 10.1016/S0092-8674(00)81684-0; Parenteau J, 1999, MOL CELL BIOL, V19, P4143; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; Rossi R, 1999, EMBO J, V18, P5745, DOI 10.1093/emboj/18.20.5745; Schub O, 2001, J BIOL CHEM, V276, P38076; Schurtenberger P, 1998, J MOL BIOL, V275, P123, DOI 10.1006/jmbi.1997.1435; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Storici F, 2002, EMBO J, V21, P5930, DOI 10.1093/emboj/cdf587; Stucki M, 2001, J BIOL CHEM, V276, P7843, DOI 10.1074/jbc.M008829200; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; Vas A, 2001, MOL CELL BIOL, V21, P5767, DOI 10.1128/MCB.21.17.5767-5777.2001; Voitenleitner C, 1997, ONCOGENE, V14, P1611, DOI 10.1038/sj.onc.1200975; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; Wu SM, 1998, J BIOL CHEM, V273, P9561, DOI 10.1074/jbc.273.16.9561; Wu XT, 1999, P NATL ACAD SCI USA, V96, P1303, DOI 10.1073/pnas.96.4.1303; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036	56	83	87	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4301	4313		10.1038/sj.onc.1206606	http://dx.doi.org/10.1038/sj.onc.1206606			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853968				2022-12-17	WOS:000183978900001
J	Sommer, KW; Schamberger, CJ; Schmidt, GE; Sasgary, S; Cerni, C				Sommer, KW; Schamberger, CJ; Schmidt, GE; Sasgary, S; Cerni, C			Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras	ONCOGENE			English	Article						survivin; c-H-ras; PI3-K; MEK1; HaCat; rat cell lines; apoptosis; transformation	WILD-TYPE P53; PHOSPHATIDYLINOSITOL-3-OH KINASE; SP1 PHOSPHORYLATION; ENDOTHELIAL-CELLS; CDK INHIBITORS; IN-VIVO; PATHWAY; GENE; EXPRESSION; CANCER	Among the inhibitors of apoptosis proteins (IAPs), survivin has attracted special attention through its involvement in human cancer. The mechanism underlying tumour-associated survivin re-expression is not known. We found a correlation between exogenous c-H-Ras oncoprotein and endogenous survivin in a series of rat cell lines, which expressed defined oncogenes. Moreover, human HaCat cells, transfected with a constitutively activated c-H-ras gene, had significantly increased survivin levels. To study the interdependence of the two proteins, we generated a rat cell line that expressed a dexamethasone-inducible c-H-ras construct. Induction of c-H-Ras expression was followed by rapid upregulation of survivin. Conversely, downregulation of the oncoprotein resulted in prompt reduction of survivin to baseline value. c-H-Ras-induced survivin was expressed constitutively and independent of cell cycle progression or proliferation. Compromising Ras-stimulated PI3-K activity and MEK1 by chemicals abolished survivin expression and was associated with apoptotic cell death. Upregulation of survivin appeared to be an important activity of c-H-Ras oncoprotein, since cotransfection of a survivin-antisense construct into c-myc/c-H-ras-transfected primary rat embryo cells resulted in profound reduction of transformed clones. It is tempted to speculate that the frequent presence of survivin in human cancer cells might be a consequence of activated Ras-signalling pathways.	Univ Vienna, Inst Canc Res, A-1090 Vienna, Austria	University of Vienna	Cerni, C (corresponding author), Univ Vienna, Inst Canc Res, Borschkegasse 8A, A-1090 Vienna, Austria.	Christa.Cerni@univie.ac.at						Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Bao RD, 2002, J NATL CANCER I, V94, P522; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CERNI C, 1986, CURR TOP MICROBIOL, V132, P193; CERNI C, 1995, ONCOGENE, V11, P587; Cerni C, 2002, ONCOGENE, V21, P447, DOI 10.1038/sj.onc.1205107; CERNI C, 1990, VIROLOGY, V177, P427, DOI 10.1016/0042-6822(90)90506-M; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Fortugno P, 2002, J CELL SCI, V115, P575; Fraser AG, 1999, CURR BIOL, V9, P292, DOI 10.1016/S0960-9822(99)80137-7; Fuhrmann G, 2001, ONCOGENE, V20, P4542, DOI 10.1038/sj.onc.1204499; Fuhrmann G, 1999, MUTAT RES-REV MUTAT, V437, P205, DOI 10.1016/S1383-5742(99)00084-8; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hayne C, 2000, J BIOL CHEM, V275, P31876, DOI 10.1074/jbc.M002766200; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Holmstrom TH, 1998, J IMMUNOL, V160, P2626; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Monzo M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100; Natesan S, 1997, NATURE, V390, P349, DOI 10.1038/37019; Notarbartolo M, 2002, CANCER LETT, V180, P91, DOI 10.1016/S0304-3835(01)00834-5; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Pruitt K, 2000, J BIOL CHEM, V275, P40916, DOI 10.1074/jbc.M006682200; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Sarela AI, 2000, GUT, V46, P645, DOI 10.1136/gut.46.5.645; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shields JM, 2002, MOL CELL BIOL, V22, P2304, DOI 10.1128/MCB.22.7.2304-2317.2002; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Simonitsch I, 2001, FASEB J, V15, P1416, DOI 10.1096/fj.00-0678fje; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Tamm I, 1998, CANCER RES, V58, P5315; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Uren AG, 1999, P NATL ACAD SCI USA, V96, P10170, DOI 10.1073/pnas.96.18.10170; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Volmat V, 2001, BIOL CELL, V93, P71, DOI 10.1016/S0248-4900(01)01129-7; Wurl P, 2002, LANCET, V359, P943, DOI 10.1016/S0140-6736(02)07990-4; Zhu L, 2001, FEBS LETT, V508, P369, DOI 10.1016/S0014-5793(01)03084-8	67	83	87	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2003	22	27					4266	4280		10.1038/sj.onc.1206509	http://dx.doi.org/10.1038/sj.onc.1206509			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833149				2022-12-17	WOS:000183979800013
J	Shonukan, T; Bagayogo, I; McCrea, PD; Chao, M; Hempstead, B				Shonukan, T; Bagayogo, I; McCrea, PD; Chao, M; Hempstead, B			Neurotrophin-induced melanoma cell migration is mediated through the actin-bundling protein fascin	ONCOGENE			English	Article						fascin; melanoma; migration; NGF; p75(NTR)	NERVE GROWTH-FACTOR; HEPARAN-SULFATE SUBPOPULATIONS; INVASION SELECTED ENHANCEMENT; NF-KAPPA-B; RECEPTOR; P75; BINDING; ACTIVATION; TRK; STIMULATION	Expression of the p75 neurotrophin receptor (p75(NTR)) in primary melanomas is associated with deeply invasive lesions. In turn, there is expression of high levels of neurotrophins at the invasion front of normal tissue adjacent to brain metastases, thus implicating this growth factor-receptor system in melanoma tumorigenesis. The neurotrophins nerve growth factor (NGF) and neurotrophin-3 (NT-3) are potent chemotactic agents for human melanoma cells which express p75(NTR)in vitro. Here we show that the actin-bundling protein fascin specifically interacts with p75(NTR) in an NGF-dependent manner by co-immunoprecipitation and colocalization in melanoma cells that express the two proteins endogenously. In addition, expression of a fascin point mutant at the serine phosphorylation site (serine 39) regulating actin binding abrogates neurotrophin-induced migration. These results suggest a causal role for NGF-mediated dephosphorylation of serine 39 on fascin in mediating actin binding and subsequent melanoma cell migration.	Univ Miami, Sch Med, Dept Med, Div Hematol Oncol,Sylvester Canc Ctr, Miami, FL 33136 USA; Cornell Univ, Weill Med Coll, Dept Med, Div Hematol Oncol, New York, NY 10021 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Skirball Inst Biomol Med, Dept Cell Biol, Mol Neurobiol Program, New York, NY 10016 USA	University of Miami; Cornell University; University of Texas System; UTMD Anderson Cancer Center	Shonukan, T (corresponding author), Univ Miami, Sch Med, Dept Med, Div Hematol Oncol,Sylvester Canc Ctr, Pap 110,M-877,1550 NW 10th Ave, Miami, FL 33136 USA.	oshonukan@med.miami.edu		Chao, Moses/0000-0002-6969-3744	NIGMS NIH HHS [R01 GM052112] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JC, 1997, MOL BIOL CELL, V8, P2345, DOI 10.1091/mbc.8.11.2345; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; Bhakar AL, 1999, J BIOL CHEM, V274, P21443, DOI 10.1074/jbc.274.30.21443; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; BRYAN J, 1986, METHOD ENZYMOL, V134, P13; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CONNOLLY JL, 1985, J NEUROSCI RES, V13, P183, DOI 10.1002/jnr.490130113; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; Gallo G, 1998, J NEUROSCI, V18, P5403, DOI 10.1523/JNEUROSCI.18-14-05403.1998; Iwamoto S, 1996, J AM ACAD DERMATOL, V35, P725, DOI 10.1016/S0190-9622(96)90728-8; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Marchetti D, 1996, CANCER RES, V56, P2856; MARCHETTI D, 1993, INT J CANCER, V55, P692, DOI 10.1002/ijc.2910550430; Marchetti D, 1997, ADV ENZYME REGUL, V37, P111, DOI 10.1016/S0065-2571(96)00019-2; Marchetti D, 1997, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 2, NO 1, AUGUST 1997, P99, DOI 10.1038/jidsymp.1997.19; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; Nicolson GL, 1995, CANCER METAST REV, V14, P303, DOI 10.1007/BF00690600; Ono S, 1997, J BIOL CHEM, V272, P2527; OTTO JJ, 1979, CELL, V17, P285, DOI 10.1016/0092-8674(79)90154-5; OTTO JJ, 1980, CELL MOTIL CYTOSKEL, V1, P31, DOI 10.1002/cm.970010104; Ryden M, 1997, J BIOL CHEM, V272, P16322, DOI 10.1074/jbc.272.26.16322; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; Wong V, 1999, J BIOL CHEM, V274, P5443, DOI 10.1074/jbc.274.9.5443; Yamashiro S, 1998, MOL BIOL CELL, V9, P993, DOI 10.1091/mbc.9.5.993; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9	28	83	86	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2003	22	23					3616	3623		10.1038/sj.onc.1206561	http://dx.doi.org/10.1038/sj.onc.1206561			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789270				2022-12-17	WOS:000183399200012
J	Luo, RZ; Fang, XJ; Marquez, R; Liu, SY; Mills, GB; Liao, WSL; Yu, YH; Bast, RC				Luo, RZ; Fang, XJ; Marquez, R; Liu, SY; Mills, GB; Liao, WSL; Yu, YH; Bast, RC			ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers	ONCOGENE			English	Article						ARHI; tumor suppressor gene; GTP-binding protein; GTPase; mutagenesis; protein function; Ras superfamily	TUMOR-SUPPRESSOR GENE; GTPASE-ACTIVATING PROTEIN; BIOCHEMICAL-PROPERTIES; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; RHO-FAMILY; DOMAIN; FARNESYLATION; ASSOCIATION; MEMBRANE	Our group recently identified Ras homolog member I (ARHI), a novel maternally imprinted tumor suppressor gene that encodes a 26kDa GTP-binding protein with high homology to Ras and Rap. Unlike other Ras family members, ARHI exhibits several unusual structural and functional properties. ARHI contains a unique 34 amino-acid extension at the N-terminus, and differs from Ras in residues critical for GTPase activity and in its putative effector domain. Like Ras, ARHI can bind to GTP with high affinity but has low intrinsic GTPase activity. In addition, while Ras is an oncogene, ARHI functions as an inhibitor for cell growth. 12 Phosphorus labeling showed that ARHI is maintained in a constitutively activated GTP-bound state in resting cells, possibly because of impaired GTPase activity. ARHI is associated at the cell membrane through its prenylation at the C-terminal cysteine residue. Mutation of the conserved CAAX box at the C-terminus led to a loss of its membrane association and a decreased ability to inhibit cell growth. Conversion of Ser(51) to Asn decreased GTP binding and reduced ARHI's biological activity. Mutation of Ala(46) to Val increased the ability of ARHI to inhibit cell growth, associated with a further decrease of its intrinsic GTPase activity. Moreover, conversion of residues in ARHI that are conserved in the Ras family for GTPase activity partially restored the GTPase activity in ARHI. Most strikingly, deletion of ARHI's unique N-terminal extension nearly abolished its inhibitory effect on cell growth, suggesting its importance in ARHI's inhibitory function. Thus, ARHI is a unique Ras family member that retains basic small GTPase function, but exhibits many unusual features. In contrast to most other Ras family members, ARHI has a long N-terminal extension, modest GTPase activity, and constitutive GTP binding in resting cells. Furthermore, unlike the Ras oncogene, ARHI inhibits cell growth, and loss of its expression in cells may contribute to the development of breast and ovarian cancers.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Bast, RC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Rm Y7-5821,Box 355, Houston, TX 77030 USA.	rbast@mdanderson.org	Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462	NATIONAL CANCER INSTITUTE [P01CA064602] Funding Source: NIH RePORTER; NCI NIH HHS [CA80957, CA64602] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashar HR, 2000, J BIOL CHEM, V275, P30451, DOI 10.1074/jbc.M003469200; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1995, METHOD ENZYMOL, V225, P161; BOUNE HR, 1991, NATURE, V349, P117; Chen JM, 1996, J PROTEIN CHEM, V15, P511, DOI 10.1007/BF01908532; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; Ellis CA, 2002, P NATL ACAD SCI USA, V99, P9876, DOI 10.1073/pnas.142193799; Fiegen D, 2002, FEBS LETT, V525, P100, DOI 10.1016/S0014-5793(02)03094-6; Finlin BS, 2001, J BIOL CHEM, V276, P42259, DOI 10.1074/jbc.M105888200; Foster R, 1996, MOL CELL BIOL, V16, P2689; Garavini H, 2002, BIOCHEMISTRY-US, V41, P6303, DOI 10.1021/bi025651h; Gotoh T, 2000, J BIOL CHEM, V275, P30118, DOI 10.1074/jbc.M003074200; HALL A, 1986, J BIOL CHEM, V261, P963; Hofemeister H, 2000, MOL BIOL CELL, V11, P3233, DOI 10.1091/mbc.11.9.3233; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Luo RZ, 2001, BBA-GENE STRUCT EXPR, V1519, P216, DOI 10.1016/S0167-4781(01)00226-3; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; Murphy GA, 1999, ONCOGENE, V18, P3831, DOI 10.1038/sj.onc.1202758; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; Patton SE, 1998, CANCER RES, V58, P2253; Peng HQ, 2000, INT J CANCER, V86, P690, DOI 10.1002/(SICI)1097-0215(20000601)86:5<690::AID-IJC14>3.0.CO;2-K; Piddini E, 2001, EMBO J, V20, P4076, DOI 10.1093/emboj/20.15.4076; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SUNYER T, 1984, J BIOL CHEM, V259, P5447; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; Xu FJ, 2000, CANCER RES, V60, P4913; Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77; ZHU JH, 1995, J BIOL CHEM, V270, P4805, DOI 10.1074/jbc.270.9.4805	41	83	89	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2003	22	19					2897	2909		10.1038/sj.onc.1206380	http://dx.doi.org/10.1038/sj.onc.1206380			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771940				2022-12-17	WOS:000182824800004
J	Majumdar, S; Aggarwal, BB				Majumdar, S; Aggarwal, BB			Adenosine suppresses activation of nuclear factor-kappa B selectively induced by tumor necrosis factor in different cell types	ONCOGENE			English	Article						HIV; NF-kappa B; TNF; rheumatoid arthritis; inflammation; purines	FACTOR-ALPHA PRODUCTION; TRANSCRIPTION FACTOR; RECEPTOR AGONISTS; TNF-ALPHA; CARBOCYCLIC NUCLEOSIDE; MEDIATED CYTOTOXICITY; INDUCED ARTHRITIS; A(2) RECEPTORS; KINASE; MACROPHAGES	Adenosine is an endogenous immunomodulator that has been shown to exhibit anti-inflammatory and immunosuppressive properties through a mechanism that is not fully established. Owing to the pivotal role of nuclear factor (NF)-kappaB in these responses, we tested the hypothesis that adenosine mediates its effects through suppression of NF-kappaB activation. We investigated the effects of adenosine on NF-kappaB activation induced by various inflammatory agents in human myeloid KBM-5 cells. The treatment of these cells with adenosine suppressed TNF-induced NF-kappaB activation, but had no effect on activation of another redox-sensitive transcription factor, AP-1. These effects were not restricted to myeloid cells, as NF-kappaB activation in other lymphocytic and epithelial cell types was also inhibited. The effect on TNF-induced NF-kappaB activation was selective as adenosine had minimal effect on NF-kappaB activation induced by H2O2, PMA, LPS, okadaic acid, or ceramide, suggesting differences in the pathway leading to NF-kappaB activation by different agents. Adenosine also suppressed NF-kappaB-dependent reporter gene expression activated by TNF or by overexpression of TNFR1, TRAIT 2, NIK, and P65 subunit of NF-kappaB. The suppression of TNF-induced NF-kappaB activation by adenosine was found not to be because of inhibition of TNF-induced IkappaBalpha phosphorylation and degradation or IkappaBalpha kinase activation. The suppression of TNF-induced NF-kappaB activation was unique to adenosine, as neither its metabolites (inosine, AMP, and ATP) nor pyrimidines (thymidine and uridine) had any effect. Overall, our results clearly demonstrate that adenosine selectively suppresses TNF-induced NF-kappaB activation, which may contribute to its role in suppression of inflammation and of the immune system.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Cytokine Res Lab, Box 143,1515 Holcombe Blvd, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013					ALBRECHT H, 1995, J INFLAMM, V45, P64; BERGMANN S, 1994, J IMMUNOL, V153, P1736; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Bouma MG, 1997, SHOCK, V8, P313, DOI 10.1097/00024382-199711000-00001; BOUMA MG, 1994, J IMMUNOL, V153, P4159; Bouma MG, 1996, AM J PHYSIOL-CELL PH, V270, pC522, DOI 10.1152/ajpcell.1996.270.2.C522; Bowlin TL, 1997, CELL MOL BIOL, V43, P345; Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585; CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5, DOI 10.1152/jappl.1994.76.1.5; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; DAVAL JL, 1991, LIFE SCI, V49, P1435, DOI 10.1016/0024-3205(91)90043-B; Daval JL, 1996, PHARMACOL THERAPEUT, V71, P325, DOI 10.1016/S0163-7258(96)00094-0; DELAHARPE J, 1989, J IMMUNOL, V143, P596; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GREEN PG, 1991, P NATL ACAD SCI USA, V88, P4162, DOI 10.1073/pnas.88.10.4162; Guo Y, 2001, J MOL CELL CARDIOL, V33, P825, DOI 10.1006/jmcc.2001.1338; Hajra L, 2000, P NATL ACAD SCI USA, V97, P9052, DOI 10.1073/pnas.97.16.9052; Hasko G, 2000, BRIT J PHARMACOL, V129, P909, DOI 10.1038/sj.bjp.0703134; Hasko G, 1996, J IMMUNOL, V157, P4634; Hasko G, 2000, FASEB J, V14, P2065, DOI 10.1096/fj.99-0508com; JANIER MF, 1993, AM J PHYSIOL, V264, pH163, DOI 10.1152/ajpheart.1993.264.1.H163; Jeong SY, 1999, J BIOL CHEM, V274, P18981, DOI 10.1074/jbc.274.27.18981; John GR, 2001, J NEUROSCI, V21, P4134, DOI 10.1523/JNEUROSCI.21-12-04134.2001; LI C, 2001, AM J PHYSIOL, V28, pH1264; Li CF, 2000, SURGERY, V127, P161, DOI 10.1067/msy.2000.101582; Li CF, 1999, AM J PHYSIOL-HEART C, V276, pH543, DOI 10.1152/ajpheart.1999.276.2.H543; Liu JSH, 2000, J NEUROSCI, V20, P5292, DOI 10.1523/JNEUROSCI.20-14-05292.2000; MAHON TM, 1995, J BIOL CHEM, V270, P28557, DOI 10.1074/jbc.270.48.28557; Majumdar S, 2001, J IMMUNOL, V167, P2911, DOI 10.4049/jimmunol.167.5.2911; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Manna SK, 2000, J IMMUNOL, V165, P4927, DOI 10.4049/jimmunol.165.9.4927; Manna SK, 2000, J BIOL CHEM, V275, P13297, DOI 10.1074/jbc.275.18.13297; MARANGOS PJ, 1990, PROG CLIN BIOL RES, V361, P331; McWhinney CD, 1996, EUR J PHARMACOL, V310, P209, DOI 10.1016/0014-2999(96)00272-5; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Nie ZZ, 1998, MOL PHARMACOL, V53, P663, DOI 10.1124/mol.53.4.663; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PARMELY MJ, 1993, J IMMUNOL, V151, P389; REINSTEIN LJ, 1994, HEPATOLOGY, V19, P1445, DOI 10.1002/hep.1840190620; Salvatore CA, 2000, J BIOL CHEM, V275, P4429, DOI 10.1074/jbc.275.6.4429; SCHRIER DJ, 1990, J IMMUNOL, V145, P1874; SULLIVAN GW, 1990, J IMMUNOL, V145, P1537; Szabo C, 1998, BRIT J PHARMACOL, V125, P379, DOI 10.1038/sj.bjp.0702040; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; Wagner DR, 1998, CIRCULATION, V97, P521; Wagner DR, 1998, CIRC RES, V82, P47; Xia DX, 2000, BIOCHEM PHARMACOL, V60, P717, DOI 10.1016/S0006-2952(00)00367-1; Yin YZ, 2001, LEUKEMIA RES, V25, P423, DOI 10.1016/S0145-2126(00)00147-8; Zwacka RM, 1998, HEPATOLOGY, V28, P1022, DOI 10.1002/hep.510280417	52	83	89	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 27	2003	22	8					1206	1218		10.1038/sj.onc.1206184	http://dx.doi.org/10.1038/sj.onc.1206184			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606947				2022-12-17	WOS:000181249700009
J	Fukuma, M; Okita, H; Hata, J; Umezawa, A				Fukuma, M; Okita, H; Hata, J; Umezawa, A			Upregulation of Id2, an oncogenic helix-loop-helix protein, is mediated by the chimeric EWS/ets protein in Ewing sarcoma	ONCOGENE			English	Article						Ewing sarcoma; Id2; EWS/ets; chimeric protein	DNA-BINDING; EWS GENE; TRANSCRIPTIONAL ACTIVATION; FUSION PROTEIN; CELL-CYCLE; ETS; EXPRESSION; FAMILY; TRANSLOCATION; EWS-FLI1	The chromosomal translocation specifically linked to the Ewing sarcoma family results in the generation of fusion proteins comprising the amino terminal portion of EWS and the DNA-binding domain of ets transcription factors. The EWS/ets chimeric proteins act as aberrant transcription factors leading to tumorigenic processes. We searched for genes specifically activated in Ewing sarcoma cells but not in other tumor cell lines using the gene array technique, and found significantly enhanced expression of the Id2 gene. High levels of Id2 transcripts were detected in Ewing sarcoma cell lines and tumor tissues. The EWS/ ets chimeric proteins activated the Id2 gene via the 5'-upstream promoter sequence. Chromatin-immunoprecipitation revealed a direct interaction of EWS/Fli-1 with the promoter regions of the 142, TGF-beta type 11 receptor, cyclin D1, and c-myc genes. Since EWS/Fti-1 transactivates c-myc, a cooperative action of the chimeric protein and c-myc leads to overexpression of Id2. In the present study, we suggest that Id2 is a target of the chimeric proteins and that the c-myc/Id2 pathway plays a pivotal role in the tumorigenic processes provoked by EWS/ets proteins.	Keio Univ, Dept Pathol, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan	Keio University	Umezawa, A (corresponding author), Keio Univ, Dept Pathol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	umezawa@1985.jukuin.keio.ac.jp						BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; Edelman GM, 2000, P NATL ACAD SCI USA, V97, P3038, DOI 10.1073/pnas.040569897; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Im YH, 2000, CANCER RES, V60, P1536; JEON IS, 1995, ONCOGENE, V10, P1229; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Martinsen BJ, 1998, SCIENCE, V281, P988, DOI 10.1126/science.281.5379.988; Matsumoto Y, 2001, BRIT J CANCER, V84, P768, DOI 10.1054/bjoc.2000.1652; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NEUMAN T, 1993, DEV BIOL, V160, P186, DOI 10.1006/dbio.1993.1297; NOGUERA R, 1992, LAB INVEST, V66, P143; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; OHNO T, 1994, ONCOGENE, V9, P3087; PANKOV R, 1994, MOL CELL BIOL, V14, P7744, DOI 10.1128/MCB.14.12.7744; Paulussen M, 2001, J CLIN ONCOL, V19, P1818, DOI 10.1200/JCO.2001.19.6.1818; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; SETH A, 1993, AIDS RES HUM RETROV, V9, P1017, DOI 10.1089/aid.1993.9.1017; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Sugimoto T, 1997, VIRCHOWS ARCH, V430, P41, DOI 10.1007/BF01008015; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; Thompson AD, 1996, ONCOGENE, V13, P2649; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; Urano F, 1998, JPN J CANCER RES, V89, P703, DOI 10.1111/j.1349-7006.1998.tb03274.x; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812	37	83	90	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2003	22	1					1	9		10.1038/sj.onc.1206055	http://dx.doi.org/10.1038/sj.onc.1206055			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527902				2022-12-17	WOS:000180166900001
J	Thompson, CL; Sancar, A				Thompson, CL; Sancar, A			Photolyase/cryptochrome blue-light photoreceptors use photon energy to repair DNA and reset the circadian clock	ONCOGENE			English	Article						pyrimidine dimers; DNA photorepair; circadian clock; photosensory pigment	NUCLEOTIDE EXCISION-REPAIR; ESCHERICHIA-COLI; PHOTOREACTIVATING ENZYME; CRYSTAL-STRUCTURE; ARABIDOPSIS-THALIANA; ANACYSTIS-NIDULANS; 2ND CHROMOPHORE; MAMMALIAN-CELLS; FOWLPOX VIRUS; PHYTOCHROME-B	Blue light governs a number of cellular responses in bacteria, plants, and animals, including photoreactivation, plant development, and circadian photoentrainment. These activities are mediated by a family of highly conserved flavoproteins, the photolyase/cryptochrome family. Photolyase binds to UV photoproducts in DNA and repairs them in a process called photoreactivation in which blue light is used to initiate a cyclic electron transfer to break bonds and restore the integrity of DNA. Cryptochrome, which has a high degree of sequence identity to photolyase, works as the main circadian photoreceptor and as a component of the molecular clock in animals, including mammals, and regulates growth and development in plants.	Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Sancar, A (corresponding author), Univ N Carolina, Sch Med, Dept Biochem & Biophys, CB 7260, Chapel Hill, NC 27599 USA.	aziz_sancar@med.unc.edu						ADAMS MD, 1995, NATURE, V377, P3; Afonso CL, 2000, J VIROL, V74, P3815, DOI 10.1128/JVI.74.8.3815-3831.2000; Afonso CL, 1999, J VIROL, V73, P533, DOI 10.1128/JVI.73.1.533-552.1999; Ahmad M, 1998, MOL CELL, V1, P939, DOI 10.1016/S1097-2765(00)80094-5; AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Akashi M, 2002, MOL CELL BIOL, V22, P1693, DOI 10.1128/MCB.22.6.1693-1703.2002; Anderson LE, 2000, CANCER LETT, V148, P121, DOI 10.1016/S0304-3835(99)00320-1; BAER ME, 1993, J BIOL CHEM, V268, P16717; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262; Briggs WR, 1999, ANNU REV CELL DEV BI, V15, P33, DOI 10.1146/annurev.cellbio.15.1.33; Camacho F, 2001, FEBS LETT, V489, P159, DOI 10.1016/S0014-5793(00)02434-0; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Deisenhofer J, 2000, MUTAT RES-DNA REPAIR, V460, P143, DOI 10.1016/S0921-8777(00)00023-9; Egan ES, 1999, J NEUROSCI, V19, P3665; Eide EJ, 2002, J BIOL CHEM, V277, P17248, DOI 10.1074/jbc.M111466200; EKER AP, 1988, BIOCHEMISTRY-US, V27, P1758, DOI 10.1021/bi00405a056; EKER APM, 1981, PHOTOCHEM PHOTOBIOL, V33, P65, DOI 10.1111/j.1751-1097.1981.tb04298.x; Elich TD, 1997, PLANT CELL, V9, P2271, DOI 10.1105/tpc.9.12.2271; Emery P, 2000, NATURE, V404, P456, DOI 10.1038/35006558; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; HAHN RA, 1991, EPIDEMIOLOGY, V2, P459, DOI 10.1097/00001648-199111000-00015; Hattar S, 2002, SCIENCE, V295, P1065, DOI 10.1126/science.1069609; HAYS JB, 1985, J BACTERIOL, V161, P602, DOI 10.1128/JB.161.2.602-608.1985; Helfrich-Forster C, 2001, NEURON, V30, P249, DOI 10.1016/S0896-6273(01)00277-X; Hitomi K, 2000, NUCLEIC ACIDS RES, V28, P2353, DOI 10.1093/nar/28.12.2353; Hoffman PD, 1996, MOL GEN GENET, V253, P259, DOI 10.1007/s004380050321; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; Ishikawa T, 1999, GENES CELLS, V4, P57, DOI 10.1046/j.1365-2443.1999.00237.x; JOCHLE W, 1964, ANN NY ACAD SCI, V117, P88, DOI 10.1111/j.1749-6632.1964.tb48164.x; JOHNSON JL, 1988, P NATL ACAD SCI USA, V85, P2046, DOI 10.1073/pnas.85.7.2046; JORNS MS, 1984, BIOCHEMISTRY-US, V23, P2673, DOI 10.1021/bi00307a021; Kanai S, 1997, J MOL EVOL, V45, P535, DOI 10.1007/PL00006258; KATO T, 1994, NUCLEIC ACIDS RES, V22, P4119, DOI 10.1093/nar/22.20.4119; KIENER A, 1989, J BIOL CHEM, V264, P13880; KIM ST, 1994, J BIOL CHEM, V269, P8535; Kobayashi Y, 2000, GENES CELLS, V5, P725, DOI 10.1046/j.1365-2443.2000.00364.x; Komori H, 2001, P NATL ACAD SCI USA, V98, P13560, DOI 10.1073/pnas.241371398; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; LI YF, 1993, P NATL ACAD SCI USA, V90, P4389, DOI 10.1073/pnas.90.10.4389; Lin CT, 1998, P NATL ACAD SCI USA, V95, P2686, DOI 10.1073/pnas.95.5.2686; Lin CT, 1996, PLANT J, V10, P893, DOI 10.1046/j.1365-313X.1996.10050893.x; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; Lin FJ, 2001, MOL CELL BIOL, V21, P7287, DOI 10.1128/MCB.21.21.7287-7294.2001; MALHOTRA K, 1992, J BIOL CHEM, V267, P15406; MALHOTRA K, 1994, BIOCHEMISTRY-US, V33, P8712, DOI 10.1021/bi00195a012; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; Mas P, 2000, NATURE, V408, P207, DOI 10.1038/35041583; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; Miyamoto Y, 1999, MOL BRAIN RES, V71, P238, DOI 10.1016/S0169-328X(99)00192-8; Ng WO, 2001, MOL GEN GENET, V264, P924, DOI 10.1007/s004380000383; Ozer Z, 1995, BIOCHEMISTRY-US, V34, P15886, DOI 10.1021/bi00049a002; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P7715, DOI 10.1021/bi00485a021; PAYNE G, 1987, BIOCHEMISTRY-US, V26, P7121, DOI 10.1021/bi00396a038; Petit C, 1999, M S-MED SCI, V15, P1411, DOI 10.4267/10608/1284; Provencio I, 2002, NATURE, V415, P493, DOI 10.1038/415493a; Provencio I, 2000, J NEUROSCI, V20, P600, DOI 10.1523/JNEUROSCI.20-02-00600.2000; Roenneberg T, 1997, PHOTOCHEM PHOTOBIOL, V66, P549, DOI 10.1111/j.1751-1097.1997.tb03188.x; Rosato E, 2001, CURR BIOL, V11, P909, DOI 10.1016/S0960-9822(01)00259-7; Sancar A, 2000, ANNU REV BIOCHEM, V69, P31, DOI 10.1146/annurev.biochem.69.1.31; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; SANCAR A, 1984, P NATL ACAD SCI-BIOL, V81, P7397, DOI 10.1073/pnas.81.23.7397; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SANCAR GB, 1987, TRENDS BIOCHEM SCI, V12, P259, DOI 10.1016/0968-0004(87)90130-7; SANCAR GB, 1987, J BIOL CHEM, V262, P15457; SANCAR GB, 1989, MOL CELL BIOL, V9, P4767, DOI 10.1128/MCB.9.11.4767; Selby CP, 1999, PHOTOCHEM PHOTOBIOL, V69, P105, DOI 10.1562/0031-8655(1999)069<0105:ATMOTP>2.3.CO;2; Selby CP, 2000, P NATL ACAD SCI USA, V97, P14697, DOI 10.1073/pnas.260498597; Shalitin D, 2002, NATURE, V417, P763, DOI 10.1038/nature00815; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Somers DE, 1998, SCIENCE, V282, P1488, DOI 10.1126/science.282.5393.1488; Srinivasan V, 2001, J VIROL, V75, P1681, DOI 10.1128/JVI.75.4.1681-1688.2001; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Stevens RG, 2001, CANCER CAUSE CONTROL, V12, P279, DOI 10.1023/A:1011237000609; Tamada T, 1997, NAT STRUCT BIOL, V4, P887, DOI 10.1038/nsb1197-887; TAMARKIN L, 1982, SCIENCE, V216, P1003, DOI 10.1126/science.7079745; TAMARKIN L, 1981, CANCER RES, V41, P4432; Thompson CL, 2001, P NATL ACAD SCI USA, V98, P11708, DOI 10.1073/pnas.201301498; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; Todo T, 1999, MUTAT RES-DNA REPAIR, V434, P89, DOI 10.1016/S0921-8777(99)00013-0; Todo T, 1997, MUTAT RES-DNA REPAIR, V384, P195, DOI 10.1016/S0921-8777(97)00032-3; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; TODO T, 1993, NATURE, V361, P371, DOI 10.1038/361371a0; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; Vielhaber E, 2000, MOL CELL BIOL, V20, P4888, DOI 10.1128/MCB.20.13.4888-4899.2000; Vielhaber EL, 2001, J BIOL CHEM, V276, P45921, DOI 10.1074/jbc.M107726200; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; Willer DO, 1999, VIROLOGY, V264, P319, DOI 10.1006/viro.1999.0002; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Yagita K, 2000, GENE DEV, V14, P1353; Yang HQ, 2000, CELL, V103, P815, DOI 10.1016/S0092-8674(00)00184-7; YASUI A, 1994, EMBO J, V13, P6143, DOI 10.1002/j.1460-2075.1994.tb06961.x; Yu WJ, 2002, BIOCHEM BIOPH RES CO, V290, P933, DOI 10.1006/bbrc.2001.6300; Zhao SY, 1997, PHOTOCHEM PHOTOBIOL, V66, P727, DOI 10.1111/j.1751-1097.1997.tb03214.x; Zhao XD, 1997, J BIOL CHEM, V272, P32580, DOI 10.1074/jbc.272.51.32580	99	83	85	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2002	21	58					9043	9056		10.1038/sj.onc.1205958	http://dx.doi.org/10.1038/sj.onc.1205958			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	626TP	12483519				2022-12-17	WOS:000179889500014
J	Lakka, SS; Rajan, M; Gondi, C; Yanamandra, N; Chandrasekar, N; Jasti, SL; Adachi, Y; Siddique, K; Gujrati, M; Olivero, W; Dinh, DH; Kouraklis, G; Kyritsis, AP; Rao, JS				Lakka, SS; Rajan, M; Gondi, C; Yanamandra, N; Chandrasekar, N; Jasti, SL; Adachi, Y; Siddique, K; Gujrati, M; Olivero, W; Dinh, DH; Kouraklis, G; Kyritsis, AP; Rao, JS			Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion	ONCOGENE			English	Article						ECM; MMP-9; MT-MMP; adenovirus; antisense; glioma	MATRIX-METALLOPROTEINASE INHIBITOR; PLASMINOGEN-ACTIVATOR RECEPTOR; IV COLLAGENASE; GELATINASE-B; IN-VIVO; MATRIX-METALLOPROTEINASE-9 EXPRESSION; EXTRACELLULAR-MATRIX; DOWN-REGULATION; METASTASIS; PROLIFERATION	Matrix metalloproteinase 9 (MMP-9) is known to play a major role in cell migration and invasion in both physiological and pathological processes. Our previous work has shown that increased MMP-9 levels are associated with human glioma tumor progression. In this study, we evaluated the ability of an adenovirus containing a 528 bp cDNA sequence in antisense orientation to the 5' end of the human MMP-9 gene (Ad-MMP-9AS) to inhibit the invasiveness and migratory capacity of the human glioblastoma cell line SBN19 in in vitro and in vivo models. Infection of glioma cells with Ad-MMP-9AS reduced MMP-9 enzyme activity by approximately 90% compared with mock- or Ad-CMV-infected cells. Migration and invasion of glioblastoma cells infected with Ad-MMP-9AS were significantly inhibited relative to Ad-CMV-infected controls in spheroid and Matrigel assays. Intracranial injections of SNB19 cells infected with Ad-MMP-9AS did not produce tumors in nude mice. However, injecting the Ad-MMP-9AS construct into subcutaneous U87MG tumors in nude mice caused regression of tumor growth. These results support the theory that adenoviral-mediated delivery of the MMP-9 gene in the antisense orientation has therapeutic potential for treating gliomas.	Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA; Univ Illinois, Dept Neuropathol, Peoria, IL 61656 USA; Univ Texas, MD Anderson Canc Ctr, Dept Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Okayama Univ, Sch Med, Dept Neurol Surg, Okayama 700, Japan; Univ Athens, Sch Med, Dept Propedeut Surg, GR-11527 Athens, Greece; Univ Ioannina, Sch Med, Dept Neurol, GR-45110 Ioannina, Greece	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Okayama University; Athens Medical School; National & Kapodistrian University of Athens; University of Ioannina	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Box 1649, Peoria, IL 61656 USA.	jsrao@uic.edu		Gondi, Christopher/0000-0002-3036-9920	NCI NIH HHS [CA75557, CA76350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075557, R01CA076350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi Y, 2001, J BIOL CHEM, V276, P47171, DOI 10.1074/jbc.M104334200; Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Arndt GM, 1997, GENOME, V40, P785, DOI 10.1139/g97-802; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Baxter AD, 2000, CANC DRUG DISC DEV, P193; Brown PD, 1999, APMIS, V107, P174, DOI 10.1111/j.1699-0463.1999.tb01541.x; Brown PD, 2000, EXPERT OPIN INV DRUG, V9, P2167, DOI 10.1517/13543784.9.9.2167; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Chintala SK, 1996, CANCER LETT, V102, P57, DOI 10.1016/0304-3835(96)04163-8; Chintala SK, 1996, CANCER LETT, V101, P107, DOI 10.1016/0304-3835(96)04124-9; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P14419, DOI 10.1021/bi00252a007; DAVIES B, 1993, CANCER RES, V53, P5365; DAVIES B, 1993, CANCER RES, V53, P2087; Dubois B, 1999, J CLIN INVEST, V104, P1507, DOI 10.1172/JCI6886; Eberhardt W, 2000, J IMMUNOL, V165, P5788, DOI 10.4049/jimmunol.165.10.5788; Folkman J, 1999, NAT BIOTECHNOL, V17, P749, DOI 10.1038/11676; Forsyth PA, 1998, J NEURO-ONCOL, V36, P21, DOI 10.1023/A:1005879027267; GARBISA S, 1987, CANCER RES, V47, P1523; Go Y, 1997, CLIN EXP METASTAS, V15, P440, DOI 10.1023/A:1018410523635; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; HOUDE M, 1993, INT J CANCER, V53, P395, DOI 10.1002/ijc.2910530309; Hua J, 1996, CANCER RES, V56, P5279; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; Jones JL, 1999, J PATHOL, V189, P161, DOI 10.1002/(SICI)1096-9896(199910)189:2<161::AID-PATH406>3.0.CO;2-2; Kahari VM, 1999, ANN MED, V31, P34, DOI 10.3109/07853899909019260; Kin Y, 2000, INT J ONCOL, V17, P61; Kondraganti S, 2000, CANCER RES, V60, P6851; Konduri SD, 2000, CLIN EXP METASTAS, V18, P303, DOI 10.1023/A:1011085820250; KOOCHEKPOUR S, 1995, NEUROSCI LETT, V186, P53, DOI 10.1016/0304-3940(95)11280-A; Lakka SS, 2000, CLIN EXP METASTAS, V18, P245, DOI 10.1023/A:1006724826083; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Lozonschi L, 1999, CANCER RES, V59, P1252; Mohan PM, 1999, CLIN EXP METASTAS, V17, P617, DOI 10.1023/A:1006779902978; Nakada M, 1999, AM J PATHOL, V154, P417, DOI 10.1016/S0002-9440(10)65288-1; NAKAJIMA M, 1993, CANCER RES, V53, P5802; Parks PJ, 1999, GENE THER, V6, P1349, DOI 10.1038/sj.gt.3301013; Price A, 1999, CLIN CANCER RES, V5, P845; Rao JS, 1996, CLIN EXP METASTAS, V14, P12, DOI 10.1007/BF00157681; RAO JS, 1993, CANCER RES, V53, P2208; Rasmussen HS, 1997, PHARMACOL THERAPEUT, V75, P69, DOI 10.1016/S0163-7258(97)00023-5; SATO H, 1993, ONCOGENE, V8, P395; Scatena R, 2000, EXPERT OPIN INV DRUG, V9, P2159, DOI 10.1517/13543784.9.9.2159; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Shalinsky DR, 1999, ANN NY ACAD SCI, V878, P236, DOI 10.1111/j.1749-6632.1999.tb07689.x; Shingleton WD, 1996, BIOCHEM CELL BIOL, V74, P759, DOI 10.1139/o96-083; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; Tonn JC, 1999, INT J CANCER, V80, P764, DOI 10.1002/(SICI)1097-0215(19990301)80:5<764::AID-IJC22>3.0.CO;2-J; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Yamamoto M, 1996, CANCER RES, V56, P384; Yip D, 1999, INVEST NEW DRUG, V17, P387, DOI 10.1023/A:1006386406584	53	83	93	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2002	21	52					8011	8019		10.1038/sj.onc.1205894	http://dx.doi.org/10.1038/sj.onc.1205894			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439751				2022-12-17	WOS:000179097200010
J	Xia, SH; Hu, LP; Hu, H; Ying, WT; Xu, X; Cai, Y; Han, YL; Chen, BS; Wei, F; Qian, XH; Cai, YY; Shen, Y; Wu, M; Wang, MR				Xia, SH; Hu, LP; Hu, H; Ying, WT; Xu, X; Cai, Y; Han, YL; Chen, BS; Wei, F; Qian, XH; Cai, YY; Shen, Y; Wu, M; Wang, MR			Three isoforms of annexin I are preferentially expressed in normal esophageal epithelia but down-regulated in esophageal squamous cell carcinomas	ONCOGENE			English	Article						annexin 1; esophageal squamous cell carcinoma; down-regulated protein	LIPOCORTIN-I; PROTEIN; DIFFERENTIATION; INDUCTION; CANCER	The development and progression of human cancer are believed to be due to the alterations of multiple genes or/and their protein products. For identifying the proteins associated with esophageal cancer, we analysed the protein profiles of 24 pairs of esophageal squamous cell carcinomas/matched adjacent normal epithelia. Microdissection of routinely unstained frozen sections was performed to purify cancerous and epithelial cells. The protein expression profiles were obtained by two-dimensional electrophoresis. Selected proteins dysregulated in tumors were identified by MALDI-TOF-MS. Three isoforms of annexin I were detected in normal esophageal mucosa and down-regulated in esophageal squamous cell carcinomas. RT-PCR analysis showed annexin I mRNA levels were significantly reduced in 17 out of 24 carcinomas. Immunohistochemistry demonstrated that annexin I appeared strong positive in all normal epithelia layers except basal cells. In cancer tissues, decreased expression of annexin I was observed in 12 out of 16 well differentiated tumors, 16 out of 17 moderately differentiated tumors, and 3 out of 3 poorly differentiated tumors as compared with the corresponding normal esophageal epithelia. There was a significant correlation between annexin I expression and the status of tumor differentiation. Well differentiated tumors presented stronger immunohistochemical reaction than moderately and poorly differentiated tumors. These data suggested that there existed three different isoforms of annexin I in normal esophageal epithelia, which may be the results of post-translational modification. Down-expression of three annexin I isoforms was a frequent event in esophageal carcinogenesis.	Chinese Acad Med Sci, PUMC, Canc Inst Hosp, Natl Lab Mol Oncol, Beijing 100021, Peoples R China; Chinese Acad Med Sci, Inst Basic Med, Natl Lab Med Mol Biol, Beijing 100007, Peoples R China; Peking Union Med Coll, Beijing 100007, Peoples R China; Natl Ctr Biomed Assay, Beijing 100085, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Wang, MR (corresponding author), Chinese Acad Med Sci, PUMC, Canc Inst Hosp, Natl Lab Mol Oncol, Beijing 100021, Peoples R China.	wangmr@pubem.cicams.ac.cn	Hu, Hai/G-3864-2012					Ahn SH, 1997, CLIN EXP METASTAS, V15, P151, DOI 10.1023/A:1018452810915; Beranova-Giorgianni S, 2000, RAPID COMMUN MASS SP, V14, P161, DOI 10.1002/(SICI)1097-0231(20000215)14:3<161::AID-RCM859>3.0.CO;2-7; Canaider S, 2000, LIFE SCI, V66, pPL265, DOI 10.1016/S0024-3205(00)00500-2; Chang MC, 2001, J FORMOS MED ASSOC, V100, P352; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; de Coupade C, 2000, HEPATOLOGY, V31, P371, DOI 10.1002/hep.510310217; Emmert-Buck MR, 2000, MOL CARCINOGEN, V27, P158, DOI 10.1002/(SICI)1098-2744(200003)27:3<158::AID-MC2>3.0.CO;2-2; Koseki H, 1997, SURG TODAY, V27, P30, DOI 10.1007/BF01366936; Lam AKY, 2000, CRIT REV ONCOL HEMAT, V33, P71, DOI 10.1016/S1040-8428(99)00054-2; Ornstein DK, 2000, ELECTROPHORESIS, V21, P2235, DOI 10.1002/1522-2683(20000601)21:11<2235::AID-ELPS2235>3.0.CO;2-A; Ou K, 2001, ELECTROPHORESIS, V22, P2804, DOI 10.1002/1522-2683(200108)22:13<2804::AID-ELPS2804>3.0.CO;2-G; Paweletz CP, 2000, CANCER RES, V60, P6293; PISANI P, 1993, INT J CANCER, V55, P891, DOI 10.1002/ijc.2910550604; Rothhut B, 1997, CELL MOL LIFE SCI, V53, P522, DOI 10.1007/s000180050066; ROYCHOUDHURY S, 1988, P NATL ACAD SCI USA, V85, P2014, DOI 10.1073/pnas.85.6.2014; SCHLAEPFER DD, 1990, J CELL BIOL, V111, P229, DOI 10.1083/jcb.111.1.229; Solito E, 1998, CELL GROWTH DIFFER, V9, P327; TAIT JF, 1988, BIOCHEMISTRY-US, V27, P6268, DOI 10.1021/bi00417a011; VIOLETTE SM, 1990, J CELL PHYSIOL, V142, P70, DOI 10.1002/jcp.1041420110; VISHWANATH BS, 1992, ENDOCRINOLOGY, V130, P585, DOI 10.1210/en.130.2.585; Wu YL, 2000, BRIT J HAEMATOL, V111, P807, DOI 10.1046/j.1365-2141.2000.02397.x	21	83	90	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2002	21	43					6641	6648		10.1038/sj.onc.1205818	http://dx.doi.org/10.1038/sj.onc.1205818			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242662				2022-12-17	WOS:000178202300010
J	Matei, D; Graeber, TG; Baldwin, RL; Karlan, BY; Rao, JY; Chang, DD				Matei, D; Graeber, TG; Baldwin, RL; Karlan, BY; Rao, JY; Chang, DD			Gene expression in epithelial ovarian carcinoma	ONCOGENE			English	Article						ovarian epithelial cells; oligonucleotide arrays; RT-PCR; periostin	CELL ADHESION MOLECULE; TISSUE TRANSGLUTAMINASE; GROWTH-FACTOR; SERUM LEVEL; CANCER; PROTEIN; CLONING; PERIOSTIN; ONCOGENE; HOMOLOG	We analysed the mRNA levels corresponding to 12 600 transcripts in primary cultures of ovarian epithelial cells derived from nine normal ovaries and 21 epithelial ovarian carcinoma. The class distinction and hierarchical clustering of expression data revealed a clear distinction in gene expression between normal and carcinoma-derived ovarian epithelial cells. Comparison of expression levels revealed 111 genes with mean expression values of >2.5-fold higher in carcinoma cells. Similarly, 62 genes were expressed at >2.5-fold higher levels in normal ovarian epithelial cells. For a few selected genes, we demonstrate that the pattern of differential expression observed in cultured epithelial cells is present in the normal ovaries and epithelial ovarian carcinoma. Use of cultured epithelial cells represents a novel strategy to study gene expression in a cell-type specific manner.	Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Energy, Lab Struct Biol & Mol Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Cedars Sinai Med Ctr, Div Gynecol Oncol, Los Angeles, CA 90048 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center	Chang, DD (corresponding author), Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Factor 11-934,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	ddchang@mednet.ucla.edu		Graeber, Thomas/0000-0001-8574-9181; Matei, Daniela/0000-0003-2169-5035	NCI NIH HHS [T32CA09297] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009297] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200; AUERSPERG N, 1994, LAB INVEST, V71, P510; BELL DA, 1994, CANCER, V73, P1859, DOI 10.1002/1097-0142(19940401)73:7<1859::AID-CNCR2820730714>3.0.CO;2-L; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Dubeau L, 1999, GYNECOL ONCOL, V72, P437, DOI 10.1006/gyno.1998.5275; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Foster KA, 1996, CANCER RES, V56, P3622; FRAIJ BM, 1992, J BIOL CHEM, V267, P22616; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Greenwood M, 2000, HIST TODAY, V50, P3; Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181; HENRIKSEN R, 1993, CANCER RES, V53, P4550; Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239; Hough CD, 2000, CANCER RES, V60, P6281; ISHIKAWA J, 1995, GENOMICS, V26, P527, DOI 10.1016/0888-7543(95)80171-H; Ismail RS, 2000, CANCER RES, V60, P6744; JACOBS I, 1989, HUM REPROD, V4, P1; KARLAN BY, 1995, GYNECOL ONCOL, V59, P67, DOI 10.1006/gyno.1995.1269; Kozma R, 1996, MOL CELL BIOL, V16, P5069; Lee TC, 1999, J BIOL CHEM, V274, P595, DOI 10.1074/jbc.274.2.595; LEJEUNE S, 1995, CLIN CANCER RES, V1, P215; Lin CJ, 1996, GYNECOL ONCOL, V60, P347, DOI 10.1006/gyno.1996.0054; Mains RE, 1997, BIOCHEM J, V321, P587, DOI 10.1042/bj3210587; MARKS JR, 1991, CANCER RES, V51, P2979; Mertens C, 1996, J CELL BIOL, V135, P1009, DOI 10.1083/jcb.135.4.1009; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Nanda N, 2001, J BIOL CHEM, V276, P20673, DOI 10.1074/jbc.M010846200; Ono K, 2000, CANCER RES, V60, P5007; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; PRESS WH, 1992, NUMERICAL RECIPES C, P226; Sasaki H, 2001, CANCER-AM CANCER SOC, V92, P843, DOI 10.1002/1097-0142(20010815)92:4<843::AID-CNCR1391>3.0.CO;2-P; Sasaki H, 2001, CANCER LETT, V172, P37, DOI 10.1016/S0304-3835(01)00633-4; Schummer M, 1999, GENE, V238, P375, DOI 10.1016/S0378-1119(99)00342-X; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Singh US, 2001, EMBO J, V20, P2413, DOI 10.1093/emboj/20.10.2413; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Stasko SE, 2001, DEV DYNAM, V220, P49, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1086>3.0.CO;2-5; TAKAHASHI H, 1995, CANCER RES, V55, P2998; TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Yamaguchi TP, 1999, DEVELOPMENT, V126, P1211; YOUNY RC, 2001, CANC PRINCIPLES PRAC, P1226	43	83	86	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2002	21	41					6289	6298		10.1038/sj.onc.1205785	http://dx.doi.org/10.1038/sj.onc.1205785			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590NM	12214269				2022-12-17	WOS:000177829000005
J	Kim, KM; Shibata, D				Kim, KM; Shibata, D			Methylation reveals a niche: stem cell succession in human colon crypts	ONCOGENE			English	Article						colorectal cancer; progression; stem cells; niche; crypt	COLORECTAL-CANCER; SOMATIC MUTATION; DNA METHYLATION; CPG-ISLAND; EVOLUTION; DEFICIENCY; PATTERNS; P53; TUMORIGENICITY; SUPPRESSION	Little it known about human stem cells although they are likely to be the earliest progenitors of carcinomas. Just as methylation can substitute for mutations to inactivate tumor suppressor genes, methylation can also substitute for mutations in a phylogenetic analysis. This review explains why stem cell dynamics may be important to tumor progression and how methylation patterns found in a normal human colon can be used to reconstruct the behavior of crypt stem cells. Histories are recorded in sequences and strategies used to reconstruct phylogenies from sequences likely apply to methylation patterns because both exhibit somatic inheritance. Such a quantitative analysis of colon methylation patterns infers stem cells live in niches containing multiple 'stem' cells. Although niche stem cell numbers remain constant, clonal succession is inherent to niches because periodically progeny from a single stem cell become dominant. These niche succession cycles may potentially accumulate multiple alterations because they resemble superficially the clonal succession of tumor progression except that they occur invisibly in the absence of selection or phenotypic change. Alterations without immediate selective value may hitchhike passively in the stem cells that become dominant during niche succession cycles. The inherent ability of a niche to fix alterations (Muller's ratchet) is another potential mechanism besides instability and selection to sequentially accumulate multiple alterations. Many alterations found in colorectal tumors may reflect such occult clonal progression in normal colon.	Univ So Calif, Sch Med, Norris Canc Ctr, Dept Pathol, Los Angeles, CA 90089 USA	University of Southern California	Shibata, D (corresponding author), 1200 N State St,Unit 1,Room 2428, Los Angeles, CA 90033 USA.				NIDDK NIH HHS [DK 61140] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK061140] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahuja N, 1998, CANCER RES, V58, P5489; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BIRD RP, 1995, CANCER LETT, V93, P55, DOI 10.1016/0304-3835(95)03788-X; Booth C, 2000, J CLIN INVEST, V105, P1493, DOI 10.1172/JCI10229; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; Campbell F, 1996, GUT, V39, P569, DOI 10.1136/gut.39.4.569; Chao L, 1997, GENE, V205, P301, DOI 10.1016/S0378-1119(97)00405-8; CHAO L, 1990, NATURE, V348, P454, DOI 10.1038/348454a0; CHARLESWORTH B, 1978, P NATL ACAD SCI USA, V75, P5618, DOI 10.1073/pnas.75.11.5618; CHENG H, 1984, GASTROENTEROLOGY, V86, P78; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; CLARKE AR, 1995, ONCOGENE, V11, P1913; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FELSENSTEIN J, 1974, GENETICS, V78, P737; FOULDS L, 1954, CANCER RES, V14, P327; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Issa JP, 2000, CURR TOP MICROBIOL, V249, P101; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; LOEB LA, 1991, CANCER RES, V51, P3075; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; PARK HS, 1995, AM J PATHOL, V147, P1416; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; Pearson H, 2002, NATURE, V415, P8, DOI 10.1038/415008a; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; POTTEN CS, 1992, GUT, V33, P71, DOI 10.1136/gut.33.1.71; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Ro S, 2001, P NATL ACAD SCI USA, V98, P10519, DOI 10.1073/pnas.201405498; Shoemaker AR, 2000, ONCOGENE, V19, P2774, DOI 10.1038/sj.onc.1203574; SMITH JM, 1990, NATURE, V348, P391, DOI 10.1038/348391a0; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; Tomlinson IPM, 1996, P NATL ACAD SCI USA, V93, P14800, DOI 10.1073/pnas.93.25.14800; Turker MS, 1997, MUTAT RES-REV MUTAT, V386, P119, DOI 10.1016/S1383-5742(96)00048-8; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; WIGLER M, 1981, CELL, V24, P33, DOI 10.1016/0092-8674(81)90498-0; WILLIAMS ED, 1992, AM J PATHOL, V141, P773; Yatabe Y, 2001, P NATL ACAD SCI USA, V98, P10839, DOI 10.1073/pnas.191225998	47	83	90	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	2002	21	35					5441	5449		10.1038/sj.onc.1205604	http://dx.doi.org/10.1038/sj.onc.1205604			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579VC	12154406				2022-12-17	WOS:000177197700010
J	Bloom, D; Dhakshinamoorthy, S; Jaiswal, AK				Bloom, D; Dhakshinamoorthy, S; Jaiswal, AK			Site-directed mutagenesis of cysteine to serine in the DNA binding region of Nrf2 decreases its capacity to upregulate antioxidant response element-mediated expression and antioxidant induction of NAD(P)H : quinone oxidoreductase1 gene	ONCOGENE			English	Article						NQO1; ARE; detoxifying genes; Nrf2; cysteine; redox regulation	GLUTATHIONE S-TRANSFERASES; DT-DIAPHORASE; TRANSCRIPTION FACTOR; ACTIVATION; CANCER; CELLS; FOS; XENOBIOTICS; RADICALS; MAFG	NF-E2 related factor 2 (Nrf2) is a CNC/b-zip protein that regulates antioxidant response element (ARE)mediated expression, and antioxidant induction, of detoxifying enzyme genes, including NAD(P)H:quinone oxidoreductasel (NQO1). A comparison of Nrf2 from different species, and with other b-zip proteins, revealed the presence of a highly conserved cysteine residue at position 506 in the DNA binding domain of Nrf2. Site-directed mutagenesis was used to mutate this cysteine, to serine. Transfection/over expression experiments in human hepatoblastoma (Hep-G2) cells demonstrated that mutant Nrf2 (mNrf2), containing the C506S mutation, was significantly less efficient in activating ARE-mediated gene expression, and induction in response to tert-butyl hydroquinone (t-BHQ), as copmpared with wild-type Nrf2. N-ethyl malemide (NEM), a sulfhydryl cross- linker, inhibited Nrf2 but not mNrf2C506S-mediated expression of NQO1. This further implicated the cysteine at position 506 in Nrf2 regulation of ARE-mediated gene expression. Nuclear localization experiments revealed that C506S mutation did not affect the retention of Nrf2 by INrf2/Keap1 in the cytosol, or its release in response to antioxidants. However, band and supershift assays showed a significant reduction in the binding of mNrf2C506S to the NQO1 gene ARE as compared with wild-type Nrf2. Therefore, the C506S mutation in Nrf2 lowered its affinity for the ARE, leading to decreased expression, and antioxidant induction, of NQO1.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Baylor College of Medicine	Jaiswal, AK (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Pl, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047466, R29GM047466] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47466] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; BERGELSON S, 1994, CANCER RES, V54, P36; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; Chan PK, 1999, BIOCHEM BIOPH RES CO, V264, P305, DOI 10.1006/bbrc.1999.1255; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dhakshinamoorthy S, 2000, CURR TOP CELL REGUL, V36, P201; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; ERNSTER L, 1987, CHEM SCRIPTA, V27A, P1; Gong PF, 2001, J BIOL CHEM, V276, P27018, DOI 10.1074/jbc.M103658200; Grisham MB, 1986, PHYSL OXYGEN RADICAL, P01; Huang HC, 2001, P NATL ACAD SCI USA, V98, P379; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; JAYEPAUL J, 2000, BIOCHEM PHARMACOL, V59, P1433; JOSEPH P, 1994, ONCOL RES, V6, P525; LI Y, 1992, J BIOL CHEM, V267, P15097; LI Y, 1994, EUR J BIOCHEM, V226, P31, DOI 10.1111/j.1432-1033.1994.tb20023.x; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; OESCH F, 1991, NATO ADV SCI I A-LIF, V202, P447; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; Radjendirane Venugopal, 1997, P441; RILEY RJ, 1992, BIOCHEM PHARMACOL, V43, P1657, DOI 10.1016/0006-2952(92)90694-E; ROSEN GM, 1995, FASEB J, V9, P200, DOI 10.1096/fasebj.9.2.7540156; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; SHERTZER HG, 1995, CHEM RES TOXICOL, V8, P431, DOI 10.1021/tx00045a015; Talalay P, 1995, TOXICOL LETT, V82-3, P173, DOI 10.1016/0378-4274(95)03553-2; TEPHLY TR, 1990, TRENDS PHARMACOL SCI, V11, P276, DOI 10.1016/0165-6147(90)90008-V; THELEN M, 1993, PHYSIOL REV, V73, P797, DOI 10.1152/physrev.1993.73.4.797; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; WARD JF, 1994, INT J RADIAT BIOL, V66, P427, DOI 10.1080/09553009414551401; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; XIE T, 1995, J BIOL CHEM, V270, P6894, DOI 10.1074/jbc.270.12.6894; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997	40	83	87	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2191	2200		10.1038/sj.onc.1205288	http://dx.doi.org/10.1038/sj.onc.1205288			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948402				2022-12-17	WOS:000174555300008
J	Mahoney, MG; Simpson, A; Jost, M; Noe, M; Kari, C; Pepe, D; Choi, YW; Uitto, J; Rodeck, U				Mahoney, MG; Simpson, A; Jost, M; Noe, M; Kari, C; Pepe, D; Choi, YW; Uitto, J; Rodeck, U			Metastasis-associated protein (MTA)1 enhances migration, invasion, and anchorage-independent survival of immortalized human keratinocytes	ONCOGENE			English	Article						anoikis; epidermal growth factor; epithelial cells	EPIDERMAL-GROWTH-FACTOR; BCL-X-L; FACTOR RECEPTOR; BCL-X(L) EXPRESSION; MONOCLONAL-ANTIBODY; ESTROGEN-RECEPTOR; MAMMALIAN-CELLS; GENE; MTA1; MATRIX	The human metastasis-associated gene (MTA1), a member of the nucleosome remodeling complex with histone deacetylase activity, is frequently overexpressed in biologically aggressive epithelial neoplasms. Here, we extend this observation to squamous carcinoma cells, which express high levels of MTA1 relative to normal or immortalized keratinocytes. To address functional aspects of MTA1 expression, we established variants of human immortalized keratinocytes (HaCaT cells) by expressing MTA1 cDNA in both the sense and antisense orientations. We demonstrate that (1) forced MAT1 expression enhances migration and invasion of immortalized keratinocytes; (2) MTA1 expression is necessary but not sufficient for cell survival in the anchorage independent state; (3) MTA1 contributes to expression of the anti-apoptotic Bcl-2 family member Bcl-x(L); (4) MTA1 expression in immortalized keratinocytes depends, in part, on activation of the epidermal growth factor receptor (EGFR). These results establish that, in keratinocytes, MTA1 expression contributes to several aspects of the metastatic phenotype including survival in the anchorage independent state, migration, and invasion.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Inst Mol Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University	Mahoney, MG (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA.	My.Mahoney@mail.tju.edu	Mahoney, My/A-2716-2009					Ahmed NU, 1997, BRIT J DERMATOL, V136, P908, DOI 10.1111/j.1365-2133.1997.tb03932.x; BARNARD JA, 1994, J BIOL CHEM, V269, P22817; BASU A, 1987, CANCER RES, V47, P2531; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Futamura M, 1999, J HUM GENET, V44, P52, DOI 10.1007/s100380050107; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Herman MA, 1999, DEVELOPMENT, V126, P1055; Jost M, 1999, J INVEST DERMATOL, V112, P443, DOI 10.1046/j.1523-1747.1999.00543.x; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; Jost M, 2001, J BIOL CHEM, V276, P6320, DOI 10.1074/jbc.M008210200; Jost M, 1997, NUCLEIC ACIDS RES, V25, P3131, DOI 10.1093/nar/25.15.3131; KAWAHARA E, 1995, J CANCER RES CLIN, V121, P133, DOI 10.1007/BF01198094; Kleene R, 1999, J CELL SCI, V112, P2539; LEJEUNE S, 1993, CANCER RES, V53, P3597; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Mahoney MG, 1998, J INVEST DERMATOL, V111, P308, DOI 10.1046/j.1523-1747.1998.00279.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; MCNEILL H, 1990, CELL REGUL, V1, P843, DOI 10.1091/mbc.1.11.843; MUKAIDA H, 1991, CANCER, V68, P142, DOI 10.1002/1097-0142(19910701)68:1<142::AID-CNCR2820680126>3.0.CO;2-X; MURTHY U, 1987, ARCH BIOCHEM BIOPHYS, V252, P549, DOI 10.1016/0003-9861(87)90062-2; MURTHY U, 1990, BIOCHEM BIOPH RES CO, V172, P471, DOI 10.1016/0006-291X(90)90696-K; Nawa A, 2000, J CELL BIOCHEM, V79, P202, DOI 10.1002/1097-4644(20001101)79:2<202::AID-JCB40>3.0.CO;2-L; OZAWA S, 1989, CANCER, V63, P2169, DOI 10.1002/1097-0142(19890601)63:11<2169::AID-CNCR2820631117>3.0.CO;2-W; Paterno GD, 1997, J BIOL CHEM, V272, P25591, DOI 10.1074/jbc.272.41.25591; Pinkas-Kramarski R, 1998, ONCOGENE, V16, P1249, DOI 10.1038/sj.onc.1201642; RODECK U, 1991, J INVEST DERMATOL, V97, P20, DOI 10.1111/1523-1747.ep12477822; RODECK U, 1987, CANCER RES, V47, P3692; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Simpson A, 2001, GENE, V273, P29, DOI 10.1016/S0378-1119(01)00563-7; TOH Y, 1995, GENE, V159, P97, DOI 10.1016/0378-1119(94)00410-T; Toh Y, 2000, J EXP CLIN CANC RES, V19, P105; Toh Y, 1999, BRIT J CANCER, V79, P1723, DOI 10.1038/sj.bjc.6690274; TOH Y, 1994, J BIOL CHEM, V269, P22958; YONEDA T, 1991, CANCER RES, V51, P4430; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhu Z, 2000, CANCER RES, V61, P1707	39	83	93	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2161	2170		10.1038/sj.onc.1205277	http://dx.doi.org/10.1038/sj.onc.1205277			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948399				2022-12-17	WOS:000174555300005
J	Foddis, R; De Rienzo, A; Broccoli, D; Bocchetta, M; Stekala, E; Rizzo, P; Tosolini, A; Grobelny, JV; Jhanwar, SC; Pass, HI; Testa, JR; Carbone, M				Foddis, R; De Rienzo, A; Broccoli, D; Bocchetta, M; Stekala, E; Rizzo, P; Tosolini, A; Grobelny, JV; Jhanwar, SC; Pass, HI; Testa, JR; Carbone, M			SV40 infection induces telomerase activity in human mesothelial cells	ONCOGENE			English	Article						SV40; telomerase; asbestos; mesothelioma	LARGE-T-ANTIGEN; IMMORTALIZATION; ASSOCIATION; SIMIAN-VIRUS-40; TRANSFORMATION; EXPRESSION; PROTEIN; FIBROBLASTS; ELONGATION; ACTIVATION	Mesotheliomas are malignant tumors of the pleural and peritoneal membranes which are often associated with asbestos exposure and with Simian virus 40 (SV40) infection. Telomerase activity is repressed in somatic cells and tissues but is activated in immortal and malignant cells. We evaluated telomerase activity in seven primary malignant mesothelioma biopsies and matched lung specimens and 20 mesothelioma cell lines and eight corresponding primary tumor cultures. All the tumor biopsies, and nearly all primary cell mesothelioma cultures and cell lines were telomerase positive. The findings in cell lines paralleled those observed in primary cultures in cases where paired samples were available. Next, we found that SV40, a DNA tumor virus present in similar to50% of mesothelioma biopsies in the USA, induced telomerase activity in primary human mesothelial cells, but not in primary fibroblasts. Telomerase activity became detectable as early as 72 h following wild-type (strain 776) SV40 infection, and a clear DNA ladder was detectable I week after infection. The amount of telomerase activity increased during passage in cell culture and appeared to parallel increases in the cellular amounts of the SV40 large T-antigen. Thus, SV40 infection leads to telomerase activity before the infected mesothelial cells become transformed and immortalized. SV40 infection of human fibroblasts did not cause detectable telomerase activity. We also determined that the SV40 small t-antigen (tag) plays an important role in inducing telomerase activity because this activity was undetectable or minimal in mesothelial cells infected and/or transformed by SV40 tag mutants. Asbestos alone did not induce telomerase activity, and asbestos did not influence telomerase activity in mesothelial cells infected with SV40. Induction of telomerase activity by SV40 may be related to the very high rate of mesothelial cell immortalization that is characteristically associated with SV40 infection of mesothelial cells.	Loyola Univ Chicago, Cardinal Bernardin Canc Ctr, Dept Pathol, Canc Immunol Program, Maywood, IL 60153 USA; Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Tumor Cell Biol Program, Philadelphia, PA 19111 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Wayne State Univ, Karmanos Canc Inst, Aerodigest Program, Detroit, MI 48201 USA	Loyola University Chicago; Fox Chase Cancer Center; Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center; Barbara Ann Karmanos Cancer Institute; Wayne State University	Carbone, M (corresponding author), Loyola Univ Chicago, Cardinal Bernardin Canc Ctr, Dept Pathol, Canc Immunol Program, Rm 205 2160 S 1st Ave, Maywood, IL 60153 USA.	mcarbon@orion.it.luc.edu		rizzo, paola/0000-0001-7174-9674; Pass, Harvey/0000-0003-3222-3471	NCI NIH HHS [CA-06927, CA-45745] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Bocchetta M, 2000, P NATL ACAD SCI USA, V97, P10214, DOI 10.1073/pnas.170207097; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Cacciotti P, 2001, P NATL ACAD SCI USA, V98, P12032, DOI 10.1073/pnas.211026798; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; CARBONE M, 1991, NATO ADV SCI I A-LIF, V209, P195; CARBONE M, 2002, IN PRESS SEMIN ONCOL; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Jasani B, 2001, SEMIN CANCER BIOL, V11, P49, DOI 10.1006/scbi.2000.0346; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; KE Y, 1989, AM J PATHOL, V134, P979; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLEIN B, 1990, EXP CELL RES, V191, P256, DOI 10.1016/0014-4827(90)90012-Y; Klein G, 2000, P NATL ACAD SCI USA, V97, P9830, DOI 10.1073/pnas.190325697; Klein G, 2002, ONCOGENE, V21, P1141, DOI 10.1038/sj.onc.1205173; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; Ozer HL, 1996, EXP GERONTOL, V31, P303, DOI 10.1016/0531-5565(95)00024-0; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Rizzo P, 1998, Monaldi Arch Chest Dis, V53, P202; Rundell K, 2001, SEMIN CANCER BIOL, V11, P5, DOI 10.1006/scbi.2000.0341; SAGER R, 1984, CANCER CELL, V2, P487; Schrump DS, 2001, SEMIN CANCER BIOL, V11, P73, DOI 10.1006/scbi.2000.0348; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; Shay JW, 1996, TRENDS GENET, V12, P129, DOI 10.1016/0168-9525(96)30018-8; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; Shay JW, 2001, HUM MOL GENET, V10, P677, DOI 10.1093/hmg/10.7.677; Stewart SA, 2000, SEMIN CANCER BIOL, V10, P399, DOI 10.1006/scbi.2000.0339; Testa JR, 1998, CANCER RES, V58, P4505; Testa JR, 2001, SEMIN CANCER BIOL, V11, P31, DOI 10.1006/scbi.2000.0344; Testa JR, 2001, CANC PRINCIPLES PRAC, P1937; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wright WE, 1996, DEV GENET, V18, P173; Yeager TR, 1999, CANCER RES, V59, P4175; YU J, 2002, VIROLOGY, V230, P132; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	46	83	91	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1434	1442		10.1038/sj.onc.1205203	http://dx.doi.org/10.1038/sj.onc.1205203			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857086				2022-12-17	WOS:000173861000013
J	Goytisolo, FA; Blasco, MA				Goytisolo, FA; Blasco, MA			Many ways to telomere dysfunction: in vivo studies using mouse models	ONCOGENE			English	Review						telomeres; telomerase; mouse models	SEVERE COMBINED IMMUNODEFICIENCY; POLY(ADP-RIBOSE) POLYMERASE; CATALYTIC SUBUNIT; DEFICIENT MICE; CELLS LACKING; ATAXIA-TELANGIECTASIA; REVERSE-TRANSCRIPTASE; TARGETED DISRUPTION; MAMMALIAN TELOMERES; DNA-REPAIR	The existence of a capping structure at the extremities of chromosomes was first deduced in the 1930s by Herman Muller (Muller, 1938), who showed that X-irradiation of Drosophila rarely resulted in terminal deletions or inversions of chromosomes, suggesting that chromosome ends have protective structures that distinguish them from broken chromosomes, which he named telomeres. In this review, we will focus on mammalian telomeres and, in particular, on the analysis of different mouse models for proteins that are important for telomere function, such as telomerase and various telomere-binding proteins. These murine models are helping us to understand the consequences of telomere dysfunction for cancer, aging and DNA repair, as well as, the molecular mechanisms by which telomeres exert their protective function.	CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Blasco, MA (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.	mblasco@cnb.uam.es	Blasco, Maria A./M-1694-2014	Blasco, Maria A./0000-0002-4211-233X				Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barkle A., 2000, DNA DAMAGE STRESS SI, P80; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Bianchi A, 1999, J BIOL CHEM, V274, P21223, DOI 10.1074/jbc.274.30.21223; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Blasco Maria A., 1999, Genes and Development, V13, P2353, DOI 10.1101/gad.13.18.2353; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Chen QJ, 2001, MOL CELL BIOL, V21, P1819, DOI 10.1128/MCB.21.5.1819-1827.2001; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Cohen H, 2001, P NATL ACAD SCI USA, V98, P3174, DOI 10.1073/pnas.061579598; Collins K, 2000, CURR OPIN CELL BIOL, V12, P378, DOI 10.1016/S0955-0674(00)00103-4; de Lange T, 2001, SCIENCE, V292, P1075; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; di Fagagna FD, 1999, NAT GENET, V23, P76; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Goytisolo FA, 2001, MOL CELL BIOL, V21, P3642, DOI 10.1128/MCB.21.11.3642-3651.2001; Goytisolo FA, 2000, J EXP MED, V192, P1625, DOI 10.1084/jem.192.11.1625; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; Greider CW, 1999, CELL, V97, P419, DOI 10.1016/S0092-8674(00)80750-3; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Guarente L, 1997, SCIENCE, V275, P943, DOI 10.1126/science.275.5302.943; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hande MP, 1999, J CELL BIOL, V144, P589, DOI 10.1083/jcb.144.4.589; Hande MP, 2001, HUM MOL GENET, V10, P519, DOI 10.1093/hmg/10.5.519; Hande P, 1999, GENOMICS, V56, P221, DOI 10.1006/geno.1998.5668; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Hemann MT, 2000, NUCLEIC ACIDS RES, V28, P4474, DOI 10.1093/nar/28.22.4474; Hemann MT, 1999, NUCLEIC ACIDS RES, V27, P3964, DOI 10.1093/nar/27.20.3964; Herrera E, 2000, EMBO J, V19, P472, DOI 10.1093/emboj/19.3.472; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; Herrera E, 1999, EMBO J, V18, P1172, DOI 10.1093/emboj/18.5.1172; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Huang PH, 2001, CURR BIOL, V11, P125, DOI 10.1016/S0960-9822(01)00021-5; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Kaminker PG, 2001, J BIOL CHEM, V276, P35891, DOI 10.1074/jbc.M105968200; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Le S, 1999, GENETICS, V152, P143; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lee KH, 2001, P NATL ACAD SCI USA, V98, P3381, DOI 10.1073/pnas.051629198; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Liu Y, 2000, CURR BIOL, V10, P1459, DOI 10.1016/S0960-9822(00)00805-8; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; McElligott R, 1997, EMBO J, V16, P3705, DOI 10.1093/emboj/16.12.3705; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; Naito T, 1998, NAT GENET, V20, P203, DOI 10.1038/2517; Niida H, 1998, NAT GENET, V19, P203, DOI 10.1038/580; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Ohki R, 2001, MOL CELL BIOL, V21, P5753, DOI 10.1128/MCB.21.17.5753-5766.2001; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; Rizki A, 2001, NATURE, V411, P713, DOI 10.1038/35079641; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Samper E, 2001, EMBO REP, V2, P800, DOI 10.1093/embo-reports/kve174; Samper E, 2001, J CELL BIOL, V154, P49, DOI 10.1083/jcb.200103049; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; Smilenov LB, 1997, ONCOGENE, V15, P2659, DOI 10.1038/sj.onc.1201449; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Song K, 2000, FEBS LETT, V481, P81, DOI 10.1016/S0014-5793(00)01958-X; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; Wu L, 2001, SCIENCE, V292, P229, DOI 10.1126/science.1060832; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Yankiwski V, 2000, P NATL ACAD SCI USA, V97, P5214, DOI 10.1073/pnas.090525897; Yuan XM, 1999, GENES CELLS, V4, P563, DOI 10.1046/j.1365-2443.1999.00284.x; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423; Zumstein LA, 1999, NAT MED, V5, P1129, DOI 10.1038/13451	106	83	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2002	21	4					584	591		10.1038/sj.onc.1205085	http://dx.doi.org/10.1038/sj.onc.1205085			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850783				2022-12-17	WOS:000173390500010
J	Toouli, CD; Huschtscha, LI; Neumann, AA; Noble, JR; Colgin, LM; Hukku, B; Reddel, RR				Toouli, CD; Huschtscha, LI; Neumann, AA; Noble, JR; Colgin, LM; Hukku, B; Reddel, RR			Comparison of human mammary epithelial cells immortalized by simian virus 40 T-Antigen or by the telomerase catalytic subunit	ONCOGENE			English	Article						hTERT; SV40-TAg; human mammary epithelial cells; immortalization; differentiation	MUTANT P53-INDUCED IMMORTALIZATION; LIFE-SPAN; HUMAN FIBROBLASTS; REVERSE-TRANSCRIPTASE; P53 PROTEIN; WILD-TYPE; EXPRESSION; GROWTH; INACTIVATION; EXTENSION	We directly compared two methods of immortalizing human mammary epithelial cells (HMECs). Cells were transfected with an expression plasmid either for hTERT, the catalytic subunit of telomerase, or for the simian virus 40 (SV40) early region genes. Under standard culture conditions, HMECs were not immortalized by hTERT unless they had spontaneously ceased expression of the p16(INK4a) tumor suppressor gene. Untransfected HMECs had low levels of telomerase expression, and immortalization by both methods was associated with an increase in telomerase activity and prevention of telomere shortening. SV40-induced immortalization was accompanied by aberrant differentiation, loss of DNA damage response, karyotypic instability and, in some cases, tumorigenicity. hTERT-immortalized cells had fewer karyotypic changes, but had intact DNA damage responses, and features of normal differentiation. Although SV40-immortalized cells are useful for studies of carcinogenesis, hTERT-immortalized cells retain more properties of normal cells.	Childrens Med Res Inst, Westmead, NSW 2145, Australia; Childrens Hosp Michigan, Cell Culture Lab, Detroit, MI 48201 USA	Children's Medical Research Institute - Australia; Children's Hospital of Michigan	Reddel, RR (corresponding author), Childrens Med Res Inst, 214 Hawkesbury Rd, Westmead, NSW 2145, Australia.		Reddel, Roger R/A-6635-2014; Neumann, Axel/D-3319-2012	Reddel, Roger R/0000-0002-6302-6107; 				ALMASAN A, 1995, CANCER METAST REV, V14, P59, DOI 10.1007/BF00690212; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Cao YA, 1997, CANCER RES, V57, P5584; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; Colgin LM, 2000, NEOPLASIA, V2, P426, DOI 10.1038/sj.neo.7900112; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Farwell DG, 2000, AM J PATHOL, V156, P1537, DOI 10.1016/S0002-9440(10)65025-0; Foster SA, 1996, ONCOGENE, V12, P1773; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Gao QS, 1996, CANCER RES, V56, P3129; Garbe J, 1999, ONCOGENE, V18, P2169, DOI 10.1038/sj.onc.1202523; Gollahon LS, 1996, ONCOGENE, V12, P715; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Hooijberg E, 2000, J IMMUNOL, V165, P4239, DOI 10.4049/jimmunol.165.8.4239; Huschtscha LI, 1998, CANCER RES, V58, P3508; Huschtscha LI, 2001, EXP CELL RES, V265, P125, DOI 10.1006/excr.2001.5178; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; KAO CY, 1995, CARCINOGENESIS, V16, P531, DOI 10.1093/carcin/16.3.531; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; LEBEAU J, 1995, INT J CANCER, V60, P244, DOI 10.1002/ijc.2910600219; MacKenzie KL, 2000, EXP CELL RES, V259, P336, DOI 10.1006/excr.2000.4982; Migliaccio M, 2000, J IMMUNOL, V165, P4978, DOI 10.4049/jimmunol.165.9.4978; Mitelman F., 1995, ISCN INT SYSTEM HUMA; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Nonet GH, 2001, CANCER RES, V61, P1250; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Perrem K, 1999, ONCOGENE, V18, P3383, DOI 10.1038/sj.onc.1202752; Peterson W D Jr, 1979, Methods Enzymol, V58, P164; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; Sack MN, 1998, INT J MOL MED, V1, P17; SAKAMOTO K, 1993, ONCOGENE, V8, P1887; SMYTH CM, 1993, PATHOLOGY, V25, P388, DOI 10.3109/00313029309090865; Sprung CN, 1999, EXP CELL RES, V247, P29, DOI 10.1006/excr.1998.4293; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; Stampfer MR, 2001, P NATL ACAD SCI USA, V98, P4498, DOI 10.1073/pnas.071483998; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; Sun W, 1999, CANCER RES, V59, P6118; TAYLORPAPADIMITRIOU J, 1989, J CELL SCI, V94, P403; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; WAZER DE, 1994, MOL CELL BIOL, V14, P2468, DOI 10.1128/MCB.14.4.2468; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Yeager TR, 1999, CANCER RES, V59, P4175; YILMAZ A, 1993, BRIT J CANCER, V68, P868, DOI 10.1038/bjc.1993.447	59	83	93	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2002	21	1					128	139		10.1038/sj.onc.1205014	http://dx.doi.org/10.1038/sj.onc.1205014			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791183	Green Submitted			2022-12-17	WOS:000172887800013
J	Rosenkilde, MM; Waldhoer, M; Luttichau, HR; Schwartz, TW				Rosenkilde, MM; Waldhoer, M; Luttichau, HR; Schwartz, TW			Virally encoded 7TM receptors	ONCOGENE			English	Review						viral chemokine receptors; vGPCR; viral 7TM; constitutive signalling	SARCOMA-ASSOCIATED HERPESVIRUS; PROTEIN-COUPLED RECEPTOR; CHEMOKINE BINDING-PROTEIN; KAPOSIS-SARCOMA; HUMAN CYTOMEGALOVIRUS; MULTIPLE-SCLEROSIS; CX3C CHEMOKINE; DNA-SEQUENCES; NUCLEOTIDE-SEQUENCE; INVERSE AGONISTS	A number of herpes- and poxviruses encode 7TM G-protein coupled receptors most of which clearly are derived from their host chemokine system as well as induce high expression of certain 7TM receptors in the infected cells. The receptors appear to be exploited by the virus for either immune evasion, cellular reprogramming, tissue targeting or for cell entry. Through their efficient evolutionary machinery and through in vivo selection performed directly on the human cellular and molecular targets, virus have been able to optimize the encoded receptors for distinct pharmacological profiles to help in various parts of the viral life cyclus, Most of the receptors encoded by human pathogenic virus are still orphan receptors, i.e. the endogenous ligand is unknown, In the few cases where it has been possible to characterize these receptors pharmacologically, they have been found to bind a broad spectrum of either CC chemokines, US28 from human cytomegalovirus, or CXC chemokines, ORF74 from human herpesvirus 8, Nevertheless, US28 has been specifically optimized for recognition of the membrane bound chemokine, fractalkine, conceivably involved in cell-cell transfer of virus; whereas ORF74 among the endogenous CXC chemokines has selected angiogenic chemokines as agonists and angiostatic/modulatory chemokines as inverse agonists, ORF74 possess substantial cell-transforming properties and signals with high constitutive activity through the phospholipase C and MAP kinase pathways. Interestingly, transgenic expression of this single gene in certain lymphocyte cell lineages leads to the development of lesions which are remarkably similar to Kaposi's sarcoma, a human herpesvirus 8 associated disease. Thus, this and other virally encoded 7TM receptors appear to be attractive future drug targets.	Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Pharmacol Lab, DK-2200 Copenhagen, Denmark; Rigshosp, Dept Infect Dis, DK-2100 Copenhagen, Denmark; 7TM Pharma AS, DK-2100 Copenhagen, Denmark	University of Copenhagen; Rigshospitalet; University of Copenhagen	Rosenkilde, MM (corresponding author), Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Pharmacol Lab, DK-2200 Copenhagen, Denmark.		; Waldhoer, Maria/HDO-0619-2022	Schwartz, Thue W./0000-0002-0261-6904; Luttichau, Hans Rudolf/0000-0002-5428-4075; Rosenkilde, Mette Marie/0000-0001-9600-3254; Waldhoer, Maria/0000-0003-3534-1959				Ahuja SK, 1999, CONT IMMUN, V8, P235; AHUJA SK, 1993, J BIOL CHEM, V268, P20691; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Beisser PS, 1998, J VIROL, V72, P2352, DOI 10.1128/JVI.72.3.2352-2363.1998; Beisser PS, 1999, J VIROL, V73, P7218, DOI 10.1128/JVI.73.9.7218-7230.1999; Billstrom MA, 1999, AM J RESP CELL MOL, V21, P163, DOI 10.1165/ajrcmb.21.2.3673; Billstrom MA, 1998, J VIROL, V72, P5535, DOI 10.1128/JVI.72.7.5535-5544.1998; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; Bodaghi B, 1998, J EXP MED, V188, P855, DOI 10.1084/jem.188.5.855; Boshoff C, 1998, NATURE, V391, P24, DOI 10.1038/34054; Brauner-Osborne H, 1996, EUR J PHARMACOL, V295, P93, DOI 10.1016/0014-2999(95)00639-7; Campadelli-Fiume G, 1999, EMERG INFECT DIS, V5, P353, DOI 10.3201/eid0503.990306; Carlquist JF, 1999, J INFECT DIS, V179, P1094, DOI 10.1086/314734; Casarosa P, 2001, J BIOL CHEM, V276, P1133, DOI 10.1074/jbc.M008965200; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHALLONER PB, 1995, P NATL ACAD SCI USA, V92, P7440, DOI 10.1073/pnas.92.16.7440; CHAMBEY ET, 2000, J VIROL, V74, P1973; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen SH, 1998, J EXP MED, V188, P193, DOI 10.1084/jem.188.1.193; Daibata M, 1998, LEUKEMIA, V12, P1002, DOI 10.1038/sj.leu.2401036; Daibata M, 1999, BLOOD, V94, P1545, DOI 10.1182/blood.V94.5.1545.417a25_1545_1549; Dairaghi DJ, 1998, SEMIN VIROL, V8, P377, DOI 10.1006/smvy.1997.0146; Dairaghi DJ, 1999, J BIOL CHEM, V274, P21569, DOI 10.1074/jbc.274.31.21569; Damon I, 1998, P NATL ACAD SCI USA, V95, P6403, DOI 10.1073/pnas.95.11.6403; DavisPoynter NJ, 1997, J VIROL, V71, P1521, DOI 10.1128/JVI.71.2.1521-1529.1997; Dupin N, 1999, P NATL ACAD SCI USA, V96, P4546, DOI 10.1073/pnas.96.8.4546; Enbom M, 1999, CLIN DIAGN LAB IMMUN, V6, P545, DOI 10.1128/CDLI.6.4.545-549.1999; Endres MJ, 1999, J EXP MED, V189, P1993, DOI 10.1084/jem.189.12.1993; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Fong AM, 2000, J BIOL CHEM, V275, P3781, DOI 10.1074/jbc.275.6.3781; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; GAO JL, 1994, J BIOL CHEM, V269, P28539; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; Geras-Raaka E, 1998, BIOCHEM BIOPH RES CO, V253, P725, DOI 10.1006/bbrc.1998.9557; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; GOMPELS UA, 1995, VIROLOGY, V209, P29, DOI 10.1006/viro.1995.1228; Guo HG, 1997, VIROLOGY, V228, P371, DOI 10.1006/viro.1996.8386; HALL CB, 1994, NEW ENGL J MED, V331, P432, DOI 10.1056/NEJM199408183310703; HASEGAWA H, 1994, J VIROL, V68, P5326, DOI 10.1128/JVI.68.8.5326-5329.1994; Haskell CA, 2000, J BIOL CHEM, V275, P34183, DOI 10.1074/jbc.M005731200; Ho HH, 1999, J BIOL CHEM, V274, P31327, DOI 10.1074/jbc.274.44.31327; HORUK R, 1994, TRENDS PHARMACOL SCI, V15, P159, DOI 10.1016/0165-6147(94)90077-9; Isegawa Y, 1998, J VIROL, V72, P6104, DOI 10.1128/JVI.72.7.6104-6112.1998; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; Jung JU, 1999, SEMIN CANCER BIOL, V9, P231, DOI 10.1006/scbi.1998.0115; Kirshner JR, 1999, J VIROL, V73, P6006, DOI 10.1128/JVI.73.7.6006-6014.1999; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8; KUHN DE, 1995, BIOCHEM BIOPH RES CO, V211, P325, DOI 10.1006/bbrc.1995.1814; Lalani AS, 1999, CYTOKINE GROWTH F R, V10, P219, DOI 10.1016/S1359-6101(99)00018-0; Lee LF, 2000, P NATL ACAD SCI USA, V97, P6091, DOI 10.1073/pnas.97.11.6091; LUPPI M, 1993, J MED VIROL, V40, P44, DOI 10.1002/jmv.1890400110; Luppi M, 1996, HAEMATOLOGICA, V81, P265; Luttichau H R, 2000, Curr Opin Drug Discov Devel, V3, P610; Luttichau HR, 2000, J EXP MED, V191, P171, DOI 10.1084/jem.191.1.171; Margulies BJ, 1996, VIROLOGY, V225, P111, DOI 10.1006/viro.1996.0579; Matloubian M, 2000, NAT IMMUNOL, V1, P298, DOI 10.1038/79738; MELNICK JL, 1983, LANCET, V2, P644; Menotti L, 1999, J VIROL, V73, P325, DOI 10.1128/JVI.73.1.325-333.1999; Milne RSB, 2000, J IMMUNOL, V164, P2396, DOI 10.4049/jimmunol.164.5.2396; Mirandola P, 1999, NEUROLOGY, V53, P1367, DOI 10.1212/WNL.53.6.1367-a; Moore BB, 1998, TRENDS CARDIOVAS MED, V8, P51, DOI 10.1016/S1050-1738(97)00128-X; Munshi N, 1999, J BIOL CHEM, V274, P31863, DOI 10.1074/jbc.274.45.31863; Murphy PM, 2000, PHARMACOL REV, V52, P145; Neipel F, 1997, J VIROL, V71, P4187, DOI 10.1128/JVI.71.6.4187-4192.1997; Nicholas J, 1996, J VIROL, V70, P5975, DOI 10.1128/JVI.70.9.5975-5989.1996; Nieto FJ, 1999, AM HEART J, V138, pS453, DOI 10.1016/S0002-8703(99)70274-7; Orenstein JM, 1997, AIDS, V11, pF35, DOI 10.1097/00002030-199705000-00001; Parravicini C, 2000, AM J PATHOL, V156, P743, DOI 10.1016/S0002-9440(10)64940-1; Parry CM, 2000, J EXP MED, V191, P573, DOI 10.1084/jem.191.3.573; Penfold MET, 1999, P NATL ACAD SCI USA, V96, P9839, DOI 10.1073/pnas.96.17.9839; Pleskoff O, 1998, J VIROL, V72, P6389, DOI 10.1128/JVI.72.8.6389-6397.1998; Pleskoff O, 1997, SCIENCE, V276, P1874, DOI 10.1126/science.276.5320.1874; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rosenkilde MM, 2000, J BIOL CHEM, V275, P26309, DOI 10.1074/jbc.M003800200; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Rosenkilde MM, 2000, MOL PHARMACOL, V57, P602, DOI 10.1124/mol.57.3.602; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Shibutani T, 1997, J CLIN INVEST, V100, P2054, DOI 10.1172/JCI119738; Simas JP, 1998, TRENDS MICROBIOL, V6, P276; Sodhi A, 2000, CANCER RES, V60, P4873; Soldan SS, 1997, NAT MED, V3, P1394, DOI 10.1038/nm1297-1394; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; Stine JT, 2000, BLOOD, V95, P1151, DOI 10.1182/blood.V95.4.1151.004k37_1151_1157; Streblow DN, 1999, CELL, V99, P511, DOI 10.1016/S0092-8674(00)81539-1; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; Sun R, 1999, J VIROL, V73, P2232, DOI 10.1128/JVI.73.3.2232-2242.1999; Van Berkel V, 2000, J VIROL, V74, P6741, DOI 10.1128/JVI.74.15.6741-6747.2000; Vieira J, 1998, J VIROL, V72, P8158, DOI 10.1128/JVI.72.10.8158-8165.1998; Wang JM, 1999, CONT CANC RES, P129; Wells TNC, 1997, CURR OPIN BIOTECH, V8, P741, DOI 10.1016/S0958-1669(97)80129-2; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803; Zhou YF, 1996, NEW ENGL J MED, V335, P624, DOI 10.1056/NEJM199608293350903; Zhu H, 1998, P NATL ACAD SCI USA, V95, P14470, DOI 10.1073/pnas.95.24.14470; Zou P, 1999, J VIROL, V73, P5926, DOI 10.1128/JVI.73.7.5926-5933.1999	102	83	87	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2001	20	13					1582	1593		10.1038/sj.onc.1204191	http://dx.doi.org/10.1038/sj.onc.1204191			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313905				2022-12-17	WOS:000168089800008
J	Lewitzky, M; Kardinal, C; Gehring, NH; Schmidt, EK; Konkol, B; Eulitz, M; Birchmeier, W; Schaeper, U; Feller, SM				Lewitzky, M; Kardinal, C; Gehring, NH; Schmidt, EK; Konkol, B; Eulitz, M; Birchmeier, W; Schaeper, U; Feller, SM			The C-terminal SH3 domain of the adapter protein Grb2 binds with high affinity to sequences in Gab1 and SLP-76 which lack the SH3-typical P-x-x-P core motif	ONCOGENE			English	Article						SH3; Grb2; Gab1; SLP-76	GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; EPIDERMAL GROWTH-FACTOR; SRC HOMOLOGY-3 DOMAIN; PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; RAS PATHWAY; CBL PROTOONCOGENE; MOLECULAR-CLONING; EGF-RECEPTOR	The adapter Grb2 is an important mediator of normal cell proliferation and oncogenic signal transduction events. It consists of a central SH2 domain flanked by two SH3 domains, While the binding specificities of the Grb2 SH2 and N-terminal SH3 domain [Grb2 SH3(N)] have been studied in detail, binding properties of the Grb2 SH3(C) domain remained poorly defined. Gab1, a receptor tyrosine kinase substrate which associates with Grb2 and the c-Met receptor, was previously shown to bind Grb2 via a region which lacks a Grb2 SH3(N)-typical motif (P-x-x-P-x-R), Precipitation experiments with the domains of Grb2 shaw now that Gab1 can bind stably to the Grb2 SH3(C) domain. For further analyses, Gab1 mutants mere generated by PCR to test in vivo residues thought to be crucial for Grb2 SH3(C) binding. The Grb2 SH3(C) binding region of Gab1 has significant homology to a region of the adapter protein SLP-76. Peptides corresponding to epitopes SLP-76, Gab1, SoS and other proteins with related sequences, as well as mutant peptides were synthesized and analysed by tryptophan-fluorescence spectrometry and by irt vitro competition experiments. These experiments define a 13 amino acid sequence with the unusual consensus motif P-x-x-x-R-x-x-(K) under bar-(P) under bar as required for a stable binding to the SH3(C) domain of Grb2. Additional analyses point to a distinct binding specificity of the Grb2-homologous adapter protein Mona (Gads), indicating that the proteins of the Grb2 adapter family may have partially overlapping, yet distinct protein binding properties.	Univ Wurzburg, MSZ, Mol Oncol Lab, D-97078 Wurzburg, Germany; GSF, Munich, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany	University of Wurzburg; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Feller, SM (corresponding author), Univ Wurzburg, MSZ, Mol Oncol Lab, Versbacher Str 5, D-97078 Wurzburg, Germany.							Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BRUGGE JS, 1993, SCIENCE, V260, P918, DOI 10.1126/science.8388123; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Carlier MF, 2000, J BIOL CHEM, V275, P21946, DOI 10.1074/jbc.M000687200; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; COWBURN D, 1995, J BIOL CHEM, V270, P26738, DOI 10.1074/jbc.270.45.26738; Cussac D, 1999, FASEB J, V13, P31, DOI 10.1096/fasebj.13.1.31; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EIJKELENBOOM APAM, 1995, NAT STRUCT BIOL, V2, P807, DOI 10.1038/nsb0995-807; Ellis JH, 2000, J IMMUNOL, V164, P5805, DOI 10.4049/jimmunol.164.11.5805; FELLER SM, 1995, METHOD ENZYMOL, V255, P369; FELLER SM, 1995, ONCOGENE, V10, P1465; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; GOUDREAU N, 1994, NAT STRUCT BIOL, V1, P898, DOI 10.1038/nsb1294-898; Hildt E, 1999, J EXP MED, V189, P1707, DOI 10.1084/jem.189.11.1707; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; Kardinal C, 2000, FASEB J, V14, P1529, DOI 10.1096/fj.14.11.1529; KIESS M, 1995, ONCOGENE, V10, P61; Kim HH, 1998, J BIOL CHEM, V273, P296, DOI 10.1074/jbc.273.1.296; Kishan KVR, 1997, NAT STRUCT BIOL, V4, P739; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KOHDA D, 1994, STRUCTURE, V2, P1029, DOI 10.1016/S0969-2126(94)00106-5; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Liu SK, 2000, J IMMUNOL, V165, P1417, DOI 10.4049/jimmunol.165.3.1417; Liu SK, 1998, ONCOGENE, V17, P3073, DOI 10.1038/sj.onc.1202337; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Nguyen JT, 2000, CHEM BIOL, V7, P463, DOI 10.1016/S1074-5521(00)00130-7; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Okkenhaug K, 1998, J BIOL CHEM, V273, P21194, DOI 10.1074/jbc.273.33.21194; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Park RK, 1998, J IMMUNOL, V160, P5018; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; Pomerance M, 1998, J BIOL CHEM, V273, P24301, DOI 10.1074/jbc.273.38.24301; Posern G, 1998, ONCOGENE, V16, P1903, DOI 10.1038/sj.onc.1201714; Qiu MS, 1998, BIOCHEM BIOPH RES CO, V253, P443, DOI 10.1006/bbrc.1998.9795; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Takenawa T, 1998, CURR TOP MICROBIOL, V228, P325; Tanaka N, 1999, J BIOL CHEM, V274, P19129, DOI 10.1074/jbc.274.27.19129; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; Trenkle T, 2000, GENE, V245, P139, DOI 10.1016/S0378-1119(00)00026-3; Whisstock JC, 1999, TRENDS BIOCHEM SCI, V24, P132, DOI 10.1016/S0968-0004(99)01366-3; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678	73	83	86	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2001	20	9					1052	1062		10.1038/sj.onc.1204202	http://dx.doi.org/10.1038/sj.onc.1204202			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314042				2022-12-17	WOS:000167232100005
J	Adnane, J; Jackson, RJ; Nicosia, SV; Cantor, AB; Pledger, WJ; Sebti, SM				Adnane, J; Jackson, RJ; Nicosia, SV; Cantor, AB; Pledger, WJ; Sebti, SM			Loss of p21(WAF1/CIP1) accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model	ONCOGENE			English	Article						p21(WAF1/CIP1); mammary tumor model; ras oncogene	CELL-CYCLE ARREST; NIH 3T3 CELLS; HA-RAS; SKIN CARCINOGENESIS; GROWTH ARREST; C-MYC; MALIGNANT CONVERSION; INDUCED APOPTOSIS; ACTIVATED RAS; G(1) ARREST	Upregulation of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and subsequent cell growth arrest or senescence is one mechanism by which normal cells are believed to respond to stress induced by the constitutively activated GTPase Ras. We hypothesize that in the absence of p21, the onset of Ras-dependent oncogenesis is accelerated. To test this hypothesis, we crossed MMTV/v-Ha-ras transgenic mice into a p21-deficient background. By 63 days of age, all 8 ras/p21(-/-) mice developed either malignant (mammary and/or salivary adenocarcinomas) or benign (Harderian hyperplasia) tumors. In contrast, by the same age, only one out of nine of the ras/p21(+/+) mice developed a tumor. Furthermore, by 94 days of age, half of the ras/p21(-/-) mice, but none of the ras/p21(+/+) mice, developed mammary tumors. p21-deficiency also accelerated the development of salivary (T-50 = 66 days for ras/21(-/-) vs T-50 = 136 days for ras/p21(+/+)) and Harderian (T-50 = 52 days for ras/p21(-/-) vs T-50>221 days for ras/p21(+/+)) tumors. Furthermore, two out of the eight ras/p21(-/-) mice had metastatic lesions, one in its lungs, the other in its abdomen. None of the nine ras/p21(+/+) mice had metastatic lesions. By 4 months of age, the mammary tumor multiplicity was 10-fold greater in ras/p21(-/-) (average 3.40 tumors/mouse) than in ras/p21(+/+) (average 0.33 tumor/mouse) mice. However, once the tumors appeared, their growth rate, apoptosis level, and mitotic index were not affected by the loss of p21, suggesting that loss of p21 is critical in early but not late events of Ras oncogenesis. Altogether, the results show that tumor onset in MMTV/v-Ha-ras mice is p21-dependent with loss of p21 associated with earlier tumor appearance and increased tumor multiplicity and aggressiveness.	Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Dept Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Dept Pathol & Lab Med, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Sebti, SM (corresponding author), Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia, Tampa, FL 33612 USA.				NATIONAL CANCER INSTITUTE [P01CA078038, U19CA067771, R01CA072694] Funding Source: NIH RePORTER; NCI NIH HHS [CA67771, CA72694, CA78038] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; Arber N, 1996, ONCOGENE, V12, P1903; ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; Balbin M, 1996, J BIOL CHEM, V271, P15782, DOI 10.1074/jbc.271.26.15782; Balomenos D, 2000, NAT MED, V6, P171, DOI 10.1038/72272; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BOS JL, 1989, CANCER RES, V49, P4682; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHEN CH, 1994, RADIAT RES, V139, P307, DOI 10.2307/3578828; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; CHOOI KF, 1994, CANCER RES, V54, P6434; Daphna-Iken D, 1998, ONCOGENE, V17, P2711, DOI 10.1038/sj.onc.1202212; Davis R W, 1980, Methods Enzymol, V65, P404; Delgado MD, 2000, ONCOGENE, V19, P783, DOI 10.1038/sj.onc.1203384; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Downward J, 1997, CURR BIOL, V7, pR258, DOI 10.1016/S0960-9822(06)00116-3; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EFRAT S, 1990, MOL CELL BIOL, V10, P1779, DOI 10.1128/MCB.10.4.1779; Ewen M E, 2000, Prog Cell Cycle Res, V4, P1; FILMUS J, 1994, ONCOGENE, V9, P3627; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GAO X, 1995, ONCOGENE, V11, P1395; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; HEATH LA, 1992, INT J CANCER, V51, P310, DOI 10.1002/ijc.2910510222; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; Hitomi M, 1999, MOL CELL BIOL, V19, P4623; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; IWAMOTO T, 1990, ONCOGENE, V5, P535; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jones JM, 1999, CELL GROWTH DIFFER, V10, P213; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; KINOSHITA T, 1995, ONCOGENE, V10, P2207; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; LUCCHINI F, 1992, CANCER LETT, V64, P203, DOI 10.1016/0304-3835(92)90044-V; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MILLER BE, 1988, CANCER RES, V48, P5747; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; NAMBA H, 1995, CANCER RES, V55, P2075; NOOTER K, 1995, BRIT J CANCER, V71, P556, DOI 10.1038/bjc.1995.109; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; Ritland SR, 1997, CANCER RES, V57, P3520; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; SANDGREN EP, 1989, ONCOGENE, V4, P715; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TAYLOR CR, 1994, HUM PATHOL, V25, P263, DOI 10.1016/0046-8177(94)90198-8; Terry LA, 1996, MOL CARCINOGEN, V16, P221, DOI 10.1002/(SICI)1098-2744(199608)16:4<221::AID-MC6>3.0.CO;2-I; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; TREMBLAY PJ, 1989, MOL CELL BIOL, V9, P854, DOI 10.1128/MCB.9.2.854; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Weinberg WC, 1997, ONCOGENE, V15, P685, DOI 10.1038/sj.onc.1201230; Weinberg WC, 1999, CANCER RES, V59, P2050; Winston JT, 1996, ONCOGENE, V12, P127; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xia K, 1999, MOL CELL BIOL, V19, P4819; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; Yao Y, 1999, ONCOGENE, V18, P5159, DOI 10.1038/sj.onc.1202908	75	83	85	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2000	19	47					5338	5347		10.1038/sj.onc.1203956	http://dx.doi.org/10.1038/sj.onc.1203956			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103935				2022-12-17	WOS:000165302300005
J	Kim, JW; Choi, EJ; Joe, CO				Kim, JW; Choi, EJ; Joe, CO			Activation of death-inducing signaling complex (DISC) by pro-apoptotic C-terminal fragment of RIP	ONCOGENE			English	Article						RIP; caspase-8; apoptosis; NF-kappa B activation; I-kappa B kinase	NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; INDUCED CELL-DEATH; DOMAIN KINASE RIP; CONTAINS 2; IKK-ALPHA; PROTEIN; CLEAVAGE; CD95; PHOSPHORYLATION	The two opposite signaling pathways that stimulate NF-kappa B activation and apoptosis are both mediated by tumor necrosis factor receptor 1 (TNFR1) and its cytosolic associated proteins. In this study, we demonstrate that the proteolytic cleavage of receptor interacting protein (RIP) by caspase-8 during TNF-induced apoptosis abrogates the stimulatory role of RIP on TNF-induced NF-kappa B activation. The uncleavable RIPD324A mutant was less apoptotic, but its ability to activate NF-kappa B activation was greater than the wild type counterpart, Ectopic expression of the pro-apoptotic C-terminal fragment of RIP inhibited TNF-induced NF-kappa B activation by suppressing the activity of I-kappa B kinase beta (IKK beta) which phosphorylates I-kappa B, an inhibitor of NF-kappa B, and triggers its ubiquitin-mediated degradation, The C-terminal fragment of RIP also enhanced the association between TNFR1 and death domain proteins including TNFR1 associated death domain (TRADD) and Fas associated death domain (FADD), resulting in the activation of caspase-8 and stimulation of apoptosis, The present study suggest that the C-terminal fragment of RIP produced by caspase-8 activates death-inducing signaling complex (DISC), attenuates NF-kappa B activation, and thereby amplifies the activation of caspase-8 which initiates the downstream apoptotic events.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Korea Univ, Grad Sch Biotechnol, Natl Creat Res Initiat Cell Death, Seoul 156701, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea University	Joe, CO (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.		Joe, Cheol O/C-1917-2011; KIM, JIN WOO/C-1655-2011	KIM, JIN WOO/0000-0003-0767-1918				Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Grimm S, 1996, P NATL ACAD SCI USA, V93, P10923, DOI 10.1073/pnas.93.20.10923; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Komoriya A, 2000, J EXP MED, V191, P1819, DOI 10.1084/jem.191.11.1819; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Sun XQ, 1999, J BIOL CHEM, V274, P16871, DOI 10.1074/jbc.274.24.16871; Tamm I, 1998, CANCER RES, V58, P5315; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Varfolomeev EE, 1996, J EXP MED, V183, P1271, DOI 10.1084/jem.183.3.1271; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	39	83	86	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2000	19	39					4491	4499		10.1038/sj.onc.1203796	http://dx.doi.org/10.1038/sj.onc.1203796			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352UT	11002422				2022-12-17	WOS:000089236800006
J	Echlin, DR; Tae, HJ; Mitin, N; Taparowsky, EJ				Echlin, DR; Tae, HJ; Mitin, N; Taparowsky, EJ			B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos	ONCOGENE			English	Article						AP-1; transcription regulation; protein; DNA interactions; transformation	C-JUN; DNA-BINDING; C3H10T1/2 CELLS; V-MYC; ACTIVATION; PROTEIN; EXPRESSION; ONCOGENE; MUTANT; MAF	B-ATF is a nuclear basic Leucine zipper protein that belongs to the AP-1/ATF superfamily of transcription factors. Northern blot analysis reveals that the human B-ATF gene is expressed most highly in hematopoietic tissues. Interaction studies in vitro and in vivo show that the leucine zipper of B-ATF mediates dimerization with members of the Jun family of proteins. Chimeric proteins consisting of portions of B-ATF and the DNA binding domain of the yeast activator GAL4 do not stimulate reporter gene expression in mammalian cells, indicating that B-ATF does not contain a conventional transcription activation domain. Jun/B-ATF dimers display similar DNA binding profiles as Jun/Fos dimers, with a bias toward binding TRE (12-O-tetradecanolyphorbol-13-acetate-response element) over CRE (cyclic AMP-response element) DNA sites. B-ATF inhibits transcriptional activation of a reporter gene containing TRE sites in a dose-dependent manner, presumably by competing with Fos for Jun and forming transcriptionally inert Jun/B-ATF heterodimers, Stable expression of B-ATF in C3H10T1/2 cells does not reduce cell viability, but does result in a reduced cellular growth rate when compared to controls, This effect is dominant in the presence of the growth promoting effects of the H-Ras or the v-Fos oncoproteins, since expression of B-ATF restricts the efficiency of focus formation by these transforming agents. These findings demonstrate that B-ATF is a tissue-specific transcription factor with the potential to function as a dominant-negative to AP-1.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Taparowsky, EJ (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.		Mitin, Natalia/E-8043-2012		NATIONAL CANCER INSTITUTE [R01CA078264] Funding Source: NIH RePORTER; NCI NIH HHS [CA-78264] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; Carrozza ML, 1997, ONCOGENE, V14, P1083, DOI 10.1038/sj.onc.1200921; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DAVENPORT EA, 1992, EXP CELL RES, V202, P532, DOI 10.1016/0014-4827(92)90108-K; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Dorsey MJ, 1995, ONCOGENE, V11, P2255; Foletta VC, 1998, J LEUKOCYTE BIOL, V63, P139, DOI 10.1002/jlb.63.2.139; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Hasegawa H, 1996, BIOCHEM BIOPH RES CO, V222, P164, DOI 10.1006/bbrc.1996.0700; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KERPPOLA TK, 1994, ONCOGENE, V9, P675; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; Lemercier C, 1997, DEV BIOL, V182, P101, DOI 10.1006/dbio.1996.8454; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Meyer NP, 1998, MAMM GENOME, V9, P849, DOI 10.1007/s003359900881; MILLER AD, 1985, J VIROL, V55, P521, DOI 10.1128/JVI.55.3.521-526.1985; MIN SY, 1994, CELL GROWTH DIFFER, V5, P563; MIN SY, 1992, ONCOGENE, V7, P1531; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; Vandel L, 1996, MOL CELL BIOL, V16, P1881; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Wang HL, 1996, J CELL BIOL, V135, P1151, DOI 10.1083/jcb.135.4.1151; WANG S, 1994, APPL LASER, V14, P1; Wang XY, 1999, MOL ENDOCRINOL, V13, P254, DOI 10.1210/me.13.2.254; WICK M, 1992, ONCOGENE, V7, P859; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; XANTHOUDAKIS S, 1996, BIOL REACTIVE INTERM, V5	53	83	88	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2000	19	14					1752	1763		10.1038/sj.onc.1203491	http://dx.doi.org/10.1038/sj.onc.1203491			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777209				2022-12-17	WOS:000086292500003
J	Nakagawa, H; Koyama, K; Murata, Y; Morito, M; Akiyama, T; Nakamura, Y				Nakagawa, H; Koyama, K; Murata, Y; Morito, M; Akiyama, T; Nakamura, Y			EB3, a novel member of the EB1 family preferentially expressed in the central nervous system, binds to a CNS-specific APC homologue	ONCOGENE			English	Article						APC; APCL; EB1; EB3; microtubules; central nervous system	TUMOR-SUPPRESSOR PROTEIN; GENE; CHROMOSOME-5Q21; IDENTIFICATION; MUTATIONS; FAP	APCL, a homologue of the adenomatous polyposis coli (APC) tumor suppressor, can deplete cytoplasmic betacatenin like APC, However, as its biological function remains unclear, we have been using a yeast two-hybrid system to search for proteins that associate with its carboxyl region. Among several cDNA clones we isolated from a fetal-brain cDNA library as candidates, six included an identical sequence with significant homology to EB1, a protein known to bind to APC, The full-length cDNA of this novel homologue of EB1, named EB3, encoded a protein of 282 amino acids with 54% identity to EB1, and it was expressed preferentially in brain tissue on Northern blots. Confocal microscopy demonstrated that exogenous EB3, like EB1, is associated with the cytoplasmic microtubule network, Moreover, in these experiments EB3 and APCL appeared together in the perinucleus and the cytoplasmic microtubule network. Since APCL is also expressed highly and specifically in the central nervous system, APCL;EB3 interaction may be specific to the CNS, possibly involving stability and/or extension of microtubules during neuritogenesis.	Univ Tokyo, Inst Med Sci, Mol Med Lab, Ctr Human Genome,Minato Ku, Tokyo 1088639, Japan; Osaka Univ, Sch Med, Div Clin Genet, Biomed Res Ctr, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Ongone Res, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Surg 2, Osaka 5650871, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Dept Human Genome Anal, Tokyo 1708544, Japan	University of Tokyo; Osaka University; Osaka University; Osaka University; Japanese Foundation for Cancer Research	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Mol Med Lab, Ctr Human Genome,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.			Murata, Yoji/0000-0002-9576-7030				BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Beinhauer JD, 1997, J CELL BIOL, V139, P717, DOI 10.1083/jcb.139.3.717; Berrueta L, 1999, CURR BIOL, V9, P425, DOI 10.1016/S0960-9822(99)80190-0; Berrueta L, 1998, P NATL ACAD SCI USA, V95, P10596, DOI 10.1073/pnas.95.18.10596; BHAT RV, 1994, J NEUROSCI, V14, P3059; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Laurent-Puig P, 1998, NUCLEIC ACIDS RES, V26, P269, DOI 10.1093/nar/26.1.269; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MINEMATSU S, 1995, P NATL ACAD SCI USA, V92, P3046; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morrison EE, 1998, ONCOGENE, V17, P3471, DOI 10.1038/sj.onc.1202247; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; Nakagawa H, 1998, CANCER RES, V58, P5176; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; SMITH KJ, 1994, CANCER RES, V54, P3672; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1995, CANCER RES, V55, P2972	19	83	89	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2000	19	2					210	216		10.1038/sj.onc.1203308	http://dx.doi.org/10.1038/sj.onc.1203308			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10644998				2022-12-17	WOS:000084844400005
J	Chen, WX; Bowden, GT				Chen, WX; Bowden, GT			Activation of p38 MAP kinase and ERK are required for ultraviolet-B induced c-fos gene expression in human keratinocytes	ONCOGENE			English	Article						UVB; p38; ERK; c-fos; AP-1	MAMMALIAN UV RESPONSE; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; CELLULAR STRESSES; SUBSTRATE-SPECIFICITY; AP-1 ACTIVITY; JUN; PHOSPHORYLATION; TRANSCRIPTION; INHIBITION	The effects of p38 MAP kinase and ERK on UVB induced c-fos gene expression were studied in a human keratinocyte cell line, FL30, UVB significantly increased c-fos gene expression at both the transcriptional and protein le,els. p38 and ERK were also significantly activated after UVB irradiation. Treating the cells with p38 inhibitor SB202190 inhibited p38 activation, but not ERK; treating the cells with MEK-1 inhibitor PD98059 inhibited ERK activation without suppressing p38 activation, The kinase activation was determined by Western blots using phospho-p38 or ERK antibodies, or an in vivo p38 activity assay. Further studies demonstrated that blocking p38 almost completely abrogated UVB induced c-fos gene transcription and c-Fos protein synthesis. Inhibiting ERK partially abrogated UVB induced c-fos transcriptional and protein levels, Suppression of both p38 and ERK not only completely blocked UVB induced c-fos expression, but also decreased c-fos gene basal expression. Our data indicated that p38 may play a more important role than ERK in UVB induced c-fos expression in human keratinocytes, Since c-fos expression may play an important role in UVB induced AP-1 activation, and AP-1 activation is known to play a role in tumor promotion, both p38 and ERK could be potential targets for chemoprevention of skin cancer.	Univ Arizona, Coll Med, Arizona Canc Ctr, Dept Radiat Oncol, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona	Bowden, GT (corresponding author), Univ Arizona, Coll Med, Arizona Canc Ctr, Dept Radiat Oncol, Tucson, AZ 85724 USA.				NATIONAL CANCER INSTITUTE [P30CA023074, P01CA027502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER; NCI NIH HHS [CA27502, CA23074] Funding Source: Medline; NIEHS NIH HHS [P30 ESO6694] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Barthelman M, 1998, CARCINOGENESIS, V19, P2201, DOI 10.1093/carcin/19.12.2201; Barthelman M, 1998, CANCER RES, V58, P711; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BUSCHER M, 1988, ONCOGENE, V3, P301; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; Chen WX, 1997, NUTR CANCER, V29, P205, DOI 10.1080/01635589709514625; Chen WX, 1999, MOL CARCINOGEN, V24, P79, DOI 10.1002/(SICI)1098-2744(199902)24:2<79::AID-MC1>3.0.CO;2-E; Chen WX, 1998, J BIOL CHEM, V273, P32176, DOI 10.1074/jbc.273.48.32176; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; Dong ZG, 1997, J BIOL CHEM, V272, P9962; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; HALL EJ, 1988, AM J CLIN ONCOL-CANC, V11, P220, DOI 10.1097/00000421-198806000-00003; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Huang CS, 1999, ONCOGENE, V18, P2828, DOI 10.1038/sj.onc.1202639; Huwiler A, 1999, J EXP BIOL, V202, P655; JANKNECHT R, 1995, IMMUNOBIOLOGY, V193, P137, DOI 10.1016/S0171-2985(11)80536-X; JANKNECHT R, 1993, EMBO J, V12, P5057; Kaminska B, 1999, MOL CELL NEUROSCI, V13, P405, DOI 10.1006/mcne.1999.0757; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LOZANO J, 1994, J BIOL CHEM, V269, P6687; MATSUI MS, 1995, SKIN CANC MECH HUMAN, P21; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RAINES MA, 1993, J BIOL CHEM, V268, P14572; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rosenberger SF, 1999, ONCOGENE, V18, P3626, DOI 10.1038/sj.onc.1202695; Rosenberger SF, 1996, ONCOGENE, V12, P2301; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Wilson KP, 1997, CHEM BIOL, V4, P423, DOI 10.1016/S1074-5521(97)90194-0; WOODGETT JR, 1995, CLIN EXP PHARMACOL P, V22, P281, DOI 10.1111/j.1440-1681.1995.tb01995.x; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	47	83	90	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7469	7476		10.1038/sj.onc.1203210	http://dx.doi.org/10.1038/sj.onc.1203210			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602506				2022-12-17	WOS:000084119600008
J	Murphy, KM; Streips, UN; Lock, RB				Murphy, KM; Streips, UN; Lock, RB			Bax membrane insertion during Fas(CD95)-induced apoptosis precedes cytochrome c release and is inhibited by Bcl-2	ONCOGENE			English	Article						Fas; Bax; Bcl-2; caspase; cytochrome c	FAS-MEDIATED APOPTOSIS; INDUCED CELL-DEATH; NECROSIS-FACTOR; MITOCHONDRIAL RELEASE; CPP32-LIKE PROTEASES; SIGNALING COMPLEX; CD95 FAS/APO-1; ICE-LIKE; ACTIVATION; PROTEIN	Ligation of the Fas cell surface receptor leads to activation of caspases and subsequent apoptosis. Members of the Bcl-2 family of proteins control the cellular commitment to apoptosis, although their role in Fas-induced apoptosis is ill-defined. In this report we demonstrate that the pro-apoptotic protein, Bax, translocates from the cytosol specifically to the mitochondria following Fas ligation in MCF10A1 breast epithelial cells. Bax translocation was dependent on caspase activation, and preceded the release of cytochrome c and loss of mitochondrial respiratory activity. Bax translocation occurred in concert with activation of downstream caspases as determined by cleavage of a synthetic substrate, proteolysis of poly(ADP-ribose) polymerase, and processing of procaspase-3 and -7, Overexpression of the anti-apoptotic protein, Bcl-2, prevented Bax insertion, cytochrome c release, complete processing of procaspase-3 and -7, and full activation of DEVD-specific cleavage activity. These data establish a role for Bax mitochondrial insertion during Fas-mediated apoptosis, and support a model in which Bax insertion amplifies the Fas apoptotic cascade through cytochrome c release and complete processing of caspases-3 and -7. In addition, our findings indicate that prevention of Bax insertion into the mitochondria represents a novel mechanism by which Bcl-2 inhibits Fas-induced apoptosis.	Sydney Childrens Hosp, Childrens Canc Inst Asutralia Med Res, Randwick, NSW 2031, Australia; Univ Louisville, Dept Microbiol & Immunol, Louisville, KY 40292 USA	University of Louisville	Lock, RB (corresponding author), Sydney Childrens Hosp, Childrens Canc Inst Asutralia Med Res, Randwick, NSW 2031, Australia.		Lock, Richard/G-4253-2013	Lock, Richard/0000-0002-3436-9071				Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cory S, 1998, BBA-REV CANCER, V1377, pR25, DOI 10.1016/S0304-419X(98)00003-1; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Keane MM, 1996, CANCER RES, V56, P4791; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lock RB, 1996, CANCER RES, V56, P4006; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rosen A, 1997, J CELL BIOCHEM, V64, P50, DOI 10.1002/(SICI)1097-4644(199701)64:1<50::AID-JCB8>3.0.CO;2-Z; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	49	83	86	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 28	1999	18	44					5991	5999		10.1038/sj.onc.1203001	http://dx.doi.org/10.1038/sj.onc.1203001			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557088				2022-12-17	WOS:000083359100005
J	Suzuki, T; Uchida-Toita, M; Yoshida, M				Suzuki, T; Uchida-Toita, M; Yoshida, M			Tax protein of HTLV-1 inhibits CBP/p300-mediated transcription by interfering with recruitment of CBP/p300 onto DNA element of E-box or p53 binding site	ONCOGENE			English	Article						HTLV-1; Tax; trans-repression; CBP/p300	T-CELL LEUKEMIA; VIRUS TYPE-1 TAX; ACUTE MYELOID-LEUKEMIA; NF-KAPPA-B; CREB BINDING; GENE-EXPRESSION; HISTONE ACETYLTRANSFERASE; TRANSACTIVATOR TAX; ONCOPROTEIN TAX; COACTIVATOR CBP	Tax protein of human T-cell leukemia virus type 1 (HTLV-1) is a potent transcriptional regulator which can activate or repress specific cellular genes and has been proposed to contribute to leukemogenic processes in adult T-cell leukemia, The molecular mechanism of Tax-mediated trans-activation has been well investigated. However, trans-repression by Tax remains to be studied in detail, although it is known to require a specific DIVA element such as E-box or p53 binding site. Examining possible mechanisms of trans-repression, we found that co-expression of E47 and p300 activated E-box dependent transcription and this activation was efficiently repressed by Tax. In this system, Tax bound to p300 and decreased the level of p300 complexed on the E-box element. Similarly, Tax inhibited transcription directed by p53 and CBP, reducing the level of CBP on the p53 binding site. These results indicate that Tax interferes with recruitment of CBP/p300 into protein complexes on E-box and p53 binding site through its binding to CBP/p300. In contrast to these findings, we observed that Tax increased the level of CBP on the viral 21-bp enhancer which is trans-activated by Tax. From these observations, we propose a universal mechanism for Tax-mediated trans-repression and trans-activation of transcription in which Tax binds to CBP/p300 and determines the accessibility of CBP/p300 to protein complexes on specific DNA element.	Univ Tokyo, Inst Med Sci, Dept Cellular & Mol Biol, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Yoshida, M (corresponding author), Univ Tokyo, Inst Med Sci, Dept Cellular & Mol Biol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.							Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Colgin MA, 1998, J VIROL, V72, P9396, DOI 10.1128/JVI.72.11.9396-9399.1998; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; Muraoka M, 1996, ONCOGENE, V12, P1565; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; POEISZ BJ, 1980, P NATL ACAD SCI USA, V77, P7415; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; SUZUKI T, 1994, ONCOGENE, V9, P3099; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; UITTENBOGAARD MN, 1994, J BIOL CHEM, V269, P22466; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yoshida M, 1993, Trends Microbiol, V1, P131, DOI 10.1016/0966-842X(93)90127-D; YOSHIDA M, 1995, CURR TOP MICROBIOL, V193, P79; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	42	83	84	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4137	4143		10.1038/sj.onc.1202766	http://dx.doi.org/10.1038/sj.onc.1202766			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435595				2022-12-17	WOS:000081431000011
J	Casini, T; Pelicci, PG				Casini, T; Pelicci, PG			A function of p21 during promyelocytic leukemia cell differentiation independent of CDK inhibition and cell cycle arrest	ONCOGENE			English	Article						APL; cell cycle; p21; PML/RAR alpha; RA	RETINOIC ACID RECEPTOR; TRANSCRIPTIONAL ACTIVATION; RAR-ALPHA; TERMINAL DIFFERENTIATION; HISTONE DEACETYLASE; DEPENDENT KINASES; FUSION PROTEINS; EXPRESSION; P21(CIP1/WAF1); P21(WAF1/CIP1)	Retinoic Acid (RA) treatment induces disease remission of Acute Promyelocytic Leukemias (APL) by triggering differentiation of neoplastic cells. Differentiation is mediated by the APL-specific transforming protein PML/RAR alpha and involves its activity as ligand-dependent enhancer factor on RA-target genes. We report here the identification of p21 as a transcriptional target of PML/RAR alpha during RA-induced differentiation of APL cells. We found that RA-treated APL cells undergo two rounds of cell division before entering post mitotic G1, that progression through the G1-S is indispensable for differentiation and coincides with the duration of commitment. RA-treatment induced two peaks of p21 synthesis: early (from the 2nd to the 6th hour), dependent on PML/RAR alpha expression and associated with G1-S transition and high CDK activity; late (from 3rd to the 4th day), independent from PML/RAR alpha and associated with G1 block and low CDK activity, Increased p21 in PML/RAR alpha cells during G1-S had no effect on the cell cycle while an antisense p21 prevented RA-induced differentiation without altering G1-S transition and the late ct block. These results demonstrate that p21 is an effector of the activity of PML/RAR alpha on differentiation and suggest that p21 exerts a function in G1-S connected to differentiation-commitment and uncoupled from cell cycle and CDK inhibition.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	IRCCS European Institute of Oncology (IEO)	Pelicci, PG (corresponding author), European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy.		Pelicci, Pier Giuseppe/AAL-6572-2020					Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHAMBON P, 1996, FASEB J, V10, P954; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DYNLACHT B, 1997, CELL CYCLE CONTROL 2; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; GRIGNANI F, 1994, BLOOD, V83, P10; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; GRIGNANI F, 1993, CELL, V74, P1; GRIGNANI F, 1998, CANC RES, V58; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; LIZHEN H, 1997, PNAS, V94, P5302; LUBBERT M, 1991, BLOOD, V77, P909; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; ROVERA G, 1980, NATURE, V284, P69, DOI 10.1038/284069a0; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SPRIGGS LL, 1992, BIOCHEM CELL BIOL, V70, P555, DOI 10.1139/o92-086; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yoshida H, 1996, CANCER RES, V56, P2945; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	42	83	85	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 27	1999	18	21					3235	3243		10.1038/sj.onc.1202630	http://dx.doi.org/10.1038/sj.onc.1202630			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359529				2022-12-17	WOS:000080523800006
J	Cha, HJ; Park, MT; Chung, HY; Kim, ND; Sato, H; Seiki, M; Kim, KW				Cha, HJ; Park, MT; Chung, HY; Kim, ND; Sato, H; Seiki, M; Kim, KW			Ursolic acid-induced down-regulation of MMP-9 gene is mediated through the nuclear translocation of glucocorticoid receptor in HT1080 human fibrosarcoma cells	ONCOGENE			English	Article						ursolic acid; matrix metalloproteinase; glucocorticoid receptor	PROTEIN-PROTEIN-INTERACTION; BASEMENT-MEMBRANE COLLAGEN; NF-KAPPA-B; NEGATIVE REGULATION; IV COLLAGENASE; FUNCTIONAL INTERFERENCE; OLEANOLIC ACID; DNA-BINDING; TUMOR-CELLS; C-JUN	We have previously reported that ursolic acid, a pentacyclic triterpene acid, inhibited the invasion of human fibrosarcoma cells by reducing: the of matrix metalloproteinase-9. Since the chemical structure of ursolic acid is very similar to that of dexamethasone, a synthetic glucocorticoid, we investigated whether ursolic acid acts through the glucocorticoid receptor, The expression of matrix metalloproteinase-9 is thought to be regulated similarly with matrix metalloproteinase-l and matrix metalloproteinase-3 as containing common 2-O-tetradecanoylphorbol-acetate responsible region, where AP-1 proteins can bind, Dexamethasone has been studied to repress the 2-O-tetradecanoylphorbol-acetate-induced expression of matrix metalloproteinase-l and matrix metalloproteinase-3 through a glucocorticoid receptor-mediated manner, In Northern blot analysis, we found that ursolic acid reduced the expression of matrix metalloproteinase-l and matrix metalloproteinase-3 induced by 2-O-tetradecanoylphorbol-acetate, Similarly, ursolic acid down-regulated 2-O-tetradecanoylphorbol-acetate-induction of matrix metalloproteinase-9 gene in the same manner of dexamethasone. RU486, a potent glucocorticoid receptor antagonist, was used for identifying that ursolic acid-indnced down-regulation of matrix metalloproteinase-9 expression is mediated by its binding to glucocorticoid receptor, The effect of ursolic acid on the matrix metalloproteinase-9 expression was blocked by RU486, suggesting that ursolic acid acts via a glucocorticoid receptor in the regulation of matrix metalloproteinase-9, Western blot analysis and immunocytochemistry showed that ursolic acid increased glucocorticoid receptor fraction in the nucleus, although it decreased the synthesis of glucocorticoid receptor mRNA., In addition, ursolic acid did not decrease the expression of c-jun and DNA-binding activity of AP-1 to its cognate sequences, Taken together, we suggest that ursolic acid may induce the repression of matrix metalloproteinase-9 by stimulating the nuclear translocation of glucocorticoid receptor, and the translocated glucocorticoid receptor probably down-modulating the trans-activating function of AP-1 to 2-O-tetradecanoylphorbol-acetate responsible element of matrix metalloproteinase-9 promoter region.	Pusan Natl Univ, Dept Mol Biol, Pusan 609735, South Korea; Pusan Natl Univ, Res Inst Basic Sci, Pusan 609735, South Korea; Pusan Natl Univ, Pusan Canc Res Ctr, Pusan 609735, South Korea; Pusan Natl Univ, Dept Pharm, Pusan 609735, South Korea; Kanazawa Univ, Canc Res Inst, Dept Mol Virol & Oncol, Kanazawa, Ishikawa 920, Japan; Univ Tokyo, Inst Med Sci, Dept Canc Cell Res, Minato Ku, Tokyo 108, Japan	Pusan National University; Pusan National University; Pusan National University; Pusan National University; Kanazawa University; University of Tokyo	Kim, KW (corresponding author), Pusan Natl Univ, Dept Mol Biol, Pusan 609735, South Korea.		Seiki, Motoharu/K-9443-2015; Cha, Hee-Jae/AFO-8772-2022; SATO, Hiroshi/D-8454-2015					ADCOCK IM, 1995, J IMMUNOL, V154, P3500; AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ALEXANDROVA M, 1992, J STEROID BIOCHEM, V41, P723, DOI 10.1016/0960-0760(92)90412-C; BROWN PD, 1990, CANCER RES, V50, P6184; CELADA A, 1993, J EXP MED, V177, P691, DOI 10.1084/jem.177.3.691; Cha HJ, 1996, CANCER RES, V56, P2281; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DROUIN J, 1989, MOL CELL BIOL, V9, P5305, DOI 10.1128/MCB.9.12.5305; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GUO DF, 1995, CIRC RES, V77, P249, DOI 10.1161/01.RES.77.2.249; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HIRANO M, 1995, BIOCHEM BIOPH RES CO, V206, P429, DOI 10.1006/bbrc.1995.1059; HUANG MT, 1994, CANCER RES, V54, P701; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; LEE HY, 1994, J CANCER RES CLIN, V120, P513, DOI 10.1007/BF01221027; Li JJ, 1997, CANCER RES, V57, P3569; LIOTTA LA, 1979, P NATL ACAD SCI USA, V76, P2268, DOI 10.1073/pnas.76.5.2268; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; LIU W, 1995, MOL CELL BIOL, V15, P1005; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MCRAE AC, 1994, J REPROD FERTIL, V100, P307, DOI 10.1530/jrf.0.1000307; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OHIGASHI H, 1986, CANCER LETT, V30, P143, DOI 10.1016/0304-3835(86)90082-0; ORO AE, 1988, CELL, V55, P1109, DOI 10.1016/0092-8674(88)90255-3; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; ROSEWICZ S, 1988, J BIOL CHEM, V263, P2581; SATO H, 1992, ONCOGENE, V7, P77; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1993, ONCOGENE, V8, P395; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHON KH, 1995, CANCER LETT, V94, P213, DOI 10.1016/0304-3835(95)03856-R; STROMSTEDT PE, 1991, MOL CELL BIOL, V11, P3379, DOI 10.1128/MCB.11.6.3379; TAKINO T, 1995, GENE, V155, P293, DOI 10.1016/0378-1119(94)00637-8; TEMPLETON NS, 1990, CANCER RES, V50, P5413; TOKUDA H, 1986, CANCER LETT, V33, P279, DOI 10.1016/0304-3835(86)90067-4; TOURAY M, 1991, ONCOGENE, V6, P1227; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TVERBERG LA, 1992, J BIOL CHEM, V267, P17567; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YLIKOMI T, 1992, EMBO J, V11, P3681, DOI 10.1002/j.1460-2075.1992.tb05453.x; Young Han-Suk, 1995, Natural Medicines, V49, P190	47	83	90	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	1998	16	6					771	778		10.1038/sj.onc.1201587	http://dx.doi.org/10.1038/sj.onc.1201587			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488041				2022-12-17	WOS:000071931800009
J	Chintala, SK; Fueyo, J; GomezManzano, C; Venkaiah, B; Bjerkvig, R; Yung, WKA; Sawaya, R; Kyritsis, AP; Rao, JS				Chintala, SK; Fueyo, J; GomezManzano, C; Venkaiah, B; Bjerkvig, R; Yung, WKA; Sawaya, R; Kyritsis, AP; Rao, JS			Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro	ONCOGENE			English	Article						p16; glioma; invasion; MMP-2; tumor-suppressor	IN-VITRO; CELL-CYCLE; IV COLLAGENASE; PLASMINOGEN-ACTIVATOR; EXTRACELLULAR-MATRIX; GLIOBLASTOMA CELLS; TUMOR PROGRESSION; MALIGNANT GLIOMAS; RAT BRAIN; EXPRESSION	Malignant gliomas extensively infiltrate the surrounding normal brain, and their diffuse invasion is one of the most important barriers to successful therapy, Recent studies indicate that the progression of gliomas from low-grade to high-grade may depend on the acquisition of a new phenotype and the subsequent addition of genetic defects, One of the most frequent abnormalities in the progression of gliomas is the inactivation of tumor-suppressor gene p16, suggesting that loss of p16 is associated with acquisition of malignant characteristics. Consistent with this hypothesis, our previous studies showed that restoring wild-type p16 activity into p16-null malignant glioma cells modified their phenotype, In order to understand whether the biological consequences of p16 inactivation in high-grade gliomas included facilitating invasiveness, we used a recombinant replication-deficient adenovirus carrying the cDNA of the p16/CDKN2 gene to infect and express high levels of p16 protein in p16-null SNB19 glioma cells, Invasion of SNB19 glioma cells was tested into two models: invasion of glioma cells through Matrigel-coated transwell inserts and invasion of tumor-cell spheroids into fetal rat-brain aggregates in a co-culture system, Matrigel invasion assays showed that the SNB19 cells expressing exogenous p16 exhibited significantly reduced invasion, Similarly, invasion of p16-treated SNB19 cells into fetal rat-brain aggregates was reduced during a 72 h time period compared to invasion of the adenovirus-control and mock-infected cells, Expression of matrix metalloproteinase-2 (MMP-2), an enzyme involved in tumor-cell invasion, in SNB19 cells expressing p16 was significantly reduced compared to that of parental SNB19 and vector-infected cells, Our results show that restoring wild-type p16 activity into p16-null SNB19 glioma cells significantly inhibits tumor-cell invasion, thus suggesting a novel function of the p16 gene.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT NEUROSURG,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT NEUROONCOL,HOUSTON,TX 77030; UNIV BERGEN,DEPT ANAT & CELL BIOL,BERGEN,NORWAY	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Bergen				Fueyo, Juan/0000-0001-6941-2335; Gomez-Manzano, Candelaria/0000-0002-1259-2133	NATIONAL CANCER INSTITUTE [R01CA056792] Funding Source: NIH RePORTER; NCI NIH HHS [CA56792] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKLI S, 1993, NAT GENET, V3, P224, DOI 10.1038/ng0393-224; ALBELDA SM, 1993, LAB INVEST, V68, P4; ARAP W, 1995, CANCER RES, V55, P1351; BJERKVIG R, 1986, CANCER RES, V46, P4071; Chintala S.K., 1996, FRONT BIOSCI, V1, pd324, DOI 10.2741/a135; CHINTALA SK, 1996, CANC LETT, V103, P102; COLLINS VP, 1993, FASEB J, V7, P926, DOI 10.1096/fasebj.7.10.8344489; EASTHAM JA, 1995, CANCER RES, V55, P5151; Fueyo J, 1996, ONCOGENE, V12, P103; Fueyo J, 1996, ONCOGENE, V13, P1615; GIANI C, 1994, CANCER RES, V54, P6338; Giese A, 1996, NEUROSURGERY, V39, P235, DOI 10.1097/00006123-199608000-00001; Go Y, 1996, CANCER LETT, V110, P225, DOI 10.1016/S0304-3835(96)04515-6; GOMEZMANZANO C, 1996, CANCER RES, V54, P6353; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HIRVONEN HE, 1994, BRIT J CANCER, V69, P16, DOI 10.1038/bjc.1994.3; Hsu SC, 1996, CANCER RES, V56, P5684; IWASAKI T, 1995, INT J CANCER, V63, P282, DOI 10.1002/ijc.2910630223; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASALLE GL, 1993, SCIENCE, V259, P988, DOI 10.1126/science.8382374; Li J, 1996, ONCOGENE, V13, P2379; LI Y, 1994, CANCER RES, V54, P6078; Liotta L A, 1990, Semin Cancer Biol, V1, P99; MASUYAMA JI, 1992, J IMMUNOL, V148, P1367; MERZAK A, 1994, BRIT J CANCER, V70, P199, DOI 10.1038/bjc.1994.280; Miele ME, 1996, MOL CARCINOGEN, V15, P284, DOI 10.1002/(SICI)1098-2744(199604)15:4<284::AID-MC6>3.0.CO;2-G; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Mohanam S, 1997, ONCOGENE, V14, P1351, DOI 10.1038/sj.onc.1200963; MOHANAM S, 1993, CANCER RES, V53, P4143; Nakagawa T, 1996, J NEURO-ONCOL, V28, P13, DOI 10.1007/BF00300442; NAKAJIMA M, 1990, J NATL CANCER I, V82, P1890, DOI 10.1093/jnci/82.24.1890; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Nygaard SJT, 1995, INVAS METAST, V15, P179; PEDERSEN PH, 1993, CANCER RES, V53, P5158; RAO JS, 1994, J NEURO-ONCOL, V18, P129, DOI 10.1007/BF01050419; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; RATNER S, 1988, J IMMUNOL, V140, P583; REED JA, 1995, CANCER RES, V55, P2713; Sawaya RE, 1996, CLIN EXP METASTAS, V14, P35, DOI 10.1007/BF00157684; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Uhm JH, 1996, CLIN EXP METASTAS, V14, P421, DOI 10.1007/BF00128958; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; WELCH DR, 1994, ONCOGENE, V9, P255; WILKINSON PC, 1986, IMMUNOLOGY, V57, P281; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868	50	83	86	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2049	2057		10.1038/sj.onc.1201382	http://dx.doi.org/10.1038/sj.onc.1201382			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366522				2022-12-17	WOS:A1997YC28400006
J	Ponten, F; Berg, C; Ahmadian, A; Ren, ZP; Nister, M; Lundeberg, J; Uhlen, M; Ponten, J				Ponten, F; Berg, C; Ahmadian, A; Ren, ZP; Nister, M; Lundeberg, J; Uhlen, M; Ponten, J			Molecular pathology in basal cell cancer with p53 as a genetic marker	ONCOGENE			English	Article						p53; BCC; mutation; LOH; heterogeneity; clonality	SKIN-CANCER; MUTATIONS; CARCINOMA; SUNLIGHT; EXPOSURE; PATTERN	Human basal cell cancer (BCC) has unique growth characteristics with virtual inability to metastasize, We investigated clonality and genetic progression using p53 mutations as marker. Sampling was done through microdissection of frozen immunohistochemically stained 16 mu m slices of tumors. From 11 BCC tumors 78 samples were analysed. Direct DIVA sequencing of exons 5-8 was performed, haplotypes were determined after cloning of p53 exons and loss of heterozygosity (LOH) ascertained by microsatellite analysis, All tumors had p53 mutations and in a majority both p53 alleles were affected, commonly through missense mutations. Microdissection of small parts (50-100 cells) of individual tumors showed BCC to be composed of a dominant cell clone and prone to genetic progression with appearance of subclones with a second and even third p53 mutation, Samples from normal immunohistochemically negative epidermis always showed wild type sequence, except for a case of previously unknown germline p53 mutation. Our analysis also included p53 immunoreactive patches i.e. morphologically normal epidermis with a compact pattern of p53 immunoreactivity. Mutations within those were never the same as in the adjacent BCC. This detailed study of only one gene thus uncovered a remarkable heterogeneity within a tumor category famous for its benign clinical behavior.	ROYAL INST TECHNOL,DEPT BIOCHEM & BIOTECHNOL,KTH,S-10044 STOCKHOLM,SWEDEN	Royal Institute of Technology	Ponten, F (corresponding author), UNIV UPPSALA HOSP,DEPT PATHOL,S-75185 UPPSALA,SWEDEN.		Uhlen, Mathias/AAV-8746-2021; Uhlen, Mathias/B-3262-2016; Williams, Cecilia/A-6677-2009	Uhlen, Mathias/0000-0002-4858-8056; Williams, Cecilia/0000-0002-0602-2062				BERG C, 1995, CLIN CHEM, V41, P1461; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Brash DE, 1996, J INVEST DERMATOL S, V1, P136; CAMPBELL C, 1993, J INVEST DERMATOL, V100, P746, DOI 10.1111/1523-1747.ep12475717; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DIFFEY BL, 1979, PHYS MED BIOL, V24, P931, DOI 10.1088/0031-9155/24/5/006; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FUTREAL PA, 1992, CANCER RES, V52, P2624; GALLAGHER RP, 1995, ARCH DERMATOL, V131, P157, DOI 10.1001/archderm.131.2.157; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HARRIS CC, 1995, ANN S BIOL SKIN, V1, P115; HEDRUM A, 1994, BIOTECHNIQUES, V17, P118; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; IMAYAMA S, 1987, AM J PATHOL, V128, P497; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KANJILAL S, 1995, CANCER RES, V55, P3604; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KRESS S, 1992, CANCER RES, V52, P6400; KRICKER A, 1994, CANCER CAUSE CONTROL, V5, P367, DOI 10.1007/BF01804988; KUBO Y, 1994, J INVEST DERMATOL, V102, P440, DOI 10.1111/1523-1747.ep12373002; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MADSEN A, 1965, ACTA PATHOL MICROB S, V177, P9; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; PONTEN F, 1994, J INVEST DERMATOL, V102, P304, DOI 10.1111/1523-1747.ep12371787; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; RADY P, 1992, CANCER RES, V52, P3804; Ren ZP, 1996, ONCOGENE, V12, P765; REN ZP, 1996, INT J CANCER, V66, P174; REN ZP, 1996, ROLE MUTATIONS P52 G; RUTHER U, 1982, NUCLEIC ACIDS RES, V10, P5765, DOI 10.1093/nar/10.19.5765; VANSCOTT EJV, 1982, J INVEST DERMATOL, V36, P109; VONDOMARUS H, 1984, J AM ACAD DERMATOL, V10, P1043; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	36	83	84	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1059	1067		10.1038/sj.onc.1201435	http://dx.doi.org/10.1038/sj.onc.1201435			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285560				2022-12-17	WOS:A1997XT16100007
J	Kessis, TD; Connolly, DC; Hedrick, L; Cho, KR				Kessis, TD; Connolly, DC; Hedrick, L; Cho, KR			Expression of HPV16 E6 or E7 increases integration of foreign DNA	ONCOGENE			English	Article						HPV; viral integration; cervical carcinoma; DNA damage; carcinogenesis	HUMAN PAPILLOMAVIRUS TYPE-16; WILD-TYPE P53; CERVICAL INTRAEPITHELIAL NEOPLASIA; CELL-CYCLE ARREST; GROWTH ARREST; ATAXIA-TELANGIECTASIA; GENE AMPLIFICATION; PHYSICAL STATE; SEQUENCES; CARCINOMA	In most invasive cervical carcinomas, high-risk human papillomavirus (HPV) DIVA is integrated into the host genome, while in pre-invasive cervical lesions the viral genome is typically maintained exclusively as an episome. In contrast, integration of low-risk HPV DIVA is rare, as is the association of low-risk HPVs with carcinomas. High-risk HPV integration is associated with a selective growth advantage of affected cells, and hence, integration is likely to be an important genetic alteration contributing to cervical tumor progression. Expression of high-risk, but not low-risk, HPV E6 or E7 proteins disrupts the p53-dependent G(1) arrest that cells normally display in response to DIVA damage. Absence of this cell cycle checkpoint may predispose cells containing high-risk HPVs to genetic instability and to the accumulation of the genetic alterations that appear to be required for HPV-associated cervical tumor progression. We hypothesized that integration of highrisk HPV DNA into the host cell genome may be facilitated by E6- and/or E7-mediated disruption of the normal DIVA damage response pathway. To test this hypothesis, we assessed the integration frequency of a reporter plasmid (pHyGal) in RKO cells expressing individual E6 or E7 genes of either high-risk (HPV16) or low-risk (HPV6, HPV11) type viruses. Cells expressing HPV16 E6 or HPV16 E7 exhibited a significantly increased frequency of pHyGal integration in comparison to RKO control cells or cells expressing low-risk HPV E6 or E7. Thus, expression of high-risk, but not low-risk, E6 and E7 proteins increases the frequency of foreign DNA integration into the host genome. These findings suggest that at least some of the difference in oncogenic potential observed between high-risk and low-risk HPV types may be determined by the increased ability of high-risk HPVs to integrate into host DNA.	JOHNS HOPKINS UNIV, SCH MED, DEPT PATHOL, BALTIMORE, MD 21205 USA	Johns Hopkins University				Cho, Kathleen/0000-0003-0500-9998	NATIONAL CANCER INSTITUTE [R29CA064466] Funding Source: NIH RePORTER; NCI NIH HHS [CA64466] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARDER P, 1993, ONCOGENE, V8, P1397; CHEN SL, 1993, CANCER-AM CANCER SOC, V72, P1939, DOI 10.1002/1097-0142(19930915)72:6<1939::AID-CNCR2820720624>3.0.CO;2-2; CHOO KB, 1987, VIROLOGY, V161, P259, DOI 10.1016/0042-6822(87)90195-4; CHOO KB, 1987, J MED VIROL, V21, P101, DOI 10.1002/jmv.1890210202; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DURST M, 1992, VIROLOGY, V189, P132, DOI 10.1016/0042-6822(92)90688-L; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FIRZLAFF JM, 1987, CANCER CELL, V5, P105; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; FUKUSHIMA M, 1990, CANCER, V66, P2155, DOI 10.1002/1097-0142(19901115)66:10<2155::AID-CNCR2820661019>3.0.CO;2-Q; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HAVRE PA, 1995, CANCER RES, V55, P4420; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HIGGINS GD, 1992, J GEN VIROL, V73, P2047, DOI 10.1099/0022-1317-73-8-2047; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; JENISON SA, 1990, J INFECT DIS, V162, P60, DOI 10.1093/infdis/162.1.60; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MANIAS DA, 1989, CANCER RES, V49, P2514; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MORRIS JDH, 1993, ONCOGENE, V8, P893; MUNGER K, 1991, J VIROL, V65, P3943; MUNGER K, 1989, J VIROL, V63, P4417; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OSTOR AG, 1993, INT J GYNECOL PATHOL, V12, P186; ROMANCZUK H, 1992, P NATL ACAD SCI USA, V89, P3159, DOI 10.1073/pnas.89.7.3159; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SIEGEL J, 1995, ONCOGENE, V11, P1363; SLEBOS RJC, 1995, VIROLOGY, V208, P111, DOI 10.1006/viro.1995.1134; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; VOUSDEN KH, 1989, CANCER CELL-MON REV, V1, P43; WAHLS WP, 1990, SOMAT CELL MOLEC GEN, V16, P321, DOI 10.1007/BF01232460; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; XIA F, 1994, MOL CELL BIOL, V14, P5850, DOI 10.1128/MCB.14.9.5850; XIA F, 1995, CANCER RES, V55, P12; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	50	83	86	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	1996	13	2					427	431						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710383				2022-12-17	WOS:A1996VA25200023
J	Cano, E; Doza, YN; BenLevy, R; Cohen, P; Mahadevan, LC				Cano, E; Doza, YN; BenLevy, R; Cohen, P; Mahadevan, LC			Identification of anisomycin-activated kinases p45 and p55 in murine cells as MAPKAP kinase-2	ONCOGENE			English	Article						growth-factors; anisomycin; stress kinases; intracellular signalling; MAP kinases; MAPKAP kinase-2	DISTINCT MECHANISMS; PROTEIN-SYNTHESIS; PHOSPHORYLATION	We recently showed that EGF and anisomycin activate two kinases, p45 and p55, whose distinguishing feature is that their detection in in-gel kinase assays is enhanced by copolymerised poly-Glu/Tyr or poly-Glu/Phe (Cane E, Hazzalin CA and Mahadevan LC, Mol. Cell, Biol,, 20:117-121). Their activation characteristics and sizes are strikingly similar to those of JNK/SAPKs, which are also strongly activated by anisomycin. However, we show here that p45 and p55 are not JNK/SAPKs but murine forms of MAPKAP kinase-2 because: (i) Detection of immunoprecipitated JNK/SAPKs is completely dependent on the presence of c-Jun as substrate in the in-gel kinase assays, whereas detection of p45 and p55 is not, (ii) Detection of p45 and p55 activity is enhanced by the presence of poly-Glu/Tyr or poly-Glu/Phe, whereas JNK/SAPKs are not detectable under these conditions. (iii) Although the sizes of the murine JNK/SAPKs and MAPKAP K-2 are similar, human JNK/SAPKs migrate at 45 and 55 kDa whereas human MAPKAP K-2 migrates at 50 kDa; the poly-Glu/Tyr-enhanced activity in human cells migrates at 50 kDa. (iv) Purified rabbit muscle MAPKAP K-2 is detectable as two bands of activity on in-gel kinase assays and their detection is enhanced by poly-Glu/Tyr. (v) Finally, the anisomycin-activated poly-Glu/Tyr-enhanced p45 and p55 kinases can be immunoprecipitated from murine cells using an anti-MAPKAP K-2 antibody. Thus, EGF- and anisomycin-activated p45 and p55 are not JNK/SAPKs but MAPKAP K-2, implying that both these agents activate the p38/RK MAP kinase cascade.	UNIV LONDON KINGS COLL,RANDALL INST,DEV BIOL RES CTR,NUCL SIGNALLING LAB,LONDON WC2B 5RL,ENGLAND; UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND; INST CANC RES,CHESTER BEATTY LABS,CRC,LONDON SW3 6JB,ENGLAND	University of London; King's College London; University of Dundee; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK			Cano, Eva/A-2049-2010	Cano, Eva/0000-0003-2750-6135				BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; BARRATT MJ, 1994, EMBO J, V13, P4524, DOI 10.1002/j.1460-2075.1994.tb06774.x; BENLEVY R, IN PRESS EMBO J; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CANO E, 1995, J CELL SCI, V108, P3599; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARDALINOU E, 1994, MOL CELL BIOL, V14, P1066, DOI 10.1128/MCB.14.2.1066; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; YAN MH, 1994, NATURE, V372, P798	30	83	83	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					805	812						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632902				2022-12-17	WOS:A1996TW68600011
J	Hwang, ES; Naeger, LK; DiMaio, D				Hwang, ES; Naeger, LK; DiMaio, D			Activation of the endogenous p53 growth inhibitory pathway in HeLa cervical carcinoma cells by expression of the bovine papillomavirus E2 gene	ONCOGENE			English	Article						tumour suppressor protein; growth arrest; human papillomavirus	WILD-TYPE P53; MOUSE B-MYB; CELLULAR-RESPONSE; DNA DAMAGE; PROTEIN; E6; TRANSCRIPTION; PRODUCT; RB; KERATINOCYTES	We previously showed that expression of the bovine papillomavirus (BPV) E2 gene results in a dramatic inhibition of the proliferation of several human cervical carcinoma cell lines, including HeLa cells which contain human papillomavirus (HPV) type 18 DNA. We have assessed the status of endogenous G1 cell cycle regulatory proteins, including the tumor suppressor proteins, p53 and p105Rb, in order to investigate growth regulatory pathways in HeLa expression. The p53 tumor suppressor stabilized following the introduction of the E2 gene into HeLa cells. This results in the induction of the p53-responsive gene encoding the cyclin dependent kinase (cdk) inhibitor, p21/WAF1, complex formation between p21/WAF1 and cdk2 and reduction of in vitro cdk2/cyclin E kinase activity. The reduced cdk kinase activity is accompanied by the accumulation of the growth inhibitory hypophosphorylated form of the tumor suppressor protein, p105Rb. The level of the p105Rb-regulated transcription factor, E2F1, is reduced, as is transcription of a variety of E2F1-regulated genes, including B-myb. Thus, the p53 growth inhibitory pathway has evidently not accumulated mutations in HeLa cells but rather appears intact. However, this pathway remains dormant, until it is mobilized by appropriate manipulations, such as the expression of the BPV E2 protein.	YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA	Yale University					NATIONAL CANCER INSTITUTE [P01CA016038] Funding Source: NIH RePORTER; NCI NIH HHS [CA16038] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUTZ K, 1995, ONCOGENE, V10, P927; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; CROOK T, 1991, ONCOGENE, V6, P873; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUJITA M, 1992, CANCER RES, V52, P5323; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HASHIDA T, 1991, J GEN VIROL, V72, P1569, DOI 10.1099/0022-1317-72-7-1569; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAVRE PA, 1995, CANCER RES, V55, P4420; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; HWANG ES, 1993, J VIROL, V67, P3720, DOI 10.1128/JVI.67.7.3720-3729.1993; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; PECORARO G, 1991, AM J PATHOL, V138, P1; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THIERRY F, 1987, EMBO J, V6, P3391, DOI 10.1002/j.1460-2075.1987.tb02662.x; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	52	83	84	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					795	803						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632901				2022-12-17	WOS:A1996TW68600010
J	JOHNSON, DG				JOHNSON, DG			REGULATION OF E2F-1 GENE-EXPRESSION BY P130 (RB2) AND D-TYPE CYCLIN KINASE-ACTIVITY	ONCOGENE			English	Article						E2F; D-TYPE CYCLIN; P130 (RB2); TRANSCRIPTIONAL REPRESSION	TRANSCRIPTION FACTOR; RETINOBLASTOMA PROTEIN; GROWTH SUPPRESSION; BINDING PROTEIN; CELLULAR GENES; PRODUCT; CLONING; IDENTIFICATION; PROMOTER; FAMILY	Previous experiments have demonstrated that the regulation of E2F-1 transcription factor activity is critical for the maintenance of normal cell proliferation control. Regulation of E2F-1 is accomplished through at least two mechanisms: posttranslational regulation by binding proteins such as Rb and transcriptional regulation of the E2F-1 gene. The E2F-1 gene promoter has recently been isolated to examine this latter aspect of E2F-1 regulation. Preliminary studies demonstrate that the E2F-1 promoter is under E2F-dependent negative control during the cell growth response, being transcriptionally repressed through E2F sites in GO and early G1. We now demonstrate that the presence of an E2F DNA-binding complex containing the Rb-related p13O protein (Rb2) correlates with E2F-1 gene repression and that overexpression of p13O inhibits transcription from the E2F-1 promoter. Moreover, D-type cyclin-dependent kinase activity specifically activates the E2F-1 promoter by relieving E2F-mediated repression but is inhibited by coexpression of the cdk4 and cdk6 inhibitor p16 (CDKN2, MTS1, INK4). Taken together, these findings suggest that E2F-1 gene expression is controlled during cell cycle progression by a regulatory network involving at least one oncogene (cyclin D1) and several potential tumor suppressor genes.			JOHNSON, DG (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CARCINOGENESIS,DIV SCI PK RES,SMITHVILLE,TX 78957, USA.			Johnson, David/0000-0002-6223-1790				ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COLBRINIK D, 1993, GENE DEV, V7, P2392; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DAGNINO L, 1995, CELL GROWTH DIFFER, V6, P191; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GIAN KL, 1994, GENE DEV, V8, P2939; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1993, CELL, V70, P993; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MAYOL X, 1993, ONCOGENE, V8, P2561; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MELILLO RM, 1994, MOL CELL BIOL, V14, P8241, DOI 10.1128/MCB.14.12.8241; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NEVINS JR, 1992, SCIENCE, V258, P424; OHTANIFUJITA N, 1994, ONCOGENE, V6, P1703; OSWALD F, 1994, ONCOGENE, V9, P2029; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHULZE A, 1994, ONCOGENE, V9, P3475; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAO A, 1995, ONCOGENE, V10, P221; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMITH EJ, 1995, MOL CELL BIOL, V15, P338, DOI 10.1128/MCB.15.1.338; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WU CL, 1995, MOL CELL BIOL, V15, P2536; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; YEUNG RS, 1993, ONCOGENE, V8, P3465	64	83	84	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1685	1692						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478595				2022-12-17	WOS:A1995TD09400002
J	ARTUSO, M; ESTEVE, A; BRESIL, H; VUILLAUME, M; HALL, J				ARTUSO, M; ESTEVE, A; BRESIL, H; VUILLAUME, M; HALL, J			THE ROLE OF THE ATAXIA-TELANGIECTASIA GENE IN THE P53, WAF1/CIP1(P21)- AND GADD45-MEDIATED RESPONSE TO DNA-DAMAGE PRODUCED BY IONIZING-RADIATION	ONCOGENE			English	Article						DNA DAMAGE; ATAXIA TELANGIECTASIA; P53 PROTEIN; WAF1/CIP1(P21); GADD45; CELL CYCLE	TUMOR-SUPPRESSOR PROTEIN; CYCLIN-DEPENDENT KINASES; IONIZING-RADIATION; GROWTH ARREST; HUMAN-CELLS; INDUCTION; SENSITIVITY; CANCER; ANTIGEN; UV	The inducible response of the tumour suppressor gene p53 has been examined following exposure to DNA-damaging agents in Ataxia telangiectasia (AT) cell lines, an autosomal recessive disorder with multiple clinical and biological abnormalities including sensitivity to ionising radiation. The p53 induction was significantly delayed and reduced in the 8 AT cell lines examined over the 6 h following irradiation with no dose response in p53 induction being observed compared to control cells, The increase of WAF1/CIP1(p21) and GADD45 mRNA, two genes transcriptionally activated by p53, was also reduced in the AT cell lines after such treatment. In contrast, the increase in p53 protein, WAF1/CIP1(p21) and GADD45 mRNA expression following exposure to the alkylating agent methylmethane sulphonate (25 and 100 mu g ml(-1)) was similar in both cell types, No alterations in the expression of EBNA-5, an EBV-encoded nuclear antigen which has been shown to bind p53 or mutations in the p53 gene (exons 4 to 8) were found in the AT cell lines studied, The AT gene product would thus appear to be involved upstream of p53, GADD45 and WAF1/CIP1 (p21) in the signalling of the presence of strand breaks produced by ionising radiation, with this defect in response contributing to the high cancer risk and radiosensitivity observed in this disorder.	INT AGCY RES CANC,MECH CARCINOGENESIS UNIT,F-69372 LYON 08,FRANCE	World Health Organization; International Agency for Research on Cancer (IARC)			hall, janet/G-1372-2013	hall, janet/0000-0002-4397-6295				BALALKIN G, 1994, P NATL ACAD SCI USA, V91, P413; CANMAN CE, 1994, CANCER RES, V54, P5054; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V54, P1169; ELDEIRY WS, 1994, CANCER RES, V54, P1174; ESTEVE A, 1993, MOL CARCINOGEN, V8, P306, DOI 10.1002/mc.2940080414; FINKE J, 1987, J VIROL, V61, P3870, DOI 10.1128/JVI.61.12.3870-3878.1987; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FRITSCHE M, 1993, ONCOGENE, V8, P307; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN WK, 1991, MOL CELL BIOL, V11, P3711, DOI 10.1128/MCB.11.7.3711; KEMP CJ, 1994, GENETICS, V8, P66; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LITTLE JB, 1968, NATURE, V218, P1064, DOI 10.1038/2181064a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACILWRATH AJ, 1994, CANCER RES, V54, P3718; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Maniatis T., 1982, MOL CLONING; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; MORRELL D, 1986, J NATL CANCER I, V77, P89; MURNANE JP, 1993, SEMIN CANCER BIOL, V4, P93; NAGASAWA H, 1985, MUTAT RES, V148, P71, DOI 10.1016/0027-5107(85)90209-X; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OCONNOR PM, 1992, CELL GROWTH DIFFER, V3, P43; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PIENTENPOL JA, 1993, NATURE, V211, P31; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RUDOLPH NS, 1989, MUTAT RES, V211, P31, DOI 10.1016/0027-5107(89)90104-8; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SVITSKY K, 1995, SCIENCE, V268, P1749; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; THACKER J, 1990, MUTAT RES, V235, P49, DOI 10.1016/0921-8777(90)90057-C; TOLMACH LJ, 1977, RADIAT RES, V71, P653, DOI 10.2307/3574633; TROELSTRA C, 1994, CURR BIOL, V4, P1149, DOI 10.1016/S0960-9822(00)00260-8; VOGELSTEIN B, 1992, NATURE, V355, P209, DOI 10.1038/355209a0; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, CANCER RES, V54, P2755	61	83	83	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1427	1435						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478567				2022-12-17	WOS:A1995TC53500001
J	NUNOUE, K; OHASHI, K; OKANO, I; MIZUNO, K				NUNOUE, K; OHASHI, K; OKANO, I; MIZUNO, K			LIMK-1 AND LIMK-2, 2 MEMBERS OF A LIM MOTIF-CONTAINING PROTEIN-KINASE FAMILY	ONCOGENE			English	Article						PROTEIN KINASE; LIMK; LIM-KINASE; LIM; LIM MOTIF; ZINC FINGER	CYSTEINE-RICH PROTEIN; ZINC-FINGER MOTIF; CONSERVED FEATURES; INSULIN GENE; DOMAIN; HOMEODOMAIN; ACTIVATION; RECEPTOR; ELEGANS; TTG-1	We previously isolated human cDNA encoding LIM-kinase (LIMK), a putative protein kinase which contains two repeats of the LIM motif at the N-terminus and a protein kinase consensus sequence at the C-terminus. Using as a probe a cDNA fragment of human LIMK, we isolated from a rat brain cDNA library cDNA clones encoding two distinct protein kinases (termed LIMK-1 and LIMK-2) related to human LIMK. LIMK-1 shares with human LIMK 95% of the total 647 amino acids and is probably a rat equivalent of human LIMK. LIMK-2 has an overall sequence and a domain structure similar to that of human LIMK and rat LIMK-1, but overall identity is 50-51% at the amino acid level, Like human LIMK, the protein kinase domains of rat LIMK-1 and -2 contain a characteristic sequence DLNSHN in subdomain VIB and a highly basic insert between subdomain VII and VIII. LIMK-1 and -2 are therefore closely related but distinct members of a novel LIM-containing protein kinase subfamily. Several forms of LIMK-2 transcripts encoding proteins that are N-terminally modified and/or C-terminally truncated are generated by alternative splicing or alternative initiation. Northern blot analysis revealed the expression of LIMK-1 mRNA predominantly in the brain and the expression of LIMK-2 mRNA in various tissues in the rat. Antibody raised against LIMK-1 specifically immunoprecipitated and identified in Rat2 fibroblast cells a 72 kDa protein, which has no detectable autophosphorylating activity but is capable of phosphorylating serine and threonine residues of myelin basic protein, by in vitro kinase reaction. As the LIMK family kinases have unique structural features, they are likely to have specific functions in previously uncharacterized signaling pathways.	KYUSHU UNIV, FAC SCI, DEPT BIOL, FUKUOKA 812, JAPAN; RES DEV CORP JAPAN, PRESTO, INHERITANCE & VARIAT GRP, TOKYO, JAPAN	Kyushu University; Japan Science & Technology Agency (JST)			Mizuno, Kensaku/G-8631-2015	Ohashi, Kazumasa/0000-0001-7617-403X				BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; BIRKENMEIER EH, 1986, P NATL ACAD SCI USA, V83, P2516, DOI 10.1073/pnas.83.8.2516; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; LIEBHABER SA, 1990, NUCLEIC ACIDS RES, V18, P3871, DOI 10.1093/nar/18.13.3871; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MIZUNO K, 1994, ONCOGENE, V9, P1605; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHASHI K, 1994, J BIOCHEM, V116, P636, DOI 10.1093/oxfordjournals.jbchem.a124573; OHASHI K, 1994, ONCOGENE, V9, P699; OKANO I, 1993, FEBS LETT, V333, P51, DOI 10.1016/0014-5793(93)80373-3; PERZALVARDO GC, 1994, NAT STRUCT BIOL, V1, P388; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; TURNER CE, 1994, J CELL SCI, V107, P1583; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WANG XK, 1992, J BIOL CHEM, V267, P9176; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	36	83	91	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	1995	11	4					701	710						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651734				2022-12-17	WOS:A1995RQ46900012
J	ISHIOKA, C; ENGLERT, C; WINGE, P; YAN, YX; ENGELSTEIN, M; FRIEND, SH				ISHIOKA, C; ENGLERT, C; WINGE, P; YAN, YX; ENGELSTEIN, M; FRIEND, SH			MUTATIONAL ANALYSIS OF THE CARBOXY-TERMINAL PORTION OF P53 USING BOTH YEAST AND MAMMALIAN-CELL ASSAYS IN-VIVO	ONCOGENE			English	Article						P53; CELL CYCLE ARREST; TUMOR SUPPRESSOR GENE	WILD-TYPE P53; CYCLIN-DEPENDENT KINASES; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; GENE AMPLIFICATION; PROTEIN; APOPTOSIS; CANCER; LINE; TRANSFORMATION	Increasing evidence indicates that p53 is a transcriptional tuans-activator through its sequence-specific DNA binding domain. Tumor-derived p53 mutations disrupt the tuans-activation ability mainly due to loss of its sequence-specific DNA binding, Using both yeast and mammalian cell assays, the effect of p53 mutations in the carboxy terminal portion was investigated in order to address how p53 mutations outside of the DNA binding domain affect p53 function, The p53 cDNA in the carboxy-terminus was randomly mutagenized by error-prone polymerase chain reactions and the amplified cDNA was screened for the ability to trans-activate using a yeast assay, Four p53 mutations, including two missense and two nonsense mutations located in the carboxy-terminal oligomerization domain, were further analysed for trans-activation, cell cycle arrest and colony formation in a human osteosarcoma cell line, Saos-2. These functional properties of p53 were disrupted by the missense mutations. Surprisingly, one of the nonsense mutations disrupts the trans-activation function and the ability to G1 arrest but shows a strong inhibition of colony formation, These results confirm that mutations in the oligomerization domain can inactivate p53 function and also indicate that p53-mediated cell growth inhibition does not necessarily depend on the ability to arrest cell cycle.	MASSACHUSETTS GEN HOSP,CTR CANC,DIV MOLEC GENET,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129; CHILDRENS HOSP,DANA FARBER INST,DIV HEMATOL ONCOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	ISHIOKA, C (corresponding author), TOHOKU UNIV,INST DEV AGING & CANC,DEPT CLIN ONCOL,SENDAI,MIYAGI 980,JAPAN.							AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DAMICO D, 1992, ONCOGENE, V7, P339; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FREBOURG T, 1992, CANCER RES, V52, P6976; FREBOURG T, 1994, CANCER RES, V54, P878; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; NISHIDA N, 1993, CANCER RES, V53, P368; OKAMOTO A, 1991, CANCER RES, V51, P5632; OROURKE RW, 1990, ONCOGENE, V5, P1829; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Reed Michael, 1993, Gene Expression, V3, P95; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; YAMADA Y, 1991, CANCER RES, V51, P5800; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	57	83	85	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1485	1492						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731702				2022-12-17	WOS:A1995QU68100003
J	JIMENEZ, B; ARENDS, M; ESTEVE, P; PERONA, R; SANCHEZ, R; CAJAL, SR; WYLLIE, A; LACAL, JC				JIMENEZ, B; ARENDS, M; ESTEVE, P; PERONA, R; SANCHEZ, R; CAJAL, SR; WYLLIE, A; LACAL, JC			INDUCTION OF APOPTOSIS IN NIH3T3 CELLS AFTER SERUM DEPRIVATION BY OVEREXPRESSION OF RHO-P21, A GTPASE PROTEIN OF THE RAS SUPERFAMILY	ONCOGENE			English	Article						RHO; APOPTOSIS; TRANSFORMATION	SWISS 3T3 CELLS; BINDING PROTEIN; RHO P21; ADP-RIBOSYLATION; GENE-PRODUCT; EXPRESSION; EXCHANGE; GROWTH; ENDONUCLEASE; ACTIVATION	Oncogenes appear to influence apoptosis in two ways. Some activate cells from a growth-arrested state to one in which both apoptosis and entry to S-phase become possible, the choice between them being determined by a second signal, such as cytokine or growth factor. Cells in this state are often sensitive to apoptosis induced by a wide variety of agents, including several drugs used in cancer chemotherapy. Other oncogenes prevent activation of the apoptosis effector pathway, even in the presence of a death stimulus, the affected cells therefore being resistant to chemotherapeutic agents. In rodent fibroblasts, c-myc or the adenovirus oncogene E1A effect the first type of change, whereas bcl-2, v-abl, E1B or activated uas effect the second. Here we study in rodent fibroblast the effect of expression of rho genes, members of the ras superfamily which we have previously shown to be tumorigenic when highly expressed in this cell type. We show that expression of wild-type who from Aplysia californica stimulates apoptosis in cultured cell lines and that the apoptotic index in tumors generated by these cell lines is similar to those induced by E1A-transformed cells. In contrast, mutated rho, activated by Val(14) substitution in the GTP binding site, it less potent as a stimulator of apoptosis, generating a phenotype more similar to that obtained with activated vas. Thus, rho genes may play a critical role in the regulation of apoptosis.	CSIC, INST INVEST BIOMED, MADRID, SPAIN; UNIV EDINBURGH, DEPT PATHOL, CRC LABS, EDINBURGH, MIDLOTHIAN, SCOTLAND; CLIN PUERTA HIERRO, SERV ANAT PATOL, MADRID, SPAIN; UNIV AUTONOMA MADRID, DEPT BIOQUIM, MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Edinburgh; Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda; Autonomous University of Madrid			Espinosas, Maribel/H-8083-2012; Sanchez-Prieto, Ricardo/AAY-4271-2021; Ramon y Cajal, Santiago/H-4955-2016; Lacal, Juan Carlos/AAL-2235-2020; Cuenca, Benilde Jimenez/K-9959-2014; Sanchez-Prieto, Ricardo/B-6877-2008; Prieto, Ricardo/AAZ-7221-2021; Lacal, Juan Carlos/N-9064-2015	Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Ramon y Cajal, Santiago/0000-0002-3867-1390; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Lacal, Juan Carlos/0000-0002-1908-2777; Jimenez Cuenca, Benilde/0000-0002-1806-6636				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AEPFELBACHER M, 1994, P NATL ACAD SCI USA, V91, P4263, DOI 10.1073/pnas.91.10.4263; ARENDS MJ, 1990, AM J PATHOL, V136, P593; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; ARENDS MJ, 1994, AM J PATHOL, V144, P1045; ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; ARENDS MJ, 1994, MOL BIOL HISTOPATHOL, P151; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; AVRAHAM H, 1990, BIOCHEM BIOPH RES CO, V168, P114, DOI 10.1016/0006-291X(90)91682-I; BALLESTERO RP, 1991, NATO ADV SCI I A-LIF, V220, P237; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHEN WN, 1994, J BIOL CHEM, V269, P820; CHU G, 1994, J BIOL CHEM, V269, P787; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HOFFMAN B, 1994, ONCOGENE, V9, P1807; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LACAL JC, 1994, ONCOL REP, V1, P677; LANG P, 1992, J BIOL CHEM, V267, P11677; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARCHETTI E, 1994, INT J ONCOL, V5, P611; MIURA Y, 1993, J BIOL CHEM, V268, P510; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; MORII N, 1992, J BIOL CHEM, V267, P20921; PERONA R, 1993, ONCOGENE, V8, P1285; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SUBRAMANIAN T, 1993, GENE, V124, P173, DOI 10.1016/0378-1119(93)90391-F; SUGAI M, 1992, J BIOL CHEM, V267, P21297; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; VICENT S, 1992, MOL CELL BIOL, V12, P3138; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; ZHANG, 1994, J BIOL CHEM, V269, P2369; ZHANG J, 1993, J BIOL CHEM, V268, P22251	53	83	84	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	1995	10	5					811	816						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898922				2022-12-17	WOS:A1995QL03800001
J	THAKUR, S; LIN, HC; TSENG, WT; KUMAR, S; BRAVO, R; FOSS, F; GELINAS, C; RABSON, AB				THAKUR, S; LIN, HC; TSENG, WT; KUMAR, S; BRAVO, R; FOSS, F; GELINAS, C; RABSON, AB			REARRANGEMENT AND ALTERED EXPRESSION OF THE NFKB-2 GENE IN HUMAN CUTANEOUS T-LYMPHOMA CELLS	ONCOGENE			English	Article							NF-KAPPA-B; ENHANCER-BINDING PROTEINS; DNA-BINDING; C-REL; CHROMOSOMAL TRANSLOCATION; TRANSCRIPTION FACTORS; ANTISENSE INHIBITION; LEUKEMIA-VIRUS; P50 PRECURSOR; HOMEOBOX GENE	The NF-kappa B/Rel and I kappa B proteins are important regulators of lymphocyte activation and gene expression. We have identified a rearrangement of the NFKB-2 gene in the HUT 78 human cutaneous T-cell leukemia (CTCL) line. cDNA and genomic DNA sequence predicted the presence of a truncated 80 kD NFKB-2 precursor protein (p80HT), instead of the normal p100 protein. No wild-type allele was identified. Elevated levels of two aberrantly sized RNAs were detected, and high levels of p80HT and processed p52 protein were present in HUT 78 cell nuclei. The p52 protein bound to a palindromic KB DNA motif, however p80HT did not. Rearrangement of the NFKB-2 gene was also detected in DNA from two patients with CTCL. Rearrangement and overexpression of the NFKB-2 gene may contribute to the genesis of a subset of T-cell malignancies.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543; BOSTON UNIV,SCH MED,DEPT MED,MED ONCOL SECT,BOSTON,MA 02118	Rutgers State University New Brunswick; Rutgers State University Medical Center; Bristol-Myers Squibb; Boston University					NCI NIH HHS [CA55487] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055487] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; CHEN TR, 1992, J NATL CANCER I, V84, P1922, DOI 10.1093/jnci/84.24.1922; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COGSWELL PC, 1993, J IMMUNOL, V150, P2794; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DALESSANDRO E, 1990, CANCER GENET CYTOGEN, V45, P231, DOI 10.1016/0165-4608(90)90087-Q; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DUBE ID, 1991, BLOOD, V78, P2996; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; FINGER LR, 1988, P NATL ACAD SCI USA, V85, P9158, DOI 10.1073/pnas.85.23.9158; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; FRANKLIN RB, 1974, INTERVIROLOGY, V3, P342, DOI 10.1159/000149771; GAZDAR AF, 1980, BLOOD, V55, P409; GIMBLE JM, 1988, J VIROL, V62, P4104, DOI 10.1128/JVI.62.11.4104-4112.1988; GRILLI M, 1993, INT REV CYTOL, V148, P1; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LANOIX J, 1994, ONCOGENE, V9, P841; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LIPTAY S, 1992, GENOMICS, V13, P287, DOI 10.1016/0888-7543(92)90244-M; LU D, 1991, ONCOGENE, V6, P1235; MANN DL, 1989, AIDS RES HUM RETROV, V5, P253, DOI 10.1089/aid.1989.5.253; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PAN L, 1991, CLIN EXP IMMUNOL, V86, P240; POPOVIC M, 1984, LANCET, V2, P1472; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; POTTER DA, 1993, J BIOL CHEM, V268, P18882; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; STREBEL K, 1986, J VIROL, V57, P983, DOI 10.1128/JVI.57.3.983-991.1986; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; THEILEN GH, 1966, J NATL CANCER I, V37, P731; TSUDO M, 1987, P NATL ACAD SCI USA, V84, P4215, DOI 10.1073/pnas.84.12.4215	65	83	86	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2335	2344						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036016				2022-12-17	WOS:A1994NX62900027
J	ALONIGRINSTEIN, R; ZANBAR, I; ALBOUM, I; GOLDFINGER, N; ROTTER, V				ALONIGRINSTEIN, R; ZANBAR, I; ALBOUM, I; GOLDFINGER, N; ROTTER, V			WILD-TYPE P53 FUNCTIONS AS A CONTROL PROTEIN IN THE DIFFERENTIATION PATHWAY OF THE B-CELL LINEAGE	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; MOUSE CELLS; TRANSCRIPTIONAL ACTIVATION; ATAXIA-TELANGIECTASIA; BURKITT-LYMPHOMA; CYCLE CONTROL; REGION GENES; MUTATIONS; EXPRESSION; MUTANT	An analysis of cell lines representing different stages of the B-cell differentiation pathway indicated that about 50% of the cell lines examined expressed exclusively wild type p53 protein. These lines therefore offer a convenient system to study the involvement of p53 in cell differentiation. When 70Z/3, a pre-B cell line which expresses wild type p53, was treated with the differentiation inducer lipopolysaccharide (LPS), it was seen that increased levels of p53 mRNA preceded specific changes in kappa (kappa) immunoglobulin expression. This increased expression of kappa specific mRNA, which was evaluated by specific PCR analysis, was blocked following transfection with mutant p53 coding plasmids. Treatment of 13A60, another cell line which endogenously expresses wild type p53, with LPS caused a secretion of IgA antibodies, also accompanied by increased p53 mRNA expression. The conclusion was that induction of B-cell differentiation involves the transcription of the p53 gene. This was further substantiated by experiments showing that differentiation of stable clones derived from the 70Z/3 cell line, harboring a p53-promoter-CAT plasmid, induced increased CAT activity. Furthermore, wild type p53 transactivated the promoter control sequences of the kappa light chain gene. Taken together, these results suggest that p53 is involved in B-cell differentiation, a pathway which involves DNA rearrangements that may be accompanied by generation of faulty DNA. The fact that wild type p53 was shown to function as a transcriptional factor, coupled with the notion that it is associated with DNA repair systems, may designate p53 as a control protein in the B-cell differentiation pathway.	TEL AVIV UNIV,SACKLER FAC MED,DEPT HUMAN MICROBIOL,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine	ROTTER, V (corresponding author), WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL.			Aloni-Grinstein, Ronit/0000-0003-1695-5576				AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; BOYD AW, 1981, J IMMUNOL, V126, P2461; CHENG J, 1992, CANCER RES, V52, P222; CORALIA IR, 1992, BLOOD, V79, P1982; DEPPERT W, 1990, ONCOGENE, V5, P1701; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; FENAUX P, 1992, LEUKEMIA, V6, P42; FENAUX P, 1992, BRIT J HAEMATOL, V80, P178, DOI 10.1111/j.1365-2141.1992.tb08897.x; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRITSCHE M, 1993, ONCOGENE, V8, P307; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1990, ONCOGENE, V5, P1285; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALL PA, 1993, ONCOGENE, V8, P203; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HECHT F, 1990, CANCER GENET CYTOGEN, V46, P9, DOI 10.1016/0165-4608(90)90003-S; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KASTAN MB, 1991, CANCER RES, V51, P4279; KELMAN Z, 1989, BLOOD, V74, P2318; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7492; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEBOEUF RD, 1989, GENE, V82, P371, DOI 10.1016/0378-1119(89)90065-6; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MORA PT, 1980, NATURE, V288, P722, DOI 10.1038/288722a0; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5683; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OROURKE RW, 1990, ONCOGENE, V5, P1829; PAIGE CJ, 1978, J IMMUNOL, V121, P641; PERRY RP, 1979, CELL, V18, P1333, DOI 10.1016/0092-8674(79)90243-5; PORAT Y, 1993, BIOCH BIOPHYSICAL RE, V194, P391; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; Rotter Varda, 1993, Trends in Cell Biology, V3, P46, DOI 10.1016/0962-8924(93)90151-P; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; SANTO H, 1973, J EXP MED, V138, P593; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1991, CANCER RES, V51, P5232; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SORIANO P, 1991, CELL, V64, P639; STAVNEZER J, 1988, P NATL ACAD SCI USA, V85, P7704, DOI 10.1073/pnas.85.20.7704; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WIMAN KG, 1991, ONCOGENE, V6, P1633; WOLF D, 1984, MOL CELL BIOL, V4, P1402, DOI 10.1128/MCB.4.7.1402; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	76	83	84	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3297	3305						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247532				2022-12-17	WOS:A1993MG78200013
J	WOODWORTH, CD; CHENG, ST; SIMPSON, S; HAMACHER, L; CHOW, LT; BROKER, TR; DIPAOLO, JA				WOODWORTH, CD; CHENG, ST; SIMPSON, S; HAMACHER, L; CHOW, LT; BROKER, TR; DIPAOLO, JA			RECOMBINANT RETROVIRUSES ENCODING HUMAN PAPILLOMAVIRUS TYPE-18 E6 AND E7 GENES STIMULATE PROLIFERATION AND DELAY DIFFERENTIATION OF HUMAN KERATINOCYTES EARLY AFTER INFECTION	ONCOGENE			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; HUMAN FORESKIN KERATINOCYTES; SERUM-FREE MEDIUM; EPITHELIAL-CELLS; TERMINAL DIFFERENTIATION; CERVICAL-CARCINOMA; GENITAL CANCER; GROWTH; DNA; TRANSFORMATION	Human papillomavirus (HPV) DNAs are detected in most genital dysplasias and cancers, suggesting that these viruses perturb epithelial growth and differentiation. The E6 and E7 genes of HPV type 18 induce immortality in keratinocytes cultured from genital tract epithelia, and the immortal cell lines display aberrant squamous differentiation. To examine whether the E6 and E7 proteins directly alter keratinocyte growth and differentiation, high-titer recombinant retroviruses were constructed for efficient transfer and expression of HPV-18 genes E6, E6* and E7 in cultures of normal human keratinocytes. Infection with retroviruses encoding E6 and E7 stimulated cell proliferation, reduced the requirement for bovine pituitary extract and induced immortality. E6 and E7 also delayed but did not prevent the onset of terminal squamous differentiation. The magnitude of effects on growth and differentiation of cultured cells was directly related to levels of E7 protein expression. Thus, expression of the HPV-18 E6 and E7 genes stimulates cell proliferation and delays differentiation of keratinocytes in vitro.	UNIV ROCHESTER, SCH MED, DEPT BIOCHEM, ROCHESTER, NY 14642 USA	University of Rochester	WOODWORTH, CD (corresponding author), NCI, BIOL LAB, BETHESDA, MD 20892 USA.				NATIONAL CANCER INSTITUTE [R01CA036200] Funding Source: NIH RePORTER; NCI NIH HHS [CA36200] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASSELINEAU D, 1984, BRIT J DERMATOL, V111, P219, DOI 10.1111/j.1365-2133.1984.tb15608.x; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BANKS L, 1990, ONCOGENE, V5, P833; BARBOSA MS, 1989, ONCOGENE, V4, P1529; BLANTON RA, 1991, AM J PATHOL, V138, P673; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; BOYCE ST, 1983, J INVEST DERMATOL, V81, pS33, DOI 10.1111/1523-1747.ep12540422; BRAUN L, 1990, CANCER RES, V50, P7324; BROWN KW, 1985, INT J CANCER, V35, P799, DOI 10.1002/ijc.2910350617; CHERINGTON V, 1986, P NATL ACAD SCI USA, V83, P4307, DOI 10.1073/pnas.83.12.4307; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DURST M, 1987, ONCOGENE, V1, P251; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; ESTERVIG DN, 1990, J CELL PHYSIOL, V142, P552, DOI 10.1002/jcp.1041420314; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; GALLOWAY DA, 1989, ADV VIRUS RES, V37, P125; GROSS G, 1987, PAPILLOMAVIRUSES HUM, P197; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HAUSEN HZ, 1989, CANCER RES, V49, P4677; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KOPAN R, 1987, J CELL BIOL, V105, P427, DOI 10.1083/jcb.105.1.427; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LORINCZ AT, 1987, J NATL CANCER I, V79, P671; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; PECORARO G, 1991, AM J PATHOL, V138, P1; PFISTER H, 1987, ADV CANCER RES, V48, P113, DOI 10.1016/S0065-230X(08)60691-0; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; REEVES WC, 1989, REV INFECT DIS, V11, P426; Reiss M, 1989, Cancer Commun, V1, P75; RHEINWALD JG, 1980, CELL, V22, P629, DOI 10.1016/0092-8674(80)90373-6; ROTENBERG MO, 1989, VIROLOGY, V172, P468, DOI 10.1016/0042-6822(89)90189-X; SATO H, 1989, VIROLOGY, V168, P195, DOI 10.1016/0042-6822(89)90423-6; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHNEIDERGADICKE A, 1988, CANCER RES, V48, P2969; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; WATT FM, 1988, P NATL ACAD SCI USA, V85, P5576, DOI 10.1073/pnas.85.15.5576; WILLE JJ, 1984, J CELL PHYSIOL, V121, P31, DOI 10.1002/jcp.1041210106; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; WOODWORTH CD, 1988, CANCER RES, V48, P4620; WOODWORTH CD, 1990, J VIROL, V64, P4767, DOI 10.1128/JVI.64.10.4767-4775.1990; WOODWORTH CD, 1990, CANCER RES, V50, P3709; YUSPA SH, 1989, J VIROL, V63, P159	57	83	86	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1992	7	4					619	626						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1314365				2022-12-17	WOS:A1992HQ68200002
J	ABATE, C; MARSHAK, DR; CURRAN, T				ABATE, C; MARSHAK, DR; CURRAN, T			FOS IS PHOSPHORYLATED BY P34CDC2, CAMP-DEPENDENT PROTEIN-KINASE AND PROTEIN-KINASE-C AT MULTIPLE SITES CLUSTERED WITHIN REGULATORY REGIONS	ONCOGENE			English	Article							DNA-BINDING DOMAINS; OSTEO-SARCOMA VIRUS; LEUCINE ZIPPER; JUN; TRANSCRIPTION; IDENTIFICATION; ACTIVATION; ONCOGENE; INVITRO; SERUM	The proto-oncogene c-fos encodes a nuclear protein (Fos) that functions in transcriptional regulation in response to extracellular signals. Fos is extensively modified in the nucleus by serine and threonine phosphorylation. It has been suggested that phosphorylation may play an important role in regulating Fos function in normal and transformed cells. As a first step in addressing this issue, we have used purified Fos as a substrate for several serine-threonine protein kinases, including cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and p34cdc2. Each of these kinases phosphorylated Fos at several unique sites. These sites were located within two regions that were previously shown to reduce the transcriptional activity of Fos in vitro. Several of the sites modified in vitro were also shown to be phosphorylated in serum-stimulated fibroblasts. These findings demonstrate that Fos is a target for several protein kinases involved in signal transduction and suggest that phosphorylation could regulate the transcriptional properties of Fos.	ROCHE INST MOLEC BIOL, ROCHE RES CTR, DEPT MOLEC ONCOL & VIROL, NUTLEY, NJ 07110 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Roche Holding; Cold Spring Harbor Laboratory			Curran, Tom/C-1164-2008; Curran, Tom/D-7515-2011; Abate-Shen, Cory/O-2520-2014; Curran, Thomas/AAE-7631-2019; Curran, Tom/F-5234-2018	Curran, Tom/0000-0003-1444-7551; Abate-Shen, Cory/0000-0002-5021-0570; Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ABATE C, 1991, MOL CELL BIOL, V11, P3629; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1987, BIOESSAYS, V7, P255, DOI 10.1002/bies.950070606; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1987, ONCOGENE, V2, P79; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; CURRAN T, 1984, CELL, V36, P259; Curran T, 1988, ONCOGENE HDB, P307; CURRAN T, 1991, TRANSCRIPTION REGULA; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HIRAI SI, 1990, ONCOGENE, V5, P39; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; KEMP BE, 1983, P NATL ACAD SCI-BIOL, V80, P7471, DOI 10.1073/pnas.80.24.7471; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521; LUO K, 1990, ONCOGENE, V5, P921; MARSHAK DR, 1991, J CELL BIOCHEM, V45, P391, DOI 10.1002/jcb.240450413; MARSHAK DR, 1991, METHOD ENZYMOL, V200, P134; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; REDDY EPA, 1988, ONCOGENE HDB; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; TURNER RS, 1985, J BIOL CHEM, V260, P1503	37	83	83	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1991	6	12					2179	2185						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766667				2022-12-17	WOS:A1991GX73500002
J	HENSEL, CH; XIANG, RH; SAKAGUCHI, AY; NAYLOR, SL				HENSEL, CH; XIANG, RH; SAKAGUCHI, AY; NAYLOR, SL			USE OF THE SINGLE-STRAND CONFORMATION POLYMORPHISM TECHNIQUE AND PCR TO DETECT P53 GENE-MUTATIONS IN SMALL-CELL LUNG-CANCER	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; THERMOSTABLE DNA-POLYMERASE; TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; POINT MUTATIONS; OSTEO-SARCOMA; T-ANTIGEN; EXPRESSION; CARCINOMA; TRANSFORMATION	Recent studies have suggested that the p53 oncoprotein might function normally as a tumor suppressor. Mutations in highly conserved regions of the p53 gene have been observed in numerous types of tumors and tumor cell lines. To detect in a more sensitive manner p53 gene mutations in small cell lung cancer (SCLC) we utilized the single strand conformation polymorphism (SSCP) technique of Orita et al., (1989). Using PCR primers for the most highly conserved regions of the p53 gene, including exons 4-9, we have identified p53 mutations in 5 of 9 small cell lung cancer (SCLC) tumor DNA samples and in 1 SCLC cell line. None of the mutations seen in tumor DNA samples were present in normal DNA from the same patients, indicating that mutation of the p53 gene in these tumors was a somatic event. Of the six mutations observed, two were found in exon 7, three were found in the region encompassing exons 8 and 9, and one was found in the region encompassing exons 5 and 6. Nucleotide sequencing of one of the exon 7 mutations and one of the exon 8-9 mutations indicated that each was a C to T transition. In SCLC-6 the mutation resulted in substitution of serine for proline at amino acid 278 and in SCLC-4 substitution of tryptophan for arginine at amino acid 248, both nonconservative amino acid substitutions. Both of these changes are in regions of the p53 gene where mutations have been observed in other tumors. Two additional mutations were observed in SCLC cell lines using conventional PCR techniques. One of these is a mutation which results in altered splicing of the p53 pre-mRNA.			HENSEL, CH (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78284, USA.				NATIONAL CANCER INSTITUTE [R29CA044764, F32CA008711] Funding Source: NIH RePORTER; NCI NIH HHS [CA44764, CA08711] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; CHENG J, 1990, BLOOD, V75, P730; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEND SH, 1988, NEW ENGL J MED, V318, P618; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GIBBS RA, 1989, P NATL ACAD SCI USA, V86, P1919, DOI 10.1073/pnas.86.6.1919; GRIPPO P, 1968, J MOL BIOL, V36, P195, DOI 10.1016/0022-2836(68)90375-6; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HENSEL CH, 1990, CANCER RES, V50, P3067; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1984, NATURE, V312, P641; JOHNSON BE, 1988, J CLIN INVEST, V82, P502, DOI 10.1172/JCI113624; KNUDSON AG, 1985, CANCER RES, V45, P1437; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KRICKER MC, 1989, GENE, V85, P199, DOI 10.1016/0378-1119(89)90481-2; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEDUC F, 1989, AM J HUM GENET, V44, P282; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MORI N, 1989, CANCER RES, V49, P5130; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; VARLEY JM, 1989, ONCOGENE, V4, P725; WANG LM, 1988, BIOTECHNIQUES, V6, P839; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; XU HJ, 1989, ONCOGENE, V4, P807; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1988, ONCOGENE, V3, P471	54	83	83	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1067	1071						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1648702				2022-12-17	WOS:A1991GU62200025
J	LUCIBELLO, FC; NEUBERG, M; HUNTER, JB; JENUWEIN, T; SCHUERMANN, M; WALLICH, R; STEIN, B; SCHONTHAL, A; HERRLICH, P; MULLER, R				LUCIBELLO, FC; NEUBERG, M; HUNTER, JB; JENUWEIN, T; SCHUERMANN, M; WALLICH, R; STEIN, B; SCHONTHAL, A; HERRLICH, P; MULLER, R			TRANSACTIVATION OF GENE-EXPRESSION BY FOS PROTEIN - INVOLVEMENT OF A BINDING-SITE FOR THE TRANSCRIPTION FACTOR AP-1	ONCOGENE			English	Article									KERNFORSCHUNGSZENTRUM KARLSRUHE GMBH,INST GENET & TOXIKOL,D-7500 KARLSRUHE 1,FED REP GER	Helmholtz Association; Karlsruhe Institute of Technology	LUCIBELLO, FC (corresponding author), EUROPEAN MOLEC BIOL LAB,POSTFACH 102209,D-6900 HEIDELBERG,FED REP GER.			Schonthal, Axel/0000-0003-0662-5653				ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HERRLICH P, 1986, UCLA S MOL CELLULAR; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KARIN M, 1987, IN PRESS GENES SIGNA; KINGSTON RE, 1985, CELL, V41, P3, DOI 10.1016/0092-8674(85)90049-2; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MERCOLA D, 1987, J THEOR BIOL, V126, P243, DOI 10.1016/S0022-5193(87)80231-X; MOLDERS H, 1987, ONCOGENE, V1, P377; MULLER R, 1984, EMBO J, V3, P1121, DOI 10.1002/j.1460-2075.1984.tb01939.x; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; MULLER R, 1988, IN PRESS CELLULAR ON; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RENZ M, 1987, NUCLEIC ACIDS RES, V15, P277, DOI 10.1093/nar/15.1.277; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SAMBUCETTI LC, 1986, SCIENCE, V234, P1417, DOI 10.1126/science.3491427; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SETOYAMA C, 1986, BIOCHEM BIOPH RES CO, V136, P1042, DOI 10.1016/0006-291X(86)90438-9; VANBEVEREN C, 1984, VIROLOGY, V135, P229, DOI 10.1016/0042-6822(84)90133-8; VERMA IM, 1986, TRENDS GENET, V2, P93, DOI 10.1016/0168-9525(86)90191-5; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0	37	83	85	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1988	3	1					43	51						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	P0354					2022-12-17	WOS:A1988P035400007
J	Raoof, S; Mulford, IJ; Frisco-Cabanos, H; Nangia, V; Timonina, D; Labrot, E; Hafeez, N; Bilton, SJ; Drier, Y; Ji, F; Greenberg, M; Williams, A; Kattermann, K; Damon, L; Sovath, S; Rakiec, DP; Korn, JM; Ruddy, DA; Benes, CH; Hammerman, PS; Piotrowska, Z; Sequist, LV; Niederst, MJ; Barretina, J; Engelman, JA; Hata, AN				Raoof, Sana; Mulford, Iain J.; Frisco-Cabanos, Heidie; Nangia, Varuna; Timonina, Daria; Labrot, Emma; Hafeez, Nafeeza; Bilton, Samantha J.; Drier, Yotam; Ji, Fei; Greenberg, Max; Williams, August; Kattermann, Krystina; Damon, Leah; Sovath, Sosathya; Rakiec, Daniel P.; Korn, Joshua M.; Ruddy, David A.; Benes, Cyril H.; Hammerman, Peter S.; Piotrowska, Zofia; Sequist, Lecia, V; Niederst, Matthew J.; Barretina, Jordi; Engelman, Jeffrey A.; Hata, Aaron N.			Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; GROWTH-FACTOR RECEPTOR-3; ACTIVATING MUTATIONS; ACQUIRED-RESISTANCE; MET AMPLIFICATION; MULTIPLE-MYELOMA; GEFITINIB; INHIBITOR; PATHWAY; METASTASIS	Evolved resistance to tyrosine kinase inhibitor (TKI)-targeted therapies remains a major clinical challenge. In epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC), failure of EGFR TKIs can result from both genetic and epigenetic mechanisms of acquired drug resistance. Widespread reports of histologic and gene expression changes consistent with an epithelial-to-mesenchymal transition (EMT) have been associated with initially surviving drug-tolerant persister cells, which can seed bona fide genetic mechanisms of resistance to EGFR TKIs. While therapeutic approaches targeting fully resistant cells, such as those harboring an EGFR(T79M) mutation, have been developed, a clinical strategy for preventing the emergence of persister cells remains elusive. Using mesenchymal cell lines derived from biopsies of patients who progressed on EGFR TKI as surrogates for persister populations, we performed whole-genome CRISPR screening and identified fibroblast growth factor receptor 1 (FGFR1) as the top target promoting survival of mesenchymal EGFR mutant cancers. Although numerous previous reports of FGFR signaling contributing to EGFR TKI resistance in vitro exist, the data have not yet been sufficiently compelling to instigate a clinical trial testing this hypothesis, nor has the role of FGFR in promoting the survival of persister cells been elucidated. In this study, we find that combining EGFR and FGFR inhibitors inhibited the survival and expansion of EGFR mutant drug-tolerant cells over long time periods, preventing the development of fully resistant cancers in multiple vitro models and in vivo. These results suggest that dual EGFR and FGFR blockade may be a promising clinical strategy for both preventing and overcoming EMT-associated acquired drug resistance and provide motivation for the clinical study of combined EGFR and FGFR inhibition in EGFR-mutated NSCLCs.	[Raoof, Sana; Frisco-Cabanos, Heidie; Nangia, Varuna; Timonina, Daria; Bilton, Samantha J.; Drier, Yotam; Ji, Fei; Greenberg, Max; Williams, August; Kattermann, Krystina; Damon, Leah; Benes, Cyril H.; Piotrowska, Zofia; Sequist, Lecia, V; Hata, Aaron N.] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; [Mulford, Iain J.; Labrot, Emma; Hafeez, Nafeeza; Sovath, Sosathya; Rakiec, Daniel P.; Korn, Joshua M.; Ruddy, David A.; Hammerman, Peter S.; Niederst, Matthew J.; Barretina, Jordi; Engelman, Jeffrey A.] Novartis Inst Biomed Res, Oncol Dis Area, Cambridge, MA USA; [Benes, Cyril H.; Piotrowska, Zofia; Sequist, Lecia, V; Hata, Aaron N.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Novartis; Harvard University; Harvard Medical School	Hata, AN (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA.; Hata, AN (corresponding author), Harvard Med Sch, Dept Med, Boston, MA 02115 USA.	ahata@mgh.harvard.edu	Drier, Yotam/K-5208-2012	Drier, Yotam/0000-0003-1725-2995; Cabanos, Heidie/0000-0003-2643-8273; Nangia, Varuna/0000-0001-5142-4653; Damon, Leah/0000-0002-0863-0328; Williams, August/0000-0003-1994-2033	NIH [F30 CA213726-01A1, K08CA197389, R01CA137008]; Doris Duke Charitable Foundation; Stand Up To Cancer; National Science Foundation; V Foundation; Ludwig Cancer Research; LungStrong; Be a Piece of the Solution; NATIONAL CANCER INSTITUTE [R01CA137008, F30CA213726, K08CA197389] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); Stand Up To Cancer; National Science Foundation(National Science Foundation (NSF)); V Foundation; Ludwig Cancer Research; LungStrong; Be a Piece of the Solution; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr. Rafael Irizarry and Irineo Cabreros for guidance in statistical analyses related to shRNA dropout screening. We also thank Drs. Cyril Benes, Daniel Haber, Joan Brugge, Kornelia Polyak, and Robert Weinberg for helpful discussions throughout the development of this work. This study was funded by support from the NIH F30 CA213726-01A1 (SR), K08CA197389 (ANH), R01CA137008 (LVS), Doris Duke Charitable Foundation (ANH), Stand Up To Cancer (ANH and LVS), National Science Foundation (JAE), V Foundation (JAE), Ludwig Cancer Research (ANH), LungStrong, and Be a Piece of the Solution.	Azuma K, 2014, ONCOTARGET, V5, P5908, DOI 10.18632/oncotarget.1866; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bhang HEC, 2015, NAT MED, V21, P440, DOI 10.1038/nm.3841; Cardnell RJ, 2013, CLIN CANCER RES, V19, P6322, DOI 10.1158/1078-0432.CCR-13-1975; Cheng T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057284; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Crystal AS, 2014, SCIENCE, V346, P1480, DOI 10.1126/science.1254721; Dailey L, 2003, J CELL BIOL, V161, P1053, DOI 10.1083/jcb.200302075; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Floyd SR, 2013, NATURE, V498, P246, DOI 10.1038/nature12147; Gainor JF, 2016, CANCER DISCOV, V6, P1118, DOI 10.1158/2159-8290.CD-16-0596; Goyal L, 2017, CANCER DISCOV, V7, P252, DOI 10.1158/2159-8290.CD-16-1000; Guagnano V, 2011, J MED CHEM, V54, P7066, DOI 10.1021/jm2006222; Hata AN, 2016, NAT MED, V22, P262, DOI 10.1038/nm.4040; Haugsten EM, 2010, MOL CANCER RES, V8, P1439, DOI 10.1158/1541-7786.MCR-10-0168; Isozaki H, 2016, CANCER RES, V76, P1506, DOI 10.1158/0008-5472.CAN-15-1010; Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817; Javle M, 2018, J CLIN ONCOL, V36, P276, DOI 10.1200/JCO.2017.75.5009; Jia Y, 2016, CANCER RES, V76, P1591, DOI 10.1158/0008-5472.CAN-15-2581; Kanai M, 1997, J BIOL CHEM, V272, P6621, DOI 10.1074/jbc.272.10.6621; Katayama R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003316; Kitai H, 2016, CANCER DISCOV, V6, P754, DOI 10.1158/2159-8290.CD-15-1377; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Loboda A, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-9; LOEWE S, 1953, ARZNEIMITTEL-FORSCH, V3, P285; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Manchado E, 2016, NATURE, V534, P647, DOI 10.1038/nature18600; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Moon AM, 2006, DEV CELL, V10, P71, DOI 10.1016/j.devcel.2005.12.003; Moosa S, 2016, SEMIN CELL DEV BIOL, V53, P115, DOI 10.1016/j.semcdb.2015.12.005; Ornitz DM, 2015, WIRES DEV BIOL, V4, P215, DOI 10.1002/wdev.176; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Quintanal-Villalonga A, 2019, J THORAC ONCOL, V14, P641, DOI 10.1016/j.jtho.2018.12.021; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Sarabipour S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10262; Seo JH, 2009, MOL CELL BIOL, V29, P3076, DOI 10.1128/MCB.01686-08; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Song KA, 2018, CLIN CANCER RES, V24, P197, DOI 10.1158/1078-0432.CCR-17-1577; Terai H, 2013, MOL CANCER RES, V11, P759, DOI 10.1158/1541-7786.MCR-12-0652; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; Uramoto H, 2010, ANTICANCER RES, V30, P2513; Viswanathan VS, 2017, NATURE, V547, P453, DOI 10.1038/nature23007; Ware KE, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.4; Ware Kathryn E, 2010, PLoS One, V5, pe14117, DOI 10.1371/journal.pone.0014117; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064; Zhou WY, 2016, CANCER BIOL MED, V13, P260, DOI 10.20892/j.issn.2095-3941.2015.0102	51	82	86	2	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2019	38	37					6399	6413		10.1038/s41388-019-0887-2	http://dx.doi.org/10.1038/s41388-019-0887-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IX6FR	31324888	Green Accepted			2022-12-17	WOS:000485778800001
J	Comito, G; Iscaro, A; Bacci, M; Morandi, A; Ippolito, L; Parri, M; Montagnani, I; Raspollini, MR; Serni, S; Simeoni, L; Giannoni, E; Chiarugi, P				Comito, G.; Iscaro, A.; Bacci, M.; Morandi, A.; Ippolito, L.; Parri, M.; Montagnani, I.; Raspollini, M. R.; Serni, S.; Simeoni, L.; Giannoni, E.; Chiarugi, P.			Lactate modulates CD4(+) T-cell polarization and induces an immunosuppressive environment, which sustains prostate carcinoma progression via TLR8/miR21 axis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CANCER-ASSOCIATED FIBROBLASTS; FACTOR-KAPPA-B; LACTIC-ACID; TGF-BETA; TUMOR; METABOLISM; ACTIVATION; EXPRESSION; GLUTAMINE	Leukocyte infiltration plays an active role in controlling tumor development. In the early stages of carcinogenesis, T cells counteract tumor growth. However, in advanced stages, cancer cells and infiltrating stromal components interfere with the immune control and instruct immune cells to support, rather than counteract, tumor malignancy, via cell-cell contact or soluble mediators. In particular, metabolites are emerging as active players in driving immunosuppression. Here we demonstrate that in a prostate cancer model lactate released by glycolytic cancer-associated fibroblasts (CAFs) acts on CD4(+) T cells, shaping T-cell polarization. In particular, CAFs exposure (i) reduces the percentage of the antitumoral Th1 subset, inducing a lactate-dependent, SIRT1-mediated deacetylation/degradation of T-bet transcription factor; (ii) increases T-reg cells, driving naive T cells polarization, through a lactate-based NF-kB activation and FoxP3 expression. In turn, this metabolic-based CAF-immunomodulated environment exerts a pro-invasive effect on prostate cancer cells, by activating a previously unexplored miR21/TLR8 axis that sustains cancer malignancy.	[Comito, G.; Bacci, M.; Morandi, A.; Ippolito, L.; Parri, M.; Giannoni, E.; Chiarugi, P.] Univ Florence, Dept Expt & Clin Biomed Sci, I-50134 Florence, Italy; [Iscaro, A.] Univ Sheffield, Med Sch, Dept Oncol & Metab, Beech Hill Rd, Sheffield, S Yorkshire, England; [Montagnani, I.; Raspollini, M. R.] Univ Hosp Careggi, Histopathol & Mol Diagnost, Largo Brambilla 3, I-50134 Florence, Italy; [Serni, S.] Univ Florence, Careggi Hosp, Dept Urol Robot Surg & Renal Transplantat, I-50134 Florence, Italy; [Simeoni, L.] Otto Von Guericke Univ, Inst Mol & Clin Immunol, Leipziger Str 44, D-39120 Magdeburg, Germany; [Chiarugi, P.] Tuscany Tumor Inst ITT, I-50134 Florence, Italy; [Chiarugi, P.] Excellence Ctr Res Transfer & High Educ DenoTHE, I-50134 Florence, Italy	University of Florence; University of Sheffield; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Florence; Azienda Ospedaliero Universitaria Careggi; Otto von Guericke University; ISPRO Istituto per lo studio, la prevenzione e la rete oncologica	Giannoni, E (corresponding author), Univ Florence, Dept Expt & Clin Biomed Sci, I-50134 Florence, Italy.	elisa.giannoni@unifi.it	Giannoni, Elisa/AAE-2092-2020; Chiarugi, Paola/CDD-7988-2022; Bacci, Marina/AFN-8715-2022; Morandi, Andrea/AAC-1901-2022	Morandi, Andrea/0000-0002-9222-5332; Ippolito, Luigi/0000-0001-7927-8555; Chiarugi, Paola/0000-0001-7655-2969	Fondazione Umberto Veronesi; Associazione Italiana Ricerca sul Cancro (AIRC) [8797]; AIRC; Fondazione Cassa di Risparmio di Firenze [19515]; Istituto Toscano Tumori [0203607]; Programma operativo regionale Obiettivo "Competitivita regionale e occupazione" della Regione Toscana cofinanziato dal Fondo europeo di sviluppo regionale 2007-2013 (POR CReO FESR 2007-2013)	Fondazione Umberto Veronesi(Fondazione Umberto Veronesi); Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); AIRC(Fondazione AIRC per la ricerca sul cancro); Fondazione Cassa di Risparmio di Firenze(Fondazione Cassa Risparmio Firenze); Istituto Toscano Tumori; Programma operativo regionale Obiettivo "Competitivita regionale e occupazione" della Regione Toscana cofinanziato dal Fondo europeo di sviluppo regionale 2007-2013 (POR CReO FESR 2007-2013)	The work was supported by Fondazione Umberto Veronesi to GC and AM, Associazione Italiana Ricerca sul Cancro (AIRC) (grant 8797 to PC), AIRC and Fondazione Cassa di Risparmio di Firenze (grant 19515 to PC and AM), Istituto Toscano Tumori (grant 0203607 to PC), Programma operativo regionale Obiettivo "Competitivita regionale e occupazione" della Regione Toscana cofinanziato dal Fondo europeo di sviluppo regionale 2007-2013 (POR CReO FESR 2007-2013, grant to PC). The authors thank Dr. Lavinia Ferrone for technical support.	Alsaab HO, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00561; Anari F, 2018, FUTURE ONCOL, V14, P1409, DOI 10.2217/fon-2017-0585; Angelin A, 2017, CELL METAB, V25, P1282, DOI 10.1016/j.cmet.2016.12.018; Biswas SK, 2015, IMMUNITY, V43, P435, DOI 10.1016/j.immuni.2015.09.001; Brand A, 2016, CELL METAB, V24, P657, DOI 10.1016/j.cmet.2016.08.011; Buck MD, 2017, CELL, V169, P570, DOI 10.1016/j.cell.2017.04.004; Calcinotto A, 2012, CANCER RES, V72, P2746, DOI 10.1158/0008-5472.CAN-11-1272; Carr EL, 2010, J IMMUNOL, V185, P1037, DOI 10.4049/jimmunol.0903586; Chang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011; Eidelman E, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00131; Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109; Fang DF, 2017, J EXP MED, V214, P1861, DOI 10.1084/jem.20170494; Fiaschi Tania, 2012, Int J Cell Biol, V2012, P762825, DOI 10.1155/2012/762825; Fiaschi T, 2012, CANCER RES, V72, P5130, DOI 10.1158/0008-5472.CAN-12-1949; Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972; Flammiger A, 2013, EUR J CANCER, V49, P1273, DOI 10.1016/j.ejca.2012.11.035; Gambini J, 2011, ARCH BIOCHEM BIOPHYS, V512, P24, DOI 10.1016/j.abb.2011.04.020; Geltink RIK, 2018, ANNU REV IMMUNOL, V36, P461, DOI 10.1146/annurev-immunol-042617-053019; Giannoni E, 2015, ONCOTARGET, V6, P24061, DOI 10.18632/oncotarget.4448; Giannoni E, 2011, ANTIOXID REDOX SIGN, V14, P2361, DOI 10.1089/ars.2010.3727; Giannoni E, 2010, CANCER RES, V70, P6945, DOI 10.1158/0008-5472.CAN-10-0785; Gottfried E, 2006, BLOOD, V107, P2013, DOI 10.1182/blood-2005-05-1795; Guarente L, 2013, GENE DEV, V27, P2072, DOI 10.1101/gad.227439.113; Ha Tai-You, 2009, Immune Netw, V9, P209, DOI 10.4110/in.2009.9.6.209; Haas R, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002202; Hatley ME, 2010, CANCER CELL, V18, P282, DOI 10.1016/j.ccr.2010.08.013; Hensley CT, 2013, J CLIN INVEST, V123, P3678, DOI 10.1172/JCI69600; Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293; Huber V, 2017, SEMIN CANCER BIOL, V43, P74, DOI 10.1016/j.semcancer.2017.03.001; Hude I, 2017, HAEMATOLOGICA, V102, P30, DOI 10.3324/haematol.2016.150656; Husain Z, 2013, J IMMUNOL, V191, P1486, DOI 10.4049/jimmunol.1202702; Johnston CJC, 2016, CELL IMMUNOL, V299, P14, DOI 10.1016/j.cellimm.2015.10.006; Krichevsky AM, 2009, J CELL MOL MED, V13, px, DOI 10.1111/j.1582-4934.2008.00556.x; Levine BL, 1997, J IMMUNOL, V159, P5921; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Lim S, 2017, CANCER RES, V77, P1245, DOI 10.1158/0008-5472.CAN-16-1647; Long MX, 2009, IMMUNITY, V31, P921, DOI 10.1016/j.immuni.2009.09.022; Ludin A, 2017, NATURE, V552, P41, DOI 10.1038/nature24759; Lyssiotis CA, 2017, TRENDS CELL BIOL, V27, P873, DOI 10.1016/j.tcb.2017.06.003; Macintyre AN, 2014, CELL METAB, V20, P61, DOI 10.1016/j.cmet.2014.05.004; MacIver NJ, 2013, ANNU REV IMMUNOL, V31, P259, DOI 10.1146/annurev-immunol-032712-095956; Mendler AN, 2012, INT J CANCER, V131, P633, DOI 10.1002/ijc.26410; Metzler B, 2016, J IMMUNOL, V196, P3618, DOI 10.4049/jimmunol.1501756; Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613; Mishra R, 2018, J CLIN INVEST, V128, P4472, DOI 10.1172/JCI99397; Montanari M, 2017, ONCOTARGET, V8, P35376, DOI 10.18632/oncotarget.15686; Morrot A, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00081; Murray CM, 2005, NAT CHEM BIOL, V1, P371, DOI 10.1038/nchembio744; Neuzillet C, 2015, PHARMACOL THERAPEUT, V147, P22, DOI 10.1016/j.pharmthera.2014.11.001; Pavlides S, 2009, CELL CYCLE, V8, P3984, DOI 10.4161/cc.8.23.10238; Pearce EL, 2010, CURR OPIN IMMUNOL, V22, P314, DOI 10.1016/j.coi.2010.01.018; Pfeffer SR, 2015, DRUG DEVELOP RES, V76, P270, DOI 10.1002/ddr.21257; Polet F, 2013, J INTERN MED, V273, P156, DOI 10.1111/joim.12016; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Renner K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00248; Romero-Garcia S, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00052; Ruan QG, 2012, ADV EXP MED BIOL, V946, P207, DOI 10.1007/978-1-4614-0106-3_12; Saada A, 2014, INT J BIOCHEM CELL B, V48, P60, DOI 10.1016/j.biocel.2013.12.010; Shime H, 2008, J IMMUNOL, V180, P7175, DOI 10.4049/jimmunol.180.11.7175; Siska PJ, 2015, TRENDS IMMUNOL, V36, P257, DOI 10.1016/j.it.2015.02.007; Sonveaux P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033418; Sotgia F, 2012, CELL CYCLE, V11, P1445, DOI 10.4161/cc.19841; Su SC, 2017, CELL RES, V27, P461, DOI 10.1038/cr.2017.34; Sugiura A, 2018, J IMMUNOL, V200, P400, DOI 10.4049/jimmunol.1701041; Thompson ED, 2010, J EXP MED, V207, P1791, DOI 10.1084/jem.20092454; van Loosdregt J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019047; Vegran F, 2011, CANCER RES, V71, P2550, DOI 10.1158/0008-5472.CAN-10-2828; Wang F, 2012, ONCOGENE, V31, P1546, DOI 10.1038/onc.2011.347; Wang X, 2016, ONCOTARGETS THER, V9, P5023, DOI 10.2147/OTT.S105862; Wong N, 2014, CANCER INVEST, V32, P330, DOI 10.3109/07357907.2014.919306; Yoshida GJ, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0221-y; Zhang Q, 2009, CLIN CANCER RES, V15, P3557, DOI 10.1158/1078-0432.CCR-08-1656; Ziani L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00414	75	82	84	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3681	3695		10.1038/s41388-019-0688-7	http://dx.doi.org/10.1038/s41388-019-0688-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30664688				2022-12-17	WOS:000467379600009
J	Nguyen, PH; Giraud, J; Staedel, C; Chambonnier, L; Dubus, P; Chevret, E; Boeuf, H; Gauthereau, X; Rousseau, B; Fevre, M; Soubeyran, I; Belleannee, G; Evrard, S; Collet, D; Megraud, F; Varon, C				Nguyen, P. H.; Giraud, J.; Staedel, C.; Chambonnier, L.; Dubus, P.; Chevret, E.; Boeuf, H.; Gauthereau, X.; Rousseau, B.; Fevre, M.; Soubeyran, I.; Belleannee, G.; Evrard, S.; Collet, D.; Megraud, F.; Varon, C.			All-trans retinoic acid targets gastric cancer stem cells and inhibits patient-derived gastric carcinoma tumor growth	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; HELICOBACTER-PYLORI INFECTION; ALDEHYDE DEHYDROGENASES; CELLULAR-LEVELS; RECEPTOR-ALPHA; BREAST-CANCER; PATHWAY; EXPRESSION; IDENTIFICATION; CHEMOTHERAPY	Gastric carcinoma is the third leading cause of cancer-related death worldwide. This cancer, most of the time metastatic, is essentially treated by surgery associated with conventional chemotherapy, and has a poor prognosis. The existence of cancer stem cells (CSC) expressing CD44 and a high aldehyde dehydrogenase (ALDH) activity has recently been demonstrated in gastric carcinoma and has opened new perspectives to develop targeted therapy. In this study, we evaluated the effects of all-transretinoic acid (ATRA) on CSCs in human gastric carcinoma. ATRA effects were evaluated on the proliferation and tumorigenic properties of gastric carcinoma cells from patient-derived tumors and cell lines in conventional 2D cultures, in 3D culture systems (tumorsphere assay) and in mouse xenograft models. ATRA inhibited both tumorspheres initiation and growth in vitro, which was associated with a cell-cycle arrest through the upregulation of cyclin-dependent kinase (CDK) inhibitors and the downregulation of cell-cycle progression activators. More importantly, ATRA downregulated the expression of the CSC markers CD44 and ALDH as well as stemness genes such as Klf4 and Sox2 and induced differentiation of tumorspheres. Finally, 2 weeks of daily ATRA treatment were sufficient to inhibit gastric tumor progression in vivo, which was associated with a decrease in CD44, ALDH1, Ki67 and PCNA expression in the remaining tumor cells. Administration of ATRA appears to be a potent strategy to efficiently inhibit tumor growth and more importantly to target gastric CSCs in both intestinal and diffuse types of gastric carcinoma.	[Nguyen, P. H.; Giraud, J.; Chambonnier, L.; Megraud, F.; Varon, C.] INSERM, U853, Bordeaux, France; [Nguyen, P. H.; Giraud, J.; Staedel, C.; Chambonnier, L.; Dubus, P.; Chevret, E.; Boeuf, H.; Gauthereau, X.; Rousseau, B.; Fevre, M.; Megraud, F.; Varon, C.] Univ Bordeaux, Bordeaux, France; [Staedel, C.] INSERM, ARNA Lab, U869, Bordeaux, France; [Dubus, P.; Chevret, E.] Univ Bordeaux, EA2406, Bordeaux, France; [Dubus, P.; Megraud, F.] Univ Hosp Ctr, Bordeaux, France; [Boeuf, H.; Gauthereau, X.] CIRID, UMR CNRS 5164, Bordeaux, France; [Rousseau, B.; Fevre, M.] Univ Bordeaux, Serv Commun Animaleries, Bordeaux, France; [Soubeyran, I.] Inst Bergonie, Dept Biopathol, Bordeaux, France; [Belleannee, G.] Haut Leveque Hosp, Dept Histopathol Tumors, Bordeaux, France; [Evrard, S.] Inst Bergonie, Dept Digest Oncol, Bordeaux, France; [Collet, D.] Haut Leveque Hosp, Dept Digest Surg, Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; CHU Bordeaux; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; UNICANCER; Institut Bergonie; CHU Bordeaux; UNICANCER; Institut Bergonie; CHU Bordeaux	Varon, C (corresponding author), Univ Bordeaux, INSERM, U853, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	christine.varon@u-bordeaux.fr		Giraud, Julie/0000-0001-6173-4276; Dubus, Pierre/0000-0003-1803-4711; Varon, Christine/0000-0003-4026-2016; Megraud, Francis/0000-0002-2481-1612; Staedel, Cathy/0000-0003-0488-0239; EVRARD, Serge/0000-0003-1063-6822	French 'Institut National du Cancer' [2014-152]; French 'Association pour la Recherche contre le Cancer' [8412]; Institut National du Cancer [2014-152, 07/3D1616/IABC-23-12/NC-NG]; Conseil Regional d'Aquitaine [20071301017, 20081302203]; French National Society for Gastroenterology; SIRIC BRIO (Site de Recherche Integree sur le Cancer - Bordeaux Recherche Integree Oncologie) [INCa-DGOS-INSERM 6046]	French 'Institut National du Cancer'; French 'Association pour la Recherche contre le Cancer'(Fondation ARC pour la Recherche sur le Cancer); Institut National du Cancer(Institut National du Cancer (INCA) France); Conseil Regional d'Aquitaine(Region Nouvelle-Aquitaine); French National Society for Gastroenterology; SIRIC BRIO (Site de Recherche Integree sur le Cancer - Bordeaux Recherche Integree Oncologie)	The post-doctoral fellowship of Julie Giraud was granted by the French 'Institut National du Cancer' (grant 2014-152). We thank Vincent Pitard and Santiago Gonzalez (Flow Cytometry and FACS Platform, University of Bordeaux), Lamia Azzi-Martin and Jacky Ferrer (EA2406, University of Bordeaux), Elodie Siffre and Armelle Menard (INSERM U853) for technical assistance and helpful advice. We thank the French 'Association pour la Recherche contre le Cancer' (grant number 8412), the 'Institut National du Cancer' (grant 07/3D1616/IABC-23-12/NC-NG and grant 2014-152), the 'Conseil Regional d'Aquitaine' (grant numbers 20071301017 and 20081302203) and the French National Society for Gastroenterology for financial support. This project is part of SIRIC BRIO (Site de Recherche Integree sur le Cancer - Bordeaux Recherche Integree Oncologie; grant INCa-DGOS-INSERM 6046).	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Abdullah LN, 2013, CLIN TRANSL MED, V2, DOI 10.1186/2001-1326-2-3; Alison MR, 2010, J CELL SCI, V123, P2357, DOI 10.1242/jcs.054296; Baud J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060315; Bessede E, 2015, ONCOGENE, V34, P2547, DOI 10.1038/onc.2014.187; Bessede E, 2014, ONCOGENE, V33, P4123, DOI 10.1038/onc.2013.380; Chao TY, 1997, BRIT J CANCER, V75, P1284, DOI 10.1038/bjc.1997.218; Chen WJ, 2013, HEPATO-GASTROENTEROL, V60, P949, DOI 10.5754/hge12881; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Connolly RM, 2013, CLIN CANCER RES, V19, P1651, DOI 10.1158/1078-0432.CCR-12-3175; Czyzewska J, 2009, FOLIA HISTOCHEM CYTO, V47, P289, DOI 10.2478/v10042-009-0042-y; Ferrand J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019569; Flejou Jean-Francois, 2011, Ann Pathol, V31, pS27, DOI 10.1016/j.annpat.2011.08.001; Gonzalez CA, 2012, ANN ONCOL, V23, P1320, DOI 10.1093/annonc/mdr384; IARC, 1994, IARC MON EV CARC RIS, V61, P177; Isozaki H, 1996, J SURG ONCOL, V61, P106, DOI 10.1002/(SICI)1096-9098(199602)61:2<106::AID-JSO4>3.0.CO;2-G; Lau WM, 2014, CANCER RES, V74, P2630, DOI 10.1158/0008-5472.CAN-13-2309; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Li XL, 2014, MOL CELL BIOL, V34, P533, DOI 10.1128/MCB.01043-13; Lim YC, 2012, EUR J CANCER, V48, P3310, DOI 10.1016/j.ejca.2012.04.013; Liu MR, 2009, P NATL ACAD SCI USA, V106, P19035, DOI 10.1073/pnas.0910009106; Liu S, 2001, WORLD J GASTROENTERO, V7, P662; Lo-Coco F, 2013, NEW ENGL J MED, V369, P111, DOI 10.1056/NEJMoa1300874; Megraud F, 2015, CLIN MICROBIOL INFEC, V21, P984, DOI 10.1016/j.cmi.2015.06.004; Nishikawa S, 2013, INT J ONCOL, V42, P1437, DOI 10.3892/ijo.2013.1837; Schenk T, 2014, BRIT J CANCER, V111, P2039, DOI 10.1038/bjc.2014.412; Shin CS, 2013, MOL PHARMACEUT, V10, P2167, DOI 10.1021/mp300595a; SHYU RY, 1995, EUR J CANCER, V31A, P237, DOI 10.1016/0959-8049(94)00481-J; Sladek NE, 2002, CANCER CHEMOTH PHARM, V49, P309, DOI 10.1007/s00280-001-0412-4; Sreerama L, 1997, CLIN CANCER RES, V3, P1901; Staedel C, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.18; Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30; Tanaka T, 2001, BIOCHEM PHARMACOL, V61, P1347, DOI 10.1016/S0006-2952(01)00600-1; Varon C, 2012, GASTROENTEROLOGY, V142, P281, DOI 10.1053/j.gastro.2011.10.036; Ying M, 2011, ONCOGENE, V30, P3454, DOI 10.1038/onc.2011.58; Zhang JP, 2007, J DIGEST DIS, V8, P29, DOI 10.1111/j.1443-9573.2007.00280.x	36	82	83	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2016	35	43					5619	5628		10.1038/onc.2016.87	http://dx.doi.org/10.1038/onc.2016.87			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XP	27157616				2022-12-17	WOS:000386998300005
J	Perdigao-Henriques, R; Petrocca, F; Altschuler, G; Thomas, MP; Le, MTN; Tan, SM; Hide, W; Lieberman, J				Perdigao-Henriques, R.; Petrocca, F.; Altschuler, G.; Thomas, M. P.; Le, M. T. N.; Tan, S. M.; Hide, W.; Lieberman, J.			miR-200 promotes the mesenchymal to epithelial transition by suppressing multiple members of the Zeb2 and Snail1 transcriptional repressor complexes	ONCOGENE			English	Article							NEGATIVE BREAST-CANCER; E-CADHERIN; GENE-EXPRESSION; WIDE IDENTIFICATION; COLORECTAL-CANCER; PROGNOSTIC-FACTOR; CELL; FAMILY; TARGETS; PROTEIN	The miR-200 family promotes the epithelial state by suppressing the Zeb1/Zeb2 epithelial gene transcriptional repressors. To identify other miR-200-regulated genes, we isolated mRNAs bound to transfected biotinylated miR-200c in mouse breast cancer cells. In all, 520 mRNAs were significantly enriched in miR-200c binding at least twofold. Putative miR-200-regulated genes included Zeb2, enriched 3.5-fold in the pull down. However, Zeb2 knockdown does not fully recapitulate miR-200c overexpression, suggesting that regulating other miR-200 targets contributes to miR-200's enhancement of epithelial gene expression. Candidate genes were highly enriched for miR-200c seed pairing in their 3'UTR and coding sequence and for genes that were downregulated by miR-200c overexpression. Epidermal growth factor receptor and downstream MAPK signaling pathways were the most enriched pathways. Genes whose products mediate transforming growth factor (TGF)-beta signaling were also significantly overrepresented, and miR-200 counteracted the suppressive effects of TGF-beta and bone morphogenic protein 2 (BMP-2) on epithelial gene expression. miR-200c regulated the 3'UTRs of 12 of 14 putative miR-200c-binding mRNAs tested. The extent of mRNA binding to miR-200c strongly correlated with gene suppression. Twelve targets of miR-200c (Crtap, Fhod1, Smad2, Map3k1, Tob1, Ywhag/14-3-3 gamma, Ywhab/14-3-3 beta, Smad5, Zfp36, Xbp1, Mapk12, Snail1) were experimentally validated by identifying their 3'UTR miR-200 recognition elements. Smad2 and Smad5 form a complex with Zeb2 and Ywhab/14-3-3 beta and Ywhag/14-3-3 gamma form a complex with Snail1. These complexes that repress transcription assemble on epithelial gene promoters. miR-200 overexpression induced RNA polymerase II localization and reduced Zeb2 and Snail1 binding to epithelial gene promoters. Expression of miR-200-resistant Smad5 modestly, but significantly, reduced epithelial gene induction by miR-200. miR-200 expression and Zeb2 knockdown are known to inhibit cell invasion in in vitro assays. Knockdown of each of three novel miR-200 target genes identified here, Smad5, Ywhag and Crtap, also profoundly suppressed cell invasion. Thus, miR-200 suppresses TGF-beta/BMP signaling, promotes epithelial gene expression and suppresses cell invasion by regulating a network of genes.	[Perdigao-Henriques, R.; Petrocca, F.; Thomas, M. P.; Le, M. T. N.; Tan, S. M.; Lieberman, J.] Childrens Hosp Boston, Program Cellular & Mol Med, Boston, MA 02115 USA; [Perdigao-Henriques, R.] Univ Nova Lisboa, ITQB, Anim Cell Technol Unit, P-2780156 Oeiras, Portugal; [Perdigao-Henriques, R.] IBET, Oeiras, Portugal; [Altschuler, G.; Hide, W.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Hide, W.] Univ Sheffield, Dept Neurosci, Sheffield Inst Translat Neurosci, Sheffield, S Yorkshire, England; [Lieberman, J.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Universidade Nova de Lisboa; Harvard University; Harvard T.H. Chan School of Public Health; University of Sheffield; Harvard University; Harvard Medical School	Lieberman, J (corresponding author), Childrens Hosp Boston, Program Cellular & Mol Med, 200 Longwood Ave,Warren Alpert Bldg 255, Boston, MA 02115 USA.	judy.lieberman@childrens.harvard.edu	Hide, Winston Hide/C-7217-2009; Hide, Winston/R-3815-2019; Hide, Winston A/V-2727-2017; Lieberman, Judy/A-2717-2015	Hide, Winston Hide/0000-0002-8621-3271; Hide, Winston/0000-0002-8621-3271; Hide, Winston A/0000-0002-8621-3271; LE, Thi Nguyet Minh/0000-0002-6077-1566	Portuguese Ministry of Science and Technology (FCT) [SFRH/BD/37188/2007]	Portuguese Ministry of Science and Technology (FCT)	R Perdigao-Henriques acknowledges the Portuguese Ministry of Science and Technology (FCT) for Ph.D. fellowship SFRH/BD/37188/2007. We thank Alex Amiet and Devin Leake (Dharmacon) for providing the biotinylated miRNAs, Linfeng Huang (Lieberman laboratory) for assistance with ChIP assays and Francisco Navarro (Lieberman laboratory) for helpful suggestions.	Ahmadi H, 2013, GENOMICS, V101, P94, DOI 10.1016/j.ygeno.2012.11.005; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Baum B, 2008, SEMIN CELL DEV BIOL, V19, P294, DOI 10.1016/j.semcdb.2008.02.001; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Bracken CP, 2014, EMBO J, V33, P2040, DOI 10.15252/embj.201488641; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Capobianco V, 2012, J PROTEOME RES, V11, P3358, DOI 10.1021/pr300152z; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Chan YC, 2011, J BIOL CHEM, V286, P2047, DOI 10.1074/jbc.M110.158790; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chen R, 2007, NAT METHODS, V4, P879, DOI 10.1038/nmeth1107-879; Chen X, 2014, NATURE, V508, P103, DOI 10.1038/nature13119; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Chi SW, 2009, NATURE, V460, P479, DOI 10.1038/nature08170; Cloonan N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-12-r126; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Cuevas BD, 2003, EMBO J, V22, P3346, DOI 10.1093/emboj/cdg322; Dai YM, 2013, NUCLEIC ACID THER, V23, P29, DOI 10.1089/nat.2012.0385; Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181; Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915; Feng B, 2012, CANCER-AM CANCER SOC, V118, P3365, DOI 10.1002/cncr.26560; Garcia DM, 2011, NAT STRUCT MOL BIOL, V18, P1139, DOI 10.1038/nsmb.2115; Garibaldi F, 2012, CELL DEATH DIFFER, V19, P937, DOI 10.1038/cdd.2011.175; Grafel I, 2014, NAT MED, V20, P670, DOI 10.1038/nm.3544; Gravgaard KH, 2012, BREAST CANCER RES TR, V134, P207, DOI 10.1007/s10549-012-1969-9; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Hafner M, 2010, CELL, V141, P129, DOI 10.1016/j.cell.2010.03.009; Helwak A, 2013, CELL, V153, P654, DOI 10.1016/j.cell.2013.03.043; Hou ZY, 2010, CANCER RES, V70, P4385, DOI 10.1158/0008-5472.CAN-10-0070; Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013; Itoh T, 2009, J BIOL CHEM, V284, P19272, DOI 10.1074/jbc.M109.014001; Jurmeister S, 2012, MOL CELL BIOL, V32, P633, DOI 10.1128/MCB.06212-11; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kang H, 2012, J BIOL CHEM, V287, P3976, DOI 10.1074/jbc.M111.303156; Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135; Koka S, 2003, J CELL SCI, V116, P1745, DOI 10.1242/jcs.00386; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Krishnan K, 2013, RNA, V19, P230, DOI 10.1261/rna.034926.112; Lal A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002363; Langer EM, 2008, DEV CELL, V14, P424, DOI 10.1016/j.devcel.2008.01.005; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li A, 2010, CANCER RES, V70, P5226, DOI 10.1158/0008-5472.CAN-09-4227; Li J, 2013, CANCER LETT, V329, P84, DOI 10.1016/j.canlet.2012.10.019; Liu IM, 2009, EMBO J, V28, P88, DOI 10.1038/emboj.2008.266; Liu YN, 2013, ONCOGENE, V32, P296, DOI 10.1038/onc.2012.58; Mishra SK, 2004, J BIOL CHEM, V279, P32709, DOI 10.1074/jbc.M402942200; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Obri A, 2014, NATURE, V505, P648, DOI 10.1038/nature12922; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Petrocca F, 2013, CANCER CELL, V24, P182, DOI 10.1016/j.ccr.2013.07.008; Pichler M, 2014, BRIT J CANCER, V110, P1614, DOI 10.1038/bjc.2014.51; Pico AR, 2008, PLOS BIOL, V6, P1403, DOI 10.1371/journal.pbio.0060184; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Reinhold WC, 2012, CANCER RES, V72, P3499, DOI 10.1158/0008-5472.CAN-12-1370; Samavarchi-Tehrani P, 2010, CELL STEM CELL, V7, P64, DOI 10.1016/j.stem.2010.04.015; Schickel R, 2010, MOL CELL, V38, P908, DOI 10.1016/j.molcel.2010.05.018; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Shin JO, 2012, HISTOCHEM CELL BIOL, V137, P67, DOI 10.1007/s00418-011-0876-1; Sun L, 2012, ONCOGENE, V31, P432, DOI 10.1038/onc.2011.263; Tan SM, 2014, CELL REP, V8, P1225, DOI 10.1016/j.celrep.2014.07.023; Tanjore H, 2011, J BIOL CHEM, V286, P30972, DOI 10.1074/jbc.M110.181164; Taylor DD, 2008, GYNECOL ONCOL, V110, P13, DOI 10.1016/j.ygyno.2008.04.033; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Toiyama Y, 2014, ANN SURG, V259, P735, DOI 10.1097/SLA.0b013e3182a6909d; Uhlmann S, 2010, ONCOGENE, V29, P4297, DOI 10.1038/onc.2010.201; Venkov CD, 2007, J CLIN INVEST, V117, P482, DOI 10.1172/JCI29544; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Wells A, 2008, CLIN EXP METASTAS, V25, P621, DOI 10.1007/s10585-008-9167-1; Xia W, 2010, MOL CELL BIOCHEM, V344, P261, DOI 10.1007/s11010-010-0550-2; Yamazaki D, 2005, GENES CELLS, V10, P381, DOI 10.1111/j.1365-2443.2005.00845.x; Yao CX, 2013, RNA BIOL, V10, P465, DOI 10.4161/rna.24370; Ye F, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-17; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhu W, 2012, CANCER CHEMOTH PHARM, V69, P723, DOI 10.1007/s00280-011-1752-3	79	82	85	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2016	35	2					158	172		10.1038/onc.2015.69	http://dx.doi.org/10.1038/onc.2015.69			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB0JH	25798844	Green Accepted			2022-12-17	WOS:000368193900003
J	Choudhry, H; Albukhari, A; Morotti, M; Haider, S; Moralli, D; Smythies, J; Schodel, J; Green, CM; Camps, C; Buffa, F; Ratcliffe, P; Ragoussis, J; Harris, AL; Mole, DR				Choudhry, H.; Albukhari, A.; Morotti, M.; Haider, S.; Moralli, D.; Smythies, J.; Schoedel, J.; Green, C. M.; Camps, C.; Buffa, F.; Ratcliffe, P.; Ragoussis, J.; Harris, A. L.; Mole, D. R.			Tumor hypoxia induces nuclear paraspeckle formation through HIF-2 alpha dependent transcriptional activation of NEAT1 leading to cancer cell survival (vol 34, pg 4482, 2015)	ONCOGENE			English	Correction													Harris, Adrian L/ABA-3343-2020; Buffa, Francesca/D-2574-2013; Albukhari, Ashwag/M-3690-2016; Ragoussis, Ioannis/AAD-9790-2022; Morotti, Matteo/AAE-8922-2020	Harris, Adrian L/0000-0003-1376-8409; Buffa, Francesca/0000-0003-0409-406X; Albukhari, Ashwag/0000-0003-3669-1184; Morotti, Matteo/0000-0002-1790-1185; Ragoussis, Ioannis/0000-0002-8515-0934; Mole, David/0000-0002-0984-300X; Green, Catherine/0000-0002-7068-7106; Schodel, Johannes/0000-0002-3587-8839; Ratcliffe, Peter/0000-0002-2853-806X; Choudhry, Hani/0000-0003-0401-6619				Choudhry H, 2015, ONCOGENE, V34, P4482, DOI 10.1038/onc.2014.378	1	82	86	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2015	34	34					4546	4546		10.1038/onc.2014.431	http://dx.doi.org/10.1038/onc.2014.431			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BR	26289678	Bronze, Green Published			2022-12-17	WOS:000360189200014
J	Li, T; Lu, YY; Zhao, XD; Guo, HQ; Liu, CH; Li, H; Zhou, L; Han, YN; Wu, KC; Nie, YZ; Shi, YQ; Fan, DM				Li, T.; Lu, Y. Y.; Zhao, X. D.; Guo, H. Q.; Liu, C. H.; Li, H.; Zhou, L.; Han, Y. N.; Wu, K. C.; Nie, Y. Z.; Shi, Y. Q.; Fan, D. M.			MicroRNA-296-5p increases proliferation in gastric cancer through repression of Caudal-related homeobox 1	ONCOGENE			English	Article						CDX1; miR-296-5p; gastric cancer; proliferation; apoptosis	MESSENGER-RNA EXPRESSION; HELICOBACTER-PYLORI; EPITHELIAL-CELLS; GENE-EXPRESSION; DOWN-REGULATION; KINASE PATHWAY; CDX1; CARCINOMA; MIR-296; TARGET	Caudal-related homeobox 1 (CDX1), an intestinal-specific transcription factor, has been reported to have vital roles in gastric intestinal metaplasia (IM). Although IM is a high-risk factor for gastric cancer (GC), the specific role of CDX1 in GC is largely unknown. In this study, we investigated the expression of CDX1 and its functional roles in GC, and its upstream regulatory mechanisms at the microRNA (miRNA) level were further explored. We found that CDX1 is lost in GC when compared with adjacent IM tissues. Gain-of-function studies showed that CDX1 significantly inhibited GC cell growth by inducing cell cycle arrest and apoptosis. Interestingly, we identified and verified an onco-mir, miR-296-5p, as a direct upstream regulator of CDX1. miR-296-5p overexpression significantly promoted GC cell growth and attenuated the CDX1-induced anti-growth effects by recurring cell cycle distribution and apoptotic status, whereas knockdown of miR-296-5p decreased GC cell growth. Furthermore, we found that the extracellular signal-regulated kinases 1 and 2 (ERK1/2) activation and the subsequent downstream changes in protein levels related to cell cycle and apoptosis partly account for the miR-296-5p-CDX1-induced GC growth promotion. In addition, the detection of miR-296-5p and expression of CDX1 in primary GC tissues and adjacent IM tissues revealed that miR-296-5p is inversely correlated with CDX1, further supporting our in vitro results. Our results showed an anti-growth effect of CDX1 and identified its miRNA regulatory mechanism in GC. The identification of this novel miR-296-5p-CDX1-ERK1/2 axis sheds new light on the understanding of the process from IM to GC and may provide therapeutic targets for the treatment of GC.	Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, Xian 710032, Peoples R China; Fourth Mil Med Univ, Xijing Hosp, Dept Gastroenterol, Xian 710032, Peoples R China	Air Force Military Medical University; Air Force Military Medical University	Shi, YQ (corresponding author), Xijing Hosp Digest Dis, State Key Lab Canc Biol, West Changle Rd, Xian 710032, Shaan Xi, Peoples R China.	shiyquan@fmmu.edu.cn; daimingfan@fmmu.edu.cn	Shi, Yongquan/AAE-3954-2020		National 973 Project of China [2010CB732405, 2010CB529300, 2010CB529302, 2010CB529305, 2010CB529306]; National Natural Science Foundation of China [81030044, 81270445, 81172062]	National 973 Project of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We acknowledge Z CHEN, GB TANG, JH DOU and G REN from the State Key Laboratory of Cancer Biology for the assistance in tissue sample collection. This work was supported by the National 973 Project of China (no. 2010CB732405, 05; 2010CB529300, 02, 05, 06) and the National Natural Science Foundation of China (no. 81030044, 81270445, 81172062).	ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Boussioutas A, 2003, CANCER RES, V63, P2569; Camilo V, 2012, CARCINOGENESIS, V33, P1985, DOI 10.1093/carcin/bgs233; Chan CWM, 2009, P NATL ACAD SCI USA, V106, P1936, DOI 10.1073/pnas.0812904106; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chaudhuri K, 2007, DNA CELL BIOL, V26, P321, DOI 10.1089/dna.2006.0549; Darido C, 2011, CANCER CELL, V20, P635, DOI 10.1016/j.ccr.2011.10.014; Domon-Dell C, 2003, ONCOGENE, V22, P7913, DOI 10.1038/sj.onc.1206756; Fornari F, 2010, CANCER RES, V70, P5184, DOI 10.1158/0008-5472.CAN-10-0145; Guo RJ, 2004, J BIOL CHEM, V279, P36865, DOI 10.1074/jbc.M405213200; Hong L, 2010, ANN SURG, V251, P1056, DOI 10.1097/SLA.0b013e3181dd4ea9; Hou J, 2011, CANCER CELL, V19, P232, DOI 10.1016/j.ccr.2011.01.001; Ito K, 2011, GASTROENTEROLOGY, V140, P1536, DOI 10.1053/j.gastro.2011.01.043; Jeon SH, 2007, J BIOL CHEM, V282, P14482, DOI 10.1074/jbc.M611129200; Johnstone CN, 2002, J BIOL CHEM, V277, P34531, DOI 10.1074/jbc.M204865200; Kan T, 2009, GASTROENTEROLOGY, V136, P1689, DOI 10.1053/j.gastro.2009.02.002; Kazumori H, 2009, GUT, V58, P620, DOI 10.1136/gut.2008.152975; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lynch J, 2003, ONCOGENE, V22, P6395, DOI 10.1038/sj.onc.1206770; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; Lynch JP, 2008, NEOPLASIA, V10, P8, DOI 10.1593/neo.07703; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; Meloche S, 2007, ONCOGENE, V26, P3227, DOI 10.1038/sj.onc.1210414; Mutoh H, 2004, GUT, V53, P1416, DOI 10.1136/gut.2003.032482; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Pucci B, 2009, J CELL BIOCHEM, V108, P1166, DOI 10.1002/jcb.22345; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; Soubeyran P, 2001, ONCOGENE, V20, P4180, DOI 10.1038/sj.onc.1204551; Suh ER, 2002, J BIOL CHEM, V277, P35795, DOI 10.1074/jbc.M205567200; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Vaira V, 2012, ONCOGENE, V31, P27, DOI 10.1038/onc.2011.209; Wong NACS, 2005, P NATL ACAD SCI USA, V102, P7565, DOI 10.1073/pnas.0502031102; Wong NACS, 2004, P NATL ACAD SCI USA, V101, P574, DOI 10.1073/pnas.0307190101; Wurdinger T, 2008, CANCER CELL, V14, P382, DOI 10.1016/j.ccr.2008.10.005; Xia L, 2008, INT J CANCER, V123, P372, DOI 10.1002/ijc.23501; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Xu Y, 2012, ONCOGENE, V31, P1398, DOI 10.1038/onc.2011.340; Xu Y, 2012, J ENG FIBER FABR, V7, P7; Yoon A, 2011, NUCLEIC ACIDS RES, V39, P8078, DOI 10.1093/nar/gkr492; You WC, 1999, INT J CANCER, V83, P615, DOI 10.1002/(SICI)1097-0215(19991126)83:5&lt;615::AID-IJC8&gt;3.0.CO;2-L; Zhao X, 2013, ONCOGENE, V32, P1363, DOI 10.1038/onc.2012.156	48	82	86	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					783	793		10.1038/onc.2012.637	http://dx.doi.org/10.1038/onc.2012.637			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL	23353818				2022-12-17	WOS:000331129200012
J	Du, W; Wang, S; Zhou, Q; Li, X; Chu, J; Chang, Z; Tao, Q; Ng, EKW; Fang, J; Sung, JJY; Yu, J				Du, W.; Wang, S.; Zhou, Q.; Li, X.; Chu, J.; Chang, Z.; Tao, Q.; Ng, E. K. W.; Fang, J.; Sung, J. J. Y.; Yu, J.			ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer	ONCOGENE			English	Article						ADAMTS9; tumor suppressor; AKT/mTOR pathway; gastric cancer; prognosis	NASOPHARYNGEAL CARCINOMA; GENE; MTOR; METHYLATION; EXPRESSION; ESOPHAGEAL; APOPTOSIS; THERAPY; CELLS; AKT	Using genome-wide promoter methylation analysis, we identified a disintegrin-like and metalloprotease with thrombospondin type 1 motif 9 (ADAMTS9) is methylated in cancer. We aim to clarify its epigenetic inactivation, biological function and clinical implication in gastric cancer. ADAMTS9 was silenced in 6 out of 8 gastric cancer cell lines. The loss of ADAMTS9 expression was regulated by promoter hypermethylation and could be restored by demethylation agent. Ectopic expression of ADAMTS9 in gastric cancer cell lines (AGS, BGC823) inhibited cell growth curve in both the cell lines (P<0.0001), suppressed colony formation (P<0.01) and induced apoptosis (P<0.001 in AGS, P<0.01 in BGC823). Moreover, conditioned culture medium from ADAMTS9-transfected cell lines significantly disrupted the human umbilical vein endothelial cell tube formation capacity on Matrigel (P<0.01 in AGS, P<0.001 in BGC823). The in vivo growth of ADAMTS9 cells in nude mice was also markedly diminished after stable expression of ADAMTS9 (P<0.001). On the other hand, ADAMTS9 knockdown promoted cell proliferation (P<0.001). We further revealed that ADAMTS9 inhibited tumor growth by blocking activation of Akt and its downstream target the mammalian target of rapamycin (mTOR). ADAMTS9 also reduced phosphorylation of mTOR downstream targets p70 ribosomal S6 kinase, eIF4E-binding protein and downregulated hypoxia-inducible factor-1 alpha. Therefore, this is the first demonstration that ADAMTS9 is a critical tumor suppressor of gastric cancer progression at least in part through suppression of oncogenic AKT/mTOR signaling. Moreover, promoter methylation of ADAMTS9 was detected in 29.2% (21/72) of primary gastric tumors. Multivariate analysis showed that patients with ADAMTS9 methylation had a poorer overall survival (relative risk (RR) = 2.788; 95% confidence interval, 1.474-5.274; P = 0.002). Kaplan-Meier survival curves showed that ADAMTS9 methylation was significantly associated with shortened survival in gastric cancer patients (P = 0.001, log-rank test). In conclusion, ADAMTS9 acts as a functional tumor suppressor in gastric cancer through inhibiting oncogenic AKT/mTOR signaling pathway. Methylation of ADAMTS9 is an independent prognostic factor of gastric cancer.	[Du, W.; Wang, S.; Li, X.; Sung, J. J. Y.; Yu, J.] Chinese Univ Hong Kong, Prince Wales Hosp, Inst Digest Dis, Shatin, Hong Kong, Peoples R China; [Du, W.; Wang, S.; Li, X.; Sung, J. J. Y.; Yu, J.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China; [Du, W.; Fang, J.] Shanghai Jiao Tong Univ, Div Gastroenterol, Sch Med,Minist Hlth,State Key Lab Oncogene & Rela, Renji Hosp,Shanghai Inst Digest Disease,Key Lab G, Shanghai 200030, Peoples R China; [Zhou, Q.; Tao, Q.] Chinese Univ Hong Kong, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China; [Chu, J.] Hong Kong Baptist Univ, Sch Chinese Med, Ctr Canc & Inflammat Res, Kowloon, Hong Kong, Peoples R China; [Chang, Z.] Tsinghua Univ, Sch Med, Dept Biol Sci & Biotechnol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China; [Ng, E. K. W.] Chinese Univ Hong Kong, Dept Surg, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Shanghai Jiao Tong University; Chinese University of Hong Kong; Hong Kong Baptist University; Tsinghua University; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Inst Digest Dis, Shatin, Hong Kong, Peoples R China.	jingyuanfang@yahoo.com; junyu@cuhk.edu.hk	Ng, Enders/T-3881-2019; Yu, Jun/D-8569-2015; Sung, Joseph J. Y./R-3203-2018; Chang, Zhijie/AAH-8109-2019; Tao, Qian/T-4743-2018; Li, Xiao-xing/B-9114-2008; Ng, Enders Kwok Wai/E-8276-2016; Ng, Enders K.O./F-2787-2010	Ng, Enders/0000-0002-6955-0030; Yu, Jun/0000-0001-5008-2153; Sung, Joseph J. Y./0000-0003-3125-5199; Tao, Qian/0000-0001-5383-4808; Li, Xiao-xing/0000-0001-8791-7505; Ng, Enders K.O./0000-0002-6955-0030; Ng, Enders Kai-on/0000-0002-5293-3529	National Basic Research Program of China (973 Program) [2010CB529305]; Shenzhen Basic Research Program [JC20110520111A]; Research Grants Council RGC CERG CUHK [473008]; Group Research Scheme CUHK [3110043]; CUHK Focused Investment Gant [1903026]; RFCID [10090942, 11100022]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); Shenzhen Basic Research Program; Research Grants Council RGC CERG CUHK; Group Research Scheme CUHK; CUHK Focused Investment Gant; RFCID	This project was supported by National Basic Research Program of China (973 Program, 2010CB529305); Shenzhen Basic Research Program (JC20110520111A); Research Grants Council RGC CERG CUHK (473008); Group Research Scheme CUHK (3110043); CUHK Focused Investment Gant (1903026), and RFCID (10090942, 11100022).	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Asnaghi L, 2004, ONCOGENE, V23, P5781, DOI 10.1038/sj.onc.1207698; Averous J, 2008, ONCOGENE, V27, P1106, DOI 10.1038/sj.onc.1210715; Cheung KF, 2012, CANCER-AM CANCER SOC, V118, P947, DOI 10.1002/cncr.26189; Cicenas J, 2011, J CANCER RES CLIN, V137, P1409, DOI 10.1007/s00432-011-1039-4; Clark ME, 2000, GENOMICS, V67, P343, DOI 10.1006/geno.2000.6246; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Jin ZY, 2005, CANCER BIOL THER, V4, P139, DOI 10.4161/cbt.4.2.1508; Jungers KA, 2005, GENE EXPR PATTERNS, V5, P609, DOI 10.1016/j.modgep.2005.03.004; Kern CB, 2010, MATRIX BIOL, V29, P304, DOI 10.1016/j.matbio.2010.01.005; Koo BH, 2006, J BIOL CHEM, V281, P12485, DOI 10.1074/jbc.M511083200; Koo BH, 2010, AM J PATHOL, V176, P1494, DOI 10.2353/ajpath.2010.090655; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Leung WK, 2006, CLIN CANCER RES, V12, P3216, DOI 10.1158/1078-0432.CCR-05-2442; Liu WL, 2011, HEPATOLOGY, V53, P843, DOI 10.1002/hep.24124; Liu YJ, 2006, ONCOGENE, V25, P2452, DOI 10.1038/sj.onc.1209287; Lo PHY, 2007, ONCOGENE, V26, P148, DOI 10.1038/sj.onc.1209767; Lo PHY, 2010, CANCER RES, V70, P5567, DOI 10.1158/0008-5472.CAN-09-4510; Lung HL, 2008, INT J CANCER, V123, P401, DOI 10.1002/ijc.23528; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Musgrove EA, 2011, NAT REV CANCER, V11, P558, DOI 10.1038/nrc3090; Sepulveda AR, 2010, GASTROENTEROLOGY, V138, P1836, DOI 10.1053/j.gastro.2009.12.042; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Troiano L, 2007, NAT PROTOC, V2, P2719, DOI 10.1038/nprot.2007.405; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Yecies JL, 2011, J MOL MED, V89, P221, DOI 10.1007/s00109-011-0726-6; Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267; Yu J, 2009, CANCER-AM CANCER SOC, V115, P49, DOI 10.1002/cncr.23989; Yu J, 2009, GASTROENTEROLOGY, V136, P640, DOI 10.1053/j.gastro.2008.10.050; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	33	82	89	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 11	2013	32	28					3319	3328		10.1038/onc.2012.359	http://dx.doi.org/10.1038/onc.2012.359			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	180TM	22907434				2022-12-17	WOS:000321620200002
J	Pollina, EA; Brunet, A				Pollina, E. A.; Brunet, A.			Epigenetic regulation of aging stem cells	ONCOGENE			English	Review						neural stem cells; hematopoietic stem cells; aging; epigenetic; chromatin; FOXO transcription factors	FOXO TRANSCRIPTION FACTORS; ADULT MAMMALIAN FOREBRAIN; NUCLEAR RECEPTOR TAILLESS; MURINE HEMATOPOIETIC STEM; MUSCLE SATELLITE CELLS; DNA-DAMAGE RESPONSE; AGE-RELATED-CHANGES; HISTONE METHYLTRANSFERASE ACTIVITY; DEMETHYLASE JMJD3 CONTRIBUTES; CHROMATIN REMODELING COMPLEX	The function of adult tissue-specific stem cells declines with age, which may contribute to the physiological decline in tissue homeostasis and the increased risk of neoplasm during aging. Old stem cells can be 'rejuvenated' by environmental stimuli in some cases, raising the possibility that a subset of age-dependent stem cell changes is regulated by reversible mechanisms. Epigenetic regulators are good candidates for such mechanisms, as they provide a versatile checkpoint to mediate plastic changes in gene expression and have recently been found to control organismal longevity. Here, we review the importance of chromatin regulation in adult stem cell compartments. We particularly focus on the roles of chromatin-modifying complexes and transcription factors that directly impact chromatin in aging stem cells. Understanding the regulation of chromatin states in adult stem cells is likely to have important implications for identifying avenues to maintain the homeostatic balance between sustained function and neoplastic transformation of aging stem cells. Oncogene (2011) 30, 3105-3126; doi:10.1038/onc.2011.45; published online 28 March 2011	[Pollina, E. A.; Brunet, A.] Stanford Univ, Dept Genet, Stanford, CA 94305 USA; [Pollina, E. A.; Brunet, A.] Stanford Univ, Canc Biol Program, Stanford, CA 94305 USA	Stanford University; Stanford University	Brunet, A (corresponding author), Stanford Univ, Dept Genet, 300 Pasteur Dr,Alway M336, Stanford, CA 94305 USA.	anne.brunet@stanford.edu			California Institute of Regenerative Medicine; Ellison Medical Foundation; NSF; NATIONAL INSTITUTE ON AGING [P01AG036695, F31AG043232] Funding Source: NIH RePORTER	California Institute of Regenerative Medicine(California Institute for Regenerative Medicine); Ellison Medical Foundation(Lawrence Ellison Foundation); NSF(National Science Foundation (NSF)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Eric L Greer and Wendy W Pang for critical reading of the manuscript and helpful suggestions. This work was supported by a California Institute of Regenerative Medicine New Faculty Award (AB), an Ellison Medical Foundation Senior Award (AB) and an NSF graduate fellowship (EAP).	Adler AS, 2007, GENE DEV, V21, P3244, DOI 10.1101/gad.1588507; Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809; Ahlenius H, 2009, J NEUROSCI, V29, P4408, DOI 10.1523/JNEUROSCI.6003-08.2009; Anselmi CV, 2009, REJUV RES, V12, P95, DOI 10.1089/rej.2008.0827; Anthony TE, 2004, NEURON, V41, P881, DOI 10.1016/S0896-6273(04)00140-0; Arantes-Oliveira N, 2002, SCIENCE, V295, P502, DOI 10.1126/science.1065768; Attema JL, 2009, ONCOGENE, V28, P2238, DOI 10.1038/onc.2009.94; Banks AS, 2008, CELL METAB, V8, P333, DOI 10.1016/j.cmet.2008.08.014; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; Beckervordersandforth R, 2010, CELL STEM CELL, V7, P744, DOI 10.1016/j.stem.2010.11.017; Beerman I, 2010, CURR OPIN IMMUNOL, V22, P500, DOI 10.1016/j.coi.2010.06.007; Beerman I, 2010, P NATL ACAD SCI USA, V107, P5465, DOI 10.1073/pnas.1000834107; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Berger SL, 2009, GENE DEV, V23, P781, DOI 10.1101/gad.1787609; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Biteau B, 2008, CELL STEM CELL, V3, P442, DOI 10.1016/j.stem.2008.07.024; Biteau B, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001159; Blanpain C, 2007, CELL, V128, P445, DOI 10.1016/j.cell.2007.01.014; Blasco MA, 2007, NAT REV GENET, V8, P299, DOI 10.1038/nrg2047; Bockhold KJ, 1998, MUSCLE NERVE, V21, P173, DOI 10.1002/(SICI)1097-4598(199802)21:2<173::AID-MUS4>3.0.CO;2-8; Bondolfi L, 2004, NEUROBIOL AGING, V25, P333, DOI 10.1016/S0197-4580(03)00083-6; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Bouchard C, 2007, GENE DEV, V21, P2775, DOI 10.1101/gad.453107; Boyle M, 2007, CELL STEM CELL, V1, P470, DOI 10.1016/j.stem.2007.08.002; Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090; Brack AS, 2009, DEV BIOL, V335, P93, DOI 10.1016/j.ydbio.2009.08.014; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Breton-Provencher V, 2009, J NEUROSCI, V29, P15245, DOI 10.1523/JNEUROSCI.3606-09.2009; Bruggeman SWM, 2007, CANCER CELL, V12, P328, DOI 10.1016/j.ccr.2007.08.032; Bruggeman SWM, 2005, GENE DEV, V19, P1438, DOI 10.1101/gad.1299305; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Bug G, 2005, CANCER RES, V65, P2537, DOI 10.1158/0008-5472.CAN-04-3011; Buszczak M, 2006, CELL, V125, P233, DOI 10.1016/j.cell.2006.04.004; Cameron HA, 1999, NAT NEUROSCI, V2, P894, DOI 10.1038/13197; Carlson ME, 2008, NATURE, V454, P528, DOI 10.1038/nature07034; Carlson ME, 2007, AGING CELL, V6, P371, DOI 10.1111/j.1474-9726.2007.00286.x; Carlson ME, 2009, EMBO MOL MED, V1, P381, DOI 10.1002/emmm.200900045; Cavalli G, 1998, CELL, V93, P505, DOI 10.1016/S0092-8674(00)81181-2; Challen GA, 2010, CELL STEM CELL, V6, P265, DOI 10.1016/j.stem.2010.02.002; Chambers SM, 2007, PLOS BIOL, V5, P1750, DOI 10.1371/journal.pbio.0050201; Chen JK, 2010, MOL CELL BIOL, V30, P5621, DOI 10.1128/MCB.00465-10; Chen S, 2009, P NATL ACAD SCI USA, V106, P1496, DOI 10.1073/pnas.0802674106; Cheshier SP, 1999, P NATL ACAD SCI USA, V96, P3120, DOI 10.1073/pnas.96.6.3120; Cheung I, 2010, P NATL ACAD SCI USA, V107, P8824, DOI 10.1073/pnas.1001702107; Cho RH, 2008, BLOOD, V111, P5553, DOI 10.1182/blood-2007-11-123547; Choi JK, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040010; Chuikov S, 2010, NAT CELL BIOL, V12, P999, DOI 10.1038/ncb2101; Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215; Conboy IM, 2005, CELL CYCLE, V4, P407, DOI 10.4161/cc.4.3.1518; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Conboy IM, 2003, SCIENCE, V302, P1575, DOI 10.1126/science.1087573; Corbu A, 2010, NEUROL RES, V32, P63, DOI 10.1179/174313209X385725; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Curtis MA, 2007, SCIENCE, V315, P1243, DOI 10.1126/science.1136281; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Dang WW, 2009, NATURE, V459, P802, DOI 10.1038/nature08085; de Haan G, 1999, BLOOD, V93, P3294, DOI 10.1182/blood.V93.10.3294.410k07_3294_3301; deHaan G, 1997, BLOOD, V89, P1543, DOI 10.1182/blood.V89.5.1543.1543_1543_1550; Deka J, 2010, CANCER RES, V70, P6619, DOI 10.1158/0008-5472.CAN-10-0148; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Dumble M, 2007, BLOOD, V109, P1736, DOI 10.1182/blood-2006-03-010413; Dykstra B, 2007, CELL STEM CELL, V1, P218, DOI 10.1016/j.stem.2007.05.015; Enwere E, 2004, J NEUROSCI, V24, P8354, DOI 10.1523/JNEUROSCI.2751-04.2004; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Fasano CA, 2007, CELL STEM CELL, V1, P87, DOI 10.1016/j.stem.2007.04.001; Feige JN, 2008, CELL METAB, V8, P347, DOI 10.1016/j.cmet.2008.08.017; Fiedler M, 2008, MOL CELL, V30, P507, DOI 10.1016/j.molcel.2008.03.011; Flachsbart F, 2009, P NATL ACAD SCI USA, V106, P2700, DOI 10.1073/pnas.0809594106; Flores I, 2005, SCIENCE, V309, P1253, DOI 10.1126/science.1115025; Frescas D, 2005, J BIOL CHEM, V280, P20589, DOI 10.1074/jbc.M412357200; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Gheusi C, 2000, P NATL ACAD SCI USA, V97, P1823, DOI 10.1073/pnas.97.4.1823; Giannakou ME, 2004, SCIENCE, V305, P361, DOI 10.1126/science.1098219; GIBSON MC, 1983, MUSCLE NERVE, V6, P574, DOI 10.1002/mus.880060807; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Goodman RH, 2000, GENE DEV, V14, P1553; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Greer EL, 2010, NATURE, V466, P383, DOI 10.1038/nature09195; Grewal SIS, 1996, CELL, V86, P95, DOI 10.1016/S0092-8674(00)80080-X; Gu BN, 2009, J CELL BIOL, V185, P811, DOI 10.1083/jcb.200810133; Guerrettaz LM, 2008, P NATL ACAD SCI USA, V105, P11898, DOI 10.1073/pnas.0805498105; Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506; Hatta M, 2007, J BIOL CHEM, V282, P35583, DOI 10.1074/jbc.M704735200; Hattiangady B, 2008, NEUROBIOL AGING, V29, P129, DOI 10.1016/j.neurobiolaging.2006.09.015; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hennighausen L, 2005, NAT REV MOL CELL BIO, V6, P715, DOI 10.1038/nrm1714; Hirabayashi Y, 2009, NEURON, V63, P600, DOI 10.1016/j.neuron.2009.08.021; Hisahara S, 2008, P NATL ACAD SCI USA, V105, P15599, DOI 10.1073/pnas.0800612105; Ho L, 2010, NATURE, V463, P474, DOI 10.1038/nature08911; Ho L, 2009, P NATL ACAD SCI USA, V106, P5181, DOI 10.1073/pnas.0812889106; Holland EC, 2000, AM J PATHOL, V157, P1031, DOI 10.1016/S0002-9440(10)64615-9; Hsieh J, 2004, P NATL ACAD SCI USA, V101, P16659, DOI 10.1073/pnas.0407643101; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Imayoshi I, 2008, NAT NEUROSCI, V11, P1153, DOI 10.1038/nn.2185; Iwama A, 2004, IMMUNITY, V21, P843, DOI 10.1016/j.immuni.2004.11.004; Jackson EL, 2006, NEURON, V51, P187, DOI 10.1016/j.neuron.2006.06.012; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Janzen V, 2006, NATURE, V443, P421, DOI 10.1038/nature05159; Jaskelioff M, 2011, NATURE, V469, P102, DOI 10.1038/nature09603; Jawerka M, 2010, NEURON GLIA BIOL, V6, P93, DOI 10.1017/S1740925X10000049; Jepsen K, 2007, NATURE, V450, P415, DOI 10.1038/nature06270; Jones DL, 2007, STEM CELL REV, V3, P192, DOI 10.1007/s12015-007-0009-3; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Jude CD, 2007, CELL STEM CELL, V1, P324, DOI 10.1016/j.stem.2007.05.019; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kamminga LM, 2006, BLOOD, V107, P2170, DOI 10.1182/blood-2005-09-3585; Kamminga LM, 2005, STEM CELLS, V23, P82, DOI 10.1634/stemcells.2004-0066; KAPLAN MS, 1984, J NEUROSCI, V4, P1429; Katsumoto T, 2006, GENE DEV, V20, P1321, DOI 10.1101/gad.1393106; Kawahara TLA, 2009, CELL, V136, P62, DOI 10.1016/j.cell.2008.10.052; Kawakami K, 2009, BIOGERONTOLOGY, V10, P415, DOI 10.1007/s10522-008-9176-0; Kee N, 2007, NAT NEUROSCI, V10, P355, DOI 10.1038/nn1847; Kempermann G, 1998, J NEUROSCI, V18, P3206; Kempermann G, 1998, CURR BIOL, V8, P939, DOI 10.1016/S0960-9822(07)00377-6; Kempermann G, 2002, ANN NEUROL, V52, P135, DOI 10.1002/ana.10262; Ketel CS, 2005, MOL CELL BIOL, V25, P6857, DOI 10.1128/MCB.25.16.6857-6868.2005; Kim HS, 2010, CELL METAB, V12, P224, DOI 10.1016/j.cmet.2010.06.009; Kim M, 2003, ANN NY ACAD SCI, V996, P195, DOI 10.1111/j.1749-6632.2003.tb03247.x; Kordon EC, 1998, DEVELOPMENT, V125, P1921; Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Kronenberg G, 2006, NEUROBIOL AGING, V27, P1505, DOI 10.1016/j.neurobiolaging.2005.09.016; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Kukekov VG, 1999, EXP NEUROL, V156, P333, DOI 10.1006/exnr.1999.7028; Kung AL, 2000, GENE DEV, V14, P272; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Lagace DC, 2007, J NEUROSCI, V27, P12623, DOI 10.1523/JNEUROSCI.3812-07.2007; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Lessard J, 2007, NEURON, V55, P201, DOI 10.1016/j.neuron.2007.06.019; LEWIS PD, 1968, NATURE, V217, P974, DOI 10.1038/217974a0; Li J, 2008, PLOS BIOL, V6, P1870, DOI 10.1371/journal.pbio.0060233; Li Y, 2009, HUM MOL GENET, V18, P4897, DOI 10.1093/hmg/ddp459; Liang Y, 2005, BLOOD, V106, P1479, DOI 10.1182/blood-2004-11-4282; Lichtenwalner RJ, 2001, NEUROSCIENCE, V107, P603, DOI 10.1016/S0306-4522(01)00378-5; Lim DA, 2007, NEURO-ONCOLOGY, V9, P424, DOI 10.1215/15228517-2007-023; Lim DA, 2009, NATURE, V458, P529, DOI 10.1038/nature07726; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Liu HK, 2008, GENE DEV, V22, P2473, DOI 10.1101/gad.479308; Liu HK, 2010, GENE DEV, V24, P683, DOI 10.1101/gad.560310; Liu HJ, 2007, SCIENCE, V317, P803, DOI 10.1126/science.1143578; Liu J, 2009, NATURE, V459, P387, DOI 10.1038/nature08040; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Longo VD, 2006, CELL, V126, P257, DOI 10.1016/j.cell.2006.07.002; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Lugert S, 2010, CELL STEM CELL, V6, P445, DOI 10.1016/j.stem.2010.03.017; Ma DKK, 2010, NAT NEUROSCI, V13, P1338, DOI 10.1038/nn.2672; Ma DK, 2009, SCIENCE, V323, P1074, DOI 10.1126/science.1166859; Major MB, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.2000037; Martin C, 2007, CURR OPIN CELL BIOL, V19, P266, DOI 10.1016/j.ceb.2007.04.002; Maslov AY, 2004, J NEUROSCI, V24, P1726, DOI 10.1523/JNEUROSCI.4608-03.2004; Matsuzaki H, 2005, P NATL ACAD SCI USA, V102, P11278, DOI 10.1073/pnas.0502738102; McMahon KA, 2007, CELL STEM CELL, V1, P338, DOI 10.1016/j.stem.2007.07.002; Merkle FT, 2007, SCIENCE, V317, P381, DOI 10.1126/science.1144914; Merson TD, 2006, J NEUROSCI, V26, P11359, DOI 10.1523/JNEUROSCI.2247-06.2006; Michallet M, 2000, EXP HEMATOL, V28, P858, DOI 10.1016/S0301-472X(00)00169-7; Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140; Michishita E, 2008, NATURE, V452, P492, DOI 10.1038/nature06736; Miyamoto K, 2007, CELL STEM CELL, V1, P101, DOI 10.1016/j.stem.2007.02.001; Miyamoto K, 2008, BLOOD, V112, P4485, DOI 10.1182/blood-2008-05-159848; Molofsky AV, 2006, NATURE, V443, P448, DOI 10.1038/nature05091; Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; MONAGHAN AP, 1995, DEVELOPMENT, V121, P839; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Morgan DE, 2010, DEV BIOL, V346, P204, DOI 10.1016/j.ydbio.2010.07.022; Morgan JE, 2003, INT J BIOCHEM CELL B, V35, P1151, DOI 10.1016/S1357-2725(03)00042-6; Morita Y, 2010, J EXP MED, V207, P1173, DOI 10.1084/jem.20091318; Morrison SJ, 2008, CELL, V132, P598, DOI 10.1016/j.cell.2008.01.038; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cb.11.110195.000343; Morrison SJ, 1996, NAT MED, V2, P1011, DOI 10.1038/nm0996-1011; Morshead CM, 1998, DEVELOPMENT, V125, P2251; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; Mostoslavsky R, 2006, CELL, V124, P315, DOI [10.1016/j.cell.2005.11.044, 10.1016/J.CEL.2005.11.044]; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Musaro A, 2004, P NATL ACAD SCI USA, V101, P1206, DOI 10.1073/pnas.0303792101; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Narala SR, 2008, MOL BIOL CELL, V19, P1210, DOI 10.1091/mbc.E07-09-0965; Narita M, 2006, CELL, V126, P503, DOI 10.1016/j.cell.2006.05.052; Nijnik A, 2007, NATURE, V447, P686, DOI 10.1038/nature05875; Nishimura EK, 2005, SCIENCE, V307, P720, DOI 10.1126/science.1099593; Nishino J, 2008, CELL, V135, P227, DOI 10.1016/j.cell.2008.09.017; Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025; Ogawa T, 2000, MECH AGEING DEV, V117, P57, DOI 10.1016/S0047-6374(00)00137-8; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oguro H, 2006, J EXP MED, V203, P2247, DOI 10.1084/jem.20052477; Oguro H, 2010, CELL STEM CELL, V6, P279, DOI 10.1016/j.stem.2010.01.005; OH YH, 1972, LIFE SCI 2-BIOCH GEN, V11, P1207, DOI 10.1016/0024-3205(72)90188-9; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Ou XA, 2011, BLOOD, V117, P440, DOI 10.1182/blood-2010-03-273011; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Paik JH, 2009, CELL STEM CELL, V5, P540, DOI 10.1016/j.stem.2009.09.013; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Parent JM, 1997, J NEUROSCI, V17, P3727; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Park JI, 2009, NATURE, V460, P66, DOI 10.1038/nature08137; Pastrana E, 2009, P NATL ACAD SCI USA, V106, P6387, DOI 10.1073/pnas.0810407106; Pawlikowska L, 2009, AGING CELL, V8, P460, DOI 10.1111/j.1474-9726.2009.00493.x; Pearce DJ, 2007, STEM CELLS, V25, P828, DOI 10.1634/stemcells.2006-0405; Peinado MA, 1998, MICROSC RES TECHNIQ, V43, P34, DOI 10.1002/(SICI)1097-0029(19981001)43:1<34::AID-JEMT6>3.0.CO;2-G; Peleg S, 2010, SCIENCE, V328, P753, DOI 10.1126/science.1186088; Perez-Campo FM, 2009, BLOOD, V113, P4866, DOI 10.1182/blood-2008-04-152017; Prozorovski T, 2008, NAT CELL BIOL, V10, P385, DOI 10.1038/ncb1700; Ramadori G, 2010, CELL METAB, V12, P78, DOI 10.1016/j.cmet.2010.05.010; Rando TA, 2005, NAT MED, V11, P829, DOI 10.1038/nm0805-829; Rando TA, 2006, NATURE, V441, P1080, DOI 10.1038/nature04958; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; Renault V, 2002, AGING CELL, V1, P132, DOI 10.1046/j.1474-9728.2002.00017.x; Renault VM, 2009, CELL STEM CELL, V5, P527, DOI 10.1016/j.stem.2009.09.014; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Rietze RL, 2001, NATURE, V412, P736, DOI 10.1038/35089085; RINE J, 1979, GENETICS, V93, P877; Ringrose L, 2007, DEVELOPMENT, V134, P223, DOI 10.1242/dev.02723; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036; Rossi DJ, 2007, CELL CYCLE, V6, P2371, DOI 10.4161/cc.6.19.4759; Rossi DJ, 2007, NATURE, V447, P725, DOI 10.1038/nature05862; Rossi DJ, 2005, P NATL ACAD SCI USA, V102, P9194, DOI 10.1073/pnas.0503280102; Roy K, 2004, J NEUROSCI, V24, P8333, DOI 10.1523/JNEUROSCI.1148-04.2004; Roy NS, 2000, J NEUROSCI RES, V59, P321, DOI 10.1002/(SICI)1097-4547(20000201)59:3<321::AID-JNR5>3.0.CO;2-9; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Sacco A, 2008, NATURE, V456, P502, DOI 10.1038/nature07384; Sahin E, 2010, NATURE, V464, P520, DOI 10.1038/nature08982; Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Scheller M, 2006, NAT IMMUNOL, V7, P1037, DOI 10.1038/ni1387; SCHULTZ E, 1982, MECH AGEING DEV, V20, P377, DOI 10.1016/0047-6374(82)90105-1; SCHULTZ E, 1978, J EXP ZOOL, V206, P451, DOI 10.1002/jez.1402060314; Sen GL, 2008, GENE DEV, V22, P1865, DOI 10.1101/gad.1673508; Sen GL, 2010, NATURE, V463, P563, DOI 10.1038/nature08683; Sgarra R, 2005, PROTEOMICS, V5, P1494, DOI 10.1002/pmic.200401028; Sgarra R, 2008, PROTEOMICS, V8, P4721, DOI 10.1002/pmic.200800193; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Sharpless NE, 2007, NAT REV MOL CELL BIO, V8, P703, DOI 10.1038/nrm2241; Shen SM, 2008, NAT NEUROSCI, V11, P1024, DOI 10.1038/nn.2172; Shi Y, 2007, NAT REV GENET, V8, P829, DOI 10.1038/nrg2218; Shi YH, 2004, NATURE, V427, P78, DOI 10.1038/nature02211; Shizuru JA, 2005, ANNU REV MED, V56, P509, DOI 10.1146/annurev.med.54.101601.152334; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Siebold AP, 2010, P NATL ACAD SCI USA, V107, P169, DOI 10.1073/pnas.0907739107; Siebzehnrubl FA, 2007, EXP BRAIN RES, V176, P672, DOI 10.1007/s00221-006-0831-x; Song HJ, 2002, NAT NEUROSCI, V5, P438, DOI 10.1038/nn844; Song ZF, 2009, EXP GERONTOL, V44, P75, DOI 10.1016/j.exger.2008.06.009; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Su IH, 2003, NAT IMMUNOL, V4, P124, DOI 10.1038/ni876; Su XH, 2009, CELL STEM CELL, V5, P64, DOI 10.1016/j.stem.2009.04.003; Sudo K, 2000, J EXP MED, V192, P1273, DOI 10.1084/jem.192.9.1273; Sun GQ, 2007, P NATL ACAD SCI USA, V104, P15282, DOI 10.1073/pnas.0704089104; Sun GQ, 2010, MOL CELL BIOL, V30, P1997, DOI 10.1128/MCB.01116-09; Taraldsrud E, 2009, SCAND J CLIN LAB INV, V69, P79, DOI 10.1080/00365510802419447; Thomas T, 2006, GENE DEV, V20, P1175, DOI 10.1101/gad.1382606; Thomas T, 2000, DEVELOPMENT, V127, P2537; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tothova Z, 2007, CELL STEM CELL, V1, P140, DOI 10.1016/j.stem.2007.07.017; Tropepe V, 1997, J NEUROSCI, V17, P7850; Trowbridge Jennifer J, 2010, Epigenetics, V5, P189; Trowbridge JJ, 2009, CELL STEM CELL, V5, P442, DOI 10.1016/j.stem.2009.08.016; Uchida N, 1998, J CLIN INVEST, V101, P961, DOI 10.1172/JCI1681; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; van der Flier LG, 2009, ANNU REV PHYSIOL, V71, P241, DOI 10.1146/annurev.physiol.010908.163145; van der Heide LP, 2005, TRENDS BIOCHEM SCI, V30, P81, DOI 10.1016/j.tibs.2004.12.002; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; VAQUERO A, 2003, SCI AGING KNOWLEDGE, pRE4, DOI DOI 10.1126/SAGEKE.2003.14.RE4; VICK NA, 1977, ACTA NEUROPATHOL, V40, P63, DOI 10.1007/BF00688574; Vidanes GM, 2005, CELL, V121, P973, DOI 10.1016/j.cell.2005.06.013; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Voog J, 2010, CELL STEM CELL, V6, P103, DOI 10.1016/j.stem.2010.01.011; Wagers AJ, 2002, GENE THER, V9, P606, DOI 10.1038/sj.gt.3301717; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Waterstrat Amanda, 2008, P111, DOI 10.1007/978-3-540-73709-4_6; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Wu H, 2010, SCIENCE, V329, P444, DOI 10.1126/science.1190485; Xing ZL, 2006, BLOOD, V108, P2190, DOI 10.1182/blood-2005-12-010272; Yalcin S, 2008, J BIOL CHEM, V283, P25692, DOI 10.1074/jbc.M800517200; Yang XJ, 2007, ONCOGENE, V26, P5310, DOI 10.1038/sj.onc.1210599; Zammit PS, 2002, EXP CELL RES, V281, P39, DOI 10.1006/excr.2002.5653; Zencak D, 2005, J NEUROSCI, V25, P5774, DOI 10.1523/JNEUROSCI.3452-04.2005; Zhang CL, 2008, NATURE, V451, P1004, DOI 10.1038/nature06562; Zhang RL, 2004, J NEUROSCI, V24, P5810, DOI 10.1523/JNEUROSCI.1109-04.2004; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zhao XY, 2003, P NATL ACAD SCI USA, V100, P6777, DOI 10.1073/pnas.1131928100; Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041; Zhu Y, 2005, CANCER CELL, V8, P119, DOI 10.1016/j.ccr.2005.07.004; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	308	82	88	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	28					3105	3126		10.1038/onc.2011.45	http://dx.doi.org/10.1038/onc.2011.45			22	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	792FQ	21441951				2022-12-17	WOS:000292726300001
J	Merlin, J; Stechly, L; de Beauce, S; Monte, D; Leteurtre, E; van Seuningen, I; Huet, G; Pigny, P				Merlin, J.; Stechly, L.; de Beauce, S.; Monte, D.; Leteurtre, E.; van Seuningen, I.; Huet, G.; Pigny, P.			Galectin-3 regulates MUC1 and EGFR cellular distribution and EGFR downstream pathways in pancreatic cancer cells	ONCOGENE			English	Article						pancreatic cancer; galectin-3; MUC1; EGFR; intracellular localization; endocytosis	GROWTH-FACTOR RECEPTOR; NUCLEAR-LOCALIZATION; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; PRIMARY TUMORS; BETA-CATENIN; C-SRC; ENDOCYTOSIS; CARCINOMA; TRAFFICKING	MUC1 is a transmembrane glycoprotein which is typically expressed at the apical membrane of normal epithelial cells. In cancer cells, the over-expression of MUC1 and its aberrant localization around the cell membrane and in the cytoplasm favours its interaction with different protein partners such as epidermal growth factor receptor (EGFR) and can promote tumour proliferation through the activation of oncogenic signalling pathways. Our aims were to study the mechanisms inducing MUC1 cytoplasmic localization in pancreatic cancer cells, and to decipher their impact on EGFR cellular localization and activation. Our results showed that galectin-3, an endogenous lectin, is co-expressed with MUC1 in human pancreatic ductal adenocarcinoma, and that it favours the endocytosis of MUC1 and EGFR. Depletion of galectin-3 by RNA interference increased the interaction between MUC1 and EGFR, EGFR and ERK-1,2 phosphorylation, and translocation of EGFR to the nucleus. On the contrary, silencing of galectin-3 led to a decrease of cyclin-D1 levels and of cell proliferation. The galectin-3-dependent regulation of MUC1/EGFR functions may represent an interesting mechanism modulating the EGFR-stimulated cell growth of pancreatic cancer cells. Oncogene (2010) 30, 2514-2525; doi: 10.1038/onc.2010.631; published online 24 January 2011	[Merlin, J.; Stechly, L.; de Beauce, S.; Leteurtre, E.; van Seuningen, I.; Huet, G.; Pigny, P.] INSERM, U837, Equipe Mucines Differenciat & Cancerogenese Epith, F-59045 Lille, France; [Merlin, J.; Stechly, L.; de Beauce, S.; Leteurtre, E.; van Seuningen, I.; Huet, G.; Pigny, P.] Univ Lille 2, Ctr Rech Jean Pierre Aubert, Lille, France; [Stechly, L.; Huet, G.; Pigny, P.] CHRU, Ctr Biol & Pathol, Lab Biochimie & Hormonol, Lille, France; [Leteurtre, E.] CHRU, Ctr Biol & Pathol, Serv Anat Pathol, Lille, France; [Monte, D.] Univ Lille 1, Ctr Hyperfrequences & Semicond, CNRS, Inst Rech Interdisciplinaire,USR3078, F-59655 Villeneuve Dascq, France	Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille	Pigny, P (corresponding author), INSERM, U837, Equipe Mucines Differenciat & Cancerogenese Epith, Team 5 Pl Verdun, F-59045 Lille, France.	pascal.pigny@inserm.fr	VAN SEUNINGEN, Isabelle/N-6176-2016	VAN SEUNINGEN, Isabelle/0000-0002-3131-2694; monte, didier/0000-0002-0613-6203	Comite du Nord de la Ligue Nationale contre le Cancer; french Ligue Nationale contre le Cancer (comite du Nord); Universite de Lille 2; Region Nord-Pas de Calais	Comite du Nord de la Ligue Nationale contre le Cancer; french Ligue Nationale contre le Cancer (comite du Nord); Universite de Lille 2; Region Nord-Pas de Calais(Region Hauts-de-France)	We acknowledge expert support provided by D Trinel, N Jouy and M Figeac. We thank Professor N Porchet and MP Ducourouble for their constant support; G Grard, E Creme, MH Gevaert, R Siminsky, M Samyn and V Dumetz for their technical assistance. J Merlin is a recipient of a PhD fellowship from the Universite de Lille 2 and Region Nord-Pas de Calais. This work was supported by a grant from the Comite du Nord de la Ligue Nationale contre le Cancer (to PP). This work was supported by a grant from the french Ligue Nationale contre le Cancer (comite du Nord).	Altschuler Y, 2000, MOL BIOL CELL, V11, P819, DOI 10.1091/mbc.11.3.819; Andre S, 2006, BIOORGAN MED CHEM, V14, P6314, DOI 10.1016/j.bmc.2006.05.045; Berberat PO, 2001, J HISTOCHEM CYTOCHEM, V49, P539, DOI 10.1177/002215540104900414; Bitler BG, 2010, J CELL SCI, V123, P1716, DOI 10.1242/jcs.062661; Davidson PJ, 2006, GLYCOBIOLOGY, V16, P602, DOI 10.1093/glycob/cwj088; Delacour D, 2007, TRAFFIC, V8, P379, DOI 10.1111/j.1600-0854.2007.00539.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dumic J, 2006, BBA-GEN SUBJECTS, V1760, P616, DOI 10.1016/j.bbagen.2005.12.020; Elad-Sfadia G, 2004, J BIOL CHEM, V279, P34922, DOI 10.1074/jbc.M312697200; Emlet DR, 1997, J BIOL CHEM, V272, P4079, DOI 10.1074/jbc.272.7.4079; Furtak V, 2001, BIOCHEM BIOPH RES CO, V289, P845, DOI 10.1006/bbrc.2001.6064; Hattrup CL, 2008, ANNU REV PHYSIOL, V70, P431, DOI 10.1146/annurev.physiol.70.113006.100659; Henderson NC, 2006, P NATL ACAD SCI USA, V103, P5060, DOI 10.1073/pnas.0511167103; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Hsu SC, 2007, J BIOL CHEM, V282, P10432, DOI 10.1074/jbc.M610014200; HUANG L, 2003, CANC BIOL THERAP, V2, P1; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; Jonckheere N, 2009, BRIT J CANCER, V101, P637, DOI 10.1038/sj.bjc.6605190; Lahm H, 2000, INT J ONCOL, V17, P519; Langbein S, 2007, HISTOPATHOLOGY, V51, P681, DOI 10.1111/j.1365-2559.2007.02852.x; Leroy X, 2003, UROLOGY, V62, P771, DOI 10.1016/S0090-4295(03)00560-0; Leroy X, 2002, AM J CLIN PATHOL, V118, P47; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; LITVINOV SV, 1993, J BIOL CHEM, V268, P21364; Lo HW, 2006, J CELL BIOCHEM, V98, P1570, DOI 10.1002/jcb.20876; Loukopoulos P, 2004, PANCREAS, V29, P193, DOI 10.1097/00006676-200410000-00004; Maitra A, 2003, MODERN PATHOL, V16, P902, DOI 10.1097/01.MP.0000086072.56290.FB; Monges GM, 1999, AM J CLIN PATHOL, V112, P635; Nakahara S, 2006, J BIOL CHEM, V281, P39649, DOI 10.1074/jbc.M608069200; Nassar H, 2004, MODERN PATHOL, V17, P1045, DOI 10.1038/modpathol.3800166; Ozaki N, 2009, MOL CANCER RES, V7, P1572, DOI 10.1158/1541-7786.MCR-08-0567; Partridge EA, 2004, SCIENCE, V306, P120, DOI 10.1126/science.1102109; Peng W, 2008, CANCER RES, V68, P7228, DOI 10.1158/0008-5472.CAN-08-1245; Perrais M, 2001, J BIOL CHEM, V276, P30923, DOI 10.1074/jbc.M104204200; Pochampalli MR, 2007, ONCOGENE, V26, P1693, DOI 10.1038/sj.onc.1209976; Ramasamy S, 2007, MOL CELL, V27, P992, DOI 10.1016/j.molcel.2007.07.031; Reddish MA, 1998, TUMOR BIOL, V19, P57, DOI 10.1159/000056505; Reis CA, 1998, TUMOR BIOL, V19, P127, DOI 10.1159/000056514; Resat H, 2003, BIOPHYS J, V85, P730, DOI 10.1016/S0006-3495(03)74516-0; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Singh PK, 2006, TRENDS CELL BIOL, V16, P467, DOI 10.1016/j.tcb.2006.07.006; Song SM, 2009, CANCER RES, V69, P1343, DOI 10.1158/0008-5472.CAN-08-4153; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Stechly L, 2009, TRAFFIC, V10, P438, DOI 10.1111/j.1600-0854.2009.00882.x; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; Wang YN, 2010, ONCOGENE, V29, P3997, DOI 10.1038/onc.2010.157; Wang Y, 2007, INT J CANCER, V121, P2716, DOI 10.1002/ijc.22997; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; Yu LG, 2007, J BIOL CHEM, V282, P773, DOI 10.1074/jbc.M606862200; Zhao QC, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-154	53	82	83	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	22					2514	2525		10.1038/onc.2010.631	http://dx.doi.org/10.1038/onc.2010.631			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	771ZE	21258405				2022-12-17	WOS:000291198400003
J	Huynh, C; Segura, MF; Gaziel-Sovran, A; Menendez, S; Darvishian, F; Chiriboga, L; Levin, B; Meruelo, D; Osman, I; Zavadil, J; Marcusson, EG; Hernando, E				Huynh, C.; Segura, M. F.; Gaziel-Sovran, A.; Menendez, S.; Darvishian, F.; Chiriboga, L.; Levin, B.; Meruelo, D.; Osman, I.; Zavadil, J.; Marcusson, E. G.; Hernando, E.			Efficient in vivo microRNA targeting of liver metastasis	ONCOGENE			English	Article						microRNA; melanoma; metastasis; liver; miR-182	ANTISENSE OLIGONUCLEOTIDES; LUNG-CANCER; MELANOMA; THERAPY; CELLS; EXPRESSION; MIR-182; SIRNA; PROGRESSION; PRIMATES	Targeting oncogenic microRNAs ( miRNAs) is emerging as a promising strategy for cancer therapy. In this study, we provide proof of principle for the safety and efficacy of miRNA targeting against metastatic tumors. We tested the impact of targeting miR-182, a pro-metastatic miRNA frequently overexpressed in melanoma, the in vitro silencing of which represses invasion and induces apoptosis. Specifically, we assessed the effect of anti-miR-182 oligo-nucleotides synthesized with 20 sugar modifications and a phosphorothioate backbone in a mouse model of melanoma liver metastasis. Luciferase imaging showed that mice treated with anti-miR-182 had a lower burden of liver metastases compared with control. We confirmed that miR-182 levels were effectively downregulated in the tumors of anti-miR-treated mice compared with tumors of control-treated mice, both in the liver and in the spleen. This effect was accompanied by an upregulation of multiple miR-182 direct targets. Transcriptional profiling of tumors treated with anti-miR-182 or with control oligo-nucleotides revealed an enrichment of genes controlling survival, adhesion and migration modulated in response to anti-miR-182 treatment. These data indicate that in vivo administration of anti-miRs allows for efficient miRNA targeting and concomitant upregulation of miRNA-controlled genes. Our results demonstrate that the use of anti-miR-182 is a promising therapeutic strategy for metastatic melanoma and provide a solid basis for testing similar strategies in human metastatic tumors. Oncogene (2011) 30, 1481-1488; doi:10.1038/onc.2010.523; published online 22 November 2010	[Huynh, C.; Segura, M. F.; Gaziel-Sovran, A.; Menendez, S.; Darvishian, F.; Chiriboga, L.; Levin, B.; Meruelo, D.; Zavadil, J.; Hernando, E.] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; [Huynh, C.] NYU, Sch Med, Dept Med, New York, NY 10016 USA; [Osman, I.] NYU, Sch Med, Dept Dermatol, New York, NY 10016 USA; [Zavadil, J.] NYU, Sch Med, NYU Ctr Hlth Informat & Bioinformat, New York, NY 10016 USA; [Huynh, C.; Segura, M. F.; Gaziel-Sovran, A.; Menendez, S.; Darvishian, F.; Chiriboga, L.; Osman, I.; Hernando, E.] NYU, Sch Med, Interdisciplinary Melanoma Cooperat Grp, New York, NY 10016 USA; [Marcusson, E. G.] Regulus Therapeut Inc, San Diego, CA USA	New York University; New York University; New York University; New York University; New York University; Isis Pharmaceuticals Inc	Hernando, E (corresponding author), NYU, Sch Med, Dept Pathol, 550 1st Ave,Smilow 305, New York, NY 10016 USA.	eva.hernando@med.nyu.edu	Segura, Miguel F/J-4749-2013; Zavadil, Jiri/ABG-1780-2020	Segura, Miguel F/0000-0003-0916-3618; Zavadil, Jiri/0000-0003-0640-5562; Marcusson, Eric/0000-0002-0504-8674; Hernando, Eva/0000-0003-1023-0312; Chiriboga, Luis/0000-0002-2028-6873	ConCerN foundation; Harry Lloyd Charitable Trust; NYU; National Cancer Center; NIH [T32 CA09454-19]; NATIONAL CANCER INSTITUTE [T32CA009454] Funding Source: NIH RePORTER	ConCerN foundation; Harry Lloyd Charitable Trust; NYU; National Cancer Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the NYU Cancer Institute Genomics Facility for array profiling. We are grateful to Dr Cindy Loomis and members of the NYU Histopathology (Tim Macatee) and the Immunohistochemistry Core Laboratories for tissue processing and histological staining, and to Dr Elisa de Stanchina (MSKCC Antitumor Assessment core facility) for mouse blood work. This work was funded by the ConCerN foundation and the Harry Lloyd Charitable Trust. CH is supported by the NYU Physician Scientist Training Program, National Cancer Center Postdoctoral fellowship and the NIH T32 CA09454-19 fellowship training grant. MFS by a National Cancer Center Postdoctoral fellowship.	Bandres E, 2007, ONCOL REP, V17, P1089; Brown BD, 2007, NAT BIOTECHNOL, V25, P1457, DOI 10.1038/nbt1372; Camacho LH, 2009, J CLIN ONCOL, V27, P1075, DOI 10.1200/JCO.2008.19.2435; Chi KN, 2008, CLIN CANCER RES, V14, P833, DOI 10.1158/1078-0432.CCR-07-1310; Chijiwa Tsuyoshi, 2009, Int J Oncol, V34, P5; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956; Davis S, 2009, NUCLEIC ACIDS RES, V37, P70, DOI 10.1093/nar/gkn904; de Fougerolles A, 2007, NAT REV DRUG DISCOV, V6, P443, DOI 10.1038/nrd2310; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Devi GR, 2006, CANCER GENE THER, V13, P819, DOI 10.1038/sj.cgt.7700931; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Esau C, 2006, CELL METAB, V3, P87, DOI 10.1016/j.cmet.2006.01.005; Garbe C, 2009, CLIN DERMATOL, V27, P3, DOI 10.1016/j.clindermatol.2008.09.001; Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791; Guttilla IK, 2009, J BIOL CHEM, V284, P23204, DOI 10.1074/jbc.M109.031427; Hau P, 2009, EXPERT REV ANTICANC, V9, P1663, DOI [10.1586/era.09.138, 10.1586/ERA.09.138]; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jansen B, 2000, LANCET, V356, P1728, DOI 10.1016/S0140-6736(00)03207-4; Jemal A, 2008, JNCI-J NATL CANCER I, V100, P1672, DOI 10.1093/jnci/djn389; Jiang LL, 2010, AM J PATHOL, V177, P29, DOI 10.2353/ajpath.2010.090812; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Krumschnabel G, 2009, ONCOGENE, V28, P3093, DOI 10.1038/onc.2009.173; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lanford RE, 2010, SCIENCE, V327, P198, DOI 10.1126/science.1178178; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Ma L, 2010, NAT BIOTECHNOL, V28, P341, DOI 10.1038/nbt.1618; Paschos KA, 2010, HEPATOL RES, V40, P83, DOI 10.1111/j.1872-034X.2009.00578.x; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Rubin Krista M, 2009, Oncology (Williston Park), V23, P13; Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tolcher AW, 2002, CLIN CANCER RES, V8, P2530; Tong AW, 2008, CANCER GENE THER, V15, P341, DOI 10.1038/cgt.2008.8; Trang P, 2010, ONCOGENE, V29, P1580, DOI 10.1038/onc.2009.445; Treisman J, 2010, CLIN PLAST SURG, V37, P127, DOI 10.1016/j.cps.2009.07.008; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Valastyan S, 2009, RNA BIOL, V6, P541, DOI 10.4161/rna.6.5.10081; Valastyan S, 2009, CELL CYCLE, V8, P3506, DOI 10.4161/cc.8.21.9802; Wiggins JF, 2010, CANCER RES, V70, P5923, DOI 10.1158/0008-5472.CAN-10-0655; Xu SB, 2007, J BIOL CHEM, V282, P25053, DOI 10.1074/jbc.M700501200; Yang H, 2010, CANCER RES, V70, P5518, DOI 10.1158/0008-5472.CAN-10-0646	43	82	88	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	12					1481	1488		10.1038/onc.2010.523	http://dx.doi.org/10.1038/onc.2010.523			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	739UM	21102518				2022-12-17	WOS:000288743800010
J	Di Marcotullio, L; Greco, A; Mazza, D; Canettieri, G; Pietrosanti, L; Infante, P; Coni, S; Moretti, M; De Smaele, E; Ferretti, E; Screpanti, I; Gulino, A				Di Marcotullio, L.; Greco, A.; Mazza, D.; Canettieri, G.; Pietrosanti, L.; Infante, P.; Coni, S.; Moretti, M.; De Smaele, E.; Ferretti, E.; Screpanti, I.; Gulino, A.			Numb activates the E3 ligase Itch to control Gli1 function through a novel degradation signal	ONCOGENE			English	Article						Hedgehog; Gli1; Itch; Numb; ubiquitination; medulloblastoma	UBIQUITIN-PROTEIN LIGASE; WW DOMAINS; IN-VITRO; MEDULLOBLASTOMA; TARGETS; PROLIFERATION; ENZYME; FAMILY; PHOSPHORYLATION; TRANSCRIPTION	Hedgehog pathway regulates tissue patterning and cell proliferation. Gli1 transcription factor is the major effector of Hedgehog signaling and its deregulation is often associated to medulloblastoma formation. Proteolytic processes represent a critical mechanism by which this pathway is turned off. Here, we characterize the regulation of an ubiquitin-mediated mechanism of Gli1 degradation, promoted by the coordinated action of the E3 ligase Itch and the adaptor protein Numb. We show that Numb activates the catalytic activity of Itch, releasing it from an inhibitory intramolecular interaction between its homologous to E6-AP C-terminus and WW domains. The consequent activation of Itch, together with the recruitment of Gli1 through direct binding with Numb, allows Gli1 to enter into the complex, resulting in Gli1 ubiquitination and degradation. This process is mediated by a novel Itch-dependent degron, composed of a combination of two PPXYs and a phospho-serine/proline motifs, localized in Gli1 C-terminal region, indicating the role of two different WW docking sites in Gli1 ubiquitination. Remarkably, Gli1 protein mutated in these modules is no longer regulated by Itch and Numb, and determines enhanced Gli1-dependent medulloblastoma growth, migration and invasion abilities, as well as in vitro transforming activity. Our data reveal a novel mechanism of regulation of Gli1 stability and function, which influences Hedgehog/Gli1 oncogenic potential. Oncogene (2011) 30, 65-76; doi: 10.1038/onc.2010.394; published online 6 September 2010	[Moretti, M.; De Smaele, E.; Ferretti, E.; Gulino, A.] Univ Roma La Sapienza, Dept Expt Med, I-00161 Rome, Italy; [Di Marcotullio, L.; Greco, A.; Mazza, D.; Canettieri, G.; Pietrosanti, L.; Infante, P.; Coni, S.; Screpanti, I.; Gulino, A.] Univ Roma La Sapienza, Dept Mol Med, I-00161 Rome, Italy; [Screpanti, I.; Gulino, A.] Univ Roma La Sapienza, Inst Pasteur, Cenci Bolognetti Fdn, I-00161 Rome, Italy; [Gulino, A.] Neuromed Inst, Pozzilli, Italy	Sapienza University Rome; Sapienza University Rome; Fondazione Cenci Bolognetti; Sapienza University Rome; IRCCS Neuromed	Gulino, A (corresponding author), Univ Roma La Sapienza, Dept Expt Med, 324 Viale Regina Elena, I-00161 Rome, Italy.	alberto.gulino@uniroma1.it	Infante, Paola/G-9094-2018; De Smaele, Enrico/C-1124-2013; Mazzà, Daniela/AAK-3687-2021; Moretti, Marta/AAQ-7090-2020; Ferretti, Elisabetta/G-5413-2013	De Smaele, Enrico/0000-0003-4524-4423; Mazzà, Daniela/0000-0003-4754-9394; Infante, Paola/0000-0003-0682-3916; CANETTIERI, Gianluca/0000-0001-6694-2613; Ferretti, Elisabetta/0000-0001-7265-6429; DI MARCOTULLIO, LUCIA/0000-0003-0274-7178	Associazione Italiana per la Ricerca sul Cancro (AIRC); Telethon [GGP07118]; Ministry of University and Research, (FIRB); Ministry of Health, Fondazione Roma and Fondazione Mariani	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Telethon(Fondazione Telethon); Ministry of University and Research, (FIRB)(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); Ministry of Health, Fondazione Roma and Fondazione Mariani	We thank Dr A Oro for providing the various Gli1 mutants and G Giannini for advice and critical discussion. This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), Telethon Grant GGP07118 and the Ministry of University and Research, (FIRB), the Ministry of Health, Fondazione Roma and Fondazione Mariani.	Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Argenti B, 2005, J NEUROSCI, V25, P8338, DOI 10.1523/JNEUROSCI.2438-05.2005; Bar EE, 2007, AM J PATHOL, V170, P347, DOI 10.2353/ajpath.2007.060066; Bedford MT, 2000, J BIOL CHEM, V275, P10359, DOI 10.1074/jbc.275.14.10359; Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001; Boname JM, 2001, IMMUNITY, V15, P627, DOI 10.1016/S1074-7613(01)00213-8; Canettieri G, 2010, NAT CELL BIOL, V12, P132, DOI 10.1038/ncb2013; Canettieri G, 2009, P NATL ACAD SCI USA, V106, P1445, DOI 10.1073/pnas.0808749106; Cayouette M, 2002, NAT NEUROSCI, V5, P1265, DOI 10.1038/nn1202-1265; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; Di Marcotullio L, 2004, P NATL ACAD SCI USA, V101, P10833, DOI 10.1073/pnas.0400690101; Di Marcotullio L, 2006, NAT CELL BIOL, V8, P1415, DOI 10.1038/ncb1510; Espanel X, 1999, J BIOL CHEM, V274, P17284, DOI 10.1074/jbc.274.24.17284; Fang DY, 2004, P NATL ACAD SCI USA, V101, P14782, DOI 10.1073/pnas.0404445101; Fang DY, 2002, NAT IMMUNOL, V3, P281, DOI 10.1038/ni763; Gallagher E, 2006, P NATL ACAD SCI USA, V103, P1717, DOI 10.1073/pnas.0510664103; Galvin KE, 2008, STEM CELLS, V26, P1027, DOI 10.1634/stemcells.2007-0879; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Guerreiro AS, 2008, CLIN CANCER RES, V14, P6761, DOI 10.1158/1078-0432.CCR-08-0385; Gulino A, 2010, EXP CELL RES, V316, P900, DOI 10.1016/j.yexcr.2009.11.017; Haas AL, 1997, FASEB J, V11, P1257; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Huntzicker EG, 2006, GENE DEV, V20, P276, DOI 10.1101/gad.1380906; Ikeda A, 2003, J VIROL, V77, P5529, DOI 10.1128/JVI.77.9.5529-5534.2003; Ingham PW, 2006, NAT REV GENET, V7, P841, DOI 10.1038/nrg1969; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Jia JH, 2005, DEV CELL, V9, P819, DOI 10.1016/j.devcel.2005.10.006; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Kimura H, 2005, ONCOGENE, V24, P4026, DOI 10.1038/sj.onc.1208567; Laner-Plamberger S, 2009, ONCOGENE, V28, P1639, DOI 10.1038/onc.2009.10; Liu YC, 2004, ANNU REV IMMUNOL, V22, P81, DOI 10.1146/annurev.immunol.22.012703.104813; Lohr NJ, 2010, AM J HUM GENET, V86, P447, DOI 10.1016/j.ajhg.2010.01.028; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; Melino G, 2008, CELL DEATH DIFFER, V15, P1103, DOI 10.1038/cdd.2008.60; Mouchantaf R, 2006, J BIOL CHEM, V281, P38738, DOI 10.1074/jbc.M605959200; Mund T, 2009, EMBO REP, V10, P501, DOI 10.1038/embor.2009.30; Omerovic J, 2007, FASEB J, V21, P2849, DOI 10.1096/fj.06-7925com; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Shembade N, 2008, NAT IMMUNOL, V9, P254, DOI 10.1038/ni1563; Sudol M, 2005, IUBMB LIFE, V57, P773, DOI 10.1080/15216540500389039; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Traweger A, 2002, J BIOL CHEM, V277, P10201, DOI 10.1074/jbc.M111384200; Van Sant C, 2001, P NATL ACAD SCI USA, V98, P8815, DOI 10.1073/pnas.161283098; Welchman RL, 2005, NAT REV MOL CELL BIO, V6, P599, DOI 10.1038/nrm1700; Zhang Q, 2006, DEV CELL, V10, P719, DOI 10.1016/j.devcel.2006.05.004	55	82	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	1					65	76		10.1038/onc.2010.394	http://dx.doi.org/10.1038/onc.2010.394			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	703EQ	20818436				2022-12-17	WOS:000285959300006
J	Draheim, KM; Chen, HB; Tao, Q; Moore, N; Roche, M; Lyle, S				Draheim, K. M.; Chen, H-B; Tao, Q.; Moore, N.; Roche, M.; Lyle, S.			ARRDC3 suppresses breast cancer progression by negatively regulating integrin beta 4	ONCOGENE			English	Article						ARRDC3; breast cancer; integrin beta 4; TLIMP	ALPHA-6-BETA-4 INTEGRIN; CARCINOMA-CELLS; SIGNALING PATHWAYS; EPIDERMAL-GROWTH; MIGRATING CELLS; TUMOR-GROWTH; RECEPTOR; ENDOCYTOSIS; INVASION; PROTEIN	Large-scale genetic analyses of human tumor samples have been used to identify novel oncogenes, tumor suppressors and prognostic factors, but the functions and molecular interactions of many individual genes have not been determined. In this study we examined the cellular effects and molecular mechanism of the arrestin family member, ARRDC3, a gene preferentially lost in a subset of breast cancers. Oncomine data revealed that the expression of ARRDC3 decreases with tumor grade, metastases and recurrences. ARRDC3 overexpression represses cancer cell proliferation, migration, invasion, growth in soft agar and in vivo tumorigenicity, whereas downregulation of ARRCD3 has the opposite effects. Mechanistic studies showed that ARRDC3 functions in a novel regulatory pathway that controls the cell surface adhesion molecule, beta-4 integrin (ITG beta 4), a protein associated with aggressive tumor behavior. Our data indicates ARRDC3 directly binds to a phosphorylated form of ITG beta 4 leading to its internalization, ubiquitination and ultimate degradation. The results identify the ARRCD3-ITG beta 4 pathway as a new therapeutic target in breast cancer and show the importance of connecting genetic arrays with mechanistic studies in the search for new treatments. Oncogene (2010) 29, 5032-5047; doi:10.1038/onc.2010.250; published online 5 July 2010	[Draheim, K. M.; Chen, H-B; Moore, N.; Roche, M.; Lyle, S.] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; [Tao, Q.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Beth Israel Deaconess Medical Center	Lyle, S (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, 364 Plantat St,LRB 411, Worcester, MA 01605 USA.	stephen.lyle@umassmed.edu		Roche, Michael/0000-0001-8064-3556	National Cancer Institute of the National Institutes of Health [CA118916]; Worcester Foundation for Biotechnology Research; NATIONAL CANCER INSTITUTE [R01CA118916] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Worcester Foundation for Biotechnology Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funding: this work was supported by the National Cancer Institute of the National Institutes of Health (grant number CA118916) and The Worcester Foundation for Biotechnology Research (SRL).	Adelaide J, 2007, CANCER RES, V67, P11565, DOI 10.1158/0008-5472.CAN-07-2536; Alvarez CE, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-222; Arnaout MA, 2005, ANNU REV CELL DEV BI, V21, P381, DOI 10.1146/annurev.cellbio.21.090704.151217; Aubry L, 2009, CURR GENOMICS, V10, P133, DOI 10.2174/138920209787847014; Baril P, 2007, ONCOGENE, V26, P2082, DOI 10.1038/sj.onc.1210009; Bhandari D, 2007, J BIOL CHEM, V282, P36971, DOI 10.1074/jbc.M705085200; Buchanan FG, 2006, P NATL ACAD SCI USA, V103, P1492, DOI 10.1073/pnas.0510562103; Caswell P, 2008, TRENDS CELL BIOL, V18, P257, DOI 10.1016/j.tcb.2008.03.004; Caswell PT, 2006, TRAFFIC, V7, P14, DOI 10.1111/j.1600-0854.2005.00362.x; Chen M, 2009, J BIOL CHEM, V284, P1484, DOI 10.1074/jbc.M803997200; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Diaz LK, 2005, MODERN PATHOL, V18, P1165, DOI 10.1038/modpathol.3800411; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Dutta U, 2008, CANCER RES, V68, P8779, DOI 10.1158/0008-5472.CAN-08-2125; Ezratty EJ, 2009, J CELL BIOL, V187, P733, DOI 10.1083/jcb.200904054; FALCIONI R, 1989, MOL CARCINOGEN, V2, P361, DOI 10.1002/mc.2940020611; Fuchs E, 1997, CURR OPIN GENET DEV, V7, P672, DOI 10.1016/S0959-437X(97)80016-0; Gagnoux-Palacios L, 2003, J CELL BIOL, V162, P1189, DOI 10.1083/jcb.200305006; Germain EC, 2009, MOL BIOL CELL, V20, P56, DOI 10.1091/mbc.E08-06-0646; Gurevich EV, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-9-236; Hemler ME, 2001, DEV CELL, V1, P728, DOI 10.1016/S1534-5807(01)00102-2; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kendall RT, 2009, CELL MOL LIFE SCI, V66, P2953, DOI 10.1007/s00018-009-0088-1; LEE EC, 1992, J CELL BIOL, V117, P671, DOI 10.1083/jcb.117.3.671; Li TT, 2009, MOL CANCER RES, V7, P1064, DOI 10.1158/1541-7786.MCR-08-0578; Lipscomb EA, 2005, CANCER RES, V65, P10970, DOI 10.1158/0008-5472.CAN-05-2327; Lipscomb EA, 2005, CANCER METAST REV, V24, P413, DOI 10.1007/s10555-005-5133-4; Lipscomb EA, 2003, CLIN EXP METASTAS, V20, P569, DOI 10.1023/A:1025819521707; Lu S, 2008, CLIN CANCER RES, V14, P1050, DOI 10.1158/1078-0432.CCR-07-4116; Luttrell LM, 2002, J CELL SCI, V115, P455; Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Nikolopoulos SN, 2004, CANCER CELL, V6, P471, DOI 10.1016/j.ccr.2004.09.029; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; Oka S, 2006, ENDOCRINOLOGY, V147, P733, DOI 10.1210/en.2005-0679; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Rabinovitz I, 2004, MOL CELL BIOL, V24, P4351, DOI 10.1128/MCB.24.10.4351-4360.2004; Rabinovitz I, 1996, BIOCHEM CELL BIOL, V74, P811, DOI 10.1139/o96-087; Raghuwanshi SK, 2008, J IMMUNOL, V180, P5699, DOI 10.4049/jimmunol.180.8.5699; Rakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748; Rakha EA, 2009, PATHOLOGY, V41, P40, DOI 10.1080/00313020802563510; Raymond K, 2007, MOL BIOL CELL, V18, P4210, DOI 10.1091/mbc.E06-08-0720; Santoro MM, 2003, DEV CELL, V5, P257, DOI 10.1016/S1534-5807(03)00201-6; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Shi F, 2008, J CELL SCI, V121, P2360, DOI 10.1242/jcs.014977; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289; Vicente-Manzanares M, 2009, J CELL SCI, V122, P199, DOI 10.1242/jcs.018564; Voduc D, 2008, CLIN BREAST CANCER, V8, pS171, DOI 10.3816/CBC.2008.s.014; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; Wilhelmsen K, 2006, MOL CELL BIOL, V26, P2877, DOI 10.1128/MCB.26.8.2877-2886.2006; Wilhelmsen K, 2007, MOL BIOL CELL, V18, P3512, DOI 10.1091/mbc.E07-04-0306; Yoon SO, 2005, CANCER RES, V65, P2761, DOI 10.1158/0008-5472.CAN-04-4122; Zhang ZP, 2009, CELL SIGNAL, V21, P1195, DOI 10.1016/j.cellsig.2009.03.010	56	82	85	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	36					5032	5047		10.1038/onc.2010.250	http://dx.doi.org/10.1038/onc.2010.250			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	647LN	20603614	Green Published, hybrid			2022-12-17	WOS:000281620100004
J	Munro, S; Khaire, N; Inche, A; Carr, S; La Thangue, NB				Munro, S.; Khaire, N.; Inche, A.; Carr, S.; La Thangue, N. B.			Lysine methylation regulates the pRb tumour suppressor protein	ONCOGENE			English	Article						tumour suppressor; pRb; lysine methylation; Set7/9; HP1	RETINOBLASTOMA GENE-PRODUCT; CELL-CYCLE CONTROL; TRANSCRIPTION FACTOR; HISTONE METHYLATION; MUSCLE-CELLS; IN-VIVO; DIFFERENTIATION; E2F; ACETYLATION; BINDING	The pRb tumour suppressor protein has a central role in coordinating early cell cycle progression. An important level of control imposed on pRb occurs through post-translational modi. cation, for example, phosphorylation. We describe here a new level of regulation on pRb, mediated through the targeted methylation of lysine residues, by the methyltransferase Set7/9. Set7/9 methylates the C-terminal region of pRb, both in vitro and in cells, and methylated pRb interacts with heterochromatin protein HP1. pRb methylation is required for pRb-dependent cell cycle arrest and transcriptional repression, as well as pRb-dependent differentiation. Our results indicate that methylation can influence the properties of pRb, and raise the interesting possibility that methylation modulates pRb tumour suppressor activity. Oncogene (2010) 29, 2357-2367; doi:10.1038/onc.2009.511; published online 8 February 2010	[Munro, S.; Khaire, N.; Inche, A.; Carr, S.; La Thangue, N. B.] Univ Oxford, Canc Biol Lab, Dept Clin Pharmacol, Div Med Sci, Oxford OX3 7DQ, England	University of Oxford	La Thangue, NB (corresponding author), Univ Oxford, Canc Biol Lab, Dept Clin Pharmacol, Div Med Sci, Old Rd Campus Res Bldg,Old Rd Campus, Oxford OX3 7DQ, England.	Nick.LaThangue@clinpharm.ox.ac.uk			CRUK; EU; LRF; MRC; AICR; MRC [G9400953, G0500905] Funding Source: UKRI; Medical Research Council [G0500905, G9400953] Funding Source: researchfish	CRUK(Cancer Research UK); EU(European Commission); LRF; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); AICR; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank the CRUK, EU, LRF, MRC and AICR for supporting this work and R Williams for assistance in preparing the paper.	BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chen TT, 2000, MOL CELL BIOL, V20, P5571, DOI 10.1128/MCB.20.15.5571-5580.2000; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Fry CJ, 1997, MOL CELL BIOL, V17, P1966, DOI 10.1128/MCB.17.4.1966; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Hediger F, 2006, CURR OPIN GENET DEV, V16, P143, DOI 10.1016/j.gde.2006.02.013; Hub MS, 2004, J CELL BIOL, V166, P865, DOI 10.1083/jcb.200403004; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kinkade R, 2008, CANCER RES, V68, P3810, DOI 10.1158/0008-5472.CAN-07-6672; Kouskouti A, 2004, MOL CELL, V14, P175, DOI 10.1016/S1097-2765(04)00182-0; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kurash JK, 2008, MOL CELL, V29, P392, DOI 10.1016/j.molcel.2007.12.025; LEE SW, 1992, BIOCHIM BIOPHYS ACTA, V1135, P115, DOI 10.1016/0167-4889(92)90126-V; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Markham D, 2006, EMBO REP, V7, P192, DOI 10.1038/sj.embor.7400591; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Sherr CJ, 2000, CANCER RES, V60, P3689; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; Stevens C, 2003, ARCH BIOCHEM BIOPHYS, V412, P157, DOI 10.1016/S0003-9861(03)00054-7; Subramanian K, 2008, MOL CELL, V30, P336, DOI 10.1016/j.molcel.2008.03.022; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; THORBURN AM, 1993, MOL BIOL CELL, V4, P705, DOI 10.1091/mbc.4.7.705; van den Heuvel S, 2008, NAT REV MOL CELL BIO, V9, P713, DOI 10.1038/nrm2469; Vandromme M, 2008, MOL CANCER RES, V6, P418, DOI 10.1158/1541-7786.MCR-07-0381; Wang J, 1997, CANCER RES, V57, P351; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; Wilson JR, 2002, CELL, V111, P105, DOI 10.1016/S0092-8674(02)00964-9; Xiao B, 2003, CURR OPIN STRUC BIOL, V13, P699, DOI 10.1016/j.sbi.2003.10.003; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zalmas LP, 2008, EMBO REP, V9, P252, DOI 10.1038/sj.embor.7401158; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	46	82	87	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	16					2357	2367		10.1038/onc.2009.511	http://dx.doi.org/10.1038/onc.2009.511			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	586YK	20140018				2022-12-17	WOS:000276951500005
J	Bouteille, N; Driouch, K; El Hage, P; Sin, S; Formstecher, E; Camonis, J; Lidereau, R; Lallemand, F				Bouteille, N.; Driouch, K.; El Hage, P.; Sin, S.; Formstecher, E.; Camonis, J.; Lidereau, R.; Lallemand, F.			Inhibition of the Wnt/beta-catenin pathway by the WWOX tumor suppressor protein	ONCOGENE			English	Article						WWOX; dishevelled; Wnt; beta-catenin; signaling pathway	CHROMOSOMAL FRAGILE SITE; WNT SIGNALING PATHWAY; KINASE-I-EPSILON; CANCER CELL-GROWTH; BREAST-CANCER; BETA-CATENIN; BINDING PROTEIN; GENE WWOX; C-JUN; EXPRESSION	The WWOX gene encodes a candidate tumor suppressor protein (WWOX) implicated in a variety of human diseases such as cancer. To better understand the molecular mechanisms of WWOX action, we investigated novel partners of this protein. Using the two-hybrid system and a coimmunoprecipitation assay, we observed a physical association between WWOX and the Dishevelled protein (Dvl) family signaling elements involved in the Wnt/beta-catenin pathway. We found that enforced WWOX expression inhibited, and inhibition of endogenous WWOX expression stimulated the transcriptional activity of the Wnt/beta-catenin pathway. Inhibition of endogenous WWOX expression also enhanced the effect of Wnt-3a on beta-catenin stability. Moreover, we observed the sequestration of Dvl-2 wild type and Dvl-2NESm, a mutated form of Dvl-2 predominantly localized in the nucleus, in the cytoplasm compartment by WWOX. Our results indicate that WWOX is a novel inhibitor of the Wnt/beta-catenin pathway. WWOX would act, at least in part, by preventing the nuclear import of the Dvl proteins. Oncogene (2009) 28, 2569-2580; doi: 10.1038/onc.2009.120; published online 25 May 2009	[Lallemand, F.] Ctr Rene Huguenin, Serv Oncogenet, INSERM, U528,FNCLCC, F-92210 St Cloud, France; [Bouteille, N.; Driouch, K.; El Hage, P.; Sin, S.; Lidereau, R.; Lallemand, F.] INSERM, U735, St Cloud, France; [Formstecher, E.] Hybrigenics, Paris, France; [Camonis, J.] Inst Curie, INSERM, U528, Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Rene Huguenin Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Lallemand, F (corresponding author), Ctr Rene Huguenin, Serv Oncogenet, INSERM, U528,FNCLCC, 35 Rue Dailly, F-92210 St Cloud, France.	f.lallemand@stcloud-huguenin.org			GenHomme Network [02490-6088]; Institut Curie	GenHomme Network; Institut Curie	We are grateful to Dr Trevor Dale for donating HA-Dvl-2 (mouse) expression vector, Dr Akira Kikuchi for donating pCCN/Dvl-1 (human) and pEF-BOS-myc/Dvl-3 (human) plasmids, Dr Howe PH for donating pCDNA3-myc/Axin (human) and Dr Shinji Takada for donating mouse. broblast L cells producing Wnt-3a and Lcells stably transfected with the pGKneo plasmid. We thank Ivan Bieche and Christian Gespash for useful comments, Florence Copigny and Cedrick Lefol for excellent technical assistance, and Philippe Leclerc (IFR 93, kremelin Bicetre, France) for immunofluorescence analysis. This work was supported by a GenHomme Network Grant (02490-6088) to Hybrigenics and Institut Curie. We thank all the Hybrigenics staff for their contribution and the staff of the Drosoman laboratory, headed by Jacques Camonis and supported by Institut Curie.	Aqeilan RI, 2007, CANCER RES, V67, P5606, DOI 10.1158/0008-5472.CAN-07-1081; Aqeilan RI, 2007, P NATL ACAD SCI USA, V104, P3949, DOI 10.1073/pnas.0609783104; Aqeilan RI, 2005, CANCER RES, V65, P6764, DOI 10.1158/0008-5472.CAN-05-1150; Aqeilan RI, 2004, P NATL ACAD SCI USA, V101, P4401, DOI 10.1073/pnas.0400805101; Aqeilan RI, 2004, CANCER RES, V64, P8256, DOI 10.1158/0008-5472.CAN-04-2055; Aqeilian RI, 2007, CANCER RES, V67, P9330, DOI 10.1158/0008-5472.CAN-07-2147; Bednarek AK, 2000, CANCER RES, V60, P2140; Bednarek AK, 2001, CANCER RES, V61, P8068; Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065; Brown AMC, 2001, BREAST CANCER RES, V3, P351, DOI 10.1186/bcr321; Chang NS, 2005, ONCOGENE, V24, P714, DOI 10.1038/sj.onc.1208124; Chang NS, 2001, J BIOL CHEM, V276, P3361, DOI 10.1074/jbc.M007140200; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cong F, 2004, MOL CELL BIOL, V24, P2000, DOI 10.1128/MCB.24.5.2000-2011.2004; Davidson G, 2005, NATURE, V438, P867, DOI 10.1038/nature04170; Driouch K, 2002, ONCOGENE, V21, P1832, DOI 10.1038/sj.onc.1205273; Fabbri M, 2005, P NATL ACAD SCI USA, V102, P15611, DOI 10.1073/pnas.0505485102; Gan XQ, 2008, J CELL BIOL, V180, P1087, DOI 10.1083/jcb.200710050; Gaudio E, 2006, CANCER RES, V66, P11585, DOI 10.1158/0008-5472.CAN-06-3376; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; Guler G, 2005, PATHOL INT, V55, P471, DOI 10.1111/j.1440-1827.2005.01855.x; Guler G, 2004, CANCER, V100, P1605, DOI 10.1002/cncr.20137; HERBER B, 1994, ONCOGENE, V9, P1295; Hezova Renata, 2007, Biomedical Papers (Olomouc), V151, P11; Hino S, 2003, J BIOL CHEM, V278, P14066, DOI 10.1074/jbc.M213265200; Hino SI, 2001, MOL CELL BIOL, V21, P330, DOI 10.1128/MCB.21.1.330-342.2001; Iliopoulos D, 2005, ONCOGENE, V24, P1625, DOI 10.1038/sj.onc.1208398; Iliopoulos D, 2007, CLIN CANCER RES, V13, P268, DOI 10.1158/1078-0432.CCR-06-2038; Ishii H, 2003, MOL CANCER RES, V1, P940; Itoh Keiji, 2005, J Biol, V4, P3, DOI 10.1186/jbiol20; Kadoya T, 2000, J BIOL CHEM, V275, P37030, DOI 10.1074/jbc.M005984200; Kikuchi A, 2006, EXP MOL MED, V38, P1, DOI 10.1038/emm.2006.1; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Klimowski LK, 2006, FEBS J, V273, P4594, DOI 10.1111/j.1742-4658.2006.05462.x; Kuroki T, 2004, CLIN CANCER RES, V10, P2459, DOI 10.1158/1078-0432.CCR-03-0096; Lallemand F, 2005, J BIOL CHEM, V280, P27645, DOI 10.1074/jbc.M500188200; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Ludes-Meyers JH, 2004, ONCOGENE, V23, P5049, DOI 10.1038/sj.onc.1207680; Ludes-Meyers JH, 2003, CYTOGENET GENOME RES, V100, P101, DOI 10.1159/000072844; Ludes-Meyers JH, 2007, GENE CHROMOSOME CANC, V46, P1129, DOI 10.1002/gcc.20497; Mangelsdorf M, 2000, CANCER RES, V60, P1683; Nunez M, 2005, BREAST CANCER RES TR, V89, P99, DOI 10.1007/s10549-004-1474-x; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Paige AJW, 2000, CANCER RES, V60, P1690; Pimenta FJ, 2006, INT J CANCER, V118, P1154, DOI 10.1002/ijc.21446; Pluciennik E, 2006, EJSO-EUR J SURG ONC, V32, P153, DOI 10.1016/j.ejso.2005.11.002; Polakis P, 2000, GENE DEV, V14, P1837; Qin HR, 2007, MOL CANCER RES, V5, P957, DOI 10.1158/1541-7786.MCR-07-0211; Rain JC, 2001, NATURE, V409, P211, DOI 10.1038/35051615; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; Shibamoto S, 1998, GENES CELLS, V3, P659; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Torres MA, 2000, J CELL BIOL, V149, P1433, DOI 10.1083/jcb.149.7.1433; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Wang X, 2009, TUMOR BIOL, V30, P8, DOI 10.1159/000197911; Watanabe A, 2003, CANCER RES, V63, P8629; Wharton KA, 2003, DEV BIOL, V253, P1, DOI 10.1006/dbio.2002.0869; Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006; Yokoyama Noriko, 2007, J Mol Signal, V2, P11, DOI 10.1186/1750-2187-2-11; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185; Zeng X, 2008, DEVELOPMENT, V135, P367, DOI 10.1242/dev.013540	63	82	85	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2009	28	28					2569	2580		10.1038/onc.2009.120	http://dx.doi.org/10.1038/onc.2009.120			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	471LJ	19465938				2022-12-17	WOS:000268058900003
J	Liu, Y; Borchert, GL; Surazynski, A; Phang, JM				Liu, Y.; Borchert, G. L.; Surazynski, A.; Phang, J. M.			Proline oxidase, a p53-induced gene, targets COX-2/PGE(2) signaling to induce apoptosis and inhibit tumor growth in colorectal cancers	ONCOGENE			English	Article						proline oxidase; COX-2; signaling cross talk; colorectal cancer; tumor suppressor	FACTOR RECEPTOR; COLON-CANCER; POSTTRANSCRIPTIONAL CONTROL; CYCLOOXYGENASE-2; EXPRESSION; CARCINOGENESIS; PATHWAY; OXYGEN; CELLS; CHEMOPREVENTION	Proline oxidase (POX), a flavoenzyme localized at the inner mitochondrial membrane, catalyzes the first step of proline degradation by converting proline to pyrroline-5-carboxylate (P5C). POX is markedly elevated during p53-induced apoptosis and generates proline-dependent reactive oxygen species (ROS), specifically superoxide radicals, to induce apoptosis through both mitochondrial and death receptor pathways. These previous studies also showed suppression of the mitogen-activated protein kinase pathway leading us to broaden our exploration of proliferative signaling. In our current report, we used DLD-1 colorectal cancer cells stably transfected with the POX gene under the control of a tetracycline-inducible promoter and found that three pathways which cross talk with each other were downregulated by POX: the cyclooxygenase-2(COX-2) pathway, the epidermal growth factor receptor (EGFR) pathway and the Wnt/beta-catenin pathway. First, POX markedly reduced COX-2 expression, suppressed the production of prostaglandin E2 (PGE2) and importantly, the growth inhibition by POX was partially reversed by treatment with PGE2. Phosphorylation of EGFR was decreased with POX expression and the addition of EGF partially reversed the POX-dependent downregulation of COX-2. Wnt/beta-catenin signaling was decreased by POX in that phosphorylation of glycogen synthase kinase-3 beta (GSK-3 beta) was decreased on the one hand and phosphorylation of beta-catenin was increased on the other. There changes led to decreased accumulation of beta-catenin and decreased beta-catenin/TCF/LEF-mediated transcription. Our newly described POX-mediated suppression of proliferative signaling together with the previously reported induction of apoptosis suggested that POX could function as a tumor suppressor. Indeed, in human colorectal tissue samples, immunohistochemically-monitored POX was dramatically decreased in tumors compared with normal counterparts. Thus, POX metabolism of substrate proline affects multiple signaling pathways, modulating both apoptosis and tumor growth, and could be an attractive target to metabolically control the cancer phenotypes.	[Liu, Y.; Borchert, G. L.] NCI, Basic Res Program, SAIC Frederick Inc, Frederick, MD 21702 USA; [Surazynski, A.; Phang, J. M.] NCI, Ctr Canc Res, Comparat Carcinogenesis Lab, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Liu, Y (corresponding author), NCI, Basic Res Program, SAIC Frederick Inc, Bldg 538,Room 144, Frederick, MD 21702 USA.	liuy@ncifcrf.gov	Surażynski, Arkadiusz/ABG-2795-2020	Surażynski, Arkadiusz/0000-0003-4475-873X	NIH [N01-CO-12400]; National Cancer Institute; Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC010743] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research is supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. This project also has been funded in part with Federal funds from the National Cancer Institute, National Institutes of Health under Contract No. N01-CO-12400. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.	Albini A, 2007, NAT REV CANCER, V7, P139, DOI 10.1038/nrc2067; Araki Y, 2003, CANCER RES, V63, P728; Bensaad K, 2007, TRENDS CELL BIOL, V17, P286, DOI 10.1016/j.tcb.2007.04.004; Buchanan FG, 2003, J BIOL CHEM, V278, P35451, DOI 10.1074/jbc.M302474200; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chen JJ, 2005, MOL BIOL CELL, V16, P5579, DOI 10.1091/mbc.E05-08-0778; Dannenberg AJ, 2005, J CLIN ONCOL, V23, P254, DOI 10.1200/JCO.2005.09.112; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dixon DA, 2004, CURR PHARM DESIGN, V10, P635, DOI 10.2174/1381612043453171; Donald SP, 2001, CANCER RES, V61, P1810; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; HAGEDORN CH, 1986, ARCH BIOCHEM BIOPHYS, V248, P166, DOI 10.1016/0003-9861(86)90413-3; Huang B, 2002, ACTA NEUROPATHOL, V103, P415, DOI 10.1007/s00401-001-0479-3; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kawamori T, 1998, CANCER RES, V58, P409; Kim J, 2005, CANCER RES, V65, P8242, DOI 10.1158/0008-5472.CAN-05-0942; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korswagen HC, 2006, DEV CELL, V10, P687, DOI 10.1016/j.devcel.2006.05.007; Liu LZ, 2004, SER INF MANAGE SCI, V3, P279; Liu XL, 2006, ADV ANAT PATHOL, V13, P270, DOI 10.1097/01.pap.0000213046.61941.5c; Liu Y, 2006, ONCOGENE, V25, P5640, DOI 10.1038/sj.onc.1209564; Liu YM, 2005, CARCINOGENESIS, V26, P1335, DOI 10.1093/carcin/bgi083; Maxwell SA, 2003, J BIOL CHEM, V278, P9784, DOI 10.1074/jbc.M210012200; McDonald-McGinn DM, 2006, AM J MED GENET A, V140A, P906, DOI 10.1002/ajmg.a.31199; Merida Isabel, 2006, Clin Transl Oncol, V8, P711, DOI 10.1007/s12094-006-0117-6; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pandhare J, 2006, J BIOL CHEM, V281, P2044, DOI 10.1074/jbc.M507867200; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prescott SM, 2000, BBA-REV CANCER, V1470, pM69, DOI 10.1016/S0304-419X(00)00006-8; Rivera A, 2005, J BIOL CHEM, V280, P29346, DOI 10.1074/jbc.M504852200; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Shao JY, 2004, J BIOL CHEM, V279, P14287, DOI 10.1074/jbc.M313276200; Shao JY, 2005, J BIOL CHEM, V280, P26565, DOI 10.1074/jbc.M413056200; Surazynski A, 2008, INT J CANCER, V122, P1435, DOI 10.1002/ijc.23263; Williams CS, 1997, J CLIN INVEST, V100, P1325, DOI 10.1172/JCI119651; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Worthley DL, 2007, WORLD J GASTROENTERO, V13, P3784; YEH GC, 1988, J BIOL CHEM, V263, P13083	38	82	84	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2008	27	53					6729	6737		10.1038/onc.2008.322	http://dx.doi.org/10.1038/onc.2008.322			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	371XO	18794809	Green Accepted			2022-12-17	WOS:000260866200003
J	Demidenko, ZN; Kalurupalle, S; Hanko, C; Lim, CU; Broude, E; Blagosklonny, MV				Demidenko, Z. N.; Kalurupalle, S.; Hanko, C.; Lim, C-u; Broude, E.; Blagosklonny, M. V.			Mechanism of G1-like arrest by low concentrations of paclitaxel: next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis	ONCOGENE			English	Article						cell cycle; cancer; G1 arrest; paclitaxel; mitosis	MAMMALIAN-CELLS; MITOTIC ARREST; G(1) ARREST; P53; CHECKPOINT; TRANSCRIPTION; INHIBITORS; TAXOL; P21; REREPLICATION	Paclitaxel (PTX) and other microtubule inhibitors cause mitotic arrest. However, low concentrations of PTX (low PTX) paradoxically cause G1 arrest ( without mitotic arrest). Here, we demonstrated that unexpectedly, low PTX did not cause G1 arrest in the first cell cycle and did not prevent cells from passing through S phase and entering mitosis. Mitosis was prolonged but cells still divided, producing either two or three cells (tripolar mitosis), thus explaining a sub G1 peak caused by low PTX. Importantly, sub G1 cells were viable and non-apoptotic. Some cells fused back and then progressed to mitosis, frequently producing three cells again before becoming arrested in the next cell-cycle interphase. Thus, low PTX caused postmitotic arrest in second and even the third cell cycles. By increasing concentration of PTX, tripolar mitosis was transformed to mitotic slippage, thus eliminating a sub G1 peak. Time-lapse microscopy revealed that prolonged mitosis ensured a p53-dependent postmitotic arrest. We conclude that PTX directly affects cells only in mitosis and the duration of mitosis determines cell fate, including p53-dependent G1-like arrest.	[Kalurupalle, S.; Hanko, C.; Lim, C-u; Broude, E.; Blagosklonny, M. V.] Ctr Canc, Ordway Res Inst, Albany, NY 12208 USA; [Demidenko, Z. N.; Blagosklonny, M. V.] Oncotarget, Ordway Res Inst, Albany, NY USA	Ordway Research Institute; Ordway Research Institute	Blagosklonny, MV (corresponding author), Ctr Canc, Ordway Res Inst, 150 New Scotland Ave, Albany, NY 12208 USA.	blagosklonny@oncotarget.com						Abal M, 2003, CURR CANCER DRUG TAR, V3, P193, DOI 10.2174/1568009033481967; An WG, 1998, EXP CELL RES, V244, P54, DOI 10.1006/excr.1998.4193; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Blagosklonny MV, 2007, CELL CYCLE, V6, P70, DOI 10.4161/cc.6.1.3682; Blagosklonny MV, 2002, CELL CYCLE, V1, P67, DOI 10.4161/cc.1.1.102; Blagosklonny MV, 2004, CELL CYCLE, V3, P1050; Blagosklonny MV, 2006, CELL CYCLE, V5, P971, DOI 10.4161/cc.5.9.2711; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Broude EV, 2007, CELL CYCLE, V6, P1468; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Demidenko ZN, 2004, CANCER RES, V64, P3653, DOI 10.1158/0008-5472.CAN-04-0204; Di Leonardo A, 1997, CANCER RES, V57, P1013; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; Giannakakou P, 2002, P NATL ACAD SCI USA, V99, P10855, DOI 10.1073/pnas.132275599; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; Jordan MA, 1996, CANCER RES, V56, P816; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; KESSOUS A, 1980, CANCER RES, V40, P1354; Khan SH, 1998, CANCER RES, V58, P396; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Mantel C, 2008, CELL CYCLE, V7, P484, DOI 10.4161/cc.7.4.5316; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; PRESCOTT DM, 1964, PROG NUCLEIC ACID RE, V3, P33, DOI 10.1016/S0079-6603(08)60738-2; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; Shtutman M, 2006, CANCER RES, V66, P11370, DOI 10.1158/0008-5472.CAN-06-2106; Stark B, 2001, CANCER GENET CYTOGEN, V128, P108, DOI 10.1016/S0165-4608(01)00411-3; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Uetake Y, 2007, CURR BIOL, V17, P2081, DOI 10.1016/j.cub.2007.10.065; Wong C, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-6	33	82	84	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2008	27	32					4402	4410		10.1038/onc.2008.82	http://dx.doi.org/10.1038/onc.2008.82			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18469851				2022-12-17	WOS:000257881700003
J	Geserick, P; Drewniok, C; Hupe, M; Haas, TL; Diessenbacher, P; Sprick, MR; Schon, MP; Henkler, F; Gollnick, H; Walczak, H; Leverkus, M				Geserick, P.; Drewniok, C.; Hupe, M.; Haas, T. L.; Diessenbacher, P.; Sprick, M. R.; Schoen, M. P.; Henkler, F.; Gollnick, H.; Walczak, H.; Leverkus, M.			Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis	ONCOGENE			English	Article						apoptosis; TRAIL; cFLIP; TRAIL-R1; TRAIL-R2; melanoma	NF-KAPPA-B; RECEPTOR-SELECTIVE MUTANTS; DOWN-REGULATION; DEATH RECEPTORS; UP-REGULATION; BCL-2 FAMILY; LIGAND; EXPRESSION; CASPASE-8; RESISTANCE	Death ligands such as tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and certain forms of CD95L are attractive therapeutic options for metastatic melanoma. Since knowledge about the regulation of death receptor sensitivity in melanoma is sparse, we have analysed these signaling pathways in detail. The loss of CD95 or TRAIL-R1, but not of TRAIL-R2, surface expression correlated with apoptosis sensitivity in a panel of melanoma cell lines. In contrast, the expression of proteins of the apical apoptosis signaling cascade (FADD, initiator caspases-8 and cFLIP) did not predict apoptosis sensitivity. Since both TRAIL-R1 and -R2 transmit apoptotic signals, we asked whether cFLIP, highly expressed in several of the cell lines tested, is sufficient to maintain resistance to TRAIL-R2-mediated apoptosis. Downregulation of cFLIP in TRAIL-R2-positive, TRAIL-resistant IGR cells dramatically increased TRAIL sensitivity. Conversely ectopic expression of cFLIP in TRAIL-sensitive, TRAIL-R2-expressing RPM-EP melanoma cells inhibited TRAIL- and CD95L- mediated cell death. Thus, modulation of cFLIP is sufficient to sensitize TRAIL-R2-expressing cells for TRAIL. Taken together, albeit expressing all proteins necessary for death receptor-mediated apoptosis, TRAIL-R1 negative melanoma cells cannot undergo TRAIL- or CD95L-induced apoptosis due to expression of cFLIP. Hence, cFLIP represents an attractive therapeutic target for melanoma treatment, especially in combination with TRAIL receptor agonists.	[Geserick, P.; Drewniok, C.; Hupe, M.; Diessenbacher, P.; Gollnick, H.; Leverkus, M.] Otto von Guericke Univ, Lab Expt Dermatol, Dept Dermatol & Venerol, D-39120 Magdeburg, Saxonia Anhalt, Germany; [Haas, T. L.; Sprick, M. R.; Walczak, H.] German Canc Res Ctr, Dept Apoptosis Regulat, D-6900 Heidelberg, Germany; [Sprick, M. R.] Acad Med Centrum UVA, Lab Expt Oncol & Radiat, Amsterdam, Netherlands; [Schoen, M. P.] Univ Wurzburg, DFG Res Ctr Expt Biomed, Rudolf Virchow Ctr, Wurzburg, Germany; [Schoen, M. P.] Univ Wurzburg, Dept Dermatol Venerol & Allergol, Wurzburg, Germany; [Henkler, F.] Univ Wurzburg, Med Policlin, Wurzburg, Germany	Otto von Guericke University; Helmholtz Association; German Cancer Research Center (DKFZ); University of Amsterdam; Academic Medical Center Amsterdam; German Research Foundation (DFG); University of Wurzburg; University of Wurzburg; University of Wurzburg	Leverkus, M (corresponding author), Otto von Guericke Univ, Lab Expt Dermatol, Dept Dermatol & Venerol, Leipziger St 44, D-39120 Magdeburg, Saxonia Anhalt, Germany.	leverkus@medizin.uni-magdeburg.de	Walczak, Henning/AAV-2214-2020; Sprick, Martin R./A-8611-2008; Sprick, Martin R./I-7995-2019	Walczak, Henning/0000-0002-6312-4591; Sprick, Martin R./0000-0001-9691-7574; Sprick, Martin R./0000-0001-9691-7574; Hupe, Mike/0000-0002-7735-2958; Haas, Tobias/0000-0003-2336-0263				Allen JD, 2005, CELL DEATH DIFFER, V12, P680, DOI 10.1038/sj.cdd.4401634; Bae SI, 2008, ONCOGENE, V27, P490, DOI 10.1038/sj.onc.1210655; Buchsbaum Donald J, 2007, Future Oncol, V3, P405, DOI 10.2217/14796694.3.4.405; BYERS HR, 1991, AM J PATHOL, V139, P423; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Diessenbacher P, 2008, J INVEST DERMATOL, V128, P1134, DOI 10.1038/sj.jid.5701141; Falschlehner C, 2007, INT J BIOCHEM CELL B, V39, P1462, DOI 10.1016/j.biocel.2007.02.007; Fecker LF, 2006, J INVEST DERMATOL, V126, P1366, DOI 10.1038/sj.jid.5700192; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Golks A, 2005, J BIOL CHEM, V280, P14507, DOI 10.1074/jbc.M414425200; Golks A, 2006, J EXP MED, V203, P1295, DOI 10.1084/jem.20051556; Griffith TS, 1998, J IMMUNOL, V161, P2833; Hamai A, 2006, ONCOGENE, V25, P7618, DOI 10.1038/sj.onc.1209738; Hymowitz SG, 2005, NAT CHEM BIOL, V1, P353, DOI 10.1038/nchembio1205-353; Ivanov VN, 2006, EXP CELL RES, V312, P4120, DOI 10.1016/j.yexcr.2006.09.019; Ivanov VN, 2003, ONCOGENE, V22, P3152, DOI 10.1038/sj.onc.1206456; Karst AM, 2007, CELL MOL LIFE SCI, V64, P318, DOI 10.1007/s00018-006-6364-4; Kataoka T, 2005, CRIT REV IMMUNOL, V25, P31, DOI 10.1615/CritRevImmunol.v25.i1.30; Kelley RF, 2005, J BIOL CHEM, V280, P2205, DOI 10.1074/jbc.M410660200; Kimberley FC, 2004, CELL RES, V14, P359, DOI 10.1038/sj.cr.7290236; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Kurbanov BM, 2007, ONCOGENE, V26, P3364, DOI 10.1038/sj.onc.1210134; Lavrik I, 2003, CELL DEATH DIFFER, V10, P144, DOI 10.1038/sj.cdd.4401156; Leverkus M, 2000, CANCER RES, V60, P553; Leverkus M, 2003, J INVEST DERMATOL, V121, P149, DOI 10.1046/j.1523-1747.2003.12332.x; Leverkus M, 2003, MOL CELL BIOL, V23, P777, DOI 10.1128/MCB.23.3.777-790.2003; MacFarlane M, 2005, CANCER RES, V65, P11265, DOI 10.1158/0008-5472.CAN-05-2801; Meng XW, 2006, CURR OPIN CELL BIOL, V18, P668, DOI 10.1016/j.ceb.2006.10.008; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Muhlenbeck F, 2000, J BIOL CHEM, V275, P32208, DOI 10.1074/jbc.M000482200; Naito M, 2004, MOL CELL BIOL, V24, P8418, DOI 10.1128/MCB.24.19.8418-8427.2004; Natoni A, 2007, BRIT J HAEMATOL, V139, P568, DOI 10.1111/j.1365-2141.2007.06852.x; Neise D, 2008, ONCOGENE, V27, P1387, DOI 10.1038/sj.onc.1210773; Nguyen T, 2001, CLIN CANCER RES, V7, p966S; Peltenburg LTC, 2005, CELL DEATH DIFFER, V12, P678, DOI 10.1038/sj.cdd.4401630; Peter ME, 2007, CELL, V129, P447, DOI 10.1016/j.cell.2007.04.031; Rudner J, 2005, ONCOGENE, V24, P130, DOI 10.1038/sj.onc.1208191; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Sprick MR, 2004, BBA-MOL CELL RES, V1644, P125, DOI 10.1016/j.bbamcr.2003.11.002; Takeda K, 2007, ONCOGENE, V26, P3745, DOI 10.1038/sj.onc.1210374; Trauzold A, 2006, ONCOGENE, V25, P7434, DOI 10.1038/sj.onc.1209719; Van der Sloot AM, 2006, P NATL ACAD SCI USA, V103, P8634, DOI 10.1073/pnas.0510187103; Wachter T, 2004, J BIOL CHEM, V279, P52824, DOI 10.1074/jbc.M409554200; Wendt J, 2005, ONCOGENE, V24, P4052, DOI 10.1038/sj.onc.1208580; Zhang XD, 1999, CANCER RES, V59, P2747; Zhuang LQ, 2006, HUM PATHOL, V37, P1286, DOI 10.1016/j.humpath.2006.04.026	46	82	87	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	22					3211	3220		10.1038/sj.onc.1210985	http://dx.doi.org/10.1038/sj.onc.1210985			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18084329				2022-12-17	WOS:000255897600014
J	Kanehira, M; Harada, Y; Takata, R; Shuin, T; Miki, T; Fujioka, T; Nakamura, Y; Katagiri, T				Kanehira, M.; Harada, Y.; Takata, R.; Shuin, T.; Miki, T.; Fujioka, T.; Nakamura, Y.; Katagiri, T.			Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis	ONCOGENE			English	Article						bladder cancer; cDNA microarray; molecular-target; small-interfering RNA	GENE-EXPRESSION; PROTEIN; CHEMOTHERAPY; GROWTH; GEMCITABINE; CARCINOMA; PATHWAYS; CANCERS; KINASE; DOMAIN	In an attempt to disclose mechanisms of bladder carcinogenesis and discover novel target molecules for development of treatment, we applied a cDNA microarray to screen genes that were significantly transactivated in bladder cancer cells. Among the upregulated genes, we here focused on a novel gene, (DEPDC1) DEP domain containing 1, whose overexpression was confirmed by northern blot and immunohistochemical analyses. Immunocytochemical staining analysis detected strong staining of endogenous DEPDC1 protein in the nucleus of bladder cancer cells. Since DEPDC1 expression was hardly detectable in any of 24 normal human tissues we examined except the testis, we considered this gene-product to be a novel cancer/testis antigen. Suppression of DEPDC1 expression with small-interfering RNA significantly inhibited growth of bladder cancer cells. Taken together, these findings suggest that DEPDC1 might play an essential role in the growth of bladder cancer cells, and would be a promising molecular-target for novel therapeutic drugs or cancer peptide-vaccine to bladder cancers.	Univ Tokyo, Inst Med Sci, Human Genome Ctr, Mol Med Lab,Minato Ku, Tokyo 108, Japan; Iwate Med Univ, Dept Urol, Morioka, Iwate 020, Japan; Kochi Med Sch, Dept Urol, Nankoku, Kochi, Japan; Kyoto Prefectural Univ Med, Dept Urol, Kamigyo Ku, Kyoto, Japan	University of Tokyo; Iwate Medical University; Kochi University; Kyoto Prefectural University of Medicine	Katagiri, T (corresponding author), Univ Tokyo, Inst Med Sci, Human Genome Ctr, Mol Med Lab,Minato Ku, 4-6-1 Shirokanedai, Tokyo 108, Japan.	tkatagi@ims.u-tokyo.ac.jp	Katagiri, Toyomasa/I-7344-2012	Kanehira, Mitsugu/0000-0001-8811-8158				Anazawa Y, 2005, CANCER RES, V65, P4578, DOI 10.1158/0008-5472.CAN-04-4564; Ardavanis A, 2005, BRIT J CANCER, V92, P645, DOI 10.1038/sj.bjc.6602378; Ashida S, 2006, CLIN CANCER RES, V12, P2767, DOI 10.1158/1078-0432.CCR-05-1995; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Kharrat A, 1998, BBA-PROTEIN STRUCT M, V1385, P157, DOI 10.1016/S0167-4838(98)00041-7; Lehmann J, 2002, WORLD J UROL, V20, P144, DOI 10.1007/s00345-002-0252-9; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Marty-Roix R, 2003, TISSUE ENG, V9, P175, DOI 10.1089/107632703762687654; Nagayama S, 2004, ONCOGENE, V23, P5551, DOI 10.1038/sj.onc.1207710; Nagayama S, 2005, ONCOGENE, V24, P6201, DOI 10.1038/sj.onc.1208780; Park JH, 2006, CANCER RES, V66, P9186, DOI 10.1158/0008-5472.CAN-06-1601; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Petricoin EF, 2002, NAT GENET, V32, P474, DOI 10.1038/ng1029; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; Rosenberg JE, 2005, J UROLOGY, V174, P14, DOI 10.1097/01.ju.0000162039.38023.5f; Saito-Hisaminato A, 2002, DNA RES, V9, P35, DOI 10.1093/dnares/9.2.35; Shima K, 2003, IEEE T ENERGY CONVER, V18, P63, DOI 10.1109/TEC.2002.808337; Shimo A, 2007, CANCER SCI, V98, P174, DOI 10.1111/j.1349-7006.2006.00381.x; STERNBERG CN, 1995, ANN ONCOL, V6, P113, DOI 10.1093/oxfordjournals.annonc.a059105; Takata R, 2005, CLIN CANCER RES, V11, P2625, DOI 10.1158/1078-0432.CCR-04-1988; Taniuchi K, 2005, CANCER RES, V65, P3092, DOI 10.1158/0008.5472.CAN-04-3646; Taniuchi K, 2005, CANCER RES, V65, P105; Theodore C, 2005, EUR J CANCER, V41, P1150, DOI 10.1016/j.ejca.2005.02.015; Togashi A, 2005, CANCER RES, V65, P4817, DOI 10.1158/0008-5472.CAN-05-0120; Vaughn DJ, 1999, SEMIN ONCOL, V26, P117	26	82	92	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2007	26	44					6448	6455		10.1038/sj.onc.1210466	http://dx.doi.org/10.1038/sj.onc.1210466			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17452976				2022-12-17	WOS:000249737600009
J	Demidov, ON; Kek, C; Shreeram, S; Timofeev, O; Fornace, AJ; Appella, E; Bulavin, DV				Demidov, O. N.; Kek, C.; Shreeram, S.; Timofeev, O.; Fornace, A. J.; Appella, E.; Bulavin, D. V.			The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis	ONCOGENE			English	Article						Wip1 phosphatase; p38 MAPK; MKK6; breast cancer; ErbB2; proliferation; MMTV	TUMOR-SUPPRESSOR ACTIVITY; WIP1 PHOSPHATASE; BREAST-CANCER; PROTEIN PHOSPHATASE; IN-VIVO; PPM1D; AMPLIFICATION; KINASE; P53; ACTIVATION	There is increasing evidence for the role of wild-type p53 induced phosphatase 1( Wip1) phosphatase in the regulation of tumorigenesis. To evaluate Wip1 as a breast cancer oncogene, we generated a mouse strain with targeted expression of Wip1 to the breast epithelium. We found that these mice are prone to cancer when intercrossed with transgenics expressing the ErbB2 oncogene but not conditional knockouts for Brca2. This tumor-prone phenotype of Wip1 is fully eliminated through attenuation of proliferation by activating the MKK6/p38 mitogen-activated protein kinases ( MAPK) cascade in mice bearing a constitutively active form of MKK6. We propose that Wip1 phosphatase operates within the MKK6/p38 MAPK signaling pathway to promote ErbB2-driven mammary gland tumorigenesis.	Natl Univ Singapore, Inst Mol & Cell Biol, Cell Cycle Control & Tumorigenesis Grp, Singapore 138673, Singapore; NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard T.H. Chan School of Public Health	Bulavin, DV (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, Cell Cycle Control & Tumorigenesis Grp, 61 Biopolis Dr, Singapore 138673, Singapore.	dvbulavin@imcb.a-star.edu.sg	Demidov, Oleg/U-2050-2017; Fornace, Albert J/A-7407-2008; Demidov, Oleg/AAC-4462-2021	Demidov, Oleg/0000-0003-4323-7174; Fornace, Albert J/0000-0001-9695-085X; Demidov, Oleg/0000-0003-4323-7174; Sathyavageeswaran, Shreeram/0000-0002-6111-1818; Timofeev, Oleg/0000-0002-3114-6403	NATIONAL CANCER INSTITUTE [Z01BC005599, ZIABC005599] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belova GI, 2005, CANCER BIOL THER, V4, P1154, DOI 10.4161/cbt.4.10.2204; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Hirasawa A, 2003, CLIN CANCER RES, V9, P1995; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rauta J, 2006, BREAST CANCER RES TR, V95, P257, DOI 10.1007/s10549-005-9017-7; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Shreeram S, 2006, MOL CELL, V23, P757, DOI 10.1016/j.molcel.2006.07.010; Sinclair CS, 2003, BREAST CANCER RES TR, V78, P313, DOI 10.1023/A:1023081624133; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Timofeev O, 2005, CELL CYCLE, V4, P118, DOI 10.4161/cc.4.1.1342; Trost TM, 2005, CANCER RES, V65, P840; Yamaguchi H, 2005, BIOCHEMISTRY-US, V44, P5285, DOI 10.1021/bi0476634	20	82	89	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2007	26	17					2502	2506		10.1038/sj.onc.1210032	http://dx.doi.org/10.1038/sj.onc.1210032			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17016428				2022-12-17	WOS:000245831000010
J	Takada, Y; Ichikawa, H; Pataer, A; Swisher, S; Aggarwal, BB				Takada, Y.; Ichikawa, H.; Pataer, A.; Swisher, S.; Aggarwal, B. B.			Genetic deletion of PKR abrogates TNF-induced activation of I kappa B alpha kinase, JNK, Akt and cell proliferation but potentiates p44/p42 MAPK and p38 MAPK activation	ONCOGENE			English	Article						PKR; Akt; MAPK; JNK; NF-kappa B; TNF; survival; apoptosis	DOUBLE-STRANDED-RNA; DEPENDENT PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; ENDOTHELIAL-CELLS; INFLAMMATORY STIMULI; SIGNAL-TRANSDUCTION; UP-REGULATION; INTERFERON; EXPRESSION; APOPTOSIS	Double-stranded RNA-dependent protein kinase (PKR), a ubiquitously expressed serine/threonine kinase, has been implicated in the regulation or modulation of cell growth through multiple signaling pathways, but how PKR regulates tumor necrosis factor (TNF)-induced signaling pathways is poorly understood. In the present study, we used. broblasts derived from PKR gene-deleted mice to investigate the role of PKR in TNF-induced activation of nuclear factor-kappa B (NF-kappa B), mitogen-activated protein kinases (MAPKs) and growth modulation. We found that in wild-type mouse embryonic fibroblast (MEF), TNF induced NF-kappa B activation as measured by DNA binding but deletion of PKR abolished this activation. This inhibition was associated with suppression of inhibitory subunit of NF-kappa B (I kappa B)alpha kinase (IKK) activation, I kappa B alpha phosphorylation and degradation, p65 phosphorylation and nuclear translocation, and NF-kappa B-dependent reporter gene transcription. TNF-induced Akt activation needed for IKK activation was also abolished by deletion of PKR. NF-kappa B activation was diminished in PKR-deleted cells transfected with TNF receptor ( TNFR) 1, TNFR-associated death domain and TRAF2 plasmids; NF-kappa B activated by NF-kappa B-inducing kinase, IKK or p65, however, was minimally affected. Among the MAPKs, it was interesting that whereas TNF-induced c-Jun N-terminal kinase (JNK) activation was abolished, activation of p44/p42 MAPK and p38 MAPK was potentiated in PKR-deleted cells. TNF induced the expression of NF-kappa B-regulated gene products cyclin D1, c-Myc, matrix metalloproteinase-9, survivin, X-linked inhibitor-of-apoptosis protein (IAP), IAP1, Bcl-x(L), A1/Bfl-1 and Fas-associated death domain protein-like IL-1 beta-converting enzyme-inhibitory protein in wild-type MEF but not in PKR-/- cells. Similarly, TNF induced the proliferation of wild-type cells, but this proliferation was completely suppressed in PKR-deleted cells. Overall, our results indicate that PKR differentially regulates TNF signaling; IKK, Akt and JNK were positively regulated, whereas p44/p42 MAPK and p38 MAPK were negatively regulated.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, 1515 Holcombe Blvd,Unit 143, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013		NCI NIH HHS [P01 CA91844, P50CA97007] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA091844, P50CA097007] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Bandyopadhyay SK, 2000, J IMMUNOL, V164, P2077, DOI 10.4049/jimmunol.164.4.2077; Bonnet MC, 2000, MOL CELL BIOL, V20, P4532, DOI 10.1128/MCB.20.13.4532-4542.2000; CARROLL K, 1993, J BIOL CHEM, V268, P12837; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Cheshire JL, 1999, J BIOL CHEM, V274, P4801, DOI 10.1074/jbc.274.8.4801; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Deb A, 2001, J IMMUNOL, V166, P6170, DOI 10.4049/jimmunol.166.10.6170; Demarchi F, 1999, J VIROL, V73, P7080, DOI 10.1128/JVI.73.8.7080-7086.1999; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Donze O, 2004, EMBO J, V23, P564, DOI 10.1038/sj.emboj.7600078; Esteves E, 2002, MATH RES LETT, V9, P1; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gil J, 2000, ONCOGENE, V19, P1369, DOI 10.1038/sj.onc.1203448; Gil J, 2004, MOL CELL BIOL, V24, P4502, DOI 10.1128/MCB.24.10.4502-4512.2004; Gil J, 2001, ONCOGENE, V20, P385, DOI 10.1038/sj.onc.1204109; Gilbert SJ, 2004, ARTHRITIS RES THER, V6, pR46, DOI 10.1186/ar1024; Goh KC, 2000, EMBO J, V19, P4292, DOI 10.1093/emboj/19.16.4292; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; GUSELLA GL, 1995, J IMMUNOL, V154, P345; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Iordanov MS, 2000, MOL CELL BIOL, V20, P617, DOI 10.1128/MCB.20.2.617-627.2000; Ishii T, 2001, ONCOGENE, V20, P1900, DOI 10.1038/sj.onc.1204267; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; ITO T, 1994, P NATL ACAD SCI USA, V91, P7455, DOI 10.1073/pnas.91.16.7455; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Kronfeld-Kinar Y, 1999, CELL GROWTH DIFFER, V10, P201; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Maggi LB, 2003, J BIOL CHEM, V278, P16683, DOI 10.1074/jbc.M211744200; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MUNDSCHAU LJ, 1995, J BIOL CHEM, V270, P3100, DOI 10.1074/jbc.270.7.3100; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Ozes ON, 1999, NATURE, V401, P82; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; Peters GA, 2001, MOL CELL BIOL, V21, P1908, DOI 10.1128/MCB.21.6.1908-1920.2001; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; Silva AM, 2004, J BIOL CHEM, V279, P37670, DOI 10.1074/jbc.M406554200; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Takada Y, 2004, J BIOL CHEM, V279, P39541, DOI 10.1074/jbc.M403449200; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Takada Y, 2004, J BIOL CHEM, V279, P15096, DOI 10.1074/jbc.M311192200; Takada Y, 2004, J BIOL CHEM, V279, P4750, DOI 10.1074/jbc.M304546200; Takada Y, 2003, J BIOL CHEM, V278, P23390, DOI 10.1074/jbc.M213237200; Takizawa T, 2002, EUR J BIOCHEM, V269, P6126, DOI 10.1046/j.1432-1033.2002.03325.x; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Williams B R, 2001, Sci STKE, V2001, pre2, DOI 10.1126/stke.2001.89.re2; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; Xu Z, 2000, MOL CELL BIOL, V20, P5285, DOI 10.1128/MCB.20.14.5285-5299.2000; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; Yeung MC, 1998, J BIOL CHEM, V273, P25198, DOI 10.1074/jbc.273.39.25198; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zhu L, 2001, FEBS LETT, V508, P369, DOI 10.1016/S0014-5793(01)03084-8; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	65	82	82	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1201	1212		10.1038/sj.onc.1209906	http://dx.doi.org/10.1038/sj.onc.1209906			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16924232				2022-12-17	WOS:000244406400010
J	Ohlenschlager, O; Seiboth, T; Zengerling, H; Briese, L; Marchanka, A; Ramachandran, R; Baum, M; Korbas, M; Meyer-Klaucke, W; Durst, M; Gorlach, M				Ohlenschlaeger, O.; Seiboth, T.; Zengerling, H.; Briese, L.; Marchanka, A.; Ramachandran, R.; Baum, M.; Korbas, M.; Meyer-Klaucke, W.; Duerst, M.; Goerlach, M.			Solution structure of the partially folded high-risk human papilloma virus 45 oncoprotein E7	ONCOGENE			English	Article						human papilloma virus; E7; carcinogenesis; NMR solution structure	HUMAN-PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA TUMOR-SUPPRESSOR; TORSION ANGLE DYNAMICS; E7 ONCOPROTEIN; HPV E7; HUMAN KERATINOCYTES; ADENOVIRUS E1A; ZINC-BINDING; RB BINDING; PROTEIN	The oncoprotein E7 of human papilloma viruses (HPV) is involved in the pathogenesis and maintenance of human cervical cancers. The most prevalent HPV types found in cervix carcinomas are HPV16, 18 and 45. The structure of the E7 dimer from HPV45 (PDB 2F8B) was determined by nuclear magnetic resonance spectroscopy. Each monomer comprises an unfolded N-terminus and a well-structured C-terminal domain with a beta 1 beta 2 alpha 1 beta 3 alpha 2 topology representing a unique zinc-binding fold found only for E7. Dimerization occurs through the alpha 1/alpha 1' helices and intermolecular beta-sheet formation but excludes the zinc-binding sites. E7 is reported to interact with a number of cellular proteins (e.g. pRb, p21(CIP1)). Binding of a peptide derived from the C-terminus of p21(CIP1) to the C-terminal domain of E7 was characterized by monitoring chemical shift perturbations of the amide groups of E7. This provides direct evidence that a shallow groove situated between alpha 1 and beta 1 of the E7 C-terminal domain is interacting with the C-terminus of p21CIP1. Intriguingly, this binding site overlaps with the low-affinity binding site on E7 for the C-domain of pRb.	Fritz Lipmann Inst, NMR Spectroscopy, D-07745 Jena, Germany; DESY, European Mol Biol Lab, D-2000 Hamburg, Germany; Univ Jena, Frauenklin, D-6900 Jena, Germany	Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Friedrich Schiller University of Jena	Gorlach, M (corresponding author), Fritz Lipmann Inst, NMR Spectroscopy, Beutenbergstr 11, D-07745 Jena, Germany.	mago@fli-leibniz.de	Korbas, Malgorzata/B-4024-2009; Meyer-Klaucke, Wolfram/G-1148-2010	Korbas, Malgorzata/0000-0003-3064-0132; Marchanka, Alexander/0000-0003-0810-2020; Ohlenschlaeger, Oliver/0000-0002-6428-4423				Alonso LG, 2002, BIOCHEMISTRY-US, V41, P10510, DOI 10.1021/bi025579n; Avvakumov N, 2003, ONCOGENE, V22, P3833, DOI 10.1038/sj.onc.1206562; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BINSTED N, 1992, BIOCHEMISTRY-US, V31, P12117, DOI 10.1021/bi00163a021; Bischof O, 2005, MOL CELL BIOL, V25, P1013, DOI 10.1128/MCB.25.3.1013-1024.2005; Bosch F Xavier, 2003, J Natl Cancer Inst Monogr, P3; Braspenning J, 1998, ONCOGENE, V16, P1085, DOI 10.1038/sj.onc.1201617; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Clements A, 2000, BIOCHEMISTRY-US, V39, P16033, DOI 10.1021/bi002111g; de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Guntert P, 1998, J BIOMOL NMR, V12, P543, DOI 10.1023/A:1008391403193; Helt AM, 2002, J VIROL, V76, P10559, DOI 10.1128/JVI.76.20.10559-10568.2002; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Liu X, 2006, J BIOL CHEM, V281, P578, DOI 10.1074/jbc.M508455200; Mannhardt B, 2000, MOL CELL BIOL, V20, P6483, DOI 10.1128/MCB.20.17.6483-6495.2000; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Munger K, 2004, J VIROL, V78, P11451, DOI 10.1128/JVI.78.21.11451-11460.2004; MUNGER K, 1989, J VIROL, V63, P4417; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; Schlott B, 2002, J MOL BIOL, V318, P533, DOI 10.1016/S0022-2836(02)00014-1; Singh M, 2005, J BIOL CHEM, V280, P37868, DOI 10.1074/jbc.M504877200; Villa LL, 1997, ADV CANCER RES, V71, P321, DOI 10.1016/S0065-230X(08)60102-5; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Xiao B, 2003, P NATL ACAD SCI USA, V100, P2363, DOI 10.1073/pnas.0436813100; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q; Zwerschke W, 2000, ADV CANCER RES, V78, P1	43	82	86	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2006	25	44					5953	5959		10.1038/sj.onc.1209584	http://dx.doi.org/10.1038/sj.onc.1209584			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16636661				2022-12-17	WOS:000240826300004
J	Lim, CP; Phan, TT; Lim, IJ; Cao, X				Lim, C. P.; Phan, T-T; Lim, I. J.; Cao, X.			Stat3 contributes to keloid pathogenesis via promoting collagen production, cell proliferation and migration	ONCOGENE			English	Article						Stat3; keloid; scar; fibroblasts; collagen; migration	POTENT ANTITUMOR-ACTIVITY; GROWTH-FACTOR-BETA; GENE-REGULATION; CANCER-CELLS; FIBROBLASTS; ACTIVATION; SCAR; TRANSCRIPTION; DISRUPTION; EXPRESSION	Keloids, partially considered as benign tumors, represent the most extreme example of cutaneous scarring that uniquely afflicts humans as a pathological response to wound healing. It is characterized by excessive deposition of collagen and other extracellular matrix components by dermal fibroblasts. Upon cutaneous injury, cocktails of chemokines, cytokines and growth factors are secreted temporally and spatially to direct appropriate responses from neutrophils, macrophages, keratinocytes and fibroblasts to facilitate normal wound healing. Signal transducer and activator of transcription 3 (Stat3) is an oncogene and a latent transcription factor activated by various cytokines and growth factors. We investigated the possible role of Stat3 in keloid scar pathogenesis by examining skin tissue and cultured fibroblasts from keloid-scarred patients. We observed enhanced expression and phosphorylation of Stat3 in keloid scar tissue, and in cultured keloid fibroblasts (KFs) in vitro. Increased activation of Janus kinase (Jak)2, but not Jak1, was detected in KFs, and suppression of Jak2 by its inhibitor repressed Stat3 Y705 phosphorylation. Inhibition of Stat3 expression and phosphorylation by short interfering RNA or Cucurbitacin I resulted in the loss of collagen production, impaired proliferation and delayed cell migration in KFs. We show, for the first time, a role of Stat3 in keloid pathogenesis. Inhibitors of Stat3 may be useful therapeutic strategies for the prospective treatment of keloid scars.	Inst Mol & Cell Biol, Cell Signaling Lab, Proteos, Singapore 138673, Singapore; Natl Univ Singapore, Dept Surg, Singapore 117548, Singapore; Natl Univ Singapore, Dept Bioengn, Singapore 117548, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore	Cao, X (corresponding author), Inst Mol & Cell Biol, Cell Signaling Lab, Proteos, 61 Biopolis Dr, Singapore 138673, Singapore.	mcbcaoxm@imcb.a-star.edu.sg	Phan, Toan Thang/A-5527-2009					ABERGEL RP, 1985, J INVEST DERMATOL, V84, P384, DOI 10.1111/1523-1747.ep12265471; Alster TS, 2003, AM J CLIN DERMATOL, V4, P235, DOI 10.2165/00128071-200304040-00003; BABU M, 1992, J INVEST DERMATOL, V99, P650, DOI 10.1111/1523-1747.ep12668146; BABU M, 1989, MOL CELL BIOL, V9, P1642, DOI 10.1128/MCB.9.4.1642; Blaskovich MA, 2003, CANCER RES, V63, P1270; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Calderon M, 1996, J SURG RES, V61, P343, DOI 10.1006/jsre.1996.0127; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; COSMAN B, 1961, PLAST RECONSTR SURG, V27, P335, DOI 10.1097/00006534-196104000-00001; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dauer DJ, 2005, ONCOGENE, V24, P3397, DOI 10.1038/sj.onc.1208469; DIEGELMANN RF, 1979, J CELL PHYSIOL, V98, P341, DOI 10.1002/jcp.1040980210; Edmondson SR, 2003, ENDOCR REV, V24, P737, DOI 10.1210/er.2002-0021; HAISA M, 1994, J INVEST DERMATOL, V103, P560, DOI 10.1111/1523-1747.ep12396856; Lee TY, 1999, ANN PLAS SURG, V43, P179; Leong PL, 2003, P NATL ACAD SCI USA, V100, P4138, DOI 10.1073/pnas.0534764100; Lim IJ, 2002, AM J PHYSIOL-CELL PH, V283, pC212, DOI 10.1152/ajpcell.00555.2001; Mustoe TA, 2004, BRIT MED J, V328, P1329, DOI 10.1136/bmj.328.7452.1329; Naitoh M, 2001, BIOCHEM BIOPH RES CO, V280, P1316, DOI 10.1006/bbrc.2001.4257; Ng DCH, 2006, J CELL BIOL, V172, P245, DOI 10.1083/jcb.200503021; Ragoowansi R, 2001, BRIT J PLAST SURG, V54, P504, DOI 10.1054/bjps.2001.3656; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Song H, 2005, P NATL ACAD SCI USA, V102, P4700, DOI 10.1073/pnas.0409894102; Sun JZ, 2005, ONCOGENE, V24, P3236, DOI 10.1038/sj.onc.1208470; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Takeda K, 2000, CYTOKINE GROWTH F R, V11, P199, DOI 10.1016/S1359-6101(00)00005-8; Tuan TL, 1998, MOL MED TODAY, V4, P19, DOI 10.1016/S1357-4310(97)80541-2; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; Wu YD, 2004, AM J PHYSIOL-CELL PH, V286, pC905, DOI 10.1152/ajpcell.00200.2003; Xue H, 2000, J SURG RES, V89, P74, DOI 10.1006/jsre.1999.5805; Yang GP, 2003, WOUND REPAIR REGEN, V11, P411, DOI 10.1046/j.1524-475X.2003.11604.x; Yoshimoto H, 1999, AM J PATHOL, V154, P883, DOI 10.1016/S0002-9440(10)65335-7; YOUNAI S, 1994, ANN PLAS SURG, V33, P148, DOI 10.1097/00000637-199408000-00005	38	82	99	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2006	25	39					5416	5425		10.1038/sj.onc.1209531	http://dx.doi.org/10.1038/sj.onc.1209531			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16619044				2022-12-17	WOS:000240144900006
J	Weitzman, MD; Ornelles, DA				Weitzman, MD; Ornelles, DA			Inactivating intracellular antiviral responses during adenovirus infection	ONCOGENE			English	Review						adenovirus; DNA repair; DNA damage response; protein translation	DEPENDENT PROTEIN-KINASE; LATE GENE-EXPRESSION; STRAND BREAK REPAIR; DNA-DAMAGE RESPONSE; ADENOASSOCIATED VIRUS GENOME; TELANGIECTASIA-LIKE DISORDER; E1B 55-KILODALTON PROTEIN; P53 TUMOR-SUPPRESSOR; E4 ORF3 PROTEIN; EARLY REGION-4	DNA viruses promote cell cycle progression, stimulate unscheduled DNA synthesis, and present the cell with an extraordinary amount of exogenous DNA. These insults elicit vigorous responses mediated by cellular factors that govern cellular homeostasis. To ensure productive infection, adenovirus has developed means to inactivate these intracellular antiviral responses. Among the challenges to the host cell is the viral DNA genome, which is viewed as DNA damage and elicits a cellular response to inhibit replication. Adenovirus therefore encodes proteins that dismantle the cellular DNA damage machinery. Studying virus-host interactions has yielded insights into the molecular functioning of fundamental cellular mechanisms. In addition, it has suggested ways that viral cytotoxicity can be exploited to offer a selective means of restricted growth in tumor cells as a therapy against cancer. In this review, we discuss aspects of the intracellular response that are unique to adenovirus infection and how adenoviral proteins produced from the early region E4 act to neutralize antiviral defenses, with a particular focus on DNA damage signaling.	Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; Wake Forest Univ, Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA	Salk Institute; Wake Forest University	Weitzman, MD (corresponding author), Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	weitzman@salk.edu			NATIONAL CANCER INSTITUTE [R01CA077342, R01CA097093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI035589, R01AI043341] Funding Source: NIH RePORTER; NCI NIH HHS [CA77342, CA97093] Funding Source: Medline; NIAID NIH HHS [AI35589, AI43341] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAM SA, 1987, J VIROL, V61, P3276, DOI 10.1128/JVI.61.10.3276-3283.1987; ANDERSON KP, 1987, J VIROL, V61, P787, DOI 10.1128/JVI.61.3.787-795.1987; ARAUJO FD, 2005, IN PRESS J VIROL; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bell J. C., 2002, Current Gene Therapy, V2, P243, DOI 10.2174/1566523024605582; Ben-Israel H, 2002, FRONT BIOSCI-LANDMRK, V7, pD1369, DOI 10.2741/ben; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Bondesson M, 1996, J VIROL, V70, P3844, DOI 10.1128/JVI.70.6.3844-3851.1996; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Boyer J, 1999, VIROLOGY, V263, P307, DOI 10.1006/viro.1999.9866; Boyer JL, 2000, J BIOL CHEM, V275, P14969, DOI 10.1074/jbc.M000566200; Branton PE, 2001, ONCOGENE, V20, P7855, DOI 10.1038/sj.onc.1204862; BRIDGE E, 1993, VIROLOGY, V193, P794, DOI 10.1006/viro.1993.1188; BRIDGE E, 1989, J VIROL, V63, P631, DOI 10.1128/JVI.63.2.631-638.1989; Burgert HG, 2002, CURR TOP MICROBIOL, V269, P273; Burma S, 2004, DNA REPAIR, V3, P909, DOI 10.1016/j.dnarep.2004.03.021; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; Cascallo M, 2003, CANCER RES, V63, P5544; Cathomen T, 2000, J VIROL, V74, P11407, DOI 10.1128/JVI.74.23.11407-11412.2000; Chen Y, 2001, CANCER RES, V61, P5453; Collis SJ, 2005, ONCOGENE, V24, P949, DOI 10.1038/sj.onc.1208332; Cuconati A, 2002, GENE DEV, V16, P2465, DOI 10.1101/gad.1012702; Cuesta R, 2001, COLD SPRING HARB SYM, V66, P259, DOI 10.1101/sqb.2001.66.259; Cuesta R, 2000, EMBO J, V19, P3465, DOI 10.1093/emboj/19.13.3465; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; De Jong RN, 2003, CURR TOP MICROBIOL, V272, P187; Dilley J, 2005, CANCER GENE THER, V12, P715, DOI 10.1038/sj.cgt.7700835; Dix BR, 2001, J VIROL, V75, P5443, DOI 10.1128/JVI.75.12.5443-5447.2001; DIX I, 1993, J VIROL, V67, P3226, DOI 10.1128/JVI.67.6.3226-3231.1993; Dobbelstein M, 2004, CURR TOP MICROBIOL, V273, P291; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Dobner T, 2001, CURR TOP MICROBIOL, V259, P25; Doucas V, 1996, GENE DEV, V10, P196, DOI 10.1101/gad.10.2.196; Duan DS, 2003, J VIROL, V77, P4751, DOI 10.1128/JVI.77.8.4751-4759.2003; Evans JD, 2005, J VIROL, V79, P6207, DOI 10.1128/JVI.79.10.6207-6215.2005; Evans JD, 2003, J VIROL, V77, P5295, DOI 10.1128/JVI.77.9.5295-5304.2003; Everett RD, 2001, ONCOGENE, V20, P7266, DOI 10.1038/sj.onc.1204759; FALGOUT B, 1987, J VIROL, V61, P3759, DOI 10.1128/JVI.61.12.3759-3768.1987; Fessler SP, 2004, CURR TOP MICROBIOL, V273, P113; Flint SJ, 2003, CURR TOP MICROBIOL, V272, P287; Frese KK, 2003, ONCOGENE, V22, P710, DOI 10.1038/sj.onc.1206151; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; GHADGE GD, 1994, J VIROL, V68, P4137, DOI 10.1128/JVI.68.7.4137-4151.1994; Gingras MC, 2002, MOL CELL BIOL, V22, P41, DOI 10.1128/MCB.22.1.41-56.2002; Gonzalez RA, 2002, J VIROL, V76, P4507, DOI 10.1128/JVI.76.9.4507-4519.2002; Goodrum FD, 1999, J VIROL, V73, P7474, DOI 10.1128/JVI.73.9.7474-7488.1999; Goodrum FD, 1997, J VIROL, V71, P548, DOI 10.1128/JVI.71.1.548-561.1997; Goodrum FD, 1998, J VIROL, V72, P9479, DOI 10.1128/JVI.72.12.9479-9490.1998; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; HALBERT DN, 1985, J VIROL, V56, P250, DOI 10.1128/JVI.56.1.250-257.1985; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harada JN, 2002, J VIROL, V76, P9194, DOI 10.1128/JVI.76.18.9194-9206.2002; Harada JN, 1999, J VIROL, V73, P5333, DOI 10.1128/JVI.73.7.5333-5344.1999; Hart LS, 2005, J BIOL CHEM, V280, P1474, DOI 10.1074/jbc.M409934200; Hiscott J, 2003, ANN NY ACAD SCI, V1010, P237, DOI 10.1196/annals.1299.042; Horwitz MS, 2001, VIROLOGY, V279, P1, DOI 10.1006/viro.2000.0738; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; HUANG MM, 1989, J VIROL, V63, P2605, DOI 10.1128/JVI.63.6.2605-2615.1989; Kaempfer R, 2003, EMBO REP, V4, P1043, DOI 10.1038/sj.embor.7400005; Kapp LD, 2004, ANNU REV BIOCHEM, V73, P657, DOI 10.1146/annurev.biochem.73.030403.080419; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kirn D, 2000, ONCOGENE, V19, P6660, DOI 10.1038/sj.onc.1204094; KITAJEWSKI J, 1986, MOL CELL BIOL, V6, P4493, DOI 10.1128/MCB.6.12.4493; Kleinberger T, 2004, PROG MOL SUBCELL BIO, V36, P245; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; Kobayashi J, 2004, DNA REPAIR, V3, P855, DOI 10.1016/j.dnarep.2004.03.023; Konig C, 1999, J VIROL, V73, P2253; Kratzer F, 2000, ONCOGENE, V19, P850, DOI 10.1038/sj.onc.1203395; Lang SE, 2003, ONCOGENE, V22, P2836, DOI 10.1038/sj.onc.1206376; Lavin MF, 2004, DNA REPAIR, V3, P1515, DOI 10.1016/j.dnarep.2004.07.001; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Lavoie JN, 2000, J CELL BIOL, V150, P1037, DOI 10.1083/jcb.150.5.1037; Leonard GT, 1996, VIROLOGY, V224, P25, DOI 10.1006/viro.1996.0503; Leppard KN, 1997, J GEN VIROL, V78, P2131, DOI 10.1099/0022-1317-78-9-2131; Li YH, 2001, CANCER RES, V61, P6428; Lichtenstein DL, 2004, INT REV IMMUNOL, V23, P75, DOI 10.1080/08830180490265556; Lilley CE, 2005, P NATL ACAD SCI USA, V102, P5844, DOI 10.1073/pnas.0501916102; Liu H, 2003, CURR TOP MICROBIOL, V272, P131; Look DC, 1998, IMMUNITY, V9, P871, DOI 10.1016/S1074-7613(00)80652-4; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Lyles DS, 2000, MICROBIOL MOL BIOL R, V64, P709, DOI 10.1128/MMBR.64.4.709-724.2000; Marcellus RC, 1998, J VIROL, V72, P7144, DOI 10.1128/JVI.72.9.7144-7153.1998; Marcellus RC, 2000, J VIROL, V74, P7869, DOI 10.1128/JVI.74.17.7869-7877.2000; Maul GG, 1998, BIOESSAYS, V20, P660, DOI 10.1002/(SICI)1521-1878(199808)20:8<660::AID-BIES9>3.0.CO;2-M; McNees AL, 2002, VIRUS RES, V88, P87, DOI 10.1016/S0168-1702(02)00122-3; Meek K, 2004, IMMUNOL REV, V200, P132, DOI 10.1111/j.0105-2896.2004.00162.x; Miller DG, 2004, NAT GENET, V36, P767, DOI 10.1038/ng1380; MUNDSCHAU LJ, 1994, BIOCHIMIE, V76, P792, DOI 10.1016/0300-9084(94)90083-3; MUNOZFONTELA C, 2005, IN PRESS ONCOGENE; NEVINS JR, 1995, CURR TOP MICROBIOL, V199, P25; O'Shea C, 2005, EMBO J, V24, P1211, DOI 10.1038/sj.emboj.7600597; O'Shea CC, 2005, CURR OPIN GENET DEV, V15, P18, DOI 10.1016/j.gde.2004.12.010; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; Orlando JS, 1999, J VIROL, V73, P4600, DOI 10.1128/JVI.73.6.4600-4610.1999; Pestka S, 2003, CANCER CELL, V4, P85, DOI 10.1016/S1535-6108(03)00193-4; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Raj K, 2001, NATURE, V412, P914, DOI 10.1038/35091082; REICH N, 1988, J VIROL, V62, P114, DOI 10.1128/JVI.62.1.114-119.1988; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; RILEY D, 1993, J VIROL, V67, P3586, DOI 10.1128/JVI.67.6.3586-3595.1993; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Russell A, 2004, PROG MOL SUBCELL BIO, V36, P207; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; SANDLER AB, 1989, J VIROL, V63, P624, DOI 10.1128/JVI.63.2.624-630.1989; Schneider RJ, 2003, TRENDS BIOCHEM SCI, V28, P130, DOI 10.1016/S0968-0004(03)00029-X; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; SHCAACK J, 2005, VIRAL IMMUNOL, V18, P79; SHENK T, 1991, ADV CANCER RES, V57, P47; SHENK T, 1996, FIELDS VIROLOGY, V2, P2111; Shepard RN, 2003, J VIROL, V77, P8593, DOI 10.1128/JVI.77.15.8593-8595.2003; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; Shtrichman R, 1998, J VIROL, V72, P2975, DOI 10.1128/JVI.72.4.2975-2982.1998; SINCLAIR WK, 1966, RADIAT RES, V29, P450, DOI 10.2307/3572025; SKALKA AM, 2005, CELL DEATH DIFFER; Steegenga WT, 1999, ONCOGENE, V18, P5032, DOI 10.1038/sj.onc.1202886; Steegenga WT, 1998, ONCOGENE, V16, P349, DOI 10.1038/sj.onc.1201540; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stracker TH, 2005, J VIROL, V79, P6664, DOI 10.1128/JVI.79.11.6664-6673.2005; Stracker TH, 2004, DNA REPAIR, V3, P845, DOI 10.1016/j.dnarep.2004.03.014; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; TAKEDA T, 1994, J IMMUNOL, V153, P4573; Tauber B, 2001, GENE, V278, P1, DOI 10.1016/S0378-1119(01)00722-3; Tauber B, 2001, ONCOGENE, V20, P7847, DOI 10.1038/sj.onc.1204914; Taylor AMR, 2004, DNA REPAIR, V3, P1219, DOI 10.1016/j.dnarep.2004.04.009; Taylor TJ, 2004, J VIROL, V78, P5856, DOI 10.1128/JVI.78.11.5856-5866.2004; Thompson SR, 2000, CURR OPIN MICROBIOL, V3, P366, DOI 10.1016/S1369-5274(00)00106-5; Tollefson AE, 1996, J VIROL, V70, P2296, DOI 10.1128/JVI.70.4.2296-2306.1996; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; WEIDEN MD, 1994, P NATL ACAD SCI USA, V91, P153, DOI 10.1073/pnas.91.1.153; WEINBERG DH, 1986, J VIROL, V57, P833, DOI 10.1128/JVI.57.3.833-838.1986; Wilkinson DE, 2004, J VIROL, V78, P4783, DOI 10.1128/JVI.78.9.4783-4796.2004; Xi QR, 2005, J VIROL, V79, P5676, DOI 10.1128/JVI.79.9.5676-5683.2005; Xi QR, 2004, GENE DEV, V18, P1997, DOI 10.1101/gad.1212504; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YODER SS, 1986, J VIROL, V60, P779, DOI 10.1128/JVI.60.2.779-781.1986; Zentilin L, 2001, J VIROL, V75, P12279, DOI 10.1128/JVI.75.24.12279-12287.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	146	82	83	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7686	7696		10.1038/sj.onc.1209063	http://dx.doi.org/10.1038/sj.onc.1209063			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299529				2022-12-17	WOS:000233372600005
J	Evangelopoulos, ME; Weis, J; Kruttgen, A				Evangelopoulos, ME; Weis, J; Kruttgen, A			Signalling pathways leading to neuroblastoma differentiation after serum withdrawal: HDL blocks neuroblastoma differentiation by inhibition of EGFR	ONCOGENE			English	Article						cholesterol; lipoproteins; rafts; neurotrophin	EPIDERMAL-GROWTH-FACTOR; HIGH-DENSITY LIPOPROTEINS; BREAST-CANCER-CELLS; CHOLESTEROL DEPLETION; FACTOR RECEPTORS; RETINOIC ACID; LIPID RAFTS; ACTIVATION; PROLIFERATION; BINDING	Neuroblastoma is the second most common pediatric malignancy, characterized by a high rate of unexplained spontaneous remissions. Much progress has been made in understanding neuroblastoma differentiation triggered by certain agents such as retinoic acid. However, little is known about the signalling pathways that lead to differentiation of neuroblastoma cells due to serum withdrawal. We found that in Neuro2a neuroblastoma cells, EGFR, ERK1/2 and Akt showed increased phosphorylation after serum withdrawal, and that the activation of EGFR was necessary for the activation of Akt and ERK1/2. Inhibition of EGFR, ERK1/2 and PI3K blocked neuroblastoma differentiation after serum withdrawal. Interestingly, addition of high-density lipoprotein (HDL) abrogated serum-withdrawal induced neuroblastoma differentiation, as well as the activation of EGFR. Our results demonstrate a novel role for serum-derived lipoproteins in the control of receptor tyrosine kinase activity.	Univ Bern, Inst Pathol, Div Neuropathol, CH-3010 Bern, Switzerland; Rhein Westfal TH Aachen, Inst Neuropathol, Univ Hosp, D-52074 Aachen, Germany	University of Bern; RWTH Aachen University; RWTH Aachen University Hospital	Kruttgen, A (corresponding author), Univ Bern, Inst Pathol, Div Neuropathol, Murtenstr 31, CH-3010 Bern, Switzerland.	akruettgen@ukaachen.de	Kruttgen, Alexander P/E-9232-2010; Weis, Joachim/G-1984-2014	Weis, Joachim/0000-0003-3280-6773; EVANGELOPOULOS, MARIA ELEFTHERIA/0000-0003-4654-7477				Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Canon E, 2004, MOL BIOL CELL, V15, P5583, DOI 10.1091/mbc.E04-05-0439; Cao WM, 2004, CANCER RES, V64, P1515, DOI 10.1158/0008-5472.CAN-03-0675; Chen X, 2002, J BIOL CHEM, V277, P49631, DOI 10.1074/jbc.M208327200; Conti L, 2001, NAT NEUROSCI, V4, P579, DOI 10.1038/88395; Cortes-Canteli M, 2002, J BIOL CHEM, V277, P5460, DOI 10.1074/jbc.M108761200; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIAZNIDO J, 1991, J CELL SCI, P51; Dimitroulakos J, 1996, NAT MED, V2, P326, DOI 10.1038/nm0396-326; Evangelopoulos ME, 2004, J NEURO-ONCOL, V66, P101, DOI 10.1023/B:NEON.0000013492.37426.0c; FAN K, 1983, NEUROSCI LETT, V41, P205, DOI 10.1016/0304-3940(83)90248-3; Fidge NH, 1999, J LIPID RES, V40, P187; Fischer OM, 2003, BIOCHEM SOC T, V31, P1203; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GOSPODAROWICZ D, 1982, CANCER RES, V42, P3704; Grewal T, 2003, J BIOL CHEM, V278, P16478, DOI 10.1074/jbc.C300085200; Li HY, 2003, BLOOD, V101, P3628, DOI 10.1182/blood-2002-07-2283; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; Ma XF, 1998, AM J PHYSIOL-CELL PH, V274, pC1206, DOI 10.1152/ajpcell.1998.274.5.C1206; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; Pahlman S, 2000, NEUROBLASTOMA, P9; Paratcha G, 2002, CURR OPIN NEUROBIOL, V12, P542, DOI 10.1016/S0959-4388(02)00363-X; Pignatelli M, 1999, FEBS LETT, V461, P37, DOI 10.1016/S0014-5793(99)01420-9; Ringerike T, 2002, J CELL SCI, V115, P1331; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Roepstorff K, 2002, J BIOL CHEM, V277, P18954, DOI 10.1074/jbc.M201422200; ROTHENEDER M, 1989, INT J CANCER, V43, P875, DOI 10.1002/ijc.2910430523; SCHUBERT D, 1969, P NATL ACAD SCI USA, V64, P316, DOI 10.1073/pnas.64.1.316; SEEDS NW, 1970, P NATL ACAD SCI USA, V66, P160, DOI 10.1073/pnas.66.1.160; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Ullrich A, 2002, ONCOLOGY-BASEL, V63, P1, DOI 10.1159/000066202; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; WALTER M, 1995, ARTERIOSCL THROM VAS, V15, P1975, DOI 10.1161/01.ATV.15.11.1975; Westover EJ, 2003, J BIOL CHEM, V278, P51125, DOI 10.1074/jbc.M304332200; Wong RWC, 2004, CYTOKINE GROWTH F R, V15, P147, DOI 10.1016/j.cytogfr.2004.01.004	38	82	83	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3309	3318		10.1038/sj.onc.1208494	http://dx.doi.org/10.1038/sj.onc.1208494			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735700				2022-12-17	WOS:000228881800009
J	Soung, YH; Lee, JW; Kim, SY; Sung, YJ; Park, WS; Nam, SW; Kim, SH; Lee, JY; Yoo, NJ; Lee, SH				Soung, YH; Lee, JW; Kim, SY; Sung, YJ; Park, WS; Nam, SW; Kim, SH; Lee, JY; Yoo, NJ; Lee, SH			Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225_1226delTG in hepatocellular carcinomas	ONCOGENE			English	Article						caspase-8; mutation; hepatocellular carcinoma; apoptosis; caspases	CELL-DEATH; CANCER; APOPTOSIS; MECHANISMS	Evidence exists that alterations of the genes encoding apoptosis-related proteins contribute to either development or progression of human cancers. Caspase-8 plays a crucial role in the initiation phase of apoptosis. To explore the possibility that the genetic alteration of caspase-8 gene is involved in the development of hepatocellular carcinomas (HCCs), we have analysed the entire coding region of human caspase-8 gene for the detection of somatic mutations by polymerase chain reaction-single-strand conformation polymorphism in 69 HCCs with low-grade dysplastic nodule (LGDN, n = 2) or high-grade dysplastic nodule (HGDN, n = 2) or without any dysplastic nodules (n = 65). Overall, we detected a total of nine somatic mutations in 69 HCCs (13.0%). Interestingly, all of the nine mutations were an identical frameshift mutation with two base-pair deletion (1225_1226delTG), which would result in a premature termination of amino-acid synthesis in the p10 protease subunit. In a patient sample, we detected the 1225_1226delTG mutation both in HCC and LDGN lesions, suggesting that caspase-8 mutation could be involved in the early stage of HCC carcinogenesis. We expressed the tumor-derived caspase-8 mutant in the cells and found that the mutant abolished cell death activity of caspase-8. Our data indicate that caspase-8 gene is frequently mutated in HCC and the majority of the mutations may be the frameshift mutation 1225_1226delTG. Also, the data suggest that caspase-8 gene mutation might lead to the loss of its cell death function and contribute to the pathogenesis of HCC.	Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea	Catholic University of Korea	Lee, SH (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, 505 Banpo Dong, Seoul 137701, South Korea.	suhulee@catholic.ac.kr	Yoo, Nam Jin/GNM-9060-2022					BAE JM, 2002, CANC RES TREAT, V34, P708; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jiang XJ, 2003, SCIENCE, V299, P223, DOI 10.1126/science.1076807; Kim HS, 2003, GASTROENTEROLOGY, V125, P708, DOI 10.1016/S0016-5085(03)01059-X; Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; Lee SH, 1999, CANCER RES, V59, P3068; Li SP, 2001, J HEPATOL, V34, P840, DOI 10.1016/S0168-8278(01)00047-2; Liu BL, 2002, J BIOL CHEM, V277, P30159, DOI 10.1074/jbc.M203566200; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maggioni M, 2000, HEPATOLOGY, V32, P942, DOI 10.1053/jhep.2000.18425; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094; Soung YH, 2003, ONCOGENE, V22, P8048, DOI 10.1038/sj.onc.1206727; Takita J, 2001, ONCOGENE, V20, P4424, DOI 10.1038/sj.onc.1204521; WANLESS IR, 1995, HEPATOLOGY, V22, P983, DOI 10.1002/hep.1840220341	26	82	89	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					141	147		10.1038/sj.onc.1208244	http://dx.doi.org/10.1038/sj.onc.1208244			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15531912				2022-12-17	WOS:000226125800016
J	Choi, MC; Jong, HS; Kim, TY; Song, SH; Lee, DS; Lee, JW; Kim, TY; Kim, NK; Bang, YJ				Choi, MC; Jong, HS; Kim, TY; Song, SH; Lee, DS; Lee, JW; Kim, TY; Kim, NK; Bang, YJ			AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity	ONCOGENE			English	Article						AKAP12; alternative promoter; DNA methylation; histone deacetylation; apoptosis	CPG ISLAND METHYLATION; C-KINASE SUBSTRATE; CANCER CELLS; SIGNALING COMPLEXES; LUNG CARCINOMAS; DNA METHYLATION; CYCLIN-D; GENE; PROTEIN; EXPRESSION	AKAP12/Gravin, one of the A-kinase anchoring proteins (AKAPs), functions as a kinase scaffold protein and as a dynamic regulator of the beta(2)-adrenergic receptor complex. However, the biological role of AKAP12 in cancer development is not well understood. The AKAP12 gene encodes two major isoforms of 305 and 287 kDa ( designated AKAP12A and AKAP12B, respectively, in this report). We found that these two isoforms are independently expressed and that they are probably under the control of two different promoters. Moreover, both isoforms were absent from the majority of human gastric cancer cells. The results from methylation-specific PCR (MSP) and bisulfite sequencing revealed that the 5' CpG islands of both AKAP12A and AKAP12B are frequently hypermethylated in gastric cancer cells. Treatment with DNA methyltransferase inhibitor and/or histone deacetylase inhibitor efficiently restored the expression of AKAP12 isoforms, confirming that DNA methylation is directly involved in the transcriptional silencing of AKAP12 in gastric cancer cells. Hypermethylation of AKAP12A CpG island was also detected in 56% ( 10 of 18) of primary gastric tumors. The restoration of AKAP12A in AKAP12-nonexpressing cells reduced colony formation and induced apoptotic cell death. In conclusion, our results suggest that AKAP12A may function as an important negative regulator of the survival pathway in human gastric cancer.	Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Natl Res Lab Canc Epigenet, Seoul 110799, South Korea; Seoul Natl Univ, Coll Med, Dept Clin Pathol, Seoul 110744, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Bang, YJ (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, 28 Yongon Dong, Seoul 110744, South Korea.	bangyj@plaza.snu.ac.kr	Lee, Jung Weon/AAC-1146-2020; Kim, Tae-You/J-2750-2012; Bang, Yung Jue/J-2759-2012; Lee, Jung Weon/F-9149-2012; Lee, Dong soon/E-5079-2012	Lee, Jung Weon/0000-0003-2722-8200; Bang, Yung Jue/0000-0001-6000-4597; KIM, TAI YOUNG/0000-0001-8086-2476				Burgers WA, 2002, TRENDS GENET, V18, P275, DOI 10.1016/S0168-9525(02)02667-7; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Conway KE, 2000, CANCER RES, V60, P6236; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Diviani D, 2001, J CELL SCI, V114, P1431; Du Y, 2001, CANCER RES, V61, P8094; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; Gelman IH, 2002, FRONT BIOSCI-LANDMRK, V7, pD1782, DOI 10.2741/gelman; GORDON T, 1992, J CLIN INVEST, V90, P992, DOI 10.1172/JCI115976; Issa JPJ, 2001, CANCER RES, V61, P3573; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jong HS, 2002, BIOCHEM BIOPH RES CO, V292, P383, DOI 10.1006/bbrc.2002.6666; Kang GH, 2001, CANCER RES, V61, P2847; Kang SH, 1999, BRIT J CANCER, V80, P1144, DOI 10.1038/sj.bjc.6690478; Kim SG, 2001, ONCOGENE, V20, P1254, DOI 10.1038/sj.onc.1204203; Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573; Lee SW, 2003, NAT MED, V9, P900, DOI 10.1038/nm889; Li B, 2001, CANCER RES, V61, P8014; Lin FB, 2000, J BIOL CHEM, V275, P19025, DOI 10.1074/jbc.275.25.19025; Lin XY, 2000, MOL CELL BIOL, V20, P7259, DOI 10.1128/MCB.20.19.7259-7272.2000; Lin XY, 1997, CANCER RES, V57, P2304; Lin XY, 2002, BIOCHEM BIOPH RES CO, V290, P1368, DOI 10.1006/bbrc.2002.6357; LIN XY, 1995, MOL CELL BIOL, V15, P2754; Liu LM, 1997, J BIOL CHEM, V272, P2984, DOI 10.1074/jbc.272.5.2984; MILLIKIN D, 1991, CANCER RES, V51, P5449; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; Park JH, 2003, CLIN CANCER RES, V9, P433; Sato N, 1998, J BIOCHEM-TOKYO, V123, P1119; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; Song SH, 2000, INT J CANCER, V87, P236, DOI 10.1002/1097-0215(20000715)87:2<236::AID-IJC14>3.0.CO;2-M; Song SH, 2001, CANCER RES, V61, P4628; Tibiletti MB, 2000, CLIN CANCER RES, V6, P1422; Toyooka KO, 2001, CANCER RES, V61, P4556; Xia W, 2001, CANCER RES, V61, P5644; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532	40	82	96	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2004	23	42					7095	7103		10.1038/sj.onc.1207932	http://dx.doi.org/10.1038/sj.onc.1207932			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	854EX	15258566				2022-12-17	WOS:000223885100010
J	Scian, MJ; Stagliano, KER; Deb, D; Ellis, MA; Carchman, EH; Das, A; Valerie, K; Deb, SP; Deb, S				Scian, MJ; Stagliano, KER; Deb, D; Ellis, MA; Carchman, EH; Das, A; Valerie, K; Deb, SP; Deb, S			Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes	ONCOGENE			English	Article						'gain of function'; mutations; p53; transactivation; microarray	WILD-TYPE P53; CREB-BINDING-PROTEIN; ASPARAGINE SYNTHETASE GENE; HUMAN LEUKEMIA-CELLS; GAIN-OF-FUNCTION; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; HETERO-OLIGOMERIZATION; VIRAL PROMOTERS; BREAST-CANCER	We have studied the mechanism of mutant p53-mediated oncogenesis using several tumor-derived mutants. Using a colony formation assay, we found that the majority of the mutants increased the number of colonies formed compared to the vector. Expression of tumor-derived p53 mutants increases the rate of cell growth, suggesting that the p53 mutants have 'gain of function' properties. We have studied the gene expression pro. le of cells expressing tumor-derived p53-D281G to identify genes transactivated by mutant p53. We report the transactivation of two genes, asparagine synthetase and human telomerase reverse transcriptase. Quantitative real-time PCR confirms this upregulation. Transient transfection promoter assays verify that tumor-derived p53 mutants trans-activate these promoters significantly. An electrophoretic mobility shift assay shows that tumor-derived p53-mutants cannot bind to the wild-type p53 consensus sequence. The results presented here provide some evidence of a possible mechanism for mutant p53-mediated transactivation.	Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Deb, S (corresponding author), Virginia Commonwealth Univ, Dept Biochem, POB 980614, Richmond, VA 23298 USA.	sdeb@hsc.vcu.edu	Das, Anindita/K-8003-2013; Valerie, Kristoffer/AAL-8299-2021	Das, Anindita/0000-0003-4422-7277; Anderson, Michelle/0000-0003-1510-2942	NATIONAL CANCER INSTITUTE [F31CA097520, R01CA070712, R01CA074172] Funding Source: NIH RePORTER; NCI NIH HHS [1 F31 CA97520, CA74172, CA70712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aslanian AM, 2001, BIOCHEM J, V357, P321, DOI 10.1042/0264-6021:3570321; Asschert JGW, 1999, INT J CANCER, V81, P236, DOI 10.1002/(SICI)1097-0215(19990412)81:2<236::AID-IJC12>3.0.CO;2-R; Barbosa-Tessmann IP, 2000, J BIOL CHEM, V275, P26976; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; Bensaad K, 2003, J BIOL CHEM, V278, P10546, DOI 10.1074/jbc.M208233200; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P200, DOI 10.1093/nar/26.1.200; Bronder JL, 2003, J BIOL CHEM, V278, P48861, DOI 10.1074/jbc.M304844200; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Davis BB, 2003, AM J PHYSIOL-CELL PH, V284, pC16, DOI 10.1152/ajpcell.00211.2002; Deb D, 2002, ONCOGENE, V21, P176, DOI 10.1038/sj/onc/1205035; Deb D, 2001, INT J ONCOL, V18, P401; Deb D, 1999, INT J ONCOL, V15, P413; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEB SP, 1994, ONCOGENE, V9, P1341; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; Doyle L Austin, 2002, Expert Rev Anticancer Ther, V2, P217, DOI 10.1586/14737140.2.2.217; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ellis MJ, 1998, BREAST CANCER RES TR, V52, P175, DOI 10.1023/A:1006127621512; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; Giebler HA, 2000, MOL CELL BIOL, V20, P4849, DOI 10.1128/MCB.20.13.4849-4858.2000; GRECO A, 1989, MOL CELL BIOL, V9, P2350, DOI 10.1128/MCB.9.6.2350; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Hassan S, 2003, J BIOL CHEM, V278, P38860, DOI 10.1074/jbc.M305040200; Herbert BS, 2001, BREAST CANCER RES, V3, P146, DOI 10.1186/bcr288; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hussain SP, 1998, TOXICOL LETT, V103, P219, DOI 10.1016/S0378-4274(98)00310-5; Hutson RG, 1997, AM J PHYSIOL-CELL PH, V272, pC1691, DOI 10.1152/ajpcell.1997.272.5.C1691; JUVEN T, 1993, ONCOGENE, V8, P3411; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kannan K, 2001, ONCOGENE, V20, P3449, DOI 10.1038/sj.onc.1204446; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; KERN SE, 1991, ONCOGENE, V6, P131; Kerns RT, 2003, METHODS, V31, P274, DOI 10.1016/S1046-2023(03)00156-7; Kiyooka K, 1999, Ann Thorac Cardiovasc Surg, V5, P293; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; LENG P, 1995, ONCOGENE, V10, P1275; Leung-Pineda V, 2002, J BIOL CHEM, V277, P16585, DOI 10.1074/jbc.M110972200; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1995, ONCOGENE, V10, P2387; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; MARTIN DW, 1993, BIOCHEM BIOPH RES CO, V195, P428, DOI 10.1006/bbrc.1993.2061; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; Matsui H, 1999, CARDIOVASC RES, V42, P104, DOI 10.1016/S0008-6363(98)00285-5; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Morali OG, 2000, DEV BIOL, V227, P133, DOI 10.1006/dbio.2000.9875; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; Polanowska J, 2000, GENE CHROMOSOME CANC, V28, P126, DOI 10.1002/(SICI)1098-2264(200005)28:1<126::AID-GCC15>3.3.CO;2-7; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Preuss U, 2000, INT J CANCER, V88, P162, DOI 10.1002/1097-0215(20001015)88:2<162::AID-IJC3>3.0.CO;2-M; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Prives C, 1999, J PATHOL, V187, P112; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Scheel C, 2002, VIRCHOWS ARCH, V440, P573, DOI 10.1007/s00428-002-0634-9; Scolnick DM, 1997, CANCER RES, V57, P3693; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; Sigal A, 2000, CANCER RES, V60, P6788; Smith ER, 2001, J BIOL CHEM, V276, P31483, DOI 10.1074/jbc.C100351200; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; SPERGEL JM, 1992, J VIROL, V66, P1021, DOI 10.1128/JVI.66.2.1021-1030.1992; STORY MD, 1993, CANCER CHEMOTH PHARM, V32, P129, DOI 10.1007/BF00685615; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Valerie E, 1999, UROLOGY, V54, P1082, DOI 10.1016/S0090-4295(99)00311-8; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Webb SJ, 2002, J DENT RES, V81, P17, DOI 10.1177/154405910208100105; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xiang H, 2002, ONCOGENE, V21, P3784, DOI 10.1038/sj.onc.1205455; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang CR, 2000, FASEB J, V14, P379, DOI 10.1096/fasebj.14.2.379; Zhao RB, 2000, GENE DEV, V14, P981; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	90	82	83	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2004	23	25					4430	4443		10.1038/sj.onc.1207553	http://dx.doi.org/10.1038/sj.onc.1207553			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	824CJ	15077194				2022-12-17	WOS:000221661300009
J	Yoshida, K; Inoue, I				Yoshida, K; Inoue, I			Regulation of Geminin and Cdt1 expression by E2F transcription factors	ONCOGENE			English	Article						Geminin; Cdt1; DNA replication; promoter; transcription; E2F	CELL-CYCLE REGULATION; MURINE THYMIDINE KINASE; DNA-REPLICATION; RETINOBLASTOMA PROTEIN; S-PHASE; DISTINCT ROLES; FAMILY-MEMBERS; BINDING-SITE; IN-VIVO; E GENE	Geminin and Cdt1 play an essential role in the initiation of DNA replication, by regulating the chromatin loading of the MCM complex. In this study, we showed that the transcription of human Geminin and Cdt1, as well as that of MCM7, is activated by transcription factors E2F1-4, but not by factors E2F5-7. Analysis of various Geminin and Cdt1 promoter constructs showed that an E2F-responsive sequence in the vicinity of the transcription initiation site is necessary for the transcriptional activation. The promoter activity for human Geminin was activated by the E7, but not E6, oncogene of human papillomavirus type 16. While E2F1-induced activation of human Cdt1 gene transcription was suppressed by pRb, but not by p107 or p130, its E2F4-induced activation was suppressed by pRb, p107, and p130. Furthermore, the promoter activities of human Geminin and Cdt1 were demonstrated to be growth-dependent. Taken together, the results demonstrate that Geminin and Cdt1 constitute targets for various members of the E2F family of transcription factors, and that expression of Geminin and Cdt1 is perhaps mediated by the activation of a pRb/E2F pathway.	Univ Tokyo, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Yoshida, K (corresponding author), Univ Tokyo, Inst Med Sci, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yoshidak@ims.u-tokyo.ac.jp						BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; Botz J, 1996, MOL CELL BIOL, V16, P3401; Boyer SN, 1996, CANCER RES, V56, P4620; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; Duronio RJ, 1998, MOL CELL BIOL, V18, P141, DOI 10.1128/MCB.18.1.141; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; FURUKAWA Y, 1994, J BIOL CHEM, V269, P26249; Geng Y, 1996, ONCOGENE, V12, P1173; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Hansel DE, 2003, AM J PATHOL, V163, P217, DOI 10.1016/S0002-9440(10)63645-0; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Huet X, 1996, MOL CELL BIOL, V16, P3789; Humbert PO, 2000, GENE DEV, V14, P690; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Kulartz M, 2003, BIOCHEM BIOPH RES CO, V305, P412, DOI 10.1016/S0006-291X(03)00773-3; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Li Q, 1999, MOL CELL BIOL, V19, P5339; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Mai S, 1996, ONCOGENE, V12, P277; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1998, ONCOGENE, V17, P1777, DOI 10.1038/sj.onc.1202105; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Ohtani K, 1999, ONCOGENE, V18, P2299, DOI 10.1038/sj.onc.1202544; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; Rotheneder H, 1999, J MOL BIOL, V293, P1005, DOI 10.1006/jmbi.1999.3213; Schlisio S, 2002, EMBO J, V21, P5775, DOI 10.1093/emboj/cdf577; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shohet JM, 2002, CANCER RES, V62, P1123; Slansky JE, 1996, BIOESSAYS, V18, P55, DOI 10.1002/bies.950180111; Suzuki S, 1998, GENE, V216, P85, DOI 10.1016/S0378-1119(98)00323-0; Takahashi Y, 2000, GENE DEV, V14, P804; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wohlschlegel JA, 2002, AM J PATHOL, V161, P267, DOI 10.1016/S0002-9440(10)64178-8; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; ZHANG YH, 1995, ONCOGENE, V10, P2085; zur Hausen H, 1999, SEMIN CANCER BIOL, V9, P405, DOI 10.1006/scbi.1999.0144	54	82	87	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	2004	23	21					3802	3812		10.1038/sj.onc.1207488	http://dx.doi.org/10.1038/sj.onc.1207488			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	14990995				2022-12-17	WOS:000221242500007
J	Liu, MT; Chen, YR; Chen, SC; Hu, CY; Lin, CS; Chang, YT; Wang, WB; Chen, JY				Liu, MT; Chen, YR; Chen, SC; Hu, CY; Lin, CS; Chang, YT; Wang, WB; Chen, JY			Epstein-Barr virus latent membrane protein 1 induces micronucleus formation, represses DNA repair and enhances sensitivity to DNA-damaging agents in human epithelial cells	ONCOGENE			English	Article						Epstein-Barr virus LMP1; DNA repair; micronucleus formation	TUMOR-SUPPRESSOR GENE; NASOPHARYNGEAL CARCINOMA; P53 GENE; EXCISION-REPAIR; POINT MUTATION; MICE LACKING; IN-VITRO; PROTEIN; CHROMOSOME; EXPRESSION	The latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV) is a viral oncogene and it is essential for the transformation of resting B cells by the virus. The protein acts as a ligand-less membrane receptor and triggers numerous cellular signaling pathways. Cellular transformation frequently has been associated with genomic instability. To investigate whether EBV LMP1 induces chromosomal aberrations, micronucleus (MN) formation was examined in LMP1-expressing epithelial cells. The expression of wild-type LMP1 enhanced both spontaneous and bleomycin-induced MN formation. MN formation may be induced by inactivation of DNA repair and, therefore, we investigated the effect of LMP1 on DNA repair, using a host cell reactivation (HCR) assay. In the HCR assay, LMP1 reduced the capacity for DNA repair of both NPC-TW01 (p53-wild-type) and H1299 (p53-defficient) cells. As reduction of DNA repair by LMP1 occurs in p53-wild-type and p53-defficient cells, it seems that LMP1 can repress DNA repair in a p53-independent manner. Inactivation of DNA repair may render cells sensitive to DNA-damaging agents. In this study, H1299 cells harboring LMP1 were shown to be more sensitive to UV and bleomycin than those with a vector control. Using various deletion mutants of EBV LMP1 to determine the regions of LMP1 required to enhance MN formation, inhibit DNA repair and sensitize cells to DNA-damaging agents, we found that the region a. a. 189-222 (located within the CTAR1 domain) was responsible for sensitizing cells to UV and bleomycin, as well as for enhancing MN formation and repressing DNA repair. Based on these results, we suggest that disruption of DNA repair by LMP-1 results in an accumulation of unrepaired DNA and consequent genomic instability, which may contribute to the oncogenesis of LMP1 in human epithelial cells.	Natl Hlth Res Inst, Taipei 114, Taiwan; Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 100, Taiwan	National Health Research Institutes - Taiwan; National Taiwan University	Chen, JY (corresponding author), Natl Hlth Res Inst, 3F 109,Sect 6,Min Chuan E Rd, Taipei 114, Taiwan.	cjy@nhri.org.tw	Chen, Jen-Yang/D-2085-2010; Lin, Chang-Shen/X-2189-2019; Lin, Chang-Shen/D-5140-2009	Lin, Chang-Shen/0000-0001-7415-2187; 				AARONSON SA, 1970, NATURE, V228, P359, DOI 10.1038/228359a0; AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; ABRAHAMS PJ, 1976, MUTAT RES, V35, P13, DOI 10.1016/0027-5107(76)90164-0; AMES BN, 1995, P NATL ACAD SCI USA, V92, P5258, DOI 10.1073/pnas.92.12.5258; ATHAS WF, 1991, CANCER RES, V51, P5786; BLANCO M, 1973, MUTAT RES, V17, P293, DOI 10.1016/0027-5107(73)90001-8; Butel JS, 1996, TRENDS MICROBIOL, V4, P119, DOI 10.1016/0966-842X(96)81529-0; Capovilla A, 1997, BIOCHEM BIOPH RES CO, V232, P255, DOI 10.1006/bbrc.1997.6269; Chang Y, 2002, HEAD NECK-J SCI SPEC, V24, P143, DOI 10.1002/hed.10039; CHEN JY, 1985, J MED VIROL, V17, P47, DOI 10.1002/jmv.1890170107; CHEN JY, 1989, J MED VIROL, V27, P269, DOI 10.1002/jmv.1890270403; CHEN JY, 1982, CHINESE J MICROBIOLO, V15, P255; Chen MR, 2001, J MED VIROL, V64, P51, DOI 10.1002/jmv.1017; Chen YJ, 1999, GENE CHROMOSOME CANC, V25, P169, DOI 10.1002/(SICI)1098-2264(199906)25:2<169::AID-GCC13>3.3.CO;2-9; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; CHIECOBIANCHI L, 1988, LEUKEMIA, V2, pS223; Chien YC, 2001, NEW ENGL J MED, V345, P1877, DOI 10.1056/NEJMoa011610; Cho EY, 2003, CANCER EPIDEM BIOMAR, V12, P1100; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; Duensing S, 2002, CANCER RES, V62, P7075; Fenech M, 2002, DRUG DISCOV TODAY, V7, P1128, DOI 10.1016/S1359-6446(02)02502-3; Floettmann JL, 1998, ONCOGENE, V17, P2383, DOI 10.1038/sj.onc.1202144; Gualandi G, 2001, MUTAGENESIS, V16, P203, DOI 10.1093/mutage/16.3.203; Gulley ML, 1998, HUM PATHOL, V29, P252, DOI 10.1016/S0046-8177(98)90044-2; HEDDLE JA, 1973, MUTAT RES, V18, P187, DOI 10.1016/0027-5107(73)90035-3; HENLE G, 1976, INT J CANCER, V17, P1, DOI 10.1002/ijc.2910170102; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HILDESHEIM A, 1993, EPIDEMIOL REV, V15, P466, DOI 10.1093/oxfordjournals.epirev.a036130; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HSU TY, 1992, J MED VIROL, V38, P214, DOI 10.1002/jmv.1890380311; HUANG DP, 1991, CANCER GENET CYTOGEN, V54, P91, DOI 10.1016/0165-4608(91)90035-S; HUANG DP, 1989, INT J CANCER, V43, P936, DOI 10.1002/ijc.2910430535; HUEN DS, 1995, ONCOGENE, V10, P549; JACOB F, 1953, COLD SPRING HARB SYM, V18, P101, DOI 10.1101/SQB.1953.018.01.019; KAMADA N, 1992, CANCER RES, V52, P1481; Kao SY, 2000, ONCOGENE, V19, P2240, DOI 10.1038/sj.onc.1203559; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; KLOCKER H, 1986, EUR J CELL BIOL, V39, P346; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; LEHMANN AR, 1985, NUCLEIC ACIDS RES, V13, P2087, DOI 10.1093/nar/13.6.2087; Lin CS, 2000, J MOL BIOL, V303, P7, DOI 10.1006/jmbi.2000.4121; LIN CT, 1990, LAB INVEST, V62, P713; Liu MY, 1998, J MED VIROL, V56, P179, DOI 10.1002/(SICI)1096-9071(199811)56:3<179::AID-JMV1>3.0.CO;2-4; Liu MY, 1997, J MED VIROL, V52, P262, DOI 10.1002/(SICI)1096-9071(199707)52:3&lt;262::AID-JMV5&gt;3.0.CO;2-0; LIU MY, 1989, J MED VIROL, V28, P101, DOI 10.1002/jmv.1890280209; LO KW, 1992, ANTICANCER RES, V12, P1957; LO KW, 1995, CANCER RES, V55, P2039; Lu JJY, 1996, J GEN VIROL, V77, P1883, DOI 10.1099/0022-1317-77-8-1883; Lung ML, 1998, CANCER LETT, V133, P89, DOI 10.1016/S0304-3835(98)00209-2; LYTLE CD, 1972, INT J RADIAT BIOL RE, V22, P159, DOI 10.1080/716100000; Macera MJ, 1996, AM J HEMATOL, V52, P53, DOI 10.1002/(SICI)1096-8652(199605)52:1&lt;53::AID-AJH9&gt;3.0.CO;2-5; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; MARUYAMA K, 1990, CANCER RES, V50, pS5697; MATSUOKA A, 1992, MUTAT RES, V272, P223, DOI 10.1016/0165-1161(92)91535-Y; MITSUDOMI T, 1992, ONCOGENE, V7, P171; OLD LJ, 1966, P NATL ACAD SCI USA, V56, P1699, DOI 10.1073/pnas.56.6.1699; PARRY JM, 1987, MUTAT RES, V181, P267, DOI 10.1016/0027-5107(87)90104-7; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; PROTICSABLJIC M, 1985, P NATL ACAD SCI USA, V82, P6622, DOI 10.1073/pnas.82.19.6622; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; Shao JY, 2001, ANTICANCER RES, V21, P3021; SMITH ML, 1995, ONCOGENE, V10, P1053; SPRUCK CH, 1992, CANCER RES, V52, P4787; STERNES KL, 1989, MUTAGENESIS, V4, P425, DOI 10.1093/mutage/4.6.425; Stopper H, 1997, MUTAT RES-DNA REPAIR, V383, P107, DOI 10.1016/S0921-8777(96)00049-3; SUN Y, 1992, P NATL ACAD SCI USA, V89, P6516, DOI 10.1073/pnas.89.14.6516; SUN Y, 1995, ONCOGENE, V10, P785; THODAY JM, 1951, BRIT J RADIOL, V24, P572, DOI 10.1259/0007-1285-24-286-572; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; VANDEREB AJ, 1967, BIOCHEM BIOPH RES CO, V28, P284, DOI 10.1016/0006-291X(67)90442-1; ZENG Y, 1982, INT J CANCER, V29, P139, DOI 10.1002/ijc.2910290204	75	82	83	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2531	2539		10.1038/sj.onc.1207375	http://dx.doi.org/10.1038/sj.onc.1207375			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14716302				2022-12-17	WOS:000220558000010
J	Barnhart, BC; Lee, JC; Alappat, EC; Peter, ME				Barnhart, BC; Lee, JC; Alappat, EC; Peter, ME			The death effector domain protein family	ONCOGENE			English	Review						apoptosis; DD fold; cancer	TRAIL-INDUCED APOPTOSIS; NF-KAPPA-B; FLICE-INHIBITORY PROTEIN; FAS-MEDIATED APOPTOSIS; INDUCED CELL-DEATH; REGULATES FAS/TNFR1-INDUCED APOPTOSIS; CHRONIC LYMPHOCYTIC-LEUKEMIA; DOMINANT INTERFERING MUTANT; NECROSIS-FACTOR RECEPTOR-1; INDUCED-PROXIMITY MODEL	Apoptosis signaling is regulated and executed by specialized proteins that often carry protein/protein interaction domains. One of these domains is the death effector domain (DED) that is predominantly found in components of the death-inducing signaling complex, which forms at the members of the death receptor family following their ligation. Both proapoptotic- and antiapoptotic-DED-containing proteins have been identified, which makes these proteins exquisitely suited to the regulation of apoptosis. Aside from their pivotal role in the control of the apoptotic program, DED-containing proteins have recently been demonstrated to exert their influence on other cellular processes as well, including cell proliferation. These data highlight the multiple roles for the members of this family, suggesting that they are suited to control both life and death decisions of cells. Additionally, because they can act proapoptotically, antiapoptotically, or in the regulation of the cell cycle, this family of proteins may be excellent candidates for cancer therapy targets.	Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA	University of Chicago	Peter, ME (corresponding author), Univ Chicago, Ben May Inst Canc Res, 924 E 57th St, Chicago, IL 60637 USA.	MPeter@uchicago.edu		Peter, Marcus Ernst/0000-0003-3216-036X; Lee, Justine C./0000-0002-8943-0837				Adachi T, 1996, EMBO J, V15, P1534, DOI 10.1002/j.1460-2075.1996.tb00497.x; Alcivar A, 2003, ONCOGENE, V22, P291, DOI 10.1038/sj.onc.1206099; Algeciras-Schimnich A, 1999, J IMMUNOL, V162, P5205; ALGECIRASSCHIMN.A, 2003, IN PRESS P NATL SCI; ALGECIRASSCHIMN.A, 2002, CASPASES LANDES BIOS, P123; ARAUJO H, 1993, J BIOL CHEM, V268, P5911; Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; BERA TK, 1994, P NATL ACAD SCI USA, V91, P9789, DOI 10.1073/pnas.91.21.9789; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Breckenridge DG, 2002, P NATL ACAD SCI USA, V99, P4331, DOI 10.1073/pnas.072088099; Bullani RR, 2001, J INVEST DERMATOL, V117, P360, DOI 10.1046/j.0022-202x.2001.01418.x; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chang DW, 2003, EMBO J, V22, P4132, DOI 10.1093/emboj/cdg414; Chatterjee D, 2001, CANCER RES, V61, P7148; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Choi YH, 2001, J BIOL CHEM, V276, P25073, DOI 10.1074/jbc.M102941200; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Condorelli G, 2002, J BIOL CHEM, V277, P11013, DOI 10.1074/jbc.M110934200; DANZIGER N, 1995, J NEUROCHEM, V64, P1016; Derfuss T, 2002, CURR TOP MICROBIOL, V269, P257; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Dong G, 2001, CANCER RES, V61, P4797; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Eggert A, 2000, MED PEDIATR ONCOL, V35, P603, DOI 10.1002/1096-911X(20001201)35:6<603::AID-MPO24>3.0.CO;2-1; Eggert A, 2001, CANCER RES, V61, P1314; Estelles A, 1999, DEV BIOL, V216, P16, DOI 10.1006/dbio.1999.9510; Fairbrother WJ, 2001, PROTEIN SCI, V10, P1911, DOI 10.1110/ps.13801; Fan LF, 1999, HUM GENE THER, V10, P2273, DOI 10.1089/10430349950016924; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Fulda S, 2000, CANCER RES, V60, P3947; Gervais FG, 2002, NAT CELL BIOL, V4, P95, DOI 10.1038/ncb735; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Griffith TS, 1998, J IMMUNOL, V161, P2833; Hackam AS, 2000, J BIOL CHEM, V275, P41299, DOI 10.1074/jbc.M008408200; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hao CH, 2001, CANCER RES, V61, P1162; Harada K, 2002, CANCER RES, V62, P5897; Held J, 2001, DRUG RESIST UPDATE, V4, P243, DOI 10.1054/drup.2001.0208; Hennino A, 2001, J EXP MED, V193, P447, DOI 10.1084/jem.193.4.447; Hill JM, 2002, EMBO J, V21, P6494, DOI 10.1093/emboj/cdf641; Horrevoets AJG, 1999, BLOOD, V93, P3418, DOI 10.1182/blood.V93.10.3418.410k23_3418_3431; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu SM, 1997, J BIOL CHEM, V272, P9621; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Hua ZC, 2003, IMMUNITY, V18, P513, DOI 10.1016/S1074-7613(03)00083-9; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Hueber AO, 2000, J BIOL CHEM, V275, P10453, DOI 10.1074/jbc.275.14.10453; Hyer ML, 2002, CANCER BIOL THER, V1, P401, DOI 10.4161/cbt.1.4.15; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irisarri M, 2000, LEUKEMIA, V14, P2149, DOI 10.1038/sj.leu.2401954; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jeong EJ, 1999, J BIOL CHEM, V274, P16337, DOI 10.1074/jbc.274.23.16337; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kaufmann M, 2002, FEBS LETT, V527, P250, DOI 10.1016/S0014-5793(02)03146-0; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kelly MM, 2002, CANCER BIOL THER, V1, P520, DOI 10.4161/cbt.1.5.169; Kim PKM, 2001, DRUG RESIST UPDATE, V4, P293, DOI 10.1054/drup.2001.0223; Kim PKM, 1996, J IMMUNOL, V157, P5461; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kinoshita H, 2000, INT J CANCER, V88, P986, DOI 10.1002/1097-0215(20001215)88:6<986::AID-IJC23>3.0.CO;2-B; Kirchhoff S, 2000, EUR J IMMUNOL, V30, P2765, DOI 10.1002/1521-4141(200010)30:10<2765::AID-IMMU2765>3.0.CO;2-W; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kitsberg D, 1999, J NEUROSCI, V19, P8244; Koga S, 2001, ANTICANCER RES, V21, P1937; Komata T, 2001, INT J ONCOL, V19, P1015; Kondo S, 1998, HUM GENE THER, V9, P1599, DOI 10.1089/hum.1998.9.11-1599; Koonin EV, 1999, NATURE, V401, P662, DOI 10.1038/44317; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Kubes M, 1998, J NEUROCHEM, V71, P1307; Kumar D, 2000, J BIOL CHEM, V275, P2973, DOI 10.1074/jbc.275.4.2973; Lee JC, 2002, J CELL BIOL, V158, P1051, DOI 10.1083/jcb.200112124; Lens SMA, 2002, MOL CELL BIOL, V22, P5419, DOI 10.1128/MCB.22.15.5419-5433.2002; Leo CP, 1998, ENDOCRINOLOGY, V139, P4839, DOI 10.1210/en.139.12.4839; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu BL, 2002, J BIOL CHEM, V277, P30159, DOI 10.1074/jbc.M203566200; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane M, 2002, ONCOGENE, V21, P6809, DOI 10.1038/sj.onc.1205853; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Micheau O, 1999, BIOCHEM BIOPH RES CO, V256, P603, DOI 10.1006/bbrc.1999.0391; Morgan MJ, 2001, CELL DEATH DIFFER, V8, P696, DOI 10.1038/sj.cdd.4400866; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Newton K, 2001, CURR BIOL, V11, P273, DOI 10.1016/S0960-9822(01)00067-7; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Ng PWP, 1999, J BIOL CHEM, V274, P10301, DOI 10.1074/jbc.274.15.10301; Nguyen M, 2000, MOL CELL BIOL, V20, P6731, DOI 10.1128/MCB.20.18.6731-6740.2000; Olsson A, 2001, LEUKEMIA, V15, P1868, DOI 10.1038/sj.leu.2402287; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Petak Istvan, 2001, Pathology and Oncology Research, V7, P95; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Ramos JW, 2000, MOL BIOL CELL, V11, P2863, DOI 10.1091/mbc.11.9.2863; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Roth W, 2002, J BIOL CHEM, V277, P7501, DOI 10.1074/jbc.M110749200; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schickling O, 2001, CELL DEATH DIFFER, V8, P1157, DOI 10.1038/sj.cdd.4400928; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094; Shin MS, 2002, ONCOGENE, V21, P4129, DOI 10.1038/sj.onc.1205527; Shivapurkar N, 2002, ONCOGENE, V21, P8510, DOI 10.1038/sj.onc.1205941; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Siegmund D, 2002, MOL MED, V8, P725, DOI 10.1007/BF03402036; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Stegh AH, 1998, EMBO J, V17, P5974, DOI 10.1093/emboj/17.20.5974; Stegh AH, 2002, J BIOL CHEM, V277, P4351, DOI 10.1074/jbc.M108947200; Stegh Alexander H., 2001, Cardiology Clinics, V19, P13, DOI 10.1016/S0733-8651(05)70192-2; Strasser A, 1999, INT J BIOCHEM CELL B, V31, P533, DOI 10.1016/S1357-2725(99)00003-5; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Teitz T, 2001, J MOL MED, V79, P428, DOI 10.1007/s001090100233; Telliez JB, 2000, J MOL BIOL, V300, P1323, DOI 10.1006/jmbi.2000.3899; Thomas LR, 2002, J BIOL CHEM, V277, P34343, DOI 10.1074/jbc.M204169200; Thomas RK, 2002, AM J PATHOL, V160, P1521, DOI 10.1016/S0002-9440(10)62578-3; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Tschopp J, 1998, CURR OPIN GENET DEV, V8, P82, DOI 10.1016/S0959-437X(98)80066-X; Tsukamoto T, 2000, CANCER LETT, V149, P105, DOI 10.1016/S0304-3835(99)00350-X; Uzzo RG, 2001, CLIN CANCER RES, V7, P3276; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vaughn DE, 1999, J MOL BIOL, V293, P439, DOI 10.1006/jmbi.1999.3177; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X; Wang J, 2000, EUR J IMMUNOL, V30, P155, DOI 10.1002/1521-4141(200001)30:1<155::AID-IMMU155>3.3.CO;2-O; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Xiao C, 2002, J BIOL CHEM, V277, P25020, DOI 10.1074/jbc.M202946200; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; You ZB, 2001, J BIOL CHEM, V276, P26398, DOI 10.1074/jbc.M102464200; Zhan Y, 2002, CELL DEATH DIFFER, V9, P439, DOI 10.1038/sj.cdd.4401038; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597; Zhang J, 1996, MOL CELL BIOL, V16, P2756; Zhang J, 2001, J BIOL CHEM, V276, P29815, DOI 10.1074/jbc.M103838200; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhang Y, 2000, J BIOL CHEM, V275, P35224, DOI 10.1074/jbc.M003329200; Zheng LX, 2001, J BIOL CHEM, V276, P31945, DOI 10.1074/jbc.M102799200; Zhou P, 1999, P NATL ACAD SCI USA, V96, P11265, DOI 10.1073/pnas.96.20.11265; Zuzak TJ, 2002, EUR J CANCER, V38, P83, DOI 10.1016/S0959-8049(01)00355-0	163	82	85	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2003	22	53					8634	8644		10.1038/sj.onc.1207103	http://dx.doi.org/10.1038/sj.onc.1207103			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	745YX	14634625				2022-12-17	WOS:000186720000009
J	Gondi, CS; Lakka, SS; Yanamandra, N; Siddique, K; Dinh, DH; Olivero, WC; Gujrati, M; Rao, JS				Gondi, CS; Lakka, SS; Yanamandra, N; Siddique, K; Dinh, DH; Olivero, WC; Gujrati, M; Rao, JS			Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis	ONCOGENE			English	Article						adenovirus; antisense; glioma; invasion; uPA and uPAR	PLASMINOGEN-ACTIVATOR RECEPTOR; HUMAN GLIOBLASTOMA CELLS; UROKINASE RECEPTOR; MEDIATED DELIVERY; MONOCLONAL-ANTIBODY; ACTIN CYTOSKELETON; SURFACE UROKINASE; IN-VITRO; CANCER; MICE	Urokinase-type plasminogen activator (uPA) and its receptor (uPAR) play an important role in the invasiveness of gliomas and other infiltrative tumors. In glioma cell lines and tumors, high grade correlates with increased expression of uPAR and uPA. We report here the downregulation of uPAR and uPA by delivery of antisense sequences of uPAR and uPA in a single adenoviral vector, Ad-uPAR-uPA (Ad, adenovirus). The bicistronic construct (Ad-uPAR-uPA) infected glioblastoma cell line had significantly reduced levels of uPAR, uPA enzymatic activity and immunoreactivity for these proteins when compared to controls. The Ad-uPAR-uPA infected cells showed a markedly lower level of invasion in the Matrigel invasion assays, and their spheroids failed to invade the fetal rat brain aggregates in the coculture system. Intracranial injection of SNB19 cells with the Ad-uPAR-uPA antisense bicistronic construct showed inhibited invasiveness and tumorigenicity. Subcutaneous injections of bicistronic antisense constructs into established tumors (U87 MG) caused regression of those tumors. Our results support the therapeutic potential of targeting the individual components of the uPAR-uPA system by using a single adenovirus construct for the treatment of glioma and other invasive cancers.	Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA; Univ Illinois, Dept Neurosurg, Peoria, IL USA; Univ Illinois, Dept Pathol, Peoria, IL USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA.	jsrao@uic.edu		Gondi, Christopher/0000-0002-3036-9920	NCI NIH HHS [CA 75557] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075557] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi Y, 2001, J BIOL CHEM, V276, P47171, DOI 10.1074/jbc.M104334200; Adachi Y, 2002, ONCOGENE, V21, P87, DOI 10.1038/sj.onc.1204999; Blasi F, 1999, APMIS, V107, P96, DOI 10.1111/j.1699-0463.1999.tb01531.x; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P5899, DOI 10.1073/pnas.93.12.5899; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; Carmeliet P, 1998, J CELL BIOL, V140, P233, DOI 10.1083/jcb.140.1.233; Chang AW, 1998, ARTERIOSCL THROM VAS, V18, P1855, DOI 10.1161/01.ATV.18.12.1855; Chintala SK, 1998, J BIOL CHEM, V273, P13545, DOI 10.1074/jbc.273.22.13545; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; ELLIS V, 1993, J BIOL CHEM, V268, P4806; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; Fibbi G, 1998, LAB INVEST, V78, P1109; FOEKENS JA, 1995, J NATL CANCER I, V87, P751, DOI 10.1093/jnci/87.10.751; Ghiso JAA, 1999, EUR J BIOCHEM, V263, P295, DOI 10.1046/j.1432-1327.1999.00507.x; Go Y, 1997, CLIN EXP METASTAS, V15, P440, DOI 10.1023/A:1018410523635; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Gutierrez LS, 2000, CANCER RES, V60, P5839; Kjoller L, 2002, BIOL CHEM, V383, P5, DOI 10.1515/BC.2002.002; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; KOBAYASHI H, 1993, JPN J CANCER RES, V84, P633, DOI 10.1111/j.1349-7006.1993.tb02023.x; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; Koshelnick Y, 1997, J BIOL CHEM, V272, P28563, DOI 10.1074/jbc.272.45.28563; LAFRENIE RM, 1992, CANCER RES, V52, P2202; Li H, 1998, GENE THER, V5, P1105, DOI 10.1038/sj.gt.3300742; Min HY, 1996, CANCER RES, V56, P2428; Mohan PM, 1999, CANCER RES, V59, P3369; MOHANAM S, 1993, CANCER RES, V53, P4143; NIELSEN LS, 1982, BIOCHEMISTRY-US, V21, P6410, DOI 10.1021/bi00268a014; Park IK, 1997, INT J CANCER, V71, P867, DOI 10.1002/(SICI)1097-0215(19970529)71:5<867::AID-IJC27>3.0.CO;2-3; SAPPINO AP, 1987, CANCER RES, V47, P4043; SCHMITT M, 1992, BIOL CHEM H-S, V373, P611, DOI 10.1515/bchm3.1992.373.2.611; Sieuwerts AM, 2002, THROMB HAEMOSTASIS, V87, P674; Sturge J, 2002, J CELL SCI, V115, P699; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; YAMAMOTO M, 1994, CANCER RES, V54, P5016; YAMAMOTO M, 1994, CANCER RES, V54, P3656; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767	37	82	93	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					5967	5975		10.1038/sj.onc.1206535	http://dx.doi.org/10.1038/sj.onc.1206535			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955075				2022-12-17	WOS:000185137800005
J	Israel, BF; Kenney, SC				Israel, BF; Kenney, SC			Virally targeted therapies for EBV-associated malignancies	ONCOGENE			English	Article						EBV; malignancy; therapeutics	EPSTEIN-BARR-VIRUS; IMMEDIATE-EARLY GENE; CYTOTOXIC T-LYMPHOCYTES; LATENTLY INFECTED-CELLS; PROTEIN-KINASE-C; TRANSCRIPTION FACTOR; LYTIC CYCLE; HODGKINS-DISEASE; BRLF1 PROMOTER; BZLF1 PROMOTER	In Epstein-Barr virus (EBV)-positive lymphomas, the presence of the EBV genome in virtually all tumor cells, but very few normal cells, suggests that novel, EBV-targeted therapies could be used to treat these malignancies. In this paper, we review a variety of different approaches currently under development that specifically target EBV-infected cells for destruction. EBV-based strategies for treating cancer include prevention of viral oncogene expression, inducing loss of the EBV episome, the purposeful induction of the lytic form of EBV infection, and enhancing the host immune response to virally encoded antigens.	Univ N Carolina, Dept Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Kenney, SC (corresponding author), Univ N Carolina, Dept Med, Lineberger Comprehens Canc Ctr, CB 7295, Chapel Hill, NC 27599 USA.	shann@med.unc.edu			NCI NIH HHS [R01-CA66519, R01-CA58853] Funding Source: Medline; NIAID NIH HHS [K23-AI51200] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058853, R01CA066519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI051200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adamson AL, 2000, J VIROL, V74, P1224, DOI 10.1128/JVI.74.3.1224-1233.2000; Aghi M, 1998, J NATL CANCER I, V90, P370, DOI 10.1093/jnci/90.5.370; Ambinder RF, 1996, SEMIN CANCER BIOL, V7, P217, DOI 10.1006/scbi.1996.0029; BENSASSON SA, 1981, INT J CANCER, V28, P131, DOI 10.1002/ijc.2910280204; Binne UK, 2002, J VIROL, V76, P10282, DOI 10.1128/JVI.76.20.10282-10289.2002; Bollard CM, 2002, BLOOD, V99, P3179, DOI 10.1182/blood.V99.9.3179; Bonnet M, 1999, J NATL CANCER I, V91, P1376, DOI 10.1093/jnci/91.16.1376; Bryant H, 2002, J VIROL, V76, P10290, DOI 10.1128/JVI.76.20.10290-10298.2002; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; Campbell KS, 1999, CURR OPIN IMMUNOL, V11, P256, DOI 10.1016/S0952-7915(99)80042-9; Cayrol C, 1996, EMBO J, V15, P2748, DOI 10.1002/j.1460-2075.1996.tb00635.x; Chang LK, 2000, NUCLEIC ACIDS RES, V28, P3918, DOI 10.1093/nar/28.20.3918; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; Chapman ALN, 2001, CANCER RES, V61, P6219; Chatila T, 1997, J VIROL, V71, P6560, DOI 10.1128/JVI.71.9.6560-6567.1997; CHEN CY, 1995, HUM GENE THER, V6, P1467, DOI 10.1089/hum.1995.6.11-1467; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3243, DOI 10.1002/j.1460-2075.1986.tb04635.x; Chodosh J, 1998, J INFECT DIS, V177, P1194, DOI 10.1086/515290; Chua D, 2001, INT J CANCER, V94, P73, DOI 10.1002/ijc.1430; Coburn GA, 2002, J VIROL, V76, P9225, DOI 10.1128/JVI.76.18.9225-9231.2002; Connors TA, 1995, GENE THER, V2, P702; COUNTRYMAN J, 1985, P NATL ACAD SCI USA, V82, P4085, DOI 10.1073/pnas.82.12.4085; DAIBATA M, 1994, VIROLOGY, V198, P446, DOI 10.1006/viro.1994.1056; Darr CD, 2001, J VIROL, V75, P6135, DOI 10.1128/JVI.75.13.6135-6142.2001; DATTA R, 1993, P NATL ACAD SCI USA, V90, P2419, DOI 10.1073/pnas.90.6.2419; DAVIES AH, 1991, J VIROL, V65, P6838, DOI 10.1128/JVI.65.12.6838-6844.1991; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; FAGGIONI A, 1986, SCIENCE, V232, P1554, DOI 10.1126/science.3012779; Falk KI, 1999, ARCH VIROL, V144, P2219, DOI 10.1007/s007050050636; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; Feederle R, 2000, EMBO J, V19, P3080, DOI 10.1093/emboj/19.12.3080; Feng WH, 2002, J VIROL, V76, P10951, DOI 10.1128/JVI.76.21.10951-10959.2002; Feng WH, 2002, CANCER RES, V62, P1920; FLEMINGTON E, 1990, J VIROL, V64, P1227, DOI 10.1128/JVI.64.3.1227-1232.1990; Franken M, 1996, NAT MED, V2, P1379, DOI 10.1038/nm1296-1379; FREEMAN SM, 1993, CANCER RES, V53, P5274; Gahn B, 2001, INT J CANCER, V93, P706, DOI 10.1002/ijc.1396; Gitlin L, 2002, NATURE, V418, P430, DOI 10.1038/nature00873; Gottschalk S, 2001, BLOOD, V97, P835, DOI 10.1182/blood.V97.4.835; Gradoville L, 2002, J VIROL, V76, P5612, DOI 10.1128/JVI.76.11.5612-5626.2002; Grinstein S, 2002, CANCER RES, V62, P4876; Gruffat H, 2002, EMBO REP, V3, P141, DOI 10.1093/embo-reports/kvf031; Gutierrez MI, 1996, CANCER RES, V56, P969; HARDWICK JM, 1988, J VIROL, V62, P2274, DOI 10.1128/JVI.62.7.2274-2284.1988; Hirai H, 1997, BIOCHEM BIOPH RES CO, V241, P112, DOI 10.1006/bbrc.1997.7776; Inman GJ, 2001, J VIROL, V75, P2400, DOI 10.1128/JVI.75.5.2400-2410.2001; Jenkins PJ, 2000, J VIROL, V74, P710, DOI 10.1128/JVI.74.2.710-720.2000; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Judde JG, 1996, HUM GENE THER, V7, P647, DOI 10.1089/hum.1996.7.5-647; Kenney JL, 1998, BLOOD, V92, P1721, DOI 10.1182/blood.V92.5.1721.417a08_1721_1727; Kenney S, 1998, HUM GENE THER, V9, P1131, DOI 10.1089/hum.1998.9.8-1131; KIEFF E, 2001, FIELDS VIROLOGY, V2, P2397; KIEFF E, 2001, FIELDS VIROLOGY, V2, P2343; Kim SH, 1997, J NEURO-ONCOL, V33, P189, DOI 10.1023/A:1005764324900; Kraus RJ, 2001, J VIROL, V75, P867, DOI 10.1128/JVI.75.2.867-877.2001; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Li JH, 2002, CANCER RES, V62, P171; Lim CP, 1998, ONCOGENE, V16, P2915, DOI 10.1038/sj.onc.1201834; Liu SF, 1997, EMBO J, V16, P143, DOI 10.1093/emboj/16.1.143; LUKA J, 1979, VIROLOGY, V94, P228, DOI 10.1016/0042-6822(79)90455-0; Meij P, 2002, INT J CANCER, V99, P93, DOI 10.1002/ijc.10309; Mentzer S J, 2001, Transpl Infect Dis, V3, P177, DOI 10.1034/j.1399-3062.2001.003003177.x; Mentzer SJ, 1998, BLOOD CELL MOL DIS, V24, P114, DOI 10.1006/bcmd.1998.0178; MILLER CL, 1995, IMMUNITY, V2, P155, DOI 10.1016/S1074-7613(95)80040-9; MONTALVO EA, 1995, J VIROL, V69, P4158, DOI 10.1128/JVI.69.7.4158-4165.1995; Moore SM, 2001, ANTIMICROB AGENTS CH, V45, P2082, DOI 10.1128/AAC.45.7.2082-2091.2001; Murono S, 2000, CANCER RES, V60, P2555; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725; Putnam DA, 1996, AM J HEALTH-SYST PH, V53, P151; Ragoczy T, 1998, J VIROL, V72, P7978, DOI 10.1128/JVI.72.10.7978-7984.1998; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; Robertson K D, 1995, Curr Top Microbiol Immunol, V194, P145; ROONEY C, 1988, P NATL ACAD SCI USA, V85, P9801, DOI 10.1073/pnas.85.24.9801; Rooney C M, 1998, J Natl Cancer Inst Monogr, P89; ROONEY CM, 1989, J VIROL, V63, P3109, DOI 10.1128/JVI.63.7.3109-3116.1989; Roskrow MA, 1998, BLOOD, V91, P2925, DOI 10.1182/blood.V91.8.2925.2925_2925_2934; Ruf IK, 1999, MOL CELL BIOL, V19, P1651; Slobod KS, 2000, LANCET, V356, P1493, DOI 10.1016/S0140-6736(00)02879-8; Speck SH, 1997, TRENDS MICROBIOL, V5, P399, DOI 10.1016/S0966-842X(97)01129-3; Su Z, 2001, EUR J IMMUNOL, V31, P947, DOI 10.1002/1521-4141(200103)31:3<947::AID-IMMU947>3.0.CO;2-M; Sugawara Y, 2000, SCAND J GASTROENTERO, V35, P981, DOI 10.1080/003655200750023075; TAKADA K, 1986, J VIROL, V57, P1016, DOI 10.1128/JVI.57.3.1016-1022.1986; TAKADA K, 1984, INT J CANCER, V33, P27, DOI 10.1002/ijc.2910330106; Tamir Y, 2000, J BIOL CHEM, V275, P34424, DOI 10.1074/jbc.M005815200; TIBERGHIEN P, 1994, J LEUKOCYTE BIOL, V56, P203, DOI 10.1002/jlb.56.2.203; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Wang YCJ, 1997, VIROLOGY, V227, P323, DOI 10.1006/viro.1996.8326; Westphal EM, 2000, CANCER RES, V60, P5781; Westphal EM, 2000, CANCER GENE THER, V7, P97, DOI 10.1038/sj.cgt.7700102; Westphal EM, 1999, CANCER RES, V59, P1485; Wildner O, 1999, CANCER RES, V59, P5233; ZALANI S, 1992, J VIROL, V66, P7282, DOI 10.1128/JVI.66.12.7282-7292.1992; Zalani S, 1997, J VIROL, V71, P3268, DOI 10.1128/JVI.71.4.3268-3274.1997; ZALANI S, 1995, J VIROL, V69, P3816, DOI 10.1128/JVI.69.6.3816-3823.1995; Zalani S, 1996, P NATL ACAD SCI USA, V93, P9194, DOI 10.1073/pnas.93.17.9194; Zhao M, 1999, MOL CELL BIOL, V19, P21; ZURHAUSEN H, 1978, NATURE, V272, P373	99	82	85	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2003	22	33					5122	5130		10.1038/sj.onc.1206548	http://dx.doi.org/10.1038/sj.onc.1206548			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709FL	12910249				2022-12-17	WOS:000184615100003
J	Achison, M; Hupp, TR				Achison, M; Hupp, TR			Hypoxia attenuates the p53 response to cellular damage	ONCOGENE			English	Article						p53; hypoxia; CK2; HIF-1; apoptosis	DNA-BINDING FUNCTION; RNA-POLYMERASE-II; P53-DEPENDENT TRANSCRIPTION; TUMOR-SUPPRESSOR; PHOSPHORYLATION; CANCER; PROTEIN; KINASE; CELLS; MDM2	The tumour suppressor activity of p53 in vivo can be subject to pressure from the physiological stress of hypoxia and we report on the development of a cell system to define the p53-dependent stages in the adaptation of cells to hypoxia. p53(+/+) cells exposed to hypoxia exhibited a transient arrest in G2/M, but escaped from this checkpoint and entered a long-term G(0)/G(1) arrest. By contrast, isogenic p53-null cells exposed to hypoxic conditions exhibited a 6-10-fold higher level of apoptosis, suggesting that p53 acts as a survival factor under limiting oxygen concentrations. Surprisingly, hypoxia-dependent growth arrest in p53(+/+) cells did not result in either p21(WAF1) or HIF-1 protein stabilization, but rather promoted a significant decrease in Ser(392)-site phosphorylation at the CK2/FACT site. However, chemically induced anoxia induced Ser(392)-site phosphorylation as well as stabilization of both p53 and HIF-1 proteins. In contrast to hypoxia, 5-flourouracil (5-FU)-induced p53-dependent cell death correlated with enhanced Ser(392) phosphorylation of p53 and elevated p21(WAF1) protein levels. Hypoxia inhibited 5-FU-induced p53-dependent cell death and attenuated p53 phosphorylation at the ATM and CK2/FACT phosphorylation sites. Although anoxia activates the p53 response, hypoxia silences the p53 transactivation pathway and identifies a physiological signalling model to study mechanisms of p53 inactivation under hypoxic conditions.	Univ Dundee, Dept Mol & Cellular Pathol, Canc Res UK Labs, Dundee DD1 9SY, Scotland	University of Dundee	Hupp, TR (corresponding author), Univ Dundee, Dept Mol & Cellular Pathol, Canc Res UK Labs, Dundee DD1 9SY, Scotland.	t.r.hupp@dundee.ac.uk						Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Blaydes JP, 2000, ONCOGENE, V19, P3829, DOI 10.1038/sj.onc.1203773; Blaydes JP, 2001, J BIOL CHEM, V276, P4699, DOI 10.1074/jbc.M003485200; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHAN DA, 2002, J BIOL CHEM, V16, P16; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Dornan D, 2001, EMBO REP, V2, P139, DOI 10.1093/embo-reports/kve025; Dornan D, 2003, J BIOL CHEM, V278, P13431, DOI 10.1074/jbc.M211460200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Hansen S, 1996, J BIOL CHEM, V271, P30922, DOI 10.1074/jbc.271.48.30922; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; Hupp TR, 2000, METH MOL B, V99, P465; Hupp TR, 2000, BIOCHEM J, V352, P1, DOI 10.1042/0264-6021:3520001; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Kanovsky M, 2001, P NATL ACAD SCI USA, V98, P12438, DOI 10.1073/pnas.211280698; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Kotala V, 2001, CELL MOL LIFE SCI, V58, P1333, DOI 10.1007/PL00000944; Koumenis C, 1997, MOL CELL BIOL, V17, P7306, DOI 10.1128/MCB.17.12.7306; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; Magnusson KP, 1998, ONCOGENE, V17, P2333, DOI 10.1038/sj.onc.1202149; Maxwell PH, 2002, CLIN MED, V2, P356, DOI 10.7861/clinmedicine.2-4-356; Nichols NM, 2002, BIOCHEMISTRY-US, V41, P170, DOI 10.1021/bi011736r; Nitta M, 1997, ONCOGENE, V15, P561, DOI 10.1038/sj.onc.1201210; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Scott MT, 2000, J BIOL CHEM, V275, P11529, DOI 10.1074/jbc.275.15.11529; Shieh SY, 2000, GENE DEV, V14, P289; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang H, 2002, MOL MED, V8, P185, DOI 10.1007/BF03402011; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WENG H, 2002, MOL MED, V16, P1151; Williams AC, 1999, ONCOGENE, V18, P3199, DOI 10.1038/sj.onc.1202660; Williams KJ, 2002, ONCOGENE, V21, P282, DOI 10.1038/sj.onc.1205047; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; Yuan ZM, 1999, J BIOL CHEM, V274, P1883, DOI 10.1074/jbc.274.4.1883; Zhao RB, 2000, GENE DEV, V14, P981	57	82	92	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2003	22	22					3431	3440		10.1038/sj.onc.1206434	http://dx.doi.org/10.1038/sj.onc.1206434			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776195				2022-12-17	WOS:000183128500010
J	Demple, B; DeMott, MS				Demple, B; DeMott, MS			Dynamics and diversions in base excision DNA repair of oxidized abasic lesions	ONCOGENE			English	Review						AP endonuclease; Apel protein; 2-deoxyribonolactone; 3 '-phosphoglycolate; radiation damage	CELL NUCLEAR ANTIGEN; APURINIC APYRIMIDINIC ENDONUCLEASE; HUMAN APURINIC/APYRIMIDINIC ENDONUCLEASE-1; DEOXYRIBOSE PHOSPHATE EXCISION; COLI EXONUCLEASE-III; ENZYME APEX NUCLEASE; ESCHERICHIA-COLI; POLYMERASE-BETA; STRAND BREAKS; SACCHAROMYCES-CEREVISIAE		Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Demple, B (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA.							BENNETT RAO, 1993, BIOCHEMISTRY-US, V32, P3188, DOI 10.1021/bi00063a034; Bennett RAO, 1999, MOL CELL BIOL, V19, P1800; BERNELOTMOENS C, 1989, NUCLEIC ACIDS RES, V17, P587, DOI 10.1093/nar/17.2.587; Betti M, 2001, J BIOL CHEM, V276, P18038, DOI 10.1074/jbc.M010648200; Blaisdell JO, 2001, P NATL ACAD SCI USA, V98, P7426, DOI 10.1073/pnas.131077798; Cappelli E, 2001, CARCINOGENESIS, V22, P387, DOI 10.1093/carcin/22.3.387; CHAN E, 1987, P NATL ACAD SCI USA, V84, P3189, DOI 10.1073/pnas.84.10.3189; Chappell C, 2002, EMBO J, V21, P2827, DOI 10.1093/emboj/21.11.2827; Chatgilialoglu C, 2001, EXP GERONTOL, V36, P1459, DOI 10.1016/S0531-5565(01)00132-2; Chaudhry MA, 1999, BIOCHEM PHARMACOL, V57, P531, DOI 10.1016/S0006-2952(98)00327-X; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; David-Cordonnier MH, 2001, BIOCHEMISTRY-US, V40, P5738, DOI 10.1021/bi002605d; DEDON PC, 1992, CHEM RES TOXICOL, V5, P311, DOI 10.1021/tx00027a001; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; DeMott MS, 2002, J BIOL CHEM, V277, P7637, DOI 10.1074/jbc.C100577200; DeMott MS, 1998, J BIOL CHEM, V273, P27492, DOI 10.1074/jbc.273.42.27492; DEMPLE B, 1983, J BACTERIOL, V153, P1079, DOI 10.1128/JB.153.2.1079-1082.1983; DEMPLE B, 1986, P NATL ACAD SCI USA, V83, P7731, DOI 10.1073/pnas.83.20.7731; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; Dizdaroglu M, 2002, FREE RADICAL BIO MED, V32, P1102, DOI 10.1016/S0891-5849(02)00826-2; Feng JA, 1998, BIOCHEMISTRY-US, V37, P9605, DOI 10.1021/bi9808619; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Fung H, 1998, CANCER RES, V58, P189; GILONI L, 1981, J BIOL CHEM, V256, P8608; GOODHEAD DT, 1994, INT J RADIAT BIOL, V65, P7, DOI 10.1080/09553009414550021; Grosch S, 1999, BIOCHEM BIOPH RES CO, V261, P859, DOI 10.1006/bbrc.1999.1125; Grosch S, 1998, CANCER RES, V58, P4410; Hadi MZ, 2002, J MOL BIOL, V316, P853, DOI 10.1006/jmbi.2001.5382; Hadi MZ, 2000, ENVIRON MOL MUTAGEN, V36, P312, DOI 10.1002/1098-2280(2000)36:4<312::AID-EM7>3.0.CO;2-K; HARING M, 1994, NUCLEIC ACIDS RES, V22, P2010, DOI 10.1093/nar/22.11.2010; Harrison L, 1998, NUCLEIC ACIDS RES, V26, P932, DOI 10.1093/nar/26.4.932; Hashimoto M, 2001, J AM CHEM SOC, V123, P3161, DOI 10.1021/ja003354z; Hengge-Aronis R, 1999, CURR OPIN MICROBIOL, V2, P148, DOI 10.1016/S1369-5274(99)80026-5; HENNER WD, 1983, J BIOL CHEM, V258, P711; Hwang JT, 1999, NUCLEIC ACIDS RES, V27, P3805, DOI 10.1093/nar/27.19.3805; IDE H, 1994, BIOCHEMISTRY-US, V33, P7842, DOI 10.1021/bi00191a011; Izumi T, 2000, CARCINOGENESIS, V21, P1329, DOI 10.1093/carcin/21.7.1329; Jilani A, 2002, BIOCHEMISTRY-US, V41, P7688, DOI 10.1021/bi012213m; Jilani A, 1999, J CELL BIOCHEM, V73, P188, DOI 10.1002/(SICI)1097-4644(19990501)73:2<188::AID-JCB5>3.3.CO;2-8; Jilani A, 1999, J BIOL CHEM, V274, P24176, DOI 10.1074/jbc.274.34.24176; JOHNSON AW, 1988, J BIOL CHEM, V263, P18017; JOHNSON AW, 1988, J BIOL CHEM, V263, P18009; Johnson RE, 1998, GENE DEV, V12, P3137, DOI 10.1101/gad.12.19.3137; Johnson RE, 1998, CURR GENET, V34, P21, DOI 10.1007/s002940050362; Jourdan M, 1999, BIOCHEMISTRY-US, V38, P3985, DOI 10.1021/bi982743r; Kanno S, 1999, NUCLEIC ACIDS RES, V27, P3096, DOI 10.1093/nar/27.15.3096; Karmakar P, 2001, MUTAGENESIS, V16, P225, DOI 10.1093/mutage/16.3.225; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kotera M, 2000, CHEM-EUR J, V6, P4163, DOI 10.1002/1521-3765(20001117)6:22<4163::AID-CHEM4163>3.0.CO;2-K; Lenox HJ, 2001, ORG LETT, V3, P2415, DOI 10.1021/ol016255e; Levin JD, 1996, NUCLEIC ACIDS RES, V24, P885, DOI 10.1093/nar/24.5.885; MARSHALL LE, 1981, BIOCHEMISTRY-US, V20, P244, DOI 10.1021/bi00505a003; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Meijler MM, 1997, J AM CHEM SOC, V119, P1135, DOI 10.1021/ja962409n; Minko IG, 2002, P NATL ACAD SCI USA, V99, P1905, DOI 10.1073/pnas.042700399; Mol CD, 2000, MUTAT RES-DNA REPAIR, V460, P211, DOI 10.1016/S0921-8777(00)00028-8; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; Nakamura J, 2000, J BIOL CHEM, V275, P5323, DOI 10.1074/jbc.275.8.5323; Nakamura J, 1999, CANCER RES, V59, P2522; Olivares M, 1999, J BIOL CHEM, V274, P23883, DOI 10.1074/jbc.274.34.23883; ONO Y, 1994, MUTAT RES, V315, P55, DOI 10.1016/0921-8777(94)90028-0; Perrin DM, 1996, PROG NUCLEIC ACID RE, V52, P123, DOI 10.1016/S0079-6603(08)60966-6; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; Pomposiello PJ, 2002, ADV MICROB PHYSIOL, V46, P319, DOI 10.1016/S0065-2911(02)46007-9; Pomposiello PJ, 2001, J BACTERIOL, V183, P3890, DOI 10.1128/JB.183.13.3890-3902.2001; POPE LM, 1982, J BIOL CHEM, V257, P2121; POPOFF SC, 1990, P NATL ACAD SCI USA, V87, P4193, DOI 10.1073/pnas.87.11.4193; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; RALEIGH JA, 1989, FREE RADICAL RES COM, V6, P141, DOI 10.3109/10715768909073453; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; RAMOTAR D, 1993, J BIOL CHEM, V268, P20533; RICHARDSON CC, 1964, J BIOL CHEM, V239, P251; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; SAK BD, 1989, P NATL ACAD SCI USA, V86, P3271, DOI 10.1073/pnas.86.9.3271; Sander M, 1997, BIOCHEMISTRY-US, V36, P6100, DOI 10.1021/bi970048y; SANDER M, 1995, BIOCHEMISTRY-US, V34, P1267, DOI 10.1021/bi00004a021; SEKI S, 1991, J BIOL CHEM, V266, P20797; SEKI S, 1991, BIOCHIM BIOPHYS ACTA, V1079, P57, DOI 10.1016/0167-4838(91)90024-T; SIWEK B, 1988, NUCLEIC ACIDS RES, V16, P5031, DOI 10.1093/nar/16.11.5031; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; SOLTIS DA, 1982, J BIOL CHEM, V257, P1332; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; Sutherland BM, 2000, P NATL ACAD SCI USA, V97, P103, DOI 10.1073/pnas.97.1.103; Sutherland BM, 2000, BIOCHEMISTRY-US, V39, P8026, DOI 10.1021/bi9927989; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; Tsuchimoto D, 2001, NUCLEIC ACIDS RES, V29, P2349, DOI 10.1093/nar/29.11.2349; Unk I, 2001, MOL CELL BIOL, V21, P1656, DOI 10.1128/MCB.21.5.1656-1661.2001; von Sonntag C., 1987, CHEM BASIS RAD BIOL; WALKER LJ, 1994, NUCLEIC ACIDS RES, V22, P4884, DOI 10.1093/nar/22.23.4884; Whitehouse CJ, 2001, CELL, V104, P107, DOI 10.1016/S0092-8674(01)00195-7; Wilson DM, 1995, NUCLEIC ACIDS RES, V23, P5027; WINTERS TA, 1994, NUCLEIC ACIDS RES, V22, P1866, DOI 10.1093/nar/22.10.1866; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XU Y, 2002, IN PRESS DNA REPAIR; Xu YJ, 1998, J BIOL CHEM, V273, P28837, DOI 10.1074/jbc.273.44.28837; Zelenko O, 1998, INORG CHEM, V37, P2198, DOI 10.1021/ic971154r	109	82	82	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	2002	21	58					8926	8934		10.1038/sj.onc.1206178	http://dx.doi.org/10.1038/sj.onc.1206178			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	626TP	12483509				2022-12-17	WOS:000179889500004
J	Cagatay, T; Ozturk, M				Cagatay, T; Ozturk, M			p53 mutation as a source of aberrant beta-catenin accumulation in cancer cells	ONCOGENE			English	Article						beta-catenin; p53; mutation; hepatocellular carcinoma; wnt pathway	HUMAN HEPATOCELLULAR CARCINOMAS; TRANSGENIC MICE; COLORECTAL-CANCER; GENE-MUTATIONS; BREAST-CANCER; CYCLIN D1; PROTEIN; FREQUENT; PATHWAY; ACTIVATION	b-catenin is involved in both cell-cell interactions and wnt pathway-dependent cell fate determination through its interactions with E-cadherin and TCF/LEF transcription factors, respectively. Cytoplasmic/nuclear levels of beta-catenin are important in regulated transcriptional activation of TCF/LEF target genes. Normally, these levels are kept low by proteosomal degradation of beta-catenin through Axin1- and APC-dependent phosphorylation by CKI and GSK-3beta. Deregulation of beta-catenin degradation results in its aberrant accumulation, often leading to cancer. Accordingly, aberrant accumulation of beta-catenin is observed at high frequency in many cancers. This accumulation correlates with either mutational activation of CTNNB1 (beta-catenin) or mutational inactivation of APC and Axin1 genes in some tumors. However, there are many tumors that display beta-catenin accumulation in the absence of a mutation in these genes. Thus, there must be additional sources for aberrant beta-catenin accumulation in cancer cells. Here, we provide experimental evidence that wild-type beta-catenin accumulates in hepatocellular carcinoma (HCC) cells in association with mutational inactivation of p53 gene. We also show that worldwide p53 and beta-catenin mutation rates are inversely correlated in HCC. These data suggest that inactivation of p53 is an important cause of aberrant accumulation of beta-catenin in cancer cells.	Bilkent Univ, Dept Mol Biol & Genet, TR-06533 Bilkent, Turkey	Ihsan Dogramaci Bilkent University	Ozturk, M (corresponding author), Bilkent Univ, Dept Mol Biol & Genet, TR-06533 Bilkent, Turkey.	ozturk@fen.bilkent.edu.tr	OZTURK, MEHMET/AAS-7241-2021; ozturk, mehmet/G-3330-2014	OZTURK, MEHMET/0000-0002-6092-9706; 				Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Barker N, 2000, ADV CANCER RES, V77, P1; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Cadoret A, 2001, CANCER RES, V61, P3245; Calvisi DF, 2001, CANCER RES, V61, P2085; Candidus S, 1996, CANCER RES, V56, P49; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Devereux TR, 2001, MOL CARCINOGEN, V31, P68, DOI 10.1002/mc.1041; FREBOURG T, 1992, CANCER RES, V52, P6976; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Fujie H, 2001, HEPATOL RES, V20, P39, DOI 10.1016/S1386-6346(00)00116-9; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hommura F, 2002, CANCER-AM CANCER SOC, V94, P752, DOI 10.1002/cncr.10213; Hsu HC, 2000, AM J PATHOL, V157, P763, DOI 10.1016/S0002-9440(10)64590-7; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Huang H, 1999, AM J PATHOL, V155, P1795, DOI 10.1016/S0002-9440(10)65496-X; Inagawa S, 2002, CLIN CANCER RES, V8, P450; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Jonsson M, 2000, EUR J CANCER, V36, P242, DOI 10.1016/S0959-8049(99)00276-2; Kinzler KW, 1998, GENETIC BASIS HUMAN, P565; Koch A, 1999, CANCER RES, V59, P269; Kondo Y, 1999, JPN J CANCER RES, V90, P1301, DOI 10.1111/j.1349-7006.1999.tb00712.x; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Miyoshi Y, 1998, CANCER RES, V58, P2524; Monga SPS, 2001, HEPATOLOGY, V33, P1098, DOI 10.1053/jhep.2001.23786; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Ozdag H, 2000, EUR J CANCER, V36, P2076, DOI 10.1016/S0959-8049(00)00277-X; Ozturk M, 1999, SEMIN LIVER DIS, V19, P235, DOI 10.1055/s-2007-1007113; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; Park WS, 2001, J PATHOL, V193, P483; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Polakis P, 2000, GENE DEV, V14, P1837; PONCHEL F, 1994, CANCER RES, V54, P2064; Renard CA, 2000, ONCOGENE, V19, P2678, DOI 10.1038/sj.onc.1203617; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Sadot E, 2001, MOL CELL BIOL, V21, P6768, DOI 10.1128/MCB.21.20.6768-6781.2001; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Sayan AE, 2001, ONCOGENE, V20, P5111, DOI 10.1038/sj.onc.1204669; Sayan BS, 2001, J CELL BIOL, V155, P719, DOI 10.1083/jcb.200106044; Shinohara A, 2001, GYNECOL ONCOL, V82, P450, DOI 10.1006/gyno.2001.6298; Sparks AB, 1998, CANCER RES, V58, P1130; Terris B, 1999, ONCOGENE, V18, P6583, DOI 10.1038/sj.onc.1203051; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863; Umeda T, 2000, INT J ONCOL, V16, P1133; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; Wei Y, 2000, ONCOGENE, V19, P498, DOI 10.1038/sj.onc.1203356; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Yakicier MC, 1999, ONCOGENE, V18, P4879, DOI 10.1038/sj.onc.1202866; Yolcu E, 2001, ONCOGENE, V20, P1398, DOI 10.1038/sj.onc.1204240	61	82	86	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2002	21	52					7971	7980		10.1038/sj.onc.1205919	http://dx.doi.org/10.1038/sj.onc.1205919			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439747	Green Published			2022-12-17	WOS:000179097200006
J	Zhao, YF; Oberley, TD; Chaiswing, L; Lin, SM; Epstein, CJ; Huang, TT; St Clair, D				Zhao, YF; Oberley, TD; Chaiswing, L; Lin, SM; Epstein, CJ; Huang, TT; St Clair, D			Manganese superoxide dismutase deficiency enhances cell turnover via tumor promoter-induced alterations in AP-1 and p53-mediated pathways in a skin cancer model	ONCOGENE			English	Article						MnSOD; apoptosis; AP-1; p53; skin cancer	PROTEIN-KINASE-C; GENE-EXPRESSION; CYTOCHROME-C; ORNITHINE-DECARBOXYLASE; MALIGNANT PHENOTYPE; XANTHINE-OXIDASE; APOPTOSIS; OVEREXPRESSION; P53; SUPPRESSION	Previous studies in our laboratories demonstrated that overexpression of manganese superoxide dismutase (MnSOD) suppressed both the incidence and multiplicity of papillomas in a DMBA/TPA multi-stage skin carcinogenesis model. The activity of activator protein- 1 (AP-1), which is associated with tumor promotion, was reduced in MnSOD transgenic mice overexpressing MnSOD in the skin, suggesting that MnSOD may reduce tumor incidence by suppressing AP-1 activation. In the present study, we report that reduction of MnSOD by heterozygous knockout of the MnSOD gene (Sod2 -/+, MnSOD KO) increased the levels of oxidative damage proteins and the activity of AP-1 following TPA treatment. RNA levels of ornithine decarboxylase (ODC) were also increased, suggesting an increase in cell proliferation in the KO mice. Histological examination confirmed that the number of proliferating cells in DMBA/TPA-treated mouse skin were higher in the KO mice. Interestingly, histological examination also demonstrated greater numbers of apoptotic cells in the KO mice after DMBA/TPA treatment. Evidence of apoptosis, including DNA fragmentation, cytochrome e release from mitochondria, and caspase 3 activation were also observed by biochemical assays of the skin tissues. Apoptosis was associated with an increase in nuclear levels of p53 as determined by Western analysis. Quantitative immuno-gold ultrastructural analysis confirmed that p53 immunoreactive protein levels were increased to a greater level in the nuclei of epidermal cells from MnSOD KO mice compared to epidermal nuclei from wild type mice similarly treated. Moreover, p53 levels further increased in the mitochondria of DMBA/TPA treated mice, and this increase was much greater in the MnSOD KO than in the wild type mice, suggesting a link between MnSOD deficiency and mitochondrial-mediated apoptosis. Pathological examination reveals no difference in the incidence and frequency of papillomas comparing the KO mice and their wild type littermates. Taken together, these results suggest that: (1) MnSOD deficiency enhanced TPA-induced oxidative stress and AP-1 and p53 levels, consistent with the increase in both proliferation and apoptosis events in the MnSOD KO mice, and (2) increased apoptosis may negate increased proliferation in the MnSOD deficient mice during an early stage of tumor development.	Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Mahidol Univ, Fac Med Technol, Bangkok 10700, Thailand; Univ Wisconsin, VA Hosp, Madison, WI 53705 USA; Univ Wisconsin, Dept Pathol, Madison, WI 53705 USA	University of Kentucky; University of California System; University of California San Francisco; Mahidol University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	St Clair, D (corresponding author), Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA.	dstc100@pop.uky.edu			NCI NIH HHS [CA 73599-S1, CA 73599] Funding Source: Medline; NIA NIH HHS [AG 08938] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG008938] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGARWAL R, 1993, MOL CARCINOGEN, V8, P290, DOI 10.1002/mc.2940080412; Amstad PA, 1997, CARCINOGENESIS, V18, P479, DOI 10.1093/carcin/18.3.479; BERNSTEIN LR, 1991, ENVIRON HEALTH PERSP, V93, P111, DOI 10.2307/3431178; BOWDEN GT, 1995, SKIN CANC MECH HUMAN, P99; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Das KC, 1998, J BIOL CHEM, V273, P34639, DOI 10.1074/jbc.273.51.34639; Donahue RJ, 2001, FASEB J, V15, P635, DOI 10.1096/fj.00-0262com; Drane P, 2001, ONCOGENE, V20, P430, DOI 10.1038/sj.onc.1204101; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Epperly MW, 2000, INT J CANCER, V90, P128, DOI 10.1002/1097-0215(20000620)90:3<128::AID-IJC2>3.0.CO;2-U; FISCHER SM, 1989, CANCER RES, V49, P6693; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; GUIDOT DM, 1995, J CLIN INVEST, V96, P1131, DOI 10.1172/JCI118100; Hohmeier HE, 1998, J CLIN INVEST, V101, P1811, DOI 10.1172/JCI1489; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Keller JN, 1998, J NEUROSCI, V18, P687; Khajuria A, 1998, MOL CELL BIOCHEM, V189, P113, DOI 10.1023/A:1006877614411; Kiningham KK, 1999, FASEB J, V13, P1601, DOI 10.1096/fasebj.13.12.1601; Kinscherf R, 1998, FASEB J, V12, P461, DOI 10.1096/fasebj.12.6.461; Lam EWN, 1997, CANCER RES, V57, P5550; Lam EWN, 1999, FREE RADICAL BIO MED, V27, P572, DOI 10.1016/S0891-5849(99)00109-4; LI JJ, 1995, ONCOGENE, V10, P1989; Li N, 1998, PROSTATE, V35, P221, DOI 10.1002/(SICI)1097-0045(19980515)35:3<221::AID-PROS8>3.0.CO;2-J; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Liu RG, 1997, HUM GENE THER, V8, P585, DOI 10.1089/hum.1997.8.5-585; Majima HJ, 1998, J BIOL CHEM, V273, P8217, DOI 10.1074/jbc.273.14.8217; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; McGarrity TJ, 2001, CANCER LETT, V163, P33, DOI 10.1016/S0304-3835(00)00663-7; MCSWINEKENNICK RL, 1991, J BIOL CHEM, V266, P15135; MIYASHITA T, 1995, CELL, V80, P293; Moll UM, 2001, FEBS LETT, V493, P65, DOI 10.1016/S0014-5793(01)02284-0; Nakamura Y, 1999, CANCER LETT, V140, P37, DOI 10.1016/S0304-3835(99)00048-8; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; PENCE BC, 1987, CANCER RES, V47, P6388; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Porter AG, 1999, TRENDS CELL BIOL, V9, P394, DOI 10.1016/S0962-8924(99)01624-4; REINERS JJ, 1987, CANCER RES, V47, P1775; REINERS JJ, 1991, CARCINOGENESIS, V12, P2337, DOI 10.1093/carcin/12.12.2337; RUGGERI BA, 1995, SKIN CANC MECH HUMAN, P339; SAFFORD SE, 1994, CANCER RES, V54, P4261; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; STCLAIR DK, 1991, FEBS LETT, V293, P199, DOI 10.1016/0014-5793(91)81186-C; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7; URANO M, 1995, CANCER RES, V55, P2490; Van Remmen H, 1999, ARCH BIOCHEM BIOPHYS, V363, P91, DOI 10.1006/abbi.1998.1060; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; VERMA AK, 1986, CANCER RES, V46, P6149; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Xu Y, 1999, ONCOGENE, V18, P93, DOI 10.1038/sj.onc.1202265; Yan T, 1996, CANCER RES, V56, P2864; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Zhao YF, 2001, CANCER RES, V61, P6082; Zhao YF, 2001, ANTIOXID REDOX SIGN, V3, P375, DOI 10.1089/15230860152409022; Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852	61	82	85	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2002	21	24					3836	3846		10.1038/sj.onc.1205477	http://dx.doi.org/10.1038/sj.onc.1205477			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032821				2022-12-17	WOS:000175847200002
J	Xiang, H; Wang, J; Mao, YW; Liu, MY; Reddy, VN; Li, DWC				Xiang, H; Wang, J; Mao, YW; Liu, MY; Reddy, VN; Li, DWC			Human telomerase accelerates growth of lens epithelial cells through regulation of the genes mediating RB/E2F pathway	ONCOGENE			English	Article						human lens epithelial cells; telomerase; cell growth; E2F; RB; p53; GCIP	EXPRESSION; CYCLE; E2F; P53; IMMORTALIZATION; INHIBITOR; PROTEIN; PROLIFERATION; INDUCTION; APOPTOSIS	Telomerase is a specialized reverse transcriptase that extends telomeres of eukaryotic chromosomes. The catalytic core of human telomerase is composed of an RNA template known as hTER (human telomerase RNA) and a protein subunit named hTERT (human telomerase reverse transcriptase). We have been studying other functions of the telomerase besides its major role in telomere maintenance. In our previous work, we have demonstrated that the hTERT can functionally interact with a rabbit TER to regulate expression of other genes and also attenuate the induced apoptosis. Here we report that overexpression of hTERT in a human lens epithelial cell fine accelerates growth of the transfected lens epithelial cells. Associated with the acceleration of cell growth, expression of p53, p21 and GCIP (Grap2 cyclin-D interacting protein) is downregulated in the hTERT-transfected cells. With the downregulation of p21 and GCIP, the retinoblastoma protein (RB) is completely hyperphosphorylated in the hTERT-transfected cells. As expected, in the presence of RB hyperphosphorylation, the E2F transactivity is upregulated. Inhibition of telomerase activity abolishes the observed growth acceleration and also the related molecular changes. Furthermore, expression of hTERT in telomerase-negative human lens epithelial cells derived from primary cultures also accelerates growth of the transfected cells. Taken together, our results suggest that hTERT, when overexpressed in human lens epithelial cells, accelerates cell growth rate through regulation of RB/E2F pathway and possibly other genes.	Univ Med & Dent New Jersey, Sch Osteopath Med, Dept Biol Mol, Stratford, NJ 08084 USA; Univ Texas, Hlth Sci Ctr, Dept Med Biochem & Genet, Inst Biosci & Technol,Ctr Canc Biol & Nutr, Houston, TX 77030 USA; Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol, Ann Arbor, MI 48105 USA	Rowan University; Rowan University School of Osteopathic Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Texas System; University of Texas Health Science Center Houston; University of Michigan System; University of Michigan	Li, DWC (corresponding author), Univ Med & Dent New Jersey, Sch Osteopath Med, Dept Biol Mol, 2 Med Ctr Dr, Stratford, NJ 08084 USA.	DWL168@att.net	Li, David/AAN-9205-2021	Mao, Yingwei/0000-0001-7339-1565; xiang, hua/0000-0003-0369-1225; Liu, Mingyao/0000-0001-7339-5048	NATIONAL EYE INSTITUTE [R37EY000484, R29EY011372, R01EY000484] Funding Source: NIH RePORTER; NEI NIH HHS [EY 00484, EY 11372, EY 07003] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; CHEN JD, 1992, ONCOGENE, V7, P1167; Collins K, 2000, CURR OPIN CELL BIOL, V12, P378, DOI 10.1016/S0955-0674(00)00103-4; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Gunes C, 2000, CANCER RES, V60, P2116; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hess RD, 1997, ONCOGENE, V15, P2501, DOI 10.1038/sj.onc.1201404; Ibaraki N, 1998, EXP EYE RES, V67, P577, DOI 10.1006/exer.1998.0551; Klingelhutz AJ, 1999, ANTICANCER RES, V19, P4823; Kohli M, 1999, BIOCHEM BIOPH RES CO, V257, P168, DOI 10.1006/bbrc.1999.0389; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Lania L, 1999, J CELL PHYSIOL, V179, P134, DOI 10.1002/(SICI)1097-4652(199905)179:2<134::AID-JCP3>3.0.CO;2-O; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Li DWC, 1998, EUR J BIOCHEM, V257, P351, DOI 10.1046/j.1432-1327.1998.2570351.x; Li DWC, 2001, EXP CELL RES, V266, P279, DOI 10.1006/excr.2001.5223; Li H, 1999, ONCOGENE, V18, P6785, DOI 10.1038/sj.onc.1203061; Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091; Magnenat L, 1999, MOL CELL BIOL, V19, P3457; Mao YW, 2001, J BIOL CHEM, V276, P43435, DOI 10.1074/jbc.M102195200; Mata JE, 1997, TOXICOL APPL PHARM, V144, P189, DOI 10.1006/taap.1997.8103; Meyerson M, 2000, J CLIN ONCOL, V18, P2626, DOI 10.1200/JCO.2000.18.13.2626; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang S, 1999, MOL CELL BIOL, V19, P7447; Xia CZ, 2000, J BIOL CHEM, V275, P20942, DOI 10.1074/jbc.M002598200; Xiang H, 2000, BIOCHEM BIOPH RES CO, V278, P503, DOI 10.1006/bbrc.2000.3834; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	39	82	87	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3784	3791		10.1038/sj.onc.1205455	http://dx.doi.org/10.1038/sj.onc.1205455			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032846				2022-12-17	WOS:000175676000013
J	Qin, JZ; Chaturvedi, V; Denning, MF; Bacon, P; Panella, J; Choubey, D; Nickoloff, BJ				Qin, JZ; Chaturvedi, V; Denning, MF; Bacon, P; Panella, J; Choubey, D; Nickoloff, BJ			Regulation of apoptosis by p53 in UV-irradiated human epidermis, psoriatic plaques and senescent keratinocytes	ONCOGENE			English	Article						apoptosis; human skin; keratinocytes; p53; psoriasis; senescence	NF-KAPPA-B; POSTTRANSLATIONAL MODIFICATIONS; TRANSCRIPTIONAL TARGET; ULTRAVIOLET-RADIATION; CELLULAR SENESCENCE; MOUSE SKIN; DNA; EXPRESSION; INDUCTION; PROTEIN	The carcinogenic effects of sunlight in human epidermis may be thwarted by either: transient growth arrest and repair of DNA photodamage in keratinocytes (KCs); elimination of KCs with damaged DNA via apoptosis; or by stimulating a senescence switch whereby KCs become irreversibly growth arrested. Using normal human skin organ cultures and living epidermal equivalents, we demonstrate that in the proliferative basal layer, removal of KCs via apoptosis had a rapid onset (beginning within 2 h) following UV-light exposure generating progressively greater numbers of KCs with thymine dimers as the dose of UV-light was increased; involved induction of Apaf-1, activation of caspase-3, and was dependent on p53 activation as addition of a p53 chemical inhibitor blocked the apoptotic response. Suprabasal layer KCs underwent apoptosis at much later time points (> 8 h). KCs in the basal layer repaired DNA damage more rapidly than KCs in suprabasal layers. Steady state levels of p53 increased in irradiated cells, and the increase was accompanied by phosphorylation of serine 9 and serine 15, but not serine 6 residues. By contrast, cultured KCs undergoing spontaneous replicative senescence were resistant to UV-induced apoptosis. Senescent KCs constitutively contained low levels of p53, which were neither increased nor phosphorylated or acetylated after UV-exposure and possessed minimal DNA binding activity, indicative of functional inactivation. Furthermore, treatment of senescent KCs with DNA damaging agent adriamycin did not result in activation of latent p53 or apoptosis. When KCs within psoriatic plaques were examined, they resembled senescent KCs in that they expressed p53, which was not phosphorylated or acetylated. Thus, UV-light induces DNA damage in human epidermal KCs triggering p53 activation, and subsequent apoptosis involving distinct cell layers and kinetics. However, the lack of p53 activation as seen in senescent KCs and psoriatic plaques, is associated with a relative resistance of KCs to UV-induced apoptosis. In conclusion, the sensitivity and resistance of KCs to apoptosis depends not only on the location within various layers of epidermis and levels of p53, but may also involve p53 activation via post-translational modifications.	Loyola Univ, Ctr Med, Dept Pathol, Maywood, IL USA; Loyola Univ, Ctr Med, Dept Radiat Oncol, Maywood, IL USA	Loyola University Chicago; Loyola University Chicago	Nickoloff, BJ (corresponding author), Loyola Univ, Ctr Med, Dept Pathol, Maywood, IL USA.	Bnickol@lumc.edu	Choubey, Divaker/A-4771-2008		NIAMS NIH HHS [AR 40065, AR 47307] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047307, R01AR040065] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Berg RJW, 1996, P NATL ACAD SCI USA, V93, P274, DOI 10.1073/pnas.93.1.274; Brash DE, 1996, NAT MED, V2, P525, DOI 10.1038/nm0596-525; Brash DE, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P136; Burren R, 1998, INT J CANCER, V76, P201, DOI 10.1002/(SICI)1097-0215(19980413)76:2<201::AID-IJC6>3.0.CO;2-0; Campbell T, 1998, EXOT PET PRACT, V3, P1; Campisi J, 2000, IN VIVO, V14, P183; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; CLEAVER JE, 1996, CANC MED, P307; Dazard JE, 2000, ONCOGENE, V19, P3693, DOI 10.1038/sj.onc.1203695; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Fukuchi Y, 2001, ONCOGENE, V20, P704, DOI 10.1038/sj.onc.1204142; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gniadecki R, 1997, J INVEST DERMATOL, V109, P163, DOI 10.1111/1523-1747.ep12319216; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; HALL PA, 1993, ONCOGENE, V8, P203; HELANDER SD, 1993, J AM ACAD DERMATOL, V29, P741, DOI 10.1016/0190-9622(93)70240-T; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kubilus J, 1996, IN VITRO TOXICOL, V9, P157; KULJU KS, 1995, EXP CELL RES, V217, P336, DOI 10.1006/excr.1995.1095; Kulms D, 1999, P NATL ACAD SCI USA, V96, P7974, DOI 10.1073/pnas.96.14.7974; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li G, 1998, J INVEST DERMATOL, V110, P72, DOI 10.1046/j.1523-1747.1998.00090.x; Li G, 1996, AM J PATHOL, V148, P1113; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Morris RJ, 1997, CANCER RES, V57, P3436; NAKAMURA H, 1994, DEV HYDROB, V91, P3; Nickoloff B J, 2001, J Invest Dermatol, V117, P1; Nickoloff BJ, 2001, J CUTAN PATHOL, V28, P57, DOI 10.1034/j.1600-0560.2001.280201.x; Pavey S, 1999, CANCER RES, V59, P4185; Pavey S, 2001, ONCOGENE, V20, P6103, DOI 10.1038/sj.onc.1204707; Ponten F, 2001, JNCI-J NATL CANCER I, V93, P128, DOI 10.1093/jnci/93.2.128; Qin JZ, 1999, J BIOL CHEM, V274, P37957, DOI 10.1074/jbc.274.53.37957; Qin JZ, 2001, J INVEST DERMATOL, V117, P898, DOI 10.1046/j.0022-202x.2001.01477.x; REES JL, 1995, J INVEST DERMATOL, V104, P883, DOI 10.1111/1523-1747.ep12606149; Robles AI, 2001, CANCER RES, V61, P6660; SAGER R, 1991, ENVIRON HEALTH PERSP, V93, P59, DOI 10.2307/3431170; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; SOINI Y, 1994, BRIT J DERMATOL, V131, P514; SPANDAU DF, 1994, ONCOGENE, V9, P1861; Stege H, 2000, P NATL ACAD SCI USA, V97, P1790, DOI 10.1073/pnas.030528897; Terui T, 2001, CURR OPIN ALLERGY CL, V1, P461, DOI 10.1097/01.all.0000011061.54491.2e; TORNALETTI S, 1993, ONCOGENE, V8, P2051; Tron VA, 1998, AM J PATHOL, V153, P579, DOI 10.1016/S0002-9440(10)65600-3; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; WOLF P, 1995, J INVEST DERMATOL, V104, P287, DOI 10.1111/1523-1747.ep12612828; WRONESMITH T, 1995, AM J PATHOL, V146, P1079; WroneSmith T, 1997, AM J PATHOL, V151, P1321; Yaar M, 1998, J Investig Dermatol Symp Proc, V3, P47; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	60	82	87	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					2991	3002		10.1038/sj.onc.1205404	http://dx.doi.org/10.1038/sj.onc.1205404			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082529	Bronze			2022-12-17	WOS:000175262700006
J	Kasof, GM; Lu, JJ; Liu, DR; Speer, B; Mongan, KN; Gomes, BC; Lorenzi, MV				Kasof, GM; Lu, JJ; Liu, DR; Speer, B; Mongan, KN; Gomes, BC; Lorenzi, MV			Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappa B	ONCOGENE			English	Article						prostate cancer; apoptosis; androgens; transcription; chromosome 6p21.1; TNF-alpha	PROSTATIC INTRAEPITHELIAL NEOPLASIA; TRAIL-INDUCED APOPTOSIS; CELL-DEATH; CANCER-CELLS; MEDIATED APOPTOSIS; KINASE-ALPHA; LIGAND TRAIL; GENE; PROTEIN; FADD	The tumor necrosis factor (TNF) receptor family are ligand-regulated transmembrane proteins that mediate apoptosis as well as activation of the transcription factor NF-kappaB. Exogenous expression of DR6, a recently identified member of the TNF receptor family, induced apoptosis in untransformed or tumor-derived cells and the apoptotic function of DR6 was inhibited by coexpression of Bcl-2, Bcl-X-L or the inhibitor-of-apoptosis (IAP) family member, survivin. Expression of a dominant negative mutant of FADD failed to protect from DR6-mediated apoptosis indicating that unlike TNFR1 and Fas, DR6 induced apoptosis via a FADD-independent mechanism. Despite the ability of exogenous DR6 expression to induce apoptosis, DR6 mRNA and protein were found to be elevated in prostate tumor cell lines and in advanced stages of prostate cancer. Analysis of several anti-apoptotic proteins revealed that Bcl-X-L levels and serine 32 phosphorylation of I kappaB, the natural inhibitor of NF-kappaB, were similarly elevated in cells expressing high levels of DR6, suggesting that NF-kappaB-regulated survival proteins may protect from DR6-induced apoptosis and that DR6 is a target of NF-kappaB regulation. Treatment of LnCAP cells with TNF-alpha resulted in increases in both DR6 mRNA and protein levels, and this induction was suppressed by inhibitors of NF-kappaB. Similarly, treatment of cells expressing high levels of DR6 with indomethacin and ibuprofen, compounds also known to perturb NF-kappaB function, resulted in a dose-dependent decrease in DR6 protein and mRNA levels. These results demonstrate that TNF-alpha signaling induces the expression of a member of its own receptor family through activation of NF-kappaB.	AstraZeneca Pharmaceut, Dept Enabling Sci & Technol, Worcester, MA 01605 USA	AstraZeneca	Kasof, GM (corresponding author), AstraZeneca Pharmaceut, Dept Enabling Sci & Technol, 3 Biotech Pk,1 Innovat Dr, Worcester, MA 01605 USA.							Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bonavida B, 1999, INT J ONCOL, V15, P793; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Granville DJ, 1998, LAB INVEST, V78, P893; Haussler O, 1999, HUM PATHOL, V30, P1077, DOI 10.1016/S0046-8177(99)90226-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Johnson MI, 1998, PROSTATE, V37, P223, DOI 10.1002/(SICI)1097-0045(19981201)37:4<223::AID-PROS3>3.0.CO;2-O; Kasof GM, 2000, FEBS LETT, V473, P285, DOI 10.1016/S0014-5793(00)01473-3; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lorenzi MV, 1996, P NATL ACAD SCI USA, V93, P8956, DOI 10.1073/pnas.93.17.8956; LORENZI MV, 1995, ONCOGENE, V10, P2051; Lorenzi MV, 1999, GENOMICS, V62, P59, DOI 10.1006/geno.1999.5980; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Munshi A, 2001, ONCOGENE, V20, P3757, DOI 10.1038/sj.onc.1204504; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Pan GH, 1998, FEBS LETT, V431, P351, DOI 10.1016/S0014-5793(98)00791-1; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Ravi R, 1998, CANCER RES, V58, P882; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rokhlin OW, 2001, ONCOGENE, V20, P2836, DOI 10.1038/sj.onc.1204410; Sheikh MS, 1999, ONCOGENE, V18, P4153, DOI 10.1038/sj.onc.1202763; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; SUPAKAR PC, 1995, J BIOL CHEM, V270, P837, DOI 10.1074/jbc.270.2.837; Tamm I, 1998, CANCER RES, V58, P5315; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yu R, 2000, CANCER RES, V60, P2384; Zhang XD, 1999, CANCER RES, V59, P2747	42	82	87	0	11	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2001	20	55					7965	7975		10.1038/sj.onc.1204985	http://dx.doi.org/10.1038/sj.onc.1204985			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753679				2022-12-17	WOS:000172288700005
J	Saenz-Robles, MT; Sullivan, CS; Pipas, JM				Saenz-Robles, MT; Sullivan, CS; Pipas, JM			Transforming functions of Simian Virus 40	ONCOGENE			English	Review						SV40; tumor suppressor; chaperone; tumor virus	LARGE-T-ANTIGEN; SV40 LARGE T; SIMIAN-VIRUS-40 LARGE-T; TRANSGENIC MOUSE MODEL; LARGE TUMOR-ANTIGEN; HUMAN ALPHA-1-ANTITRYPSIN GENE; VILLUS-ASSOCIATED ENTEROCYTES; RETINAL-PIGMENT EPITHELIUM; TISSUE-SPECIFIC EXPRESSION; AMINO-TERMINAL DOMAIN		Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Pipas, JM (corresponding author), Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA.	pipas@pitt.edu						Asa SL, 1996, VIRCHOWS ARCH, V427, P595; Asamoto M, 2001, CANCER RES, V61, P4693; Baratin M, 2001, CANCER GENE THER, V8, P193, DOI 10.1038/sj.cgt.7700285; Beermann F, 1999, PIGM CELL RES, V12, P71, DOI 10.1111/j.1600-0749.1999.tb00746.x; BEHRINGER RR, 1988, P NATL ACAD SCI USA, V85, P2648, DOI 10.1073/pnas.85.8.2648; BELL RH, 1990, CARCINOGENESIS, V11, P1393, DOI 10.1093/carcin/11.8.1393; Bennoun M, 1998, ONCOGENE, V17, P1253, DOI 10.1038/sj.onc.1202047; Berjanskii MV, 2000, J BIOL CHEM, V275, P36094, DOI 10.1074/jbc.M006572200; Bollag B, 2000, VIROLOGY, V274, P165, DOI 10.1006/viro.2000.0451; Bowman T, 1996, GENE DEV, V10, P826, DOI 10.1101/gad.10.7.826; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; BUTEL JS, 1990, INTERVIROLOGY, V31, P85, DOI 10.1159/000150142; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; CAVENDER JF, 1995, J VIROL, V69, P923, DOI 10.1128/JVI.69.2.923-934.1995; CECI JD, 1991, ONCOGENE, V6, P323; Chandrasekaran C, 1996, J BIOL CHEM, V271, P28414, DOI 10.1074/jbc.271.45.28414; CHEAH KSE, 1995, J CELL BIOL, V128, P223, DOI 10.1083/jcb.128.1.223; CHEN JD, 1992, ONCOGENE, V7, P1167; CHEN JD, 1989, J VIROL, V63, P2204, DOI 10.1128/JVI.63.5.2204-2214.1989; CHEN JD, 1991, MOL CELL BIOL, V11, P5968, DOI 10.1128/MCB.11.12.5968; Chiu IM, 2000, ONCOGENE, V19, P6229, DOI 10.1038/sj.onc.1204021; Coopersmith CM, 1997, J CELL BIOL, V138, P167, DOI 10.1083/jcb.138.1.167; DAUD AI, 1993, AM J PHYSIOL, V264, pH1693, DOI 10.1152/ajpheart.1993.264.5.H1693; DeCaprio JA, 1999, BIOLOGICALS, V27, P23, DOI 10.1006/biol.1998.0173; DICKMANNS A, 1994, J VIROL, V68, P5496, DOI 10.1128/JVI.68.9.5496-5508.1994; DYER KR, 1989, AM J PATHOL, V135, P401; Eckner R, 1996, MOL CELL BIOL, V16, P3454; EFRAT S, 1988, NEURON, V1, P605, DOI 10.1016/0896-6273(88)90110-9; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; Fields BN., 1996, VIROLOGY; FOX N, 1989, SCIENCE, V244, P460, DOI 10.1126/science.2785714; Garabedian EM, 1997, J BIOL CHEM, V272, P23729, DOI 10.1074/jbc.272.38.23729; Garabedian EM, 1998, P NATL ACAD SCI USA, V95, P15382, DOI 10.1073/pnas.95.26.15382; Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280; Gum JR, 2001, CANCER RES, V61, P3472; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Harris KF, 1998, MOL CELL BIOL, V18, P1746, DOI 10.1128/MCB.18.3.1746; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; Herring BP, 1999, J BIOL CHEM, V274, P17725, DOI 10.1074/jbc.274.25.17725; Herzig M, 1999, BIOL CHEM, V380, P203, DOI 10.1515/BC.1999.028; Husler MR, 1998, TRANSGENIC RES, V7, P253, DOI 10.1023/A:1008865911660; JENSEN NA, 1993, P NATL ACAD SCI USA, V90, P3192, DOI 10.1073/pnas.90.8.3192; JIANG D, 1993, ONCOGENE, V8, P2805; KIM SH, 1994, P NATL ACAD SCI USA, V91, P6914, DOI 10.1073/pnas.91.15.6914; KIM SH, 1993, J CELL BIOL, V123, P877, DOI 10.1083/jcb.123.4.877; KNOWLES BB, 1990, AM J PATHOL, V137, P259; KOHRMAN DC, 1992, J VIROL, V66, P1752, DOI 10.1128/JVI.66.3.1752-1760.1992; Le Menuet D, 2000, KIDNEY INT, V57, P1299, DOI 10.1046/j.1523-1755.2000.00966.x; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LEE YC, 1992, J BIOL CHEM, V267, P10705; LI QT, 1995, J BIOL CHEM, V270, P15777, DOI 10.1074/jbc.270.26.15777; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; LOPEZ MJ, 1995, J BIOL CHEM, V270, P885, DOI 10.1074/jbc.270.25.14989; Luo XL, 1996, NAT STRUCT BIOL, V3, P1034, DOI 10.1038/nsb1296-1034; Manickan E, 2001, J BIOL CHEM, V276, P13989, DOI 10.1074/jbc.M009770200; March KL, 1999, ONCOGENE, V18, P3773, DOI 10.1038/sj.onc.1202994; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MURPHY D, 1987, AM J PATHOL, V129, P552; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; PASCALL JC, 1994, J MOL ENDOCRINOL, V12, P313, DOI 10.1677/jme.0.0120313; Pasumarthi KBS, 2001, CIRC RES, V88, P1004, DOI 10.1161/hh1001.090878; Penna D, 1998, ONCOGENE, V17, P2601, DOI 10.1038/sj.onc.1202196; PERRAUD F, 1992, ONCOGENE, V7, P993; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; RASSOULZADEGAN M, 1978, J VIROL, V28, P1; Ratineau C, 2000, GASTROENTEROLOGY, V119, P1305, DOI 10.1053/gast.2000.19278; REYNOLDS RK, 1988, P NATL ACAD SCI USA, V85, P3135, DOI 10.1073/pnas.85.9.3135; Riley MI, 1997, J VIROL, V71, P6068, DOI 10.1128/JVI.71.8.6068-6074.1997; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; Rundell K, 2001, SEMIN CANCER BIOL, V11, P5, DOI 10.1006/scbi.2000.0341; Sachsenmeier KF, 2001, VIROLOGY, V283, P40, DOI 10.1006/viro.2001.0866; SANDGREN EP, 1989, ONCOGENE, V4, P715; SANDMOLLER A, 1995, CELL GROWTH DIFFER, V6, P97; SANDMOLLER A, 1994, ONCOGENE, V9, P2805; Schulze-Garg C, 2000, ONCOGENE, V19, P1028, DOI 10.1038/sj.onc.1203281; SEIF R, 1977, J VIROL, V24, P721, DOI 10.1128/JVI.24.3.721-728.1977; SEPULVEDA AR, 1989, CANCER RES, V49, P6108; Sheng Q, 1997, J VIROL, V71, P9410, DOI 10.1128/JVI.71.12.9410-9416.1997; SMITH MS, 1992, DNA CELL BIOL, V11, P345, DOI 10.1089/dna.1992.11.345; Sock E, 1999, MOL CELL BIOL, V19, P2455; SPENCE SL, 1994, J VIROL, V68, P4227, DOI 10.1128/JVI.68.7.4227-4240.1994; SPENCE SL, 1994, VIROLOGY, V204, P200, DOI 10.1006/viro.1994.1524; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; Sullivan CS, 2001, J VIROL, V75, P1601, DOI 10.1128/JVI.75.4.1601-1610.2001; Sullivan CS, 2000, MOL CELL BIOL, V20, P6233, DOI 10.1128/MCB.20.17.6233-6243.2000; Sullivan CS, 2000, MOL CELL BIOL, V20, P5749, DOI 10.1128/MCB.20.15.5749-5757.2000; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; SYMONDS HS, 1993, MOL CELL BIOL, V13, P3255, DOI 10.1128/MCB.13.6.3255; Tevethia MJ, 1997, J VIROL, V71, P8157, DOI 10.1128/JVI.71.11.8157-8166.1997; Tevethia MJ, 1997, J VIROL, V71, P1888, DOI 10.1128/JVI.71.3.1888-1896.1997; THEURING F, 1990, ONCOGENE, V5, P225; Thompson J, 2000, INT J CANCER, V86, P863, DOI 10.1002/(SICI)1097-0215(20000615)86:6<863::AID-IJC16>3.0.CO;2-4; Tsai SC, 2000, J BIOL CHEM, V275, P3239, DOI 10.1074/jbc.275.5.3239; VANDYKE TA, 1987, J VIROL, V61, P2029, DOI 10.1128/JVI.61.6.2029-2032.1987; WIKENHEISER KA, 1992, CANCER RES, V52, P5342; WILKIE TM, 1994, ONCOGENE, V9, P2889; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; Zennaro MC, 1998, J CLIN INVEST, V101, P1254, DOI 10.1172/JCI1915	100	82	86	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2001	20	54					7899	7907		10.1038/sj.onc.1204936	http://dx.doi.org/10.1038/sj.onc.1204936			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495JF	11753672				2022-12-17	WOS:000172336500009
J	Pucci, S; Mazzarelli, P; Rabitti, C; Giai, M; Gallucci, M; Flammia, G; Alcini, A; Altomare, V; Fazio, VM				Pucci, S; Mazzarelli, P; Rabitti, C; Giai, M; Gallucci, M; Flammia, G; Alcini, A; Altomare, V; Fazio, VM			Tumor specific modulation of KU70/80 DNA binding activity in breast and bladder human tumor biopsies	ONCOGENE			English	Article						Ku70/80 heterodimer; DNA repair; DNA double-strand breaks; DNA-PK; human tumors	DEPENDENT PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; KU-PROTEIN; V(D)J RECOMBINATION; PROGNOSTIC MARKERS; CELL-SURFACE; ANTIGEN-KU; CANCER; AUTOANTIGEN; REPAIR	The Ku70/80 heterodimer is the regulatory subunit of the DNA-dependent protein kinase (DNA-PK) and its DNA-binding activity mediates DNA double-strand breaks repair. Although Ku80 was recently proposed as a caretaker gene involved in the control of genome integrity, no data are available on Ku70/80 DNA-binding activity in human tumors. Heterodimer DNA-binding activity and protein expression were assayed by electrophoretic-mobility-shift-assay (EMSA) and Western blot analysis, in nuclear and cytoplasmic extracts from eight breast, seven bladder primary tumors and three metastatic nodes from breast cancers. Corresponding normal tissues of the same patients were used as controls. Ten out of 15 tumors showed nuclear Ku-binding activity 3-10 times higher than in the normal tissues, irrespective of bladder or breast origin. Conversely, in 5/15 primary tumors and in all the metastatic nodes analysed, nuclear Ku-activity was 1.5-4.5-fold lower than in the corresponding normal tissues. Cytoplasmic heterodimer activity significantly differed between tumor and normal tissues, displaying a 2-10-fold increase in neoplastic tissues. Three different patterns combining both Ku expression and activity with tumor characteristics were identified. In low aggressive breast tumors p70/p80 proteins were expressed in tumor but not in normal tissues. The heterodimer binding-activity matched the protein levels. In non-invasive bladder carcinomas no significant differences in protein expression between tumor and the corresponding normal tissues were found, however heterodimer binding-activity was increased in tumor samples. In breast and bladder tumors, at the advanced stage and in node metastases, the binding activity was strongly reduced in tumor biopsies, however no differences mere demonstrated between normal and tumor protein levels, Our results suggest a different modulation of Ku70/80 DNA-binding activity in human neoplastic tissues, possibly related to tumor progression. Findings provide further data on tissue-specific protein expression and post-translational regulation of heterodimer activity.	CNR, Inst Expt Med, I-00133 Rome, Italy; Lab Mol Med & Biotechnol, I-00155 Rome, Italy; Lab Histopathol, I-00155 Rome, Italy; Dept Urol, I-00155 Rome, Italy; Dept Gen Surg, I-00155 Rome, Italy; IRCCS H Casa Sollievo Sofferenza, Lab Mol Pathol, I-71013 San Giovanni Rotondo, FG, Italy	Consiglio Nazionale delle Ricerche (CNR); IRCCS Casa Sollievo Della Sofferenza	Fazio, VM (corresponding author), CNR, Inst Expt Med, Via Fosso Cavaliere 100, I-00133 Rome, Italy.		Pucci, Sabina/J-2542-2012; Fazio, Vito Michele VMF/H-3007-2016; Gallucci, Michele/K-9600-2016	Fazio, Vito Michele VMF/0000-0002-7751-1867; Pucci, Sabina/0000-0002-2418-6482; Gallucci, Michele/0000-0002-3637-6531; Altomare, Vittorio/0000-0002-9839-4129				Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Berwick M, 2000, JNCI-J NATL CANCER I, V92, P874, DOI 10.1093/jnci/92.11.874; Bogue M, 1996, CURR OPIN IMMUNOL, V8, P175, DOI 10.1016/S0952-7915(96)80055-0; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; Cordon-Cardo C, 1998, CANCER SURV, V32, P115; Dahiya R, 1998, BREAST CANCER RES TR, V52, P185, DOI 10.1023/A:1006101729631; DALZIEL RG, 1992, AUTOIMMUNITY, V13, P265, DOI 10.3109/08916939209112334; DEVITA R, 1991, EUR UROL, V19, P65; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Frasca D, 1998, MECH AGEING DEV, V100, P197, DOI 10.1016/S0047-6374(97)00137-1; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Hwang BJ, 1999, METH MOL B, V113, P103; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Jhappan C, 1997, NAT GENET, V17, P483, DOI 10.1038/ng1297-483; Jin SF, 1997, CANCER SURV, V29, P221; Jin SF, 1997, EMBO J, V16, P6874, DOI 10.1093/emboj/16.22.6874; Kessel David, 1994, In Vivo (Attiki), V8, P829; Kinsella AR, 1997, BRIT J CANCER, V75, P935, DOI 10.1038/bjc.1997.164; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Koike M, 1999, J CELL SCI, V112, P4031; Korkolopoulou P, 1997, PATHOL RES PRACT, V193, P767, DOI 10.1016/S0344-0338(97)80055-6; LEROMANCER M, 1994, J BIOL CHEM, V269, P17464; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; Loeb KR, 2000, CARCINOGENESIS, V21, P379, DOI 10.1093/carcin/21.3.379; MIMORI T, 1986, J BIOL CHEM, V261, P2274; Moll U, 1999, ONCOGENE, V18, P3114, DOI 10.1038/sj.onc.1202640; MORGAN WF, 1995, CANCER METAST REV, V14, P49, DOI 10.1007/BF00690211; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; ONEILL KL, 1992, MED LAB SCI, V49, P244; POWELL SN, 1993, CYTOTECHNOLOGY, V12, P325, DOI 10.1007/BF00744671; PRABHAKAR BS, 1990, J CLIN INVEST, V86, P1301, DOI 10.1172/JCI114838; SATO T, 1991, CANCER RES, V51, P5794; Sekowski JW, 1998, CANCER RES, V58, P3259; Teoh G, 1998, J CLIN INVEST, V101, P1379; Tovari J, 1998, CELL SIGNAL, V10, P277, DOI 10.1016/S0898-6568(97)00128-9; Wang JS, 1998, J BIOL CHEM, V273, P31068, DOI 10.1074/jbc.273.47.31068; Wong SWJ, 1999, PATHOLOGY, V31, P90, DOI 10.1080/003130299105241; Yang CR, 1999, NUCLEIC ACIDS RES, V27, P2165, DOI 10.1093/nar/27.10.2165; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907; Yoo S, 1998, BIOCHEMISTRY-US, V37, P1336, DOI 10.1021/bi972100w; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2	43	82	83	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2001	20	6					739	747		10.1038/sj.onc.1204148	http://dx.doi.org/10.1038/sj.onc.1204148			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314007				2022-12-17	WOS:000166806000009
J	Russell, JP; Powell, DJ; Cunnane, M; Greco, A; Portella, G; Santoro, M; Fusco, A; Rothstein, JL				Russell, JP; Powell, DJ; Cunnane, M; Greco, A; Portella, G; Santoro, M; Fusco, A; Rothstein, JL			The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium	ONCOGENE			English	Article						neoplasia; nerve growth factor receptor; papillary thyroid carcinoma; RET/PTC; transgenic mice; TRK-T1	CHERNOBYL REACTOR ACCIDENT; COILED-COIL DOMAIN; PAPILLARY CARCINOMAS; RET/PTC1 ONCOGENE; RET REARRANGEMENT; TRANSGENIC MICE; TARGETED EXPRESSION; MOLECULAR-GENETICS; HIGH PREVALENCE; ACTIVATION	Genetic analysis of human papillary thyroid carcinomas (PTC) has revealed unique chromosomal translocations that form oncogenic fusion proteins and promote thyroid tumorigenesis in up to 60% of tumors examined, Although, the majority of thyroid specific translocations involve the growth factor receptor c-RET, variant rearrangements of the receptor for nerve growth factor, NTRK1 have also been described, One such translocation, TRK=T1, forms a fusion protein composed of the carboxyl terminal tyrosine kinase domain of NTRK1 and the amino terminal portion of TPR (Translocated Promoter Region), To determine if TRK-TI expression can cause thyroid cancer in vivo, we developed transgenic mice that express the human TRK-T1 fusion protein in the thyroid. Immunohistochemical analysis of TRK=T1 transgenic mouse thyroids revealed TRK-T1 staining within the thyroid follicular epithelium. In contrast to nontransgenic littermates, 54% of transgenic mice developed thyroid abnormalities that included follicular hyperplasia and papillary carcinoma. Furthermore, all transgenic mice examined greater than 7 months of age developed thyroid hyperplasia and/or carcinoma. These data support the conclusion that TRK-T1 is oncogenic iii vivo and contributes to the neoplastic transformation of the thyroid.	Thomas Jefferson Univ, Dept Microbiol Immunol & Otolaryngol HNS, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA; Inst Nazl Tumori, Div Expt Oncol A, Milan, Italy; Univ Naples, Ctr Endocrinol & Oncol Sperimentale, CNR,Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Fac Med & Chirurg, Dipartimento Med Sperimentale & Clin, I-88100 Cantanzaro, Italy	Jefferson University; Jefferson University; Fondazione IRCCS Istituto Nazionale Tumori Milan; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Rothstein, JL (corresponding author), Thomas Jefferson Univ, Dept Microbiol Immunol & Otolaryngol HNS, Kimmel Canc Inst, Philadelphia, PA 19107 USA.		Greco, Angela/C-1953-2017; Portella, Giuseppe/AFU-6826-2022	Greco, Angela/0000-0003-2994-0349; Fusco, Alfredo/0000-0003-3332-5197; PORTELLA, Giuseppe/0000-0001-8276-9769	NATIONAL CANCER INSTITUTE [P01CA021124, P01CA076259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007492] Funding Source: NIH RePORTER; NCI NIH HHS [CA21124, CA76259] Funding Source: Medline; NIAID NIH HHS [T32-AI07492] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; Beimfohr C, 1999, INT J CANCER, V80, P842, DOI 10.1002/(SICI)1097-0215(19990315)80:6<842::AID-IJC7>3.0.CO;2-Z; Bongarzone I, 1998, CLIN CANCER RES, V4, P223; Bongarzone I, 1998, ONCOGENE, V16, P2295, DOI 10.1038/sj.onc.1201759; BONGARZONE I, 1989, ONCOGENE, V4, P1457; Bongarzone I, 1996, J CLIN ENDOCR METAB, V81, P2006, DOI 10.1210/jc.81.5.2006; Delvincourt C, 1996, CLIN BIOCHEM, V29, P267, DOI 10.1016/0009-9120(96)00006-9; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GRECO A, 1995, MOL CELL BIOL, V15, P6118; GRECO A, 1992, ONCOGENE, V7, P237; Greco A, 1998, ONCOGENE, V16, P809, DOI 10.1038/sj.onc.1201596; Hogan B., 1986, MANIPULATING MOUSE E; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Klugbauer S, 1996, ONCOGENE, V13, P1099; Klugbauer S, 1995, ONCOGENE, V11, P2459; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; Portella G, 1999, ONCOL RES, V11, P421; Powell DJ, 1998, CANCER RES, V58, P5523; Rabes HM, 1998, RECENT RES CANCER, V154, P248; Rochefort P, 1996, ONCOGENE, V12, P111; ROSAI J, 1990, TUMORS THYROID GLAND; Sagartz JE, 1997, LAB INVEST, V76, P307; Santoro M, 1996, ONCOGENE, V12, P1821; SOZZI G, 1992, GENE CHROMOSOME CANC, V5, P212, DOI 10.1002/gcc.2870050307; WAJJWALKU W, 1992, JPN J CANCER RES, V83, P671, DOI 10.1111/j.1349-7006.1992.tb01963.x; WynfordThomas D, 1997, HORM RES, V47, P145, DOI 10.1159/000185458	28	82	83	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5729	5735		10.1038/sj.onc.1203922	http://dx.doi.org/10.1038/sj.onc.1203922			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126359				2022-12-17	WOS:000165477700004
J	Sato, N; Mizumoto, K; Nakamura, M; Ueno, H; Minamishima, YA; Farber, JL; Tanaka, M				Sato, N; Mizumoto, K; Nakamura, M; Ueno, H; Minamishima, YA; Farber, JL; Tanaka, M			A possible role for centrosome overduplication in radiation-induced cell death	ONCOGENE			English	Article						centrosome; ionizing radiation; multinucleated cells; mitotic cell death; apoptosis; p21(Waf1/Cip1)	TERMINAL PROLIFERATION ARREST; PANCREATIC-CANCER CELLS; HAMSTER OVARY CELLS; TUMOR-CELLS; GENOMIC INSTABILITY; DNA-SYNTHESIS; CYCLE ARREST; P53; APOPTOSIS; DAMAGE	Radiotherapy plays a key role in the treatment of many tumors; however, the precise mechanisms responsible for radiation-induced cell death remain uncertain. We have reported previously that ionizing radiation induces centrosome overduplication in human tumor cells. The present study was designed to elucidate a possible link between centrosome dysregulation and radiation-induced cell death. Exposure to 10 Gy gamma -radiation resulted in a substantial increase in cells containing an abnormally high number of centrosomes in a variety of cell lines derived from different types of human solid tumors. These aberrant centrosomes contribute to the assembly of multipolar spindles, thereby causing an unbalanced division of chromosomes and mitotic cell death characterized by the appearance of multi- or micronucleated cells. An extensive analysis of a panel of 10 tumor cell lines revealed a positive correlation between the fraction of cells with multiple centrosomes and the fraction with these nuclear abnormalities after irradiation. When the centrosome overduplication was blocked by enforced expression of p21(Waf1/Cip1), the radiation-induced lethality was drastically rescued. Taken together, these results indicate that centrosome overduplication may be a critical event leading to mitotic failure and subsequent cell death following exposure to ionizing radiation.	Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Fukuoka 8128582, Japan; Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19017 USA	Kyushu University; Kyushu University; Jefferson University	Mizumoto, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka 8128582, Japan.		Minamishima, Yoji Andrew/E-5380-2010	Minamishima, Yoji Andrew/0000-0001-7995-9318				BAE IS, 1995, CANCER RES, V55, P2387; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chang BD, 1999, CANCER RES, V59, P3761; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; CHANG WP, 1991, INT J RADIAT BIOL, V60, P483, DOI 10.1080/09553009114552331; Cohen-Jonathan E, 1999, CURR OPIN CHEM BIOL, V3, P77, DOI 10.1016/S1367-5931(99)80014-3; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; Doxsey S, 1998, NAT GENET, V20, P104, DOI 10.1038/2392; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; Hendry JH, 1997, INT J RADIAT BIOL, V71, P709, DOI 10.1080/095530097143716; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; KAN ZY, 1995, MOL CELL BIOL, V15, P5849; KASTAN MB, 1991, CANCER RES, V51, P6304; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; Kuo KK, 2000, HEPATOLOGY, V31, P59, DOI 10.1002/hep.510310112; Kusumoto M, 1999, CLIN CANCER RES, V5, P2140; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Lock RB, 1996, CANCER RES, V56, P4006; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; McDonald E, 1996, CANCER RES, V56, P2250; Muller WU, 1996, MUTAT RES-REV GENET, V366, P163, DOI 10.1016/S0165-1110(96)90037-8; Pihan GA, 1998, CANCER RES, V58, P3974; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; Sablina AA, 1998, J CELL SCI, V111, P977; Sato N, 2000, EXP CELL RES, V255, P321, DOI 10.1006/excr.1999.4797; Sato N, 1999, CLIN CANCER RES, V5, P963; Schwartz D, 1997, ONCOGENE, V15, P2597, DOI 10.1038/sj.onc.1201436; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Ueno H, 1997, ANN NY ACAD SCI, V811, P401, DOI 10.1111/j.1749-6632.1997.tb52020.x; UENO H, 1995, ARTERIOSCL THROM VAS, V15, P2246, DOI 10.1161/01.ATV.15.12.2246; Urbani L, 1999, CURR BIOL, V9, pR315, DOI 10.1016/S0960-9822(99)80201-2; Wang YC, 1999, ONCOGENE, V18, P2643, DOI 10.1038/sj.onc.1202632; Weber RG, 1998, CYTOGENET CELL GENET, V83, P266, DOI 10.1159/000015168; Winey M, 1996, CURR BIOL, V6, P962, DOI 10.1016/S0960-9822(02)00639-5; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zhang L, 1999, CANCER LETT, V142, P129, DOI 10.1016/S0304-3835(99)00107-X	47	82	89	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2000	19	46					5281	5290		10.1038/sj.onc.1203902	http://dx.doi.org/10.1038/sj.onc.1203902			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077445				2022-12-17	WOS:000165059700009
J	Jin, SQ; Zhao, HC; Fan, FY; Blanck, P; Fan, WH; Colchagie, AB; Fornace, AJ; Zhan, QM				Jin, SQ; Zhao, HC; Fan, FY; Blanck, P; Fan, WH; Colchagie, AB; Fornace, AJ; Zhan, QM			BRCA1 activation of the GADD45 promoter	ONCOGENE			English	Article						GADD45; BRCA1; p53; gene regulation	P53-REGULATED PROTEIN GADD45; MAMMARY EPITHELIAL-CELLS; DNA-DAMAGE; OVARIAN-CANCER; CYCLE CHECKPOINT; GENE-EXPRESSION; BREAST; P53; INDUCTION; GROWTH	Breast cancer susceptibility gene BRCA1 has been implicated in the control of gene regulation and such regulated genes are thought to mediate the biological role of BRCA1. Overexpression of BRCA1 induces GADD45, a p53-regulated and stress-inducible gene. However, the molecular mechanism by which BRCA1 induces the expression GADD45 remains unclear. In this report, we have shown that the GADD45 promoter is strongly activated following expression of wild-type BRCA1, In contrast, both the tumor-derived BRCA1 mutants (p1749R and Y1853insA) and truncated BRCA1 mutant protein (Delta 500-1863 BRCA1), which lack transactivation activity, were unable to activate the GADD45 promoter, indicating that the BRCA1-mediated activation of the GADD45 promoter requires normal transcriptional properties of BRCA1. BRCA1 did not induce the c-Jun and c-fos promoters, which rules out a general effect of BRCA1 on other immediate-responsive genes. Expression of the human papillomavirus E6 and the dominant-negative mutant p53 proteins had no effect on the induction of the GADD45 promoter by BRCA1, suggesting that activation of the GADD45 promoter by BRCA1 is independent of cellular p53 function. With the 5'-deletion analysis, the BRCA1-responsive element of the GADD45 promoter was mapped at the region from -121 to -75. Disruption of this region resulted in the abrogation of BRCA1 activation of the GADD45 promoter. Taken together, these results demonstrate that the mechanism by which BRCA1 induces GADD45 is mainly through the transactivation of the GADD45 promoter, further demonstrating the evidence that GADD45 acts as one of the BRCA1-regulated genes.	Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, Pittsburgh, PA 15213 USA; NCI, Gene Response Sect, DBS, NIH, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zhan, QM (corresponding author), Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, BST W-945,200 Lothrop St, Pittsburgh, PA 15213 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; EASTON DF, 1995, AM J HUM GENET, V56, P265; FORD D, 1995, BRIT J CANCER, V72, P805, DOI 10.1038/bjc.1995.417; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Larson JS, 1997, CANCER RES, V57, P3351; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Rao VN, 1996, ONCOGENE, V12, P523; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1996, ONCOGENE, V13, P2255; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	38	82	86	2	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2000	19	35					4050	4057		10.1038/sj.onc.1203759	http://dx.doi.org/10.1038/sj.onc.1203759			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962562				2022-12-17	WOS:000088825300011
J	Gillert, E; Leis, T; Repp, R; Reichel, M; Hosch, A; Breitenlohner, I; Angermuller, S; Borkhardt, A; Harbott, J; Lampert, F; Griesinger, F; Greil, J; Fey, GH; Marschalek, R				Gillert, E; Leis, T; Repp, R; Reichel, M; Hosch, A; Breitenlohner, I; Angermuller, S; Borkhardt, A; Harbott, J; Lampert, F; Griesinger, F; Greil, J; Fey, GH; Marschalek, R			A DNA damage repair mechanism is involved in the origin of chromosomal translocations t(4;11) in primary leukemic cells	ONCOGENE			English	Article						MLL gene; AF-4/FEL gene; leukemia; chromosomal translocation t(4;11); recombination	BREAKPOINT CLUSTER REGION; TOPOISOMERASE-II INHIBITORS; NONHOMOLOGOUS RECOMBINATION; EXON/INTRON STRUCTURE; DROSOPHILA-TRITHORAX; SEQUENCE-ANALYSIS; MAMMALIAN-CELLS; ALL-1 GENE; AF-4 GENE; 11Q23	Some chromosomal translocations involved in the origin of leukemias and lymphomas are due to malfunctions of the recombinatorial machinery of immunoglobulin and T-cell receptor-genes, This mechanism has also been proposed for translocations t(4;11)(q21;q23), which are regularly associated with acute pro-B cell leukemias in early childhood. Here, reciprocal chromosomal breakpoints in primary biopsy material of fourteen t(4;11)leukemia patients were analysed. In all cases, duplications, deletions and inversions of less than a few hundred nucleotides indicative of malfunctioning DNA repair mechanisms were observed. We concluded that these translocation events were initiated by several DNA strand breaks on both participating chromosomes and subsequent DNA repair by 'error-prone-repair' mechanisms, but not by the action of recombinases of the immune system.	Univ Erlangen Nurnberg, Chair Genet, D-91058 Erlangen, Germany; Univ Giessen, Childrens Hosp, Dept Pediat Hematol & Oncol, D-35392 Giessen, Germany; Univ Gottingen Hosp, D-37075 Gottingen, Germany; Univ Erlangen Nurnberg, Dept Pediat, D-91054 Erlangen, Germany	University of Erlangen Nuremberg; Justus Liebig University Giessen; University of Gottingen; University of Erlangen Nuremberg	Marschalek, R (corresponding author), Univ Erlangen Nurnberg, Chair Genet, Staudtstr 5, D-91058 Erlangen, Germany.		Marschalek, Rolf/D-3404-2011	Marschalek, Rolf/0000-0003-4870-3445; Reichel, Martin/0000-0001-7886-2784				Aplan PD, 1996, BLOOD, V87, P2649, DOI 10.1182/blood.V87.7.2649.bloodjournal8772649; Barr FG, 1998, NAT GENET, V19, P121, DOI 10.1038/475; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; BREIT TM, 1993, J EXP MED, V177, P965, DOI 10.1084/jem.177.4.965; CANAANI E, 1995, ADV CANCER RES, V66, P213, DOI 10.1016/S0065-230X(08)60255-9; CHEN SJ, 1989, ONCOGENE, V4, P195; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; FORD AM, 1993, NATURE, V363, P358, DOI 10.1038/363358a0; Greaves MF, 1997, LANCET, V349, P344, DOI 10.1016/S0140-6736(96)09412-3; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1994, CANCER RES, V54, P2327; GU Y, 1992, P NATL ACAD SCI USA, V89, P10464, DOI 10.1073/pnas.89.21.10464; HALUSKA FG, 1990, MOL GENETICS CANC DI, P143; HARTL P, 1987, MOL CELL BIOL, V7, P2037, DOI 10.1128/MCB.7.6.2037; Leis T, 1998, LEUKEMIA, V12, P758, DOI 10.1038/sj.leu.2401006; Marschalek R, 1997, LEUKEMIA LYMPHOMA, V27, P417, DOI 10.3109/10428199709058308; MARSCHALEK R, 1995, BRIT J HAEMATOL, V90, P308, DOI 10.1111/j.1365-2141.1995.tb05151.x; NEGRINI M, 1993, CANCER RES, V53, P4489; Nilson I, 1996, BRIT J HAEMATOL, V93, P966, DOI 10.1046/j.1365-2141.1996.d01-1748.x; Nilson I, 1997, BRIT J HAEMATOL, V98, P157, DOI 10.1046/j.1365-2141.1997.1522966.x; ONNO M, 1992, ONCOGENE, V7, P2519; PLESNER P, 1987, P NATL ACAD SCI USA, V84, P1936, DOI 10.1073/pnas.84.7.1936; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAIMONDI SC, 1995, BLOOD, V86, P1881, DOI 10.1182/blood.V86.5.1881.bloodjournal8651881; Reichel M, 1998, ONCOGENE, V17, P3035, DOI 10.1038/sj.onc.1202229; REPP R, 1995, LEUKEMIA, V9, P210; ROTH DB, 1985, MOL CELL BIOL, V5, P2599, DOI 10.1128/MCB.5.10.2599; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; Stanulla M, 1997, LEUKEMIA, V11, P490, DOI 10.1038/sj.leu.2400632; Stanulla M, 1997, MOL CELL BIOL, V17, P4070, DOI 10.1128/MCB.17.7.4070; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; VANDERPOEL SZ, 1991, P NATL ACAD SCI USA, V88, P10735	32	82	84	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	1999	18	33					4663	4671		10.1038/sj.onc.1202842	http://dx.doi.org/10.1038/sj.onc.1202842			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467413				2022-12-17	WOS:000082154400003
J	Soto, U; Das, BC; Lengert, M; Finzer, P; zur Hausen, H; Rosl, F				Soto, U; Das, BC; Lengert, M; Finzer, P; zur Hausen, H; Rosl, F			Conversion of HPV 18 positive non-tumorigenic HeLa-fibroblast hybrids to invasive growth involves loss of TNF-alpha mediated repression of viral transcription and modification of the AP-1 transcription complex	ONCOGENE			English	Article						human papillomavirus; cervical cancer; AP-1; negative regulation; cytokines	HUMAN PAPILLOMAVIRUS TYPE-16; TUMOR-NECROSIS-FACTOR; UPSTREAM REGULATORY REGION; CERVICAL-CARCINOMA CELLS; C-FOS; HUMAN KERATINOCYTES; GENE-EXPRESSION; FORESKIN KERATINOCYTES; SELECTIVE SUPPRESSION; TRANSFORMING ACTIVITY	AP-1 represents a transcription factor, which plays a pivotal role in initiating and maintaining the expression of human papillomavirus (HPV) oncoproteins E6 and E7 during HPV-linked carcinogenesis of the uterine cervix. AP-1 stands as a synonym for different proteins such as c-Jun, JunB, JunD, c-Fos, FosB as well as the Fos-related antigens Fra-1 and Fra-2, which can either homo- or heterodimerize to build up a functional transcription complex, AP-1 is mainly considered as a positive regulator, which binds to cognate DNA sequences within the viral upstream regulatory region, By using nontumorigenic HeLa-fibroblast hybrids ('444'), their tumorigenic segregants ('CGL3') as well as HPV 18 positive HeLa cells as a experimental model system, evidence is provided that AP-1 composition differs considerably between these cell lines, In nuclear extracts obtained from non-tumorigenic cells, Jun-family members (in the order c-Jun > JunD > JunB) were mainly heterodimerized with Fra-1, a protein, known to be involved in the abrogation of AP-1 activity under certain experimental conditions, In contrast, Fra-1 concentration is low in extracts from tumorigenic cells, Conversely, c-Fos, the canonical dimerization partner of Jun proteins is expressed in substantial quantity in HeLa- and 'CGL3' cells, but it is completely absent in AP-1 complexes from non-tumorigenic '444' cells, Ectopical expression of c-fos under a heterologous promoter in '444'-cells induces tumorigenicity and a change of the Jun/Fra-1 ratio towards a constellation initially detected in 'CGL3'-and HeLa cells. Furthermore, conversion to tumorigenicity is accompanied with a resistance against TNF-alpha, a cytokine, capable to selectively suppress HPV 18 transcription in formerly non-malignant cells, These data propose a novel role for AP-1 as an essential component of an inter- and intracellular surveillance mechanism negatively controlling HPV transcription in non-tumorigenic cells.	Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Angew Tumorvirol, D-69120 Heidelberg, Germany; Maulana Azad Med Coll, Inst Cytol & Prevent Oncol, Div Mol Oncol, New Delhi, India	Helmholtz Association; German Cancer Research Center (DKFZ); Indian Council of Medical Research (ICMR); ICMR - National Institute of Cancer Prevention & Research (NICPR); Maulana Azad Medical College	Rosl, F (corresponding author), Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Angew Tumorvirol, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; Arts J, 1997, NUCLEIC ACIDS RES, V25, P311, DOI 10.1093/nar/25.2.311; ATTIA MAM, 1966, CANCER RES, V26, P1787; BARTSCH D, 1992, EMBO J, V11, P2283, DOI 10.1002/j.1460-2075.1992.tb05287.x; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BOSCH FX, 1990, J VIROL, V64, P4743, DOI 10.1128/JVI.64.10.4743-4754.1990; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; BUTZ K, 1993, J VIROL, V67, P6476, DOI 10.1128/JVI.67.11.6476-6486.1993; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; CRIPE T P, 1990, New Biologist, V2, P450; CRUM CP, 1989, AM J PATHOL, V134, P1183; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; Durst M, 1995, CANCER GENET CYTOGEN, V85, P105, DOI 10.1016/0165-4608(95)00155-7; DURST M, 1987, ONCOGENE, V1, P251; DURST M, 1991, J VIROL, V65, P796; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FINZER P, 1999, UNPUB; FUJII M, 1991, ONCOGENE, V6, P1023; GARCIACARRANCA A, 1988, J VIROL, V62, P4321, DOI 10.1128/JVI.62.11.4321-4330.1988; GIUS D, 1989, J VIROL, V63, P555, DOI 10.1128/JVI.63.2.555-563.1989; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAUSEN HZ, 1994, LANCET, V343, P955, DOI 10.1016/S0140-6736(94)90070-1; HOPPESEYLER F, 1991, J VIROL, V65, P5613, DOI 10.1128/JVI.65.10.5613-5618.1991; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JESUDASAN RA, 1995, AM J HUM GENET, V56, P705; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KAUR P, 1989, VIROLOGY, V173, P302, DOI 10.1016/0042-6822(89)90247-X; KHAN MA, 1993, CANCER RES, V53, P905; KHANDJIAN EW, 1986, ANAL BIOCHEM, V159, P227, DOI 10.1016/0003-2697(86)90332-5; KLEINE K, 1995, MOL CARCINOGEN, V14, P179, DOI 10.1002/mc.2940140307; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOETSCHER H, 1991, CANCER CELL-MON REV, V3, P221; Mils V, 1997, ONCOGENE, V14, P1555, DOI 10.1038/sj.onc.1200991; MOROSOV A, 1994, J BIOL CHEM, V269, P18434; OFFORD EA, 1990, J VIROL, V64, P4792, DOI 10.1128/JVI.64.10.4792-4798.1990; OHARA BM, 1987, MOL CELL BIOL, V7, P2941, DOI 10.1128/MCB.7.8.2941; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; Parker JN, 1997, CELL GROWTH DIFFER, V8, P751; PEI XF, 1993, VIROLOGY, V196, P855, DOI 10.1006/viro.1993.1546; Pognonec P, 1997, ONCOGENE, V14, P2091, DOI 10.1038/sj.onc.1201046; POLACK A, 1987, EMBO J, V6, P2959, DOI 10.1002/j.1460-2075.1987.tb02601.x; ROLLINS BJ, 1991, CANCER CELL-MON REV, V3, P517; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; ROSL F, 1988, EMBO J, V7, P1321, DOI 10.1002/j.1460-2075.1988.tb02947.x; ROSL F, 1991, EMBO J, V10, P1337, DOI 10.1002/j.1460-2075.1991.tb07653.x; ROSL F, 1994, J VIROL, V68, P2142; Rosl F, 1997, J VIROL, V71, P362; ROSL F, 1999, IN PRESS CHEMOKINES; ROSL F, 1997, MOL B INT U, P25; Rutberg SE, 1997, ONCOGENE, V15, P1337, DOI 10.1038/sj.onc.1201293; Rutberg SE, 1996, ONCOGENE, V13, P167; RYSECK RP, 1991, ONCOGENE, V6, P533; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHEPARD HM, 1988, J CLIN IMMUNOL, V8, P333, DOI 10.1007/BF00917148; SINKE RJ, 1993, GENOMICS, V18, P165, DOI 10.1006/geno.1993.1447; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITS PHM, 1990, VIROLOGY, V176, P158, DOI 10.1016/0042-6822(90)90240-R; SMITS PHM, 1992, EMBO J, V11, P4601, DOI 10.1002/j.1460-2075.1992.tb05562.x; SRIVATSAN ES, 1991, AM J HUM GENET, V49, P868; STANBRIDGE EJ, 1984, CANCER SURV, V3, P335; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; TSUCHIYA H, 1993, J VIROL, V67, P7001, DOI 10.1128/JVI.67.12.7001-7007.1993; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; Wang HL, 1996, J CELL BIOL, V135, P1151, DOI 10.1083/jcb.135.4.1151; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; Zhao W, 1997, J VIROL, V71, P8832, DOI 10.1128/JVI.71.11.8832-8840.1997; ZURHAUSEN H, 1994, COLD SPRING HARB SYM, V59, P623, DOI 10.1101/SQB.1994.059.01.071; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55; ZURHAUSEN H, 1986, LANCET, V11, P489	81	82	89	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	1999	18	21					3187	3198		10.1038/sj.onc.1202765	http://dx.doi.org/10.1038/sj.onc.1202765			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359524				2022-12-17	WOS:000080523800001
J	Canitrot, Y; Lautier, D; Laurent, G; Frechet, M; Ahmed, A; Turhan, AG; Salles, B; Cazaux, C; Hoffmann, JS				Canitrot, Y; Lautier, D; Laurent, G; Frechet, M; Ahmed, A; Turhan, AG; Salles, B; Cazaux, C; Hoffmann, JS			Mutator phenotype of BCR-ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta	ONCOGENE			English	Article						bcr-abl; mutator phenotype; DNA polymerase beta	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOCYTIC-LEUKEMIA; CLONAL EVOLUTION; BLAST CRISIS; P53 GENE; RAS; MUTATIONS; ONCOGENE; OVEREXPRESSION; TRANSFORMATION	Chronic myelogenous leukemia (CML) is characterized by the Philadelphia chromosome resulting from the translocation t(9-22) producing the chimeric 190 and 210 kDa BCR-ABL fusion proteins. Evolution of the CML to the more aggressive acute myelogenous leukemia (AML) is accompanied by increased cellular proliferation and genomic instability at the cytogenetic level. We hypothezised that genomic instability at the nucleotide level and spontaneous error in DNA replication may also contribute to the evolution of CML to AML. Murine Ba/F3 cell line was transfected with the p190 and p210-encoding BCR-ABL oncogenes, and spontaneous mutation frequency at the Na-K-ATPase and the hypoxanthine guanine phosphoribosyl transferase (HPRT) loci were measured. A significant 3-5-fold increase in mutation frequency for the transfected cells relative to the untransfected control cells was found. Furthermore, we observed that BCR-ABL transfection induced an overexpression of DNA polymerase beta, the most inaccurate of the mammalian DNA polymerases, as well as an increase in its activity, suggesting that inaccuracy of DNA replication may account for the observed mutator phenotype. These data suggest that the Philadelphia abnormality confers a mutator phenotype and may have implications for the potential role of DNA polymerase beta in this process.	CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France; Inst Claudius Regaud, INSERM, F-31052 Toulouse, France; Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	Hoffmann, JS (corresponding author), CNRS, Inst Pharmacol & Biol Struct, UPR 9062,205 Route Narbonne, F-31077 Toulouse, France.		Lautier, Dominique/G-3959-2017; Hoffmann, Jean-Sebastien/O-9183-2014; salles, bernard/B-8531-2008	Hoffmann, Jean-Sebastien/0000-0003-2222-354X; TURHAN, Ali/0000-0002-4861-0137				Ahmed M, 1998, ONCOGENE, V16, P489, DOI 10.1038/sj.onc.1201556; AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; BERNSTEIN R, 1988, SEMIN HEMATOL, V25, P20; Bouayadi K, 1997, CANCER RES, V57, P110; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Canitrot Y, 1998, P NATL ACAD SCI USA, V95, P12586, DOI 10.1073/pnas.95.21.12586; COLLINS SJ, 1989, BLOOD, V73, P1028; COPELAND WC, 1992, J BIOL CHEM, V267, P21459; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016/0002-9343(77)90124-3; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; Hoffmann JS, 1996, P NATL ACAD SCI USA, V93, P13766, DOI 10.1073/pnas.93.24.13766; KEDAR PS, 1990, MOL CELL BIOL, V10, P3852, DOI 10.1128/MCB.10.7.3852; KELMAN Z, 1989, BLOOD, V74, P2318; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; LANEUVILLE P, 1992, BLOOD, V80, P1788; LEMAISTRE A, 1989, BLOOD, V73, P889; LOEB LA, 1991, CANCER RES, V51, P3075; MANDANAS RA, 1993, BLOOD, V82, P1838; MASHAL R, 1990, BLOOD, V75, P180; MCCARTHY DM, 1984, LANCET, V2, P1362; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SCANLON KJ, 1989, CANCER INVEST, V7, P581, DOI 10.3109/07357908909017533; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; WADA C, 1994, BLOOD, V83, P3449, DOI 10.1182/blood.V83.12.3449.bloodjournal83123449; WIND N, 1995, CELL, V82, P321; ZMUDZKA BZ, 1988, NUCLEIC ACIDS RES, V16, P9589	30	82	84	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2676	2680		10.1038/sj.onc.1202619	http://dx.doi.org/10.1038/sj.onc.1202619			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348341				2022-12-17	WOS:000080124900002
J	Smith, PD; Crossland, S; Parker, G; Osin, P; Brooks, L; Waller, J; Philp, E; Crompton, MR; Gusterson, BA; Allday, MJ; Crook, T				Smith, PD; Crossland, S; Parker, G; Osin, P; Brooks, L; Waller, J; Philp, E; Crompton, MR; Gusterson, BA; Allday, MJ; Crook, T			Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions	ONCOGENE			English	Article						p53; novel; mutation; breast; BRCA-1; BRCA-2	CELL-CYCLE ARREST; TRANSCRIPTIONAL ACTIVATION; P53-DEPENDENT APOPTOSIS; DNA-REPAIR; CANCER; BREAST; GENE; MUTATION; MDM2; P21(WAF1/CIP1)	Inheritance of germ-line mutant alleles of BRCA1 and BRCA2 confers a markedly increased risk of breast cancer and we have previously reported a higher incidence of p53 mutations in these tumours than in grade matched sporadic tumours, We have now characterized these p53 mutants, The results of these studies identify a novel class of p53 mutants previously undescribed in human cancer Set with multiple occurrences in BRCA-associated tumours which retain a profile of p53-dependent activities in terms of transactivation, growth suppression and apoptosis induction which is close or equal to wild-type. However, these mutants fail to suppress transformation and exhibit gain of function transforming activity in rat embryo fibroblasts, These mutants therefore fall into a novel category of p53 mutants which dissociate transformation suppression from other wild-type functions. The rarity of these mutants in human cancer and their multiple occurrence in BRCA-associated breast tumours suggests that these novel p53 mutants are selected during malignant progression in the unique genetic background of BRCA1- and BRCA2-associated tumours.	Inst Canc Res, Haddow Labs, Sutton SM2 5NG, Surrey, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Sect Virol & Cell Biol, London W2 1PG, England; London Sch Hyg & Trop Med, Div Clin Sci, London W1, England; Inst Canc Res, Toby Robins Breast Canc Res Ctr, London SW3 6JB, England	University of London; Institute of Cancer Research - UK; Imperial College London; Ludwig Institute for Cancer Research; Imperial College London; University of London; London School of Hygiene & Tropical Medicine; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Crook, T (corresponding author), Inst Canc Res, Haddow Labs, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.		gusterson, barry a/D-3752-2009		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; COLLINS N, 1995, ONCOGENE, V10, P1673; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Crook T, 1998, ONCOGENE, V16, P1429, DOI 10.1038/sj.onc.1201699; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lakhani SR, 1997, LANCET, V349, P1505; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LUDWIG T, 1997, GENE DEV, V11, P1126; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MIYASHITA T, 1995, CELL, V80, P293; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Parker GA, 1996, ONCOGENE, V13, P2541; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SMITH AP, 1992, HDB HUMAN PERFORMANC, V2, P2; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	39	82	87	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2451	2459		10.1038/sj.onc.1202565	http://dx.doi.org/10.1038/sj.onc.1202565			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229196				2022-12-17	WOS:000079703300005
J	Koken, MHM; Daniel, MT; Gianni, M; Zelent, A; Licht, J; Buzyn, A; Minard, P; Degos, L; Varet, B; de The, H				Koken, MHM; Daniel, MT; Gianni, M; Zelent, A; Licht, J; Buzyn, A; Minard, P; Degos, L; Varet, B; de The, H			Retinoic acid, but not arsenic trioxide, degrades the PLZF/RAR alpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient	ONCOGENE			English	Article						nuclear dot; leukaemia; degradation; PML; t(15;17); translocation	ACUTE PROMYELOCYTIC LEUKEMIA; PML GROWTH-SUPPRESSOR; RECEPTOR-ALPHA; T(15-17) TRANSLOCATION; NUCLEAR-BODIES; DNA-BINDING; CELLS; ONCOPROTEIN; GENE; EXPRESSION	Primary blasts of a t(11;17)(q23;q21) acute promyelocytic leukaemia (APL) patient were analysed with respect to retinoic acid (RA) and arsenic trioxide (As2O3) sensitivity as well as PLZF/RAR alpha status. Although RA induced partial monocytic differentiation ex vivo, but not in vivo, As203 failed to induce apoptosis in culture, contrasting with t(15;17) APL and arguing against the clinical use of As203 in t(11;17)(q23;q21) APL. Prior to cell culture, PLZF/RAR alpha was found to exactly co-localize with PML onto PML nuclear bodies. However upon cell culture, it quickly shifted towards microspeckles, its localization found in transfection experiments. Arsenic trioxide, known to induce aggregation of PML nuclear bodies, left the microspeckled PLZF/RAR alpha localization completely unaffected. RA treatment led to PLZF/RARa degradation. However, this complete PLZF/RAR alpha degradation was not accompanied by differentiation or apoptosis, which could suggest a contribution of the reciprocal RAR alpha/PLZF fusion product in leukaemogenesis or the existence of irreversible changes induced by the chimera.	Hop St Louis, Lab Associe Comite Paris Ligue Contre Canc, CNRS, UPR 90 51, F-75010 Paris, France; Hop St Louis, Serv Clin Malad Sang, Paris, France; Hop Necker Enfants Malad, Hematol Serv, Paris, France; Hop Moulins, Serv Med Interne, Moulins, France; Hop St Louis, Hematol Serv, Paris, France; Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England; CUNY, Mt Sinai Med Ctr, New York, NY USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Koken, MHM (corresponding author), Hop St Louis, Lab Associe Comite Paris Ligue Contre Canc, CNRS, UPR 90 51, 1 Av Claude Vellefaux, F-75010 Paris, France.		Gianni, Maurizio/ABG-6322-2020; Minard, Philippe/GRS-4797-2022; Licht, Jonathan/L-4239-2019; Zelent, Arthur/B-3532-2009; koken, marcel/J-8154-2012; koken, marcel/N-1349-2019	Gianni, Maurizio/0000-0002-6945-708X; Minard, Philippe/0000-0002-3256-528X; koken, marcel/0000-0002-0839-0125; Licht, Jonathan/0000-0002-3942-1369; Zelent, Arthur/0000-0002-7968-9888				BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Chen GQ, 1997, BLOOD, V89, P3345; Chen GQ, 1996, BLOOD, V88, P1052; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DANIEL MT, 1993, BLOOD, V82, P1858; DEGOS L, 1993, LEUKEMIA, V7, P766; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He L. Z., 1997, Blood, V90, p320A; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Quignon F, 1997, BBA-REV CANCER, V1333, pM53, DOI 10.1016/S0304-419X(97)00025-5; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; Stadler M, 1995, ONCOGENE, V11, P2565; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Yeyati P. L., 1997, Blood, V90, p245A; Yoshida H, 1996, CANCER RES, V56, P2945; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	40	82	84	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1113	1118		10.1038/sj.onc.1202414	http://dx.doi.org/10.1038/sj.onc.1202414			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023688				2022-12-17	WOS:000078510600029
J	Fuks, F; Milner, J; Kouzarides, T				Fuks, F; Milner, J; Kouzarides, T			BRCA2 associates with acetyltransferase activity when bound to P/CAF	ONCOGENE			English	Article						BRCA2; P/CAF; histone acetyltransferase	HISTONE ACETYLTRANSFERASE; ACTIVATION; GENE; CBP	Predisposition to hereditary breast cancer has been attributed in part to inherited mutations in the BRCA2 gene. The large protein it encodes is still poorly characterized with respect to functions. We have previously shown that BRCA2 has transcriptional activation potential conferred by its amino-terminal third exon, Here, me show that BRCA2 interacts with a transcriptional co-activator protein, P/CAF, which possesses histone acetyltransferase activity, The interaction with P/CAF is demonstrated in vitro as well as in vivo and is shown to be mediated by residues 290-453 of BRCA2, Consistent with the binding to an acetyltransferase, BRCA2 is shown to associate with acetyltransferase activity in nuclear extracts. Contrary to a recent report, we find no evidence in support of an intrinsic HAT activity in BRCA2 amino-terminus. Our results further substantiate the notion that BRCA2 has transcriptional activation function and suggest that one mechanism by which BRCA2 regulates transcription may be through the recruitment of histone-modifying activity of the P/CAF co-activator.	Univ Cambridge, Wellcome CRC Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QR, England	University of Cambridge; University of Cambridge	Kouzarides, T (corresponding author), Univ Cambridge, Wellcome CRC Inst, Tennis Court Rd, Cambridge CB2 1QR, England.			Kouzarides, Tony/0000-0002-8918-4162	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Davie JR, 1998, CURR OPIN GENET DEV, V8, P173, DOI 10.1016/S0959-437X(98)80138-X; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Nordling M, 1998, CANCER RES, V58, P1372; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Siddique H, 1998, ONCOGENE, V16, P2283, DOI 10.1038/sj.onc.1202003; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	19	82	84	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2531	2534		10.1038/sj.onc.1202475	http://dx.doi.org/10.1038/sj.onc.1202475			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824164				2022-12-17	WOS:000076927300013
J	Erickson, S; Sangfelt, O; Heyman, M; Castro, J; Einhorn, S; Grander, D				Erickson, S; Sangfelt, O; Heyman, M; Castro, J; Einhorn, S; Grander, D			Involvement of the Ink4 proteins p16 and p15 in T-lymphocyte senescence	ONCOGENE			English	Article						T-lymphocytes; p16; p15 senescence	DEPENDENT KINASE INHIBITORS; CELL-CYCLE CONTROL; REPLICATIVE SENESCENCE; TUMOR SUPPRESSION; HUMAN-FIBROBLASTS; MAMMALIAN-CELLS; TGF-BETA; EXPRESSION; GENE; INACTIVATION	Little is known about the molecular background to senescence in T-lymphocytes. In fibroblast systems replicative senescence has been shown to correlate with a number of changes in the expression of the proteins normally regulating progression through the G1 phase of the cell cycle, and recently the Ink4 inhibitor p16 was implicated as a central regulator of replicative senescence in human fibroblasts. It has, however, been claimed that p16 is not expressed in T-lymphocytes, In the present study we have analysed G1 regulating proteins in ageing human T-lymphocytes, We show that PHA and IL-2 stimulated T-lymphocytes cease to proliferate after around 20 population doublings, these cells can not thereafter be restimulated to growth, and were also found to exhibit markers for senescence, We found that T-lymphocytes accumulate p16 and p15 protein during successive population doublings and display high levels of these proteins as they enter into replicative senescence. There was also an increased binding of p16 to the Cdk6 kinase in senescent cells, and a decreased Cdk6 as well as Cdk2 kinase activity. The levels of other G1 regulating proteins were also altered in the senescent cells, such as slightly elevated levels of p21/WAF1, and downregulation of Cdk2 and cyclinD3, The levels off p27/Kipl is down regulated in proliferating cells but rise to approximately 15% of the levels in un-stimulated quiescent cells. As a high proportion of T-cell childhood acute lymphoblastic leukaemias have deletions of both p15 and p16, our data suggest that inactivation of these genes makes it possible for leukemic cells to avoid senescence.	Karolinska Hosp & Inst, Dept Pathol & Oncol, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Grander, D (corresponding author), Karolinska Hosp & Inst, Dept Pathol & Oncol, S-17176 Stockholm, Sweden.							Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; ATADJA P, 1995, P NATL ACAD SI US, V92, P8328; Batova A, 1997, CANCER RES, V57, P832; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Effros RB, 1996, EXP GERONTOL, V31, P21, DOI 10.1016/0531-5565(95)00017-8; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GOLDSTEIN S, 1994, J CELL PHYSIOL, V161, P571, DOI 10.1002/jcp.1041610321; GRANA X, 1995, ONCOGENE, V11, P211; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Herman JG, 1996, CANCER RES, V56, P722; Heyman M, 1996, LEUKEMIA LYMPHOMA, V23, P235, DOI 10.3109/10428199609054826; HIRAMA T, 1995, BLOOD, V86, P841; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Kamb A, 1994, Nat Genet, V8, P23; LaThangue NB, 1996, BIOCHEM SOC T, V24, P54; LOIS AF, 1995, CANCER RES, V55, P4010; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PERILLO NL, 1993, EXP CELL RES, V207, P131, DOI 10.1006/excr.1993.1171; RASOOL O, 1995, BLOOD, V85, P3431, DOI 10.1182/blood.V85.12.3431.bloodjournal85123431; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Reznikoff CA, 1996, CANCER RES, V56, P2886; RYAN QC, 1993, CELL IMMUNOL, V149, P65, DOI 10.1006/cimm.1993.1136; Sangfelt O, 1997, CELL GROWTH DIFFER, V8, P343; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; SONODA Y, 1995, ONCOGENE, V11, P2145; STONE S, 1995, ONCOGENE, V11, P987; STONE S, 1995, CANCER RES, V55, P2988; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; TAM SW, 1994, CANCER RES, V54, P5816; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; ULLBERG M, 1983, SCAND J IMMUNOL, V17, P365, DOI 10.1111/j.1365-3083.1983.tb00801.x	44	82	85	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					595	602		10.1038/sj.onc.1201965	http://dx.doi.org/10.1038/sj.onc.1201965			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704925				2022-12-17	WOS:000075195300007
J	Mostert, MC; Verkerk, AJMH; van de Pol, M; Heighway, J; Marynen, P; Rosenberg, C; van Kessel, AG; van Echten, J; de Jong, B; Oosterhuis, JW; Looijenga, LHJ				Mostert, MC; Verkerk, AJMH; van de Pol, M; Heighway, J; Marynen, P; Rosenberg, C; van Kessel, AG; van Echten, J; de Jong, B; Oosterhuis, JW; Looijenga, LHJ			Identification of the critical region of 12p over-representation in testicular germ cell tumors of adolescents and adults	ONCOGENE			English	Article						testicular germ cell tumors; 12p; overrepresentation; critical region; candidate gene(s)	COMPARATIVE GENOMIC HYBRIDIZATION; IN-SITU HYBRIDIZATION; LACTATE-DEHYDROGENASE ISOENZYME-1; MOLECULAR CYTOGENETIC ANALYSIS; CHROMOSOMAL LOCALIZATION; CARCINOMA-INSITU; SHORT ARM; ENDOPLASMIC-RETICULUM; EUROPEAN COUNTRIES; LECTIN SUPERFAMILY	Cytogenetically, testicular germ cell tumors of adolescents and adults (TGCTs) are characterized by gain of 12p-sequences, most often through isochromosome formation (i(12p)), Fluorescence in situ hybridization (FISH) has shown that i(12p))-negative TGCTs also cryptically contain extra 12p-sequences. The consistency of 12p-over-representation in all histological subtypes of TGCTs, including their preinvasive stage, suggests that gain of one or more genes on 12p is crucial in the development of this cancer. So far, studies aimed at the identification of the relevant gene(s) were based on the 'candidate-gene approach'. No convincing evidence in favor of or against a particular gene has been reported. We combined conventional karyotyping, comparative genomic hybridization, and FISH to identify TGCTs with amplifications of restricted regions of 12p, Out of 49 primary TGCTs (23 without i(12p), 13 with and 13 unknown), eight tumors (six without i(12p) and two unknown) showed amplifications corresponding to 12p11.1-p12.1. Using bicolour-FISH, physical mapping, and semi-quantitative polymerase chain reactions, the size of the shortest region of overlap of amplification (SROA) was estimated to be between 1750-3000 kb, In addition, we mapped a number of genes in and around this region. While fourteen known genes could be excluded as candidates based on their location outside this region, we demonstrate that KRAS2, JAW1 and SOX5 genes are localized within the SROA, While KRAS2 and JAW1 map to the proximal border of the SROA, SOX5 maps centrally in the SROA, KRAS2 and JAW1 are expressed in all TGCTs, whereas one 12p amplicon-positive TGCT lacks expression of SOX5, The critical region of 12p over-represented in TGCTs is less than 8% of the total length of the short arm of chromosome 12, It will be helpful in the identification of the gene(s) involved in TGCT-development.	Univ Rotterdam Hosp, Dr Daniel Den Hoed Canc Ctr, Lab Expt Pathooncol, Rotterdam, Netherlands; Christie Hosp NHS Trust, Paterson Inst Canc Res, Dept Canc Genet, Manchester M20 4BX, Lancs, England; Katholieke Univ Leuven VIB, Ctr Human Genet, Louvain, Belgium; Leiden Univ, Dept Cytochem & Cytometry, Leiden, Netherlands; Univ Nijmegen, Dept Human Genet, Nijmegen, Netherlands; Univ Groningen Hosp, Dept Med Genet, Groningen, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Flanders Institute for Biotechnology (VIB); KU Leuven; Leiden University; Leiden University - Excl LUMC; Radboud University Nijmegen; University of Groningen	Mostert, MC (corresponding author), Univ Rotterdam Hosp, Dr Daniel Den Hoed Canc Ctr, Lab Expt Pathooncol, Rotterdam, Netherlands.		van Kessel, Ad Geurts/A-2810-2010; rosenberg, carla/N-4148-2015; Looijenga, Leendert/B-8145-2019	rosenberg, carla/0000-0003-3253-4448; Looijenga, Leendert/0000-0002-8146-1911; Verkerk, Annemieke JMH/0000-0002-7523-3656				ADAMI HO, 1994, INT J CANCER, V59, P33, DOI 10.1002/ijc.2910590108; ANDREWS PW, 1990, DIFFERENTIATION, V43, P131, DOI 10.1111/j.1432-0436.1990.tb00439.x; ATKIN NB, 1983, CANCER GENET CYTOGEN, V10, P199, DOI 10.1016/0165-4608(83)90125-5; BEHRENS TW, 1994, J IMMUNOL, V153, P682; Behrens TW, 1996, J BIOL CHEM, V271, P23528, DOI 10.1074/jbc.271.38.23528; Bergstrom R, 1996, J NATL CANCER I, V88, P727, DOI 10.1093/jnci/88.11.727; Betticher DC, 1996, BRIT J CANCER, V73, P294, DOI 10.1038/bjc.1996.52; Bosl GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406; CARICASOLE AAD, IN PRESS ONCOGENE; CASTEDO SMMJ, 1989, CANCER RES, V49, P439; CHANG CW, 1995, EUR J IMMUNOL, V25, P2433, DOI 10.1002/eji.1830250904; COTTER FE, 1991, GENOMICS, V9, P473, DOI 10.1016/0888-7543(91)90413-9; DMITROVSKY E, 1990, ONCOGENE, V5, P543; FEUER EJ, 1995, J NATL CANCER I, V87, P405; FUCHS P, 1992, GENOMICS, V13, P219, DOI 10.1016/0888-7543(92)90226-I; GIBBS RA, 1989, P NATL ACAD SCI USA, V86, P1919, DOI 10.1073/pnas.86.6.1919; GILLIS AJM, 1994, LAB INVEST, V71, P874; Heighway J, 1996, GENOMICS, V35, P207, DOI 10.1006/geno.1996.0340; HOOVERS JMN, 1993, GENOMICS, V15, P525, DOI 10.1006/geno.1993.1104; Houldsworth J, 1997, CELL GROWTH DIFFER, V8, P293; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KAWASE E, 1994, DEV BIOL, V161, P91, DOI 10.1006/dbio.1994.1011; Korn WM, 1996, GENE CHROMOSOME CANC, V17, P78, DOI 10.1002/(SICI)1098-2264(199610)17:2<78::AID-GCC2>3.0.CO;2-Y; KRAUTER K, 1995, NATURE, V377, P321; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; Larramendy ML, 1997, AM J PATHOL, V150, P685; LI SSL, 1988, CYTOGENET CELL GENET, V48, P16, DOI 10.1159/000132578; LOOIJENGA LHJ, 1990, CYTOGENET CELL GENET, V53, P216, DOI 10.1159/000132934; LOOIJENGA LHJ, 1991, LAB INVEST, V64, P113; LOOIJENGA LHJ, 1993, LAB INVEST, V68, P211; LOPEZCABRERA M, 1993, J EXP MED, V178, P537, DOI 10.1084/jem.178.2.537; MANDICH P, 1994, GENOMICS, V22, P216, DOI 10.1006/geno.1994.1366; MANIATIS T, 1982, MOL CLONING LABORATO, P280; Marynen P, 1996, CYTOGENET CELL GENET, V73, P1, DOI 10.1159/000134308; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; Mitelman F, 1995, ISCN INT SYSTEM HUMA; MOLLER H, 1995, INT J CANCER, V61, P761, DOI 10.1002/ijc.2910610604; Mostert MMC, 1996, CANCER GENET CYTOGEN, V87, P95, DOI 10.1016/0165-4608(95)00233-2; Mostert MMC, 1996, CANCER GENET CYTOGEN, V89, P146, DOI 10.1016/0165-4608(96)00043-X; MOSTOFI FK, 1973, SEM DIAGN PATHOL; MOUL JW, 1992, GENE CHROMOSOME CANC, V5, P109, DOI 10.1002/gcc.2870050204; MUKHERJEE AB, 1991, GENE CHROMOSOME CANC, V3, P300, DOI 10.1002/gcc.2870030409; NEWGARD CB, 1986, P NATL ACAD SCI USA, V83, P8132, DOI 10.1073/pnas.83.21.8132; NUTTALL FQ, 1994, GENOMICS, V19, P404, DOI 10.1006/geno.1994.1086; OLIE RA, 1995, GENE CHROMOSOME CANC, V12, P110, DOI 10.1002/gcc.2870120205; OOSTERHUIS JW, 1989, LAB INVEST, V60, P14; POPESCU NC, 1985, SOMAT CELL MOLEC GEN, V11, P149, DOI 10.1007/BF01534703; PUGH RCB, 1976, PATHOLOGY TESTIS, P245; PURANAM KL, 1995, GENOMICS, V26, P595, DOI 10.1016/0888-7543(95)80181-K; RAAP AK, 1995, HUM MOL GENET, V4, P529, DOI 10.1093/hmg/4.4.529; RAEYMAEKERS P, 1995, GENOMICS, V29, P170, DOI 10.1006/geno.1995.1228; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; RODRIGUEZ E, 1993, GENE CHROMOSOME CANC, V8, P230, DOI 10.1002/gcc.2870080405; RODRIQUEZ E, 1993, CANCER RES, V52, P2285; Sandberg AA, 1996, J UROLOGY, V155, P1531, DOI 10.1016/S0022-5347(01)66124-X; SCHNITTGER S, 1993, EUR J IMMUNOL, V23, P2711, DOI 10.1002/eji.1830231051; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; SMOLAREK TA, 1995, GENE CHROMOSOME CANC, V14, P252, DOI 10.1002/gcc.2870140403; STAMP IM, 1995, AM J SURG PATHOL, V19, P489, DOI 10.1097/00000478-199504000-00019; SUIJKERBUIJK RF, 1993, CANCER GENET CYTOGEN, V70, P85, DOI 10.1016/0165-4608(93)90173-J; SUIJKERBUIJK RF, 1994, CANCER GENET CYTOGEN, V78, P145, DOI 10.1016/0165-4608(94)90082-5; TAYLOR RE, 1986, EUR J CANCER CLIN ON, V22, P647, DOI 10.1016/0277-5379(86)90161-6; VANECHTEN J, 1995, GENE CHROMOSOME CANC, V14, P133, DOI 10.1002/gcc.2870140208; VANKESSEL AG, 1989, CANCER GENET CYTOGEN, V40, P129, DOI 10.1016/0165-4608(89)90154-4; VONEYBEN FE, 1988, J UROLOGY, V140, P986, DOI 10.1016/S0022-5347(17)41906-9; VONEYBEN FE, 1992, MOL GEN GENET, V235, P140, DOI 10.1007/BF00286191; VOS A, 1990, CANCER GENET CYTOGEN, V46, P75, DOI 10.1016/0165-4608(90)90011-X; White GRM, 1996, BRIT J CANCER, V74, P863, DOI 10.1038/bjc.1996.449; Wunderle VM, 1996, GENOMICS, V36, P354, DOI 10.1006/geno.1996.0474	72	82	84	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2617	2627		10.1038/sj.onc.1201787	http://dx.doi.org/10.1038/sj.onc.1201787			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632138				2022-12-17	WOS:000073698200006
J	Watson, MA; Darrow, C; Zimonjic, DB; Popescu, NC; Fleming, TP				Watson, MA; Darrow, C; Zimonjic, DB; Popescu, NC; Fleming, TP			Structure and transcriptional regulation of the human mammaglobin gene, a breast cancer associated member of the uteroglobin gene family localized to chromosome 11q13	ONCOGENE			English	Article						mammaglobin; breast cancer; genomic organization; promoter	STEROID-BINDING-PROTEIN; TRANSGENIC MICE; SECRETORY PROTEIN; DNA-SEQUENCE; C-3 GENES; PROMOTER; CELLS; PROSTATE; ANTIGEN; MAP	The mammaglobin gene encodes a novel secreted protein whose corresponding mRNA is frequently up-regulated in human breast cancer, In non-malignant tissues, expression is also strictly limited to the mammary epithelium. To better understand the mechanisms controlling these patterns of expression, we have isolated the human mammaglobin gene and performed an initial assessment of its promoter activity, Mammaglobin gene architecture is very similar to that of a family of related genes that includes uteroglobin and rat prostatein subunits C1, C2, and C3. However, the mammaglobin gene itself is not well conserved phylogenetically. The human mammaglobin gene is localized by fluorescent in situ hybridization to chromosome 11 band q13, a genomic region frequently amplified in breast neoplasia, The sequence of proximal 1 kb of mammaglobin promoter contains several potential transcriptional control elements and directs high-level expression of a transfected reporter construct in human breast tumor cell lines, However, comparable levels of reporter gene expression are also seen in non-mammary human cell lines, These data suggest that, unlike related gene family members, the striking breast-specific expression and tumor-associated overexpression of mammaglobin is mediated by complex transcriptional control at more distal sequence elements,.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Ophthalmol, St Louis, MO 63110 USA; NCI, Expt Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	Washington University (WUSTL); Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Watson, MA (corresponding author), Washington Univ, Sch Med, Dept Pathol, Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.		Zimonjic, Drazen/AAX-7513-2020					ALLISON J, 1989, MOL CELL BIOL, V9, P2254, DOI 10.1128/MCB.9.5.2254; Britten RJ, 1996, P NATL ACAD SCI USA, V93, P9374, DOI 10.1073/pnas.93.18.9374; CELIS L, 1993, MOL CELL ENDOCRINOL, V94, P165, DOI 10.1016/0303-7207(93)90165-G; Chen JH, 1996, ONCOGENE, V13, P1667; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; FANTL V, 1993, CANCER SURV, V18, P77; GILLETT C, 1994, CANCER RES, V54, P1812; Greenberg N M, 1992, Cancer Treat Res, V61, P379; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; HURST HC, 1983, EMBO J, V2, P769, DOI 10.1002/j.1460-2075.1983.tb01498.x; JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; LEA OA, 1979, J BIOL CHEM, V254, P6196; LEE CS, 1992, J BIOL CHEM, V267, P5797; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; McKnight R A, 1992, Cancer Treat Res, V61, P399; MIELE L, 1987, ENDOCR REV, V8, P474, DOI 10.1210/edrv-8-4-474; MIELE L, 1994, J ENDOCRINOL INVEST, V17, P679, DOI 10.1007/BF03349687; NEZNANOV NS, 1993, MOL CELL BIOL, V13, P1815, DOI 10.1128/MCB.13.3.1815; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; PARKER M, 1982, NATURE, V298, P92, DOI 10.1038/298092a0; PARKER MG, 1983, J BIOL CHEM, V258, P12; Ray MK, 1996, MOL CELL BIOL, V16, P2056; SANDMOLLER A, 1994, ONCOGENE, V9, P2805; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; THOREY IS, 1993, MOL CELL BIOL, V13, P6742, DOI 10.1128/MCB.13.11.6742; Toonen RFG, 1996, BIOCHEM J, V316, P467, DOI 10.1042/bj3160467; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WATSON MA, 1994, CANCER RES, V54, P4598; Watson MA, 1996, CANCER RES, V56, P860; ZHUANG Z, 1995, CANCER RES, V55, P4676; ZIMONJIC DB, 1994, CYTOGENET CELL GENET, V65, P184, DOI 10.1159/000133628; ZIMONJIC DB, 1995, CANCER GENET CYTOGEN, V80, P100, DOI 10.1016/0165-4608(94)00161-4	32	82	94	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 12	1998	16	6					817	824		10.1038/sj.onc.1201597	http://dx.doi.org/10.1038/sj.onc.1201597			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488047				2022-12-17	WOS:000071931800015
J	Cai, ZZ; Capoulade, C; MoyretLalle, C; AmorGueret, M; Feunteun, J; Larsen, AK; BressacdePaillerets, B; Chouaib, S				Cai, ZZ; Capoulade, C; MoyretLalle, C; AmorGueret, M; Feunteun, J; Larsen, AK; BressacdePaillerets, B; Chouaib, S			Resistance of MCF7 human breast carcinoma cells to TNF-induced cell death is associated with loss of p53 function	ONCOGENE			English	Article						cell death; p53; resistance; TNF	TUMOR-NECROSIS-FACTOR; WILD-TYPE P53; FACTOR-ALPHA; C-MYC; ADRIAMYCIN-RESISTANT; SUPEROXIDE-DISMUTASE; FACTOR CYTOTOXICITY; HUMAN FIBROBLASTS; INDUCED APOPTOSIS; GENE-EXPRESSION	We have investigated the relationship between the development of tumor resistance towards the cytotoxic action of tumor necrosis factor-alpha (TNF) and p53 function, using the TNF-sensitive MCF7 human breast adenocarcinoma cell line and two TNF-resistant sublines, MCF7/R-A1 and MCF7/Adr, Use of single-strand conformation polymorphism (SSCP) analysis and DNA sequencing shows that MCF7 has a wild-type p53 gene, whereas both TNF-resistant sublines exhibit mutant p53, This includes a point mutation R280K in MCF7/R-A1 cells, and a point mutation at the splicing acceptor site on the upstream border of exon 5 resulting in a 21 pb deletion in MCF7/Adr cells, These mutations result in loss of p53 capacity to transactivate FASAY (functional assay in yeast), In contrast to what is observed for parental MCF7 cells, treatment of resistant sublines with TNF or gamma-irradiation fails neither to induce the expression of the p53-regulated gene products p21(waf1/CIP1) and MDM2, nor to arrest the cells in the G(1) phase of the cell cycle, Disruption of p53 wild-type function in MCF7 cells by transfection with human papillomavirus type-16 E6 gene, leads to abrogation of the cytotoxic, but not the cytostatic activity of TNF, Altogether, our results strongly suggest that wild-type p53 is involved in cytotoxic action of TNF, and point out that loss of p53 function contributes to resistance of tumor cell to TNF-induced killing.	INST GUSTAVE ROUSSY,INSERM,CJF 9411,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,CNRS,URA 1156,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,UNITE MARQUEURS GENET CANC,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,CNRS,URA 147,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,CNRS,URA 1967,F-94805 VILLEJUIF,FRANCE; CTR LEON BERARD,INSERM,U453,F-69373 LYON,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard			Paillerets, Brigitte Bressac-de/D-8954-2018; Chouaib, Salem/F-7939-2016; Feunteun, Jean/AAZ-1267-2020; Moyret-Lalle, Caroline/G-2742-2013	Paillerets, Brigitte Bressac-de/0000-0003-0245-8608; Moyret-Lalle, Caroline/0000-0002-8359-2018; Feunteun, Jean/0000-0003-1212-9189				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Cai ZZ, 1996, INT J CANCER, V68, P535, DOI 10.1002/(SICI)1097-0215(19961115)68:4<535::AID-IJC21>3.0.CO;2-2; Cai ZZ, 1997, J BIOL CHEM, V272, P6918, DOI 10.1074/jbc.272.11.6918; CAIGNARD A, 1997, IN PRESS ONCOLOGY RE, V4; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHOU SK, 1994, MOL CELL BIOL, V14, P2556; CHOUAIB S, 1992, B CANCER, V79, P935; CHOUAIB S, 1991, IMMUNOL TODAY, V12, P141, DOI 10.1016/0167-5699(91)90076-6; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DARZYNKIEWICZ Z, 1984, CANCER RES, V44, P83; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FAN SJ, 1995, CANCER RES, V55, P1649; FERNANDEZ A, 1994, ONCOGENE, V9, P2009; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Gallardo D, 1996, CANCER RES, V56, P4891; HARRISON DJ, 1995, J PATHOL, V175, P7, DOI 10.1002/path.1711750103; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JAATTELA M, 1995, ONCOGENE, V10, P2297; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; KASTAN MB, 1991, CANCER RES, V51, P6304; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEJEUNE F, 1994, CIRC SHOCK, V43, P191; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NEVINS JR, 1992, SCIENCE, V258, P424; OCONNOR PM, 1993, CANCER RES, V53, P4776; Ogretmen B, 1997, ONCOGENE, V14, P499, DOI 10.1038/sj.onc.1200855; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; PAGLIACCI MC, 1993, LYMPHOKINE CYTOK RES, V12, P439; PUSZTAI L, 1993, BRIT J CANCER, V67, P290, DOI 10.1038/bjc.1993.55; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shiohara M, 1996, J CELL PHYSIOL, V166, P568, DOI 10.1002/(SICI)1097-4652(199603)166:3<568::AID-JCP11>3.0.CO;2-3; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; VANHAESEBROECK B, 1992, J IMMUNOL, V148, P2785; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAZER DE, 1994, MOL CELL BIOL, V14, P2468, DOI 10.1128/MCB.14.4.2468; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WU H, 1993, GENE DEV, V7, P1126; Yang B, 1996, CLIN CANCER RES, V2, P1649; YIN D, 1995, NEUROSURGERY, V27, P762; ZYAD A, 1994, CANCER RES, V54, P825	63	82	83	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2817	2826		10.1038/sj.onc.1201445	http://dx.doi.org/10.1038/sj.onc.1201445			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419972				2022-12-17	WOS:A1997YJ80300007
J	Qing, J; Maher, VM; Tran, H; Argraves, WS; Dunstan, RW; McCormick, JJ				Qing, J; Maher, VM; Tran, H; Argraves, WS; Dunstan, RW; McCormick, JJ			Suppression of anchorage-independent growth and matrigel invasion and delayed tumor formation by elevated expression of fibulin-1D in human fibrosarcoma-derived cell lines	ONCOGENE			English	Article						differential mRNA display; fibulin-1D; anchorage-independent growth; tumorigenicity; matrigel invasion	LAMININ-BINDING INTEGRIN; EXTRACELLULAR-MATRIX; MALIGNANT TRANSFORMATION; DIFFERENTIAL DISPLAY; MESSENGER-RNA; HUMAN-FIBROBLASTS; PROTEIN; FIBRONECTIN; ONCOGENE; GENE	Using differential display, we identified an mRNA that is markedly down-regulated in cell line 6A/SB1, derived from a fibrosarcoma formed in an athymic mouse following injection of carcinogen-transformed MSU-1.1 cells, The nontumorigenic parental cell strain, MSU-1.1, expresses high levels of this mRNA, Sequencing of the corresponding cDNA fragment revealed that it corresponded to an expressed sequence tag, which ultimately led to its identification as the fibulin-1D gene, Fibulin-1 is a cysteine-rich, calcium-binding extracellular matrix and plasma protein, which has four isoforms, A-D, derived from alternative splicing, Northern and Western blotting analysis of 16 cell lines established from tumors formed in athymic mice by MSU-1.1-derived cell strains independently transformed in culture showed that 44% exhibited low level or lack of expression of fibulin-1D mRNA and protein, In a similar analysis of 15 malignant cell lines derived from patients, 80% showed low level or no expression, To study the role of fibulin-1D in transformation, we transfected 6A/SB1 cells and a human fibrosarcoma-derived cell line (SHAC) with a fibulin-1D cDNA expression construct, Transfectants displaying high levels of fibulin-1D were isolated and characterized, Elevated expression of fibulin-1D led to reduced ability to form colonies in soft agar and reduced invasive potential as tested in a matrigel in vitro invasion assay, Furthermore, expression of fibulin-1D resulted in a markedly extended latency in tumor formation in athymic mice, These results indicate that low expression of fibulin-1D plays a role in tumor formation and invasion.	MICHIGAN STATE UNIV,DEPT BIOCHEM,CARCINOGENESIS LAB,E LANSING,MI 48824; MICHIGAN STATE UNIV,CTR CANC,DEPT MICROBIOL,E LANSING,MI 48824; MED UNIV S CAROLINA,DEPT CELL BIOL & ANAT,CHARLESTON,SC 29425; MICHIGAN STATE UNIV,DEPT PATHOL,E LANSING,MI 48824	Michigan State University; Michigan State University; Medical University of South Carolina; Michigan State University					NATIONAL CANCER INSTITUTE [R01CA060907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042912] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011026] Funding Source: NIH RePORTER; NCI NIH HHS [CA60907] Funding Source: Medline; NIA NIH HHS [AG11026] Funding Source: Medline; NIGMS NIH HHS [GM42912] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akamatsu H, 1996, CANCER RES, V56, P4541; ALBINI A, 1987, CANCER RES, V47, P3239; ALI IU, 1977, CELL, V11, P115, DOI 10.1016/0092-8674(77)90322-1; ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; ARGRAVES WS, 1991, IN VIVO, V5, P489; AUMAILLEY M, 1990, EXP CELL RES, V188, P55, DOI 10.1016/0014-4827(90)90277-H; BALBONA K, 1992, J BIOL CHEM, V267, P20120; BROWN JC, 1994, J CELL SCI, V107, P329; CALLARD D, 1994, BIOTECHNIQUES, V16, P1096; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; Clinton GM, 1996, P NATL ACAD SCI USA, V93, P316, DOI 10.1073/pnas.93.1.316; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GEE SH, 1993, J BIOL CHEM, V268, P14972; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; GEHLSEN KR, 1989, J BIOL CHEM, V264, P19034; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HURLIN PJ, 1989, P NATL ACAD SCI USA, V86, P187, DOI 10.1073/pnas.86.1.187; Jones Peter Lloyd, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P137; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Mok SC, 1996, ONCOGENE, V12, P1895; MORGAN TL, 1991, EXP CELL RES, V197, P125, DOI 10.1016/0014-4827(91)90489-H; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PAN TC, 1993, EUR J BIOCHEM, V215, P733, DOI 10.1111/j.1432-1033.1993.tb18086.x; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; ROCKWELL SC, 1972, J NATL CANCER I, V49, P735; Sasaki T, 1996, EUR J BIOCHEM, V240, P427, DOI 10.1111/j.1432-1033.1996.0427h.x; SONNENBERG A, 1991, EXP CELL RES, V197, P234, DOI 10.1016/0014-4827(91)90428-W; STEEL DM, 1989, J CELL SCI, V93, P515; Tran H, 1997, MATRIX BIOL, V15, P479, DOI 10.1016/S0945-053X(97)90021-4; VONDERMARK H, 1991, J BIOL CHEM, V266, P23595; WEINBERG RA, 1989, CANCER RES, V49, P3713; WILSON DM, 1990, CANCER RES, V50, P5587; YANG DJ, 1992, P NATL ACAD SCI USA, V89, P2237, DOI 10.1073/pnas.89.6.2237; ZHANG RZ, 1994, GENOMICS, V22, P425, DOI 10.1006/geno.1994.1404	43	82	83	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 30	1997	15	18					2159	2168		10.1038/sj.onc.1201385	http://dx.doi.org/10.1038/sj.onc.1201385			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393974				2022-12-17	WOS:A1997YD01900004
J	McGregor, JM; Berkhout, RJM; Rozycka, M; terSchegget, J; Bavinck, JNB; Brooks, L; Crook, T				McGregor, JM; Berkhout, RJM; Rozycka, M; terSchegget, J; Bavinck, JNB; Brooks, L; Crook, T			p53 mutations implicate sunlight in post-transplant skin cancer irrespective of human papillomavirus status	ONCOGENE			English	Article						non-melanoma skin; transplantation; p53 gene; human papillomavirus	RENAL-TRANSPLANTATION; DNA; GENE; RECIPIENTS; ASSOCIATION; INSERTIONS; CARCINOMA; DELETIONS; CELLS; RISK	Mutations in p53 were detected in 11/23 (48%) of non melanoma skin cancers in renal allograft recipients and in 5/8 (63%) of sporadic tumours from immune competent patients, 9/12 (75%) of mutations in transplant patients and all 5 mutations in non transplant tumours were consistent with damage caused by ultraviolet (u,v,) irradiation, DNA sequences, predominantly of the epidermodysplasia verruciformis (EV) subgroup, were detected in 9/23 (39%) of transplant tumours and in 2/8 (25%) of eight non-transplant tumours, There was no relationship between HPV status and p53 mutation, HPV DNA being present in 5/16 (31%) of tumours with p53 mutation and 6/15 (40%) of tumours lacking p53 mutation, These data are consistent with an important role for sunlight in the development of post-transplant skin cancer, and with limited functional data suggesting that E6 proteins of the cutaneous and EV-related papillomaviruses do not target p53 for ubiquitin-mediated degradation.	INST CANC RES,HADDOW LABS,SECT CELL BIOL & EXPT PATHOL,SUTTON SM2 5NG,SURREY,ENGLAND; ST THOMAS HOSP,ST JOHNS INST DERMATOL,DEPT PHOTOBIOL,LONDON SE1 7EH,ENGLAND; UNIV AMSTERDAM,ACAD MED CTR,DEPT VIROL,NL-1105 AZ AMSTERDAM,NETHERLANDS; KATHOLIEKE UNIV LEUVEN HOSP,DEPT DERMATOL,LEIDEN,NETHERLANDS; LONDON SCH HYG & TROP MED,DEPT CLIN SCI,LONDON WC1,ENGLAND	University of London; Institute of Cancer Research - UK; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Amsterdam; Academic Medical Center Amsterdam; University of London; London School of Hygiene & Tropical Medicine								BAVINCK JNB, 1993, BRIT J DERMATOL, V129, P242, DOI 10.1111/j.1365-2133.1993.tb11841.x; BERKHOUT RJM, 1995, J CLIN MICROBIOL, V33, P690, DOI 10.1128/JCM.33.3.690-695.1995; BIRKELAND SA, 1995, INT J CANCER, V60, P183, DOI 10.1002/ijc.2910600209; BLUM HF, 1948, J NATL CANCER I, V9, P247; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CHENG KC, 1992, J BIOL CHEM, V267, P166; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; DOLL R, 1970, BRIT MED J, V4, P420, DOI 10.1136/bmj.4.5732.420; Greenblatt MS, 1996, CANCER RES, V56, P2130; HARTEVELT MM, 1990, TRANSPLANTATION, V49, P506, DOI 10.1097/00007890-199003000-00006; IARC, 1995, IARC MONOGRAPHS EVAL, V64; IFTNER T, 1988, J VIROL, V62, P3655, DOI 10.1128/JVI.62.10.3655-3661.1988; JEGO N, 1993, ONCOGENE, V8, P209; KELLY GE, 1987, BRIT J DERMATOL, V117, P429, DOI 10.1111/j.1365-2133.1987.tb04922.x; KIYONO T, 1989, VIROLOGY, V173, P551, DOI 10.1016/0042-6822(89)90567-9; LENNARD L, 1985, BRIT J DERMATOL, V113, P723, DOI 10.1111/j.1365-2133.1985.tb02408.x; Lewandowsky F, 1922, ARCH DERMATOL SYPH-G, V141, P193, DOI 10.1007/BF01938833; LONDON NJ, 1995, LANCET, V346, P403, DOI 10.1016/S0140-6736(95)92780-8; MCGREGOR JM, 1995, LANCET, V346, P964, DOI 10.1016/S0140-6736(95)91584-2; McGregor JM, 1996, CANCER SURV, V26, P219; MORRIS JDH, 1995, LANCET, V346, P754, DOI 10.1016/S0140-6736(95)91510-9; NATARAJ AJ, 1995, PHOTOCHEM PHOTOBIOL, V62, P218, DOI 10.1111/j.1751-1097.1995.tb05262.x; PIETTE J, 1991, J PHOTOCH PHOTOBIO B, V11, P241, DOI 10.1016/1011-1344(91)80030-L; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; STEGER G, 1992, ARCH VIROL, V125, P355, DOI 10.1007/BF01309654; Swann PF, 1996, SCIENCE, V273, P1109, DOI 10.1126/science.273.5278.1109; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	28	82	83	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1737	1740		10.1038/sj.onc.1201339	http://dx.doi.org/10.1038/sj.onc.1201339			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349508	Green Published			2022-12-17	WOS:A1997XY63100014
J	Visser, M; Sijmons, C; Bras, J; Arceci, RJ; Godfried, M; Valentijn, LJ; Voute, PA; Baas, F				Visser, M; Sijmons, C; Bras, J; Arceci, RJ; Godfried, M; Valentijn, LJ; Voute, PA; Baas, F			Allelotype of pediatric rhabdomyosarcoma	ONCOGENE			English	Article						RMS; Rhabdomyosarcoma; alleotype; TSG, Tumor Suppressor Gene; LOH, loss of heterozygosity; SRD	TUMOR ALVEOLAR RHABDOMYOSARCOMA; BECKWITH-WIEDEMANN SYNDROME; DEPENDENT KINASE INHIBITOR; HUMAN P57(KIP2) GENE; GROWTH-FACTOR-II; WILMS-TUMORS; HEPATOCELLULAR-CARCINOMA; SUPPRESSOR GENE; ALLELIC LOSS; HETEROZYGOSITY	An allelotype covering all autosomes was constructed for the embryonal form of childhood rhabdomyosarcoma (ERMS) in order to identify regions encompassing tumorsuppressor genes (TSG) involved in ERMS. Thusfar most studies were focussed on chromosome 11p15.5,which frequently shows loss of heterozygozity (LOH) in embryonal tumors like RMS and Wilms' tumor (WT). In this study we show that, besides LOH of chromosome 11p15.5 (72%), LOH of chromosome 16q was present in 54% of the tumors analysed. Delineation of these two regions shows that the smallest region of overlap (SRO) for chromosome 11 was between D11S988 and D11S922. This region, estimated to be 7 cM and 3-5 Mb, is also the location of the putative Wilms' tumor WT2 TSG. It contains several genes including IGF2 and potential tumorsuppressor genes like H19 and p57(kip2), which might contribute to the carcinogenesis of RMS. Analysis of chromosome 16q LOH defined the SRO between D16S752 and D16S413. LOH of chromosome 16 is also found in other tumors, including WT. Our data suggest that genes involved in the development of RMS and WT may not only be similar for chromosome 11 but also for chromosome 16.	ACAD MED CTR,DEPT PEDIAT ONCOL,NL-1100 DE AMSTERDAM,NETHERLANDS; ACAD MED CTR,NEUROZINTUIGEN LAB,NL-1100 DE AMSTERDAM,NETHERLANDS; ACAD MED CTR,DEPT PATHOL,NL-1100 DE AMSTERDAM,NETHERLANDS; CHILDRENS HOSP,MED CTR,DEPT PEDIAT,DIV HEMATOL & ONCOL,CINCINNATI,OH 45229; CHILDRENS HOSP RES FDN,CINCINNATI,OH 45229	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation			Baas, Frank/F-9574-2010	Baas, Frank/0000-0003-3912-5428				AGAMANOLIS DP, 1986, HUM PATHOL, V17, P778, DOI 10.1016/S0046-8177(86)80198-8; AUSTRUY E, 1995, GENE CHROMOSOME CANC, V14, P285, DOI 10.1002/gcc.2870140407; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BARR FG, 1995, JAMA-J AM MED ASSOC, V273, P553, DOI 10.1001/jama.273.7.553; BesnardGuerin C, 1996, HUM GENET, V97, P163, DOI 10.1007/BF02265259; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; DAVIS RJ, 1994, CANCER RES, V54, P2869; FUJIMORI M, 1991, CANCER RES, V51, P89; GAIGER AM, 1981, NATL CANCER I MONOGR, V56, P19; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GRUNDY PE, 1994, CANCER RES, V54, P2331; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; Hatada I, 1996, HUM MOL GENET, V5, P783, DOI 10.1093/hmg/5.6.783; Hoovers JMN, 1995, P NATL ACAD SCI USA, V92, P12456, DOI 10.1073/pnas.92.26.12456; KNOWLES MA, 1994, CANCER RES, V54, P531; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; MAW MA, 1992, CANCER RES, V52, P3094; NEWSHAM I, 1994, GENOMICS, V19, P433, DOI 10.1006/geno.1994.1091; NEWSHAM I, 1995, GENE CHROMOSOME CANC, V12, P1, DOI 10.1002/gcc.2870120102; Orlow I, 1996, CANCER RES, V56, P1219; PAPPO AS, 1995, J CLIN ONCOL, V13, P2123, DOI 10.1200/JCO.1995.13.8.2123; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; Reid LH, 1996, HUM MOL GENET, V5, P239, DOI 10.1093/hmg/5.2.239; Reid LH, 1996, CANCER RES, V56, P1214; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; SCRABLE H, 1989, GENE CHROMOSOME CANC, V1, P23, DOI 10.1002/gcc.2870010106; Tokino T, 1996, HUM GENET, V97, P625, DOI 10.1007/s004390050106; TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791; TSUDA H, 1994, CANCER RES, V54, P513; Visser M, 1996, P NATL ACAD SCI USA, V93, P9172, DOI 10.1073/pnas.93.17.9172; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WeberHall SR, 1996, CANCER RES, V56, P3220; WINQVIST R, 1993, CANCER RES, V53, P4486; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61	41	82	87	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 11	1997	15	11					1309	1314		10.1038/sj.onc.1201302	http://dx.doi.org/10.1038/sj.onc.1201302			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315099				2022-12-17	WOS:A1997XV84500009
J	Pasini, A; Geneste, O; Legrand, P; Schlumberger, M; Rossel, M; Fournier, L; Rudkin, BB; Schuffenecker, I; Lenoir, GM; Billaud, M				Pasini, A; Geneste, O; Legrand, P; Schlumberger, M; Rossel, M; Fournier, L; Rudkin, BB; Schuffenecker, I; Lenoir, GM; Billaud, M			Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain	ONCOGENE			English	Article						MEN2; MTC; RET proto-oncogene; tyrosine kinase	MEDULLARY-THYROID CARCINOMA; MEN 2A; CRYSTAL-STRUCTURE; CELL-LINE; PROTOONCOGENE; RECEPTOR; ISOFORMS; FAMILIES; DISEASE; GENE	Multiple endocrine neoplasia type 2A (MEN 2A) and familial medullary thyroid carcinoma (FMTC) are two dominantly inherited disorders caused by germline mutations of the RET proto-oncogene. The RET gene codes for a receptor tyrosine kinase. The majority of MEN2A and FMTC mutations are clustered in the extra-cellular cysteine-rich domain and result in constitutive activation of the tyrosine kinase through the formation of disulfide-bonded RET homodimers. Recently, two novel paint mutations have been identified in the germline of five distinct FMTC families. Both mutations occur catalytic domain of the RET kinase and lead to the substitution of either glutamic acid 768 or valine 804 by an aspartic acid and a leucine respectively, We have introduced each FMTC mutation in two RET isoforms: RET51 the long isoform (1114 aa) and RET9 the short isoform (1072 aa) which differ in the C-terminal region of the protein. The RET51 isoform carrying either E768D or V804L mutation was autophosphorylated, displayed a transforming activity upon expression in Rat1 fibroblasts and induced neuronal differentiation of PC12 cells. However, the transforming capacity of these RET51-FMTC mutants was found to be severalfold less potent compared to the same isoform carrying either the MEN2A mutation (C634R) or the MEN2B mutation (M918T). In contrast, RET9 containing mutations E768D or V804L was not autophosphorylated, exhibited a poor oncogenic potential in fibroblasts and did not promote neuritic outgrowth upon expression in PC12 cells. Overall, these findings demonstrate that mutations E768D and V804L are gain-of-function mutations that confer to the long RET isoform the capacity to exert a biological effect, although these mutations are more weakly activating than the MEN2A and MEN2B mutations. These results may provide a biochemical basis as to why the phenotypic consequences of these mutations are restricted to thyroid C-cells.	UNIV LYON 1,GENET LAB,CNRS,UMR 5641,F-69372 LYON 08,FRANCE; INST BIOL STRUCT JEAN PIERRE EBEL,CEA,CNRS,CRISTALLOG & CRISTALLOGENESE PROT LAB,F-38027 GRENOBLE 1,FRANCE; INST GUSTAVE ROUSSY,NUCL MED SERV,F-94805 VILLEJUIF,FRANCE; UNIV UTAH,ECCLES INST HUMAN GENET 5440,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112; ECOLE NORMALE SUPER LYON,BIOL CELLULAIRE & MOL LAB,CNRS,UMR 49,F-69364 LYON,FRANCE; HOP EDOUARD HERRIOT,GENET LAB,LYON 03,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); CHU Lyon			LEGRAND, Pierre/G-7709-2011; Billaud, Marc N/M-6954-2013	LEGRAND, Pierre/0000-0003-2431-2255; RUDKIN, Brian B./0000-0003-3700-1982; Rossel, Mireille/0000-0003-2275-0817				Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BOLINO A, 1995, ONCOGENE, V10, P2415; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/0968-0004(96)10033-5; Borrello MG, 1995, ONCOGENE, V11, P2419; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Califano D, 1996, P NATL ACAD SCI USA, V93, P7933, DOI 10.1073/pnas.93.15.7933; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; ENG C, 1995, ONCOGENE, V10, P509; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; ENG C, 1994, HUM MOL GENET, V3, P234; Fink M, 1996, INT J CANCER, V69, P312, DOI 10.1002/(SICI)1097-0215(19960822)69:4<312::AID-IJC13>3.0.CO;2-7; GOODFELLOW PJ, 1994, CURR OPIN GENET DEV, V4, P446, DOI 10.1016/0959-437X(94)90034-5; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Iwashita T, 1996, ONCOGENE, V12, P481; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; LORENZO MJ, 1995, ONCOGENE, V10, P1377; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; MULLIGAN LM, 1995, J CLIN ENDOCR METAB, V80, P1989, DOI 10.1210/jc.80.7.1989; MYERS SM, 1995, ONCOGENE, V11, P2039; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; ROSSEL M, 1995, HUM GENET, V95, P403; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCHUFFENECKER I, 1994, HUM MOL GENET, V3, P1939, DOI 10.1093/hmg/3.11.1939; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TANIGUCHI M, 1991, BIOCHEM BIOPH RES CO, V181, P416, DOI 10.1016/S0006-291X(05)81435-4; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	48	82	82	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					393	402		10.1038/sj.onc.1201199	http://dx.doi.org/10.1038/sj.onc.1201199			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242375				2022-12-17	WOS:A1997XM23800003
J	Lamphere, L; Fiore, F; Xu, X; Brizuela, L; Keezer, S; Sardet, C; Draetta, GF; Gyuris, J				Lamphere, L; Fiore, F; Xu, X; Brizuela, L; Keezer, S; Sardet, C; Draetta, GF; Gyuris, J			Interaction between Cdc37 and Cdk4 in human cells	ONCOGENE			English	Article						Cdk; cyclin; cdc37; hsp90	SUPPRESSOR GENE-PRODUCT; PROTEIN-KINASE ACTIVITY; DEPENDENT KINASES; DIVISION; COMPLEX; CDC28; G(1); ASSOCIATION; INHIBITORS; CYCLINS	Using the yeast two-hybrid system we have identified novel potential Cdk4 interacting proteins. Here we described the interaction of Cdk4 with a human homologue of the yeast Drosophila CDC37 gene products. Cdc37 protein specifically interacts with Cdk4 and Cdk6, but not with Cdc2, Cdk2, Cdk3, Cdk5 and any of a number of cyclins tested. Cdc37 is not an inhibitor nor an activator of the Cdk4/cyclin D1 kinase, while it appears to facilitate complex assembly between Cdk4 and cyclin D1 in vitro. Cdc37 competes with p16 for binding to Cdk4, suggesting that p16 might exert part of its inhibitory function by affecting the formation of Cdk4/cyclin D1 complexes via Cdc37.	MITOTIX INC,CAMBRIDGE,MA 02139; WHITEHEAD INST BIOMED RES,CAMBRIDGE CTR 9,CAMBRIDGE,MA 02139; EUROPEAN INST ONCOL,DEPT EXPT ONCOL,I-20141 MILAN,ITALY	Massachusetts Institute of Technology (MIT); Whitehead Institute; IRCCS European Institute of Oncology (IEO)								CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; FERGUSON J, 1986, NUCLEIC ACIDS RES, V14, P6681, DOI 10.1093/nar/14.16.6681; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIORE F, 1995, CELL CYCLE MATERIALS, P211; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; REED SI, 1980, GENETICS, V95, P561; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; WICK ST, 1995, ONCOGENE, V11, P2013	25	82	86	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 24	1997	14	16					1999	2004		10.1038/sj.onc.1201036	http://dx.doi.org/10.1038/sj.onc.1201036			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150368				2022-12-17	WOS:A1997WV80400014
J	Luo, WP; Wood, CG; Earley, K; Hung, MC; Lin, SH				Luo, WP; Wood, CG; Earley, K; Hung, MC; Lin, SH			Suppression of tumorigenicity of breast cancer cells by an epithelial cell adhesion molecule (C-CAM1): The adhesion and growth suppression are mediated by different domains	ONCOGENE			English	Article						cell adhesion molecule; breast cancer; tumor suppression	BILIARY GLYCOPROTEIN-I; TUMOR-SUPPRESSOR; C-CAM; CARCINOEMBRYONIC ANTIGEN; SECONDARY-STRUCTURE; CYTOPLASMIC DOMAIN; LIVER DEVELOPMENT; PROSTATE-CANCER; RAT-TISSUES; ECTO-ATPASE	C-CAM1 is an epithelial adhesion molecule of immunoglobulin supergene family and has been implicated in the growth suppression of prostate cancer cells. Here we show that C-CAM1 can also suppress the tumorigenicity of breast cancer cells. These observations suggest that C-CAM1 may be a general growth suppressor in epithelial cells. In addition, we have identified the cytoplasmic domain, but not the extracellular adhesion domain, of C-CAM1 as critical for the growth suppression. Thus, the adhesion and the growth suppression functions of C-CAM1 are independent of each other. Furthermore, mutation at the tyrosine phosphorylation site in the cytoplasmic domain of C-CAM1 did not obliterate C-CAM1's growth suppression function, suggesting that tyrosine phosphorylation is not involved in the signal transduction pathway leading to cell growth suppression. These studies provide the structural basis for future development of therapeutics that may selectively activate C-CAM1's growth suppression function.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOL PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT UROL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; CHEUNG PH, 1993, J BIOL CHEM, V268, P24303; CHEUNG PH, 1993, BIOCHEM J, V295, P427, DOI 10.1042/bj2950427; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HINODA Y, 1989, P NATL ACAD SCI USA, V86, P1668; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; HIXSON DC, 1985, CANCER RES, V45, P3742; HSIEH JT, 1995, CANCER RES, V55, P190; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KLEINERMAN DI, 1995, CANCER RES, V55, P2831; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; Kunath T, 1995, ONCOGENE, V11, P2375; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN SH, 1995, BIOCHEM J, V311, P239, DOI 10.1042/bj3110239; LIN SH, 1991, BIOCHEM J, V278, P155, DOI 10.1042/bj2780155; LIN SH, 1989, J BIOL CHEM, V264, P14408; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; ODIN P, 1988, J HISTOCHEM CYTOCHEM, V36, P729, DOI 10.1177/36.7.3290331; Prall F, 1996, J HISTOCHEM CYTOCHEM, V44, P35, DOI 10.1177/44.1.8543780; ROCKWELL SC, 1972, J NATL CANCER I, V49, P735; ROSENBERG M, 1993, CANCER RES, V53, P4938; THOMPSON NL, 1994, PATHOBIOLOGY, V62, P209, DOI 10.1159/000163912; THOMPSON NL, 1993, CELL GROWTH DIFFER, V4, P257	27	82	86	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1697	1704		10.1038/sj.onc.1200999	http://dx.doi.org/10.1038/sj.onc.1200999			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135071				2022-12-17	WOS:A1997WR89300008
J	Sakai, M; Imaki, J; Yoshida, K; Ogata, A; MatsushimaHibiya, Y; Kuboki, Y; Nishizawa, M; Nishi, S				Sakai, M; Imaki, J; Yoshida, K; Ogata, A; MatsushimaHibiya, Y; Kuboki, Y; Nishizawa, M; Nishi, S			Rat maf related genes: Specific expression in chondrocytes, lens and spinal cord	ONCOGENE			English	Article						maf; transcription factor; chondrocyte; lens; spinal cord	TRANSFERASE-P EXPRESSION; TRANSCRIPTION FACTOR; FACTOR NF-E2; V-MAF; FOS; JUN; ONCOGENE; PROTEINS; ENCODES; DOMAIN	maf is a family of oncogenes originally identified from avian oncogenic retrovirus, AS42, encoding a nuclear bZip transcription factor, We have isolated two maf related cDNA clones, maf-1 and maf-2, from a rat liver cDNA library, Comparison of the sequence homologies of the proteins encoded by maf-1 and maf-2 with those of c-maf and chicken mafB indicated that maf-1 and maf-2 are the rat homologues of mafB and c-maf, respectively, Both genes are expressed at low levels in a wide variety of rat tissues, including spleen, kidney, muscle and liver. Immunohistochemical studies and ill situ hybridization analyses show that maf-2 and maf-2 are strongly expressed in the late stages of chondrocyte development in the femur epiphysis and the rib and limb cartilage of 15 day old (E15) embryo in rat, Cartilage cells, induced by subcutaneous implantation of bone morphogenic protein, also expressed maf-1 and maf-2. In situ hybridization analyses of E15 embryos show that both genes are expressed in the eye lens and the spinal cord as well as the cartilage, However, the expression patterns of maf-1 and maf-2 in lens and spinal cord are different.	HOKKAIDO UNIV,SCH DENT,DEPT BIOCHEM,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; NIPPON MED COLL,DEPT ANAT,BUNKYO KU,TOKYO 113,JAPAN; KYOTO UNIV,FAC MED,DEPT MOL ONCOL,SAKYO KU,KYOTO 606,JAPAN	Hokkaido University; Nippon Medical School; Kyoto University	Sakai, M (corresponding author), HOKKAIDO UNIV,SCH MED,DEPT BIOCHEM,KITA KU,N15 W7,SAPPORO,HOKKAIDO 060,JAPAN.		Sakai, Masaharu/A-4773-2012					ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; FROHMAN MA, 1993, DEVELOPMENT, V117, P925; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Kataoka K, 1996, ONCOGENE, V12, P53; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KUBOKI Y, 1995, CONNECTIVE TISSUE RE, V12, P207; Liu Q, 1996, ONCOGENE, V12, P207; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; SAKAI M, 1992, BIOCHEM BIOPH RES CO, V187, P976, DOI 10.1016/0006-291X(92)91293-Y; SAKAI M, 1995, CANCER RES, V55, P5370; SENBA E, 1982, J COMP NEUROL, V208, P54, DOI 10.1002/cne.902080105; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; URIST MR, 1984, P NATL ACAD SCI-BIOL, V81, P371, DOI 10.1073/pnas.81.2.371	21	82	86	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 13	1997	14	6					745	750		10.1038/sj.onc.1200869	http://dx.doi.org/10.1038/sj.onc.1200869			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WG430	9038383				2022-12-17	WOS:A1997WG43000014
J	Petrocelli, T; Poon, R; Drucker, DJ; Slingerland, JM; Rosen, CF				Petrocelli, T; Poon, R; Drucker, DJ; Slingerland, JM; Rosen, CF			UVB radiation induces p21(Cip1/WAF1) and mediates G1 and S phase checkpoints	ONCOGENE			English	Review						cell cycle; checkpoint; p21(Cip1/WAF1); cyclin G; UVB irradiation	CELL-CYCLE CHECKPOINT; NORMAL HUMAN-SKIN; WILD-TYPE P53; PYRIMIDINE DIMERS; MAMMALIAN-CELLS; RETINOBLASTOMA PROTEIN; RAT KERATINOCYTES; DEPENDENT KINASE; DNA-REPLICATION; CDK2 ACTIVITY	In a search for effecters and targets of UVB signaling in mammalian cells, we screened a keratinocyte cDNA library with differentially subtracted UVB-enriched cDNA probes. One of the UVB induced cDNA clones proved to be the rat p21(Cip1/WAF1) homologue. UVB irradiation caused a rise in p53 protein levels, in association with induction of p21(Cip1/WAF1) and cyclin G expression. The effects of UVB irradiation induced p21(Cip1/WAF1) on the cell cycle were examined. In contrast to gamma irradiation, which caused G2 arrest, UVB treatment of asynchronous neonatal rat keratinocytes (NK) led to a marked inhibition of replicative DNA synthesis and prolonged G1 and S phase arrests, persisting to 18-24 h, with recovery of cycling by 36 h post-UVB. G1 arrest was accompanied by inhibition of cyclin D-, E- and A-associated kinases. Kinase inhibition was not due to reduction in cyclin or cdk proteins. While the association of cyclin E with Cdk2 was moderately reduced, cyclin D1/Cdk4 and cyclin A/Cdk2 complexes were not disrupted. The activating threonine 160 phosphorylation of Cdk2 in cyclin complexes was not inhibited. An incremental binding of p21 with Cdk4 paralleled the inhibition of cyclin D1/Cdk4 kinase and a similar rise in Cdk2 binding to p21 was associated with inhibition of cyclin E and cyclin A dependent kinases. Furthermore, a rise in measurable p21(Cip1/WAF1)-Cdk2 inhibitory activity paralleled the loss of G1 cyclin-dependent kinase activity, supporting a role for p21(Cip1/WAF1) in the UVB-induced checkpoints.	UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DIV CANC BIOL, DEPT MED BIOPHYS, TORONTO, ON M4N 3M5, CANADA; UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DIV CANC BIOL, DEPT MED, TORONTO, ON M4N 3M5, CANADA; UNIV TORONTO, DEPT MED & CLIN BIOCHEM, TORONTO, ON M5S 1B2, CANADA; UNIV TORONTO, DEPT MED GENET, TORONTO, ON M5S 1B2, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto			Drucker, Daniel J/A-4092-2010					BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BRASH DE, 1982, NATURE, V298, P189, DOI 10.1038/298189a0; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAMPBELL C, 1993, CANCER RES, V53, P2697; CANMAN CE, 1994, CANCER RES, V54, P5054; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DOMON M, 1968, RADIAT RES, V35, P350, DOI 10.2307/3572382; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLISON MJ, 1981, PHOTOCHEM PHOTOBIOL, V34, P465, DOI 10.1111/j.1751-1097.1981.tb09026.x; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FREEMAN SE, 1988, J INVEST DERMATOL, V90, P814, DOI 10.1111/1523-1747.ep12462039; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HALL PA, 1993, ONCOGENE, V8, P203; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HONIGSMANN H, 1987, J PHOTOCH PHOTOBIO B, V1, P33, DOI 10.1016/1011-1344(87)80004-0; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KAUFMANN WK, 1991, MOL CELL BIOL, V11, P3711, DOI 10.1128/MCB.11.7.3711; KAUFMANN WK, 1994, MUTAT RES, V314, P67, DOI 10.1016/0921-8777(94)90062-0; KEYSE SM, 1988, MOL CELL BIOL, V8, P5425, DOI 10.1128/MCB.8.12.5425; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAU CC, 1994, P NATL ACAD SCI USA, V79, P7491; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI JJ, 1993, CELL, V74, P223, DOI 10.1016/0092-8674(93)90413-K; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI Y, 1994, ONCOGENE, V9, P2261; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; LIU M, 1995, ONCOGENE, V10, P1955; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURNANE JP, 1995, CANCER METAST REV, V14, P17, DOI 10.1007/BF00690208; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PEACOCK JW, 1995, MOL CELL BIOL, V15, P1446; PEAK MJ, 1987, PHOTOCHEM PHOTOBIOL, V45, P381, DOI 10.1111/j.1751-1097.1987.tb05390.x; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Romerdahl C A, 1989, Cancer Commun, V1, P209; ROSEN CF, 1990, CANCER RES, V50, P2631; ROSEN CF, 1992, AM J PHYSIOL, V263, pC1103, DOI 10.1152/ajpcell.1992.263.5.C1103; ROSEN CF, 1995, AM J PHYSIOL-CELL PH, V268, pC846, DOI 10.1152/ajpcell.1995.268.4.C846; ROSENSTEIN BS, 1987, PHOTOCHEM PHOTOBIOL, V45, P775, DOI 10.1111/j.1751-1097.1987.tb07881.x; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SLINGERLAND JM, 1991, BLOOD, V77, P1500; SMITH ML, 1995, ONCOGENE, V10, P1053; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; TAMURA K, 1993, ONCOGENE, V8, P2113; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1993, ONCOGENE, V8, P1593; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAMASHITA M, 1992, DEV BIOL, V149, P8, DOI 10.1016/0012-1606(92)90259-J; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZOLZER F, 1984, PHOTOCHEM PHOTOBIOL, V40, P49, DOI 10.1111/j.1751-1097.1984.tb04552.x	112	82	83	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	1996	12	7					1387	1396						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622854				2022-12-17	WOS:A1996UF07600002
J	Mai, S; HanleyHyde, J; Fluri, M				Mai, S; HanleyHyde, J; Fluri, M			c-Myc overexpression associated DHFR gene amplification in hamster, rat, mouse and human cell lines	ONCOGENE			English	Article						c-Myc deregulation; DHFR; genomic instability	DIHYDROFOLATE-REDUCTASE GENE; WILD-TYPE P53; DNA AMPLIFICATION; METHOTREXATE RESISTANCE; SV40 REPLICATION; CANCER; CYCLE; TRANSCRIPTION; EXPRESSION; ONCOGENES	We have analysed relative DHFR gene copy numbers in nine cell fines of various cell type and species origins. The cells studied expressed either low, low and inducible or constitutively elevated levels of c-Myc protein. DHFR gene amplification was observed only when c-Myc protein levels were upregulated. The amplification of the DHFR gene was transient in inducible cell Lines. Cell lines exhibiting constitutively deregulated c-Myc protein levels, however, showed both DHFR gene amplification and ongoing rearrangements of the DHFR locus. In contrast, the relative gene copy numbers of ribonucleotide reductase R1 subunit, ornithine decarboxylase, syndecan 2, glyceraldehyde-3-phosphate-dehydrogenase and cyclin C remained unaffected irrespective of c-Myc protein levels, suggesting a locus-specific genomic instability of the DHFR gene in cells with deregulated c-Myc protein levels. Overall, the results of the present study support the notion that DHFR gene amplification as a consequence of c-Myc deregulation may occur in a variety of cell lines irrespective of their cell type and species origins.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92837 USA	Scripps Research Institute	Mai, S (corresponding author), BASEL INST IMMUNOL, GRENZACHERSTR 487, CH-4005 BASEL, SWITZERLAND.		Mai, Sabine/E-5667-2017	Mai, Sabine/0000-0002-5797-2201				AHNEN DJ, 1992, CELL BIOCH S G, V16, P143; ALITALO K, 1985, TRENDS BIOCHEM SCI, V10, P194, DOI 10.1016/0968-0004(85)90190-2; ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENEVISTY N, 1992, GENE DEV, V6, P2513; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOURHIS J, 1991, CANCER RES, V51, P33; CHANG ACY, 1978, NATURE, V275, P617, DOI 10.1038/275617a0; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; CLASSON M, 1993, GENE, V133, P153, DOI 10.1016/0378-1119(93)90633-E; CLASSON M, 1990, ONCOGENE, V5, P1371; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DELIDAKIS C, 1989, EMBO J, V8, P891, DOI 10.1002/j.1460-2075.1989.tb03450.x; DENIS N, 1991, ONCOGENE, V6, P1453; DIJKWEL PA, 1994, NUCLEIC ACIDS RES, V22, P4989, DOI 10.1093/nar/22.23.4989; ECKHARDT SG, 1994, P NATL ACAD SCI USA, V91, P6674, DOI 10.1073/pnas.91.14.6674; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEO S, 1994, ONCOGENE, V9, P955; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HUANG AP, 1994, EXP CELL RES, V213, P335, DOI 10.1006/excr.1994.1207; HUANG AP, 1995, CANCER RES, V55, P1758; HUANG AP, 1994, ONCOGENE, V9, P491; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KAHANA C, 1985, P NATL ACAD SCI USA, V82, P1673, DOI 10.1073/pnas.82.6.1673; KARN J, 1989, ONCOGENE, V4, P773; LAVI S, 1981, P NATL ACAD SCI-BIOL, V78, P6144, DOI 10.1073/pnas.78.10.6144; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Luecke-Huhle Christine, 1994, Carcinogenesis (Oxford), V15, P695; LUECKEHUHLE C, 1990, INT J RADIAT BIOL, V58, P577; LUECKEHUHLE C, 1989, MOL TOXICOL, V2, P237; MA C, 1990, MOL CELL BIOL, V10, P1338, DOI 10.1128/MCB.10.4.1338; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; MAI S, 1990, UCLA SYM BI, V136, P319; MAI S, 1995, GENOME, V38, P780, DOI 10.1139/g95-099; MAI S, 1994, GENE, V148, P253, DOI 10.1016/0378-1119(94)90696-3; MAI S, 1994, NUCLEIC ACIDS RES, V22, P2264, DOI 10.1093/nar/22.12.2264; MAI S, 1995, NUCLEIC ACIDS RES, V23, P1, DOI 10.1093/nar/23.1.1; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARIANI BD, 1984, J BIOL CHEM, V259, P1901; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; OTTO E, 1989, J BIOL CHEM, V264, P3390; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PIERCE A, 1992, J BIOL CHEM, V267, P3894; POTTER M, 1992, CARCINOGENESIS, V13, P1681, DOI 10.1093/carcin/13.10.1681; PRODY CA, 1989, P NATL ACAD SCI USA, V86, P690, DOI 10.1073/pnas.86.2.690; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Sambrook J., 1989, MOL CLONING LAB MANU; SANTELLI RV, 1991, MECH DEVELOP, V36, P59, DOI 10.1016/0925-4773(91)90072-E; SCHIMKE RT, 1978, SCIENCE, V202, P1051, DOI 10.1126/science.715457; SHAH DM, 1986, SCIENCE, V233, P478, DOI 10.1126/science.233.4762.478; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STARK GR, 1993, ADV CANCER RES, V61, P87, DOI 10.1016/S0065-230X(08)60956-2; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; TEMIN HM, 1988, CANCER RES, V48, P1697; THELANDER L, 1986, MOL CELL BIOL, V6, P3433, DOI 10.1128/MCB.6.10.3433; TLSTY TD, 1990, P NATL ACAD SCI USA, V87, P3132, DOI 10.1073/pnas.87.8.3132; TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441; TLSTY TD, 1984, MOL CELL BIOL, V4, P1050, DOI 10.1128/MCB.4.6.1050; VAUGHN JP, 1990, CELL, V61, P1075, DOI 10.1016/0092-8674(90)90071-L; WAHL GM, 1989, CANCER RES, V49, P1333; WEINBERG RA, 1989, CANCER RES, V49, P3713; WOLFFE AP, 1991, J CELL SCI, V99, P210; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; YALKINOGLU AO, 1991, J VIROL, V65, P3175, DOI 10.1128/JVI.65.6.3175-3184.1991; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	75	82	85	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					277	288						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570205				2022-12-17	WOS:A1996TR53800007
J	WANG, ZY; QIU, QQ; HUANG, J; GURRIERI, M; DEUEL, TF				WANG, ZY; QIU, QQ; HUANG, J; GURRIERI, M; DEUEL, TF			PRODUCTS OF ALTERNATIVELY SPLICED TRANSCRIPTS OF THE WILMS-TUMOR SUPPRESSOR GENE, WT1, HAVE ALTERED DNA-BINDING SPECIFICITY AND REGULATE TRANSCRIPTION IN DIFFERENT WAYS	ONCOGENE			English	Article						WT1; TRANSCRIPTIONAL FACTOR; ZINC FINGER PROTEIN; ALTERNATIVE SPLICING	ZINC FINGER GENE; EXPRESSION; KRUPPEL; PROTEIN; CELLS; REPRESSION; DOMAINS; GROWTH; LOCUS; E1A	The Wilms' tumor susceptibility gene, wt1, encodes a transcription factor of the zinc finger protein family. Mutations in the WT1 gene product have been detected in both sporadic and familial Wilms' tumors, suggesting that alterations in WT1 may disrupt its normal function as a transcriptional regulator. The transcripts of wt1 are alternatively spliced; however, roles of the alternatively spliced forms have not been defined. The major transcript of wt1 encodes a WT1 protein [WT1(+KTS)+17AA] that contains three amino acids (+KTS) between the third and fourth zinc fingers and a serine-rich, 17 amino acid (+17AA) domain N-terminal to the zinc finger region. We now show that the WT1(+KTS) forms functionally bind to a unique G + C-rich sequence within the PDGF A-chain promoter. We also show that WT1 (+KTS)+17AA functions as a strong transciptional repressor and that +17AA alone fused to the zinc-finger domain of WT1 or to the heterologous DNA binding domain of GAL4 functions independently as a repressor. Deletion of four serine residues within +17AA abolishes the repressor activity of +17AA. These results indicate that wt1 products with +17AA contain an additional dominant repressor domain and that the presence or absence of +KTS determines alternative DNA binding specificity.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL)			Huang, Jeffrey K./AAH-2418-2021; Huang, Jeffrey/J-5248-2017	Huang, Jeffrey K./0000-0003-0996-9451; Huang, Jeffrey/0000-0003-0996-9451	NCI NIH HHS [CA49712] Funding Source: Medline; NHLBI NIH HHS [HL31102, HL14147] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, R01HL031102, R37HL031102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ARMSTRONG JF, 1992, MECH DEVELOP, V40, P85; BASCH I, 1993, EMBO J, V12, P4229; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BORDEREAUX D, 1990, ONCOGENE, V5, P925; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; GESSLER M, 1990, NATURE, V343, P744; GORMAN GM, 1982, MOL CELL BIOL, V8, P1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HABER DA, 1992, P NATL ACAD SCI USA, V89, P6010, DOI 10.1073/pnas.89.13.6010; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HAHN S, 1992, Current Biology, V2, P152, DOI 10.1016/0960-9822(92)90268-F; HSA TT, 1992, SCIENCE, V257, P1946; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LIN XH, 1992, J BIOL CHEM, V267, P25614; MADDEN SL, 1992, SCIENCE, V253, P1550; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RACKLEY RR, 1993, CELL GROWTH DIFFER, V4, P1023; RAUSCHER FJ, 1990, SCIENCE, V250, P1257; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WANG ZY, 1993, P NATL ACAD SCI USA, V268, P8896; ZUO P, 1991, GENE DEV, V5, P254, DOI 10.1101/gad.5.2.254	35	82	86	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					415	422						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845666				2022-12-17	WOS:A1995QF64800001
J	KOZLOSKY, CJ; MARASKOVSKY, E; MCGREW, JT; VANDENBOS, T; TEEPE, M; LYMAN, SD; SRINIVASAN, S; FLETCHER, FA; GAYLE, RB; CERRETTI, DP; BECKMANN, MP				KOZLOSKY, CJ; MARASKOVSKY, E; MCGREW, JT; VANDENBOS, T; TEEPE, M; LYMAN, SD; SRINIVASAN, S; FLETCHER, FA; GAYLE, RB; CERRETTI, DP; BECKMANN, MP			LIGANDS FOR THE RECEPTOR TYROSINE KINASES HEK AND ELK - ISOLATION OF CDNAS ENCODING A FAMILY OF PROTEINS	ONCOGENE			English	Article						LIGANDS; ELK; HEK; RECEPTOR TYROSINE KINASES	TUMOR-NECROSIS-FACTOR; PROTO-ONCOGENE; IL-1 RECEPTOR; GENE; EXPRESSION; SEQUENCE; CLONING; CELLS; IDENTIFICATION; STIMULATION	Hek is a member of the eph subfamily of receptor tyrosine kinases whose members include elk, hek2, sek, eph and eck among others. Using a soluble form of hek consisting of the extracellular region of the receptor fused to the Fc domain of human IgG1 and an expression cloning strategy, we have isolated two different but related cDNAs from the human T-lymphoma line HSB-2 that encode ligands for hek. The cDNAs encode proteins of 238 and 201 amino acids (44% amino acid identity) that are anchored to the membrane by glycosyl-phosphatidylinositol (GPI)-linkage. The proteins encoded by these cDNAs are bound by hek with affinity constants of 2 x 10(8) m(-1). These proteins also bind the elk tyrosine kinase receptor. These cDNAs are related to other cDNAs that we have recently isolated from a human placental library that encode ligands for both hek and elk and define an emerging family of ligands for eph-related kinases (LERKs).	IMMUNEX RES & DEV CORP,DEPT GENE EXPRESS,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT CELLULAR IMMUNOL,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT BIOCHEM,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT MOLEC GENET,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT PROT CHEM,SEATTLE,WA 98101; IMMUNEX RES & DEV CORP,DEPT MOLEC IMMUNOL,SEATTLE,WA 98101									ARMITAGE RJ, 1992, EUR J IMMUNOL, V22, P2071, DOI 10.1002/eji.1830220817; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BOHME B, 1993, ONCOGENE, V8, P2857; BOYD AW, 1992, J BIOL CHEM, V267, P3262; CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047; CERRETTI DP, 1988, MOL IMMUNOL, V25, P761, DOI 10.1016/0161-5890(88)90112-5; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GILARDIHEBENSTREIT, 1992, ONCOGENE, V7, P2499; GOODWIN RG, 1993, CELL, V73, P447, DOI 10.1016/0092-8674(93)90133-B; GRIBSKOV M, 1988, COMPUT APPL BIOSCI, V4, P61; GRUBER LN, 1983, AM J CLIN HYPN, V25, P263; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MCGREW JT, 1991, CELL IMMUNOL, V137, P118, DOI 10.1016/0008-8749(91)90062-G; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; SAJJADI FG, 1991, NEW BIOL, V3, P769; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILLIAMS D E, 1991, Progress in Growth Factor Research, V3, P235, DOI 10.1016/0955-2235(91)90002-L; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	39	82	91	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					299	306						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838529				2022-12-17	WOS:A1995QC62400009
J	VOJTESEK, B; DOLEZALOVA, H; LAUEROVA, L; SVITAKOVA, M; HAVLIS, P; KOVARIK, J; MIDGLEY, CA; LANE, DP				VOJTESEK, B; DOLEZALOVA, H; LAUEROVA, L; SVITAKOVA, M; HAVLIS, P; KOVARIK, J; MIDGLEY, CA; LANE, DP			CONFORMATIONAL-CHANGES IN P53 ANALYZED USING NEW ANTIBODIES TO THE CORE DNA-BINDING DOMAIN OF THE PROTEIN	ONCOGENE			English	Note						P53; DNA BINDING; CONFORMATION; ANTIBODIES; MUTANTS	MONOCLONAL-ANTIBODIES; IMMUNOCHEMICAL ANALYSIS; CANCER; MUTATIONS; EXPRESSION; SUPPRESSOR; APOPTOSIS; FORM	The p53 protein contains a protease resistant core section that binds to DNA in a sequence specific manner and whose crystal structure has been determined. This core is flanked at the N-terminus by the transcriptional transactivation domain and at the C-terminus by sequences involved in the oligomerisation of the protein. Extensive immunochemical analysis of p53 has shown that dominant antigenic sites lie within these N- and C-terminal domains while few antibodies to the central core have been identified; One of these, PAb240, has been extensively characterised as its epitope is cryptic in the native DNA binding core structure but is exposed by denaturation. This epitope is also exposed on many p53 proteins that contain point mutations in the core domain suggesting that these mutations may have a common affect on the structure of the core. To investigate this further we have generated several new antibodies to novel sites on p53 and mapped their epitopes using synthetic peptides. We find that antibodies to two other discrete sites in the core can also, like PAb240, recognize cryptic epitopes and distinguish mutant from wild-type conformations implying that the point mutations found in p53 in human tumours have widespread effects on the folding pattern of the DNA binding domain.	MASARYK MEM CANC INST,DEPT CELLULAR & MOLEC ONCOL,CR-65653 BRNO,CZECH REPUBLIC; UNIV DUNDEE,CANC RES CAMPAIGN LABS,DUNDEE DD1 4HN,SCOTLAND	Masaryk Memorial Cancer Institute; University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1993, J PATHOL, V169, P27, DOI 10.1002/path.1711690106; BARTEK J, 1990, ONCOGENE, V5, P893; CHO Y, 1994, SCIENCE, V256, P346; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLMAN PM, 1987, IMMUNOL TODAY, V8, P44; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LEGROS Y, 1994, ONCOGENE, V9, P2071; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1993, ONCOGENE, V8, P2001; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SCHLICHTHOLZ B, 1992, CANCER RES, V52, P6380; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x	24	82	84	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					389	393						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7530828				2022-12-17	WOS:A1995QC62400018
J	LYMAN, SD; JAMES, L; ESCOBAR, S; DOWNEY, H; DEVRIES, P; BRASEL, K; STOCKING, K; BECKMANN, MP; COPELAND, NG; CLEVELAND, LS; JENKINS, NA; BELMONT, JW; DAVISON, BL				LYMAN, SD; JAMES, L; ESCOBAR, S; DOWNEY, H; DEVRIES, P; BRASEL, K; STOCKING, K; BECKMANN, MP; COPELAND, NG; CLEVELAND, LS; JENKINS, NA; BELMONT, JW; DAVISON, BL			IDENTIFICATION OF SOLUBLE AND MEMBRANE-BOUND ISOFORMS OF THE MURINE FLT3 LIGAND GENERATED BY ALTERNATIVE SPLICING OF MESSENGER-RNAS	ONCOGENE			English	Article						FT13 LIGAND; GROWTH FACTOR; GENE LOCATION; TYROSINE KINASE RECEPTOR; HEMATOPOIESIS	COLONY-STIMULATING FACTOR; MESSENGER-RNA PRECURSORS; CELL GROWTH-FACTOR; KIT-LIGAND; MOLECULAR-CLONING; HUMAN CSF-1; GENE; MOUSE; TRANSMEMBRANE; ORGANIZATION	We have recently described a novel hematopoietic growth factor, referred to as the flt3 ligand, that stimulates the proliferation of sub-populations of hematopoietic cells that are enriched for stem and progenitor cells, This factor is a transmembrane protein that undergoes proteolytic cleavage to generate a soluble form of the protein. We have isolated additional flt3 ligand isoforms by PCR that contain an extra exon and encode what are predicted to be either a soluble form of the ligand or a longer version of the transmembrane protein. We have also isolated cDNAs from murine T cell libraries that encode an isoform of the flt3 ligand that has an unusual C-terminus, This isoform results from a failure to splice out an intron during mRNA processing. The protein encoded by this cDNA is expressed on the cell surface, where it is biologically active. However, this novel isoform does not appear to give rise to a soluble form of the protein, Regulation of mRNA splicing is likely to control the generation of cell bound or soluble forms of this hematopoietic growth factor, Genetic mapping studies localize the gene encoding the flt3 ligand to the proximal portion of mouse chromosome 7 and to human chromosome 19q13.3.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Baylor College of Medicine	LYMAN, SD (corresponding author), IMMUNEX RES & DEV CORP,51 UNIV ST,SEATTLE,WA 98101, USA.		Belmont, John/AAH-6084-2021; Belmont, John W/AAI-2494-2019	Belmont, John W/0000-0001-7409-3578	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ANDERSON DM, 1991, CELL GROWTH DIFFER, V2, P373; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CERRETTI DP, 1988, MOL IMMUNOL, V25, P761, DOI 10.1016/0161-5890(88)90112-5; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; Green EL, 1981, GENETICS PROBABILITY, P77; HANNUM C, 1994, NATURE, V368, P643, DOI 10.1038/368643a0; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; HUANG EJ, 1990, CELL, V5, P225; IJDO JW, 1992, GENOMICS, V14, P1019, DOI 10.1016/S0888-7543(05)80125-9; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; LAW CL, 1993, J IMMUNOL, V151, P175; LEFF SE, 1992, NAT GENET, V2, P259, DOI 10.1038/ng1292-259; LU HS, 1991, J BIOL CHEM, V266, P8102; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; LYMAN SD, 1994, BLOOD, V83, P2795, DOI 10.1182/blood.V83.10.2795.2795; LYMAN SD, 1991, BLOOD CELL GROWTH FACTORS : THEIR PRESENT AND FUTURE USE IN HEMATOLOGY AND ONCOLOGY, P183; MAJUMDAR MK, 1994, J BIOL CHEM, V269, P1237; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.biochem.55.1.1119; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Silver W. K., 1979, COAT COLORS MICE MOD, P243; SIRACUSA LD, 1991, GENETICS, V127, P169; STEIN J, 1990, BLOOD, V76, P1308, DOI 10.1182/blood.V76.7.1308.bloodjournal7671308; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	32	82	87	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					149	157						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824267				2022-12-17	WOS:A1995QA98000017
J	LEBRUN, DP; CLEARY, ML				LEBRUN, DP; CLEARY, ML			FUSION WITH E2A ALTERS THE TRANSCRIPTIONAL PROPERTIES OF THE HOMEODOMAIN PROTEIN PBX1 IN T(119) LEUKEMIAS	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; GLUTATHIONE-S-TRANSFERASE; HUMAN PROTOONCOGENE PBX1; LOOP-HELIX PROTEINS; DNA-BINDING; MAMMALIAN-CELLS; PRE-B; CHROMOSOMAL TRANSLOCATIONS; ENHANCER BINDING; GENE	The t(1;19) chromosomal translocation is observed in pre-B cell acute lymphoblastic leukemias and results in expression of chimeric E2A-PBX1 proteins that contain transcriptional activation domains from E2A and the homeodomain of PBX1. Since homeodomains mediate DNA-binding, a potential model for the action of E2A-PBX1 is that it disrupts the transcriptional regulation of genes normally controlled by PBX1 or its closely-related family members PBX2 or PBX3. Using a binding site selection assay, we identified a consensus nucleotide sequence ATCAATCA specifically bound by the PBX1 homeodomain and those of its closely-related family members PBX2 and PBX3. An endogenous protein with the properties of PBX3b specifically bound to this sequence in nuclear extracts of precursor B cells. Transfection of reporter genes containing PBX binding sites linked to a minimal promoter demonstrated transactivation by E2A-PBX1 fusion protein dependent upon presence of the homeodomain. In contrast, wild-type PBX proteins were incapable of activating transcription. The striking differences in transcriptional properties of fusion and wild-type PBX proteins,provides strong functional evidence for the importance of aberrant transcriptional regulation in the genesis of t(l;19)-bearing leukemias.			LEBRUN, DP (corresponding author), STANFORD UNIV,MED CTR,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305, USA.				NCI NIH HHS [CA42971] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042971, R37CA042971] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BURGLIN TR, 1992, NAT GENET, V1, P319, DOI 10.1038/ng0892-319; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; CRIST WM, 1990, BLOOD, V76, P117; DOLAN JW, 1991, BIOCHIM BIOPHYS ACTA, V1088, P155, DOI 10.1016/0167-4781(91)90051-M; FAINSOD A, 1991, NUCLEIC ACIDS RES, V19, P4005, DOI 10.1093/nar/19.14.4005; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HUNGER SP, 1992, GENE DEV, V6, P1608, DOI 10.1101/gad.6.9.1608; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; MELLENTIN JD, 1989, SCIENCE, V246, P379, DOI 10.1126/science.2799390; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; WEISS MJ, 1988, J BIOL CHEM, V263, P12002; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3	31	82	84	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1641	1647						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183558				2022-12-17	WOS:A1994NL81500015
J	JOLLY, KW; MALKIN, D; DOUGLASS, EC; BROWN, TF; SINCLAIR, AE; LOOK, AT				JOLLY, KW; MALKIN, D; DOUGLASS, EC; BROWN, TF; SINCLAIR, AE; LOOK, AT			SPLICE-SITE MUTATION OF THE P53 GENE IN A FAMILY WITH HEREDITARY BREAST-OVARIAN CANCER	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; SINGLE BASE SUBSTITUTIONS; LI-FRAUMENI SYNDROME; GEL-ELECTROPHORESIS; GERMLINE MUTATIONS; PRONE FAMILY; DNA; NEOPLASMS; P53-GENE; JUNCTION	Germline mutations within evolutionary conserved exons of the p53 gene predispose to tumor development in several familial cancer syndromes. We now report identification of a novel p53 mutation affecting the splice acceptor site of exon 6 in the germline DNA of a family with hereditary breast-ovarian cancer. This splice-site mutation, which results in omission of exon 6 and creates a frame-shift and premature stop codon in transcripts from the mutant allele, was found in seven family members-four of whom have developed breast, ovarian or choroid plexus tumors before age 35. Our finding suggests the need to examine the entire p53 gene for frame-shift, and nonsense (as well as missense) mutations in families with early-onset hereditary breast and breast-ovarian cancers not linked to the BRCA1 gene on chromosome 17q. We propose that the term 'p53 familial cancer syndrome' be applied to dusters of tumors in families with documented germline p53 mutations, regardless of the histopathologic findings or pattern of tumor development.	ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; HOSP SICK CHILDREN, DEPT PEDIAT, DIV ONCOL, TORONTO M5G 1X8, ON, CANADA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)					NATIONAL CANCER INSTITUTE [P30CA021765, P01CA023099] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA-23099, CA-21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORRESEN AL, 1992, CANCER RES, V52, P3234; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; Bunn HF, 1986, HEMOGLOBIN MOL GENET; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; GARBER JE, 1990, CANCER-AM CANCER SOC, V66, P2658, DOI 10.1002/1097-0142(19901215)66:12<2658::AID-CNCR2820661232>3.0.CO;2-C; GITSCHIER J, 1991, THROMB HAEMOSTASIS, V66, P37; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HARTLEY AL, 1989, CANCER GENET CYTOGEN, V42, P221, DOI 10.1016/0165-4608(89)90090-3; JENKINS JR, 1988, ONCOGENE HDB, P403; KING MC, 1992, NAT GENET, V2, P89, DOI 10.1038/ng1092-89; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LAW JC, 1991, CANCER RES, V51, P6385; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1988, CANCER RES, V48, P5381; LIVINGSTON D, 1992, CANCER RES, V52, P3246; LYNCH HT, 1978, CANCER-AM CANCER SOC, V41, P1543, DOI 10.1002/1097-0142(197804)41:4<1543::AID-CNCR2820410444>3.0.CO;2-Y; LYNCH HT, 1984, CANCER GENET CYTOGEN, V13, P43, DOI 10.1016/0165-4608(84)90087-6; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; METZGER AK, 1991, P NATL ACAD SCI USA, V88, P7825, DOI 10.1073/pnas.88.17.7825; MONTENARH M, 1992, ONCOGENE, V7, P1673; MYERS RM, 1985, NUCLEIC ACIDS RES, V13, P3131, DOI 10.1093/nar/13.9.3131; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; NAROD SA, 1991, LANCET, V338, P82; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OHSHIMA Y, 1987, J MOL BIOL, V195, P247, DOI 10.1016/0022-2836(87)90647-4; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PUISIEUX A, 1991, CANCER RES, V51, P6185; REES DJG, 1985, NATURE, V316, P643, DOI 10.1038/316643a0; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SIDRANSKY D, 1992, CANCER RES, V52, P2984; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	40	82	82	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					97	102						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302608				2022-12-17	WOS:A1994MW24700012
J	PARK, DJ; WILCZYNSKI, SP; PAQUETTE, RL; MILLER, CW; KOEFFLER, HP				PARK, DJ; WILCZYNSKI, SP; PAQUETTE, RL; MILLER, CW; KOEFFLER, HP			P53 MUTATIONS IN HPV-NEGATIVE CERVICAL-CARCINOMA	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; POLYMERASE CHAIN-REACTION; TUMOR SUPPRESSOR GENE; CELL LUNG-CANCER; DNA; ASSOCIATION; EXPRESSION; SEQUENCE; LINES; TRANSCRIPTION	Human papillomavirus (HPV) infection has been strongly linked to the development of cervical carcinoma. Two viral oncoproteins, E6 and E7, produced by HPV, have been shown to immortalize primary human genital epithelial cells by interacting with the protein products of cellular tumor suppressor genes p53 and Rb, respectively. E6 binds to the cellular p53 protein promoting p53 degradation and inactivity. This mechanism has been suggested to contribute to the oncogenesis of HPV-positive anogential cancers. In HPV-negative cervical carcinoma, p53 mutation is thought to be the possible mechanism of oncogenesis. We have studied 257 cervical carcinoma specimens for HPV infection by Southern blot analysis and polymerase chain reaction (PCR). Of 257 samples, 39 were HPV-negative. We have further studied 21 HPV-negative specimens for p53 mutations utilizing PCR amplification of genomic DNA followed by single-stranded conformation polymorphism (SSCP) analysis and DNA sequencing. We found only two missense point mutations of p53 gene. In summary, although inactivation of p53 mediated either by E6 or by mutations may be an important key step in the development of cervical carcinoma, our study suggests that other mechanisms may also be involved in development of cervical cancer.	CITY HOPE NATL MED CTR, DEPT PATHOL, DUARTE, CA 91010 USA	City of Hope	PARK, DJ (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, CEDARS SINAI MED CTR, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90048 USA.				NCI NIH HHS [CA42710, CA32737] Funding Source: Medline; NIDDK NIH HHS [DK42792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042710, P30CA042710, P01CA032737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATKIN NB, 1989, CANCER GENET CYTOGEN, V37, P229, DOI 10.1016/0165-4608(89)90053-8; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BLOSS JD, 1991, HUM PATHOL, V22, P711, DOI 10.1016/0046-8177(91)90294-Y; BORRESEN AL, 1992, LANCET, V339, P1350; BUSBYEARLE RMC, 1992, LANCET, V339, P1350, DOI 10.1016/0140-6736(92)91993-I; CHIBA I, 1990, ONCOGENE, V5, P1603; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1991, ONCOGENE, V6, P873; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DURST M, 1985, J GEN VIROL, V66, P1515, DOI 10.1099/0022-1317-66-7-1515; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUJITA M, 1992, CANCER RES, V52, P5323; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hayashi K, 1991, PCR Methods Appl, V1, P34; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLY EA, 1986, J NATL CANCER I, V76, P983; Hoskins WJ, 1989, CANC PRINCIPLES PRAC, P1099; HOWLEY PM, 1991, CANCER RES, V51, pS5019; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MANOS MM, 1989, CANCER CEL, V7, P209; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MAZUR M, 1988, SOMAT CELL MOLEC GEN, V14, P393, DOI 10.1007/BF01534647; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILLER CW, 1992, CANCER RES, V52, P1695; MUNGER K, 1989, J VIROL, V63, P4417; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OROURKE RW, 1990, ONCOGENE, V5, P1829; PAQUETTE RL, 1993, CANCER-AM CANCER SOC, V72, P1272, DOI 10.1002/1097-0142(19930815)72:4<1272::AID-CNCR2820720420>3.0.CO;2-Q; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SRIVASTAVA S, 1992, CARCINOGENESIS, V13, P1273, DOI 10.1093/carcin/13.7.1273; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WERNESS BA, 1991, IMPORTANT ADV ONCOLO, P2; WILCZYNSKI SP, 1988, HUM PATHOL, V19, P697, DOI 10.1016/S0046-8177(88)80176-X; WINKELSTEIN W, 1990, AM J EPIDEMIOL, V131, P945, DOI 10.1093/oxfordjournals.aje.a115614; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	49	82	82	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					205	210						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302581				2022-12-17	WOS:A1994MW24700025
J	VOLKMANN, M; HOFMANN, WJ; MULLER, M; RATH, U; OTTO, G; ZENTGRAF, H; GALLE, PR				VOLKMANN, M; HOFMANN, WJ; MULLER, M; RATH, U; OTTO, G; ZENTGRAF, H; GALLE, PR			P53 OVEREXPRESSION IS FREQUENT IN EUROPEAN HEPATOCELLULAR-CARCINOMA AND LARGELY INDEPENDENT OF THE CODON-249 HOT-SPOT MUTATION	ONCOGENE			English	Article							HEPATITIS-B VIRUS; CELL-LINE; GENE; EXPRESSION; CONFORMATION; AFLATOXIN; ETIOLOGY	Mutations in the p53 tumour suppressor gene have been recently described in hepatocellular carcinomas (HCC) from high risk areas such as China and South Africa. Our study was designed to assess the importance of p53 aberrations in HCCs from Europe, where the major risk factors in hepatocarcinogenesis, aflatoxin exposure and chronic hepatitis B virus (HBV) infection, do not play a dominant role. We investigated 22 HCCs and, as controls, their corresponding tumour-free liver tissues, seven livers with primary biliary cirrhosis and four morphologically normal livers. p53 overexpression, which is usually associated with point mutations of the p53 gene, was detected in 10 of the 22 HCCs by immunoblotting and immunohistochemistry. p53 expression was restricted to the nucleus in the positive cells, while all cells in the control tissues were negative. There was no obvious etiological preference in the p53 positive tumours. Particularly, underlying chronic HBV infection did not appear to be associated with an increased rate of p53 overexpression in European HCCs. SSCP and sequence analysis of exons 5-8 of the p53 gene revealed point mutations in six out of eight tumours with increased steady state levels of p53. In conclusion, our study demonstrates increased p53 levels due to point mutations in a significant proportion of European HCCs. The codon 249 mutation, which was detected in one of the cases, is not predominant in these tumours.	UNIV HEIDELBERG,DEPT INTERNAL MED,GASTROENTEROL ABT,D-69115 HEIDELBERG,GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM,ANGEW TUMORVIROL,D-69115 HEIDELBERG,GERMANY; UNIV HEIDELBERG,DEPT PATHOL,D-69115 HEIDELBERG,GERMANY; UNIV HEIDELBERG,DEPT SURG,D-69115 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg			Galle, Peter/ABE-2872-2021; Galle, Peter R/T-5292-2018; Martina, Mueller-Schilling/R-4162-2016	Galle, Peter/0000-0001-8294-0992; Galle, Peter R/0000-0001-8294-0992; 				ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUETOW KH, 1992, P NATL ACAD SCI USA, V89, P9622, DOI 10.1073/pnas.89.20.9622; CARBONE D, 1991, ONCOGENE, V6, P1691; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; FUSUN Y, 1986, ADV CANCER RES, V47, P297; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN MC, 1993, INT J CANCER, V53, P51, DOI 10.1002/ijc.2910530111; HOSONO S, 1991, ONCOGENE, V6, P237; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JOHNSON PJ, 1987, J HEPATOL, V4, P140, DOI 10.1016/S0168-8278(87)80021-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI DZ, 1993, CARCINOGENESIS, V14, P169, DOI 10.1093/carcin/14.2.169; MACNAB GM, 1976, BRIT J CANCER, V34, P509, DOI 10.1038/bjc.1976.205; MURAKAMI Y, 1991, CANCER RES, V51, P552; NAKABAYASHI H, 1984, JPN J CANCER RES, V75, P151; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHIDA N, 1993, CANCER RES, V53, P368; ODA T, 1992, CANCER RES, V52, P6358; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; PUISIEUX A, 1991, CANCER RES, V51, P6185; RAJAGOPALAN MS, 1986, LIFE SCI, V39, P1287, DOI 10.1016/0024-3205(86)90190-6; SCORSONE KA, 1992, CANCER RES, V52, P1635; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X	31	82	84	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					195	204						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302580				2022-12-17	WOS:A1994MW24700024
J	CHENEVIXTRENCH, G; LEARY, J; KERR, J; MICHEL, J; KEFFORD, R; HURST, T; PARSONS, PG; FRIEDLANDER, M; KHOO, SK				CHENEVIXTRENCH, G; LEARY, J; KERR, J; MICHEL, J; KEFFORD, R; HURST, T; PARSONS, PG; FRIEDLANDER, M; KHOO, SK			FREQUENT LOSS OF HETEROZYGOSITY ON CHROMOSOME-18 IN OVARIAN ADENOCARCINOMA WHICH DOES NOT ALWAYS INCLUDE THE DCC LOCUS	ONCOGENE			English	Article							COLORECTAL CARCINOMAS; LUNG-CANCER; ALLELE LOSS; DNA; GENE; REGION; MUTATIONS; TUMORS; P53	Inactivation of the DCC gene on chromosome 18 owing to loss of heterozygosity is a common finding in colorectal cancer. Because both ovarian and colon cancer are features of Lynch syndrome II, which has been provisionally mapped to chromosome 18, we hypothesized that loss of heterozygosity at the DCC locus may also occur in ovarian neoplasia. Fifty-two sporadic ovarian adenocarcinoma tumours were analysed by Southern blotting for loss of heterozygosity (LOH) at six chromosome 18 loci. Overall, tumours from 31 patients (60%) showed allelic loss at one or more of these loci. A similarly high level of LOH, 66%, was found at D17S5 (17p13.3). In contrast, moderate levels of LOH, of 31%, 39% and 33%, were found at MYCL1 (1p32), D1S57 (1p) and D14S20 (14q32.33) respectively. However, analysis of partial chromosome deletions in 11 patients indicates that the smallest region of overlap appears to exclude the DCC gene but to be between the D18S5 and D18S11 loci. This suggests that another locus, as well as or apart from DCC, may be involved.	QUEENSLAND INST MED RES,JOINT ONCOL PROGRAMME,RES UNIT,QUEENSLAND CANC FUND,BRISBANE,AUSTRALIA; UNIV QUEENSLAND,DEPT OBSTET & GYNAECOL,BRISBANE,QLD 4000,AUSTRALIA; UNIV SYDNEY,WESTMEAD HOSP,DEPT OBSTET & GYNAECOL,SYDNEY,NSW 2006,AUSTRALIA; UNIV SYDNEY,WESTMEAD HOSP,DEPT MED,SYDNEY,NSW 2006,AUSTRALIA; PRINCE WALES HOSP,DEPT MED ONCOL,SYDNEY,NSW,AUSTRALIA	Cancer Council Queensland; QIMR Berghofer Medical Research Institute; University of Queensland; University of Sydney; University of Sydney			Chenevix-Trench, Georgia/AAV-2014-2020; Parsons, Peter/J-4683-2013	Chenevix-Trench, Georgia/0000-0002-1878-2587; Kefford, Richard/0000-0001-9251-9229; Parsons, Peter/0000-0002-0473-3346				ATKIN NB, 1987, CANCER GENET CYTOGEN, V26, P355, DOI 10.1016/0165-4608(87)90070-7; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BERTELSEN K, 1987, GYNECOL ONCOL, V28, P161, DOI 10.1016/0090-8258(87)90210-1; BOMAN BM, 1988, CANCER GENET CYTOGEN, V34, P153, DOI 10.1016/0165-4608(88)90182-3; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; DEVILEE P, 1991, ONCOGENE, V6, P311; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; ECCLES DM, 1990, ONCOGENE, V5, P1599; EHLEN T, 1990, ONCOGENE, V5, P219; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOULKES W, 1991, LANCET, V338, P444, DOI 10.1016/0140-6736(91)91065-3; GENDLER SJ, 1990, INT J CANCER, V45, P431, DOI 10.1002/ijc.2910450309; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEBEAU MM, 1989, CYTOGENET CELL GENET, V51, P338, DOI 10.1159/000132798; LEE JH, 1990, CANCER RES, V50, P2724; LEE JH, 1989, CANCER RES, V49, P1220; LI S, 1991, J NATL CANCER I, V83, P337; LYNCH HT, 1985, CANCER, V56, P934, DOI 10.1002/1097-0142(19850815)56:4<934::AID-CNCR2820560439>3.0.CO;2-I; MARHLENS F, 1987, NUCLEIC ACIDS RES, V15, P1348; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MITELMAN F, 1991, CATALOG CHROMOSOME A; MULERIS M, 1987, CANCER GENET CYTOGEN, V29, P289, DOI 10.1016/0165-4608(87)90239-1; MULLER U, 1987, CYTOGENET CELL GENET, V45, P16, DOI 10.1159/000132418; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P4747, DOI 10.1093/nar/16.10.4747; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P6257, DOI 10.1093/nar/16.13.6257; NAROD SA, 1991, LANCET, V338, P82; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NISHISHO I, 1987, JPN J HUM GENET, V32, P1, DOI 10.1007/BF01876521; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OCONNELL P, 1988, GENOMICS, V3, P367, DOI 10.1016/0888-7543(88)90129-2; OKAMOTO A, 1991, CANCER RES, V51, P5171; PELTOMAKI P, 1991, CANCER RES, V51, P4135; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; SATO T, 1991, CANCER RES, V51, P5118; SILVERMAN GA, 1991, GENOMICS, V9, P219, DOI 10.1016/0888-7543(91)90245-A; TSUJIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P1329, DOI 10.1073/pnas.84.5.1329; VIALLET J, 1990, AM J RESP CELL MOL, V2, P225, DOI 10.1165/ajrcmb/2.3.225; VIEL A, 1991, TUMORI, V77, P16, DOI 10.1177/030089169107700104; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; YOUNG J, 1990, NUCLEIC ACIDS RES, V18, P7196, DOI 10.1093/nar/18.23.7196; ZHENG JP, 1991, CANCER RES, V51, P4045	47	82	82	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1059	1065						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594239				2022-12-17	WOS:A1992HU64200002
J	CESANO, A; HOXIE, JA; LANGE, B; NOWELL, PC; BISHOP, J; SANTOLI, D				CESANO, A; HOXIE, JA; LANGE, B; NOWELL, PC; BISHOP, J; SANTOLI, D			THE SEVERE COMBINED IMMUNODEFICIENT (SCID) MOUSE AS A MODEL FOR HUMAN MYELOID LEUKEMIAS	ONCOGENE			English	Article							NUDE-MICE; HU MOUSE; HIV-INFECTION; CELL-LINES; T LEUKEMIA; DIFFERENTIATION; GROWTH; TRANSPLANTATION; LYMPHOCYTES; SEQUENCES	Recent work has demonstrated the ability of lymphoblastic leukemias of pre-B- and T-cell origin to grow in severe combined immunodeficient (SCID) mice with a pattern reminiscent of the human clinical disease. Here, we investigated the possibility of engrafting human myeloid leukemias using both established cell lines and primary patient material. Whereas the two growth factor-independent cell lines K562 and U937 grew aggressively and induced leukemia in these animals, three other myeloid cell lines which require interleukin 3 or granulocyte-macrophage colony-stimulating factor for continuous growth in vitro failed to induce disease. Primary bone marrow and peripheral blood cells from five out of seven patients with different types of myeloid leukemias (undifferentiated, megakaryoblastic, monoblastic and chronic myelogenous leukemia in blast crisis) induced patterns of leukemic infiltration that were distinct for each leukemia subtype. The diagnosis of leukemia in SCID mice was established by microscopic detection of myeloblasts in the bone marrow, peripheral blood and, in some instances, in extramedullary sites, including the central nervous system and gonads. The karyotype and phenotype of the blasts recovered from mouse tissues were identical to those of the original patient cells. Moreover, human specific ALU sequences were amplified from the bone marrow DNA by polymerase chain reaction. Despite their ability to grow in vivo by serial transfers in SCID mice, the leukemic cells recovered from mouse tissues could not be maintained in vitro, even in the presence of recombinant cytokines. Overall, these data indicate that the SCID mouse may represent a useful animal model for human myeloid leukemias and for the development of new pharmacological and molecular approaches to therapy.	WISTAR INST, 3601 SPRUCE ST, PHILADELPHIA, PA 19104 USA; HOSP UNIV PENN, DEPT MED, DIV HEMATOL ONCOL, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, PHILADELPHIA, PA 19104 USA	The Wistar Institute; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania					NCI NIH HHS [CA42232, CA47589] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047589, R35CA042232] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVANZI GC, 1990, J CELL PHYSIOL, V145, P458, DOI 10.1002/jcp.1041450310; BANKERT RB, 1989, CURR TOP MICROBIOL, V152, P201; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; CANNON MJ, 1990, J CLIN INVEST, V85, P1333, DOI 10.1172/JCI114573; CESANO A, 1991, BLOOD, V77, P2463; CHARLEY MR, 1990, J INVEST DERMATOL, V94, P381, DOI 10.1111/1523-1747.ep12874500; CLUTTERBUCK RD, 1985, LEUKEMIA RES, V9, P1511, DOI 10.1016/0145-2126(85)90044-X; DICK JE, 1991, CANCER CELL-MON REV, V3, P39; DORSHKIND K, 1989, CURR TOP MICROBIOL, V152, P169; DORSHKIND K, 1984, J IMMUNOL, V132, P1804; DORSHKIND K, 1985, J IMMUNOL, V134, P3798; DUCHOSAL MA, 1990, J EXP MED, V172, P985, DOI 10.1084/jem.172.3.985; FRANKS CR, 1977, BRIT J CANCER, V35, P697, DOI 10.1038/bjc.1977.107; GHOSE T, 1988, AM J HEMATOL, V28, P146, DOI 10.1002/ajh.2830280304; KAMELREID S, 1988, SCIENCE, V242, P1706, DOI 10.1126/science.2904703; KAMELREID S, 1989, SCIENCE, V246, P1597, DOI 10.1126/science.2595371; LANGE B, 1987, BLOOD, V70, P192; LOZZIO BB, 1976, J EXP MED, V143, P225, DOI 10.1084/jem.143.1.225; MACHADO EA, 1984, BLOOD, V63, P1015; MCCUNE JM, 1990, SCIENCE, V247, P564, DOI 10.1126/science.2300816; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MCCUNE JM, 1989, CURR TOP MICROBIOL, V152, P183; MOSIER DE, 1990, J CLIN IMMUNOL, V10, P185, DOI 10.1007/BF00918650; MOSIER DE, 1989, CURR TOP MICROBIOL, V152, P195; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; MOSIER DE, 1991, SCIENCE, V251, P791, DOI 10.1126/science.1990441; NAMIKAWA R, 1988, SCIENCE, V242, P1684, DOI 10.1126/science.3201256; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; NILSSON K, 1977, INT J CANCER, V19, P337, DOI 10.1002/ijc.2910190309; OCONNOR R, 1990, J IMMUNOL, V145, P3779; OCONNOR R, 1991, BLOOD, V77, P1534; SANTOLI D, 1990, J IMMUNOL, V144, P4703; SILVER SM, 1987, BLOOD, V69, P1031; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TIGHE H, 1990, EUR J IMMUNOL, V20, P1843, DOI 10.1002/eji.1830200832; WATANABE S, 1980, CANCER RES, V40, P2588	38	82	87	3	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1992	7	5					827	836						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1570153				2022-12-17	WOS:A1992HP64200001
J	BRATTHAUER, GL; FANNING, TG				BRATTHAUER, GL; FANNING, TG			ACTIVE LINE-1 RETROTRANSPOSONS IN HUMAN TESTICULAR CANCER	ONCOGENE			English	Article							EMBRYONAL CARCINOMA-CELLS; DNA-SEQUENCES; FAMILY; ELEMENT; END	An antibody to the protein encoded by the first open reading frame of the human LINE-1 (L1Hs) element was used to examine immunohistochemically 59 formalin-fixed, human testicular germ cell tumors. Six tumors were positive for L1Hs expression. In all cases the L1Hs-positive cells were epithelial and most had the very characteristic, undifferentiated appearance of embryonal carcinoma or yolk sac tumor cells. One L1Hs-positive tumor had metastasized to the lung and lymph nodes and the metastatic cells also expressed L1Hs. This is the first observation of widespread retrotransposon expression in human tissue. These observations raise the possibility that L1Hs-encoded proteins may function as oncoproteins in some cancers.	ARMED FORCES INST PATHOL,DEPT CELLULAR PATHOL,WASHINGTON,DC 20306	United States Department of Defense								ANDREWS PW, 1987, TERATOCARCINOMAS EMB, P207; BRAWN PN, 1987, CANCER, V59, P2042, DOI 10.1002/1097-0142(19870615)59:12<2042::AID-CNCR2820591213>3.0.CO;2-R; DERAGON JM, 1990, EMBO J, V9, P3363, DOI 10.1002/j.1460-2075.1990.tb07537.x; FANNING TG, 1987, BIOCHIM BIOPHYS ACTA, V910, P203, DOI 10.1016/0167-4781(87)90112-6; GRIMALDI G, 1984, EMBO J, V3, P1753, DOI 10.1002/j.1460-2075.1984.tb02042.x; HATTORI M, 1986, NATURE, V321, P625, DOI 10.1038/321625a0; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; LEIBOLD DM, 1990, P NATL ACAD SCI USA, V87, P6990, DOI 10.1073/pnas.87.18.6990; LOEB DD, 1986, MOL CELL BIOL, V6, P168, DOI 10.1128/MCB.6.1.168; LOEHRER PL, 1987, SEMIN ONCOL, V12, P304; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; SINGER MF, 1988, BANBURY REPORT, V30, P71; SKOWRONSKI J, 1985, P NATL ACAD SCI USA, V82, P6050, DOI 10.1073/pnas.82.18.6050; SKOWRONSKI J, 1988, MOL CELL BIOL, V8, P1385, DOI 10.1128/MCB.8.4.1385; SKOWRONSKI J, 1986, COLD SPRING HARB SYM, V51, P457, DOI 10.1101/SQB.1986.051.01.055; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; SWERGOLD GD, 1990, MOL CELL BIOL, V10, P6718, DOI 10.1128/MCB.10.12.6718; VARMUS H, 1989, ONCOGENES MOL ORIGIN, P3; [No title captured]	19	82	91	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					507	510						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1312702				2022-12-17	WOS:A1992HK00500016
J	CHEN, SJ; CHEN, Z; DAURIOL, L; LECONIAT, M; GRAUSZ, D; BERGER, R				CHEN, SJ; CHEN, Z; DAURIOL, L; LECONIAT, M; GRAUSZ, D; BERGER, R			PH1+BCR- ACUTE LEUKEMIAS - IMPLICATION OF ALU SEQUENCES IN A CHROMOSOMAL TRANSLOCATION OCCURRING IN THE NEW CLUSTER REGION WITHIN THE BCR GENE	ONCOGENE			English	Article									HOP ST LOUIS,INSERM,U301,1 AV CLAUDE VELLEFAUX,F-75475 PARIS 10,FRANCE; HOP ST LOUIS,CENT HEMATOL LAB,F-75475 PARIS 10,FRANCE; HOP ST LOUIS,CNRS,HEMATOL EXPTL LAB,LOI,UM7,F-75475 PARIS 10,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite								AGUILERA RJ, 1987, CELL, V51, P909, DOI 10.1016/0092-8674(87)90578-2; AKIRA S, 1987, SCIENCE, V238, P1134, DOI 10.1126/science.3120312; ASSOULINE Z, 1988, BIOCHEM BIOPH RES CO, V153, P1159, DOI 10.1016/S0006-291X(88)81349-4; AVIVI L, 1980, HUM GENET, V55, P281, DOI 10.1007/BF00290206; BAER R, 1985, CELL, V43, P705, DOI 10.1016/0092-8674(85)90243-0; BERNARD O, 1988, ONCOGENE, V2, P195; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BRITTEN RJ, 1988, P NATL ACAD SCI USA, V85, P4770, DOI 10.1073/pnas.85.13.4770; CHEN SJ, 1988, LEUKEMIA, V2, P634; CHEN SJ, 1988, LEUKEMIA, V2, P261; CHEN Z, IN PRESS BLOOD; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; CLEARY ML, 1988, J EXP MED, V167, P682, DOI 10.1084/jem.167.2.682; COLLINS S, 1987, MOL CELL BIOL, V7, P2870, DOI 10.1128/MCB.7.8.2870; CREMER T, 1988, EXP CELL RES, V176, P199, DOI 10.1016/0014-4827(88)90325-4; DARBY MK, 1986, EMBO J, V5, P2257, DOI 10.1002/j.1460-2075.1986.tb04493.x; DEKLEIN A, 1986, NUCLEIC ACIDS RES, V14, P7071, DOI 10.1093/nar/14.17.7071; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; ELDER JT, 1981, NUCLEIC ACIDS RES, V9, P1171, DOI 10.1093/nar/9.5.1171; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINGER LR, 1986, SCIENCE, V234, P982, DOI 10.1126/science.3490692; Fox G M, 1983, Cold Spring Harb Symp Quant Biol, V47 Pt 2, P1131; GALE RP, 1988, LEUKEMIA, V2, P321; GROFFEN J, 1986, COLD SPRING HARB SYM, V51, P911, DOI 10.1101/SQB.1986.051.01.104; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HALUSKA FG, 1987, P NATL ACAD SCI USA, V84, P6835, DOI 10.1073/pnas.84.19.6835; HARPER ME, 1981, CHROMOSOMA, V83, P431, DOI 10.1007/BF00327364; HARTL P, 1987, MOL CELL BIOL, V7, P2037, DOI 10.1128/MCB.7.6.2037; HEIM S, 1987, CANCER CYTOGENETICS, P141; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HEISTERKAMP N, 1985, NATURE, V317, P559, DOI 10.1038/317559b0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; JELINEK WR, 1982, ANNU REV BIOCHEM, V51, P813, DOI 10.1146/annurev.bi.51.070182.004121; JURKA J, 1988, P NATL ACAD SCI USA, V85, P4774; KLOBECK HG, 1987, NUCLEIC ACIDS RES, V15, P4877, DOI 10.1093/nar/15.12.4877; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; KURZROCK R, 1987, BLOOD, V70, P1584; LEHRMAN MA, 1987, J BIOL CHEM, V262, P3354; LEHRMAN MA, 1987, CELL, V48, P827, DOI 10.1016/0092-8674(87)90079-1; LIFSHITZ B, 1988, ONCOGENE, V2, P113; LIN CS, 1988, CELL, V54, P153, DOI 10.1016/0092-8674(88)90547-8; MATHIEUMAHUL D, 1985, EMBO J, V4, P3427, DOI 10.1002/j.1460-2075.1985.tb04100.x; PAOLELLA G, 1983, EMBO J, V2, P691, DOI 10.1002/j.1460-2075.1983.tb01486.x; PEAR WS, 1988, ONCOGENE, V2, P499; RABBITTS PH, 1988, ONCOGENE, V3, P99; ROGERS J, 1985, NATURE, V317, P559, DOI 10.1038/317559a0; ROUYER F, 1987, CELL, V51, P417, DOI 10.1016/0092-8674(87)90637-4; RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; TSUJIMOTO Y, 1988, ONCOGENE, V2, P347; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; VANIN EF, 1983, CELL, V35, P701, DOI 10.1016/0092-8674(83)90103-4; VERMA RS, 1988, INT J CANCER, V41, P829, DOI 10.1002/ijc.2910410609; YUNIS JJ, 1978, CYTOGENET CELL GENET, V22, P679, DOI 10.1159/000131052	57	82	87	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1989	4	2					195	202						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5675	2648256				2022-12-17	WOS:A1989U567500011
J	Zhang, T; Li, J; Yin, F; Lin, B; Wang, Z; Xu, J; Wang, H; Zuo, D; Wang, G; Hua, Y; Cai, Z				Zhang, T.; Li, J.; Yin, F.; Lin, B.; Wang, Z.; Xu, J.; Wang, H.; Zuo, D.; Wang, G.; Hua, Y.; Cai, Z.			Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITOR; BREAST-CANCER; TUMOR-METASTASIS; MALIGNANT-CELLS; EXPRESSION; ANGIOGENESIS; ACTIVATION; PATHWAY; OVEREXPRESSION; SPECIFICITY	Signal transducer and activator of transcription 3(STAT3) is an emerging target for cancer therapy. In this study, we identify Toosendanin (TSN) is an effective inhibitor of STAT3, leading to the impediment of various oncogenic processes in osteosarcoma. TSN selectively inactivates phospho-STAT3 (Tyr-705); subsequent molecular docking and in vitro SPR analysis uncover TSN directly binds to the SH2 domain of STAT3. Consequently, TSN blocks STAT3 dimerization and impairs the complex formation of STAT3 and epidermal growth factor receptor (EGFR). In an animal tumor model study, TSN is well tolerated, inhibits osteosarcoma growth and metastasis. In another osteosarcoma patient-derived xenografts (PDX) model, we find TSN triggers strong inhibitory effects on patient-derived tumors. Further studies show that TSN also displays activity against other solid tumors. Our preclinical work therefore supports that TSN acts as a novel inhibitor of STAT3 that blocks tumorigenesis in ostoesarcoma.	[Zhang, T.; Yin, F.; Wang, Z.; Hua, Y.; Cai, Z.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Orthoped, Shanghai, Peoples R China; [Zhang, T.; Yin, F.; Lin, B.; Wang, Z.; Wang, H.; Zuo, D.; Wang, G.; Hua, Y.; Cai, Z.] Shanghai Bone Tumor Inst, Shanghai, Peoples R China; [Li, J.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Inst Translat Med, Shanghai, Peoples R China; [Xu, J.] Shanghai Jiao Tong Univ, Sch Med, Inst Med Sci, Dept Pharmacol, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Zhang, T; Hua, Y; Cai, Z (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Orthopaed, 100 Haining Rd, Shanghai 200080, Peoples R China.	zhangtaoabc@2008.sina.com; hua_yingqi@163.com; czd856@vip.163.com			NSFC [81502604]; Shanghai Science and Technology Commission [14140904000]; Doctoral Innovation Fund of Shanghai Jiaotong University School of Medicine [BXJ201732]; Research Grant from Shanghai Hospital Development Center [SHDC12013107]	NSFC(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Commission(Shanghai Science & Technology CommitteeScience & Technology Commission of Shanghai Municipality (STCSM)); Doctoral Innovation Fund of Shanghai Jiaotong University School of Medicine; Research Grant from Shanghai Hospital Development Center	This work was supported by NSFC (81502604); Shanghai Science and Technology Commission (14140904000); Doctoral Innovation Fund of Shanghai Jiaotong University School of Medicine (No. BXJ201732) and Research Grant from Shanghai Hospital Development Center (SHDC12013107).	Bharadwaj U, 2015, ONCOGENE, V34, P1341, DOI 10.1038/onc.2014.72; Bharti AC, 2003, J IMMUNOL, V171, P3863, DOI 10.4049/jimmunol.171.7.3863; Butler MS, 2008, NAT PROD REP, V25, P475, DOI 10.1039/b514294f; Cao L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111928; Chun J, 2015, CANCER LETT, V357, P393, DOI 10.1016/j.canlet.2014.11.049; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Devarajan E, 2009, CURR MOL MED, V9, P626, DOI 10.2174/156652409788488720; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Fossey SL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-81; Haan S, 1999, J BIOL CHEM, V274, P1342, DOI 10.1074/jbc.274.3.1342; Hao WS, 2008, BIOORG MED CHEM LETT, V18, P4988, DOI 10.1016/j.bmcl.2008.08.032; Hayakawa F, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.63; Hsieh FC, 2005, BIOCHEM BIOPH RES CO, V335, P292, DOI 10.1016/j.bbrc.2005.07.075; Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kotha A, 2006, MOL CANCER THER, V5, P621, DOI 10.1158/1535-7163.MCT-05-0268; Li JJ, 2015, BRIT J PHARMACOL, V172, P3817, DOI 10.1111/bph.13165; Lu XY, 2016, SCI REP-UK, V6, DOI 10.1038/srep34225; Malaney P, 2014, CANCER LETT, V344, P1, DOI 10.1016/j.canlet.2013.10.010; Marangoni E, 2007, CLIN CANCER RES, V13, P3989, DOI 10.1158/1078-0432.CCR-07-0078; Nair RR, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00030; Nakajima M, 1991, Semin Cancer Biol, V2, P115; NICOLSON GL, 1988, CANCER METAST REV, V7, P143, DOI 10.1007/BF00046483; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Picci P, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-6; Real PJ, 2002, ONCOGENE, V21, P7611, DOI 10.1038/sj.onc.1206004; Ryu K, 2010, J ORTHOP RES, V28, P971, DOI 10.1002/jor.21088; Sakai I, 2002, BLOOD, V100, P2926, DOI 10.1182/blood-2002-01-0073; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Su YX, 2009, CLIN EXP METASTAS, V26, P599, DOI 10.1007/s10585-009-9259-6; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Wang JQ, 2014, BREAST CANCER RES TR, V148, P279, DOI 10.1007/s10549-014-3165-6; Xiong H, 2012, J BIOL CHEM, V287, P5819, DOI 10.1074/jbc.M111.295964; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang HY, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3640; ZHANG T, 2016, CELL DEATH DIS, V7; Zhang T, 2014, NEOPLASIA, V16, P665, DOI 10.1016/j.neo.2014.07.009; Zhang T, 2012, BREAST CANCER RES TR, V135, P445, DOI 10.1007/s10549-012-2175-5; Zhang XL, 2013, CANCER RES, V73, P1922, DOI 10.1158/0008-5472.CAN-12-3175; Zhang XL, 2010, BIOCHEM PHARMACOL, V79, P1398, DOI 10.1016/j.bcp.2010.01.001	43	81	84	3	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6627	6639		10.1038/onc.2017.270	http://dx.doi.org/10.1038/onc.2017.270			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28783167	Green Published, hybrid			2022-12-17	WOS:000416049200011
J	Selth, LA; Das, R; Townley, SL; Coutinho, I; Hanson, AR; Centenera, MM; Stylianou, N; Sweeney, K; Soekmadji, C; Jovanovic, L; Nelson, CC; Zoubeidi, A; Butler, LM; Goodall, GJ; HoIlier, BG; Gregory, PA; Tilley, WD				Selth, L. A.; Das, R.; Townley, S. L.; Coutinho, I.; Hanson, A. R.; Centenera, M. M.; Stylianou, N.; Sweeney, K.; Soekmadji, C.; Jovanovic, L.; Nelson, C. C.; Zoubeidi, A.; Butler, L. M.; Goodall, G. J.; HoIlier, B. G.; Gregory, P. A.; Tilley, W. D.			A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer	ONCOGENE			English	Article							MICRORNA EXPRESSION PROFILES; CIRCULATING TUMOR-CELLS; MESENCHYMAL TRANSITION; ANDROGEN RECEPTOR; METASTATIC COLONIZATION; MIR-200 FAMILY; BREAST-CANCER; MESSENGER-RNA; PROGRESSION; REPRESSION	MicroRNA-375 (miR-375) is frequently elevated in prostate tumors and cell-free fractions of patient blood, but its role in genesis and progression of prostate cancer is poorly understood. In this study, we demonstrated that miR-375 is inversely correlated with epithelial-mesenchymal transition signatures (EMT) in clinical samples and can drive mesenchymal-epithelial transition (MET) in model systems. Indeed, miR-375 potently inhibited invasion and migration of multiple prostate cancer lines. The transcription factor YAP1 was found to be a direct target of miR-375 in prostate cancer. Knockdown of YAP1 phenocopied miR-375 overexpression, and overexpression of YAP1 rescued anti-invasive effects mediated by miR-375. Furthermore, transcription of the miR-375 gene was shown to be directly repressed by the EMT transcription factor, ZEB1. Analysis of multiple patient cohorts provided evidence for this ZEB1-miR-375-YAP1 regulatory circuit in clinical samples. Despite its anti -invasive and anti-EMT capacities, plasma miR-375 was found to be correlated with circulating tumor cells in men with metastatic disease. Collectively, this study provides new insight into the function of miR-375 in prostate cancer, and more broadly identifies a novel pathway controlling epithelial plasticity and tumor cell invasion in this disease.	[Selth, L. A.; Das, R.; Townley, S. L.; Coutinho, I.; Hanson, A. R.; Tilley, W. D.] Univ Adelaide, Sch Med, Dame Roma Mitchell Canc Res Labs, Level 4,Hanson Inst Bldg,DX 650 801, Adelaide, SA 5005, Australia; [Selth, L. A.; Das, R.; Townley, S. L.; Coutinho, I.; Hanson, A. R.; Centenera, M. M.; Butler, L. M.; Tilley, W. D.] Univ Adelaide, Freemasons Fdn, Ctr Mens Hlth, Discipline Med, Adelaide, SA, Australia; [Selth, L. A.; Das, R.; Townley, S. L.; Coutinho, I.; Hanson, A. R.; Centenera, M. M.; Butler, L. M.; Goodall, G. J.; Gregory, P. A.; Tilley, W. D.] Univ Adelaide, Discipline Med, Adelaide, SA, Australia; [Centenera, M. M.; Butler, L. M.] South Australian Hlth & Med Res Inst, Canc Theme, Adelaide, SA, Australia; [Stylianou, N.; Sweeney, K.; Soekmadji, C.; Jovanovic, L.; Nelson, C. C.; HoIlier, B. G.] Queensland Univ Technol, Princess Alexandra Hosp, Translat Res Inst,Inst Hlth & Biomed Innovat, Australian Prostate Canc Res Ctr Queensland, Brisbane, Qld, Australia; [Zoubeidi, A.] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC, Canada; [Goodall, G. J.; Gregory, P. A.] SA Pathol, Ctr Canc Biol, Adelaide, SA, Australia; [Goodall, G. J.] Univ South Australia, Adelaide, SA, Australia; [Goodall, G. J.] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA, Australia	Hanson Institute; University of Adelaide; University of Adelaide; University of Adelaide; South Australian Health & Medical Research Institute (SAHMRI); Queensland University of Technology (QUT); University of British Columbia; Centre for Cancer Biology; SA Pathology; University of South Australia; University of Adelaide	Selth, LA (corresponding author), Univ Adelaide, Sch Med, Dame Roma Mitchell Canc Res Labs, Level 4,Hanson Inst Bldg,DX 650 801, Adelaide, SA 5005, Australia.	luke.selth@adelaide.edu.au	Stylianou, Nataly/GOP-1782-2022; Butler, Lisa/AAP-9088-2020; Selth, Luke/AAH-4823-2021; Butler, Lisa M/C-9843-2010; Soekmadji, Carolina/M-2757-2016; Gregory, Philip/F-4089-2013	Butler, Lisa/0000-0003-2698-3220; Selth, Luke/0000-0002-4686-1418; Soekmadji, Carolina/0000-0002-6920-6627; Gregory, Philip/0000-0002-0999-0632; Tilley, Wayne/0000-0003-1893-2626; centenera, margaret/0000-0002-2206-0632; Stylianou, Nataly/0000-0002-8006-5730; Goodall, Gregory/0000-0003-1294-0692; coutinho, isabel/0000-0003-3389-033X	Young Investigator Awards from the Prostate Cancer Foundation [14]; Prostate Cancer Foundation of Australia (PCFA)/Movember [YI 0810, YI 0412]; PCFA/Movember/Cancer Australia [1012337, 1043482]; National Health and Medical Research Council [1083961]; Cancer Council of South Australia; Queensland government Smart Futures Fund Fellowship; Movember Foundation; Prostate Cancer Foundation of Australia through Movember Revolutionary Team Awards; National Breast Cancer Foundation [CG-10-04] Funding Source: researchfish	Young Investigator Awards from the Prostate Cancer Foundation; Prostate Cancer Foundation of Australia (PCFA)/Movember; PCFA/Movember/Cancer Australia; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council of South Australia(Cancer Council South Australia); Queensland government Smart Futures Fund Fellowship; Movember Foundation; Prostate Cancer Foundation of Australia through Movember Revolutionary Team Awards; National Breast Cancer Foundation	The YAP1 3'-UTR plasmids were a kind gift from Prof Takashi Takahashi, Nagoya University. The results published here are in part based on the data generated by The Cancer Genome Atlas, established by the National Cancer Institute and the National Human Genome Research Institute, and we are grateful to the specimen donors and relevant research groups associated with this project. We also acknowledge the ENCODE Consortium and the Myers laboratory at the HudsonAlpha Institute for Biotechnology for generating the ZEB1 ChIP-seq data set used in this study. This work was supported by: Young Investigator Awards from the Prostate Cancer Foundation (the Foundation 14 award; LAS) and the Prostate Cancer Foundation of Australia (PCFA)/Movember (YI 0810; LAS, YI 0412; MMC) and grants from PCFA/Movember/Cancer Australia (Grant IDs 1012337 and 1043482; WDT, LAS and LMB) and the National Health and Medical Research Council (Grant ID 1083961). PAG is supported by a Beat Cancer Project fellowship from the Cancer Council of South Australia. BGH is supported by a Queensland government Smart Futures Fund Fellowship. The research programs of LAS, MMC, LMB, CCN, BGH and WDT are supported by the Movember Foundation and the Prostate Cancer Foundation of Australia through Movember Revolutionary Team Awards.	Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Banyard J, 2013, SCI REP-UK, V3, DOI 10.1038/srep03151; Bitting RL, 2014, CANCER METAST REV, V33, P441, DOI 10.1007/s10555-013-9483-z; Blower PE, 2007, MOL CANCER THER, V6, P1483, DOI 10.1158/1535-7163.MCT-07-0009; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Brase JC, 2011, INT J CANCER, V128, P608, DOI 10.1002/ijc.25376; Bray F, 2013, INT J CANCER, V132, P1133, DOI 10.1002/ijc.27711; Bryant RJ, 2012, BRIT J CANCER, V106, P768, DOI 10.1038/bjc.2011.595; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Celia-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218; Christensen LL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096767; Chu ML, 2014, ONCOL REP, V31, P34, DOI 10.3892/or.2013.2810; Costa-Pinheiro P, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0076-2; Das R, 2014, TRENDS MOL MED, V20, P643, DOI 10.1016/j.molmed.2014.09.004; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; de Souza Rocha Simonini P, 2010, CANCER RES, V70, P9175, DOI DOI 10.1158/0008-5472.CAN-10-1318; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Gasch C, 2015, SCI REP-UK, V5, DOI 10.1038/srep15980; Gregory PA, 2008, CELL CYCLE, V7, P3112, DOI 10.4161/cc.7.20.6851; Kohn KW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035716; Kolesnikoff N, 2014, J BIOL CHEM, V289, P11194, DOI 10.1074/jbc.M113.529172; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Lin PC, 2013, CANCER RES, V73, P1232, DOI 10.1158/0008-5472.CAN-12-2968; Liu HF, 2010, MOL CANCER THER, V9, P1080, DOI 10.1158/1535-7163.MCT-09-0965; Lokman NA, 2012, INT J MOL SCI, V13, P9959, DOI 10.3390/ijms13089959; Madhavan D, 2012, CLIN CANCER RES, V18, P5972, DOI 10.1158/1078-0432.CCR-12-1407; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marrocco DL, 2007, MOL CANCER THER, V6, P51, DOI 10.1158/1535-7163.MCT-06-0144; Martens-Uzunova ES, 2012, ONCOGENE, V31, P978, DOI 10.1038/onc.2011.304; Moore NL, 2012, ENDOCR-RELAT CANCER, V19, P599, DOI 10.1530/ERC-12-0065; Nauseef JT, 2011, NAT REV UROL, V8, P428, DOI 10.1038/nrurol.2011.85; Neilsen PM, 2013, ONCOGENE, V32, P2992, DOI 10.1038/onc.2012.305; Nishikawa E, 2011, CANCER RES, V71, P6165, DOI 10.1158/0008-5472.CAN-11-1020; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Oka T, 2008, J BIOL CHEM, V283, P27534, DOI 10.1074/jbc.M804380200; Ota M, 2008, DEVELOPMENT, V135, P4059, DOI 10.1242/dev.027151; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Schaefer A, 2010, NAT REV UROL, V7, P286, DOI 10.1038/nrurol.2010.45; Schmidt D, 2009, METHODS, V48, P240, DOI 10.1016/j.ymeth.2009.03.001; Selth LA, 2013, BRIT J CANCER, V109, P641, DOI 10.1038/bjc.2013.369; Selth LA, 2012, ENDOCR-RELAT CANCER, V19, pR99, DOI 10.1530/ERC-12-0010; Selth LA, 2012, INT J CANCER, V131, P652, DOI 10.1002/ijc.26405; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; Sokilde R, 2011, MOL CANCER THER, V10, P375, DOI 10.1158/1535-7163.MCT-10-0605; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Wach S, 2012, INT J CANCER, V130, P611, DOI 10.1002/ijc.26064; Ward A, 2013, ONCOGENE, V32, P1173, DOI 10.1038/onc.2012.128; Wu JN, 2014, CANCER-AM CANCER SOC, V120, P818, DOI 10.1002/cncr.28485; Yu XZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030605; Yuan TC, 2006, ENDOCR-RELAT CANCER, V13, P151, DOI 10.1677/erc.1.01043; Zhang JS, 2012, CANCER METAST REV, V31, P653, DOI 10.1007/s10555-012-9368-6	55	81	84	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2017	36	1					24	34		10.1038/onc.2016.185	http://dx.doi.org/10.1038/onc.2016.185			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK6XJ	27270433	Green Accepted			2022-12-17	WOS:000394069100003
J	Jeffery, J; Sinha, D; Srihari, S; Kalimutho, M; Khanna, KK				Jeffery, J.; Sinha, D.; Srihari, S.; Kalimutho, M.; Khanna, K. K.			Beyond cytokinesis: the emerging roles of CEP55 in tumorigenesis	ONCOGENE			English	Review							GENE-EXPRESSION PROFILES; SQUAMOUS-CELL CARCINOMA; BREAST-CANCER; ESCRT-III; PLK1-DEPENDENT PHOSPHORYLATION; INTERCELLULAR BRIDGES; CENTROSOMAL PROTEIN; UP-REGULATION; KINASE 1; MIDBODY	CEP55 was initially identified as a pivotal component of abscission, the final stage of cytokinesis, serving to regulate the physical separation of two daughter cells. Over the past 10 years, several studies have illuminated additional roles for CEP55 including regulating the PI3K/AKT pathway and midbody fate. Concurrently, CEP55 has been studied in the context of cancers including those of the breast, lung, colon and liver. CEP55 overexpression has been found to significantly correlate with tumor stage, aggressiveness, metastasis and poor prognosis across multiple tumor types and therefore has been included as part of several prognostic 'gene signatures' for cancer. Here by discussing in depth the functions of CEP55 across different effector pathways, and also its roles as a biomarker and driver of tumorigenesis, we assemble an exhaustive review, thus commemorating a decade of research on CEP55.	[Jeffery, J.; Sinha, D.; Kalimutho, M.; Khanna, K. K.] QIMR Berghofer Med Res Inst, Signal Transduct Lab, 300 Hcrston Rd, Brisbane, Qld, Australia; [Sinha, D.] Griffith Univ, Sch Nat Sci, Brisbane, Qld 4111, Australia; [Srihari, S.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia	QIMR Berghofer Medical Research Institute; Griffith University; University of Queensland	Khanna, KK (corresponding author), QIMR Berghofer Med Res Inst, Signal Transduct Lab, 300 Hcrston Rd, Brisbane, Qld, Australia.	kumkum.khanna@gimrberghofer.edu.au	Sinha, Debottam/J-5521-2019; Kalimutho, Murugan/AAD-1441-2019; Srihari, Sriganesh/H-1740-2013	Sinha, Debottam/0000-0001-7153-856X; Khanna, Kum Kum/0000-0001-8650-5381; Kalimutho, Murugan/0000-0002-0772-8673; Srihari, Sriganesh/0000-0002-0713-6723	Griffith University International and Postgraduate Research Scholarship; Cancer Council Queensland [ID1087363]; National Health & Medical Research Council (NHMRC) [1017028]	Griffith University International and Postgraduate Research Scholarship; Cancer Council Queensland(Cancer Council Queensland); National Health & Medical Research Council (NHMRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)National Health and Medical Research Council (NHMRC) of Australia)	DS is supported by a Griffith University International and Postgraduate Research Scholarship. MK is supported by a project grant from Cancer Council Queensland (ID1087363). This work was supported by a program grant from the National Health & Medical Research Council (NHMRC) to KKK (ID 1017028). KKK is a NHMRC Senior Principal Research Fellow (ID 613638).	Al-Ejeh F, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.14; Anastassiou D, 2012, Biomolecular events in cancer revealed by attractor metagenes. USA, Patent No. [PCT/US2013/037720, 2013037720]; Azmi AS, 2013, CANCER METAST REV, V32, P623, DOI 10.1007/s10555-013-9441-9; Bastos RN, 2010, J CELL BIOL, V191, P751, DOI 10.1083/jcb.201008108; Carlton JG, 2008, P NATL ACAD SCI USA, V105, P10541, DOI 10.1073/pnas.0802008105; Carlton JG, 2007, SCIENCE, V316, P1908, DOI 10.1126/science.1143422; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Carter SL, 2005, Prognosis indicators for solid human tumors. USA, Patent No. [PCT/US2006/047662, 2006047662]; Chang YC, 2012, J BIOL CHEM, V287, P4376, DOI 10.1074/jbc.M111.289108; Chang YC, 2010, J CELL BIOCHEM, V109, P1274, DOI 10.1002/jcb.22517; Chen CH, 2007, ONCOGENE, V26, P4272, DOI 10.1038/sj.onc.1210207; Chen CH, 2009, ONCOGENE, V28, P2723, DOI 10.1038/onc.2009.128; Chen CH, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-93; Chen CH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005052; Chen DT, 2011, Malignancy-risk signature from histologically normal breast tissue. USA, Patent No. [PCT/US2009/030778, 2009030778]; Chen DT, 2010, BREAST CANCER RES TR, V119, P335, DOI 10.1007/s10549-009-0344-y; Cheng WY, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002920; Cheung M, 2013, CURR CANCER DRUG TAR, V13, P234, DOI 10.2174/1568009611313030002; Colak D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063204; Coutant C, 2011, CLIN CANCER RES, V17, P2591, DOI 10.1158/1078-0432.CCR-10-1045; Cuzick J, 2011, LANCET ONCOL, V12, P245, DOI 10.1016/S1470-2045(10)70295-3; Ettinger AW, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1511; Fabbro M, 2005, DEV CELL, V9, P477, DOI 10.1016/j.devcel.2005.09.003; Fournier MV, 2006, CANCER RES, V66, P7095, DOI 10.1158/0008-5472.CAN-06-0515; Fratta E, 2011, MOL ONCOL, V5, P164, DOI 10.1016/j.molonc.2011.02.001; Fu Z, 2008, NAT CELL BIOL, V10, P1076, DOI 10.1038/ncb1767; Gemenetzidis E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004849; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Green RA, 2012, ANNU REV CELL DEV BI, V28, P29, DOI 10.1146/annurev-cellbio-101011-155718; Greenbaum MP, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005850; Greenbaum MP, 2006, P NATL ACAD SCI USA, V103, P4982, DOI 10.1073/pnas.0505123103; Gromley A, 2005, CELL, V123, P75, DOI 10.1016/j.cell.2005.07.027; Guizetti J, 2011, SCIENCE, V331, P1616, DOI 10.1126/science.1201847; Hemmings BA, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011189; Hong BS, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-556; Hu Y, 2012, P NATL ACAD SCI USA, V109, P3184, DOI 10.1073/pnas.1117872109; Hwang CF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084218; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Inoda S, 2011, AM J PATHOL, V178, P1805, DOI 10.1016/j.ajpath.2011.01.004; Inoda S, 2011, EXP MOL PATHOL, V90, P55, DOI 10.1016/j.yexmp.2010.10.001; Inoda S, 2009, J IMMUNOTHER, V32, P474, DOI 10.1097/CJI.0b013e3181a1d109; Iwamori T, 2010, MOL CELL BIOL, V30, P2280, DOI 10.1128/MCB.01392-09; Jeffery J, FASEB J; Jones J, 2005, CLIN CANCER RES, V11, P5730, DOI 10.1158/1078-0432.CCR-04-2225; Kao H, 2001, J EXP MED, V194, P1313, DOI 10.1084/jem.194.9.1313; Kato K, 2005, J CANCER RES CLIN, V131, P340, DOI 10.1007/s00432-004-0654-8; Kikuchi T, 2003, ONCOGENE, V22, P2192, DOI 10.1038/sj.onc.1206288; Kruger TE, 2014, CRIT REV ONCOL HEMAT, V89, P330, DOI 10.1016/j.critrevonc.2013.08.013; Kumar A, 2013, PROTOPLASMA, V250, P965, DOI 10.1007/s00709-013-0488-9; Kuo TC, 2011, NAT CELL BIOL, V13, P1214, DOI 10.1038/ncb2332; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Laoukili J, 2007, BBA-REV CANCER, V1775, P92, DOI 10.1016/j.bbcan.2006.08.006; Lee HH, 2008, SCIENCE, V322, P576, DOI 10.1126/science.1162042; Lekomtsev S, 2010, J CELL SCI, V123, P1395, DOI 10.1242/jcs.068015; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Martin KJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002994; Martin KJ, 2010, Gene expression signature as a predictor of chemotherapeutic response in breast cancer. USA, Patent No. [PCT/US2011/039325, 2011039325]; Martinez-Garay I, 2006, GENOMICS, V87, P243, DOI 10.1016/j.ygeno.2005.11.006; McKenzie L, 2010, CELL CYCLE, V9, P4200, DOI 10.4161/cc.9.20.13532; Mierzwa B, 2014, DEV CELL, V31, P525, DOI 10.1016/j.devcel.2014.11.006; Mondal G, 2012, DEV CELL, V23, P137, DOI 10.1016/j.devcel.2012.05.008; Montero-Conde C, 2008, ONCOGENE, V27, P1554, DOI 10.1038/sj.onc.1210792; Morita E, 2007, EMBO J, V26, P4215, DOI 10.1038/sj.emboj.7601850; Morita E, 2010, P NATL ACAD SCI USA, V107, P12889, DOI 10.1073/pnas.1005938107; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Naderi A, 2007, ONCOGENE, V26, P1507, DOI 10.1038/sj.onc.1209920; Neto H, 2013, MOL BIOL CELL, V24, P3663, DOI 10.1091/mbc.E13-06-0302; Ochi T, 2009, BLOOD, V113, P66, DOI 10.1182/blood-2008-06-164889; Pandit B, 2009, CELL CYCLE, V8, P3425, DOI 10.4161/cc.8.20.9628; Perou CM, 2008, Gene expression profiles to predict breast cancer outcomes. USA, Patent No. [PCT/US2009/045820, 2009045820]; Perou CM, 2012, Methods of Treating Breast Cancer With Taxane Therapy. USA, Patent No. [PCT/US2012/067317, 2012067317]; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Sakai M, 2006, ONCOGENE, V25, P480, DOI 10.1038/sj.onc.1209051; Sauer G, 2005, MOL CELL PROTEOMICS, V4, P35, DOI 10.1074/mcp.M400158-MCP200; Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007; Singh PK, 2015, IMMUNOBIOLOGY, V220, P103, DOI 10.1016/j.imbio.2014.08.014; St-Denis N, 2015, MOL CELL PROTEOMICS, V14, P946, DOI 10.1074/mcp.M114.046086; Stone S, 2010, Gene signatures for cancer diagnosis and prognosis. USA, Patent No. [PCT/US2011/049760, 2011049760]; Takahashi M, 2002, MOL BIOL CELL, V13, P3235, DOI 10.1091/mbc.E02-02-0112; Tao JQ, 2014, TUMOR BIOL, V35, P4389, DOI 10.1007/s13277-013-1578-1; Tsai CY, 2015, BIOCHEM PHARMACOL, V93, P34, DOI 10.1016/j.bcp.2014.10.018; van der Horst A, 2009, CELL CYCLE, V8, P3742, DOI 10.4161/cc.8.22.10047; van der Horst A, 2009, CANCER RES, V69, P6651, DOI 10.1158/0008-5472.CAN-09-0825; Wagner S, 2011, Gene signatures for lung cancer prognosis and therapy selection. USA, Patent No. [PCT/US2012/051447, 2012051447]; Waseem A, 2010, ORAL ONCOL, V46, P536, DOI 10.1016/j.oraloncology.2010.03.022; Yanagisawa H, 2009, J CELL COMMUN SIGNAL, V3, P337, DOI 10.1007/s12079-009-0065-3; Zhang HG, 2011, CLIN CANCER RES, V17, P959, DOI 10.1158/1078-0432.CCR-10-1489; Zhao WM, 2006, MOL BIOL CELL, V17, P3881, DOI 10.1091/mbc.E06-01-0015; Zhou W, 2013, CANCER CELL, V23, P48, DOI 10.1016/j.ccr.2012.12.001	92	81	84	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					683	690		10.1038/onc.2015.128	http://dx.doi.org/10.1038/onc.2015.128			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	25915844				2022-12-17	WOS:000370331300002
J	Koo, BS; Lee, SH; Kim, JM; Huang, S; Kim, SH; Rho, YS; Bae, WJ; Kang, HJ; Kim, YS; Moon, JH; Lim, YC				Koo, B. S.; Lee, S. H.; Kim, J. M.; Huang, S.; Kim, S. H.; Rho, Y. S.; Bae, W. J.; Kang, H. J.; Kim, Y. S.; Moon, J. H.; Lim, Y. C.			Oct4 is a critical regulator of stemness in head and neck squamous carcinoma cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CANCER CELLS; RESISTANCE; IDENTIFICATION; PLURIPOTENCY; EXPRESSION; DISEASE; PROTEIN	Cancer stem cells (CSCs) have been suggested as responsible for the initiation and progression of cancers. Octamer-binding transcription factor 4 (Oct4) is an important regulator of embryonic stem cell fate. Here, we investigated whether Oct4 regulates stemness of head and neck squamous carcinoma (HNSC) CSCs. Our study showed that ectopic expression of Oct4 promotes tumor growth through cyclin E activation, increases chemoresistance through ABCC6 expression and enhances tumor invasion through slug expression. Also, Oct4 dedifferentiates differentiated HNSC cells to CSC-like cells. Furthermore, Oct4(high) HNSC CSCs have more stem cell-like traits compared with Oct4(low) cells, such as self-renewal, stem cell markers' expression, chemoresistance, invasion capacity and xenograft tumorigeneity in vitro and in vivo. In addition, knockdown of Oct4 led to markedly lower HNSC CSC stemness. Finally, there was a significant correlation between Oct4 expression and survival of 119 HNSC patients. Collectively, these data suggest that Oct4 may be a critical regulator of HNSC CSCs and its targeting may be potentially valuable in the treatment of HNSC CSCs.	[Koo, B. S.; Kim, S. H.] Canc Res Inst, Dept Otolaryngol Head & Neck Surg, Taejon, South Korea; [Lee, S. H.] Sungkyunkwan Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Kangbuk Samsung Hosp, Seoul, South Korea; [Kim, J. M.; Huang, S.] Chungnam Natl Univ, Coll Med, Res Inst Med Sci & Pathol, Taejon, South Korea; [Rho, Y. S.] Ewha Womans Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Seoul, South Korea; [Bae, W. J.] Hallym Univ, Coll Med, Dept Otolaryngol Head & Neck Surg, Seoul, South Korea; [Kang, H. J.; Kim, Y. S.; Moon, J. H.; Lim, Y. C.] Konkuk Univ, Dept Otorhinolaryngol Head & Neck Surg, Res Inst Med Sci, Sch Med, Seoul 143729, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Chungnam National University; Ewha Womans University; Hallym University; Konkuk University; Konkuk University Medical Center	Lim, YC (corresponding author), Konkuk Univ, Dept Otorhinolaryngol Head & Neck Surg, Res Inst Med Sci, Sch Med, 120-1 Neungdong Ro Hwayang Dong, Seoul 143729, South Korea.	yclim69@hanmail.net		KIM, JIN MAN/0000-0003-0905-9730; Koo, Bon Seok/0000-0002-5928-0006	Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [A111700]; National Research Foundation of Korea (NRF) grant - Korea government (MEST) [2012R1A2A2A01046214, 2013R1A2A2A01015281]	Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea; National Research Foundation of Korea (NRF) grant - Korea government (MEST)	This work was supported by a grant of the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (Grant number A111700 to YCL) and by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (Grant number 2012R1A2A2A01046214 to YCL and 2013R1A2A2A01015281 to BSK).	Chang CC, 2008, CANCER RES, V68, P6281, DOI 10.1158/0008-5472.CAN-08-0094; Chen KG, 2012, CLIN CANCER RES, V18, P1863, DOI 10.1158/1078-0432.CCR-11-1590; Chiou SH, 2008, CLIN CANCER RES, V14, P4085, DOI 10.1158/1078-0432.CCR-07-4404; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Ge N, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-94; Gerrard L, 2005, STEM CELLS, V23, P124, DOI 10.1634/stemcells.2004-0102; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Joo KM, 2008, LAB INVEST, V88, P808, DOI 10.1038/labinvest.2008.57; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Jung JW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028068; Kumar SM, 2012, ONCOGENE, V31, P4898, DOI 10.1038/onc.2011.656; Lengner CJ, 2008, CELL CYCLE, V7, P725, DOI 10.4161/cc.7.6.5573; Lim YC, 2011, ORAL ONCOL, V47, P83, DOI 10.1016/j.oraloncology.2010.11.011; Looijenga LHJ, 2003, CANCER RES, V63, P2244; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; Steg AD, 2012, CLIN CANCER RES, V18, P869, DOI 10.1158/1078-0432.CCR-11-2188; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tsai LL, 2011, J ORAL PATHOL MED, V40, P621, DOI 10.1111/j.1600-0714.2011.01015.x; Wang XQ, 2010, HEPATOLOGY, V52, P528, DOI 10.1002/hep.23692; Wiegand S, 2005, CANCER-AM CANCER SOC, V104, P94, DOI 10.1002/cncr.21131; Xie LQ, 2010, ANN SURG ONCOL, V17, P1927, DOI 10.1245/s10434-010-0922-6; Yamano Y, 2010, INT J CANCER, V126, P437, DOI 10.1002/ijc.24704; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yu FG, 2013, LARYNGOSCOPE, V123, P1903, DOI 10.1002/lary.24003	27	81	85	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2317	2324		10.1038/onc.2014.174	http://dx.doi.org/10.1038/onc.2014.174			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	24954502	Bronze			2022-12-17	WOS:000353824800005
J	Zhang, L; Xu, Z; Xu, X; Zhang, B; Wu, H; Wang, M; Zhang, X; Yang, T; Cai, J; Yan, Y; Mao, F; Zhu, W; Shao, Q; Qian, H; Xu, W				Zhang, L.; Xu, Z.; Xu, X.; Zhang, B.; Wu, H.; Wang, M.; Zhang, X.; Yang, T.; Cai, J.; Yan, Y.; Mao, F.; Zhu, W.; Shao, Q.; Qian, H.; Xu, W.			SALL4, a novel marker for human gastric carcinogenesis and metastasis	ONCOGENE			English	Article						SALL4; gastric cancer; metastasis; EMT; stemness	EPITHELIAL-MESENCHYMAL TRANSITION; CANCER STEM-CELLS; EARLY EMBRYONIC-DEVELOPMENT; ACUTE MYELOID-LEUKEMIA; PROSPECTIVE IDENTIFICATION; BREAST-CANCER; GENE; PLURIPOTENCY; EPIDEMIOLOGY; EXPRESSION	SALL4, a zinc-finger transcriptional factor for embryonic stem cell self-renewal and pluripotency, has been suggested to be involved in tumorigenesis. The role of SALL4 in human gastric cancer, however, remains largely unknown. In this study, we demonstrated that SALL4 was aberrantly expressed at both mRNA and protein levels in human gastric cancer tissues, and SALL4 level was highly correlated with lymph node metastasis. Enforced expression of SALL4 enhanced the proliferation and migration of human gastric cancer cells, whereas knockdown of SALL4 by siRNA led to the opposite effects. In addition, SALL4 overexpression promoted the growth and metastasis of gastric xenograft tumor in vivo. SALL4 overexpression induced epithelial-mesenchymal transition (EMT) in gastric cancer cells, with increased expression of Twist1, N-cadherin and decreased expression of E-cadherin. Moreover, SALL4 promoted the acquirement of stemness in gastric cancer cells through the induction of Bmi-1 and Lin28B. Taken together, our findings indicate that SALL4 has oncogenic roles in gastric cancer through the modulation of EMT and cell stemness, suggesting SALL4 as a novel target for human gastric cancer diagnosis and therapy.	[Zhang, L.; Xu, Z.; Xu, X.; Zhang, B.; Wang, M.; Zhang, X.; Yang, T.; Cai, J.; Yan, Y.; Mao, F.; Zhu, W.; Shao, Q.; Qian, H.; Xu, W.] Jiangsu Univ, Sch Med Sci & Lab Med, Zhenjiang 212013, Jiangsu, Peoples R China; [Wu, H.] First Peoples Hosp Lianyungang, Dept Cent Lab, Lianyungang, Peoples R China; [Xu, W.] Jiangsu Univ, Affiliated Hosp, Zhenjiang 212013, Jiangsu, Peoples R China	Jiangsu University; Jiangsu University	Xu, W (corresponding author), Jiangsu Univ, Sch Med Sci & Lab Med, 301 Xuefu Rd, Zhenjiang 212013, Jiangsu, Peoples R China.	lstmmmlst@163.com; icls@ujs.edu.cn	B, Zhang/R-4316-2019; Zhang, Bin/HCP-1386-2022	B, Zhang/0000-0002-2879-379X; Qian, Hui/0000-0002-0098-3196	Major Research Plan of the National Natural Science Foundation of China [91129718]; National Natural Science Foundation of China [81071421]; Natural Science Foundation of the Jiangsu Province [BK2012709]; Jiangsu Province's Project of Scientific and Technological Innovation and Achievements Transformation [BL2012055]; Jiangsu Province's Outstanding Medical Academic Leader and Sci-tech Innovation Team Program [LJ201117]; Jiangsu Province Doctoral Innovation Fund [CXLX12_0678]; Doctoral Program Foundation of State Education Ministry [20113227110011]	Major Research Plan of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of the Jiangsu Province(Natural Science Foundation of Jiangsu Province); Jiangsu Province's Project of Scientific and Technological Innovation and Achievements Transformation; Jiangsu Province's Outstanding Medical Academic Leader and Sci-tech Innovation Team Program; Jiangsu Province Doctoral Innovation Fund; Doctoral Program Foundation of State Education Ministry	This work was supported by the Major Research Plan of the National Natural Science Foundation of China (Grant no. 91129718), the National Natural Science Foundation of China (Grant no. 81071421), the Natural Science Foundation of the Jiangsu Province (Grant no. BK2012709), Jiangsu Province's Project of Scientific and Technological Innovation and Achievements Transformation (Grant no. BL2012055), Jiangsu Province's Outstanding Medical Academic Leader and Sci-tech Innovation Team Program (Grant no. LJ201117), Jiangsu Province Doctoral Innovation Fund (Grant no. CXLX12_0678) and Doctoral Program Foundation of State Education Ministry (Grant no. 20113227110011).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bard JD, 2009, FASEB J, V23, P1405, DOI 10.1096/fj.08-117721; Bjerkvig R, 2005, NAT REV CANCER, V5, P899, DOI 10.1038/nrc1740; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Brenner Hermann, 2009, V472, P467, DOI 10.1007/978-1-60327-492-0_23; Cao DF, 2009, CANCER-AM CANCER SOC, V115, P2640, DOI 10.1002/cncr.24308; Chen Z, 2009, J SURG ONCOL, V99, P414, DOI 10.1002/jso.21270; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Crew KD, 2006, WORLD J GASTROENTERO, V12, P354, DOI 10.3748/wjg.v12.i3.354; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Desai Anant M, 2004, Gastric Cancer, V7, P196, DOI 10.1007/s10120-004-0289-0; Elling U, 2006, P NATL ACAD SCI USA, V103, P16319, DOI 10.1073/pnas.0607884103; Giraud AS, 2012, EXPERT OPIN THER TAR, V16, P889, DOI 10.1517/14728222.2012.709238; Kanda N, 2004, ONCOGENE, V23, P4921, DOI 10.1038/sj.onc.1207606; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kobayashi D, 2011, INT J ONCOL, V38, P933, DOI 10.3892/ijo.2011.929; Kopper L, 2004, PATHOL ONCOL RES, V10, P69, DOI 10.1007/BF02893458; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lim CY, 2008, CELL STEM CELL, V3, P543, DOI 10.1016/j.stem.2008.08.004; Lin T, 2012, MED ONCOL, V29, P878, DOI 10.1007/s12032-011-9860-9; Lu JY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005577; Ma YP, 2006, BLOOD, V108, P2726, DOI 10.1182/blood-2006-02-001594; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Matsuoka J, 2012, J SURG RES, V174, P130, DOI 10.1016/j.jss.2010.11.903; Oikawa T, 2013, HEPATOLOGY, V57, P1469, DOI 10.1002/hep.26159; Palafox M, 2012, CANCER RES, V72, P2879, DOI 10.1158/0008-5472.CAN-12-0044; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Takaishi S, 2008, J CLIN ONCOL, V26, P2876, DOI 10.1200/JCO.2007.15.2603; Ushiku T, 2010, AM J SURG PATHOL, V34, P533, DOI 10.1097/PAS.0b013e3181d1dcdd; Voon DCC, 2012, STEM CELLS, V30, P2088, DOI 10.1002/stem.1183; Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284; Warren M, 2007, GENESIS, V45, P51, DOI 10.1002/dvg.20264; Wu Q, 2006, J BIOL CHEM, V281, P24090, DOI 10.1074/jbc.C600122200; Yang JC, 2008, BLOOD, V112, P805, DOI 10.1182/blood-2007-11-126326; Yang JC, 2007, P NATL ACAD SCI USA, V104, P10494, DOI 10.1073/pnas.0704001104; Yang JC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010766; Yang ZF, 2008, HEPATOLOGY, V47, P919, DOI 10.1002/hep.22082; Zhang JQ, 2006, NAT CELL BIOL, V8, P1114, DOI 10.1038/ncb1481; Zhang XW, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-40; Zhou Q, 2007, P NATL ACAD SCI USA, V104, P16438, DOI 10.1073/pnas.0701014104	40	81	92	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2014	33	48					5491	5500		10.1038/onc.2013.495	http://dx.doi.org/10.1038/onc.2013.495			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZO	24276240				2022-12-17	WOS:000346087900002
J	Dey, P; Strom, A; Gustafsson, JA				Dey, P.; Stroem, A.; Gustafsson, J-A			Estrogen receptor beta upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer	ONCOGENE			English	Article						ER beta; apoptosis; p53; FOXO3a; PUMA	FORKHEAD TRANSCRIPTION FACTOR; HUMAN BREAST-CANCER; ER-BETA; CELL-PROLIFERATION; OPPOSING ROLES; PATHWAY; 5-ALPHA-ANDROSTANE-3-BETA,17-BETA-DIOL; EXPRESSION; GROWTH; MICE	Estrogen receptor beta (ER beta) is emerging as a critical factor in understanding prostate cancer biology. Although reduced in prostate cancer above Gleason grade 3, ER beta is a potential drug target at the initial stage of the disease. In human prostate cancer cells, we found that ERb causes apoptosis by increasing the expression of pro-apoptotic factor p53-upregulated modulator of apoptosis (PUMA), independent of p53, but dependent on the forkhead transcription factor class-O family member, FOXO3a. FOXO3a has previously been shown to induce PUMA after growth factor withdrawal and inhibition of the Akt pathway. Surprisingly, the phosphorylation of FOXO3a remained unchanged, while the mRNA and total protein levels of FOXO3a were increased in response to ER beta expression or treatment of PC3, 22Rv1 and LNCaP cells with the ER beta-specific ligands 3 beta-Adiol (5 alpha-androstane-3 beta, 17 beta-diol), DPN (diarylpropionitrile) or 8 beta-VE2 (8-vinylestra-1,3,5 (10)-triene-3,17 beta-diol). Knockdown of FOXO3a or ER beta expression abolished the increase of PUMA in response to 3 beta-Adiol in LNCaP and PC3 cells, suggesting that FOXO3a mediates the apoptotic effect of 3 beta-Adiol-activated ER beta. Moreover, the ventral prostate of ER beta-/- mice had decreased expression of FOXO3a and PUMA compared with the ERb-/- mice, indicating a relationship between ER beta and FOXO3a expression. The regulation of FOXO3a by ER beta in normal basal epithelial cells indicates a function of ER beta in cell differentiation and maintenance of cells in a quiescent state. In addition, the expression of ER beta, FOXO3a and PUMA is comparable and higher in benign prostatic hyperplasia than in prostate cancer Gleason grade 4 or higher, where there is substantial loss of ER beta, FOXO3a and PUMA. We conclude that ER beta induces apoptosis of prostate cancer cells by increasing transcription of FOXO3a, leading to an increase of PUMA and subsequent triggering of apoptosis via the intrinsic pathway involving caspase-9. Furthermore, we conclude that ligands specifically activating ER beta could be useful pharmaceuticals in the treatment of prostate cancer.	[Dey, P.; Stroem, A.; Gustafsson, J-A] Univ Houston, Dept Biol & Biochem, Ctr Nucl Receptors & Cell Signaling, Houston, TX 77204 USA; [Gustafsson, J-A] Karolinska Inst, Dept Biosci & Nutr, Huddinge, Sweden	University of Houston System; University of Houston; Karolinska Institutet	Strom, A (corresponding author), Univ Houston, Dept Biol & Biochem, Ctr Nucl Receptors & Cell Signaling, 3605 Cullen Blvd,Sci & Engn Res Ctr Bldg 545, Houston, TX 77204 USA.	amstrom@uh.edu			Cancer Prevention and Research Institute of Texas (CPRIT) [HIRP100680, RP110444]; Texas Emerging Technology Fund [300-9-1958]; Robert A. Welch Foundation [E-0004]; Swedish Cancer Fund	Cancer Prevention and Research Institute of Texas (CPRIT); Texas Emerging Technology Fund; Robert A. Welch Foundation(The Welch Foundation); Swedish Cancer Fund	This work was supported by The Cancer Prevention and Research Institute of Texas (CPRIT) grants HIRP100680 and RP110444, the Texas Emerging Technology Fund under Agreement number 300-9-1958, the Robert A. Welch Foundation (E-0004) and the Swedish Cancer Fund. We are grateful to Linda Waage, Department of Urology at Danderyd Hospital, Stockholm, Sweden, for providing us the human prostate cancer samples, and Ulf Bergerheim for Gleason grading the tissue samples.	Bossard C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044787; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cornforth AN, 2008, ONCOGENE, V27, P4422, DOI 10.1038/onc.2008.80; Cvoro A, 2006, MOL CELL, V21, P555, DOI 10.1016/j.molcel.2006.01.014; Cvoro A, 2007, ENDOCRINOLOGY, V148, P538, DOI 10.1210/en.2006-0803; Dey P, 2012, MOL ENDOCRINOL, V26, P1991, DOI 10.1210/me.2012.1227; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dondi D, 2010, ENDOCR-RELAT CANCER, V17, P731, DOI 10.1677/ERC-10-0032; Ellem SJ, 2009, ANN NY ACAD SCI, V1155, P174, DOI 10.1111/j.1749-6632.2009.04360.x; Giroux V, 2008, INT J CANCER, V123, P303, DOI 10.1002/ijc.23532; Giroux V, 2011, MOL CARCINOGEN, V50, P359, DOI 10.1002/mc.20719; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Hartman J, 2004, ONCOGENE, V23, P8826, DOI 10.1038/sj.onc.1208139; Hartman J, 2006, CANCER RES, V66, P11207, DOI 10.1158/0008-5472.CAN-06-0017; Hartman J, 2009, CANCER RES, V69, P6100, DOI 10.1158/0008-5472.CAN-09-0506; Helguero LA, 2006, ENDOCRINOLOGY, V147, P3249, DOI 10.1210/en.2005-1651; Hodges-Gallagher L, 2008, BREAST CANCER RES TR, V109, P241, DOI 10.1007/s10549-007-9640-6; Hussain S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040732; Ji Q, 2005, MOL CELL ENDOCRINOL, V229, P103, DOI 10.1016/j.mce.2004.08.012; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Leung YK, 2010, ENDOCR-RELAT CANCER, V17, P675, DOI 10.1677/ERC-09-0294; Maggiolini M, 2004, J MOL ENDOCRINOL, V32, P777, DOI 10.1677/jme.0.0320777; Mak P, 2010, CANCER CELL, V17, P319, DOI 10.1016/j.ccr.2010.02.030; McPherson SJ, 2010, P NATL ACAD SCI USA, V107, P3123, DOI 10.1073/pnas.0905524107; Muthusamy S, 2011, P NATL ACAD SCI USA, V108, P20090, DOI 10.1073/pnas.1117772108; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nanni S, 2009, J CLIN INVEST, V119, P1093, DOI 10.1172/JCI35079; Oliveira AG, 2007, STEROIDS, V72, P914, DOI 10.1016/j.steroids.2007.08.001; Olsson M, 2007, PROSTATE, V67, P1439, DOI 10.1002/pros.20630; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Roberts CG, 2011, ONCOGENE, V30, P3186, DOI 10.1038/onc.2011.36; Saijo K, 2011, CELL, V145, P584, DOI 10.1016/j.cell.2011.03.050; Saleiro D, 2010, CANCER PREV RES, V3, P1198, DOI 10.1158/1940-6207.CAPR-10-0044; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Slusarz A, 2012, ENDOCRINOLOGY, V153, P4160, DOI 10.1210/en.2012-1030; Strom A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Weihua Z, 2002, P NATL ACAD SCI USA, V99, P13589, DOI 10.1073/pnas.162477299; Yamamoto M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016841; You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zou YY, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1872	43	81	88	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2014	33	33					4213	4225		10.1038/onc.2013.384	http://dx.doi.org/10.1038/onc.2013.384			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MB	24077289				2022-12-17	WOS:000341155800003
J	Duijf, PHG; Benezra, R				Duijf, P. H. G.; Benezra, R.			The cancer biology of whole-chromosome instability	ONCOGENE			English	Review						whole-chromosome instability; aneuploidy; cancer biology; oncogene-induced mitotic stress; non-cell autonomous; tumor microenvironment	CELL-CYCLE PROGRESSION; AGING-ASSOCIATED PHENOTYPES; EARLY EMBRYONIC-DEVELOPMENT; TUMOR-SPECIFIC ANTIGENS; IN-SITU HYBRIDIZATION; DNA-DAMAGE; CENTROSOME AMPLIFICATION; GENOMIC INSTABILITY; SPINDLE ABNORMALITIES; MITOTIC CHECKPOINT	One form of chromosome instability (CIN), the recurrent missegregation of whole chromosomes during cell division (W-CIN), leads to aneuploidy. Although W-CIN is a hallmark of most cancers, mutations in genes involved in chromosome segregation are exceedingly rare. We discuss an oncogene-induced mitotic stress model that provides a mechanistic framework to explain this paradox. We also review the tumor-promoting and tumor-suppressing consequences of W-CIN. Importantly, we do this in the context of cancer as a complex systemic disease, rather than as a simple linearly progressing disorder that arises from a single abnormal cell population. Accordingly, we highlight the often neglected effects of W-CIN on key non-cell-autonomous entities, such as the immune system and the tumor microenvironment. Distinct tissue-specific susceptibilities to W-CIN-induced tumorigenesis and the clinical implications of W-CIN are also discussed.	[Duijf, P. H. G.; Benezra, R.] Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, New York, NY 10021 USA; [Duijf, P. H. G.] Univ Queensland, Diamantina Inst, Princess Alexandra Hosp, Brisbane, Qld 4102, Australia	Memorial Sloan Kettering Cancer Center; University of Queensland	Duijf, PHG (corresponding author), Univ Queensland, Diamantina Inst, Princess Alexandra Hosp, Ipswich Rd, Brisbane, Qld 4102, Australia.	p.duijf@uq.edu.au; r-benezra@ski.mskcc.org	Duijf, Pascal H.G./E-7110-2012	Duijf, Pascal H.G./0000-0001-8646-9843	Young Investigator Award from Alex's Lemonade Stand Foundation; Breast Cancer Research Foundation	Young Investigator Award from Alex's Lemonade Stand Foundation; Breast Cancer Research Foundation	We thank Peter J Cook, Zvi Granot, Rozario I Thomas, Daniel Marks and Rocio Sotillo for critical reading of the manuscript. PHGD is supported by a Young Investigator Award from Alex's Lemonade Stand Foundation and RB by the Breast Cancer Research Foundation.	Aivaliotis IL, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/536761; Guerrero AA, 2010, P NATL ACAD SCI USA, V107, P4159, DOI 10.1073/pnas.0912143106; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Babu JR, 2003, J CELL BIOL, V160, P341, DOI 10.1083/jcb.200211048; Baker DJ, 2004, NAT GENET, V36, P744, DOI 10.1038/ng1382; Baker DJ, 2006, J CELL BIOL, V172, P529, DOI 10.1083/jcb.200507081; Barboza JA, 2006, P NATL ACAD SCI USA, V103, P19842, DOI 10.1073/pnas.0606343104; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bedard PL, 2010, NAT REV CLIN ONCOL, V7, P22, DOI 10.1038/nrclinonc.2009.186; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bhattacharya A, 2011, CLIN CANCER RES, V17, P7024, DOI 10.1158/1078-0432.CCR-11-1944; Bitomsky N, 2009, FEBS J, V276, P6074, DOI 10.1111/j.1742-4658.2009.07331.x; Burds AA, 2005, P NATL ACAD SCI USA, V102, P11296, DOI 10.1073/pnas.0505053102; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Celton-Morizur S, 2010, ADV EXP MED BIOL, V676, P123; Chang CC, 2006, J BIOL CHEM, V281, P18763, DOI 10.1074/jbc.M511525200; Chesnokova V, 2005, MOL ENDOCRINOL, V19, P2371, DOI 10.1210/me.2005-0137; Choi CM, 2009, LUNG CANCER, V64, P66, DOI 10.1016/j.lungcan.2008.07.016; Chulada PC, 2000, CANCER RES, V60, P4705; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; Coschi CH, 2010, GENE DEV, V24, P1351, DOI 10.1101/gad.1917610; Crasta K, 2012, NATURE, V482, P53, DOI 10.1038/nature10802; Cui YP, 2010, CANCER RES, V70, P675, DOI 10.1158/0008-5472.CAN-09-1491; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Deng YB, 2008, NAT REV CANCER, V8, P450, DOI 10.1038/nrc2393; Diaz-Rodriguez E, 2008, P NATL ACAD SCI USA, V105, P16719, DOI 10.1073/pnas.0803504105; Duensing A, 2010, ADV EXP MED BIOL, V676, P93; Duesberg P, 2000, P NATL ACAD SCI USA, V97, P14295, DOI 10.1073/pnas.97.26.14295; Duijf PH, INT J CANCER, DOI [10.1002/ijc.27924, DOI 10.1002/IJC.27924)]; Duncan AW, 2010, NATURE, V467, P707, DOI 10.1038/nature09414; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; DuPage M, 2012, NATURE, V482, P405, DOI 10.1038/nature10803; Ehlers JP, 2008, CLIN CANCER RES, V14, P115, DOI 10.1158/1078-0432.CCR-07-1825; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Galluzzi L, 2011, INT REV CEL MOL BIO, V289, P1, DOI 10.1016/B978-0-12-386039-2.00001-8; Garcia-Higuera I, 2008, NAT CELL BIOL, V10, P802, DOI 10.1038/ncb1742; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Gogvadze V, 2008, TRENDS CELL BIOL, V18, P165, DOI 10.1016/j.tcb.2008.01.006; Gordon DJ, 2012, NAT REV GENET, V13, P189, DOI 10.1038/nrg3123; Granot Z, 2011, CANCER CELL, V20, P300, DOI 10.1016/j.ccr.2011.08.012; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gutenberg A, 2010, CANCER GENET CYTOGEN, V198, P47, DOI 10.1016/j.cancergencyto.2009.12.006; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hasle H, 2000, LANCET, V355, P165, DOI 10.1016/S0140-6736(99)05264-2; HASLE H, 1995, BRIT J CANCER, V71, P416, DOI 10.1038/bjc.1995.85; Hayashi MT, 2012, NAT STRUCT MOL BIOL, V19, P387, DOI 10.1038/nsmb.2245; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Iwanaga Y, 2007, CANCER RES, V67, P160, DOI 10.1158/0008-5472.CAN-06-3326; Janisson-Dargaud D, 2008, J CUTAN PATHOL, V35, P916, DOI 10.1111/j.1600-0560.2007.00935.x; Janssen A, 2011, SCIENCE, V333, P1895, DOI 10.1126/science.1210214; Janssen A, 2009, P NATL ACAD SCI USA, V106, P19108, DOI 10.1073/pnas.0904343106; Jeganathan K, 2007, J CELL BIOL, V179, P255, DOI 10.1083/jcb.200706015; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kabeche L, 2012, CURR BIOL, V22, P638, DOI 10.1016/j.cub.2012.02.030; Kamata T, 2010, CANCER RES, V70, P8475, DOI 10.1158/0008-5472.CAN-10-0603; Karna P, 2011, CELL DEATH DIFFER, V18, P632, DOI 10.1038/cdd.2010.133; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811; Ko MA, 2005, NAT GENET, V37, P883, DOI 10.1038/ng1605; Kreike B, 2009, CLIN CANCER RES, V15, P4181, DOI 10.1158/1078-0432.CCR-08-2644; Kwon M, 2008, GENE DEV, V22, P2189, DOI 10.1101/gad.1700908; Lagarde P, 2012, CLIN CANCER RES, V18, P826, DOI 10.1158/1078-0432.CCR-11-1610; Lakovschek IC, 2011, AM J MED GENET A, V155A, P2626, DOI 10.1002/ajmg.a.34284; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lewis CE, 2007, CANCER RES, V67, P8429, DOI 10.1158/0008-5472.CAN-07-1684; Li M, 2010, P NATL ACAD SCI USA, V107, P14188, DOI 10.1073/pnas.1005960107; Li M, 2009, J CELL BIOL, V185, P983, DOI 10.1083/jcb.200904020; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Liu PF, 2011, CELL, V146, P888, DOI 10.1016/j.cell.2011.07.042; Loeb LA, 2001, CANCER RES, V61, P3230; Lonkar P, 2011, INT J CANCER, V128, P1999, DOI 10.1002/ijc.25815; Lu LY, 2008, J BIOL CHEM, V283, P31785, DOI 10.1074/jbc.M805880200; Lu LY, 2008, MOL CELL BIOL, V28, P6870, DOI 10.1128/MCB.00392-08; Malumbres M, 2011, CANCER CELL, V19, P691, DOI 10.1016/j.ccr.2011.05.023; Manchado E, 2012, CELL DEATH DIFFER, V19, P369, DOI 10.1038/cdd.2011.197; Manning AL, 2010, GENE DEV, V24, P1364, DOI 10.1101/gad.1917310; Mason SD, 2011, TRENDS CELL BIOL, V21, P228, DOI 10.1016/j.tcb.2010.12.002; McClelland SE, 2009, CELL CYCLE, V8, P3262, DOI 10.4161/cc.8.20.9690; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Mikule K, 2007, NAT CELL BIOL, V9, P160, DOI 10.1038/ncb1529; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; Mukherjee M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022167; Nelsen CJ, 2005, J BIOL CHEM, V280, P768, DOI 10.1074/jbc.M407105200; Nguyen HG, 2009, FASEB J, V23, P2741, DOI 10.1096/fj.09-130963; Oikawa T, 2005, MOL CELL BIOL, V25, P4046, DOI 10.1128/MCB.25.10.4046-4061.2005; Oliveira RA, 2010, BIOCHEM SOC T, V38, P1639, DOI 10.1042/BST0381639; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Ostrand-Rosenberg S, 2008, CURR OPIN GENET DEV, V18, P11, DOI 10.1016/j.gde.2007.12.007; Pavelka N, 2010, NATURE, V468, P321, DOI 10.1038/nature09529; Pinto AE, 2012, CLIN ENDOCRINOL, V77, P302, DOI 10.1111/j.1365-2265.2012.04363.x; Png KJ, 2012, NATURE, V481, P190, DOI 10.1038/nature10661; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Puente XS, 2011, NATURE, V475, P101, DOI 10.1038/nature10113; Rebacz B, 2007, CANCER RES, V67, P6342, DOI 10.1158/0008-5472.CAN-07-0663; Reinhardt HC, 2012, TRENDS GENET, V28, P128, DOI 10.1016/j.tig.2011.12.002; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ricke RM, 2008, TRENDS GENET, V24, P457, DOI 10.1016/j.tig.2008.07.002; Ricke RM, 2011, J CELL BIOL, V193, P1049, DOI 10.1083/jcb.201012035; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Saavedra HI, 1999, J BIOL CHEM, V274, P38083, DOI 10.1074/jbc.274.53.38083; SANDA MG, 1995, J NATL CANCER I, V87, P280, DOI 10.1093/jnci/87.4.280; Satge D, 1998, CANCER RES, V58, P448; Sato H, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-182; Schardt JA, 2005, CANCER CELL, V8, P227, DOI 10.1016/j.ccr.2005.08.003; Schliekelman M, 2009, CANCER RES, V69, P45, DOI 10.1158/0008-5472.CAN-07-6330; Schmidt-Kittler O, 2003, P NATL ACAD SCI USA, V100, P7737, DOI 10.1073/pnas.1331931100; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Schvartzman JM, 2011, CANCER CELL, V19, P701, DOI 10.1016/j.ccr.2011.04.017; Schvartzman JM, 2010, NAT REV CANCER, V10, P102, DOI 10.1038/nrc2781; Seremet T, 2011, CANCER J, V17, P325, DOI 10.1097/PPO.0b013e3182326004; Sheltzer JM, 2011, SCIENCE, V333, P1026, DOI 10.1126/science.1206412; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Skirnisdottir I, 2001, INT J ONCOL, V19, P1295; Smid M, 2011, BREAST CANCER RES TR, V128, P23, DOI 10.1007/s10549-010-1026-5; Solomon DA, 2011, SCIENCE, V333, P1039, DOI 10.1126/science.1203619; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Sotillo R, 2010, NATURE, V464, P436, DOI 10.1038/nature08803; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Stoecklein NH, 2008, CANCER CELL, V13, P441, DOI 10.1016/j.ccr.2008.04.005; Susini T, 2011, INT J GYNECOL CANCER, V21, P678, DOI 10.1097/IGC.0b013e3182126f85; Swanton C, 2009, P NATL ACAD SCI USA, V106, P8671, DOI 10.1073/pnas.0811835106; Swerdlow AJ, 2005, J NATL CANCER I, V97, P1204, DOI 10.1093/jnci/dji240; Tang YC, 2011, CELL, V144, P499, DOI 10.1016/j.cell.2011.01.017; Terrano DT, 2010, MOL CELL BIOL, V30, P640, DOI 10.1128/MCB.00882-09; Thompson SL, 2010, CURR BIOL, V20, pR285, DOI 10.1016/j.cub.2010.01.034; Thompson SL, 2010, J CELL BIOL, V188, P369, DOI 10.1083/jcb.200905057; Torres EM, 2007, SCIENCE, V317, P916, DOI 10.1126/science.1142210; Torres EM, 2010, CELL, V143, P71, DOI 10.1016/j.cell.2010.08.038; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47; van Harn T, 2010, GENE DEV, V24, P1377, DOI 10.1101/gad.580710; van Ree JH, 2010, J CELL BIOL, V188, P83, DOI 10.1083/jcb.200906147; Visconti R, 2009, IDRUGS, V12, P240; Walther A, 2008, GUT, V57, P941, DOI 10.1136/gut.2007.135004; Wang ZY, 2001, MOL ENDOCRINOL, V15, P1870, DOI 10.1210/me.15.11.1870; Warth A, 2009, EXP MOL MED, V41, P349, DOI 10.3858/emm.2009.41.5.039; Weaver BAA, 2007, CANCER CELL, V11, P25, DOI 10.1016/j.ccr.2006.12.003; Weckermann D, 2009, J CLIN ONCOL, V27, P1549, DOI 10.1200/JCO.2008.17.0563; White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262; Williams BR, 2008, SCIENCE, V322, P703, DOI 10.1126/science.1160058; Wu GK, 2008, CANCER RES, V68, P8393, DOI 10.1158/0008-5472.CAN-08-1915; Yamada HY, 2012, CELL CYCLE, V11, P479, DOI 10.4161/cc.11.3.18994; Yang QH, 2002, LANCET, V359, P1019, DOI 10.1016/S0140-6736(02)08092-3; Zhang D, 2008, ONCOGENE, V27, P4305, DOI 10.1038/onc.2008.76; Zheng L, 2007, NAT MED, V13, P812, DOI 10.1038/nm1599; Zhou YL, 2003, J BIOL CHEM, V278, P462, DOI 10.1074/jbc.M203793200	155	81	82	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2013	32	40					4727	4736		10.1038/onc.2012.616	http://dx.doi.org/10.1038/onc.2012.616			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23318433				2022-12-17	WOS:000325274700001
J	Ferreira, LMR; Hebrant, A; Dumont, JE				Ferreira, L. M. R.; Hebrant, A.; Dumont, J. E.			Metabolic reprogramming of the tumor	ONCOGENE			English	Review						cancer; metabolism; microenvironment; evolution	ACTIVATED PROTEIN-KINASE; EPITHELIAL-MESENCHYMAL TRANSITIONS; ENDOTHELIAL GROWTH-FACTOR; BREAST-CANCER CELLS; ATP CITRATE LYASE; MESSENGER-RNA; AEROBIC GLYCOLYSIS; LACTIC-ACID; STEM-CELLS; OXIDATIVE-PHOSPHORYLATION	Cancer is classically considered as a genetic and, more recently, epigenetic multistep disease. Despite seminal studies in the 1920s by Warburg showing a characteristic metabolic pattern for tumors, cancer bioenergetics has often been relegated to the backwaters of cancer biology. This review aims to provide a historical account on cancer metabolism research, and to try to integrate and systematize the metabolic strategies in which cancer cells engage to overcome selective pressures during their inception and evolution. Implications of this renovated view on some common concepts and in therapeutics are also discussed. Oncogene (2012) 31, 3999-4011; doi:10.1038/onc.2011.576; published online 9 January 2012	[Ferreira, L. M. R.] Univ Coimbra, Fac Sci & Technol, Dept Life Sci, P-3001401 Coimbra, Portugal; [Hebrant, A.; Dumont, J. E.] Univ Libre Bruxelles, Sch Med, Inst Interdisciplinary Res IRIBHM, B-1070 Brussels, Belgium	Universidade de Coimbra; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Ferreira, LMR (corresponding author), Univ Coimbra, Fac Sci & Technol, Dept Life Sci, Rua Estudos, P-3001401 Coimbra, Portugal.	leonardo_m_r_ferreira@yahoo.com; jedumont@ulb.ac.be	Ferreira, Leonardo/J-7984-2019	Ferreira, Leonardo/0000-0003-2491-9866				Ahmad IM, 2005, J BIOL CHEM, V280, P4254, DOI 10.1074/jbc.M411662200; Akakura N, 2001, CANCER RES, V61, P6548; Alexander S, 2008, HISTOCHEM CELL BIOL, V130, P1147, DOI 10.1007/s00418-008-0529-1; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; ATKINSON DE, 1968, BIOCHEMISTRY-US, V7, P4030, DOI 10.1021/bi00851a033; Bauer DE, 2005, ONCOGENE, V24, P6314, DOI 10.1038/sj.onc.1208773; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Berardi MJ, 2011, CURR OPIN GENET DEV, V21, P59, DOI 10.1016/j.gde.2010.10.001; Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Berx G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003129; Bonora E, 2006, CANCER RES, V66, P6087, DOI 10.1158/0008-5472.CAN-06-0171; Boveri T., 1914, FRAGE ENTSTEHUNG MAL; Boyland E, 1935, BIOCHEM J, V30, P224; Brahimi-Horn MC, 2011, CURR OPIN GENET DEV, V21, P67, DOI 10.1016/j.gde.2010.10.006; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bucay AH, 2009, MED HYPOTHESES, V73, P271, DOI 10.1016/j.mehy.2009.03.018; BURK D, 1956, SCIENCE, V124, P270; Cai ZQ, 2005, CIRC RES, V97, P1351, DOI 10.1161/01.RES.0000195656.52760.30; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Cannito S, 2010, ANTIOXID REDOX SIGN, V12, P1383, DOI 10.1089/ars.2009.2737; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Carrel A, 1921, J EXP MED, V34, P599, DOI 10.1084/jem.34.6.599; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; Cori CF, 1925, J BIOL CHEM, V64, P11; Cori CF, 1925, J BIOL CHEM, V65, P397; Cramer W, 1926, BMJ-BRIT MED J, V1926, P175; D'Errico I, 2011, P NATL ACAD SCI USA, V108, P6603, DOI 10.1073/pnas.1016354108; Dang CV, 2008, NAT REV CANCER, V8, P51, DOI 10.1038/nrc2274; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; De Bari L, 2010, INT J ONCOL, V37, P1607, DOI 10.3892/ijo_00000815; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; DROGE W, 1992, IMMUNOL TODAY, V13, P211, DOI 10.1016/0167-5699(92)90156-2; ECK HP, 1989, J CANCER RES CLIN, V115, P571, DOI 10.1007/BF00391360; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Eng CH, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000911; ERECINSKA M, 1995, J NEUROCHEM, V65, P2765; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Feng ZH, 2010, TRENDS CELL BIOL, V20, P427, DOI 10.1016/j.tcb.2010.03.004; Ferreira LMR, 2010, EXP MOL PATHOL, V89, P372, DOI 10.1016/j.yexmp.2010.08.006; Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; Floor S, 2011, ONCOGENE, V30, P4609, DOI 10.1038/onc.2011.184; Fogal V, 2010, MOL CELL BIOL, V30, P1303, DOI 10.1128/MCB.01101-09; Folkman J, 2003, CURR MOL MED, V3, P643, DOI 10.2174/1566524033479465; Friedl P, 2009, NAT REV MOL CELL BIO, V10, P445, DOI 10.1038/nrm2720; Funes JM, 2007, P NATL ACAD SCI USA, V104, P6223, DOI 10.1073/pnas.0700690104; Gallagher SM, 2007, CANCER RES, V67, P4182, DOI 10.1158/0008-5472.CAN-06-3184; Gao P, 2007, CANCER CELL, V12, P230, DOI 10.1016/j.ccr.2007.08.004; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Geschwind JFH, 2002, CANCER RES, V62, P3909; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Gil J, 2005, CANCER RES, V65, P2179, DOI 10.1158/0008-5472.CAN-03-4030; Gladden LB, 2004, J PHYSIOL-LONDON, V558, P5, DOI 10.1113/jphysiol.2003.058701; GOLDBLATT H, 1953, J EXP MED, V97, P525, DOI 10.1084/jem.97.4.525; GUPPY M, 1993, EUR J BIOCHEM, V212, P95, DOI 10.1111/j.1432-1033.1993.tb17637.x; Guppy M, 2002, BIOCHEM BIOPH RES CO, V299, P676, DOI 10.1016/S0006-291X(02)02710-9; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hammond EM, 2005, BIOCHEM BIOPH RES CO, V331, P718, DOI 10.1016/j.bbrc.2005.03.154; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hansemann D., 1890, ARCH PATHOL ANAT PH, V119, P299, DOI DOI 10.1007/BF01882039; Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008; HOLLEY RW, 1974, P NATL ACAD SCI USA, V71, P2942, DOI 10.1073/pnas.71.8.2942; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hu S, 2011, CELL METAB, V14, P131, DOI 10.1016/j.cmet.2011.04.012; HUEBNER RJ, 1969, P NATL ACAD SCI USA, V64, P1087, DOI 10.1073/pnas.64.3.1087; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Imai T, 2003, AM J PATHOL, V163, P1437, DOI 10.1016/S0002-9440(10)63501-8; Isidoro A, 2004, BIOCHEM J, V378, P17, DOI 10.1042/BJ20031541; Johnston LA, 2009, SCIENCE, V324, P1679, DOI 10.1126/science.1163862; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kiebish MA, 2008, J LIPID RES, V49, P2545, DOI 10.1194/jlr.M800319-JLR200; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07; Kim JW, 2004, MOL CELL BIOL, V24, P5923, DOI 10.1128/MCB.24.13.5923-5936.2004; King A, 2006, ONCOGENE, V25, P4675, DOI 10.1038/sj.onc.1209594; Klimova T, 2008, CELL DEATH DIFFER, V15, P660, DOI 10.1038/sj.cdd.4402307; KNOX WE, 1969, CANCER RES, V29, P669; KNOX WE, 1967, CANCER RES, V27, P1456; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kondoh H, 2005, CANCER RES, V65, P177; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Koukourakis MI, 2006, CANCER RES, V66, P632, DOI 10.1158/0008-5472.CAN-05-3260; KREBS H. A., 1937, Enzymologia, V4, P148; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Lardner A, 2001, J LEUKOCYTE BIOL, V69, P522; Lebedeva MA, 2009, BBA-BIOENERGETICS, V1787, P328, DOI 10.1016/j.bbabio.2009.01.004; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Lin CM, 1999, NUTRITION, V15, P687, DOI 10.1016/S0899-9007(99)00153-7; LOEFFLER DA, 1992, BRIT J CANCER, V66, P619, DOI 10.1038/bjc.1992.326; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Luo J, 2009, CELL SCI REV, V6, P49; Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054; Lynen F, 1942, NATURWISSENSCHAFTEN, V30, P398, DOI 10.1007/BF01475305; Madsen CD, 2010, DEV CELL, V19, P13, DOI 10.1016/j.devcel.2010.06.013; Mandriota SJ, 1998, CIRC RES, V83, P852, DOI 10.1161/01.RES.83.8.852; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; MartinezZaguilan R, 1996, CLIN EXP METASTAS, V14, P176, DOI 10.1007/BF00121214; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677; Miles FL, 2008, CLIN EXP METASTAS, V25, P305, DOI 10.1007/s10585-007-9098-2; Milovanova TN, 2008, MOL CELL BIOL, V28, P6248, DOI 10.1128/MCB.00795-08; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; Miyamoto S, 2008, CELL DEATH DIFFER, V15, P521, DOI 10.1038/sj.cdd.4402285; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Newberne PM, 2002, TOXICOL SCI, V67, P1; Oakhill JS, 2011, SCIENCE, V332, P1433, DOI 10.1126/science.1200094; Okoshi R, 2008, J BIOL CHEM, V283, P3979, DOI 10.1074/jbc.M705232200; Oliva CR, 2010, J BIOL CHEM, V285, P39759, DOI 10.1074/jbc.M110.147504; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Pasteur L, 1876, CR HEBD ACAD SCI, V52, P1260; Pauwels EKJ, 2000, J CANCER RES CLIN, V126, P549, DOI 10.1007/PL00008465; Pinner S, 2009, CANCER RES, V69, P7969, DOI 10.1158/0008-5472.CAN-09-0781; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; RACKER E, 1981, SCIENCE, V213, P303, DOI 10.1126/science.6264596; Ralph SJ, 2010, MOL ASPECTS MED, V31, P29, DOI 10.1016/j.mam.2009.12.006; Ramos-Montoya A, 2006, INT J CANCER, V119, P2733, DOI 10.1002/ijc.22227; Ravi R, 2000, GENE DEV, V14, P34; REMPEL A, 1994, BBA-GENE STRUCT EXPR, V1219, P660, DOI 10.1016/0167-4781(94)90225-9; Reshkin SJ, 2000, FASEB J, V14, P2185, DOI 10.1096/fj.00-0029com; Rischin D, 2005, J CLIN ONCOL, V23, P79, DOI 10.1200/JCO.2005.01.072; Rischin D, 2010, J CLIN ONCOL, V28, P2989, DOI 10.1200/JCO.2009.27.4449; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Ronzoni E, 1936, J BIOL CHEM, V115, P749; Samudio I, 2009, CANCER RES, V69, P2163, DOI 10.1158/0008-5472.CAN-08-3722; Santamaria G, 2006, CARCINOGENESIS, V27, P925, DOI 10.1093/carcin/bgi315; Schulz TJ, 2006, J BIOL CHEM, V281, P977, DOI 10.1074/jbc.M511064200; SCHUMAN VL, 1982, INT J RADIAT ONCOL, V8, P589, DOI 10.1016/0360-3016(82)90690-3; Schwartzenberg-Bar-Yoseph F, 2004, CANCER RES, V64, P2627, DOI 10.1158/0008-5472.CAN-03-0846; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Semenza GL, 2009, SEMIN CANCER BIOL, V19, P12, DOI 10.1016/j.semcancer.2008.11.009; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Shin YK, 2005, CANCER RES, V65, P3162, DOI 10.1158/0008-5472.CAN-04-3300; SONG CW, 1978, BRIT J CANCER, V37, P136; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; STEHELIN D, 1976, J MOL BIOL, V101, P349, DOI 10.1016/0022-2836(76)90152-2; Stern R, 2002, EXP CELL RES, V276, P24, DOI 10.1006/excr.2002.5508; Stewart TJ, 2008, ONCOGENE, V27, P5894, DOI 10.1038/onc.2008.268; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Thangaraju M, 2006, CANCER RES, V66, P11560, DOI 10.1158/0008-5472.CAN-06-1950; Thierbach R, 2005, HUM MOL GENET, V14, P3857, DOI 10.1093/hmg/ddi410; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; THOMLINSON RH, 1955, BRIT J CANCER, V9, P539, DOI 10.1038/bjc.1955.55; Tjio J. H., 1956, HEREDITAS, V42, P1, DOI [10.1007/978-94-011-6621-8_13, DOI 10.1111/J.1601-5223.1956.TB03010.X]; Toffoli S, 2008, FEBS J, V275, P2991, DOI 10.1111/j.1742-4658.2008.06454.x; Tubiana Maurice, 2008, Nat Rev Cancer, V8, P990, DOI 10.1038/nrc2419-c1; VANDERHEIDEN MG, 2010, LOGIC CIRCUITS CARBO, V329, P1492; Varum S, 2009, STEM CELL RES, V3, P142, DOI 10.1016/j.scr.2009.07.002; WARBURG O, 1952, Z NATURFORSCH B, V7, P193; Warburg O, 1930, BIOCHEM Z, V228, P257; WARBURG O, 1956, SCIENCE, V124, P269; Warburg O, 1923, BIOCHEM Z, V142, P317; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warburg O, 1924, BIOCHEM Z, V152, P309; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Warburg O, 1929, BIOCHEM Z, V204, P482; Warburg O, 1923, KLIN WOCHENSCHR, V2, P776, DOI DOI 10.1007/BF01712130; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; WEINHOUSE S, 1972, CANCER RES, V32, P2007; WEINHOUSE S, 1956, SCIENCE, V124, P267, DOI 10.1126/science.124.3215.267; WENNER CE, 1953, CANCER RES, V13, P21; Williams AC, 1999, ONCOGENE, V18, P3199, DOI 10.1038/sj.onc.1202660; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Wu KJ, 2009, ACTA PHARMACOL SIN, V30, P1162, DOI 10.1038/aps.2009.94; Yalcin A, 2009, EXP MOL PATHOL, V86, P174, DOI 10.1016/j.yexmp.2009.01.003	178	81	83	2	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	36					3999	4011		10.1038/onc.2011.576	http://dx.doi.org/10.1038/onc.2011.576			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NQ	22231450				2022-12-17	WOS:000308688800001
J	Ahn, SM; Cha, JY; Kim, J; Kim, D; Trang, HTH; Kim, YM; Cho, YH; Park, D; Hong, S				Ahn, S-M; Cha, J-Y; Kim, J.; Kim, D.; Trang, H. T. H.; Kim, Y-M; Cho, Y-H; Park, D.; Hong, S.			Smad3 regulates E-cadherin via miRNA-200 pathway	ONCOGENE			English	Article						Smad3; miRNA-200; E-cadherin; ZEB1/2; gastric cancer	GROWTH-FACTOR-BETA; EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN GASTRIC-CANCER; II RECEPTOR GENE; TGF-BETA; MIR-200 FAMILY; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; REPRESSORS ZEB1; TUMOR INVASION	To identify potential microRNA (miRNA) links between Smad3, a mediator of TGF-beta (transforming growth factor-beta) signaling, and E-cadherin, we characterized the miRNA profiles of two gastric cancer cell lines: SNU484-LPCX, which does not express Smad3, and SNU484-Smad3, in which Smad3 is overexpressed. We found that among differentially expressed miRNAs, miR-200 family members are overexpressed in SNU484-Smad3 cells. Subsequent studies, including analysis of the effects of silencing Smad3 in SNU484-Smad3 cells and a luciferase reporter assay, revealed that Smad3 directly binds to a Smad-binding element located in the promoter region of miR-200b/a, where it functions as a transcriptional activator. TGF-beta did not affect the regulatory role of Smad3 in transcription of miR-200 and expression of epithelial-mesenchymal transition markers. We conclude that Smad3 regulates, at the transcriptional level, miR-200 family members, which themselves regulate ZEB1 and ZEB2, known transcriptional repressors of E-cadherin, at the posttranscriptional level in a TGF-beta-independent manner. This represents a novel link between Smad3 and posttranscriptional regulation by miRNAs in epithelial-mesenchymal transition in gastric cancer cells. Oncogene (2012) 31, 3051-3059; doi: 10.1038/onc.2011.484; published online 24 October 2011	[Park, D.] Gachon Univ Gil Hosp, Dept Gastroenterol, Inchon, South Korea; [Ahn, S-M; Cha, J-Y; Kim, J.; Kim, D.; Trang, H. T. H.; Kim, Y-M; Cho, Y-H; Hong, S.] Gachon Univ Med & Sci, Lee Gil Ya Canc & Diabet Inst, Canc Cell Biol Lab, Dept Mol Med, Yeonsu 406840, Incheon, South Korea; [Ahn, S-M] Gachon Univ Gil Hosp, Dept Translat Med, Inchon, South Korea	Gachon University; Gachon University; Gachon University	Park, D (corresponding author), Gachon Univ Gil Hosp, Dept Gastroenterol, Inchon, South Korea.	pdk66@gilhospital.com; sthong@gachon.ac.kr		Ahn, Sung-Min/0000-0002-5031-1929; Cha, JI-Young/0000-0002-8557-6214	National Research Foundation; Korea government (MEST) [KRF-2008-313-C00676, 2009-0081756, 2009-0081789]; department of gastroenterology, Gachon University Gil Hospital	National Research Foundation; Korea government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government); department of gastroenterology, Gachon University Gil Hospital	We thank Dr GJ Goodall for kindly providing the DNA constructs. This work was supported by the National Research Foundation grant funded by the Korea government (MEST) to S Hong (KRF-2008-313-C00676 and no. 2009-0081756), JY Cha and SM Ahn (no. 2009-0081789) and by the generous funding from the department of gastroenterology, Gachon University Gil Hospital to D Park.	Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Chung ACK, 2010, J AM SOC NEPHROL, V21, P249, DOI 10.1681/ASN.2009010018; Corcoran DL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005279; Elliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047; Fink SP, 2001, CANCER RES, V61, P256; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Han SU, 2004, ONCOGENE, V23, P1333, DOI 10.1038/sj.onc.1207259; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Humar B, 2009, CANCER RES, V69, P2050, DOI 10.1158/0008-5472.CAN-08-2457; Inoue Y, 2009, J CELL BIOCHEM, V108, P285, DOI 10.1002/jcb.22252; Kim BG, 2006, NATURE, V441, P1015, DOI 10.1038/nature04846; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Kurrasch DM, 2004, METHOD ENZYMOL, V389, P3; Levy C, 2010, MOL CELL, V40, P841, DOI 10.1016/j.molcel.2010.11.020; Li A, 2010, CANCER RES, V70, P5226, DOI 10.1158/0008-5472.CAN-09-4227; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Ma L, 2008, CELL CYCLE, V7, P570, DOI 10.4161/cc.7.5.5547; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 2000, GENE DEV, V14, P627; Neves Rui, 2010, BMC Res Notes, V3, P219, DOI 10.1186/1756-0500-3-219; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; PARSONS R, 1995, CANCER RES, V55, P5548; Pohl M, 2010, ANTICANCER RES, V30, P2603; Roberts AB, 2006, CYTOKINE GROWTH F R, V17, P19, DOI 10.1016/j.cytogfr.2005.09.008; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Saika S, 2004, AM J PATHOL, V164, P651, DOI 10.1016/S0002-9440(10)63153-7; Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425; Schmierer B, 2007, NAT REV MOL CELL BIO, V8, P970, DOI 10.1038/nrm2297; Sen GL, 2010, NATURE, V463, P563, DOI 10.1038/nature08683; Takagi Y, 1998, BRIT J CANCER, V78, P1152, DOI 10.1038/bjc.1998.645; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697; Wheeler JMD, 2001, GUT, V48, P367, DOI 10.1136/gut.48.3.367; Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461; Yanagisawa K, 2000, ONCOGENE, V19, P2305, DOI 10.1038/sj.onc.1203591; Yang FY, 2009, HYPERTENSION, V54, P877, DOI 10.1161/HYPERTENSIONAHA.109.136531; Zhu EL, 2010, NUCLEIC ACIDS RES, V38, pW392, DOI 10.1093/nar/gkq393	46	81	83	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	25					3051	3059		10.1038/onc.2011.484	http://dx.doi.org/10.1038/onc.2011.484			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964OP	22020340				2022-12-17	WOS:000305705900004
J	Kim, EK; Yun, SJ; Ha, JM; Kim, YW; Jin, IH; Yun, J; Shin, HK; Song, SH; Kim, JH; Lee, JS; Kim, CD; Bae, SS				Kim, E. K.; Yun, S. J.; Ha, J. M.; Kim, Y. W.; Jin, I. H.; Yun, J.; Shin, H. K.; Song, S. H.; Kim, J. H.; Lee, J. S.; Kim, C. D.; Bae, S. S.			Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis	ONCOGENE			English	Article						Akt; invasion; metastasis; mTOR; P-Rex1	FACTOR-I RECEPTOR; PROTEIN-KINASE-B; ACTIN CYTOSKELETON; INSULIN-RESISTANCE; BREAST-CANCER; GROWTH; MTOR; MOTILITY; AKT/PKB; INHIBITION	Mammalian target of rapamycin complex (mTORC) regulates a variety of cellular responses including proliferation, growth, differentiation and cell migration. In this study, we show that mammalian target of rapamycin complex 2 (mTORC2) regulates invasive cancer cell migration through selective activation of Akt1. Insulin-like growth factor-1 (IGF-1)-induced SKOV-3 cell migration was completely abolished by phosphatidylinositol 3-kinase (PI3K) (LY294002, 10 mu M) or Akt inhibitors (SH-5, 50 mu M), whereas inhibition of extracellular-regulated kinase by an ERK inhibitor (PD98059, 10 mu M) or inhibition of mammalian target of rapamycin complex 1 (mTORC1) by an mTORC1 inhibitor (Rapamycin, 100 nM) did not affect IGF-1-induced SKOV-3 cell migration. Inactivation of mTORC2 by silencing Rapamycin-insensitive companion of mTOR (Rictor), abolished IGF-1-induced SKOV-3 cell migration as well as activation of Akt. However, inactivation of mTORC1 by silencing of Raptor had no effect. Silencing of Akt1 but not Akt2 attenuated IGF-1-induced SKOV-3 cell migration. Rictor was preferentially associated with Akt1 rather than Akt2, and overexpression of Rictor facilitated IGF-1-induced Akt1 activation. Expression of PIP3-dependent Rac exchanger1 (P-Rex1), a Rac guanosine exchange factor and a component of the mTOR complex, strongly stimulated activation of Akt1. Furthermore, knockdown of P-Rex1 attenuated Akt activation as well as IGF-1-induced SKOV-3 cell migration. Silencing of Akt1 or P-Rex1 abolished IGF-1-induced SKOV-3 cell invasion. Finally, silencing of Akt1 blocked in vivo metastasis, whereas silencing of Akt2 did not. Given these results, we suggest that selective activation of Akt1 through mTORC2 and P-Rex1 regulates cancer cell migration, invasion and metastasis. Oncogene (2011) 30, 2954-2963; doi:10.1038/onc.2011.22; published online 21 February 2011	[Kim, E. K.; Yun, S. J.; Ha, J. M.; Kim, Y. W.; Jin, I. H.; Kim, C. D.; Bae, S. S.] Pusan Natl Univ, Sch Med, Dept Pharmacol, MRC Ischem Tissue Regenerat, Yangsan 626870, Kyungnam, South Korea; [Yun, J.] Dong A Univ, Sch Med, Dept Biochem, Yangsan, South Korea; [Shin, H. K.] Pusan Natl Univ, Sch Korean Med, Dept Anat, Yangsan 626870, Kyungnam, South Korea; [Song, S. H.] Pusan Natl Univ, Sch Med, Dept Internal Med, Yangsan 626870, Kyungnam, South Korea; [Kim, J. H.] Pusan Natl Univ, Sch Med, Dept Physiol, Yangsan 626870, Kyungnam, South Korea; [Lee, J. S.] Pusan Natl Univ, Sch Med, Dept Orthoped Surg, Yangsan 626870, Kyungnam, South Korea; [Kim, E. K.; Yun, S. J.; Ha, J. M.; Kim, Y. W.; Jin, I. H.; Kim, C. D.; Bae, S. S.] Pusan Natl Univ, Sch Med, Dept Pharmacol, MRC Med Res Inst, Yangsan 626870, Kyungnam, South Korea	Pusan National University; Pusan National University Hospital; Dong A University; Pusan National University; Pusan National University Hospital; Pusan National University; Pusan National University; Pusan National University Hospital; Pusan National University; Pusan National University Hospital; Pusan National University; Pusan National University Hospital; Pusan National University; Pusan National University Hospital	Bae, SS (corresponding author), Pusan Natl Univ, Sch Med, Dept Pharmacol, MRC Ischem Tissue Regenerat, Yangsan 626870, Kyungnam, South Korea.	sunsik@pusan.ac.kr			Korea government (MEST) [2010-0015808]; Cancer Control, Ministry for Health, Welfare and Family affairs, Republic of Korea [0920050]	Korea government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government); Cancer Control, Ministry for Health, Welfare and Family affairs, Republic of Korea	This work was supported partly by the MRC program of the NRF (2010-0001247), a National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (2010-0015808), and the National R&D Program for Cancer Control, Ministry for Health, Welfare and Family affairs, Republic of Korea (0920050).	Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Barber Mark A, 2006, Bull Cancer, V93, pE44; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Chung CY, 2000, P NATL ACAD SCI USA, V97, P5225, DOI 10.1073/pnas.97.10.5225; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dunn SE, 1998, CANCER RES, V58, P3353; Enomoto A, 2005, DEV CELL, V9, P389, DOI 10.1016/j.devcel.2005.08.001; Grille SJ, 2003, CANCER RES, V63, P2172; Hernandez-Negrete I, 2007, J BIOL CHEM, V282, P23708, DOI 10.1074/jbc.M703771200; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Ju XM, 2007, P NATL ACAD SCI USA, V104, P7438, DOI 10.1073/pnas.0605874104; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kim EK, 2008, CELL SIGNAL, V20, P2030, DOI 10.1016/j.cellsig.2008.07.012; Kim EK, 2008, EXP MOL MED, V40, P445, DOI 10.3858/emm.2008.40.4.445; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Sheng SJ, 2009, J CELL PHYSIOL, V218, P451, DOI 10.1002/jcp.21616; van Golen CM, 2006, CANCER RES, V66, P6570, DOI 10.1158/0008-5472.CAN-05-1448; Wu YP, 2002, CANCER RES, V62, P1030; Yun SJ, 2009, FEBS LETT, V583, P685, DOI 10.1016/j.febslet.2009.01.005; Zhang HB, 2007, J CLIN INVEST, V117, P730, DOI 10.1172/JCI28984; Zhang J, 2008, J BIOL CHEM, V283, P35375, DOI 10.1074/jbc.M806480200; Zhou GL, 2006, J BIOL CHEM, V281, P36443, DOI 10.1074/jbc.M600788200	31	81	85	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	26					2954	2963		10.1038/onc.2011.22	http://dx.doi.org/10.1038/onc.2011.22			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	785QZ	21339740				2022-12-17	WOS:000292245100006
J	Wang, ZA; Shen, MM				Wang, Z. A.; Shen, M. M.			Revisiting the concept of cancer stem cells in prostate cancer	ONCOGENE			English	Review						cancer stem cell; prostate cancer; mouse models; cell of origin; tumor-initiating cell	TUMOR-INITIATING CELLS; ACUTE MYELOID-LEUKEMIA; BASAL-CELLS; IN-VIVO; PROSPECTIVE IDENTIFICATION; RECOMBINASE ACTIVITY; MOLECULAR-GENETICS; EPITHELIAL-CELLS; MURINE PROSTATE; BREAST-CANCER	The cancer stem cell (CSC) model proposes that cells within a tumor are organized in a hierarchical lineage relationship and display different tumorigenic potential, suggesting that effective therapeutics should target rare CSCs that sustain tumor malignancy. Here we review the current status of studies to identify CSCs in human prostate cancer as well as mouse models, with an emphasis on discussing different functional assays and their advantages and limitations. We also describe current controversies regarding the identification of prostate epithelial stem cells and cell types of origin for prostate cancer, and present potential resolutions of these issues. Although definitive evidence for the existence of CSCs in prostate cancer is still lacking, future directions pursuing the identification of tumor-initiating stem cells in the mouse may provide important advances in evaluating the CSC model for prostate cancer. Oncogene (2011) 30, 1261-1271; doi: 10.1038/onc.2010.530; published online 29 November 2010	[Shen, M. M.] Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, Dept Med, New York, NY 10032 USA; Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, Dept Genet & Dev, New York, NY 10032 USA	Columbia University; Columbia University	Shen, MM (corresponding author), Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, Dept Med, 1130 St Nicholas Ave, New York, NY 10032 USA.	mshen@columbia.edu	Shen, Michael M/C-7546-2009	Shen, Michael M/0000-0002-4042-1657; Wang, Zhu/0000-0002-8855-8951	NIH; DOD	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense)	We would like to thank Cory Abate-Shen for comments on the manuscript. We apologize for our inability to cite many relevant papers due to length constraints. This work was supported by grants to MMS from the NIH and the DOD Prostate Cancer Research Program. MMS is a member of the NCI Mouse Models of Human Cancer Consortium.	Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Abate-Shen C, 2008, DIFFERENTIATION, V76, P717, DOI 10.1111/j.1432-0436.2008.00292.x; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Attard G, 2009, CANCER CELL, V16, P458, DOI 10.1016/j.ccr.2009.11.006; Barabe F, 2007, SCIENCE, V316, P600, DOI 10.1126/science.1139851; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Birnie R, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-5-r83; Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Bonkhoff H, 1996, PROSTATE, V28, P98; BONKHOFF H, 1994, PROSTATE, V24, P114, DOI 10.1002/pros.2990240303; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Burger PE, 2005, P NATL ACAD SCI USA, V102, P7180, DOI 10.1073/pnas.0502761102; Chen Y, 2008, CURR OPIN PHARMACOL, V8, P440, DOI 10.1016/j.coph.2008.07.005; Cho RW, 2008, STEM CELLS, V26, P364, DOI 10.1634/stemcells.2007-0440; Clark J, 2008, ONCOGENE, V27, P1993, DOI 10.1038/sj.onc.1210843; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Collins AT, 2001, J CELL SCI, V114, P3865; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; CUNHA GR, 1978, J EXP ZOOL, V205, P181, DOI 10.1002/jez.1402050203; Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106; ENGLISH HF, 1987, PROSTATE, V11, P229, DOI 10.1002/pros.2990110304; EVANS GS, 1987, PROSTATE, V11, P339, DOI 10.1002/pros.2990110406; Feil R, 1997, BIOCHEM BIOPH RES CO, V237, P752, DOI 10.1006/bbrc.1997.7124; Garraway IP, 2010, PROSTATE, V70, P491, DOI 10.1002/pros.21083; Goldstein AS, 2010, SCIENCE, V329, P568, DOI 10.1126/science.1189992; Goldstein AS, 2008, P NATL ACAD SCI USA, V105, P20882, DOI 10.1073/pnas.0811411106; Gu GY, 2007, CANCER RES, V67, P4807, DOI 10.1158/0008-5472.CAN-06-4608; Gurel B, 2008, MODERN PATHOL, V21, P1156, DOI 10.1038/modpathol.2008.111; Haffner MC, 2010, NAT GENET, V42, P668, DOI 10.1038/ng.613; Hill RP, 2006, CANCER RES, V66, P1891, DOI 10.1158/0008-5472.CAN-05-3450; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Hurt EM, 2008, BRIT J CANCER, V98, P756, DOI 10.1038/sj.bjc.6604242; Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324; Isaacs JT, 1985, BENIGN PROSTATIC HYP, P85; Ishizawa K, 2010, CELL STEM CELL, V7, P279, DOI 10.1016/j.stem.2010.08.009; Korsten H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005662; Kurita T, 2004, DEVELOPMENT, V131, P4955, DOI 10.1242/dev.01384; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lawson DA, 2007, P NATL ACAD SCI USA, V104, P181, DOI 10.1073/pnas.0609684104; Lawson DA, 2010, P NATL ACAD SCI USA, V107, P2610, DOI 10.1073/pnas.0913873107; Leong KG, 2008, NATURE, V456, P804, DOI 10.1038/nature07427; Li H, 2008, CANCER RES, V68, P1820, DOI 10.1158/0008-5472.CAN-07-5878; Liao CP, 2010, CANCER RES, V70, P7294, DOI 10.1158/0008-5472.CAN-09-3982; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Lin CR, 2009, CELL, V139, P1069, DOI 10.1016/j.cell.2009.11.030; Mani RS, 2009, SCIENCE, V326, P1230, DOI 10.1126/science.1178124; Mazzucchelli R, 2008, BJU INT, V102, P1369, DOI 10.1111/j.1464-410X.2008.08074.x; Meeker AK, 2002, CANCER RES, V62, P6405; Miki J, 2007, CANCER RES, V67, P3153, DOI 10.1158/0008-5472.CAN-06-4429; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Missol-Kolka E, 2011, PROSTATE, V71, P254, DOI 10.1002/pros.21239; Mlarotta LLC, 2009, CURR OPIN GENET DEV, V19, P44, DOI 10.1016/j.gde.2008.12.003; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Mosquera JM, 2008, CLIN CANCER RES, V14, P3380, DOI 10.1158/1078-0432.CCR-07-5194; Mosquera JM, 2009, CLIN CANCER RES, V15, P4706, DOI 10.1158/1078-0432.CCR-08-2927; Mulholland DJ, 2009, CANCER RES, V69, P8555, DOI 10.1158/0008-5472.CAN-08-4673; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Passegue E, 2004, CELL, V119, P431, DOI 10.1016/j.cell.2004.10.010; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Patrawala L, 2007, CANCER RES, V67, P6796, DOI 10.1158/0008-5472.CAN-07-0490; Peehl DM, 2005, ENDOCR-RELAT CANCER, V12, P19, DOI 10.1677/erc.1.00795; Pfeiffer MJ, 2010, EUR UROL, V57, P246, DOI 10.1016/j.eururo.2009.01.015; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Richardson GD, 2004, J CELL SCI, V117, P3539, DOI 10.1242/jcs.01222; Risbridger GP, 2008, ENDOCRINOLOGY, V149, P4303, DOI 10.1210/en.2008-0465; Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837; Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017; Sharifi N, 2006, CANCER BIOL THER, V5, P901, DOI 10.4161/cbt.5.8.2949; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Simak R, 2000, HISTOL HISTOPATHOL, V15, P365, DOI 10.14670/HH-15.365; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Snippert HJ, 2010, SCIENCE, V327, P1385, DOI 10.1126/science.1184733; Spradling AC, 2008, COLD SH Q B, V73, P49, DOI 10.1101/sqb.2008.73.023; Tang Y, 2010, INT J CLIN EXP PATHO, V3, P128; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tsujimura A, 2002, J CELL BIOL, V157, P1257, DOI 10.1083/jcb.200202067; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Ugolkov AV, 2011, PROSTATE, V71, P18, DOI 10.1002/pros.21217; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; van Leenders G, 2000, LAB INVEST, V80, P1251, DOI 10.1038/labinvest.3780133; VERHAGEN APM, 1988, PROSTATE, V13, P25, DOI 10.1002/pros.2990130104; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Wang JCY, 2005, TRENDS CELL BIOL, V15, P494, DOI 10.1016/j.tcb.2005.07.004; Wang SY, 2006, P NATL ACAD SCI USA, V103, P1480, DOI 10.1073/pnas.0510652103; Wang X, 2009, NATURE, V461, P495, DOI 10.1038/nature08361; Wei C, 2007, CANCER BIOL THER, V6, P763, DOI 10.4161/cbt.6.5.3996; Xin L, 2005, P NATL ACAD SCI USA, V102, P6942, DOI 10.1073/pnas.0502320102; Xin L, 2003, P NATL ACAD SCI USA, V100, P11896, DOI 10.1073/pnas.1734139100; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Zhang M, 2008, CANCER RES, V68, P4674, DOI 10.1158/0008-5472.CAN-07-6353; Zhu LQ, 2009, NATURE, V457, P603, DOI 10.1038/nature07589	98	81	86	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	11					1261	1271		10.1038/onc.2010.530	http://dx.doi.org/10.1038/onc.2010.530			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	736JX	21119602				2022-12-17	WOS:000288492100001
J	Takayama, K; Tsutsumi, S; Katayama, S; Okayama, T; Horie-Inoue, K; Ikeda, K; Urano, T; Kawazu, C; Hasegawa, A; Ikeo, K; Gojyobori, T; Ouchi, Y; Hayashizaki, Y; Aburatani, H; Inoue, S				Takayama, K.; Tsutsumi, S.; Katayama, S.; Okayama, T.; Horie-Inoue, K.; Ikeda, K.; Urano, T.; Kawazu, C.; Hasegawa, A.; Ikeo, K.; Gojyobori, T.; Ouchi, Y.; Hayashizaki, Y.; Aburatani, H.; Inoue, S.			Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells	ONCOGENE			English	Article						androgen receptor; prostate cancer; CAGE; Chip-chip	TRANSCRIPTION FACTOR; GROWTH; IDENTIFICATION; NETWORK; PROTEIN; BIOINFORMATICS; PROGRESSION; REGION; ETV1	The androgen receptor (AR) is a critical transcriptional factor that contributes to the development and the progression of prostate cancer (PCa) by regulating the transcription of various target genes. Genome-wide screening of androgen target genes provides useful information to understand a global view of AR-mediated gene network in PCa. In this study, we performed 50-cap analysis of gene expression (CAGE) to determine androgen-regulated transcription start sites (TSSs) and chromatin immunoprecipitation (ChIP) on array (ChIP-chip) analysis to identify AR binding sites (ARBSs) and histone H3 acetylated (AcH3) sites in the human genome. CAGE determined 13 110 distinct, androgen-regulated TSSs (P<0.01), and ChIP-chip analysis identified 2872 androgen-dependent ARBSs (P<1e-5) and 25 945 AcH3 sites (P<1e-4). Both androgen-regulated coding genes and noncoding RNAs, including microRNAs (miRNAs) were determined as androgen target genes. Besides prototypic androgen-regulated TSSs in annotated gene promoter regions, there are many androgen-dependent TSSs that are widely distributed throughout the genome, including those in antisense (AS) direction of RefSeq genes. Several pairs of sense/antisense promoters were newly identified within single RefSeq gene regions. The integration of CAGE and ChIP-chip analyses successfully identified a cluster of androgen-inducible miRNAs, as exemplified by the miR-125b-2 cluster on chromosome 21. Notably, the number of androgen-upregulated genes was larger in LNCaP cells treated with R1881 for 24 h than for 6 h, and the percentage of androgen-upregulated genes accompanied with adjacent ARBSs was also much higher in cells treated with R1881 for 24 h than 6 h. On the basis of the Oncomine database, the majority of androgen-upregulated genes containing adjacent ARBSs and CAGE tag clusters in our study were previously confirmed as androgen target genes in PCa. The integrated high-throughput genome analyses of CAGE and ChIP-chip provide useful information for elucidating the AR-mediated transcriptional network that contributes to the development and progression of PCa. Oncogene (2011) 30, 619-630; doi: 10.1038/onc.2010.436; published online 4 October 2010	[Takayama, K.; Urano, T.; Inoue, S.] Univ Tokyo, Dept Antiaging Med, Grad Sch Med, Bunkyo Ku, Tokyo 1130032, Japan; [Takayama, K.; Urano, T.; Ouchi, Y.; Inoue, S.] Univ Tokyo, Grad Sch Med, Bunkyo Ku, Tokyo 1130032, Japan; [Takayama, K.; Horie-Inoue, K.; Ikeda, K.; Urano, T.; Inoue, S.] Saitama Med Univ, Div Gene Regulat & Signal Transduct, Res Ctr Genom Med, Hidaka, Saitama, Japan; [Tsutsumi, S.; Aburatani, H.] Univ Tokyo, Genome Sci Div, Res Ctr Adv Sci & technol, Meguro Ku, Tokyo 1130032, Japan; [Katayama, S.; Kawazu, C.; Hasegawa, A.; Hayashizaki, Y.] RIKEN Yokohama Inst, Riken Om Sci Ctr, Kanagawa, Japan; [Okayama, T.; Ikeo, K.; Gojyobori, T.] Natl Inst Genet, Shizuoka, Japan	University of Tokyo; University of Tokyo; Saitama Medical University; University of Tokyo; RIKEN; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Inoue, S (corresponding author), Univ Tokyo, Dept Antiaging Med, Grad Sch Med, Bunkyo Ku, Tokyo 1130032, Japan.	INOUE-GER@h.u-tokyo.ac.jp	Takayama, Kenichi/AAK-9238-2020; Urano, Tomohiko/AFS-9574-2022; Katayama, Shintaro/F-2958-2010	Katayama, Shintaro/0000-0001-7581-5157	MEXT; Japan Society for the Promotion of Science; MHLW; NIBIO; Grants-in-Aid for Scientific Research [22591016] Funding Source: KAKEN	MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); MHLW(Ministry of Health, Labour and Welfare, Japan); NIBIO(National Institute of Biomedical Innovation); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported by the Genome Network Project, Cell Innovation Program and Support Project of Strategic Research Center in Private Universities from the MEXT, grants from the Japan Society for the Promotion of Science, grants-in-aid from the MHLW and the Program for Promotion of Fundamental Studies in Health Sciences of the NIBIO. We are grateful to T Murata for helpful discussion and Hiromi Sano and Kazumi Yamaguchi for their assistance.	Attard G, 2008, BRIT J CANCER, V99, P314, DOI 10.1038/sj.bjc.6604472; Balint I, 2004, GENE, V332, P45, DOI 10.1016/j.gene.2004.02.045; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Debes JD, 2004, NEW ENGL J MED, V351, P1488, DOI 10.1056/NEJMp048178; Dehm SM, 2006, J CELL BIOCHEM, V99, P333, DOI 10.1002/jcb.20794; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Hermans KG, 2008, CANCER RES, V68, P7541, DOI 10.1158/0008-5472.CAN-07-5930; Ho LL, 2008, PROSTATE, V68, P1421, DOI 10.1002/pros.20809; Horie-Inoue K, 2006, BIOCHEM BIOPH RES CO, V339, P99, DOI 10.1016/j.bbrc.2005.10.188; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Katayama S, 2005, SCIENCE, V309, P1564, DOI 10.1126/science.1112009; Katayama S, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-3-r42; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; LEITE KR, 2009, UROL ONCOL; Liu PB, 2006, CANCER RES, V66, P4011, DOI 10.1158/0008-5472.CAN-05-3055; Louro R, 2007, BMC BIOL, V5, DOI 10.1186/1741-7007-5-4; Luo J, 2002, CANCER RES, V62, P2220; Maeda N, 2008, BIOTECHNIQUES, V45, P95, DOI 10.2144/000112814; Massie CE, 2007, EMBO REP, V8, P871, DOI 10.1038/sj.embor.7401046; Pandini G, 2009, ANN NY ACAD SCI, V1155, P263, DOI 10.1111/j.1749-6632.2009.04361.x; Pflueger D, 2009, NEOPLASIA, V11, P804, DOI 10.1593/neo.09572; Prescott JL, 1998, PROSTATE, V35, P71, DOI 10.1002/(SICI)1097-0045(19980401)35:1<71::AID-PROS10>3.0.CO;2-H; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Santagata S, 2004, CANCER RES, V64, P6854, DOI 10.1158/0008-5472.CAN-04-2500; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Shi XB, 2007, P NATL ACAD SCI USA, V104, P19983, DOI 10.1073/pnas.0706641104; Shiraki T, 2003, P NATL ACAD SCI USA, V100, P15776, DOI 10.1073/pnas.2136655100; Sun T, 2009, CANCER RES, V69, P3356, DOI 10.1158/0008-5472.CAN-08-4112; Suzuki H, 2003, ENDOCR-RELAT CANCER, V10, P209, DOI 10.1677/erc.0.0100209; Suzuki H, 2009, NAT GENET, V41, P553, DOI 10.1038/ng.375; Takayama K, 2007, ONCOGENE, V26, P4453, DOI 10.1038/sj.onc.1210229; Takayama KI, 2009, CANCER RES, V69, P137, DOI 10.1158/0008-5472.CAN-08-3633; Takayama K, 2008, BIOCHEM BIOPH RES CO, V374, P388, DOI 10.1016/j.bbrc.2008.07.056; Velasco AM, 2004, ENDOCRINOLOGY, V145, P3913, DOI 10.1210/en.2004-0311; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Wilson BJ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-419; Yochum GS, 2007, J BIOL CHEM, V282, P871, DOI 10.1074/jbc.M609391200; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Yu SYM, 2009, TUMOR BIOL, V30, P80, DOI 10.1159/000216843	46	81	82	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	5					619	630		10.1038/onc.2010.436	http://dx.doi.org/10.1038/onc.2010.436			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	715WG	20890304				2022-12-17	WOS:000286922300010
J	Wilson, CH; McIntyre, RE; Arends, MJ; Adams, DJ				Wilson, C. H.; McIntyre, R. E.; Arends, M. J.; Adams, D. J.			The activating mutation R201C in GNAS promotes intestinal tumourigenesis in Apc(Min/+) mice through activation of Wnt and ERK1/2 MAPK pathways	ONCOGENE			English	Article						cAMP; colorectal cancer; GNAS	MCCUNE-ALBRIGHT-SYNDROME; STIMULATORY G-PROTEIN; K-RAS; ADRENAL-HYPERPLASIA; COLORECTAL-CANCER; HUMAN BREAST; CELL-GROWTH; A33 ANTIGEN; EXPRESSION; CAMP	Somatically acquired, activating mutations of GNAS, the gene encoding the stimulatory G-protein Gsa subunit, have been identified in kidney, thyroid, pituitary, leydig cell, adrenocortical and, more recently, in colorectal tumours, suggesting that mutations such as R201C may be oncogenic in these tissues. To study the role of GNAS in intestinal tumourigenesis, we placed GNAS R201C under the control of the A33-antigen promoter (Gpa33), which is almost exclusively expressed in the intestines. The GNAS R201C mutation has been shown to result in the constitutive activation of Gs alpha and adenylate cyclase and to lead to the autonomous synthesis of cyclic adenosine monophosphate (cAMP). Gpa33(tm1(GnasR201C) Wtsi/+) mice showed significantly elevated cAMP levels and a compensatory upregulation of cAMP-specific phosphodiesterases in the intestinal epithelium. GNAS R201C alone was not sufficient to induce tumourigenesis by 12 months, but there was a significant increase in adenoma formation when Gpa(33tm1(GnasR201C) Wtsi/+) mice were bred onto an Apc(Min/+) background. GNAS R201C expression was associated with elevated expression of Wnt and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase (ERK1/2 MAPK) pathway target genes, increased phosphorylation of ERK1/2 MAPK and increased immunostaining for the proliferation marker Ki67. Furthermore, the effects of GNAS R201C on the Wnt pathway were additive to the inactivation of Apc. Our data strongly suggest that activating mutations of GNAS cooperate with inactivation of APC and are likely to contribute to colorectal tumourigenesis. Oncogene (2010) 29, 4567-4575; doi: 10.1038/onc.2010.202; published online 7 June 2010	[Wilson, C. H.; McIntyre, R. E.; Adams, D. J.] Sanger Inst, Wellcome Trust, Hinxton CB10 1SA, England; [Arends, M. J.] Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Cambridge CB2 2QQ, England	Wellcome Trust Sanger Institute; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Adams, DJ (corresponding author), Sanger Inst, Wellcome Trust, Wellcome Trust Genome Campus, Hinxton CB10 1SA, England.	da1@sanger.ac.uk		Adams, David/0000-0001-9490-0306; Wilson, Catherine/0000-0002-5333-0295	Cancer Research UK (CR-UK); Wellcome Trust	Cancer Research UK (CR-UK)(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission)	Work in the DJ Adams Laboratory and the MJ Arends Laboratory is funded by Cancer Research UK (CR-UK) and the Wellcome Trust. We thank Dr Mattias Ernst for providing the Gpa33 targeting vector.	Abud HE, 2000, MECH DEVELOP, V98, P111, DOI 10.1016/S0925-4773(00)00438-X; Araki Y, 2003, CANCER RES, V63, P728; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; Brink M, 2003, CARCINOGENESIS, V24, P703, DOI 10.1093/carcin/bgg009; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chen CJ, 2004, J PEDIATR ENDOCR MET, V17, P365; Collins MT, 2003, J CLIN ENDOCR METAB, V88, P4413, DOI 10.1210/jc.2002-021642; Conti M, 2007, ANNU REV BIOCHEM, V76, P481, DOI 10.1146/annurev.biochem.76.060305.150444; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Fragoso MCBV, 1998, J CLIN ENDOCR METAB, V83, P2074, DOI 10.1210/jc.83.6.2074; Fragoso MCBV, 2003, J CLIN ENDOCR METAB, V88, P2147, DOI 10.1210/jc.2002-021362; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Haigis KM, 2008, NAT GENET, V40, P600, DOI 10.1038/ng.115; HAPPLE R, 1986, CLIN GENET, V29, P321; Hayward BE, 2001, J CLIN INVEST, V107, pR31, DOI 10.1172/JCI11887; Horvath A, 2008, EUR J HUM GENET, V16, P1245, DOI 10.1038/ejhg.2008.85; Horvath A, 2006, NAT GENET, V38, P794, DOI 10.1038/ng1809; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Johnstone CN, 2000, AM J PHYSIOL-GASTR L, V279, pG500, DOI 10.1152/ajpgi.2000.279.3.G500; Kalfa N, 2006, J UROLOGY, V176, P891, DOI 10.1016/j.juro.2006.04.023; Kirk JMW, 1999, J PEDIATR-US, V134, P789, DOI 10.1016/S0022-3476(99)70302-1; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; Kotoula V, 2009, ENDOCR-RELAT CANCER, V16, P565, DOI 10.1677/ERC-08-0101; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEVY DB, 1994, CANCER RES, V54, P5953; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo F, 2007, ONCOGENE, V26, P4415, DOI 10.1038/sj.onc.1210231; Luo FJ, 2009, INT J EXP PATHOL, V90, P558, DOI 10.1111/j.1365-2613.2009.00667.x; MacMahon H E, 1971, Pathol Annu, V6, P81; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; Nishihara H, 2004, J BIOL CHEM, V279, P26176, DOI 10.1074/jbc.M313346200; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Orner GA, 2002, MUTAT RES-FUND MOL M, V506, P121, DOI 10.1016/S0027-5107(02)00158-6; Palos-Paz F, 2008, EUR J ENDOCRINOL, V159, P623, DOI 10.1530/EJE-08-0313; Plagge A, 2008, J ENDOCRINOL, V196, P193, DOI 10.1677/JOE-07-0544; Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815; Rudolph JA, 2004, J BIOL CHEM, V279, P14828, DOI 10.1074/jbc.M310289200; Sansom OJ, 2006, P NATL ACAD SCI USA, V103, P14122, DOI 10.1073/pnas.0604130103; Sieber OM, 2000, MOL MED TODAY, V6, P462; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Stratakis CA, 2003, TRENDS ENDOCRIN MET, V14, P404, DOI 10.1016/j.tem.2003.08.005; Su H, 2002, GENESIS, V32, P187, DOI 10.1002/gene.10043; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Taboada GF, 2009, PITUITARY, V12, P165, DOI 10.1007/s11102-008-0136-0; Taketo MM, 2006, CANCER SCI, V97, P355, DOI 10.1111/j.1349-7006.2006.00190.x; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; Weinstein LS, 2004, ENDOCRINOLOGY, V145, P5459, DOI 10.1210/en.2004-0865; Wilkins JA, 2008, CANCER RES, V68, P4963, DOI 10.1158/0008-5472.CAN-07-5558; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Yang GCH, 1999, MODERN PATHOL, V12, P969; Zhang T, 2001, CANCER RES, V61, P8664	54	81	83	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2010	29	32					4567	4575		10.1038/onc.2010.202	http://dx.doi.org/10.1038/onc.2010.202			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	638AQ	20531296	Green Accepted, Green Submitted			2022-12-17	WOS:000280862300007
J	Zanella, F; Renner, O; Garcia, B; Callejas, S; Dopazo, A; Peregrina, S; Carnero, A; Link, W				Zanella, F.; Renner, O.; Garcia, B.; Callejas, S.; Dopazo, A.; Peregrina, S.; Carnero, A.; Link, W.			Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells	ONCOGENE			English	Article						TRIB2; FOXO; melanoma; RNAi; screening	TRANSCRIPTION FACTORS; PROTEINS; TRIBBLES; SCREEN; MORPHOGENESIS; METASTASIS; EXPRESSION; DROSOPHILA; SURVIVAL; LINEAGE	FOXO transcription factors are evolutionarily conserved proteins that orchestrate gene expression programs known to control a variety of cellular processes such as cell cycle, apoptosis, DNA repair and protection from oxidative stress. As the abrogation of FOXO function is a key feature of many tumor cells, regulation of FOXO factors is receiving increasing attention in cancer research. In order to discover genes involved in the regulation of FOXO activity, we performed a large-scale RNA-mediated interference (RNAi) screen using cell-based reporter systems that monitor transcriptional activity and subcellular localization of FOXO. We identified genes previously implicated in phosphoinositide 3-kinase/Akt signaling events, which are known to be important for FOXO function. In addition, we discovered a previously unrecognized FOXO-repressor function of TRIB2, the mammalian homolog of the Drosophila gene tribbles. A cancer-profiling array revealed specific overexpression of TRIB2 in malignant melanoma, but not in other types of skin cancer. We provide experimental evidence that TRIB2 transcript levels correlate with the degree of cytoplasmic localization of FOXO3a. Moreover, we show that TRIB2 is important in the maintenance of the oncogenic properties of melanoma cells, as its silencing reduces cell proliferation, colony formation and wound healing. Tumor growth was also substantially reduced upon RNAi-mediated TRIB2 knockdown in an in vivo melanoma xenograft model. Our studies suggest that TRIB2 provides the melanoma cells with growth and survival advantages through the abrogation of FOXO function. Altogether, our results show the potential of large-scale cell-based RNAi screens to identify promising diagnostic markers and therapeutic targets. Oncogene (2010) 29, 2973-2982; doi:10.1038/onc.2010.58; published online 8 March 2010	[Zanella, F.; Renner, O.; Garcia, B.; Peregrina, S.; Carnero, A.; Link, W.] CNIO, Expt Therapeut Program, Madrid 28029, Spain; [Callejas, S.; Dopazo, A.] CNIC, Genom Unit, Madrid 28029, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Cardiovasculares (CNIC)	Link, W (corresponding author), CNIO, Expt Therapeut Program, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	wlink@cnio.es	IBIS, CANCER/P-3323-2015; Renner, Oliver/M-7002-2015; Link, Wolfgang/F-4435-2012; Dopazo, Ana/N-1159-2014	Renner, Oliver/0000-0002-4046-0517; Link, Wolfgang/0000-0002-3340-5165; Dopazo, Ana/0000-0002-4910-1684; Callejas, Sergio/0000-0003-3351-4940; Carnero, Amancio/0000-0003-4357-3979	Spanish MEC [BIO2006-02432]; Marie Curie Fellowship	Spanish MEC(Spanish Government); Marie Curie Fellowship(European Commission)	This work was supported by a grant from the Spanish MEC (project BIO2006-02432). FZ is the recipient of a Marie Curie Fellowship. We acknowledge the expert technical assistance of D Megias, J C Cigudosa, J Monsech and O Dominguez. We thank M Hu, T Unterman and E Kiss-Toth for providing plasmids and JF Martinez for helpful discussions and critical reading of this paper. We are indebted to R Bernards for advice and for providing us with the NKI shRNA library.	Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Birmingham A, 2006, NAT METHODS, V3, P199, DOI 10.1038/NMETH854; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Dansen TB, 2008, TRENDS CELL BIOL, V18, P421, DOI 10.1016/j.tcb.2008.07.004; Gomes AR, 2008, CELL CYCLE, V7, P3133, DOI 10.4161/cc.7.20.6920; Grosshans J, 2000, CELL, V101, P523, DOI 10.1016/S0092-8674(00)80862-4; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Hegedus Z, 2007, CELL SIGNAL, V19, P238, DOI 10.1016/j.cellsig.2006.06.010; Hegedus Z, 2006, CELL MOL LIFE SCI, V63, P1632, DOI 10.1007/s00018-006-6007-9; Hellemans J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r19; Hilmi C, 2008, PIGM CELL MELANOMA R, V21, P139, DOI 10.1111/j.1755-148X.2008.00440.x; Hou L, 2000, DEVELOPMENT, V127, P5379; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Hui RCY, 2008, MOL CANCER THER, V7, P670, DOI 10.1158/1535-7163.MCT-07-0397; Keeshan K, 2006, CANCER CELL, V10, P401, DOI 10.1016/j.ccr.2006.09.012; Mata J, 2000, CELL, V101, P511, DOI 10.1016/S0092-8674(00)80861-2; Meier F, 2007, BRIT J DERMATOL, V156, P1204, DOI 10.1111/j.1365-2133.2007.07821.x; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Rosado A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001823; Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Yang HL, 2005, ONCOGENE, V24, P1924, DOI 10.1038/sj.onc.1208352; Zanella F, 2008, CHEMBIOCHEM, V9, P2229, DOI 10.1002/cbic.200800255; Zanella F, 2007, ASSAY DRUG DEV TECHN, V5, P333, DOI 10.1089/adt.2007.058; Zanella F, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-14	28	81	82	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2010	29	20					2973	2982		10.1038/onc.2010.58	http://dx.doi.org/10.1038/onc.2010.58			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599DM	20208562				2022-12-17	WOS:000277890400008
J	Lambert, JMR; Moshfegh, A; Hainaut, P; Wiman, KG; Bykov, VJN				Lambert, J. M. R.; Moshfegh, A.; Hainaut, P.; Wiman, K. G.; Bykov, V. J. N.			Mutant p53 reactivation by PRIMA-1(MET) induces multiple signaling pathways converging on apoptosis	ONCOGENE			English	Article						cancer; mutant p53; apoptosis; novel therapy	ENDOPLASMIC-RETICULUM STRESS; UNFOLDED-PROTEIN RESPONSE; WILD-TYPE P53; TUMOR-SUPPRESSOR; P53-DEPENDENT APOPTOSIS; P53-INDUCED APOPTOSIS; TARGET GENES; CANCER-CELLS; CORE DOMAIN; ER STRESS	The low molecular weight compound PRIMA-1(MET) reactivates mutant p53 and triggers mutant p53-dependent apoptosis in human tumor cells. We investigated the effect of PRIMA-1(MET) on global gene expression using microarray analysis of Saos-2 cells expressing His273 mutant p53 and parental p53 null Saos-2 cells. PRIMA-1(MET) affected transcription of a significantly larger number of genes in the mutant p53-expressing cells compared to the p53 null cells. Genes affected by PRIMA-1(MET) in a mutant p53-dependent manner include the cell-cycle regulators GADD45B and 14-3-3 gamma and the pro-apoptotic Noxa. Several of the affected genes are known p53 target genes and/or contain p53 DNA-binding motifs. We also found mutant p53-dependent disruption of the cytoskeleton, as well as transcriptional activation of the XBP1 gene and cleavage of its mRNA, a marker for endoplasmic reticulum stress. Our data show that PRIMA-1(MET) induces apoptosis through multiple transcription-dependent and -independent pathways. Such integral engagement of multiple pathways leading to apoptosis is consistent with restoration of wild-type properties to mutant p53 and is likely to reduce the risk of drug resistance development in clinical applications of PRIMA-1(MET). Oncogene (2010) 29, 1329-1338; doi:10.1038/onc.2009.425; published online 30 November 2009	[Lambert, J. M. R.; Moshfegh, A.; Wiman, K. G.; Bykov, V. J. N.] Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, SE-17176 Stockholm, Sweden; [Lambert, J. M. R.; Hainaut, P.] Int Agcy Res Canc, Mol Carcinogenesis & Biomarkers Grp, F-69372 Lyon, France	Karolinska Institutet; World Health Organization; International Agency for Research on Cancer (IARC)	Wiman, KG (corresponding author), Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, SE-17176 Stockholm, Sweden.	klas.wiman@ki.se	Wiman, Klas/AAB-8399-2021; Hainaut, Pierre/B-6018-2012	Wiman, Klas/0000-0002-7113-524X; Hainaut, Pierre/0000-0002-1303-1610; Nakade Bykov, Vladimir/0000-0002-7199-8942	Swedish Cancer Society (Cancerfonden); Cancerforeningen; Karolinska Institutet; EU	Swedish Cancer Society (Cancerfonden)(Swedish Cancer Society); Cancerforeningen; Karolinska Institutet(Karolinska Institutet); EU(European Commission)	We thank Bert Vogelstein, Johns Hopkins Oncology Center, for HCT116 cells. This work was supported by the Swedish Cancer Society (Cancerfonden), Cancerforeningen, Karolinska Institutet and the EU 6th framework program. This publication reflects the author's views and not necessarily those of the EC. The information in this document is provided as is and no guarantee or warranty is given that the information is fit for any particular purpose. The user thereof uses the information at his/her sole risk and liability. The Community is not liable for any use that may be made of the information contained herein.	Abcouwer SF, 2002, INVEST OPHTH VIS SCI, V43, P2791; Andersson J, 2005, ANN ONCOL, V16, P743, DOI 10.1093/annonc/mdi150; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bykov VJN, 2005, ONCOGENE, V24, P3484, DOI 10.1038/sj.onc.1208419; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Ceribelli M, 2006, CELL CYCLE, V5, P1102, DOI 10.4161/cc.5.10.2777; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Gronroos E, 2004, P NATL ACAD SCI USA, V101, P12165, DOI 10.1073/pnas.0402283101; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; He SK, 2008, GRAEF ARCH CLIN EXP, V246, P677, DOI 10.1007/s00417-008-0770-2; Hetz C, 2006, SCIENCE, V312, P572, DOI 10.1126/science.1123480; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Hossain MM, 2003, AM J PHYSIOL-CELL PH, V284, pC156, DOI 10.1152/ajpcell.00233.2002; INESI G, 1992, ARCH BIOCHEM BIOPHYS, V298, P313, DOI 10.1016/0003-9861(92)90416-T; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lai ED, 2007, PHYSIOLOGY, V22, P193, DOI 10.1152/physiol.00050.2006; Lambert JMR, 2009, CANCER CELL, V15, P376, DOI 10.1016/j.ccr.2009.03.003; Li JZ, 2006, J BIOL CHEM, V281, P7260, DOI 10.1074/jbc.M509868200; Li Y, 2005, MOL CANCER THER, V4, P901, DOI 10.1158/1535-7163.MCT-04-0206; Livneh Z, 2006, CELL CYCLE, V5, P1918, DOI 10.4161/cc.5.17.3193; Mirza A, 2003, ONCOGENE, V22, P3645, DOI 10.1038/sj.onc.1206477; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rahman R, 2005, ONCOGENE, V24, P1320, DOI 10.1038/sj.onc.1208232; Rogojina A, 2003, MOL VIS, V9, P482; Rokaeus N, 2007, ONCOGENE, V26, P982, DOI 10.1038/sj.onc.1209858; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Shen J, 2008, ONCOGENE, V27, P6571, DOI 10.1038/onc.2008.249; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Wang T, 2007, BIOCHEM BIOPH RES CO, V352, P203, DOI 10.1016/j.bbrc.2006.11.006; Westhoff B, 2005, CURR BIOL, V15, P1058, DOI 10.1016/j.cub.2005.04.058; Wulfkuhle JD, 1999, J CELL SCI, V112, P2125; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yakovleva T, 2004, BIOCHEM BIOPH RES CO, V318, P615, DOI 10.1016/j.bbrc.2004.04.065; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Zache N, 2008, CELL ONCOL, V30, P411, DOI 10.3233/CLO-2008-0440	48	81	84	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 4	2010	29	9					1329	1338		10.1038/onc.2009.425	http://dx.doi.org/10.1038/onc.2009.425			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	19946333				2022-12-17	WOS:000275170600008
J	Chinnadurai, G; Vijayalingam, S; Rashmi, R				Chinnadurai, G.; Vijayalingam, S.; Rashmi, R.			BIK, the founding member of the BH3-only family proteins: mechanisms of cell death and role in cancer and pathogenic processes	ONCOGENE			English	Review						BIK; BH3-only; apoptosis; ER; cancer; viral pathogenesis	PRO-APOPTOTIC PROTEIN; CYTOCHROME-C RELEASE; ADENOVIRUS-INDUCED APOPTOSIS; BCL-2 FAMILY; GENE-EXPRESSION; ENDOPLASMIC-RETICULUM; PROTEASOME INHIBITORS; MITOCHONDRIAL APOPTOSIS; INFECTED CELLS; BH3 DOMAIN	BIK is the founding member of the BH3-only family proapoptotic proteins. BIK is predominantly localized in the ER and induces apoptosis through the mitochondrial pathway by mobilizing calcium from the ER to the mitochondria and remodeling the mitochondrial cristae. BIK-mediated apoptosis is mediated by selective activation of BAX. BIK also induces non-apoptotic cell death in certain cell types by unknown mechanisms. BIK is nonessential for animal development, but appears to be functionally redundant for certain developmental functions with BIM. BIK is implicated in the selection of mature B cells in humans. BIK is a pro-apoptotic tumor suppressor in several human tissues and its expression in cancers is prevented by chromosomal deletions encompassing the Bik locus or by epigenetic silencing. BIK appears to be a critical effector in apoptosis induced by toxins, cytokines and virus infection. Several anti-cancer drugs transcriptionally activate Bik gene expression through transcriptional pathways dependent on factors such as E2F and p53 or by removal of epigenetic marks on the chromatin. BIK appears to be a prominent target for anti-cancer drugs that inhibit proteasomal functions. BIK has also been used as a therapeutic molecule in gene therapy-based approaches to treat difficult cancers. Oncogene (2009) 27, S20-S29; doi: 10.1038/onc.2009.40	[Chinnadurai, G.; Vijayalingam, S.] St Louis Univ, Inst Mol Virol, Doisy Res Ctr, Hlth Sci Ctr, St Louis, MO 63104 USA; [Rashmi, R.] St Louis Univ, Dept Pediat, Doisy Res Ctr, Hlth Sci Ctr, St Louis, MO 63104 USA	Saint Louis University; Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Inst Mol Virol, Doisy Res Ctr, Hlth Sci Ctr, 1100 S Grand Blvd, St Louis, MO 63104 USA.	chinnag@slu.edu	Pillai, Rashmi Ramachandran/B-8130-2012	Pillai, Rashmi Ramachandran/0000-0002-1619-7763	NCI NIH HHS [R01 CA073803, R01 CA073803-09, R01 CA033616, CA-33616, R01 CA033616-28, CA-73803] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073803, R01CA033616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aouacheria A, 2005, MOL BIOL EVOL, V22, P2395, DOI 10.1093/molbev/msi234; Arena V, 2003, GENE CHROMOSOME CANC, V38, P91, DOI 10.1002/gcc.10245; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, ONCOGENE, V11, P1921; Bredel M, 2005, CANCER RES, V65, P4088, DOI 10.1158/0008-5472.CAN-04-4229; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Castells A, 1999, GASTROENTEROLOGY, V117, P831, DOI 10.1016/S0016-5085(99)70341-0; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Coultas L, 2005, EMBO J, V24, P3963, DOI 10.1038/sj.emboj.7600857; Coultas L, 2004, MOL CELL BIOL, V24, P1570, DOI 10.1128/MCB.24.4.1570-1581.2004; Dai ZY, 2006, BIOCHEM BIOPH RES CO, V351, P455, DOI 10.1016/j.bbrc.2006.10.055; Daniel PT, 1999, BLOOD, V94, P1100, DOI 10.1182/blood.V94.3.1100.415a16_1100_1107; Diallo JS, 2008, BRIT J CANCER, V99, P1613, DOI 10.1038/sj.bjc.6604730; Dong F, 2005, INFECT IMMUN, V73, P1861, DOI 10.1128/IAI.73.3.1861-1864.2005; Elangovan B, 1997, J BIOL CHEM, V272, P24494, DOI 10.1074/jbc.272.39.24494; Fan T, 1998, J EXP MED, V187, P487, DOI 10.1084/jem.187.4.487; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Garcia N, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-93; Germain M, 2005, EMBO J, V24, P1546, DOI 10.1038/sj.emboj.7600592; Germain M, 2002, J BIOL CHEM, V277, P18053, DOI 10.1074/jbc.M201235200; Giatromanolaki A, 2004, CLIN CANCER RES, V10, P5566, DOI 10.1158/1078-0432.CCR-04-0076; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Gillissen B, 2007, J CELL BIOL, V179, P701, DOI 10.1083/jcb.200703040; Han J, 1996, MOL CELL BIOL, V16, P5857; Hegde R, 1998, J BIOL CHEM, V273, P7783, DOI 10.1074/jbc.273.14.7783; Hinds MG, 2007, CELL DEATH DIFFER, V14, P128, DOI 10.1038/sj.cdd.4401934; Hur J, 2006, CANCER RES, V66, P10153, DOI 10.1158/0008-5472.CAN-05-3696; Hur JY, 2004, P NATL ACAD SCI USA, V101, P2351, DOI 10.1073/pnas.0307337101; Jiang AM, 2001, J IMMUNOL, V166, P6025, DOI 10.4049/jimmunol.166.10.6025; Klein U, 2003, ANN NY ACAD SCI, V987, P166, DOI 10.1111/j.1749-6632.2003.tb06045.x; Li CY, 2008, MOL CANCER THER, V7, P1647, DOI 10.1158/1535-7163.MCT-07-2444; Li YM, 2003, CANCER RES, V63, P7630; Lomonosova E, 2002, J VIROL, V76, P11283, DOI 10.1128/JVI.76.22.11283-11290.2002; Lu Y, 2006, PLOS MED, V3, P2229, DOI 10.1371/journal.pmed.0030467; Marshansky V, 2001, J IMMUNOL, V166, P3130, DOI 10.4049/jimmunol.166.5.3130; Mathai JP, 2005, J BIOL CHEM, V280, P23829, DOI 10.1074/jbc.M500800200; Mathai JP, 2002, ONCOGENE, V21, P2534, DOI 10.1038/sj.onc.1205340; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Mebratu YA, 2008, J CELL BIOL, V183, P429, DOI 10.1083/jcb.200801186; Milutinovic S, 2004, J BIOL CHEM, V279, P27915, DOI 10.1074/jbc.M312823200; Naumann U, 2003, HUM GENE THER, V14, P1235, DOI 10.1089/104303403767740777; Nikrad M, 2005, MOL CANCER THER, V4, P443; OLTVAI ZN, 1993, CELL, V74, P619; Oppermann M, 2005, ONCOGENE, V24, P7369, DOI 10.1038/sj.onc.1208890; PANARETAKIS T, 2002, J BIOL CHEM, V21, P21; Paquet C, 2004, APOPTOSIS, V9, P815, DOI 10.1023/B:APPT.0000045791.55282.91; Pompeia C, 2004, CANCER RES, V64, P3465, DOI 10.1158/0008-5472.CAN-03-3970; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Sowter HM, 2003, J PATHOL, V201, P573, DOI 10.1002/path.1486; SPENDER LC, 2009, CELL DEATH IN PRESS; Sturm I, 2006, CELL DEATH DIFFER, V13, P619, DOI 10.1038/sj.cdd.4401782; Subramanian T, 2007, J VIROL, V81, P10486, DOI 10.1128/JVI.00808-07; Sundararajan R, 2001, J BIOL CHEM, V276, P45120, DOI 10.1074/jbc.M106386200; Theodorakis P, 2002, CANCER RES, V62, P3373; Tong Y, 2001, MOL CANCER THER, V1, P95; Valdez BC, 2008, LEUKEMIA RES, V32, P1684, DOI 10.1016/j.leukres.2008.01.016; Verma S, 2000, GENE, V254, P157, DOI 10.1016/S0378-1119(00)00276-6; Verma S, 2001, J BIOL CHEM, V276, P4671, DOI 10.1074/jbc.M008983200; Wang Y, 2008, CELL MOL LIFE SCI, V65, P3822, DOI 10.1007/s00018-008-8452-0; Warr MR, 2005, FEBS LETT, V579, P5603, DOI 10.1016/j.febslet.2005.09.028; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Willison HJ, 2005, NAT CLIN PRACT NEURO, V1, P2, DOI 10.1038/ncpneuro0001; Xie XM, 2007, CANCER CELL, V12, P52, DOI 10.1016/j.ccr.2007.05.009; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yeung BHY, 2006, J BIOL CHEM, V281, P11923, DOI 10.1074/jbc.M508533200; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zhu HB, 2005, CANCER BIOL THER, V4, P781, DOI 10.4161/cbt.4.7.1897; Zhu HB, 2005, ONCOGENE, V24, P4993, DOI 10.1038/sj.onc.1208683; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601; Zou YY, 2002, CANCER RES, V62, P8	71	81	82	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27			1			S20	S29		10.1038/onc.2009.40	http://dx.doi.org/10.1038/onc.2009.40			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	478DA	19641504	Green Accepted			2022-12-17	WOS:000268566800002
J	Chaudhary, K; Deb, S; Moniaux, N; Ponnusamy, MP; Batra, SK				Chaudhary, K.; Deb, S.; Moniaux, N.; Ponnusamy, M. P.; Batra, S. K.			Human RNA polymerase II-associated factor complex: dysregulation in cancer	ONCOGENE			English	Review						PAF complex; transcription; tumor suppressor genes; Wnt signaling	COMPARATIVE GENOMIC HYBRIDIZATION; NUCLEAR-LOCALIZATION SIGNAL; PANCREATIC-CANCER; CHROMOSOMAL-ABERRATIONS; CELL-LINES; HUMAN HOMOLOG; PAF1 COMPLEX; EXPRESSION; GENE; PARAFIBROMIN	Genetic instabilities are believed to be one of the major causes of developing a cancer phenotype in humans. During the progression of cancer, aberrant expression of proteins, either owing to genetic (amplification, mutation and deletion) or epigenetic modi. cations (DNA methylation and histone deacetylation), contributes in different ways to the development of cancer. By differential screening analysis, an amplification of the 19q13 locus containing a novel pancreatic differentiation 2 (PD2) gene was identified. PD2 is the human homolog of the yeast RNA polymerase II-associated factor 1 (yPaf1) and is part of the human RNA polymerase II-associated factor (hPAF) complex. hPAF is comprised of five subunits that include PD2/hPaf1, parafibromin, hLeo1, hCtr9 and hSki8. This multifaceted complex was first identified in yeast (yPAF) and subsequently in Drosophila and human. Recent advances in the study on PAF have revealed various functions of the complex in human, which are similar to yPAF, including efficient transcription elongation, mRNA quality control and cell-cycle regulation. Although the precise function of this complex in cancer is not clearly known, some of its subunits have been linked to a malignant phenotype. Its core subunit, PD2/hPaf1, is amplified and overexpressed in many cancers. Further, an overexpression of PD2/hPaf1 results in the induction of a transformed phenotype, suggesting its possible involvement in tumorigenesis. The para. bromin subunit of the hPAF complex is a product of the HRPT-2 (hereditary hyperparathyroidism type 2) tumor suppressor gene, which is mutated in the germ line of hyperparathyroidism-jaw tumor patients. This review focuses on the functions of the PAF complex and its individual subunits, the interaction of the subunits with each other and/or with other molecules, and dysregulation of the complex, providing an insight into its potential involvement in the development of cancer.	Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Batra, SK (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, 600 S 42nd St, Omaha, NE 68198 USA.	sbatra@unmc.edu	Moniaux, Nicolas/Y-3243-2018	Moniaux, Nicolas/0000-0001-9718-1386; Palanimuthu Ponnusamy, Moorthy/0000-0001-5744-193X	NCI NIH HHS [CA78590, CA111294] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078590, U01CA111294] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armengol G, 2000, CANCER GENET CYTOGEN, V116, P133, DOI 10.1016/S0165-4608(99)00118-1; Bashyam MD, 2005, NEOPLASIA, V7, P556, DOI 10.1593/neo.04586; BATRA SK, 1994, LAB INVEST, V71, P621; BATRA SK, 1991, J BIOL CHEM, V266, P6830; Birkenkamp-Demtroder K, 2002, CANCER RES, V62, P4352; Bradley KJ, 2007, ONCOGENE, V26, P1213, DOI 10.1038/sj.onc.1209893; Camps J, 2006, CARCINOGENESIS, V27, P419, DOI 10.1093/carcin/bgi244; Cavalli LR, 2003, CANCER GENET CYTOGEN, V146, P33, DOI 10.1016/S0165-4608(03)00123-7; Chang MC, 2005, ONCOL REP, V14, P867; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Curtis LJ, 1998, GENOMICS, V53, P42, DOI 10.1006/geno.1998.5405; DE PK, 2005, J CLIN ONCOL, V23, P3167; Grandori C, 2004, CELL CYCLE, V3, P22; Hahn MA, 2005, ONCOGENE, V24, P6241, DOI 10.1038/sj.onc.1208778; Heidenblad M, 2005, ONCOGENE, V24, P1794, DOI 10.1038/sj.onc.1208383; Honore B, 2002, ONCOGENE, V21, P1123, DOI 10.1038/sj.onc.1205186; Huntsman DG, 1999, ONCOGENE, V18, P7975, DOI 10.1038/sj.onc.1203291; Knudsen KE, 2006, ONCOGENE, V25, P1620, DOI 10.1038/sj.onc.1209371; Koch C, 1999, NUCLEIC ACIDS RES, V27, P2126, DOI 10.1093/nar/27.10.2126; Korshunov A, 2005, MODERN PATHOL, V18, P1258, DOI 10.1038/modpathol.3800415; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; Mahlamaki EH, 2004, NEOPLASIA, V6, P432, DOI 10.1593/neo.04130; Mao X, 2002, GENE CHROMOSOME CANC, V35, P144, DOI 10.1002/gcc.10104; Moniaux N, 2006, ONCOGENE, V25, P3247, DOI 10.1038/sj.onc.1209353; Mosimann C, 2006, CELL, V125, P327, DOI 10.1016/j.cell.2006.01.053; Mueller CL, 2004, MOL CELL, V14, P447, DOI 10.1016/S1097-2765(04)00257-6; Nathrath MH, 2002, ONCOGENE, V21, P5975, DOI 10.1038/sj.onc.1205764; Parada LA, 1998, GENE CHROMOSOME CANC, V23, P26; Pavri R, 2006, CELL, V125, P703, DOI 10.1016/j.cell.2006.04.029; REDEKER E, 1995, CYTOGENET CELL GENET, V68, P222, DOI 10.1159/000133917; Rozenblatt-Rosen O, 2005, MOL CELL BIOL, V25, P612, DOI 10.1128/MCB.25.2.612-620.2005; Rybakin V, 2005, BIOESSAYS, V27, P625, DOI 10.1002/bies.20235; Schleger C, 2000, J PATHOL, V191, P27, DOI 10.1002/(SICI)1096-9896(200005)191:1<27::AID-PATH582>3.0.CO;2-J; Schwienbacher C, 2000, P NATL ACAD SCI USA, V97, P5445, DOI 10.1073/pnas.090087497; Stange DE, 2006, CLIN CANCER RES, V12, P345, DOI 10.1158/1078-0432.CCR-05-1633; Tang TCM, 2002, CANCER RES, V62, P7157; Tarkkanen M, 2006, EUR J CANCER, V42, P1172, DOI 10.1016/j.ejca.2006.01.035; Thiagalingam S, 2006, CANCER RES, V66, P7379, DOI 10.1158/0008-5472.CAN-06-0993; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Woodard GE, 2005, ONCOGENE, V24, P1272, DOI 10.1038/sj.onc.1208274; Zhang C, 2006, BIOCHEM BIOPH RES CO, V350, P17, DOI 10.1016/j.bbrc.2006.08.169; Zhu B, 2005, GENE DEV, V19, P1668, DOI 10.1101/gad.1292105	42	81	82	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7499	7507		10.1038/sj.onc.1210582	http://dx.doi.org/10.1038/sj.onc.1210582			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17599057				2022-12-17	WOS:000251282100001
J	Spankuch, B; Kurunci-Csacsko, E; Kaufmann, M; Strebhardt, K				Spaenkuch, B.; Kurunci-Csacsko, E.; Kaufmann, M.; Strebhardt, K.			Rational combinations of siRNAs targeting Plk1 with breast cancer drugs	ONCOGENE			English	Article						plk1-. siRNA; paclitaxel; drug sensitivity; Herceptin	POLO-LIKE KINASE; DOWN-REGULATION; IN-VIVO; TRASTUZUMAB RESISTANCE; INDUCED APOPTOSIS; RNA INTERFERENCE; MAMMALIAN-CELLS; TUMOR-CELLS; GENE; GROWTH	Commonly used drugs for the treatment of breast cancer patients like paclitaxel and Herceptin often show severe side effects or induce resistance in clinical settings. Thus, we analysed a combination of Plk1 (polo-like kinase 1)-specific small interfering RNAs (siRNAs), a powerful tool to induce 'mitotic catastrophe' in cancer cells, together with these drugs to identify conditions for enhanced drug sensitivity. After transfection, the antineoplastic agents were added and cell proliferation, apoptosis and cell cycle distribution in breast cancer cells (MCF-7, SK-BR-3, MDA-MIB-435 and BT-474) and in primary human mammary epithelial cells were determined. Downregulation of cellular Plk1 levels led to an elevated percentage of cells in G(2)/M phase. The percentage of apoptotic nuclei in MCF-7, MDA-MB-435, SK-BR-3 and BT-474 cells was clearly increased after incubation with Plk1-specific siRNAs and paclitaxel. Interestingly, the caspase pathway was activated after treatment with Plk1-specific siRNAs and paclitaxel or Herceptin. Treatment of breast cancer cells with siRNAs targeting Plk1 improved the sensitivity toward paclitaxel and Herceptin in a synergistic manner. In all experiments, very low concentrations across a wide range of clinically relevant concentrations were sufficient to induce an anti proliferative effect. The combination of Plk1-specific siRNAs with modern breast cancer drugs seems to represent rational combinations to be tested in preclinical trials.	Univ Frankfurt, Sch Med, Dept Obstet & Gynecol, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Spankuch, B (corresponding author), Univ Frankfurt, Sch Med, Dept Obstet & Gynecol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	birgit.spaenkuch@t-online.de	Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763				Ahmad N, 2004, FASEB J, V18, P5, DOI 10.1096/fj.03-0848hyp; Ando K, 2004, J BIOL CHEM, V279, P25549, DOI 10.1074/jbc.M314182200; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Blain SW, 2003, CANCER CELL, V3, P111, DOI 10.1016/S1535-6108(03)00026-6; Blajeski AL, 2001, EXP CELL RES, V270, P277, DOI 10.1006/excr.2001.5349; Check E, 2005, NAT MED, V11, P243, DOI 10.1038/nm0305-243; Chen XM, 2000, BIOCHEM BIOPH RES CO, V277, P757, DOI 10.1006/bbrc.2000.3731; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cogswell JP, 2000, CELL GROWTH DIFFER, V11, P615; Crown J, 2003, BREAST CANCER RES TR, V79, pS11; Dai DH, 2005, CANCER RES, V65, P9517, DOI 10.1158/0008-5472.CAN-05-1613; Dubska L, 2005, FEBS LETT, V579, P4149, DOI 10.1016/j.febslet.2005.06.047; Eckerdt F, 2005, ONCOGENE, V24, P267, DOI 10.1038/sj.onc.1208273; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Esteva FJ, 2002, J CLIN ONCOL, V20, P1800, DOI 10.1200/JCO.2002.07.058; Gleave ME, 2005, NAT REV CANCER, V5, P468, DOI 10.1038/nrc1631; Gumireddy K, 2005, CANCER CELL, V7, P275, DOI 10.1016/j.ccr.2005.02.009; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Liu XQ, 2006, MOL CELL BIOL, V26, P2093, DOI 10.1128/MCB.26.6.2093-2108.2006; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Marches R, 2004, INT J CANCER, V112, P492, DOI 10.1002/ijc.20378; Mimura K, 2005, CLIN CANCER RES, V11, P4898, DOI 10.1158/1078-0432.CCR-04-2476; Nahta R, 2004, CANCER RES, V64, P3981, DOI 10.1158/0008-5472.CAN-03-3900; Nahta R, 2006, CANCER LETT, V232, P123, DOI 10.1016/j.canlet.2005.01.041; Nahta R, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1612; Nishii K, 1996, ONCOGENE, V13, P2225; Nogawa M, 2005, J CLIN INVEST, V115, P978, DOI 10.1172/JCI200523043; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Spankuch B, 2006, CANCER RES, V66, P5836, DOI 10.1158/0008-5472.CAN-06-0343; Spankuch B, 2005, CURR PHARM DESIGN, V11, P3405, DOI 10.2174/138161205774370834; Spankuch B, 2004, JNCI-J NATL CANCER I, V96, P862, DOI 10.1093/jnci/djh146; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Spankuch-Schmitt B, 2002, ONCOGENE, V21, P3162, DOI 10.1038/sj.onc.1205412; STREBHARDT K, 2001, ENCY MOL MED, P2530; Templeton NS, 2002, BIOSCIENCE REP, V22, P283; Therasse P, 2002, EUR J CANCER, V38, P1817, DOI 10.1016/S0959-8049(02)00182-X; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Xia WL, 2006, CANCER RES, V66, P1640, DOI 10.1158/0008-5472.CAN-05-2000; Yuan J, 2006, ONCOGENE, V25, P1753, DOI 10.1038/sj.onc.1209202; Yuan JP, 1997, AM J PATHOL, V150, P1165; Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688	49	81	88	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	39					5793	5807		10.1038/sj.onc.1210355	http://dx.doi.org/10.1038/sj.onc.1210355			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17369857				2022-12-17	WOS:000248885100011
J	Yan, Y; Black, CP; Cowan, KH				Yan, Y.; Black, C. P.; Cowan, K. H.			Irradiation-induced G2/M checkpoint response requires ERK1/2 activation	ONCOGENE			English	Article						ATM/ATR; Cdc2; Cdc25A/C; Chk1; ERK1/2; irradiation and wee1	DNA-DAMAGE CHECKPOINT; CELL-CYCLE ARREST; 14-3-3 PROTEIN-BINDING; IONIZING-RADIATION; TYROSINE PHOSPHORYLATION; CDC25 PHOSPHATASES; S-PHASE; KINASE; CHK1; ATR	Following DNA damage, cells undergo G2/M cell cycle arrest, allowing time for DNA repair. G2/M checkpoint activation involves activation of Wee1 and Chk1 kinases and inhibition of Cdc25A and Cdc25C phosphatases, which results in inhibition of Cdc2 kinase. Results presented in this report indicate that gamma-irradiation (IR) exposure of MCF-7 cells resulted in extracellular signal regulated protein kinase 1 and 2 (ERK1/2) activation and induction of G2/M arrest. Furthermore, inhibition of ERK1/2 signaling resulted in >= 85% attenuation in IR-induced G2/M arrest and concomitant diminution of IR-induced activation of ataxia telangiectasia mutated-and rad3-related (ATR), Chk1 and Wee1 kinases as well as phosphorylation of Cdc25A-Thr506, Cdc25C-Ser216 and Cdc2-Tyr15. Moreover, incubation of cells with caffeine, which inhibits ataxia telangiectasia mutated (ATM)/ATR, or transfection of cells with short interfering RNA targeting ATR abrogated IR-induced Chk1 phosphorylation and G2/M arrest but had no effect on IR-induced ERK1/2 activation. In contrast, inhibition of ERK1/2 signaling resulted in marked attenuation in IR-induced ATR activity with little, if any, effect on IR-induced ATM activation. These results implicate IR-induced ERK1/2 activation as an important regulator of G2/M checkpoint response to IR in MCF-7 cells.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Cowan, KH (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 986805 Nebraska Med Ctr,ECI 6010, Omaha, NE 68198 USA.	kcowan@unmc.edu						Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; Ahn JY, 2000, CANCER RES, V60, P5934; Bulavin DV, 2003, NAT CELL BIOL, V5, P545, DOI 10.1038/ncb994; Chen MS, 2003, MOL CELL BIOL, V23, P7488, DOI 10.1128/MCB.23.21.7488-7497.2003; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Cui W, 2000, MOL CARCINOGEN, V29, P219, DOI 10.1002/1098-2744(200012)29:4<219::AID-MC1004>3.3.CO;2-4; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; KHARBANDA S, 1994, CANCER RES, V54, P1412; Koundrioukoff S, 2004, DNA REPAIR, V3, P969, DOI 10.1016/j.dnarep.2004.03.010; Kristjansdottir K, 2004, CHEM BIOL, V11, P1043, DOI 10.1016/j.chembiol.2004.07.007; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Nagasawa H, 1998, CANCER RES, V58, P2036; O'Connell MJ, 2005, J CELL SCI, V118, P1, DOI 10.1242/jcs.01626; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Sarkaria JN, 1999, CANCER RES, V59, P4375; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Ward I, 2004, CURR TOP DEV BIOL, V63, P1, DOI 10.1016/S0070-2153(04)63001-8; Wellbrock C, 2002, J BIOL CHEM, V277, P6443, DOI 10.1074/jbc.M110684200; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu Bo, 2004, Methods Mol Biol, V281, P283; Yan Y, 2005, ONCOGENE, V24, P3285, DOI 10.1038/sj.onc.1208492; Yan Y, 2002, J BIOL CHEM, V277, P33422, DOI 10.1074/jbc.M201147200; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	34	81	85	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2007	26	32					4689	4698		10.1038/sj.onc.1210268	http://dx.doi.org/10.1038/sj.onc.1210268			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297454				2022-12-17	WOS:000248037900009
J	Denning, G; Jean-Joseph, B; Prince, C; Durden, DL; Vogt, PK				Denning, G.; Jean-Joseph, B.; Prince, C.; Durden, D. L.; Vogt, P. K.			A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth	ONCOGENE			English	Article						PTEN; tumor suppressor; mutation; lipid binding; cytoplasmic localization signal	HUMAN GLIOBLASTOMA CELLS; TUMOR-SUPPRESSOR; NUCLEAR-LOCALIZATION; CHROMOSOME-10 PTEN; PHOSPHATASE; PROTEIN; GENE; MEMBRANE; CANCER; CYCLE	Phosphatase and tensin homolog deleted on chromosome 10 ( PTEN) is an important negative regulator of cell growth and a tumor suppressor. Its growth-attenuating activity is based on the dephosphorylation of phosphatidylinositol 3,4,5-trisphosphate ( PIP3), an essential second messenger for the phosphoinositide 3-kinase/Akt signaling pathway. This activity may require localization of PTEN to cytoplasmic membranes. Yet PTEN can also localize to the cell nucleus where its functions remain unclear. Here we present data that de. ne a short sequence in the N-terminal region of PTEN required for cytoplasmic localization. We will refer to this sequence as cytoplasmic localization signal ( CLS). It could function as a non-canonical signal for nuclear export or as a cytoplasmic retention signal of PTEN. Mutations within the CLS induce nuclear localization and impair growth suppressive activities of PTEN while preserving lipid phosphatase activity. We propose that nuclear localization of PTEN is not compatible with plasma membrane-targeted growth suppressive functions of PTEN.	Emory Univ, Sch Med, Winship Canc Ctr, Dept Pediat, Atlanta, GA 30322 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA USA; Emory Univ, Sch Med, Dept Pediat,Div Pediat Hematol & Oncol, AFLAC Canc Ctr & Blood Disorder Serv, Atlanta, GA 30322 USA	Emory University; Scripps Research Institute; Emory University	Denning, G (corresponding author), Emory Univ, Sch Med, Winship Canc Ctr, Dept Pediat, 1365 Clifton Rd,Bldg C,Room 5054D, Atlanta, GA 30322 USA.	gabriela_denning@oz.ped.emory.edu	Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NATIONAL CANCER INSTITUTE [R01CA094233, R01CA078230, R56CA094233, P01CA078045] Funding Source: NIH RePORTER; NCI NIH HHS [CA078045, CA078230, CA94233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bonneau D, 2000, HUM MUTAT, V16, P109, DOI 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0; Chung JH, 2005, CANCER RES, V65, P8096, DOI 10.1158/0008-5472.CAN-05-1888; Chung JH, 2005, CANCER RES, V65, P4108, DOI 10.1158/0008-5472.CAN-05-0124; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Gil A, 2006, MOL BIOL CELL, V17, P4002, DOI 10.1091/mbc.E06-05-0380; Leslie NR, 2005, BIOCHEM SOC T, V33, P1507, DOI 10.1042/BST0331507; Leslie NR, 2004, BIOCHEM J, V382, P1, DOI 10.1042/BJ20040825; Li DM, 1997, CANCER RES, V57, P2124; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lian ZL, 2005, ONCOGENE, V24, P7394, DOI 10.1038/sj.onc.1209089; Liu JL, 2005, MOL CELL BIOL, V25, P6211, DOI 10.1128/MCB.25.14.6211-6224.2005; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Su JD, 2003, CANCER RES, V63, P3585; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Trotman LC, 2003, CANCER CELL, V3, P97, DOI 10.1016/S1535-6108(03)00022-9; VAN MEIR EG, 1994, CANCER RES, V54, P649; Vazquez F, 2006, P NATL ACAD SCI USA, V103, P3633, DOI 10.1073/pnas.0510570103; Vazquez F, 2006, CELL CYCLE, V5, P1523, DOI 10.4161/cc.5.14.3005; Vogt PK, 2001, TRENDS MOL MED, V7, P482, DOI 10.1016/S1471-4914(01)02161-X; Walker SM, 2004, BIOCHEM J, V379, P301, DOI 10.1042/BJ20031839; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798	31	81	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					3930	3940		10.1038/sj.onc.1210175	http://dx.doi.org/10.1038/sj.onc.1210175			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213812				2022-12-17	WOS:000247144500003
J	Alinari, L; Lapalombella, R; Andritsos, L; Baiocchi, RA; Lin, TS; Byrd, JC				Alinari, L.; Lapalombella, R.; Andritsos, L.; Baiocchi, R. A.; Lin, T. S.; Byrd, J. C.			Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia	ONCOGENE			English	Review						B-cell chronic lymphocytic leukemia; CD52 antigen; alemtuzumab; monoclonal antibody therapy; T-cell depletion; immunosuppression	MONOCLONAL-ANTIBODY THERAPY; STEM-CELL TRANSPLANTATION; INTENSITY ALLOGENEIC TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; PHASE-II TRIAL; RESIDUAL DISEASE; T-CELLS; LYMPHOPROLIFERATIVE DISORDERS; SUBCUTANEOUS ALEMTUZUMAB; PROLYMPHOCYTIC LEUKEMIA	Alemtuzumab (Campath-1H) is a humanized IgG1 monoclonal antibody that targets the human CD52 antigen. CD52 is expressed by a variety of lymphoid neoplasms and most human mononuclear cell subsets. In 2001, alemtuzumab was approved for marketing in the United States and Europe for use in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL). In heavily pretreated patients with CLL, the overall response rate (ORR) is approximately 35%, and in previously untreated patients the ORR is greater than 80%, with a recent randomized study suggesting it is superior to alkylator-based therapy. Importantly, alemtuzumab is effective in patients with high-risk del(17p13.1) and del(11q22.3) CLL. Alemtuzumab combination studies with fludarabine and/or monoclonal antibodies such as rituximab have demonstrated promising results. Alemtuzumab is also being studied in CLL patients as consolidation therapy for treatment of minimal residual disease, in preparation for stem cell transplantation and to prevent acute and chronic graft versus host disease. Alemtuzumab is frequently associated with acute 'first-dose' reactions when administered intravenously, but is much better tolerated when administered subcutaneously without loss of therapeutic efficacy. Additional potential adverse events associated with alemtuzumab administration include myelosuppression as well as profound cellular immune dysfunction with the associated risk of viral reactivation and other opportunistic infections. Additional studies detailing the mechanism of action of alemtuzumab as well as new strategies for prevention of opportunistic infections will aid in the future therapeutic development of this agent.	Ohio State Univ, Dept Med, Div Hematol Oncol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Byrd, JC (corresponding author), Ohio State Univ, Dept Internal Med, Div Hematol Oncol, B301 Starling Loving Hall,320 W 10th Ave, Columbus, OH 43210 USA.	john.byrd@osumc.edu	Lapalombella, Rosa/C-2837-2014; Lapalombella, Rosa/AAG-1856-2021					Bowen AL, 1997, BRIT J HAEMATOL, V96, P617, DOI 10.1046/j.1365-2141.1997.d01-2061.x; Buggins AGS, 2002, BLOOD, V100, P1715, DOI 10.1182/blood.V100.5.1715.h81702001715_1715_1720; Byrd John C, 2004, Hematology Am Soc Hematol Educ Program, P163; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Cheson BD, 2006, CANCER IMMUNOL IMMUN, V55, P188, DOI 10.1007/s00262-005-0010-0; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; CROWE JS, 1992, CLIN EXP IMMUNOL, V87, P105; Deans JP, 2002, IMMUNOLOGY, V107, P176, DOI 10.1046/j.1365-2567.2002.01495.x; Delgado J, 2006, BLOOD, V107, P1724, DOI 10.1182/blood-2005-08-3372; Dyer MJS, 1997, BRIT J HAEMATOL, V97, P669, DOI 10.1046/j.1365-2141.1997.1062924.x; Elsner J, 1996, BLOOD, V88, P4684, DOI 10.1182/blood.V88.12.4684.bloodjournal88124684; Elter T, 2005, J CLIN ONCOL, V23, P7024, DOI 10.1200/JCO.2005.01.9950; Faderl S, 2003, BLOOD, V101, P3413, DOI 10.1182/blood-2002-07-1952; Faulkner RD, 2004, BLOOD, V103, P428, DOI 10.1182/blood-2003-05-1406; Ferrajoli A, 2003, CANCER, V98, P773, DOI 10.1002/cncr.11551; Flinn IW, 1998, SEMIN ONCOL, V25, P60; Flynn JM, 2000, CURR OPIN ONCOL, V12, P574, DOI 10.1097/00001622-200011000-00010; Frampton JE, 2003, DRUGS, V63, P1229, DOI 10.2165/00003495-200363120-00003; Garcia A, 2003, BIOCHIMIE, V85, P727, DOI 10.1016/j.biochi.2003.09.005; GILLEECE MH, 1993, BLOOD, V82, P807; Ginaldi L, 1998, LEUKEMIA RES, V22, P185, DOI 10.1016/S0145-2126(97)00158-6; Golay J, 2004, HAEMATOLOGICA, V89, P1476; Hale G, 2004, BLOOD, V104, P948, DOI 10.1182/blood-2004-02-0593; HALE G, 1985, J IMMUNOL, V134, P3056; HALE G, 1990, TISSUE ANTIGENS, V35, P118, DOI 10.1111/j.1399-0039.1990.tb01767.x; Hale G, 2001, CYTOTHERAPY, V3, P137, DOI 10.1080/146532401753174098; HALE G, 1993, J REPROD IMMUNOL, V23, P189, DOI 10.1016/0165-0378(93)90007-5; Hale G, 2002, BONE MARROW TRANSPL, V30, P797, DOI 10.1038/sj.bmt.1703733; HALE G, 1983, BLOOD, V62, P873; Hillmen P, 2006, J CLIN ONCOL, V24, p339S; ISAACS JD, 1992, LANCET, V340, P748, DOI 10.1016/0140-6736(92)92294-P; Juliusson G, 2006, BONE MARROW TRANSPL, V37, P503, DOI 10.1038/sj.bmt.1705263; Keating MJ, 2002, BLOOD, V99, P3554, DOI 10.1182/blood.V99.10.3554; Kennedy B, 2002, BLOOD, V99, P2245, DOI 10.1182/blood.V99.6.2245; Klangsinsirikul P, 2002, BLOOD, V99, P2586, DOI 10.1182/blood.V99.7.2586; Kottaridis PD, 2000, BLOOD, V96, P2419; Lenihan DJ, 2004, BLOOD, V104, P655, DOI 10.1182/blood-2003-07-2345; Lin TS, 2005, LEUKEMIA, V19, P1207, DOI 10.1038/sj.leu.2403782; Lin TS, 2005, BLOOD, V105, P289, DOI 10.1182/blood-2004-02-0651; Lozanski G, 2004, BLOOD, V103, P3278, DOI 10.1182/blood-2003-10-3729; Lundin J, 2004, LEUKEMIA, V18, P484, DOI 10.1038/sj.leu.2403258; Lundin J, 2002, BLOOD, V100, P768, DOI 10.1182/blood-2002-01-0159; Martino R, 2001, BRIT J HAEMATOL, V115, P653, DOI 10.1046/j.1365-2141.2001.03153.x; Michallet M, 1996, ANN INTERN MED, V124, P311, DOI 10.7326/0003-4819-124-3-199602010-00005; Mone AP, 2006, LEUKEMIA, V20, P272, DOI 10.1038/sj.leu.2404014; Montillo M, 2006, J CLIN ONCOL, V24, P2337, DOI 10.1200/JCO.2005.04.6037; Moreton P, 2005, J CLIN ONCOL, V23, P2971, DOI 10.1200/JCO.2005.04.021; Morris E, 2004, BLOOD, V104, P3865, DOI 10.1182/blood-2004-03-1105; Nguyen DD, 2002, CLIN LYMPHOMA, V3, P105, DOI 10.3816/CLM.2002.n.016; Nuckel H, 2005, EUR J PHARMACOL, V514, P217, DOI 10.1016/j.ejphar.2005.03.024; O'Brien S, 2005, BLOOD, V106, p830A; O'Brien SM, 2003, CANCER, V98, P2657, DOI 10.1002/cncr.11871; Osterborg A, 1996, BRIT J HAEMATOL, V93, P151, DOI 10.1046/j.1365-2141.1996.450989.x; Osterborg A, 1997, J CLIN ONCOL, V15, P1567, DOI 10.1200/JCO.1997.15.4.1567; Osterborg A, 2006, SEMIN ONCOL, V33, pS29, DOI 10.1053/j.seminoncol.2006.01.027; Perez-Simon JA, 2002, BLOOD, V100, P3121, DOI 10.1182/blood-2002-03-0701; Perkins JG, 2002, CANCER-AM CANCER SOC, V94, P2033, DOI 10.1002/cncr.0680; Rai KR, 2002, J CLIN ONCOL, V20, P3891, DOI 10.1200/JCO.2002.06.119; Ratzinger G, 2003, BLOOD, V101, P1422, DOI 10.1182/blood-2002-04-1093; Robak T, 2005, BIODRUGS, V19, P9, DOI 10.2165/00063030-200519010-00002; Rossmann E D, 2001, Hematol J, V2, P300, DOI 10.1038/sj.thj.6200119; Rowan W, 1998, IMMUNOLOGY, V95, P427; ROZMAN C, 1995, NEW ENGL J MED, V333, P1052, DOI 10.1056/NEJM199510193331606; Smolewski P, 2005, LEUKEMIA LYMPHOMA, V46, P87, DOI 10.1080/13693780400007151; Sorror ML, 2005, J CLIN ONCOL, V23, P3819, DOI 10.1200/JCO.2005.04.569; Stanglmaier M, 2004, ANN HEMATOL, V83, P634, DOI 10.1007/s00277-004-0917-0; Stilgenbauer S, 2002, NEW ENGL J MED, V347, P452, DOI 10.1056/NEJM200208083470619; Watanabe T, 2006, CLIN IMMUNOL, V120, P247, DOI 10.1016/j.clim.2006.05.006; Wendtner CM, 2004, LEUKEMIA, V18, P1093, DOI 10.1038/sj.leu.2403354; Wierda W, 2004, BLOOD, V104, p101A, DOI 10.1182/blood.V104.11.340.340; Wing MG, 1996, J CLIN INVEST, V98, P2819, DOI 10.1172/JCI119110; XIA MQ, 1993, MOL IMMUNOL, V30, P1089; XIA MQ, 1993, BIOCHEM J, V293, P633, DOI 10.1042/bj2930633; Zent CS, 2004, LEUKEMIA RES, V28, P495, DOI 10.1016/j.leukres.2003.09.011; Zhang ML, 2006, BLOOD, V108, P705, DOI 10.1182/blood-2005-11-4607	75	81	93	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3644	3653		10.1038/sj.onc.1210380	http://dx.doi.org/10.1038/sj.onc.1210380			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530018				2022-12-17	WOS:000246816100007
J	Wada, T; Hata, K; Yamaguchi, K; Shiozaki, K; Koseki, K; Moriya, S; Miyagi, T				Wada, T.; Hata, K.; Yamaguchi, K.; Shiozaki, K.; Koseki, K.; Moriya, S.; Miyagi, T.			A crucial role of plasma membrane-associated sialidase in the survival of human cancer cells	ONCOGENE			English	Article						sialidase; apoptosis; cancer; gangliosides; Ras; EGFR	GROWTH-FACTOR RECEPTOR; GANGLIOSIDE SIALIDASE; MOLECULAR-CLONING; GM3; GLYCOSYLATION; EXPRESSION; PHOSPHORYLATION; APOPTOSIS; NEU3; OVEREXPRESSION	Human plasma membrane-associated sialidase (NEU3), a key enzyme for ganglioside degradation, is markedly upregulated in human cancers, leading to apoptosis suppression. To de. ne molecular mechanisms and the possible target for NEU3, its encoding gene was silenced by small interference RNA (siRNA) or overexpressed in human cells. NEU3 siRNA-induced apoptosis with no special stimuli in HeLa cells, accompanied with decreased Bcl-xL and increased mda7 and GM3 synthase mRNA levels, whereas overexpression resulted in the opposite. Carcinoma HT-29 and MCF-7 cells appeared to be similarly affected, but normal cell lines demonstrated no significant changes. NEU3 siRNA was found to inhibit and NEU3 overexpression to stimulate Ras activation with consequent influence on extracellular signal-regulated kinases and Akt. Ras activation by NEU3 was abrogated by PP2 (src inhibitor) or AG1478 (epidermal growth factor receptor (EGFR) inhibitor), and NEU3 actually enhanced EGF-stimulated tyrosine-phosphorylation of EGFR, suggesting that the upstream targets might be tyrosine kinases including src and EGFR, and the subsequent stimulation of Ras cascade leads to the inhibition of cell apoptosis. Glycolipid changes observed seemed to be one of the causes of the cell effects. NEU3 may thus be an essential gene for cancer cell survival and siRNAs targeting this protein could have utility for gene-based therapy of human cancers.	Miyagi Canc Ctr, Inst Res, Div Biochem, Natori, Miyagi 9811293, Japan	Miyagi Cancer Center	Miyagi, T (corresponding author), Miyagi Canc Ctr, Inst Res, Div Biochem, 47-1 Nodayama, Natori, Miyagi 9811293, Japan.	miyagi-ta173@pref.miyagi.jp		Shiozaki, Kazuhiro/0000-0002-0523-838X				Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; BREMER EG, 1986, J BIOL CHEM, V261, P2434; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Da Silva JS, 2005, NAT NEUROSCI, V8, P606, DOI 10.1038/nn1442; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; Dent P, 2005, J CELL BIOCHEM, V95, P712, DOI 10.1002/jcb.20502; Hakomori S, 1996, CANCER RES, V56, P5309; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; Hasegawa T, 2000, J BIOL CHEM, V275, P8007, DOI 10.1074/jbc.275.11.8007; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; Kakugawa Y, 2002, P NATL ACAD SCI USA, V99, P10718, DOI 10.1073/pnas.152597199; Kato K, 2006, BIOCHEM J, V394, P647, DOI 10.1042/BJ20050737; Kim YJ, 1997, GLYCOCONJUGATE J, V14, P569, DOI 10.1023/A:1018580324971; LI K, 1992, J CHROMATOGR-BIOMED, V579, P209, DOI 10.1016/0378-4347(92)80384-3; MACALA LJ, 1983, J LIPID RES, V24, P1243; MANGENEY M, 1991, EUR J IMMUNOL, V21, P1131, DOI 10.1002/eji.1830210507; Miura Y, 2004, P NATL ACAD SCI USA, V101, P16204, DOI 10.1073/pnas.0407297101; Miyagi T, 2004, TRENDS GLYCOSCI GLYC, V16, P371, DOI 10.4052/tigg.16.371; Miyagi T, 2003, GLYCOCONJUGATE J, V20, P189, DOI 10.1023/B:GLYC.0000024250.48506.bf; Miyagi T, 1999, J BIOL CHEM, V274, P5004, DOI 10.1074/jbc.274.8.5004; Monti E, 2000, BIOCHEM J, V349, P343, DOI 10.1042/0264-6021:3490343; Monti E, 2002, NEUROCHEM RES, V27, P649, DOI 10.1023/A:1020276000901; Sasaki A, 2003, J BIOL CHEM, V278, P27896, DOI 10.1074/jbc.M212200200; Sohn H, 2006, FASEB J, V20, P1248, DOI 10.1096/fj.05-4911fje; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Ueno S, 2006, J BIOL CHEM, V281, P7756, DOI 10.1074/jbc.M509668200; Valaperta R, 2006, FASEB J, V20, P1227, DOI 10.1096/fj.05-5077fje; Wada T, 1999, BIOCHEM BIOPH RES CO, V261, P21, DOI 10.1006/bbrc.1999.0973; Wang XQ, 2003, J BIOL CHEM, V278, P48770, DOI 10.1074/jbc.M308818200; Wang Y, 2002, J BIOL CHEM, V277, P26252, DOI 10.1074/jbc.M110515200; Watanabe R, 2002, CANCER RES, V62, P3850; Yamaguchi K, 2005, BIOCHEM J, V390, P85, DOI 10.1042/BJ20050017	35	81	103	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2007	26	17					2483	2490		10.1038/sj.onc.1210341	http://dx.doi.org/10.1038/sj.onc.1210341			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17334392				2022-12-17	WOS:000245831000008
J	Liu, B; Lee, KW; Anzo, M; Zhang, B; Zi, X; Tao, Y; Shiry, L; Pollak, M; Lin, S; Cohen, P				Liu, B.; Lee, K. -W; Anzo, M.; Zhang, B.; Zi, X.; Tao, Y.; Shiry, L.; Pollak, M.; Lin, S.; Cohen, P.			Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis	ONCOGENE			English	Article						insulin-like growth factor-binding protein-3; prostate cancer; angiogenesis; apoptosis	FACTOR IGF; ENDOTHELIAL-CELLS; TARGETED DISRUPTION; TUMOR ANGIOGENESIS; BREAST-CANCER; EXPRESSION; IGFBP-3; INDUCTION; ZEBRAFISH; APOPTOSIS	Insulin-like growth factor-binding protein-3 (IGFBP-3) is a multifunctional protein that induces apoptosis utilizing both insulin-like growth factor receptor (IGF)-dependent and -independent mechanisms. We investigated the effects of IGFBP-3 on tumor growth and angiogenesis utilizing a human CaP xenograft model in severe-combined immunodeficiency mice. A 16-day course of IGFBP-3 injections reduced tumor size and increased apoptosis and also led to a reduction in the number of vessels stained with CD31. In vitro, IGFBP-3 inhibited both vascular endothelial growth factor- and IGF-stimulated human umbilical vein endothelial cells vascular network formation in a matrigel assay. This action is primarily IGF independent as shown by studies utilizing the non-IGFBP-binding IGF-1 analog Long-R3. Additionally, we used a fibroblast growth factor- enriched matrigel-plug assay and chick allantoic membrane assays to show that IGFBP-3 has potent antiangiogenic actions in vivo. Finally, overexpression of IGFBP-3 or the non-IGF-binding GGG-IGFBP-3 mutant in Zebrafish embryos confirmed that both IGFBP-3 and the non-IGF-binding mutant inhibited vessel formation in vivo, indicating that the antiangiogenic effect of IGFBP-3 is an IGF-independent phenomenon. Together, these studies provide the first evidence that IGFBP-3 has direct, IGF-independent inhibitory effects on angiogenesis providing an additional mechanism by which it exerts its tumor suppressive effects and further supporting its development for clinical use in the therapy of patients with prostate cancer.	Univ Calif Los Angeles, David Geffen Sch Med, Div Pediat Endocrinol, Dept Pediat,Mattel Childrens Hosp, Los Angeles, CA 90095 USA; Peking Univ, Coll Life Sci, Ctr Dev Biol & Genet, Beijing 100871, Peoples R China; UCI, Dept Urol, Irvine, CA USA; UCI, Chao Family Comprehens Canc Ctr, Irvine, CA USA; McGill Univ, Dept Med, Div Expt Med, Montreal, PQ H2W 1S4, Canada; McGill Univ, Dept Oncol, Montreal, PQ H2W 1S4, Canada; INSMED Corp, Charlottesville, VA USA; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Peking University; University of California System; University of California Irvine; University of California System; University of California Irvine; McGill University; McGill University; University of California System; University of California Los Angeles	Cohen, P (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Pediat Endocrinol, Dept Pediat,Mattel Childrens Hosp, Los Angeles, CA 90095 USA.	hassy@mednet.ucla.edu	Zi, Xiaolin/D-3924-2009; Zhang, Bo/K-7162-2012; Pollak, Michael/G-9094-2011	Pollak, Michael/0000-0003-3047-0604	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD034610] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA100938, P50CA092131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020954] Funding Source: NIH RePORTER; NCI NIH HHS [P50CA92131, R01CA100938] Funding Source: Medline; NIA NIH HHS [R01AG20954] Funding Source: Medline; NICHD NIH HHS [2K12HD34610] Funding Source: Medline; NIDDK NIH HHS [R01DK054508] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acker T, 2003, CELL TISSUE RES, V314, P145, DOI 10.1007/s00441-003-0763-8; Arakawa A, 1997, PROSTATE CANCER P D, V1, P32, DOI 10.1038/sj.pcan.4500204; Bagheri-Yarmand R, 1999, CANCER RES, V59, P507; Bettencourt MC, 1998, J UROLOGY, V160, P459, DOI 10.1016/S0022-5347(01)62925-2; Bono AV, 2002, PROSTATE CANCER P D, V5, P123, DOI 10.1038/sj.pcan.4500572; Booth BA, 1996, GROWTH REGULAT, V6, P206; Brown TA, 2001, DOMEST ANIM ENDOCRIN, V20, P203, DOI 10.1016/S0739-7240(01)00092-3; Buckway CK, 2001, J CLIN ENDOCR METAB, V86, P4943, DOI 10.1210/jc.86.10.4943; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Chan SSY, 2005, J CLIN ENDOCR METAB, V90, P6588, DOI 10.1210/jc.2005-0595; Cross LM, 2003, ARTERIOSCL THROM VAS, V23, P911, DOI 10.1161/01.ATV.0000068685.72914.7E; Dahlfors G, 2000, ENDOCRINOLOGY, V141, P2062, DOI 10.1210/en.141.6.2062; Delafontaine P, 1996, BIOCHEM BIOPH RES CO, V222, P478, DOI 10.1006/bbrc.1996.0769; Diaz-Gonzalez JA, 2005, CANCER BIOL THER, V4, P1055, DOI 10.4161/cbt.4.10.2195; Eivers E, 2004, INT J DEV BIOL, V48, P1131, DOI 10.1387/ijdb.041913ee; ERICKSON GF, 1993, ENDOCRINOLOGY, V133, P1147, DOI 10.1210/en.133.3.1147; Erondu NE, 1996, GROWTH REGULAT, V6, P1; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Folkman J, 2004, APMIS, V112, P496, DOI 10.1111/j.1600-0463.2004.apm11207-0809.x; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Franklin SL, 2003, J CLIN ENDOCR METAB, V88, P900, DOI 10.1210/jc.2002-020472; Fraser HM, 1998, HUM REPROD, V13, P2180, DOI 10.1093/humrep/13.8.2180; Fraser HM, 2000, J CLIN ENDOCR METAB, V85, P1672, DOI 10.1210/jc.85.4.1672; Grimberg A, 2005, J CLIN ENDOCR METAB, V90, P3568, DOI 10.1210/jc.2004-1213; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Huang SS, 2003, FASEB J, V17, P2068, DOI 10.1096/fj.03-0256com; Ikonen M, 2003, P NATL ACAD SCI USA, V100, P13042, DOI 10.1073/pnas.2135111100; Iwatsuki K, 2005, ONCOGENE, V24, P1129, DOI 10.1038/sj.onc.1208287; Jackson MW, 1997, J UROLOGY, V157, P2323, DOI 10.1016/S0022-5347(01)64774-8; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Jones HE, 2005, ENDOCR-RELAT CANCER, V12, pS173, DOI 10.1677/erc.1.01004; Klauber N, 1997, CANCER RES, V57, P81; Koong AC, 2000, CANCER RES, V60, P883; LEE HS, 1999, J INJECTION MOLDING, V3, P11; Lee HY, 2002, CANCER RES, V62, P3530; Lee KW, 2005, J BIOL CHEM, V280, P16942, DOI 10.1074/jbc.M412757200; Liu BR, 2000, J BIOL CHEM, V275, P33607, DOI 10.1074/jbc.M002547200; Liu BR, 2005, CLIN CANCER RES, V11, P4851, DOI 10.1158/1078-0432.CCR-04-2160; Odenthal J, 1996, DEVELOPMENT, V123, P103; Oh SH, 2006, CLIN CANCER RES, V12, P653, DOI 10.1158/1078-0432.CCR-05-1725; OLNEY RC, 1995, J ENDOCRINOL, V146, P279, DOI 10.1677/joe.0.1460279; PRATT SE, 1994, BIOCHEM BIOPH RES CO, V198, P292, DOI 10.1006/bbrc.1994.1041; Schmitt HJ, 2003, LANCET INFECT DIS, V3, P103, DOI 10.1016/S1473-3099(03)00519-X; Singh RP, 2003, CANCER EPIDEM BIOMAR, V12, P933; Singh RP, 2004, CLIN CANCER RES, V10, P244, DOI 10.1158/1078-0432.CCR-1080-3; Singh RP, 2004, INT J CANCER, V108, P733, DOI 10.1002/ijc.11620; Tucci M, 1998, J ENDOCRINOL, V157, P13, DOI 10.1677/joe.0.1570013; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; van Moorselaar RJA, 2002, MOL CELL ENDOCRINOL, V197, P239, DOI 10.1016/S0303-7207(02)00262-9; Voskuil DW, 2005, CANCER EPIDEM BIOMAR, V14, P195; WEIDNER N, 1993, AM J PATHOL, V143, P401; Zadeh SM, 1997, ENDOCRINOLOGY, V138, P3069, DOI 10.1210/en.138.7.3069	54	81	85	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	12					1811	1819		10.1038/sj.onc.1209977	http://dx.doi.org/10.1038/sj.onc.1209977			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16983336				2022-12-17	WOS:000244955600015
J	Jarvinen, AK; Autio, R; Haapa-Paananen, S; Wolf, M; Saarela, M; Grenman, R; Leivo, I; Kallioniemi, O; Makitie, AA; Monni, O				Jarvinen, A-K; Autio, R.; Haapa-Paananen, S.; Wolf, M.; Saarela, M.; Grenman, R.; Leivo, I.; Kallioniemi, O.; Makitie, A. A.; Monni, O.			Identification of target genes in laryngeal squamous cell carcinoma by high-resolution copy number and gene expression microarray analyses	ONCOGENE			English	Article						head and neck cancer; cDNA microarrays; oligonucleotide microarrays; comparative genomic hybridization	BREAST-CANCER; CDNA MICROARRAYS; MOLECULAR CLASSIFICATION; 17Q23 AMPLICON; HIGH-FREQUENCY; NECK-CANCER; PHASE-II; HEAD; RECURRENT; PATTERNS	Molecular mechanisms contributing to initiation and progression of head and neck squamous cell carcinoma are still poorly known. Numerous genetic alterations have been described, but molecular consequences of such alterations in most cases remain unclear. Here, we performed an integrated high-resolution microarray analysis of gene copy number and expression in 20 laryngeal cancer cell lines and primary tumors. Our aim was to identify genetic alterations that play a key role in disease pathogenesis and pinpoint genes whose expression is directly impacted by these events. Integration of DNA level data from array-based comparative genomic hybridization with RNA level information from oligonucleotide microarrays was achieved with custom-developed bioinformatic methods. High-level amplifications had a clear impact on gene expression. Across the genome, overexpression of 739 genes could be attributed to gene amplification events in cell lines, with 325 genes showing the same phenomenon in primary tumors including FADD and PPFIA1 at 11q13. The analysis of gene ontology and pathway distributions further pinpointed genes that may identify potential targets of therapeutic intervention. Our data highlight genes that may be critically important to laryngeal cancer progression and offer potential therapeutic targets.	Univ Helsinki, Biomedicum Biochip Ctr, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biomed, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Otorhinolaryngol Head & Neck Surg, Helsinki, Finland; Tampere Univ Technol, Inst Signal Proc, FIN-33101 Tampere, Finland; VTT Tech Res Ctr Finland, Turku, Finland; Turku Univ, FIN-20520 Turku, Finland; Turku Univ, Cent Hosp, Dept Otorhinolaryngol Head & Neck Surg, Turku, Finland; Turku Univ, Dept Biochem Med, Turku, Finland; Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Tampere University; VTT Technical Research Center Finland; University of Turku; University of Turku; University of Turku; University of Helsinki	Monni, O (corresponding author), Univ Helsinki, Biomedicum Biochip Ctr, POB 63,Rm A415B,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	outi.monni@helsinki.fi	Autio, Reija/D-2037-2014; Haapa-Paananen, Saija/D-3075-2012; Kallioniemi, Olli P/H-5111-2011	Kallioniemi, Olli P/0000-0002-3231-0332; Autio, Reija/0000-0002-6519-2715				Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Autio R, 2003, BIOINFORMATICS, V19, P1714, DOI 10.1093/bioinformatics/btg230; Baldwin C, 2005, CANCER RES, V65, P7561, DOI 10.1158/0008-5472.CAN-05-1513; Baselga J, 2005, J CLIN ONCOL, V23, P2445, DOI 10.1200/JCO.2005.11.890; Baudis M, 2001, BIOINFORMATICS, V17, P1228, DOI 10.1093/bioinformatics/17.12.1228; Belbin TJ, 2002, CANCER RES, V62, P1184; Choi P, 2005, CANCER-AM CANCER SOC, V104, P1113, DOI 10.1002/cncr.21293; Chung CH, 2004, CANCER CELL, V5, P489, DOI 10.1016/S1535-6108(04)00112-6; Cohen EEW, 2003, J CLIN ONCOL, V21, P1980, DOI 10.1200/JCO.2003.10.051; Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; Dong YY, 2005, CLIN CANCER RES, V11, P259; Garcia MJ, 2005, ONCOGENE, V24, P5235, DOI 10.1038/sj.onc.1208741; Ginos MA, 2004, CANCER RES, V64, P55, DOI 10.1158/0008-5472.CAN-03-2144; Gollin SM, 2001, HEAD NECK-J SCI SPEC, V23, P238, DOI 10.1002/1097-0347(200103)23:3<238::AID-HED1025>3.0.CO;2-H; GRENMAN R, 1992, ARCH OTOLARYNGOL, V118, P542; Hautaniemi S, 2004, J FRANKLIN I, V341, P77, DOI 10.1016/j.jfranklin.2003.12.005; Heidenblad M, 2005, ONCOGENE, V24, P1794, DOI 10.1038/sj.onc.1208383; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Hyman E, 2002, CANCER RES, V62, P6240; Imoto I, 2001, CANCER RES, V61, P6629; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Joslyn CA, 2004, BIOINFORMATICS, V20, P169, DOI 10.1093/bioinformatics/bth921; LANSFORD CD, 1999, HUMAN CELL CULTURE, V2, P185; Lin M, 2006, ONCOGENE, V25, P1424, DOI 10.1038/sj.onc.1209166; Mao EJ, 1998, J ORAL PATHOL MED, V27, P297; Mao L, 2004, CANCER CELL, V5, P311, DOI 10.1016/S1535-6108(04)00090-X; Miller CT, 2003, CANCER RES, V63, P4136; Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298; Nawata S, 2003, ELECTROPHORESIS, V24, P2277, DOI 10.1002/elps.200305501; Newton K, 2000, EMBO J, V19, P931, DOI 10.1093/emboj/19.5.931; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Redon R, 2002, CANCER RES, V62, P6211; Reed AL, 1996, CANCER RES, V56, P3630; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Sinclair CS, 2003, BREAST CANCER RES TR, V78, P313, DOI 10.1023/A:1023081624133; Soulieres D, 2004, J CLIN ONCOL, V22, P77, DOI 10.1200/JCO.2004.06.075; Strojan P, 2004, BRIT J CANCER, V90, P1961, DOI 10.1038/sj.bjc.6601830; Strome SE, 2003, CANCER RES, V63, P6501	40	81	82	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	52					6997	7008		10.1038/sj.onc.1209690	http://dx.doi.org/10.1038/sj.onc.1209690			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16715129				2022-12-17	WOS:000241732300010
J	Myllykangas, S; Himberg, J; Bohling, T; Nagy, B; Hollmen, J; Knuutila, S				Myllykangas, S.; Himberg, J.; Bohling, T.; Nagy, B.; Hollmen, J.; Knuutila, S.			DNA copy number amplification profiling of human neoplasms	ONCOGENE			English	Article						cancer; gene amplification; fragile site; bioinformatics; data mining; molecular pathology	ACUTE LYMPHOBLASTIC-LEUKEMIA; DIHYDROFOLATE-REDUCTASE GENE; COMMON FRAGILE SITES; WILD-TYPE P53; MICROARRAY ANALYSIS; BREAST-CANCER; TUMORS; CELLS; CHROMOSOMES; IMBALANCES	DNA copy number amplications activate oncogenes and are hallmarks of nearly all advanced tumors. Amplified genes represent attractive targets for therapy, diagnostics and prognostics. To investigate DNA amplications in different neoplasms, we performed a bibliomics survey using 838 published chromosomal comparative genomic hybridization studies and collected amplification data at chromosome band resolution from more than 4500 cases. Amplification profiles were determined for 73 distinct neoplasms. Neoplasms were clustered according to the amplification profiles, and frequently amplificed chromosomal loci (amplification hot spots) were identified using computational modeling. To investigate the site specificity and mechanisms of gene amplifications, colocalization of amplification hot spots, cancer genes, fragile sites, virus integration sites and gene size cohorts were tested in a statistical framework. Amplification-based clustering demonstrated that cancers with similar etiology, cell-of-origin or topographical location have a tendency to obtain convergent amplification profiles. The identified amplification hot spots were colocalized with the known fragile sites, cancer genes and virus integration sites, but global statistical significance could not be ascertained. Large genes were significantly over-represented on the fragile sites and the reported amplifcation hot spots. These findings indicate that amplifications are selected in the cancer tissue environment according to the qualitative traits and localization of cancer genes.	Univ Helsinki, Haartman Inst, Dept Pathol, FI-00014 Helsinki, Finland; Univ Helsinki, HUSLAB, FI-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Helsinki, Finland; Helsinki Univ Technol, Lab Comp & Informat Sci, FIN-02150 Espoo, Finland; Scmmclwcis Univ, Dept Obstet & Gynecol 1, Budapest, Hungary	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Aalto University	Myllykangas, S (corresponding author), Univ Helsinki, Haartman Inst, Dept Pathol, POB 21, FI-00014 Helsinki, Finland.	samuel.myllykangas@helsinki.fi	Nagy, Balint/F-6943-2012					Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; [Anonymous], [No title captured]; Atiye J, 2005, GENE CHROMOSOME CANC, V42, P158, DOI 10.1002/gcc.20120; Bernasconi P, 2005, CANCER GENET CYTOGEN, V162, P146, DOI 10.1016/j.cancergencyto.2005.04.002; Birney E, 2004, GENOME RES, V14, P925, DOI 10.1101/gr.1860604; Buttel I, 2004, ANN NY ACAD SCI, V1028, P14, DOI 10.1196/annals.1322.002; El-Rifai W, 1998, AM J PATHOL, V153, P985, DOI 10.1016/S0002-9440(10)65640-4; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; GOKER E, 1995, BLOOD, V86, P677, DOI 10.1182/blood.V86.2.677.bloodjournal862677; Good P, 2000, PERMUTATION TESTS PR, V2; Graux C, 2004, NAT GENET, V36, P1084, DOI 10.1038/ng1425; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; HAHN PJ, 1993, BIOESSAYS, V15, P477, DOI 10.1002/bies.950150707; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; Himberg J, 2004, NEUROIMAGE, V22, P1214, DOI 10.1016/j.neuroimage.2004.03.027; HIMBERG J, 2001, 3 INT WORKSH IND COM, P552; Hyman E, 2002, CANCER RES, V62, P6240; ISCN, 1995, INT SYST HUM CYT NOM; JOHNSTON RN, 1983, P NATL ACAD SCI-BIOL, V80, P3711, DOI 10.1073/pnas.80.12.3711; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Looijenga LHJ, 1999, REV REPROD, V4, P90, DOI 10.1530/ror.0.0040090; MAURER BJ, 1987, NATURE, V327, P434, DOI 10.1038/327434a0; Monni O, 1999, LEUKEMIA LYMPHOMA, V34, P45, DOI 10.3109/10428199909083379; Myllykangas S, 2006, CANCER LETT, V232, P79, DOI 10.1016/j.canlet.2005.07.045; Ozaki T, 2002, INT J CANCER, V102, P355, DOI 10.1002/ijc.10709; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Rieker RJ, 2002, INT J CANCER, V99, P68, DOI 10.1002/ijc.10287; Roumier C, 2003, LEUKEMIA, V17, P9, DOI 10.1038/sj.leu.2402766; Schwab M, 1998, BIOESSAYS, V20, P473, DOI 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.3.CO;2-N; Schwab M, 2004, CANCER LETT, V204, P179, DOI 10.1016/S0304-3835(03)00454-3; Sell S, 2004, CRIT REV ONCOL HEMAT, V51, P1, DOI 10.1016/j.critrevonc.2004.04.007; Shannon KM, 2002, CANCER CELL, V2, P99, DOI 10.1016/S1535-6108(02)00101-0; Torchia EC, 2003, CANCER RES, V63, P3464; WAHL GM, 1979, J BIOL CHEM, V254, P8679; Weng WH, 2003, BRIT J CANCER, V89, P720, DOI 10.1038/sj.bjc.6601069; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Zatkova A, 2004, GENE CHROMOSOME CANC, V39, P263, DOI 10.1002/gcc.20002	41	81	85	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	55					7324	7332		10.1038/sj.onc.1209717	http://dx.doi.org/10.1038/sj.onc.1209717			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16751803				2022-12-17	WOS:000242244700011
J	Midorikawa, Y; Yamamoto, S; Ishikawa, S; Kamimura, N; Igarashi, H; Sugimura, H; Makuuchi, M; Aburatani, H				Midorikawa, Y.; Yamamoto, S.; Ishikawa, S.; Kamimura, N.; Igarashi, H.; Sugimura, H.; Makuuchi, M.; Aburatani, H.			Molecular karyotyping of human hepatocellular carcinoma using single-nucleotide polymorphism arrays	ONCOGENE			English	Article						liver cancer; oligonucleotide array; SNP; allelic imbalance; copy number	COMPARATIVE GENOMIC HYBRIDIZATION; UNIPARENTAL PATERNAL DISOMY; HIGH-RESOLUTION ANALYSIS; COPY NUMBER VARIATION; HETEROZYGOSITY ANALYSIS; MICROARRAY ANALYSIS; ANALYSIS REVEALS; CPG ISLANDS; CANCER; DNA	Genomic amplification of oncogenes and inactivation of suppressor genes are critical in the pathogenesis of human cancer. To identify chromosomal alterations associated with hepatocarcinogenesis, we performed allelic gene dosage analysis on 36 hepatocellular carcinomas (HCCs). Data from high-density single-nucleotide polymorphism arrays were analysed using the Genome Imbalance Map (GIM) algorithm, which simultaneously detects DNA copy number alterations and loss of heterozygosity (LOH) events. Genome Imbalance Map analysis identified allelic imbalance regions, including uniparental disomy, and predicted the coexistence of a heterozygous population of cancer cells. We observed that gains of 1q, 5p, 5q, 6p, 7q, 8q, 17q and 20q, and LOH of 1p, 4q, 6q, 8p, 10q, 13q, 16p, 16q and 17p were significantly associated with HCC. On 6q24-25, which contains imprinting gene clusters, we observed reduced levels of PLAGL1 expression owing to loss of the unmethylated allele. Finally, we integrated the copy number data with gene expression intensity, and found that genome dosage is correlated with alteration in gene expression. These observations indicated that high-resolution GIM analysis can accurately determine the localizations of genomic regions with allelic imbalance, and when integrated with epigenetic information, a mechanistic basis for inactivation of a tumor suppressor gene in HCC was elucidated.	Univ Tokyo, Adv Sci & Technol Res Ctr, Genome Sci Div, Meguro Ku, Tokyo 1538904, Japan; Hamamatsu Univ Sch Med, Dept Pathol 1, Shizuoka, Japan; Univ Tokyo, Hepato Biliary Pancreat Surg Div, Tokyo, Japan	University of Tokyo; Hamamatsu University School of Medicine; University of Tokyo	Aburatani, H (corresponding author), Univ Tokyo, Adv Sci & Technol Res Ctr, Genome Sci Div, Meguro Ku, 4-6-1 Komaba, Tokyo 1538904, Japan.	haburata-tky@umin.ac.jp	幕内, 雅敏 m/A-2140-2012					Abdollahi A, 1997, CANCER RES, V57, P2029; Abdollahi A, 2003, J BIOL CHEM, V278, P6041, DOI 10.1074/jbc.M210361200; Benetkiewicz M, 2005, GENE CHROMOSOME CANC, V42, P228, DOI 10.1002/g.cc.20128; Bignell GR, 2004, GENOME RES, V14, P287, DOI 10.1101/gr.2012304; Boige V, 1997, CANCER RES, V57, P1986; Buckley PG, 2005, CANCER RES, V65, P2653, DOI 10.1158/0008-5472.CAN-04-3651; Cvetkovic D, 2004, GYNECOL ONCOL, V95, P449, DOI 10.1016/j.ygyno.2004.08.051; ENGEL E, 1993, AM J MED GENET, V46, P670, DOI 10.1002/ajmg.1320460613; ENGEL E, 1980, AM J MED GENET, V6, P137, DOI 10.1002/ajmg.1320060207; GRUNDY P, 1994, AM J HUM GENET, V54, P282; Hashimoto K, 2004, MODERN PATHOL, V17, P617, DOI 10.1038/modpathol.3800107; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hoque MO, 2003, CANCER RES, V63, P2216; Ishikawa S, 2005, BIOCHEM BIOPH RES CO, V333, P1309, DOI 10.1016/j.bbrc.2005.06.040; Janne PA, 2004, ONCOGENE, V23, P2716, DOI 10.1038/sj.onc.1207329; Jou YS, 2004, CANCER RES, V64, P3030, DOI 10.1158/0008-5472.CAN-03-2320; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Kano M, 2003, PHYSIOL GENOMICS, V13, P31, DOI 10.1152/physiolgenomics.00116.2002; Katoh H, 2005, J HEPATOL, V43, P863, DOI 10.1016/j.jhep.2005.05.033; Kennedy GC, 2003, NAT BIOTECHNOL, V21, P1233, DOI 10.1038/nbt869; Kitayama Y, 2003, LAB INVEST, V83, P1311, DOI 10.1097/01.LAB.0000087622.80751.C5; Kondo Y, 2000, HEPATOLOGY, V32, P970, DOI 10.1053/jhep.2000.19797; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Lieberfarb ME, 2003, CANCER RES, V63, P4781; Lindblad-Toh K, 2000, NAT BIOTECHNOL, V18, P1001, DOI 10.1038/79269; Lucito R, 2003, GENOME RES, V13, P2291, DOI 10.1101/gr.1349003; MALCOLM S, 1991, LANCET, V337, P694, DOI 10.1016/0140-6736(91)90278-W; Mei R, 2000, GENOME RES, V10, P1126, DOI 10.1101/gr.10.8.1126; Midorikawa Y, 2002, JPN J CANCER RES, V93, P636, DOI 10.1111/j.1349-7006.2002.tb01301.x; Midorikawa Y, 2004, CANCER RES, V64, P7263, DOI 10.1158/0008-5472.CAN-04-1275; Murthy SK, 2002, MODERN PATHOL, V15, P1241, DOI 10.1097/01.MP.0000032535.62750.D1; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Nannya Y, 2005, CANCER RES, V65, P6071, DOI 10.1158/0008-5472.CAN-05-0465; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; Niketeghad F, 2001, BRIT J CANCER, V85, P697, DOI 10.1054/bjoc.2001.1963; Okabe H, 2000, HEPATOLOGY, V31, P1073, DOI 10.1053/he.2000.6409; Patil MA, 2005, CARCINOGENESIS, V26, P2050, DOI 10.1093/carcin/bgi178; Piao Z, 1998, INT J CANCER, V75, P29, DOI 10.1002/(SICI)1097-0215(19980105)75:1<29::AID-IJC5>3.3.CO;2-#; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Raghavan M, 2005, CANCER RES, V65, P375; Sano T, 2006, PATHOL INT, V56, P117, DOI 10.1111/j.1440-1827.2006.01940.x; TAGUCHI T, 1993, CANCER RES, V53, P4349; TEMPLE IK, 1995, NAT GENET, V9, P110, DOI 10.1038/ng0295-110; THRASHBINGHAM CA, 1995, CANCER RES, V55, P6189; Upender MB, 2004, CANCER RES, V64, P6941, DOI 10.1158/0008-5472.CAN-04-0474; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; Zhao XJ, 2004, CANCER RES, V64, P3060, DOI 10.1158/0008-5472.CAN-03-3308	53	81	86	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2006	25	40					5581	5590		10.1038/sj.onc.1209537	http://dx.doi.org/10.1038/sj.onc.1209537			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16785998				2022-12-17	WOS:000240370400012
J	Khidr, L; Chen, PL				Khidr, L.; Chen, P-L			RB, the conductor that orchestrates life, death and differentiation	ONCOGENE			English	Review						RB; differentiation; E2F; EID-1	RETINOBLASTOMA GENE-PRODUCT; TUMOR-SUPPRESSOR PROTEIN; SKELETAL-MUSCLE CELLS; ADIPOCYTE DIFFERENTIATION; S-PHASE; HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; INHIBITS TRANSACTIVATION; SUSCEPTIBILITY GENE; RESTRICTION POINT	The retinoblastoma susceptibility gene was the first tumor suppressor gene identified in humans and the first tumor suppressor gene knocked out by targeted deletion in mice. RB serves as a transducer between the cell cycle machinery and promoter-specific transcription factors, its most documented activity being the repression of the E2F family of transcription factors, which regulate the expression of genes involved in cell proliferation and survival. Recent investigations of RB function suggest that it works as a fundamental regulator to coordinate pathways of cellular growth and differentiation. In this review, we unravel the novel role of an equally important aspect of RB in downregulating the differentiation inhibitor EID-1 during cellular differentiation by teasing apart the signal, which elicit differentiation and limit cell cycle progression, since the molecular mechanisms relating to RB activation of differentiation is much less understood. We review the various roles for RB in differentiation of neurons, muscle, adipose tissue, and the retina. In addition, we provide an update for the current models of the role of RB in cell cycle to entry and exit, extending the view toward chromatin remodeling and expose the dichotomies in the regulation of RB family members. We conclude with a discussion of a novel RB regulatory network, incorporating the dynamic contribution of EID family proteins.	Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Chen, PL (corresponding author), Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA.	plchen@uci.edu	Chen, Phang-Lang/J-5031-2013					Ait-Si-Ali S, 2004, EMBO J, V23, P605, DOI 10.1038/sj.emboj.7600074; Barbie DA, 2004, MOL CELL BIOL, V24, P595, DOI 10.1128/MCB.24.2.595-607.2004; Bavner A, 2005, NUCLEIC ACIDS RES, V33, P3561, DOI 10.1093/nar/gki667; Bavner A, 2002, EMBO REP, V3, P478, DOI 10.1093/embo-reports/kvf087; BENEDICT WF, 1983, SCIENCE, V219, P973, DOI 10.1126/science.6336308; Black EP, 2003, CANCER RES, V63, P3716; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chen D, 2004, CANCER CELL, V5, P539, DOI 10.1016/j.ccr.2004.05.025; CHEN PL, 1995, CELL GROWTH DIFFER, V6, P199; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2000, P NATL ACAD SCI USA, V97, P10826, DOI 10.1073/pnas.190343597; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; COPPOLA JA, 1990, ONCOGENE, V5, P1731; Cvekl A, 2004, INT J DEV BIOL, V48, P829, DOI 10.1387/ijdb.041866ac; Cvekl A, 1999, INVEST OPHTH VIS SCI, V40, P1343; de Bruin A, 2003, P NATL ACAD SCI USA, V100, P6546, DOI 10.1073/pnas.1031853100; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Delehouzee S, 2005, GENES CELLS, V10, P717, DOI 10.1111/j.1365-2443.2005.00873.x; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; DOU QP, 1993, CANCER RES, V53, P1493; Dyer MA, 2005, NAT REV CANCER, V5, P91, DOI 10.1038/nrc1545; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eckner R, 1996, BIOL CHEM, V377, P685; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FERGUSON KL, 2005, EMBO J; Ferreira R, 2001, EMBO REP, V2, P794, DOI 10.1093/embo-reports/kve173; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Goodman RH, 2000, GENE DEV, V14, P1553; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Hannan KM, 2000, ONCOGENE, V19, P3487, DOI 10.1038/sj.onc.1203690; Hansen JB, 2004, P NATL ACAD SCI USA, V101, P4112, DOI 10.1073/pnas.0301964101; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; Higgins C, 1996, J VIROL, V70, P745, DOI 10.1128/JVI.70.2.745-752.1996; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Hub MS, 2004, J CELL BIOL, V166, P865, DOI 10.1083/jcb.200403004; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Ji AM, 2003, GENE, V318, P35, DOI 10.1016/j.gene.2003.06.001; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KATO J, 1993, GENE DEV, V7, P331; Krutzfeldt M, 2005, MOL CELL, V18, P213, DOI 10.1016/j.molcel.2005.03.009; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; MacLellan WR, 2000, MOL CELL BIOL, V20, P8903, DOI 10.1128/MCB.20.23.8903-8915.2000; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mantela J, 2005, DEVELOPMENT, V132, P2377, DOI 10.1242/dev.01834; MAYOL X, 1993, ONCOGENE, V8, P2561; McDonnell TJ, 1999, J PATHOL, V188, P322, DOI 10.1002/(SICI)1096-9896(199907)188:3<322::AID-PATH372>3.0.CO;2-F; Miyake S, 2000, MOL CELL BIOL, V20, P8889, DOI 10.1128/MCB.20.23.8889-8902.2000; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; NEVINS JR, 1992, SCIENCE, V258, P424; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Nicolas E, 2003, MOL CELL BIOL, V23, P1614, DOI 10.1128/MCB.23.5.1614-1622.2003; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; OBEYESEKERE MN, 1995, ONCOGENE, V11, P1199; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Pradhan S, 2002, EMBO J, V21, P779, DOI 10.1093/emboj/21.4.779; RAY SK, 1992, MOL CELL BIOL, V12, P4327, DOI 10.1128/MCB.12.10.4327; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rodier G, 2005, J CELL BIOL, V168, P55, DOI 10.1083/jcb.200404146; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; Sage C, 2005, SCIENCE, V307, P1114, DOI 10.1126/science.1106642; Sandmoller A, 1996, MOL CELL BIOL, V16, P5846; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; Scime A, 2005, CELL METAB, V2, P283, DOI 10.1016/j.cmet.2005.10.002; Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Slack RS, 1998, J CELL BIOL, V140, P1497, DOI 10.1083/jcb.140.6.1497; Takahashi Y, 2000, GENE DEV, V14, P804; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; WINDLE JJ, 1990, NATURE, V343, P665, DOI 10.1038/343665a0; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zhang HS, 2001, ONCOGENE, V20, P3134, DOI 10.1038/sj.onc.1204338; Zhang JK, 2004, NAT GENET, V36, P351, DOI 10.1038/ng1318; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	116	81	82	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5210	5219		10.1038/sj.onc.1209612	http://dx.doi.org/10.1038/sj.onc.1209612			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936739				2022-12-17	WOS:000240064100004
J	Caslini, C; D Capo-Chichi, C; Roland, IH; Nicolas, E; T Yeung, A; Xu, XX				Caslini, C.; D Capo-Chichi, C.; Roland, I. H.; Nicolas, E.; T Yeung, A.; Xu, X-X			Histone modifications silence the GATA transcription factor genes in ovarian cancer	ONCOGENE			English	Article						ovarian epithelial cells; ovarian carcinomas; chromatin; transcription repression; GATA transcription factors; Disabled-2 (DAB2)	TUMOR-SUPPRESSOR GENE; H3 LYSINE 9; METHYLATION PATTERNS; HYPERSENSITIVE SITE; GASTRIC-CANCER; ALLELIC LOSS; ACETYLATION; EXPRESSION; DNA; CARCINOMAS	Altered expression of GATA factors was found and proposed as the underlying mechanism for dedifferentiation in ovarian carcinogenesis. In particular, GATA6 is lost or excluded from the nucleus in 85% of ovarian tumors and GATA4 expression is absent in majority of ovarian cancer cell lines. Here, we evaluated their DNA and histone epigenetic modi. cations in five ovarian epithelial and carcinoma cell lines (human 'immortalized' ovarian surface epithelium (HIO)-117, HIO-114, A2780, SKOV3 and ES2). GATA4 and GATA6 gene silencing was found to correlate with hypoacetylation of histones H3 and H4 and loss of histone H3/lysine K4 trimethylation at their promoters in all lines. Conversely, histone H3/lysine K9 di-methylation and HP1 gamma association were not observed, excluding reorganization of GATA genes into heterochromatic structures. The histone deacetylase inhibitor trichostatin A, but not the DNA methylation inhibitor 5'-aza-2'-deoxycytidine, re-established the expression of GATA4 and/or GATA6 in A2780 and HIO-114 cells, correlating with increased histone H3 and H4 acetylation, histone H3 lysine K4 methylation and DNase I sensitivity at the promoters. Therefore, altered histone modi. cation of the promoter loci is one mechanism responsible for the silencing of GATA transcription factors and the subsequent loss of a target gene, the tumor suppressor Disabled-2, in ovarian carcinogenesis.	Fox Chase Canc Ctr, Ovarian Canc Program, Dept Med Oncol, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Tumor Cell Biol Program, Dept Med Oncol, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Basic Sci & Fannie E Rippel Biochem & Biotechnol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center; Fox Chase Cancer Center; Fox Chase Cancer Center	Xu, XX (corresponding author), Fox Chase Canc Ctr, Ovarian Canc Program, Dept Med Oncol, 333 Cottman Ave, Philadelphia, PA 19111 USA.	xiangxi.xu@fccc.edu	Caslini, Corrado/A-1689-2012; Caslini, Corrado/W-6123-2019	Caslini, Corrado/0000-0001-8326-8368; Caslini, Corrado/0000-0001-8326-8368; CAPO-CHICHI, D. Callinice/0000-0003-4941-7301	NATIONAL CANCER INSTITUTE [P30CA006927, R01CA075389, R01CA079716, P50CA083638] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA79716, P50 CA083638, R01 CA75389, P30 CA006927, CA006927, P50 CA83638, R01 CA079716] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bai YQ, 2000, MOL CARCINOGEN, V28, P184, DOI 10.1002/1098-2744(200007)28:3<184::AID-MC7>3.0.CO;2-6; Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BOVA GS, 1993, CANCER RES, V53, P3869; Capo-Chichi CD, 2003, CANCER RES, V63, P4967; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; FUJIWARA Y, 1993, CANCER RES, V53, P1172; Gong QH, 1996, MOL CELL BIOL, V16, P6055; Gregory PD, 2001, EXP CELL RES, V265, P195, DOI 10.1006/excr.2001.5187; Guo MZ, 2004, CLIN CANCER RES, V10, P7917, DOI 10.1158/1078-0432.CCR-04-1140; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Ho CL, 2004, CANCER RES, V64, P6915, DOI 10.1158/0008-5472.CAN-04-2067; JACKSON PD, 1985, P NATL ACAD SCI USA, V82, P2296, DOI 10.1073/pnas.82.8.2296; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lassus H, 2001, LAB INVEST, V81, P517, DOI 10.1038/labinvest.3780260; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Morrisey EE, 2000, J BIOL CHEM, V275, P19949, DOI 10.1074/jbc.M001331200; Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013; Nemer G, 1999, MAMM GENOME, V10, P993, DOI 10.1007/s003359901146; Park IK, 2004, J CLIN INVEST, V113, P175, DOI 10.1172/JCI200420800; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Sheng ZJ, 2000, ONCOGENE, V19, P4847, DOI 10.1038/sj.onc.1203853; Spencer VA, 2003, METHODS, V31, P67, DOI 10.1016/S1046-2023(03)00089-6; Umlauf David, 2004, Methods Mol Biol, V287, P99; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; WAKANA K, 2005, CANC LETT; Yang DH, 2002, DEV BIOL, V251, P27, DOI 10.1006/dbio.2002.0810; Yang DH, 2002, CANCER-AM CANCER SOC, V94, P2380, DOI 10.1002/cncr.10497; ZHENG JP, 1995, J NATL CANCER I, V87, P1146, DOI 10.1093/jnci/87.15.1146; ZHENG JP, 1993, CANCER RES, V53, P4138	44	81	84	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	39					5446	5461		10.1038/sj.onc.1209533	http://dx.doi.org/10.1038/sj.onc.1209533			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16607277	Green Accepted			2022-12-17	WOS:000240144900009
J	Shulewitz, M; Soloviev, I; Wu, T; Koeppen, H; Polakis, P; Sakanaka, C				Shulewitz, M.; Soloviev, I.; Wu, T.; Koeppen, H.; Polakis, P.; Sakanaka, C.			Repressor roles for TCF-4 and Sfrp1 in Wnt signaling in breast cancer	ONCOGENE			English	Article						Wnt; TCF-4; Sfrp1; breast cancer	BETA-CATENIN; COLORECTAL-CANCER; PROGNOSTIC MARKER; CYCLIN D1; EXPRESSION; TRANSCRIPTION; GENE; CELLS; PROTEIN; APC	Mutations in Wnt pathway genes are rare in human breast cancer, yet activation of the pathway is evident from the misolocalization of beta-catenin. We searched for relationships in the expression of Wnt pathway genes and found that both secreted frizzled related protein 1 (Sfrp1) and TCF-4 transcripts were all highly downregulated in a common subset of breast cancers relative to normal breast tissue. Sfrp1 has been previously characterized as a Wnt inhibitor, and we found that interfering with its expression in the human mammary epithelial cell line MCF10A activated Wnt signaling. Reduction of TCF-4 levels in breast cancer was surprising as it is a transcription factor that is responsive to Wnt signaling. Therefore, we investigated a possible inhibitory role for TCF-4 in human breast cells as well as further characterizing Sfrp1. We identified CD24 as a Wnt target in MCF10A cells and used its expression a marker of Wnt signaling. Interfering with either Sfrp1 or TCF-4 in this cell line enhanced CD24 expression. Furthermore, removal of TCF/LEF binding sites in a CD24-luciferase reporter resulted in elevated reporter gene expression. Our results indicate that both Sfrp1 and TCF-4 repress Wnt signaling in breast tissue and their downregulation contributes to the activation of Wnt signaling.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Bioinformat, San Francisco, CA 94080 USA; Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Sakanaka, C (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way,MS40, San Francisco, CA 94080 USA.	chies@gene.com						Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Brannon M, 1999, DEVELOPMENT, V126, P3159; Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; Bukholm IK, 2000, J PATHOL, V190, P15; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chung GG, 2004, CANCER, V100, P2084, DOI 10.1002/cncr.20232; Cowin P, 2005, CURR OPIN CELL BIOL, V17, P499, DOI 10.1016/j.ceb.2005.08.014; Dorsky RI, 2003, DEVELOPMENT, V130, P1937, DOI 10.1242/dev.00402; Duval A, 2000, CANCER RES, V60, P3872; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Hatsell S, 2003, J MAMMARY GLAND BIOL, V8, P145, DOI 10.1023/A:1025944723047; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/ng0501-53; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Kim CH, 2000, NATURE, V407, P913, DOI 10.1038/35038097; Kouzmenko AP, 2004, J BIOL CHEM, V279, P40255, DOI 10.1074/jbc.C400331200; Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7; Kristiansen G, 2003, CLIN CANCER RES, V9, P4906; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lo MC, 2004, CELL, V117, P95, DOI 10.1016/S0092-8674(04)00203-X; Merrill BJ, 2004, DEVELOPMENT, V131, P263, DOI 10.1242/dev.00935; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PIRRUCCELLO SJ, 1986, J IMMUNOL, V136, P3779; Polakis P, 2000, GENE DEV, V14, P1837; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Sinner D, 2004, DEVELOPMENT, V131, P3069, DOI 10.1242/dev.01176; SOULE HD, 1990, CANCER RES, V50, P6075; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Thorpe CJ, 2004, DEVELOPMENT, V131, P2899, DOI 10.1242/dev.01171; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Wong SCC, 2002, J PATHOL, V196, P145, DOI 10.1002/path.1035	48	81	87	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2006	25	31					4361	4369		10.1038/sj.onc.1209470	http://dx.doi.org/10.1038/sj.onc.1209470			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16532032				2022-12-17	WOS:000239240100011
J	Mitra, SK; Lim, ST; Chi, A; Schlaepfer, DD				Mitra, S. K.; Lim, S-T; Chi, A.; Schlaepfer, D. D.			Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model	ONCOGENE			English	Article						FAK; FRNK; shRNA; uPA; invasion; metastasis	CELL MOTILITY; GROWTH-FACTOR; FAK EXPRESSION; CANCER CELLS; MIGRATION; INVASION; SRC; PROMOTES; APOPTOSIS; DEATH	Expression of focal adhesion kinase (FAK) is elevated in malignant breast cancer, yet the role of intrinsic FAK activity in promoting tumor progression remains undefined. Here, we have inhibited FAK activity or expression in murine 4T1 breast carcinoma cells via dominant-negative focal adhesion kinase-related non-kinase (FRNK) or anti-FAK short hairpin RNA (shRNA) expression, respectively. Neither FRNK nor FAK shRNA (similar to 80% reduced FAK levels) affected 4T1 proliferation in culture, whereas reduced FAK activity or expression blocked 4T1 cell invasion through Matrigel and resulted in 2-3-fold lower urokinase plasminogen activator (uPA) expression. Control 4T1 cells implanted into mammary fat pads of BALB/c mice exhibited spontaneous metastasis to the lungs, to the peritoneal cavity, and resulted in 90% lethality within 21 days. Whereas FAK shRNA-expressing 4T1 cells formed tumors in mice with low levels of apoptosis, when mammary-injected, these cells did not exhibit lung metastasis after 21 days and caused only 40% lethality up to 60 days. Transient re-expression of wildtype but not kinase-dead FAK in 4T1 FAK shRNA cells promoted uPA production and mammary to lung metastasis within 7 days. In fact, stable human uPA overexpression in 4T1 FAK shRNA cells promoted Matrigel invasion and lung metastasis equal to 4T1 controls. Conversely, treatment with plasminogen activator inhibitor-1 or neutralizing antibody to uPA blocked Matrigel invasion of 4T1 control cells. These studies provide the first direct proof that FAK catalytic activity can facilitate metastatic breast cancer progression by regulating uPA expression.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Schlaepfer, DD (corresponding author), Scripps Res Inst, Dept Immunol, IMM 21,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dschlaep@scripps.edu		Lim, Steve/0000-0003-0323-8607	NATIONAL CANCER INSTITUTE [R29CA075240, R01CA087038, R01CA102310, R01CA075240] Funding Source: NIH RePORTER; NCI NIH HHS [CA75240, CA87038, CA102310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdel-Ghany M, 2002, J BIOL CHEM, V277, P34391, DOI 10.1074/jbc.M205307200; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Benlimame N, 2005, J CELL BIOL, V171, P505, DOI 10.1083/jcb.200504124; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Buccione R, 2004, NAT REV MOL CELL BIO, V5, P647, DOI 10.1038/nrm1436; Duxbury MS, 2003, BIOCHEM BIOPH RES CO, V311, P786, DOI 10.1016/j.bbrc.2003.10.060; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Ghiso JAA, 2002, ONCOGENE, V21, P2513, DOI 10.1038/sj/onc/1205342; Golubovskaya V, 2002, J BIOL CHEM, V277, P38978, DOI 10.1074/jbc.M205002200; Han EKH, 2004, ANTICANCER RES, V24, P3899; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; Hauck CR, 2002, J BIOL CHEM, V277, P12487, DOI 10.1074/jbc.C100760200; Hauck CR, 2001, CANCER RES, V61, P7079; Heppner GH, 2000, BREAST CANCER RES, V2, P331; Hess AR, 2005, CANCER RES, V65, P9851, DOI 10.1158/0008-5472.CAN-05-2172; Hsia DA, 2005, MOL CELL BIOL, V25, P9700, DOI 10.1128/MCB.25.21.9700-9712.2005; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Itoh S, 2004, CLIN CANCER RES, V10, P2812, DOI 10.1158/1078-0432.CCR-1046-03; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Lightfoot HM, 2004, BREAST CANCER RES TR, V88, P109, DOI 10.1007/s10549-004-1022-8; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Miyazaki T, 2003, BRIT J CANCER, V89, P140, DOI 10.1038/sj.bjc.6601050; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Oktay MH, 2003, HUM PATHOL, V34, P240, DOI 10.1053/hupa.2003.40; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Recher C, 2004, CANCER RES, V64, P3191, DOI 10.1158/0008-5472.CAN-03-3005; Rubio CA, 2003, EUR J CLIN INVEST, V33, P406, DOI 10.1046/j.1365-2362.2003.01151.x; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Sood AK, 2004, AM J PATHOL, V165, P1087, DOI 10.1016/S0002-9440(10)63370-6; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tilghman RW, 2005, J CELL SCI, V118, P2613, DOI 10.1242/jcs.02380; van Nimwegen MJ, 2005, CANCER RES, V65, P4698, DOI 10.1158/0008-5472.CAN-04-4126; Watermann DO, 2005, BRIT J CANCER, V93, P694, DOI 10.1038/sj.bjc.6602744; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Wu XY, 2005, DEV CELL, V9, P185, DOI 10.1016/j.devcel.2005.06.006; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Xu LH, 1998, CELL GROWTH DIFFER, V9, P999; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; YU H, 1990, CANCER RES, V50, P7623	48	81	88	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	32					4429	4440		10.1038/sj.onc.1209482	http://dx.doi.org/10.1038/sj.onc.1209482			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16547501				2022-12-17	WOS:000239326000006
J	Liu, Y; Chen, L; Ko, TC; Fields, AP; Thompson, EA				Liu, Y.; Chen, L.; Ko, T. C.; Fields, A. P.; Thompson, E. A.			Evi1 is a survival factor which conveys resistance to both TGFb-beta and taxol-mediated cell death via PI3K/AKT	ONCOGENE			English	Article						apoptosis; carcinogenesis; colon cancer; cell signaling; chemotherapy	KINASE-C-IOTA; INDUCED APOPTOSIS; PROTEIN; GROWTH; GENE; TRANSCRIPTION; AMPLIFICATION; EXPRESSION; ACTIVATION; INHIBITION	In hematopoietic cells the transforming potential of the ecotropic viral integration site 1 (Evi1) oncogene is thought to be dependent upon the ability to inhibit TGF beta signaling. Although Evi1 has recently been implicated in certain epithelial cancers, the effects of Evi1 on transformation and TGF beta signaling in epithelial cells are not completely understood. Herein, we have determined the effects of Evi1 on TGF beta signaling in intestinal epithelial cells. Stable expression of Evi1 in non-transformed intestinal epithelial cells inhibited induction of some Smad3-dependent TGF beta target genes, such as PAI1. However, TGF beta-mediated induction of cellular adhesion signaling components such as integrin1 and paxillin was not inhibited by Evi1; nor did Evi1 inhibit TGF beta-mediated epithelial to mesenchymal transition. Likewise, Evi1 did not inhibit TGF beta-mediated downregulation of cyclin D1 or block TGF beta-mediated growth inhibition. However, Evi1 did inhibit TGF beta-mediated apoptosis by a process that involves phosphoinositide-3-kinase (PI3K) and its downstream effector AKT. The ability of Evi1 to suppress apoptosis is not restricted to TGF beta-mediated cell death, since Evi1 also protects intestinal epithelial cells from taxol-mediated apoptosis. Evi1 is overexpressed in some human colon cancer cell lines, and overexpression is associated with amplification of the Evi1 gene. Knockdown of Evi1 by siRNA inhibited AKT phosphorylation in HT-29 human colon cancer cells and increased their sensitivity to taxol-mediated apoptosis. These data indicate that Evi1 functions as a survival gene in intestinal epithelial cells and colon cancer cells, activating PI3K/AKT and conveying resistance to both physiological and therapeutic apoptotic stimuli.	Mayo Clin, Dept Canc Biol, Ctr Comprehens Canc, Jacksonville, FL 32224 USA; Univ Texas, Med Branch, Dept Surg, Galveston, TX 77550 USA	Mayo Clinic; University of Texas System; University of Texas Medical Branch Galveston	Fields, AP (corresponding author), Mayo Clin, Dept Canc Biol, Ctr Comprehens Canc, 4500 San Pablo Rd,Griffin Canc Res Bldg,RM310, Jacksonville, FL 32224 USA.	fields.alan@mayo.edu; thompson.aubrey@mayo.edu			NCI NIH HHS [R01CA64701] Funding Source: Medline; NIDDK NIH HHS [R01DK060105, P01DK35608] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060105, P01DK035608] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Alliston T, 2005, J BIOL CHEM, V280, P24227, DOI 10.1074/jbc.M414305200; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; Bergamo NA, 2000, CANCER GENET CYTOGEN, V119, P48, DOI 10.1016/S0165-4608(99)00213-7; Brass N, 1996, EUR J CANCER, V32A, P1205, DOI 10.1016/0959-8049(96)00016-0; Brooks DJ, 1996, BRIT J CANCER, V74, P1518, DOI 10.1038/bjc.1996.583; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hay ED, 1995, ACTA ANAT, V154, P8; Higashidani Y, 2003, DIS COLON RECTUM, V46, P327, DOI 10.1007/s10350-004-6551-z; Hirai H, 1999, INT J BIOCHEM CELL B, V31, P1367, DOI 10.1016/S1357-2725(99)00064-3; Imoto I, 2001, BIOCHEM BIOPH RES CO, V286, P559, DOI 10.1006/bbrc.2001.5428; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; KO TC, 1995, ONCOGENE, V10, P177; KO TC, 1994, AM J SURG, V167, P14, DOI 10.1016/0002-9610(94)90048-5; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kurokawa M, 2000, EMBO J, V19, P2958, DOI 10.1093/emboj/19.12.2958; MARKOWITZ S, 1995, CLIN CANCER RES, V1, P441; Mochizuki N, 2000, BLOOD, V96, P3209, DOI 10.1182/blood.V96.9.3209.h8003209_3209_3214; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; Murray NR, 2002, J CELL BIOL, V157, P915, DOI 10.1083/jcb.200201127; Ogawa S, 1996, ONCOGENE, V13, P183; Palmer S, 2001, J BIOL CHEM, V276, P25834, DOI 10.1074/jbc.M102343200; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; PARSONS R, 1995, CANCER RES, V55, P5548; Racz A, 1999, EUR J CANCER, V35, P641, DOI 10.1016/S0959-8049(98)00419-5; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Riggins GJ, 1997, CANCER RES, V57, P2578; Roman C, 2001, MICROSC RES TECHNIQ, V52, P450, DOI 10.1002/1097-0029(20010215)52:4<450::AID-JEMT1030>3.0.CO;2-O; Sattler HP, 2000, PROSTATE, V45, P207, DOI 10.1002/1097-0045(20001101)45:3<207::AID-PROS2>3.0.CO;2-H; Shih WL, 2000, J BIOL CHEM, V275, P25858, DOI 10.1074/jbc.M003578200; Sonoda G, 1997, GENE CHROMOSOME CANC, V20, P320; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; Sugita M, 2000, CANCER GENET CYTOGEN, V117, P9, DOI 10.1016/S0165-4608(99)00135-1; TANAKA T, 1994, J BIOL CHEM, V269, P24020; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Winesett MP, 1996, CARCINOGENESIS, V17, P989, DOI 10.1093/carcin/17.5.989; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zhang J, 2004, J BIOL CHEM, V279, P22118, DOI 10.1074/jbc.M400774200	46	81	87	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3565	3575		10.1038/sj.onc.1209403	http://dx.doi.org/10.1038/sj.onc.1209403			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16462766				2022-12-17	WOS:000238448200009
J	Annicotte, JS; Chavey, C; Servant, N; Teyssier, J; Bardin, A; Licznar, A; Badia, E; Pujol, P; Vignon, F; Maudelonde, T; Lazennec, G; Cavailles, V; Fajas, L				Annicotte, JS; Chavey, C; Servant, N; Teyssier, J; Bardin, A; Licznar, A; Badia, E; Pujol, P; Vignon, F; Maudelonde, T; Lazennec, G; Cavailles, V; Fajas, L			The nuclear receptor liver receptor homolog-1 is an estrogen receptor target gene	ONCOGENE			English	Article						breast cancer; E2; estrogen receptor; Ftz-F1; LRH-1; nuclear receptors; transcription	CYCLIN D1; BREAST-CANCER; INDEPENDENT ACTIVATION; REGULATES EXPRESSION; LRH-1; ELEMENT; PROLIFERATION; RECRUITMENT; PROGRESSION; AROMATASE	Liver receptor homolog-1 (LRH-1) is a nuclear receptor previously known to have distinct functions during mouse development and essential roles in cholesterol homeostasis. Recently, a new role for LRH-1 has been discovered in tumor progression, giving LRH-1 potential transforming functions. In order to identify critical factors stimulating LRH-1 expression leading to deregulated cellular proliferation, we studied its expression and its regulation in several breast cancer cell lines. We observed that LRH-1 expression was increased in estrogen receptor (ER) alpha expressing cell lines, whereas weak-to-no expression was found in nonexpressing ER alpha cell lines. In MCF7, LRH-1 expression was highly induced after treatment with 17 beta-estradiol (E2). This transcriptional regulation was the result of a direct binding of the ER to the LRH-1 promoter, as demonstrated by gelshift and chromatin immunoprecipitation assays. Interestingly, siRNA-mediated inactivation of LRH-1 decreased the E2-dependent proliferation of MCF7 cells. Finally, LRH-1 protein expression was detected by immunohistochemistry in tumor cells of human mammary ductal carcinomas. Altogether, these data demonstrate that LRH-1 is transcriptionally regulated by the ER a and reinforce the hypothesis that LRH-1 could exert potential oncogenic effects during breast cancer formation.	INSERM, Equipe Avenir, U540, F-34090 Montpellier, France; INSERM, Equipe Avenir, F-34090 Montpellier, France; CHU Arnaud Villeneuve, Biol Cellulaire Lab, F-34090 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier	Fajas, L (corresponding author), INSERM, Equipe Avenir, U540, 60 Rue Navacelles, F-34090 Montpellier, France.	fajas@montp.inserm.fr	cavailles, vincent/C-6277-2017; Coll, Lluis Fajas/C-8567-2014; Annicotte, Jean-Sébastien/H-4641-2018; Cavailles, Vincent/Y-5379-2019	Annicotte, Jean-Sébastien/0000-0002-2109-4849; Cavailles, Vincent/0000-0002-7160-3074; Lazennec, Gwendal/0000-0002-8522-1763; Fajas, Lluis/0000-0002-1283-9503; BADIA, Eric/0000-0002-8922-9834; Chavey, Carine/0000-0002-5267-5638				Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Annicotte JS, 2003, MOL CELL BIOL, V23, P6713, DOI 10.1128/MCB.23.19.6713-6724.2003; Bardin A, 2004, ENDOCR-RELAT CANCER, V11, P537, DOI 10.1677/erc.1.00800; Botrugno OA, 2004, MOL CELL, V15, P499, DOI 10.1016/j.molcel.2004.07.009; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; Cicatiello L, 2004, MOL CELL BIOL, V24, P7260, DOI 10.1128/MCB.24.16.7260-7274.2004; Clyne CD, 2002, J BIOL CHEM, V277, P20591, DOI 10.1074/jbc.M201117200; Falender AE, 2003, ENDOCRINOLOGY, V144, P3598, DOI 10.1210/en.2002-0137; Fayard E, 2004, TRENDS CELL BIOL, V14, P250, DOI 10.1016/j.tcb.2004.03.008; Hinshelwood MM, 2003, MOL CELL ENDOCRINOL, V207, P39, DOI 10.1016/S0303-7207(03)00257-0; Krylova IN, 2005, CELL, V120, P343, DOI 10.1016/j.cell.2005.01.024; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Pare JF, 2004, J BIOL CHEM, V279, P21206, DOI 10.1074/jbc.M401523200; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Sablin EP, 2003, MOL CELL, V11, P1575, DOI 10.1016/S1097-2765(03)00236-3; SCHOONJANS K, 2005, P NATL ACAD SCI US; Zhou J, 2005, CANCER RES, V65, P657; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	24	81	87	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2005	24	55					8167	8175		10.1038/sj.onc.1208950	http://dx.doi.org/10.1038/sj.onc.1208950			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16091743	Green Accepted, Green Submitted			2022-12-17	WOS:000233809400008
J	Vega, MI; Huerta-Yepez, S; Jazirehi, AR; Garban, H; Bonavida, B				Vega, MI; Huerta-Yepez, S; Jazirehi, AR; Garban, H; Bonavida, B			Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis	ONCOGENE			English	Article						non-Hodgkin's lymphoma; Fas; NF-kappa B; YY1; sensitization	NON-HODGKINS-LYMPHOMA; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACTIVATED PROTEIN-KINASE; FACTOR-KAPPA-B; IN-VIVO; SIGNALING PATHWAY; CONSTITUTIVE ACTIVATION; MONOCLONAL-ANTIBODY; DOWN-REGULATION; UP-REGULATION	Rituximab (chimeric anti-CD20 monoclonal antibodies) is currently being used in the treatment of B non-Hodgkin's lymphoma (NHL). We have recently reported that rituximab triggers and modifies various intracellular signaling pathways in NHL B-cell lines, resulting in reverting the chemoresistant phenotype to a sensitive phenotype. This study investigated whether rituximab also modifies intracellular signaling pathways resulting in the sensitization of NHL cells to Fas-induced apoptosis. Treatment of the Fas-resistant NHL cell lines (2F7, Ramos and Raji) with rituximab sensitized the cells to CH-11 (FasL agonist mAb)-induced apoptosis and synergy was achieved. Fas expression was upregulated by rituximab as early as 6 h post-treatment as determined by flow cytometry, reverse transcriptase-polymerase chain reaction and Western blot. Rituximab inhibited both the expression and activity of the transcription repressor Yin-Yang 1 (YY1) that negatively regulates Fas transcription. Inhibition of YY1 resulted in the upregulation of Fas expression and sensitization of the tumor cells to CH-11-induced apoptosis. The downregulation of YY1 expression was the result of rituximab- induced inhibition of both the p38 mitogen-activated protein kinase (MAPK) signaling pathway and constitutive nuclear factor kappa of B cells (NF-kappa B) activity. The involvement of NF-kappa B and YY1 in the regulation of Fas expression was corroborated by the use of Ramos cells with a dominant-active inhibitor of NF-kappa B (Ramos I kappa B-estrogen receptor (ER) mutant) and by silencing YY1 with YY1 siRNA, respectively. Further, the role of rituximab- mediated inhibition of the p38 MAPK/NF-kappa B/YY1 pathway in the regulation of Fas and sensitization to CH-11-induced apoptosis was validated by the use of specific chemical inhibitors of this pathway and which mimicked rituximab-mediated effects. These findings provide a novel mechanism of rituximab-mediated activity by sensitizing NHL cells to Fas-induced apoptosis.	Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Jonnson Comprehens Canc Ctr, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Bonavida, B (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, 10833 Le Conte Ave,A2-060 CHS, Los Angeles, CA 90095 USA.	bbonavida@mednet.ucla.edu	Vega, Mario/AAZ-4315-2020	Garban, Hermes/0000-0001-7754-5357; Vega, Mario I/0000-0002-3932-2483	FIC NIH HHS [D43 TW00013-14] Funding Source: Medline; NIAID NIH HHS [AI28697] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW000013] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028697] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alas S, 2001, CLIN CANCER RES, V7, P709; Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; BERENBAUM MC, 1981, ADV CANCER RES, V35, P269, DOI 10.1016/S0065-230X(08)60912-4; Byrd JC, 2002, BLOOD, V99, P1038, DOI 10.1182/blood.V99.3.1038; CANFIELD SM, 1991, J EXP MED, V173, P1483, DOI 10.1084/jem.173.6.1483; Cragg MS, 2004, BLOOD, V103, P2738, DOI 10.1182/blood-2003-06-2031; DEANS JP, 1995, J BIOL CHEM, V270, P22632, DOI 10.1074/jbc.270.38.22632; Emmanouilides C, 2003, HEMATOL ONCOL, V21, P99, DOI 10.1002/hon.712; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; FREEDMAN AS, 1991, HEMATOL ONCOL CLIN N, V5, P871, DOI 10.1016/S0889-8588(18)30390-3; Garban HJ, 2001, J IMMUNOL, V167, P75, DOI 10.4049/jimmunol.167.1.75; Golay J, 2001, BLOOD, V98, P3383, DOI 10.1182/blood.V98.12.3383; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HONGO F, 2004, 95 ANN M AM ASS CANC, V45, P105; Huerta-Yepez S, 2004, ONCOGENE, V23, P4993, DOI 10.1038/sj.onc.1207655; Iida M, 1999, LEUKEMIA, V13, P585, DOI 10.1038/sj.leu.2401369; Iwasaki S, 1999, J BIOL CHEM, V274, P26503, DOI 10.1074/jbc.274.37.26503; Jazirehi AR, 2005, ONCOGENE, V24, P2121, DOI 10.1038/sj.onc.1208349; Jazirehi AR, 2004, CANCER RES, V64, P7117, DOI 10.1158/0008-5472.CAN-03-3500; Jazirehi AR, 2003, MOL CANCER THER, V2, P1183; Jazirehi AR, 2005, CANCER RES, V65, P264; Kennedy AD, 2003, BLOOD, V101, P1071, DOI 10.1182/blood-2002-03-0876; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Li-Weber M, 2003, SEMIN IMMUNOL, V15, P145, DOI 10.1016/S1044-5323(03)00030-7; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; Mori N, 2001, VIRUS GENES, V22, P279, DOI 10.1023/A:1011158021749; Ogasawara T, 2003, INT J HEMATOL, V77, P364, DOI 10.1007/BF02982645; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; REFF ME, 1994, BLOOD, V83, P435; Shan DM, 2000, CANCER IMMUNOL IMMUN, V48, P673, DOI 10.1007/s002620050016; Vega MI, 2004, ONCOGENE, V23, P3530, DOI 10.1038/sj.onc.1207336	31	81	93	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8114	8127		10.1038/sj.onc.1208954	http://dx.doi.org/10.1038/sj.onc.1208954			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16103877				2022-12-17	WOS:000233809400004
J	Grasemann, C; Gratias, S; Stephan, H; Schuler, A; Schramm, A; Klein-Hitpass, L; Rieder, H; Schneider, S; Kappes, F; Eggert, A; Lohmann, DR				Grasemann, C; Gratias, S; Stephan, H; Schuler, A; Schramm, A; Klein-Hitpass, L; Rieder, H; Schneider, S; Kappes, F; Eggert, A; Lohmann, DR			Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma	ONCOGENE			English	Article						retinoblastoma; tumour progression; chromosome 6p; oncogene; microarray analysis; quantitative PCR	COMPARATIVE GENOMIC HYBRIDIZATION; ACUTE MYELOID-LEUKEMIA; CHROMATIN PROTEIN DEK; TUMOR-SUPPRESSOR; BLADDER-CANCER; AMPLIFICATION; GENE; EXPRESSION; OSTEOSARCOMA; INVOLVEMENT	The paediatric eye tumour retinoblastoma is initiated by inactivation of RB1, a tumour suppressor on chromosome 13q. In addition to RB1 loss, many retinoblastomas show other genetic alterations including gains on chromosomes 6p21-pter and 1q31-q32. Recently, the minimal region of gains on chromosome 6 was narrowed to band p22. We examined genomic gains and expression changes in primary retinoblastomas to identify potential target genes in 6p22. Quantitative multiplex PCR detected copy numbers >= 3 in 25 (33%) tumours and no gains in 31 of 76 (40%) tumours. The remaining 20 (26%) samples showed gains only at some loci, most often including E2F3 and DEK in 6p22.3. Analysis of RNA from 21 primary retinoblastomas showed that expression levels of these and some other genes in 6p22 correspond to DNA gains. However, KIF 13A, a reported candidate oncogene on 6p, was expressed at low levels or absent. Clinical manifestation of tumours with gains at all 6p22 loci was distinct in that distribution of age at diagnosis was markedly shifted to older age compared to tumours with no or partial gains. In summary, our results suggest that DEK and E2F3 are potential targets of 6p gains in retinoblastoma.	Univ Klinikum Essen, Inst Humangenet, D-45122 Essen, Germany; Univ Childrens Hosp Essen, Univ Klinikum Essen, D-45122 Essen, Germany; Univ Klinikum Essen, Augenklin, D-45122 Essen, Germany; Univ Klinikum Essen, Inst Zellbiol, D-45122 Essen, Germany; Univ Dusseldorf, Inst Human Genet & Anthropol, D-40225 Dusseldorf, Germany; Univ Klinikum Marburg, Inst Klin Genet, D-35033 Marburg, Germany; Univ Konstanz, Dept Biol, D-78457 Constance, Germany	University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Duisburg Essen; Heinrich Heine University Dusseldorf; University of Konstanz	Lohmann, DR (corresponding author), Univ Klinikum Essen, Inst Humangenet, D-45122 Essen, Germany.	dietmar.lohmann@uni-essen.de	Ferdinand, Kappes/H-4445-2014; Schramm, Alexander/G-5688-2010; Lohmann, Dietmar R/B-4041-2013; Eggert, Angelika/AAE-6907-2022; Grasemann, Corinna/AAG-3861-2021; Stephan, Harald/AAT-6802-2021; Lohmann, Dietmar R./X-4895-2019	Ferdinand, Kappes/0000-0002-0369-0065; Schramm, Alexander/0000-0001-7670-7529; Lohmann, Dietmar R/0000-0002-2624-9889; Eggert, Angelika/0000-0003-3476-8184; Lohmann, Dietmar R./0000-0002-2624-9889; Grasemann, Corinna/0000-0003-1793-4603				Baugh LR, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.5.e29; Boonstra R, 2003, VIRCHOWS ARCH, V443, P164, DOI 10.1007/s00428-003-0836-9; CANO J, 1994, CANCER GENET CYTOGEN, V76, P112, DOI 10.1016/0165-4608(94)90459-6; Casas S, 2003, LEUKEMIA LYMPHOMA, V44, P1935, DOI 10.1080/1042819031000119299; Chen D, 2002, CANCER RES, V62, P967; Chen DN, 2001, CANCER GENET CYTOGEN, V129, P57, DOI 10.1016/S0165-4608(01)00427-7; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Feber A, 2004, ONCOGENE, V23, P1627, DOI 10.1038/sj.onc.1207274; Fletcher O, 2004, JNCI-J NATL CANCER I, V96, P357, DOI 10.1093/jnci/djh058; Foster CS, 2004, ONCOGENE, V23, P5871, DOI 10.1038/sj.onc.1207800; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Gallie BL, 1999, CANCER RES, V59, p1731S; Ginsberg D, 2004, DEV CELL, V6, P742, DOI 10.1016/j.devcel.2004.05.012; Herzog S, 2001, HUM GENET, V108, P98, DOI 10.1007/s004390000450; Hoglund M, 2004, INT J CANCER, V108, P57, DOI 10.1002/ijc.11558; HORSTHEMKE B, 1992, CANCER GENET CYTOGEN, V63, P1, DOI 10.1016/0165-4608(92)90055-D; Hui R, 1997, ONCOGENE, V15, P1617, DOI 10.1038/sj.onc.1201311; Kappes F, 2004, MOL CELL BIOL, V24, P6011, DOI 10.1128/MCB.24.13.6011-6020.2004; Kappes F, 2004, MOL CELL BIOL, V24, P6000, DOI 10.1128/MCB.24.13.6000-6010.2004; Koon N, 2004, NEOPLASIA, V6, P143, DOI 10.1593/neo.03385; Lau CC, 2004, GENE CHROMOSOME CANC, V39, P11, DOI 10.1002/gcc.10291; Mairal A, 2000, GENE CHROMOSOME CANC, V28, P370, DOI 10.1002/1098-2264(200008)28:4<370::AID-GCC2>3.0.CO;2-8; Micci F, 2003, CANCER GENET CYTOGEN, V144, P119, DOI 10.1016/S0165-4608(03)00025-6; Mittnacht S, 2005, EUR J CELL BIOL, V84, P97, DOI 10.1016/j.ejcb.2004.12.012; Nakagawa T, 1997, P NATL ACAD SCI USA, V94, P9654, DOI 10.1073/pnas.94.18.9654; Oeggerli M, 2004, ONCOGENE, V23, P5616, DOI 10.1038/sj.onc.1207749; Parisi T, 2002, BIOCHEM BIOPH RES CO, V291, P1138, DOI 10.1006/bbrc.2002.6591; Partheen K, 2004, GENE CHROMOSOME CANC, V40, P342, DOI 10.1002/gcc.20053; REIFENBERGER G, 1994, CANCER RES, V54, P4299; Saavedra HI, 2002, CELL GROWTH DIFFER, V13, P215; Sakowicz R, 2004, CANCER RES, V64, P3276, DOI 10.1158/0008-5472.CAN-03-3839; Sitwala KV, 2003, ANTICANCER RES, V23, P2155; SQUIRE J, 1985, HUM GENET, V70, P291, DOI 10.1007/BF00295364; SQUIRE J, 1984, HUM GENET, V66, P46, DOI 10.1007/BF00275185; van der Wal JE, 2003, J CLIN PATHOL, V56, P26, DOI 10.1136/jcp.56.1.26; VOGEL F, 1979, HUM GENET, V52, P1; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687	37	81	83	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6441	6449		10.1038/sj.onc.1208792	http://dx.doi.org/10.1038/sj.onc.1208792			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007192				2022-12-17	WOS:000232038200011
J	Fernandez-Garcia, NI; Palmer, HG; Garcia, M; Gonzalez-Martin, A; del Rio, M; Barettino, D; Volpert, O; Munoz, A; Jimenez, B				Fernandez-Garcia, NI; Palmer, HG; Garcia, M; Gonzalez-Martin, A; del Rio, M; Barettino, D; Volpert, O; Munoz, A; Jimenez, B			1 alpha, 25-Dihydroxyvitamin D-3 regulates the expression of Id1 and Id2 genes and the angiogenic phenotype of human colon carcinoma cells	ONCOGENE			English	Article						Id; 1 alpha, 25( OH)(2)D-3; colon carcinoma; angiogenesis; E-cadherin	LOOP-HELIX PROTEINS; VITAMIN-D ANALOGS; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; CYCLE CONTROL; PHASE-I; DIFFERENTIATION; CANCER; PROLIFERATION; INHIBITION; 1,25-DIHYDROXYVITAMIN-D3	1 alpha,25-Dihydroxyvitamin D-3 (1 alpha,25(OH)(2)D-3) has antitumor activity in addition to its classical action on calcium metabolism and bone tissue biology. It is thought to regulate the expression of multiple target genes and thus modulate processes critical for tumor growth and metastases. Here we show that 1 alpha, 25(OH)(2)D-3 differentially regulates the expression of Id1 and Id2 genes, members of a family of transcriptional regulators of cell proliferation and differentiation. 1 alpha,25(OH)(2)D-3 induced epithelial differentiation in SW480-ADH human colon carcinoma cell line by promoting expression of the proteins implicated in adherent junction formation, including E-cadherin, and by inhibiting beta-catenin transcriptional activity. 1 alpha,25(OH)(2)D-3 activated the human Id1 gene promoter and rapidly induced Id1 RNA and protein. E-cadherin, overexpression of Id1 was not sufficient to induce E-cadherin, which was critical for the morphological changes induced by 1 alpha,25(OH)(2)D-3 in SW480-ADH cells. Conversely, Id2 transcription rate, RNA and protein levels were decreased by 1 alpha,25(OH)(2)D-3. Id2 downregulation by 1 alpha,25(OH)(2)D-3 mediated the antiproliferative effect of 1 alpha,25(OH)(2)D-3 on SW480-ADH cells. In addition, we showed that 1 alpha,25(OH)(2)D-3 changed the levels of the inducer of angiogenesis, vascular endothelial growth factor and the potent antiangiogenic factor thrombospondin-1, leading to a balanced change in the angiogenic potential of SW480-ADH human colon carcinoma cells.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed, Madrid 28029, Spain; Univ Autonoma Madrid, Dept Biochem, Madrid 28029, Spain; Canc Res, London WC2A 3PX, England; CIEMAT, Project Damage, Repair & Tissue Engn, E-28040 Madrid, Spain; CSIC, Inst Biomed Valencia, E-46010 Valencia, Spain; Northwestern Univ, Sch Med, Dept Urol, Chicago, IL 60611 USA	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); Northwestern University	Jimenez, B (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed, Artuto Duperier 4, Madrid 28029, Spain.	bjimenez@iib.uam.es	Gonzalez-Martin, Alicia/B-1702-2017; DEL RIO, MARCELA/H-2796-2015; Palmer, Héctor G./AAG-8332-2019; Cuenca, Benilde Jimenez/K-9959-2014; Munoz, Alberto/O-6393-2014	Gonzalez-Martin, Alicia/0000-0002-6179-089X; DEL RIO, MARCELA/0000-0003-2910-7189; Munoz, Alberto/0000-0003-3890-4251; Jimenez Cuenca, Benilde/0000-0002-1806-6636; Palmer, Hector/0000-0002-9823-5638				Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; Bernardi RJ, 2002, ENDOCRINOLOGY, V143, P2508, DOI 10.1210/en.143.7.2508; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Dalhoff K, 2003, BRIT J CANCER, V89, P252, DOI 10.1038/sj.bjc.6601104; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Diaz GD, 2000, CANCER RES, V60, P2304; Evans SRT, 2000, INT J ONCOL, V16, P1249; Ezura Y, 1997, J BIOL CHEM, V272, P29865, DOI 10.1074/jbc.272.47.29865; Gross C, 1998, J UROLOGY, V159, P2035, DOI 10.1016/S0022-5347(01)63236-1; Gulliford T, 1998, BRIT J CANCER, V78, P6, DOI 10.1038/bjc.1998.434; Gumireddy K, 2003, BIOCHEM PHARMACOL, V65, P1943, DOI 10.1016/S0006-2952(03)00205-3; Guyton KZ, 2001, ANNU REV PHARMACOL, V41, P421, DOI 10.1146/annurev.pharmtox.41.1.421; HALLINE AG, 1994, ENDOCRINOLOGY, V134, P1710, DOI 10.1210/en.134.4.1710; Hewitt RE, 2000, J PATHOL, V192, P446; Iseki K, 1999, INT J CANCER, V81, P730, DOI 10.1002/(SICI)1097-0215(19990531)81:5&lt;730::AID-IJC11&gt;3.0.CO;2-Q; Israel MA, 1999, CANCER RES, V59, p1726S; Jensen SS, 2001, MOL ENDOCRINOL, V15, P1370, DOI 10.1210/me.15.8.1370; Koli K, 2000, CELL GROWTH DIFFER, V11, P221; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 2002, CANCER RES, V62, P301; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; Liu YH, 2004, MOL CELL BIOL, V24, P2662, DOI 10.1128/MCB.24.7.2662-2672.2004; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Mantell DJ, 2000, CIRC RES, V87, P214, DOI 10.1161/01.RES.87.3.214; Matsumura ME, 2002, J BIOL CHEM, V277, P7293, DOI 10.1074/jbc.M108986200; Nehlin JO, 1997, BIOCHEM BIOPH RES CO, V231, P628, DOI 10.1006/bbrc.1997.6152; Nishii Y, 2001, STEROIDS, V66, P137, DOI 10.1016/S0039-128X(00)00227-0; Palmer HG, 2003, CANCER RES, V63, P7799; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Ramsauer M, 2002, J CLIN INVEST, V110, P1615, DOI 10.1172/JCI200217326; Rockman SP, 2001, J BIOL CHEM, V276, P45113, DOI 10.1074/jbc.M107742200; Ruzinova MB, 2003, CANCER CELL, V4, P277, DOI 10.1016/S1535-6108(03)00240-X; Scaglione-Sewell BA, 2000, ENDOCRINOLOGY, V141, P3931, DOI 10.1210/en.141.11.3931; Schlaeppi JM, 1997, ENDOCR RES, V23, P213, DOI 10.3109/07435809709031855; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Smith DC, 1999, CLIN CANCER RES, V5, P1339; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; Verlinden L, 1998, MOL CELL ENDOCRINOL, V142, P57, DOI 10.1016/S0303-7207(98)00117-8; Volpert OV, 2002, CANCER CELL, V2, P473, DOI 10.1016/S1535-6108(02)00209-X; Wilson JW, 2001, CANCER RES, V61, P8803; Woo PL, 2000, J BIOL CHEM, V275, P28649, DOI 10.1074/jbc.M910373199; Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018-002-8510-y; Yokota Y, 2001, ONCOGENE, V20, P8290, DOI 10.1038/sj.onc.1205090; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092	48	81	88	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6533	6544		10.1038/sj.onc.1208801	http://dx.doi.org/10.1038/sj.onc.1208801			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16007183				2022-12-17	WOS:000232204100007
J	Grewal, T; Evans, R; Rentero, C; Tebar, F; Cubells, L; de Diego, I; Kirchhoff, MF; Hughes, WE; Heeren, J; Rye, KA; Rinninger, F; Daly, RJ; Pol, A; Enrich, C				Grewal, T; Evans, R; Rentero, C; Tebar, F; Cubells, L; de Diego, I; Kirchhoff, MF; Hughes, WE; Heeren, J; Rye, KA; Rinninger, F; Daly, RJ; Pol, A; Enrich, C			Annexin A6 stimulates the membrane recruitment of p120GAP to modulate Ras and Raf-1 activity	ONCOGENE			English	Article						Ras; Raf-1; HDL; EGF; annexin 6A; p120GAP	PROTEIN-PROTEIN INTERACTIONS; DENSITY-LIPOPROTEINS INDUCE; SMOOTH-MUSCLE CELLS; KINASE-C-ALPHA; BINDING DOMAIN; SCAVENGER RECEPTOR; PLASMA-MEMBRANE; VI; CALCIUM; ACTIVATION	Annexin A6 is a calcium-dependent membrane-binding protein that interacts with signalling proteins, including the GTPase-activating protein p120GAP, one of the most important inactivators of Ras. Since we have demonstrated that annexin A6 inhibits EGF- and TPA-induced Ras signalling, we investigated whether modulation of Ras activity by annexin A6 was mediated via altered subcellular localization of p120GAP. First, we exploited our observation that high-density lipoproteins (HDL) can activate the Ras/MAP kinase pathway. Expression of annexin A6 caused a significant reduction in HDL-induced activation of Ras and Raf-1. Annexin A6 promoted membrane binding of p120GAP in vitro, and plasma membrane targeting of p120GAP in living cells, both in a Ca2+-dependent manner, which is consistent with annexin A6 promoting the Ca2+-dependent assembly of p120GAP-Ras at the plasma membrane. We then extended these studies to other cell types and stimuli. Expression of annexin A6 in A431 cells reduced, while RNAi-mediated suppression of annexin A6 in HeLa cells enhanced EGF- induced Ras and Erk activation. Importantly, the enhancement of Ras activation following RNAi-mediated reduction in p120GAP levels was more marked in annexin A6-expressing A431 cells than controls, indicating that the effect of annexin A6 on Ras was mediated via p120GAP. Finally, we demonstrated that annexin A6 promotes plasma membrane targeting of p120GAP in A431 cells in response to a variety of stimuli, resulting in colocalization with H-Ras. These findings demonstrate an important role for annexin A6 in regulating plasma membrane localization of p120GAP and hence Ras activity.	Univ Barcelona, Fac Med, Dept Cellular Biol, IDIBAPS, E-08036 Barcelona, Spain; Univ New S Wales, St Vincents Hosp, Ctr Immunol, Kensington, NSW 2033, Australia; Univ Hamburg, Hosp Eppendorf, Dept Mol Cell Biol, Inst Med Biochem & Mol Biol, D-20246 Hamburg, Germany; Garvan Inst Med Res, Sydney, NSW, Australia; Heart Res Inst, Camperdown, NSW, Australia; Univ Hamburg, Hosp Eppendorf, Dept Internal Med, D-20246 Hamburg, Germany	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of New South Wales Sydney; University of Hamburg; Garvan Institute of Medical Research; University of Sydney; Heart Research Institute; University of Hamburg	Enrich, C (corresponding author), Univ Barcelona, Fac Med, Dept Cellular Biol, IDIBAPS, Casanova 143, E-08036 Barcelona, Spain.	enrich@ub.edu	de Diego Martinez, Iñaki/AAB-4712-2019; Rentero Alfonso, Carles/L-4430-2017; Tebar, Francesc/H-1498-2015; Daly, Roger J/C-8179-2009; Pol, Albert/M-1865-2014	de Diego Martinez, Iñaki/0000-0002-6156-4032; Rentero Alfonso, Carles/0000-0003-4684-0278; Tebar, Francesc/0000-0002-9522-9726; Pol, Albert/0000-0002-1750-1085; Hughes, William/0000-0002-7149-3987; Daly, Roger/0000-0002-5739-8027; Grewal, Thomas/0000-0002-7937-8887; Enrich, Carlos/0000-0003-0382-2993				BANDOROWICZPIKU.J, 2004, ANNEXINS, V1, P68; BAREL M, 1991, J IMMUNOL, V147, P1286; Bivona TG, 2003, CURR OPIN CELL BIOL, V15, P136, DOI 10.1016/S0955-0674(03)00016-4; BOCHKOV V, 1992, BIOCHEM BIOPH RES CO, V188, P1295, DOI 10.1016/0006-291X(92)91372-W; CHECUTI A, 2001, CANCER RES, V61, P6331; Chow A, 1999, FEBS LETT, V460, P166, DOI 10.1016/S0014-5793(99)01336-8; Chow A, 1999, CELL SIGNAL, V11, P443, DOI 10.1016/S0898-6568(99)00015-7; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; Davis AJ, 1996, J BIOL CHEM, V271, P24333, DOI 10.1074/jbc.271.40.24333; de Diego I, 2002, J BIOL CHEM, V277, P32187, DOI 10.1074/jbc.M205499200; Deeg MA, 1997, ARTERIOSCL THROM VAS, V17, P1667, DOI 10.1161/01.ATV.17.9.1667; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Donovan S, 2002, BBA-REV CANCER, V1602, P23, DOI 10.1016/S0304-419X(01)00041-5; Fleet A, 1999, BIOCHEM BIOPH RES CO, V260, P540, DOI 10.1006/bbrc.1999.0915; Francia G, 1996, CANCER RES, V56, P3855; Fridman M, 2000, J BIOL CHEM, V275, P30363, DOI 10.1074/jbc.M003193200; GAWLER DJ, 1995, ONCOGENE, V10, P817; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Grewal T, 2000, J BIOL CHEM, V275, P33806, DOI 10.1074/jbc.M002662200; Grewal T, 2003, J BIOL CHEM, V278, P16478, DOI 10.1074/jbc.C300085200; GREWAL T, 2004, ANNEXINS, V1, P62; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Hawkins TE, 1999, MOL CELL BIOL, V19, P8028; Hayes MJ, 2004, BIOCHEM BIOPH RES CO, V322, P1166, DOI 10.1016/j.bbrc.2004.07.124; Herr C, 2001, MOL CELL BIOL, V21, P4119, DOI 10.1128/MCB.21.13.4119-4128.2001; Hirai I, 2002, J BIOL CHEM, V277, P25722, DOI 10.1074/jbc.M203079200; Honda HM, 1999, ATHEROSCLEROSIS, V143, P299, DOI 10.1016/S0021-9150(98)00302-5; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; KING ICL, 1986, BIOCHEM BIOPH RES CO, V140, P837, DOI 10.1016/0006-291X(86)90710-2; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Li XM, 2002, J BIOL CHEM, V277, P27256, DOI 10.1074/jbc.M203267200; Ling Q, 2004, J CLIN INVEST, V113, P38, DOI 10.1172/JCI200419684; Liu JW, 2003, ONCOGENE, V22, P1475, DOI 10.1038/sj.onc.1206196; Lockyer PJ, 2001, CURR BIOL, V11, P981, DOI 10.1016/S0960-9822(01)00261-5; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Nofer JR, 2001, J BIOL CHEM, V276, P34480, DOI 10.1074/jbc.M103782200; Nofer JR, 2001, THROMB HAEMOSTASIS, V85, P730; Nofer JR, 2000, BIOCHEMISTRY-US, V39, P15199, DOI 10.1021/bi001162a; O'Malley DM, 1999, METH MOL B, V122, P261; Orito A, 2001, J NEUROSCI RES, V64, P235, DOI 10.1002/jnr.1071; Pol A, 1999, HEPATOLOGY, V29, P1848, DOI 10.1002/hep.510290602; Pons M, 2001, FEBS LETT, V501, P69, DOI 10.1016/S0014-5793(01)02635-7; PORN MI, 1991, BIOCHEM J, V279, P29; RINNINGER F, 1994, HEPATOLOGY, V19, P1100, DOI 10.1016/0270-9139(94)90856-7; Schmitz-Peiffer C, 1998, BIOCHEM J, V330, P675, DOI 10.1042/bj3300675; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Srivastava M, 2001, P NATL ACAD SCI USA, V98, P4575, DOI 10.1073/pnas.071055798; Tebar F, 2002, MOL BIOL CELL, V13, P2057, DOI 10.1091/mbc.01-12-0571; THEOBALD J, 1994, BBA-MOL CELL RES, V1223, P383, DOI 10.1016/0167-4889(94)90099-X; THEOBALD J, 1995, BRIT J CANCER, V71, P786, DOI 10.1038/bjc.1995.152; Tsubouchi A, 2002, J CELL BIOL, V159, P673, DOI 10.1083/jcb.200202117; Van Ginkel PR, 1998, BBA-MOL CELL RES, V1448, P290, DOI 10.1016/S0167-4889(98)00133-5; Walker SA, 2004, EMBO J, V23, P1749, DOI 10.1038/sj.emboj.7600197; Walker SA, 2003, FEBS LETT, V546, P6, DOI 10.1016/S0014-5793(03)00412-5; Wang ZX, 1996, CELL GROWTH DIFFER, V7, P123	56	81	86	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5809	5820		10.1038/sj.onc.1208743	http://dx.doi.org/10.1038/sj.onc.1208743			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	15940262				2022-12-17	WOS:000231590400003
J	Ravid, D; Maor, S; Werner, H; Liscovitch, M				Ravid, D; Maor, S; Werner, H; Liscovitch, M			Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling	ONCOGENE			English	Article						Akt; anoikis; cancer; caveolin; cell survival; IGF-I; p53; signal transduction	BREAST-CANCER-CELLS; ANCHORAGE-INDEPENDENT GROWTH; FOCAL ADHESION KINASE; ONCOGENICALLY TRANSFORMED-CELLS; PROSTATE-CANCER; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN EXPRESSION; INDUCED APOPTOSIS; MATRIX ADHESION; MICE	Caveolin-1 is an essential structural constituent of caveolae that has been implicated in mitogenic signaling and oncogenesis. Utilizing MCF-7 human breast cancer cells, stably transfected with caveolin-1 (MCF-7/Cav1), we previously demonstrated that caveolin-1 expression decreases MCF-7 cell proliferation and colony formation in soft agar. However, the loss of anchor age-independent growth is associated with inhibition of anoikis, as MCF-7/ Cav1 cells exhibit increased survival after detachment. Herein we show that this phenotype is associated with suppression of detachment-induced activation of p53 and of the consequent induction of cyclin-dependent kinase inhibitor p2lWAF1/Cip1. In contrast, activation of p53 and p21 WAF1/Cipt induced by doxorubicin in MCF-7/Cav1 cells remains largely unaffected. The phenotypic changes observed in MCF-7/Cav1 cells are not accompanied by changes in caspase-6, -7, -8 and -9 and cannot be explained by changes in Bid and Bcl-2 expression. However, MCF-7/Cav1 cells exhibit a constitutively phosphorylated Akt kinase and at least one phosphorylated high molecular weight putative Akt substrate which we designated pp340. In addition, MCF-7/Cavl cells exhibit elevated expression of insulin-like growth factor-1 (IGF-1) receptor expression and increased IGF-1 signaling to Erkl/2 and to Akt, as well as IGF-1-induced stimulation of pp340 phosphorylation. The addition of IGF-I to the medium rescues the parental MCF-7 cells from anoikis, indicating that IGF-1 can act as a survival factor for suspended MCF-7 cells. Finally, the levels of caveolin-1 are dramatically elevated in a time-dependent manner upon detachment of anoikis-resistant MCF-7/ Cav1 cells and HT-29-MDR human multidrug resistant colon cancer cells. We conclude that expression of caveolin-1 in human breast cancer cells enhances matrix-independent cell survival that is mediated by upregulation of IGF-I receptor expression and signaling.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine	Liscovitch, M (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, Candiotty 138,POB 26, IL-76100 Rehovot, Israel.	moti.liscovitch@weizmann.ac.il						Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Benjamin CW, 1998, MOL PHARMACOL, V53, P446, DOI 10.1124/mol.53.3.446; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Capozza F, 2003, AM J PATHOL, V162, P2029, DOI 10.1016/S0002-9440(10)64335-0; Cohen AW, 2003, AM J PHYSIOL-ENDOC M, V285, pE1151, DOI 10.1152/ajpendo.00324.2003; Cohen AW, 2003, AM J PHYSIOL-CELL PH, V285, pC222, DOI 10.1152/ajpcell.00006.2003; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Duxbury MS, 2004, J BIOL CHEM, V279, P23176, DOI 10.1074/jbc.M402051200; Engelman JA, 1998, FEBS LETT, V436, P403, DOI 10.1016/S0014-5793(98)01134-X; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Fra AM, 1999, GENOMICS, V56, P355, DOI 10.1006/geno.1998.5723; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Galbiati F, 1998, P NATL ACAD SCI USA, V95, P10257, DOI 10.1073/pnas.95.17.10257; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hayashi K, 2001, CANCER RES, V61, P2361; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Lavie Y, 1998, J BIOL CHEM, V273, P32380, DOI 10.1074/jbc.273.49.32380; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Li WP, 2001, J CELL SCI, V114, P1397; LISCOVITCH M, 2004, MEMBRANE MICRODOMAIN, P161; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; McGill G, 1997, J CELL BIOL, V138, P901, DOI 10.1083/jcb.138.4.901; Nasu Y, 1998, NAT MED, V4, P1062, DOI 10.1038/2048; Nikiforov MA, 1996, ONCOGENE, V13, P1709; Podar K, 2003, J BIOL CHEM, V278, P5794, DOI 10.1074/jbc.M208636200; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Razani B, 2001, J BIOL CHEM, V276, P38121; Razani B, 2001, BIOCHEM SOC T, V29, P494, DOI 10.1042/BST0290494; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Scotlandi K, 2002, INT J CANCER, V101, P11, DOI 10.1002/ijc.10537; Tahir SA, 2001, CANCER RES, V61, P3882; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Timme TL, 2000, ONCOGENE, V19, P3256, DOI 10.1038/sj.onc.1203654; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; Volonte D, 2002, MOL BIOL CELL, V13, P2502, DOI 10.1091/mbc.01-11-0529; WERNER H, 1994, J BIOL CHEM, V269, P12577; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; Williams TM, 2003, MOL BIOL CELL, V14, P1027, DOI 10.1091/mbc.E02-08-0503; WOSIKOWSKI K, 1995, CELL GROWTH DIFFER, V6, P1395; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962; Zhang H, 2002, J BIOL CHEM, V277, P39379, DOI 10.1074/jbc.M206399200; Zundel W, 2000, MOL CELL BIOL, V20, P1507, DOI 10.1128/MCB.20.5.1507-1514.2000	58	81	85	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1338	1347		10.1038/sj.onc.1208337	http://dx.doi.org/10.1038/sj.onc.1208337			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15592498				2022-12-17	WOS:000227092600004
J	Fukushima, N; Sato, N; Prasad, N; Leach, SD; Hruban, RH; Goggins, M				Fukushima, N; Sato, N; Prasad, N; Leach, SD; Hruban, RH; Goggins, M			Characterization of gene expression in mucinous cystic neoplasms of the pancreas using oligonucleotide microarrays	ONCOGENE			English	Article						mucinous cystic neoplasm; oligonucleotide microarray; 'ovarian-type' stroma	MULTIPLE GENES; FLUID ANALYSIS; DIFFERENTIAL-DIAGNOSIS; CELL-DIFFERENTIATION; ABERRANT METHYLATION; SERIAL ANALYSIS; TUMOR-MARKERS; CPG ISLANDS; K-RAS; NOTCH	Mucinous cystic neoplasms (MCNs) of the pancreas are uncommon neoplasms usually located in the body or tail of the pancreas and usually in females (>90% of cases). Clinically, they are often misdiagnosed as non-neoplastic pseudocysts leading to failed opportunities for curative resection. To better understand the biology of MCNs and to identify markers of the disease, we performed global gene expression profiling of MCNs using oligonucleotide microarrays. Using laser capture microdissection applied to frozen sections, RNA was extracted from the neoplastic epithelium of MCNs, from the adjacent 'ovarian-type' stroma of MCNs, from histologically normal pancreatic ductal epithelium, from pancreatic acinar tissue and from fibrous stroma in pancreata affected by chronic pancreatitis. Each RNA sample was subjected to two rounds of linear amplification followed by hybridization with U133A gene chips (Affymetrix). The expression patterns of selected genes were confirmed by quantitative RT-PCR and by immunohistochemistry using tissue microarrays containing 19 resected MCNs. A total of 114 known genes were overexpressed in the neoplastic epithelium compared to normal pancreatic ductal epithelium (>3-fold) including S100P, PSCA, c-myc, STK6/STKI5, cathepsin E and pepsinogen C. Activation of the Notch pathway in the epithelial component of MCNs was evident by the demonstration of overexpression of Jagged1 and the downstream Notch pathway member Hes1. In the 'ovarian-type' stroma, several genes involved in estrogen metabolism were overexpressed including STAR and ESR1 genes. Some of the genes identified as overexpressed in these neoplasms may be useful as markers that can distinguish MCNs from non-neoplastic pancreatic cystic lesions.	Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Surg, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Goggins, M (corresponding author), Johns Hopkins Med Inst, Dept Pathol Med & Oncol, 632 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	mgoggins@jhmi.edu			NATIONAL CANCER INSTITUTE [P50CA062924] Funding Source: NIH RePORTER; NCI NIH HHS [CA62924] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; COMPAGNO J, 1978, AM J CLIN PATHOL, V69, P573; Crnogorac-Jurcevic T, 2002, ONCOGENE, V21, P4587, DOI 10.1038/sj.onc.1205570; Deichmann M, 2003, J CUTAN PATHOL, V30, P363, DOI 10.1034/j.1600-0560.2003.00073.x; Demos TC, 2002, AM J ROENTGENOL, V179, P1375, DOI 10.2214/ajr.179.6.1791375; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Ernst T, 2002, AM J PATHOL, V160, P2169, DOI 10.1016/S0002-9440(10)61165-0; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Fogel M, 2003, LANCET, V362, P869, DOI 10.1016/S0140-6736(03)14342-5; Fogel M, 2003, CANCER LETT, V189, P237, DOI 10.1016/S0304-3835(02)00513-X; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Fukuhara K, 2002, J CLIN ENDOCR METAB, V87, P1729, DOI 10.1210/jc.87.4.1729; Fukushima N, 1997, PATHOL INT, V47, P806, DOI 10.1111/j.1440-1827.1997.tb04462.x; Fukushima N, 1999, ADV ANAT PATHOL, V6, P65, DOI 10.1097/00125480-199903000-00001; HAMMEL P, 1995, GASTROENTEROLOGY, V108, P1230, DOI 10.1016/0016-5085(95)90224-4; Hodgson JG, 2003, BREAST CANCER RES TR, V78, P337, DOI 10.1023/A:1023085825042; Hruban RH, 2001, CANCER J, V7, P251; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Iacobuzio-Donahue CA, 2003, CANCER RES, V63, P8614; Iacobuzio-Donahue CA, 2002, AM J PATHOL, V160, P1239, DOI 10.1016/S0002-9440(10)62551-5; Izumo A, 2003, ONCOL REP, V10, P515; Jabara S, 2003, J CLIN ENDOCR METAB, V88, P484, DOI 10.1210/jc.2002-021274; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136; Jundt F, 2002, BLOOD, V99, P3398, DOI 10.1182/blood.V99.9.3398; Kalus I, 2003, J BIOL CHEM, V278, P10381, DOI 10.1074/jbc.M208351200; Kamiguchi H, 1998, MOL CELL NEUROSCI, V12, P48, DOI 10.1006/mcne.1998.0702; Kern SE, 2002, CANCER BIOL THER, V1, P607, DOI 10.4161/cbt.307; Klein AP, 2001, CANCER J, V7, P266; KOWITZ A, 1992, EUR J IMMUNOL, V22, P1199, DOI 10.1002/eji.1830220514; Li DH, 2003, CLIN CANCER RES, V9, P991; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Logsdon CD, 2003, CANCER RES, V63, P2649; Luttges J, 2002, AM J SURG PATHOL, V26, P466, DOI 10.1097/00000478-200204000-00008; Mahlamaki EH, 2002, GENE CHROMOSOME CANC, V35, P353, DOI 10.1002/gcc.10122; Maillard I, 2003, CANCER CELL, V3, P203, DOI 10.1016/S1535-6108(03)00052-7; Miao XP, 2004, CANCER RES, V64, P2680, DOI 10.1158/0008-5472.CAN-04-0651; Miyamoto Y, 2003, CANCER CELL, V3, P565, DOI 10.1016/S1535-6108(03)00140-5; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Ohhashi K., 1982, PROG DIG ENDOSC, V203, P348; RUBIN D, 1994, SURGERY, V115, P52; Ryu B, 2002, CANCER RES, V62, P819; Ryu B, 2001, CANCER RES, V61, P1833; Sand JA, 1996, SURGERY, V119, P275, DOI 10.1016/S0039-6060(96)80113-9; Sato N, 2003, CANCER RES, V63, P4158; Sato N, 2004, AM J PATHOL, V164, P903, DOI 10.1016/S0002-9440(10)63178-1; Sato N, 2002, GASTROENTEROLOGY, V123, P365, DOI 10.1053/gast.2002.34160; Sato N, 2001, AM J PATHOL, V159, P2017, DOI 10.1016/S0002-9440(10)63053-2; Sato N, 2003, CANCER RES, V63, P3735; Sausville EA, 2004, NAT MED, V10, P234, DOI 10.1038/nm0304-234; Schachner M, 1997, CURR OPIN CELL BIOL, V9, P627, DOI 10.1016/S0955-0674(97)80115-9; SESSA F, 1994, VIRCHOWS ARCH, V425, P357; Seth P, 2002, CANCER RES, V62, P4540; SOLCIA E, 1997, TUMORS PANCREAS, P220; Sorianello E, 2002, EUR J ENDOCRINOL, V147, P387, DOI 10.1530/eje.0.1470387; Sperti C, 1997, AM J GASTROENTEROL, V92, P672; Sperti C, 1996, CANCER, V78, P237, DOI 10.1002/(SICI)1097-0142(19960715)78:2<237::AID-CNCR8>3.0.CO;2-I; Su GH, 2001, P NATL ACAD SCI USA, V98, P3254, DOI 10.1073/pnas.051484398; Terris B, 2002, AM J PATHOL, V160, P1745, DOI 10.1016/S0002-9440(10)61121-2; Thompson LDR, 1999, AM J SURG PATHOL, V23, P1, DOI 10.1097/00000478-199901000-00001; THOR G, 1987, EMBO J, V6, P2581, DOI 10.1002/j.1460-2075.1987.tb02548.x; Ueki T, 2000, CANCER RES, V60, P1835; Ueki T, 2001, CANCER RES, V61, P8540; van der Heijden MS, 2003, CANCER RES, V63, P2585; WARSHAW AL, 1990, ANN SURG, V212, P432, DOI 10.1097/00000658-199010000-00006; Yoshizawa K, 2002, VIRCHOWS ARCH, V441, P437, DOI 10.1007/s00428-002-0645-6; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zamboni G, 1999, AM J SURG PATHOL, V23, P410, DOI 10.1097/00000478-199904000-00005; Zamboni G.K.G., 2000, WHO CLASSIFICATION T, P234	69	81	87	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9042	9051		10.1038/sj.onc.1208117	http://dx.doi.org/10.1038/sj.onc.1208117			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489895				2022-12-17	WOS:000225492800005
J	Shi, RX; Ong, CN; Shen, HM				Shi, RX; Ong, CN; Shen, HM			Luteolin sensitizes tumor necrosis factor-alpha-induced apoptosis in human tumor cells	ONCOGENE			English	Article						luteolin; TNF alpha; NF-kappa B; JNK; apoptosis	NF-KAPPA-B; ZINC-FINGER PROTEIN; TNF-INDUCED APOPTOSIS; DOMAIN KINASE RIP; DEATH DOMAIN; INDUCED ACTIVATION; TERMINAL KINASE; JNK ACTIVATION; CANCER; INDUCTION	Tumor necrosis factor-alpha (TNFalpha) activates both cell death and cell survival pathways, which render most cancer cells resistant to its cytotoxicity. In this study, we found that pretreatment with luteolin, a plant flavonoid, greatly sensitized TNFalpha-induced apoptotic cell death in a number of human cancer cell lines; including colorectal cancer COLO205, HCT116 cells and cervical cancer HeLa cells. In the search of the molecular mechanisms responsible for the sensitization effect of luteolin, we discovered that luteolin inhibited TNFalpha-induced activation of nuclear transcription factor-kappa B (NF-kappaB), the main survival factor in TNFa signaling. As a result, luteolin suppressed the expression of NF-kappaB-targeted antiapoptotic genes, including A20 and cellular inhibitor of apoptosis protein-1 (c-IAP1). The role of A20 and c-IAP1 was further confirmed by ectopic expression of these two genes, which significantly protected cell death induced by luteolin followed by TNFalpha. In addition, inhibition of NF-kappaB by luteolin led to augmentation and prolongation of c-Jun N-terminal kinase (JNK) activation induced by TNFalpha. Suppression of JNK activation, either by a synthetic JNK inhibitor ( SP600125) or by overexpression of the dominant negative forms of JNK kinase 1 (JNKK1) and JNK kinase 2 (JNKK2), conferred significant protection against apoptotic cell death induced by luteolin and TNFalpha, suggesting that NF-kappaB and JNK are closely associated with the sensitization effect of luteolin. Data from this study reveal a novel function of luteolin and enhance the value of luteolin as an anticancer agent.	Natl Univ Singapore, Fac Med, Dept Community Occupat & Family Med, Singapore 117597, Singapore	National University of Singapore	Shen, HM (corresponding author), Natl Univ Singapore, Fac Med, Dept Community Occupat & Family Med, 16 Med Dr, Singapore 117597, Singapore.	cofshm@nus.edu.sg	Shi, Ranxin/F-9817-2012; SHEN, Han-Ming/B-5942-2011; Shi, Ranxin/E-5934-2012; Ong, Choon Nam/E-8638-2010	SHEN, Han-Ming/0000-0001-7369-5227; 				Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Birt DF, 2001, PHARMACOL THERAPEUT, V90, P157, DOI 10.1016/S0163-7258(01)00137-1; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Darzynkiewicz Z, 1998, Hum Cell, V11, P3; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Denecker G, 2001, CELL DEATH DIFFER, V8, P829, DOI 10.1038/sj.cdd.4400883; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Farah M, 2003, AM J PHYSIOL-GASTR L, V285, pG919, DOI 10.1152/ajpgi.00205.2003; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; He KL, 2002, MOL CELL BIOL, V22, P6034, DOI 10.1128/MCB.22.17.6034-6045.2002; Hehner SP, 1999, J IMMUNOL, V163, P5617; Hehner SP, 1998, J BIOL CHEM, V273, P18117, DOI 10.1074/jbc.273.29.18117; Huang YT, 1999, BRIT J PHARMACOL, V128, P999, DOI 10.1038/sj.bjp.0702879; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kim DM, 2003, CANCER RES, V63, P621; Kim SH, 2003, BIOCHEM PHARMACOL, V66, P955, DOI 10.1016/S0006-2952(03)00465-9; Ko WG, 2002, PHYTOTHER RES, V16, P295, DOI 10.1002/ptr.871; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Lademann U, 2001, CELL DEATH DIFFER, V8, P265, DOI 10.1038/sj.cdd.4400805; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mafune K, 1999, CLIN CANCER RES, V5, P4073; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Petak I, 2000, CLIN CANCER RES, V6, P4119; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Shen HM, 2000, FREE RADICAL BIO MED, V28, P1115, DOI 10.1016/S0891-5849(00)00206-9; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; Strasser A, 1999, INT J BIOCHEM CELL B, V31, P533, DOI 10.1016/S1357-2725(99)00003-5; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Ueda H, 2003, BIOL PHARM BULL, V26, P560, DOI 10.1248/bpb.26.560; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wu M, 2002, J BIOL CHEM, V277, P25617, DOI 10.1074/jbc.M202285200; Xagorari A, 2001, J PHARMACOL EXP THER, V296, P181; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yang CF, 2000, ARCH BIOCHEM BIOPHYS, V380, P319, DOI 10.1006/abbi.2000.1939; Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954	55	81	94	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7712	7721		10.1038/sj.onc.1208046	http://dx.doi.org/10.1038/sj.onc.1208046			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15334063				2022-12-17	WOS:000224306700012
J	Mao, XL; Seidlitz, E; Truant, R; Hitt, M; Ghosh, HP				Mao, XL; Seidlitz, E; Truant, R; Hitt, M; Ghosh, HP			Re-expression of TSLC1 in a non-small-cell lung cancer cell line induces apoptosis and inhibits tumor growth	ONCOGENE			English	Article						TSLC1; lung cancer; adenovirus vector; apoptosis; tumorigenesis	SUPPRESSOR ACTIVITY; BINDING INTERFACE; GLYCOPHORIN-C; PDZ DOMAINS; GENE; PROMOTER; PROTEIN; ADENOCARCINOMA; TUMORIGENICITY; ASSOCIATION	The TSLC1 tumor-suppressor gene is silenced in a number of human cancer tissues and cell lines, including lung, prostate, liver, stomach, pancreatic, and breast cancers. Expression of TSLC1 in a non-small-cell lung cancer (NSCLC) cell line A549 suppresses tumorigenicity in nude mice. However, the molecular mechanism of TSLC1 action is not yet elucidated. In the present study, we show that the expression of TSLC1 from a recombinant adenovirus vector (Ad-TSLC1) inhibited cell proliferation and induced apoptosis in the NSCLC cell line A549. We also demonstrated that subcutaneous tumor growth in nude mice induced by A549 cells was suppressed to the extent of 70-80% by intratumoral injection of Ad-TSLC1. Re-expression of TSLC1 also resulted in activation of the apoptotic protease caspase-3, accompanied by the cleavage of its substrate poly (ADP-ribose) polymerase (PARP). The antiproliferative and proapoptotic activity of TSLC1 required the presence of the FERM-binding and PDZ-interacting motifs located in the cytoplasmic domain. Our results demonstrate the proapoptotic and oncosuppressive activity of TSLC1 protein, and suggest the potential of TSLC1 for gene therapy.	McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; Hamilton Reg Canc Ctr, Hamilton, ON L8V 5C2, Canada; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University; McMaster University	Ghosh, HP (corresponding author), McMaster Univ, Dept Biochem, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	ghosh@mcmaster.ca	Seidlitz, Eric P/K-6765-2013; Singh, Gurmit/C-6744-2014	Seidlitz, Eric P/0000-0001-9760-1133; 				Allinen M, 2002, GENE CHROMOSOME CANC, V34, P384, DOI 10.1002/gcc.10079; ASHE PC, 2003, BIOL PSYCHIAT, V27, P199; Aznar S, 2001, CANCER LETT, V165, P1, DOI 10.1016/S0304-3835(01)00412-8; Fujita E, 2003, EXP CELL RES, V287, P57, DOI 10.1016/S0014-4827(03)00095-8; Fukami T, 2003, INT J CANCER, V107, P53, DOI 10.1002/ijc.11348; Fukuhara H, 2003, ONCOGENE, V22, P6160, DOI 10.1038/sj.onc.1206744; Fukuhara H, 2002, JPN J CANCER RES, V93, P605, DOI 10.1111/j.1349-7006.2002.tb01297.x; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harris BZ, 2001, J CELL SCI, V114, P3219; Honda T, 2002, JPN J CANCER RES, V93, P857, DOI 10.1111/j.1349-7006.2002.tb01329.x; Hoover KB, 2000, CURR OPIN CELL BIOL, V12, P229, DOI 10.1016/S0955-0674(99)00080-0; Ito A, 2003, LAB INVEST, V83, P1175, DOI 10.1097/01.LAB.0000081391.28136.80; Jansen M, 2002, CANCER BIOL THER, V1, P293, DOI 10.4161/cbt.84; Ji L, 1999, CANCER RES, V59, P3333; Katsuda K, 2002, ONCOGENE, V21, P2108, DOI 10.1038/sj.onc.1205272; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Mao XL, 2003, CANCER RES, V63, P7979; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Masuda M, 2002, J BIOL CHEM, V277, P31014, DOI 10.1074/jbc.M203620200; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; Ng Philip, 2002, Methods Mol Med, V69, P389; Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799; Saeki T, 2002, ONCOGENE, V21, P4558, DOI 10.1038/sj.onc.1205553; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Smith SA, 1996, GENOMICS, V31, P145, DOI 10.1006/geno.1996.0025; Tran YK, 1999, CANCER RES, V59, P35; Uchino K, 2003, CANCER-AM CANCER SOC, V98, P1002, DOI 10.1002/cncr.11599; Yageta M, 2002, CANCER RES, V62, P5129	30	81	93	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5632	5642		10.1038/sj.onc.1207756	http://dx.doi.org/10.1038/sj.onc.1207756			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184878				2022-12-17	WOS:000222629500008
J	Piccolo, E; Vignati, S; Maffucci, T; Innominato, PF; Riley, AM; Potter, BVL; Pandolfi, PP; Broggini, M; Iacobelli, S; Innocenti, P; Falasca, M				Piccolo, E; Vignati, S; Maffucci, T; Innominato, PF; Riley, AM; Potter, BVL; Pandolfi, PP; Broggini, M; Iacobelli, S; Innocenti, P; Falasca, M			Inositol pentakisphosphate promotes apoptosis through the PI3-K/Akt pathway	ONCOGENE			English	Article						phosphoinositide 3-kinase; pleckstrin homology domain; inositol polyphosphates; protein kinase B-Akt; apoptosis	PROTEIN-KINASE-B; PLECKSTRIN HOMOLOGY DOMAIN; LUNG-CANCER CELLS; PHOSPHOINOSITIDE 3-KINASE; DRUG-RESISTANCE; MEMBRANE; ACTIVATION; AKT; SPECIFICITY; PHOSPHATES	Phosphoinositide 3-kinase ( PI 3-K) is implicated in a wide array of biological and pathophysiological responses, including tumorigenesis, invasion and metastasis, therefore specific inhibitors of the kinase may prove useful in cancer therapy. We propose that specific inositol polyphosphates have the potential to antagonize the activation of PI 3-K pathways by competing with the binding of PtdIns(3,4,5) P-3 to pleckstrin homology (PH) domains. Here we show that Ins(1,3,4,5,6) P-5 inhibits the serine phosphorylation and the kinase activity of Akt/PKB. As a consequence of this inhibition, Ins(1,3,4,5,6) P-5 induces apoptosis in ovarian, lung and breast cancer cells. Overexpression of constitutively active Akt protects SKBR-3 cells from Ins(1,3,4,5,6) P-5-induced apoptosis. Furthermore, Ins(1,3,4,5,6) P-5 enhances the proapoptotic effect of cisplatin and etoposide in ovarian and lung cancer cells, respectively. These results support a role for Ins(1,3,4,5,6) P-5 as a specific inhibitor of the PI 3-K/Akt signalling pathway, that may sensitize cancer cells to the action of commonly used anticancer drugs.	UCL, Dept Med, Sackler Inst, Rayne Inst, London WC1E 6JJ, England; Univ G dAnnunzio, Dept Oncol & Neurosci, Sect Med Oncol, I-66100 Chieti, Italy; Mario Negri Inst Pharmacol Res, Mol Pharmacol Lab, Dept Oncol, I-20157 Milan, Italy; Univ Bath, Wolfson Lab Med Chem, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Biol, Dept Pathol, New York, NY 10021 USA; Univ G dAnnunzio, Dept Surg Sci, I-66100 Chieti, Italy	University of London; King's College London; University College London; G d'Annunzio University of Chieti-Pescara; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Bath; Memorial Sloan Kettering Cancer Center; G d'Annunzio University of Chieti-Pescara	Falasca, M (corresponding author), UCL, Dept Med, Sackler Inst, Rayne Inst, 5 Univ St, London WC1E 6JJ, England.	m.falasca@ucl.ac.uk	Potter, Barry/AAX-4781-2020; broggini, massimo/AAA-6460-2020; Potter, Barry VL/A-1845-2012; Riley, Andrew M/F-3526-2013; Falasca, Marco/S-4020-2016	Riley, Andrew M/0000-0001-9003-3540; Falasca, Marco/0000-0002-9801-7235; BROGGINI, MASSIMO/0000-0002-8138-9358				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Aoudjit F, 2001, ONCOGENE, V20, P4995, DOI 10.1038/sj.onc.1204554; Banfic H, 1998, J BIOL CHEM, V273, P11630, DOI 10.1074/jbc.273.19.11630; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Berrie CP, 2000, FASEB J, V14, P2618, DOI 10.1096/fj.00-0096hyp; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Clark AS, 2002, MOL CANCER THER, V1, P707; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; DUKE RC, 1992, CURRENT PROTOCOLS IM; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 1998, CURR TOP MICROBIOL, V228, P39; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maffucci T, 2001, FEBS LETT, V506, P173, DOI 10.1016/S0014-5793(01)02909-X; Mills SJ, 2003, CHEM-EUR J, V9, P6207, DOI 10.1002/chem.200305207; Moore SM, 1998, CANCER RES, V58, P5239; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Ng SSW, 2001, CLIN CANCER RES, V7, P3269; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Razzini G, 2000, FASEB J, V14, P1179, DOI 10.1096/fasebj.14.9.1179; Riley AM, 1998, J ORG CHEM, V63, P295, DOI 10.1021/jo9714425; Rintoul RC, 2002, CLIN SCI, V102, P417, DOI 10.1042/CS20010216; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Shamsuddin AM, 1999, ANTICANCER RES, V19, P3733; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shears SB, 2001, CELL SIGNAL, V13, P151, DOI 10.1016/S0898-6568(01)00129-2; Stein RC, 2001, ENDOCR-RELAT CANCER, V8, P237, DOI 10.1677/erc.0.0080237; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SZWERGOLD BS, 1987, BIOCHEM BIOPH RES CO, V149, P874, DOI 10.1016/0006-291X(87)90489-X; Takeuchi H, 1997, BBA-MOL CELL RES, V1359, P275, DOI 10.1016/S0167-4889(97)00109-2; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Vikhanskaya F, 2002, INT REV CYTOL, V219, P157; Vincent SP, 2002, BIOORGAN MED CHEM, V10, P2825, DOI 10.1016/S0968-0896(02)00162-1; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450	54	81	85	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1754	1765		10.1038/sj.onc.1207296	http://dx.doi.org/10.1038/sj.onc.1207296			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	14755253				2022-12-17	WOS:000220029300011
J	Kim, PKM; Armstrong, M; Liu, Y; Yan, P; Bucher, B; Zuckerbraun, BS; Gambotto, A; Billiar, TR; Yim, JH				Kim, PKM; Armstrong, M; Liu, Y; Yan, P; Bucher, B; Zuckerbraun, BS; Gambotto, A; Billiar, TR; Yim, JH			IRF-1 expression induces apoptosis and inhibits tumor growth in mouse mammary cancer cells in vitro and in vivo	ONCOGENE			English	Article						interferon regulatory factor-1 (IRF-1); apoptosis; breast cancer; caspase	REGULATORY FACTOR-I; TRANSCRIPTION FACTOR IRF-1; HUMAN BREAST-CANCER; IFN-GAMMA; GENE-EXPRESSION; NITRIC-OXIDE; ACTIVATION; INDUCTION; CARCINOMA; FAMILY	Interferon regulatory factor-1 (IRF-1) is a nuclear transcription factor that mediates interferon and other cytokine effects and appears to have antitumor activity in vitro and in vivo in cancer cells. We have constructed a recombinant adenoviral vector (Ad-IRF-1) that infects mammary cells with high efficiency and results in high levels of functional IRF-1 protein in transfected cells. Overexpression of IRF-1 in two mouse breast cancer cell lines, C3-L5 and TS/A, resulted in apoptosis in these cell lines as assessed by Annexin V staining. The involvement of caspases was confirmed by significant inhibition of apoptosis by a caspase inhibitor, and by demonstration of caspase-3 activity, cleavage of caspase-3, and PARP cleavage. Interestingly, the growth of nonmalignant breast cell lines C127I and NMuMG did not appear to be inhibited by IRF-1 overexpression. Suppression of growth for breast cancer cell lines in vivo was demonstrated by both preinfection of breast cancer cells ex vivo and by intratumoral injection of Ad-IRF-1 into established tumors in their natural hosts. The mechanism of apoptosis may involve the transcriptional upregulation of bak, caspase-8, and caspase-7 expression. These data support the antitumor potential of IRF-1 and the use of agents that increase IRF-1 in breast cancer.	Univ Pittsburgh, Med Ctr, Dept Surg, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Yim, JH (corresponding author), Univ Pittsburgh, Med Ctr, Dept Surg, 497 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	yimjh@msx.upmc.edu	Yim, John/R-7555-2019					Baselga J, 2002, CANCER CELL, V1, P319, DOI 10.1016/S1535-6108(02)00066-1; BOUKER KB, 2002, CLIN CANC RES S, V5, P53; BRODT P, 1985, INT J CANCER, V35, P265, DOI 10.1002/ijc.2910350220; CHANG CH, 1992, IMMUNOGENETICS, V35, P378; Chapman RS, 2000, ONCOGENE, V19, P6386, DOI 10.1038/sj.onc.1204016; Doherty GM, 2001, ANN SURG, V233, P623, DOI 10.1097/00000658-200105000-00005; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GELLER DA, 1993, SURGERY, V114, P235; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Kano A, 1999, BIOCHEM BIOPH RES CO, V257, P672, DOI 10.1006/bbrc.1999.0276; KASHIWABA M, 1994, J CANCER RES CLIN, V120, P727, DOI 10.1007/BF01194271; Kim PKM, 2001, INT IMMUNOPHARMACOL, V1, P1421, DOI 10.1016/S1567-5769(01)00088-1; Kirchhoff S, 1999, ONCOGENE, V18, P3725, DOI 10.1038/sj.onc.1202704; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; Kirkwood JM, 2001, J CLIN ONCOL, V19, P2370, DOI 10.1200/JCO.2001.19.9.2370; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Kroger A, 2002, J INTERF CYTOK RES, V22, P5, DOI 10.1089/107999002753452610; Kroger A, 2003, ONCOGENE, V22, P1045, DOI 10.1038/sj.onc.1206260; Kroger A, 2001, CANCER RES, V61, P2609; Lee SH, 2003, ONCOGENE, V22, P381, DOI 10.1038/sj.onc.1206133; Li YH, 1997, J CELL BIOL, V139, P1317, DOI 10.1083/jcb.139.5.1317; NANNI P, 1983, CLIN EXP METASTAS, V1, P373, DOI 10.1007/BF00121199; Nguyen H, 1997, ONCOGENE, V15, P1425, DOI 10.1038/sj.onc.1201318; Nishizaki T, 1997, INT J CANCER, V74, P513, DOI 10.1002/(SICI)1097-0215(19971021)74:5<513::AID-IJC6>3.0.CO;2-6; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; O'Connell P, 1998, JNCI-J NATL CANCER I, V90, P697, DOI 10.1093/jnci/90.9.697; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; Paulson TG, 1999, GENOME RES, V9, P482; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; Sangfelt O, 2001, MED ONCOL, V18, P3, DOI 10.1385/MO:18:1:3; Skaar TC, 1998, J STEROID BIOCHEM, V67, P391, DOI 10.1016/S0960-0760(98)00142-3; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Spink J, 1997, J BIOL CHEM, V272, P24417, DOI 10.1074/jbc.272.39.24417; Takahashi Y, 2000, SURGERY, V128, P345, DOI 10.1067/msy.2000.107415; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 2000, SEMIN CANCER BIOL, V10, P73, DOI 10.1006/scbi.2000.0310; TANAKA N, 1994, CANCER LETT, V83, P191, DOI 10.1016/0304-3835(94)90318-2; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.3.CO;2-C; Tomita Y, 2003, INT J CANCER, V104, P400, DOI 10.1002/ijc.10956; Ulrich E, 1997, GENOMICS, V44, P195, DOI 10.1006/geno.1997.4858; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Yim JH, 1999, J INTERF CYTOK RES, V19, P723, DOI 10.1089/107999099313569; Yim JH, 1997, J IMMUNOL, V158, P1284	52	81	86	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1125	1135		10.1038/sj.onc.1207023	http://dx.doi.org/10.1038/sj.onc.1207023			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14762441				2022-12-17	WOS:000188749900011
J	Simbulan-Rosenthal, CM; Rosenthal, DS; Luo, RB; Samara, R; Espinoza, LA; Hassa, PO; Hottiger, MO; Smulson, ME				Simbulan-Rosenthal, CM; Rosenthal, DS; Luo, RB; Samara, R; Espinoza, LA; Hassa, PO; Hottiger, MO; Smulson, ME			PARP-1 binds E2F-1 independently of its DNA binding and catalytic domains, and acts as a novel coactivator of E2F-1-mediated transcription during re-entry of quiescent cells into S phase	ONCOGENE			English	Article						PARP-1; E2F-1; DNA replication; promoter activity; gene expression; cell cycle; coactivator	POLY(ADP-RIBOSE) POLYMERASE BINDS; DEPENDENT TRANSCRIPTION; RIBOSE POLYMERASE; GENE-EXPRESSION; DISTINCT ROLES; CYCLIN-A; PROTEIN; P53; CDNA; IDENTIFICATION	The transcription factor E2F-1 is implicated in the activation of S-phase genes as well as, induction of apoptosis, and is regulated by interactions with Rb and by cell cycle-dependent alterations in E2F-1 abundance. We. earlier demonstrated a pivotal role for poly(ADP-ribose) polymerase-1 (PARP-1) in the regulation of E2F-1 expression and promoter activity during S-phase re-entry when quiescent cells re-enter the cell cycle. We now investigate the putative mechanism(s) by which PARP-1 may upregulate E2F-1 promoter activity during S-phase re-entry. DNase-1 footprint assays with purified PARP-1 showed that PARP-1 did not directly bind the E2F-1 promoter in a sequence-specific manner. In contrast to p53, a positive acceptor in poly(ADP-ribosyl)ation reactions, E2F-1 was not poly(ADP-ribosyl)ated by wild-type PARP-1 in vitro, indicating that PARP-1 does not exert a dual effect on F2F-1 transcriptional activation. Protein-binding reactions and coimmunoprecipitation experiments with purified PARP-1 and E2F-1, however, revealed that PARP-1 binds to E2F-1 in vitro. More significantly, physical association of PARP-1 and E2F-1 in vivo also occurred in wild-type fibroblasts 5h after re-entry into S phase, coincident with the increase in E2F-1 promoter activity and expression of E2F-1-responsive S-phase genes cyclin A and c-Myc. Mapping of the interaction domains revealed that full-length PARP-1 as well as PARP-1 mutants lacking either the catalytic active site or the DNA-binding domain equally bind E2F-1, whereas a PARP-1 mutant lacking the automodification domain does not, suggesting that the protein interaction site is located in this central domain. Finally, get shift analysis with end-blocked E2F-1 promoter sequence probes verified that the binding of PARP-1 to E2F-1 enhances binding to the E2F-1 promoter, indicating that PARP-1 acts as a positive cofactor of E2F-1-mediated transcription.	Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20057 USA; Univ Zurich, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland	Georgetown University; University of Zurich	Simbulan-Rosenthal, CM (corresponding author), Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Basic Sci Bldg,3900 Reservoir Rd NW, Washington, DC 20057 USA.	simbulac@georgetown.edu	Rosenthal, Dean S/J-2360-2014; Hottiger, Michael O./J-7747-2013; Simbulan-Rosenthal, Cynthia M./W-8429-2019	Hottiger, Michael O./0000-0002-7323-2270; Rosenthal, Dean/0000-0002-7624-0209; Simbulan-Rosenthal, Ph.D, Cynthia M./0000-0002-5070-0342	NATIONAL CANCER INSTITUTE [P01CA074175] Funding Source: NIH RePORTER; NCI NIH HHS [CA25344, P01 CA74175] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama T, 2001, P NATL ACAD SCI USA, V98, P48, DOI 10.1073/pnas.240458597; ALKHATIB HM, 1987, P NATL ACAD SCI USA, V84, P1224, DOI 10.1073/pnas.84.5.1224; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Anderson MG, 2000, J VIROL, V74, P2169, DOI 10.1128/JVI.74.5.2169-2177.2000; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BUKI KG, 1995, J BIOL CHEM, V270, P3370, DOI 10.1074/jbc.270.7.3370; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; De Capoa A, 1999, FASEB J, V13, P89; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DESMARAIS Y, 1991, BIOCHIM BIOPHYS ACTA, V1078, P179, DOI 10.1016/0167-4838(91)99007-F; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Johansson M, 1999, GENOMICS, V57, P442, DOI 10.1006/geno.1999.5799; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; KAWAICHI M, 1981, J BIOL CHEM, V256, P9483; KAWAMITSU H, 1984, BIOCHEMISTRY-US, V23, P3771, DOI 10.1021/bi00311a032; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Kim H, 1997, BIOCHEM J, V322, P469, DOI 10.1042/bj3220469; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; Lee D, 2002, ONCOGENE, V21, P5877, DOI 10.1038/sj.onc.1205723; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; Nash RA, 1997, BIOCHEMISTRY-US, V36, P5207, DOI 10.1021/bi962281m; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; Nie J, 1998, FEBS LETT, V424, P27, DOI 10.1016/S0014-5793(98)00131-8; Nirodi C, 2001, J BIOL CHEM, V276, P9366, DOI 10.1074/jbc.M009897200; Oei SL, 1998, J BIOL CHEM, V273, P31644, DOI 10.1074/jbc.273.48.31644; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rawling JM, 1997, BIOCHEM J, V324, P249, DOI 10.1042/bj3240249; Rosenthal DS, 1997, NUCLEIC ACIDS RES, V25, P1437, DOI 10.1093/nar/25.7.1437; Shan B, 1996, CELL GROWTH DIFFER, V7, P689; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; Simbulan-Rosenthal CM, 1999, ONCOGENE, V18, P5015, DOI 10.1038/sj.onc.1202900; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Simbulan-Rosenthal CM, 2000, P NATL ACAD SCI USA, V97, P11274, DOI 10.1073/pnas.200285797; Simbulan-Rosenthal CM, 1999, CANCER RES, V59, P2190; Simbulan-Rosenthal CM, 1998, BIOCHEMISTRY-US, V37, P9363, DOI 10.1021/bi9731089; Simbulan-Rosenthal CM, 2001, NEOPLASIA, V3, P179, DOI 10.1038/sj.neo.7900155; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Smulson ME, 1998, CANCER RES, V58, P3495; TANG A, 1989, ONCOGENE, V4, P401; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wesierska-Gadek J, 2003, J CELL BIOCHEM, V89, P220, DOI 10.1002/jcb.10521; Yamane K, 2001, ONCOGENE, V20, P2859, DOI 10.1038/sj.onc.1204408; Zhang Z, 2002, VIROLOGY, V296, P107, DOI 10.1006/viro.2002.1385	65	81	85	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2003	22	52					8460	8471		10.1038/sj.onc.1206897	http://dx.doi.org/10.1038/sj.onc.1206897			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627987				2022-12-17	WOS:000186650300010
J	Crnkovic-Mertens, I; Hoppe-Seyler, F; Butz, K				Crnkovic-Mertens, I; Hoppe-Seyler, F; Butz, K			Induction of apoptosis in tumor cells by siRNA-mediated silencing of the livin/ML-IAP/KIAP gene	ONCOGENE			English	Article						RNA interference; inhibitors of apoptosis; chemotherapy; HeLa; melanoma	SMALL INTERFERING RNAS; POSITIVE CANCER-CELLS; MAMMALIAN-CELLS; IN-VIVO; PROTEIN FAMILY; IAP PROTEINS; EXPRESSION; INHIBITOR; DELIVERY; DEATH	Increased resistance to apoptosis is a hallmark of many tumor cells. The functional inhibition of specific antiapoptotic factors may provide a rational basis for the development of novel therapeutic strategies. We investigated here whether the RNA interference (RNAi) technology could be used to increase the apoptotic susceptibility of cancer cells. As a molecular target, we chose the antiapoptotic livin (ML-IAP, KIAP) gene, which is expressed in a subset of human tumors. We identified vector-borne small interfering (si)RNAs, which could efficiently block endogenous livin gene expression. Silencing of livin was associated with caspase-3 activation and a strongly increased apoptotic rate in response to different proapoptotic stimuli, such as doxorubicin, UV-irradiation, or TNFalpha. The effects were specific for Livin-expressing tumor cells. Our results (i) provide direct evidence that the intracellular interference with livin gene expression resensitizes human tumor cells to apoptosis, (ii) define the livin gene as a promising molecular target for therapeutic inhibition, and (iii) show that the livin gene is susceptible to efficient and specific silencing by the siRNA technology.	Deutsch Krebsforschungszentrum, Angewandte Tumorvirol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Butz, K (corresponding author), Deutsch Krebsforschungszentrum, Angewandte Tumorvirol, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.			Hoppe-Seyler, Felix/0000-0002-1864-300X				Agami R, 2002, CURR OPIN CHEM BIOL, V6, P829, DOI 10.1016/S1367-5931(02)00378-2; Ashhab Y, 2001, FEBS LETT, V495, P56, DOI 10.1016/S0014-5793(01)02366-3; Borkhardt A, 2002, CANCER CELL, V2, P167, DOI 10.1016/S1535-6108(02)00129-0; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; BUTZ K, 1993, J VIROL, V67, P6476, DOI 10.1128/JVI.67.11.6476-6486.1993; Butz K, 1999, ONCOGENE, V18, P2381, DOI 10.1038/sj.onc.1202557; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Gazzaniga P, 2003, ANN ONCOL, V14, P85, DOI 10.1093/annonc/mdg002; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lewis DL, 2002, NAT GENET, V32, P107, DOI 10.1038/ng944; Lin JH, 2000, BIOCHEM BIOPH RES CO, V279, P820, DOI 10.1006/bbrc.2000.4027; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Morris MC, 2000, CURR OPIN BIOTECH, V11, P461, DOI 10.1016/S0958-1669(00)00128-2; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Rittner K, 2002, MOL THER, V5, P104, DOI 10.1006/mthe.2002.0523; Rothbard JB, 2002, J MED CHEM, V45, P3612, DOI 10.1021/jm0105676; Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; SONG E, 2003, NAT MED, V10, P2002; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Tuschl T, 2002, NAT BIOTECHNOL, V20, P446, DOI 10.1038/nbt0502-446; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, APOPTOSIS, V7, P163, DOI 10.1023/A:1014318615955; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Vucic D, 2002, J BIOL CHEM, V277, P12275, DOI 10.1074/jbc.M112045200; Wilda M, 2002, ONCOGENE, V21, P5716, DOI 10.1038/sj.onc.1205653; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739	48	81	125	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2003	22	51					8330	8336		10.1038/sj.onc.1206973	http://dx.doi.org/10.1038/sj.onc.1206973			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614456				2022-12-17	WOS:000186541500011
J	Chan, ASW; Tsui, WY; Chen, X; Chu, KM; Chan, TL; Chan, ASY; Li, R; So, S; Yuen, ST; Leung, SY				Chan, ASW; Tsui, WY; Chen, X; Chu, KM; Chan, TL; Chan, ASY; Li, R; So, S; Yuen, ST; Leung, SY			Downregulation of ID4 by promoter hypermethylation in gastric adenocarcinoma	ONCOGENE			English	Article						ID4; hMLH1; microarray; promoter methylation; gastric adenocarcinoma	LOOP-HELIX PROTEINS; ISLAND METHYLATOR PHENOTYPE; GENE-EXPRESSION; MICROSATELLITE INSTABILITY; CANCER; TRANSCRIPTION; CARCINOMAS; HMLH1; CPG; MECHANISM	Promoter hypermethylation has become apparent as a common mechanism of gene silencing in cancer. Based on our published microarray expression data, we noticed a prominent downregulation of ID4 in gastric adenocarcinoma. The dense 5' CpG island covering the previously mapped upstream promoter of ID4 has prompted us to relate its downregulation to promoter hypermethylation. ID proteins are distinct members in the helix-loop-helix family of transcriptional regulators, which modulate various key developmental processes. Emerging data have suggested the involvement of ID genes in tumorigenesis. In this study using bisulfite genomic sequencing, we have found hypermethylation of ID4 promoter in most gastric cancer cell lines and 30% of primary tumors. This correlated with decreased level of ID4 expression. Restoration of ID4 expression in various gastric cancer cell lines was achieved by treatment with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine, which at times required the synergistic action of the histone deacetylase inhibitor trichostatin A, but not with trichostatin A alone. Re-expression was accompanied by the corresponding ID4 promoter demethylation. Furthermore, we have found significant association of ID4 promoter methylation with hMLH1 promoter methylation (P = 0.008) and microsatellite instability (P = 0.006). Overall, our results have shown that transcriptional silencing of ID4 is related to the aberrant methylation of its promoter in gastric cancer. The significant association of ID4 and hMLH1 promoter hypermethylation suggested that ID4 may also be among the genes being targeted in the CpG island methylator phenotype tumorigenic pathway.	Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Stanford Univ, Sch Med, Dept Surg, Stanford, CA 94305 USA; Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; Stanford University; University of Hong Kong	Yuen, ST (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.		Leung, Suet Yi/C-4340-2009; Yuen, Siu/K-6311-2014; Chu, Kent/C-4251-2009; Chan, Agnes/C-4477-2009; Leung, Suet Yi/T-9620-2019	Leung, Suet Yi/0000-0001-8614-4619				Arnold JM, 2001, BRIT J CANCER, V84, P352, DOI 10.1054/bjoc.2000.1620; Bain G, 1999, J EXP MED, V190, P1605, DOI 10.1084/jem.190.11.1605; Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; Bounpheng MA, 1999, FASEB J, V13, P2257, DOI 10.1096/fasebj.13.15.2257; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Deleu S, 2002, EXP CELL RES, V279, P62, DOI 10.1006/excr.2002.5589; Deng GR, 1999, CANCER RES, V59, P2029; Jen Y, 1996, DEV DYNAM, V207, P235; Jen Y, 1997, DEV DYNAM, V208, P92, DOI 10.1002/(SICI)1097-0177(199701)208:1<92::AID-AJA9>3.0.CO;2-X; Ji JF, 2002, ONCOGENE, V21, P6549, DOI 10.1038/sj.onc.1205829; Kee Y, 2001, MECH DEVELOP, V109, P341, DOI 10.1016/S0925-4773(01)00576-7; Kleeff J, 1998, CANCER RES, V58, P3769; Leung SY, 1999, BRIT J CANCER, V79, P582, DOI 10.1038/sj.bjc.6690092; Leung SY, 2002, P NATL ACAD SCI USA, V99, P16203, DOI 10.1073/pnas.212646299; Leung SY, 1999, CANCER RES, V59, P159; Lorincz MC, 2000, MOL CELL BIOL, V20, P842, DOI 10.1128/MCB.20.3.842-850.2000; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Morrow MA, 1999, MOL IMMUNOL, V36, P491, DOI 10.1016/S0161-5890(99)00071-1; Pagliuca A, 1998, J BIOL CHEM, V273, P7668, DOI 10.1074/jbc.273.13.7668; Paulin R, 1998, NUCLEIC ACIDS RES, V26, P5009, DOI 10.1093/nar/26.21.5009; Rivera R, 2001, ONCOGENE, V20, P8308, DOI 10.1038/sj.onc.1205091; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Toyota M, 1999, CANCER RES, V59, P5438; Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599; Vandeputte DAA, 2002, GLIA, V38, P329, DOI 10.1002/glia.10076; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799; Wice BM, 1998, J BIOL CHEM, V273, P25310, DOI 10.1074/jbc.273.39.25310; Wilson JW, 2001, CANCER RES, V61, P8803; Yuen ST, 2002, ONCOGENE, V21, P7585, DOI 10.1038/sj.onc.1205968; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092	33	81	94	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 9	2003	22	44					6946	6953		10.1038/sj.onc.1206799	http://dx.doi.org/10.1038/sj.onc.1206799			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534543				2022-12-17	WOS:000185843400017
J	Spicer, J; Rayter, S; Young, N; Elliott, R; Ashworth, A; Smith, D				Spicer, J; Rayter, S; Young, N; Elliott, R; Ashworth, A; Smith, D			Regulation of the Wnt signalling component PAR1A by the Peutz-Jeghers syndrome kinase LKB1	ONCOGENE			English	Article						cancer susceptibility; Peutz-Jeghers syndrome; Wnt signalling; colorectal cancer; protein kinase	PROTEIN-KINASES; KNOCKOUT MICE; BETA-CATENIN; CARCINOMA; POLARITY; ENCODES; INACTIVATION; POLYPOSIS; ASYMMETRY; PAR-1	Loss-of-function mutations in the LKB1 (STK11) serine-threonine kinase gene cause Peutz-Jeghers syndrome, which is associated with inherited susceptibility to colorectal and other cancers. No downstream targets of LKB1 kinase activity have been identified. Here we show that LKB1 can direct the phosphorylation of the serine-threonine kinase PAR1A. The amino-acid residues phosphorylated as a result of LKB1 activity have been identified and phosphorylation at these residues is required for PAR1A kinase activity. PAR1A has previously been implicated as a positive regulator of the Wnt-betacatenin signalling pathway. We show here that LKB1 can modify transcription driven by the Wnt-regulated TCF response element, implicating LKB1 in a pathway known to play a key role in human colorectal tumorigenesis.	Inst Canc Res, Breakthrough Breast Canc Res Ctr, Canc Res UK Gene Funct & Regulat Grp, London SW3 6JB, England	Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Ashworth, A (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, Canc Res UK Gene Funct & Regulat Grp, Fulham Rd, London SW3 6JB, England.			Spicer, James/0000-0003-3732-8491				Back W, 1999, J CLIN PATHOL, V52, P345, DOI 10.1136/jcp.52.5.345; Bosman FT, 1999, J PATHOL, V188, P1, DOI 10.1002/(SICI)1096-9896(199905)188:1<1::AID-PATH327>3.0.CO;2-J; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Jan YN, 2000, CELL, V100, P599, DOI 10.1016/S0092-8674(00)80695-9; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Marignani PA, 2001, J BIOL CHEM, V276, P32415, DOI 10.1074/jbc.C100207200; Martin SG, 2003, NATURE, V421, P379, DOI 10.1038/nature01296; Mehenni H, 1998, AM J HUM GENET, V63, P1641, DOI 10.1086/302159; Miyoshi H, 2002, CANCER RES, V62, P2261; Nakau M, 2002, CANCER RES, V62, P4549; PARSA I, 1988, CANCER RES, V48, P2265; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Smith DP, 1999, HUM MOL GENET, V8, P1479, DOI 10.1093/hmg/8.8.1479; Smith DP, 2001, HUM MOL GENET, V10, P2869, DOI 10.1093/hmg/10.25.2869; Sun TQ, 2001, NAT CELL BIOL, V3, P628, DOI 10.1038/35083016; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Tomlinson IPM, 1997, J MED GENET, V34, P1007, DOI 10.1136/jmg.34.12.1007; Watts JL, 2000, DEVELOPMENT, V127, P1467; Yoo LI, 2002, NAT REV CANCER, V2, P529, DOI 10.1038/nrc843; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	26	81	85	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2003	22	30					4752	4756		10.1038/sj.onc.1206669	http://dx.doi.org/10.1038/sj.onc.1206669			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879020				2022-12-17	WOS:000184157000016
J	Kurosu, T; Fukuda, T; Miki, T; Miura, O				Kurosu, T; Fukuda, T; Miki, T; Miura, O			BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells	ONCOGENE			English	Article						BCL6; apoptosis; chemotherapeutic reagents; reactive oxygen species; etoposide	GERMINAL-CENTER FORMATION; NON-HODGKINS-LYMPHOMA; FINGER ENCODING GENE; TRANSCRIPTIONAL REPRESSOR; PROTOONCOGENE BCL-6; EXPRESSION; DEATH; LAZ3; DIFFERENTIATION; TRANSLOCATIONS	Chromosomal translocations and somatic mutations occurring in the 5' noncoding region of the BCL6 gene, encoding a transcriptional repressor, are most frequent genetic abnormalities associated with non-Hodgkin B-cell lymphoma and result in deregulated expression of BCL6. However, the significance of deregulated expression of BCL6 in lymphomagenesis and its effect on clinical outcomes of lymphoma patients have remained elusive. In the present study, we established Daudi and Raji B-cell lymphoma cell lines that overexpress BCL6 or its mutant, BCL6-Ala333/343, in which serine residues required for degradation through the proteasome pathway in B-cell receptor-stimulated cells are mutated. BCL6 overexpression did not have any significant effect on cell proliferation, but significantly inhibited apoptosis caused by etoposide, which induced a proteasome-dependent degradation of BCL6. BCL6-Ala333/343 was not degraded after etoposide treatment and strongly inhibited apoptosis. In these lymphoma cell lines, etoposide increased the generation of reactive oxygen species (ROS) and reduced mitochondria membrane potential, both of which were inhibited by the antioxidant N-acetyl-L-cysteine (NAC). NAC also inhibited apoptosis. Furthermore, BCL6 overexpression was found to inhibit the increase in ROS levels and apoptosis in response to etoposide and other chemotherapeutic reagents. These results raise the possibility that deregulated expression of BCL6 may endow lymphoma cells with resistance to chemotherapeutic reagents, most likely by enhancing the antioxidant defense systems.	Tokyo Med & Dent Univ, Dept Hematol & Oncol, Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU)	Miura, O (corresponding author), Tokyo Med & Dent Univ, Dept Hematol & Oncol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.			Miura, Osamu/0000-0002-0981-3054				Albagli O, 1999, ONCOGENE, V18, P5063, DOI 10.1038/sj.onc.1202892; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; Barrans SL, 2002, BRIT J HAEMATOL, V117, P322, DOI 10.1046/j.1365-2141.2002.03435.x; BASTARD C, 1994, BLOOD, V83, P2423; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chabner B.A., 2001, CANC CHEMOTHERAPY BI, V3rd; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; Dent AL, 2002, CRIT REV ONCOL HEMAT, V41, P1, DOI 10.1016/S1040-8428(01)00164-0; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Dvorakova K, 2001, BLOOD, V97, P3544, DOI 10.1182/blood.V97.11.3544; Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; Jabs T, 1999, BIOCHEM PHARMACOL, V57, P231, DOI 10.1016/S0006-2952(98)00227-5; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kikuchi M, 2000, ONCOGENE, V19, P4941, DOI 10.1038/sj.onc.1203864; Kojima S, 2001, DEVELOPMENT, V128, P57; Kumagai T, 1999, ONCOGENE, V18, P467, DOI 10.1038/sj.onc.1202306; LO CF, 1994, BLOOD, V83, P1757; Lossos IS, 2001, BLOOD, V98, P945, DOI 10.1182/blood.V98.4.945; MIKI T, 1994, BLOOD, V83, P26; Nakamura Y, 2000, LEUKEMIA LYMPHOMA, V38, P505, DOI 10.3109/10428190009059269; Niu HF, 2002, HEMATOL ONCOL, V20, P155, DOI 10.1002/hon.689; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; Ohno H, 1997, LEUKEMIA LYMPHOMA, V27, P53, DOI 10.3109/10428199709068271; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Wang X, 2002, P NATL ACAD SCI USA, V99, P15018, DOI 10.1073/pnas.232581199; Yamochi T, 1999, ONCOGENE, V18, P487, DOI 10.1038/sj.onc.1202334; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073	39	81	87	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2003	22	29					4459	4468		10.1038/sj.onc.1206755	http://dx.doi.org/10.1038/sj.onc.1206755			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881702				2022-12-17	WOS:000184054700001
J	Crabtree, M; Sieber, OM; Lipton, L; Hodgson, SV; Lamlum, H; Thomas, HJW; Neale, K; Phillips, RKS; Heinimann, K; Tomlinson, IPM				Crabtree, M; Sieber, OM; Lipton, L; Hodgson, SV; Lamlum, H; Thomas, HJW; Neale, K; Phillips, RKS; Heinimann, K; Tomlinson, IPM			Refining the relation between 'first hits' and 'second hits' at the APC locus: the 'loose fit' model and evidence for differences in somatic mutation spectra among patients	ONCOGENE			English	Article						polyposis; APC; colorectal tumours; two-hit hypothesis	FAMILIAL ADENOMATOUS POLYPOSIS; COLORECTAL TUMORS; CLUSTER REGION; GENE; PHENOTYPE; GENOTYPE; GERMLINE; PROTEIN	The site of the 'first hit' in the APC tumour suppressor gene determines the type of the 'second hit', both in familial adenomatous polyposis (FAP) and sporadic colorectal tumours. Mutations near codon 1300 are associated with loss of heterozygosity (LOH) of the wild-type allele; other tumours tend to have two protein-truncating mutations. In this study, we have confirmed and refined the LOH-associated region in colorectal FAP: allelic loss in adenomatous polyps tended to occur when the germline mutation lay in the region of the APC gene between the first and second beta-catenin degradation repeats (codons 1285-1378). LOH generally occurred by mitotic recombination, leaving two identical alleles, each encoding a protein with one remaining beta-catenin degradation repeat. For patients with germline mutations that truncated the protein before the first repeat (codon 1264), LOH was very rare and tumours generally acquired a somatic mutation which left two, or less often one, repeats remaining in the protein. In our sample set, patients with germline mutations after the second beta-catenin degradation repeat tended to have undetectable, presumably cryptic, somatic mutations in their polyps. Exceptions to these rules were, however, not uncommon. Although the site of the germline mutation was the strongest determinant of the somatic mutation in FAP tumours and most patients showed no clear tendency to acquire specific types of truncating 'second hit', a minority of patients did have unusual somatic mutation spectra in their polyps. Thus, some individuals may be predisposed to particular types of 'second hit' (for example, frameshift rather than nonsense changes). Overall, disease severity (polyp number) did not vary with individuals' spectrum of somatic APC mutations, providing no clear evidence for modifier genes that influence disease severity in this fashion. Our data are consistent with the hypothesis that there exists an optimal level of beta-catenin signalling in colorectal tumours and that the APC mutation spectrum principally reflects this fact. The association between 'first hits' and 'second hits' at APC is not, however, so strong as to suggest that tumorigenesis only occurs if the genotype is optimum; we suggest 'relaxed' terminology, the 'loose fit' model, to describe this situation.	Canc Res UK, Mol & Populat Genet Lab, London WC2A 3PX, England; St Marks Hosp, Colorectal Canc Unit, Canc Res UK, Harrow HA1 3UJ, Middx, England; Guys Hosp, Dept Clin Genet, London SE1 9RT, England; St Marks Hosp, Polyposis Registry, Harrow HA1 3UJ, Middx, England; Univ Clin, Res Grp Human Genet, Div Med Genet, CH-4031 Basel, Switzerland	Cancer Research UK; Cancer Research UK; Imperial College London; Guy's & St Thomas' NHS Foundation Trust; Imperial College London	Tomlinson, IPM (corresponding author), Canc Res UK, Mol & Populat Genet Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Sieber, Oliver/M-9473-2015; Sieber, Oliver/ABA-9211-2021	Sieber, Oliver/0000-0001-9480-0786; Sieber, Oliver/0000-0001-9480-0786				Albuquerque C, 2002, HUM MOL GENET, V11, P1549, DOI 10.1093/hmg/11.13.1549; Crabtree MD, 2002, GUT, V51, P420, DOI 10.1136/gut.51.3.420; Debinski HS, 1996, GASTROENTEROLOGY, V110, P1028, DOI 10.1053/gast.1996.v110.pm8612989; Groves C, 2002, AM J PATHOL, V160, P2055, DOI 10.1016/S0002-9440(10)61155-8; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; Lamlum H, 1999, NAT MED, V5, P1071, DOI 10.1038/12511; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; NUGENT KP, 1994, GUT, V35, P1622, DOI 10.1136/gut.35.11.1622; POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Rubinfeld B, 1997, CANCER RES, V57, P4624; Sieber OM, 2002, P NATL ACAD SCI USA, V99, P2954, DOI 10.1073/pnas.042699199; Smits R, 2000, GENE CHROMOSOME CANC, V29, P229, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1033>3.0.CO;2-R; Spink KE, 2001, EMBO J, V20, P6203, DOI 10.1093/emboj/20.22.6203; Wasan HS, 1998, J PATHOL, V185, P246	16	81	84	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2003	22	27					4257	4265		10.1038/sj.onc.1206471	http://dx.doi.org/10.1038/sj.onc.1206471			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833148				2022-12-17	WOS:000183979800012
J	Janknecht, R				Janknecht, R			Regulation of the ER81 transcription factor and its coactivators by mitogen- and stress-activated protein kinase 1 (MSK1)	ONCOGENE			English	Article						CBP; ER81; MSK1; p300; phosphorylation; transcription	RUBINSTEIN-TAYBI-SYNDROME; PROTEIN-KINASE; MAP KINASE; HISTONE H3; INDUCED PHOSPHORYLATION; EXPRESSION PATTERNS; BINDING PROTEIN; ETS-DOMAIN; PEA3 GROUP; GENE	The transcription factor ER81 has been shown to be involved in ontogenesis and breast tumor formation. ER81 is activated by many signals through phosphorylation directly mediated by mitogen-activated protein kinases (MAPKs), but also by an unknown protein kinase(s). Here, mitogen- and stress-activated protein kinase I (MSK1), which itself is directly activated by distinct classes of MAPKs, is identified to regulate ER81 function. MSK1 expression enhances ER81-dependent transcription upon stimulation of especially the p38-MAPK pathway. Two serine residues in ER81 are phosphorylated by MSK1, and mutating these serine residues to alanines dramatically diminishes the ability of MSK1 to stimulate ER81. However, mutation of the MSK1 phosphorylation sites in ER81 does not completely abrogate the ability of MSK1 to activate ER81 function, suggesting that MSK1 may also target cofactors of ER81. Consistently, MSK1 interacts with two homologous coactivators of ER81, CBP and p300, and stimulates the transactivation domains of CBP. Thus, MSK1 may regulate ER81-dependent transcription via direct phosphorylation of ER81 as well as via stimulation of CBP/p300, which might be important for ER81's normal function and during mammary tumor formation.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Janknecht, R (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	janknecht.ralf@mayo.edu		Janknecht, Ralf/0000-0003-1741-1562	NATIONAL CANCER INSTITUTE [R01CA085257] Funding Source: NIH RePORTER; NCI NIH HHS [CA085257, R01 CA085257] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4; Arthur JSC, 2000, FEBS LETT, V482, P44, DOI 10.1016/S0014-5793(00)02031-7; Baert JL, 2002, J BIOL CHEM, V277, P1002, DOI 10.1074/jbc.M107139200; BARRATT MJ, 1994, EMBO J, V13, P4524, DOI 10.1002/j.1460-2075.1994.tb06774.x; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Blough RI, 2000, AM J MED GENET, V90, P29, DOI 10.1002/(SICI)1096-8628(20000103)90:1<29::AID-AJMG6>3.0.CO;2-Z; Bosc DG, 2002, J CELL BIOCHEM, V86, P174, DOI 10.1002/jcb.10205; Bosc DG, 2001, ONCOGENE, V20, P6215, DOI 10.1038/sj.onc.1204820; BredemeierErnst I, 1997, FEBS LETT, V408, P47, DOI 10.1016/S0014-5793(97)00387-6; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Chotteau-Lelievre A, 2001, MECH DEVELOP, V108, P191, DOI 10.1016/S0925-4773(01)00480-4; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Coutte L, 1999, ONCOGENE, V18, P6278, DOI 10.1038/sj.onc.1203020; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Goodman RH, 2000, GENE DEV, V14, P1553; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Hung MC, 1999, SEMIN ONCOL, V26, P51; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; Janknecht R, 2002, HISTOL HISTOPATHOL, V17, P657, DOI 10.14670/HH-17.657; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 2001, J BIOL CHEM, V276, P41856, DOI 10.1074/jbc.M106630200; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; JEON IS, 1995, ONCOGENE, V10, P1229; Kucera J, 2002, DEV DYNAM, V223, P389, DOI 10.1002/dvdy.10066; Kung AL, 2000, GENE DEV, V14, P272; Liu SL, 2000, ONCOGENE, V19, P3352, DOI 10.1038/sj.onc.1203675; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MILLER RW, 1995, AM J MED GENET, V56, P112, DOI 10.1002/ajmg.1320560125; MONTE D, 1995, ONCOGENE, V11, P771; New L, 1999, J BIOL CHEM, V274, P1026, DOI 10.1074/jbc.274.2.1026; Nomura M, 2001, J BIOL CHEM, V276, P25558, DOI 10.1074/jbc.M101164200; Papoutsopoulou S, 2000, MOL CELL BIOL, V20, P7300, DOI 10.1128/MCB.20.19.7300-7310.2000; Pearson KL, 1999, BBA-GENE STRUCT EXPR, V1489, P354, DOI 10.1016/S0167-4781(99)00166-9; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Rubin I, 2001, ANN ONCOL, V12, P3, DOI 10.1023/A:1011195320446; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; Smits PHM, 1996, ONCOGENE, V12, P1529; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Strelkov IS, 2002, CANCER RES, V62, P75; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Tomas-Zuber M, 2001, J BIOL CHEM, V276, P5892, DOI 10.1074/jbc.M005822200; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; Zhang YG, 2001, J BIOL CHEM, V276, P42534, DOI 10.1074/jbc.M106044200; Zhong SP, 2001, J BIOL CHEM, V276, P33213, DOI 10.1074/jbc.M103973200	54	81	85	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					746	755		10.1038/sj.onc.1206185	http://dx.doi.org/10.1038/sj.onc.1206185			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569367				2022-12-17	WOS:000180642100012
J	Emerling, BM; Bonifas, J; Kratz, CP; Donovan, S; Taylor, BR; Green, ED; Le Beau, MM; Shannon, KM				Emerling, BM; Bonifas, J; Kratz, CP; Donovan, S; Taylor, BR; Green, ED; Le Beau, MM; Shannon, KM			MLL5, a homolog of Drosophila trithorax located within a segment of chromosome band 7q22 implicated in myeloid leukemia	ONCOGENE			English	Article						monosomy 7; deletion 7q; myeloid leukemia; trithorax genes	BONE-MARROW CELLS; MYELOGENOUS LEUKEMIA; MUTANT MICE; GENE; FUSION; REGION; NEUROFIBROMATOSIS; T(7-11)(P15-P15); TRANSLOCATIONS; LEUKEMOGENESIS	Proteins encoded by Polycomb and Trithorax-group (Pc-G and Trx-G) genes regulate developmental fates by maintaining or repressing HOX gene expression, respectively. In a search for candidate myeloid leukemia tumor suppressor genes from a similar to2.5 Mb commonly-deleted segment within chromosome band 7q22, we identified a novel human Trithorax (Trx) family member named MLL5. Trx-G genes encode proteins that modulate transcriptional programs through protein-protein interactions that are mediated by PHD and SET domains, and by binding to DNA via A-T hooks and methyltransferase homology motifs. MLL5 is a homolog of the Drosophila gene CG9007; it encodes a 6.5 kb mRNA that is expressed widely. MLL5 includes a SET domain and a single PHD finger, but lacks A-T hooks and methyltransferase homology domains that are found in MLL. The leukemia cell line RCV-ACV-A carries a heterozygous missense mutation within the PHD domain; however, no mutations within the MLL5 coding region were detected in primary leukemias. MLL5 is a novel mammalian Trx-G gene that might modulate transcription by protein association.	Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; NHGRI, Genome Technol Branch, Bethesda, MD 20892 USA; Univ Chicago, Hematol Oncol Sect, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Ctr Canc Res, Chicago, IL 60637 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Chicago; University of Chicago	Shannon, KM (corresponding author), Univ Calif San Francisco, Dept Pediat, 513 Parnassus Ave,HSE 302, San Francisco, CA 94143 USA.		Kratz, Christian/AAC-9726-2021		NCI NIH HHS [CA 40046] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Allen RJ, 1998, LEUKEMIA, V12, P1119, DOI 10.1038/sj.leu.2401002; Baylin SB, 2000, J NATL CANCER I, V92, P1460, DOI 10.1093/jnci/92.18.1460; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; CANAANI E, 1995, ADV CANCER RES, V66, P213, DOI 10.1016/S0065-230X(08)60255-9; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; KALRA R, 1994, BLOOD, V84, P3435; KANEKO Y, 1989, LEUKEMIA, V3, P36; Kratz CP, 2001, GENOMICS, V77, P171, DOI 10.1006/geno.2001.6636; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; LAWRENCE HJ, 1992, BLOOD, V80, P2445; LeBeau MM, 1996, BLOOD, V88, P1930; LEBEAU MM, 1986, J CLIN ONCOL, V3, P325; Lessard J, 1998, BLOOD, V91, P1216, DOI 10.1182/blood.V91.4.1216; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Luna-Fineman S, 1999, BLOOD, V93, P459, DOI 10.1182/blood.V93.2.459.402k19_459_466; LUNAFINEMAN S, 1995, BLOOD, V85, P1985, DOI 10.1182/blood.V85.8.1985.bloodjournal8581985; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; Rozovskaia T, 1999, MOL CELL BIOL, V19, P6441; Rozovskaia T, 2000, ONCOGENE, V19, P351, DOI 10.1038/sj.onc.1203307; Side L, 1997, NEW ENGL J MED, V336, P1713, DOI 10.1056/NEJM199706123362404; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Thirman MJ, 1996, HEMATOL ONCOL CLIN N, V10, P293, DOI 10.1016/S0889-8588(05)70340-3; van Lohuizen M, 1999, CURR OPIN GENET DEV, V9, P355, DOI 10.1016/S0959-437X(99)80053-7; Yagi H, 1998, BLOOD, V92, P108, DOI 10.1182/blood.V92.1.108.413k11_108_117; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	35	81	85	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2002	21	31					4849	4854		10.1038/sj.onc.1205615	http://dx.doi.org/10.1038/sj.onc.1205615			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101424				2022-12-17	WOS:000176716300015
J	Eymin, B; Gazzeri, S; Brambilla, C; Brambilla, E				Eymin, B; Gazzeri, S; Brambilla, C; Brambilla, E			Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors	ONCOGENE			English	Article						carcinogenesis; cell cycle; Mdm2; lung tumor; p14(ARF)	WILD-TYPE P53; ATM-DEPENDENT PHOSPHORYLATION; RING-FINGER DOMAIN; GENE-PRODUCT; UBIQUITIN LIGASE; BETA-TRANSCRIPT; NUCLEAR EXPORT; PROTEIN; EXPRESSION; P19(ARF)	Pathways involving p53 and pRb tumor suppressor genes are frequently deregulated during lung carcinogenesis. Through its location at the interface of these pathways, Mdm2 can modulate the function of both p53 and pRb genes. We have examined here the pattern of expression of Mdm2 in a series of 192 human lung carcinomas of all histological types using both immunohistochemical and Western blot analyses and four distinct antibodies mapping different epitopes onto the Mdm2 protein. Using Immunohistochemistry (MC), Mdm2 was overexpressed as compared to normal lung in 31% (60 out of 192) of all tumors analysed, whatever their histological types. Western blotting was performed on 28 out of the 192 tumoral samples. Overexpression of p85/90, p74/76 and p57 Mdm2 isoforms was detected in 18% (5 out of 28), 25% (7 out of 28) and 39% (11 out of 28) of the cases respectively. Overall, overexpression of at least one isoform was observed in 14 out of 28 (50%) lung tumors and concomittant overexpression of at least two isoforms in 7 out of 28 (25%) cases. A good concordance (82%) was observed between immunohistochemical and Western blot data. Interestingly, a highly significant inverse relationship was detected between p14(ARF) loss and Mdm2 overexpression either in NSCLC (P = 0.0089) or in NE lung tumors (P < 0.0001). Furthermore, a Mdm2/P14(ARF) > 1 ratio was correlated with a high grade phenotype among NE tumors overexpressing Mdm2 (P = 0.0021). Taken together, these data strongly suggest that p14(ARF) and Mdm2 act on common pathway(s) to regulate p53 and/or pRb-dependent or independent functions and that the Mdm2:p14(ARF) ratio might act as a rheostat in modulating the activity of both proteins.	Inst Albert Bonniot, Grp Rech Canc Poumon, EA 2021, Equipe INSERM 9924, F-38706 La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Gazzeri, S (corresponding author), Inst Albert Bonniot, Grp Rech Canc Poumon, EA 2021, Equipe INSERM 9924, F-38706 La Tronche, France.	Sylvie.Gazzeri@ujf-grenoble.fr	Eymin, Beatrice/M-1962-2013; gazzeri, sylvie/M-1961-2013; eymin, beatrice/U-4670-2019; gazzeri, sylvie/U-4669-2019; Brambilla, Elisabeth MP/L-8796-2013	Eymin, Beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; eymin, beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; 				Aikawa H, 2000, INT J MOL MED, V5, P631; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Brambilla E, 1999, J PATHOL, V188, P351, DOI 10.1002/(SICI)1096-9896(199908)188:4<351::AID-PATH385>3.0.CO;2-W; BRAMBILLA E, 1993, AM J PATHOL, V143, P199; BuesoRamos CE, 1996, BREAST CANCER RES TR, V37, P179, DOI 10.1007/BF01806499; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHIBA I, 1990, ONCOGENE, V5, P1603; CORDONCARDO C, 1994, CANCER RES, V54, P794; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Esteller M, 2001, CANCER RES, V61, P2816; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FOULKES WD, 1995, BRIT J CANCER, V72, P883, DOI 10.1038/bjc.1995.428; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; GAZZERI S, 1994, INT J CANCER, V58, P24, DOI 10.1002/ijc.2910580106; Gazzeri S, 1998, CANCER RES, V58, P3926; Gazzeri S, 1998, ONCOGENE, V16, P497, DOI 10.1038/sj.onc.1201559; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gorgoulis VG, 2000, MOL MED, V6, P208, DOI 10.1007/BF03402115; Gorgoulis VG, 1996, MODERN PATHOL, V9, P544; Gorgoulis VG, 1996, J PATHOL, V180, P129; Gorgoulis VG, 1998, AM J PATHOL, V153, P1749, DOI 10.1016/S0002-9440(10)65690-8; GOUYER V, 1998, AM J RESP CELL MOL B, V17, P1; GUDAS JM, 1995, CLIN CANCER RES, V1, P71; Haidar MA, 1997, AM J HEMATOL, V54, P189, DOI 10.1002/(SICI)1096-8652(199703)54:3<189::AID-AJH3>3.0.CO;2-S; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Higashiyama M, 1997, BRIT J CANCER, V75, P1302, DOI 10.1038/bjc.1997.221; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Horie S, 2001, PATHOL INT, V51, P11, DOI 10.1046/j.1440-1827.2001.01159.x; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Ko JL, 2000, INT J CANCER, V89, P265, DOI 10.1002/1097-0215(20000520)89:3<265::AID-IJC9>3.0.CO;2-N; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LIANES P, 1994, J NATL CANCER I, V86, P1325, DOI 10.1093/jnci/86.17.1325; MARCHETTI A, 1995, DIAGN MOL PATHOL, V4, P93, DOI 10.1097/00019606-199506000-00004; Mariatos G, 2000, MUTAT RES-FUND MOL M, V456, P59, DOI 10.1016/S0027-5107(00)00110-X; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; McDonnell TJ, 1999, J PATHOL, V188, P322, DOI 10.1002/(SICI)1096-9896(199907)188:3<322::AID-PATH372>3.0.CO;2-F; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; O'Neill M, 1998, J PATHOL, V186, P254; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; Perry ME, 2000, J BIOL CHEM, V275, P5733, DOI 10.1074/jbc.275.8.5733; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, ONCOGENE, V11, P635; Ralhan R, 2000, AM J PATHOL, V157, P587, DOI 10.1016/S0002-9440(10)64569-5; Rasidakis A, 1998, HYBRIDOMA, V17, P339, DOI 10.1089/hyb.1998.17.339; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Ries SJ, 2000, NAT MED, V6, P1128, DOI 10.1038/80466; RODENHUIS S, 1992, CANCER RES, V52, pS2665; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Stefanaki K, 1998, ANTICANCER RES, V18, P1689; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Travis WD, 1999, HISTOLOGICAL TYPING; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Xu HJ, 1996, CLIN CANCER RES, V2, P1169; Yap DBS, 1999, ONCOGENE, V18, P7681, DOI 10.1038/sj.onc.1202954; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	73	81	86	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2002	21	17					2750	2761		10.1038/sj.onc.1205359	http://dx.doi.org/10.1038/sj.onc.1205359			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965548	Green Submitted			2022-12-17	WOS:000174996500015
J	Ahmed, N; Niu, J; Dorahy, DJ; Gu, XH; Andrews, S; Meldrum, CJ; Scott, RJ; Baker, MS; Macreadie, IG; Agrez, MV				Ahmed, N; Niu, J; Dorahy, DJ; Gu, XH; Andrews, S; Meldrum, CJ; Scott, RJ; Baker, MS; Macreadie, IG; Agrez, MV			Direct integrin alpha v beta 6-ERK binding: implications for tumour growth	ONCOGENE			English	Article						alpha v beta 6 integrin; colon cancer; ERK2; tumour growth	ACTIVATED PROTEIN-KINASE; SIGNALING PATHWAY; EXPRESSION; CELLS; TRANSDUCTION; SUBUNIT; ALPHA-NU-BETA-6; FIBRONECTIN; SPECIFICITY; ERK	Blockade of the mitogen-activated protein (MAP) kinase pathway suppresses growth of colon cancer in vivo. Here we demonstrate a direct link between the extracellular signal-regulated kinase ERK2 and the growth-promoting cell adhesion molecule, integrin alphavbeta6, in colon cancer cells. Down-regulation of beta6 integrin subunit expression inhibits tumour growth in vivo and MAP kinase activity in response to serum stimulation. In alphavbeta6-expressing cells ERK2 is bound only to the beta6 subunit. The increase in cytosolic MAP kinase activity upon epidermal growth factor stimulation is all accounted for by beta6-bound ERK. Deletion of the ERK2 binding site on the beta6 cytoplasmic domain inhibits tumour growth and leads to an association between ERK and the beta5 subunit. The physical interaction between integrin alphavbeta6 and ERK2 defines a novel paradigm of integrin-mediated signalling and provides a therapeutic target for cancer treatment.	Univ Newcastle, Fac Med & Hlth Sci, Discipline Surg Sci, Newcastle, NSW 2308, Australia; John Hunter Hosp, Hunter Med Res Inst, Newcastle Bowel Canc Res Collaborat, Newcastle, NSW, Australia; Royal Womens Hosp, Gynaecol Canc Res Ctr, Melbourne, Vic, Australia; Univ Melbourne, Melbourne, Vic, Australia; CSIRO Hlth Sci & Nutr, Parkville, Vic, Australia	University of Newcastle; Hunter Medical Research Institute; John Hunter Hospital; University of Newcastle; University of Melbourne; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Agrez, MV (corresponding author), Univ Newcastle, Fac Med & Hlth Sci, Discipline Surg Sci, Newcastle, NSW 2308, Australia.	Michael.Agrez@newcastle.edu.au	Macreadie, Ian/L-4437-2019; Macreadie, Ian/Q-7430-2019; Macreadie, Ian G/F-5997-2010; Scott, Rodney J/B-2827-2013	Macreadie, Ian/0000-0001-5335-7220; Macreadie, Ian G/0000-0001-5335-7220; Scott, Rodney J/0000-0001-7724-3404; Baker, Mark/0000-0001-5858-4035; Meldrum, Cliff/0000-0002-5685-1918				Agrez M, 1999, INT J CANCER, V81, P90, DOI 10.1002/(SICI)1097-0215(19990331)81:1<90::AID-IJC16>3.0.CO;2-K; AGREZ M, 1994, J CELL BIOL, V127, P547, DOI 10.1083/jcb.127.2.547; Agrez MV, 1996, BRIT J CANCER, V73, P887, DOI 10.1038/bjc.1996.158; Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Arihiro K, 2000, Breast Cancer, V7, P19, DOI 10.1007/BF02967183; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREUSS JM, 1995, J CELL SCI, V108, P2241; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CONE RI, 1994, CELL ADHES COMMUN, V2, P101, DOI 10.3109/15419069409004430; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Duesbery NS, 1999, NAT MED, V5, P736, DOI 10.1038/10457; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hamidi S, 2000, BRIT J CANCER, V82, P1433, DOI 10.1054/bjoc.1999.1130; HEWITT RE, 1991, INT J CANCER, V49, P666, DOI 10.1002/ijc.2910490507; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Johansson N, 2000, J CELL SCI, V113, P227; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Licato LL, 1997, GASTROENTEROLOGY, V113, P1589, DOI 10.1053/gast.1997.v113.pm9352861; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Niu J, 2001, INT J CANCER, V92, P40, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1157>3.0.CO;2-B; Partik G, 1999, J CANCER RES CLIN, V125, P379, DOI 10.1007/s004320050290; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; Thomas GJ, 1997, ORAL ONCOL, V33, P381, DOI 10.1016/S0964-1955(97)00021-3; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; Wolf I, 2001, J BIOL CHEM, V276, P24490, DOI 10.1074/jbc.M103352200; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271	37	81	90	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1370	1380		10.1038/sj.onc.1205286	http://dx.doi.org/10.1038/sj.onc.1205286			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857080				2022-12-17	WOS:000173861000007
J	Montagna, C; Andrechek, ER; Padilla-Nash, H; Muller, WJ; Ried, T				Montagna, C; Andrechek, ER; Padilla-Nash, H; Muller, WJ; Ried, T			Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu	ONCOGENE			English	Article						HER2/neu; spectral karyotyping (SKY); breast cancer model; genomic instability; double minutes (DMs); centrosome	TRANSGENIC MICE; BREAST-CANCER; C-MYC; TUMORS; HYBRIDIZATION; ABERRATIONS; TUMORIGENESIS; INSTABILITY; ONCOGENE; GENES	The conditional expression of activated HER2/neu gene under its endogenous promoter in the mammary epithelium of the mouse results in accelerated lobular development and focal mammary tumors. Carcinogenesis, however, requires amplification and considerably increased expression levels of oncogenic neu. Deducing from the multiple genetic aberrations required for human breast cancer to develop, we hypothesized that in addition to the over-expression of an activated HER2/neu, secondary aberrations would occur. We have therefore conducted a genomic screen for chromosomal imbalances and translocations using comparative genomic hybridization and spectral karyotyping. The results reveal a moderate degree of chromosomal instability and micronuclei formation in short-term cultures established from primary tumors. Genomic instability appears to be linked to the amplification of functional centrosomes, a phenomenon that we frequently observed in other tumor types. Seventy per cent of the tumors revealed genomic amplification of HER2/neu, often in the form of double minute chromosomes, which correlated with recurring loss of mouse chromosome 4D-E, a region that is orthologous to distal human chromosome 1p. It is likely that this region contains putative tumor suppressor genes whose inactivation is required for tumor formation in this model of human breast cancer.	NCI, Ctr Canc Res, Genet Branch, NIH, Bethesda, MD 20892 USA; McMaster Univ, Inst Mol Biol & Biotechnol, Dept Biol, Hamilton, ON L8S 4K1, Canada	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); McMaster University	Ried, T (corresponding author), NCI, Ctr Canc Res, Genet Branch, NIH, Bldg 9,Rm 1N105,9 Mem Dr, Bethesda, MD 20892 USA.			Andrechek, Eran/0000-0002-8680-3423	NCI NIH HHS [U01 CA105490] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA105490] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO K, 1985, LANCET, V2, P1035; AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; BIECHE I, 1994, CANCER RES, V54, P4274; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Chen XB, 2001, ONCOGENE, V20, P769, DOI 10.1038/sj.onc.1204149; DAVISSON MT, 1994, GENE, V147, P157, DOI 10.1016/0378-1119(94)90060-4; Garini Y., 1996, Bioimaging, V4, P65, DOI 10.1002/1361-6374(199606)4:2<65::AID-BIO4>3.3.CO;2-4; Ghadimi BM, 1999, AM J PATHOL, V154, P525, DOI 10.1016/S0002-9440(10)65298-4; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; Heim S, 1995, CANC CYTOGENETICS; Hennighausen L, 2000, ONCOGENE, V19, P966, DOI 10.1038/sj.onc.1203346; ISOLA JJ, 1995, AM J PATHOL, V147, P905; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; Liu ML, 1998, ONCOGENE, V17, P2403, DOI 10.1038/sj.onc.1202456; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Muller WU, 1996, MUTAT RES-REV GENET, V366, P163, DOI 10.1016/S0165-1110(96)90037-8; O'Brien SJ, 1999, SCIENCE, V286, P458, DOI 10.1126/science.286.5439.458; Revillion F, 1998, EUR J CANCER, V34, P791, DOI 10.1016/S0959-8049(97)10157-5; RIED T, 1995, CANCER RES, V55, P5415; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; Ried T, 1999, GENE CHROMOSOME CANC, V25, P195, DOI 10.1002/(SICI)1098-2264(199907)25:3<195::AID-GCC1>3.0.CO;2-8; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; Schrock E, 1996, HUM GENET, V97, P256, DOI 10.1007/BF02265277; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.3.CO;2-C; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Weaver ZA, 1999, GENE CHROMOSOME CANC, V25, P251, DOI 10.1002/(SICI)1098-2264(199907)25:3<251::AID-GCC7>3.0.CO;2-3; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743	33	81	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2002	21	6					890	898		10.1038/sj.onc.1205146	http://dx.doi.org/10.1038/sj.onc.1205146			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840334				2022-12-17	WOS:000173427100004
J	Ashrafi, GH; Tsirimonaki, E; Marchetti, B; O'Brien, PM; Sibbet, GJ; Andrew, L; Campo, MS				Ashrafi, GH; Tsirimonaki, E; Marchetti, B; O'Brien, PM; Sibbet, GJ; Andrew, L; Campo, MS			Down-regulation of MHC class I by bovine papillomavirus E5 oncoproteins	ONCOGENE			English	Article						papillomavirus; E5; MHC class I; Golgi apparatus; cell transformation	GROWTH-FACTOR RECEPTOR; COMPLEX CLASS-I; CERVICAL CARCINOMAS; INTERCELLULAR COMMUNICATION; TRANSFORMING FUNCTIONS; CELL-TRANSFORMATION; E7 ONCOPROTEINS; KINASE-ACTIVITY; E8 PROTEIN; TYPE-4 E8	The papillomavirus E5 protein is localized in the endoplasmic reticulum (ER) and Golgi apparatus (GA) of the host cell. Transformed bovine fibroblasts expressing bovine papillomavirus (BPV) E5 are highly vacuolated and have a much enlarged, distorted and fragmented GA. Major histocompatibility complex class I (MHC I) is processed and transported to the cell surface through the GA. Given the cellular localization of E5 in the GA and the morphologically abnormal GA, we investigated the expression of MHC I in cells transformed by E5 from BPV-1 and BPV-4. Two cell lines were used: bovine cells that also express E6, E7 and activated ras, and NIH3T3 cells that express only E5. In addition, PalF cells acutely infected with a recombinant retrovirus expressing E5 were also examined. In contrast to non-transformed normal cells, or transformed cells expressing other papillomavirus proteins, cells expressing E5 do not express MHC I on their surface, but retain it intracellularly, independently of the presence of other viral or cellular oncogenes, or of whether the cells are long-term transformants or acutely infected. We conclude that expression of E5 prevents expression of MHC I to the cell surface and causes its retention within the cell. In addition, lower amounts of total MHC I heavy chain and of heavy chain RNA are detected in E5-transformed cells than in control cells. As surface expression of another glycosylated membrane protein, the transferrin receptor, is not affected, it appears that E5 targets MHC I with at least a degree of specificity. In papillomavirus lesions this effect would have important implications for antigen presentation by, and immunosurveillance of, virally infected cells.	Univ Glasgow, Dept Vet Pathol, Inst Comparat Med, Papillomavirus Res Grp, Glasgow G61 1QH, Lanark, Scotland; Univ Glasgow, Dept Vet Pathol, LRF Virus Ctr, Glasgow G61 1QH, Lanark, Scotland	University of Glasgow; University of Glasgow	Campo, MS (corresponding author), Beatson Inst Canc Res, Garscube Estate, Glasgow G61 1BD, Lanark, Scotland.			Ashrafi, G. Hossein/0000-0002-4516-5111				Anderson RA, 1997, VET J, V154, P69, DOI 10.1016/S1090-0233(05)80010-3; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Ashby ADM, 2001, J GEN VIROL, V82, P2353, DOI 10.1099/0022-1317-82-10-2353; Ashrafi GH, 2000, J GEN VIROL, V81, P689, DOI 10.1099/0022-1317-81-3-689; Barr FA, 1998, EMBO J, V17, P3258, DOI 10.1093/emboj/17.12.3258; BELL SC, 1981, J REPROD IMMUNOL, V3, P3, DOI 10.1016/0165-0378(81)90024-3; BENSAID A, 1989, ANIM GENET, V20, P241; Bontkes HJ, 1998, LANCET, V351, P187, DOI 10.1016/S0140-6736(05)78209-X; Brady CS, 2000, TISSUE ANTIGENS, V55, P401, DOI 10.1034/j.1399-0039.2000.550502.x; Briggs MW, 2001, VIROLOGY, V280, P169, DOI 10.1006/viro.2000.0783; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; BURNETT S, 1992, P NATL ACAD SCI USA, V89, P5665, DOI 10.1073/pnas.89.12.5665; Chang JL, 2001, J BIOMED SCI, V8, P206, DOI 10.1007/BF02256414; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; CROMME FV, 1993, ONCOGENE, V8, P2969; CROMME FV, 1994, J EXP MED, V179, P335, DOI 10.1084/jem.179.1.335; Crusius K, 1999, ONCOGENE, V18, P6714, DOI 10.1038/sj.onc.1203075; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; Faccini AM, 1996, J VIROL, V70, P9041, DOI 10.1128/JVI.70.12.9041-9045.1996; FIMBOW ME, 1991, MOL CARCINOG, V4, P441; FRANCHINI G, 1993, J VIROL, V67, P7701, DOI 10.1128/JVI.67.12.7701-7704.1993; Frazer IH, 1999, IMMUNOL REV, V168, P131, DOI 10.1111/j.1600-065X.1999.tb01288.x; FRAZER JH, 1996, PAPILLOMAVIRUS REV, P151; Georgopoulos NT, 2000, ONCOGENE, V19, P4930, DOI 10.1038/sj.onc.1203860; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; Greenberg ME, 1998, EMBO J, V17, P2777, DOI 10.1093/emboj/17.10.2777; GU ZM, 1995, J VIROL, V69, P8051, DOI 10.1128/JVI.69.12.8051-8056.1995; JACKSON ME, 1991, MOL CARCINOGEN, V4, P382, DOI 10.1002/mc.2940040510; Johnson JM, 2001, J VIROL, V75, P6086, DOI 10.1128/JVI.75.13.6086-6094.2001; KEATING PJ, 1995, BRIT J CANCER, V72, P405, DOI 10.1038/bjc.1995.346; Kubbutat MHG, 1996, SEMIN VIROL, V7, P295, DOI 10.1006/smvy.1996.0037; KUNHE C, 1999, PAPILLOMAVIRUS REPOR, V10, P139; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; Morgan IM, 2000, PAPILLOMAVIRUS REP, V11, P127; Naessens J, 1996, VET IMMUNOL IMMUNOP, V52, P257, DOI 10.1016/0165-2427(96)05572-9; Noguchi Y, 1998, J BIOL CHEM, V273, P3649, DOI 10.1074/jbc.273.6.3649; O'Brien V, 1999, VIROLOGY, V255, P385, DOI 10.1006/viro.1998.9563; O'Brien V, 1998, ONCOGENE, V17, P293, DOI 10.1038/sj.onc.1201937; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PENNIE WD, 1993, VIROLOGY, V193, P614, DOI 10.1006/viro.1993.1169; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; RAPOSO G, 1995, J CELL BIOL, V131, P1403, DOI 10.1083/jcb.131.6.1403; Reich Z, 1997, P NATL ACAD SCI USA, V94, P2495, DOI 10.1073/pnas.94.6.2495; Rudd PM, 1999, J MOL BIOL, V293, P351, DOI 10.1006/jmbi.1999.3104; SAWHNEY SMS, 1995, IMMUNOGENETICS, V41, P246, DOI 10.1007/BF00172066; Schapiro F, 2000, J CELL BIOL, V148, P305, DOI 10.1083/jcb.148.2.305; Seliger B, 1997, IMMUNOL TODAY, V18, P292, DOI 10.1016/S0167-5699(97)01052-9; Sibbet G, 2000, J GEN VIROL, V81, P327, DOI 10.1099/0022-1317-81-2-327; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Suprynowicz FA, 2000, J BIOL CHEM, V275, P5111, DOI 10.1074/jbc.275.7.5111; Thomsen P, 2000, ONCOGENE, V19, P6023, DOI 10.1038/sj.onc.1204010; TOYE PG, 1990, IMMUNOLOGY, V70, P20; Vambutas A, 2000, CLIN DIAGN LAB IMMUN, V7, P79, DOI 10.1128/CDLI.7.1.79-85.2000; VanLeeuwen JEM, 1996, P NATL ACAD SCI USA, V93, P13997, DOI 10.1073/pnas.93.24.13997; Yewdell JW, 1999, ANNU REV CELL DEV BI, V15, P579, DOI 10.1146/annurev.cellbio.15.1.579	63	81	86	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					248	259						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803468				2022-12-17	WOS:000173026200009
J	Tobias, ES; Hurlstone, AFL; MacKenzie, E; McFarlane, R; Black, DM				Tobias, ES; Hurlstone, AFL; MacKenzie, E; McFarlane, R; Black, DM			The TES gene at 7q31,1 is methylated in tumours and encodes a novel growth-suppressing LIM domain protein	ONCOGENE			English	Article						LIM domain; TSG; methylation; chromosome 7	HUMAN GASTRIC CARCINOMAS; PRIMARY BREAST-CANCER; FREQUENT LOSS; LONG ARM; PROMOTER HYPERMETHYLATION; OVARIAN CARCINOMAS; CHROMOSOME 7Q; SQUAMOUS-CELL; ALLELIC LOSS; HETEROZYGOSITY	Many studies suggest that a multi-tissue tumour suppressor gene is located at human chromosome 7q31.1, We have cloned and characterized a novel gene at this locus. The TES gene lies within the minimal region of overlap of several LOH studies and appears to possess the properties of a tumour suppressor. TES is widely expressed and is predicted to encode a protein of 421 amino acids, with three C-terminal LIM domains. Mutation analysis of the coding TES exons in 21 human tumour-derived cell lines revealed the presence of a frameshift mutation in one allele in the breast cancer cell line ZR-75, Methylation of the CpG island at the 5 ' end of TES appears to be a remarkably frequent finding, occurring in seven out of 10 ovarian carcinomas and in each of the 30 tumour-derived cell lines tested, Moreover, forced expression of TES in HeLa or OVCAR5 cells, resulted in a profound reduction in growth potential, as determined by the colony formation assay. We believe that TES is a tumour suppressor gene that is inactivated primarily by transcriptional silencing resulting from CpG island methylation.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Univ Utrecht Hosp, Dept Immunol, NL-3584 CX Utrecht, Netherlands	Beatson Institute; Utrecht University; Utrecht University Medical Center	Black, DM (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.		Tobias, Edward/D-4246-2009	Tobias, Edward/0000-0003-2649-7695; Hurlstone, Adam/0000-0001-5260-9457				Achille A, 1996, CANCER RES, V56, P3808; ATKIN NB, 1993, CANCER GENET CYTOGEN, V67, P123, DOI 10.1016/0165-4608(93)90164-H; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; Costanzi-Strauss E, 1998, EXP CELL RES, V238, P51, DOI 10.1006/excr.1997.3810; DIVECHA N, 1995, GENE, V156, P283, DOI 10.1016/0378-1119(95)00088-N; Dreyer SD, 1998, NAT GENET, V19, P47, DOI 10.1038/ng0598-47; Edelson MI, 1997, ONCOGENE, V14, P2979, DOI 10.1038/sj.onc.1201271; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Fleisher AS, 1999, CANCER RES, V59, P1090; HERMAN JG, 1995, CANCER RES, V55, P4525; Hobert O, 2000, TRENDS GENET, V16, P75, DOI 10.1016/S0168-9525(99)01883-1; Hobert O, 1996, ONCOGENE, V12, P1577; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; Kerr J, 1996, ONCOGENE, V13, P1815; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KUNIYASU H, 1994, INT J CANCER, V59, P597, DOI 10.1002/ijc.2910590504; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Maniatis T, MOL CLONING LAB MANU; Matsuya M, 1998, J BIOL CHEM, V273, P1003, DOI 10.1074/jbc.273.2.1003; Murthy KK, 1999, J BIOL CHEM, V274, P20679, DOI 10.1074/jbc.274.29.20679; Nishiya N, 1998, NUCLEIC ACIDS RES, V26, P4267, DOI 10.1093/nar/26.18.4267; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; PEDERSEN B, 1994, CANCER GENET CYTOGEN, V78, P181, DOI 10.1016/0165-4608(94)90088-4; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Shibanuma M, 1997, MOL CELL BIOL, V17, P1224, DOI 10.1128/MCB.17.3.1224; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Shridhar V, 1997, ONCOGENE, V15, P2727, DOI 10.1038/sj.onc.1201448; Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WU RY, 1994, J BIOL CHEM, V269, P25085; Wu RY, 1996, J BIOL CHEM, V271, P15934, DOI 10.1074/jbc.271.27.15934; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; Zenklusen JC, 1996, MOL CARCINOGEN, V15, P167; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; Zenklusen JC, 1996, GENOME RES, V6, P1070, DOI 10.1101/gr.6.11.1070	43	81	89	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2844	2853		10.1038/sj.onc.1204433	http://dx.doi.org/10.1038/sj.onc.1204433			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420696	Bronze			2022-12-17	WOS:000168712000012
J	Sawada, M; Nakashima, S; Banno, Y; Yamakawa, H; Takenaka, K; Shinoda, J; Nishimura, Y; Sakai, N; Nozawa, Y				Sawada, M; Nakashima, S; Banno, Y; Yamakawa, H; Takenaka, K; Shinoda, J; Nishimura, Y; Sakai, N; Nozawa, Y			Influence of Bax or Bcl-2 overexpression on the ceramide-dependent apoptotic pathway in glioma cells	ONCOGENE			English	Article						anti-cancer agents; apoptosis; Bcl-2 family; ceramide; glioma cells; sphingomyelinase	DAUNORUBICIN-INDUCED APOPTOSIS; NECROSIS-FACTOR-ALPHA; CYTOCHROME-C; DNA-DAMAGE; CHEMOTHERAPEUTIC-AGENTS; PERMEABILITY TRANSITION; ISOLATED-MITOCHONDRIA; FAMILY PROTEINS; T-CELLS; DEATH	Ceramide has recently been regarded as a potential mediator of apoptosis, In the present study, the effects of Bcl-2 and Bax on the ceramide-mediated apoptotic pathways mere examined in glioma cells overexpressing Bcl-2 or Bax. Etoposide, cisplatin and tumor necrosis factor-alpha induced apoptosis of C6 rat glioma cells which was associated with ceramide formation due to activation of neutral sphingomyelinase, followed by release of mitochondrial cytochrome c into the cytosol and activation of caspases-9 and -3, The growth of C6 cells stably overexpressing either Bcl-2 or Bax was almost equal to that of the vector-transfected cells. Bas overexpression enhanced etoposide-induced apoptosis through acceleration of cytochrome c release and caspases activation. However, Bax had no effect on ceramide formation, Similar findings mere obtained in C6 cells and U87-MG human glioblastoma cells which mere transiently overexpressed with Bax. In contrast, Bcl-2 overexpression resulted in a retardation of the apoptotic process via prevention of cytochrome c release and caspases activation, and ceramide formation was also blocked when Bcl-2 was highly overexpressed in glioma cells. Tn addition, transient overexpression of Bcl-xL also exerted inhibitory effects on ceramide formation and apoptotic cell death induced by etoposide, These results indicate that Bax promotes apoptosis regardless of ceramide formation and that Bcl-2 or Bcl-xL prevents ceramide formation by repressing neutral sphingomyelinase as well as ceramide-induced cytochrome c release.	Gifu Univ, Sch Med, Dept Neurosurg, Gifu 5008705, Japan; Gifu Univ, Sch Med, Dept Biochem, Gifu 5008705, Japan; Gifu Int Inst Biotechnol, Mitake, Gifu 5050116, Japan	Gifu University; Gifu University	Sawada, M (corresponding author), Gifu Univ, Sch Med, Dept Neurosurg, Tsukasamachi 40, Gifu 5008705, Japan.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Allouche M, 1997, ONCOGENE, V14, P1837, DOI 10.1038/sj.onc.1201023; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; Decaudin D, 1997, CANCER RES, V57, P62; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hsu SC, 1998, BLOOD, V91, P2658, DOI 10.1182/blood.V91.8.2658.2658_2658_2663; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kim CN, 1997, CANCER RES, V57, P3115; KIM MY, 1991, J BIOL CHEM, V266, P484; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kobayashi T, 1998, ONCOGENE, V16, P1587, DOI 10.1038/sj.onc.1201681; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Sakakura C, 1997, SURG TODAY, V27, P676, DOI 10.1007/BF02388231; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SAWADA M, 2000, IN PRESS CELL DEATH; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 1996, CANCER RES, V56, P2161; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Sillence DJ, 1997, BIOCHEM J, V324, P29, DOI 10.1042/bj3240029; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Vogelbaum MA, 1998, J NEUROSURG, V88, P99, DOI 10.3171/jns.1998.88.1.0099; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Watts JD, 1999, TRENDS BIOCHEM SCI, V24, P228, DOI 10.1016/S0968-0004(99)01411-5; Watts JD, 1999, CELL DEATH DIFFER, V6, P105, DOI 10.1038/sj.cdd.4400472; Watts JD, 1997, P NATL ACAD SCI USA, V94, P7292, DOI 10.1073/pnas.94.14.7292; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yin DX, 1996, P NATL ACAD SCI USA, V93, P3394, DOI 10.1073/pnas.93.8.3394; YIN DX, 1995, CANCER RES, V55, P4922; YIN XM, 1994, COLD SPRING HARB SYM, V59, P387, DOI 10.1101/SQB.1994.059.01.043; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; Yoshimura S, 1997, J NEUROCHEM, V69, P713; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	64	81	85	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3508	3520		10.1038/sj.onc.1203699	http://dx.doi.org/10.1038/sj.onc.1203699			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918609				2022-12-17	WOS:000088346500007
J	Cook, WD; McCaw, BJ				Cook, WD; McCaw, BJ			Accommodating haploinsufficient tumour suppressor genes in Knudson's model	ONCOGENE			English	Review						tumour suppressor; haploinsufficient; p53; p27Kip1	WILD-TYPE P53; MYELOID-LEUKEMIA; RETINOBLASTOMA GENE; MICE LACKING; CELL-CYCLE; CANCER; P27(KIP1); MUTATION; INHIBITOR; TUMORIGENESIS		Royal Melbourne Hosp, Bone Marrow Res Labs, Melbourne, Vic 3050, Australia; Univ Melbourne, Dept Pathol, Melbourne, Vic 3050, Australia; Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Royal Melbourne Hospital; University of Melbourne; Walter & Eliza Hall Institute	Cook, WD (corresponding author), Royal Melbourne Hosp, Bone Marrow Res Labs, Melbourne, Vic 3050, Australia.							Alexander BJ, 1995, LEUKEMIA, V9, P2009; Asimakopoulos FA, 1996, BRIT J HAEMATOL, V95, P219; CHANG CY, 1993, CELL GROWTH DIFFER, V4, P1057; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; de la Chapelle A, 1998, CURR OPIN GENET DEV, V8, P298, DOI 10.1016/S0959-437X(98)80085-3; de Wind N, 1998, CANCER RES, V58, P248; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dong JT, 1996, CANCER RES, V56, P4387; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HASTIE ND, 1994, ANNU REV GENET, V28, P523; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JOHANSSON B, 1994, LEUKEMIA, V8, P953; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KNUDSON AG, 1985, CANCER RES, V45, P1437; Knudson AG, 1995, ADV CANCER RES, V67, P1, DOI 10.1016/S0065-230X(08)60708-3; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kobayashi T, 1999, CANCER RES, V59, P1206; LEVY DB, 1994, CANCER RES, V54, P5953; McClatchey AI, 1998, CURR OPIN GENET DEV, V8, P304, DOI 10.1016/S0959-437X(98)80086-5; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Olopade OI, 1996, LEUKEMIA, V10, P669; PEDERSENBJERGAARD J, 1995, BLOOD, V86, P3542, DOI 10.1182/blood.V86.9.3542.bloodjournal8693542; PIETENPOL JA, 1995, CANCER RES, V55, P1206; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Sedlacek Z, 1998, BRIT J CANCER, V77, P1034, DOI 10.1038/bjc.1998.172; SHANNON KM, 1994, NEW ENGL J MED, V330, P597, DOI 10.1056/NEJM199403033300903; Silver A, 1999, GENE CHROMOSOME CANC, V24, P95, DOI 10.1002/(SICI)1098-2264(199902)24:2<95::AID-GCC1>3.3.CO;2-3; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Tosi S, 1999, GENE CHROMOSOME CANC, V25, P384, DOI 10.1002/(SICI)1098-2264(199908)25:4<384::AID-GCC11>3.0.CO;2-D; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Zhao ND, 1997, P NATL ACAD SCI USA, V94, P6948, DOI 10.1073/pnas.94.13.6948	51	81	84	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 13	2000	19	30					3434	3438		10.1038/sj.onc.1203653	http://dx.doi.org/10.1038/sj.onc.1203653			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918600				2022-12-17	WOS:000088198100011
J	Sumner, R; Crawford, A; Mucenski, M; Frampton, J				Sumner, R; Crawford, A; Mucenski, M; Frampton, J			Initiation of adult myelopoiesis can occur in the absence of c-Myb whereas subsequent development is strictly dependent on the transcription factor	ONCOGENE			English	Article						c-Myb; knockout; definitive haemopoiesis; megakaryocytes; foetal liver	HEMATOPOIETIC-CELLS; STEM-CELLS; FACTOR GATA-2; YOLK-SAC; V-MYB; DIFFERENTIATION; KIT; EXPRESSION; APOPTOSIS; MOUSE	The c-Myb transcriptional regulator is crucial to the development and functioning of haemopoietic cells, so much so that mouse embryos homozygous for an inactivated c-myb allele die from anaemia at about day 15 of gestation. BS analysing c-myb(-/-) chimaeras we show that no mature cells of any lymphoid or myeloid lineage can be detected in adult haemopoietic tissues. This demonstrates that the effects of c-myb ablation on haemopoiesis are cell autonomous and correlates with an absence in the c-myb(-/-) foetal liver of uni- and multilineage CFUs. Indeed, CFU assays performed on E8.5 yolk sac cells revealed that haemopoietic progenitors are already defective at this st-age. However, although cells expressing high levels of c-Kit were absent, we could detect a high proportion of CD34(+) CD45(+) cells in the c-myb(-/-) foetal liver. Examination of chimaeric embryos revealed that c-myb(-/-) donor-derived CD34(+)/Kit(+) cells, representing committed definitive progenitors, initially populated the foetal liver, but are unable to expand like wild type progenitors. Our results showing no megakaryocytic CFUs and a reduction in the absolute numbers of megakargocytes in the c-myb(-/-) foetal liver also refute early suggestions that megakaryopoiesis is unaffected by the absence of c-Myb.	John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England; John Radcliffe Hosp, Biomed Serv, Oxford OX3 9DS, England; Childrens Hosp, Div Pulm Biol, Cincinnati, OH 45229 USA	University of Oxford; University of Oxford; Cincinnati Children's Hospital Medical Center	Frampton, J (corresponding author), John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England.							Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; Bernex F, 1996, DEVELOPMENT, V122, P3023; Bonifer C, 1998, IMMUNOL TODAY, V19, P236, DOI 10.1016/S0167-5699(98)01259-6; Dzierzak E, 1998, IMMUNOL TODAY, V19, P228, DOI 10.1016/S0167-5699(98)01258-4; Frampton J, 1997, MOL B INT U, P287; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; HOGAN B, 1994, MANIPULATING MOUSE E; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; Krause DS, 1998, EXP HEMATOL, V26, P1086; LEDBETTER JA, 1979, IMMUNOGENETICS, V8, P347, DOI 10.1007/BF01561445; Lin HH, 1997, GENOMICS, V41, P301, DOI 10.1006/geno.1997.4674; Lin HH, 1996, CURR TOP MICROBIOL, V211, P79; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; MATSUMURA G, 1989, J ANAT, V167, P181; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Mukouyama YS, 1999, CURR BIOL, V9, P833, DOI 10.1016/S0960-9822(99)80368-6; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; OGAWA M, 1993, DEVELOPMENT, V117, P1089; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Ratajczak MZ, 1998, BLOOD, V91, P1934, DOI 10.1182/blood.V91.6.1934.1934_1934_1946; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; Yoder MC, 1997, IMMUNITY, V7, P335, DOI 10.1016/S1074-7613(00)80355-6	28	81	87	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2000	19	30					3335	3342		10.1038/sj.onc.1203660	http://dx.doi.org/10.1038/sj.onc.1203660			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QX	10918590				2022-12-17	WOS:000088198100001
J	Lai, HK; Borden, KLB				Lai, HK; Borden, KLB			The promyelocytic leukemia (PML) protein suppresses cyclin D1 protein production by altering the nuclear cytoplasmic distribution of cyclin D1 mRNA	ONCOGENE			English	Article						PML; nuclear bodies; APL; RING; RNA transport	INITIATION-FACTOR 4E; RING FINGER DOMAIN; TRANSLATION INITIATION; BINDING-PROTEIN; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; ONCOPROTEIN PML; MESSENGER-RNA; GENE-PRODUCT; CELL-DEATH; BODIES	The majority of the promyelocytic leukemia (PML) protein is present in nuclear bodies which are altered in several pathogenic conditions including acute promyelocytic leukemia. PML nuclear bodies are found in nearly all cells yet their function remains unknown. Here, we demonstrate that PML and the eukaryotic initiation factor 4E (eIF-4E) co-localize and co-immunopurify. eIF-4E is involved in nucleocytoplasmic transport of specific mRNAs including cyclin D1, eIF-4E overexpression leads to increased cyclin D1 protein levels;,whereas, overexpression of PML leads to decreased cyclin D1 le,els. Neither PML nor eIF-4E cause significant changes in cyclin D1 mRNA levels. The association with eIF-4E led us to investigate if PML could alter mRNA distribution as a possible post-transcriptional mechanism for suppressing cyclin D1 production. We show that overexpression of PML results in nuclear retention of cyclin D1 mRNA and that intact PR-IL nuclear bodies are required. Addition of eIF-4E overcomes PML induced retention and alters the morphology of PML bodies suggesting a mechanism by which eIF-4E can modulate PML function. These results raise the possibility that PML nuclear bodies may participate in the regulation of nucleocytoplasmic transport of specific mRNAs.	CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Borden, KLB (corresponding author), CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Box 1218, New York, NY 10029 USA.				NCI NIH HHS [R01 CA80728] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080728] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Boddy MN, 1996, ONCOGENE, V13, P971; Boddy MN, 1997, J CELL SCI, V110, P2197; Borden KLB, 1998, J VIROL, V72, P758, DOI 10.1128/JVI.72.1.758-766.1998; Borden KLB, 1996, P NATL ACAD SCI USA, V93, P1601, DOI 10.1073/pnas.93.4.1601; Borden KLB, 1997, FEBS LETT, V418, P30, DOI 10.1016/S0014-5793(97)01344-6; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1998, J VIROL, V72, P3819, DOI 10.1128/JVI.72.5.3819-3826.1998; CAMPBELL DE, 2000, IN PRESS J VIROL; Carlile GW, 1998, BIOCHEM J, V335, P691, DOI 10.1042/bj3350691; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; Grande MA, 1996, J CELL BIOCHEM, V63, P280, DOI 10.1002/(SICI)1097-4644(19961201)63:3<280::AID-JCB3>3.0.CO;2-T; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KENTSIS A, 2000, IN PRESS CURR OPIN P; Knudsen KE, 1999, CANCER RES, V59, P2297; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; Mayfield S, 1996, CHEM BIOL, V3, P415, DOI 10.1016/S1074-5521(96)90088-5; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; STUURMAN N, 1992, J CELL SCI, V101, P773; STUURMAN N, 1997, CELL MOL BIOL LETT, V2, P137; TERRIS B, 1995, CANCER RES, V55, P1590; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Yacoub A, 1996, NUCLEIC ACIDS RES, V24, P4298, DOI 10.1093/nar/24.21.4298; ZIEMIECKI A, 1990, EMBO J, V9, P191, DOI 10.1002/j.1460-2075.1990.tb08095.x; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	42	81	87	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2000	19	13					1623	1634		10.1038/sj.onc.1203473	http://dx.doi.org/10.1038/sj.onc.1203473			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763819				2022-12-17	WOS:000086083800002
J	Dankort, DL; Muller, WJ				Dankort, DL; Muller, WJ			Signal transduction in mammary tumorigenesis: a transgenic perspective	ONCOGENE			English	Review						review; transgenic; ErbB-2/Neu; breast cancer	HUMAN-BREAST-CANCER; EPIDERMAL GROWTH-FACTOR; MIDDLE-T-ANTIGEN; PROTEIN-TYROSINE KINASES; GUANINE-NUCLEOTIDE EXCHANGE; FACTOR RECEPTOR STATUS; HA-RAS ONCOGENE; C-SRC; POLYOMA-VIRUS; NEU PROTOONCOGENE	A number of genes have been implicated in breast cancer development, yet few have been demonstrated to play causative roles in mammary tumor formation. The advent of transgenic mouse and embryonic stem cell technologies now permits manipulation of the mouse genome in such a way as to temporally and spatially control a gene product's expression. Thus, the basic researcher now can directly assess the involvement of particular genes in tumorigenesis and disease progression and, in the process, to develop mouse models of human genetic disease. The utility of such technologies is emphasized in transgenic mice expressing genes thought to play important roles in the initiation and progression of mammary carcinomas. As these transgenic strains have been the subject of several reviews, here we focus on two mouse mammary tumor models, Polyomavirus middle T antigen and the Neu/ErbB-2 receptor tyrosine kinase, which are most amenable to study specific signaling pathways in process of mammary tumorigenesis.	McMaster Univ, Inst Mol Biol & Biotechnol, Dept Biol, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Inst Mol Biol & Biotechnol, Dept Pathol, Hamilton, ON L8S 4K1, Canada	McMaster University; McMaster University	Muller, WJ (corresponding author), McMaster Univ, Inst Mol Biol & Biotechnol, Dept Biol, 1280 Main St W, Hamilton, ON L8S 4K1, Canada.			Dankort, David/0000-0002-5862-6829				ALLRED DC, 1992, HUM PATHOL, V23, P974, DOI 10.1016/0046-8177(92)90257-4; ALMANDI M, 1995, ONCOGENE, V10, P1813; Amundadottir LT, 1996, BREAST CANCER RES TR, V39, P119, DOI 10.1007/BF01806083; ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BEREBBI M, 1990, ONCOGENE, V5, P505; BERNS EMJJ, 1992, CANCER RES, V52, P1107; BOS JL, 1989, CANCER RES, V49, P4862; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CARDIFF RD, 1993, CANCER SURV, V16, P97; CARMICHAEL G, 1984, P NATL ACAD SCI-BIOL, V81, P679, DOI 10.1073/pnas.81.3.679; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DALY RJ, 1994, ONCOGENE, V9, P2723; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; DANKORT DL, 1996, MAMMARY TUMOR CELL C; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; Dougall WC, 1996, DNA CELL BIOL, V15, P31, DOI 10.1089/dna.1996.15.31; DRUKER BJ, 1992, J VIROL, V66, P5770, DOI 10.1128/JVI.66.10.5770-5776.1992; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GASPARINI G, 1992, BRIT J CANCER, V66, P970, DOI 10.1038/bjc.1992.394; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; ISRAEL MA, 1979, P NATL ACAD SCI USA, V76, P3713, DOI 10.1073/pnas.76.8.3713; JACOBS C, 1983, CANCER RES, V43, P1696; JALLAL B, 1992, J BIOL CHEM, V267, P4357; JANES PW, 1994, ONCOGENE, V9, P3601; JELINEK MA, 1992, ONCOGENE, V7, P1687; KAPLAN D R, 1988, Biochimica et Biophysica Acta, V948, P345; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; Krane IM, 1996, ONCOGENE, V12, P1781; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LEMOINE NR, 1990, ONCOGENE, V5, P237; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LUCHINI F, 1992, CANC LETT, V64, P203; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MANSOUR EG, 1994, CANCER, V74, P381, DOI 10.1002/cncr.2820741326; MARKLAND W, 1986, J VIROL, V59, P384, DOI 10.1128/JVI.59.2.384-391.1986; MARKLAND W, 1987, BIOCHIM BIOPHYS ACTA, V907, P299, DOI 10.1016/0304-419X(87)90011-4; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MIKAMI Y, 1992, P NATL ACAD SCI USA, V89, P7335, DOI 10.1073/pnas.89.16.7335; MORRISON BW, 1994, HEMATOL ONCOL CLIN N, V8, P15, DOI 10.1016/S0889-8588(18)30185-0; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; NIELSEN LL, 1991, CANCER RES, V51, P3762; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PATCHEFSKY AS, 1989, CANCER, V63, P731, DOI 10.1002/1097-0142(19890215)63:4<731::AID-CNCR2820630422>3.0.CO;2-#; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PELES E, 1992, J BIOL CHEM, V267, P12266; PELLICI G, 1995, ONCOGENE, V11, P899; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RAVDIN PM, 1995, GENE, V159, P19, DOI 10.1016/0378-1119(94)00866-Q; ROCHLITZ CF, 1989, CANCER RES, V49, P357; ROSEN N, 1996, J BIOL CHEM, V2261, P11754; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAINSBURY JRC, 1988, BRIT J CANCER, V58, P458, DOI 10.1038/bjc.1988.240; SALCINI AE, 1994, ONCOGENE, V9, P2827; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1992, CANCER RES, V52, P5229; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1992, ONCOGENE, V7, P1339; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; STOCKLIN E, 1993, J CELL BIOL, V122, P199, DOI 10.1083/jcb.122.1.199; Sudol M, 1998, ONCOGENE, V17, P1469, DOI 10.1038/sj.onc.1202182; Tzahar E, 1998, BBA-REV CANCER, V1377, pM25, DOI 10.1016/S0304-419X(97)00032-2; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; WU K, 1994, ONCOGENE, V9, P3139; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHOU DJ, 1988, ONCOGENE, V2, P279; ZOLL B, 1992, J CANCER RES CLIN, V118, P468, DOI 10.1007/BF01629432	121	81	81	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1038	1044		10.1038/sj.onc.1203272	http://dx.doi.org/10.1038/sj.onc.1203272			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713687				2022-12-17	WOS:000085796400009
J	Vomachka, AJ; Pratt, SL; Lockefeer, JA; Horseman, ND				Vomachka, AJ; Pratt, SL; Lockefeer, JA; Horseman, ND			Prolactin gene-disruption arrests mammary gland development and retards T-antigen-induced tumor growth	ONCOGENE			English	Article						breast cancer; polyoma virus; differentiation; Stat5 protein	SIGNAL-TRANSDUCTION PATHWAYS; BREAST-CANCER CELLS; PRL RECEPTOR; EXPRESSION; MICE; TRANSCRIPTION; PROTEINS; PHOSPHORYLATION; ACTIVATION; CARCINOMA	Prolactin (PRL), interacting with other hormones from the pituitary, gonad, and placenta, activates specific signals that drive the appropriately timed morphological and functional development of the mammary gland. A mouse model of isolated PRL deficiency (PRL-/-) was created by gene disruption in an effort to further understand the molecular basis of mammary gland development and breast cancer. Whereas primary ductal growth was normal in PRL-/- mice, ductal arborization was minimal (branches/mm(2) = 1.5+/-0.5), and lobular budding was absent. Replacement therapy with PBL injections stimulated a modest degree of lobular budding and ductal arborization (3.75+/-0.9). Pituitary transplants to the kidney capsule of PRL-/- mice restored lobular budding and ductal arborization, to the full extent of that seen in control animals (20.3+/-5.5). Pregnancy, established by mating progesterone-treated PRL-/- females with PRL-/- males, led to complete morphological development of the mammary gland, appropriate to the gestational stage. PRL treatment stimulated tyrosine phosphorylation and DNA binding activity of Stat5a, but not Stat1 in PRL-/- or PRL+/- females, and Stat5a, but not Stat1, was elevated by estradiol within 24 h, PRL-deficient mice were crossed with mice expressing a dominant oncogene (polyoma middle-T antigen driven by the MMTV promoter, PyVT mice). Palpable (1 mm(3)) tumors were detected an average of 9 days earlier in hormonally normal females (PRL+/-:PyVT) compared with littermates that were PRL-deficient (PRL-/-:PyVT). The growth rate of PyVT-induced tumors was 30% faster in PRL+/-, than in PRL-/- females.	Univ Cincinnati, Dept Cellular & Mol Physiol, Cincinnati, OH 45267 USA; Beaver Coll, Dept Biol, Glenside, PA 19038 USA	University System of Ohio; University of Cincinnati	Horseman, ND (corresponding author), 231 Bethesda Ave,ML 0576, Cincinnati, OH 45267 USA.							BAYNA EM, 1990, NUCLEIC ACIDS RES, V18, P2977, DOI 10.1093/nar/18.10.2977; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Das R, 1997, J MAMMARY GLAND BIOL, V2, P29, DOI 10.1023/A:1026369412612; DiMaio D, 1998, ANNU REV MICROBIOL, V52, P397, DOI 10.1146/annurev.micro.52.1.397; FORSYTH IA, 1982, OXFORD REV REPROD, P47; Gao J, 1996, MOL ENDOCRINOL, V10, P847, DOI 10.1210/me.10.7.847; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; GINSBURG E, 1995, CANCER RES, V55, P2591; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HASLAM S, 1998, J STEROID BIOCHEM, V31, P9; Horseman ND, 1997, EMBO J, V16, P6926, DOI 10.1093/emboj/16.23.6926; HORSEMAN ND, 1994, ENDOCR REV, V15, P627, DOI 10.1210/er.15.5.627; Krumenacker JS, 1998, ENDOCRINE, V9, P163, DOI 10.1385/ENDO:9:2:163; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; Liu SY, 1997, TROP MED INT HEALTH, V2, P179, DOI 10.1046/j.1365-3156.1997.d01-242.x; LYONS WR, 1958, RECENT PROG HORM RES, V14, P219; NICOLL CS, 1974, HDB PHYSIOLOGY, V4, P253; ORMANDY CJ, 1992, DNA CELL BIOL, V11, P721, DOI 10.1089/dna.1992.11.721; SIDIS Y, 1994, ENDOCRINOLOGY, V134, P1979, DOI 10.1210/en.134.4.1979; Summers SA, 1998, BIOCHEM BIOPH RES CO, V246, P76, DOI 10.1006/bbrc.1998.8575; SWANSON SM, 1994, CARCINOGENESIS, V15, P1341, DOI 10.1093/carcin/15.7.1341; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG SQ, 1990, ENDOCRINOLOGY, V127, P2183, DOI 10.1210/endo-127-5-2183; WELSCH CW, 1977, CANCER RES, V37, P951	29	81	81	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1077	1084		10.1038/sj.onc.1203348	http://dx.doi.org/10.1038/sj.onc.1203348			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713693				2022-12-17	WOS:000085796400015
J	Krutovskikh, VA; Troyanovsky, SM; Piccoli, C; Tsuda, H; Asamoto, M; Yamasaki, H				Krutovskikh, VA; Troyanovsky, SM; Piccoli, C; Tsuda, H; Asamoto, M; Yamasaki, H			Differential effect of subcellular localization of communication impairing gap junction protein connexin43 on tumor cell growth in vivo	ONCOGENE			English	Article						connexin43; dominant negative mutants; tumor suppression	C6 GLIOMA-CELLS; INTERCELLULAR COMMUNICATION; RAT-LIVER; TRANSFORMED-CELLS; CARCINOMA-CELLS; GENE MUTATION; EXPRESSION; TRANSFECTION; CARCINOGENESIS; CDNA	There is a large body of evidence suggesting the connexin gap junction proteins appear to act as tumor suppressors, and their tumor inhibitory effect is usually attributed to their main function of cell coupling through gap junctions, However, some cancer cells (e.g. the rat bladder carcinoma BC31 cell line) are cell-cell communication proficient. Using specific site-directed mutagenesis in the third membrane-spanning (3M) domain of connexin43 (Cx43), we abolished the intrinsic gap junction intercellular communication (GJIC) in BC31 cells either by closing the gap junctional channels or by disruption of the transport of connexin complexes to the lateral membrane. Clones of BC31 cells transfected with a dominant negative Cx43 mutant giving rise to gap junctional channels, permeable only for a small tracer (neurobiotin), displayed accelerated growth rate in vivo, showing the critical role of selective gap junctional permeability in the regulation of cell growth in vivo. The use of other dominant-negative mutants of Cx43 also suggested that the effect of impaired communication on the tumorigenicity of cancer cells depends on the subcellular location of connexin, Inhibition of intrinsic GJIC in BC31 cells by sequestering of Cx protein inside the cytoplasm, due to expression of dominant-negative transport-deficient Cx43 mutants, did not significantly enhance the growth of transfectants in nude mice, but occasionally slightly retarded it. In contrast, augmentation of GJIC in BC31 cells by forced expression of wild-type Cx43, or a communication-silent mutant, fully suppressed tumorigenicity of these cells, Overall, these results show that cell coupling is a strong, but not the sole, mechanism by which Cx suppresses growth of tumorigenic cells in vivo; a GJIC-independent activity of Cx proteins should be considered as another strong tumor-suppressive factor.	Int Agcy Res Canc, Unit Multistage Carcinogenesis, F-69372 Lyon, France; Washington Univ, Sch Med, Div Dermatol, St Louis, MO 63110 USA; Natl Canc Ctr, Res Inst, Div Expt Pathol Chemotherapy, Tokyo 1040045, Japan; Nagoya City Univ, Sch Med, Dept Pathol, Nagoya, Aichi 4678601, Japan	World Health Organization; International Agency for Research on Cancer (IARC); Washington University (WUSTL); National Cancer Center - Japan; Nagoya City University	Krutovskikh, VA (corresponding author), Int Agcy Res Canc, Unit Multistage Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon, France.				NATIONAL CANCER INSTITUTE [R01CA040534] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 40534] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asamoto M, 1998, JPN J CANCER RES, V89, P481, DOI 10.1111/j.1349-7006.1998.tb03287.x; ASAMOTO M, 1994, CARCINOGENESIS, V15, P2163, DOI 10.1093/carcin/15.10.2163; BOND SL, 1994, CELL GROWTH DIFFER, V5, P179; BRISSETTE JL, 1994, P NATL ACAD SCI USA, V91, P6453, DOI 10.1073/pnas.91.14.6453; BRUZZONE R, 1994, NEURON, V13, P1253, DOI 10.1016/0896-6273(94)90063-9; CHEN SC, 1995, CELL GROWTH DIFFER, V6, P681; deFeijter AW, 1996, MOL CARCINOGEN, V16, P203, DOI 10.1002/(SICI)1098-2744(199608)16:4<203::AID-MC4>3.3.CO;2-F; Deschenes SM, 1997, J NEUROSCI, V17, P9077; Donaldson P, 1997, HISTOL HISTOPATHOL, V12, P219; EGHBALI B, 1991, P NATL ACAD SCI USA, V88, P10701, DOI 10.1073/pnas.88.23.10701; FITZGERALD DJ, 1994, CARCINOGENESIS, V15, P1859, DOI 10.1093/carcin/15.9.1859; FITZGERALD DJ, 1983, CANCER RES, V43, P3614; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; GOODENOUGH DA, 1988, J CELL BIOL, V107, P1817, DOI 10.1083/jcb.107.5.1817; Hirschi KK, 1996, CELL GROWTH DIFFER, V7, P861; Huang RP, 1998, CANCER RES, V58, P5089; KLANN RC, 1989, CANCER RES, V49, P699; Krutovskikh V, 1997, HISTOL HISTOPATHOL, V12, P761; KRUTOVSKIKH V, 1994, INT J CANCER, V56, P87; Krutovskikh VA, 1998, MOL CARCINOGEN, V23, P254, DOI 10.1002/(SICI)1098-2744(199812)23:4<254::AID-MC9>3.0.CO;2-4; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; KUMAR NM, 1995, J CELL SCI, V108, P3725; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEUBE RE, 1995, J CELL SCI, V108, P883; LOEWENSTEIN WR, 1966, NATURE, V209, P1248, DOI 10.1038/2091248a0; MEHTA PP, 1991, J MEMBRANE BIOL, V124, P207, DOI 10.1007/BF01994355; MERCHENTHALER I, 1989, J HISTOCHEM CYTOCHEM, V37, P1563, DOI 10.1177/37.10.2674275; MESNIL M, 1995, CANCER RES, V55, P629; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; NAUS CCG, 1992, CANCER RES, V52, P4208; NEVEU MJ, 1994, J CELL SCI, V107, P83; Omori Y, 1996, CARCINOGENESIS, V17, P2077, DOI 10.1093/carcin/17.9.2077; Proulx AA, 1997, CELL GROWTH DIFFER, V8, P533; ROSE B, 1993, CARCINOGENESIS, V14, P1073, DOI 10.1093/carcin/14.5.1073; SAITO T, 1997, CANCER RES, V57, P376; Statuto M, 1997, J BIOL CHEM, V272, P24710, DOI 10.1074/jbc.272.39.24710; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; TROYANOVSKY SM, 1994, J CELL BIOL, V127, P151, DOI 10.1083/jcb.127.1.151; UNWIN PNT, 1980, NATURE, V283, P545, DOI 10.1038/283545a0; YAMASAKI H, 1990, CARCINOGENESIS, V11, P1051, DOI 10.1093/carcin/11.7.1051; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; YEAGER M, 1992, J MOL BIOL, V223, P929, DOI 10.1016/0022-2836(92)90253-G; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883	44	81	94	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 27	2000	19	4					505	513		10.1038/sj.onc.1203340	http://dx.doi.org/10.1038/sj.onc.1203340			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	280LL	10698520				2022-12-17	WOS:000085104200004
J	David-Pfeuty, T				David-Pfeuty, T			Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells	ONCOGENE			English	Article						cyclin-dependent kinase; protein-kinase inhibitor; wt p53; apoptosis; anti-tumor agent	PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; MAMMALIAN FIBROBLASTS; CHEMICAL INHIBITORS; PHASE-TRANSITION; DNA-REPLICATION; PURINE ANALOGS; CDC28 MUTATION; RIBOSOMAL-RNA; CANCER-CELLS	The cdk2 gene has been identified as a human cdc2/CDC28-related gene that encodes a protein kinase essential for the G1/S transition in mammalian cells, but not for the G2/M transition, which requires Cdk1, another p34(cdc2/CDC28) homolog, Novel potential functions of Cdk2 have been uncovered by using two potent and specific inhibitors of its kinase activity, roscovitine and olomoucine, on human wt p53-expresser untransformed and tumor-derived cells. At concentrations equal or superior to respectively 30- and 20-fold their in vitro IC50 values for cyclin B/Cdk1, cyclin A/Cdk2 and cyclin E/Cdk2, the Cdk inhibitors precipitately induce a dramatic nuclear accumulation of wt p53 and a delocalization of nucleolin from the nucleolus In all interphase cells, whatever their cell cycle status, acting in this way like the DNA-damaging drug, mitomycin C (7 mu g/ml). These early events are soon followed by a nucleolar fragmentation in both normal and tumor cells in the presence of the Cdk inhibitors but not in the presence of the DNA-damaging drug. Yet, treatment with either type of compounds eventually triggers rapidly the death of the tumor cells and, much more slowly, that of the normal cells. The Cdk inhibitors, however, stimulate cell death from any stage of the cell cycle, whereas the DNA-damaging drug kills more efficaciously S phase cells. These observations provide a hint that the Cdk2 kinase might be involved in controlling the nuclear le,els of the tumor suppressor wt p53 protein and in maintaining the nucleolar integrity and function, linking in this way the cell division cycle machinery to survival functions and overall cell metabolism via the control of nucleocytoplasmic transport and of ribosome production.	Ctr Univ Orsay, Inst Curie Rech, CNRS, UMR 146, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	David-Pfeuty, T (corresponding author), Ctr Univ Orsay, Inst Curie Rech, CNRS, UMR 146, Batiment 110, F-91405 Orsay, France.							Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; An B, 1997, ONCOL REP, V4, P1129; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BATES S, 1994, ONCOGENE, V9, P71; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DavidPfeuty T, 1997, CANCER RES, V57, P4482; DavidPfeuty T, 1996, CELL GROWTH DIFFER, V7, P1211; DavidPfeuty T, 1996, ONCOGENE, V13, P1447; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; GAUTIER T, 1992, J CELL SCI, V102, P729; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hara E, 1996, MOL CELL BIOL, V16, P859; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; JIANG W, 1993, ONCOGENE, V8, P3447; KARN J, 1989, ONCOGENE, V4, P773; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 1997, METHOD ENZYMOL, V283, P113; Meijer L, 1996, TRENDS CELL BIOL, V6, P393, DOI 10.1016/0962-8924(96)10034-9; Meijer L., 1995, PROGR CELL CYCLE RES, V1; MEIJER L, 1997, PROGR CELL CYCLE RES, V3; Meijer L., 1996, PROGR CELL CYCLE RES, V2; MELESE T, 1995, CURR OPIN CELL BIOL, V7, P319, DOI 10.1016/0955-0674(95)80085-9; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MICHIELI P, 1994, CANCER RES, V54, P3391; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; ONGKEKO W, 1995, J CELL SCI, V108, P2897; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Reznikoff CA, 1996, CANCER RES, V56, P2886; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Schutte B, 1997, EXP CELL RES, V236, P4, DOI 10.1006/excr.1997.3700; SEDLACEK HH, 1996, ANN ONCOL         S1, V7, P77; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WILSON GD, 1985, CYTOMETRY, V6, P641, DOI 10.1002/cyto.990060621; WIMMEL A, 1994, ONCOGENE, V9, P995; WORLAND PJ, 1993, BIOCHEM PHARMACOL, V46, P1831, DOI 10.1016/0006-2952(93)90590-S; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU Z, 1994, TRENDS CELL BIOL, V4, P414; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G; [No title captured]	79	81	87	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	1999	18	52					7409	7422		10.1038/sj.onc.1203103	http://dx.doi.org/10.1038/sj.onc.1203103			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602500				2022-12-17	WOS:000084119600002
J	Nikiforov, YE; Koshoffer, A; Nikiforova, M; Stringer, J; Fagin, JA				Nikiforov, YE; Koshoffer, A; Nikiforova, M; Stringer, J; Fagin, JA			Chromosomal breakpoint positions suggest a direct role for radiation in inducing illegitimate recombination between the ELE1 and RET genes in radiation-induced thyroid carcinomas	ONCOGENE			English	Article						RET; gene rearrangement; illegitimate recombination; radiation-induced; thyroid	CHERNOBYL NUCLEAR ACCIDENT; IN-SITU HYBRIDIZATION; IONIZING-RADIATION; MAMMALIAN-CELLS; CHILDREN; DNA; MECHANISMS; MUTATIONS; RET/PTC3; ONCOGENE	The RET/PTC3 rearrangement is formed by fusion of the ELE1 and RET genes, and is highly prevalent in radiation-induced post-Chernobyl papillary thyroid carcinomas. We characterized the breakpoints in the ELE1 and RET genes in 12 post-Chernobyl pediatric papillary carcinomas with known RET/PTC3 rearrangement. We found that the breakpoints within each intron were distributed in a relatively random fashion, except for clustering in the Alu regions of ELE1. None of the breakpoints occurred at the same base or within a similar sequence. There was also no evidence of preferential cleavage in AT-rich regions or other target DNA sites implicated in illegitimate recombination in mammalian cells. Modification of sequences at the cleavage sites was minimal, typically involving a 1-3 nucleotide deletion and/or duplication Surprisingly, the alignment of ELE1 and RET introns in opposite orientation revealed that in each tumor the position of the break in one gene corresponded to the position of the break in the other gene, This tendency suggests that the two genes may he next to each other but point in opposite directions in the nucleus, Such a structure would facilitate formation of RET/PTC3 rearrangements because a single radiation track could produce concerted breaks in both genes, leading to inversion due to reciprocal exchange via end-joining.	Univ Cincinnati, Coll Med, Dept Pathol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Div Endocrinol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Nikiforov, YE (corresponding author), Univ Cincinnati, Coll Med, Dept Pathol, POB 670529, Cincinnati, OH 45267 USA.		Koshoffer, Amy E/N-2278-2014	Koshoffer, Amy E/0000-0001-8130-103X	NCI NIH HHS [CA 72597, CA 50706] Funding Source: Medline; NIEHS NIH HHS [ES 05652] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050706, R01CA072597, R29CA050706] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bongarzone I, 1996, J CLIN ENDOCR METAB, V81, P2006, DOI 10.1210/jc.81.5.2006; Bongarzone I, 1997, GENOMICS, V42, P252, DOI 10.1006/geno.1997.4685; Cremer C, 1996, MUTAT RES-REV GENET, V366, P97, DOI 10.1016/S0165-1110(96)90031-7; EHRLICH SD, 1993, GENE, V135, P161, DOI 10.1016/0378-1119(93)90061-7; FERGUSON M, 1992, CHROMOSOMA, V101, P557, DOI 10.1007/BF00660315; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; GERDES MG, 1994, J CELL BIOL, V126, P289, DOI 10.1083/jcb.126.2.289; GROSOVSKY AJ, 1988, P NATL ACAD SCI USA, V85, P185, DOI 10.1073/pnas.85.1.185; HYRIEN O, 1987, EMBO J, V6, P2401, DOI 10.1002/j.1460-2075.1987.tb02518.x; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; Klugbauer S, 1995, ONCOGENE, V11, P2459; KOVACS MS, 1994, RADIAT RES, V137, P34, DOI 10.2307/3578788; LICHTER P, 1988, HUM GENET, V80, P222; MANUELIDIS L, 1984, P NATL ACAD SCI-BIOL, V81, P3123, DOI 10.1073/pnas.81.10.3123; MINOLETTI F, 1994, GENE CHROMOSOME CANC, V11, P51, DOI 10.1002/gcc.2870110108; Mizuno T, 1997, ONCOGENE, V15, P1455, DOI 10.1038/sj.onc.1201313; NIKIFOROV Y, 1994, CANCER-AM CANCER SOC, V74, P748, DOI 10.1002/1097-0142(19940715)74:2<748::AID-CNCR2820740231>3.0.CO;2-H; Nikiforov YE, 1997, CANCER RES, V57, P1690; Nikiforov YE, 1996, ONCOGENE, V13, P687; NIKIFOROV YE, 1998, ADV MOL CELL ENDOCR, V2, P169; Pacini F, 1997, J CLIN ENDOCR METAB, V82, P3563, DOI 10.1210/jc.82.11.3563; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1994, ONCOGENE, V9, P509; STARY A, 1992, NUCLEIC ACIDS RES, V20, P4269, DOI 10.1093/nar/20.16.4269; Suchy B, 1998, BRIT J CANCER, V77, P952, DOI 10.1038/bjc.1998.157; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/s0079-6603(08)60611-x; YOKOTA H, 1995, J CELL BIOL, V130, P1239, DOI 10.1083/jcb.130.6.1239	28	81	84	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6330	6334		10.1038/sj.onc.1203019	http://dx.doi.org/10.1038/sj.onc.1203019			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597232				2022-12-17	WOS:000083934100017
J	Caruana, G; Cambareri, AC; Ashman, LK				Caruana, G; Cambareri, AC; Ashman, LK			Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts	ONCOGENE			English	Article						c-KIT; isoforms; transformation; ligand binding; signal transduction	RECEPTOR TYROSINE KINASE; STEM-CELL FACTOR; ACUTE MYELOID-LEUKEMIA; GROWTH-FACTOR; MAST-CELLS; PHOSPHOINOSITIDE 3-KINASE; PROTOONCOGENE PRODUCT; MYELOGENOUS LEUKEMIA; CYCLE ARREST; V-KIT	Alternate splicing of mRNA encoding c-KIT results in isoforms which differ in the presence or absence of four amino acids (GNNK) in the juxtamembrane region of the extracellular domain of the receptor, In this study we show that these isoforms of human c-KIT, expressed at similar levels in NIH3T3 cells, display differential effects on various attributes of transformation. The GNNK - isoform strongly promoted anchorage independent growth (colony formation in semi-solid medium), lass of contact inhibition (focus formation), and led to tumorigenicity in nude mice. In contrast, the GNNK + isoform elicited colony formation but relatively poor focus formation and no tumorigenicity, Saturation binding analysis indicated that the isoforms do not differ significantly in their affinity for the KIT ligand, Steel Factor (SLF), Negligible ligand-independent receptor phosphorylation was observed in either case but, after ligand stimulation, the GNNK - isoform displayed more rapid and extensive tyrosine autophosphorylation and faster internalization. Both isoforms recruited the p85 subunit of phosphatidylinositol 3-kinase and led to similar phosphorylation of its downstream effector c-Akt, but the GNNK - isoform gave rise to more MAP kinase phosphorylation, Thus the c-KIT isoforms display different signalling characteristics and have different transforming activity in NIH3T3 cells.	Inst Med & Vet Sci, Hanson Ctr Canc Res, Div Haematol, Adelaide, SA 5000, Australia	Institute Medical & Veterinary Science Australia	Ashman, LK (corresponding author), Inst Med & Vet Sci, Hanson Ctr Canc Res, Div Haematol, Box 14 Rundle Mall PO, Adelaide, SA 5000, Australia.		ASHMAN, LEONIE/G-7631-2013; Norman, Robert J/A-1155-2007	ASHMAN, LEONIE/0000-0003-3559-3611; Norman, Robert J/0000-0002-3118-3896				ALEXANDER WS, 1991, EMBO J, V10, P3683, DOI 10.1002/j.1460-2075.1991.tb04936.x; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BRIZZI MF, 1994, ONCOGENE, V9, P1583; Caruana G, 1998, ONCOGENE, V16, P179, DOI 10.1038/sj.onc.1201494; Cole SR, 1996, LEUKEMIA, V10, P288; COX AD, 1994, ONCOGENE, V9, P3281; CROSIER PS, 1993, BLOOD, V82, P1151; DeBerry C, 1997, BIOCHEM J, V327, P73, DOI 10.1042/bj3270073; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; HAYASHI SI, 1991, NUCLEIC ACIDS RES, V19, P1267, DOI 10.1093/nar/19.6.1267; HERBST R, 1995, ONCOGENE, V10, P369; HERBST R, 1995, BIOCHEMISTRY-US, V34, P5971, DOI 10.1021/bi00017a026; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; Linnekin D, 1997, J BIOL CHEM, V272, P27450, DOI 10.1074/jbc.272.43.27450; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PIAO XH, 1994, BLOOD, V83, P476; RANKIN S, 1994, J BIOL CHEM, V269, P704; RAYNER JR, 1994, MOL CELL BIOL, V14, P880, DOI 10.1128/MCB.14.2.880; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Weiler SR, 1996, BLOOD, V87, P3688, DOI 10.1182/blood.V87.9.3688.bloodjournal8793688; Wisniewski D, 1996, LEUKEMIA, V10, P229; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YEE NS, 1993, J BIOL CHEM, V268, P14189; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZHU WM, 1994, LEUKEMIA LYMPHOMA, V12, P441, DOI 10.3109/10428199409073786	40	81	83	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	1999	18	40					5573	5581		10.1038/sj.onc.1202939	http://dx.doi.org/10.1038/sj.onc.1202939			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523834				2022-12-17	WOS:000082894700010
J	Thompson, AD; Teitell, MA; Arvand, A; Denny, CT				Thompson, AD; Teitell, MA; Arvand, A; Denny, CT			Divergent Ewing's sarcoma EWS/ETS fusions confer a common tumorigenic phenotype on NIH3T3 cells	ONCOGENE			English	Article						EWS/FLI1; EWS/ETV1; chimeric transcription factors; tumorigenesis; Ewing's sarcoma	DNA-BINDING DOMAIN; RNA-POLYMERASE-II; TRANSCRIPTION FACTOR; CHROMOSOME-TRANSLOCATION; CHIMERIC TRANSCRIPTS; EWS GENE; IN-VIVO; TUMORS; PROTEIN; FAMILY	Ewing's sarcomas express chimeric transcription factors resulting from a fusion of the amino terminus of the EWS gene to the carboxyl terminus of one of five ETS proteins. While the majority of tumors express EWS/FLI1 fusions, some Ewing's tumors contain variant chimeras such as EWS/ETV1 that have divergent ETS DNA-binding domains. In spite of their structural differences, both EWS/ETS fusions up regulate EAT-2, a previously described EWS/FLI1 target gene. In contrast to EWS/FLI1, NIH3T3 cells expressing EWS/ETV1 cannot form colonies in soft agar though coexpression of a dominant negative truncated ETV1 construct attenuates EWS/FLI1 mediated anchorage independent growth. When EWS/ETV1 or EWS/FLI1 expressing NIH3T3 cells are injected into SCID mice, tumors form more often and faster than with NIH3T3 cells with empty vector controls. The tumorigenic potency of each EWS/ETS fusion is linked to its C-terminal structure, with the FLI1 C-terminus confering a greater tumorigenic potential than the corresponding ETV1 domain. The resulting EWS/ETV1 and EWS/FLI1 tumors closely resemble each other at both a macroscopic and a microscopic level. These tumors differ greatly from tumors formed by NIH3T3 cells expressing activated RAS, These data indicate that in spite of their structural differences, EWS/ETV1 and EWS/FLI1 promote oncogenesis via similar biologic pathways.	Univ Calif Los Angeles, Inst Mol Biol, Gwynne Hazen Cherry Mem Labs, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Gwynne Hazen Cherry Mem Labs, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Pathol & Lab Med, Gwynne Hazen Cherry Mem Labs, Los Angeles, CA USA; Univ Calif Los Angeles, Dept Pediat, Gwynne Hazen Cherry Mem Labs, Los Angeles, CA 90024 USA; Childrens Hosp Los Angeles, Dept Pathol, Los Angeles, CA 90027 USA; Univ So Calif, Los Angeles, CA 90089 USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Children's Hospital Los Angeles; University of Southern California	Thompson, AD (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Gwynne Hazen Cherry Mem Labs, Los Angeles, CA 90024 USA.				NCI NIH HHS [CA09056, CA32737] Funding Source: Medline; NIGMS NIH HHS [GM08042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA032737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Auvinen M, 1997, CANCER RES, V57, P3016; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; BERNSTEIN SC, 1985, P NATL ACAD SCI USA, V82, P1726, DOI 10.1073/pnas.82.6.1726; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; Cardinali M, 1997, MOL CARCINOGEN, V18, P78, DOI 10.1002/(SICI)1098-2744(199702)18:2<78::AID-MC3>3.0.CO;2-M; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; de Alava E, 1998, J CLIN ONCOL, V16, P1248, DOI 10.1200/JCO.1998.16.4.1248; del Peso L, 1997, ONCOGENE, V15, P3047; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; deLaunoit Y, 1997, BIOCHEM MOL MED, V61, P127, DOI 10.1006/bmme.1997.2605; Denny CT, 1996, CANCER INVEST, V14, P83, DOI 10.3109/07357909609018438; Downing J R, 1996, Cancer Treat Res, V84, P73; Fletcher JA, 1998, J CLIN ONCOL, V16, P1241, DOI 10.1200/JCO.1998.16.4.1241; FRIDMAN R, 1992, INT J CANCER, V51, P740, DOI 10.1002/ijc.2910510513; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; Kovar H, 1998, Sarcoma, V2, P3, DOI 10.1080/13577149878109; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; KROGERMAN P, 1997, ONCOGENE, V15, P1407; KURZEPA H, 1984, J ENVIRON PATHOL TOX, V5, P131; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LO SC, 1985, AM J PATHOL, V118, P7; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; McNagny KM, 1998, EMBO J, V17, P3669, DOI 10.1093/emboj/17.13.3669; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAO VN, 1993, ONCOGENE, V8, P2167; ROWLEY JD, 1994, LEUKEMIA, V8, pS1; RUBIN H, 1984, J NATL CANCER I, V72, P375; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Sorensen PHB, 1996, SEMIN CANCER BIOL, V7, P3, DOI 10.1006/scbi.1996.0002; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Thompson AD, 1996, ONCOGENE, V13, P2649; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; WASYLYK C, 1994, ONCOGENE, V9, P3665; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; Zoubek A, 1996, J CLIN ONCOL, V14, P1245, DOI 10.1200/JCO.1996.14.4.1245; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	46	81	84	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	1999	18	40					5506	5513		10.1038/sj.onc.1202928	http://dx.doi.org/10.1038/sj.onc.1202928			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523827				2022-12-17	WOS:000082894700003
J	Ma, ZQ; Chua, SS; DeMayo, FJ; Tsai, SY				Ma, ZQ; Chua, SS; DeMayo, FJ; Tsai, SY			Induction of mammary gland hyperplasia in transgenic mice over-expressing human Cdc25B	ONCOGENE			English	Article						Cdc25B cell cycle; transgenic mice; hyperplasia	CYCLIN-DEPENDENT KINASES; CELL-CYCLE; C-MYC; FISSION YEAST; DIFFERENTIAL REGULATION; REDUNDANT CYCLIN; MITOTIC INDUCER; BREAST-CANCER; HA-RAS; OVEREXPRESSION	Cdc25 A and B are dual-specificity phosphatases which have been implicated in neoplastic transformation. Although Cdc25A and Cdc25B have been found to be over-expressed in many cancer cell lines and primary tumors, the physiological roles of Cdc25A and B in vivo are largely undefined. To investigate the roles of these proteins in the ontogenic transformation of the mammary gland we used the mouse mammary tumor virus (MMTV) promoter to target over-expression of the Cdc25B transgene in the mammary glands of transgenic mouse Lines. Here we report that the over-expression of Cdc25B enhances the proliferation of mammary epithelial cells resulting in the formation of precocious alveolar hyperplasia. At the molecular level, marked increases in cyclin D1 protein have been found in transgenic mammary epithelial cells. The accelerated growth rate of the mammary epithelial cells could also be attributed to the increased levels of cyclin E/cdk2 activity, In addition, a pronounced decrease in apoptosis was also observed during the involution of mammary gland, The reduction of apoptosis during involution correlated well with the reduced expression of c-myc and p53, both of which have been implicated in apoptosis. Taken together, our results clearly indicate that the deregulated expression of Cdc25B generates mammary gland hyperplasia.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine	Tsai, SY (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336				ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; Barnes DM, 1997, J PATHOL, V181, P267, DOI 10.1002/(SICI)1096-9896(199703)181:3<267::AID-PATH783>3.0.CO;2-X; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; BORTNER DM, 1995, CELL GROWTH DIFFER, V6, P1579; Cardiff RD, 1996, J MAMMARY GLAND BIOL, V1, P61, DOI 10.1007/BF02096303; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; Draetta G, 1997, BBA-REV CANCER, V1332, pM53, DOI 10.1016/S0304-419X(96)00049-2; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gasparotto D, 1997, CANCER RES, V57, P2366; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRANA X, 1995, ONCOGENE, V11, P211; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; GUNZBURG WH, 1992, BIOCHEM J, V283, P625; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hernandez S, 1998, CANCER RES, V58, P1762; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Humphreys RC, 1996, DEVELOPMENT, V122, P4013; Hundley JE, 1997, CANCER RES, V57, P600; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Iavarone A, 1997, NATURE, V387, P417; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; Jerry DJ, 1998, ONCOGENE, V17, P2305, DOI 10.1038/sj.onc.1202157; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Kudo Y, 1997, JPN J CANCER RES, V88, P947, DOI 10.1111/j.1349-7006.1997.tb00313.x; LI BL, 1994, CELL GROWTH DIFFER, V5, P711; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; Medina D, 1996, J MAMMARY GLAND BIOL, V1, P5, DOI 10.1007/BF02096299; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORENO S, 1991, NATURE, V351, P194, DOI 10.1038/351194b0; Morgan DO, 1996, NATURE, V382, P295, DOI 10.1038/382295a0; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; PATTENGALE PK, 1989, AM J PATHOL, V135, P39; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Saha P, 1997, MOL CELL BIOL, V17, P4338, DOI 10.1128/MCB.17.8.4338; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STRANGE R, 1992, DEVELOPMENT, V115, P49; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WICKRAMASINGHE D, 1995, DEVELOPMENT, V121, P2047; Wu WG, 1998, CANCER RES, V58, P4082; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu X, 1996, J BIOL CHEM, V271, P5118; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	58	81	83	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4564	4576		10.1038/sj.onc.1202809	http://dx.doi.org/10.1038/sj.onc.1202809			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467401				2022-12-17	WOS:000082018600006
J	Nishida, K; Kaziro, Y; Satoh, T				Nishida, K; Kaziro, Y; Satoh, T			Anti-apoptotic function of Rac in hematopoietic cells	ONCOGENE			English	Article						Akt; apoptosis; p38 mitogen-activated protein kinase; phosphatidylinositol 3-kinase; Rac	ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; COLONY-STIMULATING FACTOR; SIGNALING PATHWAY; JUN KINASE; B-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIN POLYMERIZATION; SELECTIVE ACTIVATION; CYTOKINE DEPRIVATION	The small GTP-binding protein Rac plays a pivotal role in the regulation of diverse physiological events including reorganization of the actin cytoskeleton, cell cycle progression, and transformation. Here we show an anti-apoptotic effect of Rac in interleukin-3-dependent murine hematopoietic BaF3 cells. Activated Rac(G12V), when ectopically expressed in BaF3 cells, rendered the cells resistant to apoptosis upon interleukin-3 deprivation, while activated mutants of Rho and Cdc42 displayed no significant anti-apoptotic effect. In contrast to activated Ras, which also supports cell survival in the absence of interleukin-3, Rac required fetal bovine serum for the prevention of cell death. The involvement of phosphatidylinositol 3-kinase downstream of Rac was demonstrated by the inhibition of Rac-induced cell survival by wortmannin and LY294002 and the presence of phosphatidylinositol kinase activity in the Rac immunoprecipitate, Furthermore, the serine/threonine kinase Akt was stimulated by activated Rac and fetal bovine serum in a synergistic manner. Rac-induced Akt activation was mediated by phosphorylation of threonine-308 and serine-473, In addition to the phosphatidylinositol 3-kinase/Akt pathway, the p38 mitogen-activated protein kinase pathway was crucial for Rac-dependent survival, whereas p38 mitogen-activated protein kinase was not implicated in Ras-induced anti-apoptotic signaling. These findings provide evidence for the involvement of Rac in survival signaling of hematopoietic cells.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Satoh, T (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.		Satoh, Takaya/K-2628-2014	Nishida, Kazuhiko/0000-0001-8825-8441				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kawakami Y, 1997, P NATL ACAD SCI USA, V94, P3938, DOI 10.1073/pnas.94.8.3938; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Liu R, 1997, BIOCHEM BIOPH RES CO, V234, P611, DOI 10.1006/bbrc.1997.6643; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nagata Y, 1997, BLOOD, V89, P2664, DOI 10.1182/blood.V89.8.2664; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Ohta T, 1997, J BIOL CHEM, V272, P23111, DOI 10.1074/jbc.272.37.23111; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Suzuki J, 1997, ONCOGENE, V15, P1689, DOI 10.1038/sj.onc.1201333; Tago K, 1998, J BIOCHEM-TOKYO, V123, P659; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; vanKooten C, 1997, CURR OPIN IMMUNOL, V9, P330, DOI 10.1016/S0952-7915(97)80078-7; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	74	81	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	1999	18	2					407	415		10.1038/sj.onc.1202301	http://dx.doi.org/10.1038/sj.onc.1202301			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927197				2022-12-17	WOS:000078166500013
J	Moorman, JP; Luu, D; Wickham, J; Bobak, DA; Hahn, CS				Moorman, JP; Luu, D; Wickham, J; Bobak, DA; Hahn, CS			A balance of signaling by Rho family small GTPases RhoA, Rac1 and Cdc42 coordinates cytoskeletal morphology but not cell survival	ONCOGENE			English	Article						Rho family; apoptosis; cytoskeleton; C3 exoenzyme	BINDING PROTEIN-RHO; ACTIN STRESS FIBERS; FOCAL COMPLEXES; T-LYMPHOCYTES; TOXIN-A; RAS; TRANSDUCTION; APOPTOSIS; EXPRESSION; ACTIVATION	Rho family GTPases are known to be involved in cytoskeletal reorganization. We examined the possibility that these functions may be dictated by a balance of Rho family GTPase signaling. Using transient viral expression of RhoA, Rac1, Cdc42 and their mutants, as well as C3 exoenzyme, we altered cytoskeletal organization under normal growth conditions. Overexpression of wild-type or constitutively active forms of the Rho family GTPases led to their respective activation phenotypes, Overexpression of dominant negative forms of given Rho family GTPases led to a phenotype consistent with activation of the other Rho family GTPase, Treatment with C, difficile toxin A, that inactivates all Rho family GTPases, led to the transient appearance of a variety of activation phenotypes, Previously, we reported that inactivation of Rho led to induction of apoptosis, implying that Rho may play an important role in cell survival signaling. This signaling, however, is not affected by expression of tiny forms of Rad or Cdc42, and only inactivation of Rho led to induction of apoptosis, Rho family GTPases appear to coordinate cytoskeletal organization by a balance of signaling, while cell survival is regulated by :I distinct Rho-mediated signaling pathway.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Hahn, CS (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001478, R01AI033434] Funding Source: NIH RePORTER; NIAID NIH HHS [AI01478, AI33434] Funding Source: Medline; NIGMS NIH HHS [GM54572] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; ChavesOlarte E, 1997, J CLIN INVEST, V100, P1734, DOI 10.1172/JCI119698; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; FIORENTINI C, 1991, TOXICON, V29, P543, DOI 10.1016/0041-0101(91)90050-2; Galandrini R, 1997, IMMUNITY, V7, P163, DOI 10.1016/S1074-7613(00)80519-1; Gomez J, 1997, EUR J IMMUNOL, V27, P2793, DOI 10.1002/eji.1830271108; Gulbins E, 1996, J BIOL CHEM, V271, P26389, DOI 10.1074/jbc.271.42.26389; HAHN CS, 1992, P NATL ACAD SCI USA, V89, P2679, DOI 10.1073/pnas.89.7.2679; Hall A, 1995, GUIDEBOOK SMALL GTPA, P3; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Li GP, 1997, J BIOL CHEM, V272, P10337; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Lores P, 1997, ONCOGENE, V15, P601, DOI 10.1038/sj.onc.1201378; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Moorman JP, 1996, J IMMUNOL, V156, P4146; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SZAMEL M, 1995, EUR J BIOCHEM, V228, P1; THELESTAM M, 1984, J TOXICOL-TOXIN REV, V3, P139, DOI 10.3109/15569548409097924; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	33	81	81	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					47	57		10.1038/sj.onc.1202262	http://dx.doi.org/10.1038/sj.onc.1202262			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926919				2022-12-17	WOS:000078166000006
J	Denissenko, MF; Koudriakova, TB; Smith, L; O'Connor, TR; Riggs, AD; Pfeifer, GP				Denissenko, MF; Koudriakova, TB; Smith, L; O'Connor, TR; Riggs, AD; Pfeifer, GP			The p53 codon 249 mutational hotspot in hepatocellular carcinoma is not related to selective formation or persistence of aflatoxin B-1 adducts	ONCOGENE			English	Article						aflatoxin B-1; p53 gene; hepatocellular carcinoma	TUMOR-SUPPRESSOR GENE; POLYMERASE CHAIN-REACTION; RAT-LIVER; DNA-DAMAGE; NUCLEOTIDE RESOLUTION; PYRIMIDINE DIMERS; FORMED INVIVO; LOW-FREQUENCY; CANCER; REPAIR	Sequence-dependent formation and lack of repair of polycyclic aromatic hydrocarbon-induced DNA adducts correlates well with the positions of p53 mutational hotspots in smoking-related lung cancers (Denissenko et al. 1996, 1998). The mycotoxin aflatoxin B-1 (AFB(1)) is considered to be a major causative agent in hepatocellular carcinoma (HCC) in regions with presumed high food contamination by AFB(1). A unique mutational hotspot, a G to T transversion at the third base of codon 249 of the p53 gene is observed in these tumors. To test whether a selectivity of AFB(1) adduct formation is related to this peculiar mutational spectrum, we have mapped AFB(1)-DNA adducts at nucleotide resolution using ligation-mediated PCR and terminal transferase-dependent PCR. Human HepG2 cells were exposed to AFB(1) metabolically activated in the presence of rat liver microsomes. Significant adduct formation was seen at the third base of codon 249. However, this was not the major site of AFB(1) adducts and strong adduction was also observed at codons 226, 243, 244, 245 and 248 in exon 7 of the p53 gene and at several codons in exon 8. The damage at codon 249 does not consist of a unique abasic site or ring-opened aflatoxin B-1 adduct but rather is consistent with the principal N7-guanine adduct of AFB1. Time course experiments indicate that, under the conditions used. AFB(1) adducts are not removed in a strand-selective manner and adduct removal from the third base of codon 249 proceeds at a relatively fast rate (50% in 7 h). The incomplete correspondence between sites of persistent AFB(1) damage and the specific codon 249 mutation suggests that AFB(1) may not be involved in mutation of this site or that additional mechanisms such as parallel infection with hepatitis B virus may be required for selection of codon 249 mutants in HCC.	City Hope Natl Med Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA; Ohio State Univ, Dept Pharmacol, Columbus, OH 43210 USA	City of Hope; Beckman Research Institute of City of Hope; University System of Ohio; Ohio State University	Pfeifer, GP (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA.			Riggs, Arthur/0000-0002-8184-5288; O'Connor, Timothy/0000-0001-5848-3592	NATIONAL CANCER INSTITUTE [P01CA069449, R01CA065652] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA65652, P01CA69449] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; AGUILAR F, 1994, SCIENCE, V264, P1317, DOI 10.1126/science.8191284; Bailey EA, 1996, P NATL ACAD SCI USA, V93, P1535, DOI 10.1073/pnas.93.4.1535; BENASUTTI M, 1988, BIOCHEMISTRY-US, V27, P472, DOI 10.1021/bi00401a068; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BUETOW KH, 1992, P NATL ACAD SCI USA, V89, P9622, DOI 10.1073/pnas.89.20.9622; Busby Jr W. F., 1984, CHEM CARCINOGENS, V182, P945; CHALLEN C, 1992, HEPATOLOGY, V16, P1362, DOI 10.1002/hep.1840160610; CHETSANGA CJ, 1983, CARCINOGENESIS, V4, P997, DOI 10.1093/carcin/4.8.997; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROY RG, 1981, CANCER RES, V41, P197; CROY RG, 1978, P NATL ACAD SCI USA, V75, P1745, DOI 10.1073/pnas.75.4.1745; DANDREA AD, 1978, P NATL ACAD SCI USA, V75, P4120, DOI 10.1073/pnas.75.9.4120; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Denissenko MF, 1998, ONCOGENE, V16, P1241, DOI 10.1038/sj.onc.1201647; Denissenko MF, 1997, P NATL ACAD SCI USA, V94, P3893, DOI 10.1073/pnas.94.8.3893; DUFLOT A, 1994, CARCINOGENESIS, V15, P1353, DOI 10.1093/carcin/15.7.1353; EATON DL, 1994, ANNU REV PHARMACOL, V34, P135, DOI 10.1146/annurev.pa.34.040194.001031; EISENSTADT E, 1982, P NATL ACAD SCI-BIOL, V79, P1945, DOI 10.1073/pnas.79.6.1945; ESSIGMANN JM, 1977, P NATL ACAD SCI USA, V74, P1870, DOI 10.1073/pnas.74.5.1870; ESSIGMANN JM, 1982, DRUG METAB REV, V13, P581, DOI 10.3109/03602538209011088; FUJIMOTO Y, 1992, CANCER RES, V52, P1044; Greenblatt MS, 1997, CANCER RES, V57, P426; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; HAYWARD NK, 1991, NATURE, V352, P764, DOI 10.1038/352764a0; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HULLA JE, 1993, CANCER RES, V53, P9; HUSSAIN SP, 1994, ONCOGENE, V9, P2277; Iatsimirskaia E, 1997, CLIN PHARMACOL THER, V61, P554, DOI 10.1016/S0009-9236(97)90135-1; IRVIN TR, 1985, CANCER RES, V45, P3497; Johnson WW, 1996, J AM CHEM SOC, V118, P8213, DOI 10.1021/ja960525k; Kobertz WR, 1997, P NATL ACAD SCI USA, V94, P9579, DOI 10.1073/pnas.94.18.9579; Komura J, 1998, NUCLEIC ACIDS RES, V26, P1807, DOI 10.1093/nar/26.7.1807; Koudriakova T, 1996, J PHARMACOL EXP THER, V279, P1300; KRESS S, 1992, CANCER RES, V52, P3220; Lasky T, 1997, ENVIRON HEALTH PERSP, V105, P392, DOI 10.2307/3433335; LEADON SA, 1981, CANCER RES, V41, P5125; LIN JK, 1977, CANCER RES, V37, P4430; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MUENCH KF, 1983, P NATL ACAD SCI-BIOL, V80, P6, DOI 10.1073/pnas.80.1.6; MURAKAMI Y, 1991, CANCER RES, V51, P5520; ODA T, 1992, CANCER RES, V52, P6358; OLEYKOWSKI CA, 1993, J BIOL CHEM, V268, P7990; OZTURK M, 1991, LANCET, V338, P1356, DOI 10.1016/0140-6736(91)92236-U; PFEIFER GP, 1991, P NATL ACAD SCI USA, V88, P1374, DOI 10.1073/pnas.88.4.1374; PUISIEUX A, 1991, CANCER RES, V51, P6185; REFOLO LM, 1985, P NATL ACAD SCI USA, V82, P3096, DOI 10.1073/pnas.82.10.3096; RIVKINA MB, 1994, CANCER RES, V54, P5430; RODRIGUEZ H, 1995, J BIOL CHEM, V270, P17633, DOI 10.1074/jbc.270.29.17633; ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G; SARASIN AR, 1977, CANCER RES, V37, P1786; Shen HM, 1996, MUTAT RES-REV GENET, V366, P23, DOI 10.1016/S0165-1110(96)90005-6; Tommasi S, 1997, CANCER RES, V57, P4727; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; Tornaletti Silvia, 1996, P199; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	59	81	81	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	1998	17	23					3007	3014		10.1038/sj.onc.1202214	http://dx.doi.org/10.1038/sj.onc.1202214			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881702				2022-12-17	WOS:000077427800007
J	Chen, L; Zhang, WJ; Fregien, N; Pierce, M				Chen, L; Zhang, WJ; Fregien, N; Pierce, M			The her-2/neu oncogene stimulates the transcription of N-acetylglucosaminyltransferase V and expression of its cell surface oligosaccharide products	ONCOGENE			English	Article						neu/her-2; oncogene; glycosyltransferase; glycosylation	HAMSTER-KIDNEY CELLS; ASPARAGINE-LINKED OLIGOSACCHARIDES; BETA-1-6 BRANCHED OLIGOSACCHARIDES; DISTINCT METASTATIC POTENTIALS; BREAST-CANCER; NEU-ONCOGENE; TRANSGENIC MICE; MEMBRANE-GLYCOPROTEINS; EPITHELIAL-CELLS; PROTO-ONCOGENE	Malignant transformation is associated with changes in the glycosylation of cell surface proteins. For example, the N-linked oligosaccharides containing the [GlcNAc beta(1,6)Man] branch are increased after transformation of many cell types by a number of tumor viruses and oncogenes which induce the expression of N-acetylglucosaminyl-transferase V (GlcNAc-T V), the enzyme that adds this branch, A large percentage of human breast carcinomas have increased N-linked beta(1,6) branches on glycoproteins, while up to 30% of breast carcinomas have amplified the oncogene her-2/neu (erb-B2), We tested the hypothesis that expression of her-2/neu stimulates GlcNAc-T V gene expression and increases the beta(1,6) branching of N-linked oligosaccharides, We found that neu-transformed NIH3T3 cells have a threefold increase in GlcNAc-T V enzyme activity and increased beta(1,6) branching on a specific set of glycoproteins. Promoter/reporter experiments showed that her-2/neu stimulates transcription from the human GlcNAc-T V promoter and that the her-2/neu response element was located about 400 bp 5' of the transcription initiation site and includes three Ets transcription factor binding sequences, Co-transfections with dominant-negative Raf and Ets expression plasmids demonstrated that the transcriptional activation of the GlcNAc-T V promoter by neu is mediated by the Ras-Raf-Ets signal transduction pathway.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Shanghai Jaio Tung Univ, Dept Biochem & Mol Biol, Inst Mol Biol, Shanghai, Peoples R China; Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Shanghai Jiao Tong University; University of Miami	Pierce, M (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA.				NCRR NIH HHS [RR5351] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALLRED DC, 1992, HUM PATHOL, V23, P974, DOI 10.1016/0046-8177(92)90257-4; Aperlo C, 1996, MOL CELL BIOL, V16, P6851; ARANGO J, 1988, J CELL BIOCHEM, V37, P225, DOI 10.1002/jcb.240370209; BORG A, 1991, ONCOGENE, V6, P137; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUCK CA, 1971, SCIENCE, V172, P169, DOI 10.1126/science.172.3979.169; Buckhaults P, 1997, J BIOL CHEM, V272, P19575, DOI 10.1074/jbc.272.31.19575; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CUMMINGS RD, 1982, J BIOL CHEM, V257, P13421; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1989, ONCOGENE, V4, P853; DENNIS JW, 1989, CANCER RES, V49, P945; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; DEPOTTER CR, 1990, INT J CANCER, V45, P55, DOI 10.1002/ijc.2910450112; DO KY, 1994, J BIOL CHEM, V269, P23456; FERNANDES B, 1991, CANCER RES, V51, P718; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hayes D F, 1996, Recent Results Cancer Res, V140, P101; Kang R, 1996, J BIOL CHEM, V271, P26706, DOI 10.1074/jbc.271.43.26706; KAWANO T, 1993, INT J CANCER, V53, P91, DOI 10.1002/ijc.2910530118; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEMARER N, 1992, GLYCOBIOLOGY, V2, P49, DOI 10.1093/glycob/2.1.49; Li WP, 1997, INT J CANCER, V71, P483, DOI 10.1002/(SICI)1097-0215(19970502)71:3<483::AID-IJC29>3.3.CO;2-P; LU Y, 1994, CLIN EXP METASTAS, V12, P47, DOI 10.1007/BF01784333; LU Y, 1993, MOL CELL BIOCHEM, V122, P85, DOI 10.1007/BF00925741; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PIERCE JH, 1991, ONCOGENE, V6, P1189; PIERCE M, 1986, J BIOL CHEM, V261, P772; SAITOH O, 1992, J BIOL CHEM, V267, P5700; SAWADA R, 1994, J BIOL CHEM, V269, P1425; SHOREIBAH MG, 1992, J BIOL CHEM, V267, P2920; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STANLEY P, 1983, METHOD ENZYMOL, V96, P157; Tan M, 1997, CANCER RES, V57, P1199; TIKANNEN S, 1992, J CLIN ONCOL, V10, P1044; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; YAMASHITA K, 1984, J BIOL CHEM, V259, P834; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260	47	81	82	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2087	2093		10.1038/sj.onc.1202124	http://dx.doi.org/10.1038/sj.onc.1202124			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798679				2022-12-17	WOS:000076540900007
J	Ledda-Columbano, GM; Curto, M; Piga, R; Zedda, AI; Menegazzi, M; Sartori, C; Shinozuka, H; Bluethmann, H; Poli, V; Ciliberto, G; Columbano, A				Ledda-Columbano, GM; Curto, M; Piga, R; Zedda, AI; Menegazzi, M; Sartori, C; Shinozuka, H; Bluethmann, H; Poli, V; Ciliberto, G; Columbano, A			In vivo hepatocyte proliferation is inducible through a TNF and IL-6-independent pathway	ONCOGENE			English	Article						cell proliferation; TNF; IL-6; TCPOBOP; ciprofibrate; liver	TUMOR-NECROSIS-FACTOR; PEROXISOME PROLIFERATOR; LIVER-REGENERATION; MOUSE-LIVER; C-FOS; BINDING-PROTEINS; MICE LACKING; RECEPTOR; GROWTH; ALPHA	Recent studies in mice harboring a targeted disruption of genes encoding TNF receptor 1 (TNFR-1) or Interleukin 6 (IL-6) suggested a critical role for TNF and IL-6 in initiation of liver regeneration after 2/3 partial hepatectomy. However, hepatocyte proliferation can also occur following treatment with agents that do not induce tissue loss (primary mitogens). To determine whether the above cytokines could also be involved in mitogen-induced liver cell proliferation, we studied the hepatocyte proliferative response after treatment with primary mitogens in mice knock-out for TNFR-1 or IL-6. Our results showed no difference in the proliferative response of the liver between the wild type and the knock-out mice following treatment with the mitogens I,4-bis[2-(3,5-dichloropyridyloxy)] benzene (TCPOBOP), or the peroxisome proliferator, ciprofibrate, suggesting that TNF or IL-6 may not play a major role in this type of proliferation. Gel shift assay indicated that TCPOBOP-induced hepatocyte proliferation is not associated with activation of STAT3 transcription factor, a major target of IL-6 and other growth factors/cytokines. Our results thus indicate that hepatocyte proliferation can be induced by at least two different pathways; compensatory regeneration being TNF and IL-6-dependent, and mitogen-induced direct hyperplasia which does not require TNF or IL-6.	Univ Cagliari, Dipartimento Tossicol, Sez Oncol & Patol Mol, Cagliari, Italy; Univ Rome, Dipartimento Biol Cellulare & Sviluppo, Rome, Italy; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA; Univ Verona, Ist Sci Biochim, I-37100 Verona, Italy; Hoffman LaRoche, Basel, Switzerland; IRBM, Rome, Italy	University of Cagliari; Sapienza University Rome; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Verona; Roche Holding; Merck & Company	Ledda-Columbano, GM (corresponding author), Univ Cagliari, Dipartimento Tossicol, Sez Oncol & Patol Mol, Cagliari, Italy.		Menegazzi, Marta/AAE-7079-2019; Columbano, Amedeo/C-7463-2011; Ciliberto, Gennaro/J-4131-2017; Poli, Valeria/A-9215-2012	Menegazzi, Marta/0000-0003-1310-9227; Columbano, Amedeo/0000-0002-6956-9030; Ciliberto, Gennaro/0000-0003-2851-8605; Poli, Valeria/0000-0002-3739-3966				AKERMAN P, 1992, AM J PHYSIOL, V263, pG579, DOI 10.1152/ajpgi.1992.263.4.G579; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; Beebe LE, 1996, BIOCHEM PHARMACOL, V52, P1507, DOI 10.1016/S0006-2952(96)00525-4; BENEDETTI L, 1994, ARCH BIOCHEM BIOPHYS, V309, P1, DOI 10.1006/abbi.1994.1075; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; Columbano A, 1996, FASEB J, V10, P1118, DOI 10.1096/fasebj.10.10.8751714; Columbano A, 1997, ONCOGENE, V14, P857, DOI 10.1038/sj.onc.1200891; CONI P, 1993, HEPATOLOGY, V17, P1109, DOI 10.1002/hep.1840170626; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291; Higgins GM, 1931, ARCH PATHOL, V12, P186; HONKAKOSKI P, 1992, BIOCHEM PHARMACOL, V43, P2121, DOI 10.1016/0006-2952(92)90170-N; KELLER H, 1995, MOL ENDOCRINOL, V9, P794, DOI 10.1210/me.9.7.794; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; Kubo Y, 1996, HEPATOLOGY, V23, P104, DOI 10.1002/hep.510230115; LEVINE WG, 1977, BIOCHEM PHARMACOL, V26, P939, DOI 10.1016/0006-2952(77)90470-1; MANENTI G, 1987, CHEM-BIOL INTERACT, V64, P83, DOI 10.1016/0009-2797(87)90062-7; MENGAZZI M, 1997, HEPATOLOGY, V25, P585; Ohmura T, 1996, AM J PATHOL, V148, P815; Peters JM, 1997, CARCINOGENESIS, V18, P2029, DOI 10.1093/carcin/18.11.2029; POELLINGER L, 1992, TRENDS PHARMACOL SCI, V13, P241, DOI 10.1016/0165-6147(92)90076-I; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; TRAUTWEIN C, 1994, GUT, V35, P1163, DOI 10.1136/gut.35.9.1163; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WHITE TEK, 1993, BIOCHEM BIOPH RES CO, V193, P956, DOI 10.1006/bbrc.1993.1718; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441	33	81	81	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					1039	1044		10.1038/sj.onc.1202018	http://dx.doi.org/10.1038/sj.onc.1202018			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747883				2022-12-17	WOS:000075560900012
J	Santoro, MM; Penengo, L; Minetto, M; Orecchia, S; Cilli, M; Gaudino, G				Santoro, MM; Penengo, L; Minetto, M; Orecchia, S; Cilli, M; Gaudino, G			Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor	ONCOGENE			English	Article						metastasis; Ron; signal transduction; tumorigenesis; tyrosine kinase	MACROPHAGE-STIMULATING PROTEIN; LIGAND-INDEPENDENT ACTIVATION; NEOPLASIA TYPE 2B; NIH 3T3 CELLS; C-KIT; CONSERVED FEATURES; RET PROTOONCOGENE; TRANSFORMING GENE; CATALYTIC DOMAIN; GROWTH	Ron (the receptor for Macrophage Stimulating Protein) has never been implicated before in human malignancies or in cell transformation. In this report we show that Ron can acquire oncogenic potential by means of two amino acid substitutions-D1232V and M1254T-affecting highly conserved residues in the tyrosine kinase domain, The same mutations in Kit and Pet have been found associated with two human malignancies, mastocytosis and Multiple Endocrine Neoplasia type 2B (MEN2B), respectively. Both mutations caused Ron-mediated transformation of 3T3 fibroblasts and tumour formation in nude mice. Moreover, cells transformed by the oncogenic Ron mutants displayed high metastatic potential. The Ron mutant receptors were constitutively active and the catalytic efficiency of the mutated kinase was higher than that of wild-type Ron. Oncogenic Ron mutants enhanced activation of the Ras/MAPK cascade with respect to wild type Ron, without affecting the JNK/SAPK pathway. Expression of Ron mutants in 3T3 fibroblasts led to different patterns of tyrosine-phosphorylated proteins. These data show that point mutations altering catalytic properties and possibly substrate specificity of the Ron kinase may force cells toward tumorigenesis and metastasis.	Univ Torino, Dipartimento Sci & Tecnol Avanzate, I-15100 Alessandria, Italy; Ist Sci San Raffaele, DIBIT, I-20138 Milan, Italy; Ist Nazl Ric Canc, Ctr Biotecnol Avanzate, I-16132 Genoa, Italy	University of Eastern Piedmont Amedeo Avogadro; University of Turin; Vita-Salute San Raffaele University; University of Genoa; IRCCS AOU San Martino IST	Gaudino, G (corresponding author), Univ Torino, Dipartimento Sci Med, Sede Novara,Via Solaroli 17, I-28100 Novara, Italy.		Cilli, Michele/AAB-8529-2019	PENENGO, Lorenza/0000-0001-7888-4473; SANTORO, Massimo Mattia/0000-0003-4605-5085; Cilli, Michele/0000-0003-4083-8986				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Banu N, 1996, J IMMUNOL, V156, P2933; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Collesi C, 1996, MOL CELL BIOL, V16, P5518; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Correll Pamela H., 1997, Genes and Function, V1, P69; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; del Peso L, 1997, ONCOGENE, V15, P3047; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gaudino G, 1995, ONCOGENE, V11, P2627; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kurihara N, 1996, BLOOD, V87, P3704, DOI 10.1182/blood.V87.9.3704.bloodjournal8793704; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; Pandit SD, 1996, J BIOL CHEM, V271, P5850, DOI 10.1074/jbc.271.10.5850; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; SAWYERS CL, 1994, CELL, V77, P1; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; STACEY DW, 1991, ONCOGENE, V6, P2297; TSUJIMURA T, 1994, BLOOD, V83, P2619; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; Wang MH, 1996, ONCOGENE, V13, P2167; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Willett CG, 1997, J CLIN INVEST, V99, P2979, DOI 10.1172/JCI119493	49	81	81	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	1998	17	6					741	749		10.1038/sj.onc.1201994	http://dx.doi.org/10.1038/sj.onc.1201994			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715276	Green Submitted			2022-12-17	WOS:000075337200009
J	Ben-Yosef, T; Yanuka, O; Halle, D; Benvenisty, N				Ben-Yosef, T; Yanuka, O; Halle, D; Benvenisty, N			Involvement of Myc targets in c-myc and N-myc induced human tumors	ONCOGENE			English	Article						Myc; oncogenesis; target genes	BREAST-CANCER-CELLS; ORNITHINE DECARBOXYLASE GENE; HUMAN NEUROBLASTOMA-CELLS; PROTHYMOSIN-ALPHA-GENE; HUMAN NEURO-BLASTOMA; DNA-BINDING; INDUCED APOPTOSIS; EMBRYONIC LETHALITY; ONCOGENE EXPRESSION; CONTINUOUS CULTURE	The myc proto-oncogenes are transcription factors that directly regulate the expression of other genes, by binding to the specific DNA sequence, CACGTG, Among the target genes for c-Myc regulation are ECA39, p53, ornithine decarboxylase (ODC), alpha-prothymosin and Cdc25A, In this study we examined the involvement of c-Myc target genes in human oncogenesis induced by c-myc or N-myc. In MCF-7 breast cancer cells, the induction of c-myc expression by estrogen was followed by the induction of all the Myc targets that we examined, indicating that those genes can serve as c-Myc targets in human oncogenesis, Moreover, in breast tumors exhibiting c-myc overexpression, several Myc targets were also overexpressed. A clear correlation between the expression of c-myc and its targets was also detected in Burkitt's lymphomas, which involve a specific translocation of c-myc gene, but not in other lymphoma cells. Yet, in cells derived from a neuronal origin the pattern of expression of Myc targets was more complex, In a neuroepithelioma cell line that overexpresses c-myc, only some targets were expressed. In addition in neuroblastomas, in which N-myc is amplified and overexpressed, only ODC was overexpressed in all cell lines, while all other target genes were expressed in only some of the cell lines. The more complex expression pattern found for the Myc targets in neuroblastomas suggests that genes that were identified originally as targets for c-Myc regulation may be regulated by N-Myc, but other cell specific factors are also needed for transcription of the target genes.	Hebrew Univ Jerusalem, Inst Life Sci, Dept Genet, IL-91904 Jerusalem, Israel; Shaare Zedek Med Ctr, Cell Canc Res Lab, IL-91031 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Shaare Zedek Medical Center	Benvenisty, N (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Genet, IL-91904 Jerusalem, Israel.							ALEX R, 1992, NUCLEIC ACIDS RES, V20, P2257, DOI 10.1093/nar/20.9.2257; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Bello-Fernandez C, 1992, Curr Top Microbiol Immunol, V182, P445; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; BENBASSAT H, 1980, INT J CANCER, V25, P583, DOI 10.1002/ijc.2910250506; BENBASSAT H, 1992, LEUKEMIA LYMPHOMA, V6, P513, DOI 10.3109/10428199209053591; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BenYosef T, 1996, ONCOGENE, V13, P1859; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOWLIN TL, 1986, CELL IMMUNOL, V98, P341, DOI 10.1016/0008-8749(86)90294-7; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; CHEN ZP, 1991, BIOCHIM BIOPHYS ACTA, V1133, P1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; DESIDERIO MA, 1995, CELL GROWTH DIFFER, V6, P505; DUBIK D, 1987, CANCER RES, V47, P6517; DUBIK D, 1988, J BIOL CHEM, V263, P12705; Eden A, 1996, J BIOL CHEM, V271, P20242, DOI 10.1074/jbc.271.34.20242; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ESCHENFELDT WH, 1986, P NATL ACAD SCI USA, V83, P9403, DOI 10.1073/pnas.83.24.9403; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GOMEZMARQUEZ J, 1989, J BIOL CHEM, V264, P8451; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUERIN M, 1988, ONCOGENE RES, V3, P21; HAMANN U, 1991, ONCOGENE, V6, P1745; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANDSCHULTZ WH, 1987, SCIENCE, V240, P1759; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LIMA G, 1985, CANCER RES, V45, P2466; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; Lutz W, 1996, ONCOGENE, V13, P803; MA A, 1993, ONCOGENE, V8, P1093; MURPHY W, 1986, P NATL ACAD SCI USA, V83, P2939, DOI 10.1073/pnas.83.9.2939; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; PRENDERGAST GC, 1989, NATURE, V341, P392, DOI 10.1038/341392a0; PULVERTA.RJ, 1965, J CLIN PATHOL, V18, P261, DOI 10.1136/jcp.18.3.261; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; RASCHELLA G, 1991, CANCER LETT, V56, P45, DOI 10.1016/0304-3835(91)90192-K; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sambrook J, 1989, MOL CLONING LAB MANU; Schmidt EV, 1996, NAT GENET, V14, P8, DOI 10.1038/ng0996-8; Schuldiner O, 1996, P NATL ACAD SCI USA, V93, P7143, DOI 10.1073/pnas.93.14.7143; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; THOMAS P, 1981, P NATL ACAD SCI USA, V77, P5201; THOMAS T, 1989, CANCER RES, V49, P5852; THOMPSON AM, 1990, BRIT J CANCER, V62, P78, DOI 10.1038/bjc.1990.233; TONIN PN, 1989, ONCOGENE, V4, P1117; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; YEGER H, 1988, DIFFERENTIATION, V39, P216, DOI 10.1111/j.1432-0436.1988.tb00095.x; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	75	81	82	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					165	171		10.1038/sj.onc.1201939	http://dx.doi.org/10.1038/sj.onc.1201939			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674700				2022-12-17	WOS:000074706700004
J	Kagawa, S; Fujiwara, T; Hizuta, A; Yasuda, T; Zhang, WW; Roth, JA; Tanaka, N				Kagawa, S; Fujiwara, T; Hizuta, A; Yasuda, T; Zhang, WW; Roth, JA; Tanaka, N			p53 expression overcomes p21(WAF1/CIP1)-mediated G(1) arrest and induces apoptosis in human cancer cells	ONCOGENE			English	Article						p53; p21(WAF1/CIP1); apoptosis; G(1) arrest; adenoviral vector	WILD-TYPE P53; ADENOVIRUS-MEDIATED TRANSFER; CYCLIN-DEPENDENT KINASES; LUNG-CANCER; IN-VIVO; TUMOR SUPPRESSION; GENE-TRANSFER; P21; INHIBITOR; GROWTH	The p21(WAF1/CIP1) gene, which encodes a cyclin-dependent kinase inhibitor, may be critical for tumor suppressor gene p53-induced cell cycle arrest The p53 gene is known to regulate G(1) checkpoint, which can either induce G(1) arrest or initiate apoptosis, To directly examine the role of p21(WAF1/CIP1) in the control of p53 function, we have introduced human p21(WAF1/CIP1) gene into a p53-deficient human non-small cell lung cancer cell line H1299 using a p21(WAF1/CIP1)-expressing adenoviral vector (AdCMVp21). Infection with AdCMVp21 resulted in high levels of p21(WAF1/CIP1) expression and significantly suppressed the growth of H1299 cells through the G, arrest of the cell cycle, In contrast, transient expression of the wild-type p53 gene by a recombinant adenoviral vector (AdCMVp53) in H1299 cells induced apoptotic cell death and resulted in a rapid loss of cell viability, We then examined the effects of combined infection with AdCMVp21 and AdCMVp53 on H1299 cells to explore the dominant function of these molecules, Interestingly, introduction of exogenous p53 overcame p21(WAF1/CIP1)-mediated cell cycle arrest at G(1) and induced apoptosis, although viral-transduced p21(WAF1/CIP1) expression level was unaffected, These observations suggest that p53 expression converts a p21(WAF1/CIP1)-mediated growth arrest into apoptosis, The result was repeated with two additional human colon adenocarcinoma cell lines with the different p53 status, mutant p53-expressing DLD-1 and wild-type p53-expressing LoVo, suggesting that this phemonenon is a general event among human cancer cells, Thus, p53-mediated apoptotic pathway is dominant over the growth arrest pathway, indicating that p53 may be an essential upstream mediator of p21(WAF1/CIP1) in the regulation of a cell process leading either to growth arrest or to apoptotic suicide.	OKAYAMA UNIV,SCH MED,DEPT SURG 1,OKAYAMA 700,JAPAN; OKAYAMA UNIV,SCH MED,DEPT CELL CHEM,OKAYAMA 700,JAPAN; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT THORAC & CARDIOVASC SURG,HOUSTON,TX 77030	Okayama University; Okayama University; University of Texas System; UTMD Anderson Cancer Center			Kagawa, Shunsuke/B-2189-2011	Kagawa, Shunsuke/0000-0002-3610-8211				CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN YQ, 1995, CANCER RES, V55, P4536; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; EASTHAM JA, 1995, CANCER RES, V55, P5151; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUJIWARA T, 1993, CANCER RES, V53, P4129; FUJIWARA T, 1994, CANCER RES, V54, P2287; GomezManzano C, 1996, CANCER RES, V56, P694; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, ONCOGENE, V10, P1563; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; ZHANG WW, 1994, CANCER GENE THER, V1, P5	23	81	87	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1903	1909		10.1038/sj.onc.1201362	http://dx.doi.org/10.1038/sj.onc.1201362			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365236				2022-12-17	WOS:A1997YA87200004
J	Hui, R; Campbell, DH; Lee, CSL; McCaul, K; Horsfall, DJ; Musgrove, EA; Daly, RJ; Seshadri, R; Sutherland, RL				Hui, R; Campbell, DH; Lee, CSL; McCaul, K; Horsfall, DJ; Musgrove, EA; Daly, RJ; Seshadri, R; Sutherland, RL			EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer	ONCOGENE			English	Article						EMS1; 11q13; prognosis; breast cancer	TYROSINE KINASE-ACTIVITY; SQUAMOUS-CELL CARCINOMA; PP60C-SRC PROTEIN-KINASE; CHROMOSOME 11Q13; CYCLIN D1; ONCOGENE AMPLIFICATION; POOR-PROGNOSIS; C-SRC; CLINICAL-SIGNIFICANCE; EXPRESSION	Chromosome 11q13 is amplified in about 13% of primary breast cancers, CCND1, encoding the cell cycle regulatory gene cyclin D1, and EMS1, encoding a filamentous actin binding protein, are favoured candidate onocogenes, whereas INT-2 is an unexpressed gene at this locus. In this study we tested the possibility that different regions of this large amplicon could be independently amplified and subsequently defined the phenotype of EMS1 amplified tumours in a series of 961 primary breast carcinomas. Using DNA slot blots, EMS1 was amplified in 15.2% of samples: 5.4% were coamplified for CCND1; 7.9% coamplified for INT-2 and 6.7% showed EMS1 amplification alone. The degree of amplification of CCND1 and INT-2 was highly correlated (P=0.0001). In contrast, no such relationship existed between EMS1 and CCND1 or INT-2 amplification, demonstrating independent amplification of EMS1 in 44% of amplified tumours. EMS1 amplification (greater than or equal to twofold increase in copy number) was positively correlated with patient age greater than or equal to 50 years (P=0.025), ER positivity (P=0.022), PgR positivity (P = 0.018), and was negatively correlated with HER-2/neu (c-erbB2) amplification (P=0.01). In common with CCND1/INT-2, EMS1 amplification was associated with increased risk of relapse in patients with lymph node-negative disease (P=0.028). In contrast, EMS1 and CCND1/INT-2 amplification appeared to confer different phenotypes in ER positive and negative tumours. A greater than or equal to threefold increase in EMS1 copy number was associated with an apparent increased risk of relapse and death in patients with ER negative tumours, but was without effect in ER positive tumours. In contrast, CCND1/INT-2 amplification had no effect in the patients with ER negative tumours but was associated with early relapse in ER positive patients. Thus EMS1 amplification may identify subgroups of breast cancer patients with increased probability of relapse and death distinct from those identified by CCND1/INT-2 amplification. Further studies are required to more clearly determine the functional consequences of EMS1 overexpression and a biological basis for the relationship between EMS1 amplification and phenotype in breast cancer.	ST VINCENTS HOSP, GARVAN INST MED RES, CANC RES PROGRAM, SYDNEY, NSW 2010, AUSTRALIA; S AUSTRALIAN HLTH COMMISS, EPIDEMIOL UNIT, ADELAIDE CITY CTR, SA 5000, AUSTRALIA; FLINDERS MED CTR, DEPT SURG, BEDFORD PK, SA 5042, AUSTRALIA; FLINDERS MED CTR, DEPT HAEMATOL, BEDFORD PK, SA 5042, AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Flinders Medical Centre; Flinders Medical Centre			Sutherland, Robert L/A-8378-2008; McCaul, Kieran A/B-8751-2008; Daly, Roger J/C-8179-2009	Daly, Roger/0000-0002-5739-8027; Campbell, Douglas/0000-0001-9699-1854				ADNANE J, 1989, ONCOGENE, V4, P1389; BERNS EMJJ, 1995, GENE, V159, P11, DOI 10.1016/0378-1119(94)00534-Y; BERNS EMJJ, 1992, EUR J CANCER, V28A, P697, DOI 10.1016/S0959-8049(05)80129-7; BOLLA M, 1993, BREAST CANCER RES TR, V26, P283, DOI 10.1007/BF00665806; BORG A, 1991, BRIT J CANCER, V63, P136, DOI 10.1038/bjc.1991.28; BORG A, 1990, CANCER RES, V50, P4332; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; Bringuier PP, 1996, ONCOGENE, V12, P1747; Campbell DH, 1996, INT J CANCER, V68, P485, DOI 10.1002/(SICI)1097-0215(19961115)68:4<485::AID-IJC14>3.0.CO;2-4; Dickson C, 1989, Prog Growth Factor Res, V1, P123, DOI 10.1016/0955-2235(89)90006-9; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; FANTL V, 1993, CANCER SURV, V18, P77; GAFFEY MJ, 1993, MODERN PATHOL, V6, P654; Hui R, 1996, CLIN CANCER RES, V2, P923; HUI R, 1997, UNPUB; JACOBS C, 1983, CANCER RES, V43, P1696; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; KLIJN JGM, 1992, ENDOCR REV, V13, P3, DOI 10.1210/er.13.1.3; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; MAA MC, 1992, ONCOGENE, V7, P2429; MACHOTKA SV, 1989, CLIN CHIM ACTA, V184, P207, DOI 10.1016/0009-8981(89)90053-3; MEREDITH SD, 1995, ARCH OTOLARYNGOL, V121, P790; Michalides R, 1996, BRIT J CANCER, V73, P728, DOI 10.1038/bjc.1996.128; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Patel AM, 1996, ONCOGENE, V12, P31; PETERS G, 1995, BREAST CANCER RES TR, V33, P125, DOI 10.1007/BF00682720; ROMAIN S, 1994, BRIT J CANCER, V70, P304, DOI 10.1038/bjc.1994.297; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; SCHUURING E, 1992, CANCER RES, V52, P5229; SCHUURING E, 1992, ONCOGENE, V7, P355; Seshadri R, 1996, CLIN CANCER RES, V2, P1177; Seshadri R, 1996, INT J CANCER, V69, P135, DOI 10.1002/(SICI)1097-0215(19960422)69:2<135::AID-IJC12>3.0.CO;2-8; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; THEILLET C, 1990, ONCOGENE, V5, P147; TSUDA H, 1989, CANCER RES, V49, P3104; TSUDA T, 1989, CANCER RES, V49, P5505; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; WILLIAMS ME, 1993, ARCH OTOLARYNGOL, V119, P1238; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1994, J BIOL CHEM, V269, P20221	46	81	81	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	1997	15	13					1617	1623		10.1038/sj.onc.1201311	http://dx.doi.org/10.1038/sj.onc.1201311			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380415				2022-12-17	WOS:A1997XX36900014
J	Crusius, K; Auvinen, E; Alonso, A				Crusius, K; Auvinen, E; Alonso, A			Enhancement of EGF- and PMA-mediated MAP kinase activation in cells expressing the human papillomavirus type 16 E5 protein	ONCOGENE			English	Article						EGFR; TGF-alpha; PMA; TPA; fos; raf	EPIDERMAL GROWTH-FACTOR; SIGNAL-REGULATED KINASE; TYROSINE KINASE; BOVINE PAPILLOMAVIRUS; FACTOR RECEPTOR; C-FOS; TRANSCRIPTIONAL ACTIVATION; DIFFERENTIAL ACTIVATION; TRANSFORMING ACTIVITY; GENE-PRODUCT	In this report we demonstrate that cells expressing the human papillomavirus type 16 E5 open reading frame (HPV16-E5) show a greatly enhanced transcription of the immediate early genes after EGF or PMA treatment compared to control cells. This enhancement is due to amplification of the signal transduction pathways in response to growth factors or phorbol esters. Upon short-time EGF treatment of the E5-expressing cells we observed an increase in the activation of EGF receptors, resulting in a stronger activation of MAP kinases ERK1/2 compared to control-transfected cells. We also observed that in E5-expressing cells, treatment with PMA results in an increase in membrane-associated PKC activity, and a superactivation of the ERK1/2 MAP kinases. This superactivation is PKC-dependent, since pretreatment of the cells with the PKC inhibitor Ro 31-8220 inhibits MAP kinase activation and early gene transcription almost completely. Furthermore, treatment with genistein strongly reduces the PMA-mediated superactivation of ERK1/2 kinases, demonstrating a PKC-mediated, tyrosine kinase-dependent pathway in the superinduction of MAP kinase activation. Thus, HPV16-E5 effects superactivation of MAP kinases over at least two different pathways, a PKC-mediated, and another, receptor tyrosine-kinase mediated, PKC-independent one.	DEUTSCH KREBSFORSCHUNGSZENTRUM, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)								AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BOUVARD V, 1994, VIROLOGY, V203, P73, DOI 10.1006/viro.1994.1456; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CARPENTER G, 1990, PEPTIDE GROWTH FACTO, P69; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CONRAD M, 1994, VIROLOGY, V200, P796, DOI 10.1006/viro.1994.1244; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DANESCH U, 1994, J BIOL CHEM, V269, P27258; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DIMAIO D, 1991, ADV CANCER RES, V56, P133; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GOLDSTEIN DJ, 1992, J VIROL, V66, P405, DOI 10.1128/JVI.66.1.405-413.1992; GU ZM, 1995, J VIROL, V69, P8051, DOI 10.1128/JVI.69.12.8051-8056.1995; HARVAT BL, 1995, CELL GROWTH DIFFER, V6, P955; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HOUSLAY MD, 1991, EUR J BIOCHEM, V195, P9, DOI 10.1111/j.1432-1033.1991.tb15671.x; HWANG ES, 1995, VIROLOGY, V211, P227, DOI 10.1006/viro.1995.1395; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; PIM D, 1992, ONCOGENE, V7, P27; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; Sambrook J., 1989, MOL CLONING; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHILLER JT, 1986, J VIROL, V57, P1; SEGER R, 1995, J BIOL CHEM, V270, P28325; STONE RL, 1994, J BIOL CHEM, V269, P31323; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; VALLE GF, 1995, J GEN VIROL, V76, P1239, DOI 10.1099/0022-1317-76-5-1239; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	48	81	88	3	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	1997	15	12					1437	1444		10.1038/sj.onc.1201312	http://dx.doi.org/10.1038/sj.onc.1201312			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XW411	9333019	Bronze			2022-12-17	WOS:A1997XW41100007
J	Chang, THT; Ray, FA; Thompson, DA; Schlegel, R				Chang, THT; Ray, FA; Thompson, DA; Schlegel, R			Disregulation of mitotic checkpoints and regulatory proteins following acute expression of SV40 large T antigen in diploid human cells	ONCOGENE			English	Article						mitosis; cell cycle; checkpoints; SV40 T antigen; chromosome aberrations	INDUCED PREMATURE MITOSIS; IRRADIATED HELA-CELLS; SIMIAN VIRUS-40; HUMAN-FIBROBLASTS; TUMOR-ANTIGEN; CYCLIN-B; DNA-REPLICATION; MAMMALIAN-CELLS; FISSION YEAST; TYROSINE PHOSPHORYLATION	SV40 large T antigen (T) inactivates the tumor suppressor proteins p53 and pRb, and can induce cells to enter DNA replication at inappropriate times, We show here that T also compromises three cell cycle checkpoints that regulate the entry into and exit from mitosis, Human diploid fibroblasts infected with a retrovirus expressing T displayed an attenuated radiation-induced mitotic delay, were more susceptible to chemical-induced uncoupling of mitosis from the completion of DNA replication, and were more likely to exit mitosis and rereplicate their DNA when mitotic spindle assembly was inhibited, Consistent with altered mitotic checkpoint control, cells expressing T displayed elevated protein levels and/or associated activities of the mitotic regulatory proteins cyclin A, cyclin B, Cdc25C and p34(cdc2). These changes in mitotic control were evident within 5-10 population doublings after retroviral infection, indicating a direct effect of T expression, Cells acutely infected with the T-expressing retrovirus suffered numerical and structural chromosome aberrations, including increases in aneuploidy, dicentric chromosomes, chromatid exchanges and chromosome breaks and gaps, These findings indicate that T rapidly disrupts mitotic checkpoints that help maintain genomic stability, and suggest mechanisms by which T induces chromosome aberrations and promotes the immortalization and neoplastic transformation of human cells.	HARVARD UNIV,SCH PUBL HLTH,DEPT MOL & CELLULAR TOXICOL,BOSTON,MA 02115; ALBANY MED COLL,DEPT MICROBIOL,ALBANY,NY 12208; CHIRON DIAGNOST,E WALPOLE,MA 02032	Harvard University; Harvard T.H. Chan School of Public Health; Albany Medical College								AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BROWN M, 1991, COLD SPRING HARB SYM, V61, P359; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; BUSSE PM, 1977, RADIAT RES, V71, P666, DOI 10.2307/3574634; BUSSE PM, 1978, RADIAT RES, V76, P292, DOI 10.2307/3574780; Chang THT, 1996, J CELL BIOCHEM, V60, P161, DOI 10.1002/(SICI)1097-4644(19960201)60:2<161::AID-JCB1>3.0.CO;2-V; CHOI YW, 1988, MOL CELL BIOL, V8, P3382, DOI 10.1128/MCB.8.8.3382; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DONAHUE LM, 1988, ONCOGENE, V3, P221; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FAN SJ, 1995, CANCER RES, V55, P1649; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; JOHNSON RT, 1970, NATURE, V226, P717, DOI 10.1038/226717a0; KAUFMANN WK, 1995, CANCER RES, V55, P7; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KOPROWSKI H, 1962, J CELL COMPAR PHYSL, V59, P281, DOI 10.1002/jcp.1030590308; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFFIN J, 1989, CYTOMETRY, V10, P205, DOI 10.1002/cyto.990100212; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LEVINE DS, 1991, P NATL ACAD SCI USA, V88, P6427, DOI 10.1073/pnas.88.15.6427; LIEBMANN J, 1994, CANCER CHEMOTH PHARM, V33, P331; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LIN JY, 1991, J VIROL, V65, P2066, DOI 10.1128/JVI.65.4.2066-2072.1991; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOPES NM, 1993, CANCER CHEMOTH PHARM, V32, P235, DOI 10.1007/BF00685842; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; MIGNOTTE B, 1990, ONCOGENE, V5, P1529; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1989, BIOTECHNIQUES, V7, P984; MILLER AD, 1989, BIOTECHNIQUES, V7, P989; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; NICHOLS WW, 1977, SCIENCE, V196, P60, DOI 10.1126/science.841339; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OSHIMA J, 1993, ONCOGENE, V8, P2987; PAULES RS, 1995, CANCER RES, V55, P1763; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POWELL SN, 1995, CANCER RES, V55, P1643; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RAY FA, 1992, MUTAT RES, V284, P265, DOI 10.1016/0027-5107(92)90011-P; RAY FA, 1990, J CELL BIOCHEM, V42, P13, DOI 10.1002/jcb.240420103; RAY FA, 1993, CARCINOGENESIS, V14, P1511, DOI 10.1093/carcin/14.8.1511; RICE RH, 1993, MOL BIOL CELL, V4, P185, DOI 10.1091/mbc.4.2.185; ROBERTS JR, 1990, CANCER RES, V50, P710; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; RUSSELL KJ, 1995, CANCER RES, V55, P1639; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SCHIMKE RT, 1991, COLD SH Q B, V56, P417; SCHLEGEL R, 1990, CELL GROWTH DIFFER, V1, P171; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; STEIN GH, 1985, J CELL PHYSIOL, V125, P36, DOI 10.1002/jcp.1041250106; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; STEINMANN KE, 1994, ONCOGENE, V9, P387; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; STEWART N, 1995, ONCOGENE, V10, P109; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; TACK LC, 1989, J VIROL, V63, P3362, DOI 10.1128/JVI.63.8.3362-3367.1989; TAM SW, 1995, J CELL BIOCHEM, V59, P339, DOI 10.1002/jcb.240590306; TAM SW, 1992, CELL GROWTH DIFFER, V3, P811; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WOLMAN S. R., 1964, CYTOGENETICS [BASEL], V3, P45, DOI 10.1159/000129797; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991	92	81	82	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 22	1997	14	20					2383	2393		10.1038/sj.onc.1201196	http://dx.doi.org/10.1038/sj.onc.1201196			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188853				2022-12-17	WOS:A1997WZ68000002
J	Mayol, X; Garriga, J; Grana, X				Mayol, X; Garriga, J; Grana, X			G1 cyclin/CDK-independent phosphorylation and accumulation of p130 during the transition from G1 to G0 lead to its association with E2F-4	ONCOGENE			English	Article						cell cycle; E2F; pRB; quiescence; TGF-beta	CELL-CYCLE CONTROL; LARGE-T-ANTIGEN; CDC2-RELATED PROTEIN-KINASE; RETINOBLASTOMA GENE FAMILY; TUMOR-SUPPRESSOR PROTEIN; DEPENDENT KINASES; IN-VIVO; INHIBITORS; MEMBER; EXPRESSION	During the transition from G1 to G0, p130 undergoes a specific phosphorylation event - leading to p130-form 2 - that is mediated by a kinase/s other than the known G1, S and G2/M cyclin/CDKs. Changes in the phosphorylation status of p130 during this transition are responsible, at least in part, for the concomitant formation of p130/E2F4 complexes, which are characteristic of GO. These complexes remain abundant during early G1 upon restimulation, but not after mitosis, and are dissociated in mid G1 when p130 is abruptly hyperphosphorylated to form 3. Subsequently, p130 forms 1 and 2 are no longer detected during the remainder of the cell cycle. Consistently, phosphorylation to form 3 and dissociation from E2F-4 complexes is reproduced by a cyclin/CDK holoenzyme in vitro. TGF-beta-induced G1 arrest abrogates cyclin/CDK phosphorylation of p130 but not phosphorylation to form 2. The cell cycle-dependent phosphorylation pattern of p130 is thus shown to comprise two distinct steps that are catalyzed by different kinases. The differential regulation of p130 and pRB phosphorylation during the transition from G1 to G0 may explain the fact that p130 and E2F-4 are the major components of E2F complexes in quiescent cells. Moreover, the newly described phosphorylation of p130 at the transition from G1 to G0 defines a novel mechanism of cell cycle exit regulation.	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOL BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Mayol, Xavier/C-1391-2012	Grana, Xavier/0000-0001-7134-0473; Mayol, Xavier/0000-0001-7288-195X				BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CHRISTENSEN JB, 1995, J VIROL, V69, P3945, DOI 10.1128/JVI.69.6.3945-3948.1995; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GRANA X, 1994, ONCOGENE, V9, P2097; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; GRANA X, 1995, ONCOGENE, V11, P211; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HERZINGER T, 1995, ONCOGENE, V10, P2079; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KATO M, 1995, J BIOL CHEM, V270, P12373, DOI 10.1074/jbc.270.21.12373; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MAYOL X, 1993, ONCOGENE, V8, P2561; MAYOL X, 1995, ONCOGENE, V11, P801; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NEVINS JR, 1992, SCIENCE, V258, P424; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLF DA, 1995, ONCOGENE, V10, P2067; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0	43	81	81	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					237	246						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710362				2022-12-17	WOS:A1996VA25200002
J	Arber, N; Sutter, T; Miyake, M; Kahn, SM; Venkatraj, VS; Sobrino, A; Warburton, D; Holt, PR; Weinstein, IB				Arber, N; Sutter, T; Miyake, M; Kahn, SM; Venkatraj, VS; Sobrino, A; Warburton, D; Holt, PR; Weinstein, IB			Increased expression of cyclin D1 and the RB tumor suppressor gene in c-K-ras transformed rat enterocytes	ONCOGENE			English	Article						retinoblastoma; cyclin D1; ras; colon cancer	HUMAN CANCER; COLORECTAL CARCINOMAS; RETINOBLASTOMA GENE; ESOPHAGEAL CANCER; OVEREXPRESSION; AMPLIFICATION; CELLS; CHROMOSOME-13; ABNORMALITIES; FIBROBLASTS	Activating mutations in the c-g-ras gene occur in about 40% of human colorectal carcinomas, yet the role of this oncogene in tumorigenesis is not known. We have developed a model cell culture system to study this problem, utilizing the immortalized but non-tumorigenic epithelial cell line IEC18, originally derived from normal rat intestine epithelium. These cells were cotransfected with the drug resistance selectable marker tk-neo and the plasmid pMIKcys, which encodes a mini human c-K-vas gene (15 kb) containing a cysteine mutation at codon 12, Drug resistant clones were isolated. Clones which also expressed the activated c-K-ras gene displayed a transformed morphology, decreased doubling time, increased level of diacylglycerol, anchorage independent growth in soft agar and an aneuploid karyotype and they were also tumorigenic when injected into nude mice. These clones also displayed increased expression, at both the mRNA and protein levels, of cyclin D1 and Rb. These findings may be of clinical relevance since human colorectal tumors also frequently display increased expression of both cyclin D1 and Rb. This model system may be useful for understanding the role and interrelationship between activation of the c-K-uas oncogene and increased expression of cyclin D1 and Rb in colorectal tumorigenesis.	COLUMBIA UNIV COLL PHYS & SURG,COLUMBIA PRESBYTERIAN CANC CTR,NEW YORK,NY 10032; COLUMBIA UNIV,CTR RADIOL RES,NEW YORK,NY 10032; COLUMBIA UNIV,DEPT GENET & DEV,NEW YORK,NY 10032; COLUMBIA UNIV,ST LUKES ROOSEVELT HOSP CTR,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University; Columbia University; Mount Sinai St. Luke's; Mount Sinai West				holt, peter/0000-0002-8469-2766; Arber, Nadir/0000-0001-5283-6991				ARBER N, 1996, IN PRESS GASTROENTER; BARTKOVA J, 1994, INT J CANCER, V58, P568, DOI 10.1002/ijc.2910580420; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOWCOCK AM, 1989, CYTOGENET CELL GENET, V51, P966; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; FEARON ER, 1993, J NATL CANCER I, V85, P1978, DOI 10.1093/jnci/85.24.1978; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FILMUS J, 1994, ONCOGENE, V9, P3627; GOPE R, 1990, J NATL CANCER I, V82, P310, DOI 10.1093/jnci/82.4.310; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOVIG E, 1992, GENE CHROMOSOME CANC, V5, P97, DOI 10.1002/gcc.2870050202; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; KAHN S, 1987, ANTICANCER RES, V7, P639; KATO J, 1993, GENE DEV, V7, P331; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LEACH FS, 1993, CANCER RES, V53, P1986; LOTHE RA, 1992, J NATL CANCER I, V84, P1100, DOI 10.1093/jnci/84.14.1100; LOVEC H, 1994, ONCOGENE, V9, P323; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MITELMAN F, 1992, ISCN GUIDELINES CA S; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; ONO T, 1993, JPN J GENET, V68, P617, DOI 10.1266/jjg.68.617; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; PHAN SC, 1991, CANCER RES, V51, P1571; PINES J, 1994, CELL, V79, P573; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; PRICE BD, 1989, J BIOL CHEM, V264, P16638; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TUCK AB, 1991, J NATL CANCER I, V83, P485; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WILDRICK DM, 1994, MOL CARCINOGEN, V10, P1, DOI 10.1002/mc.2940100102; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350	38	81	81	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1903	1908						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649851				2022-12-17	WOS:A1996UK49800009
J	Chiba, I; Shindoh, M; Yasuda, M; Yamazaki, Y; Amemiya, A; Sato, Y; Fujinaga, K; Notani, K; Fukuda, H				Chiba, I; Shindoh, M; Yasuda, M; Yamazaki, Y; Amemiya, A; Sato, Y; Fujinaga, K; Notani, K; Fukuda, H			Mutations in the p53 gene and human papillomavirus infection as significant prognostic factors in squamous cell carcinomas of the oral cavity	ONCOGENE			English	Article						p53; human papillomavirus; oral squamous cell carcinoma; prognosis	TUMOR-SUPPRESSOR GENE; POLYMERASE CHAIN-REACTION; CERVICAL CARCINOMAS; NECK-CANCER; LUNG-CANCER; FREQUENT; HEAD; DNA; ASSOCIATION; EXPRESSION	The p53 gene has been indicated to be a tumor is found in mutated form in common human cancers, Human papillomavirus (HPV) has oncogenic activity in cervical and oral squamous cell carcinomas (SCCs), The E6 protein of HPV is known to bind with p53 protein and inactivate the tumor suppressor activity by promoting p53 degradation, Because of this background, we examined 38 primary, resected specimens of oral SCCs for detection of p53 mutations and HPV DNAs, Exons 5 through 8 of the p53 gene were examined using the PCR-SSCP method, p53 Mutations were observed in nine cases (24%), HPV-DNA detection and typing were performed using PCR with 'high risk group' HPV-specific primers, HPV DNA sequences were detected in eight cases (21%), The AvaII digestion pattern of PCR-amplified HPV DNA showed that HPV-16 was present in all eight cases, Seven cases were p53 mutation-positive/HPV-negative, six cases were p53 mutation-negative/HPV-positive, and two intraosseus SCC cases were p53 mutation-positive/HPV-positive. Thus, 15/38 (40%) cases had inactivation of the p53 protein. Interestingly, p53 mutation-negative/HPV-negative cases had a poorer prognosis than p53 mutation positive or HPV-positive cases (P<0.01), We conclude that (1) mutation in the p53 gene and/or HPV infection are frequent (40%) in oral SCC; (2) inactivation of p53 function by mutation and HPV infection are important genetic events in the development of 40% similar to of oral SCCs; (3) p53 mutation and HPV infection are not mutually exclusive events and (4) other oncogenes or tumor suppresor genes may be crucial in the development of oral SCC if the prognosis is poor.	HOKKAIDO UNIV, SCH DENT, DEPT ORAL PATHOL, KITA KU, SAPPORO, HOKKAIDO 060, JAPAN; HOKKAIDO UNIV, SCH DENT, DEPT DENT RADIOL, KITA KU, SAPPORO, HOKKAIDO 060, JAPAN; HOKKAIDO UNIV, SCH ENGN, DEPT INFORMAT SCI, SAPPORO, HOKKAIDO 060, JAPAN; SAPPORO MED UNIV, CANC RES INST, DEPT MOLEC BIOL, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN	Hokkaido University; Hokkaido University; Hokkaido University; Sapporo Medical University	Chiba, I (corresponding author), HOKKAIDO UNIV, SCH DENT,DEPT ORAL SURG 1,KITA KU,KITA-13, NISHI 7, SAPPORO, HOKKAIDO 060, JAPAN.		Shindoh, Masanobu/A-4799-2012	Shindoh, Masanobu/0000-0002-7782-5823				BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALARAM P, 1995, INT J CANCER, V61, P450, DOI 10.1002/ijc.2910610403; BOYLE JO, 1993, CANCER RES, V53, P4477; BRACHMAN DG, 1992, CANCER RES, V52, P4832; BRANDWEIN M, 1994, MODERN PATHOL, V7, P720; BUSBYEARLE RMC, 1994, BRIT J CANCER, V69, P732, DOI 10.1038/bjc.1994.138; CAAMANO J, 1993, AM J PATHOL, V142, P1131; CARBONE DP, 1994, CHEST, V106, pS377, DOI 10.1378/chest.106.6.377S; CHANG F, 1994, BRIT J CANCER, V70, P346, DOI 10.1038/bjc.1994.305; CHIBA I, 1990, ONCOGENE, V5, P1603; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; FIELD JK, 1987, J ORAL PATHOL MED, V16, P97, DOI 10.1111/j.1600-0714.1987.tb01474.x; FRANK JL, 1994, CANCER-AM CANCER SOC, V73, P181, DOI 10.1002/1097-0142(19940101)73:1<181::AID-CNCR2820730131>3.0.CO;2-3; FUJINAGA Y, 1991, J GEN VIROL, V72, P1039, DOI 10.1099/0022-1317-72-5-1039; FUJITA M, 1992, CANCER RES, V52, P5323; Gonzalez-Moles M A, 1994, Bull Group Int Rech Sci Stomatol Odontol, V37, P79; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HELLAND A, 1993, J PATHOL, V171, P105, DOI 10.1002/path.1711710207; HERMANEK P, 1987, TNM CLASSIFICATION M, P1; HIGGINS GD, 1991, LANCET, V338, P910, DOI 10.1016/0140-6736(91)91773-N; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; LAZARUS P, 1995, INT J CANCER, V60, P458, DOI 10.1002/ijc.2910600406; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MIWA K, 1995, BRIT J CANCER, V71, P219, DOI 10.1038/bjc.1995.47; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PARK DJ, 1994, ONCOGENE, V9, P205; RIOU G, 1990, LANCET, V335, P1171; SAKAI E, 1992, ONCOGENE, V7, P927; SAKAI E, 1992, INT J CANCER, V52, P867, DOI 10.1002/ijc.2910520606; SARANATH D, 1989, JPN J CANCER RES, V80, P430, DOI 10.1111/j.1349-7006.1989.tb02332.x; SAUTER ER, 1992, AM J SURG, V164, P651, DOI 10.1016/S0002-9610(05)80727-5; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHIN DM, 1994, CANCER RES, V54, P321; SOMERS KD, 1992, CANCER RES, V52, P5997; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TASE T, 1988, CANCER RES, V48, P993; VOGELSTEIN B, 1989, RECESSIVE ONCOGENES; WAHI PN, 1971, INT HISTOLOGICAL CLA, P15; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	43	81	81	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1663	1668						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622886				2022-12-17	WOS:A1996UG45800008
J	Takle, LA; Knowles, MA				Takle, LA; Knowles, MA			Deletion mapping implicates two tumour suppressor genes on chromosome 8p in the development of bladder cancer	ONCOGENE			English	Article						chromosome 8; loss of heterozygosity; bladder cancer; tumour suppressor gene; microsatellite polymorphism	TRANSITIONAL CELL-CARCINOMA; COLORECTAL-CANCER; POLYMORPHISMS; LOCI	Chromosome 8 loss of heterozygosity (LOH) in cancer of the urinary bladder is associated with high tumour grade and stage. We have screened 193 cases of transitional cell carcinoma (TCC) of the bladder using 30 microsatellite polymorphisms on chromosome 8. Forty three cases (22%) showed LOH on 8p, the majority of which (72%) had lost the entire short arm. Using 12 tumours with partial deletions of 8p, we have defined a minimum telomeric region of deletion between D8S264 and D8S133 (8p21.1-pter). We also found LOH in the region 8p11.2-12, where we have defined at least one centromeric target for deletion within a 4 cM interval. Two tumours were identified with loss of the telomeric region only, whereas all cases with loss in the centromeric region also had telomeric deletion. Chromosome 8p deletions have also been described in prostate, colorectal, hepatocellular, lung and endometrial carcinoma and collecting duct carcinoma of the kidney. It has been postulated that loss or inactivation of at least 2 tumour suppressor genes on 8p may play an important role in progression of both prostate and colorectal carcinomas. The regions of deletion eve have identified in bladder tumours are compatible with these, suggesting that at least two genes on 8p may play a role in the development of many common solid tumours. Our findings significantly refine the localisation of the more centromeric of these loci.	MARIE CURIE RES INST,MOLEC GENET LAB,OXTED RH8 0TL,SURREY,ENGLAND					Knowles, Margaret/0000-0002-9363-8657				ATKIN NB, 1985, CANCER GENET CYTOGEN, V15, P253, DOI 10.1016/0165-4608(85)90169-4; BABU VR, 1987, CANCER RES, V47, P6800; BERGER CS, 1986, CANCER GENET CYTOGEN, V23, P1, DOI 10.1016/0165-4608(86)90145-7; BOVA GS, 1993, CANCER RES, V53, P3869; CANNIZZARO LA, 1987, CYTOGENET CELL GENET, V46, P589; CARTWRIGHT RA, 1982, LANCET, V2, P842; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; CUNNINGHAM C, 1994, BRIT J CANCER, V70, P18, DOI 10.1038/bjc.1994.243; DOBASHI Y, 1994, CANCER RES, V54, P2827; EMI M, 1992, CANCER RES, V52, P5368; FRANKE S, 1994, BIOCHEM BIOPH RES CO, V199, P52, DOI 10.1006/bbrc.1994.1192; FUJINO T, 1994, CANCER RES, V54, P4294; FUJIWARA Y, 1994, GENE CHROMOSOME CANC, V10, P7, DOI 10.1002/gcc.2870100103; FUJIWARA Y, 1993, CANCER RES, V53, P1172; FUJIWARA Y, 1995, ONCOGENE, V10, P891; GIBAS Z, 1984, CANCER RES, V44, P1257; GIBAS Z, 1986, CANCER GENET CYTOGEN, V19, P229, DOI 10.1016/0165-4608(86)90051-8; GRANBERGOHMAN I, 1984, CANCER GENET CYTOGEN, V11, P69, DOI 10.1016/0165-4608(84)90100-6; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HICKMAN D, 1994, BIOCHEM J, V297, P441, DOI 10.1042/bj2970441; ICHIKAWA T, 1994, CANCER RES, V54, P2299; JONES TA, 1993, CYTOGENET CELL GENET, V63, P35, DOI 10.1159/000133497; KEEN AJ, 1994, ONCOGENE, V9, P2083; KELEMEN PR, 1994, GENE CHROMOSOME CANC, V11, P195, DOI 10.1002/gcc.2870110308; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; KNOWLES MA, 1994, CANCER RES, V54, P531; KNOWLES MA, 1993, ONCOGENE, V8, P1357; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; OHATA H, 1993, GENE CHROMOSOME CANC, V7, P85, DOI 10.1002/gcc.2870070204; PROCTOR AJ, 1991, ONCOGENE, V6, P789; RISCH A, 1995, HUM MOL GENET, V4, P231, DOI 10.1093/hmg/4.2.231; SCHOENBERG M, 1995, GENE CHROMOSOME CANC, V12, P76, DOI 10.1002/gcc.2870120115; Spurr N. K., 1995, Cytogenetics and Cell Genetics, V68, P147, DOI 10.1159/000133908; TOMFOHRDE J, 1992, GENOMICS, V14, P144, DOI 10.1016/S0888-7543(05)80297-6; TRAPMAN J, 1994, CANCER RES, V54, P6061; VANNI R, 1988, CANCER GENET CYTOGEN, V30, P35, DOI 10.1016/0165-4608(88)90090-8; WANG LM, 1992, CANCER RES, V52, P4824; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; YAREMKO ML, 1994, GENE CHROMOSOME CANC, V10, P1, DOI 10.1002/gcc.2870100102	39	81	82	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1083	1087						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649800				2022-12-17	WOS:A1996UA88400017
